data_2my6_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2my6 _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 20.4 m-70 . . . . . 0 N--CA 1.495 1.821 0 CA-C-O 121.086 0.469 . . . . 0.0 109.831 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -60.32 -39.97 88.91 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.105 -0.997 . . . . 0.0 109.343 179.898 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.2 m -61.76 -36.86 82.27 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.465 -0.772 . . . . 0.0 110.019 -179.754 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 64.3 t -62.35 -44.98 99.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.23 -0.919 . . . . 0.0 109.631 -179.762 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 78.3 mt -59.78 -46.96 93.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.326 -0.858 . . . . 0.0 108.799 179.624 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.427 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -62.38 -35.12 78.19 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 108.969 -0.752 . . . . 0.0 108.969 179.328 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 7.3 tt0 -58.76 -41.12 85.81 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.084 -1.01 . . . . 0.0 109.526 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.672 ' CG ' ' CZ2' ' A' ' 47' ' ' TRP . 52.4 m-85 -68.7 -50.16 53.1 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.045 -1.035 . . . . 0.0 110.508 -179.807 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.433 ' CG2' ' N ' ' A' ' 12' ' ' VAL . 1.0 OUTLIER -66.12 -39.0 83.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.02 -1.05 . . . . 0.0 108.99 -179.498 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.442 ' O ' ' C ' ' A' ' 16' ' ' LEU . 74.8 t -63.56 -46.67 94.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.28 -0.888 . . . . 0.0 109.266 179.45 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -71.71 -23.6 61.66 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.23 -0.919 . . . . 0.0 109.825 179.665 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -64.09 -30.3 71.38 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.428 -0.795 . . . . 0.0 110.395 -179.078 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 72.6 t80 -139.0 -40.48 0.48 Allowed 'General case' 0 N--CA 1.494 1.731 0 O-C-N 120.969 -1.082 . . . . 0.0 110.765 -179.413 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.442 ' C ' ' O ' ' A' ' 12' ' ' VAL . 5.0 mt -120.76 80.11 32.17 Favored Pre-proline 0 N--CA 1.491 1.613 0 O-C-N 121.089 -1.007 . . . . 0.0 110.338 -179.18 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 40.7 Cg_endo -75.73 -14.78 19.48 Favored 'Trans proline' 0 C--N 1.309 -1.536 0 C-N-CA 122.439 2.093 . . . . 0.0 112.285 179.437 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -90.03 7.87 35.45 Favored 'General case' 0 N--CA 1.487 1.381 0 O-C-N 121.221 -0.925 . . . . 0.0 109.758 -179.715 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 43.2 t -111.69 134.86 52.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.417 -0.802 . . . . 0.0 109.644 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.27 119.62 75.82 Favored Pre-proline 0 N--CA 1.489 1.477 0 O-C-N 121.263 -0.898 . . . . 0.0 109.353 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_exo -51.2 -28.23 25.21 Favored 'Trans proline' 0 N--CA 1.493 1.483 0 C-N-CA 121.75 1.633 . . . . 0.0 112.109 179.531 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.91 -24.69 67.61 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.264 -0.898 . . . . 0.0 109.31 179.881 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.426 ' O ' ' OD1' ' A' ' 23' ' ' ASP . 60.0 t0 -81.87 7.23 13.42 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.319 -0.863 . . . . 0.0 109.789 -179.746 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 10.9 t -103.96 132.89 49.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.03 -1.043 . . . . 0.0 109.393 -179.884 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 87.3 m-20 -89.12 120.49 30.56 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.106 -0.996 . . . . 0.0 109.104 179.469 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 17.8 m -77.34 3.92 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.446 0 O-C-N 121.175 -0.953 . . . . 0.0 109.137 179.687 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -87.26 -13.2 44.44 Favored 'General case' 0 N--CA 1.486 1.354 0 O-C-N 121.351 -0.843 . . . . 0.0 109.149 179.518 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 41.5 tp -95.29 138.67 32.67 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.459 -0.775 . . . . 0.0 109.143 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -58.93 141.43 53.66 Favored 'General case' 0 C--N 1.303 -1.441 0 O-C-N 121.237 -0.914 . . . . 0.0 109.527 -179.605 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.488 ' H ' ' HA ' ' A' ' 68' ' ' SER . 1.3 tt -67.36 -38.66 85.16 Favored 'General case' 0 C--N 1.299 -1.589 0 O-C-N 121.706 -0.621 . . . . 0.0 110.322 -179.016 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 69.1 t -65.36 -36.25 77.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.103 -0.998 . . . . 0.0 110.497 -178.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -52.79 -33.59 49.61 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 19.7 m120 -71.05 -34.4 71.22 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.675 -0.641 . . . . 0.0 109.805 179.433 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 85.3 6.28 84.33 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 108.984 -1.646 . . . . 0.0 108.984 -179.481 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 79.4 t -61.73 -34.32 61.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.468 -1.019 . . . . 0.0 109.158 179.795 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.6 mt -87.06 117.34 31.05 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.315 -0.865 . . . . 0.0 109.78 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -117.43 -168.2 1.45 Allowed 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 179.703 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -63.2 -54.77 32.37 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.034 -1.041 . . . . 0.0 108.532 179.626 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 41.9 mt -70.96 -34.71 71.7 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 178.063 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -59.66 -39.64 95.44 Favored Glycine 0 N--CA 1.481 1.656 0 N-CA-C 108.614 -1.795 . . . . 0.0 108.614 179.105 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.6 tt -65.2 -42.62 93.36 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.579 -0.953 . . . . 0.0 108.993 179.36 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.4 tp -61.42 -46.09 91.6 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.414 -0.804 . . . . 0.0 109.234 179.601 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 24.2 mttp -61.15 -35.99 78.57 Favored 'General case' 0 C--N 1.296 -1.721 0 O-C-N 121.504 -0.748 . . . . 0.0 109.76 -179.654 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 60.6 t -61.2 -50.57 79.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.374 -0.829 . . . . 0.0 109.715 -179.663 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.547 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 1.7 mp -69.05 -31.98 52.46 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.535 0 O-C-N 121.454 -0.779 . . . . 0.0 110.721 -179.906 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -63.52 -49.42 73.58 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.108 -0.995 . . . . 0.0 111.369 -178.127 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . 0.672 ' CZ2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -80.87 -45.13 17.32 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 120.723 -1.235 . . . . 0.0 109.876 -179.544 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.548 ' CD1' HH21 ' A' ' 51' ' ' ARG . 9.7 tp -58.33 -42.51 86.99 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.307 -0.87 . . . . 0.0 109.817 -179.169 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.547 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 1.0 OUTLIER -72.66 -35.61 67.76 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.102 -0.999 . . . . 0.0 109.772 179.999 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.1 t70 -61.13 -39.15 88.95 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.159 -0.963 . . . . 0.0 110.713 -179.456 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . 0.548 HH21 ' CD1' ' A' ' 48' ' ' LEU . 66.9 mtm180 -61.51 -36.77 81.47 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.167 -0.958 . . . . 0.0 111.429 -178.727 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.531 ' CZ ' ' CG1' ' A' ' 76' ' ' VAL . 94.3 m-85 -97.13 -9.9 27.03 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.774 -1.204 . . . . 0.0 110.334 -179.057 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 71.72 31.28 65.19 Favored Glycine 0 N--CA 1.486 2.01 0 N-CA-C 108.803 -1.719 . . . . 0.0 108.803 179.874 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.48 ' O ' ' OE1' ' A' ' 49' ' ' GLU . 25.3 pt -108.48 153.26 10.14 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 O-C-N 121.593 -0.945 . . . . 0.0 109.83 -179.331 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -101.77 131.34 48.12 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.077 -1.014 . . . . 0.0 109.667 -179.735 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.503 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -67.65 -27.47 66.89 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.276 -0.89 . . . . 0.0 109.506 179.827 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -55.37 -35.09 64.9 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.156 -0.965 . . . . 0.0 109.971 -179.724 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 54.4 t0 -53.19 -36.96 61.51 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.175 -0.953 . . . . 0.0 109.953 -179.592 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.503 ' O ' ' O ' ' A' ' 56' ' ' ALA . 13.7 p -132.84 143.82 38.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.258 -0.901 . . . . 0.0 109.653 -179.859 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -88.79 134.9 33.78 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.158 -0.964 . . . . 0.0 109.331 179.93 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 67.8 mt -97.16 137.49 36.13 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 121.261 -0.899 . . . . 0.0 109.926 -179.616 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -110.37 157.01 39.36 Favored Pre-proline 0 N--CA 1.487 1.406 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 179.478 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 9.3 Cg_endo -54.08 -23.16 27.7 Favored 'Trans proline' 0 C--N 1.301 -1.955 0 C-N-CA 122.392 2.061 . . . . 0.0 111.675 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -70.31 -27.5 64.43 Favored 'General case' 0 N--CA 1.486 1.344 0 O-C-N 121.338 -0.851 . . . . 0.0 109.447 179.653 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . 0.524 ' C ' ' CD2' ' A' ' 65' ' ' HIS . 0.9 OUTLIER -65.97 -17.89 64.98 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.357 -0.84 . . . . 0.0 109.036 -179.858 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.539 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 10.5 m-85 -98.12 15.1 25.32 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 179.622 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . 0.413 ' HG2' ' H ' ' A' ' 68' ' ' SER . 6.1 ptt180 -49.67 -39.28 35.98 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.77 -0.581 . . . . 0.0 110.225 -179.661 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.488 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 80.1 p -163.39 159.23 22.12 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 120.903 -1.123 . . . . 0.0 110.101 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.408 ' H ' HD12 ' A' ' 69' ' ' ILE . 3.6 mp -57.74 -34.85 48.86 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 N-CA-C 108.211 -1.033 . . . . 0.0 108.211 178.93 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 21.3 mtp180 -57.31 -40.48 77.99 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 15.2 t -63.47 -38.51 91.41 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.401 -0.812 . . . . 0.0 109.51 179.834 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.416 ' CD1' ' NE2' ' A' ' 65' ' ' HIS . 32.4 mm -58.94 -46.73 91.25 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 O-C-N 121.269 -0.894 . . . . 0.0 109.294 -179.845 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 46.7 t0 -59.43 -43.25 93.13 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.21 -0.932 . . . . 0.0 109.102 179.813 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.44 -40.87 89.71 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.552 -0.717 . . . . 0.0 109.78 -179.858 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 69.2 t80 -62.32 -46.42 88.79 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.35 -0.844 . . . . 0.0 109.524 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.531 ' CG1' ' CZ ' ' A' ' 52' ' ' PHE . 53.5 t -61.76 -46.24 96.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 O-C-N 121.235 -0.915 . . . . 0.0 109.337 179.884 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.517 ' O ' ' O ' ' A' ' 81' ' ' THR . 53.4 t -68.62 -42.6 83.44 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 O-C-N 121.262 -0.899 . . . . 0.0 109.329 179.53 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.45 -30.27 64.73 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 110.181 -1.168 . . . . 0.0 110.181 -179.903 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -68.37 -41.23 80.91 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.264 -1.139 . . . . 0.0 111.135 -178.739 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 27.8 p -101.68 -34.59 9.41 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.971 -1.081 . . . . 0.0 110.877 -178.808 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.517 ' O ' ' O ' ' A' ' 77' ' ' VAL . 0.1 OUTLIER . . . . . 0 C--N 1.301 -1.5 0 O-C-N 121.311 -0.868 . . . . 0.0 109.834 -179.274 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 14.1 m-70 . . . . . 0 N--CA 1.496 1.864 0 CA-C-O 121.214 0.531 . . . . 0.0 109.639 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -61.19 -40.08 92.6 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.245 -0.909 . . . . 0.0 109.368 179.852 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.1 p -63.24 -34.05 76.83 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.269 -0.894 . . . . 0.0 109.658 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.406 ' HA ' HE21 ' A' ' 9' ' ' GLN . 55.4 t -62.22 -44.82 99.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.149 -0.969 . . . . 0.0 109.418 179.8 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 77.0 mt -60.13 -41.07 85.29 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 O-C-N 121.371 -0.831 . . . . 0.0 108.934 179.47 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -60.93 -38.87 87.3 Favored 'General case' 0 C--N 1.305 -1.36 0 O-C-N 121.561 -0.712 . . . . 0.0 109.543 -179.912 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . 0.406 HE21 ' HA ' ' A' ' 6' ' ' VAL . 52.1 mt-30 -63.63 -40.8 97.8 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.135 -0.978 . . . . 0.0 110.092 -179.833 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.694 ' CG ' ' CE2' ' A' ' 47' ' ' TRP . 33.7 m-85 -62.05 -50.12 73.25 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.002 -1.062 . . . . 0.0 110.628 -179.357 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 30.0 m -66.43 -41.74 89.22 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 O-C-N 121.006 -1.059 . . . . 0.0 109.18 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.414 ' O ' ' C ' ' A' ' 16' ' ' LEU . 77.0 t -64.02 -45.17 97.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.219 -0.926 . . . . 0.0 109.49 179.436 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -72.25 -23.43 61.21 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.22 -0.925 . . . . 0.0 110.341 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -64.02 -30.02 71.13 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.333 -0.854 . . . . 0.0 110.466 -178.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 71.3 t80 -138.31 -42.29 0.51 Allowed 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.012 -1.055 . . . . 0.0 110.887 -179.391 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.414 ' C ' ' O ' ' A' ' 12' ' ' VAL . 5.2 mt -120.03 80.2 26.39 Favored Pre-proline 0 N--CA 1.493 1.677 0 O-C-N 121.095 -1.003 . . . . 0.0 110.397 -179.119 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -74.77 -14.5 21.71 Favored 'Trans proline' 0 C--N 1.309 -1.511 0 C-N-CA 122.337 2.024 . . . . 0.0 112.319 179.463 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -91.59 8.87 34.63 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.22 -0.925 . . . . 0.0 109.954 -179.666 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 48.8 t -110.87 135.55 49.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.281 -0.887 . . . . 0.0 109.742 -179.815 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.67 119.21 73.99 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.298 -0.877 . . . . 0.0 109.305 179.86 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_exo -51.36 -27.23 23.23 Favored 'Trans proline' 0 N--CA 1.494 1.507 0 C-N-CA 121.781 1.654 . . . . 0.0 112.01 179.676 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.8 -25.24 67.83 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.259 -0.901 . . . . 0.0 109.253 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.411 ' O ' ' OD1' ' A' ' 23' ' ' ASP . 58.6 t0 -81.8 7.35 12.92 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.362 -0.837 . . . . 0.0 109.693 -179.863 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 11.8 t -101.89 133.11 46.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.192 -0.943 . . . . 0.0 109.303 -179.851 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.418 ' C ' ' H ' ' A' ' 27' ' ' ASP . 86.9 m-20 -88.34 120.68 29.94 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.148 -0.97 . . . . 0.0 109.131 179.385 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 29.9 m -71.39 4.47 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 O-C-N 121.122 -0.987 . . . . 0.0 109.107 179.651 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.418 ' H ' ' C ' ' A' ' 25' ' ' ASP . 92.2 m-20 -95.38 0.21 53.26 Favored 'General case' 0 N--CA 1.485 1.32 0 O-C-N 121.397 -0.814 . . . . 0.0 109.094 179.549 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 46.0 tp -100.68 132.97 45.8 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.409 -0.807 . . . . 0.0 109.331 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.7 m-20 -68.78 138.06 54.51 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.285 -0.885 . . . . 0.0 109.822 -179.549 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 90.5 mt -65.5 -38.88 90.99 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.365 -0.834 . . . . 0.0 110.817 -179.899 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 75.6 t -66.08 -38.6 82.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 120.972 -1.08 . . . . 0.0 110.671 -178.737 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -52.91 -34.02 53.1 Favored 'General case' 0 N--CA 1.489 1.475 0 N-CA-C 108.122 -1.066 . . . . 0.0 108.122 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 97.4 m-20 -71.05 -34.65 71.44 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.643 -0.661 . . . . 0.0 109.927 179.513 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 82.03 4.06 90.38 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 108.754 -1.738 . . . . 0.0 108.754 -179.205 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 70.2 t -62.7 -32.9 57.17 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 O-C-N 121.526 -0.984 . . . . 0.0 108.894 179.612 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 81.1 mt -88.57 121.24 38.58 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.368 0 O-C-N 121.318 -0.864 . . . . 0.0 110.041 -179.838 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -115.82 -159.68 0.72 Allowed 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 108.966 -0.753 . . . . 0.0 108.966 179.697 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -67.77 -54.27 20.55 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.134 -0.979 . . . . 0.0 108.959 179.691 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 43.1 mt -67.08 -32.57 73.84 Favored 'General case' 0 C--N 1.303 -1.414 0 N-CA-C 107.189 -1.412 . . . . 0.0 107.189 178.447 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -58.74 -40.4 94.89 Favored Glycine 0 N--CA 1.48 1.611 0 N-CA-C 108.465 -1.854 . . . . 0.0 108.465 179.308 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.0 tt -65.45 -42.21 92.61 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 121.578 -0.954 . . . . 0.0 108.916 178.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.5 tp -60.47 -45.83 92.31 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.429 -0.795 . . . . 0.0 109.173 179.605 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 59.9 mttp -59.69 -35.59 74.8 Favored 'General case' 0 C--N 1.297 -1.712 0 O-C-N 121.547 -0.721 . . . . 0.0 109.618 -179.727 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 54.7 t -61.68 -49.71 83.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.357 -0.839 . . . . 0.0 110.071 -179.519 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.531 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 3.3 mp -68.0 -31.83 53.6 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 O-C-N 121.281 -0.887 . . . . 0.0 110.811 -179.659 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.99 -49.99 65.87 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 120.799 -1.188 . . . . 0.0 111.359 -178.2 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . 0.694 ' CE2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -81.17 -44.94 17.13 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.774 -1.204 . . . . 0.0 110.046 -179.385 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.456 ' N ' ' CG ' ' A' ' 47' ' ' TRP . 22.4 tp -58.58 -42.07 87.16 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 121.326 -0.859 . . . . 0.0 110.095 -178.858 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.531 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 2.3 pp20? -72.59 -36.54 68.18 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.195 -0.941 . . . . 0.0 109.777 -179.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . 0.402 ' N ' ' CG ' ' A' ' 49' ' ' GLU . 55.9 t0 -60.3 -38.27 83.15 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.24 -0.913 . . . . 0.0 110.713 -179.463 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 77.0 mtp180 -61.81 -38.64 88.87 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.195 -0.941 . . . . 0.0 111.738 -178.581 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.551 ' CE1' ' CG1' ' A' ' 76' ' ' VAL . 87.7 m-85 -97.93 -9.39 26.32 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.803 -1.186 . . . . 0.0 110.482 -178.951 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 70.92 31.44 67.05 Favored Glycine 0 N--CA 1.487 2.092 0 N-CA-C 108.703 -1.759 . . . . 0.0 108.703 179.824 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.485 ' O ' ' OE1' ' A' ' 49' ' ' GLU . 26.4 pt -107.24 153.27 8.52 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.367 0 O-C-N 121.703 -0.881 . . . . 0.0 109.787 -179.392 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -99.23 134.04 42.66 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.12 -0.988 . . . . 0.0 109.806 -179.551 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.511 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -68.21 -22.99 64.77 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.312 -0.867 . . . . 0.0 109.533 179.725 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -54.71 -35.65 63.86 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.266 -0.896 . . . . 0.0 109.961 -179.626 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -55.66 -39.53 71.05 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.202 -0.936 . . . . 0.0 110.019 -179.65 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.511 ' O ' ' O ' ' A' ' 56' ' ' ALA . 13.9 p -136.3 142.31 38.9 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.291 -0.881 . . . . 0.0 109.685 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -91.92 133.39 35.73 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.029 -1.044 . . . . 0.0 109.275 179.736 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 32.5 mt -97.92 138.75 34.78 Favored 'General case' 0 C--N 1.305 -1.363 0 O-C-N 121.332 -0.855 . . . . 0.0 109.661 -179.613 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -110.09 157.11 38.81 Favored Pre-proline 0 N--CA 1.487 1.42 0 N-CA-C 108.952 -0.758 . . . . 0.0 108.952 179.518 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_endo -54.01 -24.52 32.65 Favored 'Trans proline' 0 C--N 1.302 -1.91 0 C-N-CA 122.536 2.157 . . . . 0.0 111.567 179.891 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -71.23 -27.78 63.72 Favored 'General case' 0 C--N 1.306 -1.307 0 O-C-N 121.365 -0.834 . . . . 0.0 109.531 179.825 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . 0.525 ' NE2' ' CB ' ' A' ' 75' ' ' PHE . 8.2 t-80 -65.76 -20.3 66.21 Favored 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.185 -0.947 . . . . 0.0 108.975 -179.738 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.502 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 21.9 m-85 -91.36 16.54 9.93 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 179.901 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . 0.453 ' NE ' ' CB ' ' A' ' 71' ' ' SER . 7.7 ptt180 -50.07 -37.24 32.62 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.808 -0.557 . . . . 0.0 110.254 -179.753 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.401 ' O ' ' OG ' ' A' ' 71' ' ' SER . 19.0 t -163.15 157.65 20.81 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.977 -1.077 . . . . 0.0 110.29 -179.626 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.423 ' CD1' ' H ' ' A' ' 69' ' ' ILE . 2.0 mp -58.03 -39.31 71.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.424 -0.797 . . . . 0.0 109.266 179.862 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 7.6 ptm180 -58.03 -40.68 81.49 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.574 -0.704 . . . . 0.0 109.452 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' SER . . . . . 0.453 ' CB ' ' NE ' ' A' ' 67' ' ' ARG . 83.5 p -65.14 -37.16 86.54 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.325 -0.859 . . . . 0.0 109.722 179.914 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 75.3 mt -64.86 -44.94 96.24 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.268 0 O-C-N 121.245 -0.91 . . . . 0.0 109.809 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 40.4 t0 -59.75 -41.7 91.57 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.291 -0.88 . . . . 0.0 109.396 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.75 -43.86 83.02 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.405 -0.81 . . . . 0.0 110.084 -179.777 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . 0.525 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 56.8 t80 -62.1 -46.52 88.69 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.338 -0.851 . . . . 0.0 109.537 -179.764 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.551 ' CG1' ' CE1' ' A' ' 52' ' ' PHE . 99.2 t -61.67 -44.43 98.69 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.394 0 O-C-N 121.269 -0.895 . . . . 0.0 109.027 179.92 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.522 ' O ' ' O ' ' A' ' 81' ' ' THR . 53.3 t -66.64 -43.22 90.48 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 121.374 -0.829 . . . . 0.0 109.255 179.554 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.81 -23.15 49.82 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.771 -1.332 . . . . 0.0 109.771 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.05 -28.88 68.57 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.259 -1.142 . . . . 0.0 110.353 -179.475 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 9.8 p -129.65 -32.73 1.9 Allowed 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.128 -0.983 . . . . 0.0 110.752 -179.274 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.522 ' O ' ' O ' ' A' ' 77' ' ' VAL . 0.1 OUTLIER . . . . . 0 N--CA 1.489 1.498 0 O-C-N 121.188 -0.945 . . . . 0.0 109.682 -179.396 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 46.0 m80 . . . . . 0 N--CA 1.485 1.322 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -55.81 -39.77 71.81 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.392 -0.817 . . . . 0.0 109.562 -179.433 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.1 m -60.75 -36.33 78.63 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.213 -0.93 . . . . 0.0 109.553 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 75.8 t -63.3 -45.67 97.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.21 -0.932 . . . . 0.0 109.45 -179.895 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 78.8 mt -59.69 -45.6 94.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.373 -0.829 . . . . 0.0 108.799 179.622 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -62.21 -35.27 78.38 Favored 'General case' 0 C--N 1.304 -1.374 0 N-CA-C 108.763 -0.828 . . . . 0.0 108.763 179.5 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 32.5 tt0 -59.97 -38.37 82.32 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.259 -0.901 . . . . 0.0 109.472 179.733 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.65 ' CG ' ' CZ2' ' A' ' 47' ' ' TRP . 44.0 m-85 -70.17 -47.74 60.31 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.971 -1.081 . . . . 0.0 111.205 -179.551 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.516 ' CG2' ' N ' ' A' ' 12' ' ' VAL . 0.9 OUTLIER -61.64 -46.88 95.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 120.881 -1.137 . . . . 0.0 110.312 -178.143 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.592 ' O ' ' N ' ' A' ' 16' ' ' LEU . 35.5 m -64.75 -46.0 93.46 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.394 0 O-C-N 120.799 -1.188 . . . . 0.0 109.552 179.758 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -64.55 -26.96 68.64 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 120.813 -1.179 . . . . 0.0 109.737 179.798 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -64.43 -31.47 72.69 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.445 -0.785 . . . . 0.0 110.14 -179.479 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 86.6 t80 -142.84 -33.31 0.46 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.981 -1.074 . . . . 0.0 110.794 -179.436 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.592 ' N ' ' O ' ' A' ' 12' ' ' VAL . 3.4 mt -121.95 79.8 41.95 Favored Pre-proline 0 N--CA 1.492 1.66 0 O-C-N 121.07 -1.019 . . . . 0.0 109.976 -179.32 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -76.07 -18.54 16.42 Favored 'Trans proline' 0 C--N 1.309 -1.507 0 C-N-CA 122.537 2.158 . . . . 0.0 112.873 -179.756 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.442 ' C ' ' OD1' ' A' ' 18' ' ' ASP . 50.4 p30 -89.43 12.86 15.18 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.031 -1.043 . . . . 0.0 110.131 -179.565 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 84.1 t -106.79 134.41 48.52 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.187 -0.946 . . . . 0.0 109.574 179.669 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.06 118.45 65.74 Favored Pre-proline 0 N--CA 1.488 1.443 0 O-C-N 121.323 -0.861 . . . . 0.0 108.918 179.634 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -51.31 -36.41 57.2 Favored 'Trans proline' 0 N--CA 1.492 1.389 0 C-N-CA 121.571 1.514 . . . . 0.0 111.912 179.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -68.58 -18.56 64.36 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.246 -0.909 . . . . 0.0 108.885 179.386 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.451 ' O ' ' OD1' ' A' ' 23' ' ' ASP . 60.4 t0 -81.97 7.11 13.94 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.479 -0.763 . . . . 0.0 109.91 -179.644 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 15.1 t -104.56 131.66 53.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.167 -0.958 . . . . 0.0 109.433 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 62.4 t0 -88.44 119.68 29.11 Favored 'General case' 0 C--N 1.303 -1.445 0 O-C-N 121.213 -0.929 . . . . 0.0 108.689 179.256 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.2 m -75.29 3.18 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 O-C-N 121.138 -0.977 . . . . 0.0 109.484 -179.886 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -85.49 -19.18 31.6 Favored 'General case' 0 N--CA 1.487 1.375 0 O-C-N 121.137 -0.977 . . . . 0.0 109.116 179.368 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 48.7 tp -88.84 134.04 34.07 Favored 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 108.541 -0.911 . . . . 0.0 108.541 179.552 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 89.1 m-20 -60.37 135.12 57.64 Favored 'General case' 0 C--N 1.301 -1.539 0 C-N-CA 119.185 -1.006 . . . . 0.0 109.2 -179.423 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.473 ' H ' ' HA ' ' A' ' 68' ' ' SER . 39.0 tp -62.59 -36.42 82.68 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.509 -0.745 . . . . 0.0 110.257 -179.322 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 69.2 t -64.22 -35.76 74.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.047 -1.033 . . . . 0.0 110.466 -179.384 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -52.62 -33.72 47.88 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 97.1 m-20 -70.82 -34.55 71.83 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.606 -0.684 . . . . 0.0 110.001 179.468 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 85.71 5.16 84.53 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 108.858 -1.697 . . . . 0.0 108.858 -179.324 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 73.6 t -61.7 -33.05 55.72 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 121.554 -0.968 . . . . 0.0 108.979 179.678 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 80.2 mt -83.68 114.47 24.33 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.411 0 O-C-N 121.339 -0.851 . . . . 0.0 109.723 -179.728 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -112.6 -178.82 3.49 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 179.542 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -58.82 -52.3 66.29 Favored 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 108.245 -1.021 . . . . 0.0 108.245 179.7 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 42.3 mt -70.28 -32.65 70.53 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 106.849 -1.538 . . . . 0.0 106.849 177.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -59.27 -41.01 96.61 Favored Glycine 0 N--CA 1.481 1.67 0 N-CA-C 108.525 -1.83 . . . . 0.0 108.525 179.14 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 2.9 tt -64.87 -44.49 89.52 Favored 'General case' 0 C--N 1.305 -1.35 0 O-C-N 121.636 -0.92 . . . . 0.0 109.212 179.096 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 16.7 tp -59.55 -44.78 93.14 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.353 -0.842 . . . . 0.0 109.578 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 31.7 mttp -62.05 -34.81 76.93 Favored 'General case' 0 C--N 1.298 -1.669 0 O-C-N 121.076 -1.015 . . . . 0.0 109.541 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 69.4 t -61.2 -48.63 88.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.387 -0.821 . . . . 0.0 109.993 -179.528 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.541 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 3.0 mp -67.84 -32.44 56.51 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.515 0 O-C-N 121.405 -0.81 . . . . 0.0 110.948 -179.677 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.43 -50.36 63.64 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 120.982 -1.074 . . . . 0.0 111.373 -178.112 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . 0.65 ' CZ2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -81.18 -44.62 17.57 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 120.708 -1.245 . . . . 0.0 109.853 -179.502 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.5 ' N ' ' CG ' ' A' ' 47' ' ' TRP . 38.9 tp -58.55 -42.26 87.45 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.332 -0.855 . . . . 0.0 109.958 -179.022 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.541 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 1.2 pp20? -72.63 -35.85 67.91 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.0 -1.063 . . . . 0.0 109.635 179.887 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.1 t0 -60.2 -38.25 82.73 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.237 -0.914 . . . . 0.0 110.288 -179.77 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 71.9 mtp85 -61.19 -38.12 85.4 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.244 -0.91 . . . . 0.0 111.16 -178.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.476 ' CE2' ' CG1' ' A' ' 76' ' ' VAL . 86.6 m-85 -99.53 -10.36 22.18 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 120.859 -1.151 . . . . 0.0 110.031 -179.388 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 69.98 33.49 70.14 Favored Glycine 0 N--CA 1.486 2.027 0 N-CA-C 108.558 -1.817 . . . . 0.0 108.558 179.856 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.429 HD13 HG23 ' A' ' 54' ' ' ILE . 38.5 pt -103.08 149.06 7.44 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 O-C-N 121.535 -0.979 . . . . 0.0 109.994 -179.239 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -94.2 120.1 33.96 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.3 -0.875 . . . . 0.0 109.459 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.492 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -66.65 -28.99 68.91 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.403 -0.81 . . . . 0.0 109.495 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 54.6 t0 -56.41 -35.03 67.34 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.387 -0.821 . . . . 0.0 110.249 -179.453 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -53.75 -39.11 65.07 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.055 -1.028 . . . . 0.0 109.65 -179.582 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.492 ' O ' ' O ' ' A' ' 56' ' ' ALA . 46.5 t -127.46 136.57 60.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.521 -0.737 . . . . 0.0 109.544 179.851 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -85.5 128.43 34.74 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.119 -0.988 . . . . 0.0 108.765 179.547 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 54.8 mt -98.46 141.21 31.61 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.142 -0.974 . . . . 0.0 109.997 -179.158 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -105.55 151.15 39.72 Favored Pre-proline 0 C--N 1.305 -1.361 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 179.403 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -53.67 -21.87 20.89 Favored 'Trans proline' 0 C--N 1.306 -1.659 0 C-N-CA 122.227 1.951 . . . . 0.0 111.998 -179.54 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -70.07 -28.27 65.29 Favored 'General case' 0 N--CA 1.486 1.351 0 O-C-N 121.265 -0.897 . . . . 0.0 109.586 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . 0.586 ' CD2' ' O ' ' A' ' 65' ' ' HIS . 6.5 t-160 -65.72 -20.93 66.46 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.259 -0.901 . . . . 0.0 109.277 -179.713 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.542 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 7.8 m-85 -96.51 15.99 19.96 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.525 -0.734 . . . . 0.0 109.078 -179.65 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . 0.4 ' HG2' ' H ' ' A' ' 68' ' ' SER . 1.3 ptt85 -54.36 -35.93 63.3 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.645 -0.659 . . . . 0.0 110.243 -179.765 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.473 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 90.4 p -157.54 160.38 38.13 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 120.912 -1.117 . . . . 0.0 110.287 -179.95 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.413 HD11 ' H ' ' A' ' 69' ' ' ILE . 3.1 mp -59.14 -34.03 52.26 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 179.007 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 57.6 mtp85 -56.95 -42.9 80.92 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.707 -0.621 . . . . 0.0 109.948 -179.266 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' SER . . . . . 0.55 ' HG ' ' N ' ' A' ' 72' ' ' ILE . 78.8 p -68.71 -35.82 77.65 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.298 -0.876 . . . . 0.0 110.115 -179.601 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.55 ' N ' ' HG ' ' A' ' 71' ' ' SER . 56.3 mt -65.93 -48.51 81.65 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 O-C-N 121.216 -0.928 . . . . 0.0 110.122 -179.38 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 43.9 t0 -60.17 -43.16 96.03 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.18 -0.95 . . . . 0.0 109.49 -179.757 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.95 -43.63 82.66 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.494 -0.754 . . . . 0.0 110.251 -179.579 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . 0.553 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 70.4 t80 -62.51 -45.29 93.66 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.263 -0.898 . . . . 0.0 109.697 -179.641 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.476 ' CG1' ' CE2' ' A' ' 52' ' ' PHE . 95.9 t -64.84 -47.06 90.0 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.361 0 O-C-N 121.206 -0.934 . . . . 0.0 109.665 -179.945 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 54.9 t -69.53 -45.98 76.93 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.329 0 O-C-N 121.1 -1.0 . . . . 0.0 109.731 179.857 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.48 ' O ' ' O ' ' A' ' 81' ' ' THR . . . -63.9 -30.73 78.55 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 110.307 -1.117 . . . . 0.0 110.307 -179.633 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -66.81 -39.53 87.74 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.137 -1.214 . . . . 0.0 110.516 -179.019 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 65.2 p -84.18 -28.81 27.09 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.036 -1.04 . . . . 0.0 109.778 -179.727 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.48 ' O ' ' O ' ' A' ' 78' ' ' GLY . 0.3 OUTLIER . . . . . 0 C--N 1.302 -1.471 0 O-C-N 121.478 -0.764 . . . . 0.0 109.737 -179.546 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 20.8 m170 . . . . . 0 N--CA 1.493 1.696 0 CA-C-O 121.12 0.486 . . . . 0.0 109.926 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -61.99 -33.05 73.61 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.141 -0.974 . . . . 0.0 109.547 179.856 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.3 t -57.86 -37.56 74.13 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.284 -0.885 . . . . 0.0 109.879 -179.497 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 77.2 t -63.52 -45.41 97.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.169 -0.957 . . . . 0.0 109.514 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 77.7 mt -60.06 -42.72 90.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.405 -0.809 . . . . 0.0 109.096 179.727 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -60.89 -35.83 77.65 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.54 -0.725 . . . . 0.0 109.224 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 30.9 tt0 -64.62 -41.77 95.97 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.234 -0.916 . . . . 0.0 110.191 -179.839 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.679 ' CG ' ' CZ2' ' A' ' 47' ' ' TRP . 37.4 m-85 -64.28 -50.62 67.16 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.975 -1.078 . . . . 0.0 110.719 -179.371 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 4.5 p -63.57 -41.0 91.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.047 -1.033 . . . . 0.0 109.383 -179.575 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.445 ' O ' ' C ' ' A' ' 16' ' ' LEU . 70.5 t -63.31 -46.34 95.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.121 -0.987 . . . . 0.0 109.339 179.558 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -71.13 -26.09 62.86 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.25 -0.906 . . . . 0.0 109.846 179.715 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -64.45 -30.61 71.65 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.46 -0.775 . . . . 0.0 110.664 -179.029 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 72.9 t80 -135.82 -42.9 0.67 Allowed 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.016 -1.053 . . . . 0.0 110.826 -179.084 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.445 ' C ' ' O ' ' A' ' 12' ' ' VAL . 4.2 mt -119.49 80.09 21.96 Favored Pre-proline 0 N--CA 1.493 1.723 0 O-C-N 121.088 -1.008 . . . . 0.0 110.377 -179.094 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -75.53 -14.13 20.13 Favored 'Trans proline' 0 C--N 1.309 -1.522 0 C-N-CA 122.292 1.995 . . . . 0.0 112.217 179.404 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.42 ' OD1' ' O ' ' A' ' 18' ' ' ASP . 59.9 t0 -89.55 7.02 38.4 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.274 -0.891 . . . . 0.0 109.683 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.401 ' CG1' ' OD2' ' A' ' 23' ' ' ASP . 46.1 t -111.76 135.44 51.0 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.432 -0.793 . . . . 0.0 109.651 -179.859 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . 0.468 ' O ' ' OD1' ' A' ' 23' ' ' ASP . . . -73.49 117.88 64.26 Favored Pre-proline 0 N--CA 1.489 1.514 0 O-C-N 121.304 -0.872 . . . . 0.0 109.325 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_exo -51.45 -25.53 19.14 Favored 'Trans proline' 0 N--CA 1.493 1.47 0 C-N-CA 121.858 1.705 . . . . 0.0 112.192 179.568 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.03 -23.67 67.26 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.307 -0.871 . . . . 0.0 109.739 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.468 ' OD1' ' O ' ' A' ' 20' ' ' ALA . 52.5 p30 -84.6 7.75 19.12 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.222 -0.924 . . . . 0.0 110.024 -179.635 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 10.9 t -104.57 131.39 53.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.192 -0.942 . . . . 0.0 109.397 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 87.6 m-20 -89.43 120.5 30.81 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.213 -0.93 . . . . 0.0 109.091 179.369 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.0 m -78.83 3.38 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 O-C-N 121.153 -0.967 . . . . 0.0 109.095 179.53 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 89.8 m-20 -83.5 -20.65 33.56 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 121.291 -0.881 . . . . 0.0 109.135 179.33 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 43.2 tp -88.69 137.9 31.9 Favored 'General case' 0 N--CA 1.487 1.41 0 N-CA-C 108.844 -0.798 . . . . 0.0 108.844 179.798 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 89.1 m-20 -57.33 136.27 56.55 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 121.158 -0.964 . . . . 0.0 109.35 -179.454 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.469 ' H ' ' HA ' ' A' ' 68' ' ' SER . 1.9 tt -66.0 -37.95 87.22 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.716 -0.615 . . . . 0.0 110.171 -179.179 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 69.9 t -63.14 -35.19 70.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.068 -1.02 . . . . 0.0 110.421 -178.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 90.8 m-20 -52.66 -33.89 49.18 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 108.062 -1.088 . . . . 0.0 108.062 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 97.5 m-20 -71.11 -34.62 71.27 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.571 -0.706 . . . . 0.0 109.864 179.488 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 84.4 6.83 85.59 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 108.962 -1.655 . . . . 0.0 108.962 -179.474 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 71.1 t -61.88 -35.03 65.65 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 O-C-N 121.392 -1.064 . . . . 0.0 108.95 179.74 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 99.1 mt -80.17 111.94 17.57 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.318 -0.864 . . . . 0.0 109.807 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -113.02 -166.02 1.04 Allowed 'General case' 0 C--N 1.302 -1.458 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 179.777 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -65.18 -54.38 30.55 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.146 -0.971 . . . . 0.0 108.71 179.712 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 34.0 mt -70.57 -33.29 70.94 Favored 'General case' 0 C--N 1.302 -1.489 0 N-CA-C 107.213 -1.402 . . . . 0.0 107.213 178.4 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -59.4 -41.18 96.89 Favored Glycine 0 N--CA 1.48 1.589 0 N-CA-C 108.61 -1.796 . . . . 0.0 108.61 179.205 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.7 tt -65.68 -41.55 92.29 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.519 -0.989 . . . . 0.0 109.085 179.201 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.5 tp -61.22 -46.03 92.11 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.434 -0.791 . . . . 0.0 109.361 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 63.5 mttp -60.28 -35.91 76.62 Favored 'General case' 0 C--N 1.296 -1.733 0 O-C-N 121.443 -0.786 . . . . 0.0 109.452 -179.708 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 63.2 t -62.18 -45.82 97.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.357 -0.839 . . . . 0.0 109.668 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.5 mp -67.96 -39.44 81.63 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 O-C-N 121.555 -0.716 . . . . 0.0 111.262 -179.375 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.09 -49.92 63.41 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.545 -1.347 . . . . 0.0 112.268 -177.603 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . 0.679 ' CZ2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -77.85 -46.05 22.55 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 120.637 -1.29 . . . . 0.0 110.681 -178.546 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.555 ' CD1' HH21 ' A' ' 51' ' ' ARG . 8.8 tp -58.65 -44.59 90.16 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.173 -0.955 . . . . 0.0 110.195 -178.825 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 65.4 mm-40 -69.93 -36.21 75.14 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.135 -0.978 . . . . 0.0 109.797 -179.667 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.3 t0 -62.24 -38.43 89.19 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.367 -0.833 . . . . 0.0 111.431 -179.2 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . 0.555 HH21 ' CD1' ' A' ' 48' ' ' LEU . 66.6 mtm180 -59.34 -38.92 81.58 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.023 -1.048 . . . . 0.0 111.574 -178.392 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.61 ' CE1' ' CG1' ' A' ' 76' ' ' VAL . 48.7 m-85 -90.14 -2.61 58.1 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 120.759 -1.213 . . . . 0.0 110.544 -179.199 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 73.98 29.2 63.19 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 108.797 -1.721 . . . . 0.0 108.797 179.546 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 31.4 pt -113.1 153.47 14.66 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 O-C-N 121.694 -0.886 . . . . 0.0 109.758 -179.397 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -101.83 138.76 38.37 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.255 -0.903 . . . . 0.0 109.426 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.506 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -64.65 -30.61 71.63 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.298 -0.876 . . . . 0.0 109.681 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 53.8 t0 -55.48 -36.02 66.17 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.132 -0.98 . . . . 0.0 109.827 -179.74 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -57.36 -39.89 76.94 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.199 -0.938 . . . . 0.0 110.169 -179.561 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.506 ' O ' ' O ' ' A' ' 56' ' ' ALA . 13.6 p -136.51 142.15 39.07 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.272 -0.892 . . . . 0.0 109.783 -179.941 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -101.71 137.02 40.57 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.156 -0.965 . . . . 0.0 109.433 179.815 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 5.5 mp -103.27 144.06 31.84 Favored 'General case' 0 C--N 1.305 -1.34 0 O-C-N 121.256 -0.902 . . . . 0.0 109.732 -179.843 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -103.34 153.13 38.7 Favored Pre-proline 0 C--N 1.305 -1.351 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 179.81 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 8.5 Cg_endo -53.75 -24.54 30.78 Favored 'Trans proline' 0 C--N 1.306 -1.665 0 C-N-CA 122.264 1.976 . . . . 0.0 111.82 -179.832 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -70.42 -28.39 65.01 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 121.392 -0.818 . . . . 0.0 109.257 179.69 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . 0.524 ' NE2' ' CB ' ' A' ' 75' ' ' PHE . 7.6 t-80 -66.02 -20.04 66.05 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 121.375 -0.828 . . . . 0.0 109.027 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.516 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 15.5 m-85 -91.98 15.1 13.93 Favored 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . 0.536 ' CZ ' ' OG ' ' A' ' 71' ' ' SER . 7.2 ptt180 -48.6 -37.33 17.79 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.7 -0.625 . . . . 0.0 109.866 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.469 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 92.4 p -159.55 155.86 27.08 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.092 -1.005 . . . . 0.0 109.919 179.811 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.419 HD13 ' H ' ' A' ' 69' ' ' ILE . 3.5 mp -58.58 -34.83 52.36 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 179.045 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 58.6 mtp180 -57.44 -43.25 83.73 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.67 -0.644 . . . . 0.0 109.462 -179.76 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' SER . . . . . 0.536 ' OG ' ' CZ ' ' A' ' 67' ' ' ARG . 22.7 t -65.54 -39.9 92.27 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.465 -0.772 . . . . 0.0 109.81 179.935 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 68.5 mt -61.02 -46.41 96.7 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.313 0 O-C-N 121.313 -0.867 . . . . 0.0 110.109 -179.541 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 39.4 t0 -60.28 -42.88 96.38 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.176 -0.952 . . . . 0.0 109.364 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . 0.429 ' O ' ' N ' ' A' ' 78' ' ' GLY . . . -67.13 -41.94 85.29 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.427 -0.796 . . . . 0.0 110.466 -179.708 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . 0.524 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 62.5 t80 -62.05 -45.72 92.3 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.103 -0.998 . . . . 0.0 109.637 -179.563 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.61 ' CG1' ' CE1' ' A' ' 52' ' ' PHE . 69.9 t -67.12 -48.7 78.07 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 O-C-N 121.245 -0.909 . . . . 0.0 110.014 -179.853 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 78.3 t -70.0 -43.35 79.37 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.338 0 O-C-N 121.109 -0.994 . . . . 0.0 109.571 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.429 ' N ' ' O ' ' A' ' 74' ' ' ALA . . . -61.11 -34.04 86.44 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 110.436 -1.066 . . . . 0.0 110.436 -179.461 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.78 -41.28 83.47 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.262 -1.14 . . . . 0.0 111.051 -178.692 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 49.4 p -82.79 -32.75 27.53 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.04 -1.038 . . . . 0.0 109.679 -179.511 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.301 -1.53 0 O-C-N 121.468 -0.77 . . . . 0.0 109.626 -179.383 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 93.6 m-70 . . . . . 0 N--CA 1.49 1.541 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -62.1 -34.71 76.83 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.229 -0.919 . . . . 0.0 109.634 -179.871 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.2 m -59.38 -38.9 81.68 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.293 -0.88 . . . . 0.0 109.864 -179.617 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 51.8 t -66.97 -46.34 85.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.121 -0.987 . . . . 0.0 109.742 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 87.3 mt -59.81 -50.27 80.7 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.456 0 O-C-N 121.379 -0.826 . . . . 0.0 109.847 -179.617 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.76 -42.3 97.85 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.272 -0.892 . . . . 0.0 110.78 -179.664 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 47.3 tt0 -69.41 -47.59 63.68 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 120.976 -1.078 . . . . 0.0 111.043 -178.582 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.688 ' CD1' ' N ' ' A' ' 11' ' ' VAL . 0.0 OUTLIER -71.66 -44.14 64.8 Favored 'General case' 0 C--N 1.298 -1.659 0 O-C-N 120.921 -1.112 . . . . 0.0 110.815 -179.226 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.688 ' N ' ' CD1' ' A' ' 10' ' ' PHE . 5.2 p -61.02 -47.84 91.78 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 120.996 -1.065 . . . . 0.0 110.692 -178.711 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.535 ' N ' ' CG1' ' A' ' 11' ' ' VAL . 8.6 p -63.62 -39.14 84.25 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 120.805 -1.184 . . . . 0.0 109.817 -179.686 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -65.78 -36.17 82.77 Favored 'General case' 0 N--CA 1.486 1.33 0 O-C-N 120.93 -1.106 . . . . 0.0 110.131 -179.919 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -65.95 -42.41 90.02 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.166 -0.959 . . . . 0.0 110.196 -179.694 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 86.5 m-85 -91.47 -45.04 8.75 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.183 -0.948 . . . . 0.0 110.512 -179.691 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.465 ' N ' ' O ' ' A' ' 12' ' ' VAL . 8.5 mt -122.31 80.22 45.13 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.421 -0.799 . . . . 0.0 110.223 -178.942 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_endo -70.17 -15.47 35.55 Favored 'Trans proline' 0 C--N 1.312 -1.373 0 C-N-CA 122.099 1.866 . . . . 0.0 112.333 179.704 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -96.07 9.74 39.86 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.163 -0.961 . . . . 0.0 110.229 -179.581 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 44.3 t -114.73 135.28 55.09 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.239 -0.913 . . . . 0.0 109.837 -179.782 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -74.71 118.69 72.13 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.349 -0.844 . . . . 0.0 109.122 179.743 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_exo -51.17 -36.89 57.38 Favored 'Trans proline' 0 N--CA 1.493 1.444 0 C-N-CA 121.765 1.643 . . . . 0.0 112.008 179.635 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.71 -23.0 66.06 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.282 -0.886 . . . . 0.0 108.948 179.471 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 87.6 m-20 -87.98 7.13 32.55 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.406 -0.809 . . . . 0.0 109.872 -179.729 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 10.6 t -107.07 128.49 61.91 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.188 -0.945 . . . . 0.0 109.406 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 86.9 m-20 -89.81 120.29 30.92 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.137 -0.977 . . . . 0.0 109.169 179.275 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.4 m -78.87 3.36 1.74 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.465 0 O-C-N 121.125 -0.985 . . . . 0.0 108.741 179.321 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 90.5 m-20 -83.59 -19.4 35.61 Favored 'General case' 0 N--CA 1.486 1.358 0 O-C-N 121.545 -0.722 . . . . 0.0 109.073 179.392 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 42.8 tp -88.94 138.01 31.8 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 121.481 -0.762 . . . . 0.0 109.024 179.863 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -58.61 136.92 57.75 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.11 -0.993 . . . . 0.0 109.517 -179.376 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.485 ' H ' ' HA ' ' A' ' 68' ' ' SER . 2.4 tt -66.46 -38.0 86.38 Favored 'General case' 0 C--N 1.299 -1.613 0 O-C-N 121.757 -0.59 . . . . 0.0 110.134 -179.232 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 75.7 t -62.55 -34.72 66.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.121 -0.987 . . . . 0.0 110.436 -178.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -52.45 -33.97 46.73 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 120.975 -1.078 . . . . 0.0 108.104 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 97.2 m-20 -71.08 -34.46 71.19 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.643 -0.66 . . . . 0.0 109.949 179.389 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 85.37 6.52 83.85 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 -179.446 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 76.3 t -61.52 -34.49 61.82 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.438 -1.036 . . . . 0.0 109.094 179.695 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 93.9 mt -83.14 114.4 23.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.274 -0.891 . . . . 0.0 109.735 -179.876 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -118.66 -158.41 0.72 Allowed 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 179.657 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -64.78 -54.15 35.81 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.046 -1.034 . . . . 0.0 108.506 179.631 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.597 ' CD2' ' N ' ' A' ' 39' ' ' LEU . 1.5 mm? -68.74 -32.52 72.36 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 107.32 -1.363 . . . . 0.0 107.32 178.264 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -58.79 -45.94 94.18 Favored Glycine 0 N--CA 1.483 1.781 0 N-CA-C 109.06 -1.616 . . . . 0.0 109.06 179.6 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.9 tt -64.24 -39.06 93.18 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.426 -1.043 . . . . 0.0 108.762 179.035 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.1 tp -59.68 -45.76 91.11 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.311 -0.868 . . . . 0.0 108.798 179.543 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 54.5 mttp -60.2 -35.59 75.74 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.498 -0.751 . . . . 0.0 109.536 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 68.3 t -60.17 -46.89 93.97 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.345 -0.847 . . . . 0.0 109.567 -179.925 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.7 mp -68.22 -33.23 59.52 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 O-C-N 121.359 -0.838 . . . . 0.0 110.802 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.17 -49.1 65.93 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.095 -1.003 . . . . 0.0 111.466 -178.359 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . 0.524 ' CD1' ' C ' ' A' ' 47' ' ' TRP . 0.0 OUTLIER -80.8 -41.51 23.22 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 120.583 -1.323 . . . . 0.0 109.663 -179.548 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 8.3 tt -59.55 -41.78 90.87 Favored 'General case' 0 C--N 1.3 -1.567 0 O-C-N 121.377 -0.827 . . . . 0.0 109.909 -179.331 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.52 ' O ' ' N ' ' A' ' 53' ' ' GLY . 18.4 pt-20 -73.15 -36.92 66.75 Favored 'General case' 0 C--N 1.304 -1.371 0 O-C-N 121.099 -1.001 . . . . 0.0 109.562 -179.817 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . 0.405 ' N ' ' CG ' ' A' ' 49' ' ' GLU . 55.9 t0 -59.06 -38.49 79.5 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.321 -0.862 . . . . 0.0 110.838 -179.319 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 75.1 mtm180 -61.56 -41.18 97.0 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 120.986 -1.072 . . . . 0.0 111.473 -178.649 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.592 ' CE1' ' CG1' ' A' ' 76' ' ' VAL . 36.7 m-85 -105.87 -12.54 15.81 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 120.923 -1.11 . . . . 0.0 110.173 -179.451 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.52 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 70.85 30.45 68.15 Favored Glycine 0 N--CA 1.486 2.017 0 N-CA-C 109.054 -1.618 . . . . 0.0 109.054 179.574 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 16.2 pt -97.82 129.72 47.6 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 O-C-N 121.336 -1.097 . . . . 0.0 109.756 -179.549 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -67.37 135.53 53.37 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.155 -0.966 . . . . 0.0 109.651 -179.666 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.504 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -66.37 -31.5 72.31 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.297 -0.877 . . . . 0.0 109.441 179.804 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 54.2 t0 -56.94 -36.69 70.53 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.277 -0.89 . . . . 0.0 109.999 -179.75 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 54.5 t0 -56.11 -40.38 73.61 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.182 -0.949 . . . . 0.0 109.892 -179.598 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.504 ' O ' ' O ' ' A' ' 56' ' ' ALA . 42.6 t -129.33 134.74 63.23 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.425 -0.797 . . . . 0.0 109.603 179.926 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -91.81 131.06 37.43 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.15 -0.969 . . . . 0.0 109.277 179.763 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 54.6 mt -97.82 139.27 33.92 Favored 'General case' 0 C--N 1.305 -1.327 0 O-C-N 121.297 -0.877 . . . . 0.0 109.674 -179.752 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.611 ' HG ' ' H ' ' A' ' 64' ' ' GLU . 0.1 OUTLIER -110.0 157.12 38.71 Favored Pre-proline 0 N--CA 1.489 1.495 0 N-CA-C 108.849 -0.796 . . . . 0.0 108.849 179.606 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 7.1 Cg_endo -52.83 -22.9 19.1 Favored 'Trans proline' 0 C--N 1.302 -1.903 0 C-N-CA 122.368 2.045 . . . . 0.0 111.72 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . 0.611 ' H ' ' HG ' ' A' ' 62' ' ' SER . 97.1 mt-10 -70.45 -27.52 64.31 Favored 'General case' 0 N--CA 1.485 1.304 0 O-C-N 121.386 -0.821 . . . . 0.0 109.507 179.6 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . 0.566 ' C ' ' CD2' ' A' ' 65' ' ' HIS . 0.7 OUTLIER -65.67 -19.8 66.05 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.315 -0.865 . . . . 0.0 108.95 -179.882 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.551 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 6.0 m-85 -98.25 16.11 22.42 Favored 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 179.839 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . 0.423 ' HG2' ' H ' ' A' ' 68' ' ' SER . 5.3 ptt180 -49.87 -38.49 35.69 Favored 'General case' 0 C--N 1.3 -1.547 0 O-C-N 121.79 -0.569 . . . . 0.0 110.031 -179.798 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.485 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 84.2 p -161.66 157.59 24.76 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.006 -1.059 . . . . 0.0 109.969 179.838 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.402 ' H ' HD12 ' A' ' 69' ' ' ILE . 3.4 mp -57.97 -35.04 50.4 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 179.034 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 59.6 mtp180 -57.51 -42.18 82.29 Favored 'General case' 0 N--CA 1.488 1.427 0 CA-C-O 121.442 0.639 . . . . 0.0 109.291 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 60.5 p -70.46 -36.39 73.88 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.446 -0.784 . . . . 0.0 110.047 -179.707 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 81.0 mt -62.73 -51.35 73.15 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 O-C-N 121.216 -0.928 . . . . 0.0 109.626 -179.636 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 35.0 m-20 -63.24 -42.85 99.27 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.301 -0.875 . . . . 0.0 108.651 179.883 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -67.1 -37.43 83.93 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.571 -0.706 . . . . 0.0 109.891 179.677 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 70.4 t80 -58.87 -47.62 84.28 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.028 -1.045 . . . . 0.0 109.915 -179.387 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.592 ' CG1' ' CE1' ' A' ' 52' ' ' PHE . 76.4 t -68.11 -48.56 73.66 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 O-C-N 121.238 -0.914 . . . . 0.0 110.255 -179.559 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 50.0 t -69.69 -45.27 78.16 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.306 0 O-C-N 121.047 -1.033 . . . . 0.0 109.847 -179.796 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.458 ' O ' ' O ' ' A' ' 81' ' ' THR . . . -61.19 -39.16 96.78 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 110.208 -1.157 . . . . 0.0 110.208 -179.573 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.72 -41.02 84.15 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.189 -1.183 . . . . 0.0 110.366 -179.242 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 49.5 p -82.83 -29.86 29.14 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.05 -1.031 . . . . 0.0 109.691 -179.614 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.458 ' O ' ' O ' ' A' ' 78' ' ' GLY . 0.3 OUTLIER . . . . . 0 C--N 1.303 -1.452 0 O-C-N 121.519 -0.738 . . . . 0.0 109.668 -179.561 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 60.5 m-70 . . . . . 0 N--CA 1.487 1.392 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -58.92 -41.93 88.46 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.542 -0.723 . . . . 0.0 109.746 -179.395 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' SER . . . . . 0.406 ' HG ' ' N ' ' A' ' 6' ' ' VAL . 85.8 p -63.79 -31.35 72.5 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.308 -0.87 . . . . 0.0 109.666 -179.873 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.406 ' N ' ' HG ' ' A' ' 5' ' ' SER . 73.7 t -65.05 -45.26 94.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.182 -0.949 . . . . 0.0 109.432 -179.929 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 76.0 mt -60.25 -43.58 93.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.445 -0.784 . . . . 0.0 109.165 179.771 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -60.33 -35.96 76.86 Favored 'General case' 0 C--N 1.305 -1.369 0 O-C-N 121.499 -0.75 . . . . 0.0 109.23 -179.898 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 7.3 tt0 -64.97 -41.19 95.67 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.22 -0.925 . . . . 0.0 110.142 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.693 ' CG ' ' CZ2' ' A' ' 47' ' ' TRP . 30.2 m-85 -62.6 -50.36 71.57 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.041 -1.037 . . . . 0.0 110.688 -179.381 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 24.9 m -63.82 -41.78 93.69 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 O-C-N 121.062 -1.024 . . . . 0.0 109.343 -179.473 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.453 ' O ' ' C ' ' A' ' 16' ' ' LEU . 71.2 t -63.82 -46.73 93.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.138 -0.976 . . . . 0.0 109.351 179.498 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -70.4 -29.0 65.52 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.226 -0.921 . . . . 0.0 110.124 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 83.9 tt0 -64.58 -29.98 71.0 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.346 -0.846 . . . . 0.0 110.611 -178.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 75.3 t80 -132.83 -46.1 0.87 Allowed 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.01 -1.056 . . . . 0.0 110.959 -179.075 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.453 ' C ' ' O ' ' A' ' 12' ' ' VAL . 3.3 mt -118.03 80.01 14.57 Favored Pre-proline 0 N--CA 1.493 1.72 0 O-C-N 121.216 -0.928 . . . . 0.0 110.424 -178.855 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -77.82 -11.97 16.56 Favored 'Trans proline' 0 C--N 1.308 -1.57 0 C-N-CA 122.551 2.168 . . . . 0.0 112.483 179.569 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.44 ' C ' ' OD1' ' A' ' 18' ' ' ASP . 53.2 p30 -90.19 8.38 33.31 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 121.092 -1.005 . . . . 0.0 110.125 -179.651 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 51.6 t -119.34 135.51 59.49 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.365 -0.834 . . . . 0.0 109.688 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.34 120.44 79.71 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.258 -0.901 . . . . 0.0 109.421 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_exo -51.53 -27.54 25.47 Favored 'Trans proline' 0 N--CA 1.493 1.478 0 C-N-CA 121.764 1.643 . . . . 0.0 112.036 179.478 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.77 -25.83 68.09 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.317 -0.864 . . . . 0.0 109.357 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.445 ' O ' ' OD1' ' A' ' 23' ' ' ASP . 60.0 t0 -81.78 5.82 17.43 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.368 -0.832 . . . . 0.0 109.721 -179.826 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 11.7 t -108.25 132.47 55.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.24 -0.912 . . . . 0.0 109.462 -179.952 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 86.3 m-20 -89.19 120.51 30.63 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.144 -0.973 . . . . 0.0 109.004 179.356 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.9 m -77.12 2.49 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 O-C-N 121.005 -1.059 . . . . 0.0 108.991 179.592 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 87.6 m-20 -78.83 -28.56 44.4 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.305 -0.872 . . . . 0.0 108.808 178.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 45.9 tp -83.16 139.32 33.24 Favored 'General case' 0 N--CA 1.487 1.388 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 179.53 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.5 m-20 -56.64 132.63 52.39 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.035 -1.04 . . . . 0.0 109.556 -178.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.43 ' H ' ' HA ' ' A' ' 68' ' ' SER . 50.8 tp -64.9 -36.87 85.75 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.7 -0.625 . . . . 0.0 110.552 -179.471 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 78.9 t -63.38 -34.89 69.94 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.089 -1.007 . . . . 0.0 110.54 -179.11 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 90.6 m-20 -52.58 -33.35 45.68 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.001 -1.062 . . . . 0.0 108.181 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 97.5 m-20 -70.81 -34.21 71.51 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.625 -0.672 . . . . 0.0 109.98 179.483 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 90.68 3.62 70.99 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 108.974 -1.65 . . . . 0.0 108.974 -179.267 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 75.7 t -60.92 -29.2 45.0 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 121.431 -1.041 . . . . 0.0 108.66 179.415 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 71.0 mt -95.56 134.67 32.18 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 O-C-N 121.478 -0.764 . . . . 0.0 109.406 -179.88 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.576 ' CG ' ' H ' ' A' ' 38' ' ' ALA . 50.2 t0 -138.9 -169.82 2.72 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.576 ' H ' ' CG ' ' A' ' 37' ' ' ASP . . . -62.0 -54.16 45.5 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.147 -0.971 . . . . 0.0 108.765 179.911 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.467 ' CD1' ' N ' ' A' ' 39' ' ' LEU . 6.9 mp -69.76 -32.71 71.38 Favored 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 107.201 -1.407 . . . . 0.0 107.201 178.091 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -59.39 -44.74 96.39 Favored Glycine 0 N--CA 1.483 1.805 0 N-CA-C 108.971 -1.652 . . . . 0.0 108.971 179.456 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.408 ' CD1' ' CE1' ' A' ' 66' ' ' PHE . 7.9 tt -65.0 -40.4 94.89 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.423 -1.046 . . . . 0.0 109.195 179.367 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.1 tp -59.68 -46.02 90.31 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.1 -1.0 . . . . 0.0 108.887 179.675 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 59.7 mttp -61.3 -34.89 75.96 Favored 'General case' 0 C--N 1.297 -1.71 0 O-C-N 121.546 -0.722 . . . . 0.0 109.448 -180.0 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.438 ' O ' ' CB ' ' A' ' 48' ' ' LEU . 73.8 t -59.47 -43.27 90.22 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 O-C-N 121.299 -0.876 . . . . 0.0 109.142 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.525 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 6.7 mm -66.95 -38.74 81.98 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 121.395 -0.815 . . . . 0.0 110.752 -179.363 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.21 -49.77 68.44 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.128 -0.983 . . . . 0.0 111.716 -178.064 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . 0.693 ' CZ2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -80.84 -44.34 18.59 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.648 -1.283 . . . . 0.0 109.99 -179.277 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.438 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 20.8 tp -58.93 -41.97 88.63 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.209 -0.932 . . . . 0.0 110.094 -178.921 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.525 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 1.2 pp20? -72.25 -36.87 69.19 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.009 -1.057 . . . . 0.0 109.589 -179.889 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.7 t0 -61.19 -38.18 85.61 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.232 -0.917 . . . . 0.0 110.441 -179.834 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 14.8 mmm180 -61.69 -37.09 82.86 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.308 -0.87 . . . . 0.0 111.432 -178.703 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.634 ' CZ ' ' CG1' ' A' ' 76' ' ' VAL . 72.6 m-85 -96.82 -8.0 32.16 Favored 'General case' 0 N--CA 1.487 1.375 0 O-C-N 120.769 -1.207 . . . . 0.0 110.172 -178.956 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 71.18 31.22 66.55 Favored Glycine 0 N--CA 1.485 1.945 0 N-CA-C 108.82 -1.712 . . . . 0.0 108.82 179.771 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.487 ' O ' ' OE1' ' A' ' 49' ' ' GLU . 24.7 pt -108.81 153.13 10.62 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 O-C-N 121.598 -0.942 . . . . 0.0 109.84 -179.3 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -103.79 155.49 18.56 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.411 -0.805 . . . . 0.0 109.436 -179.638 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -58.46 -26.32 63.24 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.317 -0.865 . . . . 0.0 109.325 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 60.9 t0 59.13 38.29 23.81 Favored 'General case' 0 N--CA 1.486 1.336 0 O-C-N 121.445 -0.784 . . . . 0.0 109.109 -179.79 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 54.27 44.97 28.24 Favored 'General case' 0 N--CA 1.486 1.328 0 O-C-N 121.588 -0.695 . . . . 0.0 110.354 179.272 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 52.9 t -120.85 134.08 65.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.387 -0.82 . . . . 0.0 109.091 179.339 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -102.52 130.7 49.43 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.282 -0.886 . . . . 0.0 109.664 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 60.8 mt -99.24 143.88 29.0 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.394 -0.816 . . . . 0.0 109.17 179.834 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 11.6 p -90.09 148.17 38.8 Favored Pre-proline 0 C--N 1.305 -1.346 0 O-C-N 121.053 -1.029 . . . . 0.0 108.707 179.821 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -57.62 -19.78 38.99 Favored 'Trans proline' 0 C--N 1.305 -1.754 0 C-N-CA 122.24 1.96 . . . . 0.0 111.858 -179.714 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -67.41 -30.78 70.63 Favored 'General case' 0 N--CA 1.485 1.304 0 O-C-N 121.376 -0.828 . . . . 0.0 109.226 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . 0.568 ' CD2' ' O ' ' A' ' 65' ' ' HIS . 2.7 t-80 -66.47 -19.47 65.8 Favored 'General case' 0 C--N 1.3 -1.584 0 O-C-N 121.262 -0.899 . . . . 0.0 108.815 179.82 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.54 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 6.6 m-85 -98.31 13.3 31.94 Favored 'General case' 0 C--N 1.3 -1.571 0 N-CA-C 108.89 -0.781 . . . . 0.0 108.89 -179.753 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . 0.405 ' O ' ' N ' ' A' ' 30' ' ' LEU . 1.5 ptt180 -49.82 -34.74 20.58 Favored 'General case' 0 C--N 1.299 -1.587 0 O-C-N 121.716 -0.615 . . . . 0.0 110.167 -179.778 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.43 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 23.3 t -153.17 154.88 35.63 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.101 -1.0 . . . . 0.0 110.041 -179.577 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.413 HD11 ' H ' ' A' ' 69' ' ' ILE . 3.3 mp -57.45 -33.99 45.53 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 178.886 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 60.4 mtp180 -56.99 -45.61 82.85 Favored 'General case' 0 N--CA 1.488 1.453 0 CA-C-O 121.395 0.617 . . . . 0.0 109.567 -179.516 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 22.9 t -65.82 -41.43 91.86 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.283 -0.886 . . . . 0.0 109.87 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 68.5 mt -61.38 -45.38 98.75 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 O-C-N 121.265 -0.897 . . . . 0.0 110.022 -179.566 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 41.4 t0 -60.15 -40.79 91.08 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.178 -0.951 . . . . 0.0 109.573 -179.846 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.36 -46.06 78.02 Favored 'General case' 0 C--N 1.304 -1.393 0 O-C-N 121.232 -0.917 . . . . 0.0 109.593 -179.75 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . 0.51 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 63.5 t80 -63.19 -44.07 96.41 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.247 -0.908 . . . . 0.0 109.127 179.621 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.634 ' CG1' ' CZ ' ' A' ' 52' ' ' PHE . 55.4 t -62.57 -46.66 95.84 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.309 0 O-C-N 121.407 -0.808 . . . . 0.0 109.404 179.607 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.504 ' O ' ' O ' ' A' ' 81' ' ' THR . 72.5 t -68.87 -41.71 82.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 O-C-N 121.262 -0.899 . . . . 0.0 109.402 179.803 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.38 -23.45 53.78 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.798 -1.321 . . . . 0.0 109.798 179.903 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.08 -33.2 74.97 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.283 -1.128 . . . . 0.0 110.639 -179.149 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 26.2 p -121.46 -33.75 3.58 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.232 -0.918 . . . . 0.0 110.776 -179.179 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.504 ' O ' ' O ' ' A' ' 77' ' ' VAL . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.533 0 O-C-N 121.247 -0.908 . . . . 0.0 109.759 -179.388 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 38.4 m170 . . . . . 0 N--CA 1.485 1.276 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -58.89 -43.8 91.03 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.652 -0.655 . . . . 0.0 109.944 -179.224 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 94.9 p -65.95 -32.18 73.53 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.324 -0.86 . . . . 0.0 110.083 -179.663 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 79.1 t -65.26 -47.13 88.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.101 -1.0 . . . . 0.0 109.584 -179.718 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . 0.411 HD11 HG22 ' A' ' 7' ' ' ILE . 81.2 mt -59.96 -48.82 86.35 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 O-C-N 121.315 -0.865 . . . . 0.0 109.702 179.988 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.507 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -63.29 -43.5 97.7 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.421 -0.799 . . . . 0.0 110.7 -179.349 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 44.4 tt0 -68.67 -47.58 66.14 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.97 -1.081 . . . . 0.0 110.861 -178.859 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.531 ' C ' ' CD1' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -70.96 -48.12 55.2 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.149 -0.97 . . . . 0.0 110.36 -179.651 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.446 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 4.2 p -59.92 -38.95 78.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.089 -1.007 . . . . 0.0 109.742 -179.542 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.507 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 52.0 t -63.22 -43.26 98.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.099 -1.0 . . . . 0.0 109.839 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -63.81 -38.74 92.2 Favored 'General case' 0 N--CA 1.487 1.377 0 O-C-N 121.086 -1.008 . . . . 0.0 110.252 -179.638 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 85.5 tt0 -69.95 -42.17 73.57 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.0 -1.063 . . . . 0.0 110.218 -179.698 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 79.6 t80 -84.97 -52.96 5.61 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.16 -0.963 . . . . 0.0 110.798 -179.259 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 6.3 mt -122.53 80.08 46.93 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.341 -0.85 . . . . 0.0 110.371 -179.004 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 22.0 Cg_endo -68.39 -14.54 40.32 Favored 'Trans proline' 0 C--N 1.311 -1.403 0 C-N-CA 122.012 1.808 . . . . 0.0 112.33 179.464 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.459 ' OD1' ' O ' ' A' ' 18' ' ' ASP . 60.2 t0 -94.61 6.22 49.5 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.187 -0.945 . . . . 0.0 110.137 -179.705 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 25.9 t -118.57 135.89 57.53 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.268 -0.895 . . . . 0.0 109.636 -179.896 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . 0.491 ' O ' ' OD1' ' A' ' 23' ' ' ASP . . . -77.14 117.19 63.56 Favored Pre-proline 0 N--CA 1.489 1.489 0 O-C-N 121.234 -0.916 . . . . 0.0 108.935 179.722 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_exo -51.71 -26.23 22.75 Favored 'Trans proline' 0 N--CA 1.492 1.407 0 C-N-CA 121.8 1.666 . . . . 0.0 112.211 179.693 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.09 -24.94 67.58 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.35 -0.844 . . . . 0.0 109.775 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.491 ' OD1' ' O ' ' A' ' 20' ' ' ALA . 49.2 p30 -86.38 7.07 27.15 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.104 -0.998 . . . . 0.0 110.008 -179.555 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 15.6 t -110.4 131.9 60.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.73 0 O-C-N 121.315 -0.866 . . . . 0.0 109.504 179.868 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.521 ' C ' ' H ' ' A' ' 27' ' ' ASP . 62.9 t0 -89.25 119.37 29.68 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.148 -0.97 . . . . 0.0 108.981 179.223 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -63.87 4.25 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.421 0 O-C-N 121.172 -0.955 . . . . 0.0 109.315 179.874 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.521 ' H ' ' C ' ' A' ' 25' ' ' ASP . 92.0 m-20 -105.02 6.63 33.54 Favored 'General case' 0 N--CA 1.485 1.301 0 O-C-N 121.263 -0.898 . . . . 0.0 109.32 179.772 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 45.5 tp -96.8 136.29 37.56 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.373 -0.829 . . . . 0.0 109.238 -179.828 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 80.5 m-20 -64.7 142.52 58.4 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.231 -0.918 . . . . 0.0 109.967 -179.167 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.573 ' N ' ' O ' ' A' ' 67' ' ' ARG . 76.0 mt -70.3 -35.07 73.46 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.468 -0.77 . . . . 0.0 110.987 -179.577 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.417 ' CG2' ' N ' ' A' ' 32' ' ' ASP . 35.1 m -57.75 -47.09 86.69 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.515 0 O-C-N 121.123 -0.986 . . . . 0.0 110.177 -178.958 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.417 ' N ' ' CG2' ' A' ' 31' ' ' VAL . 90.8 m-20 -61.18 -34.24 74.73 Favored 'General case' 0 C--N 1.302 -1.489 0 N-CA-C 108.439 -0.948 . . . . 0.0 108.439 179.403 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 96.6 m-20 -70.8 -34.18 71.49 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.752 -0.592 . . . . 0.0 110.115 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 86.61 6.36 80.48 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 108.872 -1.691 . . . . 0.0 108.872 -179.516 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 70.8 t -59.06 -32.21 47.36 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 O-C-N 121.464 -1.021 . . . . 0.0 108.293 179.42 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 79.8 mt -85.82 129.56 37.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 CA-C-O 121.656 0.741 . . . . 0.0 109.735 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.532 ' CG ' ' H ' ' A' ' 38' ' ' ALA . 51.2 t0 -148.85 -170.84 3.72 Favored 'General case' 0 C--N 1.298 -1.647 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 179.776 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.532 ' H ' ' CG ' ' A' ' 37' ' ' ASP . . . -61.35 -54.66 40.89 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 120.893 -1.129 . . . . 0.0 108.422 179.772 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.487 ' CD1' ' N ' ' A' ' 39' ' ' LEU . 6.8 mp -71.61 -33.22 68.79 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 107.468 -1.308 . . . . 0.0 107.468 178.094 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -59.77 -46.61 93.77 Favored Glycine 0 N--CA 1.484 1.885 0 N-CA-C 109.255 -1.538 . . . . 0.0 109.255 179.833 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 3.4 tt -63.81 -43.28 96.73 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.419 -1.047 . . . . 0.0 109.654 179.563 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 17.2 tp -59.75 -45.22 92.89 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.313 -0.867 . . . . 0.0 109.728 -179.653 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 24.8 mttm -63.36 -34.45 77.74 Favored 'General case' 0 C--N 1.297 -1.678 0 O-C-N 121.052 -1.03 . . . . 0.0 109.705 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . 0.424 ' CG1' ' CE2' ' A' ' 66' ' ' PHE . 54.7 t -61.38 -50.79 78.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.332 -0.855 . . . . 0.0 110.624 -179.077 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 3.5 mp -68.27 -40.08 82.06 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 O-C-N 121.17 -0.957 . . . . 0.0 111.34 -179.431 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.66 -49.63 61.91 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.081 -1.012 . . . . 0.0 112.215 -177.692 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . 0.551 ' C ' ' CD1' ' A' ' 47' ' ' TRP . 0.0 OUTLIER -78.76 -43.43 25.61 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.671 -1.268 . . . . 0.0 110.37 -178.717 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.415 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 16.7 tp -59.99 -41.78 92.79 Favored 'General case' 0 C--N 1.3 -1.562 0 O-C-N 121.195 -0.941 . . . . 0.0 110.326 -178.754 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.413 ' CG ' ' N ' ' A' ' 50' ' ' ASP . 17.8 pt-20 -73.02 -37.15 67.03 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.117 -0.99 . . . . 0.0 109.856 -179.673 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . 0.413 ' N ' ' CG ' ' A' ' 49' ' ' GLU . 56.8 t0 -60.0 -39.26 85.14 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.375 -0.828 . . . . 0.0 111.036 -179.269 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . 0.401 ' HD2' ' HE1' ' A' ' 47' ' ' TRP . 80.6 mtp180 -61.07 -37.61 83.28 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.105 -0.997 . . . . 0.0 111.603 -178.649 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.644 ' CZ ' ' CG1' ' A' ' 76' ' ' VAL . 48.6 m-85 -98.48 -8.18 27.14 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 120.79 -1.194 . . . . 0.0 110.456 -179.012 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 69.87 31.7 70.04 Favored Glycine 0 N--CA 1.488 2.117 0 N-CA-C 108.752 -1.739 . . . . 0.0 108.752 179.653 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 27.9 pt -108.51 153.44 10.12 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 O-C-N 121.62 -0.929 . . . . 0.0 109.908 -179.372 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -100.09 129.95 46.18 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.152 -0.968 . . . . 0.0 109.51 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.502 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -66.51 -28.82 68.86 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.294 -0.879 . . . . 0.0 109.581 179.895 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 53.9 t0 -55.41 -36.09 66.08 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.305 -0.872 . . . . 0.0 109.998 -179.642 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -56.88 -40.3 75.95 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.201 -0.937 . . . . 0.0 109.952 -179.584 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.502 ' O ' ' O ' ' A' ' 56' ' ' ALA . 42.1 t -129.16 134.81 63.31 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.393 -0.817 . . . . 0.0 109.543 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -79.25 126.63 31.03 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.097 -1.002 . . . . 0.0 109.436 179.896 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 5.3 mp -108.04 139.54 42.53 Favored 'General case' 0 C--N 1.305 -1.333 0 O-C-N 121.372 -0.83 . . . . 0.0 109.651 -179.904 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -107.02 145.34 30.92 Favored Pre-proline 0 N--CA 1.484 1.267 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 179.098 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -60.73 -19.94 63.35 Favored 'Trans proline' 0 C--N 1.306 -1.699 0 C-N-CA 122.107 1.871 . . . . 0.0 112.021 -179.55 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 90.1 mt-10 -69.25 -28.39 66.29 Favored 'General case' 0 C--N 1.305 -1.364 0 O-C-N 121.439 -0.788 . . . . 0.0 109.676 -179.613 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . 0.59 ' CD2' ' O ' ' A' ' 65' ' ' HIS . 0.0 OUTLIER -66.55 -19.12 65.7 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.199 -0.938 . . . . 0.0 109.182 -179.563 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.5 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 16.5 m-85 -96.15 11.03 35.77 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.291 -0.881 . . . . 0.0 109.317 179.794 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . 0.573 ' O ' ' N ' ' A' ' 30' ' ' LEU . 1.7 ptt180 -50.08 -21.86 1.43 Allowed 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.381 -0.824 . . . . 0.0 110.049 -179.671 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.476 ' O ' ' OG ' ' A' ' 71' ' ' SER . 34.4 t -147.14 147.03 30.13 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.137 -0.977 . . . . 0.0 109.883 -179.875 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.427 ' CD1' ' H ' ' A' ' 69' ' ' ILE . 2.3 mp -59.92 -38.72 77.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.288 -0.883 . . . . 0.0 109.566 -179.826 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.429 ' O ' ' OD2' ' A' ' 73' ' ' ASP . 6.1 ptm180 -57.6 -40.14 78.4 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.427 -0.796 . . . . 0.0 109.447 -179.748 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' SER . . . . . 0.476 ' OG ' ' O ' ' A' ' 68' ' ' SER . 95.8 p -65.07 -35.83 82.39 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.332 -0.855 . . . . 0.0 110.123 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.402 ' HA ' ' HE2' ' A' ' 65' ' ' HIS . 64.6 mt -63.31 -46.59 95.17 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.326 0 O-C-N 121.191 -0.943 . . . . 0.0 110.148 -179.419 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . 0.584 ' OD1' ' N ' ' A' ' 74' ' ' ALA . 1.3 p30 -63.14 -40.02 96.35 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.088 -1.007 . . . . 0.0 109.448 -179.648 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . 0.584 ' N ' ' OD1' ' A' ' 73' ' ' ASP . . . -66.76 -45.52 78.3 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.312 -0.867 . . . . 0.0 109.768 -179.882 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . 0.544 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 55.0 t80 -63.32 -43.87 96.55 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.326 -0.859 . . . . 0.0 109.073 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.644 ' CG1' ' CZ ' ' A' ' 52' ' ' PHE . 55.8 t -60.79 -46.8 95.48 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 O-C-N 121.493 -0.754 . . . . 0.0 109.047 179.655 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 54.7 t -69.14 -42.07 81.63 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 O-C-N 121.455 -0.778 . . . . 0.0 109.084 179.298 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.516 ' O ' ' O ' ' A' ' 81' ' ' THR . . . -68.8 -21.19 74.92 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 110.001 -1.24 . . . . 0.0 110.001 179.901 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -66.48 -36.79 83.62 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 120.955 -1.32 . . . . 0.0 109.783 -179.411 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 56.1 p -87.91 -25.58 23.16 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.216 -0.927 . . . . 0.0 109.732 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.516 ' O ' ' O ' ' A' ' 78' ' ' GLY . 0.1 OUTLIER . . . . . 0 N--CA 1.486 1.366 0 O-C-N 121.358 -0.839 . . . . 0.0 109.75 -179.63 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 66.7 m-70 . . . . . 0 N--CA 1.487 1.418 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -58.26 -37.68 75.44 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.491 -0.755 . . . . 0.0 109.577 -179.3 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 87.4 p -61.45 -32.89 72.88 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.202 -0.936 . . . . 0.0 109.469 -179.884 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.413 ' HA ' HE21 ' A' ' 9' ' ' GLN . 70.0 t -62.95 -43.9 99.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.237 -0.914 . . . . 0.0 109.196 179.75 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 79.2 mt -60.21 -40.97 85.18 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.396 -0.815 . . . . 0.0 109.024 179.606 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -60.84 -38.12 84.39 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 121.52 -0.738 . . . . 0.0 109.537 -179.724 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . 0.413 HE21 ' HA ' ' A' ' 6' ' ' VAL . 52.3 mt-30 -64.51 -40.53 95.82 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.122 -0.986 . . . . 0.0 110.105 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.688 ' CG ' ' CE2' ' A' ' 47' ' ' TRP . 30.6 m-85 -63.55 -50.43 69.53 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.146 -0.972 . . . . 0.0 110.951 -179.196 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 27.2 m -65.64 -41.37 90.46 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 120.995 -1.066 . . . . 0.0 109.426 -179.474 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.464 ' O ' ' C ' ' A' ' 16' ' ' LEU . 66.6 t -63.88 -47.0 92.66 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 O-C-N 121.26 -0.9 . . . . 0.0 109.685 179.554 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -70.53 -27.83 64.47 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.04 -1.037 . . . . 0.0 110.231 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -64.57 -33.21 75.38 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.271 -0.893 . . . . 0.0 110.845 -178.708 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 92.1 m-85 -134.11 -29.78 1.24 Allowed 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.036 -1.04 . . . . 0.0 111.123 -179.354 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.464 ' C ' ' O ' ' A' ' 12' ' ' VAL . 12.3 mt -124.74 79.68 63.09 Favored Pre-proline 0 N--CA 1.491 1.604 0 O-C-N 121.078 -1.014 . . . . 0.0 110.248 -179.157 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -78.73 -17.72 12.27 Favored 'Trans proline' 0 C--N 1.307 -1.63 0 C-N-CA 122.586 2.19 . . . . 0.0 112.317 179.642 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -93.01 7.56 43.57 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.232 -0.917 . . . . 0.0 110.125 -179.601 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.433 ' CG1' ' OD2' ' A' ' 23' ' ' ASP . 46.8 t -113.18 136.04 50.76 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.353 -0.842 . . . . 0.0 109.775 -179.844 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . 0.414 ' O ' ' CG ' ' A' ' 23' ' ' ASP . . . -72.42 117.3 57.68 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.298 -0.876 . . . . 0.0 109.499 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_exo -52.03 -25.24 21.83 Favored 'Trans proline' 0 N--CA 1.494 1.503 0 C-N-CA 121.995 1.797 . . . . 0.0 112.344 179.333 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.74 -21.5 66.77 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.268 -0.895 . . . . 0.0 109.83 -179.604 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.448 ' C ' ' OD1' ' A' ' 23' ' ' ASP . 52.8 p30 -84.45 7.56 19.33 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.245 -0.909 . . . . 0.0 110.144 -179.599 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 11.4 t -104.88 129.81 56.9 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.156 -0.965 . . . . 0.0 109.463 -179.922 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 64.0 t0 -89.58 119.86 30.37 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.142 -0.974 . . . . 0.0 109.218 179.325 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.8 m -74.84 3.95 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.428 0 O-C-N 121.172 -0.955 . . . . 0.0 109.314 179.755 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -88.99 -11.24 44.82 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 121.295 -0.878 . . . . 0.0 109.157 179.543 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 43.6 tp -95.83 138.72 33.07 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.412 -0.805 . . . . 0.0 109.016 179.793 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.0 m-20 -58.34 133.6 55.86 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.147 -0.971 . . . . 0.0 109.272 -179.625 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.477 ' H ' ' HA ' ' A' ' 68' ' ' SER . 2.0 tt -67.14 -38.25 85.21 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 121.724 -0.61 . . . . 0.0 110.099 -179.136 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 75.5 t -63.14 -35.54 72.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.011 -1.056 . . . . 0.0 110.379 -178.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 55.7 t0 -52.52 -33.52 45.62 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 120.957 -1.09 . . . . 0.0 108.151 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 97.4 m-20 -71.25 -34.61 70.89 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.634 -0.666 . . . . 0.0 109.974 179.464 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 84.98 6.44 85.02 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.083 -1.607 . . . . 0.0 109.083 -179.399 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 71.5 t -61.32 -34.5 61.2 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.428 0 O-C-N 121.412 -1.052 . . . . 0.0 109.056 179.636 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 91.8 mt -82.07 114.53 23.12 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 O-C-N 121.353 -0.842 . . . . 0.0 109.665 -179.836 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -111.58 -168.61 1.33 Allowed 'General case' 0 C--N 1.304 -1.401 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 179.745 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -64.24 -54.15 37.88 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.214 -0.929 . . . . 0.0 108.696 179.708 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 38.6 mt -70.39 -33.16 71.08 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 107.171 -1.418 . . . . 0.0 107.171 178.338 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -59.57 -40.53 96.46 Favored Glycine 0 N--CA 1.481 1.678 0 N-CA-C 108.546 -1.822 . . . . 0.0 108.546 179.131 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.7 tt -65.45 -42.8 91.95 Favored 'General case' 0 C--N 1.305 -1.36 0 O-C-N 121.492 -1.005 . . . . 0.0 109.136 179.336 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.2 tp -60.88 -46.16 91.71 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.448 -0.782 . . . . 0.0 109.269 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 51.2 mttp -61.13 -35.21 76.46 Favored 'General case' 0 C--N 1.296 -1.732 0 O-C-N 121.427 -0.795 . . . . 0.0 109.623 -179.754 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 60.5 t -61.64 -48.67 87.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.295 -0.878 . . . . 0.0 109.8 -179.605 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.6 mp -68.26 -32.62 56.52 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 O-C-N 121.501 -0.75 . . . . 0.0 110.871 -179.568 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.14 -49.76 63.68 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.0 -1.063 . . . . 0.0 111.807 -178.026 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . 0.688 ' CE2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -80.81 -43.48 20.0 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.766 -1.209 . . . . 0.0 110.015 -179.195 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.402 ' N ' ' CG ' ' A' ' 47' ' ' TRP . 24.3 tp -58.82 -41.55 87.09 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.334 -0.854 . . . . 0.0 110.1 -178.948 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.438 ' CG ' ' N ' ' A' ' 50' ' ' ASP . 17.1 pt-20 -72.99 -37.92 66.83 Favored 'General case' 0 C--N 1.305 -1.362 0 O-C-N 121.079 -1.013 . . . . 0.0 109.716 -179.835 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . 0.438 ' N ' ' CG ' ' A' ' 49' ' ' GLU . 57.2 t0 -58.17 -39.13 78.09 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.36 -0.837 . . . . 0.0 110.457 -179.509 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 22.3 mtp-105 -62.63 -36.32 82.41 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.135 -0.978 . . . . 0.0 111.411 -178.866 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 86.5 m-85 -95.55 -8.88 33.89 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 120.75 -1.218 . . . . 0.0 110.258 -179.191 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 72.86 30.72 63.16 Favored Glycine 0 N--CA 1.487 2.073 0 N-CA-C 108.905 -1.678 . . . . 0.0 108.905 179.723 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 23.1 pt -109.73 153.63 11.44 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.335 0 O-C-N 121.557 -0.967 . . . . 0.0 109.782 -179.501 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -101.68 135.96 42.32 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.264 -0.897 . . . . 0.0 109.54 -179.776 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.499 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -66.35 -28.51 68.71 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.329 -0.857 . . . . 0.0 109.647 179.878 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -56.05 -35.78 67.3 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.158 -0.964 . . . . 0.0 109.935 -179.732 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 54.5 t0 -55.0 -38.93 68.49 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.173 -0.954 . . . . 0.0 110.141 -179.569 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.499 ' O ' ' O ' ' A' ' 56' ' ' ALA . 13.6 p -135.59 142.63 38.87 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.199 -0.938 . . . . 0.0 109.721 -179.91 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -93.62 132.57 37.83 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.098 -1.001 . . . . 0.0 109.328 179.682 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 56.5 mt -99.06 140.34 33.36 Favored 'General case' 0 C--N 1.305 -1.362 0 O-C-N 121.309 -0.869 . . . . 0.0 109.865 -179.67 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -109.67 156.31 39.93 Favored Pre-proline 0 N--CA 1.487 1.412 0 N-CA-C 108.633 -0.876 . . . . 0.0 108.633 179.503 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 8.1 Cg_endo -53.36 -25.08 29.82 Favored 'Trans proline' 0 C--N 1.303 -1.83 0 C-N-CA 122.41 2.073 . . . . 0.0 111.729 -179.85 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -71.65 -27.15 62.88 Favored 'General case' 0 N--CA 1.486 1.369 0 O-C-N 121.368 -0.833 . . . . 0.0 109.508 179.757 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . 0.556 ' NE2' ' CB ' ' A' ' 75' ' ' PHE . 6.6 t-160 -65.79 -21.1 66.47 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.311 -0.868 . . . . 0.0 109.092 -179.749 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.514 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 15.3 m-85 -92.34 14.65 15.84 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 179.909 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . 0.418 ' HG2' ' H ' ' A' ' 68' ' ' SER . 6.9 ptt180 -47.9 -39.08 17.86 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.651 -0.656 . . . . 0.0 109.85 -179.972 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.477 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 86.9 p -160.04 156.55 27.14 Favored 'General case' 0 N--CA 1.487 1.401 0 O-C-N 120.993 -1.067 . . . . 0.0 110.014 179.913 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.417 HD13 ' H ' ' A' ' 69' ' ' ILE . 3.3 mp -58.84 -34.76 53.24 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 179.189 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 47.0 mtp180 -56.88 -43.78 81.6 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.721 -0.612 . . . . 0.0 109.642 -179.601 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 82.5 p -69.47 -33.67 73.24 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.364 -0.835 . . . . 0.0 110.012 -179.706 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.41 ' HA ' ' HE2' ' A' ' 65' ' ' HIS . 80.6 mt -62.24 -51.02 77.45 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 O-C-N 121.177 -0.952 . . . . 0.0 109.944 -179.656 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 42.8 t0 -61.01 -42.06 97.73 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.197 -0.94 . . . . 0.0 109.241 179.871 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . 0.432 ' O ' ' N ' ' A' ' 78' ' ' GLY . . . -66.79 -38.68 87.01 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.568 -0.708 . . . . 0.0 110.403 -179.514 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . 0.556 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 58.9 t80 -62.28 -46.88 86.8 Favored 'General case' 0 C--N 1.302 -1.462 0 O-C-N 121.105 -0.997 . . . . 0.0 109.82 -179.572 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 77.0 t -66.35 -48.65 80.24 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 121.164 -0.96 . . . . 0.0 109.816 -179.806 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 53.3 t -70.04 -46.9 71.33 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.276 0 O-C-N 121.056 -1.028 . . . . 0.0 109.67 179.882 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.475 ' O ' ' O ' ' A' ' 81' ' ' THR . . . -61.86 -30.86 76.38 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 110.317 -1.113 . . . . 0.0 110.317 -179.642 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.67 -41.13 84.19 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.149 -1.207 . . . . 0.0 110.318 -179.028 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 56.1 p -79.15 -31.79 44.11 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.127 -0.983 . . . . 0.0 109.39 -179.872 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.475 ' O ' ' O ' ' A' ' 78' ' ' GLY . 2.6 t . . . . . 0 C--N 1.305 -1.341 0 O-C-N 121.52 -0.737 . . . . 0.0 109.452 -179.766 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 50.5 m80 . . . . . 0 N--CA 1.494 1.73 0 CA-C-O 120.988 0.423 . . . . 0.0 110.655 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -62.71 -40.22 96.49 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.016 -1.052 . . . . 0.0 109.313 179.486 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.0 t -60.19 -33.96 72.94 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.392 -0.817 . . . . 0.0 109.664 -179.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 55.9 t -60.24 -45.45 96.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.297 -0.877 . . . . 0.0 109.579 -179.854 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 75.5 mt -60.94 -45.26 98.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.326 -0.859 . . . . 0.0 109.025 179.65 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -61.56 -36.39 80.49 Favored 'General case' 0 N--CA 1.486 1.344 0 O-C-N 121.481 -0.762 . . . . 0.0 109.001 179.595 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 31.0 tt0 -64.78 -40.74 95.75 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.297 -0.877 . . . . 0.0 110.107 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.703 ' CG ' ' CE2' ' A' ' 47' ' ' TRP . 19.0 m-85 -61.71 -50.42 72.53 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.12 -0.987 . . . . 0.0 110.504 -179.452 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 23.2 m -64.58 -41.07 91.21 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.5 0 O-C-N 121.051 -1.031 . . . . 0.0 109.185 -179.64 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.447 ' O ' ' C ' ' A' ' 16' ' ' LEU . 79.6 t -63.95 -46.2 94.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.246 -0.909 . . . . 0.0 109.436 179.497 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -70.55 -27.7 64.35 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.171 -0.956 . . . . 0.0 110.171 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -64.46 -30.68 71.71 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.333 -0.855 . . . . 0.0 110.558 -178.883 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.454 ' CD2' ' CG1' ' A' ' 35' ' ' VAL . 96.2 m-85 -134.11 -38.64 0.86 Allowed 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.033 -1.042 . . . . 0.0 111.075 -179.317 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.447 ' C ' ' O ' ' A' ' 12' ' ' VAL . 9.1 mt -123.23 79.83 52.5 Favored Pre-proline 0 N--CA 1.493 1.684 0 O-C-N 121.067 -1.02 . . . . 0.0 110.571 -178.835 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -74.93 -15.53 20.88 Favored 'Trans proline' 0 C--N 1.309 -1.525 0 C-N-CA 122.305 2.003 . . . . 0.0 112.199 179.39 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -91.97 8.6 36.82 Favored 'General case' 0 C--N 1.305 -1.357 0 O-C-N 121.199 -0.938 . . . . 0.0 109.883 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 44.6 t -113.61 135.08 54.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 121.387 -0.82 . . . . 0.0 109.654 -179.746 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -73.9 119.67 77.35 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.321 -0.862 . . . . 0.0 109.288 179.877 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -51.14 -26.07 18.63 Favored 'Trans proline' 0 N--CA 1.494 1.502 0 C-N-CA 121.75 1.634 . . . . 0.0 112.132 179.482 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.81 -24.68 67.62 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.347 -0.846 . . . . 0.0 109.404 179.863 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.436 ' O ' ' OD1' ' A' ' 23' ' ' ASP . 60.2 t0 -81.83 6.83 14.43 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.32 -0.863 . . . . 0.0 109.759 -179.731 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 12.3 t -107.64 133.89 51.07 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.275 -0.89 . . . . 0.0 109.275 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 87.2 m-20 -89.06 120.47 30.5 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.085 -1.01 . . . . 0.0 109.0 179.324 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.0 m -76.4 4.47 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 O-C-N 121.19 -0.944 . . . . 0.0 109.124 179.655 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -91.45 -5.13 54.78 Favored 'General case' 0 C--N 1.305 -1.351 0 O-C-N 121.344 -0.847 . . . . 0.0 109.164 179.673 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 40.8 tp -98.65 138.5 35.74 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.323 -0.86 . . . . 0.0 109.34 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -60.61 134.69 57.32 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.247 -0.908 . . . . 0.0 109.484 -179.735 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -69.06 -39.66 78.99 Favored 'General case' 0 C--N 1.301 -1.5 0 O-C-N 121.631 -0.668 . . . . 0.0 110.221 -179.293 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 70.8 t -64.04 -36.29 76.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 121.107 -0.996 . . . . 0.0 110.606 -178.759 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 56.7 t0 -52.52 -33.36 44.9 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 120.926 -1.109 . . . . 0.0 108.238 -179.904 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 97.3 m-20 -71.24 -34.69 71.01 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.661 -0.65 . . . . 0.0 110.049 179.608 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 83.24 6.16 88.22 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 108.831 -1.708 . . . . 0.0 108.831 -179.22 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.454 ' CG1' ' CD2' ' A' ' 15' ' ' PHE . 72.9 t -60.61 -30.9 47.77 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 O-C-N 121.503 -0.998 . . . . 0.0 108.356 179.329 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 89.7 mt -86.87 131.54 34.62 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.382 0 O-C-N 121.489 -0.757 . . . . 0.0 109.74 179.908 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.581 ' CG ' ' H ' ' A' ' 38' ' ' ALA . 52.0 t0 -128.01 -166.22 1.59 Allowed 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 108.646 -0.872 . . . . 0.0 108.646 179.582 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.581 ' H ' ' CG ' ' A' ' 37' ' ' ASP . . . -64.36 -54.58 30.75 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.126 -0.984 . . . . 0.0 108.886 179.849 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 34.4 mt -69.8 -32.76 71.39 Favored 'General case' 0 C--N 1.302 -1.475 0 N-CA-C 107.233 -1.395 . . . . 0.0 107.233 178.358 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -59.24 -41.39 96.75 Favored Glycine 0 N--CA 1.48 1.618 0 N-CA-C 108.668 -1.773 . . . . 0.0 108.668 179.271 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.6 tt -65.54 -41.9 92.51 Favored 'General case' 0 C--N 1.304 -1.38 0 O-C-N 121.426 -1.044 . . . . 0.0 108.942 179.219 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.2 tp -60.13 -45.98 91.18 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.435 -0.791 . . . . 0.0 109.208 179.801 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 28.5 mttp -60.11 -35.5 75.37 Favored 'General case' 0 C--N 1.296 -1.742 0 O-C-N 121.491 -0.755 . . . . 0.0 109.512 -179.783 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 69.3 t -61.98 -48.23 89.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.335 -0.853 . . . . 0.0 109.927 -179.673 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.526 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 1.7 mp -68.15 -33.26 59.83 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.569 0 O-C-N 121.507 -0.746 . . . . 0.0 110.831 -179.652 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.0 -49.84 66.37 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 120.898 -1.126 . . . . 0.0 111.344 -178.179 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . 0.703 ' CE2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -81.17 -44.54 17.71 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.718 -1.239 . . . . 0.0 109.936 -179.452 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.549 ' CD1' HH21 ' A' ' 51' ' ' ARG . 10.0 tp -58.43 -42.67 87.78 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.275 -0.891 . . . . 0.0 109.773 -179.07 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.526 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 2.3 pp20? -72.61 -35.93 67.98 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.094 -1.004 . . . . 0.0 109.786 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.2 t70 -60.02 -38.72 83.51 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.282 -0.886 . . . . 0.0 110.66 -179.517 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . 0.549 HH21 ' CD1' ' A' ' 48' ' ' LEU . 62.6 mtm180 -62.09 -38.04 87.37 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.12 -0.987 . . . . 0.0 111.418 -178.824 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.407 ' CE2' ' CG1' ' A' ' 76' ' ' VAL . 95.6 m-85 -97.8 -11.94 22.78 Favored 'General case' 0 N--CA 1.487 1.391 0 O-C-N 120.738 -1.226 . . . . 0.0 110.164 -179.039 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 72.3 30.98 64.1 Favored Glycine 0 N--CA 1.488 2.102 0 N-CA-C 108.804 -1.718 . . . . 0.0 108.804 179.912 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.469 ' O ' ' OE1' ' A' ' 49' ' ' GLU . 34.5 pt -102.89 148.37 8.19 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.4 0 O-C-N 121.414 -1.05 . . . . 0.0 109.758 -179.436 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -89.87 112.42 23.76 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.184 -0.948 . . . . 0.0 109.679 -179.728 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.502 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -68.41 -27.14 65.95 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.332 -0.855 . . . . 0.0 109.585 179.686 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -55.73 -35.9 66.66 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.168 -0.957 . . . . 0.0 110.087 -179.587 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -55.55 -38.52 69.4 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.133 -0.979 . . . . 0.0 109.857 -179.631 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.502 ' O ' ' O ' ' A' ' 56' ' ' ALA . 42.7 t -124.95 136.16 61.74 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.419 -0.801 . . . . 0.0 109.658 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -89.18 131.09 35.46 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.028 -1.045 . . . . 0.0 109.297 179.872 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 38.1 mt -99.86 142.16 31.71 Favored 'General case' 0 C--N 1.305 -1.338 0 O-C-N 121.265 -0.897 . . . . 0.0 109.701 -179.7 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.514 ' HG ' ' N ' ' A' ' 63' ' ' PRO . 0.0 OUTLIER -109.49 157.18 38.1 Favored Pre-proline 0 N--CA 1.487 1.375 0 O-C-N 121.437 -0.789 . . . . 0.0 108.942 179.64 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . 0.514 ' N ' ' HG ' ' A' ' 62' ' ' SER . 9.2 Cg_endo -55.33 -24.04 40.77 Favored 'Trans proline' 0 C--N 1.304 -1.77 0 C-N-CA 122.604 2.203 . . . . 0.0 111.827 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -69.06 -29.22 67.31 Favored 'General case' 0 C--N 1.304 -1.374 0 O-C-N 121.364 -0.835 . . . . 0.0 109.139 179.703 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . 0.531 ' CD2' ' O ' ' A' ' 65' ' ' HIS . 2.9 t-80 -66.33 -18.5 65.39 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.359 -0.838 . . . . 0.0 108.895 179.938 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.521 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 11.4 m-85 -94.69 13.77 23.3 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 179.582 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . 0.478 ' CZ ' ' OG ' ' A' ' 71' ' ' SER . 7.5 ptt180 -44.2 -38.92 4.05 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.811 -0.556 . . . . 0.0 110.545 -179.594 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 80.1 p -155.7 161.42 40.74 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.806 -1.184 . . . . 0.0 110.3 -179.629 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 31.3 mm -60.66 -44.14 96.39 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 O-C-N 121.39 -0.819 . . . . 0.0 110.172 -179.774 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.427 ' HG2' ' H ' ' A' ' 71' ' ' SER . 0.0 OUTLIER -58.88 -39.74 82.29 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.214 -0.929 . . . . 0.0 109.656 -179.304 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' SER . . . . . 0.478 ' OG ' ' CZ ' ' A' ' 67' ' ' ARG . 23.2 t -63.08 -40.61 98.17 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.248 -0.907 . . . . 0.0 109.643 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.407 ' HA ' ' HE2' ' A' ' 65' ' ' HIS . 86.0 mt -61.95 -50.56 79.64 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 O-C-N 121.214 -0.929 . . . . 0.0 110.107 -179.755 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 40.9 t0 -59.28 -41.13 88.2 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.234 -0.916 . . . . 0.0 109.357 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . 0.439 ' O ' ' N ' ' A' ' 78' ' ' GLY . . . -66.49 -37.42 85.03 Favored 'General case' 0 C--N 1.302 -1.458 0 O-C-N 121.505 -0.747 . . . . 0.0 110.266 -179.587 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . 0.531 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 62.6 t80 -61.99 -48.12 81.77 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.022 -1.049 . . . . 0.0 109.886 -179.502 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.407 ' CG1' ' CE2' ' A' ' 52' ' ' PHE . 87.6 t -64.92 -48.25 84.96 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.323 0 O-C-N 121.097 -1.002 . . . . 0.0 109.671 -179.801 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 60.8 t -69.31 -39.18 78.69 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 O-C-N 121.214 -0.929 . . . . 0.0 109.142 179.585 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.439 ' N ' ' O ' ' A' ' 74' ' ' ALA . . . -59.1 -35.35 83.66 Favored Glycine 0 N--CA 1.487 2.088 0 N-CA-C 110.207 -1.157 . . . . 0.0 110.207 -179.678 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -70.35 -41.68 72.86 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.265 -1.138 . . . . 0.0 111.044 -178.791 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 44.6 p -81.78 -34.79 30.15 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.094 -1.004 . . . . 0.0 109.497 -179.622 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.299 -1.592 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 -179.848 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 58.9 m-70 . . . . . 0 N--CA 1.494 1.762 0 CA-C-O 121.066 0.46 . . . . 0.0 110.316 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -62.25 -38.82 90.73 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.06 -1.025 . . . . 0.0 109.484 179.718 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.4 m -60.28 -36.88 78.85 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.368 -0.832 . . . . 0.0 110.107 -179.645 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 48.9 t -62.15 -44.81 99.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.124 -0.985 . . . . 0.0 109.723 -179.757 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 89.7 mt -59.53 -49.8 82.29 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.613 0 O-C-N 121.341 -0.849 . . . . 0.0 110.037 -179.504 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.469 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -63.5 -43.97 95.72 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.378 -0.826 . . . . 0.0 111.111 -179.136 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 53.0 mt-30 -69.22 -46.0 68.45 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 120.844 -1.16 . . . . 0.0 111.284 -178.607 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.705 ' CD1' ' N ' ' A' ' 11' ' ' VAL . 0.0 OUTLIER -69.82 -47.01 64.38 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 120.951 -1.093 . . . . 0.0 110.519 -179.142 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.705 ' N ' ' CD1' ' A' ' 10' ' ' PHE . 5.1 p -61.54 -38.91 81.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.062 -1.024 . . . . 0.0 109.731 -179.671 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.469 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 56.0 t -63.33 -43.44 98.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.133 -0.979 . . . . 0.0 109.821 -179.949 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -63.9 -39.02 93.22 Favored 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.166 -0.958 . . . . 0.0 110.187 -179.519 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 85.2 tt0 -70.02 -42.26 73.2 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.182 -0.949 . . . . 0.0 110.0 -179.849 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 77.7 t80 -83.58 -52.18 6.68 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.221 -0.924 . . . . 0.0 110.618 -179.435 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.424 ' N ' ' O ' ' A' ' 12' ' ' VAL . 7.3 mt -123.64 80.07 55.26 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.378 -0.826 . . . . 0.0 110.292 -179.04 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -67.02 -15.65 47.36 Favored 'Trans proline' 0 N--CA 1.492 1.401 0 C-N-CA 122.056 1.837 . . . . 0.0 112.466 179.682 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -95.26 7.34 46.47 Favored 'General case' 0 N--CA 1.486 1.335 0 O-C-N 121.083 -1.011 . . . . 0.0 110.429 -179.499 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 21.8 t -119.47 136.21 57.37 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.214 -0.929 . . . . 0.0 109.843 -179.825 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . 0.487 ' O ' ' OD1' ' A' ' 23' ' ' ASP . . . -77.58 118.69 73.71 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.241 -0.912 . . . . 0.0 108.978 179.516 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_exo -51.15 -25.75 17.84 Favored 'Trans proline' 0 N--CA 1.493 1.487 0 C-N-CA 121.798 1.665 . . . . 0.0 112.223 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.88 -27.46 68.87 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.183 -0.948 . . . . 0.0 109.726 -179.854 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.487 ' OD1' ' O ' ' A' ' 20' ' ' ALA . 47.3 p30 -87.28 7.72 27.36 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.136 -0.977 . . . . 0.0 109.84 -179.678 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 16.4 t -110.16 132.06 59.5 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 O-C-N 121.311 -0.868 . . . . 0.0 109.446 179.88 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 62.2 t0 -89.26 119.47 29.77 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.197 -0.94 . . . . 0.0 108.993 179.308 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . 0.522 ' O ' ' CG2' ' A' ' 26' ' ' VAL . 1.9 p -74.66 4.85 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 O-C-N 121.102 -0.999 . . . . 0.0 108.914 179.632 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -98.21 3.4 48.92 Favored 'General case' 0 N--CA 1.486 1.371 0 O-C-N 121.198 -0.938 . . . . 0.0 109.253 179.636 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 40.0 tp -97.95 134.6 40.84 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.354 -0.841 . . . . 0.0 109.37 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 82.2 m-20 -65.67 142.06 58.17 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.226 -0.921 . . . . 0.0 109.298 -179.71 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 91.4 mt -70.7 -33.73 71.2 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.325 -0.859 . . . . 0.0 110.698 -179.411 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.496 ' CG2' ' N ' ' A' ' 32' ' ' ASP . 20.0 m -53.56 -47.74 59.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 O-C-N 121.146 -0.971 . . . . 0.0 110.155 -178.686 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.496 ' N ' ' CG2' ' A' ' 31' ' ' VAL . 90.8 m-20 -61.11 -35.04 75.96 Favored 'General case' 0 C--N 1.3 -1.568 0 O-C-N 121.248 -0.908 . . . . 0.0 108.624 179.496 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 96.4 m-20 -70.84 -34.32 71.55 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.686 -0.634 . . . . 0.0 110.11 -179.842 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 86.17 5.32 83.1 Favored Glycine 0 N--CA 1.491 2.367 0 N-CA-C 109.158 -1.577 . . . . 0.0 109.158 -179.685 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 71.9 t -60.85 -34.41 59.25 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 O-C-N 121.402 -1.058 . . . . 0.0 108.93 179.672 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 92.1 mt -66.46 95.21 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.428 0 O-C-N 121.467 -0.771 . . . . 0.0 110.313 -179.559 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -102.95 169.36 8.62 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 178.85 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -55.55 -48.65 74.4 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 107.761 -1.2 . . . . 0.0 107.761 179.659 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.499 ' CD1' ' N ' ' A' ' 39' ' ' LEU . 6.8 mp -71.14 -32.16 68.62 Favored 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 106.984 -1.488 . . . . 0.0 106.984 177.592 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -58.77 -48.1 86.93 Favored Glycine 0 N--CA 1.483 1.795 0 N-CA-C 109.181 -1.568 . . . . 0.0 109.181 179.705 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.5 tt -63.08 -40.29 97.22 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.367 -1.078 . . . . 0.0 109.187 179.314 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.1 tp -59.73 -46.22 89.8 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.264 -0.897 . . . . 0.0 109.23 179.956 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 63.8 mttp -61.67 -34.35 75.57 Favored 'General case' 0 C--N 1.297 -1.7 0 O-C-N 121.443 -0.786 . . . . 0.0 109.604 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 78.9 t -60.8 -47.07 94.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.377 -0.827 . . . . 0.0 110.036 -179.512 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.7 mp -67.89 -36.56 76.12 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 O-C-N 121.295 -0.878 . . . . 0.0 111.35 -179.474 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.3 -49.38 64.46 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 120.965 -1.084 . . . . 0.0 111.853 -178.031 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . 0.533 ' C ' ' CD1' ' A' ' 47' ' ' TRP . 0.0 OUTLIER -78.37 -42.59 29.95 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 120.541 -1.349 . . . . 0.0 110.105 -179.062 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 7.4 tt -59.78 -42.08 92.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.242 -0.911 . . . . 0.0 110.667 -179.239 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 18.9 pt-20 -72.69 -36.51 67.9 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.101 -1.0 . . . . 0.0 109.94 -179.4 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.7 t0 -61.17 -39.61 90.76 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.362 -0.836 . . . . 0.0 111.247 -179.186 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . 0.515 ' NE ' ' HE1' ' A' ' 47' ' ' TRP . 94.0 mtt-85 -63.18 -38.91 93.04 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.094 -1.004 . . . . 0.0 112.567 -178.074 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 85.5 m-85 -99.2 -7.63 26.23 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 120.656 -1.278 . . . . 0.0 110.635 -178.682 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 69.82 30.54 70.34 Favored Glycine 0 N--CA 1.486 2.012 0 N-CA-C 108.924 -1.67 . . . . 0.0 108.924 179.425 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 26.5 pt -106.59 153.23 7.91 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 O-C-N 121.634 -0.921 . . . . 0.0 109.544 -179.557 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -98.59 134.19 41.88 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.138 -0.977 . . . . 0.0 109.639 -179.498 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.518 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -65.84 -30.29 70.89 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.28 -0.887 . . . . 0.0 109.58 179.903 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -57.71 -34.56 69.59 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.212 -0.93 . . . . 0.0 110.242 -179.741 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -54.93 -39.38 68.78 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.196 -0.94 . . . . 0.0 110.403 -179.297 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.518 ' O ' ' O ' ' A' ' 56' ' ' ALA . 31.5 m -128.67 157.05 41.41 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 O-C-N 121.275 -0.891 . . . . 0.0 109.804 -179.503 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -96.54 128.95 43.96 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.986 -1.071 . . . . 0.0 109.167 179.724 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 58.1 mt -101.39 135.33 43.05 Favored 'General case' 0 C--N 1.305 -1.334 0 O-C-N 121.214 -0.929 . . . . 0.0 109.798 -179.815 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -109.97 156.05 40.62 Favored Pre-proline 0 N--CA 1.487 1.393 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 179.395 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 10.8 Cg_endo -56.94 -24.1 55.07 Favored 'Trans proline' 0 C--N 1.303 -1.839 0 C-N-CA 122.406 2.071 . . . . 0.0 111.74 179.891 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -69.47 -29.35 67.0 Favored 'General case' 0 C--N 1.306 -1.315 0 O-C-N 121.338 -0.851 . . . . 0.0 109.172 179.721 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . 0.592 ' CD2' ' O ' ' A' ' 65' ' ' HIS . 4.3 t-160 -65.97 -17.69 64.84 Favored 'General case' 0 C--N 1.3 -1.562 0 O-C-N 121.417 -0.802 . . . . 0.0 108.966 -179.911 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.493 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 17.3 m-85 -93.14 14.86 16.71 Favored 'General case' 0 C--N 1.303 -1.445 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 179.532 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . 0.401 ' HG2' ' H ' ' A' ' 68' ' ' SER . 8.9 ptt180 -48.38 -38.53 19.64 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.816 -0.552 . . . . 0.0 110.822 -179.498 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.427 ' O ' ' OG ' ' A' ' 71' ' ' SER . 31.9 t -158.53 150.24 21.19 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 120.76 -1.213 . . . . 0.0 110.362 -179.667 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.588 ' CD1' ' H ' ' A' ' 69' ' ' ILE . 0.1 OUTLIER -57.74 -42.86 82.74 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.365 -0.835 . . . . 0.0 109.255 179.688 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 5.8 ptm180 -57.88 -40.66 80.77 Favored 'General case' 0 C--N 1.303 -1.427 0 O-C-N 121.42 -0.8 . . . . 0.0 109.326 -179.89 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' SER . . . . . 0.427 ' OG ' ' O ' ' A' ' 68' ' ' SER . 84.9 p -66.42 -34.39 77.85 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.236 -0.915 . . . . 0.0 109.514 179.538 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.41 ' HA ' ' HE2' ' A' ' 65' ' ' HIS . 91.5 mt -59.99 -51.14 76.4 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.243 0 O-C-N 121.163 -0.961 . . . . 0.0 109.749 179.969 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 42.4 t0 -59.49 -42.07 91.28 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.172 -0.955 . . . . 0.0 108.976 179.823 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . 0.556 ' O ' ' N ' ' A' ' 78' ' ' GLY . . . -66.72 -37.11 84.03 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.661 -0.649 . . . . 0.0 110.148 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . 0.459 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 64.6 t80 -61.3 -49.7 75.97 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.004 -1.06 . . . . 0.0 109.686 -179.604 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 44.3 t -68.66 -48.89 69.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.307 0 O-C-N 121.216 -0.927 . . . . 0.0 109.875 -179.568 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 82.1 t -69.62 -41.91 80.38 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.305 0 O-C-N 121.211 -0.931 . . . . 0.0 109.151 179.803 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.556 ' N ' ' O ' ' A' ' 74' ' ' ALA . . . -60.48 -39.42 96.31 Favored Glycine 0 N--CA 1.488 2.134 0 N-CA-C 109.895 -1.282 . . . . 0.0 109.895 -179.872 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -68.33 -41.07 81.33 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.159 -1.201 . . . . 0.0 110.245 -179.428 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 45.0 p -82.32 -29.86 30.8 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.189 -0.944 . . . . 0.0 109.594 -179.768 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.495 ' O ' ' O ' ' A' ' 78' ' ' GLY . 0.3 OUTLIER . . . . . 0 C--N 1.302 -1.461 0 O-C-N 121.522 -0.736 . . . . 0.0 109.457 -179.659 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 14.9 m-70 . . . . . 0 N--CA 1.496 1.842 0 CA-C-O 121.037 0.446 . . . . 0.0 110.127 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -62.26 -38.34 88.92 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.045 -1.034 . . . . 0.0 109.396 179.719 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.3 t -60.66 -38.03 83.53 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.36 -0.837 . . . . 0.0 110.049 -179.585 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 73.4 t -61.53 -43.12 96.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.203 -0.935 . . . . 0.0 109.539 -179.836 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 75.3 mt -60.32 -46.04 95.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.395 -0.816 . . . . 0.0 109.283 179.742 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -61.47 -39.24 90.18 Favored 'General case' 0 N--CA 1.486 1.372 0 O-C-N 121.268 -0.895 . . . . 0.0 108.675 179.546 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 33.2 tt0 -64.99 -35.11 80.13 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.419 -0.801 . . . . 0.0 109.143 179.289 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.612 ' CZ ' ' CD1' ' A' ' 47' ' ' TRP . 0.3 OUTLIER -60.51 -50.9 71.72 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.495 -0.753 . . . . 0.0 110.184 -179.569 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 22.7 m -66.55 -38.26 81.3 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 O-C-N 121.164 -0.96 . . . . 0.0 109.117 -179.743 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.444 ' O ' ' C ' ' A' ' 16' ' ' LEU . 73.9 t -63.47 -44.87 98.99 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.439 0 O-C-N 121.24 -0.912 . . . . 0.0 109.351 179.496 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -73.3 -19.27 61.08 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.266 -0.896 . . . . 0.0 109.939 179.746 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -63.9 -32.28 73.75 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.33 -0.857 . . . . 0.0 110.449 -178.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 64.8 t80 -142.28 -36.62 0.41 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 120.958 -1.089 . . . . 0.0 110.463 -179.62 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.444 ' C ' ' O ' ' A' ' 12' ' ' VAL . 5.6 mt -119.55 79.89 22.26 Favored Pre-proline 0 N--CA 1.491 1.615 0 O-C-N 121.211 -0.93 . . . . 0.0 110.017 -179.495 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_endo -77.97 -14.16 15.45 Favored 'Trans proline' 0 C--N 1.308 -1.58 0 C-N-CA 122.604 2.203 . . . . 0.0 112.235 179.592 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -90.31 7.25 39.37 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 121.343 -0.848 . . . . 0.0 109.9 -179.699 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 44.7 t -109.28 134.86 49.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.303 -0.873 . . . . 0.0 109.588 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . 0.489 ' O ' ' OD1' ' A' ' 23' ' ' ASP . . . -72.52 117.15 56.53 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.275 -0.89 . . . . 0.0 109.382 -179.942 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_exo -52.5 -26.16 27.64 Favored 'Trans proline' 0 N--CA 1.493 1.468 0 C-N-CA 121.891 1.728 . . . . 0.0 112.095 179.446 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.88 -23.42 67.23 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.355 -0.841 . . . . 0.0 109.731 -179.762 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.489 ' OD1' ' O ' ' A' ' 20' ' ' ALA . 52.6 p30 -84.69 7.85 19.02 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.16 -0.963 . . . . 0.0 110.003 -179.615 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 12.2 t -103.0 131.74 50.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.162 -0.961 . . . . 0.0 109.5 -179.868 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 63.5 t0 -89.0 119.94 29.98 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.101 -1.0 . . . . 0.0 108.93 179.247 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.5 m -73.12 4.28 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 O-C-N 121.079 -1.013 . . . . 0.0 109.547 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -89.67 -8.22 52.9 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.215 -0.928 . . . . 0.0 109.111 179.577 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 40.5 tp -101.62 139.46 37.23 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.427 -0.796 . . . . 0.0 109.313 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.5 m-20 -58.88 142.17 51.4 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.249 -0.907 . . . . 0.0 109.388 -179.78 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.446 ' H ' ' HA ' ' A' ' 68' ' ' SER . 1.4 tt -69.12 -38.6 78.95 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.607 -0.683 . . . . 0.0 110.743 -178.846 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 75.4 t -64.5 -36.16 76.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.086 -1.009 . . . . 0.0 110.542 -178.903 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 91.3 m-20 -52.58 -33.66 47.09 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 120.969 -1.082 . . . . 0.0 108.218 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 97.6 m-20 -70.94 -34.37 71.4 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.615 -0.678 . . . . 0.0 109.99 179.534 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 86.05 6.04 82.48 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.315 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 71.6 t -61.51 -33.01 55.14 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.411 0 O-C-N 121.413 -1.051 . . . . 0.0 109.07 179.755 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 84.7 mt -91.95 123.85 44.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.276 -0.89 . . . . 0.0 109.802 -179.859 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -114.97 -168.44 1.38 Allowed 'General case' 0 C--N 1.301 -1.501 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 179.61 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -63.77 -53.84 44.6 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.103 -0.998 . . . . 0.0 108.717 179.683 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 6.6 mp -68.88 -32.9 72.88 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 107.007 -1.479 . . . . 0.0 107.007 178.222 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -59.04 -41.91 96.7 Favored Glycine 0 N--CA 1.48 1.627 0 N-CA-C 108.691 -1.763 . . . . 0.0 108.691 179.211 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.7 tt -65.16 -41.09 95.03 Favored 'General case' 0 C--N 1.304 -1.393 0 O-C-N 121.454 -1.027 . . . . 0.0 108.851 179.066 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.1 tp -59.88 -45.81 91.31 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.365 -0.834 . . . . 0.0 109.051 179.728 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 78.6 mttt -60.34 -35.73 76.35 Favored 'General case' 0 C--N 1.298 -1.672 0 O-C-N 121.471 -0.768 . . . . 0.0 109.456 -179.863 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 77.7 t -62.03 -43.32 97.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.308 -0.87 . . . . 0.0 109.795 -179.884 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.5 mp -67.33 -39.56 83.04 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.541 0 O-C-N 121.549 -0.719 . . . . 0.0 111.196 -179.382 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.36 -50.19 60.86 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 120.637 -1.289 . . . . 0.0 112.015 -177.72 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . 0.612 ' CD1' ' CZ ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -78.65 -45.01 22.45 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.665 -1.272 . . . . 0.0 110.647 -178.701 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.424 ' N ' ' CG ' ' A' ' 47' ' ' TRP . 29.4 tp -58.5 -44.19 89.34 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.12 -0.987 . . . . 0.0 110.062 -178.862 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 68.9 mm-40 -68.06 -37.75 81.66 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.117 -0.989 . . . . 0.0 109.582 -179.819 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.1 t70 -62.37 -36.94 83.83 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.358 -0.839 . . . . 0.0 110.792 -179.754 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 35.5 mmt180 -58.1 -39.07 77.67 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.09 -1.007 . . . . 0.0 111.162 -178.641 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.604 ' CE1' ' CG1' ' A' ' 76' ' ' VAL . 9.0 m-85 -91.89 -3.57 55.84 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.842 -1.161 . . . . 0.0 110.319 -179.286 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 73.87 29.8 62.49 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 108.52 -1.832 . . . . 0.0 108.52 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 31.9 pt -113.45 153.61 14.98 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 O-C-N 121.714 -0.874 . . . . 0.0 109.866 -179.17 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -97.06 139.92 32.34 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.307 -0.871 . . . . 0.0 109.259 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.482 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -62.85 -30.71 71.71 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.24 -0.912 . . . . 0.0 109.715 -179.796 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -56.72 -38.77 72.81 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.054 -1.029 . . . . 0.0 109.681 -179.758 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 90.7 m-20 -61.36 -41.29 96.83 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.204 -0.935 . . . . 0.0 109.945 -179.878 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.482 ' O ' ' O ' ' A' ' 56' ' ' ALA . 46.8 t -130.35 133.73 63.49 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 121.408 -0.808 . . . . 0.0 109.728 -179.845 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -104.15 134.27 47.68 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.295 -0.878 . . . . 0.0 109.402 179.677 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 40.2 mt -96.23 141.82 29.13 Favored 'General case' 0 C--N 1.304 -1.387 0 O-C-N 121.217 -0.927 . . . . 0.0 109.521 -179.759 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -109.58 156.33 39.82 Favored Pre-proline 0 C--N 1.305 -1.343 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 179.684 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 1.4 Cg_endo -48.92 -22.23 4.62 Favored 'Trans proline' 0 C--N 1.305 -1.729 0 C-N-CA 121.924 1.75 . . . . 0.0 110.837 179.604 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 87.1 tt0 -71.13 -30.14 66.12 Favored 'General case' 0 N--CA 1.486 1.351 0 O-C-N 121.563 -0.711 . . . . 0.0 109.477 179.094 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . 0.54 ' C ' ' CD2' ' A' ' 65' ' ' HIS . 1.2 t60 -65.84 -16.49 63.87 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.397 -0.814 . . . . 0.0 108.97 -179.794 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.558 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 12.5 m-85 -97.53 15.38 23.45 Favored 'General case' 0 C--N 1.299 -1.598 0 CA-C-O 121.739 0.78 . . . . 0.0 108.896 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . 0.598 ' NE ' ' OG ' ' A' ' 71' ' ' SER . 6.6 ptt180 -50.71 -36.13 34.72 Favored 'General case' 0 C--N 1.301 -1.5 0 O-C-N 121.701 -0.624 . . . . 0.0 110.002 -179.719 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.587 ' HG ' ' H ' ' A' ' 71' ' ' SER . 88.8 p -162.86 153.35 16.56 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.982 -1.074 . . . . 0.0 110.216 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.412 HD11 ' H ' ' A' ' 69' ' ' ILE . 3.5 mp -58.42 -43.4 86.51 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 O-C-N 121.34 -0.85 . . . . 0.0 109.046 179.68 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 10.0 ptm180 -58.17 -40.11 80.62 Favored 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 108.96 -0.756 . . . . 0.0 108.96 179.5 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' SER . . . . . 0.598 ' OG ' ' NE ' ' A' ' 67' ' ' ARG . 25.9 t -63.46 -41.14 98.62 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.434 -0.792 . . . . 0.0 109.827 179.542 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 81.8 mt -58.91 -48.7 85.57 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.315 0 O-C-N 121.239 -0.913 . . . . 0.0 109.603 -179.615 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 37.4 t0 -60.07 -43.76 95.21 Favored 'General case' 0 N--CA 1.487 1.406 0 O-C-N 121.22 -0.925 . . . . 0.0 108.728 179.756 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . 0.5 ' O ' ' N ' ' A' ' 78' ' ' GLY . . . -66.99 -38.77 86.63 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.658 -0.651 . . . . 0.0 109.932 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . 0.464 ' O ' ' CB ' ' A' ' 79' ' ' ALA . 53.5 t80 -62.76 -47.99 81.13 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.177 -0.952 . . . . 0.0 109.473 -179.698 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.604 ' CG1' ' CE1' ' A' ' 52' ' ' PHE . 50.0 t -64.99 -48.33 84.49 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.294 0 O-C-N 121.255 -0.903 . . . . 0.0 109.774 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 88.7 t -69.88 -49.06 60.0 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 O-C-N 121.2 -0.937 . . . . 0.0 109.356 179.705 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.5 ' N ' ' O ' ' A' ' 74' ' ' ALA . . . -65.6 -26.58 72.01 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 -179.778 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . 0.464 ' CB ' ' O ' ' A' ' 75' ' ' PHE . . . -67.12 -39.39 86.65 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.145 -1.209 . . . . 0.0 110.019 -179.31 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 56.6 p -82.19 -28.7 31.89 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.197 -0.939 . . . . 0.0 109.585 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.493 ' O ' ' O ' ' A' ' 78' ' ' GLY . 2.0 t . . . . . 0 N--CA 1.489 1.522 0 O-C-N 121.389 -0.819 . . . . 0.0 109.65 -179.857 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 13.4 m-70 . . . . . 0 N--CA 1.495 1.786 0 CA-C-O 121.108 0.48 . . . . 0.0 110.225 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -62.74 -41.36 99.15 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.078 -1.014 . . . . 0.0 109.509 179.77 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.3 p -62.75 -34.57 77.47 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.204 -0.935 . . . . 0.0 109.685 -179.731 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 65.3 t -64.62 -41.66 92.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.228 -0.92 . . . . 0.0 109.183 179.75 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 77.7 mt -59.67 -44.61 93.91 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 O-C-N 121.481 -0.762 . . . . 0.0 109.238 179.875 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -62.12 -38.33 88.53 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.333 -0.854 . . . . 0.0 109.235 179.875 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 7.2 tt0 -59.09 -41.14 87.36 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.273 -0.892 . . . . 0.0 109.185 179.72 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.699 ' CG ' ' CE2' ' A' ' 47' ' ' TRP . 23.0 m-85 -63.32 -40.74 98.16 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.012 -1.055 . . . . 0.0 109.955 179.586 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 55.9 t -59.53 -50.63 79.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.276 -0.89 . . . . 0.0 110.726 -178.558 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.472 ' O ' ' C ' ' A' ' 16' ' ' LEU . 17.1 m -66.12 -39.6 84.86 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.428 0 O-C-N 120.656 -1.277 . . . . 0.0 109.813 -179.955 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . 0.401 ' N ' HG23 ' A' ' 12' ' ' VAL . 97.2 mt-10 -67.21 -20.54 65.71 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.136 -0.977 . . . . 0.0 110.39 -179.785 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 -63.34 -30.11 71.3 Favored 'General case' 0 C--N 1.299 -1.606 0 O-C-N 121.275 -0.891 . . . . 0.0 109.731 -179.309 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 63.6 t80 -149.27 -33.23 0.21 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.997 -1.064 . . . . 0.0 110.253 -179.917 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.472 ' C ' ' O ' ' A' ' 12' ' ' VAL . 3.8 mt -121.89 79.93 41.47 Favored Pre-proline 0 N--CA 1.492 1.671 0 O-C-N 121.189 -0.945 . . . . 0.0 110.126 -179.383 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -74.62 -11.98 22.3 Favored 'Trans proline' 0 C--N 1.308 -1.573 0 C-N-CA 122.403 2.068 . . . . 0.0 112.438 179.881 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -93.9 12.83 24.61 Favored 'General case' 0 N--CA 1.487 1.377 0 O-C-N 121.246 -0.909 . . . . 0.0 110.371 -179.413 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 60.5 t -111.15 134.71 52.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 121.238 -0.914 . . . . 0.0 109.831 -179.784 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . 0.49 ' O ' ' OD1' ' A' ' 23' ' ' ASP . . . -75.96 118.43 71.09 Favored Pre-proline 0 N--CA 1.489 1.515 0 O-C-N 121.338 -0.851 . . . . 0.0 109.326 179.912 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_exo -51.41 -25.63 19.15 Favored 'Trans proline' 0 N--CA 1.493 1.486 0 C-N-CA 121.77 1.647 . . . . 0.0 112.146 179.611 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.81 -25.61 67.98 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.261 -0.9 . . . . 0.0 109.732 -179.896 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.49 ' OD1' ' O ' ' A' ' 20' ' ' ALA . 49.8 p30 -85.81 7.46 23.76 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.195 -0.941 . . . . 0.0 109.925 -179.611 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 17.3 t -109.7 133.32 55.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.321 -0.862 . . . . 0.0 109.397 179.844 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 63.4 t0 -88.47 119.66 29.12 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.141 -0.974 . . . . 0.0 108.892 179.348 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.6 m -75.89 3.81 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 O-C-N 121.182 -0.949 . . . . 0.0 109.285 179.851 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -87.55 -11.38 48.93 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.333 -0.854 . . . . 0.0 108.966 179.424 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 36.4 tp -94.98 136.91 34.73 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 179.778 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -59.51 134.16 56.76 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.114 -0.991 . . . . 0.0 109.409 -179.493 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.493 ' H ' ' HA ' ' A' ' 68' ' ' SER . 2.3 tt -67.15 -37.81 84.41 Favored 'General case' 0 C--N 1.299 -1.6 0 O-C-N 121.732 -0.605 . . . . 0.0 110.154 -179.18 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 78.2 t -63.79 -34.96 71.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.05 -1.031 . . . . 0.0 110.396 -178.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 56.9 t0 -52.36 -33.66 44.08 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 120.984 -1.073 . . . . 0.0 108.11 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 21.8 m120 -71.16 -34.48 71.01 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.55 -0.719 . . . . 0.0 109.897 179.433 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 86.37 6.52 80.95 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.056 -1.617 . . . . 0.0 109.056 -179.374 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 79.6 t -61.66 -34.3 61.41 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 O-C-N 121.455 -1.026 . . . . 0.0 109.152 179.719 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 85.4 mt -86.07 117.84 31.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.324 -0.86 . . . . 0.0 109.656 -179.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -114.01 -164.59 0.94 Allowed 'General case' 0 C--N 1.302 -1.463 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 179.845 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -64.74 -54.21 34.94 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.109 -0.994 . . . . 0.0 108.682 179.704 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 38.5 mt -68.71 -32.81 72.86 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 107.105 -1.443 . . . . 0.0 107.105 178.264 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -59.15 -40.7 96.04 Favored Glycine 0 N--CA 1.48 1.592 0 N-CA-C 108.403 -1.879 . . . . 0.0 108.403 179.16 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.597 ' CD1' ' CZ ' ' A' ' 66' ' ' PHE . 7.3 tt -65.47 -41.67 93.07 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.479 -1.012 . . . . 0.0 108.888 178.978 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 tp -59.71 -45.74 91.22 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 179.443 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 25.2 mttp -60.51 -35.44 75.96 Favored 'General case' 0 C--N 1.297 -1.698 0 O-C-N 121.577 -0.702 . . . . 0.0 109.553 -179.881 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 72.5 t -60.11 -43.3 92.59 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 O-C-N 121.296 -0.877 . . . . 0.0 109.445 -179.916 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.484 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 6.4 mm -67.45 -40.03 83.74 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.559 0 O-C-N 121.476 -0.765 . . . . 0.0 111.144 -179.088 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.48 -49.09 67.78 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.038 -1.038 . . . . 0.0 112.162 -177.596 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . 0.699 ' CE2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -78.77 -46.73 18.21 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.448 -1.407 . . . . 0.0 110.679 -178.55 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.477 ' C ' ' CD1' ' A' ' 48' ' ' LEU . 3.2 tm? -58.4 -43.54 88.6 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.005 -1.06 . . . . 0.0 109.921 -178.301 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.484 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 1.2 pp20? -69.76 -36.83 76.12 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 120.943 -1.098 . . . . 0.0 109.66 -179.911 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.2 t0 -62.82 -37.88 88.54 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.181 -0.949 . . . . 0.0 110.321 179.895 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 9.7 mmt180 -60.95 -38.47 85.97 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.322 -0.861 . . . . 0.0 111.724 -178.81 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -96.82 -6.89 34.97 Favored 'General case' 0 C--N 1.304 -1.392 0 O-C-N 120.817 -1.177 . . . . 0.0 110.239 -178.947 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 70.92 30.81 67.58 Favored Glycine 0 N--CA 1.486 1.971 0 N-CA-C 108.72 -1.752 . . . . 0.0 108.72 179.653 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.47 ' O ' ' OE1' ' A' ' 49' ' ' GLU . 24.7 pt -108.59 153.07 10.35 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 O-C-N 121.587 -0.949 . . . . 0.0 109.765 -179.408 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -104.14 156.28 18.01 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.383 -0.823 . . . . 0.0 109.554 -179.78 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -58.22 -25.54 61.78 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.234 -0.916 . . . . 0.0 109.151 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 61.2 t0 59.07 39.62 23.05 Favored 'General case' 0 N--CA 1.485 1.286 0 O-C-N 121.517 -0.739 . . . . 0.0 109.075 -179.761 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 54.38 44.87 28.27 Favored 'General case' 0 N--CA 1.487 1.379 0 O-C-N 121.706 -0.621 . . . . 0.0 110.202 179.367 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 52.6 t -121.33 134.46 64.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.446 -0.784 . . . . 0.0 109.137 179.382 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -102.29 132.44 48.24 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.19 -0.944 . . . . 0.0 109.599 -179.914 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 53.1 mt -95.24 147.3 23.62 Favored 'General case' 0 C--N 1.304 -1.394 0 O-C-N 121.347 -0.846 . . . . 0.0 109.293 179.792 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.562 ' HG ' ' H ' ' A' ' 64' ' ' GLU . 0.0 OUTLIER -104.4 157.67 33.59 Favored Pre-proline 0 N--CA 1.486 1.349 0 O-C-N 121.282 -0.886 . . . . 0.0 108.92 179.872 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 2.1 Cg_endo -49.4 -19.65 3.19 Favored 'Trans proline' 0 C--N 1.302 -1.869 0 C-N-CA 122.398 2.065 . . . . 0.0 110.985 -179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . 0.562 ' H ' ' HG ' ' A' ' 62' ' ' SER . 87.4 tt0 -68.54 -32.32 72.18 Favored 'General case' 0 N--CA 1.486 1.375 0 O-C-N 121.606 -0.683 . . . . 0.0 109.56 179.404 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . 0.553 ' C ' ' CD2' ' A' ' 65' ' ' HIS . 1.5 t60 -66.33 -17.89 65.03 Favored 'General case' 0 C--N 1.3 -1.558 0 O-C-N 121.384 -0.823 . . . . 0.0 108.829 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.602 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 4.2 m-85 -101.97 14.99 30.39 Favored 'General case' 0 C--N 1.298 -1.642 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . 0.422 ' NE ' ' OG ' ' A' ' 71' ' ' SER . 4.8 ptt180 -46.17 -38.31 8.11 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.875 -0.516 . . . . 0.0 109.985 -179.684 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.496 ' HG ' ' H ' ' A' ' 71' ' ' SER . 83.8 p -163.86 159.5 21.14 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.081 -1.012 . . . . 0.0 109.905 179.578 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.41 ' H ' HD13 ' A' ' 69' ' ' ILE . 3.4 mp -57.83 -35.35 51.08 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 179.087 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 57.9 mtp180 -57.85 -42.35 84.25 Favored 'General case' 0 C--N 1.304 -1.397 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 179.644 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' SER . . . . . 0.496 ' H ' ' HG ' ' A' ' 68' ' ' SER . 8.8 t -65.18 -38.81 91.69 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.652 -0.655 . . . . 0.0 109.987 -179.935 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 71.5 mt -58.93 -51.45 72.29 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 O-C-N 121.189 -0.944 . . . . 0.0 109.713 -179.286 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 43.1 t0 -62.1 -41.07 97.83 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.15 -0.969 . . . . 0.0 108.67 179.446 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.33 -37.6 85.72 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.667 -0.646 . . . . 0.0 109.952 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 64.3 t80 -60.36 -49.23 78.41 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.225 -0.922 . . . . 0.0 109.808 -179.626 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 93.7 t -66.45 -46.84 85.61 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 O-C-N 121.201 -0.937 . . . . 0.0 109.626 -179.89 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.491 ' O ' ' O ' ' A' ' 81' ' ' THR . 74.9 t -66.41 -40.51 86.78 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 O-C-N 121.261 -0.9 . . . . 0.0 109.229 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.05 -37.52 92.89 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 -179.72 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -73.25 -41.86 63.2 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.217 -1.166 . . . . 0.0 111.105 -178.929 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 43.6 p -83.36 -36.7 24.14 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.962 -1.086 . . . . 0.0 109.425 -179.598 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.491 ' O ' ' O ' ' A' ' 77' ' ' VAL . 0.6 OUTLIER . . . . . 0 C--N 1.299 -1.593 0 O-C-N 121.541 -0.724 . . . . 0.0 109.081 -179.762 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 81.3 m-70 . . . . . 0 N--CA 1.492 1.638 0 CA-C-O 121.116 0.484 . . . . 0.0 110.018 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -60.72 -34.44 74.41 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.127 -0.983 . . . . 0.0 109.522 179.805 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.8 t -58.69 -38.61 78.62 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.295 -0.878 . . . . 0.0 109.876 -179.602 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 78.9 t -64.06 -46.28 94.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.143 -0.973 . . . . 0.0 109.353 179.936 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 77.5 mt -61.27 -46.25 96.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 179.491 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.527 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -62.22 -35.36 78.66 Favored 'General case' 0 C--N 1.303 -1.419 0 O-C-N 121.619 -0.675 . . . . 0.0 109.29 179.734 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 31.4 tt0 -62.11 -41.76 98.54 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.19 -0.944 . . . . 0.0 110.419 -179.611 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.672 ' CG ' ' CE2' ' A' ' 47' ' ' TRP . 49.6 m-85 -68.13 -50.75 52.64 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 120.896 -1.127 . . . . 0.0 111.065 -179.268 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 36.0 m -66.01 -38.95 83.21 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 O-C-N 120.972 -1.08 . . . . 0.0 109.247 -179.315 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.527 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 89.2 t -63.68 -46.27 95.16 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 O-C-N 121.261 -0.899 . . . . 0.0 109.204 179.479 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -75.09 -16.92 60.54 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.14 -0.975 . . . . 0.0 110.076 179.824 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -63.81 -33.67 76.19 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.285 -0.884 . . . . 0.0 110.439 -178.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 67.2 t80 -154.08 -19.16 0.13 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.86 -1.15 . . . . 0.0 110.471 -179.634 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.456 ' C ' ' O ' ' A' ' 12' ' ' VAL . 5.6 mt -121.57 80.05 38.86 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.198 -0.939 . . . . 0.0 109.835 -179.497 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -79.73 -17.41 11.07 Favored 'Trans proline' 0 C--N 1.307 -1.656 0 C-N-CA 122.665 2.244 . . . . 0.0 112.628 -179.877 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . 0.444 ' C ' ' OD1' ' A' ' 18' ' ' ASP . 51.8 p30 -90.09 9.99 26.04 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.166 -0.959 . . . . 0.0 110.172 -179.575 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 67.5 t -111.25 135.98 48.74 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.207 -0.933 . . . . 0.0 109.532 179.754 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -78.27 117.39 65.86 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.312 -0.867 . . . . 0.0 109.443 -179.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_exo -51.95 -35.83 61.96 Favored 'Trans proline' 0 N--CA 1.491 1.368 0 C-N-CA 121.709 1.606 . . . . 0.0 111.817 179.326 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.84 -23.73 66.73 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.3 -0.875 . . . . 0.0 108.925 179.529 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -84.71 7.46 20.41 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.418 -0.801 . . . . 0.0 109.743 -179.795 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 13.0 t -101.63 132.51 47.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.145 -0.972 . . . . 0.0 109.264 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.423 ' C ' ' H ' ' A' ' 27' ' ' ASP . 63.8 t0 -89.01 119.39 29.49 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.151 -0.968 . . . . 0.0 109.223 179.587 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -69.33 4.25 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 O-C-N 121.204 -0.935 . . . . 0.0 109.452 179.782 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.423 ' H ' ' C ' ' A' ' 25' ' ' ASP . 92.5 m-20 -95.02 -2.77 49.62 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.251 -0.905 . . . . 0.0 109.239 179.66 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 39.8 tp -99.56 136.42 39.52 Favored 'General case' 0 C--N 1.303 -1.441 0 O-C-N 121.394 -0.816 . . . . 0.0 108.92 179.714 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -58.62 137.12 57.7 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.105 -0.997 . . . . 0.0 109.196 -179.502 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.478 ' H ' ' HA ' ' A' ' 68' ' ' SER . 1.8 tt -68.35 -36.73 79.68 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.635 -0.665 . . . . 0.0 110.36 -178.981 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 69.6 t -64.75 -35.51 75.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.101 -0.999 . . . . 0.0 110.557 -179.004 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -52.54 -33.61 46.34 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 120.996 -1.065 . . . . 0.0 108.178 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 3.2 m120 -70.98 -34.52 71.47 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.604 -0.685 . . . . 0.0 109.982 179.485 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 85.96 6.05 82.72 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 108.88 -1.688 . . . . 0.0 108.88 -179.24 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 78.5 t -61.1 -31.21 49.43 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.398 0 O-C-N 121.495 -1.003 . . . . 0.0 108.68 179.512 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 81.5 mt -93.99 132.3 38.48 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 O-C-N 121.438 -0.789 . . . . 0.0 109.677 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.566 ' CG ' ' H ' ' A' ' 38' ' ' ALA . 52.4 t0 -138.97 -167.69 2.27 Favored 'General case' 0 C--N 1.301 -1.528 0 N-CA-C 108.562 -0.903 . . . . 0.0 108.562 179.602 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.566 ' H ' ' CG ' ' A' ' 37' ' ' ASP . . . -62.6 -55.22 29.14 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.928 -1.107 . . . . 0.0 108.588 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 37.4 mt -71.47 -34.79 70.51 Favored 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 107.063 -1.458 . . . . 0.0 107.063 178.024 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -59.85 -39.85 95.98 Favored Glycine 0 N--CA 1.481 1.671 0 N-CA-C 108.703 -1.759 . . . . 0.0 108.703 179.169 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . 0.518 ' C ' ' CD1' ' A' ' 41' ' ' LEU . 2.5 tm? -65.04 -43.89 90.87 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.49 -1.006 . . . . 0.0 108.622 179.386 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.2 tp -59.09 -46.03 89.33 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.343 -0.848 . . . . 0.0 109.066 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 63.2 mttp -61.49 -34.79 76.07 Favored 'General case' 0 C--N 1.295 -1.778 0 O-C-N 121.537 -0.727 . . . . 0.0 109.481 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 91.6 t -62.56 -50.43 79.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.451 -0.781 . . . . 0.0 110.166 -179.347 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.7 mp -68.34 -29.85 45.65 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 O-C-N 121.314 -0.866 . . . . 0.0 110.566 -179.774 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.47 -49.2 67.44 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.108 -0.995 . . . . 0.0 111.657 -178.177 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . 0.672 ' CE2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -81.08 -40.99 23.26 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 120.592 -1.317 . . . . 0.0 110.3 -179.015 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.411 HD11 ' HE ' ' A' ' 51' ' ' ARG . 0.2 OUTLIER -61.23 -41.62 97.19 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.154 -0.966 . . . . 0.0 109.298 -179.357 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.419 ' CG ' ' N ' ' A' ' 50' ' ' ASP . 17.0 pt-20 -73.13 -36.07 66.63 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 120.638 -1.289 . . . . 0.0 109.165 179.907 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . 0.419 ' N ' ' CG ' ' A' ' 49' ' ' GLU . 59.0 t0 -65.6 -40.84 93.12 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.632 -0.667 . . . . 0.0 111.766 -179.072 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . 0.426 HH21 HG12 ' A' ' 76' ' ' VAL . 24.3 ptt180 -71.39 -36.59 71.46 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 120.864 -1.148 . . . . 0.0 111.484 -177.712 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.414 ' CE1' ' CG1' ' A' ' 76' ' ' VAL . 5.7 m-85 -81.21 -14.74 57.21 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.577 -1.327 . . . . 0.0 109.756 -179.726 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.27 20.67 71.9 Favored Glycine 0 N--CA 1.486 2.025 0 N-CA-C 108.693 -1.763 . . . . 0.0 108.693 -179.745 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 23.1 pt -113.19 153.65 14.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.737 -0.86 . . . . 0.0 109.695 -179.573 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -101.03 132.29 46.53 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.249 -0.907 . . . . 0.0 109.519 -179.789 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.503 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -69.0 -23.55 64.12 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.316 -0.865 . . . . 0.0 109.692 179.859 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 91.3 m-20 -54.98 -36.08 65.01 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.268 -0.895 . . . . 0.0 110.146 -179.487 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -56.13 -39.36 72.12 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.18 -0.95 . . . . 0.0 110.001 -179.547 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.503 ' O ' ' O ' ' A' ' 56' ' ' ALA . 41.7 t -126.86 136.68 60.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.337 -0.852 . . . . 0.0 109.666 -179.894 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -87.58 127.23 35.27 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.117 -0.989 . . . . 0.0 109.185 179.864 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 39.4 mt -104.53 142.05 35.31 Favored 'General case' 0 C--N 1.306 -1.295 0 O-C-N 121.279 -0.888 . . . . 0.0 109.831 -179.649 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -108.75 152.54 42.31 Favored Pre-proline 0 N--CA 1.485 1.316 0 N-CA-C 108.696 -0.854 . . . . 0.0 108.696 179.377 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 12.8 Cg_endo -58.44 -21.16 52.44 Favored 'Trans proline' 0 C--N 1.304 -1.768 0 C-N-CA 122.505 2.137 . . . . 0.0 112.196 -179.748 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -69.6 -30.1 67.77 Favored 'General case' 0 N--CA 1.486 1.335 0 O-C-N 121.272 -0.892 . . . . 0.0 109.731 -179.726 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . 0.425 ' CE1' ' HB2' ' A' ' 75' ' ' PHE . 76.3 t60 -66.16 -20.66 66.21 Favored 'General case' 0 C--N 1.299 -1.588 0 O-C-N 121.233 -0.917 . . . . 0.0 108.918 -179.874 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.496 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 21.8 m-85 -89.17 12.73 15.0 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.394 -0.816 . . . . 0.0 109.203 -179.68 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 4.2 ptt85 -49.88 -34.56 20.58 Favored 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.628 -0.67 . . . . 0.0 109.513 179.719 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.478 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 89.2 p -151.65 153.54 34.62 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.154 -0.966 . . . . 0.0 109.895 179.794 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.454 ' O ' ' OD1' ' A' ' 73' ' ' ASP . 3.5 mp -59.83 -34.81 57.11 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.485 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 179.3 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 30.2 mtp85 -57.11 -45.18 83.66 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.604 -0.685 . . . . 0.0 109.765 -179.272 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 22.9 t -64.9 -46.07 83.25 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.307 -0.871 . . . . 0.0 109.781 -179.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.417 ' HA ' ' NE2' ' A' ' 65' ' ' HIS . 68.0 mt -58.95 -42.89 87.38 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 O-C-N 121.176 -0.952 . . . . 0.0 109.913 -179.735 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . 0.481 ' N ' ' OD1' ' A' ' 73' ' ' ASP . 2.0 m-20 -61.14 -37.95 84.66 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.292 -0.88 . . . . 0.0 109.842 -179.584 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -67.4 -46.91 71.85 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.035 -1.041 . . . . 0.0 110.541 -179.304 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . 0.425 ' HB2' ' CE1' ' A' ' 65' ' ' HIS . 65.8 t80 -66.03 -44.08 85.71 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.135 -0.978 . . . . 0.0 109.57 -179.737 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.426 HG12 HH21 ' A' ' 51' ' ' ARG . 43.4 t -60.68 -41.83 89.68 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 O-C-N 121.301 -0.874 . . . . 0.0 108.81 179.334 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.499 ' O ' ' O ' ' A' ' 81' ' ' THR . 65.3 t -65.0 -40.52 89.34 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.256 0 O-C-N 121.306 -0.871 . . . . 0.0 109.042 179.338 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.53 -17.23 32.47 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.753 -1.339 . . . . 0.0 109.753 179.794 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -66.71 -34.82 78.68 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.288 -1.125 . . . . 0.0 110.573 -179.176 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 49.7 p -134.49 -20.5 1.82 Allowed 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.009 -1.057 . . . . 0.0 110.709 -179.381 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.499 ' O ' ' O ' ' A' ' 77' ' ' VAL . 0.1 OUTLIER . . . . . 0 N--CA 1.49 1.528 0 O-C-N 121.144 -0.973 . . . . 0.0 109.39 -179.919 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 97.2 m-70 . . . . . 0 N--CA 1.486 1.348 0 N-CA-C 108.034 -1.099 . . . . 0.0 108.034 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.585 ' N ' ' OD2' ' A' ' 73' ' ' ASP . . . -52.94 -41.04 64.1 Favored 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.518 -0.739 . . . . 0.0 109.861 -179.078 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 21.3 m -61.11 -39.28 89.4 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.178 -0.951 . . . . 0.0 109.602 179.975 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 54.6 t -61.61 -43.88 97.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.331 -0.855 . . . . 0.0 109.483 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 82.5 mt -59.78 -40.27 82.08 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.45 0 O-C-N 121.363 -0.835 . . . . 0.0 109.076 179.697 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -60.92 -36.25 78.8 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 179.897 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 26.5 mt-30 -65.8 -39.16 90.64 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.296 -0.878 . . . . 0.0 109.967 179.757 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.66 ' CG ' ' CZ2' ' A' ' 47' ' ' TRP . 28.5 m-85 -64.2 -50.44 68.08 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.167 -0.958 . . . . 0.0 111.057 -179.28 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 2.9 p -59.89 -42.74 90.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.016 -1.053 . . . . 0.0 109.579 -179.19 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.464 ' O ' ' C ' ' A' ' 16' ' ' LEU . 86.9 t -63.46 -47.3 92.32 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 O-C-N 121.115 -0.99 . . . . 0.0 109.396 179.833 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -71.53 -24.12 61.9 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.172 -0.955 . . . . 0.0 109.96 179.825 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -64.19 -32.07 73.51 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.363 -0.836 . . . . 0.0 110.893 -178.763 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 63.1 t80 -140.83 -35.12 0.49 Allowed 'General case' 0 N--CA 1.494 1.758 0 O-C-N 120.849 -1.157 . . . . 0.0 110.742 -179.254 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.464 ' C ' ' O ' ' A' ' 12' ' ' VAL . 5.2 mt -119.17 80.04 19.4 Favored Pre-proline 0 N--CA 1.493 1.693 0 O-C-N 121.167 -0.958 . . . . 0.0 109.939 -179.397 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_endo -77.86 -15.3 15.08 Favored 'Trans proline' 0 C--N 1.308 -1.603 0 C-N-CA 122.546 2.164 . . . . 0.0 112.198 179.755 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -88.43 5.32 42.88 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 121.32 -0.862 . . . . 0.0 109.788 -179.729 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 46.3 t -110.64 134.92 51.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.387 -0.821 . . . . 0.0 109.564 -179.88 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.46 118.63 69.34 Favored Pre-proline 0 N--CA 1.489 1.503 0 O-C-N 121.279 -0.888 . . . . 0.0 109.24 179.902 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_exo -51.3 -28.62 27.25 Favored 'Trans proline' 0 N--CA 1.492 1.397 0 C-N-CA 121.728 1.619 . . . . 0.0 111.866 179.659 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.42 -23.31 66.91 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.198 -0.939 . . . . 0.0 109.286 179.688 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.45 ' O ' ' OD1' ' A' ' 23' ' ' ASP . 60.2 t0 -81.65 4.03 23.18 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.326 -0.859 . . . . 0.0 109.762 -179.762 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 13.5 t -108.75 133.32 54.19 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.245 -0.909 . . . . 0.0 109.351 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 86.9 m-20 -88.29 120.53 29.74 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.084 -1.01 . . . . 0.0 108.964 179.379 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 32.8 m -75.68 4.42 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 O-C-N 121.237 -0.915 . . . . 0.0 109.178 179.601 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -93.17 -2.75 54.98 Favored 'General case' 0 C--N 1.306 -1.318 0 O-C-N 121.316 -0.865 . . . . 0.0 108.941 179.518 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 39.8 tp -97.13 138.32 34.83 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.494 -0.754 . . . . 0.0 109.016 179.819 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 87.3 m-20 -60.09 138.5 57.87 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.154 -0.966 . . . . 0.0 109.531 -179.407 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.472 ' H ' ' HA ' ' A' ' 68' ' ' SER . 1.3 tt -75.62 -36.74 60.17 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.716 -0.615 . . . . 0.0 110.454 -179.203 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.415 HG23 ' H ' ' A' ' 32' ' ' ASP . 12.9 m -64.1 -38.4 82.36 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.659 0 O-C-N 121.111 -0.993 . . . . 0.0 110.583 -178.903 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.415 ' H ' HG23 ' A' ' 31' ' ' VAL . 92.5 m-20 -54.5 -33.45 59.87 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.142 -0.974 . . . . 0.0 108.375 179.67 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 96.1 m-20 -70.5 -34.56 72.47 Favored 'General case' 0 C--N 1.303 -1.445 0 O-C-N 121.656 -0.653 . . . . 0.0 110.0 179.875 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 82.37 5.86 89.2 Favored Glycine 0 N--CA 1.493 2.479 0 N-CA-C 109.516 -1.433 . . . . 0.0 109.516 -179.904 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 78.3 t -61.35 -34.36 60.69 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 O-C-N 121.276 -1.132 . . . . 0.0 108.697 179.501 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.7 mt -77.34 112.17 14.98 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 121.454 -0.779 . . . . 0.0 109.954 179.91 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -111.33 -164.53 0.92 Allowed 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 179.595 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -66.71 -54.25 25.01 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.125 -0.984 . . . . 0.0 108.874 179.694 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.457 ' CD1' ' N ' ' A' ' 39' ' ' LEU . 6.9 mp -69.77 -32.89 71.64 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 107.397 -1.334 . . . . 0.0 107.397 178.432 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -59.41 -43.0 97.76 Favored Glycine 0 N--CA 1.482 1.704 0 N-CA-C 109.053 -1.619 . . . . 0.0 109.053 179.509 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.5 tt -65.13 -42.73 93.59 Favored 'General case' 0 C--N 1.303 -1.415 0 O-C-N 121.413 -1.051 . . . . 0.0 109.327 179.449 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 tp -60.06 -46.25 90.18 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.375 -0.828 . . . . 0.0 109.274 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 12.7 mttm -62.39 -34.44 76.73 Favored 'General case' 0 C--N 1.297 -1.7 0 O-C-N 121.44 -0.787 . . . . 0.0 109.789 -179.694 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 53.8 t -61.47 -50.42 80.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.291 -0.881 . . . . 0.0 110.322 -179.215 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.537 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 3.5 mp -68.36 -33.73 62.0 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 121.331 -0.856 . . . . 0.0 111.011 -179.67 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.42 -49.77 67.96 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.013 -1.054 . . . . 0.0 111.655 -178.007 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . 0.66 ' CZ2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -81.2 -43.78 18.79 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.75 -1.219 . . . . 0.0 109.905 -179.3 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.4 ' N ' ' CG ' ' A' ' 47' ' ' TRP . 31.4 tp -58.82 -42.35 88.98 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.215 -0.928 . . . . 0.0 109.95 -179.267 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.537 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 1.1 pp20? -72.53 -36.02 68.2 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.082 -1.011 . . . . 0.0 109.749 -179.959 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.5 t0 -60.43 -38.51 84.35 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.251 -0.905 . . . . 0.0 110.608 -179.653 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 77.7 mtp85 -61.81 -37.83 85.87 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.167 -0.958 . . . . 0.0 111.602 -178.668 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.42 ' CE2' ' CG1' ' A' ' 76' ' ' VAL . 88.0 m-85 -95.86 -8.5 33.95 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 120.67 -1.269 . . . . 0.0 110.339 -178.97 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 71.98 30.37 65.69 Favored Glycine 0 N--CA 1.486 2.021 0 N-CA-C 108.872 -1.691 . . . . 0.0 108.872 179.682 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.501 ' O ' ' OE1' ' A' ' 49' ' ' GLU . 26.0 pt -107.55 151.13 9.66 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.402 0 O-C-N 121.654 -0.909 . . . . 0.0 109.653 -179.502 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . 0.475 ' O ' ' OD1' ' A' ' 58' ' ' ASP . . . -101.76 132.48 47.47 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.233 -0.917 . . . . 0.0 109.645 -179.661 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.5 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -67.0 -26.88 67.02 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.335 -0.853 . . . . 0.0 109.396 179.751 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 52.3 t0 -54.87 -34.79 63.36 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.317 -0.864 . . . . 0.0 110.042 -179.571 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.632 ' OD1' ' N ' ' A' ' 59' ' ' VAL . 55.3 p30 -59.47 -34.53 72.66 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.196 -0.94 . . . . 0.0 110.301 -179.459 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.632 ' N ' ' OD1' ' A' ' 58' ' ' ASP . 14.5 p -136.86 140.96 41.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.025 -1.047 . . . . 0.0 109.585 179.92 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -85.3 139.35 31.67 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.053 -1.03 . . . . 0.0 109.299 179.818 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 5.1 mp -97.72 136.9 37.41 Favored 'General case' 0 C--N 1.305 -1.345 0 O-C-N 121.198 -0.939 . . . . 0.0 109.712 -179.835 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -110.0 155.35 41.83 Favored Pre-proline 0 N--CA 1.488 1.457 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 179.489 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 7.8 Cg_endo -53.2 -23.55 23.29 Favored 'Trans proline' 0 C--N 1.302 -1.904 0 C-N-CA 122.286 1.991 . . . . 0.0 111.685 -179.898 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -70.69 -26.54 63.47 Favored 'General case' 0 N--CA 1.486 1.336 0 O-C-N 121.344 -0.847 . . . . 0.0 109.507 179.655 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . 0.546 ' C ' ' CD2' ' A' ' 65' ' ' HIS . 1.9 t60 -65.62 -20.41 66.3 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.23 -0.919 . . . . 0.0 109.215 -179.703 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.54 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 6.7 m-85 -98.2 16.24 21.95 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 121.447 -0.783 . . . . 0.0 108.965 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . 0.588 ' NE ' ' OG ' ' A' ' 71' ' ' SER . 4.8 ptt180 -52.16 -36.34 51.27 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 121.754 -0.591 . . . . 0.0 110.08 -179.775 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.472 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 35.2 p -164.9 153.31 12.12 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.016 -1.053 . . . . 0.0 110.281 -179.702 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.405 HD11 ' H ' ' A' ' 69' ' ' ILE . 3.3 mp -57.94 -40.68 77.57 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 O-C-N 121.362 -0.836 . . . . 0.0 109.161 179.904 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.411 ' HG2' ' H ' ' A' ' 71' ' ' SER . 18.9 ptt180 -58.16 -42.24 85.53 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.643 -0.66 . . . . 0.0 109.266 179.806 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' SER . . . . . 0.588 ' OG ' ' NE ' ' A' ' 67' ' ' ARG . 26.5 t -64.92 -39.25 93.22 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.204 -0.935 . . . . 0.0 109.677 179.488 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 87.8 mt -58.92 -47.14 90.59 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.289 0 O-C-N 121.176 -0.953 . . . . 0.0 109.736 -179.73 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . 0.585 ' OD2' ' N ' ' A' ' 4' ' ' ALA . 26.5 t0 -58.91 -44.23 91.23 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.147 -0.971 . . . . 0.0 108.723 179.864 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . 0.55 ' O ' ' N ' ' A' ' 78' ' ' GLY . . . -66.96 -37.36 84.13 Favored 'General case' 0 C--N 1.304 -1.399 0 O-C-N 121.432 -0.792 . . . . 0.0 109.595 179.667 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 61.9 t80 -62.82 -48.83 77.37 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.19 -0.944 . . . . 0.0 109.644 -179.833 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.42 ' CG1' ' CE2' ' A' ' 52' ' ' PHE . 71.1 t -67.56 -48.8 75.51 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.282 0 O-C-N 121.201 -0.937 . . . . 0.0 109.782 -179.847 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 55.3 t -69.89 -43.77 79.33 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.274 0 O-C-N 121.106 -0.996 . . . . 0.0 109.034 179.38 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.55 ' N ' ' O ' ' A' ' 74' ' ' ALA . . . -59.38 -30.93 68.82 Favored Glycine 0 N--CA 1.488 2.127 0 N-CA-C 110.211 -1.155 . . . . 0.0 110.211 -179.606 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -68.63 -41.5 79.36 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.153 -1.204 . . . . 0.0 110.586 -178.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 47.1 p -79.74 -32.02 41.06 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.161 -0.962 . . . . 0.0 109.326 -179.83 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.492 ' O ' ' O ' ' A' ' 78' ' ' GLY . 1.8 t . . . . . 0 N--CA 1.487 1.401 0 O-C-N 121.447 -0.783 . . . . 0.0 108.911 179.93 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 16.9 m-70 . . . . . 0 N--CA 1.494 1.757 0 CA-C-O 121.205 0.526 . . . . 0.0 109.82 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -59.74 -40.92 89.71 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.068 -1.02 . . . . 0.0 109.29 179.786 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.3 m -61.29 -39.17 89.44 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.256 -0.902 . . . . 0.0 109.65 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 58.8 t -61.13 -41.35 89.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.205 -0.935 . . . . 0.0 109.454 179.911 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 79.7 mt -59.69 -45.62 94.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 O-C-N 121.409 -0.807 . . . . 0.0 109.287 179.866 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -62.14 -42.78 99.58 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.291 -0.881 . . . . 0.0 109.109 179.723 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 26.8 mt-30 -64.7 -33.46 76.0 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.249 -0.907 . . . . 0.0 109.128 179.255 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.535 ' CG ' ' CZ2' ' A' ' 47' ' ' TRP . 0.2 OUTLIER -60.43 -50.27 74.24 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.4 -0.813 . . . . 0.0 110.235 -179.521 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 13.4 m -64.39 -39.59 86.08 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 O-C-N 121.142 -0.973 . . . . 0.0 109.33 -179.723 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.405 ' O ' ' C ' ' A' ' 16' ' ' LEU . 77.6 t -63.99 -45.29 97.18 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.166 -0.959 . . . . 0.0 109.678 179.654 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -69.4 -34.47 74.54 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.17 -0.956 . . . . 0.0 110.23 -179.842 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -65.35 -32.67 74.44 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.292 -0.88 . . . . 0.0 110.458 -179.253 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -118.47 -54.08 2.29 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.263 -0.898 . . . . 0.0 111.336 -178.713 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.405 ' C ' ' O ' ' A' ' 12' ' ' VAL . 9.0 mt -119.41 80.18 21.48 Favored Pre-proline 0 N--CA 1.493 1.688 0 O-C-N 121.19 -0.944 . . . . 0.0 111.054 -178.285 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -75.1 -16.41 20.0 Favored 'Trans proline' 0 C--N 1.309 -1.511 0 C-N-CA 122.274 1.982 . . . . 0.0 112.186 178.825 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -90.99 5.7 47.72 Favored 'General case' 0 N--CA 1.487 1.384 0 O-C-N 121.213 -0.929 . . . . 0.0 109.893 -179.844 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.425 ' CG1' ' OD2' ' A' ' 23' ' ' ASP . 44.5 t -112.84 138.37 42.42 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.456 -0.778 . . . . 0.0 109.492 -179.857 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . 0.487 ' O ' ' OD1' ' A' ' 23' ' ' ASP . . . -70.37 117.27 53.25 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.275 -0.89 . . . . 0.0 109.469 -179.831 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -51.8 -26.21 23.26 Favored 'Trans proline' 0 N--CA 1.494 1.512 0 C-N-CA 122.017 1.812 . . . . 0.0 112.229 179.505 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.63 -23.66 67.33 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.281 -0.887 . . . . 0.0 109.815 -179.744 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.487 ' OD1' ' O ' ' A' ' 20' ' ' ALA . 51.5 p30 -85.64 7.63 22.58 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.192 -0.942 . . . . 0.0 110.007 -179.428 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 11.8 t -107.88 130.07 60.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.147 -0.97 . . . . 0.0 109.329 179.927 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 87.2 m-20 -89.73 120.33 30.9 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.18 -0.95 . . . . 0.0 109.097 179.28 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 6.3 m -78.1 4.42 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 O-C-N 121.129 -0.982 . . . . 0.0 108.941 179.457 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -88.73 -10.63 47.67 Favored 'General case' 0 N--CA 1.485 1.302 0 O-C-N 121.386 -0.821 . . . . 0.0 109.043 179.408 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 42.4 tp -94.24 140.57 29.61 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 109.076 -0.713 . . . . 0.0 109.076 179.844 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 83.3 m-20 -59.08 142.0 52.58 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.133 -0.979 . . . . 0.0 109.433 -179.361 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.459 ' H ' ' HA ' ' A' ' 68' ' ' SER . 27.8 tp -73.57 -37.74 65.41 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.421 -0.799 . . . . 0.0 110.343 -179.251 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.419 ' CG2' ' N ' ' A' ' 32' ' ' ASP . 33.1 m -66.73 -43.15 90.2 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 121.263 -0.898 . . . . 0.0 110.428 -179.005 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . 0.419 ' N ' ' CG2' ' A' ' 31' ' ' VAL . 92.1 m-20 -53.94 -33.37 56.6 Favored 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 179.747 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 97.1 m-20 -70.47 -34.12 72.04 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.619 -0.676 . . . . 0.0 109.995 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 87.47 7.2 76.31 Favored Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.183 -1.567 . . . . 0.0 109.183 -179.656 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 72.6 t -61.64 -26.93 41.04 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 O-C-N 121.469 -1.018 . . . . 0.0 108.78 179.575 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 67.6 mt -93.05 123.87 45.28 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.398 0 O-C-N 121.457 -0.777 . . . . 0.0 109.929 -179.458 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -115.79 -174.87 2.61 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 108.636 -0.876 . . . . 0.0 108.636 179.339 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -61.36 -53.45 56.43 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.056 -1.028 . . . . 0.0 108.432 179.594 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.46 ' CD1' ' N ' ' A' ' 39' ' ' LEU . 7.0 mp -70.39 -32.65 70.39 Favored 'General case' 0 C--N 1.301 -1.532 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 178.008 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -59.23 -43.65 97.04 Favored Glycine 0 N--CA 1.482 1.755 0 N-CA-C 109.01 -1.636 . . . . 0.0 109.01 179.574 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.3 tt -65.13 -42.05 94.22 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.463 -1.022 . . . . 0.0 109.163 179.32 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.5 tp -59.97 -46.12 90.47 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.294 -0.879 . . . . 0.0 109.405 179.871 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 86.6 mttt -61.44 -35.7 78.31 Favored 'General case' 0 C--N 1.297 -1.701 0 O-C-N 121.443 -0.786 . . . . 0.0 109.854 -179.678 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 55.3 t -61.48 -50.75 79.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.287 -0.883 . . . . 0.0 110.36 -179.27 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 3.5 mp -68.72 -34.3 64.15 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 O-C-N 121.279 -0.888 . . . . 0.0 111.181 -179.636 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.56 -49.94 60.86 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 120.986 -1.071 . . . . 0.0 111.998 -177.913 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . 0.535 ' CZ2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -80.18 -43.62 21.23 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.655 -1.278 . . . . 0.0 110.036 -179.045 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.441 ' N ' ' CG ' ' A' ' 47' ' ' TRP . 21.7 tp -58.88 -41.63 87.56 Favored 'General case' 0 C--N 1.299 -1.606 0 O-C-N 121.294 -0.879 . . . . 0.0 110.197 -179.03 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.416 ' CG ' ' N ' ' A' ' 50' ' ' ASP . 17.3 pt-20 -73.18 -37.45 66.51 Favored 'General case' 0 C--N 1.305 -1.362 0 O-C-N 121.059 -1.026 . . . . 0.0 109.636 -179.708 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . 0.416 ' N ' ' CG ' ' A' ' 49' ' ' GLU . 56.9 t0 -58.86 -39.15 80.51 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.354 -0.841 . . . . 0.0 110.64 -179.447 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 73.4 mtp85 -61.64 -36.76 81.72 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.169 -0.957 . . . . 0.0 111.322 -178.86 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.613 ' CZ ' ' CG1' ' A' ' 76' ' ' VAL . 87.5 m-85 -94.77 -8.0 38.83 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 120.745 -1.222 . . . . 0.0 110.407 -179.129 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 73.15 29.29 64.77 Favored Glycine 0 N--CA 1.487 2.089 0 N-CA-C 108.95 -1.66 . . . . 0.0 108.95 179.712 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 20.5 pt -109.68 153.21 11.51 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 O-C-N 121.699 -0.883 . . . . 0.0 109.551 -179.587 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -103.92 134.99 46.28 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.238 -0.914 . . . . 0.0 109.7 -179.614 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.506 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -68.09 -28.39 67.31 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.334 -0.853 . . . . 0.0 109.63 179.732 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -56.36 -36.89 69.31 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.125 -0.984 . . . . 0.0 109.995 -179.625 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 21.4 t70 -56.53 -40.01 74.34 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.146 -0.971 . . . . 0.0 109.987 -179.538 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.506 ' O ' ' O ' ' A' ' 56' ' ' ALA . 42.6 t -128.67 136.21 60.44 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.311 -0.868 . . . . 0.0 109.726 -179.846 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -86.14 132.94 33.91 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.063 -1.023 . . . . 0.0 109.242 179.835 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 57.6 mt -96.12 140.81 30.3 Favored 'General case' 0 C--N 1.305 -1.336 0 O-C-N 121.219 -0.926 . . . . 0.0 109.742 -179.64 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -109.77 155.92 40.68 Favored Pre-proline 0 N--CA 1.487 1.418 0 N-CA-C 108.787 -0.82 . . . . 0.0 108.787 179.479 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 7.2 Cg_endo -52.59 -23.02 18.34 Favored 'Trans proline' 0 C--N 1.303 -1.831 0 C-N-CA 122.335 2.023 . . . . 0.0 111.926 -179.772 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -70.26 -26.95 64.06 Favored 'General case' 0 N--CA 1.486 1.37 0 O-C-N 121.339 -0.851 . . . . 0.0 109.472 179.592 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . 0.551 ' C ' ' CD2' ' A' ' 65' ' ' HIS . 1.5 t60 -65.65 -19.39 65.89 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.412 -0.805 . . . . 0.0 109.046 -179.883 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.563 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 7.0 m-85 -100.14 16.35 24.44 Favored 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.521 -0.737 . . . . 0.0 109.174 -179.686 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . 0.403 ' HG2' ' H ' ' A' ' 68' ' ' SER . 0.6 OUTLIER -53.24 -37.89 62.47 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.59 -0.694 . . . . 0.0 110.621 -179.452 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.459 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 51.8 p -167.91 166.53 13.35 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.653 -1.279 . . . . 0.0 110.699 -179.97 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 19.8 mm -58.89 -35.28 55.58 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.201 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 178.913 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 34.7 mtp180 -57.51 -43.96 84.66 Favored 'General case' 0 C--N 1.303 -1.455 0 CA-C-O 121.446 0.641 . . . . 0.0 109.468 -179.354 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 11.8 t -67.06 -39.41 86.89 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.368 -0.832 . . . . 0.0 109.953 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 76.9 mt -59.84 -50.1 81.35 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 O-C-N 121.265 -0.897 . . . . 0.0 110.074 -179.277 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 44.3 t0 -59.66 -42.78 93.58 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.13 -0.981 . . . . 0.0 109.04 -179.871 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.55 -42.21 87.5 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.535 -0.728 . . . . 0.0 109.756 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 60.0 t80 -63.58 -46.2 86.95 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.185 -0.947 . . . . 0.0 109.411 -179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.613 ' CG1' ' CZ ' ' A' ' 52' ' ' PHE . 54.6 t -60.89 -47.22 94.36 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.297 0 O-C-N 121.367 -0.833 . . . . 0.0 109.138 179.854 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 55.5 t -69.26 -42.38 81.43 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 O-C-N 121.213 -0.929 . . . . 0.0 109.107 179.338 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.493 ' O ' ' O ' ' A' ' 81' ' ' THR . . . -65.22 -28.27 73.36 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 -179.831 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.04 -38.67 86.27 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.153 -1.204 . . . . 0.0 110.299 -178.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 52.1 p -82.42 -31.33 29.6 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.111 -0.993 . . . . 0.0 109.539 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.493 ' O ' ' O ' ' A' ' 78' ' ' GLY . 0.3 OUTLIER . . . . . 0 C--N 1.302 -1.464 0 O-C-N 121.51 -0.744 . . . . 0.0 109.605 -179.864 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 62.1 m80 . . . . . 0 N--CA 1.485 1.288 0 N-CA-C 108.114 -1.069 . . . . 0.0 108.114 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -57.25 -39.48 75.69 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.518 -0.739 . . . . 0.0 109.798 -179.33 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.1 p -63.04 -33.7 75.98 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.146 -0.971 . . . . 0.0 109.491 -179.895 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 75.9 t -65.9 -43.49 92.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.222 -0.924 . . . . 0.0 109.539 179.87 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 82.6 mt -59.59 -47.3 91.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.4 -0.812 . . . . 0.0 109.845 -179.859 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.507 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -63.26 -45.13 92.94 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.28 -0.888 . . . . 0.0 110.924 -179.181 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 53.9 mt-30 -69.09 -46.65 67.21 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.835 -1.165 . . . . 0.0 110.854 -178.723 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.549 ' C ' ' CD1' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -70.28 -48.75 55.31 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.075 -1.016 . . . . 0.0 110.298 -179.392 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.452 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 4.0 p -59.88 -38.81 77.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.072 -1.017 . . . . 0.0 109.678 -179.604 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.507 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 49.5 t -63.18 -43.22 98.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.224 -0.922 . . . . 0.0 109.963 -179.928 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -63.13 -34.51 77.76 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.104 -0.997 . . . . 0.0 109.941 -179.812 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -65.43 -31.74 72.99 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.269 -0.894 . . . . 0.0 110.197 -179.649 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 77.4 t80 -113.65 -61.4 1.75 Allowed 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.326 -0.859 . . . . 0.0 111.299 -178.818 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 4.8 mt -116.08 80.19 9.06 Favored Pre-proline 0 N--CA 1.494 1.726 0 O-C-N 121.219 -0.926 . . . . 0.0 111.017 -178.354 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_endo -74.64 -14.55 22.03 Favored 'Trans proline' 0 C--N 1.31 -1.5 0 C-N-CA 122.311 2.008 . . . . 0.0 112.156 178.848 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -84.93 0.84 49.83 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.286 -0.883 . . . . 0.0 109.601 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 42.3 t -115.36 134.93 56.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 121.43 -0.794 . . . . 0.0 109.568 -179.908 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.34 117.84 60.52 Favored Pre-proline 0 N--CA 1.489 1.486 0 O-C-N 121.183 -0.948 . . . . 0.0 109.405 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_exo -51.44 -30.06 33.54 Favored 'Trans proline' 0 N--CA 1.493 1.464 0 C-N-CA 121.757 1.638 . . . . 0.0 112.064 179.614 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.8 -25.12 67.78 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.239 -0.913 . . . . 0.0 109.291 179.769 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -81.88 4.45 22.38 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.368 -0.833 . . . . 0.0 109.777 -179.755 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 10.5 t -107.79 128.91 62.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.216 -0.927 . . . . 0.0 109.485 -179.923 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.408 ' C ' ' H ' ' A' ' 27' ' ' ASP . 88.1 m-20 -89.7 120.72 31.22 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.239 -0.913 . . . . 0.0 109.078 179.213 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 28.9 m -70.9 3.89 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 O-C-N 121.11 -0.993 . . . . 0.0 109.123 179.598 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.408 ' H ' ' C ' ' A' ' 25' ' ' ASP . 91.9 m-20 -94.25 -5.24 47.29 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.363 -0.836 . . . . 0.0 109.154 179.466 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 42.0 tp -95.32 138.14 33.42 Favored 'General case' 0 C--N 1.303 -1.421 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 179.599 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -57.2 135.62 56.42 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.068 -1.02 . . . . 0.0 109.354 -179.269 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.486 ' H ' ' HA ' ' A' ' 68' ' ' SER . 39.4 tp -64.59 -37.48 87.71 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.595 -0.69 . . . . 0.0 110.467 -179.336 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 70.2 t -66.2 -37.24 79.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.022 -1.049 . . . . 0.0 110.708 -179.15 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -52.93 -33.05 48.94 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 120.956 -1.09 . . . . 0.0 108.254 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -70.68 -34.33 71.86 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.631 -0.668 . . . . 0.0 109.946 179.457 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 86.6 5.26 82.07 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 108.824 -1.71 . . . . 0.0 108.824 -179.245 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 76.2 t -61.1 -32.69 53.41 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 O-C-N 121.582 -0.952 . . . . 0.0 108.924 179.637 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 80.7 mt -83.82 116.26 27.44 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.403 -0.811 . . . . 0.0 109.843 -179.872 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -114.99 -176.08 2.83 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 179.406 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -58.95 -53.38 59.08 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.021 -1.049 . . . . 0.0 108.205 179.601 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 35.8 mt -68.57 -32.44 72.36 Favored 'General case' 0 C--N 1.301 -1.528 0 N-CA-C 106.887 -1.523 . . . . 0.0 106.887 177.868 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -58.97 -40.93 96.05 Favored Glycine 0 N--CA 1.48 1.594 0 N-CA-C 108.718 -1.753 . . . . 0.0 108.718 179.274 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.3 tt -65.21 -41.61 94.31 Favored 'General case' 0 C--N 1.305 -1.34 0 O-C-N 121.386 -1.067 . . . . 0.0 108.693 178.893 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 tp -60.17 -45.72 92.14 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 179.322 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 21.0 mttp -60.71 -35.48 76.42 Favored 'General case' 0 C--N 1.298 -1.663 0 O-C-N 121.551 -0.718 . . . . 0.0 109.522 -179.935 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 53.3 t -59.81 -50.59 79.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.325 -0.859 . . . . 0.0 109.469 -179.657 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.425 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 3.5 mp -68.33 -30.36 47.4 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 O-C-N 121.256 -0.903 . . . . 0.0 110.459 179.704 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.84 -49.2 71.53 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.107 -0.996 . . . . 0.0 111.306 -178.473 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . 0.498 ' C ' ' CD1' ' A' ' 47' ' ' TRP . 0.0 OUTLIER -81.39 -43.23 19.28 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.759 -1.213 . . . . 0.0 110.032 -179.384 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.43 ' N ' ' CG ' ' A' ' 47' ' ' TRP . 0.4 OUTLIER -58.75 -43.19 90.22 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.118 -0.989 . . . . 0.0 109.113 -179.328 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.548 ' O ' ' N ' ' A' ' 53' ' ' GLY . 2.1 pp20? -72.18 -35.62 69.02 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.054 -1.029 . . . . 0.0 109.8 179.905 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.2 t0 -60.44 -38.42 84.09 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.247 -0.908 . . . . 0.0 110.567 -179.641 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 49.9 mtp180 -60.47 -40.73 92.29 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.131 -0.981 . . . . 0.0 111.189 -178.873 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 73.4 m-85 -106.49 -11.92 15.77 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.974 -1.078 . . . . 0.0 110.041 -179.358 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . 0.548 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 70.16 30.16 69.89 Favored Glycine 0 N--CA 1.485 1.939 0 N-CA-C 109.072 -1.611 . . . . 0.0 109.072 179.5 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 12.7 pt -93.57 124.31 45.97 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 O-C-N 121.358 -1.084 . . . . 0.0 109.623 -179.604 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -65.59 140.23 58.51 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.154 -0.966 . . . . 0.0 109.817 -179.535 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.503 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -65.45 -31.86 73.17 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.429 -0.794 . . . . 0.0 109.398 179.805 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -58.46 -37.36 75.3 Favored 'General case' 0 C--N 1.303 -1.45 0 O-C-N 121.183 -0.948 . . . . 0.0 109.952 -179.815 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -58.28 -40.11 81.04 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.225 -0.922 . . . . 0.0 109.964 -179.636 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.503 ' O ' ' O ' ' A' ' 56' ' ' ALA . 42.4 t -127.12 133.67 67.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.311 -0.868 . . . . 0.0 109.555 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -89.26 129.73 35.78 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.044 -1.035 . . . . 0.0 109.336 179.803 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . 0.581 ' CD2' ' N ' ' A' ' 61' ' ' LEU . 3.5 mm? -95.9 134.15 39.23 Favored 'General case' 0 C--N 1.305 -1.347 0 O-C-N 121.322 -0.861 . . . . 0.0 109.726 -179.821 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.56 ' HG ' ' N ' ' A' ' 63' ' ' PRO . 0.1 OUTLIER -109.96 156.35 40.11 Favored Pre-proline 0 N--CA 1.487 1.382 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 179.582 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . 0.56 ' N ' ' HG ' ' A' ' 62' ' ' SER . 9.5 Cg_endo -54.22 -22.88 27.56 Favored 'Trans proline' 0 C--N 1.302 -1.902 0 C-N-CA 122.295 1.997 . . . . 0.0 111.68 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . 0.446 ' H ' ' HG ' ' A' ' 62' ' ' SER . 96.5 mt-10 -69.96 -27.36 64.67 Favored 'General case' 0 N--CA 1.485 1.308 0 O-C-N 121.297 -0.877 . . . . 0.0 109.355 179.63 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . 0.545 ' C ' ' CD2' ' A' ' 65' ' ' HIS . 1.7 t60 -65.65 -19.94 66.11 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.307 -0.87 . . . . 0.0 109.003 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.55 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 7.9 m-85 -98.43 15.78 23.75 Favored 'General case' 0 C--N 1.299 -1.622 0 CA-C-O 121.601 0.715 . . . . 0.0 109.076 -179.765 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . 0.412 ' HG2' ' H ' ' A' ' 68' ' ' SER . 1.4 ptt85 -53.66 -36.6 62.29 Favored 'General case' 0 C--N 1.299 -1.61 0 O-C-N 121.679 -0.638 . . . . 0.0 110.55 -179.378 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.486 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 41.6 t -168.07 161.23 12.51 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.754 -1.216 . . . . 0.0 110.364 -179.787 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 2.4 mp -57.69 -34.15 46.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 179.026 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 52.0 mtp85 -56.65 -41.71 77.68 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 109.081 -0.711 . . . . 0.0 109.081 -179.897 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' SER . . . . . 0.533 ' HG ' ' N ' ' A' ' 72' ' ' ILE . 61.6 p -67.92 -32.98 73.81 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.444 -0.785 . . . . 0.0 109.596 -179.972 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.533 ' N ' ' HG ' ' A' ' 71' ' ' SER . 56.5 mt -61.45 -50.6 79.69 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.361 0 O-C-N 121.294 -0.879 . . . . 0.0 109.567 -179.578 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 43.4 t0 -61.41 -41.44 97.16 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.216 -0.927 . . . . 0.0 108.894 179.655 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.21 -37.55 85.84 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.56 -0.712 . . . . 0.0 109.873 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 67.2 t80 -61.48 -46.5 89.78 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.167 -0.958 . . . . 0.0 109.64 -179.772 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 41.9 t -61.36 -47.76 91.99 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 O-C-N 121.268 -0.895 . . . . 0.0 109.358 179.692 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . 0.457 ' O ' ' N ' ' A' ' 81' ' ' THR . 47.3 t -69.0 -43.42 82.02 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 O-C-N 121.399 -0.813 . . . . 0.0 109.762 179.855 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -63.28 -40.73 99.33 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 110.284 -1.126 . . . . 0.0 110.284 -179.571 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -70.57 -41.62 72.18 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.229 -1.16 . . . . 0.0 110.833 -178.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 69.5 p -86.52 -31.15 21.44 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 120.906 -1.121 . . . . 0.0 109.955 -179.341 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.457 ' N ' ' O ' ' A' ' 77' ' ' VAL . 0.2 OUTLIER . . . . . 0 C--N 1.302 -1.496 0 O-C-N 121.466 -0.771 . . . . 0.0 109.376 -179.752 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 6.7 m80 . . . . . 0 N--CA 1.495 1.819 0 CA-C-O 120.999 0.428 . . . . 0.0 110.091 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -61.78 -41.71 98.06 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 120.981 -1.074 . . . . 0.0 109.173 179.685 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.4 m -60.97 -37.5 82.64 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.434 -0.791 . . . . 0.0 109.895 -179.801 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 49.6 t -60.33 -44.13 95.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.174 -0.954 . . . . 0.0 109.496 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 78.6 mt -59.5 -50.18 80.87 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 O-C-N 121.397 -0.815 . . . . 0.0 109.641 -179.799 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . 0.451 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -63.96 -43.82 94.62 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.315 -0.866 . . . . 0.0 110.918 -179.569 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 27.2 mt-30 -69.08 -46.08 68.67 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 120.92 -1.112 . . . . 0.0 111.435 -178.446 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.711 ' CD1' ' N ' ' A' ' 11' ' ' VAL . 0.0 OUTLIER -70.42 -46.71 63.4 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.884 -1.135 . . . . 0.0 110.492 -179.177 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . 0.711 ' N ' ' CD1' ' A' ' 10' ' ' PHE . 4.8 p -62.03 -40.33 86.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.085 -1.01 . . . . 0.0 109.807 -179.523 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.468 ' N ' ' CG1' ' A' ' 11' ' ' VAL . 55.8 t -63.28 -43.54 98.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.173 -0.955 . . . . 0.0 109.866 179.998 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -65.82 -37.3 85.86 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.214 -0.929 . . . . 0.0 110.278 -179.536 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 85.7 tt0 -65.76 -39.58 91.2 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.159 -0.963 . . . . 0.0 110.116 -179.558 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . 0.427 ' CD2' ' CG1' ' A' ' 35' ' ' VAL . 75.6 t80 -93.77 -50.72 5.23 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.174 -0.954 . . . . 0.0 110.783 -179.218 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.408 ' N ' ' O ' ' A' ' 12' ' ' VAL . 5.4 mt -120.26 80.59 28.64 Favored Pre-proline 0 N--CA 1.491 1.622 0 O-C-N 121.285 -0.884 . . . . 0.0 110.525 -178.776 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 23.5 Cg_endo -69.05 -14.52 38.49 Favored 'Trans proline' 0 N--CA 1.493 1.451 0 C-N-CA 122.095 1.863 . . . . 0.0 112.353 179.614 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -94.92 7.1 47.12 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.179 -0.95 . . . . 0.0 110.387 -179.613 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 39.3 t -119.11 136.33 56.65 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 121.271 -0.893 . . . . 0.0 109.788 -179.779 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -78.53 117.96 69.49 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.301 -0.874 . . . . 0.0 109.081 179.608 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_exo -51.76 -27.77 27.96 Favored 'Trans proline' 0 N--CA 1.493 1.478 0 C-N-CA 121.787 1.658 . . . . 0.0 112.23 179.855 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.52 -27.01 68.67 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.203 -0.936 . . . . 0.0 109.305 -179.946 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.452 ' O ' ' OD1' ' A' ' 23' ' ' ASP . 60.0 t0 -82.19 3.55 26.87 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.303 -0.873 . . . . 0.0 109.7 -179.778 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 9.7 t -109.43 128.33 65.51 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.263 -0.898 . . . . 0.0 109.561 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . 0.433 ' C ' ' H ' ' A' ' 27' ' ' ASP . 87.2 m-20 -89.96 120.56 31.28 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.189 -0.945 . . . . 0.0 109.097 179.06 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 33.7 m -70.93 4.14 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.378 0 O-C-N 121.102 -0.999 . . . . 0.0 108.941 179.47 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.433 ' H ' ' C ' ' A' ' 25' ' ' ASP . 92.2 m-20 -92.13 -5.45 52.66 Favored 'General case' 0 N--CA 1.486 1.341 0 O-C-N 121.373 -0.829 . . . . 0.0 109.031 179.423 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 44.3 tp -96.52 141.1 30.21 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.473 -0.767 . . . . 0.0 108.957 179.86 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -58.59 128.57 37.86 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.176 -0.952 . . . . 0.0 109.504 -179.407 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.416 ' H ' ' HA ' ' A' ' 68' ' ' SER . 48.7 tp -66.85 -37.23 84.07 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.551 -0.718 . . . . 0.0 110.648 -179.417 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 70.6 t -63.67 -35.96 74.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 120.928 -1.107 . . . . 0.0 110.693 -178.911 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 56.3 t0 -52.43 -33.59 44.68 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 120.974 -1.079 . . . . 0.0 108.186 -179.908 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 97.5 m-20 -71.46 -34.45 70.23 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.698 -0.626 . . . . 0.0 110.232 179.476 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 87.22 4.87 80.74 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 108.58 -1.808 . . . . 0.0 108.58 -179.043 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . 0.427 ' CG1' ' CD2' ' A' ' 15' ' ' PHE . 67.8 t -59.87 -29.55 43.39 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 O-C-N 121.484 -1.009 . . . . 0.0 108.412 179.254 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 71.8 mt -88.07 132.5 33.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 CA-C-O 121.616 0.722 . . . . 0.0 109.627 -179.897 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.587 ' CG ' ' H ' ' A' ' 38' ' ' ALA . 45.7 t0 -139.07 -160.81 1.1 Allowed 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 179.845 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.587 ' H ' ' CG ' ' A' ' 37' ' ' ASP . . . -65.48 -54.31 30.19 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.117 -0.99 . . . . 0.0 108.716 179.817 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.464 ' CD1' ' N ' ' A' ' 39' ' ' LEU . 7.0 mp -69.63 -32.81 71.72 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 107.35 -1.352 . . . . 0.0 107.35 178.405 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -59.26 -44.06 96.77 Favored Glycine 0 N--CA 1.481 1.663 0 N-CA-C 109.008 -1.637 . . . . 0.0 109.008 179.545 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 2.8 tt -65.12 -42.06 94.28 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.473 -1.016 . . . . 0.0 109.369 179.168 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 15.8 tp -59.74 -44.69 93.67 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.227 -0.921 . . . . 0.0 109.339 179.857 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 18.8 mttt -62.2 -34.29 76.18 Favored 'General case' 0 C--N 1.299 -1.589 0 O-C-N 121.156 -0.965 . . . . 0.0 109.62 179.874 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 54.0 t -60.75 -50.18 81.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.27 -0.894 . . . . 0.0 110.06 -179.488 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.525 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 3.6 mp -68.48 -34.63 66.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.247 -0.908 . . . . 0.0 111.257 -179.669 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.81 -50.16 65.65 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 120.943 -1.098 . . . . 0.0 111.758 -177.867 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . 0.652 ' HE1' ' NE ' ' A' ' 51' ' ' ARG . 0.0 OUTLIER -80.05 -43.8 21.22 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.75 -1.219 . . . . 0.0 109.78 -179.457 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.552 ' CD1' HH21 ' A' ' 51' ' ' ARG . 15.0 tp -58.73 -43.16 90.1 Favored 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.382 -0.824 . . . . 0.0 110.12 -179.12 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.525 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 1.2 pp20? -72.67 -35.85 67.78 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.135 -0.978 . . . . 0.0 109.905 -179.762 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.1 t70 -61.51 -39.72 92.02 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.226 -0.921 . . . . 0.0 111.16 -179.317 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . 0.652 ' NE ' ' HE1' ' A' ' 47' ' ' TRP . 70.5 mtm180 -62.65 -36.8 83.99 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.19 -0.944 . . . . 0.0 112.028 -178.291 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 88.5 m-85 -95.96 -6.13 39.73 Favored 'General case' 0 N--CA 1.487 1.389 0 O-C-N 120.714 -1.242 . . . . 0.0 110.454 -178.718 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 70.33 29.39 70.21 Favored Glycine 0 N--CA 1.486 1.979 0 N-CA-C 108.882 -1.687 . . . . 0.0 108.882 179.349 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.488 ' O ' ' OE1' ' A' ' 49' ' ' GLU . 24.7 pt -107.28 152.38 8.87 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 O-C-N 121.557 -0.966 . . . . 0.0 109.559 -179.571 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -105.23 154.51 20.12 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.36 -0.837 . . . . 0.0 109.721 -179.472 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.416 ' O ' ' CG1' ' A' ' 59' ' ' VAL . . . -59.8 -21.19 60.5 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.339 -0.85 . . . . 0.0 109.177 179.904 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 56.3 t0 61.95 36.6 15.6 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 121.526 -0.734 . . . . 0.0 109.328 -179.789 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 53.32 48.61 21.61 Favored 'General case' 0 C--N 1.305 -1.366 0 O-C-N 121.439 -0.788 . . . . 0.0 110.357 178.941 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.416 ' CG1' ' O ' ' A' ' 56' ' ' ALA . 8.8 p -127.86 142.87 42.53 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.364 -0.835 . . . . 0.0 109.105 179.593 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -99.19 133.5 43.39 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.177 -0.952 . . . . 0.0 109.628 -179.792 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 59.3 mt -92.52 145.38 24.49 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.43 -0.794 . . . . 0.0 109.248 179.92 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -91.71 150.73 41.42 Favored Pre-proline 0 C--N 1.305 -1.34 0 O-C-N 121.14 -0.975 . . . . 0.0 108.765 179.8 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 11.4 Cg_endo -57.23 -19.82 36.06 Favored 'Trans proline' 0 C--N 1.304 -1.81 0 C-N-CA 122.335 2.023 . . . . 0.0 112.035 -179.67 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -67.96 -31.62 71.47 Favored 'General case' 0 N--CA 1.484 1.243 0 O-C-N 121.285 -0.885 . . . . 0.0 109.453 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . 0.586 ' CD2' ' O ' ' A' ' 65' ' ' HIS . 5.2 t-160 -66.04 -20.54 66.21 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.347 -0.846 . . . . 0.0 108.737 179.787 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.526 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 8.5 m-85 -94.63 14.65 20.37 Favored 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 -179.915 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . 0.587 ' NE ' ' OG ' ' A' ' 71' ' ' SER . 6.4 ptt180 -46.47 -37.65 8.09 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.739 -0.601 . . . . 0.0 110.381 -179.59 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.416 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 46.7 t -159.71 155.05 25.33 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.933 -1.104 . . . . 0.0 110.06 -179.764 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.476 ' CD1' ' H ' ' A' ' 69' ' ' ILE . 1.6 mp -57.69 -41.75 80.1 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 O-C-N 121.29 -0.881 . . . . 0.0 109.142 179.931 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 11.1 ptm180 -58.33 -42.05 85.93 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.406 -0.809 . . . . 0.0 109.1 179.795 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' SER . . . . . 0.587 ' OG ' ' NE ' ' A' ' 67' ' ' ARG . 26.4 t -62.97 -40.9 99.13 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.333 -0.854 . . . . 0.0 109.359 179.471 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.422 ' HA ' ' HE2' ' A' ' 65' ' ' HIS . 86.1 mt -60.12 -49.78 82.77 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 O-C-N 121.218 -0.926 . . . . 0.0 109.437 179.928 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 37.2 t0 -59.53 -40.6 87.71 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.366 -0.834 . . . . 0.0 109.013 179.695 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.45 -37.76 85.87 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.637 -0.665 . . . . 0.0 110.153 -179.882 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . 0.554 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 64.4 t80 -60.73 -47.77 84.78 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.145 -0.972 . . . . 0.0 109.836 -179.413 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 98.5 t -62.47 -46.3 96.74 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.294 0 O-C-N 121.064 -1.023 . . . . 0.0 109.18 179.809 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 78.8 t -66.9 -40.24 85.31 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.389 0 O-C-N 121.472 -0.768 . . . . 0.0 109.217 179.641 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.489 ' O ' ' O ' ' A' ' 81' ' ' THR . . . -59.46 -38.57 93.72 Favored Glycine 0 N--CA 1.488 2.127 0 N-CA-C 109.913 -1.275 . . . . 0.0 109.913 -179.781 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -69.15 -41.31 77.45 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.335 -1.097 . . . . 0.0 110.489 -179.3 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 44.9 p -81.81 -31.08 31.94 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.068 -1.02 . . . . 0.0 109.449 -179.781 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.489 ' O ' ' O ' ' A' ' 78' ' ' GLY . 0.5 OUTLIER . . . . . 0 C--N 1.3 -1.558 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 -179.869 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 97.1 m-70 . . . . . 0 N--CA 1.486 1.366 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -54.37 -42.64 70.56 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.524 -0.735 . . . . 0.0 109.836 -179.181 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 24.2 m -62.11 -38.08 87.55 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.28 -0.887 . . . . 0.0 109.868 -179.84 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 53.7 t -64.19 -45.44 96.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.165 -0.959 . . . . 0.0 109.781 -179.777 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 79.4 mt -59.77 -42.43 88.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.386 -0.821 . . . . 0.0 109.279 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -60.51 -36.93 79.55 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.374 -0.828 . . . . 0.0 109.18 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 7.3 tt0 -65.28 -40.23 93.6 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.271 -0.893 . . . . 0.0 110.077 179.924 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.677 ' CG ' ' CZ2' ' A' ' 47' ' ' TRP . 20.7 m-85 -62.01 -50.04 73.63 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.102 -0.999 . . . . 0.0 110.676 -179.426 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 22.2 m -64.08 -40.48 89.19 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 O-C-N 121.06 -1.025 . . . . 0.0 109.302 -179.629 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.446 ' O ' ' C ' ' A' ' 16' ' ' LEU . 69.0 t -63.66 -46.52 94.51 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.206 -0.934 . . . . 0.0 109.309 179.571 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -70.12 -29.39 66.32 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.305 -0.872 . . . . 0.0 109.895 179.818 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -64.82 -30.42 71.42 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.48 -0.762 . . . . 0.0 110.615 -179.094 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 75.9 t80 -131.89 -46.06 0.95 Allowed 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.083 -1.01 . . . . 0.0 111.125 -178.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.446 ' C ' ' O ' ' A' ' 12' ' ' VAL . 4.7 mt -117.98 80.16 14.55 Favored Pre-proline 0 N--CA 1.494 1.755 0 O-C-N 121.097 -1.002 . . . . 0.0 110.442 -178.994 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -76.15 -14.26 18.8 Favored 'Trans proline' 0 C--N 1.308 -1.604 0 C-N-CA 122.411 2.074 . . . . 0.0 112.255 179.324 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -89.08 5.19 45.63 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.279 -0.888 . . . . 0.0 109.761 -179.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . 0.411 ' CG1' ' OD2' ' A' ' 23' ' ' ASP . 45.1 t -112.64 135.33 52.38 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.378 -0.826 . . . . 0.0 109.59 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . 0.435 ' O ' ' CG ' ' A' ' 23' ' ' ASP . . . -73.18 117.52 60.83 Favored Pre-proline 0 N--CA 1.489 1.52 0 O-C-N 121.26 -0.9 . . . . 0.0 109.443 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_exo -51.98 -25.14 21.18 Favored 'Trans proline' 0 N--CA 1.493 1.5 0 C-N-CA 121.805 1.67 . . . . 0.0 112.039 179.486 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.72 -22.92 67.09 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.29 -0.881 . . . . 0.0 109.708 -179.828 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.45 ' C ' ' OD1' ' A' ' 23' ' ' ASP . 52.3 p30 -83.98 7.62 17.81 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.249 -0.907 . . . . 0.0 109.831 -179.74 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 11.8 t -104.97 133.57 48.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.218 -0.926 . . . . 0.0 109.348 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 86.5 m-20 -88.89 120.61 30.46 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.054 -1.029 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 17.0 m -74.96 3.83 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 O-C-N 121.26 -0.9 . . . . 0.0 109.386 179.849 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . 0.449 ' C ' ' OD1' ' A' ' 27' ' ' ASP . 52.0 p30 -94.95 1.12 55.2 Favored 'General case' 0 N--CA 1.486 1.349 0 O-C-N 121.245 -0.909 . . . . 0.0 109.227 179.454 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 46.0 tp -100.44 134.61 43.12 Favored 'General case' 0 C--N 1.303 -1.437 0 N-CA-C 108.358 -0.978 . . . . 0.0 108.358 179.313 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -57.72 126.71 28.56 Favored 'General case' 0 C--N 1.3 -1.546 0 C-N-CA 118.942 -1.103 . . . . 0.0 108.998 -179.335 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.47 ' H ' ' HA ' ' A' ' 68' ' ' SER . 43.0 tp -66.08 -37.97 87.11 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.654 -0.654 . . . . 0.0 110.654 -179.153 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 54.1 t -67.43 -37.47 78.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 120.931 -1.106 . . . . 0.0 110.774 -179.155 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 84.4 m-20 -52.69 -33.17 46.25 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 120.859 -1.151 . . . . 0.0 108.111 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 20.3 m120 -70.72 -33.48 70.9 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.639 -0.663 . . . . 0.0 109.784 179.325 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 91.65 5.56 66.62 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 108.879 -1.688 . . . . 0.0 108.879 -179.304 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 74.4 t -61.44 -32.99 54.92 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 O-C-N 121.498 -1.001 . . . . 0.0 109.209 179.793 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 72.6 mt -92.31 121.13 42.62 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.396 0 O-C-N 121.302 -0.874 . . . . 0.0 109.651 -179.726 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -120.42 -169.5 1.82 Allowed 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 109.076 -0.713 . . . . 0.0 109.076 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -63.46 -54.24 39.65 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.221 -0.924 . . . . 0.0 108.615 179.702 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.468 ' CD1' ' N ' ' A' ' 39' ' ' LEU . 7.0 mp -70.78 -33.47 70.79 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 107.193 -1.41 . . . . 0.0 107.193 178.148 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -59.49 -43.12 97.79 Favored Glycine 0 N--CA 1.483 1.813 0 N-CA-C 108.809 -1.716 . . . . 0.0 108.809 179.388 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 6.6 tt -64.73 -41.63 95.81 Favored 'General case' 0 C--N 1.304 -1.374 0 O-C-N 121.384 -1.068 . . . . 0.0 109.066 179.286 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.4 tp -59.73 -45.93 90.68 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.222 -0.924 . . . . 0.0 109.044 179.705 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 56.6 mttt -60.97 -34.75 75.25 Favored 'General case' 0 C--N 1.297 -1.717 0 O-C-N 121.492 -0.755 . . . . 0.0 109.671 -179.812 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 54.3 t -61.85 -49.87 82.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.366 -0.834 . . . . 0.0 110.162 -179.401 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.547 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 3.4 mp -67.89 -32.9 58.38 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 O-C-N 121.206 -0.934 . . . . 0.0 110.678 -179.621 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.7 -50.29 67.55 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.861 -1.15 . . . . 0.0 111.13 -178.302 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . 0.677 ' CZ2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -81.28 -44.84 17.11 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.758 -1.214 . . . . 0.0 109.829 -179.657 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.475 ' N ' ' CG ' ' A' ' 47' ' ' TRP . 18.1 tp -58.37 -41.32 84.53 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.328 -0.858 . . . . 0.0 109.936 -178.955 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.547 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 1.1 pp20? -73.35 -35.63 66.02 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 120.895 -1.128 . . . . 0.0 109.521 179.769 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . 0.406 ' N ' ' HG3' ' A' ' 49' ' ' GLU . 57.4 t0 -63.48 -41.02 98.59 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.376 -0.828 . . . . 0.0 111.619 -179.111 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 8.8 ptm180 -65.0 -37.08 86.47 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.869 -1.144 . . . . 0.0 111.632 -178.122 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.445 ' CE2' ' CG1' ' A' ' 76' ' ' VAL . 72.9 m-85 -90.9 -12.14 37.02 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 120.443 -1.41 . . . . 0.0 110.021 -179.505 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 74.47 28.83 62.84 Favored Glycine 0 N--CA 1.487 2.045 0 N-CA-C 108.832 -1.707 . . . . 0.0 108.832 179.919 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . 0.49 ' O ' ' OE1' ' A' ' 49' ' ' GLU . 25.2 pt -109.18 153.4 10.95 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.575 -0.956 . . . . 0.0 109.798 -179.42 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -102.44 126.3 49.44 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.228 -0.92 . . . . 0.0 109.561 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.497 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -68.55 -28.16 66.72 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.238 -0.914 . . . . 0.0 109.525 179.784 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 21.0 t70 -55.12 -33.49 62.9 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.262 -0.899 . . . . 0.0 110.082 -179.638 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -52.76 -38.29 60.77 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.133 -0.979 . . . . 0.0 109.852 -179.465 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.497 ' O ' ' O ' ' A' ' 56' ' ' ALA . 32.7 m -127.66 157.74 39.43 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.335 0 O-C-N 121.319 -0.863 . . . . 0.0 109.557 -179.721 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -97.6 125.82 42.55 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.14 -0.975 . . . . 0.0 109.353 179.725 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 5.1 mp -107.12 141.06 38.98 Favored 'General case' 0 C--N 1.306 -1.325 0 O-C-N 121.394 -0.816 . . . . 0.0 109.699 -179.73 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' SER . . . . . 0.557 ' HG ' ' H ' ' A' ' 64' ' ' GLU . 0.1 OUTLIER -109.22 153.09 42.84 Favored Pre-proline 0 N--CA 1.487 1.406 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 179.295 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo -54.53 -23.22 30.96 Favored 'Trans proline' 0 C--N 1.303 -1.817 0 C-N-CA 122.338 2.026 . . . . 0.0 112.086 -179.548 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . 0.557 ' H ' ' HG ' ' A' ' 62' ' ' SER . 95.5 mt-10 -70.15 -26.46 63.94 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 121.352 -0.842 . . . . 0.0 109.403 179.906 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . 0.504 ' NE2' ' CB ' ' A' ' 75' ' ' PHE . 2.2 t-80 -66.03 -20.88 66.33 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.419 -0.8 . . . . 0.0 109.289 -179.843 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.535 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 9.5 m-85 -97.1 15.48 22.41 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 121.406 -0.809 . . . . 0.0 109.166 -179.815 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 1.7 ptt85 -51.99 -34.39 42.31 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.644 -0.66 . . . . 0.0 109.999 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.47 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 44.2 t -151.4 154.05 35.89 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.071 -1.018 . . . . 0.0 109.969 179.884 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.413 ' H ' HD12 ' A' ' 69' ' ' ILE . 3.2 mp -57.36 -33.91 44.99 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 179.222 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 32.1 mtp180 -56.79 -44.11 81.56 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.67 -0.644 . . . . 0.0 109.407 -179.693 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 17.0 t -66.47 -40.58 89.42 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.382 -0.823 . . . . 0.0 109.829 -179.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 62.8 mt -62.18 -50.26 80.73 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.37 0 O-C-N 121.305 -0.872 . . . . 0.0 110.286 -179.222 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 37.0 t0 -61.0 -41.88 97.35 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.11 -0.994 . . . . 0.0 109.409 -179.842 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . 0.456 ' O ' ' N ' ' A' ' 78' ' ' GLY . . . -67.02 -40.69 87.31 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.478 -0.764 . . . . 0.0 110.353 -179.443 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . 0.504 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 66.9 t80 -62.7 -46.71 86.86 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.049 -1.032 . . . . 0.0 109.663 -179.676 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.445 ' CG1' ' CE2' ' A' ' 52' ' ' PHE . 90.7 t -67.23 -48.21 79.05 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.343 0 O-C-N 121.192 -0.943 . . . . 0.0 109.78 -179.938 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 53.0 t -69.66 -41.99 80.29 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.333 0 O-C-N 121.134 -0.978 . . . . 0.0 109.63 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.486 ' O ' ' O ' ' A' ' 81' ' ' THR . . . -59.53 -36.0 87.7 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 -179.477 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.48 -40.98 85.29 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.209 -1.171 . . . . 0.0 110.475 -179.183 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 49.0 p -81.93 -30.74 31.67 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.144 -0.972 . . . . 0.0 109.698 -179.685 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.486 ' O ' ' O ' ' A' ' 78' ' ' GLY . 0.5 OUTLIER . . . . . 0 C--N 1.302 -1.458 0 O-C-N 121.541 -0.725 . . . . 0.0 109.666 -179.615 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 50.4 m-70 . . . . . 0 N--CA 1.494 1.753 0 CA-C-O 121.052 0.454 . . . . 0.0 110.575 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -61.01 -38.42 86.0 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.96 -1.088 . . . . 0.0 109.299 179.468 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 25.5 m -60.18 -35.75 76.05 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.328 -0.857 . . . . 0.0 109.914 -179.797 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 53.0 t -61.39 -45.72 98.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.193 -0.942 . . . . 0.0 109.589 -179.69 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 70.2 mt -60.04 -43.88 93.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.475 0 O-C-N 121.247 -0.908 . . . . 0.0 109.113 179.79 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -60.41 -35.89 76.84 Favored 'General case' 0 C--N 1.303 -1.424 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 179.752 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 7.3 tt0 -64.18 -38.12 89.9 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.458 -0.776 . . . . 0.0 110.137 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.684 ' CG ' ' CZ2' ' A' ' 47' ' ' TRP . 25.8 m-85 -66.52 -49.29 67.01 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 120.908 -1.12 . . . . 0.0 111.028 -179.219 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 11.6 m -59.74 -48.14 88.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.08 -1.013 . . . . 0.0 110.428 -178.518 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.578 ' O ' ' N ' ' A' ' 16' ' ' LEU . 30.6 m -64.89 -43.44 96.31 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.407 0 O-C-N 120.766 -1.208 . . . . 0.0 110.03 -179.838 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -65.16 -26.51 68.19 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.755 -1.215 . . . . 0.0 109.945 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 81.4 tt0 -64.28 -31.04 72.08 Favored 'General case' 0 C--N 1.299 -1.614 0 O-C-N 121.328 -0.857 . . . . 0.0 109.767 -179.277 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 85.9 m-85 -141.5 -35.89 0.45 Allowed 'General case' 0 N--CA 1.494 1.734 0 O-C-N 120.897 -1.127 . . . . 0.0 110.816 -179.9 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.578 ' N ' ' O ' ' A' ' 12' ' ' VAL . 8.6 mt -122.17 79.79 43.83 Favored Pre-proline 0 N--CA 1.494 1.737 0 O-C-N 121.124 -0.985 . . . . 0.0 110.418 -179.01 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 43.0 Cg_endo -75.77 -12.03 20.08 Favored 'Trans proline' 0 C--N 1.308 -1.562 0 C-N-CA 122.412 2.075 . . . . 0.0 112.545 179.79 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -93.87 13.09 23.66 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.224 -0.922 . . . . 0.0 110.385 -179.399 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 58.5 t -109.46 134.98 49.78 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.247 -0.908 . . . . 0.0 110.008 -179.724 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . 0.494 ' O ' ' OD1' ' A' ' 23' ' ' ASP . . . -73.58 117.88 64.43 Favored Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.429 -0.794 . . . . 0.0 109.337 -179.965 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_exo -52.62 -27.24 32.28 Favored 'Trans proline' 0 N--CA 1.494 1.509 0 C-N-CA 121.832 1.688 . . . . 0.0 112.394 179.786 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.85 -25.4 67.88 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.263 -0.898 . . . . 0.0 110.035 -179.561 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.494 ' OD1' ' O ' ' A' ' 20' ' ' ALA . 47.4 p30 -86.54 8.15 23.24 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.133 -0.979 . . . . 0.0 110.112 -179.566 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 11.3 t -101.11 131.64 48.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 120.972 -1.08 . . . . 0.0 109.418 -179.907 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 61.6 t0 -89.29 119.71 30.0 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.096 -1.002 . . . . 0.0 109.094 179.435 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 22.1 m -76.3 4.45 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 O-C-N 121.252 -0.905 . . . . 0.0 109.173 179.687 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -96.24 0.25 50.75 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 121.266 -0.896 . . . . 0.0 109.214 179.61 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 38.4 tp -94.62 143.22 26.61 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.43 -0.794 . . . . 0.0 109.192 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -66.79 118.78 10.79 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.091 -1.006 . . . . 0.0 109.005 -179.75 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . 0.414 ' H ' ' HA ' ' A' ' 68' ' ' SER . 41.6 tp -62.33 -37.86 87.26 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.605 -0.685 . . . . 0.0 111.09 -178.872 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 53.2 t -66.78 -38.29 81.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 120.807 -1.183 . . . . 0.0 110.863 -179.012 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -52.89 -33.36 49.87 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 120.913 -1.117 . . . . 0.0 108.212 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 20.9 m120 -71.05 -33.91 70.74 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.698 -0.626 . . . . 0.0 109.941 179.528 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 91.31 5.6 67.24 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 108.871 -1.691 . . . . 0.0 108.871 -179.231 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 78.0 t -60.19 -30.56 46.19 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 O-C-N 121.479 -1.012 . . . . 0.0 108.825 179.526 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 65.5 mt -94.72 130.5 43.46 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.344 0 O-C-N 121.386 -0.821 . . . . 0.0 109.558 -179.763 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.571 ' CG ' ' H ' ' A' ' 38' ' ' ALA . 49.1 t0 -137.92 -163.67 1.48 Allowed 'General case' 0 C--N 1.301 -1.52 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 179.948 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.571 ' H ' ' CG ' ' A' ' 37' ' ' ASP . . . -63.54 -54.76 31.13 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.995 -1.066 . . . . 0.0 108.665 179.879 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . 0.474 ' CD1' ' N ' ' A' ' 39' ' ' LEU . 6.9 mp -71.25 -34.04 70.37 Favored 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 107.323 -1.362 . . . . 0.0 107.323 178.206 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -59.47 -45.55 95.36 Favored Glycine 0 N--CA 1.482 1.725 0 N-CA-C 109.019 -1.632 . . . . 0.0 109.019 179.562 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.4 tt -64.08 -39.95 95.17 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.462 -1.022 . . . . 0.0 109.092 179.303 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 tp -60.04 -46.03 90.89 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.432 -0.792 . . . . 0.0 109.327 179.902 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 17.6 mttp -59.82 -37.11 78.28 Favored 'General case' 0 C--N 1.296 -1.729 0 O-C-N 121.474 -0.766 . . . . 0.0 109.381 -179.906 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 84.9 t -64.64 -41.49 92.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.5 -0.75 . . . . 0.0 110.2 -179.699 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . 0.485 ' O ' ' OE1' ' A' ' 49' ' ' GLU . 1.3 mp -64.89 -50.76 73.58 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.646 0 O-C-N 121.066 -1.021 . . . . 0.0 111.208 -178.84 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.68 -49.51 62.4 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.083 -1.011 . . . . 0.0 112.843 -177.531 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . 0.684 ' CZ2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -74.8 -48.86 23.05 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 120.613 -1.304 . . . . 0.0 111.358 -177.758 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -58.86 -44.52 91.04 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 120.812 -1.18 . . . . 0.0 109.345 -178.582 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.592 ' N ' ' CD ' ' A' ' 49' ' ' GLU . 0.0 OUTLIER -63.97 -38.72 92.11 Favored 'General case' 0 N--CA 1.485 1.324 0 O-C-N 120.706 -1.246 . . . . 0.0 109.818 -179.958 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 55.1 t0 -61.68 -37.25 83.4 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.298 -0.876 . . . . 0.0 110.513 -179.502 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 18.4 mmt180 -58.27 -36.51 73.39 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.089 -1.007 . . . . 0.0 111.055 -179.029 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.454 ' CE1' ' CG1' ' A' ' 76' ' ' VAL . 87.4 m-85 -96.32 -6.18 38.36 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 120.789 -1.194 . . . . 0.0 110.474 -179.144 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 73.25 30.44 62.79 Favored Glycine 0 N--CA 1.488 2.121 0 N-CA-C 108.739 -1.745 . . . . 0.0 108.739 179.761 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 20.7 pt -112.68 153.9 14.21 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 O-C-N 121.75 -0.853 . . . . 0.0 109.701 -179.436 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -93.99 130.17 40.21 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.217 -0.927 . . . . 0.0 109.407 -179.873 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.486 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -64.39 -32.24 73.78 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.202 -0.936 . . . . 0.0 109.552 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -58.06 -34.49 70.17 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.383 -0.823 . . . . 0.0 110.051 -179.835 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -53.53 -37.93 63.3 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.28 -0.888 . . . . 0.0 109.939 -179.469 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.486 ' O ' ' O ' ' A' ' 56' ' ' ALA . 13.7 p -133.67 142.72 40.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.253 -0.905 . . . . 0.0 109.567 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -100.19 128.73 46.21 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.21 -0.931 . . . . 0.0 109.322 179.781 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 51.7 mt -105.75 143.46 33.88 Favored 'General case' 0 C--N 1.305 -1.361 0 O-C-N 121.314 -0.866 . . . . 0.0 109.707 -179.719 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -97.32 151.25 37.56 Favored Pre-proline 0 C--N 1.305 -1.337 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 179.131 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -55.39 -23.25 37.41 Favored 'Trans proline' 0 C--N 1.305 -1.743 0 C-N-CA 122.366 2.044 . . . . 0.0 112.032 -179.403 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 91.9 mt-10 -71.79 -29.85 64.9 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.345 -0.847 . . . . 0.0 109.774 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . 0.421 ' CE1' ' HB2' ' A' ' 75' ' ' PHE . 63.0 t60 -65.92 -21.17 66.42 Favored 'General case' 0 C--N 1.299 -1.588 0 O-C-N 121.102 -0.999 . . . . 0.0 109.186 -179.668 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.477 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 26.0 m-85 -86.93 13.98 8.13 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.405 -0.809 . . . . 0.0 109.223 -179.659 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 5.8 ptt180 -52.73 -34.31 52.05 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.66 -0.65 . . . . 0.0 110.088 179.852 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.414 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 32.4 t -149.82 151.11 32.99 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.067 -1.021 . . . . 0.0 110.088 -179.771 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . 0.414 ' CD1' ' H ' ' A' ' 69' ' ' ILE . 2.0 mp -60.19 -39.14 79.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.428 0 O-C-N 121.48 -0.762 . . . . 0.0 109.888 -179.862 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 9.8 ptm180 -58.12 -40.99 82.64 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.493 -0.754 . . . . 0.0 110.283 -179.225 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 60.7 p -64.98 -42.91 94.12 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.201 -0.937 . . . . 0.0 110.221 -179.455 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . 0.405 ' HA ' ' NE2' ' A' ' 65' ' ' HIS . 69.6 mt -61.5 -47.39 93.63 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 O-C-N 121.136 -0.978 . . . . 0.0 110.406 -179.405 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 39.4 t0 -60.63 -37.49 81.64 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 121.184 -0.948 . . . . 0.0 109.825 -179.723 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -67.86 -46.84 70.59 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.216 -0.927 . . . . 0.0 110.604 -178.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . 0.421 ' HB2' ' CE1' ' A' ' 65' ' ' HIS . 58.4 t80 -65.88 -44.52 85.1 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.098 -1.001 . . . . 0.0 109.2 -179.728 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.454 ' CG1' ' CE1' ' A' ' 52' ' ' PHE . 55.2 t -60.76 -45.34 97.97 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 O-C-N 121.31 -0.869 . . . . 0.0 109.157 179.585 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 54.7 t -69.15 -41.16 81.27 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.281 0 O-C-N 121.214 -0.929 . . . . 0.0 108.989 179.349 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.492 ' O ' ' O ' ' A' ' 81' ' ' THR . . . -59.99 -28.13 65.74 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 110.029 -1.228 . . . . 0.0 110.029 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.02 -37.02 83.39 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.207 -1.172 . . . . 0.0 109.947 -179.391 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 44.9 p -83.38 -31.08 26.9 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.149 -0.97 . . . . 0.0 109.535 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.492 ' O ' ' O ' ' A' ' 78' ' ' GLY . 0.2 OUTLIER . . . . . 0 C--N 1.303 -1.428 0 O-C-N 121.504 -0.747 . . . . 0.0 109.788 -179.523 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 77.5 m80 . . . . . 0 N--CA 1.483 1.208 0 N-CA-C 106.683 -1.599 . . . . 0.0 106.683 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -51.88 -39.48 59.07 Favored 'General case' 0 N--CA 1.487 1.417 0 CA-C-O 121.233 0.539 . . . . 0.0 109.92 -179.052 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.8 m -59.8 -37.78 80.09 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.256 -0.902 . . . . 0.0 109.746 -179.747 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 6' ' ' VAL . . . . . 0.402 ' HA ' HE21 ' A' ' 9' ' ' GLN . 55.5 t -62.63 -42.93 97.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.251 -0.906 . . . . 0.0 109.545 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 79.3 mt -59.54 -41.43 84.82 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 O-C-N 121.348 -0.845 . . . . 0.0 109.241 179.858 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -62.21 -38.42 89.09 Favored 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.405 -0.809 . . . . 0.0 109.558 -179.789 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 9' ' ' GLN . . . . . 0.402 HE21 ' HA ' ' A' ' 6' ' ' VAL . 52.5 mt-30 -61.87 -42.07 98.62 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.108 -0.995 . . . . 0.0 109.545 179.921 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 10' ' ' PHE . . . . . 0.669 ' CG ' ' CE2' ' A' ' 47' ' ' TRP . 34.1 m-85 -61.81 -42.07 98.55 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.247 -0.908 . . . . 0.0 109.407 179.421 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 43.3 t -61.13 -45.29 98.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.367 -0.833 . . . . 0.0 109.548 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 12' ' ' VAL . . . . . 0.452 ' O ' ' C ' ' A' ' 16' ' ' LEU . 93.6 t -63.21 -46.83 94.81 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 O-C-N 121.479 -0.763 . . . . 0.0 109.735 -179.821 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -73.52 -16.46 61.28 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.396 -0.815 . . . . 0.0 110.265 -179.492 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -63.54 -31.88 73.17 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.171 -0.956 . . . . 0.0 110.299 -178.801 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 65.7 t80 -151.32 -28.99 0.19 Allowed 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.829 -1.169 . . . . 0.0 110.436 -179.761 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 16' ' ' LEU . . . . . 0.452 ' C ' ' O ' ' A' ' 12' ' ' VAL . 6.2 mt -121.77 80.14 40.6 Favored Pre-proline 0 N--CA 1.492 1.647 0 O-C-N 121.231 -0.918 . . . . 0.0 110.08 -179.405 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -77.08 -13.03 17.41 Favored 'Trans proline' 0 C--N 1.307 -1.607 0 C-N-CA 122.476 2.117 . . . . 0.0 112.375 179.759 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -93.95 9.74 36.24 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.189 -0.944 . . . . 0.0 110.263 -179.423 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 46.4 t -109.88 137.77 40.57 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.274 -0.891 . . . . 0.0 109.691 -179.769 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -78.41 117.44 66.34 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.147 -0.971 . . . . 0.0 109.442 179.941 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_exo -53.83 -24.79 32.35 Favored 'Trans proline' 0 N--CA 1.494 1.535 0 C-N-CA 121.842 1.695 . . . . 0.0 112.068 179.547 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.0 -24.51 67.74 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.304 -0.872 . . . . 0.0 109.301 -179.936 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 23' ' ' ASP . . . . . 0.409 ' O ' ' OD1' ' A' ' 23' ' ' ASP . 59.6 t0 -81.66 3.31 25.85 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.331 -0.856 . . . . 0.0 109.332 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 13.0 t -109.66 133.94 53.32 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.375 -0.828 . . . . 0.0 109.298 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 63.9 t0 -88.7 119.75 29.47 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.097 -1.002 . . . . 0.0 109.05 179.56 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 29.9 m -74.43 4.15 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.35 0 O-C-N 121.137 -0.977 . . . . 0.0 109.261 179.656 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 91.8 m-20 -90.43 -4.83 56.74 Favored 'General case' 0 N--CA 1.487 1.381 0 O-C-N 121.29 -0.881 . . . . 0.0 108.819 179.45 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 45.3 tp -98.03 139.58 33.64 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 179.832 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -58.77 137.51 57.64 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.211 -0.931 . . . . 0.0 109.655 -179.419 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 1.4 tt -66.04 -38.91 89.57 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.713 -0.617 . . . . 0.0 110.069 -179.272 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 74.6 t -63.19 -35.78 73.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 120.979 -1.076 . . . . 0.0 110.67 -178.782 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 91.0 m-20 -52.58 -33.79 47.62 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 120.984 -1.073 . . . . 0.0 108.24 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 97.2 m-20 -71.15 -34.66 71.2 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.614 -0.679 . . . . 0.0 110.047 179.516 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 84.09 5.54 87.43 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 108.99 -1.644 . . . . 0.0 108.99 -179.385 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 70.4 t -60.55 -33.86 56.15 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 O-C-N 121.407 -1.055 . . . . 0.0 108.634 179.557 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 95.0 mt -84.32 124.12 39.54 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.398 0 O-C-N 121.471 -0.768 . . . . 0.0 109.63 179.842 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 37' ' ' ASP . . . . . 0.588 ' CG ' ' H ' ' A' ' 38' ' ' ALA . 48.5 t0 -127.51 -159.53 0.94 Allowed 'General case' 0 C--N 1.301 -1.515 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 179.56 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 38' ' ' ALA . . . . . 0.588 ' H ' ' CG ' ' A' ' 37' ' ' ASP . . . -66.26 -55.07 17.93 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.848 -1.158 . . . . 0.0 108.681 179.792 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 36.5 mt -71.3 -34.37 70.55 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 107.412 -1.329 . . . . 0.0 107.412 178.237 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -59.53 -40.29 96.08 Favored Glycine 0 N--CA 1.482 1.735 0 N-CA-C 108.783 -1.727 . . . . 0.0 108.783 179.256 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 4.5 tt -65.44 -45.49 83.63 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.528 -0.984 . . . . 0.0 109.326 179.225 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 17.1 tp -59.51 -44.75 93.05 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.415 -0.803 . . . . 0.0 109.811 -179.829 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 32.0 mttp -61.74 -34.74 76.37 Favored 'General case' 0 C--N 1.298 -1.664 0 O-C-N 120.973 -1.079 . . . . 0.0 109.583 -179.875 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 53.6 t -62.29 -50.23 80.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.328 -0.858 . . . . 0.0 110.296 -179.439 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 3.5 mp -68.15 -32.66 56.91 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.216 -0.927 . . . . 0.0 110.934 -179.607 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.27 -49.85 62.69 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 120.971 -1.08 . . . . 0.0 111.757 -177.909 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 47' ' ' TRP . . . . . 0.669 ' CE2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -80.84 -43.51 19.88 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.677 -1.265 . . . . 0.0 110.089 -178.984 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 48' ' ' LEU . . . . . 0.4 ' N ' ' CG ' ' A' ' 47' ' ' TRP . 28.1 tp -58.93 -41.46 87.38 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.25 -0.906 . . . . 0.0 110.082 -179.085 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.436 ' CG ' ' N ' ' A' ' 50' ' ' ASP . 16.9 pt-20 -73.14 -37.7 66.52 Favored 'General case' 0 C--N 1.303 -1.427 0 O-C-N 121.082 -1.012 . . . . 0.0 109.589 -179.859 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 50' ' ' ASP . . . . . 0.436 ' N ' ' CG ' ' A' ' 49' ' ' GLU . 22.1 t70 -58.73 -38.16 77.77 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.406 -0.809 . . . . 0.0 110.618 -179.462 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 71.1 mtp180 -61.07 -38.66 86.99 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.156 -0.965 . . . . 0.0 111.434 -178.808 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 52' ' ' PHE . . . . . 0.454 ' CE1' ' CG1' ' A' ' 76' ' ' VAL . 75.0 m-85 -97.24 -7.42 32.31 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 120.872 -1.143 . . . . 0.0 110.582 -179.075 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 72.81 30.73 63.27 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.207 -1.557 . . . . 0.0 109.207 179.307 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 30.3 pt -106.81 153.4 8.03 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.354 0 O-C-N 121.483 -1.01 . . . . 0.0 109.571 -179.756 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -101.75 137.93 39.4 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.209 -0.932 . . . . 0.0 109.681 -179.562 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 56' ' ' ALA . . . . . 0.495 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -66.63 -26.57 67.13 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.365 -0.835 . . . . 0.0 109.724 179.899 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 57' ' ' ASP . . . . . 0.629 ' OD1' ' N ' ' A' ' 58' ' ' ASP . 54.9 p30 -60.42 -32.06 70.99 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.123 -0.986 . . . . 0.0 110.257 -179.606 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 58' ' ' ASP . . . . . 0.629 ' N ' ' OD1' ' A' ' 57' ' ' ASP . 53.8 t0 -57.95 -39.96 79.39 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.016 -1.052 . . . . 0.0 109.72 -179.908 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 59' ' ' VAL . . . . . 0.495 ' O ' ' O ' ' A' ' 56' ' ' ALA . 13.3 p -137.15 143.47 34.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.301 -0.874 . . . . 0.0 109.497 -179.969 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -90.36 132.63 35.48 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.115 -0.991 . . . . 0.0 109.221 179.847 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 57.2 mt -97.74 137.26 36.88 Favored 'General case' 0 C--N 1.305 -1.338 0 O-C-N 121.222 -0.924 . . . . 0.0 109.771 -179.668 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -110.18 156.44 40.14 Favored Pre-proline 0 N--CA 1.488 1.43 0 N-CA-C 108.841 -0.799 . . . . 0.0 108.841 179.391 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 8.0 Cg_endo -53.18 -23.28 22.2 Favored 'Trans proline' 0 C--N 1.302 -1.899 0 C-N-CA 122.388 2.059 . . . . 0.0 111.685 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -70.73 -27.78 64.22 Favored 'General case' 0 C--N 1.305 -1.34 0 O-C-N 121.335 -0.853 . . . . 0.0 109.561 179.686 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 65' ' ' HIS . . . . . 0.566 ' C ' ' CD2' ' A' ' 65' ' ' HIS . 0.4 OUTLIER -65.69 -17.81 64.88 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 121.336 -0.852 . . . . 0.0 109.056 -179.835 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 66' ' ' PHE . . . . . 0.546 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 11.6 m-85 -97.57 15.89 22.0 Favored 'General case' 0 C--N 1.301 -1.538 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 179.704 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 67' ' ' ARG . . . . . 0.594 ' NE ' ' OG ' ' A' ' 71' ' ' SER . 6.7 ptt180 -48.95 -38.58 23.4 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.796 -0.565 . . . . 0.0 110.558 -179.526 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 43.8 t -161.52 158.98 27.29 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.905 -1.122 . . . . 0.0 110.234 -179.803 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 31.6 mm -57.97 -44.01 85.97 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.361 0 O-C-N 121.319 -0.863 . . . . 0.0 109.628 179.876 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 70' ' ' ARG . . . . . 0.421 ' HG2' ' H ' ' A' ' 71' ' ' SER . 0.0 OUTLIER -58.65 -39.3 80.18 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.276 -0.89 . . . . 0.0 109.596 -179.57 . . . . . . . . 3 3 . 1 . 020 nuclear orig core ' A' A ' 71' ' ' SER . . . . . 0.594 ' OG ' ' NE ' ' A' ' 67' ' ' ARG . 41.6 t -62.59 -41.51 99.0 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.275 -0.891 . . . . 0.0 109.689 179.821 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 80.7 mt -61.01 -47.75 92.19 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 O-C-N 121.306 -0.871 . . . . 0.0 109.911 -179.62 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 32.9 t0 -60.26 -43.14 96.42 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.168 -0.958 . . . . 0.0 109.167 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 74' ' ' ALA . . . . . 0.54 ' O ' ' N ' ' A' ' 78' ' ' GLY . . . -66.84 -38.89 87.27 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.52 -0.738 . . . . 0.0 109.952 -179.829 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 71.6 t80 -61.64 -51.24 69.29 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.174 -0.953 . . . . 0.0 109.271 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' VAL . . . . . 0.454 ' CG1' ' CE1' ' A' ' 52' ' ' PHE . 77.6 t -69.51 -48.03 68.69 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 O-C-N 121.328 -0.857 . . . . 0.0 109.878 179.972 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 72.3 t -69.55 -47.0 74.23 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.328 0 O-C-N 121.175 -0.953 . . . . 0.0 109.756 -179.887 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' GLY . . . . . 0.54 ' N ' ' O ' ' A' ' 74' ' ' ALA . . . -61.93 -37.88 95.11 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.826 -1.309 . . . . 0.0 109.826 -179.752 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.61 -39.45 84.73 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.183 -1.187 . . . . 0.0 110.025 -179.508 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 50.2 p -81.33 -31.61 33.41 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.286 -0.884 . . . . 0.0 109.594 -179.859 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' THR . . . . . 0.493 ' O ' ' O ' ' A' ' 78' ' ' GLY . 0.4 OUTLIER . . . . . 0 C--N 1.304 -1.389 0 O-C-N 121.403 -0.811 . . . . 0.0 109.908 -179.646 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' -1' ' ' SER . . . . . 0.582 ' O ' ' NE2' ' A' ' 2' ' ' GLN . 13.0 t . . . . . 0 N--CA 1.49 1.531 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 0' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -56.51 -33.09 65.69 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.314 -0.866 . . . . 0.0 109.453 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.5 ' O ' ' OD2' ' A' ' 73' ' ' ASP . 65.6 mtt -59.41 -35.67 74.4 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.225 -0.922 . . . . 0.0 109.933 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.582 ' NE2' ' O ' ' A' ' -1' ' ' SER . 99.2 mm-40 55.02 49.49 17.5 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.132 -0.98 . . . . 0.0 109.068 -179.488 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.427 ' CB ' ' O ' ' A' ' 2' ' ' GLN . 20.4 m-70 74.23 54.31 0.09 Allowed 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.741 -0.6 . . . . 0.0 109.831 -179.754 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -60.32 -39.97 88.91 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.105 -0.997 . . . . 0.0 109.343 179.898 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.2 m -61.76 -36.86 82.27 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.465 -0.772 . . . . 0.0 110.019 -179.754 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 64.3 t -62.35 -44.98 99.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.23 -0.919 . . . . 0.0 109.631 -179.762 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 78.3 mt -59.78 -46.96 93.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.326 -0.858 . . . . 0.0 108.799 179.624 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.427 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -62.38 -35.12 78.19 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 108.969 -0.752 . . . . 0.0 108.969 179.328 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 7.3 tt0 -58.76 -41.12 85.81 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.084 -1.01 . . . . 0.0 109.526 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.672 ' CG ' ' CZ2' ' A' ' 47' ' ' TRP . 52.4 m-85 -68.7 -50.16 53.1 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.045 -1.035 . . . . 0.0 110.508 -179.807 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.433 ' CG2' ' N ' ' A' ' 12' ' ' VAL . 1.0 OUTLIER -66.12 -39.0 83.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.02 -1.05 . . . . 0.0 108.99 -179.498 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.442 ' O ' ' C ' ' A' ' 16' ' ' LEU . 74.8 t -63.56 -46.67 94.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.28 -0.888 . . . . 0.0 109.266 179.45 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -71.71 -23.6 61.66 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.23 -0.919 . . . . 0.0 109.825 179.665 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -64.09 -30.3 71.38 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.428 -0.795 . . . . 0.0 110.395 -179.078 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 72.6 t80 -139.0 -40.48 0.48 Allowed 'General case' 0 N--CA 1.494 1.731 0 O-C-N 120.969 -1.082 . . . . 0.0 110.765 -179.413 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.442 ' C ' ' O ' ' A' ' 12' ' ' VAL . 5.0 mt -120.76 80.11 32.17 Favored Pre-proline 0 N--CA 1.491 1.613 0 O-C-N 121.089 -1.007 . . . . 0.0 110.338 -179.18 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 40.7 Cg_endo -75.73 -14.78 19.48 Favored 'Trans proline' 0 C--N 1.309 -1.536 0 C-N-CA 122.439 2.093 . . . . 0.0 112.285 179.437 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -90.03 7.87 35.45 Favored 'General case' 0 N--CA 1.487 1.381 0 O-C-N 121.221 -0.925 . . . . 0.0 109.758 -179.715 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 43.2 t -111.69 134.86 52.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.417 -0.802 . . . . 0.0 109.644 -179.882 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.27 119.62 75.82 Favored Pre-proline 0 N--CA 1.489 1.477 0 O-C-N 121.263 -0.898 . . . . 0.0 109.353 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_exo -51.2 -28.23 25.21 Favored 'Trans proline' 0 N--CA 1.493 1.483 0 C-N-CA 121.75 1.633 . . . . 0.0 112.109 179.531 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.91 -24.69 67.61 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.264 -0.898 . . . . 0.0 109.31 179.881 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.426 ' O ' ' OD1' ' A' ' 23' ' ' ASP . 60.0 t0 -81.87 7.23 13.42 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.319 -0.863 . . . . 0.0 109.789 -179.746 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 10.9 t -103.96 132.89 49.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.03 -1.043 . . . . 0.0 109.393 -179.884 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 87.3 m-20 -89.12 120.49 30.56 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.106 -0.996 . . . . 0.0 109.104 179.469 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 17.8 m -77.34 3.92 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.446 0 O-C-N 121.175 -0.953 . . . . 0.0 109.137 179.687 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -87.26 -13.2 44.44 Favored 'General case' 0 N--CA 1.486 1.354 0 O-C-N 121.351 -0.843 . . . . 0.0 109.149 179.518 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 41.5 tp -95.29 138.67 32.67 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.459 -0.775 . . . . 0.0 109.143 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -58.93 141.43 53.66 Favored 'General case' 0 C--N 1.303 -1.441 0 O-C-N 121.237 -0.914 . . . . 0.0 109.527 -179.605 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.488 ' H ' ' HA ' ' A' ' 68' ' ' SER . 1.3 tt -67.36 -38.66 85.16 Favored 'General case' 0 C--N 1.299 -1.589 0 O-C-N 121.706 -0.621 . . . . 0.0 110.322 -179.016 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 69.1 t -65.36 -36.25 77.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.103 -0.998 . . . . 0.0 110.497 -178.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -52.79 -33.59 49.61 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 19.7 m120 -71.05 -34.4 71.22 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.675 -0.641 . . . . 0.0 109.805 179.433 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 85.3 6.28 84.33 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 108.984 -1.646 . . . . 0.0 108.984 -179.481 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 79.4 t -61.73 -34.32 61.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.468 -1.019 . . . . 0.0 109.158 179.795 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.6 mt -87.06 117.34 31.05 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.315 -0.865 . . . . 0.0 109.78 -179.938 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -117.43 -168.2 1.45 Allowed 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 179.703 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -63.2 -54.77 32.37 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.034 -1.041 . . . . 0.0 108.532 179.626 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 41.9 mt -70.96 -34.71 71.7 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 178.063 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -59.66 -39.64 95.44 Favored Glycine 0 N--CA 1.481 1.656 0 N-CA-C 108.614 -1.795 . . . . 0.0 108.614 179.105 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.6 tt -65.2 -42.62 93.36 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.579 -0.953 . . . . 0.0 108.993 179.36 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.4 tp -61.42 -46.09 91.6 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.414 -0.804 . . . . 0.0 109.234 179.601 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 24.2 mttp -61.15 -35.99 78.57 Favored 'General case' 0 C--N 1.296 -1.721 0 O-C-N 121.504 -0.748 . . . . 0.0 109.76 -179.654 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 60.6 t -61.2 -50.57 79.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.374 -0.829 . . . . 0.0 109.715 -179.663 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.547 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 1.7 mp -69.05 -31.98 52.46 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.535 0 O-C-N 121.454 -0.779 . . . . 0.0 110.721 -179.906 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -63.52 -49.42 73.58 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.108 -0.995 . . . . 0.0 111.369 -178.127 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . 0.672 ' CZ2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -80.87 -45.13 17.32 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 120.723 -1.235 . . . . 0.0 109.876 -179.544 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.548 ' CD1' HH21 ' A' ' 51' ' ' ARG . 9.7 tp -58.33 -42.51 86.99 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.307 -0.87 . . . . 0.0 109.817 -179.169 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.547 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 1.0 OUTLIER -72.66 -35.61 67.76 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.102 -0.999 . . . . 0.0 109.772 179.999 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.1 t70 -61.13 -39.15 88.95 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.159 -0.963 . . . . 0.0 110.713 -179.456 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . 0.548 HH21 ' CD1' ' A' ' 48' ' ' LEU . 66.9 mtm180 -61.51 -36.77 81.47 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.167 -0.958 . . . . 0.0 111.429 -178.727 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.531 ' CZ ' ' CG1' ' A' ' 76' ' ' VAL . 94.3 m-85 -97.13 -9.9 27.03 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.774 -1.204 . . . . 0.0 110.334 -179.057 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 71.72 31.28 65.19 Favored Glycine 0 N--CA 1.486 2.01 0 N-CA-C 108.803 -1.719 . . . . 0.0 108.803 179.874 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.48 ' O ' ' OE1' ' A' ' 49' ' ' GLU . 25.3 pt -108.48 153.26 10.14 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 O-C-N 121.593 -0.945 . . . . 0.0 109.83 -179.331 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -101.77 131.34 48.12 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.077 -1.014 . . . . 0.0 109.667 -179.735 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.503 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -67.65 -27.47 66.89 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.276 -0.89 . . . . 0.0 109.506 179.827 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -55.37 -35.09 64.9 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.156 -0.965 . . . . 0.0 109.971 -179.724 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 54.4 t0 -53.19 -36.96 61.51 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.175 -0.953 . . . . 0.0 109.953 -179.592 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.503 ' O ' ' O ' ' A' ' 56' ' ' ALA . 13.7 p -132.84 143.82 38.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.258 -0.901 . . . . 0.0 109.653 -179.859 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -88.79 134.9 33.78 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.158 -0.964 . . . . 0.0 109.331 179.93 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 67.8 mt -97.16 137.49 36.13 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 121.261 -0.899 . . . . 0.0 109.926 -179.616 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -110.37 157.01 39.36 Favored Pre-proline 0 N--CA 1.487 1.406 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 179.478 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 9.3 Cg_endo -54.08 -23.16 27.7 Favored 'Trans proline' 0 C--N 1.301 -1.955 0 C-N-CA 122.392 2.061 . . . . 0.0 111.675 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -70.31 -27.5 64.43 Favored 'General case' 0 N--CA 1.486 1.344 0 O-C-N 121.338 -0.851 . . . . 0.0 109.447 179.653 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . 0.524 ' C ' ' CD2' ' A' ' 65' ' ' HIS . 0.9 OUTLIER -65.97 -17.89 64.98 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.357 -0.84 . . . . 0.0 109.036 -179.858 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.539 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 10.5 m-85 -98.12 15.1 25.32 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 179.622 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . 0.413 ' HG2' ' H ' ' A' ' 68' ' ' SER . 6.1 ptt180 -49.67 -39.28 35.98 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.77 -0.581 . . . . 0.0 110.225 -179.661 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.488 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 80.1 p -163.39 159.23 22.12 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 120.903 -1.123 . . . . 0.0 110.101 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.408 ' H ' HD12 ' A' ' 69' ' ' ILE . 3.6 mp -57.74 -34.85 48.86 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 N-CA-C 108.211 -1.033 . . . . 0.0 108.211 178.93 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 21.3 mtp180 -57.31 -40.48 77.99 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 15.2 t -63.47 -38.51 91.41 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.401 -0.812 . . . . 0.0 109.51 179.834 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.416 ' CD1' ' NE2' ' A' ' 65' ' ' HIS . 32.4 mm -58.94 -46.73 91.25 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 O-C-N 121.269 -0.894 . . . . 0.0 109.294 -179.845 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.5 ' OD2' ' O ' ' A' ' 1' ' ' MET . 46.7 t0 -59.43 -43.25 93.13 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.21 -0.932 . . . . 0.0 109.102 179.813 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.44 -40.87 89.71 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.552 -0.717 . . . . 0.0 109.78 -179.858 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 69.2 t80 -62.32 -46.42 88.79 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.35 -0.844 . . . . 0.0 109.524 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.531 ' CG1' ' CZ ' ' A' ' 52' ' ' PHE . 53.5 t -61.76 -46.24 96.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 O-C-N 121.235 -0.915 . . . . 0.0 109.337 179.884 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.517 ' O ' ' O ' ' A' ' 81' ' ' THR . 53.4 t -68.62 -42.6 83.44 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 O-C-N 121.262 -0.899 . . . . 0.0 109.329 179.53 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.45 -30.27 64.73 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 110.181 -1.168 . . . . 0.0 110.181 -179.903 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -68.37 -41.23 80.91 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.264 -1.139 . . . . 0.0 111.135 -178.739 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 27.8 p -101.68 -34.59 9.41 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.971 -1.081 . . . . 0.0 110.877 -178.808 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.517 ' O ' ' O ' ' A' ' 77' ' ' VAL . 0.1 OUTLIER -133.21 152.63 79.87 Favored Pre-proline 0 C--N 1.301 -1.5 0 O-C-N 121.311 -0.868 . . . . 0.0 109.834 -179.274 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_exo -45.38 142.9 6.02 Favored 'Trans proline' 0 C--N 1.31 -1.496 0 C-N-CA 121.864 1.71 . . . . 0.0 111.35 179.399 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 14.8 Cg_endo -63.32 145.74 93.08 Favored 'Trans proline' 0 C--N 1.313 -1.34 0 C-N-CA 122.02 1.814 . . . . 0.0 112.622 -179.557 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.477 ' O ' ' C ' ' A' ' 85' ' ' GLU . 44.8 t -103.69 130.01 54.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 179.546 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.477 ' C ' ' O ' ' A' ' 84' ' ' VAL . 96.1 mt-10 36.96 49.63 0.81 Allowed 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.586 -0.697 . . . . 0.0 109.895 179.87 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -53.29 144.58 15.9 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.18 -0.95 . . . . 0.0 109.528 -179.733 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 12.4 mttm -58.24 -34.76 70.8 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.246 -0.909 . . . . 0.0 109.446 -179.932 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . 0.515 ' H ' ' CD1' ' A' ' 88' ' ' LEU . 6.7 mp -59.83 -35.35 74.55 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.26 -0.9 . . . . 0.0 109.452 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.0 mt-30 . . . . . 0 N--CA 1.49 1.56 0 CA-C-O 117.97 -1.014 . . . . 0.0 109.493 179.906 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' -1' ' ' SER . . . . . . . . . . . . . 1.5 m . . . . . 0 N--CA 1.49 1.573 0 CA-C-O 121.291 0.567 . . . . 0.0 109.474 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 0' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -58.08 144.03 41.5 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.181 -0.95 . . . . 0.0 109.536 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.427 ' O ' ' OD2' ' A' ' 73' ' ' ASP . 59.8 mtt -91.98 63.01 4.38 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.301 -0.874 . . . . 0.0 109.17 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.514 ' C ' ' CG ' ' A' ' 3' ' ' HIS . 95.0 mm-40 59.42 53.1 5.38 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.608 -0.683 . . . . 0.0 109.541 -179.838 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.514 ' CG ' ' C ' ' A' ' 2' ' ' GLN . 14.1 m-70 77.85 45.27 0.07 Allowed 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.701 -0.624 . . . . 0.0 109.639 -179.899 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -61.19 -40.08 92.6 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.245 -0.909 . . . . 0.0 109.368 179.852 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.1 p -63.24 -34.05 76.83 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.269 -0.894 . . . . 0.0 109.658 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.406 ' HA ' HE21 ' A' ' 9' ' ' GLN . 55.4 t -62.22 -44.82 99.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.149 -0.969 . . . . 0.0 109.418 179.8 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 77.0 mt -60.13 -41.07 85.29 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 O-C-N 121.371 -0.831 . . . . 0.0 108.934 179.47 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -60.93 -38.87 87.3 Favored 'General case' 0 C--N 1.305 -1.36 0 O-C-N 121.561 -0.712 . . . . 0.0 109.543 -179.912 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . 0.406 HE21 ' HA ' ' A' ' 6' ' ' VAL . 52.1 mt-30 -63.63 -40.8 97.8 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.135 -0.978 . . . . 0.0 110.092 -179.833 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.694 ' CG ' ' CE2' ' A' ' 47' ' ' TRP . 33.7 m-85 -62.05 -50.12 73.25 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.002 -1.062 . . . . 0.0 110.628 -179.357 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 30.0 m -66.43 -41.74 89.22 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 O-C-N 121.006 -1.059 . . . . 0.0 109.18 -179.874 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.414 ' O ' ' C ' ' A' ' 16' ' ' LEU . 77.0 t -64.02 -45.17 97.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.219 -0.926 . . . . 0.0 109.49 179.436 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -72.25 -23.43 61.21 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.22 -0.925 . . . . 0.0 110.341 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -64.02 -30.02 71.13 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.333 -0.854 . . . . 0.0 110.466 -178.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 71.3 t80 -138.31 -42.29 0.51 Allowed 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.012 -1.055 . . . . 0.0 110.887 -179.391 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.414 ' C ' ' O ' ' A' ' 12' ' ' VAL . 5.2 mt -120.03 80.2 26.39 Favored Pre-proline 0 N--CA 1.493 1.677 0 O-C-N 121.095 -1.003 . . . . 0.0 110.397 -179.119 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -74.77 -14.5 21.71 Favored 'Trans proline' 0 C--N 1.309 -1.511 0 C-N-CA 122.337 2.024 . . . . 0.0 112.319 179.463 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -91.59 8.87 34.63 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.22 -0.925 . . . . 0.0 109.954 -179.666 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 48.8 t -110.87 135.55 49.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.281 -0.887 . . . . 0.0 109.742 -179.815 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.67 119.21 73.99 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.298 -0.877 . . . . 0.0 109.305 179.86 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_exo -51.36 -27.23 23.23 Favored 'Trans proline' 0 N--CA 1.494 1.507 0 C-N-CA 121.781 1.654 . . . . 0.0 112.01 179.676 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.8 -25.24 67.83 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.259 -0.901 . . . . 0.0 109.253 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.411 ' O ' ' OD1' ' A' ' 23' ' ' ASP . 58.6 t0 -81.8 7.35 12.92 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.362 -0.837 . . . . 0.0 109.693 -179.863 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 11.8 t -101.89 133.11 46.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.192 -0.943 . . . . 0.0 109.303 -179.851 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.418 ' C ' ' H ' ' A' ' 27' ' ' ASP . 86.9 m-20 -88.34 120.68 29.94 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.148 -0.97 . . . . 0.0 109.131 179.385 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 29.9 m -71.39 4.47 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 O-C-N 121.122 -0.987 . . . . 0.0 109.107 179.651 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.418 ' H ' ' C ' ' A' ' 25' ' ' ASP . 92.2 m-20 -95.38 0.21 53.26 Favored 'General case' 0 N--CA 1.485 1.32 0 O-C-N 121.397 -0.814 . . . . 0.0 109.094 179.549 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 46.0 tp -100.68 132.97 45.8 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.409 -0.807 . . . . 0.0 109.331 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.7 m-20 -68.78 138.06 54.51 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.285 -0.885 . . . . 0.0 109.822 -179.549 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 90.5 mt -65.5 -38.88 90.99 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.365 -0.834 . . . . 0.0 110.817 -179.899 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 75.6 t -66.08 -38.6 82.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 120.972 -1.08 . . . . 0.0 110.671 -178.737 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -52.91 -34.02 53.1 Favored 'General case' 0 N--CA 1.489 1.475 0 N-CA-C 108.122 -1.066 . . . . 0.0 108.122 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 97.4 m-20 -71.05 -34.65 71.44 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.643 -0.661 . . . . 0.0 109.927 179.513 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 82.03 4.06 90.38 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 108.754 -1.738 . . . . 0.0 108.754 -179.205 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 70.2 t -62.7 -32.9 57.17 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 O-C-N 121.526 -0.984 . . . . 0.0 108.894 179.612 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 81.1 mt -88.57 121.24 38.58 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.368 0 O-C-N 121.318 -0.864 . . . . 0.0 110.041 -179.838 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -115.82 -159.68 0.72 Allowed 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 108.966 -0.753 . . . . 0.0 108.966 179.697 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -67.77 -54.27 20.55 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.134 -0.979 . . . . 0.0 108.959 179.691 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 43.1 mt -67.08 -32.57 73.84 Favored 'General case' 0 C--N 1.303 -1.414 0 N-CA-C 107.189 -1.412 . . . . 0.0 107.189 178.447 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -58.74 -40.4 94.89 Favored Glycine 0 N--CA 1.48 1.611 0 N-CA-C 108.465 -1.854 . . . . 0.0 108.465 179.308 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.0 tt -65.45 -42.21 92.61 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 121.578 -0.954 . . . . 0.0 108.916 178.982 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.5 tp -60.47 -45.83 92.31 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.429 -0.795 . . . . 0.0 109.173 179.605 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 59.9 mttp -59.69 -35.59 74.8 Favored 'General case' 0 C--N 1.297 -1.712 0 O-C-N 121.547 -0.721 . . . . 0.0 109.618 -179.727 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 54.7 t -61.68 -49.71 83.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.357 -0.839 . . . . 0.0 110.071 -179.519 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.531 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 3.3 mp -68.0 -31.83 53.6 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 O-C-N 121.281 -0.887 . . . . 0.0 110.811 -179.659 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.99 -49.99 65.87 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 120.799 -1.188 . . . . 0.0 111.359 -178.2 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . 0.694 ' CE2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -81.17 -44.94 17.13 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.774 -1.204 . . . . 0.0 110.046 -179.385 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.456 ' N ' ' CG ' ' A' ' 47' ' ' TRP . 22.4 tp -58.58 -42.07 87.16 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 121.326 -0.859 . . . . 0.0 110.095 -178.858 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.531 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 2.3 pp20? -72.59 -36.54 68.18 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.195 -0.941 . . . . 0.0 109.777 -179.976 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . 0.402 ' N ' ' CG ' ' A' ' 49' ' ' GLU . 55.9 t0 -60.3 -38.27 83.15 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.24 -0.913 . . . . 0.0 110.713 -179.463 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 77.0 mtp180 -61.81 -38.64 88.87 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.195 -0.941 . . . . 0.0 111.738 -178.581 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.551 ' CE1' ' CG1' ' A' ' 76' ' ' VAL . 87.7 m-85 -97.93 -9.39 26.32 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.803 -1.186 . . . . 0.0 110.482 -178.951 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 70.92 31.44 67.05 Favored Glycine 0 N--CA 1.487 2.092 0 N-CA-C 108.703 -1.759 . . . . 0.0 108.703 179.824 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.485 ' O ' ' OE1' ' A' ' 49' ' ' GLU . 26.4 pt -107.24 153.27 8.52 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.367 0 O-C-N 121.703 -0.881 . . . . 0.0 109.787 -179.392 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -99.23 134.04 42.66 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.12 -0.988 . . . . 0.0 109.806 -179.551 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.511 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -68.21 -22.99 64.77 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.312 -0.867 . . . . 0.0 109.533 179.725 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -54.71 -35.65 63.86 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.266 -0.896 . . . . 0.0 109.961 -179.626 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -55.66 -39.53 71.05 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.202 -0.936 . . . . 0.0 110.019 -179.65 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.511 ' O ' ' O ' ' A' ' 56' ' ' ALA . 13.9 p -136.3 142.31 38.9 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.291 -0.881 . . . . 0.0 109.685 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -91.92 133.39 35.73 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.029 -1.044 . . . . 0.0 109.275 179.736 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 32.5 mt -97.92 138.75 34.78 Favored 'General case' 0 C--N 1.305 -1.363 0 O-C-N 121.332 -0.855 . . . . 0.0 109.661 -179.613 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -110.09 157.11 38.81 Favored Pre-proline 0 N--CA 1.487 1.42 0 N-CA-C 108.952 -0.758 . . . . 0.0 108.952 179.518 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_endo -54.01 -24.52 32.65 Favored 'Trans proline' 0 C--N 1.302 -1.91 0 C-N-CA 122.536 2.157 . . . . 0.0 111.567 179.891 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -71.23 -27.78 63.72 Favored 'General case' 0 C--N 1.306 -1.307 0 O-C-N 121.365 -0.834 . . . . 0.0 109.531 179.825 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . 0.525 ' NE2' ' CB ' ' A' ' 75' ' ' PHE . 8.2 t-80 -65.76 -20.3 66.21 Favored 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.185 -0.947 . . . . 0.0 108.975 -179.738 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.502 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 21.9 m-85 -91.36 16.54 9.93 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 179.901 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . 0.453 ' NE ' ' CB ' ' A' ' 71' ' ' SER . 7.7 ptt180 -50.07 -37.24 32.62 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.808 -0.557 . . . . 0.0 110.254 -179.753 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.401 ' O ' ' OG ' ' A' ' 71' ' ' SER . 19.0 t -163.15 157.65 20.81 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.977 -1.077 . . . . 0.0 110.29 -179.626 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.423 ' CD1' ' H ' ' A' ' 69' ' ' ILE . 2.0 mp -58.03 -39.31 71.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.424 -0.797 . . . . 0.0 109.266 179.862 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 7.6 ptm180 -58.03 -40.68 81.49 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.574 -0.704 . . . . 0.0 109.452 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.453 ' CB ' ' NE ' ' A' ' 67' ' ' ARG . 83.5 p -65.14 -37.16 86.54 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.325 -0.859 . . . . 0.0 109.722 179.914 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 75.3 mt -64.86 -44.94 96.24 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.268 0 O-C-N 121.245 -0.91 . . . . 0.0 109.809 179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.427 ' OD2' ' O ' ' A' ' 1' ' ' MET . 40.4 t0 -59.75 -41.7 91.57 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.291 -0.88 . . . . 0.0 109.396 -179.828 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.75 -43.86 83.02 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.405 -0.81 . . . . 0.0 110.084 -179.777 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . 0.525 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 56.8 t80 -62.1 -46.52 88.69 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.338 -0.851 . . . . 0.0 109.537 -179.764 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.551 ' CG1' ' CE1' ' A' ' 52' ' ' PHE . 99.2 t -61.67 -44.43 98.69 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.394 0 O-C-N 121.269 -0.895 . . . . 0.0 109.027 179.92 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.522 ' O ' ' O ' ' A' ' 81' ' ' THR . 53.3 t -66.64 -43.22 90.48 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 121.374 -0.829 . . . . 0.0 109.255 179.554 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.81 -23.15 49.82 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.771 -1.332 . . . . 0.0 109.771 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.05 -28.88 68.57 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.259 -1.142 . . . . 0.0 110.353 -179.475 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 9.8 p -129.65 -32.73 1.9 Allowed 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.128 -0.983 . . . . 0.0 110.752 -179.274 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.522 ' O ' ' O ' ' A' ' 77' ' ' VAL . 0.1 OUTLIER -132.37 153.13 81.11 Favored Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.188 -0.945 . . . . 0.0 109.682 -179.396 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 13.0 Cg_endo -59.51 134.18 56.57 Favored 'Trans proline' 0 C--N 1.308 -1.573 0 C-N-CA 122.22 1.947 . . . . 0.0 111.606 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_endo -71.15 152.53 62.15 Favored 'Trans proline' 0 N--CA 1.49 1.317 0 C-N-CA 122.134 1.889 . . . . 0.0 112.58 -179.606 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.453 ' O ' ' C ' ' A' ' 85' ' ' GLU . 28.8 m -102.64 134.27 44.0 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.471 -0.768 . . . . 0.0 108.959 179.516 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.453 ' C ' ' O ' ' A' ' 84' ' ' VAL . 84.0 tt0 40.66 67.8 0.48 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.412 -0.805 . . . . 0.0 109.441 -179.739 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -52.51 148.09 7.43 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.185 -0.947 . . . . 0.0 109.599 -179.793 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.414 ' HB3' HH21 ' A' ' 67' ' ' ARG . 20.5 tttm -56.95 -36.4 70.21 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.332 -0.855 . . . . 0.0 109.427 -179.845 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 55.4 mt -90.95 142.42 27.8 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.224 -0.923 . . . . 0.0 109.448 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 63.6 tt0 . . . . . 0 N--CA 1.49 1.555 0 CA-C-O 117.954 -1.022 . . . . 0.0 109.489 179.996 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' -1' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.49 1.53 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 . . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 0' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -57.46 143.63 39.72 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.335 -0.853 . . . . 0.0 109.327 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 68.9 mtp -110.35 -121.63 0.27 Allowed 'General case' 0 N--CA 1.486 1.363 0 O-C-N 121.306 -0.871 . . . . 0.0 108.962 -179.817 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.452 ' C ' ' N ' ' A' ' 4' ' ' ALA . 94.2 mm-40 -116.87 124.18 48.87 Favored 'General case' 0 C--N 1.3 -1.557 0 N-CA-C 107.67 -1.233 . . . . 0.0 107.67 178.752 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.43 ' C ' ' O ' ' A' ' 2' ' ' GLN . 46.0 m80 46.93 22.39 0.2 Allowed 'General case' 0 C--N 1.299 -1.601 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 -178.919 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.452 ' N ' ' C ' ' A' ' 2' ' ' GLN . . . -55.81 -39.77 71.81 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.392 -0.817 . . . . 0.0 109.562 -179.433 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.1 m -60.75 -36.33 78.63 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.213 -0.93 . . . . 0.0 109.553 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 75.8 t -63.3 -45.67 97.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.21 -0.932 . . . . 0.0 109.45 -179.895 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 78.8 mt -59.69 -45.6 94.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.373 -0.829 . . . . 0.0 108.799 179.622 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -62.21 -35.27 78.38 Favored 'General case' 0 C--N 1.304 -1.374 0 N-CA-C 108.763 -0.828 . . . . 0.0 108.763 179.5 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 32.5 tt0 -59.97 -38.37 82.32 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.259 -0.901 . . . . 0.0 109.472 179.733 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.65 ' CG ' ' CZ2' ' A' ' 47' ' ' TRP . 44.0 m-85 -70.17 -47.74 60.31 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.971 -1.081 . . . . 0.0 111.205 -179.551 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.516 ' CG2' ' N ' ' A' ' 12' ' ' VAL . 0.9 OUTLIER -61.64 -46.88 95.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 120.881 -1.137 . . . . 0.0 110.312 -178.143 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.592 ' O ' ' N ' ' A' ' 16' ' ' LEU . 35.5 m -64.75 -46.0 93.46 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.394 0 O-C-N 120.799 -1.188 . . . . 0.0 109.552 179.758 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -64.55 -26.96 68.64 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 120.813 -1.179 . . . . 0.0 109.737 179.798 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -64.43 -31.47 72.69 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.445 -0.785 . . . . 0.0 110.14 -179.479 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 86.6 t80 -142.84 -33.31 0.46 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.981 -1.074 . . . . 0.0 110.794 -179.436 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.592 ' N ' ' O ' ' A' ' 12' ' ' VAL . 3.4 mt -121.95 79.8 41.95 Favored Pre-proline 0 N--CA 1.492 1.66 0 O-C-N 121.07 -1.019 . . . . 0.0 109.976 -179.32 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -76.07 -18.54 16.42 Favored 'Trans proline' 0 C--N 1.309 -1.507 0 C-N-CA 122.537 2.158 . . . . 0.0 112.873 -179.756 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.442 ' C ' ' OD1' ' A' ' 18' ' ' ASP . 50.4 p30 -89.43 12.86 15.18 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.031 -1.043 . . . . 0.0 110.131 -179.565 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 84.1 t -106.79 134.41 48.52 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.187 -0.946 . . . . 0.0 109.574 179.669 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.06 118.45 65.74 Favored Pre-proline 0 N--CA 1.488 1.443 0 O-C-N 121.323 -0.861 . . . . 0.0 108.918 179.634 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -51.31 -36.41 57.2 Favored 'Trans proline' 0 N--CA 1.492 1.389 0 C-N-CA 121.571 1.514 . . . . 0.0 111.912 179.966 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -68.58 -18.56 64.36 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.246 -0.909 . . . . 0.0 108.885 179.386 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.451 ' O ' ' OD1' ' A' ' 23' ' ' ASP . 60.4 t0 -81.97 7.11 13.94 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.479 -0.763 . . . . 0.0 109.91 -179.644 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 15.1 t -104.56 131.66 53.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.167 -0.958 . . . . 0.0 109.433 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 62.4 t0 -88.44 119.68 29.11 Favored 'General case' 0 C--N 1.303 -1.445 0 O-C-N 121.213 -0.929 . . . . 0.0 108.689 179.256 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.2 m -75.29 3.18 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 O-C-N 121.138 -0.977 . . . . 0.0 109.484 -179.886 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -85.49 -19.18 31.6 Favored 'General case' 0 N--CA 1.487 1.375 0 O-C-N 121.137 -0.977 . . . . 0.0 109.116 179.368 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 48.7 tp -88.84 134.04 34.07 Favored 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 108.541 -0.911 . . . . 0.0 108.541 179.552 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 89.1 m-20 -60.37 135.12 57.64 Favored 'General case' 0 C--N 1.301 -1.539 0 C-N-CA 119.185 -1.006 . . . . 0.0 109.2 -179.423 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.473 ' H ' ' HA ' ' A' ' 68' ' ' SER . 39.0 tp -62.59 -36.42 82.68 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.509 -0.745 . . . . 0.0 110.257 -179.322 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 69.2 t -64.22 -35.76 74.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.047 -1.033 . . . . 0.0 110.466 -179.384 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -52.62 -33.72 47.88 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 97.1 m-20 -70.82 -34.55 71.83 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.606 -0.684 . . . . 0.0 110.001 179.468 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 85.71 5.16 84.53 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 108.858 -1.697 . . . . 0.0 108.858 -179.324 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 73.6 t -61.7 -33.05 55.72 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 121.554 -0.968 . . . . 0.0 108.979 179.678 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 80.2 mt -83.68 114.47 24.33 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.411 0 O-C-N 121.339 -0.851 . . . . 0.0 109.723 -179.728 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -112.6 -178.82 3.49 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 179.542 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -58.82 -52.3 66.29 Favored 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 108.245 -1.021 . . . . 0.0 108.245 179.7 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 42.3 mt -70.28 -32.65 70.53 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 106.849 -1.538 . . . . 0.0 106.849 177.922 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -59.27 -41.01 96.61 Favored Glycine 0 N--CA 1.481 1.67 0 N-CA-C 108.525 -1.83 . . . . 0.0 108.525 179.14 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 2.9 tt -64.87 -44.49 89.52 Favored 'General case' 0 C--N 1.305 -1.35 0 O-C-N 121.636 -0.92 . . . . 0.0 109.212 179.096 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 16.7 tp -59.55 -44.78 93.14 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.353 -0.842 . . . . 0.0 109.578 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 31.7 mttp -62.05 -34.81 76.93 Favored 'General case' 0 C--N 1.298 -1.669 0 O-C-N 121.076 -1.015 . . . . 0.0 109.541 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 69.4 t -61.2 -48.63 88.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.387 -0.821 . . . . 0.0 109.993 -179.528 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.541 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 3.0 mp -67.84 -32.44 56.51 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.515 0 O-C-N 121.405 -0.81 . . . . 0.0 110.948 -179.677 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.43 -50.36 63.64 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 120.982 -1.074 . . . . 0.0 111.373 -178.112 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . 0.65 ' CZ2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -81.18 -44.62 17.57 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 120.708 -1.245 . . . . 0.0 109.853 -179.502 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.5 ' N ' ' CG ' ' A' ' 47' ' ' TRP . 38.9 tp -58.55 -42.26 87.45 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.332 -0.855 . . . . 0.0 109.958 -179.022 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.541 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 1.2 pp20? -72.63 -35.85 67.91 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.0 -1.063 . . . . 0.0 109.635 179.887 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.1 t0 -60.2 -38.25 82.73 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.237 -0.914 . . . . 0.0 110.288 -179.77 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 71.9 mtp85 -61.19 -38.12 85.4 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.244 -0.91 . . . . 0.0 111.16 -178.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.476 ' CE2' ' CG1' ' A' ' 76' ' ' VAL . 86.6 m-85 -99.53 -10.36 22.18 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 120.859 -1.151 . . . . 0.0 110.031 -179.388 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 69.98 33.49 70.14 Favored Glycine 0 N--CA 1.486 2.027 0 N-CA-C 108.558 -1.817 . . . . 0.0 108.558 179.856 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.429 HD13 HG23 ' A' ' 54' ' ' ILE . 38.5 pt -103.08 149.06 7.44 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 O-C-N 121.535 -0.979 . . . . 0.0 109.994 -179.239 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -94.2 120.1 33.96 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.3 -0.875 . . . . 0.0 109.459 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.492 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -66.65 -28.99 68.91 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.403 -0.81 . . . . 0.0 109.495 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 54.6 t0 -56.41 -35.03 67.34 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.387 -0.821 . . . . 0.0 110.249 -179.453 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -53.75 -39.11 65.07 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.055 -1.028 . . . . 0.0 109.65 -179.582 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.492 ' O ' ' O ' ' A' ' 56' ' ' ALA . 46.5 t -127.46 136.57 60.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.521 -0.737 . . . . 0.0 109.544 179.851 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -85.5 128.43 34.74 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.119 -0.988 . . . . 0.0 108.765 179.547 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 54.8 mt -98.46 141.21 31.61 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.142 -0.974 . . . . 0.0 109.997 -179.158 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -105.55 151.15 39.72 Favored Pre-proline 0 C--N 1.305 -1.361 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 179.403 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -53.67 -21.87 20.89 Favored 'Trans proline' 0 C--N 1.306 -1.659 0 C-N-CA 122.227 1.951 . . . . 0.0 111.998 -179.54 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -70.07 -28.27 65.29 Favored 'General case' 0 N--CA 1.486 1.351 0 O-C-N 121.265 -0.897 . . . . 0.0 109.586 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . 0.586 ' CD2' ' O ' ' A' ' 65' ' ' HIS . 6.5 t-160 -65.72 -20.93 66.46 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.259 -0.901 . . . . 0.0 109.277 -179.713 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.542 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 7.8 m-85 -96.51 15.99 19.96 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.525 -0.734 . . . . 0.0 109.078 -179.65 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . 0.698 ' NH2' ' HZ3' ' A' ' 87' ' ' LYS . 1.3 ptt85 -54.36 -35.93 63.3 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.645 -0.659 . . . . 0.0 110.243 -179.765 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.473 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 90.4 p -157.54 160.38 38.13 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 120.912 -1.117 . . . . 0.0 110.287 -179.95 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.413 HD11 ' H ' ' A' ' 69' ' ' ILE . 3.1 mp -59.14 -34.03 52.26 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 179.007 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 57.6 mtp85 -56.95 -42.9 80.92 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.707 -0.621 . . . . 0.0 109.948 -179.266 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.55 ' HG ' ' N ' ' A' ' 72' ' ' ILE . 78.8 p -68.71 -35.82 77.65 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.298 -0.876 . . . . 0.0 110.115 -179.601 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.55 ' N ' ' HG ' ' A' ' 71' ' ' SER . 56.3 mt -65.93 -48.51 81.65 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 O-C-N 121.216 -0.928 . . . . 0.0 110.122 -179.38 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 43.9 t0 -60.17 -43.16 96.03 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.18 -0.95 . . . . 0.0 109.49 -179.757 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.95 -43.63 82.66 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.494 -0.754 . . . . 0.0 110.251 -179.579 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . 0.553 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 70.4 t80 -62.51 -45.29 93.66 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.263 -0.898 . . . . 0.0 109.697 -179.641 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.476 ' CG1' ' CE2' ' A' ' 52' ' ' PHE . 95.9 t -64.84 -47.06 90.0 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.361 0 O-C-N 121.206 -0.934 . . . . 0.0 109.665 -179.945 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 54.9 t -69.53 -45.98 76.93 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.329 0 O-C-N 121.1 -1.0 . . . . 0.0 109.731 179.857 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.48 ' O ' ' O ' ' A' ' 81' ' ' THR . . . -63.9 -30.73 78.55 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 110.307 -1.117 . . . . 0.0 110.307 -179.633 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -66.81 -39.53 87.74 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.137 -1.214 . . . . 0.0 110.516 -179.019 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 65.2 p -84.18 -28.81 27.09 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.036 -1.04 . . . . 0.0 109.778 -179.727 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.48 ' O ' ' O ' ' A' ' 78' ' ' GLY . 0.3 OUTLIER -133.27 153.9 80.84 Favored Pre-proline 0 C--N 1.302 -1.471 0 O-C-N 121.478 -0.764 . . . . 0.0 109.737 -179.546 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -60.5 110.73 0.85 Allowed 'Trans proline' 0 C--N 1.308 -1.569 0 C-N-CA 122.328 2.018 . . . . 0.0 111.278 179.564 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -76.13 152.12 35.29 Favored 'Trans proline' 0 C--N 1.313 -1.303 0 C-N-CA 122.074 1.849 . . . . 0.0 113.139 -179.011 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.452 ' O ' ' C ' ' A' ' 85' ' ' GLU . 47.0 t -102.88 133.99 45.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 N-CA-C 108.478 -0.934 . . . . 0.0 108.478 179.137 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.452 ' C ' ' O ' ' A' ' 84' ' ' VAL . 96.1 mt-10 43.3 70.2 0.33 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.105 -0.997 . . . . 0.0 108.845 -179.315 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -50.36 148.37 3.7 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.359 -0.838 . . . . 0.0 109.842 -179.367 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.698 ' HZ3' ' NH2' ' A' ' 67' ' ' ARG . 11.2 tttm -56.71 160.37 3.39 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.356 -0.84 . . . . 0.0 109.155 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 65.8 mt -51.42 -38.02 51.41 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.15 -0.969 . . . . 0.0 109.454 -179.666 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.6 mt-30 . . . . . 0 N--CA 1.49 1.531 0 CA-C-O 117.977 -1.011 . . . . 0.0 109.513 179.914 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' -1' ' ' SER . . . . . . . . . . . . . 1.7 m . . . . . 0 N--CA 1.49 1.574 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 0' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -58.76 145.91 38.8 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.315 -0.866 . . . . 0.0 109.547 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 11.7 ptt? -179.19 106.07 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.228 -0.92 . . . . 0.0 109.273 179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.584 ' N ' ' OD2' ' A' ' 73' ' ' ASP . 67.3 tp60 -88.13 127.13 35.42 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.359 -0.838 . . . . 0.0 109.502 -179.874 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.436 ' CD2' HE21 ' A' ' 2' ' ' GLN . 20.8 m170 59.59 36.55 22.74 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.491 -0.756 . . . . 0.0 109.926 179.813 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -61.99 -33.05 73.61 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.141 -0.974 . . . . 0.0 109.547 179.856 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.3 t -57.86 -37.56 74.13 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.284 -0.885 . . . . 0.0 109.879 -179.497 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 77.2 t -63.52 -45.41 97.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.169 -0.957 . . . . 0.0 109.514 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 77.7 mt -60.06 -42.72 90.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.405 -0.809 . . . . 0.0 109.096 179.727 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -60.89 -35.83 77.65 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.54 -0.725 . . . . 0.0 109.224 -179.982 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 30.9 tt0 -64.62 -41.77 95.97 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.234 -0.916 . . . . 0.0 110.191 -179.839 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.679 ' CG ' ' CZ2' ' A' ' 47' ' ' TRP . 37.4 m-85 -64.28 -50.62 67.16 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.975 -1.078 . . . . 0.0 110.719 -179.371 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 4.5 p -63.57 -41.0 91.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.047 -1.033 . . . . 0.0 109.383 -179.575 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.445 ' O ' ' C ' ' A' ' 16' ' ' LEU . 70.5 t -63.31 -46.34 95.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.121 -0.987 . . . . 0.0 109.339 179.558 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -71.13 -26.09 62.86 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.25 -0.906 . . . . 0.0 109.846 179.715 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -64.45 -30.61 71.65 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.46 -0.775 . . . . 0.0 110.664 -179.029 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 72.9 t80 -135.82 -42.9 0.67 Allowed 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.016 -1.053 . . . . 0.0 110.826 -179.084 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.445 ' C ' ' O ' ' A' ' 12' ' ' VAL . 4.2 mt -119.49 80.09 21.96 Favored Pre-proline 0 N--CA 1.493 1.723 0 O-C-N 121.088 -1.008 . . . . 0.0 110.377 -179.094 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -75.53 -14.13 20.13 Favored 'Trans proline' 0 C--N 1.309 -1.522 0 C-N-CA 122.292 1.995 . . . . 0.0 112.217 179.404 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.42 ' OD1' ' O ' ' A' ' 18' ' ' ASP . 59.9 t0 -89.55 7.02 38.4 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.274 -0.891 . . . . 0.0 109.683 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.401 ' CG1' ' OD2' ' A' ' 23' ' ' ASP . 46.1 t -111.76 135.44 51.0 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.432 -0.793 . . . . 0.0 109.651 -179.859 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . 0.468 ' O ' ' OD1' ' A' ' 23' ' ' ASP . . . -73.49 117.88 64.26 Favored Pre-proline 0 N--CA 1.489 1.514 0 O-C-N 121.304 -0.872 . . . . 0.0 109.325 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_exo -51.45 -25.53 19.14 Favored 'Trans proline' 0 N--CA 1.493 1.47 0 C-N-CA 121.858 1.705 . . . . 0.0 112.192 179.568 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.03 -23.67 67.26 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.307 -0.871 . . . . 0.0 109.739 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.468 ' OD1' ' O ' ' A' ' 20' ' ' ALA . 52.5 p30 -84.6 7.75 19.12 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.222 -0.924 . . . . 0.0 110.024 -179.635 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 10.9 t -104.57 131.39 53.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.192 -0.942 . . . . 0.0 109.397 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 87.6 m-20 -89.43 120.5 30.81 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.213 -0.93 . . . . 0.0 109.091 179.369 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.0 m -78.83 3.38 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 O-C-N 121.153 -0.967 . . . . 0.0 109.095 179.53 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 89.8 m-20 -83.5 -20.65 33.56 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 121.291 -0.881 . . . . 0.0 109.135 179.33 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 43.2 tp -88.69 137.9 31.9 Favored 'General case' 0 N--CA 1.487 1.41 0 N-CA-C 108.844 -0.798 . . . . 0.0 108.844 179.798 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 89.1 m-20 -57.33 136.27 56.55 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 121.158 -0.964 . . . . 0.0 109.35 -179.454 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.469 ' H ' ' HA ' ' A' ' 68' ' ' SER . 1.9 tt -66.0 -37.95 87.22 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.716 -0.615 . . . . 0.0 110.171 -179.179 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 69.9 t -63.14 -35.19 70.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.068 -1.02 . . . . 0.0 110.421 -178.976 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 90.8 m-20 -52.66 -33.89 49.18 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 108.062 -1.088 . . . . 0.0 108.062 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 97.5 m-20 -71.11 -34.62 71.27 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.571 -0.706 . . . . 0.0 109.864 179.488 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 84.4 6.83 85.59 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 108.962 -1.655 . . . . 0.0 108.962 -179.474 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 71.1 t -61.88 -35.03 65.65 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 O-C-N 121.392 -1.064 . . . . 0.0 108.95 179.74 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 99.1 mt -80.17 111.94 17.57 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.318 -0.864 . . . . 0.0 109.807 -179.942 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -113.02 -166.02 1.04 Allowed 'General case' 0 C--N 1.302 -1.458 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 179.777 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -65.18 -54.38 30.55 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.146 -0.971 . . . . 0.0 108.71 179.712 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 34.0 mt -70.57 -33.29 70.94 Favored 'General case' 0 C--N 1.302 -1.489 0 N-CA-C 107.213 -1.402 . . . . 0.0 107.213 178.4 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -59.4 -41.18 96.89 Favored Glycine 0 N--CA 1.48 1.589 0 N-CA-C 108.61 -1.796 . . . . 0.0 108.61 179.205 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.7 tt -65.68 -41.55 92.29 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.519 -0.989 . . . . 0.0 109.085 179.201 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.5 tp -61.22 -46.03 92.11 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.434 -0.791 . . . . 0.0 109.361 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 63.5 mttp -60.28 -35.91 76.62 Favored 'General case' 0 C--N 1.296 -1.733 0 O-C-N 121.443 -0.786 . . . . 0.0 109.452 -179.708 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 63.2 t -62.18 -45.82 97.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.357 -0.839 . . . . 0.0 109.668 -179.916 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.5 mp -67.96 -39.44 81.63 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 O-C-N 121.555 -0.716 . . . . 0.0 111.262 -179.375 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.09 -49.92 63.41 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.545 -1.347 . . . . 0.0 112.268 -177.603 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . 0.679 ' CZ2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -77.85 -46.05 22.55 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 120.637 -1.29 . . . . 0.0 110.681 -178.546 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.555 ' CD1' HH21 ' A' ' 51' ' ' ARG . 8.8 tp -58.65 -44.59 90.16 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.173 -0.955 . . . . 0.0 110.195 -178.825 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 65.4 mm-40 -69.93 -36.21 75.14 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.135 -0.978 . . . . 0.0 109.797 -179.667 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.3 t0 -62.24 -38.43 89.19 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.367 -0.833 . . . . 0.0 111.431 -179.2 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . 0.555 HH21 ' CD1' ' A' ' 48' ' ' LEU . 66.6 mtm180 -59.34 -38.92 81.58 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.023 -1.048 . . . . 0.0 111.574 -178.392 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.61 ' CE1' ' CG1' ' A' ' 76' ' ' VAL . 48.7 m-85 -90.14 -2.61 58.1 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 120.759 -1.213 . . . . 0.0 110.544 -179.199 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 73.98 29.2 63.19 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 108.797 -1.721 . . . . 0.0 108.797 179.546 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 31.4 pt -113.1 153.47 14.66 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 O-C-N 121.694 -0.886 . . . . 0.0 109.758 -179.397 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -101.83 138.76 38.37 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.255 -0.903 . . . . 0.0 109.426 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.506 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -64.65 -30.61 71.63 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.298 -0.876 . . . . 0.0 109.681 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 53.8 t0 -55.48 -36.02 66.17 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.132 -0.98 . . . . 0.0 109.827 -179.74 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -57.36 -39.89 76.94 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.199 -0.938 . . . . 0.0 110.169 -179.561 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.506 ' O ' ' O ' ' A' ' 56' ' ' ALA . 13.6 p -136.51 142.15 39.07 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.272 -0.892 . . . . 0.0 109.783 -179.941 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -101.71 137.02 40.57 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.156 -0.965 . . . . 0.0 109.433 179.815 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 5.5 mp -103.27 144.06 31.84 Favored 'General case' 0 C--N 1.305 -1.34 0 O-C-N 121.256 -0.902 . . . . 0.0 109.732 -179.843 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -103.34 153.13 38.7 Favored Pre-proline 0 C--N 1.305 -1.351 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 179.81 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 8.5 Cg_endo -53.75 -24.54 30.78 Favored 'Trans proline' 0 C--N 1.306 -1.665 0 C-N-CA 122.264 1.976 . . . . 0.0 111.82 -179.832 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -70.42 -28.39 65.01 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 121.392 -0.818 . . . . 0.0 109.257 179.69 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . 0.524 ' NE2' ' CB ' ' A' ' 75' ' ' PHE . 7.6 t-80 -66.02 -20.04 66.05 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 121.375 -0.828 . . . . 0.0 109.027 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.516 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 15.5 m-85 -91.98 15.1 13.93 Favored 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . 0.536 ' CZ ' ' OG ' ' A' ' 71' ' ' SER . 7.2 ptt180 -48.6 -37.33 17.79 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.7 -0.625 . . . . 0.0 109.866 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.469 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 92.4 p -159.55 155.86 27.08 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.092 -1.005 . . . . 0.0 109.919 179.811 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.419 HD13 ' H ' ' A' ' 69' ' ' ILE . 3.5 mp -58.58 -34.83 52.36 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 179.045 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 58.6 mtp180 -57.44 -43.25 83.73 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.67 -0.644 . . . . 0.0 109.462 -179.76 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.536 ' OG ' ' CZ ' ' A' ' 67' ' ' ARG . 22.7 t -65.54 -39.9 92.27 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.465 -0.772 . . . . 0.0 109.81 179.935 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 68.5 mt -61.02 -46.41 96.7 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.313 0 O-C-N 121.313 -0.867 . . . . 0.0 110.109 -179.541 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.584 ' OD2' ' N ' ' A' ' 2' ' ' GLN . 39.4 t0 -60.28 -42.88 96.38 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.176 -0.952 . . . . 0.0 109.364 179.96 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . 0.429 ' O ' ' N ' ' A' ' 78' ' ' GLY . . . -67.13 -41.94 85.29 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.427 -0.796 . . . . 0.0 110.466 -179.708 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . 0.524 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 62.5 t80 -62.05 -45.72 92.3 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.103 -0.998 . . . . 0.0 109.637 -179.563 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.61 ' CG1' ' CE1' ' A' ' 52' ' ' PHE . 69.9 t -67.12 -48.7 78.07 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 O-C-N 121.245 -0.909 . . . . 0.0 110.014 -179.853 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 78.3 t -70.0 -43.35 79.37 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.338 0 O-C-N 121.109 -0.994 . . . . 0.0 109.571 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.429 ' N ' ' O ' ' A' ' 74' ' ' ALA . . . -61.11 -34.04 86.44 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 110.436 -1.066 . . . . 0.0 110.436 -179.461 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.78 -41.28 83.47 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.262 -1.14 . . . . 0.0 111.051 -178.692 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 49.4 p -82.79 -32.75 27.53 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.04 -1.038 . . . . 0.0 109.679 -179.511 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -133.47 153.93 80.61 Favored Pre-proline 0 C--N 1.301 -1.53 0 O-C-N 121.468 -0.77 . . . . 0.0 109.626 -179.383 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -63.91 115.58 3.18 Favored 'Trans proline' 0 C--N 1.307 -1.634 0 C-N-CA 122.263 1.975 . . . . 0.0 110.913 179.408 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -74.48 150.61 41.13 Favored 'Trans proline' 0 N--CA 1.488 1.201 0 C-N-CA 121.862 1.708 . . . . 0.0 113.213 -179.043 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.454 ' O ' ' C ' ' A' ' 85' ' ' GLU . 34.5 m -103.45 137.94 29.87 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 179.28 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.454 ' C ' ' O ' ' A' ' 84' ' ' VAL . 96.1 mt-10 42.35 64.34 1.15 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.206 -0.934 . . . . 0.0 109.233 -179.677 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -44.88 151.59 0.29 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.307 -0.871 . . . . 0.0 109.812 -179.61 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.409 ' HD3' HH21 ' A' ' 67' ' ' ARG . 16.6 tttm -55.42 -34.82 64.76 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.465 -0.772 . . . . 0.0 109.367 -179.858 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 50.6 mt -90.05 142.26 27.88 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.242 -0.911 . . . . 0.0 109.401 179.804 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 25.8 mt-30 . . . . . 0 N--CA 1.49 1.53 0 CA-C-O 117.94 -1.028 . . . . 0.0 109.511 -179.965 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' -1' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.489 1.507 0 CA-C-O 121.292 0.568 . . . . 0.0 109.475 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 0' ' ' GLU . . . . . 0.449 ' O ' ' C ' ' A' ' 1' ' ' MET . 84.8 tt0 -101.87 135.11 43.97 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.245 -0.909 . . . . 0.0 109.352 -179.931 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.449 ' C ' ' O ' ' A' ' 0' ' ' GLU . 68.2 mtt 41.01 88.68 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.369 -0.832 . . . . 0.0 109.493 -179.772 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.514 ' O ' ' CG ' ' A' ' 3' ' ' HIS . 94.8 mt-30 -57.73 -35.26 70.44 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.487 -0.758 . . . . 0.0 109.579 -179.863 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.514 ' CG ' ' O ' ' A' ' 2' ' ' GLN . 93.6 m-70 -156.53 60.73 0.55 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.187 -0.946 . . . . 0.0 109.486 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -62.1 -34.71 76.83 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.229 -0.919 . . . . 0.0 109.634 -179.871 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.2 m -59.38 -38.9 81.68 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.293 -0.88 . . . . 0.0 109.864 -179.617 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 51.8 t -66.97 -46.34 85.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.121 -0.987 . . . . 0.0 109.742 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 87.3 mt -59.81 -50.27 80.7 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.456 0 O-C-N 121.379 -0.826 . . . . 0.0 109.847 -179.617 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.76 -42.3 97.85 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.272 -0.892 . . . . 0.0 110.78 -179.664 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 47.3 tt0 -69.41 -47.59 63.68 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 120.976 -1.078 . . . . 0.0 111.043 -178.582 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.688 ' CD1' ' N ' ' A' ' 11' ' ' VAL . 0.0 OUTLIER -71.66 -44.14 64.8 Favored 'General case' 0 C--N 1.298 -1.659 0 O-C-N 120.921 -1.112 . . . . 0.0 110.815 -179.226 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.688 ' N ' ' CD1' ' A' ' 10' ' ' PHE . 5.2 p -61.02 -47.84 91.78 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 120.996 -1.065 . . . . 0.0 110.692 -178.711 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.535 ' N ' ' CG1' ' A' ' 11' ' ' VAL . 8.6 p -63.62 -39.14 84.25 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 120.805 -1.184 . . . . 0.0 109.817 -179.686 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -65.78 -36.17 82.77 Favored 'General case' 0 N--CA 1.486 1.33 0 O-C-N 120.93 -1.106 . . . . 0.0 110.131 -179.919 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -65.95 -42.41 90.02 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.166 -0.959 . . . . 0.0 110.196 -179.694 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 86.5 m-85 -91.47 -45.04 8.75 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.183 -0.948 . . . . 0.0 110.512 -179.691 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.465 ' N ' ' O ' ' A' ' 12' ' ' VAL . 8.5 mt -122.31 80.22 45.13 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.421 -0.799 . . . . 0.0 110.223 -178.942 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_endo -70.17 -15.47 35.55 Favored 'Trans proline' 0 C--N 1.312 -1.373 0 C-N-CA 122.099 1.866 . . . . 0.0 112.333 179.704 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -96.07 9.74 39.86 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.163 -0.961 . . . . 0.0 110.229 -179.581 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 44.3 t -114.73 135.28 55.09 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.239 -0.913 . . . . 0.0 109.837 -179.782 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -74.71 118.69 72.13 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.349 -0.844 . . . . 0.0 109.122 179.743 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_exo -51.17 -36.89 57.38 Favored 'Trans proline' 0 N--CA 1.493 1.444 0 C-N-CA 121.765 1.643 . . . . 0.0 112.008 179.635 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.71 -23.0 66.06 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.282 -0.886 . . . . 0.0 108.948 179.471 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 87.6 m-20 -87.98 7.13 32.55 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.406 -0.809 . . . . 0.0 109.872 -179.729 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 10.6 t -107.07 128.49 61.91 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.188 -0.945 . . . . 0.0 109.406 179.942 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 86.9 m-20 -89.81 120.29 30.92 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.137 -0.977 . . . . 0.0 109.169 179.275 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.4 m -78.87 3.36 1.74 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.465 0 O-C-N 121.125 -0.985 . . . . 0.0 108.741 179.321 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 90.5 m-20 -83.59 -19.4 35.61 Favored 'General case' 0 N--CA 1.486 1.358 0 O-C-N 121.545 -0.722 . . . . 0.0 109.073 179.392 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 42.8 tp -88.94 138.01 31.8 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 121.481 -0.762 . . . . 0.0 109.024 179.863 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -58.61 136.92 57.75 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.11 -0.993 . . . . 0.0 109.517 -179.376 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.485 ' H ' ' HA ' ' A' ' 68' ' ' SER . 2.4 tt -66.46 -38.0 86.38 Favored 'General case' 0 C--N 1.299 -1.613 0 O-C-N 121.757 -0.59 . . . . 0.0 110.134 -179.232 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 75.7 t -62.55 -34.72 66.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.121 -0.987 . . . . 0.0 110.436 -178.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -52.45 -33.97 46.73 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 120.975 -1.078 . . . . 0.0 108.104 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 97.2 m-20 -71.08 -34.46 71.19 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.643 -0.66 . . . . 0.0 109.949 179.389 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 85.37 6.52 83.85 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 -179.446 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 76.3 t -61.52 -34.49 61.82 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.438 -1.036 . . . . 0.0 109.094 179.695 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 93.9 mt -83.14 114.4 23.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.274 -0.891 . . . . 0.0 109.735 -179.876 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -118.66 -158.41 0.72 Allowed 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 179.657 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -64.78 -54.15 35.81 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.046 -1.034 . . . . 0.0 108.506 179.631 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.597 ' N ' ' CD2' ' A' ' 39' ' ' LEU . 1.5 mm? -68.74 -32.52 72.36 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 107.32 -1.363 . . . . 0.0 107.32 178.264 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -58.79 -45.94 94.18 Favored Glycine 0 N--CA 1.483 1.781 0 N-CA-C 109.06 -1.616 . . . . 0.0 109.06 179.6 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.9 tt -64.24 -39.06 93.18 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.426 -1.043 . . . . 0.0 108.762 179.035 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.1 tp -59.68 -45.76 91.11 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.311 -0.868 . . . . 0.0 108.798 179.543 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 54.5 mttp -60.2 -35.59 75.74 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.498 -0.751 . . . . 0.0 109.536 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 68.3 t -60.17 -46.89 93.97 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.345 -0.847 . . . . 0.0 109.567 -179.925 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.7 mp -68.22 -33.23 59.52 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 O-C-N 121.359 -0.838 . . . . 0.0 110.802 -179.915 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.17 -49.1 65.93 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.095 -1.003 . . . . 0.0 111.466 -178.359 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . 0.524 ' C ' ' CD1' ' A' ' 47' ' ' TRP . 0.0 OUTLIER -80.8 -41.51 23.22 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 120.583 -1.323 . . . . 0.0 109.663 -179.548 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 8.3 tt -59.55 -41.78 90.87 Favored 'General case' 0 C--N 1.3 -1.567 0 O-C-N 121.377 -0.827 . . . . 0.0 109.909 -179.331 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.52 ' O ' ' N ' ' A' ' 53' ' ' GLY . 18.4 pt-20 -73.15 -36.92 66.75 Favored 'General case' 0 C--N 1.304 -1.371 0 O-C-N 121.099 -1.001 . . . . 0.0 109.562 -179.817 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . 0.405 ' N ' ' CG ' ' A' ' 49' ' ' GLU . 55.9 t0 -59.06 -38.49 79.5 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.321 -0.862 . . . . 0.0 110.838 -179.319 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 75.1 mtm180 -61.56 -41.18 97.0 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 120.986 -1.072 . . . . 0.0 111.473 -178.649 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.592 ' CE1' ' CG1' ' A' ' 76' ' ' VAL . 36.7 m-85 -105.87 -12.54 15.81 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 120.923 -1.11 . . . . 0.0 110.173 -179.451 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.52 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 70.85 30.45 68.15 Favored Glycine 0 N--CA 1.486 2.017 0 N-CA-C 109.054 -1.618 . . . . 0.0 109.054 179.574 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 16.2 pt -97.82 129.72 47.6 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 O-C-N 121.336 -1.097 . . . . 0.0 109.756 -179.549 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -67.37 135.53 53.37 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.155 -0.966 . . . . 0.0 109.651 -179.666 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.504 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -66.37 -31.5 72.31 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.297 -0.877 . . . . 0.0 109.441 179.804 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 54.2 t0 -56.94 -36.69 70.53 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.277 -0.89 . . . . 0.0 109.999 -179.75 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 54.5 t0 -56.11 -40.38 73.61 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.182 -0.949 . . . . 0.0 109.892 -179.598 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.504 ' O ' ' O ' ' A' ' 56' ' ' ALA . 42.6 t -129.33 134.74 63.23 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.425 -0.797 . . . . 0.0 109.603 179.926 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -91.81 131.06 37.43 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.15 -0.969 . . . . 0.0 109.277 179.763 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 54.6 mt -97.82 139.27 33.92 Favored 'General case' 0 C--N 1.305 -1.327 0 O-C-N 121.297 -0.877 . . . . 0.0 109.674 -179.752 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.611 ' HG ' ' H ' ' A' ' 64' ' ' GLU . 0.1 OUTLIER -110.0 157.12 38.71 Favored Pre-proline 0 N--CA 1.489 1.495 0 N-CA-C 108.849 -0.796 . . . . 0.0 108.849 179.606 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 7.1 Cg_endo -52.83 -22.9 19.1 Favored 'Trans proline' 0 C--N 1.302 -1.903 0 C-N-CA 122.368 2.045 . . . . 0.0 111.72 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . 0.611 ' H ' ' HG ' ' A' ' 62' ' ' SER . 97.1 mt-10 -70.45 -27.52 64.31 Favored 'General case' 0 N--CA 1.485 1.304 0 O-C-N 121.386 -0.821 . . . . 0.0 109.507 179.6 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . 0.566 ' C ' ' CD2' ' A' ' 65' ' ' HIS . 0.7 OUTLIER -65.67 -19.8 66.05 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.315 -0.865 . . . . 0.0 108.95 -179.882 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.551 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 6.0 m-85 -98.25 16.11 22.42 Favored 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 179.839 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . 0.423 ' HG2' ' H ' ' A' ' 68' ' ' SER . 5.3 ptt180 -49.87 -38.49 35.69 Favored 'General case' 0 C--N 1.3 -1.547 0 O-C-N 121.79 -0.569 . . . . 0.0 110.031 -179.798 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.485 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 84.2 p -161.66 157.59 24.76 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.006 -1.059 . . . . 0.0 109.969 179.838 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.402 ' H ' HD12 ' A' ' 69' ' ' ILE . 3.4 mp -57.97 -35.04 50.4 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 179.034 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 59.6 mtp180 -57.51 -42.18 82.29 Favored 'General case' 0 N--CA 1.488 1.427 0 CA-C-O 121.442 0.639 . . . . 0.0 109.291 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 60.5 p -70.46 -36.39 73.88 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.446 -0.784 . . . . 0.0 110.047 -179.707 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 81.0 mt -62.73 -51.35 73.15 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 O-C-N 121.216 -0.928 . . . . 0.0 109.626 -179.636 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 35.0 m-20 -63.24 -42.85 99.27 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.301 -0.875 . . . . 0.0 108.651 179.883 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -67.1 -37.43 83.93 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.571 -0.706 . . . . 0.0 109.891 179.677 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 70.4 t80 -58.87 -47.62 84.28 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.028 -1.045 . . . . 0.0 109.915 -179.387 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.592 ' CG1' ' CE1' ' A' ' 52' ' ' PHE . 76.4 t -68.11 -48.56 73.66 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 O-C-N 121.238 -0.914 . . . . 0.0 110.255 -179.559 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.402 HG23 ' H ' ' A' ' 2' ' ' GLN . 50.0 t -69.69 -45.27 78.16 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.306 0 O-C-N 121.047 -1.033 . . . . 0.0 109.847 -179.796 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.458 ' O ' ' O ' ' A' ' 81' ' ' THR . . . -61.19 -39.16 96.78 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 110.208 -1.157 . . . . 0.0 110.208 -179.573 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.72 -41.02 84.15 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.189 -1.183 . . . . 0.0 110.366 -179.242 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 49.5 p -82.83 -29.86 29.14 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.05 -1.031 . . . . 0.0 109.691 -179.614 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.458 ' O ' ' O ' ' A' ' 78' ' ' GLY . 0.3 OUTLIER -133.21 153.64 80.8 Favored Pre-proline 0 C--N 1.303 -1.452 0 O-C-N 121.519 -0.738 . . . . 0.0 109.668 -179.561 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -68.31 112.38 2.77 Favored 'Trans proline' 0 C--N 1.308 -1.565 0 C-N-CA 122.414 2.076 . . . . 0.0 111.438 179.655 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -76.18 152.8 35.76 Favored 'Trans proline' 0 C--N 1.315 -1.212 0 C-N-CA 122.113 1.875 . . . . 0.0 112.772 -179.379 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.423 ' O ' ' C ' ' A' ' 85' ' ' GLU . 29.8 m -102.46 140.4 20.95 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 179.453 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.423 ' C ' ' O ' ' A' ' 84' ' ' VAL . 84.3 tt0 43.96 68.51 0.52 Allowed 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.192 -0.943 . . . . 0.0 109.003 -179.446 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -47.04 150.83 0.72 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.307 -0.871 . . . . 0.0 109.797 -179.598 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.408 ' HB3' HH21 ' A' ' 67' ' ' ARG . 34.1 tttm -55.63 -36.17 66.71 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.43 -0.794 . . . . 0.0 109.535 -179.852 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 53.6 mt -91.74 142.02 28.05 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.178 -0.951 . . . . 0.0 109.393 179.868 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.2 mt-30 . . . . . 0 N--CA 1.49 1.554 0 CA-C-O 117.975 -1.012 . . . . 0.0 109.457 179.983 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' -1' ' ' SER . . . . . 0.709 ' HG ' ' H ' ' A' ' 5' ' ' SER . 0.3 OUTLIER . . . . . 0 N--CA 1.49 1.563 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 . . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 0' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -57.65 -36.06 71.36 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.193 -0.942 . . . . 0.0 109.398 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 50.3 mtt -111.59 -121.5 0.28 Allowed 'General case' 0 N--CA 1.486 1.326 0 O-C-N 121.299 -0.876 . . . . 0.0 108.881 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.433 ' O ' ' C ' ' A' ' 3' ' ' HIS . 61.4 tp60 -114.43 112.11 22.5 Favored 'General case' 0 C--N 1.301 -1.528 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 178.709 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.433 ' C ' ' O ' ' A' ' 2' ' ' GLN . 60.5 m-70 47.2 29.62 1.23 Allowed 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 -178.701 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -58.92 -41.93 88.46 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.542 -0.723 . . . . 0.0 109.746 -179.395 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' SER . . . . . 0.709 ' H ' ' HG ' ' A' ' -1' ' ' SER . 85.8 p -63.79 -31.35 72.5 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.308 -0.87 . . . . 0.0 109.666 -179.873 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.406 ' N ' ' HG ' ' A' ' 5' ' ' SER . 73.7 t -65.05 -45.26 94.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.182 -0.949 . . . . 0.0 109.432 -179.929 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 76.0 mt -60.25 -43.58 93.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.445 -0.784 . . . . 0.0 109.165 179.771 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -60.33 -35.96 76.86 Favored 'General case' 0 C--N 1.305 -1.369 0 O-C-N 121.499 -0.75 . . . . 0.0 109.23 -179.898 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 7.3 tt0 -64.97 -41.19 95.67 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.22 -0.925 . . . . 0.0 110.142 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.693 ' CG ' ' CZ2' ' A' ' 47' ' ' TRP . 30.2 m-85 -62.6 -50.36 71.57 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.041 -1.037 . . . . 0.0 110.688 -179.381 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 24.9 m -63.82 -41.78 93.69 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 O-C-N 121.062 -1.024 . . . . 0.0 109.343 -179.473 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.453 ' O ' ' C ' ' A' ' 16' ' ' LEU . 71.2 t -63.82 -46.73 93.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.138 -0.976 . . . . 0.0 109.351 179.498 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -70.4 -29.0 65.52 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.226 -0.921 . . . . 0.0 110.124 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 83.9 tt0 -64.58 -29.98 71.0 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.346 -0.846 . . . . 0.0 110.611 -178.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 75.3 t80 -132.83 -46.1 0.87 Allowed 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.01 -1.056 . . . . 0.0 110.959 -179.075 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.453 ' C ' ' O ' ' A' ' 12' ' ' VAL . 3.3 mt -118.03 80.01 14.57 Favored Pre-proline 0 N--CA 1.493 1.72 0 O-C-N 121.216 -0.928 . . . . 0.0 110.424 -178.855 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -77.82 -11.97 16.56 Favored 'Trans proline' 0 C--N 1.308 -1.57 0 C-N-CA 122.551 2.168 . . . . 0.0 112.483 179.569 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.44 ' C ' ' OD1' ' A' ' 18' ' ' ASP . 53.2 p30 -90.19 8.38 33.31 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 121.092 -1.005 . . . . 0.0 110.125 -179.651 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 51.6 t -119.34 135.51 59.49 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.365 -0.834 . . . . 0.0 109.688 179.95 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.34 120.44 79.71 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.258 -0.901 . . . . 0.0 109.421 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_exo -51.53 -27.54 25.47 Favored 'Trans proline' 0 N--CA 1.493 1.478 0 C-N-CA 121.764 1.643 . . . . 0.0 112.036 179.478 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.77 -25.83 68.09 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.317 -0.864 . . . . 0.0 109.357 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.445 ' O ' ' OD1' ' A' ' 23' ' ' ASP . 60.0 t0 -81.78 5.82 17.43 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.368 -0.832 . . . . 0.0 109.721 -179.826 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 11.7 t -108.25 132.47 55.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.24 -0.912 . . . . 0.0 109.462 -179.952 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 86.3 m-20 -89.19 120.51 30.63 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.144 -0.973 . . . . 0.0 109.004 179.356 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.9 m -77.12 2.49 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 O-C-N 121.005 -1.059 . . . . 0.0 108.991 179.592 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 87.6 m-20 -78.83 -28.56 44.4 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.305 -0.872 . . . . 0.0 108.808 178.974 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 45.9 tp -83.16 139.32 33.24 Favored 'General case' 0 N--CA 1.487 1.388 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 179.53 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.5 m-20 -56.64 132.63 52.39 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.035 -1.04 . . . . 0.0 109.556 -178.969 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.43 ' H ' ' HA ' ' A' ' 68' ' ' SER . 50.8 tp -64.9 -36.87 85.75 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.7 -0.625 . . . . 0.0 110.552 -179.471 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 78.9 t -63.38 -34.89 69.94 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.089 -1.007 . . . . 0.0 110.54 -179.11 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 90.6 m-20 -52.58 -33.35 45.68 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.001 -1.062 . . . . 0.0 108.181 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 97.5 m-20 -70.81 -34.21 71.51 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.625 -0.672 . . . . 0.0 109.98 179.483 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 90.68 3.62 70.99 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 108.974 -1.65 . . . . 0.0 108.974 -179.267 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 75.7 t -60.92 -29.2 45.0 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 121.431 -1.041 . . . . 0.0 108.66 179.415 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 71.0 mt -95.56 134.67 32.18 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 O-C-N 121.478 -0.764 . . . . 0.0 109.406 -179.88 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.576 ' CG ' ' H ' ' A' ' 38' ' ' ALA . 50.2 t0 -138.9 -169.82 2.72 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.576 ' H ' ' CG ' ' A' ' 37' ' ' ASP . . . -62.0 -54.16 45.5 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.147 -0.971 . . . . 0.0 108.765 179.911 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.467 ' CD1' ' N ' ' A' ' 39' ' ' LEU . 6.9 mp -69.76 -32.71 71.38 Favored 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 107.201 -1.407 . . . . 0.0 107.201 178.091 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -59.39 -44.74 96.39 Favored Glycine 0 N--CA 1.483 1.805 0 N-CA-C 108.971 -1.652 . . . . 0.0 108.971 179.456 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.408 ' CD1' ' CE1' ' A' ' 66' ' ' PHE . 7.9 tt -65.0 -40.4 94.89 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.423 -1.046 . . . . 0.0 109.195 179.367 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.1 tp -59.68 -46.02 90.31 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.1 -1.0 . . . . 0.0 108.887 179.675 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 59.7 mttp -61.3 -34.89 75.96 Favored 'General case' 0 C--N 1.297 -1.71 0 O-C-N 121.546 -0.722 . . . . 0.0 109.448 -180.0 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.438 ' O ' ' CB ' ' A' ' 48' ' ' LEU . 73.8 t -59.47 -43.27 90.22 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 O-C-N 121.299 -0.876 . . . . 0.0 109.142 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.525 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 6.7 mm -66.95 -38.74 81.98 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 121.395 -0.815 . . . . 0.0 110.752 -179.363 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.21 -49.77 68.44 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.128 -0.983 . . . . 0.0 111.716 -178.064 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . 0.693 ' CZ2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -80.84 -44.34 18.59 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.648 -1.283 . . . . 0.0 109.99 -179.277 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.438 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 20.8 tp -58.93 -41.97 88.63 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.209 -0.932 . . . . 0.0 110.094 -178.921 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.525 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 1.2 pp20? -72.25 -36.87 69.19 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.009 -1.057 . . . . 0.0 109.589 -179.889 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.7 t0 -61.19 -38.18 85.61 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.232 -0.917 . . . . 0.0 110.441 -179.834 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 14.8 mmm180 -61.69 -37.09 82.86 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.308 -0.87 . . . . 0.0 111.432 -178.703 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.634 ' CZ ' ' CG1' ' A' ' 76' ' ' VAL . 72.6 m-85 -96.82 -8.0 32.16 Favored 'General case' 0 N--CA 1.487 1.375 0 O-C-N 120.769 -1.207 . . . . 0.0 110.172 -178.956 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 71.18 31.22 66.55 Favored Glycine 0 N--CA 1.485 1.945 0 N-CA-C 108.82 -1.712 . . . . 0.0 108.82 179.771 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.487 ' O ' ' OE1' ' A' ' 49' ' ' GLU . 24.7 pt -108.81 153.13 10.62 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 O-C-N 121.598 -0.942 . . . . 0.0 109.84 -179.3 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -103.79 155.49 18.56 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.411 -0.805 . . . . 0.0 109.436 -179.638 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -58.46 -26.32 63.24 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.317 -0.865 . . . . 0.0 109.325 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 60.9 t0 59.13 38.29 23.81 Favored 'General case' 0 N--CA 1.486 1.336 0 O-C-N 121.445 -0.784 . . . . 0.0 109.109 -179.79 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 54.27 44.97 28.24 Favored 'General case' 0 N--CA 1.486 1.328 0 O-C-N 121.588 -0.695 . . . . 0.0 110.354 179.272 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 52.9 t -120.85 134.08 65.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.387 -0.82 . . . . 0.0 109.091 179.339 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -102.52 130.7 49.43 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.282 -0.886 . . . . 0.0 109.664 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 60.8 mt -99.24 143.88 29.0 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.394 -0.816 . . . . 0.0 109.17 179.834 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 11.6 p -90.09 148.17 38.8 Favored Pre-proline 0 C--N 1.305 -1.346 0 O-C-N 121.053 -1.029 . . . . 0.0 108.707 179.821 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -57.62 -19.78 38.99 Favored 'Trans proline' 0 C--N 1.305 -1.754 0 C-N-CA 122.24 1.96 . . . . 0.0 111.858 -179.714 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -67.41 -30.78 70.63 Favored 'General case' 0 N--CA 1.485 1.304 0 O-C-N 121.376 -0.828 . . . . 0.0 109.226 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . 0.568 ' CD2' ' O ' ' A' ' 65' ' ' HIS . 2.7 t-80 -66.47 -19.47 65.8 Favored 'General case' 0 C--N 1.3 -1.584 0 O-C-N 121.262 -0.899 . . . . 0.0 108.815 179.82 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.54 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 6.6 m-85 -98.31 13.3 31.94 Favored 'General case' 0 C--N 1.3 -1.571 0 N-CA-C 108.89 -0.781 . . . . 0.0 108.89 -179.753 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . 0.406 HH21 ' HD2' ' A' ' 87' ' ' LYS . 1.5 ptt180 -49.82 -34.74 20.58 Favored 'General case' 0 C--N 1.299 -1.587 0 O-C-N 121.716 -0.615 . . . . 0.0 110.167 -179.778 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.43 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 23.3 t -153.17 154.88 35.63 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.101 -1.0 . . . . 0.0 110.041 -179.577 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.413 HD11 ' H ' ' A' ' 69' ' ' ILE . 3.3 mp -57.45 -33.99 45.53 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 178.886 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.704 ' NE ' ' HZ2' ' A' ' 87' ' ' LYS . 60.4 mtp180 -56.99 -45.61 82.85 Favored 'General case' 0 N--CA 1.488 1.453 0 CA-C-O 121.395 0.617 . . . . 0.0 109.567 -179.516 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 22.9 t -65.82 -41.43 91.86 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.283 -0.886 . . . . 0.0 109.87 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 68.5 mt -61.38 -45.38 98.75 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 O-C-N 121.265 -0.897 . . . . 0.0 110.022 -179.566 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 41.4 t0 -60.15 -40.79 91.08 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.178 -0.951 . . . . 0.0 109.573 -179.846 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.36 -46.06 78.02 Favored 'General case' 0 C--N 1.304 -1.393 0 O-C-N 121.232 -0.917 . . . . 0.0 109.593 -179.75 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . 0.51 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 63.5 t80 -63.19 -44.07 96.41 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.247 -0.908 . . . . 0.0 109.127 179.621 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.634 ' CG1' ' CZ ' ' A' ' 52' ' ' PHE . 55.4 t -62.57 -46.66 95.84 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.309 0 O-C-N 121.407 -0.808 . . . . 0.0 109.404 179.607 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.504 ' O ' ' O ' ' A' ' 81' ' ' THR . 72.5 t -68.87 -41.71 82.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 O-C-N 121.262 -0.899 . . . . 0.0 109.402 179.803 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.38 -23.45 53.78 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.798 -1.321 . . . . 0.0 109.798 179.903 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.08 -33.2 74.97 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.283 -1.128 . . . . 0.0 110.639 -179.149 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 26.2 p -121.46 -33.75 3.58 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.232 -0.918 . . . . 0.0 110.776 -179.179 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.504 ' O ' ' O ' ' A' ' 77' ' ' VAL . 0.0 OUTLIER -132.88 152.72 80.34 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.247 -0.908 . . . . 0.0 109.759 -179.388 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -43.9 148.47 0.98 Allowed 'Trans proline' 0 C--N 1.311 -1.415 0 C-N-CA 122.052 1.835 . . . . 0.0 111.491 179.63 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -63.01 150.29 89.1 Favored 'Trans proline' 0 C--N 1.31 -1.492 0 C-N-CA 122.245 1.963 . . . . 0.0 112.543 -179.589 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.453 ' O ' ' C ' ' A' ' 85' ' ' GLU . 45.6 t -102.79 130.78 52.29 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 N-CA-C 108.871 -0.789 . . . . 0.0 108.871 179.496 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.453 ' C ' ' O ' ' A' ' 84' ' ' VAL . 81.5 tt0 41.04 61.13 1.82 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.418 -0.801 . . . . 0.0 109.169 -179.688 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -52.08 147.05 7.85 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.214 -0.929 . . . . 0.0 109.538 -179.593 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.704 ' HZ2' ' NE ' ' A' ' 70' ' ' ARG . 68.0 mttm -76.41 -169.14 1.12 Allowed 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.347 -0.846 . . . . 0.0 109.891 -179.808 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 32.6 mt -81.25 144.74 31.35 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.452 -0.78 . . . . 0.0 109.483 -179.56 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 25.9 mt-30 . . . . . 0 N--CA 1.49 1.56 0 CA-C-O 117.963 -1.018 . . . . 0.0 109.463 179.981 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' -1' ' ' SER . . . . . 0.401 ' HB2' ' H ' ' A' ' 4' ' ' ALA . 2.4 p . . . . . 0 N--CA 1.49 1.574 0 CA-C-O 121.303 0.573 . . . . 0.0 109.489 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 0' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -61.56 -33.95 74.74 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.209 -0.932 . . . . 0.0 109.343 179.932 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.571 ' SD ' ' OD2' ' A' ' 73' ' ' ASP . 70.7 mtp -111.12 -121.03 0.28 Allowed 'General case' 0 C--N 1.306 -1.324 0 O-C-N 121.414 -0.804 . . . . 0.0 108.938 -179.903 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.431 ' O ' ' C ' ' A' ' 3' ' ' HIS . 61.8 tp60 -109.91 112.35 24.32 Favored 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 178.926 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.431 ' C ' ' O ' ' A' ' 2' ' ' GLN . 38.4 m170 47.39 27.19 0.87 Allowed 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 -178.765 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.404 ' N ' ' C ' ' A' ' 2' ' ' GLN . . . -58.89 -43.8 91.03 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.652 -0.655 . . . . 0.0 109.944 -179.224 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 94.9 p -65.95 -32.18 73.53 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.324 -0.86 . . . . 0.0 110.083 -179.663 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 79.1 t -65.26 -47.13 88.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.101 -1.0 . . . . 0.0 109.584 -179.718 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . 0.411 HD11 HG22 ' A' ' 7' ' ' ILE . 81.2 mt -59.96 -48.82 86.35 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 O-C-N 121.315 -0.865 . . . . 0.0 109.702 179.988 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.507 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -63.29 -43.5 97.7 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.421 -0.799 . . . . 0.0 110.7 -179.349 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 44.4 tt0 -68.67 -47.58 66.14 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.97 -1.081 . . . . 0.0 110.861 -178.859 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.531 ' C ' ' CD1' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -70.96 -48.12 55.2 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.149 -0.97 . . . . 0.0 110.36 -179.651 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.446 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 4.2 p -59.92 -38.95 78.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.089 -1.007 . . . . 0.0 109.742 -179.542 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.507 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 52.0 t -63.22 -43.26 98.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.099 -1.0 . . . . 0.0 109.839 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -63.81 -38.74 92.2 Favored 'General case' 0 N--CA 1.487 1.377 0 O-C-N 121.086 -1.008 . . . . 0.0 110.252 -179.638 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 85.5 tt0 -69.95 -42.17 73.57 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.0 -1.063 . . . . 0.0 110.218 -179.698 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 79.6 t80 -84.97 -52.96 5.61 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.16 -0.963 . . . . 0.0 110.798 -179.259 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 6.3 mt -122.53 80.08 46.93 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.341 -0.85 . . . . 0.0 110.371 -179.004 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 22.0 Cg_endo -68.39 -14.54 40.32 Favored 'Trans proline' 0 C--N 1.311 -1.403 0 C-N-CA 122.012 1.808 . . . . 0.0 112.33 179.464 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.459 ' OD1' ' O ' ' A' ' 18' ' ' ASP . 60.2 t0 -94.61 6.22 49.5 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.187 -0.945 . . . . 0.0 110.137 -179.705 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 25.9 t -118.57 135.89 57.53 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.268 -0.895 . . . . 0.0 109.636 -179.896 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . 0.491 ' O ' ' OD1' ' A' ' 23' ' ' ASP . . . -77.14 117.19 63.56 Favored Pre-proline 0 N--CA 1.489 1.489 0 O-C-N 121.234 -0.916 . . . . 0.0 108.935 179.722 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_exo -51.71 -26.23 22.75 Favored 'Trans proline' 0 N--CA 1.492 1.407 0 C-N-CA 121.8 1.666 . . . . 0.0 112.211 179.693 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.09 -24.94 67.58 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.35 -0.844 . . . . 0.0 109.775 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.491 ' OD1' ' O ' ' A' ' 20' ' ' ALA . 49.2 p30 -86.38 7.07 27.15 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.104 -0.998 . . . . 0.0 110.008 -179.555 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 15.6 t -110.4 131.9 60.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.73 0 O-C-N 121.315 -0.866 . . . . 0.0 109.504 179.868 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.521 ' C ' ' H ' ' A' ' 27' ' ' ASP . 62.9 t0 -89.25 119.37 29.68 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.148 -0.97 . . . . 0.0 108.981 179.223 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -63.87 4.25 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.421 0 O-C-N 121.172 -0.955 . . . . 0.0 109.315 179.874 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.521 ' H ' ' C ' ' A' ' 25' ' ' ASP . 92.0 m-20 -105.02 6.63 33.54 Favored 'General case' 0 N--CA 1.485 1.301 0 O-C-N 121.263 -0.898 . . . . 0.0 109.32 179.772 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 45.5 tp -96.8 136.29 37.56 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.373 -0.829 . . . . 0.0 109.238 -179.828 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 80.5 m-20 -64.7 142.52 58.4 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.231 -0.918 . . . . 0.0 109.967 -179.167 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.573 ' N ' ' O ' ' A' ' 67' ' ' ARG . 76.0 mt -70.3 -35.07 73.46 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.468 -0.77 . . . . 0.0 110.987 -179.577 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.417 ' CG2' ' N ' ' A' ' 32' ' ' ASP . 35.1 m -57.75 -47.09 86.69 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.515 0 O-C-N 121.123 -0.986 . . . . 0.0 110.177 -178.958 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.417 ' N ' ' CG2' ' A' ' 31' ' ' VAL . 90.8 m-20 -61.18 -34.24 74.73 Favored 'General case' 0 C--N 1.302 -1.489 0 N-CA-C 108.439 -0.948 . . . . 0.0 108.439 179.403 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 96.6 m-20 -70.8 -34.18 71.49 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.752 -0.592 . . . . 0.0 110.115 -179.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 86.61 6.36 80.48 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 108.872 -1.691 . . . . 0.0 108.872 -179.516 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 70.8 t -59.06 -32.21 47.36 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 O-C-N 121.464 -1.021 . . . . 0.0 108.293 179.42 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 79.8 mt -85.82 129.56 37.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 CA-C-O 121.656 0.741 . . . . 0.0 109.735 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.532 ' CG ' ' H ' ' A' ' 38' ' ' ALA . 51.2 t0 -148.85 -170.84 3.72 Favored 'General case' 0 C--N 1.298 -1.647 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 179.776 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.532 ' H ' ' CG ' ' A' ' 37' ' ' ASP . . . -61.35 -54.66 40.89 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 120.893 -1.129 . . . . 0.0 108.422 179.772 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.487 ' CD1' ' N ' ' A' ' 39' ' ' LEU . 6.8 mp -71.61 -33.22 68.79 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 107.468 -1.308 . . . . 0.0 107.468 178.094 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -59.77 -46.61 93.77 Favored Glycine 0 N--CA 1.484 1.885 0 N-CA-C 109.255 -1.538 . . . . 0.0 109.255 179.833 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 3.4 tt -63.81 -43.28 96.73 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.419 -1.047 . . . . 0.0 109.654 179.563 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 17.2 tp -59.75 -45.22 92.89 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.313 -0.867 . . . . 0.0 109.728 -179.653 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 24.8 mttm -63.36 -34.45 77.74 Favored 'General case' 0 C--N 1.297 -1.678 0 O-C-N 121.052 -1.03 . . . . 0.0 109.705 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . 0.424 ' CG1' ' CE2' ' A' ' 66' ' ' PHE . 54.7 t -61.38 -50.79 78.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.332 -0.855 . . . . 0.0 110.624 -179.077 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 3.5 mp -68.27 -40.08 82.06 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 O-C-N 121.17 -0.957 . . . . 0.0 111.34 -179.431 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.66 -49.63 61.91 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.081 -1.012 . . . . 0.0 112.215 -177.692 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . 0.551 ' C ' ' CD1' ' A' ' 47' ' ' TRP . 0.0 OUTLIER -78.76 -43.43 25.61 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.671 -1.268 . . . . 0.0 110.37 -178.717 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.415 ' CB ' ' O ' ' A' ' 44' ' ' VAL . 16.7 tp -59.99 -41.78 92.79 Favored 'General case' 0 C--N 1.3 -1.562 0 O-C-N 121.195 -0.941 . . . . 0.0 110.326 -178.754 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.413 ' CG ' ' N ' ' A' ' 50' ' ' ASP . 17.8 pt-20 -73.02 -37.15 67.03 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.117 -0.99 . . . . 0.0 109.856 -179.673 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . 0.413 ' N ' ' CG ' ' A' ' 49' ' ' GLU . 56.8 t0 -60.0 -39.26 85.14 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.375 -0.828 . . . . 0.0 111.036 -179.269 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . 0.401 ' HD2' ' HE1' ' A' ' 47' ' ' TRP . 80.6 mtp180 -61.07 -37.61 83.28 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.105 -0.997 . . . . 0.0 111.603 -178.649 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.644 ' CZ ' ' CG1' ' A' ' 76' ' ' VAL . 48.6 m-85 -98.48 -8.18 27.14 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 120.79 -1.194 . . . . 0.0 110.456 -179.012 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 69.87 31.7 70.04 Favored Glycine 0 N--CA 1.488 2.117 0 N-CA-C 108.752 -1.739 . . . . 0.0 108.752 179.653 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 27.9 pt -108.51 153.44 10.12 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 O-C-N 121.62 -0.929 . . . . 0.0 109.908 -179.372 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -100.09 129.95 46.18 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.152 -0.968 . . . . 0.0 109.51 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.502 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -66.51 -28.82 68.86 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.294 -0.879 . . . . 0.0 109.581 179.895 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 53.9 t0 -55.41 -36.09 66.08 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.305 -0.872 . . . . 0.0 109.998 -179.642 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -56.88 -40.3 75.95 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.201 -0.937 . . . . 0.0 109.952 -179.584 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.502 ' O ' ' O ' ' A' ' 56' ' ' ALA . 42.1 t -129.16 134.81 63.31 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.393 -0.817 . . . . 0.0 109.543 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -79.25 126.63 31.03 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.097 -1.002 . . . . 0.0 109.436 179.896 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 5.3 mp -108.04 139.54 42.53 Favored 'General case' 0 C--N 1.305 -1.333 0 O-C-N 121.372 -0.83 . . . . 0.0 109.651 -179.904 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -107.02 145.34 30.92 Favored Pre-proline 0 N--CA 1.484 1.267 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 179.098 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -60.73 -19.94 63.35 Favored 'Trans proline' 0 C--N 1.306 -1.699 0 C-N-CA 122.107 1.871 . . . . 0.0 112.021 -179.55 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 90.1 mt-10 -69.25 -28.39 66.29 Favored 'General case' 0 C--N 1.305 -1.364 0 O-C-N 121.439 -0.788 . . . . 0.0 109.676 -179.613 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . 0.59 ' CD2' ' O ' ' A' ' 65' ' ' HIS . 0.0 OUTLIER -66.55 -19.12 65.7 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.199 -0.938 . . . . 0.0 109.182 -179.563 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.5 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 16.5 m-85 -96.15 11.03 35.77 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.291 -0.881 . . . . 0.0 109.317 179.794 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . 0.573 ' O ' ' N ' ' A' ' 30' ' ' LEU . 1.7 ptt180 -50.08 -21.86 1.43 Allowed 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.381 -0.824 . . . . 0.0 110.049 -179.671 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.476 ' O ' ' OG ' ' A' ' 71' ' ' SER . 34.4 t -147.14 147.03 30.13 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.137 -0.977 . . . . 0.0 109.883 -179.875 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.427 ' CD1' ' H ' ' A' ' 69' ' ' ILE . 2.3 mp -59.92 -38.72 77.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.288 -0.883 . . . . 0.0 109.566 -179.826 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.429 ' O ' ' OD2' ' A' ' 73' ' ' ASP . 6.1 ptm180 -57.6 -40.14 78.4 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.427 -0.796 . . . . 0.0 109.447 -179.748 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.476 ' OG ' ' O ' ' A' ' 68' ' ' SER . 95.8 p -65.07 -35.83 82.39 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.332 -0.855 . . . . 0.0 110.123 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.402 ' HA ' ' HE2' ' A' ' 65' ' ' HIS . 64.6 mt -63.31 -46.59 95.17 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.326 0 O-C-N 121.191 -0.943 . . . . 0.0 110.148 -179.419 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.584 ' OD1' ' N ' ' A' ' 74' ' ' ALA . 1.3 p30 -63.14 -40.02 96.35 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.088 -1.007 . . . . 0.0 109.448 -179.648 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . 0.584 ' N ' ' OD1' ' A' ' 73' ' ' ASP . . . -66.76 -45.52 78.3 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.312 -0.867 . . . . 0.0 109.768 -179.882 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . 0.544 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 55.0 t80 -63.32 -43.87 96.55 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.326 -0.859 . . . . 0.0 109.073 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.644 ' CG1' ' CZ ' ' A' ' 52' ' ' PHE . 55.8 t -60.79 -46.8 95.48 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 O-C-N 121.493 -0.754 . . . . 0.0 109.047 179.655 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 54.7 t -69.14 -42.07 81.63 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 O-C-N 121.455 -0.778 . . . . 0.0 109.084 179.298 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.516 ' O ' ' O ' ' A' ' 81' ' ' THR . . . -68.8 -21.19 74.92 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 110.001 -1.24 . . . . 0.0 110.001 179.901 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -66.48 -36.79 83.62 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 120.955 -1.32 . . . . 0.0 109.783 -179.411 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 56.1 p -87.91 -25.58 23.16 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.216 -0.927 . . . . 0.0 109.732 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.516 ' O ' ' O ' ' A' ' 78' ' ' GLY . 0.1 OUTLIER -133.19 153.03 80.56 Favored Pre-proline 0 N--CA 1.486 1.366 0 O-C-N 121.358 -0.839 . . . . 0.0 109.75 -179.63 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 76.0 Cg_exo -41.14 103.33 0.04 OUTLIER 'Trans proline' 0 C--N 1.309 -1.525 0 C-N-CA 122.493 2.128 . . . . 0.0 112.058 179.644 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 23.6 Cg_exo -57.56 145.66 87.92 Favored 'Trans proline' 0 N--CA 1.492 1.42 0 C-N-CA 122.251 1.967 . . . . 0.0 112.275 -179.903 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.443 ' O ' ' C ' ' A' ' 85' ' ' GLU . 32.7 m -103.72 140.23 22.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.354 -0.841 . . . . 0.0 109.337 179.74 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.443 ' C ' ' O ' ' A' ' 84' ' ' VAL . 96.2 mt-10 40.73 43.14 1.58 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.297 -0.877 . . . . 0.0 109.703 179.748 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -59.52 146.26 41.17 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.207 -0.933 . . . . 0.0 109.573 -179.912 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.438 ' NZ ' ' CB ' ' A' ' 71' ' ' SER . 47.4 mttp -57.73 -35.64 70.96 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.262 -0.899 . . . . 0.0 109.549 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . 0.622 ' CD2' ' N ' ' A' ' 88' ' ' LEU . 2.5 mm? -95.47 141.04 29.48 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.276 -0.89 . . . . 0.0 109.413 179.754 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.6 mt-30 . . . . . 0 N--CA 1.491 1.585 0 CA-C-O 117.994 -1.003 . . . . 0.0 109.408 -179.96 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' -1' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.49 1.56 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 0' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -61.52 -34.3 75.28 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.266 -0.896 . . . . 0.0 109.546 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 83.6 mmm -95.52 -121.41 0.11 Allowed 'General case' 0 C--N 1.307 -1.275 0 O-C-N 121.233 -0.917 . . . . 0.0 109.048 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.478 ' O ' ' OD2' ' A' ' 73' ' ' ASP . 67.6 tp60 -113.53 114.48 26.56 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 178.959 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.422 ' C ' ' O ' ' A' ' 2' ' ' GLN . 66.7 m-70 46.94 29.87 1.12 Allowed 'General case' 0 N--CA 1.487 1.418 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 -178.713 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -58.26 -37.68 75.44 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.491 -0.755 . . . . 0.0 109.577 -179.3 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 87.4 p -61.45 -32.89 72.88 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.202 -0.936 . . . . 0.0 109.469 -179.884 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.413 ' HA ' HE21 ' A' ' 9' ' ' GLN . 70.0 t -62.95 -43.9 99.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.237 -0.914 . . . . 0.0 109.196 179.75 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 79.2 mt -60.21 -40.97 85.18 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.396 -0.815 . . . . 0.0 109.024 179.606 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -60.84 -38.12 84.39 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 121.52 -0.738 . . . . 0.0 109.537 -179.724 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . 0.413 HE21 ' HA ' ' A' ' 6' ' ' VAL . 52.3 mt-30 -64.51 -40.53 95.82 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.122 -0.986 . . . . 0.0 110.105 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.688 ' CG ' ' CE2' ' A' ' 47' ' ' TRP . 30.6 m-85 -63.55 -50.43 69.53 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.146 -0.972 . . . . 0.0 110.951 -179.196 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 27.2 m -65.64 -41.37 90.46 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 120.995 -1.066 . . . . 0.0 109.426 -179.474 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.464 ' O ' ' C ' ' A' ' 16' ' ' LEU . 66.6 t -63.88 -47.0 92.66 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 O-C-N 121.26 -0.9 . . . . 0.0 109.685 179.554 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -70.53 -27.83 64.47 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.04 -1.037 . . . . 0.0 110.231 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -64.57 -33.21 75.38 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.271 -0.893 . . . . 0.0 110.845 -178.708 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 92.1 m-85 -134.11 -29.78 1.24 Allowed 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.036 -1.04 . . . . 0.0 111.123 -179.354 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.464 ' C ' ' O ' ' A' ' 12' ' ' VAL . 12.3 mt -124.74 79.68 63.09 Favored Pre-proline 0 N--CA 1.491 1.604 0 O-C-N 121.078 -1.014 . . . . 0.0 110.248 -179.157 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -78.73 -17.72 12.27 Favored 'Trans proline' 0 C--N 1.307 -1.63 0 C-N-CA 122.586 2.19 . . . . 0.0 112.317 179.642 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -93.01 7.56 43.57 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.232 -0.917 . . . . 0.0 110.125 -179.601 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.433 ' CG1' ' OD2' ' A' ' 23' ' ' ASP . 46.8 t -113.18 136.04 50.76 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.353 -0.842 . . . . 0.0 109.775 -179.844 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . 0.414 ' O ' ' CG ' ' A' ' 23' ' ' ASP . . . -72.42 117.3 57.68 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.298 -0.876 . . . . 0.0 109.499 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_exo -52.03 -25.24 21.83 Favored 'Trans proline' 0 N--CA 1.494 1.503 0 C-N-CA 121.995 1.797 . . . . 0.0 112.344 179.333 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.74 -21.5 66.77 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.268 -0.895 . . . . 0.0 109.83 -179.604 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.448 ' C ' ' OD1' ' A' ' 23' ' ' ASP . 52.8 p30 -84.45 7.56 19.33 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.245 -0.909 . . . . 0.0 110.144 -179.599 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 11.4 t -104.88 129.81 56.9 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.156 -0.965 . . . . 0.0 109.463 -179.922 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 64.0 t0 -89.58 119.86 30.37 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.142 -0.974 . . . . 0.0 109.218 179.325 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.8 m -74.84 3.95 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.428 0 O-C-N 121.172 -0.955 . . . . 0.0 109.314 179.755 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -88.99 -11.24 44.82 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 121.295 -0.878 . . . . 0.0 109.157 179.543 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 43.6 tp -95.83 138.72 33.07 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.412 -0.805 . . . . 0.0 109.016 179.793 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.0 m-20 -58.34 133.6 55.86 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.147 -0.971 . . . . 0.0 109.272 -179.625 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.477 ' H ' ' HA ' ' A' ' 68' ' ' SER . 2.0 tt -67.14 -38.25 85.21 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 121.724 -0.61 . . . . 0.0 110.099 -179.136 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 75.5 t -63.14 -35.54 72.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.011 -1.056 . . . . 0.0 110.379 -178.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 55.7 t0 -52.52 -33.52 45.62 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 120.957 -1.09 . . . . 0.0 108.151 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 97.4 m-20 -71.25 -34.61 70.89 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.634 -0.666 . . . . 0.0 109.974 179.464 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 84.98 6.44 85.02 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.083 -1.607 . . . . 0.0 109.083 -179.399 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 71.5 t -61.32 -34.5 61.2 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.428 0 O-C-N 121.412 -1.052 . . . . 0.0 109.056 179.636 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 91.8 mt -82.07 114.53 23.12 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 O-C-N 121.353 -0.842 . . . . 0.0 109.665 -179.836 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -111.58 -168.61 1.33 Allowed 'General case' 0 C--N 1.304 -1.401 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 179.745 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -64.24 -54.15 37.88 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.214 -0.929 . . . . 0.0 108.696 179.708 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 38.6 mt -70.39 -33.16 71.08 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 107.171 -1.418 . . . . 0.0 107.171 178.338 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -59.57 -40.53 96.46 Favored Glycine 0 N--CA 1.481 1.678 0 N-CA-C 108.546 -1.822 . . . . 0.0 108.546 179.131 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.7 tt -65.45 -42.8 91.95 Favored 'General case' 0 C--N 1.305 -1.36 0 O-C-N 121.492 -1.005 . . . . 0.0 109.136 179.336 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.2 tp -60.88 -46.16 91.71 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.448 -0.782 . . . . 0.0 109.269 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 51.2 mttp -61.13 -35.21 76.46 Favored 'General case' 0 C--N 1.296 -1.732 0 O-C-N 121.427 -0.795 . . . . 0.0 109.623 -179.754 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 60.5 t -61.64 -48.67 87.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.295 -0.878 . . . . 0.0 109.8 -179.605 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.6 mp -68.26 -32.62 56.52 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 O-C-N 121.501 -0.75 . . . . 0.0 110.871 -179.568 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.14 -49.76 63.68 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.0 -1.063 . . . . 0.0 111.807 -178.026 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . 0.688 ' CE2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -80.81 -43.48 20.0 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.766 -1.209 . . . . 0.0 110.015 -179.195 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.402 ' N ' ' CG ' ' A' ' 47' ' ' TRP . 24.3 tp -58.82 -41.55 87.09 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.334 -0.854 . . . . 0.0 110.1 -178.948 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.438 ' CG ' ' N ' ' A' ' 50' ' ' ASP . 17.1 pt-20 -72.99 -37.92 66.83 Favored 'General case' 0 C--N 1.305 -1.362 0 O-C-N 121.079 -1.013 . . . . 0.0 109.716 -179.835 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . 0.438 ' N ' ' CG ' ' A' ' 49' ' ' GLU . 57.2 t0 -58.17 -39.13 78.09 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.36 -0.837 . . . . 0.0 110.457 -179.509 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 22.3 mtp-105 -62.63 -36.32 82.41 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.135 -0.978 . . . . 0.0 111.411 -178.866 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 86.5 m-85 -95.55 -8.88 33.89 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 120.75 -1.218 . . . . 0.0 110.258 -179.191 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 72.86 30.72 63.16 Favored Glycine 0 N--CA 1.487 2.073 0 N-CA-C 108.905 -1.678 . . . . 0.0 108.905 179.723 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 23.1 pt -109.73 153.63 11.44 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.335 0 O-C-N 121.557 -0.967 . . . . 0.0 109.782 -179.501 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -101.68 135.96 42.32 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.264 -0.897 . . . . 0.0 109.54 -179.776 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.499 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -66.35 -28.51 68.71 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.329 -0.857 . . . . 0.0 109.647 179.878 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -56.05 -35.78 67.3 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.158 -0.964 . . . . 0.0 109.935 -179.732 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 54.5 t0 -55.0 -38.93 68.49 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.173 -0.954 . . . . 0.0 110.141 -179.569 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.499 ' O ' ' O ' ' A' ' 56' ' ' ALA . 13.6 p -135.59 142.63 38.87 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.199 -0.938 . . . . 0.0 109.721 -179.91 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -93.62 132.57 37.83 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.098 -1.001 . . . . 0.0 109.328 179.682 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 56.5 mt -99.06 140.34 33.36 Favored 'General case' 0 C--N 1.305 -1.362 0 O-C-N 121.309 -0.869 . . . . 0.0 109.865 -179.67 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -109.67 156.31 39.93 Favored Pre-proline 0 N--CA 1.487 1.412 0 N-CA-C 108.633 -0.876 . . . . 0.0 108.633 179.503 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 8.1 Cg_endo -53.36 -25.08 29.82 Favored 'Trans proline' 0 C--N 1.303 -1.83 0 C-N-CA 122.41 2.073 . . . . 0.0 111.729 -179.85 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -71.65 -27.15 62.88 Favored 'General case' 0 N--CA 1.486 1.369 0 O-C-N 121.368 -0.833 . . . . 0.0 109.508 179.757 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . 0.556 ' NE2' ' CB ' ' A' ' 75' ' ' PHE . 6.6 t-160 -65.79 -21.1 66.47 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.311 -0.868 . . . . 0.0 109.092 -179.749 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.514 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 15.3 m-85 -92.34 14.65 15.84 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 179.909 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . 0.418 ' HG2' ' H ' ' A' ' 68' ' ' SER . 6.9 ptt180 -47.9 -39.08 17.86 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.651 -0.656 . . . . 0.0 109.85 -179.972 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.477 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 86.9 p -160.04 156.55 27.14 Favored 'General case' 0 N--CA 1.487 1.401 0 O-C-N 120.993 -1.067 . . . . 0.0 110.014 179.913 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.417 HD13 ' H ' ' A' ' 69' ' ' ILE . 3.3 mp -58.84 -34.76 53.24 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 179.189 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 47.0 mtp180 -56.88 -43.78 81.6 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.721 -0.612 . . . . 0.0 109.642 -179.601 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 82.5 p -69.47 -33.67 73.24 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.364 -0.835 . . . . 0.0 110.012 -179.706 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.41 ' HA ' ' HE2' ' A' ' 65' ' ' HIS . 80.6 mt -62.24 -51.02 77.45 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 O-C-N 121.177 -0.952 . . . . 0.0 109.944 -179.656 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.478 ' OD2' ' O ' ' A' ' 2' ' ' GLN . 42.8 t0 -61.01 -42.06 97.73 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.197 -0.94 . . . . 0.0 109.241 179.871 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . 0.432 ' O ' ' N ' ' A' ' 78' ' ' GLY . . . -66.79 -38.68 87.01 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.568 -0.708 . . . . 0.0 110.403 -179.514 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . 0.556 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 58.9 t80 -62.28 -46.88 86.8 Favored 'General case' 0 C--N 1.302 -1.462 0 O-C-N 121.105 -0.997 . . . . 0.0 109.82 -179.572 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 77.0 t -66.35 -48.65 80.24 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 121.164 -0.96 . . . . 0.0 109.816 -179.806 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 53.3 t -70.04 -46.9 71.33 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.276 0 O-C-N 121.056 -1.028 . . . . 0.0 109.67 179.882 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.475 ' O ' ' O ' ' A' ' 81' ' ' THR . . . -61.86 -30.86 76.38 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 110.317 -1.113 . . . . 0.0 110.317 -179.642 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.67 -41.13 84.19 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.149 -1.207 . . . . 0.0 110.318 -179.028 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 56.1 p -79.15 -31.79 44.11 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.127 -0.983 . . . . 0.0 109.39 -179.872 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.475 ' O ' ' O ' ' A' ' 78' ' ' GLY . 2.6 t -133.3 149.15 71.71 Favored Pre-proline 0 C--N 1.305 -1.341 0 O-C-N 121.52 -0.737 . . . . 0.0 109.452 -179.766 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 14.4 Cg_endo -61.11 117.57 4.37 Favored 'Trans proline' 0 C--N 1.31 -1.473 0 C-N-CA 121.915 1.743 . . . . 0.0 111.086 179.128 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -74.49 152.48 43.56 Favored 'Trans proline' 0 C--N 1.315 -1.19 0 C-N-CA 122.043 1.829 . . . . 0.0 112.993 -179.218 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.402 ' O ' ' C ' ' A' ' 85' ' ' GLU . 44.4 t -102.49 135.08 41.36 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 179.449 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.402 ' C ' ' O ' ' A' ' 84' ' ' VAL . 84.5 tt0 44.98 70.4 0.35 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.166 -0.959 . . . . 0.0 108.997 -179.404 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -46.03 153.69 0.29 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.326 -0.859 . . . . 0.0 109.855 -179.674 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 29.0 tttm -54.91 -35.65 64.36 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.396 -0.815 . . . . 0.0 109.548 -179.855 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 54.6 mt -90.17 142.13 28.02 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.21 -0.932 . . . . 0.0 109.396 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 13.8 pt20 . . . . . 0 N--CA 1.491 1.615 0 CA-C-O 118.11 -0.948 . . . . 0.0 109.407 179.998 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' -1' ' ' SER . . . . . 0.583 ' O ' ' NE2' ' A' ' 2' ' ' GLN . 0.1 OUTLIER . . . . . 0 N--CA 1.49 1.568 0 N-CA-C 109.516 -0.55 . . . . 0.0 109.516 . . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 0' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -61.32 -32.31 72.18 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.303 -0.873 . . . . 0.0 109.471 -179.918 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.489 ' O ' ' OD2' ' A' ' 73' ' ' ASP . 93.7 mmm -59.86 -33.75 72.22 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.21 -0.931 . . . . 0.0 109.345 -179.968 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.583 ' NE2' ' O ' ' A' ' -1' ' ' SER . 99.3 mm-40 57.37 94.71 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.416 -0.802 . . . . 0.0 110.415 179.891 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 50.5 m80 59.17 46.14 13.46 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.516 -0.74 . . . . 0.0 110.655 179.068 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -62.71 -40.22 96.49 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.016 -1.052 . . . . 0.0 109.313 179.486 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.0 t -60.19 -33.96 72.94 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.392 -0.817 . . . . 0.0 109.664 -179.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 55.9 t -60.24 -45.45 96.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.297 -0.877 . . . . 0.0 109.579 -179.854 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 75.5 mt -60.94 -45.26 98.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.326 -0.859 . . . . 0.0 109.025 179.65 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -61.56 -36.39 80.49 Favored 'General case' 0 N--CA 1.486 1.344 0 O-C-N 121.481 -0.762 . . . . 0.0 109.001 179.595 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 31.0 tt0 -64.78 -40.74 95.75 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.297 -0.877 . . . . 0.0 110.107 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.703 ' CG ' ' CE2' ' A' ' 47' ' ' TRP . 19.0 m-85 -61.71 -50.42 72.53 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.12 -0.987 . . . . 0.0 110.504 -179.452 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 23.2 m -64.58 -41.07 91.21 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.5 0 O-C-N 121.051 -1.031 . . . . 0.0 109.185 -179.64 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.447 ' O ' ' C ' ' A' ' 16' ' ' LEU . 79.6 t -63.95 -46.2 94.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.246 -0.909 . . . . 0.0 109.436 179.497 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -70.55 -27.7 64.35 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.171 -0.956 . . . . 0.0 110.171 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -64.46 -30.68 71.71 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.333 -0.855 . . . . 0.0 110.558 -178.883 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.454 ' CD2' ' CG1' ' A' ' 35' ' ' VAL . 96.2 m-85 -134.11 -38.64 0.86 Allowed 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.033 -1.042 . . . . 0.0 111.075 -179.317 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.447 ' C ' ' O ' ' A' ' 12' ' ' VAL . 9.1 mt -123.23 79.83 52.5 Favored Pre-proline 0 N--CA 1.493 1.684 0 O-C-N 121.067 -1.02 . . . . 0.0 110.571 -178.835 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -74.93 -15.53 20.88 Favored 'Trans proline' 0 C--N 1.309 -1.525 0 C-N-CA 122.305 2.003 . . . . 0.0 112.199 179.39 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -91.97 8.6 36.82 Favored 'General case' 0 C--N 1.305 -1.357 0 O-C-N 121.199 -0.938 . . . . 0.0 109.883 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 44.6 t -113.61 135.08 54.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 121.387 -0.82 . . . . 0.0 109.654 -179.746 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -73.9 119.67 77.35 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.321 -0.862 . . . . 0.0 109.288 179.877 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -51.14 -26.07 18.63 Favored 'Trans proline' 0 N--CA 1.494 1.502 0 C-N-CA 121.75 1.634 . . . . 0.0 112.132 179.482 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.81 -24.68 67.62 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.347 -0.846 . . . . 0.0 109.404 179.863 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.436 ' O ' ' OD1' ' A' ' 23' ' ' ASP . 60.2 t0 -81.83 6.83 14.43 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.32 -0.863 . . . . 0.0 109.759 -179.731 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 12.3 t -107.64 133.89 51.07 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.275 -0.89 . . . . 0.0 109.275 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 87.2 m-20 -89.06 120.47 30.5 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.085 -1.01 . . . . 0.0 109.0 179.324 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.0 m -76.4 4.47 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 O-C-N 121.19 -0.944 . . . . 0.0 109.124 179.655 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -91.45 -5.13 54.78 Favored 'General case' 0 C--N 1.305 -1.351 0 O-C-N 121.344 -0.847 . . . . 0.0 109.164 179.673 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 40.8 tp -98.65 138.5 35.74 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.323 -0.86 . . . . 0.0 109.34 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -60.61 134.69 57.32 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.247 -0.908 . . . . 0.0 109.484 -179.735 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 0.8 OUTLIER -69.06 -39.66 78.99 Favored 'General case' 0 C--N 1.301 -1.5 0 O-C-N 121.631 -0.668 . . . . 0.0 110.221 -179.293 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 70.8 t -64.04 -36.29 76.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 121.107 -0.996 . . . . 0.0 110.606 -178.759 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 56.7 t0 -52.52 -33.36 44.9 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 120.926 -1.109 . . . . 0.0 108.238 -179.904 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 97.3 m-20 -71.24 -34.69 71.01 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.661 -0.65 . . . . 0.0 110.049 179.608 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 83.24 6.16 88.22 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 108.831 -1.708 . . . . 0.0 108.831 -179.22 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.454 ' CG1' ' CD2' ' A' ' 15' ' ' PHE . 72.9 t -60.61 -30.9 47.77 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 O-C-N 121.503 -0.998 . . . . 0.0 108.356 179.329 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 89.7 mt -86.87 131.54 34.62 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.382 0 O-C-N 121.489 -0.757 . . . . 0.0 109.74 179.908 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.581 ' CG ' ' H ' ' A' ' 38' ' ' ALA . 52.0 t0 -128.01 -166.22 1.59 Allowed 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 108.646 -0.872 . . . . 0.0 108.646 179.582 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.581 ' H ' ' CG ' ' A' ' 37' ' ' ASP . . . -64.36 -54.58 30.75 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.126 -0.984 . . . . 0.0 108.886 179.849 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 34.4 mt -69.8 -32.76 71.39 Favored 'General case' 0 C--N 1.302 -1.475 0 N-CA-C 107.233 -1.395 . . . . 0.0 107.233 178.358 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -59.24 -41.39 96.75 Favored Glycine 0 N--CA 1.48 1.618 0 N-CA-C 108.668 -1.773 . . . . 0.0 108.668 179.271 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.6 tt -65.54 -41.9 92.51 Favored 'General case' 0 C--N 1.304 -1.38 0 O-C-N 121.426 -1.044 . . . . 0.0 108.942 179.219 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.2 tp -60.13 -45.98 91.18 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.435 -0.791 . . . . 0.0 109.208 179.801 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 28.5 mttp -60.11 -35.5 75.37 Favored 'General case' 0 C--N 1.296 -1.742 0 O-C-N 121.491 -0.755 . . . . 0.0 109.512 -179.783 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 69.3 t -61.98 -48.23 89.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.335 -0.853 . . . . 0.0 109.927 -179.673 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.526 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 1.7 mp -68.15 -33.26 59.83 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.569 0 O-C-N 121.507 -0.746 . . . . 0.0 110.831 -179.652 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.0 -49.84 66.37 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 120.898 -1.126 . . . . 0.0 111.344 -178.179 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . 0.703 ' CE2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -81.17 -44.54 17.71 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.718 -1.239 . . . . 0.0 109.936 -179.452 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.549 ' CD1' HH21 ' A' ' 51' ' ' ARG . 10.0 tp -58.43 -42.67 87.78 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.275 -0.891 . . . . 0.0 109.773 -179.07 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.526 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 2.3 pp20? -72.61 -35.93 67.98 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.094 -1.004 . . . . 0.0 109.786 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.2 t70 -60.02 -38.72 83.51 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.282 -0.886 . . . . 0.0 110.66 -179.517 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . 0.549 HH21 ' CD1' ' A' ' 48' ' ' LEU . 62.6 mtm180 -62.09 -38.04 87.37 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.12 -0.987 . . . . 0.0 111.418 -178.824 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.407 ' CE2' ' CG1' ' A' ' 76' ' ' VAL . 95.6 m-85 -97.8 -11.94 22.78 Favored 'General case' 0 N--CA 1.487 1.391 0 O-C-N 120.738 -1.226 . . . . 0.0 110.164 -179.039 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 72.3 30.98 64.1 Favored Glycine 0 N--CA 1.488 2.102 0 N-CA-C 108.804 -1.718 . . . . 0.0 108.804 179.912 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.469 ' O ' ' OE1' ' A' ' 49' ' ' GLU . 34.5 pt -102.89 148.37 8.19 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.4 0 O-C-N 121.414 -1.05 . . . . 0.0 109.758 -179.436 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -89.87 112.42 23.76 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.184 -0.948 . . . . 0.0 109.679 -179.728 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.502 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -68.41 -27.14 65.95 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.332 -0.855 . . . . 0.0 109.585 179.686 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -55.73 -35.9 66.66 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.168 -0.957 . . . . 0.0 110.087 -179.587 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -55.55 -38.52 69.4 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.133 -0.979 . . . . 0.0 109.857 -179.631 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.502 ' O ' ' O ' ' A' ' 56' ' ' ALA . 42.7 t -124.95 136.16 61.74 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.419 -0.801 . . . . 0.0 109.658 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -89.18 131.09 35.46 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.028 -1.045 . . . . 0.0 109.297 179.872 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 38.1 mt -99.86 142.16 31.71 Favored 'General case' 0 C--N 1.305 -1.338 0 O-C-N 121.265 -0.897 . . . . 0.0 109.701 -179.7 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.514 ' HG ' ' N ' ' A' ' 63' ' ' PRO . 0.0 OUTLIER -109.49 157.18 38.1 Favored Pre-proline 0 N--CA 1.487 1.375 0 O-C-N 121.437 -0.789 . . . . 0.0 108.942 179.64 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . 0.514 ' N ' ' HG ' ' A' ' 62' ' ' SER . 9.2 Cg_endo -55.33 -24.04 40.77 Favored 'Trans proline' 0 C--N 1.304 -1.77 0 C-N-CA 122.604 2.203 . . . . 0.0 111.827 -179.956 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -69.06 -29.22 67.31 Favored 'General case' 0 C--N 1.304 -1.374 0 O-C-N 121.364 -0.835 . . . . 0.0 109.139 179.703 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . 0.531 ' CD2' ' O ' ' A' ' 65' ' ' HIS . 2.9 t-80 -66.33 -18.5 65.39 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.359 -0.838 . . . . 0.0 108.895 179.938 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.521 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 11.4 m-85 -94.69 13.77 23.3 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 179.582 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . 0.478 ' CZ ' ' OG ' ' A' ' 71' ' ' SER . 7.5 ptt180 -44.2 -38.92 4.05 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.811 -0.556 . . . . 0.0 110.545 -179.594 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 80.1 p -155.7 161.42 40.74 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.806 -1.184 . . . . 0.0 110.3 -179.629 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 31.3 mm -60.66 -44.14 96.39 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 O-C-N 121.39 -0.819 . . . . 0.0 110.172 -179.774 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.711 ' NH1' ' HZ2' ' A' ' 87' ' ' LYS . 0.0 OUTLIER -58.88 -39.74 82.29 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.214 -0.929 . . . . 0.0 109.656 -179.304 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.478 ' OG ' ' CZ ' ' A' ' 67' ' ' ARG . 23.2 t -63.08 -40.61 98.17 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.248 -0.907 . . . . 0.0 109.643 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.407 ' HA ' ' HE2' ' A' ' 65' ' ' HIS . 86.0 mt -61.95 -50.56 79.64 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 O-C-N 121.214 -0.929 . . . . 0.0 110.107 -179.755 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.489 ' OD2' ' O ' ' A' ' 1' ' ' MET . 40.9 t0 -59.28 -41.13 88.2 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.234 -0.916 . . . . 0.0 109.357 -179.842 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . 0.439 ' O ' ' N ' ' A' ' 78' ' ' GLY . . . -66.49 -37.42 85.03 Favored 'General case' 0 C--N 1.302 -1.458 0 O-C-N 121.505 -0.747 . . . . 0.0 110.266 -179.587 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . 0.531 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 62.6 t80 -61.99 -48.12 81.77 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.022 -1.049 . . . . 0.0 109.886 -179.502 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.407 ' CG1' ' CE2' ' A' ' 52' ' ' PHE . 87.6 t -64.92 -48.25 84.96 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.323 0 O-C-N 121.097 -1.002 . . . . 0.0 109.671 -179.801 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 60.8 t -69.31 -39.18 78.69 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 O-C-N 121.214 -0.929 . . . . 0.0 109.142 179.585 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.439 ' N ' ' O ' ' A' ' 74' ' ' ALA . . . -59.1 -35.35 83.66 Favored Glycine 0 N--CA 1.487 2.088 0 N-CA-C 110.207 -1.157 . . . . 0.0 110.207 -179.678 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -70.35 -41.68 72.86 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.265 -1.138 . . . . 0.0 111.044 -178.791 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 44.6 p -81.78 -34.79 30.15 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.094 -1.004 . . . . 0.0 109.497 -179.622 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -133.29 153.78 80.76 Favored Pre-proline 0 C--N 1.299 -1.592 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 -179.848 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo -43.65 143.57 2.66 Favored 'Trans proline' 0 C--N 1.307 -1.631 0 C-N-CA 121.737 1.625 . . . . 0.0 111.003 179.521 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 10.9 Cg_endo -60.93 141.59 95.02 Favored 'Trans proline' 0 C--N 1.311 -1.434 0 C-N-CA 121.896 1.731 . . . . 0.0 112.748 -179.18 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.5 ' O ' ' C ' ' A' ' 85' ' ' GLU . 14.7 p -104.53 129.92 56.21 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 179.393 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.5 ' C ' ' O ' ' A' ' 84' ' ' VAL . 96.2 mt-10 36.25 40.17 0.1 Allowed 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.596 -0.69 . . . . 0.0 109.909 179.839 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -50.23 145.23 6.27 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.116 -0.99 . . . . 0.0 109.599 -179.611 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.711 ' HZ2' ' NH1' ' A' ' 70' ' ' ARG . 69.0 mttm -57.67 -34.75 69.73 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.282 -0.886 . . . . 0.0 109.443 -179.914 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 55.5 mt -93.15 142.03 27.75 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.171 -0.955 . . . . 0.0 109.424 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.3 mt-30 . . . . . 0 N--CA 1.491 1.582 0 CA-C-O 117.936 -1.031 . . . . 0.0 109.407 -179.972 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' -1' ' ' SER . . . . . . . . . . . . . 1.8 p . . . . . 0 N--CA 1.492 1.634 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 0' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -61.79 -33.44 74.11 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.19 -0.944 . . . . 0.0 109.449 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.573 ' O ' ' CB ' ' A' ' 2' ' ' GLN . 96.6 mmm -58.15 -34.1 69.93 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.304 -0.872 . . . . 0.0 109.485 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.573 ' CB ' ' O ' ' A' ' 1' ' ' MET . 28.6 tp60 84.66 66.98 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.726 0 CA-C-O 121.338 0.589 . . . . 0.0 109.541 -179.788 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 58.9 m-70 63.15 47.54 4.09 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.42 -0.8 . . . . 0.0 110.316 179.661 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -62.25 -38.82 90.73 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.06 -1.025 . . . . 0.0 109.484 179.718 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.4 m -60.28 -36.88 78.85 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.368 -0.832 . . . . 0.0 110.107 -179.645 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 48.9 t -62.15 -44.81 99.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.124 -0.985 . . . . 0.0 109.723 -179.757 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 89.7 mt -59.53 -49.8 82.29 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.613 0 O-C-N 121.341 -0.849 . . . . 0.0 110.037 -179.504 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.469 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -63.5 -43.97 95.72 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.378 -0.826 . . . . 0.0 111.111 -179.136 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 53.0 mt-30 -69.22 -46.0 68.45 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 120.844 -1.16 . . . . 0.0 111.284 -178.607 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.705 ' CD1' ' N ' ' A' ' 11' ' ' VAL . 0.0 OUTLIER -69.82 -47.01 64.38 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 120.951 -1.093 . . . . 0.0 110.519 -179.142 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.705 ' N ' ' CD1' ' A' ' 10' ' ' PHE . 5.1 p -61.54 -38.91 81.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.062 -1.024 . . . . 0.0 109.731 -179.671 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.469 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 56.0 t -63.33 -43.44 98.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.133 -0.979 . . . . 0.0 109.821 -179.949 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -63.9 -39.02 93.22 Favored 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.166 -0.958 . . . . 0.0 110.187 -179.519 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 85.2 tt0 -70.02 -42.26 73.2 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.182 -0.949 . . . . 0.0 110.0 -179.849 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 77.7 t80 -83.58 -52.18 6.68 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.221 -0.924 . . . . 0.0 110.618 -179.435 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.424 ' N ' ' O ' ' A' ' 12' ' ' VAL . 7.3 mt -123.64 80.07 55.26 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.378 -0.826 . . . . 0.0 110.292 -179.04 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -67.02 -15.65 47.36 Favored 'Trans proline' 0 N--CA 1.492 1.401 0 C-N-CA 122.056 1.837 . . . . 0.0 112.466 179.682 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -95.26 7.34 46.47 Favored 'General case' 0 N--CA 1.486 1.335 0 O-C-N 121.083 -1.011 . . . . 0.0 110.429 -179.499 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 21.8 t -119.47 136.21 57.37 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.214 -0.929 . . . . 0.0 109.843 -179.825 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . 0.487 ' O ' ' OD1' ' A' ' 23' ' ' ASP . . . -77.58 118.69 73.71 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.241 -0.912 . . . . 0.0 108.978 179.516 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_exo -51.15 -25.75 17.84 Favored 'Trans proline' 0 N--CA 1.493 1.487 0 C-N-CA 121.798 1.665 . . . . 0.0 112.223 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.88 -27.46 68.87 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.183 -0.948 . . . . 0.0 109.726 -179.854 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.487 ' OD1' ' O ' ' A' ' 20' ' ' ALA . 47.3 p30 -87.28 7.72 27.36 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.136 -0.977 . . . . 0.0 109.84 -179.678 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 16.4 t -110.16 132.06 59.5 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 O-C-N 121.311 -0.868 . . . . 0.0 109.446 179.88 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 62.2 t0 -89.26 119.47 29.77 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.197 -0.94 . . . . 0.0 108.993 179.308 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . 0.522 ' O ' ' CG2' ' A' ' 26' ' ' VAL . 1.9 p -74.66 4.85 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 O-C-N 121.102 -0.999 . . . . 0.0 108.914 179.632 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -98.21 3.4 48.92 Favored 'General case' 0 N--CA 1.486 1.371 0 O-C-N 121.198 -0.938 . . . . 0.0 109.253 179.636 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 40.0 tp -97.95 134.6 40.84 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.354 -0.841 . . . . 0.0 109.37 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 82.2 m-20 -65.67 142.06 58.17 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.226 -0.921 . . . . 0.0 109.298 -179.71 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 91.4 mt -70.7 -33.73 71.2 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.325 -0.859 . . . . 0.0 110.698 -179.411 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.496 ' CG2' ' N ' ' A' ' 32' ' ' ASP . 20.0 m -53.56 -47.74 59.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 O-C-N 121.146 -0.971 . . . . 0.0 110.155 -178.686 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.496 ' N ' ' CG2' ' A' ' 31' ' ' VAL . 90.8 m-20 -61.11 -35.04 75.96 Favored 'General case' 0 C--N 1.3 -1.568 0 O-C-N 121.248 -0.908 . . . . 0.0 108.624 179.496 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 96.4 m-20 -70.84 -34.32 71.55 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.686 -0.634 . . . . 0.0 110.11 -179.842 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 86.17 5.32 83.1 Favored Glycine 0 N--CA 1.491 2.367 0 N-CA-C 109.158 -1.577 . . . . 0.0 109.158 -179.685 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 71.9 t -60.85 -34.41 59.25 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 O-C-N 121.402 -1.058 . . . . 0.0 108.93 179.672 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 92.1 mt -66.46 95.21 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.428 0 O-C-N 121.467 -0.771 . . . . 0.0 110.313 -179.559 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -102.95 169.36 8.62 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 178.85 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -55.55 -48.65 74.4 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 107.761 -1.2 . . . . 0.0 107.761 179.659 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.499 ' CD1' ' N ' ' A' ' 39' ' ' LEU . 6.8 mp -71.14 -32.16 68.62 Favored 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 106.984 -1.488 . . . . 0.0 106.984 177.592 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -58.77 -48.1 86.93 Favored Glycine 0 N--CA 1.483 1.795 0 N-CA-C 109.181 -1.568 . . . . 0.0 109.181 179.705 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.5 tt -63.08 -40.29 97.22 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.367 -1.078 . . . . 0.0 109.187 179.314 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.1 tp -59.73 -46.22 89.8 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.264 -0.897 . . . . 0.0 109.23 179.956 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 63.8 mttp -61.67 -34.35 75.57 Favored 'General case' 0 C--N 1.297 -1.7 0 O-C-N 121.443 -0.786 . . . . 0.0 109.604 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 78.9 t -60.8 -47.07 94.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.377 -0.827 . . . . 0.0 110.036 -179.512 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.7 mp -67.89 -36.56 76.12 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 O-C-N 121.295 -0.878 . . . . 0.0 111.35 -179.474 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.3 -49.38 64.46 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 120.965 -1.084 . . . . 0.0 111.853 -178.031 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . 0.533 ' C ' ' CD1' ' A' ' 47' ' ' TRP . 0.0 OUTLIER -78.37 -42.59 29.95 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 120.541 -1.349 . . . . 0.0 110.105 -179.062 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 7.4 tt -59.78 -42.08 92.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.242 -0.911 . . . . 0.0 110.667 -179.239 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 18.9 pt-20 -72.69 -36.51 67.9 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.101 -1.0 . . . . 0.0 109.94 -179.4 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.7 t0 -61.17 -39.61 90.76 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.362 -0.836 . . . . 0.0 111.247 -179.186 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . 0.515 ' NE ' ' HE1' ' A' ' 47' ' ' TRP . 94.0 mtt-85 -63.18 -38.91 93.04 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.094 -1.004 . . . . 0.0 112.567 -178.074 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 85.5 m-85 -99.2 -7.63 26.23 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 120.656 -1.278 . . . . 0.0 110.635 -178.682 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 69.82 30.54 70.34 Favored Glycine 0 N--CA 1.486 2.012 0 N-CA-C 108.924 -1.67 . . . . 0.0 108.924 179.425 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 26.5 pt -106.59 153.23 7.91 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 O-C-N 121.634 -0.921 . . . . 0.0 109.544 -179.557 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -98.59 134.19 41.88 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.138 -0.977 . . . . 0.0 109.639 -179.498 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.518 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -65.84 -30.29 70.89 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.28 -0.887 . . . . 0.0 109.58 179.903 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -57.71 -34.56 69.59 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.212 -0.93 . . . . 0.0 110.242 -179.741 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -54.93 -39.38 68.78 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.196 -0.94 . . . . 0.0 110.403 -179.297 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.518 ' O ' ' O ' ' A' ' 56' ' ' ALA . 31.5 m -128.67 157.05 41.41 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 O-C-N 121.275 -0.891 . . . . 0.0 109.804 -179.503 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -96.54 128.95 43.96 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.986 -1.071 . . . . 0.0 109.167 179.724 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 58.1 mt -101.39 135.33 43.05 Favored 'General case' 0 C--N 1.305 -1.334 0 O-C-N 121.214 -0.929 . . . . 0.0 109.798 -179.815 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -109.97 156.05 40.62 Favored Pre-proline 0 N--CA 1.487 1.393 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 179.395 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 10.8 Cg_endo -56.94 -24.1 55.07 Favored 'Trans proline' 0 C--N 1.303 -1.839 0 C-N-CA 122.406 2.071 . . . . 0.0 111.74 179.891 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -69.47 -29.35 67.0 Favored 'General case' 0 C--N 1.306 -1.315 0 O-C-N 121.338 -0.851 . . . . 0.0 109.172 179.721 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . 0.592 ' CD2' ' O ' ' A' ' 65' ' ' HIS . 4.3 t-160 -65.97 -17.69 64.84 Favored 'General case' 0 C--N 1.3 -1.562 0 O-C-N 121.417 -0.802 . . . . 0.0 108.966 -179.911 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.493 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 17.3 m-85 -93.14 14.86 16.71 Favored 'General case' 0 C--N 1.303 -1.445 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 179.532 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . 0.415 HH21 ' HB3' ' A' ' 87' ' ' LYS . 8.9 ptt180 -48.38 -38.53 19.64 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.816 -0.552 . . . . 0.0 110.822 -179.498 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.427 ' O ' ' OG ' ' A' ' 71' ' ' SER . 31.9 t -158.53 150.24 21.19 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 120.76 -1.213 . . . . 0.0 110.362 -179.667 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.588 ' CD1' ' H ' ' A' ' 69' ' ' ILE . 0.1 OUTLIER -57.74 -42.86 82.74 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.365 -0.835 . . . . 0.0 109.255 179.688 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.406 HH12 ' HG3' ' A' ' 87' ' ' LYS . 5.8 ptm180 -57.88 -40.66 80.77 Favored 'General case' 0 C--N 1.303 -1.427 0 O-C-N 121.42 -0.8 . . . . 0.0 109.326 -179.89 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.427 ' OG ' ' O ' ' A' ' 68' ' ' SER . 84.9 p -66.42 -34.39 77.85 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.236 -0.915 . . . . 0.0 109.514 179.538 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.41 ' HA ' ' HE2' ' A' ' 65' ' ' HIS . 91.5 mt -59.99 -51.14 76.4 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.243 0 O-C-N 121.163 -0.961 . . . . 0.0 109.749 179.969 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.474 ' OD2' ' O ' ' A' ' 1' ' ' MET . 42.4 t0 -59.49 -42.07 91.28 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.172 -0.955 . . . . 0.0 108.976 179.823 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . 0.556 ' O ' ' N ' ' A' ' 78' ' ' GLY . . . -66.72 -37.11 84.03 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.661 -0.649 . . . . 0.0 110.148 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . 0.459 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 64.6 t80 -61.3 -49.7 75.97 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.004 -1.06 . . . . 0.0 109.686 -179.604 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 44.3 t -68.66 -48.89 69.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.307 0 O-C-N 121.216 -0.927 . . . . 0.0 109.875 -179.568 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 82.1 t -69.62 -41.91 80.38 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.305 0 O-C-N 121.211 -0.931 . . . . 0.0 109.151 179.803 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.556 ' N ' ' O ' ' A' ' 74' ' ' ALA . . . -60.48 -39.42 96.31 Favored Glycine 0 N--CA 1.488 2.134 0 N-CA-C 109.895 -1.282 . . . . 0.0 109.895 -179.872 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -68.33 -41.07 81.33 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.159 -1.201 . . . . 0.0 110.245 -179.428 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 45.0 p -82.32 -29.86 30.8 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.189 -0.944 . . . . 0.0 109.594 -179.768 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.495 ' O ' ' O ' ' A' ' 78' ' ' GLY . 0.3 OUTLIER -133.31 153.74 80.73 Favored Pre-proline 0 C--N 1.302 -1.461 0 O-C-N 121.522 -0.736 . . . . 0.0 109.457 -179.659 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -62.39 111.17 1.22 Allowed 'Trans proline' 0 C--N 1.308 -1.603 0 C-N-CA 122.293 1.995 . . . . 0.0 111.528 179.755 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_endo -76.34 152.09 34.33 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.116 1.877 . . . . 0.0 113.069 -179.224 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.474 ' O ' ' C ' ' A' ' 85' ' ' GLU . 43.9 t -103.77 131.67 51.89 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 O-C-N 121.561 -0.712 . . . . 0.0 109.087 179.43 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.474 ' C ' ' O ' ' A' ' 84' ' ' VAL . 84.2 tt0 38.88 69.03 0.3 Allowed 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.454 -0.779 . . . . 0.0 109.762 179.994 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -60.37 150.15 31.64 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.209 -0.932 . . . . 0.0 109.833 -179.768 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.415 ' HB3' HH21 ' A' ' 67' ' ' ARG . 21.1 tttm -55.96 -38.72 70.76 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.341 -0.849 . . . . 0.0 109.431 179.874 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 36.1 tp -58.97 -37.24 76.36 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.315 -0.865 . . . . 0.0 109.396 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.0 mt-30 . . . . . 0 N--CA 1.489 1.522 0 CA-C-O 118.046 -0.978 . . . . 0.0 109.486 -179.914 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' -1' ' ' SER . . . . . . . . . . . . . 74.3 m . . . . . 0 N--CA 1.491 1.616 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 0' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -58.66 140.44 54.57 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.216 -0.927 . . . . 0.0 109.513 -179.92 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 65.4 mtt -60.99 -36.68 80.08 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.211 -0.93 . . . . 0.0 109.823 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.484 ' C ' ' CG ' ' A' ' 3' ' ' HIS . 87.3 mt-30 56.35 49.78 14.46 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.386 -0.821 . . . . 0.0 109.34 -179.44 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.484 ' CG ' ' C ' ' A' ' 2' ' ' GLN . 14.9 m-70 76.63 54.68 0.04 OUTLIER 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.705 -0.622 . . . . 0.0 110.127 179.874 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -62.26 -38.34 88.92 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.045 -1.034 . . . . 0.0 109.396 179.719 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.3 t -60.66 -38.03 83.53 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.36 -0.837 . . . . 0.0 110.049 -179.585 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 73.4 t -61.53 -43.12 96.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.203 -0.935 . . . . 0.0 109.539 -179.836 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 75.3 mt -60.32 -46.04 95.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.395 -0.816 . . . . 0.0 109.283 179.742 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -61.47 -39.24 90.18 Favored 'General case' 0 N--CA 1.486 1.372 0 O-C-N 121.268 -0.895 . . . . 0.0 108.675 179.546 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 33.2 tt0 -64.99 -35.11 80.13 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.419 -0.801 . . . . 0.0 109.143 179.289 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.612 ' CZ ' ' CD1' ' A' ' 47' ' ' TRP . 0.3 OUTLIER -60.51 -50.9 71.72 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.495 -0.753 . . . . 0.0 110.184 -179.569 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 22.7 m -66.55 -38.26 81.3 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 O-C-N 121.164 -0.96 . . . . 0.0 109.117 -179.743 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.444 ' O ' ' C ' ' A' ' 16' ' ' LEU . 73.9 t -63.47 -44.87 98.99 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.439 0 O-C-N 121.24 -0.912 . . . . 0.0 109.351 179.496 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -73.3 -19.27 61.08 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.266 -0.896 . . . . 0.0 109.939 179.746 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -63.9 -32.28 73.75 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.33 -0.857 . . . . 0.0 110.449 -178.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 64.8 t80 -142.28 -36.62 0.41 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 120.958 -1.089 . . . . 0.0 110.463 -179.62 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.444 ' C ' ' O ' ' A' ' 12' ' ' VAL . 5.6 mt -119.55 79.89 22.26 Favored Pre-proline 0 N--CA 1.491 1.615 0 O-C-N 121.211 -0.93 . . . . 0.0 110.017 -179.495 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_endo -77.97 -14.16 15.45 Favored 'Trans proline' 0 C--N 1.308 -1.58 0 C-N-CA 122.604 2.203 . . . . 0.0 112.235 179.592 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -90.31 7.25 39.37 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 121.343 -0.848 . . . . 0.0 109.9 -179.699 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 44.7 t -109.28 134.86 49.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.303 -0.873 . . . . 0.0 109.588 -179.98 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . 0.489 ' O ' ' OD1' ' A' ' 23' ' ' ASP . . . -72.52 117.15 56.53 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.275 -0.89 . . . . 0.0 109.382 -179.942 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_exo -52.5 -26.16 27.64 Favored 'Trans proline' 0 N--CA 1.493 1.468 0 C-N-CA 121.891 1.728 . . . . 0.0 112.095 179.446 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.88 -23.42 67.23 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.355 -0.841 . . . . 0.0 109.731 -179.762 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.489 ' OD1' ' O ' ' A' ' 20' ' ' ALA . 52.6 p30 -84.69 7.85 19.02 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.16 -0.963 . . . . 0.0 110.003 -179.615 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 12.2 t -103.0 131.74 50.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.162 -0.961 . . . . 0.0 109.5 -179.868 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 63.5 t0 -89.0 119.94 29.98 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.101 -1.0 . . . . 0.0 108.93 179.247 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.5 m -73.12 4.28 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 O-C-N 121.079 -1.013 . . . . 0.0 109.547 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -89.67 -8.22 52.9 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.215 -0.928 . . . . 0.0 109.111 179.577 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 40.5 tp -101.62 139.46 37.23 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.427 -0.796 . . . . 0.0 109.313 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.5 m-20 -58.88 142.17 51.4 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.249 -0.907 . . . . 0.0 109.388 -179.78 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.446 ' H ' ' HA ' ' A' ' 68' ' ' SER . 1.4 tt -69.12 -38.6 78.95 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.607 -0.683 . . . . 0.0 110.743 -178.846 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 75.4 t -64.5 -36.16 76.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.086 -1.009 . . . . 0.0 110.542 -178.903 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 91.3 m-20 -52.58 -33.66 47.09 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 120.969 -1.082 . . . . 0.0 108.218 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 97.6 m-20 -70.94 -34.37 71.4 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.615 -0.678 . . . . 0.0 109.99 179.534 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 86.05 6.04 82.48 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.315 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 71.6 t -61.51 -33.01 55.14 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.411 0 O-C-N 121.413 -1.051 . . . . 0.0 109.07 179.755 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 84.7 mt -91.95 123.85 44.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.276 -0.89 . . . . 0.0 109.802 -179.859 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -114.97 -168.44 1.38 Allowed 'General case' 0 C--N 1.301 -1.501 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 179.61 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -63.77 -53.84 44.6 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.103 -0.998 . . . . 0.0 108.717 179.683 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 6.6 mp -68.88 -32.9 72.88 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 107.007 -1.479 . . . . 0.0 107.007 178.222 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -59.04 -41.91 96.7 Favored Glycine 0 N--CA 1.48 1.627 0 N-CA-C 108.691 -1.763 . . . . 0.0 108.691 179.211 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.7 tt -65.16 -41.09 95.03 Favored 'General case' 0 C--N 1.304 -1.393 0 O-C-N 121.454 -1.027 . . . . 0.0 108.851 179.066 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.1 tp -59.88 -45.81 91.31 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.365 -0.834 . . . . 0.0 109.051 179.728 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 78.6 mttt -60.34 -35.73 76.35 Favored 'General case' 0 C--N 1.298 -1.672 0 O-C-N 121.471 -0.768 . . . . 0.0 109.456 -179.863 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 77.7 t -62.03 -43.32 97.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.308 -0.87 . . . . 0.0 109.795 -179.884 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.5 mp -67.33 -39.56 83.04 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.541 0 O-C-N 121.549 -0.719 . . . . 0.0 111.196 -179.382 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.36 -50.19 60.86 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 120.637 -1.289 . . . . 0.0 112.015 -177.72 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . 0.612 ' CD1' ' CZ ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -78.65 -45.01 22.45 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.665 -1.272 . . . . 0.0 110.647 -178.701 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.424 ' N ' ' CG ' ' A' ' 47' ' ' TRP . 29.4 tp -58.5 -44.19 89.34 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.12 -0.987 . . . . 0.0 110.062 -178.862 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 68.9 mm-40 -68.06 -37.75 81.66 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.117 -0.989 . . . . 0.0 109.582 -179.819 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.1 t70 -62.37 -36.94 83.83 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.358 -0.839 . . . . 0.0 110.792 -179.754 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 35.5 mmt180 -58.1 -39.07 77.67 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.09 -1.007 . . . . 0.0 111.162 -178.641 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.604 ' CE1' ' CG1' ' A' ' 76' ' ' VAL . 9.0 m-85 -91.89 -3.57 55.84 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.842 -1.161 . . . . 0.0 110.319 -179.286 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 73.87 29.8 62.49 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 108.52 -1.832 . . . . 0.0 108.52 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 31.9 pt -113.45 153.61 14.98 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 O-C-N 121.714 -0.874 . . . . 0.0 109.866 -179.17 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -97.06 139.92 32.34 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.307 -0.871 . . . . 0.0 109.259 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.482 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -62.85 -30.71 71.71 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.24 -0.912 . . . . 0.0 109.715 -179.796 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -56.72 -38.77 72.81 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.054 -1.029 . . . . 0.0 109.681 -179.758 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 90.7 m-20 -61.36 -41.29 96.83 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.204 -0.935 . . . . 0.0 109.945 -179.878 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.482 ' O ' ' O ' ' A' ' 56' ' ' ALA . 46.8 t -130.35 133.73 63.49 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 121.408 -0.808 . . . . 0.0 109.728 -179.845 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -104.15 134.27 47.68 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.295 -0.878 . . . . 0.0 109.402 179.677 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 40.2 mt -96.23 141.82 29.13 Favored 'General case' 0 C--N 1.304 -1.387 0 O-C-N 121.217 -0.927 . . . . 0.0 109.521 -179.759 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -109.58 156.33 39.82 Favored Pre-proline 0 C--N 1.305 -1.343 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 179.684 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 1.4 Cg_endo -48.92 -22.23 4.62 Favored 'Trans proline' 0 C--N 1.305 -1.729 0 C-N-CA 121.924 1.75 . . . . 0.0 110.837 179.604 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 87.1 tt0 -71.13 -30.14 66.12 Favored 'General case' 0 N--CA 1.486 1.351 0 O-C-N 121.563 -0.711 . . . . 0.0 109.477 179.094 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . 0.54 ' C ' ' CD2' ' A' ' 65' ' ' HIS . 1.2 t60 -65.84 -16.49 63.87 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.397 -0.814 . . . . 0.0 108.97 -179.794 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.558 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 12.5 m-85 -97.53 15.38 23.45 Favored 'General case' 0 C--N 1.299 -1.598 0 CA-C-O 121.739 0.78 . . . . 0.0 108.896 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . 0.598 ' NE ' ' OG ' ' A' ' 71' ' ' SER . 6.6 ptt180 -50.71 -36.13 34.72 Favored 'General case' 0 C--N 1.301 -1.5 0 O-C-N 121.701 -0.624 . . . . 0.0 110.002 -179.719 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.587 ' HG ' ' H ' ' A' ' 71' ' ' SER . 88.8 p -162.86 153.35 16.56 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.982 -1.074 . . . . 0.0 110.216 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.412 HD11 ' H ' ' A' ' 69' ' ' ILE . 3.5 mp -58.42 -43.4 86.51 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 O-C-N 121.34 -0.85 . . . . 0.0 109.046 179.68 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 10.0 ptm180 -58.17 -40.11 80.62 Favored 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 108.96 -0.756 . . . . 0.0 108.96 179.5 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.598 ' OG ' ' NE ' ' A' ' 67' ' ' ARG . 25.9 t -63.46 -41.14 98.62 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.434 -0.792 . . . . 0.0 109.827 179.542 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 81.8 mt -58.91 -48.7 85.57 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.315 0 O-C-N 121.239 -0.913 . . . . 0.0 109.603 -179.615 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 37.4 t0 -60.07 -43.76 95.21 Favored 'General case' 0 N--CA 1.487 1.406 0 O-C-N 121.22 -0.925 . . . . 0.0 108.728 179.756 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . 0.5 ' O ' ' N ' ' A' ' 78' ' ' GLY . . . -66.99 -38.77 86.63 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.658 -0.651 . . . . 0.0 109.932 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . 0.464 ' O ' ' CB ' ' A' ' 79' ' ' ALA . 53.5 t80 -62.76 -47.99 81.13 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.177 -0.952 . . . . 0.0 109.473 -179.698 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.604 ' CG1' ' CE1' ' A' ' 52' ' ' PHE . 50.0 t -64.99 -48.33 84.49 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.294 0 O-C-N 121.255 -0.903 . . . . 0.0 109.774 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 88.7 t -69.88 -49.06 60.0 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 O-C-N 121.2 -0.937 . . . . 0.0 109.356 179.705 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.5 ' N ' ' O ' ' A' ' 74' ' ' ALA . . . -65.6 -26.58 72.01 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 -179.778 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . 0.464 ' CB ' ' O ' ' A' ' 75' ' ' PHE . . . -67.12 -39.39 86.65 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.145 -1.209 . . . . 0.0 110.019 -179.31 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 56.6 p -82.19 -28.7 31.89 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.197 -0.939 . . . . 0.0 109.585 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.493 ' O ' ' O ' ' A' ' 78' ' ' GLY . 2.0 t -133.04 148.77 70.66 Favored Pre-proline 0 N--CA 1.489 1.522 0 O-C-N 121.389 -0.819 . . . . 0.0 109.65 -179.857 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 87.6 Cg_exo -40.76 109.41 0.1 Allowed 'Trans proline' 0 C--N 1.311 -1.435 0 C-N-CA 122.252 1.968 . . . . 0.0 111.862 179.248 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 22.4 Cg_exo -57.55 146.43 84.18 Favored 'Trans proline' 0 N--CA 1.49 1.317 0 C-N-CA 121.966 1.777 . . . . 0.0 112.158 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.463 ' O ' ' C ' ' A' ' 85' ' ' GLU . 45.8 t -102.76 130.79 52.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.382 -0.824 . . . . 0.0 109.12 179.58 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.463 ' C ' ' O ' ' A' ' 84' ' ' VAL . 96.2 mt-10 38.59 63.59 0.86 Allowed 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.437 -0.789 . . . . 0.0 109.839 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . 0.401 ' C ' ' O ' ' A' ' 85' ' ' GLU . . . -45.3 149.11 0.55 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.19 -0.944 . . . . 0.0 109.513 -179.844 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 12.6 tttm -55.88 -33.48 64.63 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.308 -0.87 . . . . 0.0 109.519 -179.8 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 55.6 mt -80.73 143.07 33.23 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.277 -0.89 . . . . 0.0 109.46 -179.915 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 63.6 tt0 . . . . . 0 N--CA 1.49 1.541 0 CA-C-O 118.042 -0.98 . . . . 0.0 109.479 -179.924 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' -1' ' ' SER . . . . . . . . . . . . . 13.4 m . . . . . 0 N--CA 1.49 1.549 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 0' ' ' GLU . . . . . . . . . . . . . 44.7 tp10 -58.03 -34.12 69.72 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.301 -0.874 . . . . 0.0 109.277 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 65.4 mtt -60.52 -33.7 73.02 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.36 -0.837 . . . . 0.0 109.767 179.826 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.493 ' C ' ' CG ' ' A' ' 3' ' ' HIS . 90.7 mt-30 58.48 48.99 11.27 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.512 -0.742 . . . . 0.0 109.469 -179.452 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.493 ' CG ' ' C ' ' A' ' 2' ' ' GLN . 13.4 m-70 76.42 57.38 0.04 OUTLIER 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.637 -0.664 . . . . 0.0 110.225 179.677 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -62.74 -41.36 99.15 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.078 -1.014 . . . . 0.0 109.509 179.77 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.3 p -62.75 -34.57 77.47 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.204 -0.935 . . . . 0.0 109.685 -179.731 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 65.3 t -64.62 -41.66 92.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.228 -0.92 . . . . 0.0 109.183 179.75 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 77.7 mt -59.67 -44.61 93.91 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 O-C-N 121.481 -0.762 . . . . 0.0 109.238 179.875 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -62.12 -38.33 88.53 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.333 -0.854 . . . . 0.0 109.235 179.875 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 7.2 tt0 -59.09 -41.14 87.36 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.273 -0.892 . . . . 0.0 109.185 179.72 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.699 ' CG ' ' CE2' ' A' ' 47' ' ' TRP . 23.0 m-85 -63.32 -40.74 98.16 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.012 -1.055 . . . . 0.0 109.955 179.586 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 55.9 t -59.53 -50.63 79.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.276 -0.89 . . . . 0.0 110.726 -178.558 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.472 ' O ' ' C ' ' A' ' 16' ' ' LEU . 17.1 m -66.12 -39.6 84.86 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.428 0 O-C-N 120.656 -1.277 . . . . 0.0 109.813 -179.955 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . 0.401 ' N ' HG23 ' A' ' 12' ' ' VAL . 97.2 mt-10 -67.21 -20.54 65.71 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.136 -0.977 . . . . 0.0 110.39 -179.785 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 -63.34 -30.11 71.3 Favored 'General case' 0 C--N 1.299 -1.606 0 O-C-N 121.275 -0.891 . . . . 0.0 109.731 -179.309 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 63.6 t80 -149.27 -33.23 0.21 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.997 -1.064 . . . . 0.0 110.253 -179.917 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.472 ' C ' ' O ' ' A' ' 12' ' ' VAL . 3.8 mt -121.89 79.93 41.47 Favored Pre-proline 0 N--CA 1.492 1.671 0 O-C-N 121.189 -0.945 . . . . 0.0 110.126 -179.383 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -74.62 -11.98 22.3 Favored 'Trans proline' 0 C--N 1.308 -1.573 0 C-N-CA 122.403 2.068 . . . . 0.0 112.438 179.881 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -93.9 12.83 24.61 Favored 'General case' 0 N--CA 1.487 1.377 0 O-C-N 121.246 -0.909 . . . . 0.0 110.371 -179.413 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 60.5 t -111.15 134.71 52.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 121.238 -0.914 . . . . 0.0 109.831 -179.784 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . 0.49 ' O ' ' OD1' ' A' ' 23' ' ' ASP . . . -75.96 118.43 71.09 Favored Pre-proline 0 N--CA 1.489 1.515 0 O-C-N 121.338 -0.851 . . . . 0.0 109.326 179.912 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_exo -51.41 -25.63 19.15 Favored 'Trans proline' 0 N--CA 1.493 1.486 0 C-N-CA 121.77 1.647 . . . . 0.0 112.146 179.611 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.81 -25.61 67.98 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.261 -0.9 . . . . 0.0 109.732 -179.896 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.49 ' OD1' ' O ' ' A' ' 20' ' ' ALA . 49.8 p30 -85.81 7.46 23.76 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.195 -0.941 . . . . 0.0 109.925 -179.611 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 17.3 t -109.7 133.32 55.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.321 -0.862 . . . . 0.0 109.397 179.844 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 63.4 t0 -88.47 119.66 29.12 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.141 -0.974 . . . . 0.0 108.892 179.348 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.6 m -75.89 3.81 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 O-C-N 121.182 -0.949 . . . . 0.0 109.285 179.851 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -87.55 -11.38 48.93 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.333 -0.854 . . . . 0.0 108.966 179.424 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 36.4 tp -94.98 136.91 34.73 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 179.778 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -59.51 134.16 56.76 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.114 -0.991 . . . . 0.0 109.409 -179.493 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.493 ' H ' ' HA ' ' A' ' 68' ' ' SER . 2.3 tt -67.15 -37.81 84.41 Favored 'General case' 0 C--N 1.299 -1.6 0 O-C-N 121.732 -0.605 . . . . 0.0 110.154 -179.18 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 78.2 t -63.79 -34.96 71.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.05 -1.031 . . . . 0.0 110.396 -178.994 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 56.9 t0 -52.36 -33.66 44.08 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 120.984 -1.073 . . . . 0.0 108.11 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 21.8 m120 -71.16 -34.48 71.01 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.55 -0.719 . . . . 0.0 109.897 179.433 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 86.37 6.52 80.95 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.056 -1.617 . . . . 0.0 109.056 -179.374 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 79.6 t -61.66 -34.3 61.41 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 O-C-N 121.455 -1.026 . . . . 0.0 109.152 179.719 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 85.4 mt -86.07 117.84 31.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.324 -0.86 . . . . 0.0 109.656 -179.95 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -114.01 -164.59 0.94 Allowed 'General case' 0 C--N 1.302 -1.463 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 179.845 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -64.74 -54.21 34.94 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.109 -0.994 . . . . 0.0 108.682 179.704 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 38.5 mt -68.71 -32.81 72.86 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 107.105 -1.443 . . . . 0.0 107.105 178.264 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -59.15 -40.7 96.04 Favored Glycine 0 N--CA 1.48 1.592 0 N-CA-C 108.403 -1.879 . . . . 0.0 108.403 179.16 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.597 ' CD1' ' CZ ' ' A' ' 66' ' ' PHE . 7.3 tt -65.47 -41.67 93.07 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.479 -1.012 . . . . 0.0 108.888 178.978 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 tp -59.71 -45.74 91.22 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 179.443 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 25.2 mttp -60.51 -35.44 75.96 Favored 'General case' 0 C--N 1.297 -1.698 0 O-C-N 121.577 -0.702 . . . . 0.0 109.553 -179.881 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 72.5 t -60.11 -43.3 92.59 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 O-C-N 121.296 -0.877 . . . . 0.0 109.445 -179.916 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.484 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 6.4 mm -67.45 -40.03 83.74 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.559 0 O-C-N 121.476 -0.765 . . . . 0.0 111.144 -179.088 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.48 -49.09 67.78 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.038 -1.038 . . . . 0.0 112.162 -177.596 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . 0.699 ' CE2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -78.77 -46.73 18.21 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.448 -1.407 . . . . 0.0 110.679 -178.55 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.477 ' C ' ' CD1' ' A' ' 48' ' ' LEU . 3.2 tm? -58.4 -43.54 88.6 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.005 -1.06 . . . . 0.0 109.921 -178.301 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.484 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 1.2 pp20? -69.76 -36.83 76.12 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 120.943 -1.098 . . . . 0.0 109.66 -179.911 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.2 t0 -62.82 -37.88 88.54 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.181 -0.949 . . . . 0.0 110.321 179.895 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 9.7 mmt180 -60.95 -38.47 85.97 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.322 -0.861 . . . . 0.0 111.724 -178.81 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 84.5 m-85 -96.82 -6.89 34.97 Favored 'General case' 0 C--N 1.304 -1.392 0 O-C-N 120.817 -1.177 . . . . 0.0 110.239 -178.947 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 70.92 30.81 67.58 Favored Glycine 0 N--CA 1.486 1.971 0 N-CA-C 108.72 -1.752 . . . . 0.0 108.72 179.653 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.47 ' O ' ' OE1' ' A' ' 49' ' ' GLU . 24.7 pt -108.59 153.07 10.35 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 O-C-N 121.587 -0.949 . . . . 0.0 109.765 -179.408 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -104.14 156.28 18.01 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.383 -0.823 . . . . 0.0 109.554 -179.78 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -58.22 -25.54 61.78 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.234 -0.916 . . . . 0.0 109.151 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 61.2 t0 59.07 39.62 23.05 Favored 'General case' 0 N--CA 1.485 1.286 0 O-C-N 121.517 -0.739 . . . . 0.0 109.075 -179.761 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 54.38 44.87 28.27 Favored 'General case' 0 N--CA 1.487 1.379 0 O-C-N 121.706 -0.621 . . . . 0.0 110.202 179.367 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 52.6 t -121.33 134.46 64.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.446 -0.784 . . . . 0.0 109.137 179.382 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -102.29 132.44 48.24 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.19 -0.944 . . . . 0.0 109.599 -179.914 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 53.1 mt -95.24 147.3 23.62 Favored 'General case' 0 C--N 1.304 -1.394 0 O-C-N 121.347 -0.846 . . . . 0.0 109.293 179.792 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.562 ' HG ' ' H ' ' A' ' 64' ' ' GLU . 0.0 OUTLIER -104.4 157.67 33.59 Favored Pre-proline 0 N--CA 1.486 1.349 0 O-C-N 121.282 -0.886 . . . . 0.0 108.92 179.872 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 2.1 Cg_endo -49.4 -19.65 3.19 Favored 'Trans proline' 0 C--N 1.302 -1.869 0 C-N-CA 122.398 2.065 . . . . 0.0 110.985 -179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . 0.562 ' H ' ' HG ' ' A' ' 62' ' ' SER . 87.4 tt0 -68.54 -32.32 72.18 Favored 'General case' 0 N--CA 1.486 1.375 0 O-C-N 121.606 -0.683 . . . . 0.0 109.56 179.404 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . 0.553 ' C ' ' CD2' ' A' ' 65' ' ' HIS . 1.5 t60 -66.33 -17.89 65.03 Favored 'General case' 0 C--N 1.3 -1.558 0 O-C-N 121.384 -0.823 . . . . 0.0 108.829 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.602 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 4.2 m-85 -101.97 14.99 30.39 Favored 'General case' 0 C--N 1.298 -1.642 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . 0.422 ' NE ' ' OG ' ' A' ' 71' ' ' SER . 4.8 ptt180 -46.17 -38.31 8.11 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.875 -0.516 . . . . 0.0 109.985 -179.684 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.496 ' HG ' ' H ' ' A' ' 71' ' ' SER . 83.8 p -163.86 159.5 21.14 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.081 -1.012 . . . . 0.0 109.905 179.578 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.41 ' H ' HD13 ' A' ' 69' ' ' ILE . 3.4 mp -57.83 -35.35 51.08 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 179.087 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 57.9 mtp180 -57.85 -42.35 84.25 Favored 'General case' 0 C--N 1.304 -1.397 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 179.644 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.496 ' H ' ' HG ' ' A' ' 68' ' ' SER . 8.8 t -65.18 -38.81 91.69 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.652 -0.655 . . . . 0.0 109.987 -179.935 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 71.5 mt -58.93 -51.45 72.29 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 O-C-N 121.189 -0.944 . . . . 0.0 109.713 -179.286 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 43.1 t0 -62.1 -41.07 97.83 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.15 -0.969 . . . . 0.0 108.67 179.446 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.33 -37.6 85.72 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.667 -0.646 . . . . 0.0 109.952 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 64.3 t80 -60.36 -49.23 78.41 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.225 -0.922 . . . . 0.0 109.808 -179.626 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 93.7 t -66.45 -46.84 85.61 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 O-C-N 121.201 -0.937 . . . . 0.0 109.626 -179.89 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.491 ' O ' ' O ' ' A' ' 81' ' ' THR . 74.9 t -66.41 -40.51 86.78 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 O-C-N 121.261 -0.9 . . . . 0.0 109.229 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.05 -37.52 92.89 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 -179.72 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -73.25 -41.86 63.2 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.217 -1.166 . . . . 0.0 111.105 -178.929 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 43.6 p -83.36 -36.7 24.14 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.962 -1.086 . . . . 0.0 109.425 -179.598 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.491 ' O ' ' O ' ' A' ' 77' ' ' VAL . 0.6 OUTLIER -133.33 153.49 80.59 Favored Pre-proline 0 C--N 1.299 -1.593 0 O-C-N 121.541 -0.724 . . . . 0.0 109.081 -179.762 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -43.56 144.46 2.12 Favored 'Trans proline' 0 C--N 1.307 -1.629 0 C-N-CA 121.874 1.716 . . . . 0.0 110.994 179.49 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 10.4 Cg_endo -60.26 140.54 92.52 Favored 'Trans proline' 0 C--N 1.311 -1.441 0 C-N-CA 121.996 1.798 . . . . 0.0 112.747 -179.252 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.476 ' O ' ' C ' ' A' ' 85' ' ' GLU . 46.8 t -104.1 128.1 57.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 179.345 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.476 ' C ' ' O ' ' A' ' 84' ' ' VAL . 96.0 mt-10 36.74 39.55 0.11 Allowed 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.566 -0.709 . . . . 0.0 109.787 179.895 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -50.67 144.48 8.06 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.219 -0.925 . . . . 0.0 109.669 -179.551 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 42.6 mttm -58.25 -33.67 69.63 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.365 -0.834 . . . . 0.0 109.39 -179.971 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 55.4 mt -88.06 142.33 27.86 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.223 -0.923 . . . . 0.0 109.446 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 50.9 tt0 . . . . . 0 N--CA 1.492 1.645 0 CA-C-O 118.031 -0.985 . . . . 0.0 109.398 -179.968 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' -1' ' ' SER . . . . . . . . . . . . . 54.5 p . . . . . 0 N--CA 1.491 1.58 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 0' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -57.94 -33.57 68.97 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.234 -0.916 . . . . 0.0 109.484 179.912 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.405 ' O ' ' C ' ' A' ' 2' ' ' GLN . 71.4 mtm -57.97 -35.98 71.93 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.231 -0.918 . . . . 0.0 109.583 -179.919 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.417 HE21 ' CD2' ' A' ' 3' ' ' HIS . 70.2 tp60 45.24 74.1 0.14 Allowed 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.221 -0.924 . . . . 0.0 109.58 179.989 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.417 ' CD2' HE21 ' A' ' 2' ' ' GLN . 81.3 m-70 59.61 58.58 2.84 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.351 -0.843 . . . . 0.0 110.018 179.789 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -60.72 -34.44 74.41 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.127 -0.983 . . . . 0.0 109.522 179.805 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.8 t -58.69 -38.61 78.62 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.295 -0.878 . . . . 0.0 109.876 -179.602 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 78.9 t -64.06 -46.28 94.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.143 -0.973 . . . . 0.0 109.353 179.936 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 77.5 mt -61.27 -46.25 96.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 179.491 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.527 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -62.22 -35.36 78.66 Favored 'General case' 0 C--N 1.303 -1.419 0 O-C-N 121.619 -0.675 . . . . 0.0 109.29 179.734 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 31.4 tt0 -62.11 -41.76 98.54 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.19 -0.944 . . . . 0.0 110.419 -179.611 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.672 ' CG ' ' CE2' ' A' ' 47' ' ' TRP . 49.6 m-85 -68.13 -50.75 52.64 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 120.896 -1.127 . . . . 0.0 111.065 -179.268 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 36.0 m -66.01 -38.95 83.21 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 O-C-N 120.972 -1.08 . . . . 0.0 109.247 -179.315 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.527 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 89.2 t -63.68 -46.27 95.16 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 O-C-N 121.261 -0.899 . . . . 0.0 109.204 179.479 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -75.09 -16.92 60.54 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.14 -0.975 . . . . 0.0 110.076 179.824 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -63.81 -33.67 76.19 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.285 -0.884 . . . . 0.0 110.439 -178.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 67.2 t80 -154.08 -19.16 0.13 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.86 -1.15 . . . . 0.0 110.471 -179.634 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.456 ' C ' ' O ' ' A' ' 12' ' ' VAL . 5.6 mt -121.57 80.05 38.86 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.198 -0.939 . . . . 0.0 109.835 -179.497 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -79.73 -17.41 11.07 Favored 'Trans proline' 0 C--N 1.307 -1.656 0 C-N-CA 122.665 2.244 . . . . 0.0 112.628 -179.877 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . 0.444 ' C ' ' OD1' ' A' ' 18' ' ' ASP . 51.8 p30 -90.09 9.99 26.04 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.166 -0.959 . . . . 0.0 110.172 -179.575 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 67.5 t -111.25 135.98 48.74 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.207 -0.933 . . . . 0.0 109.532 179.754 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -78.27 117.39 65.86 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.312 -0.867 . . . . 0.0 109.443 -179.908 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_exo -51.95 -35.83 61.96 Favored 'Trans proline' 0 N--CA 1.491 1.368 0 C-N-CA 121.709 1.606 . . . . 0.0 111.817 179.326 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.84 -23.73 66.73 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.3 -0.875 . . . . 0.0 108.925 179.529 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -84.71 7.46 20.41 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.418 -0.801 . . . . 0.0 109.743 -179.795 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 13.0 t -101.63 132.51 47.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.145 -0.972 . . . . 0.0 109.264 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.423 ' C ' ' H ' ' A' ' 27' ' ' ASP . 63.8 t0 -89.01 119.39 29.49 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.151 -0.968 . . . . 0.0 109.223 179.587 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 0.3 OUTLIER -69.33 4.25 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 O-C-N 121.204 -0.935 . . . . 0.0 109.452 179.782 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.423 ' H ' ' C ' ' A' ' 25' ' ' ASP . 92.5 m-20 -95.02 -2.77 49.62 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.251 -0.905 . . . . 0.0 109.239 179.66 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 39.8 tp -99.56 136.42 39.52 Favored 'General case' 0 C--N 1.303 -1.441 0 O-C-N 121.394 -0.816 . . . . 0.0 108.92 179.714 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -58.62 137.12 57.7 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.105 -0.997 . . . . 0.0 109.196 -179.502 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.478 ' H ' ' HA ' ' A' ' 68' ' ' SER . 1.8 tt -68.35 -36.73 79.68 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.635 -0.665 . . . . 0.0 110.36 -178.981 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 69.6 t -64.75 -35.51 75.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.101 -0.999 . . . . 0.0 110.557 -179.004 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -52.54 -33.61 46.34 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 120.996 -1.065 . . . . 0.0 108.178 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 3.2 m120 -70.98 -34.52 71.47 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.604 -0.685 . . . . 0.0 109.982 179.485 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 85.96 6.05 82.72 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 108.88 -1.688 . . . . 0.0 108.88 -179.24 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 78.5 t -61.1 -31.21 49.43 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.398 0 O-C-N 121.495 -1.003 . . . . 0.0 108.68 179.512 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 81.5 mt -93.99 132.3 38.48 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 O-C-N 121.438 -0.789 . . . . 0.0 109.677 -179.98 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.566 ' CG ' ' H ' ' A' ' 38' ' ' ALA . 52.4 t0 -138.97 -167.69 2.27 Favored 'General case' 0 C--N 1.301 -1.528 0 N-CA-C 108.562 -0.903 . . . . 0.0 108.562 179.602 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.566 ' H ' ' CG ' ' A' ' 37' ' ' ASP . . . -62.6 -55.22 29.14 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.928 -1.107 . . . . 0.0 108.588 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 37.4 mt -71.47 -34.79 70.51 Favored 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 107.063 -1.458 . . . . 0.0 107.063 178.024 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -59.85 -39.85 95.98 Favored Glycine 0 N--CA 1.481 1.671 0 N-CA-C 108.703 -1.759 . . . . 0.0 108.703 179.169 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . 0.518 ' C ' ' CD1' ' A' ' 41' ' ' LEU . 2.5 tm? -65.04 -43.89 90.87 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.49 -1.006 . . . . 0.0 108.622 179.386 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.2 tp -59.09 -46.03 89.33 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.343 -0.848 . . . . 0.0 109.066 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 63.2 mttp -61.49 -34.79 76.07 Favored 'General case' 0 C--N 1.295 -1.778 0 O-C-N 121.537 -0.727 . . . . 0.0 109.481 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 91.6 t -62.56 -50.43 79.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.451 -0.781 . . . . 0.0 110.166 -179.347 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.7 mp -68.34 -29.85 45.65 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 O-C-N 121.314 -0.866 . . . . 0.0 110.566 -179.774 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.47 -49.2 67.44 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.108 -0.995 . . . . 0.0 111.657 -178.177 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . 0.672 ' CE2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -81.08 -40.99 23.26 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 120.592 -1.317 . . . . 0.0 110.3 -179.015 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.411 HD11 ' HE ' ' A' ' 51' ' ' ARG . 0.2 OUTLIER -61.23 -41.62 97.19 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.154 -0.966 . . . . 0.0 109.298 -179.357 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.419 ' CG ' ' N ' ' A' ' 50' ' ' ASP . 17.0 pt-20 -73.13 -36.07 66.63 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 120.638 -1.289 . . . . 0.0 109.165 179.907 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . 0.419 ' N ' ' CG ' ' A' ' 49' ' ' GLU . 59.0 t0 -65.6 -40.84 93.12 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.632 -0.667 . . . . 0.0 111.766 -179.072 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . 0.426 HH21 HG12 ' A' ' 76' ' ' VAL . 24.3 ptt180 -71.39 -36.59 71.46 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 120.864 -1.148 . . . . 0.0 111.484 -177.712 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.414 ' CE1' ' CG1' ' A' ' 76' ' ' VAL . 5.7 m-85 -81.21 -14.74 57.21 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.577 -1.327 . . . . 0.0 109.756 -179.726 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.27 20.67 71.9 Favored Glycine 0 N--CA 1.486 2.025 0 N-CA-C 108.693 -1.763 . . . . 0.0 108.693 -179.745 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 23.1 pt -113.19 153.65 14.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.737 -0.86 . . . . 0.0 109.695 -179.573 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -101.03 132.29 46.53 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.249 -0.907 . . . . 0.0 109.519 -179.789 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.503 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -69.0 -23.55 64.12 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.316 -0.865 . . . . 0.0 109.692 179.859 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 91.3 m-20 -54.98 -36.08 65.01 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.268 -0.895 . . . . 0.0 110.146 -179.487 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -56.13 -39.36 72.12 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.18 -0.95 . . . . 0.0 110.001 -179.547 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.503 ' O ' ' O ' ' A' ' 56' ' ' ALA . 41.7 t -126.86 136.68 60.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.337 -0.852 . . . . 0.0 109.666 -179.894 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -87.58 127.23 35.27 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.117 -0.989 . . . . 0.0 109.185 179.864 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 39.4 mt -104.53 142.05 35.31 Favored 'General case' 0 C--N 1.306 -1.295 0 O-C-N 121.279 -0.888 . . . . 0.0 109.831 -179.649 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -108.75 152.54 42.31 Favored Pre-proline 0 N--CA 1.485 1.316 0 N-CA-C 108.696 -0.854 . . . . 0.0 108.696 179.377 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 12.8 Cg_endo -58.44 -21.16 52.44 Favored 'Trans proline' 0 C--N 1.304 -1.768 0 C-N-CA 122.505 2.137 . . . . 0.0 112.196 -179.748 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -69.6 -30.1 67.77 Favored 'General case' 0 N--CA 1.486 1.335 0 O-C-N 121.272 -0.892 . . . . 0.0 109.731 -179.726 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . 0.425 ' CE1' ' HB2' ' A' ' 75' ' ' PHE . 76.3 t60 -66.16 -20.66 66.21 Favored 'General case' 0 C--N 1.299 -1.588 0 O-C-N 121.233 -0.917 . . . . 0.0 108.918 -179.874 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.496 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 21.8 m-85 -89.17 12.73 15.0 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.394 -0.816 . . . . 0.0 109.203 -179.68 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . 0.413 HH21 ' CD ' ' A' ' 87' ' ' LYS . 4.2 ptt85 -49.88 -34.56 20.58 Favored 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.628 -0.67 . . . . 0.0 109.513 179.719 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.478 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 89.2 p -151.65 153.54 34.62 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.154 -0.966 . . . . 0.0 109.895 179.794 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.454 ' O ' ' OD1' ' A' ' 73' ' ' ASP . 3.5 mp -59.83 -34.81 57.11 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.485 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 179.3 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.591 ' HE ' ' HZ1' ' A' ' 87' ' ' LYS . 30.2 mtp85 -57.11 -45.18 83.66 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.604 -0.685 . . . . 0.0 109.765 -179.272 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 22.9 t -64.9 -46.07 83.25 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.307 -0.871 . . . . 0.0 109.781 -179.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.417 ' HA ' ' NE2' ' A' ' 65' ' ' HIS . 68.0 mt -58.95 -42.89 87.38 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 O-C-N 121.176 -0.952 . . . . 0.0 109.913 -179.735 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.481 ' N ' ' OD1' ' A' ' 73' ' ' ASP . 2.0 m-20 -61.14 -37.95 84.66 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.292 -0.88 . . . . 0.0 109.842 -179.584 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -67.4 -46.91 71.85 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.035 -1.041 . . . . 0.0 110.541 -179.304 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . 0.425 ' HB2' ' CE1' ' A' ' 65' ' ' HIS . 65.8 t80 -66.03 -44.08 85.71 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.135 -0.978 . . . . 0.0 109.57 -179.737 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.426 HG12 HH21 ' A' ' 51' ' ' ARG . 43.4 t -60.68 -41.83 89.68 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 O-C-N 121.301 -0.874 . . . . 0.0 108.81 179.334 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.499 ' O ' ' O ' ' A' ' 81' ' ' THR . 65.3 t -65.0 -40.52 89.34 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.256 0 O-C-N 121.306 -0.871 . . . . 0.0 109.042 179.338 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.53 -17.23 32.47 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.753 -1.339 . . . . 0.0 109.753 179.794 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -66.71 -34.82 78.68 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.288 -1.125 . . . . 0.0 110.573 -179.176 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 49.7 p -134.49 -20.5 1.82 Allowed 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.009 -1.057 . . . . 0.0 110.709 -179.381 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.499 ' O ' ' O ' ' A' ' 77' ' ' VAL . 0.1 OUTLIER -132.74 152.59 80.16 Favored Pre-proline 0 N--CA 1.49 1.528 0 O-C-N 121.144 -0.973 . . . . 0.0 109.39 -179.919 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo -66.5 136.98 44.93 Favored 'Trans proline' 0 C--N 1.307 -1.613 0 C-N-CA 122.263 1.975 . . . . 0.0 111.593 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -67.28 147.62 78.66 Favored 'Trans proline' 0 N--CA 1.49 1.291 0 C-N-CA 122.111 1.874 . . . . 0.0 112.576 -179.593 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.459 ' O ' ' C ' ' A' ' 85' ' ' GLU . 41.2 t -103.57 133.0 48.68 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 O-C-N 121.497 -0.752 . . . . 0.0 109.087 179.481 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.459 ' C ' ' O ' ' A' ' 84' ' ' VAL . 95.9 mt-10 40.67 54.96 3.03 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.411 -0.806 . . . . 0.0 109.587 -179.977 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -52.59 151.92 3.98 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.275 -0.891 . . . . 0.0 109.558 -179.874 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.591 ' HZ1' ' HE ' ' A' ' 70' ' ' ARG . 68.4 mttm -64.57 144.68 57.04 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.3 -0.875 . . . . 0.0 109.365 -179.841 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . 0.418 ' C ' ' O ' ' A' ' 87' ' ' LYS . 53.8 mt 43.76 87.43 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.214 -0.929 . . . . 0.0 109.479 -179.893 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.0 mt-30 . . . . . 0 N--CA 1.491 1.591 0 CA-C-O 117.999 -1.0 . . . . 0.0 109.459 -179.98 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' -1' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.519 -0.549 . . . . 0.0 109.519 . . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 0' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -61.78 -34.04 75.18 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.208 -0.933 . . . . 0.0 109.498 -179.937 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 87.0 mmm -94.58 -121.42 0.1 Allowed 'General case' 0 C--N 1.306 -1.305 0 O-C-N 121.2 -0.937 . . . . 0.0 109.026 -179.881 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 93.5 mt-30 -110.19 -72.99 0.7 Allowed 'General case' 0 N--CA 1.491 1.592 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 179.166 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 97.2 m-70 -103.55 22.15 14.82 Favored 'General case' 0 C--N 1.303 -1.438 0 N-CA-C 108.034 -1.099 . . . . 0.0 108.034 178.764 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.585 ' N ' ' OD2' ' A' ' 73' ' ' ASP . . . -52.94 -41.04 64.1 Favored 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.518 -0.739 . . . . 0.0 109.861 -179.078 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 21.3 m -61.11 -39.28 89.4 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.178 -0.951 . . . . 0.0 109.602 179.975 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 54.6 t -61.61 -43.88 97.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.331 -0.855 . . . . 0.0 109.483 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 82.5 mt -59.78 -40.27 82.08 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.45 0 O-C-N 121.363 -0.835 . . . . 0.0 109.076 179.697 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -60.92 -36.25 78.8 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 179.897 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 26.5 mt-30 -65.8 -39.16 90.64 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.296 -0.878 . . . . 0.0 109.967 179.757 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.66 ' CG ' ' CZ2' ' A' ' 47' ' ' TRP . 28.5 m-85 -64.2 -50.44 68.08 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.167 -0.958 . . . . 0.0 111.057 -179.28 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 2.9 p -59.89 -42.74 90.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.016 -1.053 . . . . 0.0 109.579 -179.19 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.464 ' O ' ' C ' ' A' ' 16' ' ' LEU . 86.9 t -63.46 -47.3 92.32 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 O-C-N 121.115 -0.99 . . . . 0.0 109.396 179.833 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -71.53 -24.12 61.9 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.172 -0.955 . . . . 0.0 109.96 179.825 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -64.19 -32.07 73.51 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.363 -0.836 . . . . 0.0 110.893 -178.763 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 63.1 t80 -140.83 -35.12 0.49 Allowed 'General case' 0 N--CA 1.494 1.758 0 O-C-N 120.849 -1.157 . . . . 0.0 110.742 -179.254 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.464 ' C ' ' O ' ' A' ' 12' ' ' VAL . 5.2 mt -119.17 80.04 19.4 Favored Pre-proline 0 N--CA 1.493 1.693 0 O-C-N 121.167 -0.958 . . . . 0.0 109.939 -179.397 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_endo -77.86 -15.3 15.08 Favored 'Trans proline' 0 C--N 1.308 -1.603 0 C-N-CA 122.546 2.164 . . . . 0.0 112.198 179.755 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -88.43 5.32 42.88 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 121.32 -0.862 . . . . 0.0 109.788 -179.729 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 46.3 t -110.64 134.92 51.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.387 -0.821 . . . . 0.0 109.564 -179.88 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.46 118.63 69.34 Favored Pre-proline 0 N--CA 1.489 1.503 0 O-C-N 121.279 -0.888 . . . . 0.0 109.24 179.902 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_exo -51.3 -28.62 27.25 Favored 'Trans proline' 0 N--CA 1.492 1.397 0 C-N-CA 121.728 1.619 . . . . 0.0 111.866 179.659 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.42 -23.31 66.91 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.198 -0.939 . . . . 0.0 109.286 179.688 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.45 ' O ' ' OD1' ' A' ' 23' ' ' ASP . 60.2 t0 -81.65 4.03 23.18 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.326 -0.859 . . . . 0.0 109.762 -179.762 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 13.5 t -108.75 133.32 54.19 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.245 -0.909 . . . . 0.0 109.351 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 86.9 m-20 -88.29 120.53 29.74 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.084 -1.01 . . . . 0.0 108.964 179.379 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 32.8 m -75.68 4.42 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 O-C-N 121.237 -0.915 . . . . 0.0 109.178 179.601 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -93.17 -2.75 54.98 Favored 'General case' 0 C--N 1.306 -1.318 0 O-C-N 121.316 -0.865 . . . . 0.0 108.941 179.518 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 39.8 tp -97.13 138.32 34.83 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.494 -0.754 . . . . 0.0 109.016 179.819 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 87.3 m-20 -60.09 138.5 57.87 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.154 -0.966 . . . . 0.0 109.531 -179.407 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.472 ' H ' ' HA ' ' A' ' 68' ' ' SER . 1.3 tt -75.62 -36.74 60.17 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.716 -0.615 . . . . 0.0 110.454 -179.203 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.415 HG23 ' H ' ' A' ' 32' ' ' ASP . 12.9 m -64.1 -38.4 82.36 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.659 0 O-C-N 121.111 -0.993 . . . . 0.0 110.583 -178.903 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.415 ' H ' HG23 ' A' ' 31' ' ' VAL . 92.5 m-20 -54.5 -33.45 59.87 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.142 -0.974 . . . . 0.0 108.375 179.67 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 96.1 m-20 -70.5 -34.56 72.47 Favored 'General case' 0 C--N 1.303 -1.445 0 O-C-N 121.656 -0.653 . . . . 0.0 110.0 179.875 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 82.37 5.86 89.2 Favored Glycine 0 N--CA 1.493 2.479 0 N-CA-C 109.516 -1.433 . . . . 0.0 109.516 -179.904 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 78.3 t -61.35 -34.36 60.69 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 O-C-N 121.276 -1.132 . . . . 0.0 108.697 179.501 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 96.7 mt -77.34 112.17 14.98 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 121.454 -0.779 . . . . 0.0 109.954 179.91 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -111.33 -164.53 0.92 Allowed 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 179.595 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -66.71 -54.25 25.01 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.125 -0.984 . . . . 0.0 108.874 179.694 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.457 ' CD1' ' N ' ' A' ' 39' ' ' LEU . 6.9 mp -69.77 -32.89 71.64 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 107.397 -1.334 . . . . 0.0 107.397 178.432 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -59.41 -43.0 97.76 Favored Glycine 0 N--CA 1.482 1.704 0 N-CA-C 109.053 -1.619 . . . . 0.0 109.053 179.509 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.5 tt -65.13 -42.73 93.59 Favored 'General case' 0 C--N 1.303 -1.415 0 O-C-N 121.413 -1.051 . . . . 0.0 109.327 179.449 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 tp -60.06 -46.25 90.18 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.375 -0.828 . . . . 0.0 109.274 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 12.7 mttm -62.39 -34.44 76.73 Favored 'General case' 0 C--N 1.297 -1.7 0 O-C-N 121.44 -0.787 . . . . 0.0 109.789 -179.694 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 53.8 t -61.47 -50.42 80.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.291 -0.881 . . . . 0.0 110.322 -179.215 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.537 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 3.5 mp -68.36 -33.73 62.0 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 121.331 -0.856 . . . . 0.0 111.011 -179.67 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.42 -49.77 67.96 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.013 -1.054 . . . . 0.0 111.655 -178.007 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . 0.66 ' CZ2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -81.2 -43.78 18.79 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.75 -1.219 . . . . 0.0 109.905 -179.3 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.4 ' N ' ' CG ' ' A' ' 47' ' ' TRP . 31.4 tp -58.82 -42.35 88.98 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.215 -0.928 . . . . 0.0 109.95 -179.267 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.537 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 1.1 pp20? -72.53 -36.02 68.2 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.082 -1.011 . . . . 0.0 109.749 -179.959 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.5 t0 -60.43 -38.51 84.35 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.251 -0.905 . . . . 0.0 110.608 -179.653 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 77.7 mtp85 -61.81 -37.83 85.87 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.167 -0.958 . . . . 0.0 111.602 -178.668 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.42 ' CE2' ' CG1' ' A' ' 76' ' ' VAL . 88.0 m-85 -95.86 -8.5 33.95 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 120.67 -1.269 . . . . 0.0 110.339 -178.97 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 71.98 30.37 65.69 Favored Glycine 0 N--CA 1.486 2.021 0 N-CA-C 108.872 -1.691 . . . . 0.0 108.872 179.682 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.501 ' O ' ' OE1' ' A' ' 49' ' ' GLU . 26.0 pt -107.55 151.13 9.66 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.402 0 O-C-N 121.654 -0.909 . . . . 0.0 109.653 -179.502 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . 0.475 ' O ' ' OD1' ' A' ' 58' ' ' ASP . . . -101.76 132.48 47.47 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.233 -0.917 . . . . 0.0 109.645 -179.661 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.5 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -67.0 -26.88 67.02 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.335 -0.853 . . . . 0.0 109.396 179.751 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 52.3 t0 -54.87 -34.79 63.36 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.317 -0.864 . . . . 0.0 110.042 -179.571 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.632 ' OD1' ' N ' ' A' ' 59' ' ' VAL . 55.3 p30 -59.47 -34.53 72.66 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.196 -0.94 . . . . 0.0 110.301 -179.459 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.632 ' N ' ' OD1' ' A' ' 58' ' ' ASP . 14.5 p -136.86 140.96 41.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.025 -1.047 . . . . 0.0 109.585 179.92 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -85.3 139.35 31.67 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.053 -1.03 . . . . 0.0 109.299 179.818 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 5.1 mp -97.72 136.9 37.41 Favored 'General case' 0 C--N 1.305 -1.345 0 O-C-N 121.198 -0.939 . . . . 0.0 109.712 -179.835 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -110.0 155.35 41.83 Favored Pre-proline 0 N--CA 1.488 1.457 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 179.489 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 7.8 Cg_endo -53.2 -23.55 23.29 Favored 'Trans proline' 0 C--N 1.302 -1.904 0 C-N-CA 122.286 1.991 . . . . 0.0 111.685 -179.898 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -70.69 -26.54 63.47 Favored 'General case' 0 N--CA 1.486 1.336 0 O-C-N 121.344 -0.847 . . . . 0.0 109.507 179.655 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . 0.546 ' C ' ' CD2' ' A' ' 65' ' ' HIS . 1.9 t60 -65.62 -20.41 66.3 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.23 -0.919 . . . . 0.0 109.215 -179.703 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.54 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 6.7 m-85 -98.2 16.24 21.95 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 121.447 -0.783 . . . . 0.0 108.965 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . 0.588 ' NE ' ' OG ' ' A' ' 71' ' ' SER . 4.8 ptt180 -52.16 -36.34 51.27 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 121.754 -0.591 . . . . 0.0 110.08 -179.775 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.472 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 35.2 p -164.9 153.31 12.12 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.016 -1.053 . . . . 0.0 110.281 -179.702 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.405 HD11 ' H ' ' A' ' 69' ' ' ILE . 3.3 mp -57.94 -40.68 77.57 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 O-C-N 121.362 -0.836 . . . . 0.0 109.161 179.904 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.504 ' NE ' ' HZ1' ' A' ' 87' ' ' LYS . 18.9 ptt180 -58.16 -42.24 85.53 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.643 -0.66 . . . . 0.0 109.266 179.806 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.588 ' OG ' ' NE ' ' A' ' 67' ' ' ARG . 26.5 t -64.92 -39.25 93.22 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.204 -0.935 . . . . 0.0 109.677 179.488 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 87.8 mt -58.92 -47.14 90.59 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.289 0 O-C-N 121.176 -0.953 . . . . 0.0 109.736 -179.73 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.585 ' OD2' ' N ' ' A' ' 4' ' ' ALA . 26.5 t0 -58.91 -44.23 91.23 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.147 -0.971 . . . . 0.0 108.723 179.864 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . 0.55 ' O ' ' N ' ' A' ' 78' ' ' GLY . . . -66.96 -37.36 84.13 Favored 'General case' 0 C--N 1.304 -1.399 0 O-C-N 121.432 -0.792 . . . . 0.0 109.595 179.667 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 61.9 t80 -62.82 -48.83 77.37 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.19 -0.944 . . . . 0.0 109.644 -179.833 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.42 ' CG1' ' CE2' ' A' ' 52' ' ' PHE . 71.1 t -67.56 -48.8 75.51 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.282 0 O-C-N 121.201 -0.937 . . . . 0.0 109.782 -179.847 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 55.3 t -69.89 -43.77 79.33 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.274 0 O-C-N 121.106 -0.996 . . . . 0.0 109.034 179.38 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.55 ' N ' ' O ' ' A' ' 74' ' ' ALA . . . -59.38 -30.93 68.82 Favored Glycine 0 N--CA 1.488 2.127 0 N-CA-C 110.211 -1.155 . . . . 0.0 110.211 -179.606 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -68.63 -41.5 79.36 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.153 -1.204 . . . . 0.0 110.586 -178.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 47.1 p -79.74 -32.02 41.06 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.161 -0.962 . . . . 0.0 109.326 -179.83 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.492 ' O ' ' O ' ' A' ' 78' ' ' GLY . 1.8 t -133.13 150.42 75.41 Favored Pre-proline 0 N--CA 1.487 1.401 0 O-C-N 121.447 -0.783 . . . . 0.0 108.911 179.93 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 76.0 Cg_exo -42.79 138.01 3.95 Favored 'Trans proline' 0 C--N 1.309 -1.506 0 C-N-CA 121.603 1.535 . . . . 0.0 111.197 179.312 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 14.7 Cg_endo -64.18 144.58 87.2 Favored 'Trans proline' 0 N--CA 1.49 1.283 0 C-N-CA 121.957 1.771 . . . . 0.0 112.943 -179.003 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.492 ' O ' ' C ' ' A' ' 85' ' ' GLU . 13.8 p -104.52 130.86 54.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 179.525 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.492 ' C ' ' O ' ' A' ' 84' ' ' VAL . 96.1 mt-10 34.72 45.68 0.16 Allowed 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.681 -0.637 . . . . 0.0 110.249 179.647 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -52.7 149.59 5.97 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.162 -0.962 . . . . 0.0 109.416 -179.866 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.504 ' HZ1' ' NE ' ' A' ' 70' ' ' ARG . 68.4 mttm -56.07 -35.49 67.04 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.233 -0.917 . . . . 0.0 109.345 -179.839 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 55.0 mt -95.97 141.43 29.4 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.25 -0.907 . . . . 0.0 109.469 179.86 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.5 mt-30 . . . . . 0 N--CA 1.49 1.548 0 CA-C-O 118.031 -0.985 . . . . 0.0 109.406 -179.946 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' -1' ' ' SER . . . . . 0.41 ' H2 ' ' H ' ' A' ' 0' ' ' GLU . 2.2 m . . . . . 0 N--CA 1.49 1.574 0 N-CA-C 109.462 -0.569 . . . . 0.0 109.462 . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 0' ' ' GLU . . . . . 0.41 ' H ' ' H2 ' ' A' ' -1' ' ' SER . 96.1 mt-10 -57.9 144.2 39.94 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.265 -0.897 . . . . 0.0 109.466 179.927 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 70.7 mtm -58.81 -34.92 72.06 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.259 -0.9 . . . . 0.0 109.776 179.984 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.451 ' C ' ' CG ' ' A' ' 3' ' ' HIS . 92.8 mt-30 56.27 49.54 15.05 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.26 -0.9 . . . . 0.0 109.123 -179.575 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.451 ' CG ' ' C ' ' A' ' 2' ' ' GLN . 16.9 m-70 74.37 56.36 0.08 Allowed 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.689 -0.632 . . . . 0.0 109.82 -179.912 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -59.74 -40.92 89.71 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.068 -1.02 . . . . 0.0 109.29 179.786 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.3 m -61.29 -39.17 89.44 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.256 -0.902 . . . . 0.0 109.65 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 58.8 t -61.13 -41.35 89.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.205 -0.935 . . . . 0.0 109.454 179.911 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 79.7 mt -59.69 -45.62 94.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 O-C-N 121.409 -0.807 . . . . 0.0 109.287 179.866 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -62.14 -42.78 99.58 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.291 -0.881 . . . . 0.0 109.109 179.723 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 26.8 mt-30 -64.7 -33.46 76.0 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.249 -0.907 . . . . 0.0 109.128 179.255 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.535 ' CG ' ' CZ2' ' A' ' 47' ' ' TRP . 0.2 OUTLIER -60.43 -50.27 74.24 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.4 -0.813 . . . . 0.0 110.235 -179.521 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 13.4 m -64.39 -39.59 86.08 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 O-C-N 121.142 -0.973 . . . . 0.0 109.33 -179.723 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.405 ' O ' ' C ' ' A' ' 16' ' ' LEU . 77.6 t -63.99 -45.29 97.18 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.166 -0.959 . . . . 0.0 109.678 179.654 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -69.4 -34.47 74.54 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.17 -0.956 . . . . 0.0 110.23 -179.842 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -65.35 -32.67 74.44 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.292 -0.88 . . . . 0.0 110.458 -179.253 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -118.47 -54.08 2.29 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.263 -0.898 . . . . 0.0 111.336 -178.713 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.405 ' C ' ' O ' ' A' ' 12' ' ' VAL . 9.0 mt -119.41 80.18 21.48 Favored Pre-proline 0 N--CA 1.493 1.688 0 O-C-N 121.19 -0.944 . . . . 0.0 111.054 -178.285 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -75.1 -16.41 20.0 Favored 'Trans proline' 0 C--N 1.309 -1.511 0 C-N-CA 122.274 1.982 . . . . 0.0 112.186 178.825 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -90.99 5.7 47.72 Favored 'General case' 0 N--CA 1.487 1.384 0 O-C-N 121.213 -0.929 . . . . 0.0 109.893 -179.844 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.425 ' CG1' ' OD2' ' A' ' 23' ' ' ASP . 44.5 t -112.84 138.37 42.42 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.456 -0.778 . . . . 0.0 109.492 -179.857 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . 0.487 ' O ' ' OD1' ' A' ' 23' ' ' ASP . . . -70.37 117.27 53.25 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.275 -0.89 . . . . 0.0 109.469 -179.831 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -51.8 -26.21 23.26 Favored 'Trans proline' 0 N--CA 1.494 1.512 0 C-N-CA 122.017 1.812 . . . . 0.0 112.229 179.505 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.63 -23.66 67.33 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.281 -0.887 . . . . 0.0 109.815 -179.744 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.487 ' OD1' ' O ' ' A' ' 20' ' ' ALA . 51.5 p30 -85.64 7.63 22.58 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.192 -0.942 . . . . 0.0 110.007 -179.428 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 11.8 t -107.88 130.07 60.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.147 -0.97 . . . . 0.0 109.329 179.927 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 87.2 m-20 -89.73 120.33 30.9 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.18 -0.95 . . . . 0.0 109.097 179.28 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 6.3 m -78.1 4.42 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 O-C-N 121.129 -0.982 . . . . 0.0 108.941 179.457 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -88.73 -10.63 47.67 Favored 'General case' 0 N--CA 1.485 1.302 0 O-C-N 121.386 -0.821 . . . . 0.0 109.043 179.408 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 42.4 tp -94.24 140.57 29.61 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 109.076 -0.713 . . . . 0.0 109.076 179.844 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 83.3 m-20 -59.08 142.0 52.58 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.133 -0.979 . . . . 0.0 109.433 -179.361 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.459 ' H ' ' HA ' ' A' ' 68' ' ' SER . 27.8 tp -73.57 -37.74 65.41 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.421 -0.799 . . . . 0.0 110.343 -179.251 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.419 ' CG2' ' N ' ' A' ' 32' ' ' ASP . 33.1 m -66.73 -43.15 90.2 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 121.263 -0.898 . . . . 0.0 110.428 -179.005 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . 0.419 ' N ' ' CG2' ' A' ' 31' ' ' VAL . 92.1 m-20 -53.94 -33.37 56.6 Favored 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 179.747 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 97.1 m-20 -70.47 -34.12 72.04 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.619 -0.676 . . . . 0.0 109.995 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 87.47 7.2 76.31 Favored Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.183 -1.567 . . . . 0.0 109.183 -179.656 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 72.6 t -61.64 -26.93 41.04 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 O-C-N 121.469 -1.018 . . . . 0.0 108.78 179.575 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 67.6 mt -93.05 123.87 45.28 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.398 0 O-C-N 121.457 -0.777 . . . . 0.0 109.929 -179.458 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -115.79 -174.87 2.61 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 108.636 -0.876 . . . . 0.0 108.636 179.339 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -61.36 -53.45 56.43 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.056 -1.028 . . . . 0.0 108.432 179.594 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.46 ' CD1' ' N ' ' A' ' 39' ' ' LEU . 7.0 mp -70.39 -32.65 70.39 Favored 'General case' 0 C--N 1.301 -1.532 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 178.008 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -59.23 -43.65 97.04 Favored Glycine 0 N--CA 1.482 1.755 0 N-CA-C 109.01 -1.636 . . . . 0.0 109.01 179.574 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.3 tt -65.13 -42.05 94.22 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.463 -1.022 . . . . 0.0 109.163 179.32 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.5 tp -59.97 -46.12 90.47 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.294 -0.879 . . . . 0.0 109.405 179.871 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 86.6 mttt -61.44 -35.7 78.31 Favored 'General case' 0 C--N 1.297 -1.701 0 O-C-N 121.443 -0.786 . . . . 0.0 109.854 -179.678 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 55.3 t -61.48 -50.75 79.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.287 -0.883 . . . . 0.0 110.36 -179.27 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 3.5 mp -68.72 -34.3 64.15 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 O-C-N 121.279 -0.888 . . . . 0.0 111.181 -179.636 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.56 -49.94 60.86 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 120.986 -1.071 . . . . 0.0 111.998 -177.913 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . 0.535 ' CZ2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -80.18 -43.62 21.23 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.655 -1.278 . . . . 0.0 110.036 -179.045 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.441 ' N ' ' CG ' ' A' ' 47' ' ' TRP . 21.7 tp -58.88 -41.63 87.56 Favored 'General case' 0 C--N 1.299 -1.606 0 O-C-N 121.294 -0.879 . . . . 0.0 110.197 -179.03 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.416 ' CG ' ' N ' ' A' ' 50' ' ' ASP . 17.3 pt-20 -73.18 -37.45 66.51 Favored 'General case' 0 C--N 1.305 -1.362 0 O-C-N 121.059 -1.026 . . . . 0.0 109.636 -179.708 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . 0.416 ' N ' ' CG ' ' A' ' 49' ' ' GLU . 56.9 t0 -58.86 -39.15 80.51 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.354 -0.841 . . . . 0.0 110.64 -179.447 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 73.4 mtp85 -61.64 -36.76 81.72 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.169 -0.957 . . . . 0.0 111.322 -178.86 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.613 ' CZ ' ' CG1' ' A' ' 76' ' ' VAL . 87.5 m-85 -94.77 -8.0 38.83 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 120.745 -1.222 . . . . 0.0 110.407 -179.129 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 73.15 29.29 64.77 Favored Glycine 0 N--CA 1.487 2.089 0 N-CA-C 108.95 -1.66 . . . . 0.0 108.95 179.712 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 20.5 pt -109.68 153.21 11.51 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 O-C-N 121.699 -0.883 . . . . 0.0 109.551 -179.587 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -103.92 134.99 46.28 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.238 -0.914 . . . . 0.0 109.7 -179.614 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.506 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -68.09 -28.39 67.31 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.334 -0.853 . . . . 0.0 109.63 179.732 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -56.36 -36.89 69.31 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.125 -0.984 . . . . 0.0 109.995 -179.625 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 21.4 t70 -56.53 -40.01 74.34 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.146 -0.971 . . . . 0.0 109.987 -179.538 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.506 ' O ' ' O ' ' A' ' 56' ' ' ALA . 42.6 t -128.67 136.21 60.44 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.311 -0.868 . . . . 0.0 109.726 -179.846 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -86.14 132.94 33.91 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.063 -1.023 . . . . 0.0 109.242 179.835 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 57.6 mt -96.12 140.81 30.3 Favored 'General case' 0 C--N 1.305 -1.336 0 O-C-N 121.219 -0.926 . . . . 0.0 109.742 -179.64 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -109.77 155.92 40.68 Favored Pre-proline 0 N--CA 1.487 1.418 0 N-CA-C 108.787 -0.82 . . . . 0.0 108.787 179.479 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 7.2 Cg_endo -52.59 -23.02 18.34 Favored 'Trans proline' 0 C--N 1.303 -1.831 0 C-N-CA 122.335 2.023 . . . . 0.0 111.926 -179.772 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -70.26 -26.95 64.06 Favored 'General case' 0 N--CA 1.486 1.37 0 O-C-N 121.339 -0.851 . . . . 0.0 109.472 179.592 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . 0.551 ' C ' ' CD2' ' A' ' 65' ' ' HIS . 1.5 t60 -65.65 -19.39 65.89 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.412 -0.805 . . . . 0.0 109.046 -179.883 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.563 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 7.0 m-85 -100.14 16.35 24.44 Favored 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.521 -0.737 . . . . 0.0 109.174 -179.686 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . 0.614 HH21 ' CD ' ' A' ' 87' ' ' LYS . 0.6 OUTLIER -53.24 -37.89 62.47 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.59 -0.694 . . . . 0.0 110.621 -179.452 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.459 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 51.8 p -167.91 166.53 13.35 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.653 -1.279 . . . . 0.0 110.699 -179.97 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 19.8 mm -58.89 -35.28 55.58 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.201 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 178.913 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 34.7 mtp180 -57.51 -43.96 84.66 Favored 'General case' 0 C--N 1.303 -1.455 0 CA-C-O 121.446 0.641 . . . . 0.0 109.468 -179.354 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 11.8 t -67.06 -39.41 86.89 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.368 -0.832 . . . . 0.0 109.953 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 76.9 mt -59.84 -50.1 81.35 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 O-C-N 121.265 -0.897 . . . . 0.0 110.074 -179.277 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 44.3 t0 -59.66 -42.78 93.58 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.13 -0.981 . . . . 0.0 109.04 -179.871 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.55 -42.21 87.5 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.535 -0.728 . . . . 0.0 109.756 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 60.0 t80 -63.58 -46.2 86.95 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.185 -0.947 . . . . 0.0 109.411 -179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.613 ' CG1' ' CZ ' ' A' ' 52' ' ' PHE . 54.6 t -60.89 -47.22 94.36 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.297 0 O-C-N 121.367 -0.833 . . . . 0.0 109.138 179.854 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 55.5 t -69.26 -42.38 81.43 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 O-C-N 121.213 -0.929 . . . . 0.0 109.107 179.338 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.493 ' O ' ' O ' ' A' ' 81' ' ' THR . . . -65.22 -28.27 73.36 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 -179.831 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.04 -38.67 86.27 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.153 -1.204 . . . . 0.0 110.299 -178.944 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 52.1 p -82.42 -31.33 29.6 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.111 -0.993 . . . . 0.0 109.539 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.493 ' O ' ' O ' ' A' ' 78' ' ' GLY . 0.3 OUTLIER -133.38 152.65 79.68 Favored Pre-proline 0 C--N 1.302 -1.464 0 O-C-N 121.51 -0.744 . . . . 0.0 109.605 -179.864 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 64.0 Cg_endo -76.25 111.49 3.28 Favored 'Trans proline' 0 N--CA 1.496 1.652 0 C-N-CA 122.474 2.116 . . . . 0.0 111.884 179.474 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -77.13 148.49 27.44 Favored 'Trans proline' 0 N--CA 1.49 1.3 0 C-N-CA 122.079 1.852 . . . . 0.0 113.112 -179.606 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.597 ' O ' ' N ' ' A' ' 86' ' ' ALA . 42.3 t -104.44 121.93 56.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.528 -0.733 . . . . 0.0 109.069 178.894 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.504 ' C ' ' O ' ' A' ' 84' ' ' VAL . 96.1 mt-10 32.62 31.42 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.735 -0.603 . . . . 0.0 110.383 179.693 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . 0.597 ' N ' ' O ' ' A' ' 84' ' ' VAL . . . -69.75 139.16 53.28 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.047 -1.033 . . . . 0.0 110.159 -179.419 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.614 ' CD ' HH21 ' A' ' 67' ' ' ARG . 43.4 tttp 42.15 53.2 4.39 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.452 -0.78 . . . . 0.0 109.599 179.436 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . 0.4 ' C ' ' O ' ' A' ' 87' ' ' LYS . 7.7 mp 45.31 86.48 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.195 -0.94 . . . . 0.0 109.487 -179.951 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 59.2 tp60 . . . . . 0 N--CA 1.49 1.575 0 CA-C-O 118.009 -0.996 . . . . 0.0 109.464 179.979 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' -1' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.49 1.543 0 CA-C-O 121.299 0.571 . . . . 0.0 109.492 . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 0' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -57.93 145.03 37.14 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.211 -0.931 . . . . 0.0 109.504 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 74.5 mtp -105.48 -119.66 0.22 Allowed 'General case' 0 C--N 1.305 -1.346 0 O-C-N 121.295 -0.878 . . . . 0.0 108.794 179.897 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.422 ' O ' ' C ' ' A' ' 3' ' ' HIS . 97.5 mm-40 -119.87 113.75 21.05 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 178.665 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.422 ' C ' ' O ' ' A' ' 2' ' ' GLN . 62.1 m80 46.65 31.17 1.3 Allowed 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 108.114 -1.069 . . . . 0.0 108.114 -178.913 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -57.25 -39.48 75.69 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.518 -0.739 . . . . 0.0 109.798 -179.33 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.1 p -63.04 -33.7 75.98 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.146 -0.971 . . . . 0.0 109.491 -179.895 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 75.9 t -65.9 -43.49 92.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.222 -0.924 . . . . 0.0 109.539 179.87 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 82.6 mt -59.59 -47.3 91.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.4 -0.812 . . . . 0.0 109.845 -179.859 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.507 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -63.26 -45.13 92.94 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.28 -0.888 . . . . 0.0 110.924 -179.181 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 53.9 mt-30 -69.09 -46.65 67.21 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.835 -1.165 . . . . 0.0 110.854 -178.723 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.549 ' C ' ' CD1' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -70.28 -48.75 55.31 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.075 -1.016 . . . . 0.0 110.298 -179.392 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.452 ' CG1' ' N ' ' A' ' 12' ' ' VAL . 4.0 p -59.88 -38.81 77.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.072 -1.017 . . . . 0.0 109.678 -179.604 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.507 ' CG2' ' O ' ' A' ' 8' ' ' ALA . 49.5 t -63.18 -43.22 98.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.224 -0.922 . . . . 0.0 109.963 -179.928 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -63.13 -34.51 77.76 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.104 -0.997 . . . . 0.0 109.941 -179.812 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -65.43 -31.74 72.99 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.269 -0.894 . . . . 0.0 110.197 -179.649 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 77.4 t80 -113.65 -61.4 1.75 Allowed 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.326 -0.859 . . . . 0.0 111.299 -178.818 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 4.8 mt -116.08 80.19 9.06 Favored Pre-proline 0 N--CA 1.494 1.726 0 O-C-N 121.219 -0.926 . . . . 0.0 111.017 -178.354 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_endo -74.64 -14.55 22.03 Favored 'Trans proline' 0 C--N 1.31 -1.5 0 C-N-CA 122.311 2.008 . . . . 0.0 112.156 178.848 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -84.93 0.84 49.83 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.286 -0.883 . . . . 0.0 109.601 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 42.3 t -115.36 134.93 56.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 121.43 -0.794 . . . . 0.0 109.568 -179.908 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.34 117.84 60.52 Favored Pre-proline 0 N--CA 1.489 1.486 0 O-C-N 121.183 -0.948 . . . . 0.0 109.405 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_exo -51.44 -30.06 33.54 Favored 'Trans proline' 0 N--CA 1.493 1.464 0 C-N-CA 121.757 1.638 . . . . 0.0 112.064 179.614 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.8 -25.12 67.78 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.239 -0.913 . . . . 0.0 109.291 179.769 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -81.88 4.45 22.38 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.368 -0.833 . . . . 0.0 109.777 -179.755 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 10.5 t -107.79 128.91 62.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.216 -0.927 . . . . 0.0 109.485 -179.923 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.408 ' C ' ' H ' ' A' ' 27' ' ' ASP . 88.1 m-20 -89.7 120.72 31.22 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.239 -0.913 . . . . 0.0 109.078 179.213 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 28.9 m -70.9 3.89 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 O-C-N 121.11 -0.993 . . . . 0.0 109.123 179.598 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.408 ' H ' ' C ' ' A' ' 25' ' ' ASP . 91.9 m-20 -94.25 -5.24 47.29 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.363 -0.836 . . . . 0.0 109.154 179.466 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 42.0 tp -95.32 138.14 33.42 Favored 'General case' 0 C--N 1.303 -1.421 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 179.599 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -57.2 135.62 56.42 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.068 -1.02 . . . . 0.0 109.354 -179.269 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.486 ' H ' ' HA ' ' A' ' 68' ' ' SER . 39.4 tp -64.59 -37.48 87.71 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.595 -0.69 . . . . 0.0 110.467 -179.336 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 70.2 t -66.2 -37.24 79.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.022 -1.049 . . . . 0.0 110.708 -179.15 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -52.93 -33.05 48.94 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 120.956 -1.09 . . . . 0.0 108.254 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 98.4 m-20 -70.68 -34.33 71.86 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.631 -0.668 . . . . 0.0 109.946 179.457 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 86.6 5.26 82.07 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 108.824 -1.71 . . . . 0.0 108.824 -179.245 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 76.2 t -61.1 -32.69 53.41 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 O-C-N 121.582 -0.952 . . . . 0.0 108.924 179.637 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 80.7 mt -83.82 116.26 27.44 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.403 -0.811 . . . . 0.0 109.843 -179.872 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -114.99 -176.08 2.83 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 179.406 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -58.95 -53.38 59.08 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.021 -1.049 . . . . 0.0 108.205 179.601 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 35.8 mt -68.57 -32.44 72.36 Favored 'General case' 0 C--N 1.301 -1.528 0 N-CA-C 106.887 -1.523 . . . . 0.0 106.887 177.868 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -58.97 -40.93 96.05 Favored Glycine 0 N--CA 1.48 1.594 0 N-CA-C 108.718 -1.753 . . . . 0.0 108.718 179.274 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.3 tt -65.21 -41.61 94.31 Favored 'General case' 0 C--N 1.305 -1.34 0 O-C-N 121.386 -1.067 . . . . 0.0 108.693 178.893 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 tp -60.17 -45.72 92.14 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 179.322 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 21.0 mttp -60.71 -35.48 76.42 Favored 'General case' 0 C--N 1.298 -1.663 0 O-C-N 121.551 -0.718 . . . . 0.0 109.522 -179.935 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 53.3 t -59.81 -50.59 79.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.325 -0.859 . . . . 0.0 109.469 -179.657 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.425 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 3.5 mp -68.33 -30.36 47.4 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 O-C-N 121.256 -0.903 . . . . 0.0 110.459 179.704 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.84 -49.2 71.53 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.107 -0.996 . . . . 0.0 111.306 -178.473 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . 0.498 ' C ' ' CD1' ' A' ' 47' ' ' TRP . 0.0 OUTLIER -81.39 -43.23 19.28 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.759 -1.213 . . . . 0.0 110.032 -179.384 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.43 ' N ' ' CG ' ' A' ' 47' ' ' TRP . 0.4 OUTLIER -58.75 -43.19 90.22 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.118 -0.989 . . . . 0.0 109.113 -179.328 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.548 ' O ' ' N ' ' A' ' 53' ' ' GLY . 2.1 pp20? -72.18 -35.62 69.02 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.054 -1.029 . . . . 0.0 109.8 179.905 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.2 t0 -60.44 -38.42 84.09 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.247 -0.908 . . . . 0.0 110.567 -179.641 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 49.9 mtp180 -60.47 -40.73 92.29 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.131 -0.981 . . . . 0.0 111.189 -178.873 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 73.4 m-85 -106.49 -11.92 15.77 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.974 -1.078 . . . . 0.0 110.041 -179.358 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . 0.548 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 70.16 30.16 69.89 Favored Glycine 0 N--CA 1.485 1.939 0 N-CA-C 109.072 -1.611 . . . . 0.0 109.072 179.5 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 12.7 pt -93.57 124.31 45.97 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 O-C-N 121.358 -1.084 . . . . 0.0 109.623 -179.604 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -65.59 140.23 58.51 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.154 -0.966 . . . . 0.0 109.817 -179.535 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.503 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -65.45 -31.86 73.17 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.429 -0.794 . . . . 0.0 109.398 179.805 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -58.46 -37.36 75.3 Favored 'General case' 0 C--N 1.303 -1.45 0 O-C-N 121.183 -0.948 . . . . 0.0 109.952 -179.815 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -58.28 -40.11 81.04 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.225 -0.922 . . . . 0.0 109.964 -179.636 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.503 ' O ' ' O ' ' A' ' 56' ' ' ALA . 42.4 t -127.12 133.67 67.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.311 -0.868 . . . . 0.0 109.555 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -89.26 129.73 35.78 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.044 -1.035 . . . . 0.0 109.336 179.803 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . 0.581 ' CD2' ' N ' ' A' ' 61' ' ' LEU . 3.5 mm? -95.9 134.15 39.23 Favored 'General case' 0 C--N 1.305 -1.347 0 O-C-N 121.322 -0.861 . . . . 0.0 109.726 -179.821 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.56 ' HG ' ' N ' ' A' ' 63' ' ' PRO . 0.1 OUTLIER -109.96 156.35 40.11 Favored Pre-proline 0 N--CA 1.487 1.382 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 179.582 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . 0.56 ' N ' ' HG ' ' A' ' 62' ' ' SER . 9.5 Cg_endo -54.22 -22.88 27.56 Favored 'Trans proline' 0 C--N 1.302 -1.902 0 C-N-CA 122.295 1.997 . . . . 0.0 111.68 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . 0.446 ' H ' ' HG ' ' A' ' 62' ' ' SER . 96.5 mt-10 -69.96 -27.36 64.67 Favored 'General case' 0 N--CA 1.485 1.308 0 O-C-N 121.297 -0.877 . . . . 0.0 109.355 179.63 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . 0.545 ' C ' ' CD2' ' A' ' 65' ' ' HIS . 1.7 t60 -65.65 -19.94 66.11 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.307 -0.87 . . . . 0.0 109.003 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.55 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 7.9 m-85 -98.43 15.78 23.75 Favored 'General case' 0 C--N 1.299 -1.622 0 CA-C-O 121.601 0.715 . . . . 0.0 109.076 -179.765 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . 0.646 HH21 ' CD ' ' A' ' 87' ' ' LYS . 1.4 ptt85 -53.66 -36.6 62.29 Favored 'General case' 0 C--N 1.299 -1.61 0 O-C-N 121.679 -0.638 . . . . 0.0 110.55 -179.378 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.486 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 41.6 t -168.07 161.23 12.51 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.754 -1.216 . . . . 0.0 110.364 -179.787 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 2.4 mp -57.69 -34.15 46.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 179.026 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 52.0 mtp85 -56.65 -41.71 77.68 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 109.081 -0.711 . . . . 0.0 109.081 -179.897 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.533 ' HG ' ' N ' ' A' ' 72' ' ' ILE . 61.6 p -67.92 -32.98 73.81 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.444 -0.785 . . . . 0.0 109.596 -179.972 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.533 ' N ' ' HG ' ' A' ' 71' ' ' SER . 56.5 mt -61.45 -50.6 79.69 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.361 0 O-C-N 121.294 -0.879 . . . . 0.0 109.567 -179.578 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 43.4 t0 -61.41 -41.44 97.16 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.216 -0.927 . . . . 0.0 108.894 179.655 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.21 -37.55 85.84 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.56 -0.712 . . . . 0.0 109.873 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 67.2 t80 -61.48 -46.5 89.78 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.167 -0.958 . . . . 0.0 109.64 -179.772 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 41.9 t -61.36 -47.76 91.99 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 O-C-N 121.268 -0.895 . . . . 0.0 109.358 179.692 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . 0.457 ' O ' ' N ' ' A' ' 81' ' ' THR . 47.3 t -69.0 -43.42 82.02 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 O-C-N 121.399 -0.813 . . . . 0.0 109.762 179.855 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -63.28 -40.73 99.33 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 110.284 -1.126 . . . . 0.0 110.284 -179.571 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -70.57 -41.62 72.18 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.229 -1.16 . . . . 0.0 110.833 -178.989 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 69.5 p -86.52 -31.15 21.44 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 120.906 -1.121 . . . . 0.0 109.955 -179.341 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.457 ' N ' ' O ' ' A' ' 77' ' ' VAL . 0.2 OUTLIER -133.0 153.58 81.02 Favored Pre-proline 0 C--N 1.302 -1.496 0 O-C-N 121.466 -0.771 . . . . 0.0 109.376 -179.752 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo -43.57 155.18 0.18 Allowed 'Trans proline' 0 C--N 1.308 -1.567 0 C-N-CA 122.04 1.827 . . . . 0.0 111.496 179.644 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_endo -57.7 145.3 90.43 Favored 'Trans proline' 0 C--N 1.307 -1.632 0 C-N-CA 122.4 2.067 . . . . 0.0 112.446 -179.689 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.59 ' O ' ' N ' ' A' ' 86' ' ' ALA . 44.1 t -103.55 129.93 54.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.442 -0.786 . . . . 0.0 109.545 179.878 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.461 ' C ' ' O ' ' A' ' 84' ' ' VAL . 96.1 mt-10 38.58 23.39 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.551 -0.718 . . . . 0.0 110.005 179.729 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . 0.59 ' N ' ' O ' ' A' ' 84' ' ' VAL . . . 39.77 90.4 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.379 -0.826 . . . . 0.0 109.646 -179.826 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.646 ' CD ' HH21 ' A' ' 67' ' ' ARG . 13.4 tttm -57.74 -38.82 76.01 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.301 -0.875 . . . . 0.0 109.49 -179.927 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 69.2 mt -60.45 -35.3 75.52 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.234 -0.916 . . . . 0.0 109.51 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.2 mt-30 . . . . . 0 N--CA 1.49 1.563 0 CA-C-O 118.044 -0.979 . . . . 0.0 109.405 -179.973 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' -1' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.491 1.586 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 0' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -61.66 -33.43 73.97 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.293 -0.88 . . . . 0.0 109.488 -179.951 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.485 ' O ' ' OD2' ' A' ' 73' ' ' ASP . 64.8 mtt -60.03 -36.22 76.8 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.251 -0.906 . . . . 0.0 109.874 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.579 ' O ' ' ND1' ' A' ' 3' ' ' HIS . 25.0 mt-30 56.08 48.05 18.42 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.329 -0.857 . . . . 0.0 109.034 -179.391 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . 0.579 ' ND1' ' O ' ' A' ' 2' ' ' GLN . 6.7 m80 76.85 52.73 0.04 OUTLIER 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.678 -0.639 . . . . 0.0 110.091 179.937 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -61.78 -41.71 98.06 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 120.981 -1.074 . . . . 0.0 109.173 179.685 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.4 m -60.97 -37.5 82.64 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.434 -0.791 . . . . 0.0 109.895 -179.801 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 49.6 t -60.33 -44.13 95.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.174 -0.954 . . . . 0.0 109.496 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 78.6 mt -59.5 -50.18 80.87 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 O-C-N 121.397 -0.815 . . . . 0.0 109.641 -179.799 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . 0.451 ' O ' ' CG2' ' A' ' 12' ' ' VAL . . . -63.96 -43.82 94.62 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.315 -0.866 . . . . 0.0 110.918 -179.569 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 27.2 mt-30 -69.08 -46.08 68.67 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 120.92 -1.112 . . . . 0.0 111.435 -178.446 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.711 ' CD1' ' N ' ' A' ' 11' ' ' VAL . 0.0 OUTLIER -70.42 -46.71 63.4 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.884 -1.135 . . . . 0.0 110.492 -179.177 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . 0.711 ' N ' ' CD1' ' A' ' 10' ' ' PHE . 4.8 p -62.03 -40.33 86.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.085 -1.01 . . . . 0.0 109.807 -179.523 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.468 ' N ' ' CG1' ' A' ' 11' ' ' VAL . 55.8 t -63.28 -43.54 98.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.173 -0.955 . . . . 0.0 109.866 179.998 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -65.82 -37.3 85.86 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.214 -0.929 . . . . 0.0 110.278 -179.536 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 85.7 tt0 -65.76 -39.58 91.2 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.159 -0.963 . . . . 0.0 110.116 -179.558 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . 0.427 ' CD2' ' CG1' ' A' ' 35' ' ' VAL . 75.6 t80 -93.77 -50.72 5.23 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.174 -0.954 . . . . 0.0 110.783 -179.218 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.408 ' N ' ' O ' ' A' ' 12' ' ' VAL . 5.4 mt -120.26 80.59 28.64 Favored Pre-proline 0 N--CA 1.491 1.622 0 O-C-N 121.285 -0.884 . . . . 0.0 110.525 -178.776 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 23.5 Cg_endo -69.05 -14.52 38.49 Favored 'Trans proline' 0 N--CA 1.493 1.451 0 C-N-CA 122.095 1.863 . . . . 0.0 112.353 179.614 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -94.92 7.1 47.12 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.179 -0.95 . . . . 0.0 110.387 -179.613 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 39.3 t -119.11 136.33 56.65 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 121.271 -0.893 . . . . 0.0 109.788 -179.779 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -78.53 117.96 69.49 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.301 -0.874 . . . . 0.0 109.081 179.608 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_exo -51.76 -27.77 27.96 Favored 'Trans proline' 0 N--CA 1.493 1.478 0 C-N-CA 121.787 1.658 . . . . 0.0 112.23 179.855 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.52 -27.01 68.67 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.203 -0.936 . . . . 0.0 109.305 -179.946 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.452 ' O ' ' OD1' ' A' ' 23' ' ' ASP . 60.0 t0 -82.19 3.55 26.87 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.303 -0.873 . . . . 0.0 109.7 -179.778 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 9.7 t -109.43 128.33 65.51 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.263 -0.898 . . . . 0.0 109.561 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . 0.433 ' C ' ' H ' ' A' ' 27' ' ' ASP . 87.2 m-20 -89.96 120.56 31.28 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.189 -0.945 . . . . 0.0 109.097 179.06 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 33.7 m -70.93 4.14 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.378 0 O-C-N 121.102 -0.999 . . . . 0.0 108.941 179.47 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.433 ' H ' ' C ' ' A' ' 25' ' ' ASP . 92.2 m-20 -92.13 -5.45 52.66 Favored 'General case' 0 N--CA 1.486 1.341 0 O-C-N 121.373 -0.829 . . . . 0.0 109.031 179.423 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 44.3 tp -96.52 141.1 30.21 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.473 -0.767 . . . . 0.0 108.957 179.86 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -58.59 128.57 37.86 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.176 -0.952 . . . . 0.0 109.504 -179.407 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.416 ' H ' ' HA ' ' A' ' 68' ' ' SER . 48.7 tp -66.85 -37.23 84.07 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.551 -0.718 . . . . 0.0 110.648 -179.417 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 70.6 t -63.67 -35.96 74.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 120.928 -1.107 . . . . 0.0 110.693 -178.911 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 56.3 t0 -52.43 -33.59 44.68 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 120.974 -1.079 . . . . 0.0 108.186 -179.908 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 97.5 m-20 -71.46 -34.45 70.23 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.698 -0.626 . . . . 0.0 110.232 179.476 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 87.22 4.87 80.74 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 108.58 -1.808 . . . . 0.0 108.58 -179.043 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . 0.427 ' CG1' ' CD2' ' A' ' 15' ' ' PHE . 67.8 t -59.87 -29.55 43.39 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 O-C-N 121.484 -1.009 . . . . 0.0 108.412 179.254 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 71.8 mt -88.07 132.5 33.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 CA-C-O 121.616 0.722 . . . . 0.0 109.627 -179.897 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.587 ' CG ' ' H ' ' A' ' 38' ' ' ALA . 45.7 t0 -139.07 -160.81 1.1 Allowed 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 179.845 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.587 ' H ' ' CG ' ' A' ' 37' ' ' ASP . . . -65.48 -54.31 30.19 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.117 -0.99 . . . . 0.0 108.716 179.817 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.464 ' CD1' ' N ' ' A' ' 39' ' ' LEU . 7.0 mp -69.63 -32.81 71.72 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 107.35 -1.352 . . . . 0.0 107.35 178.405 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -59.26 -44.06 96.77 Favored Glycine 0 N--CA 1.481 1.663 0 N-CA-C 109.008 -1.637 . . . . 0.0 109.008 179.545 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 2.8 tt -65.12 -42.06 94.28 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.473 -1.016 . . . . 0.0 109.369 179.168 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 15.8 tp -59.74 -44.69 93.67 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.227 -0.921 . . . . 0.0 109.339 179.857 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 18.8 mttt -62.2 -34.29 76.18 Favored 'General case' 0 C--N 1.299 -1.589 0 O-C-N 121.156 -0.965 . . . . 0.0 109.62 179.874 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 54.0 t -60.75 -50.18 81.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.27 -0.894 . . . . 0.0 110.06 -179.488 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.525 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 3.6 mp -68.48 -34.63 66.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.247 -0.908 . . . . 0.0 111.257 -179.669 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.81 -50.16 65.65 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 120.943 -1.098 . . . . 0.0 111.758 -177.867 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . 0.652 ' HE1' ' NE ' ' A' ' 51' ' ' ARG . 0.0 OUTLIER -80.05 -43.8 21.22 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.75 -1.219 . . . . 0.0 109.78 -179.457 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.552 ' CD1' HH21 ' A' ' 51' ' ' ARG . 15.0 tp -58.73 -43.16 90.1 Favored 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.382 -0.824 . . . . 0.0 110.12 -179.12 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.525 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 1.2 pp20? -72.67 -35.85 67.78 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.135 -0.978 . . . . 0.0 109.905 -179.762 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.1 t70 -61.51 -39.72 92.02 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.226 -0.921 . . . . 0.0 111.16 -179.317 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . 0.652 ' NE ' ' HE1' ' A' ' 47' ' ' TRP . 70.5 mtm180 -62.65 -36.8 83.99 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.19 -0.944 . . . . 0.0 112.028 -178.291 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . . . . . . . . . 88.5 m-85 -95.96 -6.13 39.73 Favored 'General case' 0 N--CA 1.487 1.389 0 O-C-N 120.714 -1.242 . . . . 0.0 110.454 -178.718 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 70.33 29.39 70.21 Favored Glycine 0 N--CA 1.486 1.979 0 N-CA-C 108.882 -1.687 . . . . 0.0 108.882 179.349 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.488 ' O ' ' OE1' ' A' ' 49' ' ' GLU . 24.7 pt -107.28 152.38 8.87 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 O-C-N 121.557 -0.966 . . . . 0.0 109.559 -179.571 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -105.23 154.51 20.12 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.36 -0.837 . . . . 0.0 109.721 -179.472 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.416 ' O ' ' CG1' ' A' ' 59' ' ' VAL . . . -59.8 -21.19 60.5 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.339 -0.85 . . . . 0.0 109.177 179.904 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 56.3 t0 61.95 36.6 15.6 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 121.526 -0.734 . . . . 0.0 109.328 -179.789 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 53.32 48.61 21.61 Favored 'General case' 0 C--N 1.305 -1.366 0 O-C-N 121.439 -0.788 . . . . 0.0 110.357 178.941 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.416 ' CG1' ' O ' ' A' ' 56' ' ' ALA . 8.8 p -127.86 142.87 42.53 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.364 -0.835 . . . . 0.0 109.105 179.593 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -99.19 133.5 43.39 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.177 -0.952 . . . . 0.0 109.628 -179.792 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 59.3 mt -92.52 145.38 24.49 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.43 -0.794 . . . . 0.0 109.248 179.92 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -91.71 150.73 41.42 Favored Pre-proline 0 C--N 1.305 -1.34 0 O-C-N 121.14 -0.975 . . . . 0.0 108.765 179.8 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 11.4 Cg_endo -57.23 -19.82 36.06 Favored 'Trans proline' 0 C--N 1.304 -1.81 0 C-N-CA 122.335 2.023 . . . . 0.0 112.035 -179.67 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -67.96 -31.62 71.47 Favored 'General case' 0 N--CA 1.484 1.243 0 O-C-N 121.285 -0.885 . . . . 0.0 109.453 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . 0.586 ' CD2' ' O ' ' A' ' 65' ' ' HIS . 5.2 t-160 -66.04 -20.54 66.21 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.347 -0.846 . . . . 0.0 108.737 179.787 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.526 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 8.5 m-85 -94.63 14.65 20.37 Favored 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 -179.915 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . 0.587 ' NE ' ' OG ' ' A' ' 71' ' ' SER . 6.4 ptt180 -46.47 -37.65 8.09 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.739 -0.601 . . . . 0.0 110.381 -179.59 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.416 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 46.7 t -159.71 155.05 25.33 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.933 -1.104 . . . . 0.0 110.06 -179.764 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.476 ' CD1' ' H ' ' A' ' 69' ' ' ILE . 1.6 mp -57.69 -41.75 80.1 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 O-C-N 121.29 -0.881 . . . . 0.0 109.142 179.931 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 11.1 ptm180 -58.33 -42.05 85.93 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.406 -0.809 . . . . 0.0 109.1 179.795 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.587 ' OG ' ' NE ' ' A' ' 67' ' ' ARG . 26.4 t -62.97 -40.9 99.13 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.333 -0.854 . . . . 0.0 109.359 179.471 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.422 ' HA ' ' HE2' ' A' ' 65' ' ' HIS . 86.1 mt -60.12 -49.78 82.77 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 O-C-N 121.218 -0.926 . . . . 0.0 109.437 179.928 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.485 ' OD2' ' O ' ' A' ' 1' ' ' MET . 37.2 t0 -59.53 -40.6 87.71 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.366 -0.834 . . . . 0.0 109.013 179.695 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.45 -37.76 85.87 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.637 -0.665 . . . . 0.0 110.153 -179.882 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . 0.554 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 64.4 t80 -60.73 -47.77 84.78 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.145 -0.972 . . . . 0.0 109.836 -179.413 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . . . . . . . . . 98.5 t -62.47 -46.3 96.74 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.294 0 O-C-N 121.064 -1.023 . . . . 0.0 109.18 179.809 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 78.8 t -66.9 -40.24 85.31 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.389 0 O-C-N 121.472 -0.768 . . . . 0.0 109.217 179.641 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.489 ' O ' ' O ' ' A' ' 81' ' ' THR . . . -59.46 -38.57 93.72 Favored Glycine 0 N--CA 1.488 2.127 0 N-CA-C 109.913 -1.275 . . . . 0.0 109.913 -179.781 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -69.15 -41.31 77.45 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.335 -1.097 . . . . 0.0 110.489 -179.3 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 44.9 p -81.81 -31.08 31.94 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.068 -1.02 . . . . 0.0 109.449 -179.781 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.489 ' O ' ' O ' ' A' ' 78' ' ' GLY . 0.5 OUTLIER -133.01 153.9 81.14 Favored Pre-proline 0 C--N 1.3 -1.558 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 -179.869 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -63.6 136.77 55.87 Favored 'Trans proline' 0 C--N 1.306 -1.703 0 C-N-CA 122.132 1.888 . . . . 0.0 111.411 179.909 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -65.56 147.22 86.34 Favored 'Trans proline' 0 N--CA 1.492 1.416 0 C-N-CA 121.974 1.783 . . . . 0.0 112.671 -179.465 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.61 ' O ' ' N ' ' A' ' 86' ' ' ALA . 42.4 t -103.8 126.68 58.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.491 -0.756 . . . . 0.0 109.459 179.586 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.499 ' O ' ' O ' ' A' ' 86' ' ' ALA . 96.1 mt-10 38.2 22.53 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.615 -0.678 . . . . 0.0 110.237 179.61 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . 0.61 ' N ' ' O ' ' A' ' 84' ' ' VAL . . . 50.28 174.69 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.186 -0.946 . . . . 0.0 109.692 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.414 ' HD2' HH21 ' A' ' 67' ' ' ARG . 31.0 tttm -59.38 -37.95 79.26 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.195 -0.941 . . . . 0.0 109.517 179.927 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . 0.449 ' O ' ' OXT' ' A' ' 89' ' ' GLN . 52.8 mt -94.38 142.14 27.77 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.314 -0.866 . . . . 0.0 109.506 -179.905 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . 0.449 ' OXT' ' O ' ' A' ' 88' ' ' LEU . 94.1 mt-30 . . . . . 0 N--CA 1.491 1.58 0 CA-C-O 117.985 -1.007 . . . . 0.0 109.439 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' -1' ' ' SER . . . . . . . . . . . . . 59.6 p . . . . . 0 N--CA 1.489 1.525 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 0' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -108.71 155.23 20.96 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.422 -0.799 . . . . 0.0 109.5 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.402 ' H ' ' HB1' ' A' ' 4' ' ' ALA . 79.9 mtp -102.99 -122.31 0.19 Allowed 'General case' 0 C--N 1.304 -1.4 0 O-C-N 121.225 -0.922 . . . . 0.0 108.98 -179.893 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 98.8 mm-40 -105.24 -69.42 0.82 Allowed 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 179.153 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 97.1 m-70 -102.76 16.64 25.93 Favored 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 178.725 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.402 ' HB1' ' H ' ' A' ' 1' ' ' MET . . . -54.37 -42.64 70.56 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.524 -0.735 . . . . 0.0 109.836 -179.181 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 24.2 m -62.11 -38.08 87.55 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.28 -0.887 . . . . 0.0 109.868 -179.84 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 53.7 t -64.19 -45.44 96.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.165 -0.959 . . . . 0.0 109.781 -179.777 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 79.4 mt -59.77 -42.43 88.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.386 -0.821 . . . . 0.0 109.279 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -60.51 -36.93 79.55 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.374 -0.828 . . . . 0.0 109.18 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 7.3 tt0 -65.28 -40.23 93.6 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.271 -0.893 . . . . 0.0 110.077 179.924 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.677 ' CG ' ' CZ2' ' A' ' 47' ' ' TRP . 20.7 m-85 -62.01 -50.04 73.63 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.102 -0.999 . . . . 0.0 110.676 -179.426 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 22.2 m -64.08 -40.48 89.19 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 O-C-N 121.06 -1.025 . . . . 0.0 109.302 -179.629 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.446 ' O ' ' C ' ' A' ' 16' ' ' LEU . 69.0 t -63.66 -46.52 94.51 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.206 -0.934 . . . . 0.0 109.309 179.571 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -70.12 -29.39 66.32 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.305 -0.872 . . . . 0.0 109.895 179.818 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -64.82 -30.42 71.42 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.48 -0.762 . . . . 0.0 110.615 -179.094 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 75.9 t80 -131.89 -46.06 0.95 Allowed 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.083 -1.01 . . . . 0.0 111.125 -178.97 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.446 ' C ' ' O ' ' A' ' 12' ' ' VAL . 4.7 mt -117.98 80.16 14.55 Favored Pre-proline 0 N--CA 1.494 1.755 0 O-C-N 121.097 -1.002 . . . . 0.0 110.442 -178.994 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -76.15 -14.26 18.8 Favored 'Trans proline' 0 C--N 1.308 -1.604 0 C-N-CA 122.411 2.074 . . . . 0.0 112.255 179.324 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -89.08 5.19 45.63 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.279 -0.888 . . . . 0.0 109.761 -179.928 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . 0.411 ' CG1' ' OD2' ' A' ' 23' ' ' ASP . 45.1 t -112.64 135.33 52.38 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.378 -0.826 . . . . 0.0 109.59 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . 0.435 ' O ' ' CG ' ' A' ' 23' ' ' ASP . . . -73.18 117.52 60.83 Favored Pre-proline 0 N--CA 1.489 1.52 0 O-C-N 121.26 -0.9 . . . . 0.0 109.443 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_exo -51.98 -25.14 21.18 Favored 'Trans proline' 0 N--CA 1.493 1.5 0 C-N-CA 121.805 1.67 . . . . 0.0 112.039 179.486 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.72 -22.92 67.09 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.29 -0.881 . . . . 0.0 109.708 -179.828 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.45 ' C ' ' OD1' ' A' ' 23' ' ' ASP . 52.3 p30 -83.98 7.62 17.81 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.249 -0.907 . . . . 0.0 109.831 -179.74 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 11.8 t -104.97 133.57 48.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.218 -0.926 . . . . 0.0 109.348 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 86.5 m-20 -88.89 120.61 30.46 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.054 -1.029 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 17.0 m -74.96 3.83 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 O-C-N 121.26 -0.9 . . . . 0.0 109.386 179.849 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . 0.449 ' C ' ' OD1' ' A' ' 27' ' ' ASP . 52.0 p30 -94.95 1.12 55.2 Favored 'General case' 0 N--CA 1.486 1.349 0 O-C-N 121.245 -0.909 . . . . 0.0 109.227 179.454 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 46.0 tp -100.44 134.61 43.12 Favored 'General case' 0 C--N 1.303 -1.437 0 N-CA-C 108.358 -0.978 . . . . 0.0 108.358 179.313 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -57.72 126.71 28.56 Favored 'General case' 0 C--N 1.3 -1.546 0 C-N-CA 118.942 -1.103 . . . . 0.0 108.998 -179.335 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.47 ' H ' ' HA ' ' A' ' 68' ' ' SER . 43.0 tp -66.08 -37.97 87.11 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.654 -0.654 . . . . 0.0 110.654 -179.153 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 54.1 t -67.43 -37.47 78.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 120.931 -1.106 . . . . 0.0 110.774 -179.155 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 84.4 m-20 -52.69 -33.17 46.25 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 120.859 -1.151 . . . . 0.0 108.111 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 20.3 m120 -70.72 -33.48 70.9 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.639 -0.663 . . . . 0.0 109.784 179.325 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 91.65 5.56 66.62 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 108.879 -1.688 . . . . 0.0 108.879 -179.304 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 74.4 t -61.44 -32.99 54.92 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 O-C-N 121.498 -1.001 . . . . 0.0 109.209 179.793 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 72.6 mt -92.31 121.13 42.62 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.396 0 O-C-N 121.302 -0.874 . . . . 0.0 109.651 -179.726 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -120.42 -169.5 1.82 Allowed 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 109.076 -0.713 . . . . 0.0 109.076 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -63.46 -54.24 39.65 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.221 -0.924 . . . . 0.0 108.615 179.702 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.468 ' CD1' ' N ' ' A' ' 39' ' ' LEU . 7.0 mp -70.78 -33.47 70.79 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 107.193 -1.41 . . . . 0.0 107.193 178.148 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -59.49 -43.12 97.79 Favored Glycine 0 N--CA 1.483 1.813 0 N-CA-C 108.809 -1.716 . . . . 0.0 108.809 179.388 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 6.6 tt -64.73 -41.63 95.81 Favored 'General case' 0 C--N 1.304 -1.374 0 O-C-N 121.384 -1.068 . . . . 0.0 109.066 179.286 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.4 tp -59.73 -45.93 90.68 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.222 -0.924 . . . . 0.0 109.044 179.705 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 56.6 mttt -60.97 -34.75 75.25 Favored 'General case' 0 C--N 1.297 -1.717 0 O-C-N 121.492 -0.755 . . . . 0.0 109.671 -179.812 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 54.3 t -61.85 -49.87 82.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.366 -0.834 . . . . 0.0 110.162 -179.401 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.547 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 3.4 mp -67.89 -32.9 58.38 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 O-C-N 121.206 -0.934 . . . . 0.0 110.678 -179.621 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.7 -50.29 67.55 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.861 -1.15 . . . . 0.0 111.13 -178.302 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . 0.677 ' CZ2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -81.28 -44.84 17.11 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.758 -1.214 . . . . 0.0 109.829 -179.657 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.475 ' N ' ' CG ' ' A' ' 47' ' ' TRP . 18.1 tp -58.37 -41.32 84.53 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.328 -0.858 . . . . 0.0 109.936 -178.955 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.547 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 1.1 pp20? -73.35 -35.63 66.02 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 120.895 -1.128 . . . . 0.0 109.521 179.769 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . 0.406 ' N ' ' HG3' ' A' ' 49' ' ' GLU . 57.4 t0 -63.48 -41.02 98.59 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.376 -0.828 . . . . 0.0 111.619 -179.111 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 8.8 ptm180 -65.0 -37.08 86.47 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.869 -1.144 . . . . 0.0 111.632 -178.122 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.445 ' CE2' ' CG1' ' A' ' 76' ' ' VAL . 72.9 m-85 -90.9 -12.14 37.02 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 120.443 -1.41 . . . . 0.0 110.021 -179.505 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 74.47 28.83 62.84 Favored Glycine 0 N--CA 1.487 2.045 0 N-CA-C 108.832 -1.707 . . . . 0.0 108.832 179.919 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . 0.49 ' O ' ' OE1' ' A' ' 49' ' ' GLU . 25.2 pt -109.18 153.4 10.95 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.575 -0.956 . . . . 0.0 109.798 -179.42 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -102.44 126.3 49.44 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.228 -0.92 . . . . 0.0 109.561 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.497 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -68.55 -28.16 66.72 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.238 -0.914 . . . . 0.0 109.525 179.784 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 21.0 t70 -55.12 -33.49 62.9 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.262 -0.899 . . . . 0.0 110.082 -179.638 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -52.76 -38.29 60.77 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.133 -0.979 . . . . 0.0 109.852 -179.465 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.497 ' O ' ' O ' ' A' ' 56' ' ' ALA . 32.7 m -127.66 157.74 39.43 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.335 0 O-C-N 121.319 -0.863 . . . . 0.0 109.557 -179.721 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -97.6 125.82 42.55 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.14 -0.975 . . . . 0.0 109.353 179.725 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 5.1 mp -107.12 141.06 38.98 Favored 'General case' 0 C--N 1.306 -1.325 0 O-C-N 121.394 -0.816 . . . . 0.0 109.699 -179.73 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' SER . . . . . 0.557 ' HG ' ' H ' ' A' ' 64' ' ' GLU . 0.1 OUTLIER -109.22 153.09 42.84 Favored Pre-proline 0 N--CA 1.487 1.406 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 179.295 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo -54.53 -23.22 30.96 Favored 'Trans proline' 0 C--N 1.303 -1.817 0 C-N-CA 122.338 2.026 . . . . 0.0 112.086 -179.548 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . 0.557 ' H ' ' HG ' ' A' ' 62' ' ' SER . 95.5 mt-10 -70.15 -26.46 63.94 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 121.352 -0.842 . . . . 0.0 109.403 179.906 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . 0.504 ' NE2' ' CB ' ' A' ' 75' ' ' PHE . 2.2 t-80 -66.03 -20.88 66.33 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.419 -0.8 . . . . 0.0 109.289 -179.843 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.535 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 9.5 m-85 -97.1 15.48 22.41 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 121.406 -0.809 . . . . 0.0 109.166 -179.815 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . 0.407 HH21 ' HD3' ' A' ' 87' ' ' LYS . 1.7 ptt85 -51.99 -34.39 42.31 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.644 -0.66 . . . . 0.0 109.999 -179.938 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.47 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 44.2 t -151.4 154.05 35.89 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.071 -1.018 . . . . 0.0 109.969 179.884 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.413 ' H ' HD12 ' A' ' 69' ' ' ILE . 3.2 mp -57.36 -33.91 44.99 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 179.222 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 32.1 mtp180 -56.79 -44.11 81.56 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.67 -0.644 . . . . 0.0 109.407 -179.693 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 17.0 t -66.47 -40.58 89.42 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.382 -0.823 . . . . 0.0 109.829 -179.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 62.8 mt -62.18 -50.26 80.73 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.37 0 O-C-N 121.305 -0.872 . . . . 0.0 110.286 -179.222 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 37.0 t0 -61.0 -41.88 97.35 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.11 -0.994 . . . . 0.0 109.409 -179.842 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . 0.456 ' O ' ' N ' ' A' ' 78' ' ' GLY . . . -67.02 -40.69 87.31 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.478 -0.764 . . . . 0.0 110.353 -179.443 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . 0.504 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 66.9 t80 -62.7 -46.71 86.86 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.049 -1.032 . . . . 0.0 109.663 -179.676 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.445 ' CG1' ' CE2' ' A' ' 52' ' ' PHE . 90.7 t -67.23 -48.21 79.05 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.343 0 O-C-N 121.192 -0.943 . . . . 0.0 109.78 -179.938 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 53.0 t -69.66 -41.99 80.29 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.333 0 O-C-N 121.134 -0.978 . . . . 0.0 109.63 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.486 ' O ' ' O ' ' A' ' 81' ' ' THR . . . -59.53 -36.0 87.7 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 -179.477 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.48 -40.98 85.29 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.209 -1.171 . . . . 0.0 110.475 -179.183 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 49.0 p -81.93 -30.74 31.67 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.144 -0.972 . . . . 0.0 109.698 -179.685 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.486 ' O ' ' O ' ' A' ' 78' ' ' GLY . 0.5 OUTLIER -133.18 153.94 80.96 Favored Pre-proline 0 C--N 1.302 -1.458 0 O-C-N 121.541 -0.725 . . . . 0.0 109.666 -179.615 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -62.71 111.65 1.41 Allowed 'Trans proline' 0 C--N 1.308 -1.577 0 C-N-CA 122.339 2.026 . . . . 0.0 111.285 179.614 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -74.15 150.77 43.12 Favored 'Trans proline' 0 N--CA 1.49 1.284 0 C-N-CA 121.992 1.795 . . . . 0.0 113.143 -179.11 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.449 ' O ' ' C ' ' A' ' 85' ' ' GLU . 14.5 p -104.31 138.5 28.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 179.389 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.449 ' C ' ' O ' ' A' ' 84' ' ' VAL . 95.9 mt-10 41.88 47.27 3.64 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.184 -0.947 . . . . 0.0 109.329 -179.813 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -56.15 150.37 14.22 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.362 -0.836 . . . . 0.0 109.801 -179.564 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.407 ' HD3' HH21 ' A' ' 67' ' ' ARG . 53.2 mttm -56.31 -34.89 66.96 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.254 -0.904 . . . . 0.0 109.396 -179.983 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . 0.406 ' O ' ' O ' ' A' ' 89' ' ' GLN . 52.3 mt -93.18 142.44 27.31 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.28 -0.887 . . . . 0.0 109.377 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . 0.406 ' O ' ' O ' ' A' ' 88' ' ' LEU . 59.4 tp60 . . . . . 0 N--CA 1.49 1.57 0 CA-C-O 118.024 -0.988 . . . . 0.0 109.348 179.934 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' -1' ' ' SER . . . . . . . . . . . . . 25.4 t . . . . . 0 N--CA 1.49 1.545 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 0' ' ' GLU . . . . . 0.402 ' HG2' ' H ' ' A' ' 2' ' ' GLN . 84.2 tt0 -101.35 133.96 45.16 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.278 -0.889 . . . . 0.0 109.36 -179.992 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' MET . . . . . 0.492 ' O ' ' OD2' ' A' ' 73' ' ' ASP . 64.7 mtt -60.56 -35.12 75.27 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.304 -0.873 . . . . 0.0 109.693 -179.852 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . 0.402 ' H ' ' HG2' ' A' ' 0' ' ' GLU . 94.5 mt-30 56.48 94.1 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.386 -0.821 . . . . 0.0 109.581 -179.678 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 50.4 m-70 66.14 41.77 3.41 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.626 -0.671 . . . . 0.0 110.575 179.687 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -61.01 -38.42 86.0 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.96 -1.088 . . . . 0.0 109.299 179.468 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 25.5 m -60.18 -35.75 76.05 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.328 -0.857 . . . . 0.0 109.914 -179.797 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 53.0 t -61.39 -45.72 98.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.193 -0.942 . . . . 0.0 109.589 -179.69 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 70.2 mt -60.04 -43.88 93.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.475 0 O-C-N 121.247 -0.908 . . . . 0.0 109.113 179.79 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -60.41 -35.89 76.84 Favored 'General case' 0 C--N 1.303 -1.424 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 179.752 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 7.3 tt0 -64.18 -38.12 89.9 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.458 -0.776 . . . . 0.0 110.137 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.684 ' CG ' ' CZ2' ' A' ' 47' ' ' TRP . 25.8 m-85 -66.52 -49.29 67.01 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 120.908 -1.12 . . . . 0.0 111.028 -179.219 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 11.6 m -59.74 -48.14 88.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.08 -1.013 . . . . 0.0 110.428 -178.518 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.578 ' O ' ' N ' ' A' ' 16' ' ' LEU . 30.6 m -64.89 -43.44 96.31 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.407 0 O-C-N 120.766 -1.208 . . . . 0.0 110.03 -179.838 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -65.16 -26.51 68.19 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.755 -1.215 . . . . 0.0 109.945 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 81.4 tt0 -64.28 -31.04 72.08 Favored 'General case' 0 C--N 1.299 -1.614 0 O-C-N 121.328 -0.857 . . . . 0.0 109.767 -179.277 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 85.9 m-85 -141.5 -35.89 0.45 Allowed 'General case' 0 N--CA 1.494 1.734 0 O-C-N 120.897 -1.127 . . . . 0.0 110.816 -179.9 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.578 ' N ' ' O ' ' A' ' 12' ' ' VAL . 8.6 mt -122.17 79.79 43.83 Favored Pre-proline 0 N--CA 1.494 1.737 0 O-C-N 121.124 -0.985 . . . . 0.0 110.418 -179.01 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 43.0 Cg_endo -75.77 -12.03 20.08 Favored 'Trans proline' 0 C--N 1.308 -1.562 0 C-N-CA 122.412 2.075 . . . . 0.0 112.545 179.79 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -93.87 13.09 23.66 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.224 -0.922 . . . . 0.0 110.385 -179.399 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 58.5 t -109.46 134.98 49.78 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.247 -0.908 . . . . 0.0 110.008 -179.724 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . 0.494 ' O ' ' OD1' ' A' ' 23' ' ' ASP . . . -73.58 117.88 64.43 Favored Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.429 -0.794 . . . . 0.0 109.337 -179.965 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_exo -52.62 -27.24 32.28 Favored 'Trans proline' 0 N--CA 1.494 1.509 0 C-N-CA 121.832 1.688 . . . . 0.0 112.394 179.786 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.85 -25.4 67.88 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.263 -0.898 . . . . 0.0 110.035 -179.561 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.494 ' OD1' ' O ' ' A' ' 20' ' ' ALA . 47.4 p30 -86.54 8.15 23.24 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.133 -0.979 . . . . 0.0 110.112 -179.566 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 11.3 t -101.11 131.64 48.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 120.972 -1.08 . . . . 0.0 109.418 -179.907 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 61.6 t0 -89.29 119.71 30.0 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.096 -1.002 . . . . 0.0 109.094 179.435 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 22.1 m -76.3 4.45 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 O-C-N 121.252 -0.905 . . . . 0.0 109.173 179.687 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -96.24 0.25 50.75 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 121.266 -0.896 . . . . 0.0 109.214 179.61 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 38.4 tp -94.62 143.22 26.61 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.43 -0.794 . . . . 0.0 109.192 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -66.79 118.78 10.79 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.091 -1.006 . . . . 0.0 109.005 -179.75 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . 0.414 ' H ' ' HA ' ' A' ' 68' ' ' SER . 41.6 tp -62.33 -37.86 87.26 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.605 -0.685 . . . . 0.0 111.09 -178.872 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 53.2 t -66.78 -38.29 81.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 120.807 -1.183 . . . . 0.0 110.863 -179.012 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -52.89 -33.36 49.87 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 120.913 -1.117 . . . . 0.0 108.212 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 20.9 m120 -71.05 -33.91 70.74 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.698 -0.626 . . . . 0.0 109.941 179.528 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 91.31 5.6 67.24 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 108.871 -1.691 . . . . 0.0 108.871 -179.231 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 78.0 t -60.19 -30.56 46.19 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 O-C-N 121.479 -1.012 . . . . 0.0 108.825 179.526 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 65.5 mt -94.72 130.5 43.46 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.344 0 O-C-N 121.386 -0.821 . . . . 0.0 109.558 -179.763 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.571 ' CG ' ' H ' ' A' ' 38' ' ' ALA . 49.1 t0 -137.92 -163.67 1.48 Allowed 'General case' 0 C--N 1.301 -1.52 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 179.948 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.571 ' H ' ' CG ' ' A' ' 37' ' ' ASP . . . -63.54 -54.76 31.13 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.995 -1.066 . . . . 0.0 108.665 179.879 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . 0.474 ' CD1' ' N ' ' A' ' 39' ' ' LEU . 6.9 mp -71.25 -34.04 70.37 Favored 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 107.323 -1.362 . . . . 0.0 107.323 178.206 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -59.47 -45.55 95.36 Favored Glycine 0 N--CA 1.482 1.725 0 N-CA-C 109.019 -1.632 . . . . 0.0 109.019 179.562 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.4 tt -64.08 -39.95 95.17 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.462 -1.022 . . . . 0.0 109.092 179.303 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 tp -60.04 -46.03 90.89 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.432 -0.792 . . . . 0.0 109.327 179.902 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 17.6 mttp -59.82 -37.11 78.28 Favored 'General case' 0 C--N 1.296 -1.729 0 O-C-N 121.474 -0.766 . . . . 0.0 109.381 -179.906 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 84.9 t -64.64 -41.49 92.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.5 -0.75 . . . . 0.0 110.2 -179.699 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . 0.485 ' O ' ' OE1' ' A' ' 49' ' ' GLU . 1.3 mp -64.89 -50.76 73.58 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.646 0 O-C-N 121.066 -1.021 . . . . 0.0 111.208 -178.84 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.68 -49.51 62.4 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.083 -1.011 . . . . 0.0 112.843 -177.531 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . 0.684 ' CZ2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -74.8 -48.86 23.05 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 120.613 -1.304 . . . . 0.0 111.358 -177.758 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -58.86 -44.52 91.04 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 120.812 -1.18 . . . . 0.0 109.345 -178.582 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.592 ' N ' ' CD ' ' A' ' 49' ' ' GLU . 0.0 OUTLIER -63.97 -38.72 92.11 Favored 'General case' 0 N--CA 1.485 1.324 0 O-C-N 120.706 -1.246 . . . . 0.0 109.818 -179.958 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 55.1 t0 -61.68 -37.25 83.4 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.298 -0.876 . . . . 0.0 110.513 -179.502 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 18.4 mmt180 -58.27 -36.51 73.39 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.089 -1.007 . . . . 0.0 111.055 -179.029 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.454 ' CE1' ' CG1' ' A' ' 76' ' ' VAL . 87.4 m-85 -96.32 -6.18 38.36 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 120.789 -1.194 . . . . 0.0 110.474 -179.144 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 73.25 30.44 62.79 Favored Glycine 0 N--CA 1.488 2.121 0 N-CA-C 108.739 -1.745 . . . . 0.0 108.739 179.761 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 20.7 pt -112.68 153.9 14.21 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 O-C-N 121.75 -0.853 . . . . 0.0 109.701 -179.436 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -93.99 130.17 40.21 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.217 -0.927 . . . . 0.0 109.407 -179.873 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.486 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -64.39 -32.24 73.78 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.202 -0.936 . . . . 0.0 109.552 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -58.06 -34.49 70.17 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.383 -0.823 . . . . 0.0 110.051 -179.835 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -53.53 -37.93 63.3 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.28 -0.888 . . . . 0.0 109.939 -179.469 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.486 ' O ' ' O ' ' A' ' 56' ' ' ALA . 13.7 p -133.67 142.72 40.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.253 -0.905 . . . . 0.0 109.567 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -100.19 128.73 46.21 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.21 -0.931 . . . . 0.0 109.322 179.781 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 51.7 mt -105.75 143.46 33.88 Favored 'General case' 0 C--N 1.305 -1.361 0 O-C-N 121.314 -0.866 . . . . 0.0 109.707 -179.719 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -97.32 151.25 37.56 Favored Pre-proline 0 C--N 1.305 -1.337 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 179.131 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -55.39 -23.25 37.41 Favored 'Trans proline' 0 C--N 1.305 -1.743 0 C-N-CA 122.366 2.044 . . . . 0.0 112.032 -179.403 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 91.9 mt-10 -71.79 -29.85 64.9 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.345 -0.847 . . . . 0.0 109.774 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . 0.421 ' CE1' ' HB2' ' A' ' 75' ' ' PHE . 63.0 t60 -65.92 -21.17 66.42 Favored 'General case' 0 C--N 1.299 -1.588 0 O-C-N 121.102 -0.999 . . . . 0.0 109.186 -179.668 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.477 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 26.0 m-85 -86.93 13.98 8.13 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.405 -0.809 . . . . 0.0 109.223 -179.659 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . 0.41 HH21 ' HG2' ' A' ' 87' ' ' LYS . 5.8 ptt180 -52.73 -34.31 52.05 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.66 -0.65 . . . . 0.0 110.088 179.852 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.414 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 32.4 t -149.82 151.11 32.99 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.067 -1.021 . . . . 0.0 110.088 -179.771 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . 0.414 ' CD1' ' H ' ' A' ' 69' ' ' ILE . 2.0 mp -60.19 -39.14 79.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.428 0 O-C-N 121.48 -0.762 . . . . 0.0 109.888 -179.862 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.55 ' NE ' ' HZ3' ' A' ' 87' ' ' LYS . 9.8 ptm180 -58.12 -40.99 82.64 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.493 -0.754 . . . . 0.0 110.283 -179.225 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 60.7 p -64.98 -42.91 94.12 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.201 -0.937 . . . . 0.0 110.221 -179.455 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . 0.405 ' HA ' ' NE2' ' A' ' 65' ' ' HIS . 69.6 mt -61.5 -47.39 93.63 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 O-C-N 121.136 -0.978 . . . . 0.0 110.406 -179.405 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . 0.492 ' OD2' ' O ' ' A' ' 1' ' ' MET . 39.4 t0 -60.63 -37.49 81.64 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 121.184 -0.948 . . . . 0.0 109.825 -179.723 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -67.86 -46.84 70.59 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.216 -0.927 . . . . 0.0 110.604 -178.985 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . 0.421 ' HB2' ' CE1' ' A' ' 65' ' ' HIS . 58.4 t80 -65.88 -44.52 85.1 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.098 -1.001 . . . . 0.0 109.2 -179.728 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.454 ' CG1' ' CE1' ' A' ' 52' ' ' PHE . 55.2 t -60.76 -45.34 97.97 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 O-C-N 121.31 -0.869 . . . . 0.0 109.157 179.585 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 54.7 t -69.15 -41.16 81.27 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.281 0 O-C-N 121.214 -0.929 . . . . 0.0 108.989 179.349 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.492 ' O ' ' O ' ' A' ' 81' ' ' THR . . . -59.99 -28.13 65.74 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 110.029 -1.228 . . . . 0.0 110.029 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.02 -37.02 83.39 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.207 -1.172 . . . . 0.0 109.947 -179.391 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 44.9 p -83.38 -31.08 26.9 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.149 -0.97 . . . . 0.0 109.535 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.492 ' O ' ' O ' ' A' ' 78' ' ' GLY . 0.2 OUTLIER -133.4 153.17 80.35 Favored Pre-proline 0 C--N 1.303 -1.428 0 O-C-N 121.504 -0.747 . . . . 0.0 109.788 -179.523 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 27.4 Cg_endo -66.07 111.75 2.08 Favored 'Trans proline' 0 C--N 1.309 -1.547 0 C-N-CA 122.346 2.031 . . . . 0.0 111.449 179.557 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -76.67 152.37 33.12 Favored 'Trans proline' 0 N--CA 1.489 1.232 0 C-N-CA 122.111 1.874 . . . . 0.0 113.201 -179.11 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.45 ' O ' ' C ' ' A' ' 85' ' ' GLU . 32.7 m -103.12 135.81 38.82 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.52 0 N-CA-C 108.404 -0.962 . . . . 0.0 108.404 178.98 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.45 ' C ' ' O ' ' A' ' 84' ' ' VAL . 96.0 mt-10 42.25 70.34 0.29 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.225 -0.922 . . . . 0.0 109.059 -179.394 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -48.62 148.51 2.05 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.409 -0.807 . . . . 0.0 110.047 -179.291 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.55 ' HZ3' ' NE ' ' A' ' 70' ' ' ARG . 54.5 tttp -56.48 -36.56 69.24 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.417 -0.802 . . . . 0.0 109.298 179.901 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 33.1 tp -100.06 130.69 46.24 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.298 -0.876 . . . . 0.0 109.401 179.917 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 21.4 pt20 . . . . . 0 N--CA 1.49 1.544 0 CA-C-O 117.988 -1.006 . . . . 0.0 109.473 -179.95 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' -1' ' ' SER . . . . . 0.535 ' OG ' ' N ' ' A' ' 0' ' ' GLU . 0.3 OUTLIER . . . . . 0 N--CA 1.49 1.533 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 . . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 0' ' ' GLU . . . . . 0.535 ' N ' ' OG ' ' A' ' -1' ' ' SER . 84.5 tt0 51.04 104.11 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.333 -0.854 . . . . 0.0 109.643 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 1' ' ' MET . . . . . . . . . . . . . 95.8 mmm -57.51 -44.32 84.95 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.288 -0.882 . . . . 0.0 109.444 179.887 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 69.2 tp60 174.97 -80.96 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.733 0 N-CA-C 106.47 -1.678 . . . . 0.0 106.47 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 77.5 m80 -100.17 16.2 24.97 Favored 'General case' 0 C--N 1.302 -1.457 0 N-CA-C 106.683 -1.599 . . . . 0.0 106.683 177.219 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -51.88 -39.48 59.07 Favored 'General case' 0 N--CA 1.487 1.417 0 CA-C-O 121.233 0.539 . . . . 0.0 109.92 -179.052 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.8 m -59.8 -37.78 80.09 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.256 -0.902 . . . . 0.0 109.746 -179.747 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 6' ' ' VAL . . . . . 0.402 ' HA ' HE21 ' A' ' 9' ' ' GLN . 55.5 t -62.63 -42.93 97.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.251 -0.906 . . . . 0.0 109.545 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 79.3 mt -59.54 -41.43 84.82 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 O-C-N 121.348 -0.845 . . . . 0.0 109.241 179.858 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -62.21 -38.42 89.09 Favored 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.405 -0.809 . . . . 0.0 109.558 -179.789 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 9' ' ' GLN . . . . . 0.402 HE21 ' HA ' ' A' ' 6' ' ' VAL . 52.5 mt-30 -61.87 -42.07 98.62 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.108 -0.995 . . . . 0.0 109.545 179.921 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 10' ' ' PHE . . . . . 0.669 ' CG ' ' CE2' ' A' ' 47' ' ' TRP . 34.1 m-85 -61.81 -42.07 98.55 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.247 -0.908 . . . . 0.0 109.407 179.421 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 43.3 t -61.13 -45.29 98.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.367 -0.833 . . . . 0.0 109.548 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 12' ' ' VAL . . . . . 0.452 ' O ' ' C ' ' A' ' 16' ' ' LEU . 93.6 t -63.21 -46.83 94.81 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 O-C-N 121.479 -0.763 . . . . 0.0 109.735 -179.821 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -73.52 -16.46 61.28 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.396 -0.815 . . . . 0.0 110.265 -179.492 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -63.54 -31.88 73.17 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.171 -0.956 . . . . 0.0 110.299 -178.801 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 65.7 t80 -151.32 -28.99 0.19 Allowed 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.829 -1.169 . . . . 0.0 110.436 -179.761 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 16' ' ' LEU . . . . . 0.452 ' C ' ' O ' ' A' ' 12' ' ' VAL . 6.2 mt -121.77 80.14 40.6 Favored Pre-proline 0 N--CA 1.492 1.647 0 O-C-N 121.231 -0.918 . . . . 0.0 110.08 -179.405 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -77.08 -13.03 17.41 Favored 'Trans proline' 0 C--N 1.307 -1.607 0 C-N-CA 122.476 2.117 . . . . 0.0 112.375 179.759 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -93.95 9.74 36.24 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.189 -0.944 . . . . 0.0 110.263 -179.423 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 46.4 t -109.88 137.77 40.57 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.274 -0.891 . . . . 0.0 109.691 -179.769 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -78.41 117.44 66.34 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.147 -0.971 . . . . 0.0 109.442 179.941 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_exo -53.83 -24.79 32.35 Favored 'Trans proline' 0 N--CA 1.494 1.535 0 C-N-CA 121.842 1.695 . . . . 0.0 112.068 179.547 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.0 -24.51 67.74 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.304 -0.872 . . . . 0.0 109.301 -179.936 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 23' ' ' ASP . . . . . 0.409 ' O ' ' OD1' ' A' ' 23' ' ' ASP . 59.6 t0 -81.66 3.31 25.85 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.331 -0.856 . . . . 0.0 109.332 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 13.0 t -109.66 133.94 53.32 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.375 -0.828 . . . . 0.0 109.298 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 63.9 t0 -88.7 119.75 29.47 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.097 -1.002 . . . . 0.0 109.05 179.56 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 29.9 m -74.43 4.15 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.35 0 O-C-N 121.137 -0.977 . . . . 0.0 109.261 179.656 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 91.8 m-20 -90.43 -4.83 56.74 Favored 'General case' 0 N--CA 1.487 1.381 0 O-C-N 121.29 -0.881 . . . . 0.0 108.819 179.45 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 45.3 tp -98.03 139.58 33.64 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 179.832 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -58.77 137.51 57.64 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.211 -0.931 . . . . 0.0 109.655 -179.419 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 30' ' ' LEU . . . . . . . . . . . . . 1.4 tt -66.04 -38.91 89.57 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.713 -0.617 . . . . 0.0 110.069 -179.272 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 74.6 t -63.19 -35.78 73.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 120.979 -1.076 . . . . 0.0 110.67 -178.782 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 91.0 m-20 -52.58 -33.79 47.62 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 120.984 -1.073 . . . . 0.0 108.24 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 97.2 m-20 -71.15 -34.66 71.2 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.614 -0.679 . . . . 0.0 110.047 179.516 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 84.09 5.54 87.43 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 108.99 -1.644 . . . . 0.0 108.99 -179.385 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 70.4 t -60.55 -33.86 56.15 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 O-C-N 121.407 -1.055 . . . . 0.0 108.634 179.557 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 95.0 mt -84.32 124.12 39.54 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.398 0 O-C-N 121.471 -0.768 . . . . 0.0 109.63 179.842 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 37' ' ' ASP . . . . . 0.588 ' CG ' ' H ' ' A' ' 38' ' ' ALA . 48.5 t0 -127.51 -159.53 0.94 Allowed 'General case' 0 C--N 1.301 -1.515 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 179.56 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 38' ' ' ALA . . . . . 0.588 ' H ' ' CG ' ' A' ' 37' ' ' ASP . . . -66.26 -55.07 17.93 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.848 -1.158 . . . . 0.0 108.681 179.792 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 36.5 mt -71.3 -34.37 70.55 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 107.412 -1.329 . . . . 0.0 107.412 178.237 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 40' ' ' GLY . . . . . . . . . . . . . . . -59.53 -40.29 96.08 Favored Glycine 0 N--CA 1.482 1.735 0 N-CA-C 108.783 -1.727 . . . . 0.0 108.783 179.256 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 4.5 tt -65.44 -45.49 83.63 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.528 -0.984 . . . . 0.0 109.326 179.225 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 17.1 tp -59.51 -44.75 93.05 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.415 -0.803 . . . . 0.0 109.811 -179.829 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 32.0 mttp -61.74 -34.74 76.37 Favored 'General case' 0 C--N 1.298 -1.664 0 O-C-N 120.973 -1.079 . . . . 0.0 109.583 -179.875 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 53.6 t -62.29 -50.23 80.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.328 -0.858 . . . . 0.0 110.296 -179.439 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 3.5 mp -68.15 -32.66 56.91 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.216 -0.927 . . . . 0.0 110.934 -179.607 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.27 -49.85 62.69 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 120.971 -1.08 . . . . 0.0 111.757 -177.909 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 47' ' ' TRP . . . . . 0.669 ' CE2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -80.84 -43.51 19.88 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.677 -1.265 . . . . 0.0 110.089 -178.984 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 48' ' ' LEU . . . . . 0.4 ' N ' ' CG ' ' A' ' 47' ' ' TRP . 28.1 tp -58.93 -41.46 87.38 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.25 -0.906 . . . . 0.0 110.082 -179.085 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.436 ' CG ' ' N ' ' A' ' 50' ' ' ASP . 16.9 pt-20 -73.14 -37.7 66.52 Favored 'General case' 0 C--N 1.303 -1.427 0 O-C-N 121.082 -1.012 . . . . 0.0 109.589 -179.859 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 50' ' ' ASP . . . . . 0.436 ' N ' ' CG ' ' A' ' 49' ' ' GLU . 22.1 t70 -58.73 -38.16 77.77 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.406 -0.809 . . . . 0.0 110.618 -179.462 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 71.1 mtp180 -61.07 -38.66 86.99 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.156 -0.965 . . . . 0.0 111.434 -178.808 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 52' ' ' PHE . . . . . 0.454 ' CE1' ' CG1' ' A' ' 76' ' ' VAL . 75.0 m-85 -97.24 -7.42 32.31 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 120.872 -1.143 . . . . 0.0 110.582 -179.075 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 72.81 30.73 63.27 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.207 -1.557 . . . . 0.0 109.207 179.307 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 30.3 pt -106.81 153.4 8.03 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.354 0 O-C-N 121.483 -1.01 . . . . 0.0 109.571 -179.756 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -101.75 137.93 39.4 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.209 -0.932 . . . . 0.0 109.681 -179.562 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 56' ' ' ALA . . . . . 0.495 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -66.63 -26.57 67.13 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.365 -0.835 . . . . 0.0 109.724 179.899 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 57' ' ' ASP . . . . . 0.629 ' OD1' ' N ' ' A' ' 58' ' ' ASP . 54.9 p30 -60.42 -32.06 70.99 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.123 -0.986 . . . . 0.0 110.257 -179.606 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 58' ' ' ASP . . . . . 0.629 ' N ' ' OD1' ' A' ' 57' ' ' ASP . 53.8 t0 -57.95 -39.96 79.39 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.016 -1.052 . . . . 0.0 109.72 -179.908 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 59' ' ' VAL . . . . . 0.495 ' O ' ' O ' ' A' ' 56' ' ' ALA . 13.3 p -137.15 143.47 34.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.301 -0.874 . . . . 0.0 109.497 -179.969 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -90.36 132.63 35.48 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.115 -0.991 . . . . 0.0 109.221 179.847 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 57.2 mt -97.74 137.26 36.88 Favored 'General case' 0 C--N 1.305 -1.338 0 O-C-N 121.222 -0.924 . . . . 0.0 109.771 -179.668 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -110.18 156.44 40.14 Favored Pre-proline 0 N--CA 1.488 1.43 0 N-CA-C 108.841 -0.799 . . . . 0.0 108.841 179.391 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 8.0 Cg_endo -53.18 -23.28 22.2 Favored 'Trans proline' 0 C--N 1.302 -1.899 0 C-N-CA 122.388 2.059 . . . . 0.0 111.685 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -70.73 -27.78 64.22 Favored 'General case' 0 C--N 1.305 -1.34 0 O-C-N 121.335 -0.853 . . . . 0.0 109.561 179.686 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 65' ' ' HIS . . . . . 0.566 ' C ' ' CD2' ' A' ' 65' ' ' HIS . 0.4 OUTLIER -65.69 -17.81 64.88 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 121.336 -0.852 . . . . 0.0 109.056 -179.835 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 66' ' ' PHE . . . . . 0.546 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 11.6 m-85 -97.57 15.89 22.0 Favored 'General case' 0 C--N 1.301 -1.538 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 179.704 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 67' ' ' ARG . . . . . 0.594 ' NE ' ' OG ' ' A' ' 71' ' ' SER . 6.7 ptt180 -48.95 -38.58 23.4 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.796 -0.565 . . . . 0.0 110.558 -179.526 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 43.8 t -161.52 158.98 27.29 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.905 -1.122 . . . . 0.0 110.234 -179.803 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 69' ' ' ILE . . . . . . . . . . . . . 31.6 mm -57.97 -44.01 85.97 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.361 0 O-C-N 121.319 -0.863 . . . . 0.0 109.628 179.876 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' ARG . . . . . 0.685 ' NH1' ' NZ ' ' A' ' 87' ' ' LYS . 0.0 OUTLIER -58.65 -39.3 80.18 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.276 -0.89 . . . . 0.0 109.596 -179.57 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' SER . . . . . 0.594 ' OG ' ' NE ' ' A' ' 67' ' ' ARG . 41.6 t -62.59 -41.51 99.0 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.275 -0.891 . . . . 0.0 109.689 179.821 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 80.7 mt -61.01 -47.75 92.19 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 O-C-N 121.306 -0.871 . . . . 0.0 109.911 -179.62 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 32.9 t0 -60.26 -43.14 96.42 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.168 -0.958 . . . . 0.0 109.167 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' ALA . . . . . 0.54 ' O ' ' N ' ' A' ' 78' ' ' GLY . . . -66.84 -38.89 87.27 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.52 -0.738 . . . . 0.0 109.952 -179.829 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 71.6 t80 -61.64 -51.24 69.29 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.174 -0.953 . . . . 0.0 109.271 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' VAL . . . . . 0.454 ' CG1' ' CE1' ' A' ' 52' ' ' PHE . 77.6 t -69.51 -48.03 68.69 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 O-C-N 121.328 -0.857 . . . . 0.0 109.878 179.972 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 72.3 t -69.55 -47.0 74.23 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.328 0 O-C-N 121.175 -0.953 . . . . 0.0 109.756 -179.887 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' GLY . . . . . 0.54 ' N ' ' O ' ' A' ' 74' ' ' ALA . . . -61.93 -37.88 95.11 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.826 -1.309 . . . . 0.0 109.826 -179.752 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.61 -39.45 84.73 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.183 -1.187 . . . . 0.0 110.025 -179.508 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 50.2 p -81.33 -31.61 33.41 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.286 -0.884 . . . . 0.0 109.594 -179.859 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' THR . . . . . 0.493 ' O ' ' O ' ' A' ' 78' ' ' GLY . 0.4 OUTLIER -133.2 152.87 80.3 Favored Pre-proline 0 C--N 1.304 -1.389 0 O-C-N 121.403 -0.811 . . . . 0.0 109.908 -179.646 . . . . . . . . 3 3 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -44.82 111.2 0.27 Allowed 'Trans proline' 0 C--N 1.311 -1.408 0 C-N-CA 122.254 1.969 . . . . 0.0 111.823 179.286 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 22.2 Cg_exo -57.05 143.53 92.58 Favored 'Trans proline' 0 N--CA 1.492 1.4 0 C-N-CA 121.81 1.674 . . . . 0.0 111.98 179.917 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . 0.583 ' O ' ' N ' ' A' ' 86' ' ' ALA . 44.4 t -103.68 132.41 50.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.32 -0.862 . . . . 0.0 109.773 -179.998 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' GLU . . . . . 0.468 ' C ' ' O ' ' A' ' 84' ' ' VAL . 96.1 mt-10 37.33 26.0 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.584 -0.698 . . . . 0.0 110.136 179.625 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' ALA . . . . . 0.583 ' N ' ' O ' ' A' ' 84' ' ' VAL . . . 42.39 -147.34 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.2 -0.937 . . . . 0.0 109.543 -179.912 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' LYS . . . . . 0.685 ' NZ ' ' NH1' ' A' ' 70' ' ' ARG . 48.9 tttm -73.63 146.53 44.53 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.194 -0.941 . . . . 0.0 109.783 -179.91 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 7.2 tt -53.47 -38.74 63.88 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.311 -0.868 . . . . 0.0 109.336 179.488 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.3 mt-30 . . . . . 0 N--CA 1.49 1.56 0 CA-C-O 118.022 -0.989 . . . . 0.0 109.5 -179.971 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 20.4 m-70 . . . . . 0 N--CA 1.495 1.821 0 CA-C-O 121.086 0.469 . . . . 0.0 109.831 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -60.32 -39.97 88.91 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.105 -0.997 . . . . 0.0 109.343 179.898 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.2 m -61.76 -36.86 82.27 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.465 -0.772 . . . . 0.0 110.019 -179.754 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 64.3 t -62.35 -44.98 99.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.23 -0.919 . . . . 0.0 109.631 -179.762 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.493 ' O ' HG13 ' A' ' 11' ' ' VAL . 78.3 mt -59.78 -46.96 93.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.326 -0.858 . . . . 0.0 108.799 179.624 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.679 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -62.38 -35.12 78.19 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 108.969 -0.752 . . . . 0.0 108.969 179.328 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 59.6 tt0 -58.76 -41.12 85.81 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.084 -1.01 . . . . 0.0 109.526 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.672 ' CG ' ' CZ2' ' A' ' 47' ' ' TRP . 52.4 m-85 -68.7 -50.16 53.1 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.045 -1.035 . . . . 0.0 110.508 -179.807 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.493 HG13 ' O ' ' A' ' 7' ' ' ILE . 1.0 OUTLIER -66.12 -39.0 83.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.02 -1.05 . . . . 0.0 108.99 -179.498 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.679 HG23 ' O ' ' A' ' 8' ' ' ALA . 74.8 t -63.56 -46.67 94.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.28 -0.888 . . . . 0.0 109.266 179.45 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -71.71 -23.6 61.66 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.23 -0.919 . . . . 0.0 109.825 179.665 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -64.09 -30.3 71.38 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.428 -0.795 . . . . 0.0 110.395 -179.078 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 72.6 t80 -139.0 -40.48 0.48 Allowed 'General case' 0 N--CA 1.494 1.731 0 O-C-N 120.969 -1.082 . . . . 0.0 110.765 -179.413 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.484 HD22 ' CG2' ' A' ' 19' ' ' VAL . 5.0 mt -120.76 80.11 32.17 Favored Pre-proline 0 N--CA 1.491 1.613 0 O-C-N 121.089 -1.007 . . . . 0.0 110.338 -179.18 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 40.7 Cg_endo -75.73 -14.78 19.48 Favored 'Trans proline' 0 C--N 1.309 -1.536 0 C-N-CA 122.439 2.093 . . . . 0.0 112.285 179.437 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -90.03 7.87 35.45 Favored 'General case' 0 N--CA 1.487 1.381 0 O-C-N 121.221 -0.925 . . . . 0.0 109.758 -179.715 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.484 ' CG2' HD22 ' A' ' 16' ' ' LEU . 43.2 t -111.69 134.86 52.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.417 -0.802 . . . . 0.0 109.644 -179.882 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.27 119.62 75.82 Favored Pre-proline 0 N--CA 1.489 1.477 0 O-C-N 121.263 -0.898 . . . . 0.0 109.353 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_exo -51.2 -28.23 25.21 Favored 'Trans proline' 0 N--CA 1.493 1.483 0 C-N-CA 121.75 1.633 . . . . 0.0 112.109 179.531 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.91 -24.69 67.61 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.264 -0.898 . . . . 0.0 109.31 179.881 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.426 ' O ' ' OD1' ' A' ' 23' ' ' ASP . 60.0 t0 -81.87 7.23 13.42 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.319 -0.863 . . . . 0.0 109.789 -179.746 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 10.9 t -103.96 132.89 49.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.03 -1.043 . . . . 0.0 109.393 -179.884 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 87.3 m-20 -89.12 120.49 30.56 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.106 -0.996 . . . . 0.0 109.104 179.469 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 17.8 m -77.34 3.92 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.446 0 O-C-N 121.175 -0.953 . . . . 0.0 109.137 179.687 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -87.26 -13.2 44.44 Favored 'General case' 0 N--CA 1.486 1.354 0 O-C-N 121.351 -0.843 . . . . 0.0 109.149 179.518 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 41.5 tp -95.29 138.67 32.67 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.459 -0.775 . . . . 0.0 109.143 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -58.93 141.43 53.66 Favored 'General case' 0 C--N 1.303 -1.441 0 O-C-N 121.237 -0.914 . . . . 0.0 109.527 -179.605 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.979 HD13 HD11 ' A' ' 36' ' ' ILE . 1.3 tt -67.36 -38.66 85.16 Favored 'General case' 0 C--N 1.299 -1.589 0 O-C-N 121.706 -0.621 . . . . 0.0 110.322 -179.016 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 69.1 t -65.36 -36.25 77.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.103 -0.998 . . . . 0.0 110.497 -178.956 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -52.79 -33.59 49.61 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.455 ' HB3' HG23 ' A' ' 35' ' ' VAL . 82.6 m-20 -71.05 -34.4 71.22 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.675 -0.641 . . . . 0.0 109.805 179.433 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 85.3 6.28 84.33 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 108.984 -1.646 . . . . 0.0 108.984 -179.481 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.455 HG23 ' HB3' ' A' ' 33' ' ' ASN . 79.4 t -61.73 -34.32 61.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.468 -1.019 . . . . 0.0 109.158 179.795 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.979 HD11 HD13 ' A' ' 30' ' ' LEU . 96.6 mt -87.06 117.34 31.05 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.315 -0.865 . . . . 0.0 109.78 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -117.43 -168.2 1.45 Allowed 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 179.703 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -63.2 -54.77 32.37 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.034 -1.041 . . . . 0.0 108.532 179.626 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 41.9 mt -70.96 -34.71 71.7 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 178.063 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.618 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.66 -39.64 95.44 Favored Glycine 0 N--CA 1.481 1.656 0 N-CA-C 108.614 -1.795 . . . . 0.0 108.614 179.105 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.601 HD11 ' CZ ' ' A' ' 66' ' ' PHE . 7.6 tt -65.2 -42.62 93.36 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.579 -0.953 . . . . 0.0 108.993 179.36 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.4 tp -61.42 -46.09 91.6 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.414 -0.804 . . . . 0.0 109.234 179.601 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 24.2 mttp -61.15 -35.99 78.57 Favored 'General case' 0 C--N 1.296 -1.721 0 O-C-N 121.504 -0.748 . . . . 0.0 109.76 -179.654 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.618 HG23 ' O ' ' A' ' 40' ' ' GLY . 60.6 t -61.2 -50.57 79.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.374 -0.829 . . . . 0.0 109.715 -179.663 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.547 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 1.7 mp -69.05 -31.98 52.46 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.535 0 O-C-N 121.454 -0.779 . . . . 0.0 110.721 -179.906 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -63.52 -49.42 73.58 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.108 -0.995 . . . . 0.0 111.369 -178.127 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.672 ' CZ2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -80.87 -45.13 17.32 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 120.723 -1.235 . . . . 0.0 109.876 -179.544 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.887 HD12 HH21 ' A' ' 51' ' ' ARG . 9.7 tp -58.33 -42.51 86.99 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.307 -0.87 . . . . 0.0 109.817 -179.169 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.547 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 1.0 OUTLIER -72.66 -35.61 67.76 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.102 -0.999 . . . . 0.0 109.772 179.999 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.1 t70 -61.13 -39.15 88.95 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.159 -0.963 . . . . 0.0 110.713 -179.456 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.887 HH21 HD12 ' A' ' 48' ' ' LEU . 66.9 mtm180 -61.51 -36.77 81.47 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.167 -0.958 . . . . 0.0 111.429 -178.727 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.531 ' CZ ' ' CG1' ' A' ' 76' ' ' VAL . 94.3 m-85 -97.13 -9.9 27.03 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.774 -1.204 . . . . 0.0 110.334 -179.057 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 71.72 31.28 65.19 Favored Glycine 0 N--CA 1.486 2.01 0 N-CA-C 108.803 -1.719 . . . . 0.0 108.803 179.874 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.48 ' O ' ' OE1' ' A' ' 49' ' ' GLU . 25.3 pt -108.48 153.26 10.14 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 O-C-N 121.593 -0.945 . . . . 0.0 109.83 -179.331 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -101.77 131.34 48.12 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.077 -1.014 . . . . 0.0 109.667 -179.735 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.503 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -67.65 -27.47 66.89 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.276 -0.89 . . . . 0.0 109.506 179.827 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -55.37 -35.09 64.9 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.156 -0.965 . . . . 0.0 109.971 -179.724 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 54.4 t0 -53.19 -36.96 61.51 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.175 -0.953 . . . . 0.0 109.953 -179.592 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.503 ' O ' ' O ' ' A' ' 56' ' ' ALA . 13.7 p -132.84 143.82 38.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.258 -0.901 . . . . 0.0 109.653 -179.859 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -88.79 134.9 33.78 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.158 -0.964 . . . . 0.0 109.331 179.93 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 67.8 mt -97.16 137.49 36.13 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 121.261 -0.899 . . . . 0.0 109.926 -179.616 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -110.37 157.01 39.36 Favored Pre-proline 0 N--CA 1.487 1.406 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 179.478 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 9.3 Cg_endo -54.08 -23.16 27.7 Favored 'Trans proline' 0 C--N 1.301 -1.955 0 C-N-CA 122.392 2.061 . . . . 0.0 111.675 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -70.31 -27.5 64.43 Favored 'General case' 0 N--CA 1.486 1.344 0 O-C-N 121.338 -0.851 . . . . 0.0 109.447 179.653 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 65' ' ' HIS . . . . . 0.524 ' C ' ' CD2' ' A' ' 65' ' ' HIS . 0.9 OUTLIER -65.97 -17.89 64.98 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.357 -0.84 . . . . 0.0 109.036 -179.858 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.601 ' CZ ' HD11 ' A' ' 41' ' ' LEU . 10.5 m-85 -98.12 15.1 25.32 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 179.622 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 67' ' ' ARG . . . . . 0.411 ' HG2' ' H ' ' A' ' 68' ' ' SER . 6.1 ptt180 -49.67 -39.28 35.98 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.77 -0.581 . . . . 0.0 110.225 -179.661 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 68' ' ' SER . . . . . 0.511 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 80.1 p -163.39 159.23 22.12 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 120.903 -1.123 . . . . 0.0 110.101 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.63 ' H ' HD12 ' A' ' 69' ' ' ILE . 3.6 mp -57.74 -34.85 48.86 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 N-CA-C 108.211 -1.033 . . . . 0.0 108.211 178.93 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 21.3 mtp180 -57.31 -40.48 77.99 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 15.2 t -63.47 -38.51 91.41 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.401 -0.812 . . . . 0.0 109.51 179.834 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.416 ' CD1' ' NE2' ' A' ' 65' ' ' HIS . 32.4 mm -58.94 -46.73 91.25 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 O-C-N 121.269 -0.894 . . . . 0.0 109.294 -179.845 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 46.7 t0 -59.43 -43.25 93.13 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.21 -0.932 . . . . 0.0 109.102 179.813 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.44 -40.87 89.71 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.552 -0.717 . . . . 0.0 109.78 -179.858 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 69.2 t80 -62.32 -46.42 88.79 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.35 -0.844 . . . . 0.0 109.524 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.644 HG21 HD11 ' A' ' 48' ' ' LEU . 53.5 t -61.76 -46.24 96.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 O-C-N 121.235 -0.915 . . . . 0.0 109.337 179.884 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.517 ' O ' ' O ' ' A' ' 81' ' ' THR . 53.4 t -68.62 -42.6 83.44 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 O-C-N 121.262 -0.899 . . . . 0.0 109.329 179.53 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.45 -30.27 64.73 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 110.181 -1.168 . . . . 0.0 110.181 -179.903 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -68.37 -41.23 80.91 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.264 -1.139 . . . . 0.0 111.135 -178.739 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 27.8 p -101.68 -34.59 9.41 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.971 -1.081 . . . . 0.0 110.877 -178.808 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.517 ' O ' ' O ' ' A' ' 77' ' ' VAL . 0.1 OUTLIER . . . . . 0 C--N 1.301 -1.5 0 O-C-N 121.311 -0.868 . . . . 0.0 109.834 -179.274 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 14.1 m-70 . . . . . 0 N--CA 1.496 1.864 0 CA-C-O 121.214 0.531 . . . . 0.0 109.639 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -61.19 -40.08 92.6 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.245 -0.909 . . . . 0.0 109.368 179.852 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.1 p -63.24 -34.05 76.83 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.269 -0.894 . . . . 0.0 109.658 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.664 HG11 ' NH2' ' A' ' 51' ' ' ARG . 55.4 t -62.22 -44.82 99.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.149 -0.969 . . . . 0.0 109.418 179.8 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 77.0 mt -60.13 -41.07 85.29 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 O-C-N 121.371 -0.831 . . . . 0.0 108.934 179.47 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.471 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -60.93 -38.87 87.3 Favored 'General case' 0 C--N 1.305 -1.36 0 O-C-N 121.561 -0.712 . . . . 0.0 109.543 -179.912 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 50.3 mt-30 -63.63 -40.8 97.8 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.135 -0.978 . . . . 0.0 110.092 -179.833 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.694 ' CG ' ' CE2' ' A' ' 47' ' ' TRP . 33.7 m-85 -62.05 -50.12 73.25 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.002 -1.062 . . . . 0.0 110.628 -179.357 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.467 HG23 ' N ' ' A' ' 12' ' ' VAL . 30.0 m -66.43 -41.74 89.22 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 O-C-N 121.006 -1.059 . . . . 0.0 109.18 -179.874 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.471 HG23 ' O ' ' A' ' 8' ' ' ALA . 77.0 t -64.02 -45.17 97.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.219 -0.926 . . . . 0.0 109.49 179.436 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -72.25 -23.43 61.21 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.22 -0.925 . . . . 0.0 110.341 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -64.02 -30.02 71.13 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.333 -0.854 . . . . 0.0 110.466 -178.944 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 71.3 t80 -138.31 -42.29 0.51 Allowed 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.012 -1.055 . . . . 0.0 110.887 -179.391 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.513 HD22 ' CG2' ' A' ' 19' ' ' VAL . 5.2 mt -120.03 80.2 26.39 Favored Pre-proline 0 N--CA 1.493 1.677 0 O-C-N 121.095 -1.003 . . . . 0.0 110.397 -179.119 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -74.77 -14.5 21.71 Favored 'Trans proline' 0 C--N 1.309 -1.511 0 C-N-CA 122.337 2.024 . . . . 0.0 112.319 179.463 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -91.59 8.87 34.63 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.22 -0.925 . . . . 0.0 109.954 -179.666 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.513 ' CG2' HD22 ' A' ' 16' ' ' LEU . 48.8 t -110.87 135.55 49.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.281 -0.887 . . . . 0.0 109.742 -179.815 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.67 119.21 73.99 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.298 -0.877 . . . . 0.0 109.305 179.86 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_exo -51.36 -27.23 23.23 Favored 'Trans proline' 0 N--CA 1.494 1.507 0 C-N-CA 121.781 1.654 . . . . 0.0 112.01 179.676 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.8 -25.24 67.83 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.259 -0.901 . . . . 0.0 109.253 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.411 ' O ' ' OD1' ' A' ' 23' ' ' ASP . 58.6 t0 -81.8 7.35 12.92 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.362 -0.837 . . . . 0.0 109.693 -179.863 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 11.8 t -101.89 133.11 46.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.192 -0.943 . . . . 0.0 109.303 -179.851 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 86.9 m-20 -88.34 120.68 29.94 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.148 -0.97 . . . . 0.0 109.131 179.385 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 29.9 m -71.39 4.47 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 O-C-N 121.122 -0.987 . . . . 0.0 109.107 179.651 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -95.38 0.21 53.26 Favored 'General case' 0 N--CA 1.485 1.32 0 O-C-N 121.397 -0.814 . . . . 0.0 109.094 179.549 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 46.0 tp -100.68 132.97 45.8 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.409 -0.807 . . . . 0.0 109.331 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.7 m-20 -68.78 138.06 54.51 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.285 -0.885 . . . . 0.0 109.822 -179.549 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.577 HD11 HG13 ' A' ' 69' ' ' ILE . 90.5 mt -65.5 -38.88 90.99 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.365 -0.834 . . . . 0.0 110.817 -179.899 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 75.6 t -66.08 -38.6 82.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 120.972 -1.08 . . . . 0.0 110.671 -178.737 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -52.91 -34.02 53.1 Favored 'General case' 0 N--CA 1.489 1.475 0 N-CA-C 108.122 -1.066 . . . . 0.0 108.122 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.539 ' HB3' HG23 ' A' ' 35' ' ' VAL . 97.4 m-20 -71.05 -34.65 71.44 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.643 -0.661 . . . . 0.0 109.927 179.513 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 82.03 4.06 90.38 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 108.754 -1.738 . . . . 0.0 108.754 -179.205 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.539 HG23 ' HB3' ' A' ' 33' ' ' ASN . 70.2 t -62.7 -32.9 57.17 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 O-C-N 121.526 -0.984 . . . . 0.0 108.894 179.612 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 81.1 mt -88.57 121.24 38.58 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.368 0 O-C-N 121.318 -0.864 . . . . 0.0 110.041 -179.838 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -115.82 -159.68 0.72 Allowed 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 108.966 -0.753 . . . . 0.0 108.966 179.697 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -67.77 -54.27 20.55 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.134 -0.979 . . . . 0.0 108.959 179.691 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 43.1 mt -67.08 -32.57 73.84 Favored 'General case' 0 C--N 1.303 -1.414 0 N-CA-C 107.189 -1.412 . . . . 0.0 107.189 178.447 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.486 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -58.74 -40.4 94.89 Favored Glycine 0 N--CA 1.48 1.611 0 N-CA-C 108.465 -1.854 . . . . 0.0 108.465 179.308 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.0 tt -65.45 -42.21 92.61 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 121.578 -0.954 . . . . 0.0 108.916 178.982 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.5 tp -60.47 -45.83 92.31 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.429 -0.795 . . . . 0.0 109.173 179.605 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 59.9 mttp -59.69 -35.59 74.8 Favored 'General case' 0 C--N 1.297 -1.712 0 O-C-N 121.547 -0.721 . . . . 0.0 109.618 -179.727 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.486 HG23 ' O ' ' A' ' 40' ' ' GLY . 54.7 t -61.68 -49.71 83.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.357 -0.839 . . . . 0.0 110.071 -179.519 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.531 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 3.3 mp -68.0 -31.83 53.6 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 O-C-N 121.281 -0.887 . . . . 0.0 110.811 -179.659 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.99 -49.99 65.87 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 120.799 -1.188 . . . . 0.0 111.359 -178.2 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.694 ' CE2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -81.17 -44.94 17.13 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.774 -1.204 . . . . 0.0 110.046 -179.385 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.82 HD11 HG21 ' A' ' 76' ' ' VAL . 22.4 tp -58.58 -42.07 87.16 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 121.326 -0.859 . . . . 0.0 110.095 -178.858 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.531 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 2.3 pp20? -72.59 -36.54 68.18 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.195 -0.941 . . . . 0.0 109.777 -179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 50' ' ' ASP . . . . . 0.402 ' N ' ' CG ' ' A' ' 49' ' ' GLU . 55.9 t0 -60.3 -38.27 83.15 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.24 -0.913 . . . . 0.0 110.713 -179.463 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.664 ' NH2' HG11 ' A' ' 6' ' ' VAL . 77.0 mtp180 -61.81 -38.64 88.87 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.195 -0.941 . . . . 0.0 111.738 -178.581 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.553 ' CE1' HG11 ' A' ' 76' ' ' VAL . 87.7 m-85 -97.93 -9.39 26.32 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.803 -1.186 . . . . 0.0 110.482 -178.951 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 70.92 31.44 67.05 Favored Glycine 0 N--CA 1.487 2.092 0 N-CA-C 108.703 -1.759 . . . . 0.0 108.703 179.824 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.485 ' O ' ' OE1' ' A' ' 49' ' ' GLU . 26.4 pt -107.24 153.27 8.52 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.367 0 O-C-N 121.703 -0.881 . . . . 0.0 109.787 -179.392 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -99.23 134.04 42.66 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.12 -0.988 . . . . 0.0 109.806 -179.551 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.511 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -68.21 -22.99 64.77 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.312 -0.867 . . . . 0.0 109.533 179.725 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -54.71 -35.65 63.86 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.266 -0.896 . . . . 0.0 109.961 -179.626 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -55.66 -39.53 71.05 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.202 -0.936 . . . . 0.0 110.019 -179.65 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.511 ' O ' ' O ' ' A' ' 56' ' ' ALA . 13.9 p -136.3 142.31 38.9 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.291 -0.881 . . . . 0.0 109.685 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -91.92 133.39 35.73 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.029 -1.044 . . . . 0.0 109.275 179.736 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.475 HD12 ' CG1' ' A' ' 45' ' ' ILE . 32.5 mt -97.92 138.75 34.78 Favored 'General case' 0 C--N 1.305 -1.363 0 O-C-N 121.332 -0.855 . . . . 0.0 109.661 -179.613 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -110.09 157.11 38.81 Favored Pre-proline 0 N--CA 1.487 1.42 0 N-CA-C 108.952 -0.758 . . . . 0.0 108.952 179.518 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_endo -54.01 -24.52 32.65 Favored 'Trans proline' 0 C--N 1.302 -1.91 0 C-N-CA 122.536 2.157 . . . . 0.0 111.567 179.891 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -71.23 -27.78 63.72 Favored 'General case' 0 C--N 1.306 -1.307 0 O-C-N 121.365 -0.834 . . . . 0.0 109.531 179.825 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 65' ' ' HIS . . . . . 0.525 ' NE2' ' CB ' ' A' ' 75' ' ' PHE . 8.2 t-80 -65.76 -20.3 66.21 Favored 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.185 -0.947 . . . . 0.0 108.975 -179.738 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.502 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 21.9 m-85 -91.36 16.54 9.93 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 179.901 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 67' ' ' ARG . . . . . 0.453 ' NE ' ' CB ' ' A' ' 71' ' ' SER . 7.7 ptt180 -50.07 -37.24 32.62 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.808 -0.557 . . . . 0.0 110.254 -179.753 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 19.0 t -163.15 157.65 20.81 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.977 -1.077 . . . . 0.0 110.29 -179.626 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.665 ' H ' HD12 ' A' ' 69' ' ' ILE . 2.0 mp -58.03 -39.31 71.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.424 -0.797 . . . . 0.0 109.266 179.862 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 7.6 ptm180 -58.03 -40.68 81.49 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.574 -0.704 . . . . 0.0 109.452 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 71' ' ' SER . . . . . 0.453 ' CB ' ' NE ' ' A' ' 67' ' ' ARG . 83.5 p -65.14 -37.16 86.54 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.325 -0.859 . . . . 0.0 109.722 179.914 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.455 ' O ' HG23 ' A' ' 76' ' ' VAL . 75.3 mt -64.86 -44.94 96.24 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.268 0 O-C-N 121.245 -0.91 . . . . 0.0 109.809 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 40.4 t0 -59.75 -41.7 91.57 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.291 -0.88 . . . . 0.0 109.396 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.75 -43.86 83.02 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.405 -0.81 . . . . 0.0 110.084 -179.777 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 75' ' ' PHE . . . . . 0.525 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 56.8 t80 -62.1 -46.52 88.69 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.338 -0.851 . . . . 0.0 109.537 -179.764 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.82 HG21 HD11 ' A' ' 48' ' ' LEU . 99.2 t -61.67 -44.43 98.69 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.394 0 O-C-N 121.269 -0.895 . . . . 0.0 109.027 179.92 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.522 ' O ' ' O ' ' A' ' 81' ' ' THR . 53.3 t -66.64 -43.22 90.48 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 121.374 -0.829 . . . . 0.0 109.255 179.554 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.81 -23.15 49.82 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.771 -1.332 . . . . 0.0 109.771 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.05 -28.88 68.57 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.259 -1.142 . . . . 0.0 110.353 -179.475 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 9.8 p -129.65 -32.73 1.9 Allowed 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.128 -0.983 . . . . 0.0 110.752 -179.274 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.522 ' O ' ' O ' ' A' ' 77' ' ' VAL . 0.1 OUTLIER . . . . . 0 N--CA 1.489 1.498 0 O-C-N 121.188 -0.945 . . . . 0.0 109.682 -179.396 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 46.0 m80 . . . . . 0 N--CA 1.485 1.322 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -55.81 -39.77 71.81 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.392 -0.817 . . . . 0.0 109.562 -179.433 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.1 m -60.75 -36.33 78.63 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.213 -0.93 . . . . 0.0 109.553 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 75.8 t -63.3 -45.67 97.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.21 -0.932 . . . . 0.0 109.45 -179.895 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.523 ' O ' HG13 ' A' ' 11' ' ' VAL . 78.8 mt -59.69 -45.6 94.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.373 -0.829 . . . . 0.0 108.799 179.622 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.588 ' O ' HG22 ' A' ' 12' ' ' VAL . . . -62.21 -35.27 78.38 Favored 'General case' 0 C--N 1.304 -1.374 0 N-CA-C 108.763 -0.828 . . . . 0.0 108.763 179.5 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 32.5 tt0 -59.97 -38.37 82.32 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.259 -0.901 . . . . 0.0 109.472 179.733 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.65 ' CG ' ' CZ2' ' A' ' 47' ' ' TRP . 44.0 m-85 -70.17 -47.74 60.31 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.971 -1.081 . . . . 0.0 111.205 -179.551 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.523 HG13 ' O ' ' A' ' 7' ' ' ILE . 0.9 OUTLIER -61.64 -46.88 95.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 120.881 -1.137 . . . . 0.0 110.312 -178.143 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.592 ' O ' ' N ' ' A' ' 16' ' ' LEU . 35.5 m -64.75 -46.0 93.46 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.394 0 O-C-N 120.799 -1.188 . . . . 0.0 109.552 179.758 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 13' ' ' GLU . . . . . 0.536 ' N ' HG23 ' A' ' 12' ' ' VAL . 96.9 mt-10 -64.55 -26.96 68.64 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 120.813 -1.179 . . . . 0.0 109.737 179.798 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -64.43 -31.47 72.69 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.445 -0.785 . . . . 0.0 110.14 -179.479 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 86.6 t80 -142.84 -33.31 0.46 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.981 -1.074 . . . . 0.0 110.794 -179.436 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.592 ' N ' ' O ' ' A' ' 12' ' ' VAL . 3.4 mt -121.95 79.8 41.95 Favored Pre-proline 0 N--CA 1.492 1.66 0 O-C-N 121.07 -1.019 . . . . 0.0 109.976 -179.32 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -76.07 -18.54 16.42 Favored 'Trans proline' 0 C--N 1.309 -1.507 0 C-N-CA 122.537 2.158 . . . . 0.0 112.873 -179.756 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.442 ' C ' ' OD1' ' A' ' 18' ' ' ASP . 50.4 p30 -89.43 12.86 15.18 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.031 -1.043 . . . . 0.0 110.131 -179.565 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 84.1 t -106.79 134.41 48.52 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.187 -0.946 . . . . 0.0 109.574 179.669 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.06 118.45 65.74 Favored Pre-proline 0 N--CA 1.488 1.443 0 O-C-N 121.323 -0.861 . . . . 0.0 108.918 179.634 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -51.31 -36.41 57.2 Favored 'Trans proline' 0 N--CA 1.492 1.389 0 C-N-CA 121.571 1.514 . . . . 0.0 111.912 179.966 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -68.58 -18.56 64.36 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.246 -0.909 . . . . 0.0 108.885 179.386 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.451 ' O ' ' OD1' ' A' ' 23' ' ' ASP . 60.4 t0 -81.97 7.11 13.94 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.479 -0.763 . . . . 0.0 109.91 -179.644 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 15.1 t -104.56 131.66 53.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.167 -0.958 . . . . 0.0 109.433 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 62.4 t0 -88.44 119.68 29.11 Favored 'General case' 0 C--N 1.303 -1.445 0 O-C-N 121.213 -0.929 . . . . 0.0 108.689 179.256 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.2 m -75.29 3.18 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 O-C-N 121.138 -0.977 . . . . 0.0 109.484 -179.886 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -85.49 -19.18 31.6 Favored 'General case' 0 N--CA 1.487 1.375 0 O-C-N 121.137 -0.977 . . . . 0.0 109.116 179.368 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 48.7 tp -88.84 134.04 34.07 Favored 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 108.541 -0.911 . . . . 0.0 108.541 179.552 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 89.1 m-20 -60.37 135.12 57.64 Favored 'General case' 0 C--N 1.301 -1.539 0 C-N-CA 119.185 -1.006 . . . . 0.0 109.2 -179.423 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 1.043 HD23 HD11 ' A' ' 36' ' ' ILE . 39.0 tp -62.59 -36.42 82.68 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.509 -0.745 . . . . 0.0 110.257 -179.322 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 69.2 t -64.22 -35.76 74.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.047 -1.033 . . . . 0.0 110.466 -179.384 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -52.62 -33.72 47.88 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.446 ' HB3' HG23 ' A' ' 35' ' ' VAL . 97.1 m-20 -70.82 -34.55 71.83 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.606 -0.684 . . . . 0.0 110.001 179.468 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 85.71 5.16 84.53 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 108.858 -1.697 . . . . 0.0 108.858 -179.324 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.446 HG23 ' HB3' ' A' ' 33' ' ' ASN . 73.6 t -61.7 -33.05 55.72 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 121.554 -0.968 . . . . 0.0 108.979 179.678 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 1.043 HD11 HD23 ' A' ' 30' ' ' LEU . 80.2 mt -83.68 114.47 24.33 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.411 0 O-C-N 121.339 -0.851 . . . . 0.0 109.723 -179.728 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -112.6 -178.82 3.49 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 179.542 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -58.82 -52.3 66.29 Favored 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 108.245 -1.021 . . . . 0.0 108.245 179.7 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 42.3 mt -70.28 -32.65 70.53 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 106.849 -1.538 . . . . 0.0 106.849 177.922 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.606 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.27 -41.01 96.61 Favored Glycine 0 N--CA 1.481 1.67 0 N-CA-C 108.525 -1.83 . . . . 0.0 108.525 179.14 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 2.9 tt -64.87 -44.49 89.52 Favored 'General case' 0 C--N 1.305 -1.35 0 O-C-N 121.636 -0.92 . . . . 0.0 109.212 179.096 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 16.7 tp -59.55 -44.78 93.14 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.353 -0.842 . . . . 0.0 109.578 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 31.7 mttp -62.05 -34.81 76.93 Favored 'General case' 0 C--N 1.298 -1.669 0 O-C-N 121.076 -1.015 . . . . 0.0 109.541 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.606 HG23 ' O ' ' A' ' 40' ' ' GLY . 69.4 t -61.2 -48.63 88.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.387 -0.821 . . . . 0.0 109.993 -179.528 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.541 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 3.0 mp -67.84 -32.44 56.51 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.515 0 O-C-N 121.405 -0.81 . . . . 0.0 110.948 -179.677 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.43 -50.36 63.64 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 120.982 -1.074 . . . . 0.0 111.373 -178.112 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.65 ' CZ2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -81.18 -44.62 17.57 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 120.708 -1.245 . . . . 0.0 109.853 -179.502 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.5 ' N ' ' CG ' ' A' ' 47' ' ' TRP . 38.9 tp -58.55 -42.26 87.45 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.332 -0.855 . . . . 0.0 109.958 -179.022 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.541 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 1.2 pp20? -72.63 -35.85 67.91 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.0 -1.063 . . . . 0.0 109.635 179.887 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.1 t0 -60.2 -38.25 82.73 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.237 -0.914 . . . . 0.0 110.288 -179.77 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.467 ' HD2' ' HE1' ' A' ' 47' ' ' TRP . 71.9 mtp85 -61.19 -38.12 85.4 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.244 -0.91 . . . . 0.0 111.16 -178.956 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.634 ' CE2' HG11 ' A' ' 76' ' ' VAL . 86.6 m-85 -99.53 -10.36 22.18 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 120.859 -1.151 . . . . 0.0 110.031 -179.388 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 69.98 33.49 70.14 Favored Glycine 0 N--CA 1.486 2.027 0 N-CA-C 108.558 -1.817 . . . . 0.0 108.558 179.856 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 38.5 pt -103.08 149.06 7.44 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 O-C-N 121.535 -0.979 . . . . 0.0 109.994 -179.239 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -94.2 120.1 33.96 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.3 -0.875 . . . . 0.0 109.459 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.492 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -66.65 -28.99 68.91 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.403 -0.81 . . . . 0.0 109.495 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 54.6 t0 -56.41 -35.03 67.34 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.387 -0.821 . . . . 0.0 110.249 -179.453 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -53.75 -39.11 65.07 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.055 -1.028 . . . . 0.0 109.65 -179.582 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.492 ' O ' ' O ' ' A' ' 56' ' ' ALA . 46.5 t -127.46 136.57 60.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.521 -0.737 . . . . 0.0 109.544 179.851 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -85.5 128.43 34.74 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.119 -0.988 . . . . 0.0 108.765 179.547 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 54.8 mt -98.46 141.21 31.61 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.142 -0.974 . . . . 0.0 109.997 -179.158 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -105.55 151.15 39.72 Favored Pre-proline 0 C--N 1.305 -1.361 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 179.403 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -53.67 -21.87 20.89 Favored 'Trans proline' 0 C--N 1.306 -1.659 0 C-N-CA 122.227 1.951 . . . . 0.0 111.998 -179.54 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -70.07 -28.27 65.29 Favored 'General case' 0 N--CA 1.486 1.351 0 O-C-N 121.265 -0.897 . . . . 0.0 109.586 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 65' ' ' HIS . . . . . 0.586 ' CD2' ' O ' ' A' ' 65' ' ' HIS . 6.5 t-160 -65.72 -20.93 66.46 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.259 -0.901 . . . . 0.0 109.277 -179.713 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.552 ' HB3' HD13 ' A' ' 36' ' ' ILE . 7.8 m-85 -96.51 15.99 19.96 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.525 -0.734 . . . . 0.0 109.078 -179.65 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 67' ' ' ARG . . . . . 0.405 ' HG2' ' N ' ' A' ' 68' ' ' SER . 1.3 ptt85 -54.36 -35.93 63.3 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.645 -0.659 . . . . 0.0 110.243 -179.765 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 68' ' ' SER . . . . . 0.555 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 90.4 p -157.54 160.38 38.13 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 120.912 -1.117 . . . . 0.0 110.287 -179.95 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.605 ' H ' HD12 ' A' ' 69' ' ' ILE . 3.1 mp -59.14 -34.03 52.26 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 179.007 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 57.6 mtp85 -56.95 -42.9 80.92 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.707 -0.621 . . . . 0.0 109.948 -179.266 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 78.8 p -68.71 -35.82 77.65 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.298 -0.876 . . . . 0.0 110.115 -179.601 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.434 ' O ' HG23 ' A' ' 76' ' ' VAL . 56.3 mt -65.93 -48.51 81.65 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 O-C-N 121.216 -0.928 . . . . 0.0 110.122 -179.38 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 43.9 t0 -60.17 -43.16 96.03 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.18 -0.95 . . . . 0.0 109.49 -179.757 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.95 -43.63 82.66 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.494 -0.754 . . . . 0.0 110.251 -179.579 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 75' ' ' PHE . . . . . 0.553 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 70.4 t80 -62.51 -45.29 93.66 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.263 -0.898 . . . . 0.0 109.697 -179.641 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.634 HG11 ' CE2' ' A' ' 52' ' ' PHE . 95.9 t -64.84 -47.06 90.0 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.361 0 O-C-N 121.206 -0.934 . . . . 0.0 109.665 -179.945 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 54.9 t -69.53 -45.98 76.93 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.329 0 O-C-N 121.1 -1.0 . . . . 0.0 109.731 179.857 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.48 ' O ' ' O ' ' A' ' 81' ' ' THR . . . -63.9 -30.73 78.55 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 110.307 -1.117 . . . . 0.0 110.307 -179.633 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -66.81 -39.53 87.74 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.137 -1.214 . . . . 0.0 110.516 -179.019 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 65.2 p -84.18 -28.81 27.09 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.036 -1.04 . . . . 0.0 109.778 -179.727 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.48 ' O ' ' O ' ' A' ' 78' ' ' GLY . 0.3 OUTLIER . . . . . 0 C--N 1.302 -1.471 0 O-C-N 121.478 -0.764 . . . . 0.0 109.737 -179.546 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 20.8 m170 . . . . . 0 N--CA 1.493 1.696 0 CA-C-O 121.12 0.486 . . . . 0.0 109.926 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -61.99 -33.05 73.61 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.141 -0.974 . . . . 0.0 109.547 179.856 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.3 t -57.86 -37.56 74.13 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.284 -0.885 . . . . 0.0 109.879 -179.497 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 77.2 t -63.52 -45.41 97.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.169 -0.957 . . . . 0.0 109.514 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 77.7 mt -60.06 -42.72 90.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.405 -0.809 . . . . 0.0 109.096 179.727 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.58 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -60.89 -35.83 77.65 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.54 -0.725 . . . . 0.0 109.224 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 30.9 tt0 -64.62 -41.77 95.97 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.234 -0.916 . . . . 0.0 110.191 -179.839 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.679 ' CG ' ' CZ2' ' A' ' 47' ' ' TRP . 37.4 m-85 -64.28 -50.62 67.16 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.975 -1.078 . . . . 0.0 110.719 -179.371 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.422 HG13 ' N ' ' A' ' 12' ' ' VAL . 4.5 p -63.57 -41.0 91.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.047 -1.033 . . . . 0.0 109.383 -179.575 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.58 HG23 ' O ' ' A' ' 8' ' ' ALA . 70.5 t -63.31 -46.34 95.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.121 -0.987 . . . . 0.0 109.339 179.558 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -71.13 -26.09 62.86 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.25 -0.906 . . . . 0.0 109.846 179.715 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -64.45 -30.61 71.65 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.46 -0.775 . . . . 0.0 110.664 -179.029 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 72.9 t80 -135.82 -42.9 0.67 Allowed 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.016 -1.053 . . . . 0.0 110.826 -179.084 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.483 HD22 ' CG2' ' A' ' 19' ' ' VAL . 4.2 mt -119.49 80.09 21.96 Favored Pre-proline 0 N--CA 1.493 1.723 0 O-C-N 121.088 -1.008 . . . . 0.0 110.377 -179.094 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -75.53 -14.13 20.13 Favored 'Trans proline' 0 C--N 1.309 -1.522 0 C-N-CA 122.292 1.995 . . . . 0.0 112.217 179.404 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.42 ' OD1' ' O ' ' A' ' 18' ' ' ASP . 59.9 t0 -89.55 7.02 38.4 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.274 -0.891 . . . . 0.0 109.683 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.483 ' CG2' HD22 ' A' ' 16' ' ' LEU . 46.1 t -111.76 135.44 51.0 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.432 -0.793 . . . . 0.0 109.651 -179.859 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.468 ' O ' ' OD1' ' A' ' 23' ' ' ASP . . . -73.49 117.88 64.26 Favored Pre-proline 0 N--CA 1.489 1.514 0 O-C-N 121.304 -0.872 . . . . 0.0 109.325 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_exo -51.45 -25.53 19.14 Favored 'Trans proline' 0 N--CA 1.493 1.47 0 C-N-CA 121.858 1.705 . . . . 0.0 112.192 179.568 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.03 -23.67 67.26 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.307 -0.871 . . . . 0.0 109.739 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.468 ' OD1' ' O ' ' A' ' 20' ' ' ALA . 52.5 p30 -84.6 7.75 19.12 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.222 -0.924 . . . . 0.0 110.024 -179.635 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 10.9 t -104.57 131.39 53.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.192 -0.942 . . . . 0.0 109.397 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 87.6 m-20 -89.43 120.5 30.81 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.213 -0.93 . . . . 0.0 109.091 179.369 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.0 m -78.83 3.38 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 O-C-N 121.153 -0.967 . . . . 0.0 109.095 179.53 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 89.8 m-20 -83.5 -20.65 33.56 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 121.291 -0.881 . . . . 0.0 109.135 179.33 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 43.2 tp -88.69 137.9 31.9 Favored 'General case' 0 N--CA 1.487 1.41 0 N-CA-C 108.844 -0.798 . . . . 0.0 108.844 179.798 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 89.1 m-20 -57.33 136.27 56.55 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 121.158 -0.964 . . . . 0.0 109.35 -179.454 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.746 HD12 HG13 ' A' ' 69' ' ' ILE . 1.9 tt -66.0 -37.95 87.22 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.716 -0.615 . . . . 0.0 110.171 -179.179 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 69.9 t -63.14 -35.19 70.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.068 -1.02 . . . . 0.0 110.421 -178.976 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 90.8 m-20 -52.66 -33.89 49.18 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 108.062 -1.088 . . . . 0.0 108.062 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.452 ' HB3' HG23 ' A' ' 35' ' ' VAL . 97.5 m-20 -71.11 -34.62 71.27 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.571 -0.706 . . . . 0.0 109.864 179.488 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 84.4 6.83 85.59 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 108.962 -1.655 . . . . 0.0 108.962 -179.474 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.452 HG23 ' HB3' ' A' ' 33' ' ' ASN . 71.1 t -61.88 -35.03 65.65 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 O-C-N 121.392 -1.064 . . . . 0.0 108.95 179.74 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.699 HD11 HD13 ' A' ' 30' ' ' LEU . 99.1 mt -80.17 111.94 17.57 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.318 -0.864 . . . . 0.0 109.807 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -113.02 -166.02 1.04 Allowed 'General case' 0 C--N 1.302 -1.458 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 179.777 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -65.18 -54.38 30.55 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.146 -0.971 . . . . 0.0 108.71 179.712 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 34.0 mt -70.57 -33.29 70.94 Favored 'General case' 0 C--N 1.302 -1.489 0 N-CA-C 107.213 -1.402 . . . . 0.0 107.213 178.4 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.529 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.4 -41.18 96.89 Favored Glycine 0 N--CA 1.48 1.589 0 N-CA-C 108.61 -1.796 . . . . 0.0 108.61 179.205 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.7 tt -65.68 -41.55 92.29 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.519 -0.989 . . . . 0.0 109.085 179.201 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.5 tp -61.22 -46.03 92.11 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.434 -0.791 . . . . 0.0 109.361 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 63.5 mttp -60.28 -35.91 76.62 Favored 'General case' 0 C--N 1.296 -1.733 0 O-C-N 121.443 -0.786 . . . . 0.0 109.452 -179.708 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.529 HG23 ' O ' ' A' ' 40' ' ' GLY . 63.2 t -62.18 -45.82 97.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.357 -0.839 . . . . 0.0 109.668 -179.916 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.701 HG23 ' HB2' ' A' ' 56' ' ' ALA . 1.5 mp -67.96 -39.44 81.63 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 O-C-N 121.555 -0.716 . . . . 0.0 111.262 -179.375 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.09 -49.92 63.41 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.545 -1.347 . . . . 0.0 112.268 -177.603 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.679 ' CZ2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -77.85 -46.05 22.55 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 120.637 -1.29 . . . . 0.0 110.681 -178.546 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.857 HD12 HH21 ' A' ' 51' ' ' ARG . 8.8 tp -58.65 -44.59 90.16 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.173 -0.955 . . . . 0.0 110.195 -178.825 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 65.4 mm-40 -69.93 -36.21 75.14 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.135 -0.978 . . . . 0.0 109.797 -179.667 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.3 t0 -62.24 -38.43 89.19 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.367 -0.833 . . . . 0.0 111.431 -179.2 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.857 HH21 HD12 ' A' ' 48' ' ' LEU . 66.6 mtm180 -59.34 -38.92 81.58 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.023 -1.048 . . . . 0.0 111.574 -178.392 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.61 ' CE1' ' CG1' ' A' ' 76' ' ' VAL . 48.7 m-85 -90.14 -2.61 58.1 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 120.759 -1.213 . . . . 0.0 110.544 -179.199 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 73.98 29.2 63.19 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 108.797 -1.721 . . . . 0.0 108.797 179.546 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 31.4 pt -113.1 153.47 14.66 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 O-C-N 121.694 -0.886 . . . . 0.0 109.758 -179.397 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -101.83 138.76 38.37 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.255 -0.903 . . . . 0.0 109.426 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.701 ' HB2' HG23 ' A' ' 45' ' ' ILE . . . -64.65 -30.61 71.63 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.298 -0.876 . . . . 0.0 109.681 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 53.8 t0 -55.48 -36.02 66.17 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.132 -0.98 . . . . 0.0 109.827 -179.74 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -57.36 -39.89 76.94 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.199 -0.938 . . . . 0.0 110.169 -179.561 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.506 ' O ' ' O ' ' A' ' 56' ' ' ALA . 13.6 p -136.51 142.15 39.07 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.272 -0.892 . . . . 0.0 109.783 -179.941 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -101.71 137.02 40.57 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.156 -0.965 . . . . 0.0 109.433 179.815 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.492 HD23 ' ND1' ' A' ' 65' ' ' HIS . 5.5 mp -103.27 144.06 31.84 Favored 'General case' 0 C--N 1.305 -1.34 0 O-C-N 121.256 -0.902 . . . . 0.0 109.732 -179.843 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -103.34 153.13 38.7 Favored Pre-proline 0 C--N 1.305 -1.351 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 179.81 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 8.5 Cg_endo -53.75 -24.54 30.78 Favored 'Trans proline' 0 C--N 1.306 -1.665 0 C-N-CA 122.264 1.976 . . . . 0.0 111.82 -179.832 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -70.42 -28.39 65.01 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 121.392 -0.818 . . . . 0.0 109.257 179.69 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 65' ' ' HIS . . . . . 0.524 ' NE2' ' CB ' ' A' ' 75' ' ' PHE . 7.6 t-80 -66.02 -20.04 66.05 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 121.375 -0.828 . . . . 0.0 109.027 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.516 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 15.5 m-85 -91.98 15.1 13.93 Favored 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 67' ' ' ARG . . . . . 0.536 ' CZ ' ' OG ' ' A' ' 71' ' ' SER . 7.2 ptt180 -48.6 -37.33 17.79 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.7 -0.625 . . . . 0.0 109.866 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 68' ' ' SER . . . . . 0.518 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 92.4 p -159.55 155.86 27.08 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.092 -1.005 . . . . 0.0 109.919 179.811 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.746 HG13 HD12 ' A' ' 30' ' ' LEU . 3.5 mp -58.58 -34.83 52.36 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 179.045 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 58.6 mtp180 -57.44 -43.25 83.73 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.67 -0.644 . . . . 0.0 109.462 -179.76 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 71' ' ' SER . . . . . 0.536 ' OG ' ' CZ ' ' A' ' 67' ' ' ARG . 22.7 t -65.54 -39.9 92.27 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.465 -0.772 . . . . 0.0 109.81 179.935 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.401 ' HA ' ' NE2' ' A' ' 65' ' ' HIS . 68.5 mt -61.02 -46.41 96.7 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.313 0 O-C-N 121.313 -0.867 . . . . 0.0 110.109 -179.541 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 39.4 t0 -60.28 -42.88 96.38 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.176 -0.952 . . . . 0.0 109.364 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -67.13 -41.94 85.29 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.427 -0.796 . . . . 0.0 110.466 -179.708 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 75' ' ' PHE . . . . . 0.524 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 62.5 t80 -62.05 -45.72 92.3 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.103 -0.998 . . . . 0.0 109.637 -179.563 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.678 ' CG2' HD21 ' A' ' 48' ' ' LEU . 69.9 t -67.12 -48.7 78.07 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 O-C-N 121.245 -0.909 . . . . 0.0 110.014 -179.853 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 78.3 t -70.0 -43.35 79.37 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.338 0 O-C-N 121.109 -0.994 . . . . 0.0 109.571 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -61.11 -34.04 86.44 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 110.436 -1.066 . . . . 0.0 110.436 -179.461 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.78 -41.28 83.47 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.262 -1.14 . . . . 0.0 111.051 -178.692 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.467 HG21 ' CD2' ' A' ' 52' ' ' PHE . 49.4 p -82.79 -32.75 27.53 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.04 -1.038 . . . . 0.0 109.679 -179.511 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.301 -1.53 0 O-C-N 121.468 -0.77 . . . . 0.0 109.626 -179.383 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 93.6 m-70 . . . . . 0 N--CA 1.49 1.541 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -62.1 -34.71 76.83 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.229 -0.919 . . . . 0.0 109.634 -179.871 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.2 m -59.38 -38.9 81.68 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.293 -0.88 . . . . 0.0 109.864 -179.617 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 51.8 t -66.97 -46.34 85.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.121 -0.987 . . . . 0.0 109.742 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.742 HG21 ' OD1' ' A' ' 73' ' ' ASP . 87.3 mt -59.81 -50.27 80.7 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.456 0 O-C-N 121.379 -0.826 . . . . 0.0 109.847 -179.617 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.76 -42.3 97.85 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.272 -0.892 . . . . 0.0 110.78 -179.664 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 47.3 tt0 -69.41 -47.59 63.68 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 120.976 -1.078 . . . . 0.0 111.043 -178.582 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.688 ' CD1' ' N ' ' A' ' 11' ' ' VAL . 0.0 OUTLIER -71.66 -44.14 64.8 Favored 'General case' 0 C--N 1.298 -1.659 0 O-C-N 120.921 -1.112 . . . . 0.0 110.815 -179.226 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.688 ' N ' ' CD1' ' A' ' 10' ' ' PHE . 5.2 p -61.02 -47.84 91.78 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 120.996 -1.065 . . . . 0.0 110.692 -178.711 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.566 ' N ' HG13 ' A' ' 11' ' ' VAL . 8.6 p -63.62 -39.14 84.25 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 120.805 -1.184 . . . . 0.0 109.817 -179.686 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 13' ' ' GLU . . . . . 0.407 ' N ' HG13 ' A' ' 12' ' ' VAL . 96.8 mt-10 -65.78 -36.17 82.77 Favored 'General case' 0 N--CA 1.486 1.33 0 O-C-N 120.93 -1.106 . . . . 0.0 110.131 -179.919 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -65.95 -42.41 90.02 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.166 -0.959 . . . . 0.0 110.196 -179.694 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 86.5 m-85 -91.47 -45.04 8.75 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.183 -0.948 . . . . 0.0 110.512 -179.691 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.537 HD22 ' CG2' ' A' ' 19' ' ' VAL . 8.5 mt -122.31 80.22 45.13 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.421 -0.799 . . . . 0.0 110.223 -178.942 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_endo -70.17 -15.47 35.55 Favored 'Trans proline' 0 C--N 1.312 -1.373 0 C-N-CA 122.099 1.866 . . . . 0.0 112.333 179.704 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -96.07 9.74 39.86 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.163 -0.961 . . . . 0.0 110.229 -179.581 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.537 ' CG2' HD22 ' A' ' 16' ' ' LEU . 44.3 t -114.73 135.28 55.09 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.239 -0.913 . . . . 0.0 109.837 -179.782 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -74.71 118.69 72.13 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.349 -0.844 . . . . 0.0 109.122 179.743 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_exo -51.17 -36.89 57.38 Favored 'Trans proline' 0 N--CA 1.493 1.444 0 C-N-CA 121.765 1.643 . . . . 0.0 112.008 179.635 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.71 -23.0 66.06 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.282 -0.886 . . . . 0.0 108.948 179.471 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 87.6 m-20 -87.98 7.13 32.55 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.406 -0.809 . . . . 0.0 109.872 -179.729 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.466 HG21 HG21 ' A' ' 12' ' ' VAL . 10.6 t -107.07 128.49 61.91 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.188 -0.945 . . . . 0.0 109.406 179.942 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 86.9 m-20 -89.81 120.29 30.92 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.137 -0.977 . . . . 0.0 109.169 179.275 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.4 m -78.87 3.36 1.74 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.465 0 O-C-N 121.125 -0.985 . . . . 0.0 108.741 179.321 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 90.5 m-20 -83.59 -19.4 35.61 Favored 'General case' 0 N--CA 1.486 1.358 0 O-C-N 121.545 -0.722 . . . . 0.0 109.073 179.392 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 42.8 tp -88.94 138.01 31.8 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 121.481 -0.762 . . . . 0.0 109.024 179.863 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -58.61 136.92 57.75 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.11 -0.993 . . . . 0.0 109.517 -179.376 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.757 HD12 HG13 ' A' ' 69' ' ' ILE . 2.4 tt -66.46 -38.0 86.38 Favored 'General case' 0 C--N 1.299 -1.613 0 O-C-N 121.757 -0.59 . . . . 0.0 110.134 -179.232 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.418 HG23 ' O ' ' A' ' 66' ' ' PHE . 75.7 t -62.55 -34.72 66.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.121 -0.987 . . . . 0.0 110.436 -178.987 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -52.45 -33.97 46.73 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 120.975 -1.078 . . . . 0.0 108.104 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.421 ' HB3' HG23 ' A' ' 35' ' ' VAL . 97.2 m-20 -71.08 -34.46 71.19 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.643 -0.66 . . . . 0.0 109.949 179.389 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 85.37 6.52 83.85 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 -179.446 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.421 HG23 ' HB3' ' A' ' 33' ' ' ASN . 76.3 t -61.52 -34.49 61.82 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.438 -1.036 . . . . 0.0 109.094 179.695 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.629 HD11 HD13 ' A' ' 30' ' ' LEU . 93.9 mt -83.14 114.4 23.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.274 -0.891 . . . . 0.0 109.735 -179.876 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.402 ' H ' ' HA3' ' A' ' 40' ' ' GLY . 92.4 m-20 -118.66 -158.41 0.72 Allowed 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 179.657 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -64.78 -54.15 35.81 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.046 -1.034 . . . . 0.0 108.506 179.631 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.597 ' N ' ' CD2' ' A' ' 39' ' ' LEU . 1.5 mm? -68.74 -32.52 72.36 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 107.32 -1.363 . . . . 0.0 107.32 178.264 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.402 ' HA3' ' H ' ' A' ' 37' ' ' ASP . . . -58.79 -45.94 94.18 Favored Glycine 0 N--CA 1.483 1.781 0 N-CA-C 109.06 -1.616 . . . . 0.0 109.06 179.6 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.9 tt -64.24 -39.06 93.18 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.426 -1.043 . . . . 0.0 108.762 179.035 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.1 tp -59.68 -45.76 91.11 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.311 -0.868 . . . . 0.0 108.798 179.543 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 54.5 mttp -60.2 -35.59 75.74 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.498 -0.751 . . . . 0.0 109.536 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 68.3 t -60.17 -46.89 93.97 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.345 -0.847 . . . . 0.0 109.567 -179.925 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.643 HD11 HD12 ' A' ' 61' ' ' LEU . 1.7 mp -68.22 -33.23 59.52 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 O-C-N 121.359 -0.838 . . . . 0.0 110.802 -179.915 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.17 -49.1 65.93 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.095 -1.003 . . . . 0.0 111.466 -178.359 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.524 ' C ' ' CD1' ' A' ' 47' ' ' TRP . 0.0 OUTLIER -80.8 -41.51 23.22 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 120.583 -1.323 . . . . 0.0 109.663 -179.548 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.449 HD11 ' CG2' ' A' ' 76' ' ' VAL . 8.3 tt -59.55 -41.78 90.87 Favored 'General case' 0 C--N 1.3 -1.567 0 O-C-N 121.377 -0.827 . . . . 0.0 109.909 -179.331 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.52 ' O ' ' N ' ' A' ' 53' ' ' GLY . 18.4 pt-20 -73.15 -36.92 66.75 Favored 'General case' 0 C--N 1.304 -1.371 0 O-C-N 121.099 -1.001 . . . . 0.0 109.562 -179.817 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 50' ' ' ASP . . . . . 0.405 ' N ' ' CG ' ' A' ' 49' ' ' GLU . 55.9 t0 -59.06 -38.49 79.5 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.321 -0.862 . . . . 0.0 110.838 -179.319 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.46 ' NH2' HG21 ' A' ' 76' ' ' VAL . 75.1 mtm180 -61.56 -41.18 97.0 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 120.986 -1.072 . . . . 0.0 111.473 -178.649 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.898 ' CE2' HG21 ' A' ' 80' ' ' THR . 36.7 m-85 -105.87 -12.54 15.81 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 120.923 -1.11 . . . . 0.0 110.173 -179.451 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.52 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 70.85 30.45 68.15 Favored Glycine 0 N--CA 1.486 2.017 0 N-CA-C 109.054 -1.618 . . . . 0.0 109.054 179.574 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 16.2 pt -97.82 129.72 47.6 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 O-C-N 121.336 -1.097 . . . . 0.0 109.756 -179.549 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -67.37 135.53 53.37 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.155 -0.966 . . . . 0.0 109.651 -179.666 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.504 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -66.37 -31.5 72.31 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.297 -0.877 . . . . 0.0 109.441 179.804 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 54.2 t0 -56.94 -36.69 70.53 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.277 -0.89 . . . . 0.0 109.999 -179.75 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 54.5 t0 -56.11 -40.38 73.61 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.182 -0.949 . . . . 0.0 109.892 -179.598 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.504 ' O ' ' O ' ' A' ' 56' ' ' ALA . 42.6 t -129.33 134.74 63.23 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.425 -0.797 . . . . 0.0 109.603 179.926 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -91.81 131.06 37.43 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.15 -0.969 . . . . 0.0 109.277 179.763 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.643 HD12 HD11 ' A' ' 45' ' ' ILE . 54.6 mt -97.82 139.27 33.92 Favored 'General case' 0 C--N 1.305 -1.327 0 O-C-N 121.297 -0.877 . . . . 0.0 109.674 -179.752 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -110.0 157.12 38.71 Favored Pre-proline 0 N--CA 1.489 1.495 0 N-CA-C 108.849 -0.796 . . . . 0.0 108.849 179.606 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 7.1 Cg_endo -52.83 -22.9 19.1 Favored 'Trans proline' 0 C--N 1.302 -1.903 0 C-N-CA 122.368 2.045 . . . . 0.0 111.72 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -70.45 -27.52 64.31 Favored 'General case' 0 N--CA 1.485 1.304 0 O-C-N 121.386 -0.821 . . . . 0.0 109.507 179.6 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 65' ' ' HIS . . . . . 0.566 ' C ' ' CD2' ' A' ' 65' ' ' HIS . 0.7 OUTLIER -65.67 -19.8 66.05 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.315 -0.865 . . . . 0.0 108.95 -179.882 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.551 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 6.0 m-85 -98.25 16.11 22.42 Favored 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 179.839 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 67' ' ' ARG . . . . . 0.424 ' HG2' ' H ' ' A' ' 68' ' ' SER . 5.3 ptt180 -49.87 -38.49 35.69 Favored 'General case' 0 C--N 1.3 -1.547 0 O-C-N 121.79 -0.569 . . . . 0.0 110.031 -179.798 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 68' ' ' SER . . . . . 0.542 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 84.2 p -161.66 157.59 24.76 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.006 -1.059 . . . . 0.0 109.969 179.838 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.757 HG13 HD12 ' A' ' 30' ' ' LEU . 3.4 mp -57.97 -35.04 50.4 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 179.034 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 59.6 mtp180 -57.51 -42.18 82.29 Favored 'General case' 0 N--CA 1.488 1.427 0 CA-C-O 121.442 0.639 . . . . 0.0 109.291 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 60.5 p -70.46 -36.39 73.88 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.446 -0.784 . . . . 0.0 110.047 -179.707 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 81.0 mt -62.73 -51.35 73.15 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 O-C-N 121.216 -0.928 . . . . 0.0 109.626 -179.636 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.742 ' OD1' HG21 ' A' ' 7' ' ' ILE . 35.0 m-20 -63.24 -42.85 99.27 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.301 -0.875 . . . . 0.0 108.651 179.883 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -67.1 -37.43 83.93 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.571 -0.706 . . . . 0.0 109.891 179.677 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 70.4 t80 -58.87 -47.62 84.28 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.028 -1.045 . . . . 0.0 109.915 -179.387 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.592 ' CG1' ' CE1' ' A' ' 52' ' ' PHE . 76.4 t -68.11 -48.56 73.66 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 O-C-N 121.238 -0.914 . . . . 0.0 110.255 -179.559 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 50.0 t -69.69 -45.27 78.16 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.306 0 O-C-N 121.047 -1.033 . . . . 0.0 109.847 -179.796 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.458 ' O ' ' O ' ' A' ' 81' ' ' THR . . . -61.19 -39.16 96.78 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 110.208 -1.157 . . . . 0.0 110.208 -179.573 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.72 -41.02 84.15 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.189 -1.183 . . . . 0.0 110.366 -179.242 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.898 HG21 ' CE2' ' A' ' 52' ' ' PHE . 49.5 p -82.83 -29.86 29.14 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.05 -1.031 . . . . 0.0 109.691 -179.614 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.458 ' O ' ' O ' ' A' ' 78' ' ' GLY . 0.3 OUTLIER . . . . . 0 C--N 1.303 -1.452 0 O-C-N 121.519 -0.738 . . . . 0.0 109.668 -179.561 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 60.5 m-70 . . . . . 0 N--CA 1.487 1.392 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -58.92 -41.93 88.46 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.542 -0.723 . . . . 0.0 109.746 -179.395 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 85.8 p -63.79 -31.35 72.5 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.308 -0.87 . . . . 0.0 109.666 -179.873 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 73.7 t -65.05 -45.26 94.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.182 -0.949 . . . . 0.0 109.432 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.447 ' CG2' HG23 ' A' ' 69' ' ' ILE . 76.0 mt -60.25 -43.58 93.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.445 -0.784 . . . . 0.0 109.165 179.771 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.476 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -60.33 -35.96 76.86 Favored 'General case' 0 C--N 1.305 -1.369 0 O-C-N 121.499 -0.75 . . . . 0.0 109.23 -179.898 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 59.8 tt0 -64.97 -41.19 95.67 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.22 -0.925 . . . . 0.0 110.142 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.693 ' CG ' ' CZ2' ' A' ' 47' ' ' TRP . 30.2 m-85 -62.6 -50.36 71.57 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.041 -1.037 . . . . 0.0 110.688 -179.381 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.452 HG23 ' N ' ' A' ' 12' ' ' VAL . 24.9 m -63.82 -41.78 93.69 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 O-C-N 121.062 -1.024 . . . . 0.0 109.343 -179.473 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.476 HG23 ' O ' ' A' ' 8' ' ' ALA . 71.2 t -63.82 -46.73 93.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.138 -0.976 . . . . 0.0 109.351 179.498 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -70.4 -29.0 65.52 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.226 -0.921 . . . . 0.0 110.124 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 83.9 tt0 -64.58 -29.98 71.0 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.346 -0.846 . . . . 0.0 110.611 -178.996 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 75.3 t80 -132.83 -46.1 0.87 Allowed 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.01 -1.056 . . . . 0.0 110.959 -179.075 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.453 ' C ' ' O ' ' A' ' 12' ' ' VAL . 3.3 mt -118.03 80.01 14.57 Favored Pre-proline 0 N--CA 1.493 1.72 0 O-C-N 121.216 -0.928 . . . . 0.0 110.424 -178.855 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -77.82 -11.97 16.56 Favored 'Trans proline' 0 C--N 1.308 -1.57 0 C-N-CA 122.551 2.168 . . . . 0.0 112.483 179.569 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.8 ' OD1' HG23 ' A' ' 19' ' ' VAL . 53.2 p30 -90.19 8.38 33.31 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 121.092 -1.005 . . . . 0.0 110.125 -179.651 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.8 HG23 ' OD1' ' A' ' 18' ' ' ASP . 51.6 t -119.34 135.51 59.49 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.365 -0.834 . . . . 0.0 109.688 179.95 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.34 120.44 79.71 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.258 -0.901 . . . . 0.0 109.421 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_exo -51.53 -27.54 25.47 Favored 'Trans proline' 0 N--CA 1.493 1.478 0 C-N-CA 121.764 1.643 . . . . 0.0 112.036 179.478 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.77 -25.83 68.09 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.317 -0.864 . . . . 0.0 109.357 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.445 ' O ' ' OD1' ' A' ' 23' ' ' ASP . 60.0 t0 -81.78 5.82 17.43 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.368 -0.832 . . . . 0.0 109.721 -179.826 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 11.7 t -108.25 132.47 55.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.24 -0.912 . . . . 0.0 109.462 -179.952 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 86.3 m-20 -89.19 120.51 30.63 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.144 -0.973 . . . . 0.0 109.004 179.356 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.9 m -77.12 2.49 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 O-C-N 121.005 -1.059 . . . . 0.0 108.991 179.592 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 87.6 m-20 -78.83 -28.56 44.4 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.305 -0.872 . . . . 0.0 108.808 178.974 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 45.9 tp -83.16 139.32 33.24 Favored 'General case' 0 N--CA 1.487 1.388 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 179.53 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.5 m-20 -56.64 132.63 52.39 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.035 -1.04 . . . . 0.0 109.556 -178.969 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 1.045 HD23 HD11 ' A' ' 36' ' ' ILE . 50.8 tp -64.9 -36.87 85.75 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.7 -0.625 . . . . 0.0 110.552 -179.471 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 78.9 t -63.38 -34.89 69.94 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.089 -1.007 . . . . 0.0 110.54 -179.11 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 90.6 m-20 -52.58 -33.35 45.68 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.001 -1.062 . . . . 0.0 108.181 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 97.5 m-20 -70.81 -34.21 71.51 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.625 -0.672 . . . . 0.0 109.98 179.483 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 90.68 3.62 70.99 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 108.974 -1.65 . . . . 0.0 108.974 -179.267 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 75.7 t -60.92 -29.2 45.0 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 121.431 -1.041 . . . . 0.0 108.66 179.415 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 1.045 HD11 HD23 ' A' ' 30' ' ' LEU . 71.0 mt -95.56 134.67 32.18 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 O-C-N 121.478 -0.764 . . . . 0.0 109.406 -179.88 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.534 ' CG ' ' H ' ' A' ' 38' ' ' ALA . 50.2 t0 -138.9 -169.82 2.72 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.534 ' H ' ' CG ' ' A' ' 37' ' ' ASP . . . -62.0 -54.16 45.5 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.147 -0.971 . . . . 0.0 108.765 179.911 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.695 HD12 ' N ' ' A' ' 39' ' ' LEU . 6.9 mp -69.76 -32.71 71.38 Favored 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 107.201 -1.407 . . . . 0.0 107.201 178.091 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.548 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.39 -44.74 96.39 Favored Glycine 0 N--CA 1.483 1.805 0 N-CA-C 108.971 -1.652 . . . . 0.0 108.971 179.456 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.705 HD11 ' CE1' ' A' ' 66' ' ' PHE . 7.9 tt -65.0 -40.4 94.89 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.423 -1.046 . . . . 0.0 109.195 179.367 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.1 tp -59.68 -46.02 90.31 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.1 -1.0 . . . . 0.0 108.887 179.675 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 59.7 mttp -61.3 -34.89 75.96 Favored 'General case' 0 C--N 1.297 -1.71 0 O-C-N 121.546 -0.722 . . . . 0.0 109.448 -180.0 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.548 HG23 ' O ' ' A' ' 40' ' ' GLY . 73.8 t -59.47 -43.27 90.22 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 O-C-N 121.299 -0.876 . . . . 0.0 109.142 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.525 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 6.7 mm -66.95 -38.74 81.98 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 121.395 -0.815 . . . . 0.0 110.752 -179.363 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.21 -49.77 68.44 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.128 -0.983 . . . . 0.0 111.716 -178.064 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.693 ' CZ2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -80.84 -44.34 18.59 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.648 -1.283 . . . . 0.0 109.99 -179.277 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.735 HD21 ' CG2' ' A' ' 76' ' ' VAL . 20.8 tp -58.93 -41.97 88.63 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.209 -0.932 . . . . 0.0 110.094 -178.921 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.525 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 1.2 pp20? -72.25 -36.87 69.19 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.009 -1.057 . . . . 0.0 109.589 -179.889 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.7 t0 -61.19 -38.18 85.61 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.232 -0.917 . . . . 0.0 110.441 -179.834 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 14.8 mmm180 -61.69 -37.09 82.86 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.308 -0.87 . . . . 0.0 111.432 -178.703 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.634 ' CZ ' ' CG1' ' A' ' 76' ' ' VAL . 72.6 m-85 -96.82 -8.0 32.16 Favored 'General case' 0 N--CA 1.487 1.375 0 O-C-N 120.769 -1.207 . . . . 0.0 110.172 -178.956 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 71.18 31.22 66.55 Favored Glycine 0 N--CA 1.485 1.945 0 N-CA-C 108.82 -1.712 . . . . 0.0 108.82 179.771 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.487 ' O ' ' OE1' ' A' ' 49' ' ' GLU . 24.7 pt -108.81 153.13 10.62 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 O-C-N 121.598 -0.942 . . . . 0.0 109.84 -179.3 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -103.79 155.49 18.56 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.411 -0.805 . . . . 0.0 109.436 -179.638 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -58.46 -26.32 63.24 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.317 -0.865 . . . . 0.0 109.325 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 60.9 t0 59.13 38.29 23.81 Favored 'General case' 0 N--CA 1.486 1.336 0 O-C-N 121.445 -0.784 . . . . 0.0 109.109 -179.79 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 54.27 44.97 28.24 Favored 'General case' 0 N--CA 1.486 1.328 0 O-C-N 121.588 -0.695 . . . . 0.0 110.354 179.272 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 52.9 t -120.85 134.08 65.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.387 -0.82 . . . . 0.0 109.091 179.339 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -102.52 130.7 49.43 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.282 -0.886 . . . . 0.0 109.664 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 60.8 mt -99.24 143.88 29.0 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.394 -0.816 . . . . 0.0 109.17 179.834 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 11.6 p -90.09 148.17 38.8 Favored Pre-proline 0 C--N 1.305 -1.346 0 O-C-N 121.053 -1.029 . . . . 0.0 108.707 179.821 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -57.62 -19.78 38.99 Favored 'Trans proline' 0 C--N 1.305 -1.754 0 C-N-CA 122.24 1.96 . . . . 0.0 111.858 -179.714 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -67.41 -30.78 70.63 Favored 'General case' 0 N--CA 1.485 1.304 0 O-C-N 121.376 -0.828 . . . . 0.0 109.226 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 65' ' ' HIS . . . . . 0.568 ' CD2' ' O ' ' A' ' 65' ' ' HIS . 2.7 t-80 -66.47 -19.47 65.8 Favored 'General case' 0 C--N 1.3 -1.584 0 O-C-N 121.262 -0.899 . . . . 0.0 108.815 179.82 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.705 ' CE1' HD11 ' A' ' 41' ' ' LEU . 6.6 m-85 -98.31 13.3 31.94 Favored 'General case' 0 C--N 1.3 -1.571 0 N-CA-C 108.89 -0.781 . . . . 0.0 108.89 -179.753 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 67' ' ' ARG . . . . . 0.405 ' O ' ' N ' ' A' ' 30' ' ' LEU . 1.5 ptt180 -49.82 -34.74 20.58 Favored 'General case' 0 C--N 1.299 -1.587 0 O-C-N 121.716 -0.615 . . . . 0.0 110.167 -179.778 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 68' ' ' SER . . . . . 0.501 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 23.3 t -153.17 154.88 35.63 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.101 -1.0 . . . . 0.0 110.041 -179.577 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.605 ' H ' HD12 ' A' ' 69' ' ' ILE . 3.3 mp -57.45 -33.99 45.53 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 178.886 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 60.4 mtp180 -56.99 -45.61 82.85 Favored 'General case' 0 N--CA 1.488 1.453 0 CA-C-O 121.395 0.617 . . . . 0.0 109.567 -179.516 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 22.9 t -65.82 -41.43 91.86 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.283 -0.886 . . . . 0.0 109.87 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 68.5 mt -61.38 -45.38 98.75 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 O-C-N 121.265 -0.897 . . . . 0.0 110.022 -179.566 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 41.4 t0 -60.15 -40.79 91.08 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.178 -0.951 . . . . 0.0 109.573 -179.846 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.36 -46.06 78.02 Favored 'General case' 0 C--N 1.304 -1.393 0 O-C-N 121.232 -0.917 . . . . 0.0 109.593 -179.75 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 75' ' ' PHE . . . . . 0.51 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 63.5 t80 -63.19 -44.07 96.41 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.247 -0.908 . . . . 0.0 109.127 179.621 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.735 ' CG2' HD21 ' A' ' 48' ' ' LEU . 55.4 t -62.57 -46.66 95.84 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.309 0 O-C-N 121.407 -0.808 . . . . 0.0 109.404 179.607 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.504 ' O ' ' O ' ' A' ' 81' ' ' THR . 72.5 t -68.87 -41.71 82.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 O-C-N 121.262 -0.899 . . . . 0.0 109.402 179.803 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.38 -23.45 53.78 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.798 -1.321 . . . . 0.0 109.798 179.903 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.08 -33.2 74.97 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.283 -1.128 . . . . 0.0 110.639 -179.149 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 26.2 p -121.46 -33.75 3.58 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.232 -0.918 . . . . 0.0 110.776 -179.179 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.504 ' O ' ' O ' ' A' ' 77' ' ' VAL . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.533 0 O-C-N 121.247 -0.908 . . . . 0.0 109.759 -179.388 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 38.4 m170 . . . . . 0 N--CA 1.485 1.276 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -58.89 -43.8 91.03 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.652 -0.655 . . . . 0.0 109.944 -179.224 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 94.9 p -65.95 -32.18 73.53 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.324 -0.86 . . . . 0.0 110.083 -179.663 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 79.1 t -65.26 -47.13 88.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.101 -1.0 . . . . 0.0 109.584 -179.718 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.545 ' O ' HG12 ' A' ' 11' ' ' VAL . 81.2 mt -59.96 -48.82 86.35 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 O-C-N 121.315 -0.865 . . . . 0.0 109.702 179.988 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.719 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.29 -43.5 97.7 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.421 -0.799 . . . . 0.0 110.7 -179.349 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 44.4 tt0 -68.67 -47.58 66.14 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.97 -1.081 . . . . 0.0 110.861 -178.859 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.531 ' C ' ' CD1' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -70.96 -48.12 55.2 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.149 -0.97 . . . . 0.0 110.36 -179.651 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.545 HG12 ' O ' ' A' ' 7' ' ' ILE . 4.2 p -59.92 -38.95 78.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.089 -1.007 . . . . 0.0 109.742 -179.542 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.719 HG23 ' O ' ' A' ' 8' ' ' ALA . 52.0 t -63.22 -43.26 98.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.099 -1.0 . . . . 0.0 109.839 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -63.81 -38.74 92.2 Favored 'General case' 0 N--CA 1.487 1.377 0 O-C-N 121.086 -1.008 . . . . 0.0 110.252 -179.638 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 85.5 tt0 -69.95 -42.17 73.57 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.0 -1.063 . . . . 0.0 110.218 -179.698 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 79.6 t80 -84.97 -52.96 5.61 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.16 -0.963 . . . . 0.0 110.798 -179.259 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.501 HD22 ' CG2' ' A' ' 19' ' ' VAL . 6.3 mt -122.53 80.08 46.93 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.341 -0.85 . . . . 0.0 110.371 -179.004 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 22.0 Cg_endo -68.39 -14.54 40.32 Favored 'Trans proline' 0 C--N 1.311 -1.403 0 C-N-CA 122.012 1.808 . . . . 0.0 112.33 179.464 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.459 ' OD1' ' O ' ' A' ' 18' ' ' ASP . 60.2 t0 -94.61 6.22 49.5 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.187 -0.945 . . . . 0.0 110.137 -179.705 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.501 ' CG2' HD22 ' A' ' 16' ' ' LEU . 25.9 t -118.57 135.89 57.53 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.268 -0.895 . . . . 0.0 109.636 -179.896 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.491 ' O ' ' OD1' ' A' ' 23' ' ' ASP . . . -77.14 117.19 63.56 Favored Pre-proline 0 N--CA 1.489 1.489 0 O-C-N 121.234 -0.916 . . . . 0.0 108.935 179.722 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_exo -51.71 -26.23 22.75 Favored 'Trans proline' 0 N--CA 1.492 1.407 0 C-N-CA 121.8 1.666 . . . . 0.0 112.211 179.693 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.09 -24.94 67.58 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.35 -0.844 . . . . 0.0 109.775 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.503 ' OD1' HG23 ' A' ' 24' ' ' VAL . 49.2 p30 -86.38 7.07 27.15 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.104 -0.998 . . . . 0.0 110.008 -179.555 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.503 HG23 ' OD1' ' A' ' 23' ' ' ASP . 15.6 t -110.4 131.9 60.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.73 0 O-C-N 121.315 -0.866 . . . . 0.0 109.504 179.868 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 25' ' ' ASP . . . . . 0.513 ' C ' ' H ' ' A' ' 27' ' ' ASP . 62.9 t0 -89.25 119.37 29.68 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.148 -0.97 . . . . 0.0 108.981 179.223 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.439 ' O ' HG13 ' A' ' 26' ' ' VAL . 0.3 OUTLIER -63.87 4.25 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.421 0 O-C-N 121.172 -0.955 . . . . 0.0 109.315 179.874 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.513 ' H ' ' C ' ' A' ' 25' ' ' ASP . 92.0 m-20 -105.02 6.63 33.54 Favored 'General case' 0 N--CA 1.485 1.301 0 O-C-N 121.263 -0.898 . . . . 0.0 109.32 179.772 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 28' ' ' LEU . . . . . 0.404 HD23 ' OD1' ' A' ' 33' ' ' ASN . 45.5 tp -96.8 136.29 37.56 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.373 -0.829 . . . . 0.0 109.238 -179.828 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 80.5 m-20 -64.7 142.52 58.4 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.231 -0.918 . . . . 0.0 109.967 -179.167 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.576 ' N ' ' O ' ' A' ' 67' ' ' ARG . 76.0 mt -70.3 -35.07 73.46 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.468 -0.77 . . . . 0.0 110.987 -179.577 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.61 HG23 ' N ' ' A' ' 32' ' ' ASP . 35.1 m -57.75 -47.09 86.69 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.515 0 O-C-N 121.123 -0.986 . . . . 0.0 110.177 -178.958 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.61 ' N ' HG23 ' A' ' 31' ' ' VAL . 90.8 m-20 -61.18 -34.24 74.73 Favored 'General case' 0 C--N 1.302 -1.489 0 N-CA-C 108.439 -0.948 . . . . 0.0 108.439 179.403 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.404 ' OD1' HD23 ' A' ' 28' ' ' LEU . 96.6 m-20 -70.8 -34.18 71.49 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.752 -0.592 . . . . 0.0 110.115 -179.883 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 86.61 6.36 80.48 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 108.872 -1.691 . . . . 0.0 108.872 -179.516 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 70.8 t -59.06 -32.21 47.36 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 O-C-N 121.464 -1.021 . . . . 0.0 108.293 179.42 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 79.8 mt -85.82 129.56 37.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 CA-C-O 121.656 0.741 . . . . 0.0 109.735 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.49 ' CG ' ' H ' ' A' ' 38' ' ' ALA . 51.2 t0 -148.85 -170.84 3.72 Favored 'General case' 0 C--N 1.298 -1.647 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 179.776 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.49 ' H ' ' CG ' ' A' ' 37' ' ' ASP . . . -61.35 -54.66 40.89 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 120.893 -1.129 . . . . 0.0 108.422 179.772 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.718 HD12 ' N ' ' A' ' 39' ' ' LEU . 6.8 mp -71.61 -33.22 68.79 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 107.468 -1.308 . . . . 0.0 107.468 178.094 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.535 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.77 -46.61 93.77 Favored Glycine 0 N--CA 1.484 1.885 0 N-CA-C 109.255 -1.538 . . . . 0.0 109.255 179.833 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 3.4 tt -63.81 -43.28 96.73 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.419 -1.047 . . . . 0.0 109.654 179.563 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 17.2 tp -59.75 -45.22 92.89 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.313 -0.867 . . . . 0.0 109.728 -179.653 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 24.8 mttm -63.36 -34.45 77.74 Favored 'General case' 0 C--N 1.297 -1.678 0 O-C-N 121.052 -1.03 . . . . 0.0 109.705 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.591 HG11 ' CE2' ' A' ' 66' ' ' PHE . 54.7 t -61.38 -50.79 78.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.332 -0.855 . . . . 0.0 110.624 -179.077 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.497 ' H ' HD12 ' A' ' 45' ' ' ILE . 3.5 mp -68.27 -40.08 82.06 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 O-C-N 121.17 -0.957 . . . . 0.0 111.34 -179.431 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.66 -49.63 61.91 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.081 -1.012 . . . . 0.0 112.215 -177.692 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.551 ' C ' ' CD1' ' A' ' 47' ' ' TRP . 0.0 OUTLIER -78.76 -43.43 25.61 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.671 -1.268 . . . . 0.0 110.37 -178.717 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.848 HD11 HG21 ' A' ' 76' ' ' VAL . 16.7 tp -59.99 -41.78 92.79 Favored 'General case' 0 C--N 1.3 -1.562 0 O-C-N 121.195 -0.941 . . . . 0.0 110.326 -178.754 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.413 ' CG ' ' N ' ' A' ' 50' ' ' ASP . 17.8 pt-20 -73.02 -37.15 67.03 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.117 -0.99 . . . . 0.0 109.856 -179.673 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 50' ' ' ASP . . . . . 0.413 ' N ' ' CG ' ' A' ' 49' ' ' GLU . 56.8 t0 -60.0 -39.26 85.14 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.375 -0.828 . . . . 0.0 111.036 -179.269 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.464 ' HD2' ' HE1' ' A' ' 47' ' ' TRP . 80.6 mtp180 -61.07 -37.61 83.28 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.105 -0.997 . . . . 0.0 111.603 -178.649 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.644 ' CZ ' ' CG1' ' A' ' 76' ' ' VAL . 48.6 m-85 -98.48 -8.18 27.14 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 120.79 -1.194 . . . . 0.0 110.456 -179.012 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 69.87 31.7 70.04 Favored Glycine 0 N--CA 1.488 2.117 0 N-CA-C 108.752 -1.739 . . . . 0.0 108.752 179.653 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 27.9 pt -108.51 153.44 10.12 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 O-C-N 121.62 -0.929 . . . . 0.0 109.908 -179.372 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -100.09 129.95 46.18 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.152 -0.968 . . . . 0.0 109.51 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.502 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -66.51 -28.82 68.86 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.294 -0.879 . . . . 0.0 109.581 179.895 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 53.9 t0 -55.41 -36.09 66.08 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.305 -0.872 . . . . 0.0 109.998 -179.642 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -56.88 -40.3 75.95 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.201 -0.937 . . . . 0.0 109.952 -179.584 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.502 ' O ' ' O ' ' A' ' 56' ' ' ALA . 42.1 t -129.16 134.81 63.31 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.393 -0.817 . . . . 0.0 109.543 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -79.25 126.63 31.03 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.097 -1.002 . . . . 0.0 109.436 179.896 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.482 HD12 ' O ' ' A' ' 59' ' ' VAL . 5.3 mp -108.04 139.54 42.53 Favored 'General case' 0 C--N 1.305 -1.333 0 O-C-N 121.372 -0.83 . . . . 0.0 109.651 -179.904 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -107.02 145.34 30.92 Favored Pre-proline 0 N--CA 1.484 1.267 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 179.098 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -60.73 -19.94 63.35 Favored 'Trans proline' 0 C--N 1.306 -1.699 0 C-N-CA 122.107 1.871 . . . . 0.0 112.021 -179.55 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 90.1 mt-10 -69.25 -28.39 66.29 Favored 'General case' 0 C--N 1.305 -1.364 0 O-C-N 121.439 -0.788 . . . . 0.0 109.676 -179.613 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 65' ' ' HIS . . . . . 0.59 ' CD2' ' O ' ' A' ' 65' ' ' HIS . 0.0 OUTLIER -66.55 -19.12 65.7 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.199 -0.938 . . . . 0.0 109.182 -179.563 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.591 ' CE2' HG11 ' A' ' 44' ' ' VAL . 16.5 m-85 -96.15 11.03 35.77 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.291 -0.881 . . . . 0.0 109.317 179.794 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 67' ' ' ARG . . . . . 0.576 ' O ' ' N ' ' A' ' 30' ' ' LEU . 1.7 ptt180 -50.08 -21.86 1.43 Allowed 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.381 -0.824 . . . . 0.0 110.049 -179.671 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 68' ' ' SER . . . . . 0.444 ' O ' ' OG ' ' A' ' 71' ' ' SER . 34.4 t -147.14 147.03 30.13 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.137 -0.977 . . . . 0.0 109.883 -179.875 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.713 ' H ' HD12 ' A' ' 69' ' ' ILE . 2.3 mp -59.92 -38.72 77.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.288 -0.883 . . . . 0.0 109.566 -179.826 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.429 ' O ' ' OD2' ' A' ' 73' ' ' ASP . 6.1 ptm180 -57.6 -40.14 78.4 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.427 -0.796 . . . . 0.0 109.447 -179.748 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 71' ' ' SER . . . . . 0.444 ' OG ' ' O ' ' A' ' 68' ' ' SER . 95.8 p -65.07 -35.83 82.39 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.332 -0.855 . . . . 0.0 110.123 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.433 ' O ' HG23 ' A' ' 76' ' ' VAL . 64.6 mt -63.31 -46.59 95.17 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.326 0 O-C-N 121.191 -0.943 . . . . 0.0 110.148 -179.419 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.584 ' OD1' ' N ' ' A' ' 74' ' ' ALA . 1.3 p30 -63.14 -40.02 96.35 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.088 -1.007 . . . . 0.0 109.448 -179.648 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 74' ' ' ALA . . . . . 0.584 ' N ' ' OD1' ' A' ' 73' ' ' ASP . . . -66.76 -45.52 78.3 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.312 -0.867 . . . . 0.0 109.768 -179.882 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 75' ' ' PHE . . . . . 0.544 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 55.0 t80 -63.32 -43.87 96.55 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.326 -0.859 . . . . 0.0 109.073 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.848 HG21 HD11 ' A' ' 48' ' ' LEU . 55.8 t -60.79 -46.8 95.48 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 O-C-N 121.493 -0.754 . . . . 0.0 109.047 179.655 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 54.7 t -69.14 -42.07 81.63 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 O-C-N 121.455 -0.778 . . . . 0.0 109.084 179.298 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.516 ' O ' ' O ' ' A' ' 81' ' ' THR . . . -68.8 -21.19 74.92 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 110.001 -1.24 . . . . 0.0 110.001 179.901 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -66.48 -36.79 83.62 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 120.955 -1.32 . . . . 0.0 109.783 -179.411 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 56.1 p -87.91 -25.58 23.16 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.216 -0.927 . . . . 0.0 109.732 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.516 ' O ' ' O ' ' A' ' 78' ' ' GLY . 0.1 OUTLIER . . . . . 0 N--CA 1.486 1.366 0 O-C-N 121.358 -0.839 . . . . 0.0 109.75 -179.63 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 66.7 m-70 . . . . . 0 N--CA 1.487 1.418 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -58.26 -37.68 75.44 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.491 -0.755 . . . . 0.0 109.577 -179.3 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 87.4 p -61.45 -32.89 72.88 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.202 -0.936 . . . . 0.0 109.469 -179.884 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 70.0 t -62.95 -43.9 99.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.237 -0.914 . . . . 0.0 109.196 179.75 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 79.2 mt -60.21 -40.97 85.18 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.396 -0.815 . . . . 0.0 109.024 179.606 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.428 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -60.84 -38.12 84.39 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 121.52 -0.738 . . . . 0.0 109.537 -179.724 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 48.3 mt-30 -64.51 -40.53 95.82 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.122 -0.986 . . . . 0.0 110.105 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.688 ' CG ' ' CE2' ' A' ' 47' ' ' TRP . 30.6 m-85 -63.55 -50.43 69.53 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.146 -0.972 . . . . 0.0 110.951 -179.196 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.473 HG23 ' N ' ' A' ' 12' ' ' VAL . 27.2 m -65.64 -41.37 90.46 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 120.995 -1.066 . . . . 0.0 109.426 -179.474 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.473 ' N ' HG23 ' A' ' 11' ' ' VAL . 66.6 t -63.88 -47.0 92.66 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 O-C-N 121.26 -0.9 . . . . 0.0 109.685 179.554 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -70.53 -27.83 64.47 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.04 -1.037 . . . . 0.0 110.231 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -64.57 -33.21 75.38 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.271 -0.893 . . . . 0.0 110.845 -178.708 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 92.1 m-85 -134.11 -29.78 1.24 Allowed 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.036 -1.04 . . . . 0.0 111.123 -179.354 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.561 HD22 ' CG2' ' A' ' 19' ' ' VAL . 12.3 mt -124.74 79.68 63.09 Favored Pre-proline 0 N--CA 1.491 1.604 0 O-C-N 121.078 -1.014 . . . . 0.0 110.248 -179.157 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -78.73 -17.72 12.27 Favored 'Trans proline' 0 C--N 1.307 -1.63 0 C-N-CA 122.586 2.19 . . . . 0.0 112.317 179.642 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -93.01 7.56 43.57 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.232 -0.917 . . . . 0.0 110.125 -179.601 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.561 ' CG2' HD22 ' A' ' 16' ' ' LEU . 46.8 t -113.18 136.04 50.76 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.353 -0.842 . . . . 0.0 109.775 -179.844 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.414 ' O ' ' CG ' ' A' ' 23' ' ' ASP . . . -72.42 117.3 57.68 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.298 -0.876 . . . . 0.0 109.499 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_exo -52.03 -25.24 21.83 Favored 'Trans proline' 0 N--CA 1.494 1.503 0 C-N-CA 121.995 1.797 . . . . 0.0 112.344 179.333 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.74 -21.5 66.77 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.268 -0.895 . . . . 0.0 109.83 -179.604 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.448 ' C ' ' OD1' ' A' ' 23' ' ' ASP . 52.8 p30 -84.45 7.56 19.33 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.245 -0.909 . . . . 0.0 110.144 -179.599 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 11.4 t -104.88 129.81 56.9 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.156 -0.965 . . . . 0.0 109.463 -179.922 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 64.0 t0 -89.58 119.86 30.37 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.142 -0.974 . . . . 0.0 109.218 179.325 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.8 m -74.84 3.95 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.428 0 O-C-N 121.172 -0.955 . . . . 0.0 109.314 179.755 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -88.99 -11.24 44.82 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 121.295 -0.878 . . . . 0.0 109.157 179.543 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 43.6 tp -95.83 138.72 33.07 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.412 -0.805 . . . . 0.0 109.016 179.793 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.0 m-20 -58.34 133.6 55.86 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.147 -0.971 . . . . 0.0 109.272 -179.625 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.725 HD12 HG13 ' A' ' 69' ' ' ILE . 2.0 tt -67.14 -38.25 85.21 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 121.724 -0.61 . . . . 0.0 110.099 -179.136 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.563 HG23 ' O ' ' A' ' 66' ' ' PHE . 75.5 t -63.14 -35.54 72.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.011 -1.056 . . . . 0.0 110.379 -178.964 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 55.7 t0 -52.52 -33.52 45.62 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 120.957 -1.09 . . . . 0.0 108.151 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.446 ' HB3' HG23 ' A' ' 35' ' ' VAL . 97.4 m-20 -71.25 -34.61 70.89 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.634 -0.666 . . . . 0.0 109.974 179.464 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 84.98 6.44 85.02 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.083 -1.607 . . . . 0.0 109.083 -179.399 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.446 HG23 ' HB3' ' A' ' 33' ' ' ASN . 71.5 t -61.32 -34.5 61.2 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.428 0 O-C-N 121.412 -1.052 . . . . 0.0 109.056 179.636 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.696 HD11 HD13 ' A' ' 30' ' ' LEU . 91.8 mt -82.07 114.53 23.12 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 O-C-N 121.353 -0.842 . . . . 0.0 109.665 -179.836 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -111.58 -168.61 1.33 Allowed 'General case' 0 C--N 1.304 -1.401 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 179.745 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -64.24 -54.15 37.88 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.214 -0.929 . . . . 0.0 108.696 179.708 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 38.6 mt -70.39 -33.16 71.08 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 107.171 -1.418 . . . . 0.0 107.171 178.338 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.621 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.57 -40.53 96.46 Favored Glycine 0 N--CA 1.481 1.678 0 N-CA-C 108.546 -1.822 . . . . 0.0 108.546 179.131 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.7 tt -65.45 -42.8 91.95 Favored 'General case' 0 C--N 1.305 -1.36 0 O-C-N 121.492 -1.005 . . . . 0.0 109.136 179.336 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.2 tp -60.88 -46.16 91.71 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.448 -0.782 . . . . 0.0 109.269 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 51.2 mttp -61.13 -35.21 76.46 Favored 'General case' 0 C--N 1.296 -1.732 0 O-C-N 121.427 -0.795 . . . . 0.0 109.623 -179.754 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.621 HG23 ' O ' ' A' ' 40' ' ' GLY . 60.5 t -61.64 -48.67 87.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.295 -0.878 . . . . 0.0 109.8 -179.605 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.518 ' CG1' HD12 ' A' ' 61' ' ' LEU . 1.6 mp -68.26 -32.62 56.52 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 O-C-N 121.501 -0.75 . . . . 0.0 110.871 -179.568 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.14 -49.76 63.68 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.0 -1.063 . . . . 0.0 111.807 -178.026 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.688 ' CE2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -80.81 -43.48 20.0 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.766 -1.209 . . . . 0.0 110.015 -179.195 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.477 HD21 ' CG2' ' A' ' 76' ' ' VAL . 24.3 tp -58.82 -41.55 87.09 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.334 -0.854 . . . . 0.0 110.1 -178.948 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.438 ' CG ' ' N ' ' A' ' 50' ' ' ASP . 17.1 pt-20 -72.99 -37.92 66.83 Favored 'General case' 0 C--N 1.305 -1.362 0 O-C-N 121.079 -1.013 . . . . 0.0 109.716 -179.835 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 50' ' ' ASP . . . . . 0.438 ' N ' ' CG ' ' A' ' 49' ' ' GLU . 57.2 t0 -58.17 -39.13 78.09 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.36 -0.837 . . . . 0.0 110.457 -179.509 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.465 ' HD2' ' HE1' ' A' ' 47' ' ' TRP . 22.3 mtp-105 -62.63 -36.32 82.41 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.135 -0.978 . . . . 0.0 111.411 -178.866 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.783 ' CE2' HG11 ' A' ' 76' ' ' VAL . 86.5 m-85 -95.55 -8.88 33.89 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 120.75 -1.218 . . . . 0.0 110.258 -179.191 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 72.86 30.72 63.16 Favored Glycine 0 N--CA 1.487 2.073 0 N-CA-C 108.905 -1.678 . . . . 0.0 108.905 179.723 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 23.1 pt -109.73 153.63 11.44 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.335 0 O-C-N 121.557 -0.967 . . . . 0.0 109.782 -179.501 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -101.68 135.96 42.32 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.264 -0.897 . . . . 0.0 109.54 -179.776 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.499 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -66.35 -28.51 68.71 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.329 -0.857 . . . . 0.0 109.647 179.878 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -56.05 -35.78 67.3 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.158 -0.964 . . . . 0.0 109.935 -179.732 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 54.5 t0 -55.0 -38.93 68.49 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.173 -0.954 . . . . 0.0 110.141 -179.569 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.499 ' O ' ' O ' ' A' ' 56' ' ' ALA . 13.6 p -135.59 142.63 38.87 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.199 -0.938 . . . . 0.0 109.721 -179.91 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -93.62 132.57 37.83 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.098 -1.001 . . . . 0.0 109.328 179.682 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.518 HD12 ' CG1' ' A' ' 45' ' ' ILE . 56.5 mt -99.06 140.34 33.36 Favored 'General case' 0 C--N 1.305 -1.362 0 O-C-N 121.309 -0.869 . . . . 0.0 109.865 -179.67 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -109.67 156.31 39.93 Favored Pre-proline 0 N--CA 1.487 1.412 0 N-CA-C 108.633 -0.876 . . . . 0.0 108.633 179.503 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 8.1 Cg_endo -53.36 -25.08 29.82 Favored 'Trans proline' 0 C--N 1.303 -1.83 0 C-N-CA 122.41 2.073 . . . . 0.0 111.729 -179.85 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -71.65 -27.15 62.88 Favored 'General case' 0 N--CA 1.486 1.369 0 O-C-N 121.368 -0.833 . . . . 0.0 109.508 179.757 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 65' ' ' HIS . . . . . 0.556 ' NE2' ' CB ' ' A' ' 75' ' ' PHE . 6.6 t-160 -65.79 -21.1 66.47 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.311 -0.868 . . . . 0.0 109.092 -179.749 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.563 ' O ' HG23 ' A' ' 31' ' ' VAL . 15.3 m-85 -92.34 14.65 15.84 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 179.909 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 67' ' ' ARG . . . . . 0.407 ' HG2' ' H ' ' A' ' 68' ' ' SER . 6.9 ptt180 -47.9 -39.08 17.86 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.651 -0.656 . . . . 0.0 109.85 -179.972 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 68' ' ' SER . . . . . 0.535 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 86.9 p -160.04 156.55 27.14 Favored 'General case' 0 N--CA 1.487 1.401 0 O-C-N 120.993 -1.067 . . . . 0.0 110.014 179.913 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.725 HG13 HD12 ' A' ' 30' ' ' LEU . 3.3 mp -58.84 -34.76 53.24 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 179.189 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 47.0 mtp180 -56.88 -43.78 81.6 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.721 -0.612 . . . . 0.0 109.642 -179.601 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 82.5 p -69.47 -33.67 73.24 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.364 -0.835 . . . . 0.0 110.012 -179.706 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.539 HD12 ' HA ' ' A' ' 69' ' ' ILE . 80.6 mt -62.24 -51.02 77.45 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 O-C-N 121.177 -0.952 . . . . 0.0 109.944 -179.656 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 42.8 t0 -61.01 -42.06 97.73 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.197 -0.94 . . . . 0.0 109.241 179.871 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.79 -38.68 87.01 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.568 -0.708 . . . . 0.0 110.403 -179.514 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 75' ' ' PHE . . . . . 0.556 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 58.9 t80 -62.28 -46.88 86.8 Favored 'General case' 0 C--N 1.302 -1.462 0 O-C-N 121.105 -0.997 . . . . 0.0 109.82 -179.572 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.783 HG11 ' CE2' ' A' ' 52' ' ' PHE . 77.0 t -66.35 -48.65 80.24 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 121.164 -0.96 . . . . 0.0 109.816 -179.806 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.595 ' O ' HG22 ' A' ' 81' ' ' THR . 53.3 t -70.04 -46.9 71.33 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.276 0 O-C-N 121.056 -1.028 . . . . 0.0 109.67 179.882 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.475 ' O ' ' O ' ' A' ' 81' ' ' THR . . . -61.86 -30.86 76.38 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 110.317 -1.113 . . . . 0.0 110.317 -179.642 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.67 -41.13 84.19 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.149 -1.207 . . . . 0.0 110.318 -179.028 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 56.1 p -79.15 -31.79 44.11 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.127 -0.983 . . . . 0.0 109.39 -179.872 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.595 HG22 ' O ' ' A' ' 77' ' ' VAL . 2.6 t . . . . . 0 C--N 1.305 -1.341 0 O-C-N 121.52 -0.737 . . . . 0.0 109.452 -179.766 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 50.5 m80 . . . . . 0 N--CA 1.494 1.73 0 CA-C-O 120.988 0.423 . . . . 0.0 110.655 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -62.71 -40.22 96.49 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.016 -1.052 . . . . 0.0 109.313 179.486 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.0 t -60.19 -33.96 72.94 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.392 -0.817 . . . . 0.0 109.664 -179.955 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 55.9 t -60.24 -45.45 96.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.297 -0.877 . . . . 0.0 109.579 -179.854 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 75.5 mt -60.94 -45.26 98.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.326 -0.859 . . . . 0.0 109.025 179.65 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.484 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -61.56 -36.39 80.49 Favored 'General case' 0 N--CA 1.486 1.344 0 O-C-N 121.481 -0.762 . . . . 0.0 109.001 179.595 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 31.0 tt0 -64.78 -40.74 95.75 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.297 -0.877 . . . . 0.0 110.107 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.703 ' CG ' ' CE2' ' A' ' 47' ' ' TRP . 19.0 m-85 -61.71 -50.42 72.53 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.12 -0.987 . . . . 0.0 110.504 -179.452 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.439 HG23 ' N ' ' A' ' 12' ' ' VAL . 23.2 m -64.58 -41.07 91.21 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.5 0 O-C-N 121.051 -1.031 . . . . 0.0 109.185 -179.64 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.484 HG23 ' O ' ' A' ' 8' ' ' ALA . 79.6 t -63.95 -46.2 94.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.246 -0.909 . . . . 0.0 109.436 179.497 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -70.55 -27.7 64.35 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.171 -0.956 . . . . 0.0 110.171 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -64.46 -30.68 71.71 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.333 -0.855 . . . . 0.0 110.558 -178.883 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.454 ' CD2' ' CG1' ' A' ' 35' ' ' VAL . 96.2 m-85 -134.11 -38.64 0.86 Allowed 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.033 -1.042 . . . . 0.0 111.075 -179.317 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.523 HD22 ' CG2' ' A' ' 19' ' ' VAL . 9.1 mt -123.23 79.83 52.5 Favored Pre-proline 0 N--CA 1.493 1.684 0 O-C-N 121.067 -1.02 . . . . 0.0 110.571 -178.835 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -74.93 -15.53 20.88 Favored 'Trans proline' 0 C--N 1.309 -1.525 0 C-N-CA 122.305 2.003 . . . . 0.0 112.199 179.39 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -91.97 8.6 36.82 Favored 'General case' 0 C--N 1.305 -1.357 0 O-C-N 121.199 -0.938 . . . . 0.0 109.883 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.523 ' CG2' HD22 ' A' ' 16' ' ' LEU . 44.6 t -113.61 135.08 54.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 121.387 -0.82 . . . . 0.0 109.654 -179.746 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -73.9 119.67 77.35 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.321 -0.862 . . . . 0.0 109.288 179.877 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -51.14 -26.07 18.63 Favored 'Trans proline' 0 N--CA 1.494 1.502 0 C-N-CA 121.75 1.634 . . . . 0.0 112.132 179.482 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.81 -24.68 67.62 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.347 -0.846 . . . . 0.0 109.404 179.863 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.436 ' O ' ' OD1' ' A' ' 23' ' ' ASP . 60.2 t0 -81.83 6.83 14.43 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.32 -0.863 . . . . 0.0 109.759 -179.731 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 12.3 t -107.64 133.89 51.07 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.275 -0.89 . . . . 0.0 109.275 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 87.2 m-20 -89.06 120.47 30.5 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.085 -1.01 . . . . 0.0 109.0 179.324 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.0 m -76.4 4.47 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 O-C-N 121.19 -0.944 . . . . 0.0 109.124 179.655 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -91.45 -5.13 54.78 Favored 'General case' 0 C--N 1.305 -1.351 0 O-C-N 121.344 -0.847 . . . . 0.0 109.164 179.673 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 40.8 tp -98.65 138.5 35.74 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.323 -0.86 . . . . 0.0 109.34 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -60.61 134.69 57.32 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.247 -0.908 . . . . 0.0 109.484 -179.735 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.969 HD13 HD11 ' A' ' 36' ' ' ILE . 0.8 OUTLIER -69.06 -39.66 78.99 Favored 'General case' 0 C--N 1.301 -1.5 0 O-C-N 121.631 -0.668 . . . . 0.0 110.221 -179.293 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 70.8 t -64.04 -36.29 76.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 121.107 -0.996 . . . . 0.0 110.606 -178.759 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 56.7 t0 -52.52 -33.36 44.9 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 120.926 -1.109 . . . . 0.0 108.238 -179.904 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.508 ' HB3' HG23 ' A' ' 35' ' ' VAL . 97.3 m-20 -71.24 -34.69 71.01 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.661 -0.65 . . . . 0.0 110.049 179.608 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 83.24 6.16 88.22 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 108.831 -1.708 . . . . 0.0 108.831 -179.22 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.508 HG23 ' HB3' ' A' ' 33' ' ' ASN . 72.9 t -60.61 -30.9 47.77 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 O-C-N 121.503 -0.998 . . . . 0.0 108.356 179.329 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.969 HD11 HD13 ' A' ' 30' ' ' LEU . 89.7 mt -86.87 131.54 34.62 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.382 0 O-C-N 121.489 -0.757 . . . . 0.0 109.74 179.908 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.547 ' CG ' ' H ' ' A' ' 38' ' ' ALA . 52.0 t0 -128.01 -166.22 1.59 Allowed 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 108.646 -0.872 . . . . 0.0 108.646 179.582 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.547 ' H ' ' CG ' ' A' ' 37' ' ' ASP . . . -64.36 -54.58 30.75 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.126 -0.984 . . . . 0.0 108.886 179.849 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 34.4 mt -69.8 -32.76 71.39 Favored 'General case' 0 C--N 1.302 -1.475 0 N-CA-C 107.233 -1.395 . . . . 0.0 107.233 178.358 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.503 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.24 -41.39 96.75 Favored Glycine 0 N--CA 1.48 1.618 0 N-CA-C 108.668 -1.773 . . . . 0.0 108.668 179.271 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.6 tt -65.54 -41.9 92.51 Favored 'General case' 0 C--N 1.304 -1.38 0 O-C-N 121.426 -1.044 . . . . 0.0 108.942 179.219 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.2 tp -60.13 -45.98 91.18 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.435 -0.791 . . . . 0.0 109.208 179.801 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 28.5 mttp -60.11 -35.5 75.37 Favored 'General case' 0 C--N 1.296 -1.742 0 O-C-N 121.491 -0.755 . . . . 0.0 109.512 -179.783 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.503 HG23 ' O ' ' A' ' 40' ' ' GLY . 69.3 t -61.98 -48.23 89.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.335 -0.853 . . . . 0.0 109.927 -179.673 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.526 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 1.7 mp -68.15 -33.26 59.83 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.569 0 O-C-N 121.507 -0.746 . . . . 0.0 110.831 -179.652 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.0 -49.84 66.37 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 120.898 -1.126 . . . . 0.0 111.344 -178.179 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.703 ' CE2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -81.17 -44.54 17.71 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.718 -1.239 . . . . 0.0 109.936 -179.452 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.906 HD12 HH21 ' A' ' 51' ' ' ARG . 10.0 tp -58.43 -42.67 87.78 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.275 -0.891 . . . . 0.0 109.773 -179.07 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.526 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 2.3 pp20? -72.61 -35.93 67.98 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.094 -1.004 . . . . 0.0 109.786 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.2 t70 -60.02 -38.72 83.51 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.282 -0.886 . . . . 0.0 110.66 -179.517 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.906 HH21 HD12 ' A' ' 48' ' ' LEU . 62.6 mtm180 -62.09 -38.04 87.37 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.12 -0.987 . . . . 0.0 111.418 -178.824 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.834 ' CE2' HG11 ' A' ' 76' ' ' VAL . 95.6 m-85 -97.8 -11.94 22.78 Favored 'General case' 0 N--CA 1.487 1.391 0 O-C-N 120.738 -1.226 . . . . 0.0 110.164 -179.039 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 72.3 30.98 64.1 Favored Glycine 0 N--CA 1.488 2.102 0 N-CA-C 108.804 -1.718 . . . . 0.0 108.804 179.912 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.469 ' O ' ' OE1' ' A' ' 49' ' ' GLU . 34.5 pt -102.89 148.37 8.19 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.4 0 O-C-N 121.414 -1.05 . . . . 0.0 109.758 -179.436 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -89.87 112.42 23.76 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.184 -0.948 . . . . 0.0 109.679 -179.728 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.502 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -68.41 -27.14 65.95 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.332 -0.855 . . . . 0.0 109.585 179.686 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -55.73 -35.9 66.66 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.168 -0.957 . . . . 0.0 110.087 -179.587 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -55.55 -38.52 69.4 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.133 -0.979 . . . . 0.0 109.857 -179.631 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.502 ' O ' ' O ' ' A' ' 56' ' ' ALA . 42.7 t -124.95 136.16 61.74 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.419 -0.801 . . . . 0.0 109.658 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -89.18 131.09 35.46 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.028 -1.045 . . . . 0.0 109.297 179.872 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.502 HD12 HD11 ' A' ' 45' ' ' ILE . 38.1 mt -99.86 142.16 31.71 Favored 'General case' 0 C--N 1.305 -1.338 0 O-C-N 121.265 -0.897 . . . . 0.0 109.701 -179.7 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -109.49 157.18 38.1 Favored Pre-proline 0 N--CA 1.487 1.375 0 O-C-N 121.437 -0.789 . . . . 0.0 108.942 179.64 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_endo -55.33 -24.04 40.77 Favored 'Trans proline' 0 C--N 1.304 -1.77 0 C-N-CA 122.604 2.203 . . . . 0.0 111.827 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -69.06 -29.22 67.31 Favored 'General case' 0 C--N 1.304 -1.374 0 O-C-N 121.364 -0.835 . . . . 0.0 109.139 179.703 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 65' ' ' HIS . . . . . 0.531 ' CD2' ' O ' ' A' ' 65' ' ' HIS . 2.9 t-80 -66.33 -18.5 65.39 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.359 -0.838 . . . . 0.0 108.895 179.938 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.521 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 11.4 m-85 -94.69 13.77 23.3 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 179.582 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 67' ' ' ARG . . . . . 0.478 ' CZ ' ' OG ' ' A' ' 71' ' ' SER . 7.5 ptt180 -44.2 -38.92 4.05 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.811 -0.556 . . . . 0.0 110.545 -179.594 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 80.1 p -155.7 161.42 40.74 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.806 -1.184 . . . . 0.0 110.3 -179.629 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.479 ' CD1' HD12 ' A' ' 30' ' ' LEU . 31.3 mm -60.66 -44.14 96.39 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 O-C-N 121.39 -0.819 . . . . 0.0 110.172 -179.774 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.412 ' HG2' ' H ' ' A' ' 71' ' ' SER . 0.0 OUTLIER -58.88 -39.74 82.29 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.214 -0.929 . . . . 0.0 109.656 -179.304 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 71' ' ' SER . . . . . 0.478 ' OG ' ' CZ ' ' A' ' 67' ' ' ARG . 23.2 t -63.08 -40.61 98.17 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.248 -0.907 . . . . 0.0 109.643 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 86.0 mt -61.95 -50.56 79.64 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 O-C-N 121.214 -0.929 . . . . 0.0 110.107 -179.755 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 40.9 t0 -59.28 -41.13 88.2 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.234 -0.916 . . . . 0.0 109.357 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 74' ' ' ALA . . . . . 0.439 ' O ' ' N ' ' A' ' 78' ' ' GLY . . . -66.49 -37.42 85.03 Favored 'General case' 0 C--N 1.302 -1.458 0 O-C-N 121.505 -0.747 . . . . 0.0 110.266 -179.587 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 75' ' ' PHE . . . . . 0.531 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 62.6 t80 -61.99 -48.12 81.77 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.022 -1.049 . . . . 0.0 109.886 -179.502 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.834 HG11 ' CE2' ' A' ' 52' ' ' PHE . 87.6 t -64.92 -48.25 84.96 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.323 0 O-C-N 121.097 -1.002 . . . . 0.0 109.671 -179.801 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 60.8 t -69.31 -39.18 78.69 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 O-C-N 121.214 -0.929 . . . . 0.0 109.142 179.585 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.439 ' N ' ' O ' ' A' ' 74' ' ' ALA . . . -59.1 -35.35 83.66 Favored Glycine 0 N--CA 1.487 2.088 0 N-CA-C 110.207 -1.157 . . . . 0.0 110.207 -179.678 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -70.35 -41.68 72.86 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.265 -1.138 . . . . 0.0 111.044 -178.791 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 44.6 p -81.78 -34.79 30.15 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.094 -1.004 . . . . 0.0 109.497 -179.622 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.299 -1.592 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 -179.848 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 58.9 m-70 . . . . . 0 N--CA 1.494 1.762 0 CA-C-O 121.066 0.46 . . . . 0.0 110.316 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -62.25 -38.82 90.73 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.06 -1.025 . . . . 0.0 109.484 179.718 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.4 m -60.28 -36.88 78.85 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.368 -0.832 . . . . 0.0 110.107 -179.645 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 48.9 t -62.15 -44.81 99.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.124 -0.985 . . . . 0.0 109.723 -179.757 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.439 ' O ' HG12 ' A' ' 11' ' ' VAL . 89.7 mt -59.53 -49.8 82.29 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.613 0 O-C-N 121.341 -0.849 . . . . 0.0 110.037 -179.504 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.714 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.5 -43.97 95.72 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.378 -0.826 . . . . 0.0 111.111 -179.136 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 53.0 mt-30 -69.22 -46.0 68.45 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 120.844 -1.16 . . . . 0.0 111.284 -178.607 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.705 ' CD1' ' N ' ' A' ' 11' ' ' VAL . 0.0 OUTLIER -69.82 -47.01 64.38 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 120.951 -1.093 . . . . 0.0 110.519 -179.142 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.705 ' N ' ' CD1' ' A' ' 10' ' ' PHE . 5.1 p -61.54 -38.91 81.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.062 -1.024 . . . . 0.0 109.731 -179.671 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.714 HG23 ' O ' ' A' ' 8' ' ' ALA . 56.0 t -63.33 -43.44 98.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.133 -0.979 . . . . 0.0 109.821 -179.949 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -63.9 -39.02 93.22 Favored 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.166 -0.958 . . . . 0.0 110.187 -179.519 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 85.2 tt0 -70.02 -42.26 73.2 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.182 -0.949 . . . . 0.0 110.0 -179.849 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 77.7 t80 -83.58 -52.18 6.68 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.221 -0.924 . . . . 0.0 110.618 -179.435 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.478 HD22 ' CG2' ' A' ' 19' ' ' VAL . 7.3 mt -123.64 80.07 55.26 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.378 -0.826 . . . . 0.0 110.292 -179.04 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -67.02 -15.65 47.36 Favored 'Trans proline' 0 N--CA 1.492 1.401 0 C-N-CA 122.056 1.837 . . . . 0.0 112.466 179.682 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -95.26 7.34 46.47 Favored 'General case' 0 N--CA 1.486 1.335 0 O-C-N 121.083 -1.011 . . . . 0.0 110.429 -179.499 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.478 ' CG2' HD22 ' A' ' 16' ' ' LEU . 21.8 t -119.47 136.21 57.37 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.214 -0.929 . . . . 0.0 109.843 -179.825 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.487 ' O ' ' OD1' ' A' ' 23' ' ' ASP . . . -77.58 118.69 73.71 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.241 -0.912 . . . . 0.0 108.978 179.516 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_exo -51.15 -25.75 17.84 Favored 'Trans proline' 0 N--CA 1.493 1.487 0 C-N-CA 121.798 1.665 . . . . 0.0 112.223 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.88 -27.46 68.87 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.183 -0.948 . . . . 0.0 109.726 -179.854 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.487 ' OD1' ' O ' ' A' ' 20' ' ' ALA . 47.3 p30 -87.28 7.72 27.36 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.136 -0.977 . . . . 0.0 109.84 -179.678 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.463 HG23 ' OD1' ' A' ' 23' ' ' ASP . 16.4 t -110.16 132.06 59.5 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 O-C-N 121.311 -0.868 . . . . 0.0 109.446 179.88 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 62.2 t0 -89.26 119.47 29.77 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.197 -0.94 . . . . 0.0 108.993 179.308 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.637 HG22 ' O ' ' A' ' 26' ' ' VAL . 1.9 p -74.66 4.85 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 O-C-N 121.102 -0.999 . . . . 0.0 108.914 179.632 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -98.21 3.4 48.92 Favored 'General case' 0 N--CA 1.486 1.371 0 O-C-N 121.198 -0.938 . . . . 0.0 109.253 179.636 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 40.0 tp -97.95 134.6 40.84 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.354 -0.841 . . . . 0.0 109.37 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 82.2 m-20 -65.67 142.06 58.17 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.226 -0.921 . . . . 0.0 109.298 -179.71 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.58 HD11 HG13 ' A' ' 69' ' ' ILE . 91.4 mt -70.7 -33.73 71.2 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.325 -0.859 . . . . 0.0 110.698 -179.411 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.66 HG23 ' N ' ' A' ' 32' ' ' ASP . 20.0 m -53.56 -47.74 59.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 O-C-N 121.146 -0.971 . . . . 0.0 110.155 -178.686 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.66 ' N ' HG23 ' A' ' 31' ' ' VAL . 90.8 m-20 -61.11 -35.04 75.96 Favored 'General case' 0 C--N 1.3 -1.568 0 O-C-N 121.248 -0.908 . . . . 0.0 108.624 179.496 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 96.4 m-20 -70.84 -34.32 71.55 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.686 -0.634 . . . . 0.0 110.11 -179.842 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 86.17 5.32 83.1 Favored Glycine 0 N--CA 1.491 2.367 0 N-CA-C 109.158 -1.577 . . . . 0.0 109.158 -179.685 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 71.9 t -60.85 -34.41 59.25 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 O-C-N 121.402 -1.058 . . . . 0.0 108.93 179.672 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 92.1 mt -66.46 95.21 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.428 0 O-C-N 121.467 -0.771 . . . . 0.0 110.313 -179.559 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -102.95 169.36 8.62 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 178.85 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -55.55 -48.65 74.4 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 107.761 -1.2 . . . . 0.0 107.761 179.659 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.719 HD12 ' N ' ' A' ' 39' ' ' LEU . 6.8 mp -71.14 -32.16 68.62 Favored 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 106.984 -1.488 . . . . 0.0 106.984 177.592 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.5 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -58.77 -48.1 86.93 Favored Glycine 0 N--CA 1.483 1.795 0 N-CA-C 109.181 -1.568 . . . . 0.0 109.181 179.705 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.5 tt -63.08 -40.29 97.22 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.367 -1.078 . . . . 0.0 109.187 179.314 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.1 tp -59.73 -46.22 89.8 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.264 -0.897 . . . . 0.0 109.23 179.956 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 63.8 mttp -61.67 -34.35 75.57 Favored 'General case' 0 C--N 1.297 -1.7 0 O-C-N 121.443 -0.786 . . . . 0.0 109.604 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.5 HG23 ' O ' ' A' ' 40' ' ' GLY . 78.9 t -60.8 -47.07 94.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.377 -0.827 . . . . 0.0 110.036 -179.512 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.403 HD12 ' N ' ' A' ' 45' ' ' ILE . 1.7 mp -67.89 -36.56 76.12 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 O-C-N 121.295 -0.878 . . . . 0.0 111.35 -179.474 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.3 -49.38 64.46 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 120.965 -1.084 . . . . 0.0 111.853 -178.031 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.549 ' HE1' ' NE ' ' A' ' 51' ' ' ARG . 0.0 OUTLIER -78.37 -42.59 29.95 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 120.541 -1.349 . . . . 0.0 110.105 -179.062 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.458 HD11 ' CG2' ' A' ' 76' ' ' VAL . 7.4 tt -59.78 -42.08 92.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.242 -0.911 . . . . 0.0 110.667 -179.239 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 18.9 pt-20 -72.69 -36.51 67.9 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.101 -1.0 . . . . 0.0 109.94 -179.4 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.7 t0 -61.17 -39.61 90.76 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.362 -0.836 . . . . 0.0 111.247 -179.186 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.549 ' NE ' ' HE1' ' A' ' 47' ' ' TRP . 94.0 mtt-85 -63.18 -38.91 93.04 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.094 -1.004 . . . . 0.0 112.567 -178.074 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.732 ' CD1' HG11 ' A' ' 76' ' ' VAL . 85.5 m-85 -99.2 -7.63 26.23 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 120.656 -1.278 . . . . 0.0 110.635 -178.682 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 69.82 30.54 70.34 Favored Glycine 0 N--CA 1.486 2.012 0 N-CA-C 108.924 -1.67 . . . . 0.0 108.924 179.425 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 26.5 pt -106.59 153.23 7.91 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 O-C-N 121.634 -0.921 . . . . 0.0 109.544 -179.557 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -98.59 134.19 41.88 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.138 -0.977 . . . . 0.0 109.639 -179.498 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.518 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -65.84 -30.29 70.89 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.28 -0.887 . . . . 0.0 109.58 179.903 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -57.71 -34.56 69.59 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.212 -0.93 . . . . 0.0 110.242 -179.741 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -54.93 -39.38 68.78 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.196 -0.94 . . . . 0.0 110.403 -179.297 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.518 ' O ' ' O ' ' A' ' 56' ' ' ALA . 31.5 m -128.67 157.05 41.41 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 O-C-N 121.275 -0.891 . . . . 0.0 109.804 -179.503 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -96.54 128.95 43.96 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.986 -1.071 . . . . 0.0 109.167 179.724 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 58.1 mt -101.39 135.33 43.05 Favored 'General case' 0 C--N 1.305 -1.334 0 O-C-N 121.214 -0.929 . . . . 0.0 109.798 -179.815 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -109.97 156.05 40.62 Favored Pre-proline 0 N--CA 1.487 1.393 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 179.395 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 10.8 Cg_endo -56.94 -24.1 55.07 Favored 'Trans proline' 0 C--N 1.303 -1.839 0 C-N-CA 122.406 2.071 . . . . 0.0 111.74 179.891 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -69.47 -29.35 67.0 Favored 'General case' 0 C--N 1.306 -1.315 0 O-C-N 121.338 -0.851 . . . . 0.0 109.172 179.721 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 65' ' ' HIS . . . . . 0.592 ' CD2' ' O ' ' A' ' 65' ' ' HIS . 4.3 t-160 -65.97 -17.69 64.84 Favored 'General case' 0 C--N 1.3 -1.562 0 O-C-N 121.417 -0.802 . . . . 0.0 108.966 -179.911 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.493 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 17.3 m-85 -93.14 14.86 16.71 Favored 'General case' 0 C--N 1.303 -1.445 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 179.532 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 8.9 ptt180 -48.38 -38.53 19.64 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.816 -0.552 . . . . 0.0 110.822 -179.498 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 31.9 t -158.53 150.24 21.19 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 120.76 -1.213 . . . . 0.0 110.362 -179.667 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.734 ' H ' HD12 ' A' ' 69' ' ' ILE . 0.1 OUTLIER -57.74 -42.86 82.74 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.365 -0.835 . . . . 0.0 109.255 179.688 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 5.8 ptm180 -57.88 -40.66 80.77 Favored 'General case' 0 C--N 1.303 -1.427 0 O-C-N 121.42 -0.8 . . . . 0.0 109.326 -179.89 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 84.9 p -66.42 -34.39 77.85 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.236 -0.915 . . . . 0.0 109.514 179.538 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.556 HD12 ' HA ' ' A' ' 69' ' ' ILE . 91.5 mt -59.99 -51.14 76.4 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.243 0 O-C-N 121.163 -0.961 . . . . 0.0 109.749 179.969 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 42.4 t0 -59.49 -42.07 91.28 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.172 -0.955 . . . . 0.0 108.976 179.823 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 74' ' ' ALA . . . . . 0.556 ' O ' ' N ' ' A' ' 78' ' ' GLY . . . -66.72 -37.11 84.03 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.661 -0.649 . . . . 0.0 110.148 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 75' ' ' PHE . . . . . 0.459 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 64.6 t80 -61.3 -49.7 75.97 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.004 -1.06 . . . . 0.0 109.686 -179.604 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.732 HG11 ' CD1' ' A' ' 52' ' ' PHE . 44.3 t -68.66 -48.89 69.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.307 0 O-C-N 121.216 -0.927 . . . . 0.0 109.875 -179.568 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 82.1 t -69.62 -41.91 80.38 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.305 0 O-C-N 121.211 -0.931 . . . . 0.0 109.151 179.803 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.556 ' N ' ' O ' ' A' ' 74' ' ' ALA . . . -60.48 -39.42 96.31 Favored Glycine 0 N--CA 1.488 2.134 0 N-CA-C 109.895 -1.282 . . . . 0.0 109.895 -179.872 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -68.33 -41.07 81.33 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.159 -1.201 . . . . 0.0 110.245 -179.428 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 45.0 p -82.32 -29.86 30.8 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.189 -0.944 . . . . 0.0 109.594 -179.768 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.495 ' O ' ' O ' ' A' ' 78' ' ' GLY . 0.3 OUTLIER . . . . . 0 C--N 1.302 -1.461 0 O-C-N 121.522 -0.736 . . . . 0.0 109.457 -179.659 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 14.9 m-70 . . . . . 0 N--CA 1.496 1.842 0 CA-C-O 121.037 0.446 . . . . 0.0 110.127 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -62.26 -38.34 88.92 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.045 -1.034 . . . . 0.0 109.396 179.719 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.3 t -60.66 -38.03 83.53 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.36 -0.837 . . . . 0.0 110.049 -179.585 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 73.4 t -61.53 -43.12 96.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.203 -0.935 . . . . 0.0 109.539 -179.836 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 75.3 mt -60.32 -46.04 95.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.395 -0.816 . . . . 0.0 109.283 179.742 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.529 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -61.47 -39.24 90.18 Favored 'General case' 0 N--CA 1.486 1.372 0 O-C-N 121.268 -0.895 . . . . 0.0 108.675 179.546 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 33.2 tt0 -64.99 -35.11 80.13 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.419 -0.801 . . . . 0.0 109.143 179.289 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.612 ' CZ ' ' CD1' ' A' ' 47' ' ' TRP . 0.3 OUTLIER -60.51 -50.9 71.72 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.495 -0.753 . . . . 0.0 110.184 -179.569 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.734 HG11 HD11 ' A' ' 30' ' ' LEU . 22.7 m -66.55 -38.26 81.3 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 O-C-N 121.164 -0.96 . . . . 0.0 109.117 -179.743 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.529 HG23 ' O ' ' A' ' 8' ' ' ALA . 73.9 t -63.47 -44.87 98.99 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.439 0 O-C-N 121.24 -0.912 . . . . 0.0 109.351 179.496 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -73.3 -19.27 61.08 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.266 -0.896 . . . . 0.0 109.939 179.746 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -63.9 -32.28 73.75 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.33 -0.857 . . . . 0.0 110.449 -178.983 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 64.8 t80 -142.28 -36.62 0.41 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 120.958 -1.089 . . . . 0.0 110.463 -179.62 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.507 HD22 ' CG2' ' A' ' 19' ' ' VAL . 5.6 mt -119.55 79.89 22.26 Favored Pre-proline 0 N--CA 1.491 1.615 0 O-C-N 121.211 -0.93 . . . . 0.0 110.017 -179.495 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_endo -77.97 -14.16 15.45 Favored 'Trans proline' 0 C--N 1.308 -1.58 0 C-N-CA 122.604 2.203 . . . . 0.0 112.235 179.592 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -90.31 7.25 39.37 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 121.343 -0.848 . . . . 0.0 109.9 -179.699 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.507 ' CG2' HD22 ' A' ' 16' ' ' LEU . 44.7 t -109.28 134.86 49.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.303 -0.873 . . . . 0.0 109.588 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.489 ' O ' ' OD1' ' A' ' 23' ' ' ASP . . . -72.52 117.15 56.53 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.275 -0.89 . . . . 0.0 109.382 -179.942 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_exo -52.5 -26.16 27.64 Favored 'Trans proline' 0 N--CA 1.493 1.468 0 C-N-CA 121.891 1.728 . . . . 0.0 112.095 179.446 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.88 -23.42 67.23 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.355 -0.841 . . . . 0.0 109.731 -179.762 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.489 ' OD1' ' O ' ' A' ' 20' ' ' ALA . 52.6 p30 -84.69 7.85 19.02 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.16 -0.963 . . . . 0.0 110.003 -179.615 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 12.2 t -103.0 131.74 50.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.162 -0.961 . . . . 0.0 109.5 -179.868 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 63.5 t0 -89.0 119.94 29.98 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.101 -1.0 . . . . 0.0 108.93 179.247 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.5 m -73.12 4.28 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 O-C-N 121.079 -1.013 . . . . 0.0 109.547 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -89.67 -8.22 52.9 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.215 -0.928 . . . . 0.0 109.111 179.577 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 40.5 tp -101.62 139.46 37.23 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.427 -0.796 . . . . 0.0 109.313 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.5 m-20 -58.88 142.17 51.4 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.249 -0.907 . . . . 0.0 109.388 -179.78 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.841 HD13 HD11 ' A' ' 36' ' ' ILE . 1.4 tt -69.12 -38.6 78.95 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.607 -0.683 . . . . 0.0 110.743 -178.846 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 75.4 t -64.5 -36.16 76.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.086 -1.009 . . . . 0.0 110.542 -178.903 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 91.3 m-20 -52.58 -33.66 47.09 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 120.969 -1.082 . . . . 0.0 108.218 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.428 ' HB3' HG23 ' A' ' 35' ' ' VAL . 97.6 m-20 -70.94 -34.37 71.4 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.615 -0.678 . . . . 0.0 109.99 179.534 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 86.05 6.04 82.48 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.315 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.428 HG23 ' HB3' ' A' ' 33' ' ' ASN . 71.6 t -61.51 -33.01 55.14 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.411 0 O-C-N 121.413 -1.051 . . . . 0.0 109.07 179.755 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.841 HD11 HD13 ' A' ' 30' ' ' LEU . 84.7 mt -91.95 123.85 44.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.276 -0.89 . . . . 0.0 109.802 -179.859 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -114.97 -168.44 1.38 Allowed 'General case' 0 C--N 1.301 -1.501 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 179.61 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -63.77 -53.84 44.6 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.103 -0.998 . . . . 0.0 108.717 179.683 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.585 HD12 ' N ' ' A' ' 39' ' ' LEU . 6.6 mp -68.88 -32.9 72.88 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 107.007 -1.479 . . . . 0.0 107.007 178.222 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.492 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.04 -41.91 96.7 Favored Glycine 0 N--CA 1.48 1.627 0 N-CA-C 108.691 -1.763 . . . . 0.0 108.691 179.211 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.407 HD11 ' CE1' ' A' ' 66' ' ' PHE . 7.7 tt -65.16 -41.09 95.03 Favored 'General case' 0 C--N 1.304 -1.393 0 O-C-N 121.454 -1.027 . . . . 0.0 108.851 179.066 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.1 tp -59.88 -45.81 91.31 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.365 -0.834 . . . . 0.0 109.051 179.728 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 78.6 mttt -60.34 -35.73 76.35 Favored 'General case' 0 C--N 1.298 -1.672 0 O-C-N 121.471 -0.768 . . . . 0.0 109.456 -179.863 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.492 HG23 ' O ' ' A' ' 40' ' ' GLY . 77.7 t -62.03 -43.32 97.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.308 -0.87 . . . . 0.0 109.795 -179.884 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.706 ' CD1' HD12 ' A' ' 61' ' ' LEU . 1.5 mp -67.33 -39.56 83.04 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.541 0 O-C-N 121.549 -0.719 . . . . 0.0 111.196 -179.382 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.36 -50.19 60.86 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 120.637 -1.289 . . . . 0.0 112.015 -177.72 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.612 ' CD1' ' CZ ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -78.65 -45.01 22.45 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.665 -1.272 . . . . 0.0 110.647 -178.701 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.697 HD11 HG21 ' A' ' 76' ' ' VAL . 29.4 tp -58.5 -44.19 89.34 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.12 -0.987 . . . . 0.0 110.062 -178.862 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 68.9 mm-40 -68.06 -37.75 81.66 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.117 -0.989 . . . . 0.0 109.582 -179.819 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.1 t70 -62.37 -36.94 83.83 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.358 -0.839 . . . . 0.0 110.792 -179.754 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 35.5 mmt180 -58.1 -39.07 77.67 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.09 -1.007 . . . . 0.0 111.162 -178.641 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.604 ' CE1' ' CG1' ' A' ' 76' ' ' VAL . 9.0 m-85 -91.89 -3.57 55.84 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.842 -1.161 . . . . 0.0 110.319 -179.286 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 73.87 29.8 62.49 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 108.52 -1.832 . . . . 0.0 108.52 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 31.9 pt -113.45 153.61 14.98 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 O-C-N 121.714 -0.874 . . . . 0.0 109.866 -179.17 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -97.06 139.92 32.34 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.307 -0.871 . . . . 0.0 109.259 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.585 ' HB2' HG23 ' A' ' 45' ' ' ILE . . . -62.85 -30.71 71.71 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.24 -0.912 . . . . 0.0 109.715 -179.796 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -56.72 -38.77 72.81 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.054 -1.029 . . . . 0.0 109.681 -179.758 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 90.7 m-20 -61.36 -41.29 96.83 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.204 -0.935 . . . . 0.0 109.945 -179.878 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.482 ' O ' ' O ' ' A' ' 56' ' ' ALA . 46.8 t -130.35 133.73 63.49 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 121.408 -0.808 . . . . 0.0 109.728 -179.845 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -104.15 134.27 47.68 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.295 -0.878 . . . . 0.0 109.402 179.677 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.706 HD12 ' CD1' ' A' ' 45' ' ' ILE . 40.2 mt -96.23 141.82 29.13 Favored 'General case' 0 C--N 1.304 -1.387 0 O-C-N 121.217 -0.927 . . . . 0.0 109.521 -179.759 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -109.58 156.33 39.82 Favored Pre-proline 0 C--N 1.305 -1.343 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 179.684 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 1.4 Cg_endo -48.92 -22.23 4.62 Favored 'Trans proline' 0 C--N 1.305 -1.729 0 C-N-CA 121.924 1.75 . . . . 0.0 110.837 179.604 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 87.1 tt0 -71.13 -30.14 66.12 Favored 'General case' 0 N--CA 1.486 1.351 0 O-C-N 121.563 -0.711 . . . . 0.0 109.477 179.094 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 65' ' ' HIS . . . . . 0.54 ' C ' ' CD2' ' A' ' 65' ' ' HIS . 1.2 t60 -65.84 -16.49 63.87 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.397 -0.814 . . . . 0.0 108.97 -179.794 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.558 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 12.5 m-85 -97.53 15.38 23.45 Favored 'General case' 0 C--N 1.299 -1.598 0 CA-C-O 121.739 0.78 . . . . 0.0 108.896 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 67' ' ' ARG . . . . . 0.598 ' NE ' ' OG ' ' A' ' 71' ' ' SER . 6.6 ptt180 -50.71 -36.13 34.72 Favored 'General case' 0 C--N 1.301 -1.5 0 O-C-N 121.701 -0.624 . . . . 0.0 110.002 -179.719 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 68' ' ' SER . . . . . 0.462 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 88.8 p -162.86 153.35 16.56 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.982 -1.074 . . . . 0.0 110.216 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.67 ' H ' HD12 ' A' ' 69' ' ' ILE . 3.5 mp -58.42 -43.4 86.51 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 O-C-N 121.34 -0.85 . . . . 0.0 109.046 179.68 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 10.0 ptm180 -58.17 -40.11 80.62 Favored 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 108.96 -0.756 . . . . 0.0 108.96 179.5 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 71' ' ' SER . . . . . 0.598 ' OG ' ' NE ' ' A' ' 67' ' ' ARG . 25.9 t -63.46 -41.14 98.62 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.434 -0.792 . . . . 0.0 109.827 179.542 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 81.8 mt -58.91 -48.7 85.57 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.315 0 O-C-N 121.239 -0.913 . . . . 0.0 109.603 -179.615 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 37.4 t0 -60.07 -43.76 95.21 Favored 'General case' 0 N--CA 1.487 1.406 0 O-C-N 121.22 -0.925 . . . . 0.0 108.728 179.756 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.99 -38.77 86.63 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.658 -0.651 . . . . 0.0 109.932 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 75' ' ' PHE . . . . . 0.577 ' O ' ' HB2' ' A' ' 79' ' ' ALA . 53.5 t80 -62.76 -47.99 81.13 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.177 -0.952 . . . . 0.0 109.473 -179.698 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.697 HG21 HD11 ' A' ' 48' ' ' LEU . 50.0 t -64.99 -48.33 84.49 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.294 0 O-C-N 121.255 -0.903 . . . . 0.0 109.774 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.625 ' O ' HG22 ' A' ' 81' ' ' THR . 88.7 t -69.88 -49.06 60.0 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 O-C-N 121.2 -0.937 . . . . 0.0 109.356 179.705 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.493 ' O ' ' O ' ' A' ' 81' ' ' THR . . . -65.6 -26.58 72.01 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 -179.778 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 79' ' ' ALA . . . . . 0.577 ' HB2' ' O ' ' A' ' 75' ' ' PHE . . . -67.12 -39.39 86.65 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.145 -1.209 . . . . 0.0 110.019 -179.31 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 56.6 p -82.19 -28.7 31.89 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.197 -0.939 . . . . 0.0 109.585 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.625 HG22 ' O ' ' A' ' 77' ' ' VAL . 2.0 t . . . . . 0 N--CA 1.489 1.522 0 O-C-N 121.389 -0.819 . . . . 0.0 109.65 -179.857 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 13.4 m-70 . . . . . 0 N--CA 1.495 1.786 0 CA-C-O 121.108 0.48 . . . . 0.0 110.225 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -62.74 -41.36 99.15 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.078 -1.014 . . . . 0.0 109.509 179.77 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.3 p -62.75 -34.57 77.47 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.204 -0.935 . . . . 0.0 109.685 -179.731 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 65.3 t -64.62 -41.66 92.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.228 -0.92 . . . . 0.0 109.183 179.75 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 77.7 mt -59.67 -44.61 93.91 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 O-C-N 121.481 -0.762 . . . . 0.0 109.238 179.875 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -62.12 -38.33 88.53 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.333 -0.854 . . . . 0.0 109.235 179.875 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 59.2 tt0 -59.09 -41.14 87.36 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.273 -0.892 . . . . 0.0 109.185 179.72 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.699 ' CG ' ' CE2' ' A' ' 47' ' ' TRP . 23.0 m-85 -63.32 -40.74 98.16 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.012 -1.055 . . . . 0.0 109.955 179.586 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 55.9 t -59.53 -50.63 79.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.276 -0.89 . . . . 0.0 110.726 -178.558 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.472 ' O ' ' C ' ' A' ' 16' ' ' LEU . 17.1 m -66.12 -39.6 84.86 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.428 0 O-C-N 120.656 -1.277 . . . . 0.0 109.813 -179.955 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -67.21 -20.54 65.71 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.136 -0.977 . . . . 0.0 110.39 -179.785 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 -63.34 -30.11 71.3 Favored 'General case' 0 C--N 1.299 -1.606 0 O-C-N 121.275 -0.891 . . . . 0.0 109.731 -179.309 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 63.6 t80 -149.27 -33.23 0.21 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.997 -1.064 . . . . 0.0 110.253 -179.917 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.472 ' C ' ' O ' ' A' ' 12' ' ' VAL . 3.8 mt -121.89 79.93 41.47 Favored Pre-proline 0 N--CA 1.492 1.671 0 O-C-N 121.189 -0.945 . . . . 0.0 110.126 -179.383 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -74.62 -11.98 22.3 Favored 'Trans proline' 0 C--N 1.308 -1.573 0 C-N-CA 122.403 2.068 . . . . 0.0 112.438 179.881 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -93.9 12.83 24.61 Favored 'General case' 0 N--CA 1.487 1.377 0 O-C-N 121.246 -0.909 . . . . 0.0 110.371 -179.413 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 60.5 t -111.15 134.71 52.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 121.238 -0.914 . . . . 0.0 109.831 -179.784 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.49 ' O ' ' OD1' ' A' ' 23' ' ' ASP . . . -75.96 118.43 71.09 Favored Pre-proline 0 N--CA 1.489 1.515 0 O-C-N 121.338 -0.851 . . . . 0.0 109.326 179.912 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_exo -51.41 -25.63 19.15 Favored 'Trans proline' 0 N--CA 1.493 1.486 0 C-N-CA 121.77 1.647 . . . . 0.0 112.146 179.611 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.81 -25.61 67.98 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.261 -0.9 . . . . 0.0 109.732 -179.896 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.49 ' OD1' ' O ' ' A' ' 20' ' ' ALA . 49.8 p30 -85.81 7.46 23.76 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.195 -0.941 . . . . 0.0 109.925 -179.611 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' VAL . . . . . 0.47 HG23 ' OD1' ' A' ' 23' ' ' ASP . 17.3 t -109.7 133.32 55.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.321 -0.862 . . . . 0.0 109.397 179.844 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 63.4 t0 -88.47 119.66 29.12 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.141 -0.974 . . . . 0.0 108.892 179.348 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.6 m -75.89 3.81 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 O-C-N 121.182 -0.949 . . . . 0.0 109.285 179.851 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -87.55 -11.38 48.93 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.333 -0.854 . . . . 0.0 108.966 179.424 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 36.4 tp -94.98 136.91 34.73 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 179.778 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -59.51 134.16 56.76 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.114 -0.991 . . . . 0.0 109.409 -179.493 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.727 HD23 ' O ' ' A' ' 30' ' ' LEU . 2.3 tt -67.15 -37.81 84.41 Favored 'General case' 0 C--N 1.299 -1.6 0 O-C-N 121.732 -0.605 . . . . 0.0 110.154 -179.18 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.535 HG23 ' O ' ' A' ' 66' ' ' PHE . 78.2 t -63.79 -34.96 71.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.05 -1.031 . . . . 0.0 110.396 -178.994 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 56.9 t0 -52.36 -33.66 44.08 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 120.984 -1.073 . . . . 0.0 108.11 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.409 ' HB3' HG23 ' A' ' 35' ' ' VAL . 83.1 m-20 -71.16 -34.48 71.01 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.55 -0.719 . . . . 0.0 109.897 179.433 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 86.37 6.52 80.95 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.056 -1.617 . . . . 0.0 109.056 -179.374 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.409 HG23 ' HB3' ' A' ' 33' ' ' ASN . 79.6 t -61.66 -34.3 61.41 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 O-C-N 121.455 -1.026 . . . . 0.0 109.152 179.719 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.662 HD11 HD13 ' A' ' 30' ' ' LEU . 85.4 mt -86.07 117.84 31.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.324 -0.86 . . . . 0.0 109.656 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -114.01 -164.59 0.94 Allowed 'General case' 0 C--N 1.302 -1.463 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 179.845 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -64.74 -54.21 34.94 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.109 -0.994 . . . . 0.0 108.682 179.704 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 38.5 mt -68.71 -32.81 72.86 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 107.105 -1.443 . . . . 0.0 107.105 178.264 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.547 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.15 -40.7 96.04 Favored Glycine 0 N--CA 1.48 1.592 0 N-CA-C 108.403 -1.879 . . . . 0.0 108.403 179.16 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.597 ' CD1' ' CZ ' ' A' ' 66' ' ' PHE . 7.3 tt -65.47 -41.67 93.07 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.479 -1.012 . . . . 0.0 108.888 178.978 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 tp -59.71 -45.74 91.22 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 179.443 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 25.2 mttp -60.51 -35.44 75.96 Favored 'General case' 0 C--N 1.297 -1.698 0 O-C-N 121.577 -0.702 . . . . 0.0 109.553 -179.881 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.547 HG23 ' O ' ' A' ' 40' ' ' GLY . 72.5 t -60.11 -43.3 92.59 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 O-C-N 121.296 -0.877 . . . . 0.0 109.445 -179.916 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.484 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 6.4 mm -67.45 -40.03 83.74 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.559 0 O-C-N 121.476 -0.765 . . . . 0.0 111.144 -179.088 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.48 -49.09 67.78 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.038 -1.038 . . . . 0.0 112.162 -177.596 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.699 ' CE2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -78.77 -46.73 18.21 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.448 -1.407 . . . . 0.0 110.679 -178.55 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.741 HD13 ' C ' ' A' ' 48' ' ' LEU . 3.2 tm? -58.4 -43.54 88.6 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.005 -1.06 . . . . 0.0 109.921 -178.301 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.484 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 1.2 pp20? -69.76 -36.83 76.12 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 120.943 -1.098 . . . . 0.0 109.66 -179.911 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.2 t0 -62.82 -37.88 88.54 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.181 -0.949 . . . . 0.0 110.321 179.895 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 9.7 mmt180 -60.95 -38.47 85.97 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.322 -0.861 . . . . 0.0 111.724 -178.81 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.74 ' CZ ' HG11 ' A' ' 76' ' ' VAL . 84.5 m-85 -96.82 -6.89 34.97 Favored 'General case' 0 C--N 1.304 -1.392 0 O-C-N 120.817 -1.177 . . . . 0.0 110.239 -178.947 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 70.92 30.81 67.58 Favored Glycine 0 N--CA 1.486 1.971 0 N-CA-C 108.72 -1.752 . . . . 0.0 108.72 179.653 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.47 ' O ' ' OE1' ' A' ' 49' ' ' GLU . 24.7 pt -108.59 153.07 10.35 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 O-C-N 121.587 -0.949 . . . . 0.0 109.765 -179.408 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -104.14 156.28 18.01 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.383 -0.823 . . . . 0.0 109.554 -179.78 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -58.22 -25.54 61.78 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.234 -0.916 . . . . 0.0 109.151 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 57' ' ' ASP . . . . . 0.402 ' O ' HG23 ' A' ' 59' ' ' VAL . 61.2 t0 59.07 39.62 23.05 Favored 'General case' 0 N--CA 1.485 1.286 0 O-C-N 121.517 -0.739 . . . . 0.0 109.075 -179.761 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 54.38 44.87 28.27 Favored 'General case' 0 N--CA 1.487 1.379 0 O-C-N 121.706 -0.621 . . . . 0.0 110.202 179.367 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.402 HG23 ' O ' ' A' ' 57' ' ' ASP . 52.6 t -121.33 134.46 64.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.446 -0.784 . . . . 0.0 109.137 179.382 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -102.29 132.44 48.24 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.19 -0.944 . . . . 0.0 109.599 -179.914 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 53.1 mt -95.24 147.3 23.62 Favored 'General case' 0 C--N 1.304 -1.394 0 O-C-N 121.347 -0.846 . . . . 0.0 109.293 179.792 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -104.4 157.67 33.59 Favored Pre-proline 0 N--CA 1.486 1.349 0 O-C-N 121.282 -0.886 . . . . 0.0 108.92 179.872 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 2.1 Cg_endo -49.4 -19.65 3.19 Favored 'Trans proline' 0 C--N 1.302 -1.869 0 C-N-CA 122.398 2.065 . . . . 0.0 110.985 -179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 87.4 tt0 -68.54 -32.32 72.18 Favored 'General case' 0 N--CA 1.486 1.375 0 O-C-N 121.606 -0.683 . . . . 0.0 109.56 179.404 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 65' ' ' HIS . . . . . 0.553 ' C ' ' CD2' ' A' ' 65' ' ' HIS . 1.5 t60 -66.33 -17.89 65.03 Favored 'General case' 0 C--N 1.3 -1.558 0 O-C-N 121.384 -0.823 . . . . 0.0 108.829 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.602 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 4.2 m-85 -101.97 14.99 30.39 Favored 'General case' 0 C--N 1.298 -1.642 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 67' ' ' ARG . . . . . 0.422 ' NE ' ' OG ' ' A' ' 71' ' ' SER . 4.8 ptt180 -46.17 -38.31 8.11 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.875 -0.516 . . . . 0.0 109.985 -179.684 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 68' ' ' SER . . . . . 0.55 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 83.8 p -163.86 159.5 21.14 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.081 -1.012 . . . . 0.0 109.905 179.578 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.683 HG13 HD12 ' A' ' 30' ' ' LEU . 3.4 mp -57.83 -35.35 51.08 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 179.087 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 57.9 mtp180 -57.85 -42.35 84.25 Favored 'General case' 0 C--N 1.304 -1.397 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 179.644 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 71' ' ' SER . . . . . 0.422 ' OG ' ' NE ' ' A' ' 67' ' ' ARG . 8.8 t -65.18 -38.81 91.69 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.652 -0.655 . . . . 0.0 109.987 -179.935 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.454 HD12 ' HA ' ' A' ' 69' ' ' ILE . 71.5 mt -58.93 -51.45 72.29 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 O-C-N 121.189 -0.944 . . . . 0.0 109.713 -179.286 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.447 ' O ' HG23 ' A' ' 77' ' ' VAL . 43.1 t0 -62.1 -41.07 97.83 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.15 -0.969 . . . . 0.0 108.67 179.446 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.33 -37.6 85.72 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.667 -0.646 . . . . 0.0 109.952 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 64.3 t80 -60.36 -49.23 78.41 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.225 -0.922 . . . . 0.0 109.808 -179.626 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.74 HG11 ' CZ ' ' A' ' 52' ' ' PHE . 93.7 t -66.45 -46.84 85.61 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 O-C-N 121.201 -0.937 . . . . 0.0 109.626 -179.89 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.491 ' O ' ' O ' ' A' ' 81' ' ' THR . 74.9 t -66.41 -40.51 86.78 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 O-C-N 121.261 -0.9 . . . . 0.0 109.229 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.05 -37.52 92.89 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 -179.72 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -73.25 -41.86 63.2 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.217 -1.166 . . . . 0.0 111.105 -178.929 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 43.6 p -83.36 -36.7 24.14 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.962 -1.086 . . . . 0.0 109.425 -179.598 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.491 ' O ' ' O ' ' A' ' 77' ' ' VAL . 0.6 OUTLIER . . . . . 0 C--N 1.299 -1.593 0 O-C-N 121.541 -0.724 . . . . 0.0 109.081 -179.762 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 81.3 m-70 . . . . . 0 N--CA 1.492 1.638 0 CA-C-O 121.116 0.484 . . . . 0.0 110.018 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -60.72 -34.44 74.41 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.127 -0.983 . . . . 0.0 109.522 179.805 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.8 t -58.69 -38.61 78.62 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.295 -0.878 . . . . 0.0 109.876 -179.602 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 78.9 t -64.06 -46.28 94.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.143 -0.973 . . . . 0.0 109.353 179.936 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.714 HD13 ' OD1' ' A' ' 73' ' ' ASP . 77.5 mt -61.27 -46.25 96.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 179.491 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.765 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -62.22 -35.36 78.66 Favored 'General case' 0 C--N 1.303 -1.419 0 O-C-N 121.619 -0.675 . . . . 0.0 109.29 179.734 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 31.4 tt0 -62.11 -41.76 98.54 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.19 -0.944 . . . . 0.0 110.419 -179.611 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.672 ' CG ' ' CE2' ' A' ' 47' ' ' TRP . 49.6 m-85 -68.13 -50.75 52.64 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 120.896 -1.127 . . . . 0.0 111.065 -179.268 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.449 HG11 HD11 ' A' ' 30' ' ' LEU . 36.0 m -66.01 -38.95 83.21 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 O-C-N 120.972 -1.08 . . . . 0.0 109.247 -179.315 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.765 HG23 ' O ' ' A' ' 8' ' ' ALA . 89.2 t -63.68 -46.27 95.16 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 O-C-N 121.261 -0.899 . . . . 0.0 109.204 179.479 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -75.09 -16.92 60.54 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.14 -0.975 . . . . 0.0 110.076 179.824 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -63.81 -33.67 76.19 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.285 -0.884 . . . . 0.0 110.439 -178.956 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 67.2 t80 -154.08 -19.16 0.13 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.86 -1.15 . . . . 0.0 110.471 -179.634 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.469 HD22 HG21 ' A' ' 19' ' ' VAL . 5.6 mt -121.57 80.05 38.86 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.198 -0.939 . . . . 0.0 109.835 -179.497 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -79.73 -17.41 11.07 Favored 'Trans proline' 0 C--N 1.307 -1.656 0 C-N-CA 122.665 2.244 . . . . 0.0 112.628 -179.877 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 18' ' ' ASP . . . . . 0.555 ' OD1' HG23 ' A' ' 19' ' ' VAL . 51.8 p30 -90.09 9.99 26.04 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.166 -0.959 . . . . 0.0 110.172 -179.575 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.555 HG23 ' OD1' ' A' ' 18' ' ' ASP . 67.5 t -111.25 135.98 48.74 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.207 -0.933 . . . . 0.0 109.532 179.754 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -78.27 117.39 65.86 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.312 -0.867 . . . . 0.0 109.443 -179.908 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_exo -51.95 -35.83 61.96 Favored 'Trans proline' 0 N--CA 1.491 1.368 0 C-N-CA 121.709 1.606 . . . . 0.0 111.817 179.326 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.84 -23.73 66.73 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.3 -0.875 . . . . 0.0 108.925 179.529 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -84.71 7.46 20.41 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.418 -0.801 . . . . 0.0 109.743 -179.795 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 13.0 t -101.63 132.51 47.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.145 -0.972 . . . . 0.0 109.264 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 63.8 t0 -89.01 119.39 29.49 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.151 -0.968 . . . . 0.0 109.223 179.587 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' VAL . . . . . 0.448 ' O ' HG13 ' A' ' 26' ' ' VAL . 0.3 OUTLIER -69.33 4.25 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 O-C-N 121.204 -0.935 . . . . 0.0 109.452 179.782 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -95.02 -2.77 49.62 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.251 -0.905 . . . . 0.0 109.239 179.66 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 39.8 tp -99.56 136.42 39.52 Favored 'General case' 0 C--N 1.303 -1.441 0 O-C-N 121.394 -0.816 . . . . 0.0 108.92 179.714 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -58.62 137.12 57.7 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.105 -0.997 . . . . 0.0 109.196 -179.502 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.713 HD13 HD11 ' A' ' 36' ' ' ILE . 1.8 tt -68.35 -36.73 79.68 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.635 -0.665 . . . . 0.0 110.36 -178.981 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 69.6 t -64.75 -35.51 75.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.101 -0.999 . . . . 0.0 110.557 -179.004 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -52.54 -33.61 46.34 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 120.996 -1.065 . . . . 0.0 108.178 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.445 ' HB3' HG23 ' A' ' 35' ' ' VAL . 53.6 m-20 -70.98 -34.52 71.47 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.604 -0.685 . . . . 0.0 109.982 179.485 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 85.96 6.05 82.72 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 108.88 -1.688 . . . . 0.0 108.88 -179.24 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.445 HG23 ' HB3' ' A' ' 33' ' ' ASN . 78.5 t -61.1 -31.21 49.43 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.398 0 O-C-N 121.495 -1.003 . . . . 0.0 108.68 179.512 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.713 HD11 HD13 ' A' ' 30' ' ' LEU . 81.5 mt -93.99 132.3 38.48 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 O-C-N 121.438 -0.789 . . . . 0.0 109.677 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.53 ' CG ' ' H ' ' A' ' 38' ' ' ALA . 52.4 t0 -138.97 -167.69 2.27 Favored 'General case' 0 C--N 1.301 -1.528 0 N-CA-C 108.562 -0.903 . . . . 0.0 108.562 179.602 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.53 ' H ' ' CG ' ' A' ' 37' ' ' ASP . . . -62.6 -55.22 29.14 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.928 -1.107 . . . . 0.0 108.588 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 37.4 mt -71.47 -34.79 70.51 Favored 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 107.063 -1.458 . . . . 0.0 107.063 178.024 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.762 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.85 -39.85 95.98 Favored Glycine 0 N--CA 1.481 1.671 0 N-CA-C 108.703 -1.759 . . . . 0.0 108.703 179.169 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.794 ' C ' HD13 ' A' ' 41' ' ' LEU . 2.5 tm? -65.04 -43.89 90.87 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.49 -1.006 . . . . 0.0 108.622 179.386 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.2 tp -59.09 -46.03 89.33 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.343 -0.848 . . . . 0.0 109.066 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 63.2 mttp -61.49 -34.79 76.07 Favored 'General case' 0 C--N 1.295 -1.778 0 O-C-N 121.537 -0.727 . . . . 0.0 109.481 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.762 HG23 ' O ' ' A' ' 40' ' ' GLY . 91.6 t -62.56 -50.43 79.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.451 -0.781 . . . . 0.0 110.166 -179.347 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.7 mp -68.34 -29.85 45.65 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 O-C-N 121.314 -0.866 . . . . 0.0 110.566 -179.774 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.47 -49.2 67.44 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.108 -0.995 . . . . 0.0 111.657 -178.177 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.672 ' CE2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -81.08 -40.99 23.26 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 120.592 -1.317 . . . . 0.0 110.3 -179.015 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.543 ' O ' HD13 ' A' ' 48' ' ' LEU . 0.2 OUTLIER -61.23 -41.62 97.19 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.154 -0.966 . . . . 0.0 109.298 -179.357 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.419 ' CG ' ' N ' ' A' ' 50' ' ' ASP . 17.0 pt-20 -73.13 -36.07 66.63 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 120.638 -1.289 . . . . 0.0 109.165 179.907 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 50' ' ' ASP . . . . . 0.419 ' N ' ' CG ' ' A' ' 49' ' ' GLU . 59.0 t0 -65.6 -40.84 93.12 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.632 -0.667 . . . . 0.0 111.766 -179.072 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.433 HH21 HG11 ' A' ' 76' ' ' VAL . 24.3 ptt180 -71.39 -36.59 71.46 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 120.864 -1.148 . . . . 0.0 111.484 -177.712 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.414 ' CE1' ' CG1' ' A' ' 76' ' ' VAL . 5.7 m-85 -81.21 -14.74 57.21 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.577 -1.327 . . . . 0.0 109.756 -179.726 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.27 20.67 71.9 Favored Glycine 0 N--CA 1.486 2.025 0 N-CA-C 108.693 -1.763 . . . . 0.0 108.693 -179.745 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 23.1 pt -113.19 153.65 14.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.737 -0.86 . . . . 0.0 109.695 -179.573 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -101.03 132.29 46.53 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.249 -0.907 . . . . 0.0 109.519 -179.789 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.503 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -69.0 -23.55 64.12 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.316 -0.865 . . . . 0.0 109.692 179.859 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 91.3 m-20 -54.98 -36.08 65.01 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.268 -0.895 . . . . 0.0 110.146 -179.487 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -56.13 -39.36 72.12 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.18 -0.95 . . . . 0.0 110.001 -179.547 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.503 ' O ' ' O ' ' A' ' 56' ' ' ALA . 41.7 t -126.86 136.68 60.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.337 -0.852 . . . . 0.0 109.666 -179.894 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -87.58 127.23 35.27 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.117 -0.989 . . . . 0.0 109.185 179.864 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 39.4 mt -104.53 142.05 35.31 Favored 'General case' 0 C--N 1.306 -1.295 0 O-C-N 121.279 -0.888 . . . . 0.0 109.831 -179.649 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -108.75 152.54 42.31 Favored Pre-proline 0 N--CA 1.485 1.316 0 N-CA-C 108.696 -0.854 . . . . 0.0 108.696 179.377 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 12.8 Cg_endo -58.44 -21.16 52.44 Favored 'Trans proline' 0 C--N 1.304 -1.768 0 C-N-CA 122.505 2.137 . . . . 0.0 112.196 -179.748 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -69.6 -30.1 67.77 Favored 'General case' 0 N--CA 1.486 1.335 0 O-C-N 121.272 -0.892 . . . . 0.0 109.731 -179.726 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 65' ' ' HIS . . . . . 0.457 ' CE1' ' HB2' ' A' ' 75' ' ' PHE . 76.3 t60 -66.16 -20.66 66.21 Favored 'General case' 0 C--N 1.299 -1.588 0 O-C-N 121.233 -0.917 . . . . 0.0 108.918 -179.874 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.496 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 21.8 m-85 -89.17 12.73 15.0 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.394 -0.816 . . . . 0.0 109.203 -179.68 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 67' ' ' ARG . . . . . 0.402 ' HG2' ' N ' ' A' ' 68' ' ' SER . 4.2 ptt85 -49.88 -34.56 20.58 Favored 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.628 -0.67 . . . . 0.0 109.513 179.719 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 68' ' ' SER . . . . . 0.518 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 89.2 p -151.65 153.54 34.62 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.154 -0.966 . . . . 0.0 109.895 179.794 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.644 ' H ' HD12 ' A' ' 69' ' ' ILE . 3.5 mp -59.83 -34.81 57.11 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.485 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 179.3 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 30.2 mtp85 -57.11 -45.18 83.66 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.604 -0.685 . . . . 0.0 109.765 -179.272 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 71' ' ' SER . . . . . 0.424 ' HG ' ' CE1' ' A' ' 65' ' ' HIS . 22.9 t -64.9 -46.07 83.25 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.307 -0.871 . . . . 0.0 109.781 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.431 ' HA ' ' NE2' ' A' ' 65' ' ' HIS . 68.0 mt -58.95 -42.89 87.38 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 O-C-N 121.176 -0.952 . . . . 0.0 109.913 -179.735 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.714 ' OD1' HD13 ' A' ' 7' ' ' ILE . 2.0 m-20 -61.14 -37.95 84.66 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.292 -0.88 . . . . 0.0 109.842 -179.584 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -67.4 -46.91 71.85 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.035 -1.041 . . . . 0.0 110.541 -179.304 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 75' ' ' PHE . . . . . 0.457 ' HB2' ' CE1' ' A' ' 65' ' ' HIS . 65.8 t80 -66.03 -44.08 85.71 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.135 -0.978 . . . . 0.0 109.57 -179.737 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.433 HG11 HH21 ' A' ' 51' ' ' ARG . 43.4 t -60.68 -41.83 89.68 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 O-C-N 121.301 -0.874 . . . . 0.0 108.81 179.334 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.661 HG23 ' O ' ' A' ' 73' ' ' ASP . 65.3 t -65.0 -40.52 89.34 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.256 0 O-C-N 121.306 -0.871 . . . . 0.0 109.042 179.338 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.53 -17.23 32.47 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.753 -1.339 . . . . 0.0 109.753 179.794 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -66.71 -34.82 78.68 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.288 -1.125 . . . . 0.0 110.573 -179.176 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 49.7 p -134.49 -20.5 1.82 Allowed 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.009 -1.057 . . . . 0.0 110.709 -179.381 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.499 ' O ' ' O ' ' A' ' 77' ' ' VAL . 0.1 OUTLIER . . . . . 0 N--CA 1.49 1.528 0 O-C-N 121.144 -0.973 . . . . 0.0 109.39 -179.919 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 97.2 m-70 . . . . . 0 N--CA 1.486 1.348 0 N-CA-C 108.034 -1.099 . . . . 0.0 108.034 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.585 ' N ' ' OD2' ' A' ' 73' ' ' ASP . . . -52.94 -41.04 64.1 Favored 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.518 -0.739 . . . . 0.0 109.861 -179.078 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 21.3 m -61.11 -39.28 89.4 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.178 -0.951 . . . . 0.0 109.602 179.975 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 54.6 t -61.61 -43.88 97.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.331 -0.855 . . . . 0.0 109.483 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 82.5 mt -59.78 -40.27 82.08 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.45 0 O-C-N 121.363 -0.835 . . . . 0.0 109.076 179.697 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.401 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -60.92 -36.25 78.8 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 179.897 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 83.8 mt-30 -65.8 -39.16 90.64 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.296 -0.878 . . . . 0.0 109.967 179.757 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.66 ' CG ' ' CZ2' ' A' ' 47' ' ' TRP . 28.5 m-85 -64.2 -50.44 68.08 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.167 -0.958 . . . . 0.0 111.057 -179.28 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.439 HG13 ' N ' ' A' ' 12' ' ' VAL . 2.9 p -59.89 -42.74 90.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.016 -1.053 . . . . 0.0 109.579 -179.19 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.464 ' O ' ' C ' ' A' ' 16' ' ' LEU . 86.9 t -63.46 -47.3 92.32 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 O-C-N 121.115 -0.99 . . . . 0.0 109.396 179.833 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -71.53 -24.12 61.9 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.172 -0.955 . . . . 0.0 109.96 179.825 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -64.19 -32.07 73.51 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.363 -0.836 . . . . 0.0 110.893 -178.763 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 63.1 t80 -140.83 -35.12 0.49 Allowed 'General case' 0 N--CA 1.494 1.758 0 O-C-N 120.849 -1.157 . . . . 0.0 110.742 -179.254 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.464 ' C ' ' O ' ' A' ' 12' ' ' VAL . 5.2 mt -119.17 80.04 19.4 Favored Pre-proline 0 N--CA 1.493 1.693 0 O-C-N 121.167 -0.958 . . . . 0.0 109.939 -179.397 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_endo -77.86 -15.3 15.08 Favored 'Trans proline' 0 C--N 1.308 -1.603 0 C-N-CA 122.546 2.164 . . . . 0.0 112.198 179.755 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -88.43 5.32 42.88 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 121.32 -0.862 . . . . 0.0 109.788 -179.729 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.45 ' CG2' HD22 ' A' ' 16' ' ' LEU . 46.3 t -110.64 134.92 51.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.387 -0.821 . . . . 0.0 109.564 -179.88 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.46 118.63 69.34 Favored Pre-proline 0 N--CA 1.489 1.503 0 O-C-N 121.279 -0.888 . . . . 0.0 109.24 179.902 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.461 ' HA ' HG21 ' A' ' 12' ' ' VAL . 40.4 Cg_exo -51.3 -28.62 27.25 Favored 'Trans proline' 0 N--CA 1.492 1.397 0 C-N-CA 121.728 1.619 . . . . 0.0 111.866 179.659 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.42 -23.31 66.91 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.198 -0.939 . . . . 0.0 109.286 179.688 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.45 ' O ' ' OD1' ' A' ' 23' ' ' ASP . 60.2 t0 -81.65 4.03 23.18 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.326 -0.859 . . . . 0.0 109.762 -179.762 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 13.5 t -108.75 133.32 54.19 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.245 -0.909 . . . . 0.0 109.351 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 86.9 m-20 -88.29 120.53 29.74 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.084 -1.01 . . . . 0.0 108.964 179.379 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 32.8 m -75.68 4.42 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 O-C-N 121.237 -0.915 . . . . 0.0 109.178 179.601 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -93.17 -2.75 54.98 Favored 'General case' 0 C--N 1.306 -1.318 0 O-C-N 121.316 -0.865 . . . . 0.0 108.941 179.518 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 39.8 tp -97.13 138.32 34.83 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.494 -0.754 . . . . 0.0 109.016 179.819 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 87.3 m-20 -60.09 138.5 57.87 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.154 -0.966 . . . . 0.0 109.531 -179.407 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.715 HD12 HG13 ' A' ' 69' ' ' ILE . 1.3 tt -75.62 -36.74 60.17 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.716 -0.615 . . . . 0.0 110.454 -179.203 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.614 HG13 ' O ' ' A' ' 66' ' ' PHE . 12.9 m -64.1 -38.4 82.36 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.659 0 O-C-N 121.111 -0.993 . . . . 0.0 110.583 -178.903 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -54.5 -33.45 59.87 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.142 -0.974 . . . . 0.0 108.375 179.67 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 96.1 m-20 -70.5 -34.56 72.47 Favored 'General case' 0 C--N 1.303 -1.445 0 O-C-N 121.656 -0.653 . . . . 0.0 110.0 179.875 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 82.37 5.86 89.2 Favored Glycine 0 N--CA 1.493 2.479 0 N-CA-C 109.516 -1.433 . . . . 0.0 109.516 -179.904 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 78.3 t -61.35 -34.36 60.69 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 O-C-N 121.276 -1.132 . . . . 0.0 108.697 179.501 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.705 HD11 HD13 ' A' ' 30' ' ' LEU . 96.7 mt -77.34 112.17 14.98 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 121.454 -0.779 . . . . 0.0 109.954 179.91 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -111.33 -164.53 0.92 Allowed 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 179.595 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -66.71 -54.25 25.01 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.125 -0.984 . . . . 0.0 108.874 179.694 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.692 HD12 ' N ' ' A' ' 39' ' ' LEU . 6.9 mp -69.77 -32.89 71.64 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 107.397 -1.334 . . . . 0.0 107.397 178.432 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.607 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.41 -43.0 97.76 Favored Glycine 0 N--CA 1.482 1.704 0 N-CA-C 109.053 -1.619 . . . . 0.0 109.053 179.509 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.442 HD11 ' CZ ' ' A' ' 66' ' ' PHE . 7.5 tt -65.13 -42.73 93.59 Favored 'General case' 0 C--N 1.303 -1.415 0 O-C-N 121.413 -1.051 . . . . 0.0 109.327 179.449 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 tp -60.06 -46.25 90.18 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.375 -0.828 . . . . 0.0 109.274 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 12.7 mttm -62.39 -34.44 76.73 Favored 'General case' 0 C--N 1.297 -1.7 0 O-C-N 121.44 -0.787 . . . . 0.0 109.789 -179.694 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.607 HG23 ' O ' ' A' ' 40' ' ' GLY . 53.8 t -61.47 -50.42 80.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.291 -0.881 . . . . 0.0 110.322 -179.215 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.537 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 3.5 mp -68.36 -33.73 62.0 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 121.331 -0.856 . . . . 0.0 111.011 -179.67 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.42 -49.77 67.96 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.013 -1.054 . . . . 0.0 111.655 -178.007 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.66 ' CZ2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -81.2 -43.78 18.79 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.75 -1.219 . . . . 0.0 109.905 -179.3 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.582 HD21 ' CG2' ' A' ' 76' ' ' VAL . 31.4 tp -58.82 -42.35 88.98 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.215 -0.928 . . . . 0.0 109.95 -179.267 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.537 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 1.1 pp20? -72.53 -36.02 68.2 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.082 -1.011 . . . . 0.0 109.749 -179.959 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.5 t0 -60.43 -38.51 84.35 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.251 -0.905 . . . . 0.0 110.608 -179.653 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.464 ' HD2' ' HE1' ' A' ' 47' ' ' TRP . 77.7 mtp85 -61.81 -37.83 85.87 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.167 -0.958 . . . . 0.0 111.602 -178.668 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.799 ' CE2' HG11 ' A' ' 76' ' ' VAL . 88.0 m-85 -95.86 -8.5 33.95 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 120.67 -1.269 . . . . 0.0 110.339 -178.97 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 71.98 30.37 65.69 Favored Glycine 0 N--CA 1.486 2.021 0 N-CA-C 108.872 -1.691 . . . . 0.0 108.872 179.682 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.501 ' O ' ' OE1' ' A' ' 49' ' ' GLU . 26.0 pt -107.55 151.13 9.66 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.402 0 O-C-N 121.654 -0.909 . . . . 0.0 109.653 -179.502 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 55' ' ' ALA . . . . . 0.475 ' O ' ' OD1' ' A' ' 58' ' ' ASP . . . -101.76 132.48 47.47 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.233 -0.917 . . . . 0.0 109.645 -179.661 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.5 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -67.0 -26.88 67.02 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.335 -0.853 . . . . 0.0 109.396 179.751 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 52.3 t0 -54.87 -34.79 63.36 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.317 -0.864 . . . . 0.0 110.042 -179.571 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.632 ' OD1' ' N ' ' A' ' 59' ' ' VAL . 55.3 p30 -59.47 -34.53 72.66 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.196 -0.94 . . . . 0.0 110.301 -179.459 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.632 ' N ' ' OD1' ' A' ' 58' ' ' ASP . 14.5 p -136.86 140.96 41.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.025 -1.047 . . . . 0.0 109.585 179.92 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -85.3 139.35 31.67 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.053 -1.03 . . . . 0.0 109.299 179.818 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 5.1 mp -97.72 136.9 37.41 Favored 'General case' 0 C--N 1.305 -1.345 0 O-C-N 121.198 -0.939 . . . . 0.0 109.712 -179.835 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -110.0 155.35 41.83 Favored Pre-proline 0 N--CA 1.488 1.457 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 179.489 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 7.8 Cg_endo -53.2 -23.55 23.29 Favored 'Trans proline' 0 C--N 1.302 -1.904 0 C-N-CA 122.286 1.991 . . . . 0.0 111.685 -179.898 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -70.69 -26.54 63.47 Favored 'General case' 0 N--CA 1.486 1.336 0 O-C-N 121.344 -0.847 . . . . 0.0 109.507 179.655 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 65' ' ' HIS . . . . . 0.546 ' C ' ' CD2' ' A' ' 65' ' ' HIS . 1.9 t60 -65.62 -20.41 66.3 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.23 -0.919 . . . . 0.0 109.215 -179.703 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.614 ' O ' HG13 ' A' ' 31' ' ' VAL . 6.7 m-85 -98.2 16.24 21.95 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 121.447 -0.783 . . . . 0.0 108.965 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 67' ' ' ARG . . . . . 0.588 ' NE ' ' OG ' ' A' ' 71' ' ' SER . 4.8 ptt180 -52.16 -36.34 51.27 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 121.754 -0.591 . . . . 0.0 110.08 -179.775 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 68' ' ' SER . . . . . 0.525 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 35.2 p -164.9 153.31 12.12 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.016 -1.053 . . . . 0.0 110.281 -179.702 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.715 HG13 HD12 ' A' ' 30' ' ' LEU . 3.3 mp -57.94 -40.68 77.57 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 O-C-N 121.362 -0.836 . . . . 0.0 109.161 179.904 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.401 ' CG ' ' N ' ' A' ' 71' ' ' SER . 18.9 ptt180 -58.16 -42.24 85.53 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.643 -0.66 . . . . 0.0 109.266 179.806 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 71' ' ' SER . . . . . 0.588 ' OG ' ' NE ' ' A' ' 67' ' ' ARG . 26.5 t -64.92 -39.25 93.22 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.204 -0.935 . . . . 0.0 109.677 179.488 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.425 HD12 ' HA ' ' A' ' 69' ' ' ILE . 87.8 mt -58.92 -47.14 90.59 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.289 0 O-C-N 121.176 -0.953 . . . . 0.0 109.736 -179.73 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 73' ' ' ASP . . . . . 0.585 ' OD2' ' N ' ' A' ' 4' ' ' ALA . 26.5 t0 -58.91 -44.23 91.23 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.147 -0.971 . . . . 0.0 108.723 179.864 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 74' ' ' ALA . . . . . 0.535 ' O ' ' N ' ' A' ' 78' ' ' GLY . . . -66.96 -37.36 84.13 Favored 'General case' 0 C--N 1.304 -1.399 0 O-C-N 121.432 -0.792 . . . . 0.0 109.595 179.667 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 61.9 t80 -62.82 -48.83 77.37 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.19 -0.944 . . . . 0.0 109.644 -179.833 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.799 HG11 ' CE2' ' A' ' 52' ' ' PHE . 71.1 t -67.56 -48.8 75.51 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.282 0 O-C-N 121.201 -0.937 . . . . 0.0 109.782 -179.847 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.533 ' O ' HG22 ' A' ' 81' ' ' THR . 55.3 t -69.89 -43.77 79.33 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.274 0 O-C-N 121.106 -0.996 . . . . 0.0 109.034 179.38 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.535 ' N ' ' O ' ' A' ' 74' ' ' ALA . . . -59.38 -30.93 68.82 Favored Glycine 0 N--CA 1.488 2.127 0 N-CA-C 110.211 -1.155 . . . . 0.0 110.211 -179.606 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -68.63 -41.5 79.36 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.153 -1.204 . . . . 0.0 110.586 -178.998 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 47.1 p -79.74 -32.02 41.06 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.161 -0.962 . . . . 0.0 109.326 -179.83 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.533 HG22 ' O ' ' A' ' 77' ' ' VAL . 1.8 t . . . . . 0 N--CA 1.487 1.401 0 O-C-N 121.447 -0.783 . . . . 0.0 108.911 179.93 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 16.9 m-70 . . . . . 0 N--CA 1.494 1.757 0 CA-C-O 121.205 0.526 . . . . 0.0 109.82 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -59.74 -40.92 89.71 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.068 -1.02 . . . . 0.0 109.29 179.786 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.3 m -61.29 -39.17 89.44 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.256 -0.902 . . . . 0.0 109.65 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 58.8 t -61.13 -41.35 89.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.205 -0.935 . . . . 0.0 109.454 179.911 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 79.7 mt -59.69 -45.62 94.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 O-C-N 121.409 -0.807 . . . . 0.0 109.287 179.866 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -62.14 -42.78 99.58 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.291 -0.881 . . . . 0.0 109.109 179.723 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 84.3 mt-30 -64.7 -33.46 76.0 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.249 -0.907 . . . . 0.0 109.128 179.255 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.535 ' CG ' ' CZ2' ' A' ' 47' ' ' TRP . 0.2 OUTLIER -60.43 -50.27 74.24 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.4 -0.813 . . . . 0.0 110.235 -179.521 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 13.4 m -64.39 -39.59 86.08 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 O-C-N 121.142 -0.973 . . . . 0.0 109.33 -179.723 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.405 ' O ' ' C ' ' A' ' 16' ' ' LEU . 77.6 t -63.99 -45.29 97.18 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.166 -0.959 . . . . 0.0 109.678 179.654 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -69.4 -34.47 74.54 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.17 -0.956 . . . . 0.0 110.23 -179.842 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -65.35 -32.67 74.44 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.292 -0.88 . . . . 0.0 110.458 -179.253 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -118.47 -54.08 2.29 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.263 -0.898 . . . . 0.0 111.336 -178.713 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.575 HD22 ' CG2' ' A' ' 19' ' ' VAL . 9.0 mt -119.41 80.18 21.48 Favored Pre-proline 0 N--CA 1.493 1.688 0 O-C-N 121.19 -0.944 . . . . 0.0 111.054 -178.285 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -75.1 -16.41 20.0 Favored 'Trans proline' 0 C--N 1.309 -1.511 0 C-N-CA 122.274 1.982 . . . . 0.0 112.186 178.825 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -90.99 5.7 47.72 Favored 'General case' 0 N--CA 1.487 1.384 0 O-C-N 121.213 -0.929 . . . . 0.0 109.893 -179.844 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.575 ' CG2' HD22 ' A' ' 16' ' ' LEU . 44.5 t -112.84 138.37 42.42 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.456 -0.778 . . . . 0.0 109.492 -179.857 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.487 ' O ' ' OD1' ' A' ' 23' ' ' ASP . . . -70.37 117.27 53.25 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.275 -0.89 . . . . 0.0 109.469 -179.831 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -51.8 -26.21 23.26 Favored 'Trans proline' 0 N--CA 1.494 1.512 0 C-N-CA 122.017 1.812 . . . . 0.0 112.229 179.505 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.63 -23.66 67.33 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.281 -0.887 . . . . 0.0 109.815 -179.744 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.487 ' OD1' ' O ' ' A' ' 20' ' ' ALA . 51.5 p30 -85.64 7.63 22.58 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.192 -0.942 . . . . 0.0 110.007 -179.428 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 11.8 t -107.88 130.07 60.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.147 -0.97 . . . . 0.0 109.329 179.927 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 87.2 m-20 -89.73 120.33 30.9 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.18 -0.95 . . . . 0.0 109.097 179.28 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 6.3 m -78.1 4.42 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 O-C-N 121.129 -0.982 . . . . 0.0 108.941 179.457 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -88.73 -10.63 47.67 Favored 'General case' 0 N--CA 1.485 1.302 0 O-C-N 121.386 -0.821 . . . . 0.0 109.043 179.408 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 42.4 tp -94.24 140.57 29.61 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 109.076 -0.713 . . . . 0.0 109.076 179.844 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 83.3 m-20 -59.08 142.0 52.58 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.133 -0.979 . . . . 0.0 109.433 -179.361 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 1.078 HD23 HD11 ' A' ' 36' ' ' ILE . 27.8 tp -73.57 -37.74 65.41 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.421 -0.799 . . . . 0.0 110.343 -179.251 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.608 HG13 ' O ' ' A' ' 66' ' ' PHE . 33.1 m -66.73 -43.15 90.2 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 121.263 -0.898 . . . . 0.0 110.428 -179.005 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 32' ' ' ASP . . . . . 0.584 ' N ' HG23 ' A' ' 31' ' ' VAL . 92.1 m-20 -53.94 -33.37 56.6 Favored 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 179.747 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 97.1 m-20 -70.47 -34.12 72.04 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.619 -0.676 . . . . 0.0 109.995 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 87.47 7.2 76.31 Favored Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.183 -1.567 . . . . 0.0 109.183 -179.656 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 72.6 t -61.64 -26.93 41.04 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 O-C-N 121.469 -1.018 . . . . 0.0 108.78 179.575 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 1.078 HD11 HD23 ' A' ' 30' ' ' LEU . 67.6 mt -93.05 123.87 45.28 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.398 0 O-C-N 121.457 -0.777 . . . . 0.0 109.929 -179.458 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -115.79 -174.87 2.61 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 108.636 -0.876 . . . . 0.0 108.636 179.339 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -61.36 -53.45 56.43 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.056 -1.028 . . . . 0.0 108.432 179.594 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.693 HD12 ' N ' ' A' ' 39' ' ' LEU . 7.0 mp -70.39 -32.65 70.39 Favored 'General case' 0 C--N 1.301 -1.532 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 178.008 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.458 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.23 -43.65 97.04 Favored Glycine 0 N--CA 1.482 1.755 0 N-CA-C 109.01 -1.636 . . . . 0.0 109.01 179.574 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.3 tt -65.13 -42.05 94.22 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.463 -1.022 . . . . 0.0 109.163 179.32 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.5 tp -59.97 -46.12 90.47 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.294 -0.879 . . . . 0.0 109.405 179.871 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 86.6 mttt -61.44 -35.7 78.31 Favored 'General case' 0 C--N 1.297 -1.701 0 O-C-N 121.443 -0.786 . . . . 0.0 109.854 -179.678 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.458 HG23 ' O ' ' A' ' 40' ' ' GLY . 55.3 t -61.48 -50.75 79.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.287 -0.883 . . . . 0.0 110.36 -179.27 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.521 HG12 HD12 ' A' ' 61' ' ' LEU . 3.5 mp -68.72 -34.3 64.15 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 O-C-N 121.279 -0.888 . . . . 0.0 111.181 -179.636 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.56 -49.94 60.86 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 120.986 -1.071 . . . . 0.0 111.998 -177.913 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.535 ' CZ2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -80.18 -43.62 21.23 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.655 -1.278 . . . . 0.0 110.036 -179.045 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.558 HD11 HG21 ' A' ' 76' ' ' VAL . 21.7 tp -58.88 -41.63 87.56 Favored 'General case' 0 C--N 1.299 -1.606 0 O-C-N 121.294 -0.879 . . . . 0.0 110.197 -179.03 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.416 ' CG ' ' N ' ' A' ' 50' ' ' ASP . 17.3 pt-20 -73.18 -37.45 66.51 Favored 'General case' 0 C--N 1.305 -1.362 0 O-C-N 121.059 -1.026 . . . . 0.0 109.636 -179.708 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 50' ' ' ASP . . . . . 0.416 ' N ' ' CG ' ' A' ' 49' ' ' GLU . 56.9 t0 -58.86 -39.15 80.51 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.354 -0.841 . . . . 0.0 110.64 -179.447 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.443 ' HD2' ' HE1' ' A' ' 47' ' ' TRP . 73.4 mtp85 -61.64 -36.76 81.72 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.169 -0.957 . . . . 0.0 111.322 -178.86 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.613 ' CZ ' ' CG1' ' A' ' 76' ' ' VAL . 87.5 m-85 -94.77 -8.0 38.83 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 120.745 -1.222 . . . . 0.0 110.407 -179.129 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 73.15 29.29 64.77 Favored Glycine 0 N--CA 1.487 2.089 0 N-CA-C 108.95 -1.66 . . . . 0.0 108.95 179.712 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 20.5 pt -109.68 153.21 11.51 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 O-C-N 121.699 -0.883 . . . . 0.0 109.551 -179.587 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -103.92 134.99 46.28 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.238 -0.914 . . . . 0.0 109.7 -179.614 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.506 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -68.09 -28.39 67.31 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.334 -0.853 . . . . 0.0 109.63 179.732 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -56.36 -36.89 69.31 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.125 -0.984 . . . . 0.0 109.995 -179.625 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 21.4 t70 -56.53 -40.01 74.34 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.146 -0.971 . . . . 0.0 109.987 -179.538 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.506 ' O ' ' O ' ' A' ' 56' ' ' ALA . 42.6 t -128.67 136.21 60.44 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.311 -0.868 . . . . 0.0 109.726 -179.846 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -86.14 132.94 33.91 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.063 -1.023 . . . . 0.0 109.242 179.835 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.521 HD12 HG12 ' A' ' 45' ' ' ILE . 57.6 mt -96.12 140.81 30.3 Favored 'General case' 0 C--N 1.305 -1.336 0 O-C-N 121.219 -0.926 . . . . 0.0 109.742 -179.64 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -109.77 155.92 40.68 Favored Pre-proline 0 N--CA 1.487 1.418 0 N-CA-C 108.787 -0.82 . . . . 0.0 108.787 179.479 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 7.2 Cg_endo -52.59 -23.02 18.34 Favored 'Trans proline' 0 C--N 1.303 -1.831 0 C-N-CA 122.335 2.023 . . . . 0.0 111.926 -179.772 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -70.26 -26.95 64.06 Favored 'General case' 0 N--CA 1.486 1.37 0 O-C-N 121.339 -0.851 . . . . 0.0 109.472 179.592 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 65' ' ' HIS . . . . . 0.551 ' C ' ' CD2' ' A' ' 65' ' ' HIS . 1.5 t60 -65.65 -19.39 65.89 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.412 -0.805 . . . . 0.0 109.046 -179.883 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.608 ' O ' HG13 ' A' ' 31' ' ' VAL . 7.0 m-85 -100.14 16.35 24.44 Favored 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.521 -0.737 . . . . 0.0 109.174 -179.686 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -53.24 -37.89 62.47 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.59 -0.694 . . . . 0.0 110.621 -179.452 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 68' ' ' SER . . . . . 0.528 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 51.8 p -167.91 166.53 13.35 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.653 -1.279 . . . . 0.0 110.699 -179.97 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.83 HD11 HD13 ' A' ' 30' ' ' LEU . 19.8 mm -58.89 -35.28 55.58 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.201 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 178.913 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 34.7 mtp180 -57.51 -43.96 84.66 Favored 'General case' 0 C--N 1.303 -1.455 0 CA-C-O 121.446 0.641 . . . . 0.0 109.468 -179.354 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 11.8 t -67.06 -39.41 86.89 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.368 -0.832 . . . . 0.0 109.953 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.415 HD12 ' HA ' ' A' ' 69' ' ' ILE . 76.9 mt -59.84 -50.1 81.35 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 O-C-N 121.265 -0.897 . . . . 0.0 110.074 -179.277 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 44.3 t0 -59.66 -42.78 93.58 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.13 -0.981 . . . . 0.0 109.04 -179.871 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.55 -42.21 87.5 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.535 -0.728 . . . . 0.0 109.756 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 60.0 t80 -63.58 -46.2 86.95 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.185 -0.947 . . . . 0.0 109.411 -179.955 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.613 ' CG1' ' CZ ' ' A' ' 52' ' ' PHE . 54.6 t -60.89 -47.22 94.36 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.297 0 O-C-N 121.367 -0.833 . . . . 0.0 109.138 179.854 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 55.5 t -69.26 -42.38 81.43 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 O-C-N 121.213 -0.929 . . . . 0.0 109.107 179.338 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.493 ' O ' ' O ' ' A' ' 81' ' ' THR . . . -65.22 -28.27 73.36 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 -179.831 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.04 -38.67 86.27 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.153 -1.204 . . . . 0.0 110.299 -178.944 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 52.1 p -82.42 -31.33 29.6 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.111 -0.993 . . . . 0.0 109.539 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.493 ' O ' ' O ' ' A' ' 78' ' ' GLY . 0.3 OUTLIER . . . . . 0 C--N 1.302 -1.464 0 O-C-N 121.51 -0.744 . . . . 0.0 109.605 -179.864 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 62.1 m80 . . . . . 0 N--CA 1.485 1.288 0 N-CA-C 108.114 -1.069 . . . . 0.0 108.114 . . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -57.25 -39.48 75.69 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.518 -0.739 . . . . 0.0 109.798 -179.33 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.1 p -63.04 -33.7 75.98 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.146 -0.971 . . . . 0.0 109.491 -179.895 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 75.9 t -65.9 -43.49 92.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.222 -0.924 . . . . 0.0 109.539 179.87 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.515 ' O ' HG12 ' A' ' 11' ' ' VAL . 82.6 mt -59.59 -47.3 91.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.4 -0.812 . . . . 0.0 109.845 -179.859 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.716 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.26 -45.13 92.94 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.28 -0.888 . . . . 0.0 110.924 -179.181 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 53.9 mt-30 -69.09 -46.65 67.21 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.835 -1.165 . . . . 0.0 110.854 -178.723 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.549 ' C ' ' CD1' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -70.28 -48.75 55.31 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.075 -1.016 . . . . 0.0 110.298 -179.392 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.515 HG12 ' O ' ' A' ' 7' ' ' ILE . 4.0 p -59.88 -38.81 77.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.072 -1.017 . . . . 0.0 109.678 -179.604 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.716 HG23 ' O ' ' A' ' 8' ' ' ALA . 49.5 t -63.18 -43.22 98.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.224 -0.922 . . . . 0.0 109.963 -179.928 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -63.13 -34.51 77.76 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.104 -0.997 . . . . 0.0 109.941 -179.812 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -65.43 -31.74 72.99 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.269 -0.894 . . . . 0.0 110.197 -179.649 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.779 ' CD2' HG13 ' A' ' 35' ' ' VAL . 77.4 t80 -113.65 -61.4 1.75 Allowed 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.326 -0.859 . . . . 0.0 111.299 -178.818 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 4.8 mt -116.08 80.19 9.06 Favored Pre-proline 0 N--CA 1.494 1.726 0 O-C-N 121.219 -0.926 . . . . 0.0 111.017 -178.354 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_endo -74.64 -14.55 22.03 Favored 'Trans proline' 0 C--N 1.31 -1.5 0 C-N-CA 122.311 2.008 . . . . 0.0 112.156 178.848 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -84.93 0.84 49.83 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.286 -0.883 . . . . 0.0 109.601 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 42.3 t -115.36 134.93 56.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 121.43 -0.794 . . . . 0.0 109.568 -179.908 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.34 117.84 60.52 Favored Pre-proline 0 N--CA 1.489 1.486 0 O-C-N 121.183 -0.948 . . . . 0.0 109.405 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_exo -51.44 -30.06 33.54 Favored 'Trans proline' 0 N--CA 1.493 1.464 0 C-N-CA 121.757 1.638 . . . . 0.0 112.064 179.614 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.8 -25.12 67.78 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.239 -0.913 . . . . 0.0 109.291 179.769 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -81.88 4.45 22.38 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.368 -0.833 . . . . 0.0 109.777 -179.755 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 10.5 t -107.79 128.91 62.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.216 -0.927 . . . . 0.0 109.485 -179.923 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 88.1 m-20 -89.7 120.72 31.22 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.239 -0.913 . . . . 0.0 109.078 179.213 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 28.9 m -70.9 3.89 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 O-C-N 121.11 -0.993 . . . . 0.0 109.123 179.598 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -94.25 -5.24 47.29 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.363 -0.836 . . . . 0.0 109.154 179.466 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 42.0 tp -95.32 138.14 33.42 Favored 'General case' 0 C--N 1.303 -1.421 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 179.599 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -57.2 135.62 56.42 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.068 -1.02 . . . . 0.0 109.354 -179.269 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 1.041 HD23 HD11 ' A' ' 36' ' ' ILE . 39.4 tp -64.59 -37.48 87.71 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.595 -0.69 . . . . 0.0 110.467 -179.336 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 70.2 t -66.2 -37.24 79.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.022 -1.049 . . . . 0.0 110.708 -179.15 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -52.93 -33.05 48.94 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 120.956 -1.09 . . . . 0.0 108.254 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.438 ' HB3' HG23 ' A' ' 35' ' ' VAL . 98.4 m-20 -70.68 -34.33 71.86 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.631 -0.668 . . . . 0.0 109.946 179.457 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 86.6 5.26 82.07 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 108.824 -1.71 . . . . 0.0 108.824 -179.245 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.779 HG13 ' CD2' ' A' ' 15' ' ' PHE . 76.2 t -61.1 -32.69 53.41 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 O-C-N 121.582 -0.952 . . . . 0.0 108.924 179.637 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 1.041 HD11 HD23 ' A' ' 30' ' ' LEU . 80.7 mt -83.82 116.26 27.44 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.403 -0.811 . . . . 0.0 109.843 -179.872 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.406 ' H ' ' HA3' ' A' ' 40' ' ' GLY . 92.0 m-20 -114.99 -176.08 2.83 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 179.406 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -58.95 -53.38 59.08 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.021 -1.049 . . . . 0.0 108.205 179.601 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 35.8 mt -68.57 -32.44 72.36 Favored 'General case' 0 C--N 1.301 -1.528 0 N-CA-C 106.887 -1.523 . . . . 0.0 106.887 177.868 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.494 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -58.97 -40.93 96.05 Favored Glycine 0 N--CA 1.48 1.594 0 N-CA-C 108.718 -1.753 . . . . 0.0 108.718 179.274 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.3 tt -65.21 -41.61 94.31 Favored 'General case' 0 C--N 1.305 -1.34 0 O-C-N 121.386 -1.067 . . . . 0.0 108.693 178.893 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 tp -60.17 -45.72 92.14 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 179.322 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 21.0 mttp -60.71 -35.48 76.42 Favored 'General case' 0 C--N 1.298 -1.663 0 O-C-N 121.551 -0.718 . . . . 0.0 109.522 -179.935 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.494 HG23 ' O ' ' A' ' 40' ' ' GLY . 53.3 t -59.81 -50.59 79.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.325 -0.859 . . . . 0.0 109.469 -179.657 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.482 ' H ' HD12 ' A' ' 45' ' ' ILE . 3.5 mp -68.33 -30.36 47.4 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 O-C-N 121.256 -0.903 . . . . 0.0 110.459 179.704 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.84 -49.2 71.53 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.107 -0.996 . . . . 0.0 111.306 -178.473 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.498 ' C ' ' CD1' ' A' ' 47' ' ' TRP . 0.0 OUTLIER -81.39 -43.23 19.28 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.759 -1.213 . . . . 0.0 110.032 -179.384 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.674 HD11 HG22 ' A' ' 76' ' ' VAL . 0.4 OUTLIER -58.75 -43.19 90.22 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.118 -0.989 . . . . 0.0 109.113 -179.328 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.548 ' O ' ' N ' ' A' ' 53' ' ' GLY . 2.1 pp20? -72.18 -35.62 69.02 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.054 -1.029 . . . . 0.0 109.8 179.905 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.2 t0 -60.44 -38.42 84.09 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.247 -0.908 . . . . 0.0 110.567 -179.641 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.445 ' HD2' ' HE1' ' A' ' 47' ' ' TRP . 49.9 mtp180 -60.47 -40.73 92.29 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.131 -0.981 . . . . 0.0 111.189 -178.873 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.861 ' CE2' HG21 ' A' ' 80' ' ' THR . 73.4 m-85 -106.49 -11.92 15.77 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.974 -1.078 . . . . 0.0 110.041 -179.358 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 53' ' ' GLY . . . . . 0.548 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 70.16 30.16 69.89 Favored Glycine 0 N--CA 1.485 1.939 0 N-CA-C 109.072 -1.611 . . . . 0.0 109.072 179.5 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 12.7 pt -93.57 124.31 45.97 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 O-C-N 121.358 -1.084 . . . . 0.0 109.623 -179.604 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -65.59 140.23 58.51 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.154 -0.966 . . . . 0.0 109.817 -179.535 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.503 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -65.45 -31.86 73.17 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.429 -0.794 . . . . 0.0 109.398 179.805 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -58.46 -37.36 75.3 Favored 'General case' 0 C--N 1.303 -1.45 0 O-C-N 121.183 -0.948 . . . . 0.0 109.952 -179.815 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -58.28 -40.11 81.04 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.225 -0.922 . . . . 0.0 109.964 -179.636 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.503 ' O ' ' O ' ' A' ' 56' ' ' ALA . 42.4 t -127.12 133.67 67.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.311 -0.868 . . . . 0.0 109.555 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 60' ' ' GLU . . . . . 0.51 ' C ' HD22 ' A' ' 61' ' ' LEU . 84.3 tt0 -89.26 129.73 35.78 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.044 -1.035 . . . . 0.0 109.336 179.803 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.675 ' N ' HD22 ' A' ' 61' ' ' LEU . 3.5 mm? -95.9 134.15 39.23 Favored 'General case' 0 C--N 1.305 -1.347 0 O-C-N 121.322 -0.861 . . . . 0.0 109.726 -179.821 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -109.96 156.35 40.11 Favored Pre-proline 0 N--CA 1.487 1.382 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 179.582 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_endo -54.22 -22.88 27.56 Favored 'Trans proline' 0 C--N 1.302 -1.902 0 C-N-CA 122.295 1.997 . . . . 0.0 111.68 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -69.96 -27.36 64.67 Favored 'General case' 0 N--CA 1.485 1.308 0 O-C-N 121.297 -0.877 . . . . 0.0 109.355 179.63 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 65' ' ' HIS . . . . . 0.545 ' C ' ' CD2' ' A' ' 65' ' ' HIS . 1.7 t60 -65.65 -19.94 66.11 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.307 -0.87 . . . . 0.0 109.003 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.55 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 7.9 m-85 -98.43 15.78 23.75 Favored 'General case' 0 C--N 1.299 -1.622 0 CA-C-O 121.601 0.715 . . . . 0.0 109.076 -179.765 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 67' ' ' ARG . . . . . 0.404 ' HG2' ' H ' ' A' ' 68' ' ' SER . 1.4 ptt85 -53.66 -36.6 62.29 Favored 'General case' 0 C--N 1.299 -1.61 0 O-C-N 121.679 -0.638 . . . . 0.0 110.55 -179.378 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 68' ' ' SER . . . . . 0.553 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 41.6 t -168.07 161.23 12.51 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.754 -1.216 . . . . 0.0 110.364 -179.787 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.636 ' H ' HD12 ' A' ' 69' ' ' ILE . 2.4 mp -57.69 -34.15 46.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 179.026 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 52.0 mtp85 -56.65 -41.71 77.68 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 109.081 -0.711 . . . . 0.0 109.081 -179.897 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 61.6 p -67.92 -32.98 73.81 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.444 -0.785 . . . . 0.0 109.596 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.521 HD12 ' HA ' ' A' ' 69' ' ' ILE . 56.5 mt -61.45 -50.6 79.69 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.361 0 O-C-N 121.294 -0.879 . . . . 0.0 109.567 -179.578 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 43.4 t0 -61.41 -41.44 97.16 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.216 -0.927 . . . . 0.0 108.894 179.655 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.21 -37.55 85.84 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.56 -0.712 . . . . 0.0 109.873 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 75' ' ' PHE . . . . . 0.53 ' CZ ' HD11 ' A' ' 61' ' ' LEU . 67.2 t80 -61.48 -46.5 89.78 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.167 -0.958 . . . . 0.0 109.64 -179.772 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.674 HG22 HD11 ' A' ' 48' ' ' LEU . 41.9 t -61.36 -47.76 91.99 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 O-C-N 121.268 -0.895 . . . . 0.0 109.358 179.692 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 77' ' ' VAL . . . . . 0.416 ' O ' ' O ' ' A' ' 81' ' ' THR . 47.3 t -69.0 -43.42 82.02 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 O-C-N 121.399 -0.813 . . . . 0.0 109.762 179.855 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -63.28 -40.73 99.33 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 110.284 -1.126 . . . . 0.0 110.284 -179.571 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -70.57 -41.62 72.18 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.229 -1.16 . . . . 0.0 110.833 -178.989 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.861 HG21 ' CE2' ' A' ' 52' ' ' PHE . 69.5 p -86.52 -31.15 21.44 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 120.906 -1.121 . . . . 0.0 109.955 -179.341 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.416 ' O ' ' O ' ' A' ' 77' ' ' VAL . 0.2 OUTLIER . . . . . 0 C--N 1.302 -1.496 0 O-C-N 121.466 -0.771 . . . . 0.0 109.376 -179.752 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 6.7 m80 . . . . . 0 N--CA 1.495 1.819 0 CA-C-O 120.999 0.428 . . . . 0.0 110.091 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -61.78 -41.71 98.06 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 120.981 -1.074 . . . . 0.0 109.173 179.685 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.4 m -60.97 -37.5 82.64 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.434 -0.791 . . . . 0.0 109.895 -179.801 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 49.6 t -60.33 -44.13 95.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.174 -0.954 . . . . 0.0 109.496 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 7' ' ' ILE . . . . . 0.453 ' O ' HG12 ' A' ' 11' ' ' VAL . 78.6 mt -59.5 -50.18 80.87 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 O-C-N 121.397 -0.815 . . . . 0.0 109.641 -179.799 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.659 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.96 -43.82 94.62 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.315 -0.866 . . . . 0.0 110.918 -179.569 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 85.5 mt-30 -69.08 -46.08 68.67 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 120.92 -1.112 . . . . 0.0 111.435 -178.446 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.711 ' CD1' ' N ' ' A' ' 11' ' ' VAL . 0.0 OUTLIER -70.42 -46.71 63.4 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.884 -1.135 . . . . 0.0 110.492 -179.177 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.711 ' N ' ' CD1' ' A' ' 10' ' ' PHE . 4.8 p -62.03 -40.33 86.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.085 -1.01 . . . . 0.0 109.807 -179.523 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.659 HG23 ' O ' ' A' ' 8' ' ' ALA . 55.8 t -63.28 -43.54 98.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.173 -0.955 . . . . 0.0 109.866 179.998 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -65.82 -37.3 85.86 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.214 -0.929 . . . . 0.0 110.278 -179.536 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 85.7 tt0 -65.76 -39.58 91.2 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.159 -0.963 . . . . 0.0 110.116 -179.558 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 15' ' ' PHE . . . . . 0.922 ' CD2' HG13 ' A' ' 35' ' ' VAL . 75.6 t80 -93.77 -50.72 5.23 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.174 -0.954 . . . . 0.0 110.783 -179.218 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.52 HD22 ' CG2' ' A' ' 19' ' ' VAL . 5.4 mt -120.26 80.59 28.64 Favored Pre-proline 0 N--CA 1.491 1.622 0 O-C-N 121.285 -0.884 . . . . 0.0 110.525 -178.776 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 23.5 Cg_endo -69.05 -14.52 38.49 Favored 'Trans proline' 0 N--CA 1.493 1.451 0 C-N-CA 122.095 1.863 . . . . 0.0 112.353 179.614 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -94.92 7.1 47.12 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.179 -0.95 . . . . 0.0 110.387 -179.613 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.52 ' CG2' HD22 ' A' ' 16' ' ' LEU . 39.3 t -119.11 136.33 56.65 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 121.271 -0.893 . . . . 0.0 109.788 -179.779 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -78.53 117.96 69.49 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.301 -0.874 . . . . 0.0 109.081 179.608 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_exo -51.76 -27.77 27.96 Favored 'Trans proline' 0 N--CA 1.493 1.478 0 C-N-CA 121.787 1.658 . . . . 0.0 112.23 179.855 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.52 -27.01 68.67 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.203 -0.936 . . . . 0.0 109.305 -179.946 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.452 ' O ' ' OD1' ' A' ' 23' ' ' ASP . 60.0 t0 -82.19 3.55 26.87 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.303 -0.873 . . . . 0.0 109.7 -179.778 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 9.7 t -109.43 128.33 65.51 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.263 -0.898 . . . . 0.0 109.561 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 87.2 m-20 -89.96 120.56 31.28 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.189 -0.945 . . . . 0.0 109.097 179.06 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 33.7 m -70.93 4.14 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.378 0 O-C-N 121.102 -0.999 . . . . 0.0 108.941 179.47 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -92.13 -5.45 52.66 Favored 'General case' 0 N--CA 1.486 1.341 0 O-C-N 121.373 -0.829 . . . . 0.0 109.031 179.423 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 44.3 tp -96.52 141.1 30.21 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.473 -0.767 . . . . 0.0 108.957 179.86 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -58.59 128.57 37.86 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.176 -0.952 . . . . 0.0 109.504 -179.407 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 1.033 HD23 HD11 ' A' ' 36' ' ' ILE . 48.7 tp -66.85 -37.23 84.07 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.551 -0.718 . . . . 0.0 110.648 -179.417 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 70.6 t -63.67 -35.96 74.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 120.928 -1.107 . . . . 0.0 110.693 -178.911 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 56.3 t0 -52.43 -33.59 44.68 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 120.974 -1.079 . . . . 0.0 108.186 -179.908 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.426 ' HB3' HG23 ' A' ' 35' ' ' VAL . 97.5 m-20 -71.46 -34.45 70.23 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.698 -0.626 . . . . 0.0 110.232 179.476 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 87.22 4.87 80.74 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 108.58 -1.808 . . . . 0.0 108.58 -179.043 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.922 HG13 ' CD2' ' A' ' 15' ' ' PHE . 67.8 t -59.87 -29.55 43.39 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 O-C-N 121.484 -1.009 . . . . 0.0 108.412 179.254 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 1.033 HD11 HD23 ' A' ' 30' ' ' LEU . 71.8 mt -88.07 132.5 33.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 CA-C-O 121.616 0.722 . . . . 0.0 109.627 -179.897 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.554 ' CG ' ' H ' ' A' ' 38' ' ' ALA . 45.7 t0 -139.07 -160.81 1.1 Allowed 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 179.845 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.554 ' H ' ' CG ' ' A' ' 37' ' ' ASP . . . -65.48 -54.31 30.19 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.117 -0.99 . . . . 0.0 108.716 179.817 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.693 HD12 ' N ' ' A' ' 39' ' ' LEU . 7.0 mp -69.63 -32.81 71.72 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 107.35 -1.352 . . . . 0.0 107.35 178.405 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.455 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.26 -44.06 96.77 Favored Glycine 0 N--CA 1.481 1.663 0 N-CA-C 109.008 -1.637 . . . . 0.0 109.008 179.545 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.4 ' O ' HD12 ' A' ' 45' ' ' ILE . 2.8 tt -65.12 -42.06 94.28 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.473 -1.016 . . . . 0.0 109.369 179.168 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 15.8 tp -59.74 -44.69 93.67 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.227 -0.921 . . . . 0.0 109.339 179.857 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 18.8 mttt -62.2 -34.29 76.18 Favored 'General case' 0 C--N 1.299 -1.589 0 O-C-N 121.156 -0.965 . . . . 0.0 109.62 179.874 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.455 HG23 ' O ' ' A' ' 40' ' ' GLY . 54.0 t -60.75 -50.18 81.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.27 -0.894 . . . . 0.0 110.06 -179.488 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.525 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 3.6 mp -68.48 -34.63 66.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.247 -0.908 . . . . 0.0 111.257 -179.669 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.81 -50.16 65.65 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 120.943 -1.098 . . . . 0.0 111.758 -177.867 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.678 ' HE1' ' NE ' ' A' ' 51' ' ' ARG . 0.0 OUTLIER -80.05 -43.8 21.22 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.75 -1.219 . . . . 0.0 109.78 -179.457 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.98 HD12 HH21 ' A' ' 51' ' ' ARG . 15.0 tp -58.73 -43.16 90.1 Favored 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.382 -0.824 . . . . 0.0 110.12 -179.12 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.525 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 1.2 pp20? -72.67 -35.85 67.78 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.135 -0.978 . . . . 0.0 109.905 -179.762 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.1 t70 -61.51 -39.72 92.02 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.226 -0.921 . . . . 0.0 111.16 -179.317 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.98 HH21 HD12 ' A' ' 48' ' ' LEU . 70.5 mtm180 -62.65 -36.8 83.99 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.19 -0.944 . . . . 0.0 112.028 -178.291 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.79 ' CE1' HG11 ' A' ' 76' ' ' VAL . 88.5 m-85 -95.96 -6.13 39.73 Favored 'General case' 0 N--CA 1.487 1.389 0 O-C-N 120.714 -1.242 . . . . 0.0 110.454 -178.718 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 70.33 29.39 70.21 Favored Glycine 0 N--CA 1.486 1.979 0 N-CA-C 108.882 -1.687 . . . . 0.0 108.882 179.349 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.488 ' O ' ' OE1' ' A' ' 49' ' ' GLU . 24.7 pt -107.28 152.38 8.87 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 O-C-N 121.557 -0.966 . . . . 0.0 109.559 -179.571 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -105.23 154.51 20.12 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.36 -0.837 . . . . 0.0 109.721 -179.472 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.833 ' O ' HG12 ' A' ' 59' ' ' VAL . . . -59.8 -21.19 60.5 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.339 -0.85 . . . . 0.0 109.177 179.904 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 56.3 t0 61.95 36.6 15.6 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 121.526 -0.734 . . . . 0.0 109.328 -179.789 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 53.32 48.61 21.61 Favored 'General case' 0 C--N 1.305 -1.366 0 O-C-N 121.439 -0.788 . . . . 0.0 110.357 178.941 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.833 HG12 ' O ' ' A' ' 56' ' ' ALA . 8.8 p -127.86 142.87 42.53 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.364 -0.835 . . . . 0.0 109.105 179.593 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -99.19 133.5 43.39 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.177 -0.952 . . . . 0.0 109.628 -179.792 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 59.3 mt -92.52 145.38 24.49 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.43 -0.794 . . . . 0.0 109.248 179.92 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -91.71 150.73 41.42 Favored Pre-proline 0 C--N 1.305 -1.34 0 O-C-N 121.14 -0.975 . . . . 0.0 108.765 179.8 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 11.4 Cg_endo -57.23 -19.82 36.06 Favored 'Trans proline' 0 C--N 1.304 -1.81 0 C-N-CA 122.335 2.023 . . . . 0.0 112.035 -179.67 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -67.96 -31.62 71.47 Favored 'General case' 0 N--CA 1.484 1.243 0 O-C-N 121.285 -0.885 . . . . 0.0 109.453 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 65' ' ' HIS . . . . . 0.586 ' CD2' ' O ' ' A' ' 65' ' ' HIS . 5.2 t-160 -66.04 -20.54 66.21 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.347 -0.846 . . . . 0.0 108.737 179.787 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.586 ' HB3' HD13 ' A' ' 36' ' ' ILE . 8.5 m-85 -94.63 14.65 20.37 Favored 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 -179.915 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 67' ' ' ARG . . . . . 0.587 ' NE ' ' OG ' ' A' ' 71' ' ' SER . 6.4 ptt180 -46.47 -37.65 8.09 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.739 -0.601 . . . . 0.0 110.381 -179.59 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 68' ' ' SER . . . . . 0.485 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 46.7 t -159.71 155.05 25.33 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.933 -1.104 . . . . 0.0 110.06 -179.764 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.717 ' H ' HD12 ' A' ' 69' ' ' ILE . 1.6 mp -57.69 -41.75 80.1 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 O-C-N 121.29 -0.881 . . . . 0.0 109.142 179.931 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 11.1 ptm180 -58.33 -42.05 85.93 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.406 -0.809 . . . . 0.0 109.1 179.795 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 71' ' ' SER . . . . . 0.587 ' OG ' ' NE ' ' A' ' 67' ' ' ARG . 26.4 t -62.97 -40.9 99.13 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.333 -0.854 . . . . 0.0 109.359 179.471 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 86.1 mt -60.12 -49.78 82.77 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 O-C-N 121.218 -0.926 . . . . 0.0 109.437 179.928 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 37.2 t0 -59.53 -40.6 87.71 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.366 -0.834 . . . . 0.0 109.013 179.695 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.45 -37.76 85.87 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.637 -0.665 . . . . 0.0 110.153 -179.882 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 75' ' ' PHE . . . . . 0.554 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 64.4 t80 -60.73 -47.77 84.78 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.145 -0.972 . . . . 0.0 109.836 -179.413 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.79 HG11 ' CE1' ' A' ' 52' ' ' PHE . 98.5 t -62.47 -46.3 96.74 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.294 0 O-C-N 121.064 -1.023 . . . . 0.0 109.18 179.809 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 78.8 t -66.9 -40.24 85.31 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.389 0 O-C-N 121.472 -0.768 . . . . 0.0 109.217 179.641 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.489 ' O ' ' O ' ' A' ' 81' ' ' THR . . . -59.46 -38.57 93.72 Favored Glycine 0 N--CA 1.488 2.127 0 N-CA-C 109.913 -1.275 . . . . 0.0 109.913 -179.781 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -69.15 -41.31 77.45 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.335 -1.097 . . . . 0.0 110.489 -179.3 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 44.9 p -81.81 -31.08 31.94 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.068 -1.02 . . . . 0.0 109.449 -179.781 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.489 ' O ' ' O ' ' A' ' 78' ' ' GLY . 0.5 OUTLIER . . . . . 0 C--N 1.3 -1.558 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 -179.869 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 97.1 m-70 . . . . . 0 N--CA 1.486 1.366 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 . . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -54.37 -42.64 70.56 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.524 -0.735 . . . . 0.0 109.836 -179.181 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 24.2 m -62.11 -38.08 87.55 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.28 -0.887 . . . . 0.0 109.868 -179.84 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 53.7 t -64.19 -45.44 96.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.165 -0.959 . . . . 0.0 109.781 -179.777 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 79.4 mt -59.77 -42.43 88.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.386 -0.821 . . . . 0.0 109.279 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' ALA . . . . . 0.516 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -60.51 -36.93 79.55 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.374 -0.828 . . . . 0.0 109.18 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 59.8 tt0 -65.28 -40.23 93.6 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.271 -0.893 . . . . 0.0 110.077 179.924 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.677 ' CG ' ' CZ2' ' A' ' 47' ' ' TRP . 20.7 m-85 -62.01 -50.04 73.63 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.102 -0.999 . . . . 0.0 110.676 -179.426 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.42 HG23 ' N ' ' A' ' 12' ' ' VAL . 22.2 m -64.08 -40.48 89.19 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 O-C-N 121.06 -1.025 . . . . 0.0 109.302 -179.629 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.516 HG23 ' O ' ' A' ' 8' ' ' ALA . 69.0 t -63.66 -46.52 94.51 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.206 -0.934 . . . . 0.0 109.309 179.571 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -70.12 -29.39 66.32 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.305 -0.872 . . . . 0.0 109.895 179.818 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -64.82 -30.42 71.42 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.48 -0.762 . . . . 0.0 110.615 -179.094 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 75.9 t80 -131.89 -46.06 0.95 Allowed 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.083 -1.01 . . . . 0.0 111.125 -178.97 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.47 HD22 ' CG2' ' A' ' 19' ' ' VAL . 4.7 mt -117.98 80.16 14.55 Favored Pre-proline 0 N--CA 1.494 1.755 0 O-C-N 121.097 -1.002 . . . . 0.0 110.442 -178.994 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -76.15 -14.26 18.8 Favored 'Trans proline' 0 C--N 1.308 -1.604 0 C-N-CA 122.411 2.074 . . . . 0.0 112.255 179.324 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -89.08 5.19 45.63 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.279 -0.888 . . . . 0.0 109.761 -179.928 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.47 ' CG2' HD22 ' A' ' 16' ' ' LEU . 45.1 t -112.64 135.33 52.38 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.378 -0.826 . . . . 0.0 109.59 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.435 ' O ' ' CG ' ' A' ' 23' ' ' ASP . . . -73.18 117.52 60.83 Favored Pre-proline 0 N--CA 1.489 1.52 0 O-C-N 121.26 -0.9 . . . . 0.0 109.443 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_exo -51.98 -25.14 21.18 Favored 'Trans proline' 0 N--CA 1.493 1.5 0 C-N-CA 121.805 1.67 . . . . 0.0 112.039 179.486 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.72 -22.92 67.09 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.29 -0.881 . . . . 0.0 109.708 -179.828 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.45 ' C ' ' OD1' ' A' ' 23' ' ' ASP . 52.3 p30 -83.98 7.62 17.81 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.249 -0.907 . . . . 0.0 109.831 -179.74 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 11.8 t -104.97 133.57 48.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.218 -0.926 . . . . 0.0 109.348 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 86.5 m-20 -88.89 120.61 30.46 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.054 -1.029 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 17.0 m -74.96 3.83 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 O-C-N 121.26 -0.9 . . . . 0.0 109.386 179.849 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' ASP . . . . . 0.449 ' C ' ' OD1' ' A' ' 27' ' ' ASP . 52.0 p30 -94.95 1.12 55.2 Favored 'General case' 0 N--CA 1.486 1.349 0 O-C-N 121.245 -0.909 . . . . 0.0 109.227 179.454 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 46.0 tp -100.44 134.61 43.12 Favored 'General case' 0 C--N 1.303 -1.437 0 N-CA-C 108.358 -0.978 . . . . 0.0 108.358 179.313 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -57.72 126.71 28.56 Favored 'General case' 0 C--N 1.3 -1.546 0 C-N-CA 118.942 -1.103 . . . . 0.0 108.998 -179.335 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 1.023 HD23 HD11 ' A' ' 36' ' ' ILE . 43.0 tp -66.08 -37.97 87.11 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.654 -0.654 . . . . 0.0 110.654 -179.153 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 54.1 t -67.43 -37.47 78.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 120.931 -1.106 . . . . 0.0 110.774 -179.155 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 84.4 m-20 -52.69 -33.17 46.25 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 120.859 -1.151 . . . . 0.0 108.111 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 20.3 m120 -70.72 -33.48 70.9 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.639 -0.663 . . . . 0.0 109.784 179.325 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 91.65 5.56 66.62 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 108.879 -1.688 . . . . 0.0 108.879 -179.304 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 74.4 t -61.44 -32.99 54.92 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 O-C-N 121.498 -1.001 . . . . 0.0 109.209 179.793 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 1.023 HD11 HD23 ' A' ' 30' ' ' LEU . 72.6 mt -92.31 121.13 42.62 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.396 0 O-C-N 121.302 -0.874 . . . . 0.0 109.651 -179.726 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -120.42 -169.5 1.82 Allowed 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 109.076 -0.713 . . . . 0.0 109.076 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -63.46 -54.24 39.65 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.221 -0.924 . . . . 0.0 108.615 179.702 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.686 HD12 ' N ' ' A' ' 39' ' ' LEU . 7.0 mp -70.78 -33.47 70.79 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 107.193 -1.41 . . . . 0.0 107.193 178.148 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.497 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.49 -43.12 97.79 Favored Glycine 0 N--CA 1.483 1.813 0 N-CA-C 108.809 -1.716 . . . . 0.0 108.809 179.388 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.407 HD11 ' CE1' ' A' ' 66' ' ' PHE . 6.6 tt -64.73 -41.63 95.81 Favored 'General case' 0 C--N 1.304 -1.374 0 O-C-N 121.384 -1.068 . . . . 0.0 109.066 179.286 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.4 tp -59.73 -45.93 90.68 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.222 -0.924 . . . . 0.0 109.044 179.705 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 56.6 mttt -60.97 -34.75 75.25 Favored 'General case' 0 C--N 1.297 -1.717 0 O-C-N 121.492 -0.755 . . . . 0.0 109.671 -179.812 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.497 HG23 ' O ' ' A' ' 40' ' ' GLY . 54.3 t -61.85 -49.87 82.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.366 -0.834 . . . . 0.0 110.162 -179.401 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.547 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 3.4 mp -67.89 -32.9 58.38 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 O-C-N 121.206 -0.934 . . . . 0.0 110.678 -179.621 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.7 -50.29 67.55 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.861 -1.15 . . . . 0.0 111.13 -178.302 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.677 ' CZ2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -81.28 -44.84 17.11 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.758 -1.214 . . . . 0.0 109.829 -179.657 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.646 HD21 ' CG2' ' A' ' 76' ' ' VAL . 18.1 tp -58.37 -41.32 84.53 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.328 -0.858 . . . . 0.0 109.936 -178.955 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.547 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 1.1 pp20? -73.35 -35.63 66.02 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 120.895 -1.128 . . . . 0.0 109.521 179.769 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.4 t0 -63.48 -41.02 98.59 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.376 -0.828 . . . . 0.0 111.619 -179.111 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.504 ' HD3' HD12 ' A' ' 48' ' ' LEU . 8.8 ptm180 -65.0 -37.08 86.47 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.869 -1.144 . . . . 0.0 111.632 -178.122 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.858 ' CE2' HG11 ' A' ' 76' ' ' VAL . 72.9 m-85 -90.9 -12.14 37.02 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 120.443 -1.41 . . . . 0.0 110.021 -179.505 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 74.47 28.83 62.84 Favored Glycine 0 N--CA 1.487 2.045 0 N-CA-C 108.832 -1.707 . . . . 0.0 108.832 179.919 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 54' ' ' ILE . . . . . 0.49 ' O ' ' OE1' ' A' ' 49' ' ' GLU . 25.2 pt -109.18 153.4 10.95 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.575 -0.956 . . . . 0.0 109.798 -179.42 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -102.44 126.3 49.44 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.228 -0.92 . . . . 0.0 109.561 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.497 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -68.55 -28.16 66.72 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.238 -0.914 . . . . 0.0 109.525 179.784 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 21.0 t70 -55.12 -33.49 62.9 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.262 -0.899 . . . . 0.0 110.082 -179.638 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -52.76 -38.29 60.77 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.133 -0.979 . . . . 0.0 109.852 -179.465 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.497 ' O ' ' O ' ' A' ' 56' ' ' ALA . 32.7 m -127.66 157.74 39.43 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.335 0 O-C-N 121.319 -0.863 . . . . 0.0 109.557 -179.721 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -97.6 125.82 42.55 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.14 -0.975 . . . . 0.0 109.353 179.725 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.412 HD21 ' CE2' ' A' ' 75' ' ' PHE . 5.1 mp -107.12 141.06 38.98 Favored 'General case' 0 C--N 1.306 -1.325 0 O-C-N 121.394 -0.816 . . . . 0.0 109.699 -179.73 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -109.22 153.09 42.84 Favored Pre-proline 0 N--CA 1.487 1.406 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 179.295 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo -54.53 -23.22 30.96 Favored 'Trans proline' 0 C--N 1.303 -1.817 0 C-N-CA 122.338 2.026 . . . . 0.0 112.086 -179.548 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -70.15 -26.46 63.94 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 121.352 -0.842 . . . . 0.0 109.403 179.906 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 65' ' ' HIS . . . . . 0.504 ' NE2' ' CB ' ' A' ' 75' ' ' PHE . 2.2 t-80 -66.03 -20.88 66.33 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.419 -0.8 . . . . 0.0 109.289 -179.843 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.584 ' HB3' HD13 ' A' ' 36' ' ' ILE . 9.5 m-85 -97.1 15.48 22.41 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 121.406 -0.809 . . . . 0.0 109.166 -179.815 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 1.7 ptt85 -51.99 -34.39 42.31 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.644 -0.66 . . . . 0.0 109.999 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 68' ' ' SER . . . . . 0.546 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 44.2 t -151.4 154.05 35.89 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.071 -1.018 . . . . 0.0 109.969 179.884 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.637 ' H ' HD12 ' A' ' 69' ' ' ILE . 3.2 mp -57.36 -33.91 44.99 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 179.222 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 32.1 mtp180 -56.79 -44.11 81.56 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.67 -0.644 . . . . 0.0 109.407 -179.693 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 17.0 t -66.47 -40.58 89.42 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.382 -0.823 . . . . 0.0 109.829 -179.96 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 62.8 mt -62.18 -50.26 80.73 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.37 0 O-C-N 121.305 -0.872 . . . . 0.0 110.286 -179.222 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 37.0 t0 -61.0 -41.88 97.35 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.11 -0.994 . . . . 0.0 109.409 -179.842 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -67.02 -40.69 87.31 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.478 -0.764 . . . . 0.0 110.353 -179.443 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 75' ' ' PHE . . . . . 0.504 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 66.9 t80 -62.7 -46.71 86.86 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.049 -1.032 . . . . 0.0 109.663 -179.676 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.858 HG11 ' CE2' ' A' ' 52' ' ' PHE . 90.7 t -67.23 -48.21 79.05 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.343 0 O-C-N 121.192 -0.943 . . . . 0.0 109.78 -179.938 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 53.0 t -69.66 -41.99 80.29 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.333 0 O-C-N 121.134 -0.978 . . . . 0.0 109.63 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.486 ' O ' ' O ' ' A' ' 81' ' ' THR . . . -59.53 -36.0 87.7 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 -179.477 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.48 -40.98 85.29 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.209 -1.171 . . . . 0.0 110.475 -179.183 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 49.0 p -81.93 -30.74 31.67 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.144 -0.972 . . . . 0.0 109.698 -179.685 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.486 ' O ' ' O ' ' A' ' 78' ' ' GLY . 0.5 OUTLIER . . . . . 0 C--N 1.302 -1.458 0 O-C-N 121.541 -0.725 . . . . 0.0 109.666 -179.615 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 50.4 m-70 . . . . . 0 N--CA 1.494 1.753 0 CA-C-O 121.052 0.454 . . . . 0.0 110.575 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -61.01 -38.42 86.0 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.96 -1.088 . . . . 0.0 109.299 179.468 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 25.5 m -60.18 -35.75 76.05 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.328 -0.857 . . . . 0.0 109.914 -179.797 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 53.0 t -61.39 -45.72 98.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.193 -0.942 . . . . 0.0 109.589 -179.69 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 70.2 mt -60.04 -43.88 93.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.475 0 O-C-N 121.247 -0.908 . . . . 0.0 109.113 179.79 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -60.41 -35.89 76.84 Favored 'General case' 0 C--N 1.303 -1.424 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 179.752 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 59.5 tt0 -64.18 -38.12 89.9 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.458 -0.776 . . . . 0.0 110.137 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.684 ' CG ' ' CZ2' ' A' ' 47' ' ' TRP . 25.8 m-85 -66.52 -49.29 67.01 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 120.908 -1.12 . . . . 0.0 111.028 -179.219 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 11' ' ' VAL . . . . . 0.443 HG23 ' N ' ' A' ' 12' ' ' VAL . 11.6 m -59.74 -48.14 88.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.08 -1.013 . . . . 0.0 110.428 -178.518 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.573 ' O ' ' N ' ' A' ' 16' ' ' LEU . 30.6 m -64.89 -43.44 96.31 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.407 0 O-C-N 120.766 -1.208 . . . . 0.0 110.03 -179.838 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 13' ' ' GLU . . . . . 0.511 ' N ' HG23 ' A' ' 12' ' ' VAL . 95.0 mt-10 -65.16 -26.51 68.19 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.755 -1.215 . . . . 0.0 109.945 -179.981 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 81.4 tt0 -64.28 -31.04 72.08 Favored 'General case' 0 C--N 1.299 -1.614 0 O-C-N 121.328 -0.857 . . . . 0.0 109.767 -179.277 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 85.9 m-85 -141.5 -35.89 0.45 Allowed 'General case' 0 N--CA 1.494 1.734 0 O-C-N 120.897 -1.127 . . . . 0.0 110.816 -179.9 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.573 ' N ' ' O ' ' A' ' 12' ' ' VAL . 8.6 mt -122.17 79.79 43.83 Favored Pre-proline 0 N--CA 1.494 1.737 0 O-C-N 121.124 -0.985 . . . . 0.0 110.418 -179.01 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 43.0 Cg_endo -75.77 -12.03 20.08 Favored 'Trans proline' 0 C--N 1.308 -1.562 0 C-N-CA 122.412 2.075 . . . . 0.0 112.545 179.79 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -93.87 13.09 23.66 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.224 -0.922 . . . . 0.0 110.385 -179.399 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 58.5 t -109.46 134.98 49.78 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.247 -0.908 . . . . 0.0 110.008 -179.724 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 20' ' ' ALA . . . . . 0.494 ' O ' ' OD1' ' A' ' 23' ' ' ASP . . . -73.58 117.88 64.43 Favored Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.429 -0.794 . . . . 0.0 109.337 -179.965 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_exo -52.62 -27.24 32.28 Favored 'Trans proline' 0 N--CA 1.494 1.509 0 C-N-CA 121.832 1.688 . . . . 0.0 112.394 179.786 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.85 -25.4 67.88 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.263 -0.898 . . . . 0.0 110.035 -179.561 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.494 ' OD1' ' O ' ' A' ' 20' ' ' ALA . 47.4 p30 -86.54 8.15 23.24 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.133 -0.979 . . . . 0.0 110.112 -179.566 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 11.3 t -101.11 131.64 48.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 120.972 -1.08 . . . . 0.0 109.418 -179.907 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 61.6 t0 -89.29 119.71 30.0 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.096 -1.002 . . . . 0.0 109.094 179.435 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 22.1 m -76.3 4.45 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 O-C-N 121.252 -0.905 . . . . 0.0 109.173 179.687 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -96.24 0.25 50.75 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 121.266 -0.896 . . . . 0.0 109.214 179.61 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 38.4 tp -94.62 143.22 26.61 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.43 -0.794 . . . . 0.0 109.192 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -66.79 118.78 10.79 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.091 -1.006 . . . . 0.0 109.005 -179.75 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 1.027 HD23 HD11 ' A' ' 36' ' ' ILE . 41.6 tp -62.33 -37.86 87.26 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.605 -0.685 . . . . 0.0 111.09 -178.872 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 53.2 t -66.78 -38.29 81.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 120.807 -1.183 . . . . 0.0 110.863 -179.012 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -52.89 -33.36 49.87 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 120.913 -1.117 . . . . 0.0 108.212 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 20.9 m120 -71.05 -33.91 70.74 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.698 -0.626 . . . . 0.0 109.941 179.528 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 91.31 5.6 67.24 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 108.871 -1.691 . . . . 0.0 108.871 -179.231 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 78.0 t -60.19 -30.56 46.19 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 O-C-N 121.479 -1.012 . . . . 0.0 108.825 179.526 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 1.027 HD11 HD23 ' A' ' 30' ' ' LEU . 65.5 mt -94.72 130.5 43.46 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.344 0 O-C-N 121.386 -0.821 . . . . 0.0 109.558 -179.763 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.545 ' CG ' ' H ' ' A' ' 38' ' ' ALA . 49.1 t0 -137.92 -163.67 1.48 Allowed 'General case' 0 C--N 1.301 -1.52 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 179.948 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.545 ' H ' ' CG ' ' A' ' 37' ' ' ASP . . . -63.54 -54.76 31.13 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.995 -1.066 . . . . 0.0 108.665 179.879 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 39' ' ' LEU . . . . . 0.712 HD12 ' N ' ' A' ' 39' ' ' LEU . 6.9 mp -71.25 -34.04 70.37 Favored 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 107.323 -1.362 . . . . 0.0 107.323 178.206 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.425 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.47 -45.55 95.36 Favored Glycine 0 N--CA 1.482 1.725 0 N-CA-C 109.019 -1.632 . . . . 0.0 109.019 179.562 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.4 tt -64.08 -39.95 95.17 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.462 -1.022 . . . . 0.0 109.092 179.303 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 tp -60.04 -46.03 90.89 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.432 -0.792 . . . . 0.0 109.327 179.902 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 17.6 mttp -59.82 -37.11 78.28 Favored 'General case' 0 C--N 1.296 -1.729 0 O-C-N 121.474 -0.766 . . . . 0.0 109.381 -179.906 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.425 HG23 ' O ' ' A' ' 40' ' ' GLY . 84.9 t -64.64 -41.49 92.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.5 -0.75 . . . . 0.0 110.2 -179.699 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.485 ' O ' ' OE1' ' A' ' 49' ' ' GLU . 1.3 mp -64.89 -50.76 73.58 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.646 0 O-C-N 121.066 -1.021 . . . . 0.0 111.208 -178.84 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 46' ' ' ALA . . . . . 0.411 ' N ' HG22 ' A' ' 45' ' ' ILE . . . -67.68 -49.51 62.4 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.083 -1.011 . . . . 0.0 112.843 -177.531 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.684 ' CZ2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -74.8 -48.86 23.05 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 120.613 -1.304 . . . . 0.0 111.358 -177.758 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.594 ' O ' HD13 ' A' ' 48' ' ' LEU . 0.2 OUTLIER -58.86 -44.52 91.04 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 120.812 -1.18 . . . . 0.0 109.345 -178.582 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.628 ' HG2' ' HB2' ' A' ' 56' ' ' ALA . 0.0 OUTLIER -63.97 -38.72 92.11 Favored 'General case' 0 N--CA 1.485 1.324 0 O-C-N 120.706 -1.246 . . . . 0.0 109.818 -179.958 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 55.1 t0 -61.68 -37.25 83.4 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.298 -0.876 . . . . 0.0 110.513 -179.502 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 18.4 mmt180 -58.27 -36.51 73.39 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.089 -1.007 . . . . 0.0 111.055 -179.029 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.752 ' CE1' HG11 ' A' ' 76' ' ' VAL . 87.4 m-85 -96.32 -6.18 38.36 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 120.789 -1.194 . . . . 0.0 110.474 -179.144 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 73.25 30.44 62.79 Favored Glycine 0 N--CA 1.488 2.121 0 N-CA-C 108.739 -1.745 . . . . 0.0 108.739 179.761 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 20.7 pt -112.68 153.9 14.21 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 O-C-N 121.75 -0.853 . . . . 0.0 109.701 -179.436 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -93.99 130.17 40.21 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.217 -0.927 . . . . 0.0 109.407 -179.873 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.628 ' HB2' ' HG2' ' A' ' 49' ' ' GLU . . . -64.39 -32.24 73.78 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.202 -0.936 . . . . 0.0 109.552 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -58.06 -34.49 70.17 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.383 -0.823 . . . . 0.0 110.051 -179.835 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -53.53 -37.93 63.3 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.28 -0.888 . . . . 0.0 109.939 -179.469 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.486 ' O ' ' O ' ' A' ' 56' ' ' ALA . 13.7 p -133.67 142.72 40.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.253 -0.905 . . . . 0.0 109.567 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -100.19 128.73 46.21 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.21 -0.931 . . . . 0.0 109.322 179.781 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 51.7 mt -105.75 143.46 33.88 Favored 'General case' 0 C--N 1.305 -1.361 0 O-C-N 121.314 -0.866 . . . . 0.0 109.707 -179.719 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -97.32 151.25 37.56 Favored Pre-proline 0 C--N 1.305 -1.337 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 179.131 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -55.39 -23.25 37.41 Favored 'Trans proline' 0 C--N 1.305 -1.743 0 C-N-CA 122.366 2.044 . . . . 0.0 112.032 -179.403 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 91.9 mt-10 -71.79 -29.85 64.9 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.345 -0.847 . . . . 0.0 109.774 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 65' ' ' HIS . . . . . 0.453 ' CE1' ' HB2' ' A' ' 75' ' ' PHE . 63.0 t60 -65.92 -21.17 66.42 Favored 'General case' 0 C--N 1.299 -1.588 0 O-C-N 121.102 -0.999 . . . . 0.0 109.186 -179.668 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.599 ' HB3' HD13 ' A' ' 36' ' ' ILE . 26.0 m-85 -86.93 13.98 8.13 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.405 -0.809 . . . . 0.0 109.223 -179.659 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 5.8 ptt180 -52.73 -34.31 52.05 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.66 -0.65 . . . . 0.0 110.088 179.852 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 68' ' ' SER . . . . . 0.48 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 32.4 t -149.82 151.11 32.99 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.067 -1.021 . . . . 0.0 110.088 -179.771 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.665 ' H ' HD12 ' A' ' 69' ' ' ILE . 2.0 mp -60.19 -39.14 79.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.428 0 O-C-N 121.48 -0.762 . . . . 0.0 109.888 -179.862 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 9.8 ptm180 -58.12 -40.99 82.64 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.493 -0.754 . . . . 0.0 110.283 -179.225 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 60.7 p -64.98 -42.91 94.12 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.201 -0.937 . . . . 0.0 110.221 -179.455 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 72' ' ' ILE . . . . . 0.421 ' HA ' ' NE2' ' A' ' 65' ' ' HIS . 69.6 mt -61.5 -47.39 93.63 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 O-C-N 121.136 -0.978 . . . . 0.0 110.406 -179.405 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 39.4 t0 -60.63 -37.49 81.64 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 121.184 -0.948 . . . . 0.0 109.825 -179.723 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -67.86 -46.84 70.59 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.216 -0.927 . . . . 0.0 110.604 -178.985 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 75' ' ' PHE . . . . . 0.453 ' HB2' ' CE1' ' A' ' 65' ' ' HIS . 58.4 t80 -65.88 -44.52 85.1 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.098 -1.001 . . . . 0.0 109.2 -179.728 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.752 HG11 ' CE1' ' A' ' 52' ' ' PHE . 55.2 t -60.76 -45.34 97.97 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 O-C-N 121.31 -0.869 . . . . 0.0 109.157 179.585 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 54.7 t -69.15 -41.16 81.27 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.281 0 O-C-N 121.214 -0.929 . . . . 0.0 108.989 179.349 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.492 ' O ' ' O ' ' A' ' 81' ' ' THR . . . -59.99 -28.13 65.74 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 110.029 -1.228 . . . . 0.0 110.029 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.02 -37.02 83.39 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.207 -1.172 . . . . 0.0 109.947 -179.391 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 44.9 p -83.38 -31.08 26.9 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.149 -0.97 . . . . 0.0 109.535 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.492 ' O ' ' O ' ' A' ' 78' ' ' GLY . 0.2 OUTLIER . . . . . 0 C--N 1.303 -1.428 0 O-C-N 121.504 -0.747 . . . . 0.0 109.788 -179.523 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 77.5 m80 . . . . . 0 N--CA 1.483 1.208 0 N-CA-C 106.683 -1.599 . . . . 0.0 106.683 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -51.88 -39.48 59.07 Favored 'General case' 0 N--CA 1.487 1.417 0 CA-C-O 121.233 0.539 . . . . 0.0 109.92 -179.052 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.8 m -59.8 -37.78 80.09 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.256 -0.902 . . . . 0.0 109.746 -179.747 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 6' ' ' VAL . . . . . 0.546 HG11 ' CZ ' ' A' ' 51' ' ' ARG . 55.5 t -62.63 -42.93 97.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.251 -0.906 . . . . 0.0 109.545 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 79.3 mt -59.54 -41.43 84.82 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 O-C-N 121.348 -0.845 . . . . 0.0 109.241 179.858 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -62.21 -38.42 89.09 Favored 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.405 -0.809 . . . . 0.0 109.558 -179.789 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 46.5 mt-30 -61.87 -42.07 98.62 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.108 -0.995 . . . . 0.0 109.545 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 10' ' ' PHE . . . . . 0.669 ' CG ' ' CE2' ' A' ' 47' ' ' TRP . 34.1 m-85 -61.81 -42.07 98.55 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.247 -0.908 . . . . 0.0 109.407 179.421 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 43.3 t -61.13 -45.29 98.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.367 -0.833 . . . . 0.0 109.548 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 12' ' ' VAL . . . . . 0.614 HG21 ' HG3' ' A' ' 21' ' ' PRO . 93.6 t -63.21 -46.83 94.81 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 O-C-N 121.479 -0.763 . . . . 0.0 109.735 -179.821 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -73.52 -16.46 61.28 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.396 -0.815 . . . . 0.0 110.265 -179.492 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -63.54 -31.88 73.17 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.171 -0.956 . . . . 0.0 110.299 -178.801 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 65.7 t80 -151.32 -28.99 0.19 Allowed 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.829 -1.169 . . . . 0.0 110.436 -179.761 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 16' ' ' LEU . . . . . 0.546 HD22 ' CG2' ' A' ' 19' ' ' VAL . 6.2 mt -121.77 80.14 40.6 Favored Pre-proline 0 N--CA 1.492 1.647 0 O-C-N 121.231 -0.918 . . . . 0.0 110.08 -179.405 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -77.08 -13.03 17.41 Favored 'Trans proline' 0 C--N 1.307 -1.607 0 C-N-CA 122.476 2.117 . . . . 0.0 112.375 179.759 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -93.95 9.74 36.24 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.189 -0.944 . . . . 0.0 110.263 -179.423 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 19' ' ' VAL . . . . . 0.546 ' CG2' HD22 ' A' ' 16' ' ' LEU . 46.4 t -109.88 137.77 40.57 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.274 -0.891 . . . . 0.0 109.691 -179.769 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -78.41 117.44 66.34 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.147 -0.971 . . . . 0.0 109.442 179.941 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 21' ' ' PRO . . . . . 0.614 ' HG3' HG21 ' A' ' 12' ' ' VAL . 38.3 Cg_exo -53.83 -24.79 32.35 Favored 'Trans proline' 0 N--CA 1.494 1.535 0 C-N-CA 121.842 1.695 . . . . 0.0 112.068 179.547 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.0 -24.51 67.74 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.304 -0.872 . . . . 0.0 109.301 -179.936 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 23' ' ' ASP . . . . . 0.409 ' O ' ' OD1' ' A' ' 23' ' ' ASP . 59.6 t0 -81.66 3.31 25.85 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.331 -0.856 . . . . 0.0 109.332 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 13.0 t -109.66 133.94 53.32 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.375 -0.828 . . . . 0.0 109.298 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 63.9 t0 -88.7 119.75 29.47 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.097 -1.002 . . . . 0.0 109.05 179.56 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 29.9 m -74.43 4.15 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.35 0 O-C-N 121.137 -0.977 . . . . 0.0 109.261 179.656 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 91.8 m-20 -90.43 -4.83 56.74 Favored 'General case' 0 N--CA 1.487 1.381 0 O-C-N 121.29 -0.881 . . . . 0.0 108.819 179.45 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 45.3 tp -98.03 139.58 33.64 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 179.832 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -58.77 137.51 57.64 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.211 -0.931 . . . . 0.0 109.655 -179.419 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 30' ' ' LEU . . . . . 0.905 HD13 HD11 ' A' ' 36' ' ' ILE . 1.4 tt -66.04 -38.91 89.57 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.713 -0.617 . . . . 0.0 110.069 -179.272 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 74.6 t -63.19 -35.78 73.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 120.979 -1.076 . . . . 0.0 110.67 -178.782 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 91.0 m-20 -52.58 -33.79 47.62 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 120.984 -1.073 . . . . 0.0 108.24 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 33' ' ' ASN . . . . . 0.445 ' HB3' HG23 ' A' ' 35' ' ' VAL . 97.2 m-20 -71.15 -34.66 71.2 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.614 -0.679 . . . . 0.0 110.047 179.516 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 84.09 5.54 87.43 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 108.99 -1.644 . . . . 0.0 108.99 -179.385 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 35' ' ' VAL . . . . . 0.445 HG23 ' HB3' ' A' ' 33' ' ' ASN . 70.4 t -60.55 -33.86 56.15 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 O-C-N 121.407 -1.055 . . . . 0.0 108.634 179.557 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 36' ' ' ILE . . . . . 0.905 HD11 HD13 ' A' ' 30' ' ' LEU . 95.0 mt -84.32 124.12 39.54 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.398 0 O-C-N 121.471 -0.768 . . . . 0.0 109.63 179.842 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 37' ' ' ASP . . . . . 0.556 ' CG ' ' H ' ' A' ' 38' ' ' ALA . 48.5 t0 -127.51 -159.53 0.94 Allowed 'General case' 0 C--N 1.301 -1.515 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 179.56 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 38' ' ' ALA . . . . . 0.556 ' H ' ' CG ' ' A' ' 37' ' ' ASP . . . -66.26 -55.07 17.93 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.848 -1.158 . . . . 0.0 108.681 179.792 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 36.5 mt -71.3 -34.37 70.55 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 107.412 -1.329 . . . . 0.0 107.412 178.237 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 40' ' ' GLY . . . . . 0.55 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.53 -40.29 96.08 Favored Glycine 0 N--CA 1.482 1.735 0 N-CA-C 108.783 -1.727 . . . . 0.0 108.783 179.256 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 41' ' ' LEU . . . . . 0.407 ' O ' HD12 ' A' ' 45' ' ' ILE . 4.5 tt -65.44 -45.49 83.63 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.528 -0.984 . . . . 0.0 109.326 179.225 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 17.1 tp -59.51 -44.75 93.05 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.415 -0.803 . . . . 0.0 109.811 -179.829 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 32.0 mttp -61.74 -34.74 76.37 Favored 'General case' 0 C--N 1.298 -1.664 0 O-C-N 120.973 -1.079 . . . . 0.0 109.583 -179.875 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 44' ' ' VAL . . . . . 0.55 HG23 ' O ' ' A' ' 40' ' ' GLY . 53.6 t -62.29 -50.23 80.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.328 -0.858 . . . . 0.0 110.296 -179.439 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 45' ' ' ILE . . . . . 0.497 ' CG1' HD12 ' A' ' 61' ' ' LEU . 3.5 mp -68.15 -32.66 56.91 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.216 -0.927 . . . . 0.0 110.934 -179.607 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.27 -49.85 62.69 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 120.971 -1.08 . . . . 0.0 111.757 -177.909 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 47' ' ' TRP . . . . . 0.669 ' CE2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -80.84 -43.51 19.88 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.677 -1.265 . . . . 0.0 110.089 -178.984 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 48' ' ' LEU . . . . . 0.4 ' N ' ' CG ' ' A' ' 47' ' ' TRP . 28.1 tp -58.93 -41.46 87.38 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.25 -0.906 . . . . 0.0 110.082 -179.085 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.436 ' CG ' ' N ' ' A' ' 50' ' ' ASP . 16.9 pt-20 -73.14 -37.7 66.52 Favored 'General case' 0 C--N 1.303 -1.427 0 O-C-N 121.082 -1.012 . . . . 0.0 109.589 -179.859 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 50' ' ' ASP . . . . . 0.436 ' N ' ' CG ' ' A' ' 49' ' ' GLU . 22.1 t70 -58.73 -38.16 77.77 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.406 -0.809 . . . . 0.0 110.618 -179.462 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 51' ' ' ARG . . . . . 0.546 ' CZ ' HG11 ' A' ' 6' ' ' VAL . 71.1 mtp180 -61.07 -38.66 86.99 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.156 -0.965 . . . . 0.0 111.434 -178.808 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 52' ' ' PHE . . . . . 0.764 ' CE1' HG11 ' A' ' 76' ' ' VAL . 75.0 m-85 -97.24 -7.42 32.31 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 120.872 -1.143 . . . . 0.0 110.582 -179.075 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 72.81 30.73 63.27 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.207 -1.557 . . . . 0.0 109.207 179.307 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 30.3 pt -106.81 153.4 8.03 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.354 0 O-C-N 121.483 -1.01 . . . . 0.0 109.571 -179.756 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -101.75 137.93 39.4 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.209 -0.932 . . . . 0.0 109.681 -179.562 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 56' ' ' ALA . . . . . 0.495 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -66.63 -26.57 67.13 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.365 -0.835 . . . . 0.0 109.724 179.899 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 57' ' ' ASP . . . . . 0.629 ' OD1' ' N ' ' A' ' 58' ' ' ASP . 54.9 p30 -60.42 -32.06 70.99 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.123 -0.986 . . . . 0.0 110.257 -179.606 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 58' ' ' ASP . . . . . 0.629 ' N ' ' OD1' ' A' ' 57' ' ' ASP . 53.8 t0 -57.95 -39.96 79.39 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.016 -1.052 . . . . 0.0 109.72 -179.908 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 59' ' ' VAL . . . . . 0.495 ' O ' ' O ' ' A' ' 56' ' ' ALA . 13.3 p -137.15 143.47 34.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.301 -0.874 . . . . 0.0 109.497 -179.969 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -90.36 132.63 35.48 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.115 -0.991 . . . . 0.0 109.221 179.847 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 61' ' ' LEU . . . . . 0.497 HD12 ' CG1' ' A' ' 45' ' ' ILE . 57.2 mt -97.74 137.26 36.88 Favored 'General case' 0 C--N 1.305 -1.338 0 O-C-N 121.222 -0.924 . . . . 0.0 109.771 -179.668 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -110.18 156.44 40.14 Favored Pre-proline 0 N--CA 1.488 1.43 0 N-CA-C 108.841 -0.799 . . . . 0.0 108.841 179.391 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 8.0 Cg_endo -53.18 -23.28 22.2 Favored 'Trans proline' 0 C--N 1.302 -1.899 0 C-N-CA 122.388 2.059 . . . . 0.0 111.685 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -70.73 -27.78 64.22 Favored 'General case' 0 C--N 1.305 -1.34 0 O-C-N 121.335 -0.853 . . . . 0.0 109.561 179.686 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 65' ' ' HIS . . . . . 0.566 ' C ' ' CD2' ' A' ' 65' ' ' HIS . 0.4 OUTLIER -65.69 -17.81 64.88 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 121.336 -0.852 . . . . 0.0 109.056 -179.835 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 66' ' ' PHE . . . . . 0.546 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 11.6 m-85 -97.57 15.89 22.0 Favored 'General case' 0 C--N 1.301 -1.538 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 179.704 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 67' ' ' ARG . . . . . 0.594 ' NE ' ' OG ' ' A' ' 71' ' ' SER . 6.7 ptt180 -48.95 -38.58 23.4 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.796 -0.565 . . . . 0.0 110.558 -179.526 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 43.8 t -161.52 158.98 27.29 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.905 -1.122 . . . . 0.0 110.234 -179.803 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 69' ' ' ILE . . . . . 0.464 ' CD1' HD12 ' A' ' 30' ' ' LEU . 31.6 mm -57.97 -44.01 85.97 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.361 0 O-C-N 121.319 -0.863 . . . . 0.0 109.628 179.876 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 70' ' ' ARG . . . . . 0.41 ' HG2' ' H ' ' A' ' 71' ' ' SER . 0.0 OUTLIER -58.65 -39.3 80.18 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.276 -0.89 . . . . 0.0 109.596 -179.57 . . . . . . . . 3 3 . 1 . 020 nuclear build core ' A' A ' 71' ' ' SER . . . . . 0.594 ' OG ' ' NE ' ' A' ' 67' ' ' ARG . 41.6 t -62.59 -41.51 99.0 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.275 -0.891 . . . . 0.0 109.689 179.821 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 80.7 mt -61.01 -47.75 92.19 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 O-C-N 121.306 -0.871 . . . . 0.0 109.911 -179.62 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 32.9 t0 -60.26 -43.14 96.42 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.168 -0.958 . . . . 0.0 109.167 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 74' ' ' ALA . . . . . 0.54 ' O ' ' N ' ' A' ' 78' ' ' GLY . . . -66.84 -38.89 87.27 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.52 -0.738 . . . . 0.0 109.952 -179.829 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 71.6 t80 -61.64 -51.24 69.29 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.174 -0.953 . . . . 0.0 109.271 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 76' ' ' VAL . . . . . 0.764 HG11 ' CE1' ' A' ' 52' ' ' PHE . 77.6 t -69.51 -48.03 68.69 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 O-C-N 121.328 -0.857 . . . . 0.0 109.878 179.972 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 72.3 t -69.55 -47.0 74.23 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.328 0 O-C-N 121.175 -0.953 . . . . 0.0 109.756 -179.887 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 78' ' ' GLY . . . . . 0.54 ' N ' ' O ' ' A' ' 74' ' ' ALA . . . -61.93 -37.88 95.11 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.826 -1.309 . . . . 0.0 109.826 -179.752 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.61 -39.45 84.73 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.183 -1.187 . . . . 0.0 110.025 -179.508 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 80' ' ' THR . . . . . 0.523 HG23 ' O ' ' A' ' 76' ' ' VAL . 50.2 p -81.33 -31.61 33.41 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.286 -0.884 . . . . 0.0 109.594 -179.859 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 81' ' ' THR . . . . . 0.493 ' O ' ' O ' ' A' ' 78' ' ' GLY . 0.4 OUTLIER . . . . . 0 C--N 1.304 -1.389 0 O-C-N 121.403 -0.811 . . . . 0.0 109.908 -179.646 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' -1' ' ' SER . . . . . 0.431 ' O ' ' OE1' ' A' ' 2' ' ' GLN . 13.0 t . . . . . 0 N--CA 1.49 1.531 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 0' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -56.51 -33.09 65.69 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.314 -0.866 . . . . 0.0 109.453 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.5 ' O ' ' OD2' ' A' ' 73' ' ' ASP . 65.6 mtt -59.41 -35.67 74.4 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.225 -0.922 . . . . 0.0 109.933 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.431 ' OE1' ' O ' ' A' ' -1' ' ' SER . 28.5 mm100 55.02 49.49 17.5 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.132 -0.98 . . . . 0.0 109.068 -179.488 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.427 ' CB ' ' O ' ' A' ' 2' ' ' GLN . 8.6 m80 74.23 54.31 0.09 Allowed 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.741 -0.6 . . . . 0.0 109.831 -179.754 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.462 ' HB2' ' HB3' ' A' ' 1' ' ' MET . . . -60.32 -39.97 88.91 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.105 -0.997 . . . . 0.0 109.343 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.2 m -61.76 -36.86 82.27 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.465 -0.772 . . . . 0.0 110.019 -179.754 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 64.3 t -62.35 -44.98 99.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.23 -0.919 . . . . 0.0 109.631 -179.762 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.493 ' O ' HG13 ' A' ' 11' ' ' VAL . 78.3 mt -59.78 -46.96 93.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.326 -0.858 . . . . 0.0 108.799 179.624 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.679 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -62.38 -35.12 78.19 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 108.969 -0.752 . . . . 0.0 108.969 179.328 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 59.6 tt0 -58.76 -41.12 85.81 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.084 -1.01 . . . . 0.0 109.526 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.672 ' CG ' ' CZ2' ' A' ' 47' ' ' TRP . 52.4 m-85 -68.7 -50.16 53.1 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.045 -1.035 . . . . 0.0 110.508 -179.807 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.493 HG13 ' O ' ' A' ' 7' ' ' ILE . 1.0 OUTLIER -66.12 -39.0 83.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.02 -1.05 . . . . 0.0 108.99 -179.498 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.679 HG23 ' O ' ' A' ' 8' ' ' ALA . 74.8 t -63.56 -46.67 94.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.28 -0.888 . . . . 0.0 109.266 179.45 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -71.71 -23.6 61.66 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.23 -0.919 . . . . 0.0 109.825 179.665 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -64.09 -30.3 71.38 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.428 -0.795 . . . . 0.0 110.395 -179.078 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 72.6 t80 -139.0 -40.48 0.48 Allowed 'General case' 0 N--CA 1.494 1.731 0 O-C-N 120.969 -1.082 . . . . 0.0 110.765 -179.413 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.484 HD22 ' CG2' ' A' ' 19' ' ' VAL . 5.0 mt -120.76 80.11 32.17 Favored Pre-proline 0 N--CA 1.491 1.613 0 O-C-N 121.089 -1.007 . . . . 0.0 110.338 -179.18 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 40.7 Cg_endo -75.73 -14.78 19.48 Favored 'Trans proline' 0 C--N 1.309 -1.536 0 C-N-CA 122.439 2.093 . . . . 0.0 112.285 179.437 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -90.03 7.87 35.45 Favored 'General case' 0 N--CA 1.487 1.381 0 O-C-N 121.221 -0.925 . . . . 0.0 109.758 -179.715 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.484 ' CG2' HD22 ' A' ' 16' ' ' LEU . 43.2 t -111.69 134.86 52.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.417 -0.802 . . . . 0.0 109.644 -179.882 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.27 119.62 75.82 Favored Pre-proline 0 N--CA 1.489 1.477 0 O-C-N 121.263 -0.898 . . . . 0.0 109.353 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_exo -51.2 -28.23 25.21 Favored 'Trans proline' 0 N--CA 1.493 1.483 0 C-N-CA 121.75 1.633 . . . . 0.0 112.109 179.531 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.91 -24.69 67.61 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.264 -0.898 . . . . 0.0 109.31 179.881 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.426 ' O ' ' OD1' ' A' ' 23' ' ' ASP . 60.0 t0 -81.87 7.23 13.42 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.319 -0.863 . . . . 0.0 109.789 -179.746 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 10.9 t -103.96 132.89 49.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.03 -1.043 . . . . 0.0 109.393 -179.884 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 87.3 m-20 -89.12 120.49 30.56 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.106 -0.996 . . . . 0.0 109.104 179.469 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 17.8 m -77.34 3.92 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.446 0 O-C-N 121.175 -0.953 . . . . 0.0 109.137 179.687 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -87.26 -13.2 44.44 Favored 'General case' 0 N--CA 1.486 1.354 0 O-C-N 121.351 -0.843 . . . . 0.0 109.149 179.518 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 41.5 tp -95.29 138.67 32.67 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.459 -0.775 . . . . 0.0 109.143 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -58.93 141.43 53.66 Favored 'General case' 0 C--N 1.303 -1.441 0 O-C-N 121.237 -0.914 . . . . 0.0 109.527 -179.605 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.979 HD13 HD11 ' A' ' 36' ' ' ILE . 1.3 tt -67.36 -38.66 85.16 Favored 'General case' 0 C--N 1.299 -1.589 0 O-C-N 121.706 -0.621 . . . . 0.0 110.322 -179.016 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 69.1 t -65.36 -36.25 77.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.103 -0.998 . . . . 0.0 110.497 -178.956 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -52.79 -33.59 49.61 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.455 ' HB3' HG23 ' A' ' 35' ' ' VAL . 82.6 m-20 -71.05 -34.4 71.22 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.675 -0.641 . . . . 0.0 109.805 179.433 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 85.3 6.28 84.33 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 108.984 -1.646 . . . . 0.0 108.984 -179.481 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.455 HG23 ' HB3' ' A' ' 33' ' ' ASN . 79.4 t -61.73 -34.32 61.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.468 -1.019 . . . . 0.0 109.158 179.795 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.979 HD11 HD13 ' A' ' 30' ' ' LEU . 96.6 mt -87.06 117.34 31.05 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.315 -0.865 . . . . 0.0 109.78 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -117.43 -168.2 1.45 Allowed 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 179.703 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -63.2 -54.77 32.37 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.034 -1.041 . . . . 0.0 108.532 179.626 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 41.9 mt -70.96 -34.71 71.7 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 178.063 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.618 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.66 -39.64 95.44 Favored Glycine 0 N--CA 1.481 1.656 0 N-CA-C 108.614 -1.795 . . . . 0.0 108.614 179.105 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.601 HD11 ' CZ ' ' A' ' 66' ' ' PHE . 7.6 tt -65.2 -42.62 93.36 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.579 -0.953 . . . . 0.0 108.993 179.36 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.4 tp -61.42 -46.09 91.6 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.414 -0.804 . . . . 0.0 109.234 179.601 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 24.2 mttp -61.15 -35.99 78.57 Favored 'General case' 0 C--N 1.296 -1.721 0 O-C-N 121.504 -0.748 . . . . 0.0 109.76 -179.654 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.618 HG23 ' O ' ' A' ' 40' ' ' GLY . 60.6 t -61.2 -50.57 79.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.374 -0.829 . . . . 0.0 109.715 -179.663 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.547 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 1.7 mp -69.05 -31.98 52.46 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.535 0 O-C-N 121.454 -0.779 . . . . 0.0 110.721 -179.906 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -63.52 -49.42 73.58 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.108 -0.995 . . . . 0.0 111.369 -178.127 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.672 ' CZ2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -80.87 -45.13 17.32 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 120.723 -1.235 . . . . 0.0 109.876 -179.544 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.887 HD12 HH21 ' A' ' 51' ' ' ARG . 9.7 tp -58.33 -42.51 86.99 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.307 -0.87 . . . . 0.0 109.817 -179.169 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.547 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 1.0 OUTLIER -72.66 -35.61 67.76 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.102 -0.999 . . . . 0.0 109.772 179.999 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.1 t70 -61.13 -39.15 88.95 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.159 -0.963 . . . . 0.0 110.713 -179.456 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.887 HH21 HD12 ' A' ' 48' ' ' LEU . 66.9 mtm180 -61.51 -36.77 81.47 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.167 -0.958 . . . . 0.0 111.429 -178.727 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.531 ' CZ ' ' CG1' ' A' ' 76' ' ' VAL . 94.3 m-85 -97.13 -9.9 27.03 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.774 -1.204 . . . . 0.0 110.334 -179.057 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 71.72 31.28 65.19 Favored Glycine 0 N--CA 1.486 2.01 0 N-CA-C 108.803 -1.719 . . . . 0.0 108.803 179.874 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.48 ' O ' ' OE1' ' A' ' 49' ' ' GLU . 25.3 pt -108.48 153.26 10.14 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 O-C-N 121.593 -0.945 . . . . 0.0 109.83 -179.331 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -101.77 131.34 48.12 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.077 -1.014 . . . . 0.0 109.667 -179.735 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.503 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -67.65 -27.47 66.89 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.276 -0.89 . . . . 0.0 109.506 179.827 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -55.37 -35.09 64.9 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.156 -0.965 . . . . 0.0 109.971 -179.724 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 54.4 t0 -53.19 -36.96 61.51 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.175 -0.953 . . . . 0.0 109.953 -179.592 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.503 ' O ' ' O ' ' A' ' 56' ' ' ALA . 13.7 p -132.84 143.82 38.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.258 -0.901 . . . . 0.0 109.653 -179.859 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -88.79 134.9 33.78 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.158 -0.964 . . . . 0.0 109.331 179.93 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 67.8 mt -97.16 137.49 36.13 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 121.261 -0.899 . . . . 0.0 109.926 -179.616 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -110.37 157.01 39.36 Favored Pre-proline 0 N--CA 1.487 1.406 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 179.478 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 9.3 Cg_endo -54.08 -23.16 27.7 Favored 'Trans proline' 0 C--N 1.301 -1.955 0 C-N-CA 122.392 2.061 . . . . 0.0 111.675 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -70.31 -27.5 64.43 Favored 'General case' 0 N--CA 1.486 1.344 0 O-C-N 121.338 -0.851 . . . . 0.0 109.447 179.653 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 65' ' ' HIS . . . . . 0.524 ' C ' ' CD2' ' A' ' 65' ' ' HIS . 0.9 OUTLIER -65.97 -17.89 64.98 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.357 -0.84 . . . . 0.0 109.036 -179.858 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.601 ' CZ ' HD11 ' A' ' 41' ' ' LEU . 10.5 m-85 -98.12 15.1 25.32 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 179.622 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' ARG . . . . . 0.411 ' HG2' ' H ' ' A' ' 68' ' ' SER . 6.1 ptt180 -49.67 -39.28 35.98 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.77 -0.581 . . . . 0.0 110.225 -179.661 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 68' ' ' SER . . . . . 0.511 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 80.1 p -163.39 159.23 22.12 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 120.903 -1.123 . . . . 0.0 110.101 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.63 ' H ' HD12 ' A' ' 69' ' ' ILE . 3.6 mp -57.74 -34.85 48.86 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 N-CA-C 108.211 -1.033 . . . . 0.0 108.211 178.93 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.403 ' HB3' ' HZ1' ' A' ' 87' ' ' LYS . 21.3 mtp180 -57.31 -40.48 77.99 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 179.904 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 15.2 t -63.47 -38.51 91.41 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.401 -0.812 . . . . 0.0 109.51 179.834 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.416 ' CD1' ' NE2' ' A' ' 65' ' ' HIS . 32.4 mm -58.94 -46.73 91.25 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 O-C-N 121.269 -0.894 . . . . 0.0 109.294 -179.845 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.5 ' OD2' ' O ' ' A' ' 1' ' ' MET . 46.7 t0 -59.43 -43.25 93.13 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.21 -0.932 . . . . 0.0 109.102 179.813 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.44 -40.87 89.71 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.552 -0.717 . . . . 0.0 109.78 -179.858 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 69.2 t80 -62.32 -46.42 88.79 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.35 -0.844 . . . . 0.0 109.524 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.644 HG21 HD11 ' A' ' 48' ' ' LEU . 53.5 t -61.76 -46.24 96.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 O-C-N 121.235 -0.915 . . . . 0.0 109.337 179.884 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.517 ' O ' ' O ' ' A' ' 81' ' ' THR . 53.4 t -68.62 -42.6 83.44 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 O-C-N 121.262 -0.899 . . . . 0.0 109.329 179.53 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.45 -30.27 64.73 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 110.181 -1.168 . . . . 0.0 110.181 -179.903 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -68.37 -41.23 80.91 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.264 -1.139 . . . . 0.0 111.135 -178.739 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 27.8 p -101.68 -34.59 9.41 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.971 -1.081 . . . . 0.0 110.877 -178.808 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.517 ' O ' ' O ' ' A' ' 77' ' ' VAL . 0.1 OUTLIER -133.21 152.63 79.87 Favored Pre-proline 0 C--N 1.301 -1.5 0 O-C-N 121.311 -0.868 . . . . 0.0 109.834 -179.274 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_exo -45.38 142.9 6.02 Favored 'Trans proline' 0 C--N 1.31 -1.496 0 C-N-CA 121.864 1.71 . . . . 0.0 111.35 179.399 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 14.8 Cg_endo -63.32 145.74 93.08 Favored 'Trans proline' 0 C--N 1.313 -1.34 0 C-N-CA 122.02 1.814 . . . . 0.0 112.622 -179.557 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.477 ' O ' ' C ' ' A' ' 85' ' ' GLU . 44.8 t -103.69 130.01 54.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 179.546 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.477 ' C ' ' O ' ' A' ' 84' ' ' VAL . 96.1 mt-10 36.96 49.63 0.81 Allowed 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.586 -0.697 . . . . 0.0 109.895 179.87 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -53.29 144.58 15.9 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.18 -0.95 . . . . 0.0 109.528 -179.733 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.404 ' HD2' ' HE ' ' A' ' 67' ' ' ARG . 12.4 mttm -58.24 -34.76 70.8 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.246 -0.909 . . . . 0.0 109.446 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.73 ' N ' HD12 ' A' ' 88' ' ' LEU . 6.7 mp -59.83 -35.35 74.55 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.26 -0.9 . . . . 0.0 109.452 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.0 mt-30 . . . . . 0 N--CA 1.49 1.56 0 CA-C-O 117.97 -1.014 . . . . 0.0 109.493 179.906 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' -1' ' ' SER . . . . . . . . . . . . . 1.5 m . . . . . 0 N--CA 1.49 1.573 0 CA-C-O 121.291 0.567 . . . . 0.0 109.474 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 0' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -58.08 144.03 41.5 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.181 -0.95 . . . . 0.0 109.536 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.692 ' HB2' ' HB2' ' A' ' 4' ' ' ALA . 59.8 mtt -91.98 63.01 4.38 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.301 -0.874 . . . . 0.0 109.17 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.514 ' C ' ' CG ' ' A' ' 3' ' ' HIS . 95.0 mm-40 59.42 53.1 5.38 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.608 -0.683 . . . . 0.0 109.541 -179.838 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.514 ' CG ' ' C ' ' A' ' 2' ' ' GLN . 5.5 m80 77.85 45.27 0.07 Allowed 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.701 -0.624 . . . . 0.0 109.639 -179.899 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.692 ' HB2' ' HB2' ' A' ' 1' ' ' MET . . . -61.19 -40.08 92.6 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.245 -0.909 . . . . 0.0 109.368 179.852 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.1 p -63.24 -34.05 76.83 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.269 -0.894 . . . . 0.0 109.658 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.664 HG11 ' NH2' ' A' ' 51' ' ' ARG . 55.4 t -62.22 -44.82 99.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.149 -0.969 . . . . 0.0 109.418 179.8 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 77.0 mt -60.13 -41.07 85.29 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 O-C-N 121.371 -0.831 . . . . 0.0 108.934 179.47 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.471 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -60.93 -38.87 87.3 Favored 'General case' 0 C--N 1.305 -1.36 0 O-C-N 121.561 -0.712 . . . . 0.0 109.543 -179.912 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 50.3 mt-30 -63.63 -40.8 97.8 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.135 -0.978 . . . . 0.0 110.092 -179.833 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.694 ' CG ' ' CE2' ' A' ' 47' ' ' TRP . 33.7 m-85 -62.05 -50.12 73.25 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.002 -1.062 . . . . 0.0 110.628 -179.357 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.467 HG23 ' N ' ' A' ' 12' ' ' VAL . 30.0 m -66.43 -41.74 89.22 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 O-C-N 121.006 -1.059 . . . . 0.0 109.18 -179.874 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.471 HG23 ' O ' ' A' ' 8' ' ' ALA . 77.0 t -64.02 -45.17 97.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.219 -0.926 . . . . 0.0 109.49 179.436 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -72.25 -23.43 61.21 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.22 -0.925 . . . . 0.0 110.341 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -64.02 -30.02 71.13 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.333 -0.854 . . . . 0.0 110.466 -178.944 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 71.3 t80 -138.31 -42.29 0.51 Allowed 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.012 -1.055 . . . . 0.0 110.887 -179.391 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.513 HD22 ' CG2' ' A' ' 19' ' ' VAL . 5.2 mt -120.03 80.2 26.39 Favored Pre-proline 0 N--CA 1.493 1.677 0 O-C-N 121.095 -1.003 . . . . 0.0 110.397 -179.119 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -74.77 -14.5 21.71 Favored 'Trans proline' 0 C--N 1.309 -1.511 0 C-N-CA 122.337 2.024 . . . . 0.0 112.319 179.463 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -91.59 8.87 34.63 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.22 -0.925 . . . . 0.0 109.954 -179.666 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.513 ' CG2' HD22 ' A' ' 16' ' ' LEU . 48.8 t -110.87 135.55 49.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.281 -0.887 . . . . 0.0 109.742 -179.815 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.67 119.21 73.99 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.298 -0.877 . . . . 0.0 109.305 179.86 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_exo -51.36 -27.23 23.23 Favored 'Trans proline' 0 N--CA 1.494 1.507 0 C-N-CA 121.781 1.654 . . . . 0.0 112.01 179.676 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.8 -25.24 67.83 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.259 -0.901 . . . . 0.0 109.253 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.411 ' O ' ' OD1' ' A' ' 23' ' ' ASP . 58.6 t0 -81.8 7.35 12.92 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.362 -0.837 . . . . 0.0 109.693 -179.863 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 11.8 t -101.89 133.11 46.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.192 -0.943 . . . . 0.0 109.303 -179.851 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 86.9 m-20 -88.34 120.68 29.94 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.148 -0.97 . . . . 0.0 109.131 179.385 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 29.9 m -71.39 4.47 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 O-C-N 121.122 -0.987 . . . . 0.0 109.107 179.651 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -95.38 0.21 53.26 Favored 'General case' 0 N--CA 1.485 1.32 0 O-C-N 121.397 -0.814 . . . . 0.0 109.094 179.549 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 46.0 tp -100.68 132.97 45.8 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.409 -0.807 . . . . 0.0 109.331 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.7 m-20 -68.78 138.06 54.51 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.285 -0.885 . . . . 0.0 109.822 -179.549 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.577 HD11 HG13 ' A' ' 69' ' ' ILE . 90.5 mt -65.5 -38.88 90.99 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.365 -0.834 . . . . 0.0 110.817 -179.899 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 75.6 t -66.08 -38.6 82.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 120.972 -1.08 . . . . 0.0 110.671 -178.737 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -52.91 -34.02 53.1 Favored 'General case' 0 N--CA 1.489 1.475 0 N-CA-C 108.122 -1.066 . . . . 0.0 108.122 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.539 ' HB3' HG23 ' A' ' 35' ' ' VAL . 97.4 m-20 -71.05 -34.65 71.44 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.643 -0.661 . . . . 0.0 109.927 179.513 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 82.03 4.06 90.38 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 108.754 -1.738 . . . . 0.0 108.754 -179.205 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.539 HG23 ' HB3' ' A' ' 33' ' ' ASN . 70.2 t -62.7 -32.9 57.17 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 O-C-N 121.526 -0.984 . . . . 0.0 108.894 179.612 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 81.1 mt -88.57 121.24 38.58 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.368 0 O-C-N 121.318 -0.864 . . . . 0.0 110.041 -179.838 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -115.82 -159.68 0.72 Allowed 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 108.966 -0.753 . . . . 0.0 108.966 179.697 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -67.77 -54.27 20.55 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.134 -0.979 . . . . 0.0 108.959 179.691 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 43.1 mt -67.08 -32.57 73.84 Favored 'General case' 0 C--N 1.303 -1.414 0 N-CA-C 107.189 -1.412 . . . . 0.0 107.189 178.447 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.486 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -58.74 -40.4 94.89 Favored Glycine 0 N--CA 1.48 1.611 0 N-CA-C 108.465 -1.854 . . . . 0.0 108.465 179.308 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.0 tt -65.45 -42.21 92.61 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 121.578 -0.954 . . . . 0.0 108.916 178.982 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.5 tp -60.47 -45.83 92.31 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.429 -0.795 . . . . 0.0 109.173 179.605 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 59.9 mttp -59.69 -35.59 74.8 Favored 'General case' 0 C--N 1.297 -1.712 0 O-C-N 121.547 -0.721 . . . . 0.0 109.618 -179.727 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.486 HG23 ' O ' ' A' ' 40' ' ' GLY . 54.7 t -61.68 -49.71 83.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.357 -0.839 . . . . 0.0 110.071 -179.519 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.531 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 3.3 mp -68.0 -31.83 53.6 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 O-C-N 121.281 -0.887 . . . . 0.0 110.811 -179.659 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.99 -49.99 65.87 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 120.799 -1.188 . . . . 0.0 111.359 -178.2 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.694 ' CE2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -81.17 -44.94 17.13 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.774 -1.204 . . . . 0.0 110.046 -179.385 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.82 HD11 HG21 ' A' ' 76' ' ' VAL . 22.4 tp -58.58 -42.07 87.16 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 121.326 -0.859 . . . . 0.0 110.095 -178.858 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.531 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 2.3 pp20? -72.59 -36.54 68.18 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.195 -0.941 . . . . 0.0 109.777 -179.976 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 50' ' ' ASP . . . . . 0.402 ' N ' ' CG ' ' A' ' 49' ' ' GLU . 55.9 t0 -60.3 -38.27 83.15 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.24 -0.913 . . . . 0.0 110.713 -179.463 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.664 ' NH2' HG11 ' A' ' 6' ' ' VAL . 77.0 mtp180 -61.81 -38.64 88.87 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.195 -0.941 . . . . 0.0 111.738 -178.581 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.553 ' CE1' HG11 ' A' ' 76' ' ' VAL . 87.7 m-85 -97.93 -9.39 26.32 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.803 -1.186 . . . . 0.0 110.482 -178.951 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 70.92 31.44 67.05 Favored Glycine 0 N--CA 1.487 2.092 0 N-CA-C 108.703 -1.759 . . . . 0.0 108.703 179.824 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.485 ' O ' ' OE1' ' A' ' 49' ' ' GLU . 26.4 pt -107.24 153.27 8.52 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.367 0 O-C-N 121.703 -0.881 . . . . 0.0 109.787 -179.392 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -99.23 134.04 42.66 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.12 -0.988 . . . . 0.0 109.806 -179.551 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.511 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -68.21 -22.99 64.77 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.312 -0.867 . . . . 0.0 109.533 179.725 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -54.71 -35.65 63.86 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.266 -0.896 . . . . 0.0 109.961 -179.626 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -55.66 -39.53 71.05 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.202 -0.936 . . . . 0.0 110.019 -179.65 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.511 ' O ' ' O ' ' A' ' 56' ' ' ALA . 13.9 p -136.3 142.31 38.9 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.291 -0.881 . . . . 0.0 109.685 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -91.92 133.39 35.73 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.029 -1.044 . . . . 0.0 109.275 179.736 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.475 HD12 ' CG1' ' A' ' 45' ' ' ILE . 32.5 mt -97.92 138.75 34.78 Favored 'General case' 0 C--N 1.305 -1.363 0 O-C-N 121.332 -0.855 . . . . 0.0 109.661 -179.613 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -110.09 157.11 38.81 Favored Pre-proline 0 N--CA 1.487 1.42 0 N-CA-C 108.952 -0.758 . . . . 0.0 108.952 179.518 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_endo -54.01 -24.52 32.65 Favored 'Trans proline' 0 C--N 1.302 -1.91 0 C-N-CA 122.536 2.157 . . . . 0.0 111.567 179.891 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -71.23 -27.78 63.72 Favored 'General case' 0 C--N 1.306 -1.307 0 O-C-N 121.365 -0.834 . . . . 0.0 109.531 179.825 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 65' ' ' HIS . . . . . 0.525 ' NE2' ' CB ' ' A' ' 75' ' ' PHE . 8.2 t-80 -65.76 -20.3 66.21 Favored 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.185 -0.947 . . . . 0.0 108.975 -179.738 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.502 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 21.9 m-85 -91.36 16.54 9.93 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 179.901 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 67' ' ' ARG . . . . . 0.454 HH21 ' HB3' ' A' ' 87' ' ' LYS . 7.7 ptt180 -50.07 -37.24 32.62 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.808 -0.557 . . . . 0.0 110.254 -179.753 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 19.0 t -163.15 157.65 20.81 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.977 -1.077 . . . . 0.0 110.29 -179.626 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.665 ' H ' HD12 ' A' ' 69' ' ' ILE . 2.0 mp -58.03 -39.31 71.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.424 -0.797 . . . . 0.0 109.266 179.862 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 7.6 ptm180 -58.03 -40.68 81.49 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.574 -0.704 . . . . 0.0 109.452 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.453 ' CB ' ' NE ' ' A' ' 67' ' ' ARG . 83.5 p -65.14 -37.16 86.54 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.325 -0.859 . . . . 0.0 109.722 179.914 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.455 ' O ' HG23 ' A' ' 76' ' ' VAL . 75.3 mt -64.86 -44.94 96.24 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.268 0 O-C-N 121.245 -0.91 . . . . 0.0 109.809 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.427 ' OD2' ' O ' ' A' ' 1' ' ' MET . 40.4 t0 -59.75 -41.7 91.57 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.291 -0.88 . . . . 0.0 109.396 -179.828 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.75 -43.86 83.02 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.405 -0.81 . . . . 0.0 110.084 -179.777 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' PHE . . . . . 0.525 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 56.8 t80 -62.1 -46.52 88.69 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.338 -0.851 . . . . 0.0 109.537 -179.764 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.82 HG21 HD11 ' A' ' 48' ' ' LEU . 99.2 t -61.67 -44.43 98.69 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.394 0 O-C-N 121.269 -0.895 . . . . 0.0 109.027 179.92 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.522 ' O ' ' O ' ' A' ' 81' ' ' THR . 53.3 t -66.64 -43.22 90.48 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 121.374 -0.829 . . . . 0.0 109.255 179.554 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.81 -23.15 49.82 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.771 -1.332 . . . . 0.0 109.771 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.05 -28.88 68.57 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.259 -1.142 . . . . 0.0 110.353 -179.475 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 9.8 p -129.65 -32.73 1.9 Allowed 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.128 -0.983 . . . . 0.0 110.752 -179.274 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.522 ' O ' ' O ' ' A' ' 77' ' ' VAL . 0.1 OUTLIER -132.37 153.13 81.11 Favored Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.188 -0.945 . . . . 0.0 109.682 -179.396 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 13.0 Cg_endo -59.51 134.18 56.57 Favored 'Trans proline' 0 C--N 1.308 -1.573 0 C-N-CA 122.22 1.947 . . . . 0.0 111.606 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_endo -71.15 152.53 62.15 Favored 'Trans proline' 0 N--CA 1.49 1.317 0 C-N-CA 122.134 1.889 . . . . 0.0 112.58 -179.606 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.453 ' O ' ' C ' ' A' ' 85' ' ' GLU . 28.8 m -102.64 134.27 44.0 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.471 -0.768 . . . . 0.0 108.959 179.516 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.453 ' C ' ' O ' ' A' ' 84' ' ' VAL . 84.0 tt0 40.66 67.8 0.48 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.412 -0.805 . . . . 0.0 109.441 -179.739 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -52.51 148.09 7.43 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.185 -0.947 . . . . 0.0 109.599 -179.793 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.454 ' HB3' HH21 ' A' ' 67' ' ' ARG . 20.5 tttm -56.95 -36.4 70.21 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.332 -0.855 . . . . 0.0 109.427 -179.845 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 55.4 mt -90.95 142.42 27.8 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.224 -0.923 . . . . 0.0 109.448 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 63.6 tt0 . . . . . 0 N--CA 1.49 1.555 0 CA-C-O 117.954 -1.022 . . . . 0.0 109.489 179.996 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' -1' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.49 1.53 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 0' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -57.46 143.63 39.72 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.335 -0.853 . . . . 0.0 109.327 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.413 ' HB2' ' HB2' ' A' ' 4' ' ' ALA . 68.9 mtp -110.35 -121.63 0.27 Allowed 'General case' 0 N--CA 1.486 1.363 0 O-C-N 121.306 -0.871 . . . . 0.0 108.962 -179.817 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.452 ' C ' ' N ' ' A' ' 4' ' ' ALA . 94.2 mm-40 -116.87 124.18 48.87 Favored 'General case' 0 C--N 1.3 -1.557 0 N-CA-C 107.67 -1.233 . . . . 0.0 107.67 178.752 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.43 ' C ' ' O ' ' A' ' 2' ' ' GLN . 46.0 m80 46.93 22.39 0.2 Allowed 'General case' 0 C--N 1.299 -1.601 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 -178.919 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.452 ' N ' ' C ' ' A' ' 2' ' ' GLN . . . -55.81 -39.77 71.81 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.392 -0.817 . . . . 0.0 109.562 -179.433 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.1 m -60.75 -36.33 78.63 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.213 -0.93 . . . . 0.0 109.553 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 75.8 t -63.3 -45.67 97.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.21 -0.932 . . . . 0.0 109.45 -179.895 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.523 ' O ' HG13 ' A' ' 11' ' ' VAL . 78.8 mt -59.69 -45.6 94.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.373 -0.829 . . . . 0.0 108.799 179.622 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.588 ' O ' HG22 ' A' ' 12' ' ' VAL . . . -62.21 -35.27 78.38 Favored 'General case' 0 C--N 1.304 -1.374 0 N-CA-C 108.763 -0.828 . . . . 0.0 108.763 179.5 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 32.5 tt0 -59.97 -38.37 82.32 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.259 -0.901 . . . . 0.0 109.472 179.733 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.65 ' CG ' ' CZ2' ' A' ' 47' ' ' TRP . 44.0 m-85 -70.17 -47.74 60.31 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.971 -1.081 . . . . 0.0 111.205 -179.551 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.523 HG13 ' O ' ' A' ' 7' ' ' ILE . 0.9 OUTLIER -61.64 -46.88 95.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 120.881 -1.137 . . . . 0.0 110.312 -178.143 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.592 ' O ' ' N ' ' A' ' 16' ' ' LEU . 35.5 m -64.75 -46.0 93.46 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.394 0 O-C-N 120.799 -1.188 . . . . 0.0 109.552 179.758 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.536 ' N ' HG23 ' A' ' 12' ' ' VAL . 96.9 mt-10 -64.55 -26.96 68.64 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 120.813 -1.179 . . . . 0.0 109.737 179.798 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -64.43 -31.47 72.69 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.445 -0.785 . . . . 0.0 110.14 -179.479 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 86.6 t80 -142.84 -33.31 0.46 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.981 -1.074 . . . . 0.0 110.794 -179.436 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.592 ' N ' ' O ' ' A' ' 12' ' ' VAL . 3.4 mt -121.95 79.8 41.95 Favored Pre-proline 0 N--CA 1.492 1.66 0 O-C-N 121.07 -1.019 . . . . 0.0 109.976 -179.32 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -76.07 -18.54 16.42 Favored 'Trans proline' 0 C--N 1.309 -1.507 0 C-N-CA 122.537 2.158 . . . . 0.0 112.873 -179.756 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.442 ' C ' ' OD1' ' A' ' 18' ' ' ASP . 50.4 p30 -89.43 12.86 15.18 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.031 -1.043 . . . . 0.0 110.131 -179.565 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 84.1 t -106.79 134.41 48.52 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.187 -0.946 . . . . 0.0 109.574 179.669 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.06 118.45 65.74 Favored Pre-proline 0 N--CA 1.488 1.443 0 O-C-N 121.323 -0.861 . . . . 0.0 108.918 179.634 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -51.31 -36.41 57.2 Favored 'Trans proline' 0 N--CA 1.492 1.389 0 C-N-CA 121.571 1.514 . . . . 0.0 111.912 179.966 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -68.58 -18.56 64.36 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.246 -0.909 . . . . 0.0 108.885 179.386 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.451 ' O ' ' OD1' ' A' ' 23' ' ' ASP . 60.4 t0 -81.97 7.11 13.94 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.479 -0.763 . . . . 0.0 109.91 -179.644 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 15.1 t -104.56 131.66 53.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.167 -0.958 . . . . 0.0 109.433 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 62.4 t0 -88.44 119.68 29.11 Favored 'General case' 0 C--N 1.303 -1.445 0 O-C-N 121.213 -0.929 . . . . 0.0 108.689 179.256 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.2 m -75.29 3.18 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 O-C-N 121.138 -0.977 . . . . 0.0 109.484 -179.886 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -85.49 -19.18 31.6 Favored 'General case' 0 N--CA 1.487 1.375 0 O-C-N 121.137 -0.977 . . . . 0.0 109.116 179.368 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 48.7 tp -88.84 134.04 34.07 Favored 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 108.541 -0.911 . . . . 0.0 108.541 179.552 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 89.1 m-20 -60.37 135.12 57.64 Favored 'General case' 0 C--N 1.301 -1.539 0 C-N-CA 119.185 -1.006 . . . . 0.0 109.2 -179.423 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 1.043 HD23 HD11 ' A' ' 36' ' ' ILE . 39.0 tp -62.59 -36.42 82.68 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.509 -0.745 . . . . 0.0 110.257 -179.322 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 69.2 t -64.22 -35.76 74.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.047 -1.033 . . . . 0.0 110.466 -179.384 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -52.62 -33.72 47.88 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.446 ' HB3' HG23 ' A' ' 35' ' ' VAL . 97.1 m-20 -70.82 -34.55 71.83 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.606 -0.684 . . . . 0.0 110.001 179.468 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 85.71 5.16 84.53 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 108.858 -1.697 . . . . 0.0 108.858 -179.324 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.446 HG23 ' HB3' ' A' ' 33' ' ' ASN . 73.6 t -61.7 -33.05 55.72 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 121.554 -0.968 . . . . 0.0 108.979 179.678 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 1.043 HD11 HD23 ' A' ' 30' ' ' LEU . 80.2 mt -83.68 114.47 24.33 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.411 0 O-C-N 121.339 -0.851 . . . . 0.0 109.723 -179.728 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -112.6 -178.82 3.49 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 179.542 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -58.82 -52.3 66.29 Favored 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 108.245 -1.021 . . . . 0.0 108.245 179.7 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 42.3 mt -70.28 -32.65 70.53 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 106.849 -1.538 . . . . 0.0 106.849 177.922 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.606 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.27 -41.01 96.61 Favored Glycine 0 N--CA 1.481 1.67 0 N-CA-C 108.525 -1.83 . . . . 0.0 108.525 179.14 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 2.9 tt -64.87 -44.49 89.52 Favored 'General case' 0 C--N 1.305 -1.35 0 O-C-N 121.636 -0.92 . . . . 0.0 109.212 179.096 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 16.7 tp -59.55 -44.78 93.14 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.353 -0.842 . . . . 0.0 109.578 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 31.7 mttp -62.05 -34.81 76.93 Favored 'General case' 0 C--N 1.298 -1.669 0 O-C-N 121.076 -1.015 . . . . 0.0 109.541 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.606 HG23 ' O ' ' A' ' 40' ' ' GLY . 69.4 t -61.2 -48.63 88.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.387 -0.821 . . . . 0.0 109.993 -179.528 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.541 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 3.0 mp -67.84 -32.44 56.51 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.515 0 O-C-N 121.405 -0.81 . . . . 0.0 110.948 -179.677 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.43 -50.36 63.64 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 120.982 -1.074 . . . . 0.0 111.373 -178.112 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.65 ' CZ2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -81.18 -44.62 17.57 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 120.708 -1.245 . . . . 0.0 109.853 -179.502 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.5 ' N ' ' CG ' ' A' ' 47' ' ' TRP . 38.9 tp -58.55 -42.26 87.45 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.332 -0.855 . . . . 0.0 109.958 -179.022 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.541 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 1.2 pp20? -72.63 -35.85 67.91 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.0 -1.063 . . . . 0.0 109.635 179.887 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.1 t0 -60.2 -38.25 82.73 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.237 -0.914 . . . . 0.0 110.288 -179.77 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.467 ' HD2' ' HE1' ' A' ' 47' ' ' TRP . 71.9 mtp85 -61.19 -38.12 85.4 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.244 -0.91 . . . . 0.0 111.16 -178.956 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.634 ' CE2' HG11 ' A' ' 76' ' ' VAL . 86.6 m-85 -99.53 -10.36 22.18 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 120.859 -1.151 . . . . 0.0 110.031 -179.388 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 69.98 33.49 70.14 Favored Glycine 0 N--CA 1.486 2.027 0 N-CA-C 108.558 -1.817 . . . . 0.0 108.558 179.856 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 38.5 pt -103.08 149.06 7.44 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 O-C-N 121.535 -0.979 . . . . 0.0 109.994 -179.239 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -94.2 120.1 33.96 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.3 -0.875 . . . . 0.0 109.459 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.492 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -66.65 -28.99 68.91 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.403 -0.81 . . . . 0.0 109.495 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 54.6 t0 -56.41 -35.03 67.34 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.387 -0.821 . . . . 0.0 110.249 -179.453 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -53.75 -39.11 65.07 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.055 -1.028 . . . . 0.0 109.65 -179.582 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.492 ' O ' ' O ' ' A' ' 56' ' ' ALA . 46.5 t -127.46 136.57 60.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.521 -0.737 . . . . 0.0 109.544 179.851 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -85.5 128.43 34.74 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.119 -0.988 . . . . 0.0 108.765 179.547 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 54.8 mt -98.46 141.21 31.61 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.142 -0.974 . . . . 0.0 109.997 -179.158 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -105.55 151.15 39.72 Favored Pre-proline 0 C--N 1.305 -1.361 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 179.403 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -53.67 -21.87 20.89 Favored 'Trans proline' 0 C--N 1.306 -1.659 0 C-N-CA 122.227 1.951 . . . . 0.0 111.998 -179.54 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -70.07 -28.27 65.29 Favored 'General case' 0 N--CA 1.486 1.351 0 O-C-N 121.265 -0.897 . . . . 0.0 109.586 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 65' ' ' HIS . . . . . 0.586 ' CD2' ' O ' ' A' ' 65' ' ' HIS . 6.5 t-160 -65.72 -20.93 66.46 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.259 -0.901 . . . . 0.0 109.277 -179.713 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.552 ' HB3' HD13 ' A' ' 36' ' ' ILE . 7.8 m-85 -96.51 15.99 19.96 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.525 -0.734 . . . . 0.0 109.078 -179.65 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 67' ' ' ARG . . . . . 0.682 ' NH2' ' NZ ' ' A' ' 87' ' ' LYS . 1.3 ptt85 -54.36 -35.93 63.3 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.645 -0.659 . . . . 0.0 110.243 -179.765 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 68' ' ' SER . . . . . 0.555 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 90.4 p -157.54 160.38 38.13 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 120.912 -1.117 . . . . 0.0 110.287 -179.95 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.605 ' H ' HD12 ' A' ' 69' ' ' ILE . 3.1 mp -59.14 -34.03 52.26 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 179.007 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 57.6 mtp85 -56.95 -42.9 80.92 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.707 -0.621 . . . . 0.0 109.948 -179.266 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 78.8 p -68.71 -35.82 77.65 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.298 -0.876 . . . . 0.0 110.115 -179.601 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.434 ' O ' HG23 ' A' ' 76' ' ' VAL . 56.3 mt -65.93 -48.51 81.65 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 O-C-N 121.216 -0.928 . . . . 0.0 110.122 -179.38 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 43.9 t0 -60.17 -43.16 96.03 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.18 -0.95 . . . . 0.0 109.49 -179.757 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.95 -43.63 82.66 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.494 -0.754 . . . . 0.0 110.251 -179.579 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' PHE . . . . . 0.553 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 70.4 t80 -62.51 -45.29 93.66 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.263 -0.898 . . . . 0.0 109.697 -179.641 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.634 HG11 ' CE2' ' A' ' 52' ' ' PHE . 95.9 t -64.84 -47.06 90.0 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.361 0 O-C-N 121.206 -0.934 . . . . 0.0 109.665 -179.945 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 54.9 t -69.53 -45.98 76.93 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.329 0 O-C-N 121.1 -1.0 . . . . 0.0 109.731 179.857 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.48 ' O ' ' O ' ' A' ' 81' ' ' THR . . . -63.9 -30.73 78.55 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 110.307 -1.117 . . . . 0.0 110.307 -179.633 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -66.81 -39.53 87.74 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.137 -1.214 . . . . 0.0 110.516 -179.019 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 65.2 p -84.18 -28.81 27.09 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.036 -1.04 . . . . 0.0 109.778 -179.727 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.48 ' O ' ' O ' ' A' ' 78' ' ' GLY . 0.3 OUTLIER -133.27 153.9 80.84 Favored Pre-proline 0 C--N 1.302 -1.471 0 O-C-N 121.478 -0.764 . . . . 0.0 109.737 -179.546 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -60.5 110.73 0.85 Allowed 'Trans proline' 0 C--N 1.308 -1.569 0 C-N-CA 122.328 2.018 . . . . 0.0 111.278 179.564 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -76.13 152.12 35.29 Favored 'Trans proline' 0 C--N 1.313 -1.303 0 C-N-CA 122.074 1.849 . . . . 0.0 113.139 -179.011 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.452 ' O ' ' C ' ' A' ' 85' ' ' GLU . 47.0 t -102.88 133.99 45.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 N-CA-C 108.478 -0.934 . . . . 0.0 108.478 179.137 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.452 ' C ' ' O ' ' A' ' 84' ' ' VAL . 96.1 mt-10 43.3 70.2 0.33 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.105 -0.997 . . . . 0.0 108.845 -179.315 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -50.36 148.37 3.7 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.359 -0.838 . . . . 0.0 109.842 -179.367 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.682 ' NZ ' ' NH2' ' A' ' 67' ' ' ARG . 11.2 tttm -56.71 160.37 3.39 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.356 -0.84 . . . . 0.0 109.155 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 65.8 mt -51.42 -38.02 51.41 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.15 -0.969 . . . . 0.0 109.454 -179.666 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.6 mt-30 . . . . . 0 N--CA 1.49 1.531 0 CA-C-O 117.977 -1.011 . . . . 0.0 109.513 179.914 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' -1' ' ' SER . . . . . . . . . . . . . 1.7 m . . . . . 0 N--CA 1.49 1.574 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 0' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -58.76 145.91 38.8 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.315 -0.866 . . . . 0.0 109.547 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.694 ' HB2' ' HB2' ' A' ' 4' ' ' ALA . 11.7 ptt? -179.19 106.07 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.228 -0.92 . . . . 0.0 109.273 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.584 ' N ' ' OD2' ' A' ' 73' ' ' ASP . 9.6 tp-100 -88.13 127.13 35.42 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.359 -0.838 . . . . 0.0 109.502 -179.874 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 4.8 m-70 59.59 36.55 22.74 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.491 -0.756 . . . . 0.0 109.926 179.813 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.694 ' HB2' ' HB2' ' A' ' 1' ' ' MET . . . -61.99 -33.05 73.61 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.141 -0.974 . . . . 0.0 109.547 179.856 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.3 t -57.86 -37.56 74.13 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.284 -0.885 . . . . 0.0 109.879 -179.497 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 77.2 t -63.52 -45.41 97.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.169 -0.957 . . . . 0.0 109.514 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 77.7 mt -60.06 -42.72 90.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.405 -0.809 . . . . 0.0 109.096 179.727 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.58 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -60.89 -35.83 77.65 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.54 -0.725 . . . . 0.0 109.224 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 30.9 tt0 -64.62 -41.77 95.97 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.234 -0.916 . . . . 0.0 110.191 -179.839 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.679 ' CG ' ' CZ2' ' A' ' 47' ' ' TRP . 37.4 m-85 -64.28 -50.62 67.16 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.975 -1.078 . . . . 0.0 110.719 -179.371 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.422 HG13 ' N ' ' A' ' 12' ' ' VAL . 4.5 p -63.57 -41.0 91.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.047 -1.033 . . . . 0.0 109.383 -179.575 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.58 HG23 ' O ' ' A' ' 8' ' ' ALA . 70.5 t -63.31 -46.34 95.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.121 -0.987 . . . . 0.0 109.339 179.558 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -71.13 -26.09 62.86 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.25 -0.906 . . . . 0.0 109.846 179.715 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -64.45 -30.61 71.65 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.46 -0.775 . . . . 0.0 110.664 -179.029 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 72.9 t80 -135.82 -42.9 0.67 Allowed 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.016 -1.053 . . . . 0.0 110.826 -179.084 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.483 HD22 ' CG2' ' A' ' 19' ' ' VAL . 4.2 mt -119.49 80.09 21.96 Favored Pre-proline 0 N--CA 1.493 1.723 0 O-C-N 121.088 -1.008 . . . . 0.0 110.377 -179.094 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -75.53 -14.13 20.13 Favored 'Trans proline' 0 C--N 1.309 -1.522 0 C-N-CA 122.292 1.995 . . . . 0.0 112.217 179.404 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.42 ' OD1' ' O ' ' A' ' 18' ' ' ASP . 59.9 t0 -89.55 7.02 38.4 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.274 -0.891 . . . . 0.0 109.683 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.483 ' CG2' HD22 ' A' ' 16' ' ' LEU . 46.1 t -111.76 135.44 51.0 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.432 -0.793 . . . . 0.0 109.651 -179.859 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.468 ' O ' ' OD1' ' A' ' 23' ' ' ASP . . . -73.49 117.88 64.26 Favored Pre-proline 0 N--CA 1.489 1.514 0 O-C-N 121.304 -0.872 . . . . 0.0 109.325 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_exo -51.45 -25.53 19.14 Favored 'Trans proline' 0 N--CA 1.493 1.47 0 C-N-CA 121.858 1.705 . . . . 0.0 112.192 179.568 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.03 -23.67 67.26 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.307 -0.871 . . . . 0.0 109.739 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.468 ' OD1' ' O ' ' A' ' 20' ' ' ALA . 52.5 p30 -84.6 7.75 19.12 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.222 -0.924 . . . . 0.0 110.024 -179.635 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 10.9 t -104.57 131.39 53.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.192 -0.942 . . . . 0.0 109.397 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 87.6 m-20 -89.43 120.5 30.81 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.213 -0.93 . . . . 0.0 109.091 179.369 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.0 m -78.83 3.38 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 O-C-N 121.153 -0.967 . . . . 0.0 109.095 179.53 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 89.8 m-20 -83.5 -20.65 33.56 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 121.291 -0.881 . . . . 0.0 109.135 179.33 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 43.2 tp -88.69 137.9 31.9 Favored 'General case' 0 N--CA 1.487 1.41 0 N-CA-C 108.844 -0.798 . . . . 0.0 108.844 179.798 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 89.1 m-20 -57.33 136.27 56.55 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 121.158 -0.964 . . . . 0.0 109.35 -179.454 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.746 HD12 HG13 ' A' ' 69' ' ' ILE . 1.9 tt -66.0 -37.95 87.22 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.716 -0.615 . . . . 0.0 110.171 -179.179 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 69.9 t -63.14 -35.19 70.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.068 -1.02 . . . . 0.0 110.421 -178.976 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 90.8 m-20 -52.66 -33.89 49.18 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 108.062 -1.088 . . . . 0.0 108.062 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.452 ' HB3' HG23 ' A' ' 35' ' ' VAL . 97.5 m-20 -71.11 -34.62 71.27 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.571 -0.706 . . . . 0.0 109.864 179.488 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 84.4 6.83 85.59 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 108.962 -1.655 . . . . 0.0 108.962 -179.474 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.452 HG23 ' HB3' ' A' ' 33' ' ' ASN . 71.1 t -61.88 -35.03 65.65 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 O-C-N 121.392 -1.064 . . . . 0.0 108.95 179.74 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.699 HD11 HD13 ' A' ' 30' ' ' LEU . 99.1 mt -80.17 111.94 17.57 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.318 -0.864 . . . . 0.0 109.807 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -113.02 -166.02 1.04 Allowed 'General case' 0 C--N 1.302 -1.458 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 179.777 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -65.18 -54.38 30.55 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.146 -0.971 . . . . 0.0 108.71 179.712 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 34.0 mt -70.57 -33.29 70.94 Favored 'General case' 0 C--N 1.302 -1.489 0 N-CA-C 107.213 -1.402 . . . . 0.0 107.213 178.4 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.529 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.4 -41.18 96.89 Favored Glycine 0 N--CA 1.48 1.589 0 N-CA-C 108.61 -1.796 . . . . 0.0 108.61 179.205 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.7 tt -65.68 -41.55 92.29 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.519 -0.989 . . . . 0.0 109.085 179.201 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.5 tp -61.22 -46.03 92.11 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.434 -0.791 . . . . 0.0 109.361 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 63.5 mttp -60.28 -35.91 76.62 Favored 'General case' 0 C--N 1.296 -1.733 0 O-C-N 121.443 -0.786 . . . . 0.0 109.452 -179.708 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.529 HG23 ' O ' ' A' ' 40' ' ' GLY . 63.2 t -62.18 -45.82 97.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.357 -0.839 . . . . 0.0 109.668 -179.916 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.701 HG23 ' HB2' ' A' ' 56' ' ' ALA . 1.5 mp -67.96 -39.44 81.63 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 O-C-N 121.555 -0.716 . . . . 0.0 111.262 -179.375 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.09 -49.92 63.41 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.545 -1.347 . . . . 0.0 112.268 -177.603 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.679 ' CZ2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -77.85 -46.05 22.55 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 120.637 -1.29 . . . . 0.0 110.681 -178.546 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.857 HD12 HH21 ' A' ' 51' ' ' ARG . 8.8 tp -58.65 -44.59 90.16 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.173 -0.955 . . . . 0.0 110.195 -178.825 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 65.4 mm-40 -69.93 -36.21 75.14 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.135 -0.978 . . . . 0.0 109.797 -179.667 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.3 t0 -62.24 -38.43 89.19 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.367 -0.833 . . . . 0.0 111.431 -179.2 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.857 HH21 HD12 ' A' ' 48' ' ' LEU . 66.6 mtm180 -59.34 -38.92 81.58 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.023 -1.048 . . . . 0.0 111.574 -178.392 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.61 ' CE1' ' CG1' ' A' ' 76' ' ' VAL . 48.7 m-85 -90.14 -2.61 58.1 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 120.759 -1.213 . . . . 0.0 110.544 -179.199 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 73.98 29.2 63.19 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 108.797 -1.721 . . . . 0.0 108.797 179.546 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 31.4 pt -113.1 153.47 14.66 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 O-C-N 121.694 -0.886 . . . . 0.0 109.758 -179.397 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -101.83 138.76 38.37 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.255 -0.903 . . . . 0.0 109.426 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.701 ' HB2' HG23 ' A' ' 45' ' ' ILE . . . -64.65 -30.61 71.63 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.298 -0.876 . . . . 0.0 109.681 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 53.8 t0 -55.48 -36.02 66.17 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.132 -0.98 . . . . 0.0 109.827 -179.74 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -57.36 -39.89 76.94 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.199 -0.938 . . . . 0.0 110.169 -179.561 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.506 ' O ' ' O ' ' A' ' 56' ' ' ALA . 13.6 p -136.51 142.15 39.07 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.272 -0.892 . . . . 0.0 109.783 -179.941 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -101.71 137.02 40.57 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.156 -0.965 . . . . 0.0 109.433 179.815 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.492 HD23 ' ND1' ' A' ' 65' ' ' HIS . 5.5 mp -103.27 144.06 31.84 Favored 'General case' 0 C--N 1.305 -1.34 0 O-C-N 121.256 -0.902 . . . . 0.0 109.732 -179.843 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -103.34 153.13 38.7 Favored Pre-proline 0 C--N 1.305 -1.351 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 179.81 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 8.5 Cg_endo -53.75 -24.54 30.78 Favored 'Trans proline' 0 C--N 1.306 -1.665 0 C-N-CA 122.264 1.976 . . . . 0.0 111.82 -179.832 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -70.42 -28.39 65.01 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 121.392 -0.818 . . . . 0.0 109.257 179.69 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' HIS . . . . . 0.524 ' NE2' ' CB ' ' A' ' 75' ' ' PHE . 7.6 t-80 -66.02 -20.04 66.05 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 121.375 -0.828 . . . . 0.0 109.027 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.516 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 15.5 m-85 -91.98 15.1 13.93 Favored 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 67' ' ' ARG . . . . . 0.611 ' NH1' HD11 ' A' ' 88' ' ' LEU . 7.2 ptt180 -48.6 -37.33 17.79 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.7 -0.625 . . . . 0.0 109.866 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 68' ' ' SER . . . . . 0.518 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 92.4 p -159.55 155.86 27.08 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.092 -1.005 . . . . 0.0 109.919 179.811 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.746 HG13 HD12 ' A' ' 30' ' ' LEU . 3.5 mp -58.58 -34.83 52.36 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 179.045 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 58.6 mtp180 -57.44 -43.25 83.73 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.67 -0.644 . . . . 0.0 109.462 -179.76 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.536 ' OG ' ' CZ ' ' A' ' 67' ' ' ARG . 22.7 t -65.54 -39.9 92.27 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.465 -0.772 . . . . 0.0 109.81 179.935 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.401 ' HA ' ' NE2' ' A' ' 65' ' ' HIS . 68.5 mt -61.02 -46.41 96.7 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.313 0 O-C-N 121.313 -0.867 . . . . 0.0 110.109 -179.541 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.584 ' OD2' ' N ' ' A' ' 2' ' ' GLN . 39.4 t0 -60.28 -42.88 96.38 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.176 -0.952 . . . . 0.0 109.364 179.96 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -67.13 -41.94 85.29 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.427 -0.796 . . . . 0.0 110.466 -179.708 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' PHE . . . . . 0.524 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 62.5 t80 -62.05 -45.72 92.3 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.103 -0.998 . . . . 0.0 109.637 -179.563 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.678 ' CG2' HD21 ' A' ' 48' ' ' LEU . 69.9 t -67.12 -48.7 78.07 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 O-C-N 121.245 -0.909 . . . . 0.0 110.014 -179.853 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.49 HG21 ' HB3' ' A' ' 2' ' ' GLN . 78.3 t -70.0 -43.35 79.37 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.338 0 O-C-N 121.109 -0.994 . . . . 0.0 109.571 179.831 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -61.11 -34.04 86.44 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 110.436 -1.066 . . . . 0.0 110.436 -179.461 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.78 -41.28 83.47 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.262 -1.14 . . . . 0.0 111.051 -178.692 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.467 HG21 ' CD2' ' A' ' 52' ' ' PHE . 49.4 p -82.79 -32.75 27.53 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.04 -1.038 . . . . 0.0 109.679 -179.511 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -133.47 153.93 80.61 Favored Pre-proline 0 C--N 1.301 -1.53 0 O-C-N 121.468 -0.77 . . . . 0.0 109.626 -179.383 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -63.91 115.58 3.18 Favored 'Trans proline' 0 C--N 1.307 -1.634 0 C-N-CA 122.263 1.975 . . . . 0.0 110.913 179.408 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -74.48 150.61 41.13 Favored 'Trans proline' 0 N--CA 1.488 1.201 0 C-N-CA 121.862 1.708 . . . . 0.0 113.213 -179.043 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.454 ' O ' ' C ' ' A' ' 85' ' ' GLU . 34.5 m -103.45 137.94 29.87 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 179.28 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.454 ' C ' ' O ' ' A' ' 84' ' ' VAL . 96.1 mt-10 42.35 64.34 1.15 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.206 -0.934 . . . . 0.0 109.233 -179.677 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -44.88 151.59 0.29 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.307 -0.871 . . . . 0.0 109.812 -179.61 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.44 ' HD3' HH21 ' A' ' 67' ' ' ARG . 16.6 tttm -55.42 -34.82 64.76 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.465 -0.772 . . . . 0.0 109.367 -179.858 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.611 HD11 ' NH1' ' A' ' 67' ' ' ARG . 50.6 mt -90.05 142.26 27.88 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.242 -0.911 . . . . 0.0 109.401 179.804 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 82.3 mt-30 . . . . . 0 N--CA 1.49 1.53 0 CA-C-O 117.94 -1.028 . . . . 0.0 109.511 -179.965 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' -1' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.489 1.507 0 CA-C-O 121.292 0.568 . . . . 0.0 109.475 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 0' ' ' GLU . . . . . 0.449 ' O ' ' C ' ' A' ' 1' ' ' MET . 84.8 tt0 -101.87 135.11 43.97 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.245 -0.909 . . . . 0.0 109.352 -179.931 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.591 ' HB3' ' HB2' ' A' ' 4' ' ' ALA . 68.2 mtt 41.01 88.68 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.369 -0.832 . . . . 0.0 109.493 -179.772 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.514 ' O ' ' CG ' ' A' ' 3' ' ' HIS . 94.8 mt-30 -57.73 -35.26 70.44 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.487 -0.758 . . . . 0.0 109.579 -179.863 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.514 ' CG ' ' O ' ' A' ' 2' ' ' GLN . 93.6 m-70 -156.53 60.73 0.55 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.187 -0.946 . . . . 0.0 109.486 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.591 ' HB2' ' HB3' ' A' ' 1' ' ' MET . . . -62.1 -34.71 76.83 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.229 -0.919 . . . . 0.0 109.634 -179.871 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.2 m -59.38 -38.9 81.68 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.293 -0.88 . . . . 0.0 109.864 -179.617 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 51.8 t -66.97 -46.34 85.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.121 -0.987 . . . . 0.0 109.742 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.742 HG21 ' OD1' ' A' ' 73' ' ' ASP . 87.3 mt -59.81 -50.27 80.7 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.456 0 O-C-N 121.379 -0.826 . . . . 0.0 109.847 -179.617 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.76 -42.3 97.85 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.272 -0.892 . . . . 0.0 110.78 -179.664 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 47.3 tt0 -69.41 -47.59 63.68 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 120.976 -1.078 . . . . 0.0 111.043 -178.582 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.688 ' CD1' ' N ' ' A' ' 11' ' ' VAL . 0.0 OUTLIER -71.66 -44.14 64.8 Favored 'General case' 0 C--N 1.298 -1.659 0 O-C-N 120.921 -1.112 . . . . 0.0 110.815 -179.226 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.688 ' N ' ' CD1' ' A' ' 10' ' ' PHE . 5.2 p -61.02 -47.84 91.78 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 120.996 -1.065 . . . . 0.0 110.692 -178.711 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.566 ' N ' HG13 ' A' ' 11' ' ' VAL . 8.6 p -63.62 -39.14 84.25 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 120.805 -1.184 . . . . 0.0 109.817 -179.686 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.407 ' N ' HG13 ' A' ' 12' ' ' VAL . 96.8 mt-10 -65.78 -36.17 82.77 Favored 'General case' 0 N--CA 1.486 1.33 0 O-C-N 120.93 -1.106 . . . . 0.0 110.131 -179.919 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -65.95 -42.41 90.02 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.166 -0.959 . . . . 0.0 110.196 -179.694 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 86.5 m-85 -91.47 -45.04 8.75 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.183 -0.948 . . . . 0.0 110.512 -179.691 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.537 HD22 ' CG2' ' A' ' 19' ' ' VAL . 8.5 mt -122.31 80.22 45.13 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.421 -0.799 . . . . 0.0 110.223 -178.942 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_endo -70.17 -15.47 35.55 Favored 'Trans proline' 0 C--N 1.312 -1.373 0 C-N-CA 122.099 1.866 . . . . 0.0 112.333 179.704 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -96.07 9.74 39.86 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.163 -0.961 . . . . 0.0 110.229 -179.581 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.537 ' CG2' HD22 ' A' ' 16' ' ' LEU . 44.3 t -114.73 135.28 55.09 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.239 -0.913 . . . . 0.0 109.837 -179.782 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -74.71 118.69 72.13 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.349 -0.844 . . . . 0.0 109.122 179.743 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_exo -51.17 -36.89 57.38 Favored 'Trans proline' 0 N--CA 1.493 1.444 0 C-N-CA 121.765 1.643 . . . . 0.0 112.008 179.635 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.71 -23.0 66.06 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.282 -0.886 . . . . 0.0 108.948 179.471 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 87.6 m-20 -87.98 7.13 32.55 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.406 -0.809 . . . . 0.0 109.872 -179.729 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.466 HG21 HG21 ' A' ' 12' ' ' VAL . 10.6 t -107.07 128.49 61.91 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.188 -0.945 . . . . 0.0 109.406 179.942 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 86.9 m-20 -89.81 120.29 30.92 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.137 -0.977 . . . . 0.0 109.169 179.275 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.4 m -78.87 3.36 1.74 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.465 0 O-C-N 121.125 -0.985 . . . . 0.0 108.741 179.321 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 90.5 m-20 -83.59 -19.4 35.61 Favored 'General case' 0 N--CA 1.486 1.358 0 O-C-N 121.545 -0.722 . . . . 0.0 109.073 179.392 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 42.8 tp -88.94 138.01 31.8 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 121.481 -0.762 . . . . 0.0 109.024 179.863 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -58.61 136.92 57.75 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.11 -0.993 . . . . 0.0 109.517 -179.376 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.757 HD12 HG13 ' A' ' 69' ' ' ILE . 2.4 tt -66.46 -38.0 86.38 Favored 'General case' 0 C--N 1.299 -1.613 0 O-C-N 121.757 -0.59 . . . . 0.0 110.134 -179.232 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.418 HG23 ' O ' ' A' ' 66' ' ' PHE . 75.7 t -62.55 -34.72 66.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.121 -0.987 . . . . 0.0 110.436 -178.987 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -52.45 -33.97 46.73 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 120.975 -1.078 . . . . 0.0 108.104 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.421 ' HB3' HG23 ' A' ' 35' ' ' VAL . 97.2 m-20 -71.08 -34.46 71.19 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.643 -0.66 . . . . 0.0 109.949 179.389 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 85.37 6.52 83.85 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 -179.446 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.421 HG23 ' HB3' ' A' ' 33' ' ' ASN . 76.3 t -61.52 -34.49 61.82 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.438 -1.036 . . . . 0.0 109.094 179.695 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.629 HD11 HD13 ' A' ' 30' ' ' LEU . 93.9 mt -83.14 114.4 23.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.274 -0.891 . . . . 0.0 109.735 -179.876 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.402 ' H ' ' HA3' ' A' ' 40' ' ' GLY . 92.4 m-20 -118.66 -158.41 0.72 Allowed 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 179.657 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -64.78 -54.15 35.81 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.046 -1.034 . . . . 0.0 108.506 179.631 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.597 ' N ' ' CD2' ' A' ' 39' ' ' LEU . 1.5 mm? -68.74 -32.52 72.36 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 107.32 -1.363 . . . . 0.0 107.32 178.264 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.402 ' HA3' ' H ' ' A' ' 37' ' ' ASP . . . -58.79 -45.94 94.18 Favored Glycine 0 N--CA 1.483 1.781 0 N-CA-C 109.06 -1.616 . . . . 0.0 109.06 179.6 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.9 tt -64.24 -39.06 93.18 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.426 -1.043 . . . . 0.0 108.762 179.035 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.1 tp -59.68 -45.76 91.11 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.311 -0.868 . . . . 0.0 108.798 179.543 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 54.5 mttp -60.2 -35.59 75.74 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.498 -0.751 . . . . 0.0 109.536 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 68.3 t -60.17 -46.89 93.97 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.345 -0.847 . . . . 0.0 109.567 -179.925 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.643 HD11 HD12 ' A' ' 61' ' ' LEU . 1.7 mp -68.22 -33.23 59.52 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 O-C-N 121.359 -0.838 . . . . 0.0 110.802 -179.915 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.17 -49.1 65.93 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.095 -1.003 . . . . 0.0 111.466 -178.359 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.524 ' C ' ' CD1' ' A' ' 47' ' ' TRP . 0.0 OUTLIER -80.8 -41.51 23.22 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 120.583 -1.323 . . . . 0.0 109.663 -179.548 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.449 HD11 ' CG2' ' A' ' 76' ' ' VAL . 8.3 tt -59.55 -41.78 90.87 Favored 'General case' 0 C--N 1.3 -1.567 0 O-C-N 121.377 -0.827 . . . . 0.0 109.909 -179.331 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.52 ' O ' ' N ' ' A' ' 53' ' ' GLY . 18.4 pt-20 -73.15 -36.92 66.75 Favored 'General case' 0 C--N 1.304 -1.371 0 O-C-N 121.099 -1.001 . . . . 0.0 109.562 -179.817 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 50' ' ' ASP . . . . . 0.405 ' N ' ' CG ' ' A' ' 49' ' ' GLU . 55.9 t0 -59.06 -38.49 79.5 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.321 -0.862 . . . . 0.0 110.838 -179.319 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.46 ' NH2' HG21 ' A' ' 76' ' ' VAL . 75.1 mtm180 -61.56 -41.18 97.0 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 120.986 -1.072 . . . . 0.0 111.473 -178.649 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.898 ' CE2' HG21 ' A' ' 80' ' ' THR . 36.7 m-85 -105.87 -12.54 15.81 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 120.923 -1.11 . . . . 0.0 110.173 -179.451 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.52 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 70.85 30.45 68.15 Favored Glycine 0 N--CA 1.486 2.017 0 N-CA-C 109.054 -1.618 . . . . 0.0 109.054 179.574 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 16.2 pt -97.82 129.72 47.6 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 O-C-N 121.336 -1.097 . . . . 0.0 109.756 -179.549 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -67.37 135.53 53.37 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.155 -0.966 . . . . 0.0 109.651 -179.666 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.504 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -66.37 -31.5 72.31 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.297 -0.877 . . . . 0.0 109.441 179.804 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 54.2 t0 -56.94 -36.69 70.53 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.277 -0.89 . . . . 0.0 109.999 -179.75 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 54.5 t0 -56.11 -40.38 73.61 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.182 -0.949 . . . . 0.0 109.892 -179.598 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.504 ' O ' ' O ' ' A' ' 56' ' ' ALA . 42.6 t -129.33 134.74 63.23 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.425 -0.797 . . . . 0.0 109.603 179.926 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -91.81 131.06 37.43 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.15 -0.969 . . . . 0.0 109.277 179.763 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.643 HD12 HD11 ' A' ' 45' ' ' ILE . 54.6 mt -97.82 139.27 33.92 Favored 'General case' 0 C--N 1.305 -1.327 0 O-C-N 121.297 -0.877 . . . . 0.0 109.674 -179.752 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -110.0 157.12 38.71 Favored Pre-proline 0 N--CA 1.489 1.495 0 N-CA-C 108.849 -0.796 . . . . 0.0 108.849 179.606 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 7.1 Cg_endo -52.83 -22.9 19.1 Favored 'Trans proline' 0 C--N 1.302 -1.903 0 C-N-CA 122.368 2.045 . . . . 0.0 111.72 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -70.45 -27.52 64.31 Favored 'General case' 0 N--CA 1.485 1.304 0 O-C-N 121.386 -0.821 . . . . 0.0 109.507 179.6 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' HIS . . . . . 0.566 ' C ' ' CD2' ' A' ' 65' ' ' HIS . 0.7 OUTLIER -65.67 -19.8 66.05 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.315 -0.865 . . . . 0.0 108.95 -179.882 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.551 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 6.0 m-85 -98.25 16.11 22.42 Favored 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 179.839 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 67' ' ' ARG . . . . . 0.43 HH21 ' HB3' ' A' ' 87' ' ' LYS . 5.3 ptt180 -49.87 -38.49 35.69 Favored 'General case' 0 C--N 1.3 -1.547 0 O-C-N 121.79 -0.569 . . . . 0.0 110.031 -179.798 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 68' ' ' SER . . . . . 0.542 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 84.2 p -161.66 157.59 24.76 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.006 -1.059 . . . . 0.0 109.969 179.838 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.757 HG13 HD12 ' A' ' 30' ' ' LEU . 3.4 mp -57.97 -35.04 50.4 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 179.034 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 59.6 mtp180 -57.51 -42.18 82.29 Favored 'General case' 0 N--CA 1.488 1.427 0 CA-C-O 121.442 0.639 . . . . 0.0 109.291 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 60.5 p -70.46 -36.39 73.88 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.446 -0.784 . . . . 0.0 110.047 -179.707 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 81.0 mt -62.73 -51.35 73.15 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 O-C-N 121.216 -0.928 . . . . 0.0 109.626 -179.636 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.742 ' OD1' HG21 ' A' ' 7' ' ' ILE . 35.0 m-20 -63.24 -42.85 99.27 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.301 -0.875 . . . . 0.0 108.651 179.883 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -67.1 -37.43 83.93 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.571 -0.706 . . . . 0.0 109.891 179.677 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 70.4 t80 -58.87 -47.62 84.28 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.028 -1.045 . . . . 0.0 109.915 -179.387 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.592 ' CG1' ' CE1' ' A' ' 52' ' ' PHE . 76.4 t -68.11 -48.56 73.66 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 O-C-N 121.238 -0.914 . . . . 0.0 110.255 -179.559 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 50.0 t -69.69 -45.27 78.16 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.306 0 O-C-N 121.047 -1.033 . . . . 0.0 109.847 -179.796 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.458 ' O ' ' O ' ' A' ' 81' ' ' THR . . . -61.19 -39.16 96.78 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 110.208 -1.157 . . . . 0.0 110.208 -179.573 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.72 -41.02 84.15 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.189 -1.183 . . . . 0.0 110.366 -179.242 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.898 HG21 ' CE2' ' A' ' 52' ' ' PHE . 49.5 p -82.83 -29.86 29.14 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.05 -1.031 . . . . 0.0 109.691 -179.614 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.458 ' O ' ' O ' ' A' ' 78' ' ' GLY . 0.3 OUTLIER -133.21 153.64 80.8 Favored Pre-proline 0 C--N 1.303 -1.452 0 O-C-N 121.519 -0.738 . . . . 0.0 109.668 -179.561 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -68.31 112.38 2.77 Favored 'Trans proline' 0 C--N 1.308 -1.565 0 C-N-CA 122.414 2.076 . . . . 0.0 111.438 179.655 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -76.18 152.8 35.76 Favored 'Trans proline' 0 C--N 1.315 -1.212 0 C-N-CA 122.113 1.875 . . . . 0.0 112.772 -179.379 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.423 ' O ' ' C ' ' A' ' 85' ' ' GLU . 29.8 m -102.46 140.4 20.95 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 179.453 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.423 ' C ' ' O ' ' A' ' 84' ' ' VAL . 84.3 tt0 43.96 68.51 0.52 Allowed 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.192 -0.943 . . . . 0.0 109.003 -179.446 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -47.04 150.83 0.72 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.307 -0.871 . . . . 0.0 109.797 -179.598 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.43 ' HB3' HH21 ' A' ' 67' ' ' ARG . 34.1 tttm -55.63 -36.17 66.71 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.43 -0.794 . . . . 0.0 109.535 -179.852 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 53.6 mt -91.74 142.02 28.05 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.178 -0.951 . . . . 0.0 109.393 179.868 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.2 mt-30 . . . . . 0 N--CA 1.49 1.554 0 CA-C-O 117.975 -1.012 . . . . 0.0 109.457 179.983 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' -1' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.49 1.563 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 . . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 0' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -57.65 -36.06 71.36 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.193 -0.942 . . . . 0.0 109.398 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.614 ' HB2' ' HB2' ' A' ' 4' ' ' ALA . 50.3 mtt -111.59 -121.5 0.28 Allowed 'General case' 0 N--CA 1.486 1.326 0 O-C-N 121.299 -0.876 . . . . 0.0 108.881 179.937 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.433 ' O ' ' C ' ' A' ' 3' ' ' HIS . 8.8 tp-100 -114.43 112.11 22.5 Favored 'General case' 0 C--N 1.301 -1.528 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 178.709 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.433 ' C ' ' O ' ' A' ' 2' ' ' GLN . 25.8 m80 47.2 29.62 1.23 Allowed 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 -178.701 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.614 ' HB2' ' HB2' ' A' ' 1' ' ' MET . . . -58.92 -41.93 88.46 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.542 -0.723 . . . . 0.0 109.746 -179.395 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 85.8 p -63.79 -31.35 72.5 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.308 -0.87 . . . . 0.0 109.666 -179.873 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 73.7 t -65.05 -45.26 94.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.182 -0.949 . . . . 0.0 109.432 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.447 ' CG2' HG23 ' A' ' 69' ' ' ILE . 76.0 mt -60.25 -43.58 93.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.445 -0.784 . . . . 0.0 109.165 179.771 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.476 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -60.33 -35.96 76.86 Favored 'General case' 0 C--N 1.305 -1.369 0 O-C-N 121.499 -0.75 . . . . 0.0 109.23 -179.898 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 59.8 tt0 -64.97 -41.19 95.67 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.22 -0.925 . . . . 0.0 110.142 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.693 ' CG ' ' CZ2' ' A' ' 47' ' ' TRP . 30.2 m-85 -62.6 -50.36 71.57 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.041 -1.037 . . . . 0.0 110.688 -179.381 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.452 HG23 ' N ' ' A' ' 12' ' ' VAL . 24.9 m -63.82 -41.78 93.69 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 O-C-N 121.062 -1.024 . . . . 0.0 109.343 -179.473 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.476 HG23 ' O ' ' A' ' 8' ' ' ALA . 71.2 t -63.82 -46.73 93.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.138 -0.976 . . . . 0.0 109.351 179.498 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -70.4 -29.0 65.52 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.226 -0.921 . . . . 0.0 110.124 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 83.9 tt0 -64.58 -29.98 71.0 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.346 -0.846 . . . . 0.0 110.611 -178.996 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 75.3 t80 -132.83 -46.1 0.87 Allowed 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.01 -1.056 . . . . 0.0 110.959 -179.075 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.453 ' C ' ' O ' ' A' ' 12' ' ' VAL . 3.3 mt -118.03 80.01 14.57 Favored Pre-proline 0 N--CA 1.493 1.72 0 O-C-N 121.216 -0.928 . . . . 0.0 110.424 -178.855 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -77.82 -11.97 16.56 Favored 'Trans proline' 0 C--N 1.308 -1.57 0 C-N-CA 122.551 2.168 . . . . 0.0 112.483 179.569 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.8 ' OD1' HG23 ' A' ' 19' ' ' VAL . 53.2 p30 -90.19 8.38 33.31 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 121.092 -1.005 . . . . 0.0 110.125 -179.651 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.8 HG23 ' OD1' ' A' ' 18' ' ' ASP . 51.6 t -119.34 135.51 59.49 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.365 -0.834 . . . . 0.0 109.688 179.95 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.34 120.44 79.71 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.258 -0.901 . . . . 0.0 109.421 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_exo -51.53 -27.54 25.47 Favored 'Trans proline' 0 N--CA 1.493 1.478 0 C-N-CA 121.764 1.643 . . . . 0.0 112.036 179.478 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.77 -25.83 68.09 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.317 -0.864 . . . . 0.0 109.357 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.445 ' O ' ' OD1' ' A' ' 23' ' ' ASP . 60.0 t0 -81.78 5.82 17.43 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.368 -0.832 . . . . 0.0 109.721 -179.826 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 11.7 t -108.25 132.47 55.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.24 -0.912 . . . . 0.0 109.462 -179.952 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 86.3 m-20 -89.19 120.51 30.63 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.144 -0.973 . . . . 0.0 109.004 179.356 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.9 m -77.12 2.49 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 O-C-N 121.005 -1.059 . . . . 0.0 108.991 179.592 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 87.6 m-20 -78.83 -28.56 44.4 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.305 -0.872 . . . . 0.0 108.808 178.974 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 45.9 tp -83.16 139.32 33.24 Favored 'General case' 0 N--CA 1.487 1.388 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 179.53 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.5 m-20 -56.64 132.63 52.39 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.035 -1.04 . . . . 0.0 109.556 -178.969 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 1.045 HD23 HD11 ' A' ' 36' ' ' ILE . 50.8 tp -64.9 -36.87 85.75 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.7 -0.625 . . . . 0.0 110.552 -179.471 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 78.9 t -63.38 -34.89 69.94 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.089 -1.007 . . . . 0.0 110.54 -179.11 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 90.6 m-20 -52.58 -33.35 45.68 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.001 -1.062 . . . . 0.0 108.181 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 97.5 m-20 -70.81 -34.21 71.51 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.625 -0.672 . . . . 0.0 109.98 179.483 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 90.68 3.62 70.99 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 108.974 -1.65 . . . . 0.0 108.974 -179.267 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 75.7 t -60.92 -29.2 45.0 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 121.431 -1.041 . . . . 0.0 108.66 179.415 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 1.045 HD11 HD23 ' A' ' 30' ' ' LEU . 71.0 mt -95.56 134.67 32.18 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 O-C-N 121.478 -0.764 . . . . 0.0 109.406 -179.88 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.534 ' CG ' ' H ' ' A' ' 38' ' ' ALA . 50.2 t0 -138.9 -169.82 2.72 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.534 ' H ' ' CG ' ' A' ' 37' ' ' ASP . . . -62.0 -54.16 45.5 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.147 -0.971 . . . . 0.0 108.765 179.911 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.695 HD12 ' N ' ' A' ' 39' ' ' LEU . 6.9 mp -69.76 -32.71 71.38 Favored 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 107.201 -1.407 . . . . 0.0 107.201 178.091 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.548 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.39 -44.74 96.39 Favored Glycine 0 N--CA 1.483 1.805 0 N-CA-C 108.971 -1.652 . . . . 0.0 108.971 179.456 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.705 HD11 ' CE1' ' A' ' 66' ' ' PHE . 7.9 tt -65.0 -40.4 94.89 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.423 -1.046 . . . . 0.0 109.195 179.367 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.1 tp -59.68 -46.02 90.31 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.1 -1.0 . . . . 0.0 108.887 179.675 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 59.7 mttp -61.3 -34.89 75.96 Favored 'General case' 0 C--N 1.297 -1.71 0 O-C-N 121.546 -0.722 . . . . 0.0 109.448 -180.0 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.548 HG23 ' O ' ' A' ' 40' ' ' GLY . 73.8 t -59.47 -43.27 90.22 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 O-C-N 121.299 -0.876 . . . . 0.0 109.142 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.525 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 6.7 mm -66.95 -38.74 81.98 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 121.395 -0.815 . . . . 0.0 110.752 -179.363 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.21 -49.77 68.44 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.128 -0.983 . . . . 0.0 111.716 -178.064 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.693 ' CZ2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -80.84 -44.34 18.59 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.648 -1.283 . . . . 0.0 109.99 -179.277 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.735 HD21 ' CG2' ' A' ' 76' ' ' VAL . 20.8 tp -58.93 -41.97 88.63 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.209 -0.932 . . . . 0.0 110.094 -178.921 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.525 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 1.2 pp20? -72.25 -36.87 69.19 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.009 -1.057 . . . . 0.0 109.589 -179.889 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.7 t0 -61.19 -38.18 85.61 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.232 -0.917 . . . . 0.0 110.441 -179.834 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 14.8 mmm180 -61.69 -37.09 82.86 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.308 -0.87 . . . . 0.0 111.432 -178.703 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.634 ' CZ ' ' CG1' ' A' ' 76' ' ' VAL . 72.6 m-85 -96.82 -8.0 32.16 Favored 'General case' 0 N--CA 1.487 1.375 0 O-C-N 120.769 -1.207 . . . . 0.0 110.172 -178.956 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 71.18 31.22 66.55 Favored Glycine 0 N--CA 1.485 1.945 0 N-CA-C 108.82 -1.712 . . . . 0.0 108.82 179.771 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.487 ' O ' ' OE1' ' A' ' 49' ' ' GLU . 24.7 pt -108.81 153.13 10.62 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 O-C-N 121.598 -0.942 . . . . 0.0 109.84 -179.3 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -103.79 155.49 18.56 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.411 -0.805 . . . . 0.0 109.436 -179.638 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -58.46 -26.32 63.24 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.317 -0.865 . . . . 0.0 109.325 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 60.9 t0 59.13 38.29 23.81 Favored 'General case' 0 N--CA 1.486 1.336 0 O-C-N 121.445 -0.784 . . . . 0.0 109.109 -179.79 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 54.27 44.97 28.24 Favored 'General case' 0 N--CA 1.486 1.328 0 O-C-N 121.588 -0.695 . . . . 0.0 110.354 179.272 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 52.9 t -120.85 134.08 65.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.387 -0.82 . . . . 0.0 109.091 179.339 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -102.52 130.7 49.43 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.282 -0.886 . . . . 0.0 109.664 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 60.8 mt -99.24 143.88 29.0 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.394 -0.816 . . . . 0.0 109.17 179.834 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 11.6 p -90.09 148.17 38.8 Favored Pre-proline 0 C--N 1.305 -1.346 0 O-C-N 121.053 -1.029 . . . . 0.0 108.707 179.821 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -57.62 -19.78 38.99 Favored 'Trans proline' 0 C--N 1.305 -1.754 0 C-N-CA 122.24 1.96 . . . . 0.0 111.858 -179.714 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -67.41 -30.78 70.63 Favored 'General case' 0 N--CA 1.485 1.304 0 O-C-N 121.376 -0.828 . . . . 0.0 109.226 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 65' ' ' HIS . . . . . 0.568 ' CD2' ' O ' ' A' ' 65' ' ' HIS . 2.7 t-80 -66.47 -19.47 65.8 Favored 'General case' 0 C--N 1.3 -1.584 0 O-C-N 121.262 -0.899 . . . . 0.0 108.815 179.82 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.705 ' CE1' HD11 ' A' ' 41' ' ' LEU . 6.6 m-85 -98.31 13.3 31.94 Favored 'General case' 0 C--N 1.3 -1.571 0 N-CA-C 108.89 -0.781 . . . . 0.0 108.89 -179.753 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 67' ' ' ARG . . . . . 0.446 HH21 ' HD2' ' A' ' 87' ' ' LYS . 1.5 ptt180 -49.82 -34.74 20.58 Favored 'General case' 0 C--N 1.299 -1.587 0 O-C-N 121.716 -0.615 . . . . 0.0 110.167 -179.778 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 68' ' ' SER . . . . . 0.501 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 23.3 t -153.17 154.88 35.63 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.101 -1.0 . . . . 0.0 110.041 -179.577 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.605 ' H ' HD12 ' A' ' 69' ' ' ILE . 3.3 mp -57.45 -33.99 45.53 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 178.886 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.703 ' NE ' ' HZ1' ' A' ' 87' ' ' LYS . 60.4 mtp180 -56.99 -45.61 82.85 Favored 'General case' 0 N--CA 1.488 1.453 0 CA-C-O 121.395 0.617 . . . . 0.0 109.567 -179.516 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 22.9 t -65.82 -41.43 91.86 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.283 -0.886 . . . . 0.0 109.87 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 68.5 mt -61.38 -45.38 98.75 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 O-C-N 121.265 -0.897 . . . . 0.0 110.022 -179.566 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 41.4 t0 -60.15 -40.79 91.08 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.178 -0.951 . . . . 0.0 109.573 -179.846 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.36 -46.06 78.02 Favored 'General case' 0 C--N 1.304 -1.393 0 O-C-N 121.232 -0.917 . . . . 0.0 109.593 -179.75 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' PHE . . . . . 0.51 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 63.5 t80 -63.19 -44.07 96.41 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.247 -0.908 . . . . 0.0 109.127 179.621 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.735 ' CG2' HD21 ' A' ' 48' ' ' LEU . 55.4 t -62.57 -46.66 95.84 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.309 0 O-C-N 121.407 -0.808 . . . . 0.0 109.404 179.607 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.504 ' O ' ' O ' ' A' ' 81' ' ' THR . 72.5 t -68.87 -41.71 82.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 O-C-N 121.262 -0.899 . . . . 0.0 109.402 179.803 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.38 -23.45 53.78 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.798 -1.321 . . . . 0.0 109.798 179.903 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.08 -33.2 74.97 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.283 -1.128 . . . . 0.0 110.639 -179.149 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 26.2 p -121.46 -33.75 3.58 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.232 -0.918 . . . . 0.0 110.776 -179.179 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.504 ' O ' ' O ' ' A' ' 77' ' ' VAL . 0.0 OUTLIER -132.88 152.72 80.34 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.247 -0.908 . . . . 0.0 109.759 -179.388 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -43.9 148.47 0.98 Allowed 'Trans proline' 0 C--N 1.311 -1.415 0 C-N-CA 122.052 1.835 . . . . 0.0 111.491 179.63 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -63.01 150.29 89.1 Favored 'Trans proline' 0 C--N 1.31 -1.492 0 C-N-CA 122.245 1.963 . . . . 0.0 112.543 -179.589 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.453 ' O ' ' C ' ' A' ' 85' ' ' GLU . 45.6 t -102.79 130.78 52.29 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 N-CA-C 108.871 -0.789 . . . . 0.0 108.871 179.496 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.453 ' C ' ' O ' ' A' ' 84' ' ' VAL . 81.5 tt0 41.04 61.13 1.82 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.418 -0.801 . . . . 0.0 109.169 -179.688 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -52.08 147.05 7.85 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.214 -0.929 . . . . 0.0 109.538 -179.593 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.703 ' HZ1' ' NE ' ' A' ' 70' ' ' ARG . 68.0 mttm -76.41 -169.14 1.12 Allowed 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.347 -0.846 . . . . 0.0 109.891 -179.808 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 32.6 mt -81.25 144.74 31.35 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.452 -0.78 . . . . 0.0 109.483 -179.56 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 82.4 mt-30 . . . . . 0 N--CA 1.49 1.56 0 CA-C-O 117.963 -1.018 . . . . 0.0 109.463 179.981 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' -1' ' ' SER . . . . . 0.47 ' HB2' ' H ' ' A' ' 4' ' ' ALA . 2.4 p . . . . . 0 N--CA 1.49 1.574 0 CA-C-O 121.303 0.573 . . . . 0.0 109.489 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 0' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -61.56 -33.95 74.74 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.209 -0.932 . . . . 0.0 109.343 179.932 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.605 ' HB2' ' HB2' ' A' ' 4' ' ' ALA . 70.7 mtp -111.12 -121.03 0.28 Allowed 'General case' 0 C--N 1.306 -1.324 0 O-C-N 121.414 -0.804 . . . . 0.0 108.938 -179.903 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.431 ' O ' ' C ' ' A' ' 3' ' ' HIS . 9.0 tp-100 -109.91 112.35 24.32 Favored 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 178.926 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.431 ' C ' ' O ' ' A' ' 2' ' ' GLN . 4.3 m-70 47.39 27.19 0.87 Allowed 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 -178.765 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.605 ' HB2' ' HB2' ' A' ' 1' ' ' MET . . . -58.89 -43.8 91.03 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.652 -0.655 . . . . 0.0 109.944 -179.224 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 94.9 p -65.95 -32.18 73.53 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.324 -0.86 . . . . 0.0 110.083 -179.663 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 79.1 t -65.26 -47.13 88.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.101 -1.0 . . . . 0.0 109.584 -179.718 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.545 ' O ' HG12 ' A' ' 11' ' ' VAL . 81.2 mt -59.96 -48.82 86.35 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 O-C-N 121.315 -0.865 . . . . 0.0 109.702 179.988 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.719 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.29 -43.5 97.7 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.421 -0.799 . . . . 0.0 110.7 -179.349 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 44.4 tt0 -68.67 -47.58 66.14 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.97 -1.081 . . . . 0.0 110.861 -178.859 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.531 ' C ' ' CD1' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -70.96 -48.12 55.2 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.149 -0.97 . . . . 0.0 110.36 -179.651 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.545 HG12 ' O ' ' A' ' 7' ' ' ILE . 4.2 p -59.92 -38.95 78.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.089 -1.007 . . . . 0.0 109.742 -179.542 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.719 HG23 ' O ' ' A' ' 8' ' ' ALA . 52.0 t -63.22 -43.26 98.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.099 -1.0 . . . . 0.0 109.839 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -63.81 -38.74 92.2 Favored 'General case' 0 N--CA 1.487 1.377 0 O-C-N 121.086 -1.008 . . . . 0.0 110.252 -179.638 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 85.5 tt0 -69.95 -42.17 73.57 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.0 -1.063 . . . . 0.0 110.218 -179.698 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 79.6 t80 -84.97 -52.96 5.61 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.16 -0.963 . . . . 0.0 110.798 -179.259 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.501 HD22 ' CG2' ' A' ' 19' ' ' VAL . 6.3 mt -122.53 80.08 46.93 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.341 -0.85 . . . . 0.0 110.371 -179.004 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 22.0 Cg_endo -68.39 -14.54 40.32 Favored 'Trans proline' 0 C--N 1.311 -1.403 0 C-N-CA 122.012 1.808 . . . . 0.0 112.33 179.464 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.459 ' OD1' ' O ' ' A' ' 18' ' ' ASP . 60.2 t0 -94.61 6.22 49.5 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.187 -0.945 . . . . 0.0 110.137 -179.705 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.501 ' CG2' HD22 ' A' ' 16' ' ' LEU . 25.9 t -118.57 135.89 57.53 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.268 -0.895 . . . . 0.0 109.636 -179.896 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.491 ' O ' ' OD1' ' A' ' 23' ' ' ASP . . . -77.14 117.19 63.56 Favored Pre-proline 0 N--CA 1.489 1.489 0 O-C-N 121.234 -0.916 . . . . 0.0 108.935 179.722 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_exo -51.71 -26.23 22.75 Favored 'Trans proline' 0 N--CA 1.492 1.407 0 C-N-CA 121.8 1.666 . . . . 0.0 112.211 179.693 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.09 -24.94 67.58 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.35 -0.844 . . . . 0.0 109.775 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.503 ' OD1' HG23 ' A' ' 24' ' ' VAL . 49.2 p30 -86.38 7.07 27.15 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.104 -0.998 . . . . 0.0 110.008 -179.555 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.503 HG23 ' OD1' ' A' ' 23' ' ' ASP . 15.6 t -110.4 131.9 60.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.73 0 O-C-N 121.315 -0.866 . . . . 0.0 109.504 179.868 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 25' ' ' ASP . . . . . 0.513 ' C ' ' H ' ' A' ' 27' ' ' ASP . 62.9 t0 -89.25 119.37 29.68 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.148 -0.97 . . . . 0.0 108.981 179.223 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.439 ' O ' HG13 ' A' ' 26' ' ' VAL . 0.3 OUTLIER -63.87 4.25 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.421 0 O-C-N 121.172 -0.955 . . . . 0.0 109.315 179.874 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.513 ' H ' ' C ' ' A' ' 25' ' ' ASP . 92.0 m-20 -105.02 6.63 33.54 Favored 'General case' 0 N--CA 1.485 1.301 0 O-C-N 121.263 -0.898 . . . . 0.0 109.32 179.772 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 28' ' ' LEU . . . . . 0.404 HD23 ' OD1' ' A' ' 33' ' ' ASN . 45.5 tp -96.8 136.29 37.56 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.373 -0.829 . . . . 0.0 109.238 -179.828 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 80.5 m-20 -64.7 142.52 58.4 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.231 -0.918 . . . . 0.0 109.967 -179.167 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.576 ' N ' ' O ' ' A' ' 67' ' ' ARG . 76.0 mt -70.3 -35.07 73.46 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.468 -0.77 . . . . 0.0 110.987 -179.577 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.61 HG23 ' N ' ' A' ' 32' ' ' ASP . 35.1 m -57.75 -47.09 86.69 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.515 0 O-C-N 121.123 -0.986 . . . . 0.0 110.177 -178.958 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.61 ' N ' HG23 ' A' ' 31' ' ' VAL . 90.8 m-20 -61.18 -34.24 74.73 Favored 'General case' 0 C--N 1.302 -1.489 0 N-CA-C 108.439 -0.948 . . . . 0.0 108.439 179.403 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.404 ' OD1' HD23 ' A' ' 28' ' ' LEU . 96.6 m-20 -70.8 -34.18 71.49 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.752 -0.592 . . . . 0.0 110.115 -179.883 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 86.61 6.36 80.48 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 108.872 -1.691 . . . . 0.0 108.872 -179.516 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 70.8 t -59.06 -32.21 47.36 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 O-C-N 121.464 -1.021 . . . . 0.0 108.293 179.42 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 79.8 mt -85.82 129.56 37.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 CA-C-O 121.656 0.741 . . . . 0.0 109.735 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.49 ' CG ' ' H ' ' A' ' 38' ' ' ALA . 51.2 t0 -148.85 -170.84 3.72 Favored 'General case' 0 C--N 1.298 -1.647 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 179.776 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.49 ' H ' ' CG ' ' A' ' 37' ' ' ASP . . . -61.35 -54.66 40.89 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 120.893 -1.129 . . . . 0.0 108.422 179.772 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.718 HD12 ' N ' ' A' ' 39' ' ' LEU . 6.8 mp -71.61 -33.22 68.79 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 107.468 -1.308 . . . . 0.0 107.468 178.094 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.535 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.77 -46.61 93.77 Favored Glycine 0 N--CA 1.484 1.885 0 N-CA-C 109.255 -1.538 . . . . 0.0 109.255 179.833 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 3.4 tt -63.81 -43.28 96.73 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.419 -1.047 . . . . 0.0 109.654 179.563 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 17.2 tp -59.75 -45.22 92.89 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.313 -0.867 . . . . 0.0 109.728 -179.653 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 24.8 mttm -63.36 -34.45 77.74 Favored 'General case' 0 C--N 1.297 -1.678 0 O-C-N 121.052 -1.03 . . . . 0.0 109.705 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.591 HG11 ' CE2' ' A' ' 66' ' ' PHE . 54.7 t -61.38 -50.79 78.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.332 -0.855 . . . . 0.0 110.624 -179.077 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.497 ' H ' HD12 ' A' ' 45' ' ' ILE . 3.5 mp -68.27 -40.08 82.06 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 O-C-N 121.17 -0.957 . . . . 0.0 111.34 -179.431 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.66 -49.63 61.91 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.081 -1.012 . . . . 0.0 112.215 -177.692 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.551 ' C ' ' CD1' ' A' ' 47' ' ' TRP . 0.0 OUTLIER -78.76 -43.43 25.61 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.671 -1.268 . . . . 0.0 110.37 -178.717 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.848 HD11 HG21 ' A' ' 76' ' ' VAL . 16.7 tp -59.99 -41.78 92.79 Favored 'General case' 0 C--N 1.3 -1.562 0 O-C-N 121.195 -0.941 . . . . 0.0 110.326 -178.754 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.413 ' CG ' ' N ' ' A' ' 50' ' ' ASP . 17.8 pt-20 -73.02 -37.15 67.03 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.117 -0.99 . . . . 0.0 109.856 -179.673 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 50' ' ' ASP . . . . . 0.413 ' N ' ' CG ' ' A' ' 49' ' ' GLU . 56.8 t0 -60.0 -39.26 85.14 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.375 -0.828 . . . . 0.0 111.036 -179.269 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.464 ' HD2' ' HE1' ' A' ' 47' ' ' TRP . 80.6 mtp180 -61.07 -37.61 83.28 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.105 -0.997 . . . . 0.0 111.603 -178.649 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.644 ' CZ ' ' CG1' ' A' ' 76' ' ' VAL . 48.6 m-85 -98.48 -8.18 27.14 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 120.79 -1.194 . . . . 0.0 110.456 -179.012 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 69.87 31.7 70.04 Favored Glycine 0 N--CA 1.488 2.117 0 N-CA-C 108.752 -1.739 . . . . 0.0 108.752 179.653 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 27.9 pt -108.51 153.44 10.12 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 O-C-N 121.62 -0.929 . . . . 0.0 109.908 -179.372 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -100.09 129.95 46.18 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.152 -0.968 . . . . 0.0 109.51 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.502 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -66.51 -28.82 68.86 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.294 -0.879 . . . . 0.0 109.581 179.895 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 53.9 t0 -55.41 -36.09 66.08 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.305 -0.872 . . . . 0.0 109.998 -179.642 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -56.88 -40.3 75.95 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.201 -0.937 . . . . 0.0 109.952 -179.584 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.502 ' O ' ' O ' ' A' ' 56' ' ' ALA . 42.1 t -129.16 134.81 63.31 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.393 -0.817 . . . . 0.0 109.543 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -79.25 126.63 31.03 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.097 -1.002 . . . . 0.0 109.436 179.896 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.482 HD12 ' O ' ' A' ' 59' ' ' VAL . 5.3 mp -108.04 139.54 42.53 Favored 'General case' 0 C--N 1.305 -1.333 0 O-C-N 121.372 -0.83 . . . . 0.0 109.651 -179.904 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -107.02 145.34 30.92 Favored Pre-proline 0 N--CA 1.484 1.267 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 179.098 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -60.73 -19.94 63.35 Favored 'Trans proline' 0 C--N 1.306 -1.699 0 C-N-CA 122.107 1.871 . . . . 0.0 112.021 -179.55 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 90.1 mt-10 -69.25 -28.39 66.29 Favored 'General case' 0 C--N 1.305 -1.364 0 O-C-N 121.439 -0.788 . . . . 0.0 109.676 -179.613 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 65' ' ' HIS . . . . . 0.59 ' CD2' ' O ' ' A' ' 65' ' ' HIS . 0.0 OUTLIER -66.55 -19.12 65.7 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.199 -0.938 . . . . 0.0 109.182 -179.563 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.591 ' CE2' HG11 ' A' ' 44' ' ' VAL . 16.5 m-85 -96.15 11.03 35.77 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.291 -0.881 . . . . 0.0 109.317 179.794 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 67' ' ' ARG . . . . . 0.576 ' O ' ' N ' ' A' ' 30' ' ' LEU . 1.7 ptt180 -50.08 -21.86 1.43 Allowed 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.381 -0.824 . . . . 0.0 110.049 -179.671 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 68' ' ' SER . . . . . 0.444 ' O ' ' OG ' ' A' ' 71' ' ' SER . 34.4 t -147.14 147.03 30.13 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.137 -0.977 . . . . 0.0 109.883 -179.875 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.713 ' H ' HD12 ' A' ' 69' ' ' ILE . 2.3 mp -59.92 -38.72 77.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.288 -0.883 . . . . 0.0 109.566 -179.826 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.429 ' O ' ' OD2' ' A' ' 73' ' ' ASP . 6.1 ptm180 -57.6 -40.14 78.4 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.427 -0.796 . . . . 0.0 109.447 -179.748 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.453 ' CB ' ' HZ1' ' A' ' 87' ' ' LYS . 95.8 p -65.07 -35.83 82.39 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.332 -0.855 . . . . 0.0 110.123 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.433 ' O ' HG23 ' A' ' 76' ' ' VAL . 64.6 mt -63.31 -46.59 95.17 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.326 0 O-C-N 121.191 -0.943 . . . . 0.0 110.148 -179.419 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.584 ' OD1' ' N ' ' A' ' 74' ' ' ALA . 1.3 p30 -63.14 -40.02 96.35 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.088 -1.007 . . . . 0.0 109.448 -179.648 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.584 ' N ' ' OD1' ' A' ' 73' ' ' ASP . . . -66.76 -45.52 78.3 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.312 -0.867 . . . . 0.0 109.768 -179.882 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 75' ' ' PHE . . . . . 0.544 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 55.0 t80 -63.32 -43.87 96.55 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.326 -0.859 . . . . 0.0 109.073 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.848 HG21 HD11 ' A' ' 48' ' ' LEU . 55.8 t -60.79 -46.8 95.48 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 O-C-N 121.493 -0.754 . . . . 0.0 109.047 179.655 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 54.7 t -69.14 -42.07 81.63 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 O-C-N 121.455 -0.778 . . . . 0.0 109.084 179.298 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.516 ' O ' ' O ' ' A' ' 81' ' ' THR . . . -68.8 -21.19 74.92 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 110.001 -1.24 . . . . 0.0 110.001 179.901 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -66.48 -36.79 83.62 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 120.955 -1.32 . . . . 0.0 109.783 -179.411 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 56.1 p -87.91 -25.58 23.16 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.216 -0.927 . . . . 0.0 109.732 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.516 ' O ' ' O ' ' A' ' 78' ' ' GLY . 0.1 OUTLIER -133.19 153.03 80.56 Favored Pre-proline 0 N--CA 1.486 1.366 0 O-C-N 121.358 -0.839 . . . . 0.0 109.75 -179.63 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 76.0 Cg_exo -41.14 103.33 0.04 OUTLIER 'Trans proline' 0 C--N 1.309 -1.525 0 C-N-CA 122.493 2.128 . . . . 0.0 112.058 179.644 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 83' ' ' PRO . . . . . 0.443 ' HB2' ' HB2' ' A' ' 86' ' ' ALA . 23.6 Cg_exo -57.56 145.66 87.92 Favored 'Trans proline' 0 N--CA 1.492 1.42 0 C-N-CA 122.251 1.967 . . . . 0.0 112.275 -179.903 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.443 ' O ' ' C ' ' A' ' 85' ' ' GLU . 32.7 m -103.72 140.23 22.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.354 -0.841 . . . . 0.0 109.337 179.74 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.443 ' C ' ' O ' ' A' ' 84' ' ' VAL . 96.2 mt-10 40.73 43.14 1.58 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.297 -0.877 . . . . 0.0 109.703 179.748 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.443 ' HB2' ' HB2' ' A' ' 83' ' ' PRO . . . -59.52 146.26 41.17 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.207 -0.933 . . . . 0.0 109.573 -179.912 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.514 ' C ' HD22 ' A' ' 88' ' ' LEU . 47.4 mttp -57.73 -35.64 70.96 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.262 -0.899 . . . . 0.0 109.549 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.793 ' N ' HD22 ' A' ' 88' ' ' LEU . 2.5 mm? -95.47 141.04 29.48 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.276 -0.89 . . . . 0.0 109.413 179.754 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.6 mt-30 . . . . . 0 N--CA 1.491 1.585 0 CA-C-O 117.994 -1.003 . . . . 0.0 109.408 -179.96 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' -1' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.49 1.56 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 0' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -61.52 -34.3 75.28 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.266 -0.896 . . . . 0.0 109.546 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.436 ' HB2' ' HB2' ' A' ' 4' ' ' ALA . 83.6 mmm -95.52 -121.41 0.11 Allowed 'General case' 0 C--N 1.307 -1.275 0 O-C-N 121.233 -0.917 . . . . 0.0 109.048 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.478 ' O ' ' OD2' ' A' ' 73' ' ' ASP . 67.6 tp60 -113.53 114.48 26.56 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 178.959 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.422 ' C ' ' O ' ' A' ' 2' ' ' GLN . 66.7 m-70 46.94 29.87 1.12 Allowed 'General case' 0 N--CA 1.487 1.418 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 -178.713 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.436 ' HB2' ' HB2' ' A' ' 1' ' ' MET . . . -58.26 -37.68 75.44 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.491 -0.755 . . . . 0.0 109.577 -179.3 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 87.4 p -61.45 -32.89 72.88 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.202 -0.936 . . . . 0.0 109.469 -179.884 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 70.0 t -62.95 -43.9 99.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.237 -0.914 . . . . 0.0 109.196 179.75 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 79.2 mt -60.21 -40.97 85.18 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.396 -0.815 . . . . 0.0 109.024 179.606 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.428 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -60.84 -38.12 84.39 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 121.52 -0.738 . . . . 0.0 109.537 -179.724 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 48.3 mt-30 -64.51 -40.53 95.82 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.122 -0.986 . . . . 0.0 110.105 -179.934 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.688 ' CG ' ' CE2' ' A' ' 47' ' ' TRP . 30.6 m-85 -63.55 -50.43 69.53 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.146 -0.972 . . . . 0.0 110.951 -179.196 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.473 HG23 ' N ' ' A' ' 12' ' ' VAL . 27.2 m -65.64 -41.37 90.46 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 120.995 -1.066 . . . . 0.0 109.426 -179.474 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.473 ' N ' HG23 ' A' ' 11' ' ' VAL . 66.6 t -63.88 -47.0 92.66 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 O-C-N 121.26 -0.9 . . . . 0.0 109.685 179.554 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -70.53 -27.83 64.47 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.04 -1.037 . . . . 0.0 110.231 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -64.57 -33.21 75.38 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.271 -0.893 . . . . 0.0 110.845 -178.708 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 92.1 m-85 -134.11 -29.78 1.24 Allowed 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.036 -1.04 . . . . 0.0 111.123 -179.354 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.561 HD22 ' CG2' ' A' ' 19' ' ' VAL . 12.3 mt -124.74 79.68 63.09 Favored Pre-proline 0 N--CA 1.491 1.604 0 O-C-N 121.078 -1.014 . . . . 0.0 110.248 -179.157 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -78.73 -17.72 12.27 Favored 'Trans proline' 0 C--N 1.307 -1.63 0 C-N-CA 122.586 2.19 . . . . 0.0 112.317 179.642 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -93.01 7.56 43.57 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.232 -0.917 . . . . 0.0 110.125 -179.601 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.561 ' CG2' HD22 ' A' ' 16' ' ' LEU . 46.8 t -113.18 136.04 50.76 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.353 -0.842 . . . . 0.0 109.775 -179.844 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.414 ' O ' ' CG ' ' A' ' 23' ' ' ASP . . . -72.42 117.3 57.68 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.298 -0.876 . . . . 0.0 109.499 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_exo -52.03 -25.24 21.83 Favored 'Trans proline' 0 N--CA 1.494 1.503 0 C-N-CA 121.995 1.797 . . . . 0.0 112.344 179.333 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.74 -21.5 66.77 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.268 -0.895 . . . . 0.0 109.83 -179.604 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.448 ' C ' ' OD1' ' A' ' 23' ' ' ASP . 52.8 p30 -84.45 7.56 19.33 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.245 -0.909 . . . . 0.0 110.144 -179.599 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 11.4 t -104.88 129.81 56.9 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.156 -0.965 . . . . 0.0 109.463 -179.922 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 64.0 t0 -89.58 119.86 30.37 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.142 -0.974 . . . . 0.0 109.218 179.325 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.8 m -74.84 3.95 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.428 0 O-C-N 121.172 -0.955 . . . . 0.0 109.314 179.755 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -88.99 -11.24 44.82 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 121.295 -0.878 . . . . 0.0 109.157 179.543 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 43.6 tp -95.83 138.72 33.07 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.412 -0.805 . . . . 0.0 109.016 179.793 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.0 m-20 -58.34 133.6 55.86 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.147 -0.971 . . . . 0.0 109.272 -179.625 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.725 HD12 HG13 ' A' ' 69' ' ' ILE . 2.0 tt -67.14 -38.25 85.21 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 121.724 -0.61 . . . . 0.0 110.099 -179.136 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.563 HG23 ' O ' ' A' ' 66' ' ' PHE . 75.5 t -63.14 -35.54 72.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.011 -1.056 . . . . 0.0 110.379 -178.964 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 55.7 t0 -52.52 -33.52 45.62 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 120.957 -1.09 . . . . 0.0 108.151 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.446 ' HB3' HG23 ' A' ' 35' ' ' VAL . 97.4 m-20 -71.25 -34.61 70.89 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.634 -0.666 . . . . 0.0 109.974 179.464 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 84.98 6.44 85.02 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.083 -1.607 . . . . 0.0 109.083 -179.399 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.446 HG23 ' HB3' ' A' ' 33' ' ' ASN . 71.5 t -61.32 -34.5 61.2 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.428 0 O-C-N 121.412 -1.052 . . . . 0.0 109.056 179.636 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.696 HD11 HD13 ' A' ' 30' ' ' LEU . 91.8 mt -82.07 114.53 23.12 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 O-C-N 121.353 -0.842 . . . . 0.0 109.665 -179.836 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -111.58 -168.61 1.33 Allowed 'General case' 0 C--N 1.304 -1.401 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 179.745 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -64.24 -54.15 37.88 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.214 -0.929 . . . . 0.0 108.696 179.708 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 38.6 mt -70.39 -33.16 71.08 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 107.171 -1.418 . . . . 0.0 107.171 178.338 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.621 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.57 -40.53 96.46 Favored Glycine 0 N--CA 1.481 1.678 0 N-CA-C 108.546 -1.822 . . . . 0.0 108.546 179.131 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.7 tt -65.45 -42.8 91.95 Favored 'General case' 0 C--N 1.305 -1.36 0 O-C-N 121.492 -1.005 . . . . 0.0 109.136 179.336 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.2 tp -60.88 -46.16 91.71 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.448 -0.782 . . . . 0.0 109.269 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 51.2 mttp -61.13 -35.21 76.46 Favored 'General case' 0 C--N 1.296 -1.732 0 O-C-N 121.427 -0.795 . . . . 0.0 109.623 -179.754 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.621 HG23 ' O ' ' A' ' 40' ' ' GLY . 60.5 t -61.64 -48.67 87.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.295 -0.878 . . . . 0.0 109.8 -179.605 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.518 ' CG1' HD12 ' A' ' 61' ' ' LEU . 1.6 mp -68.26 -32.62 56.52 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 O-C-N 121.501 -0.75 . . . . 0.0 110.871 -179.568 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.14 -49.76 63.68 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.0 -1.063 . . . . 0.0 111.807 -178.026 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.688 ' CE2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -80.81 -43.48 20.0 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.766 -1.209 . . . . 0.0 110.015 -179.195 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.477 HD21 ' CG2' ' A' ' 76' ' ' VAL . 24.3 tp -58.82 -41.55 87.09 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.334 -0.854 . . . . 0.0 110.1 -178.948 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.438 ' CG ' ' N ' ' A' ' 50' ' ' ASP . 17.1 pt-20 -72.99 -37.92 66.83 Favored 'General case' 0 C--N 1.305 -1.362 0 O-C-N 121.079 -1.013 . . . . 0.0 109.716 -179.835 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 50' ' ' ASP . . . . . 0.438 ' N ' ' CG ' ' A' ' 49' ' ' GLU . 57.2 t0 -58.17 -39.13 78.09 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.36 -0.837 . . . . 0.0 110.457 -179.509 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.465 ' HD2' ' HE1' ' A' ' 47' ' ' TRP . 22.3 mtp-105 -62.63 -36.32 82.41 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.135 -0.978 . . . . 0.0 111.411 -178.866 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.783 ' CE2' HG11 ' A' ' 76' ' ' VAL . 86.5 m-85 -95.55 -8.88 33.89 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 120.75 -1.218 . . . . 0.0 110.258 -179.191 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 72.86 30.72 63.16 Favored Glycine 0 N--CA 1.487 2.073 0 N-CA-C 108.905 -1.678 . . . . 0.0 108.905 179.723 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 23.1 pt -109.73 153.63 11.44 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.335 0 O-C-N 121.557 -0.967 . . . . 0.0 109.782 -179.501 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -101.68 135.96 42.32 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.264 -0.897 . . . . 0.0 109.54 -179.776 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.499 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -66.35 -28.51 68.71 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.329 -0.857 . . . . 0.0 109.647 179.878 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -56.05 -35.78 67.3 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.158 -0.964 . . . . 0.0 109.935 -179.732 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 54.5 t0 -55.0 -38.93 68.49 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.173 -0.954 . . . . 0.0 110.141 -179.569 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.499 ' O ' ' O ' ' A' ' 56' ' ' ALA . 13.6 p -135.59 142.63 38.87 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.199 -0.938 . . . . 0.0 109.721 -179.91 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -93.62 132.57 37.83 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.098 -1.001 . . . . 0.0 109.328 179.682 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.518 HD12 ' CG1' ' A' ' 45' ' ' ILE . 56.5 mt -99.06 140.34 33.36 Favored 'General case' 0 C--N 1.305 -1.362 0 O-C-N 121.309 -0.869 . . . . 0.0 109.865 -179.67 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -109.67 156.31 39.93 Favored Pre-proline 0 N--CA 1.487 1.412 0 N-CA-C 108.633 -0.876 . . . . 0.0 108.633 179.503 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 8.1 Cg_endo -53.36 -25.08 29.82 Favored 'Trans proline' 0 C--N 1.303 -1.83 0 C-N-CA 122.41 2.073 . . . . 0.0 111.729 -179.85 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -71.65 -27.15 62.88 Favored 'General case' 0 N--CA 1.486 1.369 0 O-C-N 121.368 -0.833 . . . . 0.0 109.508 179.757 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' HIS . . . . . 0.556 ' NE2' ' CB ' ' A' ' 75' ' ' PHE . 6.6 t-160 -65.79 -21.1 66.47 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.311 -0.868 . . . . 0.0 109.092 -179.749 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.563 ' O ' HG23 ' A' ' 31' ' ' VAL . 15.3 m-85 -92.34 14.65 15.84 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 179.909 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 67' ' ' ARG . . . . . 0.567 ' NH1' HD11 ' A' ' 88' ' ' LEU . 6.9 ptt180 -47.9 -39.08 17.86 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.651 -0.656 . . . . 0.0 109.85 -179.972 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 68' ' ' SER . . . . . 0.535 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 86.9 p -160.04 156.55 27.14 Favored 'General case' 0 N--CA 1.487 1.401 0 O-C-N 120.993 -1.067 . . . . 0.0 110.014 179.913 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.725 HG13 HD12 ' A' ' 30' ' ' LEU . 3.3 mp -58.84 -34.76 53.24 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 179.189 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 47.0 mtp180 -56.88 -43.78 81.6 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.721 -0.612 . . . . 0.0 109.642 -179.601 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 82.5 p -69.47 -33.67 73.24 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.364 -0.835 . . . . 0.0 110.012 -179.706 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.539 HD12 ' HA ' ' A' ' 69' ' ' ILE . 80.6 mt -62.24 -51.02 77.45 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 O-C-N 121.177 -0.952 . . . . 0.0 109.944 -179.656 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.478 ' OD2' ' O ' ' A' ' 2' ' ' GLN . 42.8 t0 -61.01 -42.06 97.73 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.197 -0.94 . . . . 0.0 109.241 179.871 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.79 -38.68 87.01 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.568 -0.708 . . . . 0.0 110.403 -179.514 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' PHE . . . . . 0.556 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 58.9 t80 -62.28 -46.88 86.8 Favored 'General case' 0 C--N 1.302 -1.462 0 O-C-N 121.105 -0.997 . . . . 0.0 109.82 -179.572 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.783 HG11 ' CE2' ' A' ' 52' ' ' PHE . 77.0 t -66.35 -48.65 80.24 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 121.164 -0.96 . . . . 0.0 109.816 -179.806 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.595 ' O ' HG22 ' A' ' 81' ' ' THR . 53.3 t -70.04 -46.9 71.33 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.276 0 O-C-N 121.056 -1.028 . . . . 0.0 109.67 179.882 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.475 ' O ' ' O ' ' A' ' 81' ' ' THR . . . -61.86 -30.86 76.38 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 110.317 -1.113 . . . . 0.0 110.317 -179.642 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.67 -41.13 84.19 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.149 -1.207 . . . . 0.0 110.318 -179.028 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 56.1 p -79.15 -31.79 44.11 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.127 -0.983 . . . . 0.0 109.39 -179.872 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.595 HG22 ' O ' ' A' ' 77' ' ' VAL . 2.6 t -133.3 149.15 71.71 Favored Pre-proline 0 C--N 1.305 -1.341 0 O-C-N 121.52 -0.737 . . . . 0.0 109.452 -179.766 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 14.4 Cg_endo -61.11 117.57 4.37 Favored 'Trans proline' 0 C--N 1.31 -1.473 0 C-N-CA 121.915 1.743 . . . . 0.0 111.086 179.128 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -74.49 152.48 43.56 Favored 'Trans proline' 0 C--N 1.315 -1.19 0 C-N-CA 122.043 1.829 . . . . 0.0 112.993 -179.218 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.402 ' O ' ' C ' ' A' ' 85' ' ' GLU . 44.4 t -102.49 135.08 41.36 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 179.449 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.402 ' C ' ' O ' ' A' ' 84' ' ' VAL . 84.5 tt0 44.98 70.4 0.35 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.166 -0.959 . . . . 0.0 108.997 -179.404 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -46.03 153.69 0.29 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.326 -0.859 . . . . 0.0 109.855 -179.674 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.419 ' HB3' HH21 ' A' ' 67' ' ' ARG . 29.0 tttm -54.91 -35.65 64.36 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.396 -0.815 . . . . 0.0 109.548 -179.855 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.567 HD11 ' NH1' ' A' ' 67' ' ' ARG . 54.6 mt -90.17 142.13 28.02 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.21 -0.932 . . . . 0.0 109.396 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 13.8 pt20 . . . . . 0 N--CA 1.491 1.615 0 CA-C-O 118.11 -0.948 . . . . 0.0 109.407 179.998 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' -1' ' ' SER . . . . . 0.583 ' O ' ' NE2' ' A' ' 2' ' ' GLN . 0.1 OUTLIER . . . . . 0 N--CA 1.49 1.568 0 N-CA-C 109.516 -0.55 . . . . 0.0 109.516 . . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 0' ' ' GLU . . . . . 0.656 ' OE1' HG21 ' A' ' 84' ' ' VAL . 97.2 mt-10 -61.32 -32.31 72.18 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.303 -0.873 . . . . 0.0 109.471 -179.918 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.729 ' HB3' ' HB2' ' A' ' 4' ' ' ALA . 93.7 mmm -59.86 -33.75 72.22 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.21 -0.931 . . . . 0.0 109.345 -179.968 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.583 ' NE2' ' O ' ' A' ' -1' ' ' SER . 99.3 mm-40 57.37 94.71 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.416 -0.802 . . . . 0.0 110.415 179.891 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 50.5 m80 59.17 46.14 13.46 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.516 -0.74 . . . . 0.0 110.655 179.068 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.729 ' HB2' ' HB3' ' A' ' 1' ' ' MET . . . -62.71 -40.22 96.49 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.016 -1.052 . . . . 0.0 109.313 179.486 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.0 t -60.19 -33.96 72.94 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.392 -0.817 . . . . 0.0 109.664 -179.955 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 55.9 t -60.24 -45.45 96.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.297 -0.877 . . . . 0.0 109.579 -179.854 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 75.5 mt -60.94 -45.26 98.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.326 -0.859 . . . . 0.0 109.025 179.65 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.484 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -61.56 -36.39 80.49 Favored 'General case' 0 N--CA 1.486 1.344 0 O-C-N 121.481 -0.762 . . . . 0.0 109.001 179.595 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 31.0 tt0 -64.78 -40.74 95.75 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.297 -0.877 . . . . 0.0 110.107 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.703 ' CG ' ' CE2' ' A' ' 47' ' ' TRP . 19.0 m-85 -61.71 -50.42 72.53 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.12 -0.987 . . . . 0.0 110.504 -179.452 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.439 HG23 ' N ' ' A' ' 12' ' ' VAL . 23.2 m -64.58 -41.07 91.21 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.5 0 O-C-N 121.051 -1.031 . . . . 0.0 109.185 -179.64 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.484 HG23 ' O ' ' A' ' 8' ' ' ALA . 79.6 t -63.95 -46.2 94.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.246 -0.909 . . . . 0.0 109.436 179.497 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -70.55 -27.7 64.35 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.171 -0.956 . . . . 0.0 110.171 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -64.46 -30.68 71.71 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.333 -0.855 . . . . 0.0 110.558 -178.883 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.454 ' CD2' ' CG1' ' A' ' 35' ' ' VAL . 96.2 m-85 -134.11 -38.64 0.86 Allowed 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.033 -1.042 . . . . 0.0 111.075 -179.317 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.523 HD22 ' CG2' ' A' ' 19' ' ' VAL . 9.1 mt -123.23 79.83 52.5 Favored Pre-proline 0 N--CA 1.493 1.684 0 O-C-N 121.067 -1.02 . . . . 0.0 110.571 -178.835 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -74.93 -15.53 20.88 Favored 'Trans proline' 0 C--N 1.309 -1.525 0 C-N-CA 122.305 2.003 . . . . 0.0 112.199 179.39 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -91.97 8.6 36.82 Favored 'General case' 0 C--N 1.305 -1.357 0 O-C-N 121.199 -0.938 . . . . 0.0 109.883 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.523 ' CG2' HD22 ' A' ' 16' ' ' LEU . 44.6 t -113.61 135.08 54.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 121.387 -0.82 . . . . 0.0 109.654 -179.746 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -73.9 119.67 77.35 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.321 -0.862 . . . . 0.0 109.288 179.877 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -51.14 -26.07 18.63 Favored 'Trans proline' 0 N--CA 1.494 1.502 0 C-N-CA 121.75 1.634 . . . . 0.0 112.132 179.482 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.81 -24.68 67.62 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.347 -0.846 . . . . 0.0 109.404 179.863 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.436 ' O ' ' OD1' ' A' ' 23' ' ' ASP . 60.2 t0 -81.83 6.83 14.43 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.32 -0.863 . . . . 0.0 109.759 -179.731 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 12.3 t -107.64 133.89 51.07 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.275 -0.89 . . . . 0.0 109.275 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 87.2 m-20 -89.06 120.47 30.5 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.085 -1.01 . . . . 0.0 109.0 179.324 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.0 m -76.4 4.47 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 O-C-N 121.19 -0.944 . . . . 0.0 109.124 179.655 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -91.45 -5.13 54.78 Favored 'General case' 0 C--N 1.305 -1.351 0 O-C-N 121.344 -0.847 . . . . 0.0 109.164 179.673 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 40.8 tp -98.65 138.5 35.74 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.323 -0.86 . . . . 0.0 109.34 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -60.61 134.69 57.32 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.247 -0.908 . . . . 0.0 109.484 -179.735 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.969 HD13 HD11 ' A' ' 36' ' ' ILE . 0.8 OUTLIER -69.06 -39.66 78.99 Favored 'General case' 0 C--N 1.301 -1.5 0 O-C-N 121.631 -0.668 . . . . 0.0 110.221 -179.293 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 70.8 t -64.04 -36.29 76.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 121.107 -0.996 . . . . 0.0 110.606 -178.759 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 56.7 t0 -52.52 -33.36 44.9 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 120.926 -1.109 . . . . 0.0 108.238 -179.904 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.508 ' HB3' HG23 ' A' ' 35' ' ' VAL . 97.3 m-20 -71.24 -34.69 71.01 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.661 -0.65 . . . . 0.0 110.049 179.608 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 83.24 6.16 88.22 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 108.831 -1.708 . . . . 0.0 108.831 -179.22 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.508 HG23 ' HB3' ' A' ' 33' ' ' ASN . 72.9 t -60.61 -30.9 47.77 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 O-C-N 121.503 -0.998 . . . . 0.0 108.356 179.329 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.969 HD11 HD13 ' A' ' 30' ' ' LEU . 89.7 mt -86.87 131.54 34.62 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.382 0 O-C-N 121.489 -0.757 . . . . 0.0 109.74 179.908 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.547 ' CG ' ' H ' ' A' ' 38' ' ' ALA . 52.0 t0 -128.01 -166.22 1.59 Allowed 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 108.646 -0.872 . . . . 0.0 108.646 179.582 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.547 ' H ' ' CG ' ' A' ' 37' ' ' ASP . . . -64.36 -54.58 30.75 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.126 -0.984 . . . . 0.0 108.886 179.849 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 34.4 mt -69.8 -32.76 71.39 Favored 'General case' 0 C--N 1.302 -1.475 0 N-CA-C 107.233 -1.395 . . . . 0.0 107.233 178.358 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.503 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.24 -41.39 96.75 Favored Glycine 0 N--CA 1.48 1.618 0 N-CA-C 108.668 -1.773 . . . . 0.0 108.668 179.271 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.6 tt -65.54 -41.9 92.51 Favored 'General case' 0 C--N 1.304 -1.38 0 O-C-N 121.426 -1.044 . . . . 0.0 108.942 179.219 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.2 tp -60.13 -45.98 91.18 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.435 -0.791 . . . . 0.0 109.208 179.801 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 28.5 mttp -60.11 -35.5 75.37 Favored 'General case' 0 C--N 1.296 -1.742 0 O-C-N 121.491 -0.755 . . . . 0.0 109.512 -179.783 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.503 HG23 ' O ' ' A' ' 40' ' ' GLY . 69.3 t -61.98 -48.23 89.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.335 -0.853 . . . . 0.0 109.927 -179.673 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.526 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 1.7 mp -68.15 -33.26 59.83 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.569 0 O-C-N 121.507 -0.746 . . . . 0.0 110.831 -179.652 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.0 -49.84 66.37 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 120.898 -1.126 . . . . 0.0 111.344 -178.179 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.703 ' CE2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -81.17 -44.54 17.71 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.718 -1.239 . . . . 0.0 109.936 -179.452 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.906 HD12 HH21 ' A' ' 51' ' ' ARG . 10.0 tp -58.43 -42.67 87.78 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.275 -0.891 . . . . 0.0 109.773 -179.07 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.526 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 2.3 pp20? -72.61 -35.93 67.98 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.094 -1.004 . . . . 0.0 109.786 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.2 t70 -60.02 -38.72 83.51 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.282 -0.886 . . . . 0.0 110.66 -179.517 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.906 HH21 HD12 ' A' ' 48' ' ' LEU . 62.6 mtm180 -62.09 -38.04 87.37 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.12 -0.987 . . . . 0.0 111.418 -178.824 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.834 ' CE2' HG11 ' A' ' 76' ' ' VAL . 95.6 m-85 -97.8 -11.94 22.78 Favored 'General case' 0 N--CA 1.487 1.391 0 O-C-N 120.738 -1.226 . . . . 0.0 110.164 -179.039 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 72.3 30.98 64.1 Favored Glycine 0 N--CA 1.488 2.102 0 N-CA-C 108.804 -1.718 . . . . 0.0 108.804 179.912 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.469 ' O ' ' OE1' ' A' ' 49' ' ' GLU . 34.5 pt -102.89 148.37 8.19 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.4 0 O-C-N 121.414 -1.05 . . . . 0.0 109.758 -179.436 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -89.87 112.42 23.76 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.184 -0.948 . . . . 0.0 109.679 -179.728 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.502 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -68.41 -27.14 65.95 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.332 -0.855 . . . . 0.0 109.585 179.686 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -55.73 -35.9 66.66 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.168 -0.957 . . . . 0.0 110.087 -179.587 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -55.55 -38.52 69.4 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.133 -0.979 . . . . 0.0 109.857 -179.631 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.502 ' O ' ' O ' ' A' ' 56' ' ' ALA . 42.7 t -124.95 136.16 61.74 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.419 -0.801 . . . . 0.0 109.658 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -89.18 131.09 35.46 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.028 -1.045 . . . . 0.0 109.297 179.872 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.502 HD12 HD11 ' A' ' 45' ' ' ILE . 38.1 mt -99.86 142.16 31.71 Favored 'General case' 0 C--N 1.305 -1.338 0 O-C-N 121.265 -0.897 . . . . 0.0 109.701 -179.7 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -109.49 157.18 38.1 Favored Pre-proline 0 N--CA 1.487 1.375 0 O-C-N 121.437 -0.789 . . . . 0.0 108.942 179.64 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_endo -55.33 -24.04 40.77 Favored 'Trans proline' 0 C--N 1.304 -1.77 0 C-N-CA 122.604 2.203 . . . . 0.0 111.827 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -69.06 -29.22 67.31 Favored 'General case' 0 C--N 1.304 -1.374 0 O-C-N 121.364 -0.835 . . . . 0.0 109.139 179.703 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' HIS . . . . . 0.531 ' CD2' ' O ' ' A' ' 65' ' ' HIS . 2.9 t-80 -66.33 -18.5 65.39 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.359 -0.838 . . . . 0.0 108.895 179.938 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.521 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 11.4 m-85 -94.69 13.77 23.3 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 179.582 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 67' ' ' ARG . . . . . 0.478 ' CZ ' ' OG ' ' A' ' 71' ' ' SER . 7.5 ptt180 -44.2 -38.92 4.05 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.811 -0.556 . . . . 0.0 110.545 -179.594 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 80.1 p -155.7 161.42 40.74 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.806 -1.184 . . . . 0.0 110.3 -179.629 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.479 ' CD1' HD12 ' A' ' 30' ' ' LEU . 31.3 mm -60.66 -44.14 96.39 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 O-C-N 121.39 -0.819 . . . . 0.0 110.172 -179.774 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.618 ' HG3' ' HZ1' ' A' ' 87' ' ' LYS . 0.0 OUTLIER -58.88 -39.74 82.29 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.214 -0.929 . . . . 0.0 109.656 -179.304 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.478 ' OG ' ' CZ ' ' A' ' 67' ' ' ARG . 23.2 t -63.08 -40.61 98.17 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.248 -0.907 . . . . 0.0 109.643 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 86.0 mt -61.95 -50.56 79.64 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 O-C-N 121.214 -0.929 . . . . 0.0 110.107 -179.755 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.489 ' OD2' ' O ' ' A' ' 1' ' ' MET . 40.9 t0 -59.28 -41.13 88.2 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.234 -0.916 . . . . 0.0 109.357 -179.842 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.439 ' O ' ' N ' ' A' ' 78' ' ' GLY . . . -66.49 -37.42 85.03 Favored 'General case' 0 C--N 1.302 -1.458 0 O-C-N 121.505 -0.747 . . . . 0.0 110.266 -179.587 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 75' ' ' PHE . . . . . 0.531 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 62.6 t80 -61.99 -48.12 81.77 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.022 -1.049 . . . . 0.0 109.886 -179.502 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.834 HG11 ' CE2' ' A' ' 52' ' ' PHE . 87.6 t -64.92 -48.25 84.96 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.323 0 O-C-N 121.097 -1.002 . . . . 0.0 109.671 -179.801 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 60.8 t -69.31 -39.18 78.69 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 O-C-N 121.214 -0.929 . . . . 0.0 109.142 179.585 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.439 ' N ' ' O ' ' A' ' 74' ' ' ALA . . . -59.1 -35.35 83.66 Favored Glycine 0 N--CA 1.487 2.088 0 N-CA-C 110.207 -1.157 . . . . 0.0 110.207 -179.678 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -70.35 -41.68 72.86 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.265 -1.138 . . . . 0.0 111.044 -178.791 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 44.6 p -81.78 -34.79 30.15 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.094 -1.004 . . . . 0.0 109.497 -179.622 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -133.29 153.78 80.76 Favored Pre-proline 0 C--N 1.299 -1.592 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 -179.848 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo -43.65 143.57 2.66 Favored 'Trans proline' 0 C--N 1.307 -1.631 0 C-N-CA 121.737 1.625 . . . . 0.0 111.003 179.521 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 83' ' ' PRO . . . . . 0.538 ' HB2' ' HB2' ' A' ' 86' ' ' ALA . 10.9 Cg_endo -60.93 141.59 95.02 Favored 'Trans proline' 0 C--N 1.311 -1.434 0 C-N-CA 121.896 1.731 . . . . 0.0 112.748 -179.18 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.656 HG21 ' OE1' ' A' ' 0' ' ' GLU . 14.7 p -104.53 129.92 56.21 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 179.393 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.5 ' C ' ' O ' ' A' ' 84' ' ' VAL . 96.2 mt-10 36.25 40.17 0.1 Allowed 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.596 -0.69 . . . . 0.0 109.909 179.839 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.538 ' HB2' ' HB2' ' A' ' 83' ' ' PRO . . . -50.23 145.23 6.27 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.116 -0.99 . . . . 0.0 109.599 -179.611 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.618 ' HZ1' ' HG3' ' A' ' 70' ' ' ARG . 69.0 mttm -57.67 -34.75 69.73 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.282 -0.886 . . . . 0.0 109.443 -179.914 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 55.5 mt -93.15 142.03 27.75 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.171 -0.955 . . . . 0.0 109.424 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.3 mt-30 . . . . . 0 N--CA 1.491 1.582 0 CA-C-O 117.936 -1.031 . . . . 0.0 109.407 -179.972 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' -1' ' ' SER . . . . . . . . . . . . . 1.8 p . . . . . 0 N--CA 1.492 1.634 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 0' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -61.79 -33.44 74.11 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.19 -0.944 . . . . 0.0 109.449 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.749 ' HB3' ' HB2' ' A' ' 4' ' ' ALA . 96.6 mmm -58.15 -34.1 69.93 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.304 -0.872 . . . . 0.0 109.485 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.573 ' CB ' ' O ' ' A' ' 1' ' ' MET . 28.6 tp60 84.66 66.98 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.726 0 CA-C-O 121.338 0.589 . . . . 0.0 109.541 -179.788 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 58.9 m-70 63.15 47.54 4.09 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.42 -0.8 . . . . 0.0 110.316 179.661 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.749 ' HB2' ' HB3' ' A' ' 1' ' ' MET . . . -62.25 -38.82 90.73 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.06 -1.025 . . . . 0.0 109.484 179.718 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.4 m -60.28 -36.88 78.85 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.368 -0.832 . . . . 0.0 110.107 -179.645 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 48.9 t -62.15 -44.81 99.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.124 -0.985 . . . . 0.0 109.723 -179.757 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.439 ' O ' HG12 ' A' ' 11' ' ' VAL . 89.7 mt -59.53 -49.8 82.29 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.613 0 O-C-N 121.341 -0.849 . . . . 0.0 110.037 -179.504 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.714 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.5 -43.97 95.72 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.378 -0.826 . . . . 0.0 111.111 -179.136 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 53.0 mt-30 -69.22 -46.0 68.45 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 120.844 -1.16 . . . . 0.0 111.284 -178.607 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.705 ' CD1' ' N ' ' A' ' 11' ' ' VAL . 0.0 OUTLIER -69.82 -47.01 64.38 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 120.951 -1.093 . . . . 0.0 110.519 -179.142 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.705 ' N ' ' CD1' ' A' ' 10' ' ' PHE . 5.1 p -61.54 -38.91 81.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.062 -1.024 . . . . 0.0 109.731 -179.671 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.714 HG23 ' O ' ' A' ' 8' ' ' ALA . 56.0 t -63.33 -43.44 98.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.133 -0.979 . . . . 0.0 109.821 -179.949 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -63.9 -39.02 93.22 Favored 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.166 -0.958 . . . . 0.0 110.187 -179.519 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 85.2 tt0 -70.02 -42.26 73.2 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.182 -0.949 . . . . 0.0 110.0 -179.849 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 77.7 t80 -83.58 -52.18 6.68 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.221 -0.924 . . . . 0.0 110.618 -179.435 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.478 HD22 ' CG2' ' A' ' 19' ' ' VAL . 7.3 mt -123.64 80.07 55.26 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.378 -0.826 . . . . 0.0 110.292 -179.04 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -67.02 -15.65 47.36 Favored 'Trans proline' 0 N--CA 1.492 1.401 0 C-N-CA 122.056 1.837 . . . . 0.0 112.466 179.682 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -95.26 7.34 46.47 Favored 'General case' 0 N--CA 1.486 1.335 0 O-C-N 121.083 -1.011 . . . . 0.0 110.429 -179.499 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.478 ' CG2' HD22 ' A' ' 16' ' ' LEU . 21.8 t -119.47 136.21 57.37 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.214 -0.929 . . . . 0.0 109.843 -179.825 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.487 ' O ' ' OD1' ' A' ' 23' ' ' ASP . . . -77.58 118.69 73.71 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.241 -0.912 . . . . 0.0 108.978 179.516 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_exo -51.15 -25.75 17.84 Favored 'Trans proline' 0 N--CA 1.493 1.487 0 C-N-CA 121.798 1.665 . . . . 0.0 112.223 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.88 -27.46 68.87 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.183 -0.948 . . . . 0.0 109.726 -179.854 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.487 ' OD1' ' O ' ' A' ' 20' ' ' ALA . 47.3 p30 -87.28 7.72 27.36 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.136 -0.977 . . . . 0.0 109.84 -179.678 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.463 HG23 ' OD1' ' A' ' 23' ' ' ASP . 16.4 t -110.16 132.06 59.5 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 O-C-N 121.311 -0.868 . . . . 0.0 109.446 179.88 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 62.2 t0 -89.26 119.47 29.77 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.197 -0.94 . . . . 0.0 108.993 179.308 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.637 HG22 ' O ' ' A' ' 26' ' ' VAL . 1.9 p -74.66 4.85 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 O-C-N 121.102 -0.999 . . . . 0.0 108.914 179.632 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -98.21 3.4 48.92 Favored 'General case' 0 N--CA 1.486 1.371 0 O-C-N 121.198 -0.938 . . . . 0.0 109.253 179.636 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 40.0 tp -97.95 134.6 40.84 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.354 -0.841 . . . . 0.0 109.37 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 82.2 m-20 -65.67 142.06 58.17 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.226 -0.921 . . . . 0.0 109.298 -179.71 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.58 HD11 HG13 ' A' ' 69' ' ' ILE . 91.4 mt -70.7 -33.73 71.2 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.325 -0.859 . . . . 0.0 110.698 -179.411 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.66 HG23 ' N ' ' A' ' 32' ' ' ASP . 20.0 m -53.56 -47.74 59.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 O-C-N 121.146 -0.971 . . . . 0.0 110.155 -178.686 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.66 ' N ' HG23 ' A' ' 31' ' ' VAL . 90.8 m-20 -61.11 -35.04 75.96 Favored 'General case' 0 C--N 1.3 -1.568 0 O-C-N 121.248 -0.908 . . . . 0.0 108.624 179.496 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 96.4 m-20 -70.84 -34.32 71.55 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.686 -0.634 . . . . 0.0 110.11 -179.842 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 86.17 5.32 83.1 Favored Glycine 0 N--CA 1.491 2.367 0 N-CA-C 109.158 -1.577 . . . . 0.0 109.158 -179.685 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 71.9 t -60.85 -34.41 59.25 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 O-C-N 121.402 -1.058 . . . . 0.0 108.93 179.672 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 92.1 mt -66.46 95.21 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.428 0 O-C-N 121.467 -0.771 . . . . 0.0 110.313 -179.559 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -102.95 169.36 8.62 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 178.85 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -55.55 -48.65 74.4 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 107.761 -1.2 . . . . 0.0 107.761 179.659 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.719 HD12 ' N ' ' A' ' 39' ' ' LEU . 6.8 mp -71.14 -32.16 68.62 Favored 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 106.984 -1.488 . . . . 0.0 106.984 177.592 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.5 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -58.77 -48.1 86.93 Favored Glycine 0 N--CA 1.483 1.795 0 N-CA-C 109.181 -1.568 . . . . 0.0 109.181 179.705 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.5 tt -63.08 -40.29 97.22 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.367 -1.078 . . . . 0.0 109.187 179.314 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.1 tp -59.73 -46.22 89.8 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.264 -0.897 . . . . 0.0 109.23 179.956 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 63.8 mttp -61.67 -34.35 75.57 Favored 'General case' 0 C--N 1.297 -1.7 0 O-C-N 121.443 -0.786 . . . . 0.0 109.604 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.5 HG23 ' O ' ' A' ' 40' ' ' GLY . 78.9 t -60.8 -47.07 94.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.377 -0.827 . . . . 0.0 110.036 -179.512 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.403 HD12 ' N ' ' A' ' 45' ' ' ILE . 1.7 mp -67.89 -36.56 76.12 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 O-C-N 121.295 -0.878 . . . . 0.0 111.35 -179.474 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.3 -49.38 64.46 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 120.965 -1.084 . . . . 0.0 111.853 -178.031 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.549 ' HE1' ' NE ' ' A' ' 51' ' ' ARG . 0.0 OUTLIER -78.37 -42.59 29.95 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 120.541 -1.349 . . . . 0.0 110.105 -179.062 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.458 HD11 ' CG2' ' A' ' 76' ' ' VAL . 7.4 tt -59.78 -42.08 92.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.242 -0.911 . . . . 0.0 110.667 -179.239 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 18.9 pt-20 -72.69 -36.51 67.9 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.101 -1.0 . . . . 0.0 109.94 -179.4 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.7 t0 -61.17 -39.61 90.76 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.362 -0.836 . . . . 0.0 111.247 -179.186 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.549 ' NE ' ' HE1' ' A' ' 47' ' ' TRP . 94.0 mtt-85 -63.18 -38.91 93.04 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.094 -1.004 . . . . 0.0 112.567 -178.074 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.732 ' CD1' HG11 ' A' ' 76' ' ' VAL . 85.5 m-85 -99.2 -7.63 26.23 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 120.656 -1.278 . . . . 0.0 110.635 -178.682 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 69.82 30.54 70.34 Favored Glycine 0 N--CA 1.486 2.012 0 N-CA-C 108.924 -1.67 . . . . 0.0 108.924 179.425 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 26.5 pt -106.59 153.23 7.91 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 O-C-N 121.634 -0.921 . . . . 0.0 109.544 -179.557 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -98.59 134.19 41.88 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.138 -0.977 . . . . 0.0 109.639 -179.498 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.518 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -65.84 -30.29 70.89 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.28 -0.887 . . . . 0.0 109.58 179.903 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -57.71 -34.56 69.59 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.212 -0.93 . . . . 0.0 110.242 -179.741 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -54.93 -39.38 68.78 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.196 -0.94 . . . . 0.0 110.403 -179.297 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.518 ' O ' ' O ' ' A' ' 56' ' ' ALA . 31.5 m -128.67 157.05 41.41 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 O-C-N 121.275 -0.891 . . . . 0.0 109.804 -179.503 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -96.54 128.95 43.96 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.986 -1.071 . . . . 0.0 109.167 179.724 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 58.1 mt -101.39 135.33 43.05 Favored 'General case' 0 C--N 1.305 -1.334 0 O-C-N 121.214 -0.929 . . . . 0.0 109.798 -179.815 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -109.97 156.05 40.62 Favored Pre-proline 0 N--CA 1.487 1.393 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 179.395 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 10.8 Cg_endo -56.94 -24.1 55.07 Favored 'Trans proline' 0 C--N 1.303 -1.839 0 C-N-CA 122.406 2.071 . . . . 0.0 111.74 179.891 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -69.47 -29.35 67.0 Favored 'General case' 0 C--N 1.306 -1.315 0 O-C-N 121.338 -0.851 . . . . 0.0 109.172 179.721 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 65' ' ' HIS . . . . . 0.592 ' CD2' ' O ' ' A' ' 65' ' ' HIS . 4.3 t-160 -65.97 -17.69 64.84 Favored 'General case' 0 C--N 1.3 -1.562 0 O-C-N 121.417 -0.802 . . . . 0.0 108.966 -179.911 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.493 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 17.3 m-85 -93.14 14.86 16.71 Favored 'General case' 0 C--N 1.303 -1.445 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 179.532 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 67' ' ' ARG . . . . . 0.445 HH21 ' HB3' ' A' ' 87' ' ' LYS . 8.9 ptt180 -48.38 -38.53 19.64 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.816 -0.552 . . . . 0.0 110.822 -179.498 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 31.9 t -158.53 150.24 21.19 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 120.76 -1.213 . . . . 0.0 110.362 -179.667 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.734 ' H ' HD12 ' A' ' 69' ' ' ILE . 0.1 OUTLIER -57.74 -42.86 82.74 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.365 -0.835 . . . . 0.0 109.255 179.688 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.411 HH12 ' HG3' ' A' ' 87' ' ' LYS . 5.8 ptm180 -57.88 -40.66 80.77 Favored 'General case' 0 C--N 1.303 -1.427 0 O-C-N 121.42 -0.8 . . . . 0.0 109.326 -179.89 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 84.9 p -66.42 -34.39 77.85 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.236 -0.915 . . . . 0.0 109.514 179.538 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.556 HD12 ' HA ' ' A' ' 69' ' ' ILE . 91.5 mt -59.99 -51.14 76.4 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.243 0 O-C-N 121.163 -0.961 . . . . 0.0 109.749 179.969 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.474 ' OD2' ' O ' ' A' ' 1' ' ' MET . 42.4 t0 -59.49 -42.07 91.28 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.172 -0.955 . . . . 0.0 108.976 179.823 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.556 ' O ' ' N ' ' A' ' 78' ' ' GLY . . . -66.72 -37.11 84.03 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.661 -0.649 . . . . 0.0 110.148 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 75' ' ' PHE . . . . . 0.459 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 64.6 t80 -61.3 -49.7 75.97 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.004 -1.06 . . . . 0.0 109.686 -179.604 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.732 HG11 ' CD1' ' A' ' 52' ' ' PHE . 44.3 t -68.66 -48.89 69.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.307 0 O-C-N 121.216 -0.927 . . . . 0.0 109.875 -179.568 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.414 HG21 ' CB ' ' A' ' 2' ' ' GLN . 82.1 t -69.62 -41.91 80.38 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.305 0 O-C-N 121.211 -0.931 . . . . 0.0 109.151 179.803 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.556 ' N ' ' O ' ' A' ' 74' ' ' ALA . . . -60.48 -39.42 96.31 Favored Glycine 0 N--CA 1.488 2.134 0 N-CA-C 109.895 -1.282 . . . . 0.0 109.895 -179.872 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -68.33 -41.07 81.33 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.159 -1.201 . . . . 0.0 110.245 -179.428 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 45.0 p -82.32 -29.86 30.8 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.189 -0.944 . . . . 0.0 109.594 -179.768 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.495 ' O ' ' O ' ' A' ' 78' ' ' GLY . 0.3 OUTLIER -133.31 153.74 80.73 Favored Pre-proline 0 C--N 1.302 -1.461 0 O-C-N 121.522 -0.736 . . . . 0.0 109.457 -179.659 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -62.39 111.17 1.22 Allowed 'Trans proline' 0 C--N 1.308 -1.603 0 C-N-CA 122.293 1.995 . . . . 0.0 111.528 179.755 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_endo -76.34 152.09 34.33 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.116 1.877 . . . . 0.0 113.069 -179.224 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.474 ' O ' ' C ' ' A' ' 85' ' ' GLU . 43.9 t -103.77 131.67 51.89 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 O-C-N 121.561 -0.712 . . . . 0.0 109.087 179.43 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.474 ' C ' ' O ' ' A' ' 84' ' ' VAL . 84.2 tt0 38.88 69.03 0.3 Allowed 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.454 -0.779 . . . . 0.0 109.762 179.994 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -60.37 150.15 31.64 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.209 -0.932 . . . . 0.0 109.833 -179.768 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.445 ' HB3' HH21 ' A' ' 67' ' ' ARG . 21.1 tttm -55.96 -38.72 70.76 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.341 -0.849 . . . . 0.0 109.431 179.874 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 36.1 tp -58.97 -37.24 76.36 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.315 -0.865 . . . . 0.0 109.396 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.0 mt-30 . . . . . 0 N--CA 1.489 1.522 0 CA-C-O 118.046 -0.978 . . . . 0.0 109.486 -179.914 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' -1' ' ' SER . . . . . . . . . . . . . 74.3 m . . . . . 0 N--CA 1.491 1.616 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 0' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -58.66 140.44 54.57 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.216 -0.927 . . . . 0.0 109.513 -179.92 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.507 ' HB3' ' HB2' ' A' ' 4' ' ' ALA . 65.4 mtt -60.99 -36.68 80.08 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.211 -0.93 . . . . 0.0 109.823 179.971 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.763 ' OE1' HG22 ' A' ' 77' ' ' VAL . 87.3 mt-30 56.35 49.78 14.46 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.386 -0.821 . . . . 0.0 109.34 -179.44 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.484 ' CG ' ' C ' ' A' ' 2' ' ' GLN . 5.7 m80 76.63 54.68 0.04 OUTLIER 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.705 -0.622 . . . . 0.0 110.127 179.874 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.507 ' HB2' ' HB3' ' A' ' 1' ' ' MET . . . -62.26 -38.34 88.92 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.045 -1.034 . . . . 0.0 109.396 179.719 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.3 t -60.66 -38.03 83.53 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.36 -0.837 . . . . 0.0 110.049 -179.585 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 73.4 t -61.53 -43.12 96.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.203 -0.935 . . . . 0.0 109.539 -179.836 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 75.3 mt -60.32 -46.04 95.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.395 -0.816 . . . . 0.0 109.283 179.742 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.529 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -61.47 -39.24 90.18 Favored 'General case' 0 N--CA 1.486 1.372 0 O-C-N 121.268 -0.895 . . . . 0.0 108.675 179.546 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 33.2 tt0 -64.99 -35.11 80.13 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.419 -0.801 . . . . 0.0 109.143 179.289 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.612 ' CZ ' ' CD1' ' A' ' 47' ' ' TRP . 0.3 OUTLIER -60.51 -50.9 71.72 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.495 -0.753 . . . . 0.0 110.184 -179.569 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.734 HG11 HD11 ' A' ' 30' ' ' LEU . 22.7 m -66.55 -38.26 81.3 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 O-C-N 121.164 -0.96 . . . . 0.0 109.117 -179.743 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.529 HG23 ' O ' ' A' ' 8' ' ' ALA . 73.9 t -63.47 -44.87 98.99 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.439 0 O-C-N 121.24 -0.912 . . . . 0.0 109.351 179.496 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -73.3 -19.27 61.08 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.266 -0.896 . . . . 0.0 109.939 179.746 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -63.9 -32.28 73.75 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.33 -0.857 . . . . 0.0 110.449 -178.983 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 64.8 t80 -142.28 -36.62 0.41 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 120.958 -1.089 . . . . 0.0 110.463 -179.62 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.507 HD22 ' CG2' ' A' ' 19' ' ' VAL . 5.6 mt -119.55 79.89 22.26 Favored Pre-proline 0 N--CA 1.491 1.615 0 O-C-N 121.211 -0.93 . . . . 0.0 110.017 -179.495 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_endo -77.97 -14.16 15.45 Favored 'Trans proline' 0 C--N 1.308 -1.58 0 C-N-CA 122.604 2.203 . . . . 0.0 112.235 179.592 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -90.31 7.25 39.37 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 121.343 -0.848 . . . . 0.0 109.9 -179.699 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.507 ' CG2' HD22 ' A' ' 16' ' ' LEU . 44.7 t -109.28 134.86 49.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.303 -0.873 . . . . 0.0 109.588 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.489 ' O ' ' OD1' ' A' ' 23' ' ' ASP . . . -72.52 117.15 56.53 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.275 -0.89 . . . . 0.0 109.382 -179.942 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_exo -52.5 -26.16 27.64 Favored 'Trans proline' 0 N--CA 1.493 1.468 0 C-N-CA 121.891 1.728 . . . . 0.0 112.095 179.446 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.88 -23.42 67.23 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.355 -0.841 . . . . 0.0 109.731 -179.762 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.489 ' OD1' ' O ' ' A' ' 20' ' ' ALA . 52.6 p30 -84.69 7.85 19.02 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.16 -0.963 . . . . 0.0 110.003 -179.615 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 12.2 t -103.0 131.74 50.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.162 -0.961 . . . . 0.0 109.5 -179.868 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 63.5 t0 -89.0 119.94 29.98 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.101 -1.0 . . . . 0.0 108.93 179.247 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.5 m -73.12 4.28 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 O-C-N 121.079 -1.013 . . . . 0.0 109.547 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -89.67 -8.22 52.9 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.215 -0.928 . . . . 0.0 109.111 179.577 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 40.5 tp -101.62 139.46 37.23 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.427 -0.796 . . . . 0.0 109.313 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.5 m-20 -58.88 142.17 51.4 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.249 -0.907 . . . . 0.0 109.388 -179.78 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.841 HD13 HD11 ' A' ' 36' ' ' ILE . 1.4 tt -69.12 -38.6 78.95 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.607 -0.683 . . . . 0.0 110.743 -178.846 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 75.4 t -64.5 -36.16 76.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.086 -1.009 . . . . 0.0 110.542 -178.903 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 91.3 m-20 -52.58 -33.66 47.09 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 120.969 -1.082 . . . . 0.0 108.218 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.428 ' HB3' HG23 ' A' ' 35' ' ' VAL . 97.6 m-20 -70.94 -34.37 71.4 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.615 -0.678 . . . . 0.0 109.99 179.534 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 86.05 6.04 82.48 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.315 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.428 HG23 ' HB3' ' A' ' 33' ' ' ASN . 71.6 t -61.51 -33.01 55.14 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.411 0 O-C-N 121.413 -1.051 . . . . 0.0 109.07 179.755 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.841 HD11 HD13 ' A' ' 30' ' ' LEU . 84.7 mt -91.95 123.85 44.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.276 -0.89 . . . . 0.0 109.802 -179.859 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -114.97 -168.44 1.38 Allowed 'General case' 0 C--N 1.301 -1.501 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 179.61 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -63.77 -53.84 44.6 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.103 -0.998 . . . . 0.0 108.717 179.683 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.585 HD12 ' N ' ' A' ' 39' ' ' LEU . 6.6 mp -68.88 -32.9 72.88 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 107.007 -1.479 . . . . 0.0 107.007 178.222 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.492 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.04 -41.91 96.7 Favored Glycine 0 N--CA 1.48 1.627 0 N-CA-C 108.691 -1.763 . . . . 0.0 108.691 179.211 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.407 HD11 ' CE1' ' A' ' 66' ' ' PHE . 7.7 tt -65.16 -41.09 95.03 Favored 'General case' 0 C--N 1.304 -1.393 0 O-C-N 121.454 -1.027 . . . . 0.0 108.851 179.066 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.1 tp -59.88 -45.81 91.31 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.365 -0.834 . . . . 0.0 109.051 179.728 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 78.6 mttt -60.34 -35.73 76.35 Favored 'General case' 0 C--N 1.298 -1.672 0 O-C-N 121.471 -0.768 . . . . 0.0 109.456 -179.863 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.492 HG23 ' O ' ' A' ' 40' ' ' GLY . 77.7 t -62.03 -43.32 97.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.308 -0.87 . . . . 0.0 109.795 -179.884 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.706 ' CD1' HD12 ' A' ' 61' ' ' LEU . 1.5 mp -67.33 -39.56 83.04 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.541 0 O-C-N 121.549 -0.719 . . . . 0.0 111.196 -179.382 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.36 -50.19 60.86 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 120.637 -1.289 . . . . 0.0 112.015 -177.72 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.612 ' CD1' ' CZ ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -78.65 -45.01 22.45 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.665 -1.272 . . . . 0.0 110.647 -178.701 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.697 HD11 HG21 ' A' ' 76' ' ' VAL . 29.4 tp -58.5 -44.19 89.34 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.12 -0.987 . . . . 0.0 110.062 -178.862 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 68.9 mm-40 -68.06 -37.75 81.66 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.117 -0.989 . . . . 0.0 109.582 -179.819 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.1 t70 -62.37 -36.94 83.83 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.358 -0.839 . . . . 0.0 110.792 -179.754 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 35.5 mmt180 -58.1 -39.07 77.67 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.09 -1.007 . . . . 0.0 111.162 -178.641 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.604 ' CE1' ' CG1' ' A' ' 76' ' ' VAL . 9.0 m-85 -91.89 -3.57 55.84 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.842 -1.161 . . . . 0.0 110.319 -179.286 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 73.87 29.8 62.49 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 108.52 -1.832 . . . . 0.0 108.52 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 31.9 pt -113.45 153.61 14.98 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 O-C-N 121.714 -0.874 . . . . 0.0 109.866 -179.17 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -97.06 139.92 32.34 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.307 -0.871 . . . . 0.0 109.259 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.585 ' HB2' HG23 ' A' ' 45' ' ' ILE . . . -62.85 -30.71 71.71 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.24 -0.912 . . . . 0.0 109.715 -179.796 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -56.72 -38.77 72.81 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.054 -1.029 . . . . 0.0 109.681 -179.758 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 90.7 m-20 -61.36 -41.29 96.83 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.204 -0.935 . . . . 0.0 109.945 -179.878 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.482 ' O ' ' O ' ' A' ' 56' ' ' ALA . 46.8 t -130.35 133.73 63.49 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 121.408 -0.808 . . . . 0.0 109.728 -179.845 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -104.15 134.27 47.68 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.295 -0.878 . . . . 0.0 109.402 179.677 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.706 HD12 ' CD1' ' A' ' 45' ' ' ILE . 40.2 mt -96.23 141.82 29.13 Favored 'General case' 0 C--N 1.304 -1.387 0 O-C-N 121.217 -0.927 . . . . 0.0 109.521 -179.759 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -109.58 156.33 39.82 Favored Pre-proline 0 C--N 1.305 -1.343 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 179.684 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 1.4 Cg_endo -48.92 -22.23 4.62 Favored 'Trans proline' 0 C--N 1.305 -1.729 0 C-N-CA 121.924 1.75 . . . . 0.0 110.837 179.604 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 87.1 tt0 -71.13 -30.14 66.12 Favored 'General case' 0 N--CA 1.486 1.351 0 O-C-N 121.563 -0.711 . . . . 0.0 109.477 179.094 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 65' ' ' HIS . . . . . 0.54 ' C ' ' CD2' ' A' ' 65' ' ' HIS . 1.2 t60 -65.84 -16.49 63.87 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.397 -0.814 . . . . 0.0 108.97 -179.794 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.558 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 12.5 m-85 -97.53 15.38 23.45 Favored 'General case' 0 C--N 1.299 -1.598 0 CA-C-O 121.739 0.78 . . . . 0.0 108.896 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 67' ' ' ARG . . . . . 0.598 ' NE ' ' OG ' ' A' ' 71' ' ' SER . 6.6 ptt180 -50.71 -36.13 34.72 Favored 'General case' 0 C--N 1.301 -1.5 0 O-C-N 121.701 -0.624 . . . . 0.0 110.002 -179.719 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 68' ' ' SER . . . . . 0.462 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 88.8 p -162.86 153.35 16.56 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.982 -1.074 . . . . 0.0 110.216 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.67 ' H ' HD12 ' A' ' 69' ' ' ILE . 3.5 mp -58.42 -43.4 86.51 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 O-C-N 121.34 -0.85 . . . . 0.0 109.046 179.68 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 10.0 ptm180 -58.17 -40.11 80.62 Favored 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 108.96 -0.756 . . . . 0.0 108.96 179.5 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.598 ' OG ' ' NE ' ' A' ' 67' ' ' ARG . 25.9 t -63.46 -41.14 98.62 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.434 -0.792 . . . . 0.0 109.827 179.542 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 81.8 mt -58.91 -48.7 85.57 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.315 0 O-C-N 121.239 -0.913 . . . . 0.0 109.603 -179.615 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 37.4 t0 -60.07 -43.76 95.21 Favored 'General case' 0 N--CA 1.487 1.406 0 O-C-N 121.22 -0.925 . . . . 0.0 108.728 179.756 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.99 -38.77 86.63 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.658 -0.651 . . . . 0.0 109.932 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 75' ' ' PHE . . . . . 0.577 ' O ' ' HB2' ' A' ' 79' ' ' ALA . 53.5 t80 -62.76 -47.99 81.13 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.177 -0.952 . . . . 0.0 109.473 -179.698 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.697 HG21 HD11 ' A' ' 48' ' ' LEU . 50.0 t -64.99 -48.33 84.49 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.294 0 O-C-N 121.255 -0.903 . . . . 0.0 109.774 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.763 HG22 ' OE1' ' A' ' 2' ' ' GLN . 88.7 t -69.88 -49.06 60.0 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 O-C-N 121.2 -0.937 . . . . 0.0 109.356 179.705 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.493 ' O ' ' O ' ' A' ' 81' ' ' THR . . . -65.6 -26.58 72.01 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 -179.778 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 79' ' ' ALA . . . . . 0.577 ' HB2' ' O ' ' A' ' 75' ' ' PHE . . . -67.12 -39.39 86.65 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.145 -1.209 . . . . 0.0 110.019 -179.31 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 56.6 p -82.19 -28.7 31.89 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.197 -0.939 . . . . 0.0 109.585 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.625 HG22 ' O ' ' A' ' 77' ' ' VAL . 2.0 t -133.04 148.77 70.66 Favored Pre-proline 0 N--CA 1.489 1.522 0 O-C-N 121.389 -0.819 . . . . 0.0 109.65 -179.857 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 87.6 Cg_exo -40.76 109.41 0.1 Allowed 'Trans proline' 0 C--N 1.311 -1.435 0 C-N-CA 122.252 1.968 . . . . 0.0 111.862 179.248 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 22.4 Cg_exo -57.55 146.43 84.18 Favored 'Trans proline' 0 N--CA 1.49 1.317 0 C-N-CA 121.966 1.777 . . . . 0.0 112.158 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.463 ' O ' ' C ' ' A' ' 85' ' ' GLU . 45.8 t -102.76 130.79 52.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.382 -0.824 . . . . 0.0 109.12 179.58 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.463 ' C ' ' O ' ' A' ' 84' ' ' VAL . 96.2 mt-10 38.59 63.59 0.86 Allowed 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.437 -0.789 . . . . 0.0 109.839 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.401 ' C ' ' O ' ' A' ' 85' ' ' GLU . . . -45.3 149.11 0.55 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.19 -0.944 . . . . 0.0 109.513 -179.844 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 12.6 tttm -55.88 -33.48 64.63 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.308 -0.87 . . . . 0.0 109.519 -179.8 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 55.6 mt -80.73 143.07 33.23 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.277 -0.89 . . . . 0.0 109.46 -179.915 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 63.6 tt0 . . . . . 0 N--CA 1.49 1.541 0 CA-C-O 118.042 -0.98 . . . . 0.0 109.479 -179.924 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' -1' ' ' SER . . . . . . . . . . . . . 13.4 m . . . . . 0 N--CA 1.49 1.549 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 0' ' ' GLU . . . . . 0.472 ' HG2' HG21 ' A' ' 84' ' ' VAL . 44.7 tp10 -58.03 -34.12 69.72 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.301 -0.874 . . . . 0.0 109.277 179.952 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.555 ' HB3' ' HB2' ' A' ' 4' ' ' ALA . 65.4 mtt -60.52 -33.7 73.02 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.36 -0.837 . . . . 0.0 109.767 179.826 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.612 ' CD ' HG22 ' A' ' 77' ' ' VAL . 90.7 mt-30 58.48 48.99 11.27 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.512 -0.742 . . . . 0.0 109.469 -179.452 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.493 ' CG ' ' C ' ' A' ' 2' ' ' GLN . 5.1 m80 76.42 57.38 0.04 OUTLIER 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.637 -0.664 . . . . 0.0 110.225 179.677 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.555 ' HB2' ' HB3' ' A' ' 1' ' ' MET . . . -62.74 -41.36 99.15 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.078 -1.014 . . . . 0.0 109.509 179.77 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.3 p -62.75 -34.57 77.47 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.204 -0.935 . . . . 0.0 109.685 -179.731 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 65.3 t -64.62 -41.66 92.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.228 -0.92 . . . . 0.0 109.183 179.75 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 77.7 mt -59.67 -44.61 93.91 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 O-C-N 121.481 -0.762 . . . . 0.0 109.238 179.875 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -62.12 -38.33 88.53 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.333 -0.854 . . . . 0.0 109.235 179.875 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 59.2 tt0 -59.09 -41.14 87.36 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.273 -0.892 . . . . 0.0 109.185 179.72 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.699 ' CG ' ' CE2' ' A' ' 47' ' ' TRP . 23.0 m-85 -63.32 -40.74 98.16 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.012 -1.055 . . . . 0.0 109.955 179.586 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 55.9 t -59.53 -50.63 79.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.276 -0.89 . . . . 0.0 110.726 -178.558 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.472 ' O ' ' C ' ' A' ' 16' ' ' LEU . 17.1 m -66.12 -39.6 84.86 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.428 0 O-C-N 120.656 -1.277 . . . . 0.0 109.813 -179.955 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -67.21 -20.54 65.71 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.136 -0.977 . . . . 0.0 110.39 -179.785 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 -63.34 -30.11 71.3 Favored 'General case' 0 C--N 1.299 -1.606 0 O-C-N 121.275 -0.891 . . . . 0.0 109.731 -179.309 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 63.6 t80 -149.27 -33.23 0.21 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.997 -1.064 . . . . 0.0 110.253 -179.917 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.472 ' C ' ' O ' ' A' ' 12' ' ' VAL . 3.8 mt -121.89 79.93 41.47 Favored Pre-proline 0 N--CA 1.492 1.671 0 O-C-N 121.189 -0.945 . . . . 0.0 110.126 -179.383 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -74.62 -11.98 22.3 Favored 'Trans proline' 0 C--N 1.308 -1.573 0 C-N-CA 122.403 2.068 . . . . 0.0 112.438 179.881 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -93.9 12.83 24.61 Favored 'General case' 0 N--CA 1.487 1.377 0 O-C-N 121.246 -0.909 . . . . 0.0 110.371 -179.413 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 60.5 t -111.15 134.71 52.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 121.238 -0.914 . . . . 0.0 109.831 -179.784 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.49 ' O ' ' OD1' ' A' ' 23' ' ' ASP . . . -75.96 118.43 71.09 Favored Pre-proline 0 N--CA 1.489 1.515 0 O-C-N 121.338 -0.851 . . . . 0.0 109.326 179.912 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_exo -51.41 -25.63 19.15 Favored 'Trans proline' 0 N--CA 1.493 1.486 0 C-N-CA 121.77 1.647 . . . . 0.0 112.146 179.611 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.81 -25.61 67.98 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.261 -0.9 . . . . 0.0 109.732 -179.896 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.49 ' OD1' ' O ' ' A' ' 20' ' ' ALA . 49.8 p30 -85.81 7.46 23.76 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.195 -0.941 . . . . 0.0 109.925 -179.611 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' VAL . . . . . 0.47 HG23 ' OD1' ' A' ' 23' ' ' ASP . 17.3 t -109.7 133.32 55.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.321 -0.862 . . . . 0.0 109.397 179.844 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 63.4 t0 -88.47 119.66 29.12 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.141 -0.974 . . . . 0.0 108.892 179.348 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.6 m -75.89 3.81 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 O-C-N 121.182 -0.949 . . . . 0.0 109.285 179.851 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -87.55 -11.38 48.93 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.333 -0.854 . . . . 0.0 108.966 179.424 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 36.4 tp -94.98 136.91 34.73 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 179.778 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -59.51 134.16 56.76 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.114 -0.991 . . . . 0.0 109.409 -179.493 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.727 HD23 ' O ' ' A' ' 30' ' ' LEU . 2.3 tt -67.15 -37.81 84.41 Favored 'General case' 0 C--N 1.299 -1.6 0 O-C-N 121.732 -0.605 . . . . 0.0 110.154 -179.18 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.535 HG23 ' O ' ' A' ' 66' ' ' PHE . 78.2 t -63.79 -34.96 71.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.05 -1.031 . . . . 0.0 110.396 -178.994 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 56.9 t0 -52.36 -33.66 44.08 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 120.984 -1.073 . . . . 0.0 108.11 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.409 ' HB3' HG23 ' A' ' 35' ' ' VAL . 83.1 m-20 -71.16 -34.48 71.01 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.55 -0.719 . . . . 0.0 109.897 179.433 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 86.37 6.52 80.95 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.056 -1.617 . . . . 0.0 109.056 -179.374 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.409 HG23 ' HB3' ' A' ' 33' ' ' ASN . 79.6 t -61.66 -34.3 61.41 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 O-C-N 121.455 -1.026 . . . . 0.0 109.152 179.719 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.662 HD11 HD13 ' A' ' 30' ' ' LEU . 85.4 mt -86.07 117.84 31.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.324 -0.86 . . . . 0.0 109.656 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -114.01 -164.59 0.94 Allowed 'General case' 0 C--N 1.302 -1.463 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 179.845 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -64.74 -54.21 34.94 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.109 -0.994 . . . . 0.0 108.682 179.704 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 38.5 mt -68.71 -32.81 72.86 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 107.105 -1.443 . . . . 0.0 107.105 178.264 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.547 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.15 -40.7 96.04 Favored Glycine 0 N--CA 1.48 1.592 0 N-CA-C 108.403 -1.879 . . . . 0.0 108.403 179.16 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.597 ' CD1' ' CZ ' ' A' ' 66' ' ' PHE . 7.3 tt -65.47 -41.67 93.07 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.479 -1.012 . . . . 0.0 108.888 178.978 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 tp -59.71 -45.74 91.22 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 179.443 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 25.2 mttp -60.51 -35.44 75.96 Favored 'General case' 0 C--N 1.297 -1.698 0 O-C-N 121.577 -0.702 . . . . 0.0 109.553 -179.881 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.547 HG23 ' O ' ' A' ' 40' ' ' GLY . 72.5 t -60.11 -43.3 92.59 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 O-C-N 121.296 -0.877 . . . . 0.0 109.445 -179.916 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.484 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 6.4 mm -67.45 -40.03 83.74 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.559 0 O-C-N 121.476 -0.765 . . . . 0.0 111.144 -179.088 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.48 -49.09 67.78 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.038 -1.038 . . . . 0.0 112.162 -177.596 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.699 ' CE2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -78.77 -46.73 18.21 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.448 -1.407 . . . . 0.0 110.679 -178.55 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.741 HD13 ' C ' ' A' ' 48' ' ' LEU . 3.2 tm? -58.4 -43.54 88.6 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.005 -1.06 . . . . 0.0 109.921 -178.301 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.484 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 1.2 pp20? -69.76 -36.83 76.12 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 120.943 -1.098 . . . . 0.0 109.66 -179.911 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.2 t0 -62.82 -37.88 88.54 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.181 -0.949 . . . . 0.0 110.321 179.895 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 9.7 mmt180 -60.95 -38.47 85.97 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.322 -0.861 . . . . 0.0 111.724 -178.81 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.74 ' CZ ' HG11 ' A' ' 76' ' ' VAL . 84.5 m-85 -96.82 -6.89 34.97 Favored 'General case' 0 C--N 1.304 -1.392 0 O-C-N 120.817 -1.177 . . . . 0.0 110.239 -178.947 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 70.92 30.81 67.58 Favored Glycine 0 N--CA 1.486 1.971 0 N-CA-C 108.72 -1.752 . . . . 0.0 108.72 179.653 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.47 ' O ' ' OE1' ' A' ' 49' ' ' GLU . 24.7 pt -108.59 153.07 10.35 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 O-C-N 121.587 -0.949 . . . . 0.0 109.765 -179.408 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -104.14 156.28 18.01 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.383 -0.823 . . . . 0.0 109.554 -179.78 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -58.22 -25.54 61.78 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.234 -0.916 . . . . 0.0 109.151 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' ASP . . . . . 0.402 ' O ' HG23 ' A' ' 59' ' ' VAL . 61.2 t0 59.07 39.62 23.05 Favored 'General case' 0 N--CA 1.485 1.286 0 O-C-N 121.517 -0.739 . . . . 0.0 109.075 -179.761 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 54.38 44.87 28.27 Favored 'General case' 0 N--CA 1.487 1.379 0 O-C-N 121.706 -0.621 . . . . 0.0 110.202 179.367 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.402 HG23 ' O ' ' A' ' 57' ' ' ASP . 52.6 t -121.33 134.46 64.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.446 -0.784 . . . . 0.0 109.137 179.382 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -102.29 132.44 48.24 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.19 -0.944 . . . . 0.0 109.599 -179.914 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 53.1 mt -95.24 147.3 23.62 Favored 'General case' 0 C--N 1.304 -1.394 0 O-C-N 121.347 -0.846 . . . . 0.0 109.293 179.792 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -104.4 157.67 33.59 Favored Pre-proline 0 N--CA 1.486 1.349 0 O-C-N 121.282 -0.886 . . . . 0.0 108.92 179.872 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 2.1 Cg_endo -49.4 -19.65 3.19 Favored 'Trans proline' 0 C--N 1.302 -1.869 0 C-N-CA 122.398 2.065 . . . . 0.0 110.985 -179.963 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 87.4 tt0 -68.54 -32.32 72.18 Favored 'General case' 0 N--CA 1.486 1.375 0 O-C-N 121.606 -0.683 . . . . 0.0 109.56 179.404 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' HIS . . . . . 0.553 ' C ' ' CD2' ' A' ' 65' ' ' HIS . 1.5 t60 -66.33 -17.89 65.03 Favored 'General case' 0 C--N 1.3 -1.558 0 O-C-N 121.384 -0.823 . . . . 0.0 108.829 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.602 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 4.2 m-85 -101.97 14.99 30.39 Favored 'General case' 0 C--N 1.298 -1.642 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 67' ' ' ARG . . . . . 0.422 ' NE ' ' OG ' ' A' ' 71' ' ' SER . 4.8 ptt180 -46.17 -38.31 8.11 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.875 -0.516 . . . . 0.0 109.985 -179.684 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 68' ' ' SER . . . . . 0.55 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 83.8 p -163.86 159.5 21.14 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.081 -1.012 . . . . 0.0 109.905 179.578 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.683 HG13 HD12 ' A' ' 30' ' ' LEU . 3.4 mp -57.83 -35.35 51.08 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 179.087 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 57.9 mtp180 -57.85 -42.35 84.25 Favored 'General case' 0 C--N 1.304 -1.397 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 179.644 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.422 ' OG ' ' NE ' ' A' ' 67' ' ' ARG . 8.8 t -65.18 -38.81 91.69 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.652 -0.655 . . . . 0.0 109.987 -179.935 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.454 HD12 ' HA ' ' A' ' 69' ' ' ILE . 71.5 mt -58.93 -51.45 72.29 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 O-C-N 121.189 -0.944 . . . . 0.0 109.713 -179.286 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.447 ' O ' HG23 ' A' ' 77' ' ' VAL . 43.1 t0 -62.1 -41.07 97.83 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.15 -0.969 . . . . 0.0 108.67 179.446 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.33 -37.6 85.72 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.667 -0.646 . . . . 0.0 109.952 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 64.3 t80 -60.36 -49.23 78.41 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.225 -0.922 . . . . 0.0 109.808 -179.626 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.74 HG11 ' CZ ' ' A' ' 52' ' ' PHE . 93.7 t -66.45 -46.84 85.61 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 O-C-N 121.201 -0.937 . . . . 0.0 109.626 -179.89 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.612 HG22 ' CD ' ' A' ' 2' ' ' GLN . 74.9 t -66.41 -40.51 86.78 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 O-C-N 121.261 -0.9 . . . . 0.0 109.229 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.05 -37.52 92.89 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 -179.72 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -73.25 -41.86 63.2 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.217 -1.166 . . . . 0.0 111.105 -178.929 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 43.6 p -83.36 -36.7 24.14 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.962 -1.086 . . . . 0.0 109.425 -179.598 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.491 ' O ' ' O ' ' A' ' 77' ' ' VAL . 0.6 OUTLIER -133.33 153.49 80.59 Favored Pre-proline 0 C--N 1.299 -1.593 0 O-C-N 121.541 -0.724 . . . . 0.0 109.081 -179.762 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -43.56 144.46 2.12 Favored 'Trans proline' 0 C--N 1.307 -1.629 0 C-N-CA 121.874 1.716 . . . . 0.0 110.994 179.49 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 83' ' ' PRO . . . . . 0.558 ' HB2' ' HB2' ' A' ' 86' ' ' ALA . 10.4 Cg_endo -60.26 140.54 92.52 Favored 'Trans proline' 0 C--N 1.311 -1.441 0 C-N-CA 121.996 1.798 . . . . 0.0 112.747 -179.252 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.476 ' O ' ' C ' ' A' ' 85' ' ' GLU . 46.8 t -104.1 128.1 57.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 179.345 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.476 ' C ' ' O ' ' A' ' 84' ' ' VAL . 96.0 mt-10 36.74 39.55 0.11 Allowed 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.566 -0.709 . . . . 0.0 109.787 179.895 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.558 ' HB2' ' HB2' ' A' ' 83' ' ' PRO . . . -50.67 144.48 8.06 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.219 -0.925 . . . . 0.0 109.669 -179.551 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 42.6 mttm -58.25 -33.67 69.63 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.365 -0.834 . . . . 0.0 109.39 -179.971 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 55.4 mt -88.06 142.33 27.86 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.223 -0.923 . . . . 0.0 109.446 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 50.9 tt0 . . . . . 0 N--CA 1.492 1.645 0 CA-C-O 118.031 -0.985 . . . . 0.0 109.398 -179.968 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' -1' ' ' SER . . . . . . . . . . . . . 54.5 p . . . . . 0 N--CA 1.491 1.58 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 0' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -57.94 -33.57 68.97 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.234 -0.916 . . . . 0.0 109.484 179.912 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.65 ' HB3' ' HB2' ' A' ' 4' ' ' ALA . 71.4 mtm -57.97 -35.98 71.93 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.231 -0.918 . . . . 0.0 109.583 -179.919 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.405 ' C ' ' O ' ' A' ' 1' ' ' MET . 70.2 tp60 45.24 74.1 0.14 Allowed 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.221 -0.924 . . . . 0.0 109.58 179.989 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 29.2 m80 59.61 58.58 2.84 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.351 -0.843 . . . . 0.0 110.018 179.789 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.65 ' HB2' ' HB3' ' A' ' 1' ' ' MET . . . -60.72 -34.44 74.41 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.127 -0.983 . . . . 0.0 109.522 179.805 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.8 t -58.69 -38.61 78.62 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.295 -0.878 . . . . 0.0 109.876 -179.602 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 78.9 t -64.06 -46.28 94.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.143 -0.973 . . . . 0.0 109.353 179.936 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.714 HD13 ' OD1' ' A' ' 73' ' ' ASP . 77.5 mt -61.27 -46.25 96.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 179.491 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.765 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -62.22 -35.36 78.66 Favored 'General case' 0 C--N 1.303 -1.419 0 O-C-N 121.619 -0.675 . . . . 0.0 109.29 179.734 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 31.4 tt0 -62.11 -41.76 98.54 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.19 -0.944 . . . . 0.0 110.419 -179.611 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.672 ' CG ' ' CE2' ' A' ' 47' ' ' TRP . 49.6 m-85 -68.13 -50.75 52.64 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 120.896 -1.127 . . . . 0.0 111.065 -179.268 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.449 HG11 HD11 ' A' ' 30' ' ' LEU . 36.0 m -66.01 -38.95 83.21 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 O-C-N 120.972 -1.08 . . . . 0.0 109.247 -179.315 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.765 HG23 ' O ' ' A' ' 8' ' ' ALA . 89.2 t -63.68 -46.27 95.16 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 O-C-N 121.261 -0.899 . . . . 0.0 109.204 179.479 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -75.09 -16.92 60.54 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.14 -0.975 . . . . 0.0 110.076 179.824 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -63.81 -33.67 76.19 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.285 -0.884 . . . . 0.0 110.439 -178.956 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 67.2 t80 -154.08 -19.16 0.13 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.86 -1.15 . . . . 0.0 110.471 -179.634 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.469 HD22 HG21 ' A' ' 19' ' ' VAL . 5.6 mt -121.57 80.05 38.86 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.198 -0.939 . . . . 0.0 109.835 -179.497 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -79.73 -17.41 11.07 Favored 'Trans proline' 0 C--N 1.307 -1.656 0 C-N-CA 122.665 2.244 . . . . 0.0 112.628 -179.877 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 18' ' ' ASP . . . . . 0.555 ' OD1' HG23 ' A' ' 19' ' ' VAL . 51.8 p30 -90.09 9.99 26.04 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.166 -0.959 . . . . 0.0 110.172 -179.575 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.555 HG23 ' OD1' ' A' ' 18' ' ' ASP . 67.5 t -111.25 135.98 48.74 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.207 -0.933 . . . . 0.0 109.532 179.754 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -78.27 117.39 65.86 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.312 -0.867 . . . . 0.0 109.443 -179.908 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_exo -51.95 -35.83 61.96 Favored 'Trans proline' 0 N--CA 1.491 1.368 0 C-N-CA 121.709 1.606 . . . . 0.0 111.817 179.326 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.84 -23.73 66.73 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.3 -0.875 . . . . 0.0 108.925 179.529 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -84.71 7.46 20.41 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.418 -0.801 . . . . 0.0 109.743 -179.795 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 13.0 t -101.63 132.51 47.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.145 -0.972 . . . . 0.0 109.264 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 63.8 t0 -89.01 119.39 29.49 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.151 -0.968 . . . . 0.0 109.223 179.587 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' VAL . . . . . 0.448 ' O ' HG13 ' A' ' 26' ' ' VAL . 0.3 OUTLIER -69.33 4.25 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 O-C-N 121.204 -0.935 . . . . 0.0 109.452 179.782 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -95.02 -2.77 49.62 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.251 -0.905 . . . . 0.0 109.239 179.66 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 39.8 tp -99.56 136.42 39.52 Favored 'General case' 0 C--N 1.303 -1.441 0 O-C-N 121.394 -0.816 . . . . 0.0 108.92 179.714 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -58.62 137.12 57.7 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.105 -0.997 . . . . 0.0 109.196 -179.502 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.713 HD13 HD11 ' A' ' 36' ' ' ILE . 1.8 tt -68.35 -36.73 79.68 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.635 -0.665 . . . . 0.0 110.36 -178.981 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 69.6 t -64.75 -35.51 75.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.101 -0.999 . . . . 0.0 110.557 -179.004 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -52.54 -33.61 46.34 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 120.996 -1.065 . . . . 0.0 108.178 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.445 ' HB3' HG23 ' A' ' 35' ' ' VAL . 53.6 m-20 -70.98 -34.52 71.47 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.604 -0.685 . . . . 0.0 109.982 179.485 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 85.96 6.05 82.72 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 108.88 -1.688 . . . . 0.0 108.88 -179.24 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.445 HG23 ' HB3' ' A' ' 33' ' ' ASN . 78.5 t -61.1 -31.21 49.43 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.398 0 O-C-N 121.495 -1.003 . . . . 0.0 108.68 179.512 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.713 HD11 HD13 ' A' ' 30' ' ' LEU . 81.5 mt -93.99 132.3 38.48 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 O-C-N 121.438 -0.789 . . . . 0.0 109.677 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.53 ' CG ' ' H ' ' A' ' 38' ' ' ALA . 52.4 t0 -138.97 -167.69 2.27 Favored 'General case' 0 C--N 1.301 -1.528 0 N-CA-C 108.562 -0.903 . . . . 0.0 108.562 179.602 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.53 ' H ' ' CG ' ' A' ' 37' ' ' ASP . . . -62.6 -55.22 29.14 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.928 -1.107 . . . . 0.0 108.588 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 37.4 mt -71.47 -34.79 70.51 Favored 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 107.063 -1.458 . . . . 0.0 107.063 178.024 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.762 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.85 -39.85 95.98 Favored Glycine 0 N--CA 1.481 1.671 0 N-CA-C 108.703 -1.759 . . . . 0.0 108.703 179.169 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.794 ' C ' HD13 ' A' ' 41' ' ' LEU . 2.5 tm? -65.04 -43.89 90.87 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.49 -1.006 . . . . 0.0 108.622 179.386 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.2 tp -59.09 -46.03 89.33 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.343 -0.848 . . . . 0.0 109.066 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 63.2 mttp -61.49 -34.79 76.07 Favored 'General case' 0 C--N 1.295 -1.778 0 O-C-N 121.537 -0.727 . . . . 0.0 109.481 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.762 HG23 ' O ' ' A' ' 40' ' ' GLY . 91.6 t -62.56 -50.43 79.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.451 -0.781 . . . . 0.0 110.166 -179.347 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.7 mp -68.34 -29.85 45.65 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 O-C-N 121.314 -0.866 . . . . 0.0 110.566 -179.774 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.47 -49.2 67.44 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.108 -0.995 . . . . 0.0 111.657 -178.177 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.672 ' CE2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -81.08 -40.99 23.26 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 120.592 -1.317 . . . . 0.0 110.3 -179.015 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.543 ' O ' HD13 ' A' ' 48' ' ' LEU . 0.2 OUTLIER -61.23 -41.62 97.19 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.154 -0.966 . . . . 0.0 109.298 -179.357 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.419 ' CG ' ' N ' ' A' ' 50' ' ' ASP . 17.0 pt-20 -73.13 -36.07 66.63 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 120.638 -1.289 . . . . 0.0 109.165 179.907 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 50' ' ' ASP . . . . . 0.419 ' N ' ' CG ' ' A' ' 49' ' ' GLU . 59.0 t0 -65.6 -40.84 93.12 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.632 -0.667 . . . . 0.0 111.766 -179.072 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.433 HH21 HG11 ' A' ' 76' ' ' VAL . 24.3 ptt180 -71.39 -36.59 71.46 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 120.864 -1.148 . . . . 0.0 111.484 -177.712 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.414 ' CE1' ' CG1' ' A' ' 76' ' ' VAL . 5.7 m-85 -81.21 -14.74 57.21 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.577 -1.327 . . . . 0.0 109.756 -179.726 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.27 20.67 71.9 Favored Glycine 0 N--CA 1.486 2.025 0 N-CA-C 108.693 -1.763 . . . . 0.0 108.693 -179.745 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 23.1 pt -113.19 153.65 14.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.737 -0.86 . . . . 0.0 109.695 -179.573 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -101.03 132.29 46.53 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.249 -0.907 . . . . 0.0 109.519 -179.789 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.503 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -69.0 -23.55 64.12 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.316 -0.865 . . . . 0.0 109.692 179.859 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 91.3 m-20 -54.98 -36.08 65.01 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.268 -0.895 . . . . 0.0 110.146 -179.487 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -56.13 -39.36 72.12 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.18 -0.95 . . . . 0.0 110.001 -179.547 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.503 ' O ' ' O ' ' A' ' 56' ' ' ALA . 41.7 t -126.86 136.68 60.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.337 -0.852 . . . . 0.0 109.666 -179.894 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -87.58 127.23 35.27 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.117 -0.989 . . . . 0.0 109.185 179.864 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 39.4 mt -104.53 142.05 35.31 Favored 'General case' 0 C--N 1.306 -1.295 0 O-C-N 121.279 -0.888 . . . . 0.0 109.831 -179.649 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -108.75 152.54 42.31 Favored Pre-proline 0 N--CA 1.485 1.316 0 N-CA-C 108.696 -0.854 . . . . 0.0 108.696 179.377 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 12.8 Cg_endo -58.44 -21.16 52.44 Favored 'Trans proline' 0 C--N 1.304 -1.768 0 C-N-CA 122.505 2.137 . . . . 0.0 112.196 -179.748 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -69.6 -30.1 67.77 Favored 'General case' 0 N--CA 1.486 1.335 0 O-C-N 121.272 -0.892 . . . . 0.0 109.731 -179.726 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 65' ' ' HIS . . . . . 0.457 ' CE1' ' HB2' ' A' ' 75' ' ' PHE . 76.3 t60 -66.16 -20.66 66.21 Favored 'General case' 0 C--N 1.299 -1.588 0 O-C-N 121.233 -0.917 . . . . 0.0 108.918 -179.874 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.496 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 21.8 m-85 -89.17 12.73 15.0 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.394 -0.816 . . . . 0.0 109.203 -179.68 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 67' ' ' ARG . . . . . 0.429 HH21 ' CD ' ' A' ' 87' ' ' LYS . 4.2 ptt85 -49.88 -34.56 20.58 Favored 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.628 -0.67 . . . . 0.0 109.513 179.719 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 68' ' ' SER . . . . . 0.518 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 89.2 p -151.65 153.54 34.62 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.154 -0.966 . . . . 0.0 109.895 179.794 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.644 ' H ' HD12 ' A' ' 69' ' ' ILE . 3.5 mp -59.83 -34.81 57.11 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.485 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 179.3 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.609 ' HE ' ' HZ1' ' A' ' 87' ' ' LYS . 30.2 mtp85 -57.11 -45.18 83.66 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.604 -0.685 . . . . 0.0 109.765 -179.272 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.424 ' HG ' ' CE1' ' A' ' 65' ' ' HIS . 22.9 t -64.9 -46.07 83.25 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.307 -0.871 . . . . 0.0 109.781 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.431 ' HA ' ' NE2' ' A' ' 65' ' ' HIS . 68.0 mt -58.95 -42.89 87.38 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 O-C-N 121.176 -0.952 . . . . 0.0 109.913 -179.735 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.714 ' OD1' HD13 ' A' ' 7' ' ' ILE . 2.0 m-20 -61.14 -37.95 84.66 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.292 -0.88 . . . . 0.0 109.842 -179.584 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -67.4 -46.91 71.85 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.035 -1.041 . . . . 0.0 110.541 -179.304 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 75' ' ' PHE . . . . . 0.457 ' HB2' ' CE1' ' A' ' 65' ' ' HIS . 65.8 t80 -66.03 -44.08 85.71 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.135 -0.978 . . . . 0.0 109.57 -179.737 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.433 HG11 HH21 ' A' ' 51' ' ' ARG . 43.4 t -60.68 -41.83 89.68 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 O-C-N 121.301 -0.874 . . . . 0.0 108.81 179.334 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.661 HG23 ' O ' ' A' ' 73' ' ' ASP . 65.3 t -65.0 -40.52 89.34 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.256 0 O-C-N 121.306 -0.871 . . . . 0.0 109.042 179.338 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.53 -17.23 32.47 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.753 -1.339 . . . . 0.0 109.753 179.794 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -66.71 -34.82 78.68 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.288 -1.125 . . . . 0.0 110.573 -179.176 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 49.7 p -134.49 -20.5 1.82 Allowed 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.009 -1.057 . . . . 0.0 110.709 -179.381 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.499 ' O ' ' O ' ' A' ' 77' ' ' VAL . 0.1 OUTLIER -132.74 152.59 80.16 Favored Pre-proline 0 N--CA 1.49 1.528 0 O-C-N 121.144 -0.973 . . . . 0.0 109.39 -179.919 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo -66.5 136.98 44.93 Favored 'Trans proline' 0 C--N 1.307 -1.613 0 C-N-CA 122.263 1.975 . . . . 0.0 111.593 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -67.28 147.62 78.66 Favored 'Trans proline' 0 N--CA 1.49 1.291 0 C-N-CA 122.111 1.874 . . . . 0.0 112.576 -179.593 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.459 ' O ' ' C ' ' A' ' 85' ' ' GLU . 41.2 t -103.57 133.0 48.68 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 O-C-N 121.497 -0.752 . . . . 0.0 109.087 179.481 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.459 ' C ' ' O ' ' A' ' 84' ' ' VAL . 95.9 mt-10 40.67 54.96 3.03 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.411 -0.806 . . . . 0.0 109.587 -179.977 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -52.59 151.92 3.98 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.275 -0.891 . . . . 0.0 109.558 -179.874 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.609 ' HZ1' ' HE ' ' A' ' 70' ' ' ARG . 68.4 mttm -64.57 144.68 57.04 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.3 -0.875 . . . . 0.0 109.365 -179.841 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.418 ' C ' ' O ' ' A' ' 87' ' ' LYS . 53.8 mt 43.76 87.43 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.214 -0.929 . . . . 0.0 109.479 -179.893 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.0 mt-30 . . . . . 0 N--CA 1.491 1.591 0 CA-C-O 117.999 -1.0 . . . . 0.0 109.459 -179.98 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' -1' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.519 -0.549 . . . . 0.0 109.519 . . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 0' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -61.78 -34.04 75.18 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.208 -0.933 . . . . 0.0 109.498 -179.937 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.564 ' HB2' ' HB2' ' A' ' 4' ' ' ALA . 87.0 mmm -94.58 -121.42 0.1 Allowed 'General case' 0 C--N 1.306 -1.305 0 O-C-N 121.2 -0.937 . . . . 0.0 109.026 -179.881 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 93.5 mt-30 -110.19 -72.99 0.7 Allowed 'General case' 0 N--CA 1.491 1.592 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 179.166 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 97.2 m-70 -103.55 22.15 14.82 Favored 'General case' 0 C--N 1.303 -1.438 0 N-CA-C 108.034 -1.099 . . . . 0.0 108.034 178.764 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.585 ' N ' ' OD2' ' A' ' 73' ' ' ASP . . . -52.94 -41.04 64.1 Favored 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.518 -0.739 . . . . 0.0 109.861 -179.078 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 21.3 m -61.11 -39.28 89.4 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.178 -0.951 . . . . 0.0 109.602 179.975 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 54.6 t -61.61 -43.88 97.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.331 -0.855 . . . . 0.0 109.483 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 82.5 mt -59.78 -40.27 82.08 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.45 0 O-C-N 121.363 -0.835 . . . . 0.0 109.076 179.697 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.401 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -60.92 -36.25 78.8 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 179.897 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 83.8 mt-30 -65.8 -39.16 90.64 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.296 -0.878 . . . . 0.0 109.967 179.757 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.66 ' CG ' ' CZ2' ' A' ' 47' ' ' TRP . 28.5 m-85 -64.2 -50.44 68.08 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.167 -0.958 . . . . 0.0 111.057 -179.28 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.439 HG13 ' N ' ' A' ' 12' ' ' VAL . 2.9 p -59.89 -42.74 90.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.016 -1.053 . . . . 0.0 109.579 -179.19 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.464 ' O ' ' C ' ' A' ' 16' ' ' LEU . 86.9 t -63.46 -47.3 92.32 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 O-C-N 121.115 -0.99 . . . . 0.0 109.396 179.833 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -71.53 -24.12 61.9 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.172 -0.955 . . . . 0.0 109.96 179.825 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -64.19 -32.07 73.51 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.363 -0.836 . . . . 0.0 110.893 -178.763 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 63.1 t80 -140.83 -35.12 0.49 Allowed 'General case' 0 N--CA 1.494 1.758 0 O-C-N 120.849 -1.157 . . . . 0.0 110.742 -179.254 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.464 ' C ' ' O ' ' A' ' 12' ' ' VAL . 5.2 mt -119.17 80.04 19.4 Favored Pre-proline 0 N--CA 1.493 1.693 0 O-C-N 121.167 -0.958 . . . . 0.0 109.939 -179.397 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_endo -77.86 -15.3 15.08 Favored 'Trans proline' 0 C--N 1.308 -1.603 0 C-N-CA 122.546 2.164 . . . . 0.0 112.198 179.755 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -88.43 5.32 42.88 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 121.32 -0.862 . . . . 0.0 109.788 -179.729 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.45 ' CG2' HD22 ' A' ' 16' ' ' LEU . 46.3 t -110.64 134.92 51.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.387 -0.821 . . . . 0.0 109.564 -179.88 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.46 118.63 69.34 Favored Pre-proline 0 N--CA 1.489 1.503 0 O-C-N 121.279 -0.888 . . . . 0.0 109.24 179.902 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.461 ' HA ' HG21 ' A' ' 12' ' ' VAL . 40.4 Cg_exo -51.3 -28.62 27.25 Favored 'Trans proline' 0 N--CA 1.492 1.397 0 C-N-CA 121.728 1.619 . . . . 0.0 111.866 179.659 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.42 -23.31 66.91 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.198 -0.939 . . . . 0.0 109.286 179.688 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.45 ' O ' ' OD1' ' A' ' 23' ' ' ASP . 60.2 t0 -81.65 4.03 23.18 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.326 -0.859 . . . . 0.0 109.762 -179.762 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 13.5 t -108.75 133.32 54.19 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.245 -0.909 . . . . 0.0 109.351 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 86.9 m-20 -88.29 120.53 29.74 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.084 -1.01 . . . . 0.0 108.964 179.379 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 32.8 m -75.68 4.42 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 O-C-N 121.237 -0.915 . . . . 0.0 109.178 179.601 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -93.17 -2.75 54.98 Favored 'General case' 0 C--N 1.306 -1.318 0 O-C-N 121.316 -0.865 . . . . 0.0 108.941 179.518 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 39.8 tp -97.13 138.32 34.83 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.494 -0.754 . . . . 0.0 109.016 179.819 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 87.3 m-20 -60.09 138.5 57.87 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.154 -0.966 . . . . 0.0 109.531 -179.407 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.715 HD12 HG13 ' A' ' 69' ' ' ILE . 1.3 tt -75.62 -36.74 60.17 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.716 -0.615 . . . . 0.0 110.454 -179.203 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.614 HG13 ' O ' ' A' ' 66' ' ' PHE . 12.9 m -64.1 -38.4 82.36 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.659 0 O-C-N 121.111 -0.993 . . . . 0.0 110.583 -178.903 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -54.5 -33.45 59.87 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.142 -0.974 . . . . 0.0 108.375 179.67 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 96.1 m-20 -70.5 -34.56 72.47 Favored 'General case' 0 C--N 1.303 -1.445 0 O-C-N 121.656 -0.653 . . . . 0.0 110.0 179.875 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 82.37 5.86 89.2 Favored Glycine 0 N--CA 1.493 2.479 0 N-CA-C 109.516 -1.433 . . . . 0.0 109.516 -179.904 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 78.3 t -61.35 -34.36 60.69 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 O-C-N 121.276 -1.132 . . . . 0.0 108.697 179.501 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.705 HD11 HD13 ' A' ' 30' ' ' LEU . 96.7 mt -77.34 112.17 14.98 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 121.454 -0.779 . . . . 0.0 109.954 179.91 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -111.33 -164.53 0.92 Allowed 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 179.595 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -66.71 -54.25 25.01 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.125 -0.984 . . . . 0.0 108.874 179.694 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.692 HD12 ' N ' ' A' ' 39' ' ' LEU . 6.9 mp -69.77 -32.89 71.64 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 107.397 -1.334 . . . . 0.0 107.397 178.432 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.607 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.41 -43.0 97.76 Favored Glycine 0 N--CA 1.482 1.704 0 N-CA-C 109.053 -1.619 . . . . 0.0 109.053 179.509 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.442 HD11 ' CZ ' ' A' ' 66' ' ' PHE . 7.5 tt -65.13 -42.73 93.59 Favored 'General case' 0 C--N 1.303 -1.415 0 O-C-N 121.413 -1.051 . . . . 0.0 109.327 179.449 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 tp -60.06 -46.25 90.18 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.375 -0.828 . . . . 0.0 109.274 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 12.7 mttm -62.39 -34.44 76.73 Favored 'General case' 0 C--N 1.297 -1.7 0 O-C-N 121.44 -0.787 . . . . 0.0 109.789 -179.694 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.607 HG23 ' O ' ' A' ' 40' ' ' GLY . 53.8 t -61.47 -50.42 80.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.291 -0.881 . . . . 0.0 110.322 -179.215 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.537 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 3.5 mp -68.36 -33.73 62.0 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 121.331 -0.856 . . . . 0.0 111.011 -179.67 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.42 -49.77 67.96 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.013 -1.054 . . . . 0.0 111.655 -178.007 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.66 ' CZ2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -81.2 -43.78 18.79 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.75 -1.219 . . . . 0.0 109.905 -179.3 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.582 HD21 ' CG2' ' A' ' 76' ' ' VAL . 31.4 tp -58.82 -42.35 88.98 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.215 -0.928 . . . . 0.0 109.95 -179.267 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.537 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 1.1 pp20? -72.53 -36.02 68.2 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.082 -1.011 . . . . 0.0 109.749 -179.959 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.5 t0 -60.43 -38.51 84.35 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.251 -0.905 . . . . 0.0 110.608 -179.653 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.464 ' HD2' ' HE1' ' A' ' 47' ' ' TRP . 77.7 mtp85 -61.81 -37.83 85.87 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.167 -0.958 . . . . 0.0 111.602 -178.668 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.799 ' CE2' HG11 ' A' ' 76' ' ' VAL . 88.0 m-85 -95.86 -8.5 33.95 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 120.67 -1.269 . . . . 0.0 110.339 -178.97 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 71.98 30.37 65.69 Favored Glycine 0 N--CA 1.486 2.021 0 N-CA-C 108.872 -1.691 . . . . 0.0 108.872 179.682 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.501 ' O ' ' OE1' ' A' ' 49' ' ' GLU . 26.0 pt -107.55 151.13 9.66 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.402 0 O-C-N 121.654 -0.909 . . . . 0.0 109.653 -179.502 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.475 ' O ' ' OD1' ' A' ' 58' ' ' ASP . . . -101.76 132.48 47.47 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.233 -0.917 . . . . 0.0 109.645 -179.661 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.5 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -67.0 -26.88 67.02 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.335 -0.853 . . . . 0.0 109.396 179.751 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 52.3 t0 -54.87 -34.79 63.36 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.317 -0.864 . . . . 0.0 110.042 -179.571 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.632 ' OD1' ' N ' ' A' ' 59' ' ' VAL . 55.3 p30 -59.47 -34.53 72.66 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.196 -0.94 . . . . 0.0 110.301 -179.459 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.632 ' N ' ' OD1' ' A' ' 58' ' ' ASP . 14.5 p -136.86 140.96 41.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.025 -1.047 . . . . 0.0 109.585 179.92 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -85.3 139.35 31.67 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.053 -1.03 . . . . 0.0 109.299 179.818 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 5.1 mp -97.72 136.9 37.41 Favored 'General case' 0 C--N 1.305 -1.345 0 O-C-N 121.198 -0.939 . . . . 0.0 109.712 -179.835 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -110.0 155.35 41.83 Favored Pre-proline 0 N--CA 1.488 1.457 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 179.489 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 7.8 Cg_endo -53.2 -23.55 23.29 Favored 'Trans proline' 0 C--N 1.302 -1.904 0 C-N-CA 122.286 1.991 . . . . 0.0 111.685 -179.898 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -70.69 -26.54 63.47 Favored 'General case' 0 N--CA 1.486 1.336 0 O-C-N 121.344 -0.847 . . . . 0.0 109.507 179.655 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 65' ' ' HIS . . . . . 0.546 ' C ' ' CD2' ' A' ' 65' ' ' HIS . 1.9 t60 -65.62 -20.41 66.3 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.23 -0.919 . . . . 0.0 109.215 -179.703 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.614 ' O ' HG13 ' A' ' 31' ' ' VAL . 6.7 m-85 -98.2 16.24 21.95 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 121.447 -0.783 . . . . 0.0 108.965 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 67' ' ' ARG . . . . . 0.588 ' NE ' ' OG ' ' A' ' 71' ' ' SER . 4.8 ptt180 -52.16 -36.34 51.27 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 121.754 -0.591 . . . . 0.0 110.08 -179.775 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 68' ' ' SER . . . . . 0.525 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 35.2 p -164.9 153.31 12.12 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.016 -1.053 . . . . 0.0 110.281 -179.702 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.715 HG13 HD12 ' A' ' 30' ' ' LEU . 3.3 mp -57.94 -40.68 77.57 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 O-C-N 121.362 -0.836 . . . . 0.0 109.161 179.904 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.433 ' HE ' ' HE3' ' A' ' 87' ' ' LYS . 18.9 ptt180 -58.16 -42.24 85.53 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.643 -0.66 . . . . 0.0 109.266 179.806 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.588 ' OG ' ' NE ' ' A' ' 67' ' ' ARG . 26.5 t -64.92 -39.25 93.22 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.204 -0.935 . . . . 0.0 109.677 179.488 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.425 HD12 ' HA ' ' A' ' 69' ' ' ILE . 87.8 mt -58.92 -47.14 90.59 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.289 0 O-C-N 121.176 -0.953 . . . . 0.0 109.736 -179.73 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.585 ' OD2' ' N ' ' A' ' 4' ' ' ALA . 26.5 t0 -58.91 -44.23 91.23 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.147 -0.971 . . . . 0.0 108.723 179.864 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.535 ' O ' ' N ' ' A' ' 78' ' ' GLY . . . -66.96 -37.36 84.13 Favored 'General case' 0 C--N 1.304 -1.399 0 O-C-N 121.432 -0.792 . . . . 0.0 109.595 179.667 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 61.9 t80 -62.82 -48.83 77.37 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.19 -0.944 . . . . 0.0 109.644 -179.833 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.799 HG11 ' CE2' ' A' ' 52' ' ' PHE . 71.1 t -67.56 -48.8 75.51 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.282 0 O-C-N 121.201 -0.937 . . . . 0.0 109.782 -179.847 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.533 ' O ' HG22 ' A' ' 81' ' ' THR . 55.3 t -69.89 -43.77 79.33 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.274 0 O-C-N 121.106 -0.996 . . . . 0.0 109.034 179.38 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.535 ' N ' ' O ' ' A' ' 74' ' ' ALA . . . -59.38 -30.93 68.82 Favored Glycine 0 N--CA 1.488 2.127 0 N-CA-C 110.211 -1.155 . . . . 0.0 110.211 -179.606 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -68.63 -41.5 79.36 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.153 -1.204 . . . . 0.0 110.586 -178.998 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 47.1 p -79.74 -32.02 41.06 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.161 -0.962 . . . . 0.0 109.326 -179.83 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.533 HG22 ' O ' ' A' ' 77' ' ' VAL . 1.8 t -133.13 150.42 75.41 Favored Pre-proline 0 N--CA 1.487 1.401 0 O-C-N 121.447 -0.783 . . . . 0.0 108.911 179.93 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 76.0 Cg_exo -42.79 138.01 3.95 Favored 'Trans proline' 0 C--N 1.309 -1.506 0 C-N-CA 121.603 1.535 . . . . 0.0 111.197 179.312 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 83' ' ' PRO . . . . . 0.423 ' HB2' ' HB2' ' A' ' 86' ' ' ALA . 14.7 Cg_endo -64.18 144.58 87.2 Favored 'Trans proline' 0 N--CA 1.49 1.283 0 C-N-CA 121.957 1.771 . . . . 0.0 112.943 -179.003 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.492 ' O ' ' C ' ' A' ' 85' ' ' GLU . 13.8 p -104.52 130.86 54.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 179.525 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.492 ' C ' ' O ' ' A' ' 84' ' ' VAL . 96.1 mt-10 34.72 45.68 0.16 Allowed 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.681 -0.637 . . . . 0.0 110.249 179.647 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.423 ' HB2' ' HB2' ' A' ' 83' ' ' PRO . . . -52.7 149.59 5.97 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.162 -0.962 . . . . 0.0 109.416 -179.866 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.433 ' HE3' ' HE ' ' A' ' 70' ' ' ARG . 68.4 mttm -56.07 -35.49 67.04 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.233 -0.917 . . . . 0.0 109.345 -179.839 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 55.0 mt -95.97 141.43 29.4 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.25 -0.907 . . . . 0.0 109.469 179.86 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.5 mt-30 . . . . . 0 N--CA 1.49 1.548 0 CA-C-O 118.031 -0.985 . . . . 0.0 109.406 -179.946 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' -1' ' ' SER . . . . . . . . . . . . . 2.2 m . . . . . 0 N--CA 1.49 1.574 0 N-CA-C 109.462 -0.569 . . . . 0.0 109.462 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 0' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -57.9 144.2 39.94 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.265 -0.897 . . . . 0.0 109.466 179.927 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.518 ' HB3' ' HB2' ' A' ' 4' ' ' ALA . 70.7 mtm -58.81 -34.92 72.06 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.259 -0.9 . . . . 0.0 109.776 179.984 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.637 ' OE1' HG22 ' A' ' 77' ' ' VAL . 92.8 mt-30 56.27 49.54 15.05 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.26 -0.9 . . . . 0.0 109.123 -179.575 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.451 ' CG ' ' C ' ' A' ' 2' ' ' GLN . 6.7 m80 74.37 56.36 0.08 Allowed 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.689 -0.632 . . . . 0.0 109.82 -179.912 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.518 ' HB2' ' HB3' ' A' ' 1' ' ' MET . . . -59.74 -40.92 89.71 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.068 -1.02 . . . . 0.0 109.29 179.786 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.3 m -61.29 -39.17 89.44 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.256 -0.902 . . . . 0.0 109.65 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 58.8 t -61.13 -41.35 89.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.205 -0.935 . . . . 0.0 109.454 179.911 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 79.7 mt -59.69 -45.62 94.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 O-C-N 121.409 -0.807 . . . . 0.0 109.287 179.866 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -62.14 -42.78 99.58 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.291 -0.881 . . . . 0.0 109.109 179.723 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 84.3 mt-30 -64.7 -33.46 76.0 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.249 -0.907 . . . . 0.0 109.128 179.255 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.535 ' CG ' ' CZ2' ' A' ' 47' ' ' TRP . 0.2 OUTLIER -60.43 -50.27 74.24 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.4 -0.813 . . . . 0.0 110.235 -179.521 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 13.4 m -64.39 -39.59 86.08 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 O-C-N 121.142 -0.973 . . . . 0.0 109.33 -179.723 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.405 ' O ' ' C ' ' A' ' 16' ' ' LEU . 77.6 t -63.99 -45.29 97.18 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.166 -0.959 . . . . 0.0 109.678 179.654 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -69.4 -34.47 74.54 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.17 -0.956 . . . . 0.0 110.23 -179.842 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -65.35 -32.67 74.44 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.292 -0.88 . . . . 0.0 110.458 -179.253 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -118.47 -54.08 2.29 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.263 -0.898 . . . . 0.0 111.336 -178.713 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.575 HD22 ' CG2' ' A' ' 19' ' ' VAL . 9.0 mt -119.41 80.18 21.48 Favored Pre-proline 0 N--CA 1.493 1.688 0 O-C-N 121.19 -0.944 . . . . 0.0 111.054 -178.285 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -75.1 -16.41 20.0 Favored 'Trans proline' 0 C--N 1.309 -1.511 0 C-N-CA 122.274 1.982 . . . . 0.0 112.186 178.825 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -90.99 5.7 47.72 Favored 'General case' 0 N--CA 1.487 1.384 0 O-C-N 121.213 -0.929 . . . . 0.0 109.893 -179.844 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.575 ' CG2' HD22 ' A' ' 16' ' ' LEU . 44.5 t -112.84 138.37 42.42 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.456 -0.778 . . . . 0.0 109.492 -179.857 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.487 ' O ' ' OD1' ' A' ' 23' ' ' ASP . . . -70.37 117.27 53.25 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.275 -0.89 . . . . 0.0 109.469 -179.831 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -51.8 -26.21 23.26 Favored 'Trans proline' 0 N--CA 1.494 1.512 0 C-N-CA 122.017 1.812 . . . . 0.0 112.229 179.505 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.63 -23.66 67.33 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.281 -0.887 . . . . 0.0 109.815 -179.744 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.487 ' OD1' ' O ' ' A' ' 20' ' ' ALA . 51.5 p30 -85.64 7.63 22.58 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.192 -0.942 . . . . 0.0 110.007 -179.428 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 11.8 t -107.88 130.07 60.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.147 -0.97 . . . . 0.0 109.329 179.927 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 87.2 m-20 -89.73 120.33 30.9 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.18 -0.95 . . . . 0.0 109.097 179.28 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 6.3 m -78.1 4.42 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 O-C-N 121.129 -0.982 . . . . 0.0 108.941 179.457 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -88.73 -10.63 47.67 Favored 'General case' 0 N--CA 1.485 1.302 0 O-C-N 121.386 -0.821 . . . . 0.0 109.043 179.408 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 42.4 tp -94.24 140.57 29.61 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 109.076 -0.713 . . . . 0.0 109.076 179.844 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 83.3 m-20 -59.08 142.0 52.58 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.133 -0.979 . . . . 0.0 109.433 -179.361 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 1.078 HD23 HD11 ' A' ' 36' ' ' ILE . 27.8 tp -73.57 -37.74 65.41 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.421 -0.799 . . . . 0.0 110.343 -179.251 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.608 HG13 ' O ' ' A' ' 66' ' ' PHE . 33.1 m -66.73 -43.15 90.2 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 121.263 -0.898 . . . . 0.0 110.428 -179.005 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 32' ' ' ASP . . . . . 0.584 ' N ' HG23 ' A' ' 31' ' ' VAL . 92.1 m-20 -53.94 -33.37 56.6 Favored 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 179.747 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 97.1 m-20 -70.47 -34.12 72.04 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.619 -0.676 . . . . 0.0 109.995 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 87.47 7.2 76.31 Favored Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.183 -1.567 . . . . 0.0 109.183 -179.656 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 72.6 t -61.64 -26.93 41.04 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 O-C-N 121.469 -1.018 . . . . 0.0 108.78 179.575 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 1.078 HD11 HD23 ' A' ' 30' ' ' LEU . 67.6 mt -93.05 123.87 45.28 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.398 0 O-C-N 121.457 -0.777 . . . . 0.0 109.929 -179.458 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -115.79 -174.87 2.61 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 108.636 -0.876 . . . . 0.0 108.636 179.339 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -61.36 -53.45 56.43 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.056 -1.028 . . . . 0.0 108.432 179.594 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.693 HD12 ' N ' ' A' ' 39' ' ' LEU . 7.0 mp -70.39 -32.65 70.39 Favored 'General case' 0 C--N 1.301 -1.532 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 178.008 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.458 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.23 -43.65 97.04 Favored Glycine 0 N--CA 1.482 1.755 0 N-CA-C 109.01 -1.636 . . . . 0.0 109.01 179.574 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.3 tt -65.13 -42.05 94.22 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.463 -1.022 . . . . 0.0 109.163 179.32 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.5 tp -59.97 -46.12 90.47 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.294 -0.879 . . . . 0.0 109.405 179.871 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 86.6 mttt -61.44 -35.7 78.31 Favored 'General case' 0 C--N 1.297 -1.701 0 O-C-N 121.443 -0.786 . . . . 0.0 109.854 -179.678 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.458 HG23 ' O ' ' A' ' 40' ' ' GLY . 55.3 t -61.48 -50.75 79.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.287 -0.883 . . . . 0.0 110.36 -179.27 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.521 HG12 HD12 ' A' ' 61' ' ' LEU . 3.5 mp -68.72 -34.3 64.15 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 O-C-N 121.279 -0.888 . . . . 0.0 111.181 -179.636 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.56 -49.94 60.86 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 120.986 -1.071 . . . . 0.0 111.998 -177.913 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.535 ' CZ2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -80.18 -43.62 21.23 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.655 -1.278 . . . . 0.0 110.036 -179.045 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.558 HD11 HG21 ' A' ' 76' ' ' VAL . 21.7 tp -58.88 -41.63 87.56 Favored 'General case' 0 C--N 1.299 -1.606 0 O-C-N 121.294 -0.879 . . . . 0.0 110.197 -179.03 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.416 ' CG ' ' N ' ' A' ' 50' ' ' ASP . 17.3 pt-20 -73.18 -37.45 66.51 Favored 'General case' 0 C--N 1.305 -1.362 0 O-C-N 121.059 -1.026 . . . . 0.0 109.636 -179.708 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 50' ' ' ASP . . . . . 0.416 ' N ' ' CG ' ' A' ' 49' ' ' GLU . 56.9 t0 -58.86 -39.15 80.51 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.354 -0.841 . . . . 0.0 110.64 -179.447 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.443 ' HD2' ' HE1' ' A' ' 47' ' ' TRP . 73.4 mtp85 -61.64 -36.76 81.72 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.169 -0.957 . . . . 0.0 111.322 -178.86 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.613 ' CZ ' ' CG1' ' A' ' 76' ' ' VAL . 87.5 m-85 -94.77 -8.0 38.83 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 120.745 -1.222 . . . . 0.0 110.407 -179.129 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 73.15 29.29 64.77 Favored Glycine 0 N--CA 1.487 2.089 0 N-CA-C 108.95 -1.66 . . . . 0.0 108.95 179.712 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 20.5 pt -109.68 153.21 11.51 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 O-C-N 121.699 -0.883 . . . . 0.0 109.551 -179.587 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -103.92 134.99 46.28 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.238 -0.914 . . . . 0.0 109.7 -179.614 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.506 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -68.09 -28.39 67.31 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.334 -0.853 . . . . 0.0 109.63 179.732 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -56.36 -36.89 69.31 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.125 -0.984 . . . . 0.0 109.995 -179.625 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 21.4 t70 -56.53 -40.01 74.34 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.146 -0.971 . . . . 0.0 109.987 -179.538 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.506 ' O ' ' O ' ' A' ' 56' ' ' ALA . 42.6 t -128.67 136.21 60.44 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.311 -0.868 . . . . 0.0 109.726 -179.846 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -86.14 132.94 33.91 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.063 -1.023 . . . . 0.0 109.242 179.835 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.521 HD12 HG12 ' A' ' 45' ' ' ILE . 57.6 mt -96.12 140.81 30.3 Favored 'General case' 0 C--N 1.305 -1.336 0 O-C-N 121.219 -0.926 . . . . 0.0 109.742 -179.64 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -109.77 155.92 40.68 Favored Pre-proline 0 N--CA 1.487 1.418 0 N-CA-C 108.787 -0.82 . . . . 0.0 108.787 179.479 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 7.2 Cg_endo -52.59 -23.02 18.34 Favored 'Trans proline' 0 C--N 1.303 -1.831 0 C-N-CA 122.335 2.023 . . . . 0.0 111.926 -179.772 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -70.26 -26.95 64.06 Favored 'General case' 0 N--CA 1.486 1.37 0 O-C-N 121.339 -0.851 . . . . 0.0 109.472 179.592 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 65' ' ' HIS . . . . . 0.551 ' C ' ' CD2' ' A' ' 65' ' ' HIS . 1.5 t60 -65.65 -19.39 65.89 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.412 -0.805 . . . . 0.0 109.046 -179.883 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.608 ' O ' HG13 ' A' ' 31' ' ' VAL . 7.0 m-85 -100.14 16.35 24.44 Favored 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.521 -0.737 . . . . 0.0 109.174 -179.686 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 67' ' ' ARG . . . . . 0.633 HH21 ' CD ' ' A' ' 87' ' ' LYS . 0.6 OUTLIER -53.24 -37.89 62.47 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.59 -0.694 . . . . 0.0 110.621 -179.452 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 68' ' ' SER . . . . . 0.528 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 51.8 p -167.91 166.53 13.35 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.653 -1.279 . . . . 0.0 110.699 -179.97 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.83 HD11 HD13 ' A' ' 30' ' ' LEU . 19.8 mm -58.89 -35.28 55.58 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.201 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 178.913 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 34.7 mtp180 -57.51 -43.96 84.66 Favored 'General case' 0 C--N 1.303 -1.455 0 CA-C-O 121.446 0.641 . . . . 0.0 109.468 -179.354 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 11.8 t -67.06 -39.41 86.89 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.368 -0.832 . . . . 0.0 109.953 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.415 HD12 ' HA ' ' A' ' 69' ' ' ILE . 76.9 mt -59.84 -50.1 81.35 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 O-C-N 121.265 -0.897 . . . . 0.0 110.074 -179.277 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 44.3 t0 -59.66 -42.78 93.58 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.13 -0.981 . . . . 0.0 109.04 -179.871 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.55 -42.21 87.5 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.535 -0.728 . . . . 0.0 109.756 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 60.0 t80 -63.58 -46.2 86.95 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.185 -0.947 . . . . 0.0 109.411 -179.955 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.613 ' CG1' ' CZ ' ' A' ' 52' ' ' PHE . 54.6 t -60.89 -47.22 94.36 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.297 0 O-C-N 121.367 -0.833 . . . . 0.0 109.138 179.854 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.637 HG22 ' OE1' ' A' ' 2' ' ' GLN . 55.5 t -69.26 -42.38 81.43 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 O-C-N 121.213 -0.929 . . . . 0.0 109.107 179.338 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.493 ' O ' ' O ' ' A' ' 81' ' ' THR . . . -65.22 -28.27 73.36 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 -179.831 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.04 -38.67 86.27 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.153 -1.204 . . . . 0.0 110.299 -178.944 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 52.1 p -82.42 -31.33 29.6 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.111 -0.993 . . . . 0.0 109.539 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.493 ' O ' ' O ' ' A' ' 78' ' ' GLY . 0.3 OUTLIER -133.38 152.65 79.68 Favored Pre-proline 0 C--N 1.302 -1.464 0 O-C-N 121.51 -0.744 . . . . 0.0 109.605 -179.864 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 64.0 Cg_endo -76.25 111.49 3.28 Favored 'Trans proline' 0 N--CA 1.496 1.652 0 C-N-CA 122.474 2.116 . . . . 0.0 111.884 179.474 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -77.13 148.49 27.44 Favored 'Trans proline' 0 N--CA 1.49 1.3 0 C-N-CA 122.079 1.852 . . . . 0.0 113.112 -179.606 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.597 ' O ' ' N ' ' A' ' 86' ' ' ALA . 42.3 t -104.44 121.93 56.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.528 -0.733 . . . . 0.0 109.069 178.894 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.504 ' C ' ' O ' ' A' ' 84' ' ' VAL . 96.1 mt-10 32.62 31.42 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.735 -0.603 . . . . 0.0 110.383 179.693 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.597 ' N ' ' O ' ' A' ' 84' ' ' VAL . . . -69.75 139.16 53.28 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.047 -1.033 . . . . 0.0 110.159 -179.419 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.633 ' CD ' HH21 ' A' ' 67' ' ' ARG . 43.4 tttp 42.15 53.2 4.39 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.452 -0.78 . . . . 0.0 109.599 179.436 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.591 ' N ' HD12 ' A' ' 88' ' ' LEU . 7.7 mp 45.31 86.48 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.195 -0.94 . . . . 0.0 109.487 -179.951 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 59.2 tp60 . . . . . 0 N--CA 1.49 1.575 0 CA-C-O 118.009 -0.996 . . . . 0.0 109.464 179.979 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' -1' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.49 1.543 0 CA-C-O 121.299 0.571 . . . . 0.0 109.492 . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 0' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -57.93 145.03 37.14 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.211 -0.931 . . . . 0.0 109.504 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.49 ' HB2' ' HB2' ' A' ' 4' ' ' ALA . 74.5 mtp -105.48 -119.66 0.22 Allowed 'General case' 0 C--N 1.305 -1.346 0 O-C-N 121.295 -0.878 . . . . 0.0 108.794 179.897 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.422 ' O ' ' C ' ' A' ' 3' ' ' HIS . 97.5 mm-40 -119.87 113.75 21.05 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 178.665 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.422 ' C ' ' O ' ' A' ' 2' ' ' GLN . 62.1 m80 46.65 31.17 1.3 Allowed 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 108.114 -1.069 . . . . 0.0 108.114 -178.913 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.49 ' HB2' ' HB2' ' A' ' 1' ' ' MET . . . -57.25 -39.48 75.69 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.518 -0.739 . . . . 0.0 109.798 -179.33 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.1 p -63.04 -33.7 75.98 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.146 -0.971 . . . . 0.0 109.491 -179.895 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 75.9 t -65.9 -43.49 92.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.222 -0.924 . . . . 0.0 109.539 179.87 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.515 ' O ' HG12 ' A' ' 11' ' ' VAL . 82.6 mt -59.59 -47.3 91.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.4 -0.812 . . . . 0.0 109.845 -179.859 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.716 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.26 -45.13 92.94 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.28 -0.888 . . . . 0.0 110.924 -179.181 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 53.9 mt-30 -69.09 -46.65 67.21 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.835 -1.165 . . . . 0.0 110.854 -178.723 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.549 ' C ' ' CD1' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -70.28 -48.75 55.31 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.075 -1.016 . . . . 0.0 110.298 -179.392 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.515 HG12 ' O ' ' A' ' 7' ' ' ILE . 4.0 p -59.88 -38.81 77.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.072 -1.017 . . . . 0.0 109.678 -179.604 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.716 HG23 ' O ' ' A' ' 8' ' ' ALA . 49.5 t -63.18 -43.22 98.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.224 -0.922 . . . . 0.0 109.963 -179.928 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -63.13 -34.51 77.76 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.104 -0.997 . . . . 0.0 109.941 -179.812 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -65.43 -31.74 72.99 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.269 -0.894 . . . . 0.0 110.197 -179.649 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.779 ' CD2' HG13 ' A' ' 35' ' ' VAL . 77.4 t80 -113.65 -61.4 1.75 Allowed 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.326 -0.859 . . . . 0.0 111.299 -178.818 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 4.8 mt -116.08 80.19 9.06 Favored Pre-proline 0 N--CA 1.494 1.726 0 O-C-N 121.219 -0.926 . . . . 0.0 111.017 -178.354 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_endo -74.64 -14.55 22.03 Favored 'Trans proline' 0 C--N 1.31 -1.5 0 C-N-CA 122.311 2.008 . . . . 0.0 112.156 178.848 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -84.93 0.84 49.83 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.286 -0.883 . . . . 0.0 109.601 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 42.3 t -115.36 134.93 56.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 121.43 -0.794 . . . . 0.0 109.568 -179.908 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.34 117.84 60.52 Favored Pre-proline 0 N--CA 1.489 1.486 0 O-C-N 121.183 -0.948 . . . . 0.0 109.405 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_exo -51.44 -30.06 33.54 Favored 'Trans proline' 0 N--CA 1.493 1.464 0 C-N-CA 121.757 1.638 . . . . 0.0 112.064 179.614 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.8 -25.12 67.78 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.239 -0.913 . . . . 0.0 109.291 179.769 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -81.88 4.45 22.38 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.368 -0.833 . . . . 0.0 109.777 -179.755 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 10.5 t -107.79 128.91 62.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.216 -0.927 . . . . 0.0 109.485 -179.923 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 88.1 m-20 -89.7 120.72 31.22 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.239 -0.913 . . . . 0.0 109.078 179.213 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 28.9 m -70.9 3.89 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 O-C-N 121.11 -0.993 . . . . 0.0 109.123 179.598 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -94.25 -5.24 47.29 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.363 -0.836 . . . . 0.0 109.154 179.466 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 42.0 tp -95.32 138.14 33.42 Favored 'General case' 0 C--N 1.303 -1.421 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 179.599 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -57.2 135.62 56.42 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.068 -1.02 . . . . 0.0 109.354 -179.269 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 1.041 HD23 HD11 ' A' ' 36' ' ' ILE . 39.4 tp -64.59 -37.48 87.71 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.595 -0.69 . . . . 0.0 110.467 -179.336 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 70.2 t -66.2 -37.24 79.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.022 -1.049 . . . . 0.0 110.708 -179.15 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -52.93 -33.05 48.94 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 120.956 -1.09 . . . . 0.0 108.254 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.438 ' HB3' HG23 ' A' ' 35' ' ' VAL . 98.4 m-20 -70.68 -34.33 71.86 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.631 -0.668 . . . . 0.0 109.946 179.457 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 86.6 5.26 82.07 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 108.824 -1.71 . . . . 0.0 108.824 -179.245 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.779 HG13 ' CD2' ' A' ' 15' ' ' PHE . 76.2 t -61.1 -32.69 53.41 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 O-C-N 121.582 -0.952 . . . . 0.0 108.924 179.637 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 1.041 HD11 HD23 ' A' ' 30' ' ' LEU . 80.7 mt -83.82 116.26 27.44 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.403 -0.811 . . . . 0.0 109.843 -179.872 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.406 ' H ' ' HA3' ' A' ' 40' ' ' GLY . 92.0 m-20 -114.99 -176.08 2.83 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 179.406 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -58.95 -53.38 59.08 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.021 -1.049 . . . . 0.0 108.205 179.601 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 35.8 mt -68.57 -32.44 72.36 Favored 'General case' 0 C--N 1.301 -1.528 0 N-CA-C 106.887 -1.523 . . . . 0.0 106.887 177.868 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.494 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -58.97 -40.93 96.05 Favored Glycine 0 N--CA 1.48 1.594 0 N-CA-C 108.718 -1.753 . . . . 0.0 108.718 179.274 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.3 tt -65.21 -41.61 94.31 Favored 'General case' 0 C--N 1.305 -1.34 0 O-C-N 121.386 -1.067 . . . . 0.0 108.693 178.893 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 tp -60.17 -45.72 92.14 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 179.322 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 21.0 mttp -60.71 -35.48 76.42 Favored 'General case' 0 C--N 1.298 -1.663 0 O-C-N 121.551 -0.718 . . . . 0.0 109.522 -179.935 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.494 HG23 ' O ' ' A' ' 40' ' ' GLY . 53.3 t -59.81 -50.59 79.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.325 -0.859 . . . . 0.0 109.469 -179.657 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.482 ' H ' HD12 ' A' ' 45' ' ' ILE . 3.5 mp -68.33 -30.36 47.4 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 O-C-N 121.256 -0.903 . . . . 0.0 110.459 179.704 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.84 -49.2 71.53 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.107 -0.996 . . . . 0.0 111.306 -178.473 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.498 ' C ' ' CD1' ' A' ' 47' ' ' TRP . 0.0 OUTLIER -81.39 -43.23 19.28 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.759 -1.213 . . . . 0.0 110.032 -179.384 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.674 HD11 HG22 ' A' ' 76' ' ' VAL . 0.4 OUTLIER -58.75 -43.19 90.22 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.118 -0.989 . . . . 0.0 109.113 -179.328 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.548 ' O ' ' N ' ' A' ' 53' ' ' GLY . 2.1 pp20? -72.18 -35.62 69.02 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.054 -1.029 . . . . 0.0 109.8 179.905 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.2 t0 -60.44 -38.42 84.09 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.247 -0.908 . . . . 0.0 110.567 -179.641 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.445 ' HD2' ' HE1' ' A' ' 47' ' ' TRP . 49.9 mtp180 -60.47 -40.73 92.29 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.131 -0.981 . . . . 0.0 111.189 -178.873 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.861 ' CE2' HG21 ' A' ' 80' ' ' THR . 73.4 m-85 -106.49 -11.92 15.77 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.974 -1.078 . . . . 0.0 110.041 -179.358 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 53' ' ' GLY . . . . . 0.548 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 70.16 30.16 69.89 Favored Glycine 0 N--CA 1.485 1.939 0 N-CA-C 109.072 -1.611 . . . . 0.0 109.072 179.5 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 12.7 pt -93.57 124.31 45.97 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 O-C-N 121.358 -1.084 . . . . 0.0 109.623 -179.604 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -65.59 140.23 58.51 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.154 -0.966 . . . . 0.0 109.817 -179.535 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.503 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -65.45 -31.86 73.17 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.429 -0.794 . . . . 0.0 109.398 179.805 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -58.46 -37.36 75.3 Favored 'General case' 0 C--N 1.303 -1.45 0 O-C-N 121.183 -0.948 . . . . 0.0 109.952 -179.815 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -58.28 -40.11 81.04 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.225 -0.922 . . . . 0.0 109.964 -179.636 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.503 ' O ' ' O ' ' A' ' 56' ' ' ALA . 42.4 t -127.12 133.67 67.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.311 -0.868 . . . . 0.0 109.555 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 60' ' ' GLU . . . . . 0.51 ' C ' HD22 ' A' ' 61' ' ' LEU . 84.3 tt0 -89.26 129.73 35.78 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.044 -1.035 . . . . 0.0 109.336 179.803 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.675 ' N ' HD22 ' A' ' 61' ' ' LEU . 3.5 mm? -95.9 134.15 39.23 Favored 'General case' 0 C--N 1.305 -1.347 0 O-C-N 121.322 -0.861 . . . . 0.0 109.726 -179.821 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -109.96 156.35 40.11 Favored Pre-proline 0 N--CA 1.487 1.382 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 179.582 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_endo -54.22 -22.88 27.56 Favored 'Trans proline' 0 C--N 1.302 -1.902 0 C-N-CA 122.295 1.997 . . . . 0.0 111.68 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -69.96 -27.36 64.67 Favored 'General case' 0 N--CA 1.485 1.308 0 O-C-N 121.297 -0.877 . . . . 0.0 109.355 179.63 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 65' ' ' HIS . . . . . 0.545 ' C ' ' CD2' ' A' ' 65' ' ' HIS . 1.7 t60 -65.65 -19.94 66.11 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.307 -0.87 . . . . 0.0 109.003 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.55 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 7.9 m-85 -98.43 15.78 23.75 Favored 'General case' 0 C--N 1.299 -1.622 0 CA-C-O 121.601 0.715 . . . . 0.0 109.076 -179.765 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 67' ' ' ARG . . . . . 0.665 HH21 ' CD ' ' A' ' 87' ' ' LYS . 1.4 ptt85 -53.66 -36.6 62.29 Favored 'General case' 0 C--N 1.299 -1.61 0 O-C-N 121.679 -0.638 . . . . 0.0 110.55 -179.378 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 68' ' ' SER . . . . . 0.553 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 41.6 t -168.07 161.23 12.51 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.754 -1.216 . . . . 0.0 110.364 -179.787 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.636 ' H ' HD12 ' A' ' 69' ' ' ILE . 2.4 mp -57.69 -34.15 46.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 179.026 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 52.0 mtp85 -56.65 -41.71 77.68 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 109.081 -0.711 . . . . 0.0 109.081 -179.897 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 61.6 p -67.92 -32.98 73.81 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.444 -0.785 . . . . 0.0 109.596 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.521 HD12 ' HA ' ' A' ' 69' ' ' ILE . 56.5 mt -61.45 -50.6 79.69 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.361 0 O-C-N 121.294 -0.879 . . . . 0.0 109.567 -179.578 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 43.4 t0 -61.41 -41.44 97.16 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.216 -0.927 . . . . 0.0 108.894 179.655 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.21 -37.55 85.84 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.56 -0.712 . . . . 0.0 109.873 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' PHE . . . . . 0.53 ' CZ ' HD11 ' A' ' 61' ' ' LEU . 67.2 t80 -61.48 -46.5 89.78 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.167 -0.958 . . . . 0.0 109.64 -179.772 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.674 HG22 HD11 ' A' ' 48' ' ' LEU . 41.9 t -61.36 -47.76 91.99 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 O-C-N 121.268 -0.895 . . . . 0.0 109.358 179.692 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.416 ' O ' ' O ' ' A' ' 81' ' ' THR . 47.3 t -69.0 -43.42 82.02 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 O-C-N 121.399 -0.813 . . . . 0.0 109.762 179.855 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -63.28 -40.73 99.33 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 110.284 -1.126 . . . . 0.0 110.284 -179.571 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -70.57 -41.62 72.18 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.229 -1.16 . . . . 0.0 110.833 -178.989 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.861 HG21 ' CE2' ' A' ' 52' ' ' PHE . 69.5 p -86.52 -31.15 21.44 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 120.906 -1.121 . . . . 0.0 109.955 -179.341 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.416 ' O ' ' O ' ' A' ' 77' ' ' VAL . 0.2 OUTLIER -133.0 153.58 81.02 Favored Pre-proline 0 C--N 1.302 -1.496 0 O-C-N 121.466 -0.771 . . . . 0.0 109.376 -179.752 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo -43.57 155.18 0.18 Allowed 'Trans proline' 0 C--N 1.308 -1.567 0 C-N-CA 122.04 1.827 . . . . 0.0 111.496 179.644 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_endo -57.7 145.3 90.43 Favored 'Trans proline' 0 C--N 1.307 -1.632 0 C-N-CA 122.4 2.067 . . . . 0.0 112.446 -179.689 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.59 ' O ' ' N ' ' A' ' 86' ' ' ALA . 44.1 t -103.55 129.93 54.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.442 -0.786 . . . . 0.0 109.545 179.878 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.461 ' C ' ' O ' ' A' ' 84' ' ' VAL . 96.1 mt-10 38.58 23.39 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.551 -0.718 . . . . 0.0 110.005 179.729 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.59 ' N ' ' O ' ' A' ' 84' ' ' VAL . . . 39.77 90.4 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.379 -0.826 . . . . 0.0 109.646 -179.826 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.665 ' CD ' HH21 ' A' ' 67' ' ' ARG . 13.4 tttm -57.74 -38.82 76.01 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.301 -0.875 . . . . 0.0 109.49 -179.927 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 69.2 mt -60.45 -35.3 75.52 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.234 -0.916 . . . . 0.0 109.51 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.2 mt-30 . . . . . 0 N--CA 1.49 1.563 0 CA-C-O 118.044 -0.979 . . . . 0.0 109.405 -179.973 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' -1' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.491 1.586 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 0' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -61.66 -33.43 73.97 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.293 -0.88 . . . . 0.0 109.488 -179.951 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.485 ' O ' ' OD2' ' A' ' 73' ' ' ASP . 64.8 mtt -60.03 -36.22 76.8 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.251 -0.906 . . . . 0.0 109.874 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.684 ' CD ' HG22 ' A' ' 77' ' ' VAL . 80.9 mt-30 56.08 48.05 18.42 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.329 -0.857 . . . . 0.0 109.034 -179.391 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 3' ' ' HIS . . . . . 0.579 ' ND1' ' O ' ' A' ' 2' ' ' GLN . 6.7 m80 76.85 52.73 0.04 OUTLIER 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.678 -0.639 . . . . 0.0 110.091 179.937 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.436 ' HB2' ' HB3' ' A' ' 1' ' ' MET . . . -61.78 -41.71 98.06 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 120.981 -1.074 . . . . 0.0 109.173 179.685 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.4 m -60.97 -37.5 82.64 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.434 -0.791 . . . . 0.0 109.895 -179.801 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 49.6 t -60.33 -44.13 95.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.174 -0.954 . . . . 0.0 109.496 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 7' ' ' ILE . . . . . 0.453 ' O ' HG12 ' A' ' 11' ' ' VAL . 78.6 mt -59.5 -50.18 80.87 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 O-C-N 121.397 -0.815 . . . . 0.0 109.641 -179.799 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.659 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.96 -43.82 94.62 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.315 -0.866 . . . . 0.0 110.918 -179.569 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 85.5 mt-30 -69.08 -46.08 68.67 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 120.92 -1.112 . . . . 0.0 111.435 -178.446 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.711 ' CD1' ' N ' ' A' ' 11' ' ' VAL . 0.0 OUTLIER -70.42 -46.71 63.4 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.884 -1.135 . . . . 0.0 110.492 -179.177 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.711 ' N ' ' CD1' ' A' ' 10' ' ' PHE . 4.8 p -62.03 -40.33 86.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.085 -1.01 . . . . 0.0 109.807 -179.523 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.659 HG23 ' O ' ' A' ' 8' ' ' ALA . 55.8 t -63.28 -43.54 98.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.173 -0.955 . . . . 0.0 109.866 179.998 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -65.82 -37.3 85.86 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.214 -0.929 . . . . 0.0 110.278 -179.536 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 85.7 tt0 -65.76 -39.58 91.2 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.159 -0.963 . . . . 0.0 110.116 -179.558 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 15' ' ' PHE . . . . . 0.922 ' CD2' HG13 ' A' ' 35' ' ' VAL . 75.6 t80 -93.77 -50.72 5.23 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.174 -0.954 . . . . 0.0 110.783 -179.218 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.52 HD22 ' CG2' ' A' ' 19' ' ' VAL . 5.4 mt -120.26 80.59 28.64 Favored Pre-proline 0 N--CA 1.491 1.622 0 O-C-N 121.285 -0.884 . . . . 0.0 110.525 -178.776 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 23.5 Cg_endo -69.05 -14.52 38.49 Favored 'Trans proline' 0 N--CA 1.493 1.451 0 C-N-CA 122.095 1.863 . . . . 0.0 112.353 179.614 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -94.92 7.1 47.12 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.179 -0.95 . . . . 0.0 110.387 -179.613 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.52 ' CG2' HD22 ' A' ' 16' ' ' LEU . 39.3 t -119.11 136.33 56.65 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 121.271 -0.893 . . . . 0.0 109.788 -179.779 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -78.53 117.96 69.49 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.301 -0.874 . . . . 0.0 109.081 179.608 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_exo -51.76 -27.77 27.96 Favored 'Trans proline' 0 N--CA 1.493 1.478 0 C-N-CA 121.787 1.658 . . . . 0.0 112.23 179.855 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.52 -27.01 68.67 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.203 -0.936 . . . . 0.0 109.305 -179.946 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.452 ' O ' ' OD1' ' A' ' 23' ' ' ASP . 60.0 t0 -82.19 3.55 26.87 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.303 -0.873 . . . . 0.0 109.7 -179.778 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 9.7 t -109.43 128.33 65.51 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.263 -0.898 . . . . 0.0 109.561 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 87.2 m-20 -89.96 120.56 31.28 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.189 -0.945 . . . . 0.0 109.097 179.06 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 33.7 m -70.93 4.14 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.378 0 O-C-N 121.102 -0.999 . . . . 0.0 108.941 179.47 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -92.13 -5.45 52.66 Favored 'General case' 0 N--CA 1.486 1.341 0 O-C-N 121.373 -0.829 . . . . 0.0 109.031 179.423 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 44.3 tp -96.52 141.1 30.21 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.473 -0.767 . . . . 0.0 108.957 179.86 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -58.59 128.57 37.86 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.176 -0.952 . . . . 0.0 109.504 -179.407 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 1.033 HD23 HD11 ' A' ' 36' ' ' ILE . 48.7 tp -66.85 -37.23 84.07 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.551 -0.718 . . . . 0.0 110.648 -179.417 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 70.6 t -63.67 -35.96 74.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 120.928 -1.107 . . . . 0.0 110.693 -178.911 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 56.3 t0 -52.43 -33.59 44.68 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 120.974 -1.079 . . . . 0.0 108.186 -179.908 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.426 ' HB3' HG23 ' A' ' 35' ' ' VAL . 97.5 m-20 -71.46 -34.45 70.23 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.698 -0.626 . . . . 0.0 110.232 179.476 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 87.22 4.87 80.74 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 108.58 -1.808 . . . . 0.0 108.58 -179.043 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.922 HG13 ' CD2' ' A' ' 15' ' ' PHE . 67.8 t -59.87 -29.55 43.39 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 O-C-N 121.484 -1.009 . . . . 0.0 108.412 179.254 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 1.033 HD11 HD23 ' A' ' 30' ' ' LEU . 71.8 mt -88.07 132.5 33.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 CA-C-O 121.616 0.722 . . . . 0.0 109.627 -179.897 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.554 ' CG ' ' H ' ' A' ' 38' ' ' ALA . 45.7 t0 -139.07 -160.81 1.1 Allowed 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 179.845 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.554 ' H ' ' CG ' ' A' ' 37' ' ' ASP . . . -65.48 -54.31 30.19 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.117 -0.99 . . . . 0.0 108.716 179.817 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.693 HD12 ' N ' ' A' ' 39' ' ' LEU . 7.0 mp -69.63 -32.81 71.72 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 107.35 -1.352 . . . . 0.0 107.35 178.405 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.455 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.26 -44.06 96.77 Favored Glycine 0 N--CA 1.481 1.663 0 N-CA-C 109.008 -1.637 . . . . 0.0 109.008 179.545 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.4 ' O ' HD12 ' A' ' 45' ' ' ILE . 2.8 tt -65.12 -42.06 94.28 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.473 -1.016 . . . . 0.0 109.369 179.168 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 15.8 tp -59.74 -44.69 93.67 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.227 -0.921 . . . . 0.0 109.339 179.857 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 18.8 mttt -62.2 -34.29 76.18 Favored 'General case' 0 C--N 1.299 -1.589 0 O-C-N 121.156 -0.965 . . . . 0.0 109.62 179.874 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.455 HG23 ' O ' ' A' ' 40' ' ' GLY . 54.0 t -60.75 -50.18 81.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.27 -0.894 . . . . 0.0 110.06 -179.488 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.525 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 3.6 mp -68.48 -34.63 66.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.247 -0.908 . . . . 0.0 111.257 -179.669 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.81 -50.16 65.65 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 120.943 -1.098 . . . . 0.0 111.758 -177.867 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.678 ' HE1' ' NE ' ' A' ' 51' ' ' ARG . 0.0 OUTLIER -80.05 -43.8 21.22 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.75 -1.219 . . . . 0.0 109.78 -179.457 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.98 HD12 HH21 ' A' ' 51' ' ' ARG . 15.0 tp -58.73 -43.16 90.1 Favored 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.382 -0.824 . . . . 0.0 110.12 -179.12 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.525 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 1.2 pp20? -72.67 -35.85 67.78 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.135 -0.978 . . . . 0.0 109.905 -179.762 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.1 t70 -61.51 -39.72 92.02 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.226 -0.921 . . . . 0.0 111.16 -179.317 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.98 HH21 HD12 ' A' ' 48' ' ' LEU . 70.5 mtm180 -62.65 -36.8 83.99 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.19 -0.944 . . . . 0.0 112.028 -178.291 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.79 ' CE1' HG11 ' A' ' 76' ' ' VAL . 88.5 m-85 -95.96 -6.13 39.73 Favored 'General case' 0 N--CA 1.487 1.389 0 O-C-N 120.714 -1.242 . . . . 0.0 110.454 -178.718 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 70.33 29.39 70.21 Favored Glycine 0 N--CA 1.486 1.979 0 N-CA-C 108.882 -1.687 . . . . 0.0 108.882 179.349 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.488 ' O ' ' OE1' ' A' ' 49' ' ' GLU . 24.7 pt -107.28 152.38 8.87 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 O-C-N 121.557 -0.966 . . . . 0.0 109.559 -179.571 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -105.23 154.51 20.12 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.36 -0.837 . . . . 0.0 109.721 -179.472 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.833 ' O ' HG12 ' A' ' 59' ' ' VAL . . . -59.8 -21.19 60.5 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.339 -0.85 . . . . 0.0 109.177 179.904 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 56.3 t0 61.95 36.6 15.6 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 121.526 -0.734 . . . . 0.0 109.328 -179.789 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 53.32 48.61 21.61 Favored 'General case' 0 C--N 1.305 -1.366 0 O-C-N 121.439 -0.788 . . . . 0.0 110.357 178.941 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.833 HG12 ' O ' ' A' ' 56' ' ' ALA . 8.8 p -127.86 142.87 42.53 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.364 -0.835 . . . . 0.0 109.105 179.593 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -99.19 133.5 43.39 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.177 -0.952 . . . . 0.0 109.628 -179.792 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 59.3 mt -92.52 145.38 24.49 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.43 -0.794 . . . . 0.0 109.248 179.92 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -91.71 150.73 41.42 Favored Pre-proline 0 C--N 1.305 -1.34 0 O-C-N 121.14 -0.975 . . . . 0.0 108.765 179.8 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 11.4 Cg_endo -57.23 -19.82 36.06 Favored 'Trans proline' 0 C--N 1.304 -1.81 0 C-N-CA 122.335 2.023 . . . . 0.0 112.035 -179.67 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -67.96 -31.62 71.47 Favored 'General case' 0 N--CA 1.484 1.243 0 O-C-N 121.285 -0.885 . . . . 0.0 109.453 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 65' ' ' HIS . . . . . 0.586 ' CD2' ' O ' ' A' ' 65' ' ' HIS . 5.2 t-160 -66.04 -20.54 66.21 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.347 -0.846 . . . . 0.0 108.737 179.787 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.586 ' HB3' HD13 ' A' ' 36' ' ' ILE . 8.5 m-85 -94.63 14.65 20.37 Favored 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 -179.915 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 67' ' ' ARG . . . . . 0.587 ' NE ' ' OG ' ' A' ' 71' ' ' SER . 6.4 ptt180 -46.47 -37.65 8.09 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.739 -0.601 . . . . 0.0 110.381 -179.59 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 68' ' ' SER . . . . . 0.485 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 46.7 t -159.71 155.05 25.33 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.933 -1.104 . . . . 0.0 110.06 -179.764 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.717 ' H ' HD12 ' A' ' 69' ' ' ILE . 1.6 mp -57.69 -41.75 80.1 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 O-C-N 121.29 -0.881 . . . . 0.0 109.142 179.931 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 11.1 ptm180 -58.33 -42.05 85.93 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.406 -0.809 . . . . 0.0 109.1 179.795 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.587 ' OG ' ' NE ' ' A' ' 67' ' ' ARG . 26.4 t -62.97 -40.9 99.13 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.333 -0.854 . . . . 0.0 109.359 179.471 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 86.1 mt -60.12 -49.78 82.77 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 O-C-N 121.218 -0.926 . . . . 0.0 109.437 179.928 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.485 ' OD2' ' O ' ' A' ' 1' ' ' MET . 37.2 t0 -59.53 -40.6 87.71 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.366 -0.834 . . . . 0.0 109.013 179.695 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.45 -37.76 85.87 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.637 -0.665 . . . . 0.0 110.153 -179.882 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 75' ' ' PHE . . . . . 0.554 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 64.4 t80 -60.73 -47.77 84.78 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.145 -0.972 . . . . 0.0 109.836 -179.413 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.79 HG11 ' CE1' ' A' ' 52' ' ' PHE . 98.5 t -62.47 -46.3 96.74 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.294 0 O-C-N 121.064 -1.023 . . . . 0.0 109.18 179.809 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 77' ' ' VAL . . . . . 0.684 HG22 ' CD ' ' A' ' 2' ' ' GLN . 78.8 t -66.9 -40.24 85.31 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.389 0 O-C-N 121.472 -0.768 . . . . 0.0 109.217 179.641 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.489 ' O ' ' O ' ' A' ' 81' ' ' THR . . . -59.46 -38.57 93.72 Favored Glycine 0 N--CA 1.488 2.127 0 N-CA-C 109.913 -1.275 . . . . 0.0 109.913 -179.781 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -69.15 -41.31 77.45 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.335 -1.097 . . . . 0.0 110.489 -179.3 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 44.9 p -81.81 -31.08 31.94 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.068 -1.02 . . . . 0.0 109.449 -179.781 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.489 ' O ' ' O ' ' A' ' 78' ' ' GLY . 0.5 OUTLIER -133.01 153.9 81.14 Favored Pre-proline 0 C--N 1.3 -1.558 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 -179.869 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -63.6 136.77 55.87 Favored 'Trans proline' 0 C--N 1.306 -1.703 0 C-N-CA 122.132 1.888 . . . . 0.0 111.411 179.909 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -65.56 147.22 86.34 Favored 'Trans proline' 0 N--CA 1.492 1.416 0 C-N-CA 121.974 1.783 . . . . 0.0 112.671 -179.465 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.61 ' O ' ' N ' ' A' ' 86' ' ' ALA . 42.4 t -103.8 126.68 58.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.491 -0.756 . . . . 0.0 109.459 179.586 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.499 ' O ' ' O ' ' A' ' 86' ' ' ALA . 96.1 mt-10 38.2 22.53 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.615 -0.678 . . . . 0.0 110.237 179.61 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.61 ' N ' ' O ' ' A' ' 84' ' ' VAL . . . 50.28 174.69 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.186 -0.946 . . . . 0.0 109.692 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.453 ' HD2' HH21 ' A' ' 67' ' ' ARG . 31.0 tttm -59.38 -37.95 79.26 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.195 -0.941 . . . . 0.0 109.517 179.927 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.449 ' O ' ' OXT' ' A' ' 89' ' ' GLN . 52.8 mt -94.38 142.14 27.77 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.314 -0.866 . . . . 0.0 109.506 -179.905 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 89' ' ' GLN . . . . . 0.449 ' OXT' ' O ' ' A' ' 88' ' ' LEU . 94.1 mt-30 . . . . . 0 N--CA 1.491 1.58 0 CA-C-O 117.985 -1.007 . . . . 0.0 109.439 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' -1' ' ' SER . . . . . . . . . . . . . 59.6 p . . . . . 0 N--CA 1.489 1.525 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 0' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -108.71 155.23 20.96 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.422 -0.799 . . . . 0.0 109.5 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.618 ' HB2' ' HB2' ' A' ' 4' ' ' ALA . 79.9 mtp -102.99 -122.31 0.19 Allowed 'General case' 0 C--N 1.304 -1.4 0 O-C-N 121.225 -0.922 . . . . 0.0 108.98 -179.893 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 98.8 mm-40 -105.24 -69.42 0.82 Allowed 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 179.153 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 97.1 m-70 -102.76 16.64 25.93 Favored 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 178.725 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.618 ' HB2' ' HB2' ' A' ' 1' ' ' MET . . . -54.37 -42.64 70.56 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.524 -0.735 . . . . 0.0 109.836 -179.181 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 24.2 m -62.11 -38.08 87.55 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.28 -0.887 . . . . 0.0 109.868 -179.84 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 53.7 t -64.19 -45.44 96.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.165 -0.959 . . . . 0.0 109.781 -179.777 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 79.4 mt -59.77 -42.43 88.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.386 -0.821 . . . . 0.0 109.279 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' ALA . . . . . 0.516 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -60.51 -36.93 79.55 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.374 -0.828 . . . . 0.0 109.18 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 59.8 tt0 -65.28 -40.23 93.6 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.271 -0.893 . . . . 0.0 110.077 179.924 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.677 ' CG ' ' CZ2' ' A' ' 47' ' ' TRP . 20.7 m-85 -62.01 -50.04 73.63 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.102 -0.999 . . . . 0.0 110.676 -179.426 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.42 HG23 ' N ' ' A' ' 12' ' ' VAL . 22.2 m -64.08 -40.48 89.19 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 O-C-N 121.06 -1.025 . . . . 0.0 109.302 -179.629 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.516 HG23 ' O ' ' A' ' 8' ' ' ALA . 69.0 t -63.66 -46.52 94.51 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.206 -0.934 . . . . 0.0 109.309 179.571 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -70.12 -29.39 66.32 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.305 -0.872 . . . . 0.0 109.895 179.818 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -64.82 -30.42 71.42 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.48 -0.762 . . . . 0.0 110.615 -179.094 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 75.9 t80 -131.89 -46.06 0.95 Allowed 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.083 -1.01 . . . . 0.0 111.125 -178.97 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.47 HD22 ' CG2' ' A' ' 19' ' ' VAL . 4.7 mt -117.98 80.16 14.55 Favored Pre-proline 0 N--CA 1.494 1.755 0 O-C-N 121.097 -1.002 . . . . 0.0 110.442 -178.994 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -76.15 -14.26 18.8 Favored 'Trans proline' 0 C--N 1.308 -1.604 0 C-N-CA 122.411 2.074 . . . . 0.0 112.255 179.324 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -89.08 5.19 45.63 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.279 -0.888 . . . . 0.0 109.761 -179.928 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.47 ' CG2' HD22 ' A' ' 16' ' ' LEU . 45.1 t -112.64 135.33 52.38 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.378 -0.826 . . . . 0.0 109.59 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.435 ' O ' ' CG ' ' A' ' 23' ' ' ASP . . . -73.18 117.52 60.83 Favored Pre-proline 0 N--CA 1.489 1.52 0 O-C-N 121.26 -0.9 . . . . 0.0 109.443 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_exo -51.98 -25.14 21.18 Favored 'Trans proline' 0 N--CA 1.493 1.5 0 C-N-CA 121.805 1.67 . . . . 0.0 112.039 179.486 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.72 -22.92 67.09 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.29 -0.881 . . . . 0.0 109.708 -179.828 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.45 ' C ' ' OD1' ' A' ' 23' ' ' ASP . 52.3 p30 -83.98 7.62 17.81 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.249 -0.907 . . . . 0.0 109.831 -179.74 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 11.8 t -104.97 133.57 48.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.218 -0.926 . . . . 0.0 109.348 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 86.5 m-20 -88.89 120.61 30.46 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.054 -1.029 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 17.0 m -74.96 3.83 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 O-C-N 121.26 -0.9 . . . . 0.0 109.386 179.849 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' ASP . . . . . 0.449 ' C ' ' OD1' ' A' ' 27' ' ' ASP . 52.0 p30 -94.95 1.12 55.2 Favored 'General case' 0 N--CA 1.486 1.349 0 O-C-N 121.245 -0.909 . . . . 0.0 109.227 179.454 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 46.0 tp -100.44 134.61 43.12 Favored 'General case' 0 C--N 1.303 -1.437 0 N-CA-C 108.358 -0.978 . . . . 0.0 108.358 179.313 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -57.72 126.71 28.56 Favored 'General case' 0 C--N 1.3 -1.546 0 C-N-CA 118.942 -1.103 . . . . 0.0 108.998 -179.335 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 1.023 HD23 HD11 ' A' ' 36' ' ' ILE . 43.0 tp -66.08 -37.97 87.11 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.654 -0.654 . . . . 0.0 110.654 -179.153 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 54.1 t -67.43 -37.47 78.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 120.931 -1.106 . . . . 0.0 110.774 -179.155 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 84.4 m-20 -52.69 -33.17 46.25 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 120.859 -1.151 . . . . 0.0 108.111 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 20.3 m120 -70.72 -33.48 70.9 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.639 -0.663 . . . . 0.0 109.784 179.325 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 91.65 5.56 66.62 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 108.879 -1.688 . . . . 0.0 108.879 -179.304 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 74.4 t -61.44 -32.99 54.92 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 O-C-N 121.498 -1.001 . . . . 0.0 109.209 179.793 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 1.023 HD11 HD23 ' A' ' 30' ' ' LEU . 72.6 mt -92.31 121.13 42.62 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.396 0 O-C-N 121.302 -0.874 . . . . 0.0 109.651 -179.726 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -120.42 -169.5 1.82 Allowed 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 109.076 -0.713 . . . . 0.0 109.076 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -63.46 -54.24 39.65 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.221 -0.924 . . . . 0.0 108.615 179.702 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.686 HD12 ' N ' ' A' ' 39' ' ' LEU . 7.0 mp -70.78 -33.47 70.79 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 107.193 -1.41 . . . . 0.0 107.193 178.148 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.497 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.49 -43.12 97.79 Favored Glycine 0 N--CA 1.483 1.813 0 N-CA-C 108.809 -1.716 . . . . 0.0 108.809 179.388 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.407 HD11 ' CE1' ' A' ' 66' ' ' PHE . 6.6 tt -64.73 -41.63 95.81 Favored 'General case' 0 C--N 1.304 -1.374 0 O-C-N 121.384 -1.068 . . . . 0.0 109.066 179.286 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.4 tp -59.73 -45.93 90.68 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.222 -0.924 . . . . 0.0 109.044 179.705 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 56.6 mttt -60.97 -34.75 75.25 Favored 'General case' 0 C--N 1.297 -1.717 0 O-C-N 121.492 -0.755 . . . . 0.0 109.671 -179.812 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.497 HG23 ' O ' ' A' ' 40' ' ' GLY . 54.3 t -61.85 -49.87 82.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.366 -0.834 . . . . 0.0 110.162 -179.401 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.547 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 3.4 mp -67.89 -32.9 58.38 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 O-C-N 121.206 -0.934 . . . . 0.0 110.678 -179.621 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.7 -50.29 67.55 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.861 -1.15 . . . . 0.0 111.13 -178.302 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.677 ' CZ2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -81.28 -44.84 17.11 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.758 -1.214 . . . . 0.0 109.829 -179.657 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.646 HD21 ' CG2' ' A' ' 76' ' ' VAL . 18.1 tp -58.37 -41.32 84.53 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.328 -0.858 . . . . 0.0 109.936 -178.955 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.547 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 1.1 pp20? -73.35 -35.63 66.02 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 120.895 -1.128 . . . . 0.0 109.521 179.769 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.4 t0 -63.48 -41.02 98.59 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.376 -0.828 . . . . 0.0 111.619 -179.111 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.504 ' HD3' HD12 ' A' ' 48' ' ' LEU . 8.8 ptm180 -65.0 -37.08 86.47 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.869 -1.144 . . . . 0.0 111.632 -178.122 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.858 ' CE2' HG11 ' A' ' 76' ' ' VAL . 72.9 m-85 -90.9 -12.14 37.02 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 120.443 -1.41 . . . . 0.0 110.021 -179.505 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 74.47 28.83 62.84 Favored Glycine 0 N--CA 1.487 2.045 0 N-CA-C 108.832 -1.707 . . . . 0.0 108.832 179.919 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 54' ' ' ILE . . . . . 0.49 ' O ' ' OE1' ' A' ' 49' ' ' GLU . 25.2 pt -109.18 153.4 10.95 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.575 -0.956 . . . . 0.0 109.798 -179.42 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -102.44 126.3 49.44 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.228 -0.92 . . . . 0.0 109.561 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.497 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -68.55 -28.16 66.72 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.238 -0.914 . . . . 0.0 109.525 179.784 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 21.0 t70 -55.12 -33.49 62.9 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.262 -0.899 . . . . 0.0 110.082 -179.638 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -52.76 -38.29 60.77 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.133 -0.979 . . . . 0.0 109.852 -179.465 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.497 ' O ' ' O ' ' A' ' 56' ' ' ALA . 32.7 m -127.66 157.74 39.43 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.335 0 O-C-N 121.319 -0.863 . . . . 0.0 109.557 -179.721 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -97.6 125.82 42.55 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.14 -0.975 . . . . 0.0 109.353 179.725 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.412 HD21 ' CE2' ' A' ' 75' ' ' PHE . 5.1 mp -107.12 141.06 38.98 Favored 'General case' 0 C--N 1.306 -1.325 0 O-C-N 121.394 -0.816 . . . . 0.0 109.699 -179.73 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -109.22 153.09 42.84 Favored Pre-proline 0 N--CA 1.487 1.406 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 179.295 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo -54.53 -23.22 30.96 Favored 'Trans proline' 0 C--N 1.303 -1.817 0 C-N-CA 122.338 2.026 . . . . 0.0 112.086 -179.548 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -70.15 -26.46 63.94 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 121.352 -0.842 . . . . 0.0 109.403 179.906 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 65' ' ' HIS . . . . . 0.504 ' NE2' ' CB ' ' A' ' 75' ' ' PHE . 2.2 t-80 -66.03 -20.88 66.33 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.419 -0.8 . . . . 0.0 109.289 -179.843 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.584 ' HB3' HD13 ' A' ' 36' ' ' ILE . 9.5 m-85 -97.1 15.48 22.41 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 121.406 -0.809 . . . . 0.0 109.166 -179.815 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 67' ' ' ARG . . . . . 0.42 HH21 ' HD3' ' A' ' 87' ' ' LYS . 1.7 ptt85 -51.99 -34.39 42.31 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.644 -0.66 . . . . 0.0 109.999 -179.938 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 68' ' ' SER . . . . . 0.546 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 44.2 t -151.4 154.05 35.89 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.071 -1.018 . . . . 0.0 109.969 179.884 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.637 ' H ' HD12 ' A' ' 69' ' ' ILE . 3.2 mp -57.36 -33.91 44.99 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 179.222 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 32.1 mtp180 -56.79 -44.11 81.56 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.67 -0.644 . . . . 0.0 109.407 -179.693 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 17.0 t -66.47 -40.58 89.42 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.382 -0.823 . . . . 0.0 109.829 -179.96 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 62.8 mt -62.18 -50.26 80.73 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.37 0 O-C-N 121.305 -0.872 . . . . 0.0 110.286 -179.222 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 37.0 t0 -61.0 -41.88 97.35 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.11 -0.994 . . . . 0.0 109.409 -179.842 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -67.02 -40.69 87.31 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.478 -0.764 . . . . 0.0 110.353 -179.443 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 75' ' ' PHE . . . . . 0.504 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 66.9 t80 -62.7 -46.71 86.86 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.049 -1.032 . . . . 0.0 109.663 -179.676 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.858 HG11 ' CE2' ' A' ' 52' ' ' PHE . 90.7 t -67.23 -48.21 79.05 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.343 0 O-C-N 121.192 -0.943 . . . . 0.0 109.78 -179.938 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 53.0 t -69.66 -41.99 80.29 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.333 0 O-C-N 121.134 -0.978 . . . . 0.0 109.63 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.486 ' O ' ' O ' ' A' ' 81' ' ' THR . . . -59.53 -36.0 87.7 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 -179.477 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.48 -40.98 85.29 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.209 -1.171 . . . . 0.0 110.475 -179.183 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 49.0 p -81.93 -30.74 31.67 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.144 -0.972 . . . . 0.0 109.698 -179.685 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.486 ' O ' ' O ' ' A' ' 78' ' ' GLY . 0.5 OUTLIER -133.18 153.94 80.96 Favored Pre-proline 0 C--N 1.302 -1.458 0 O-C-N 121.541 -0.725 . . . . 0.0 109.666 -179.615 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -62.71 111.65 1.41 Allowed 'Trans proline' 0 C--N 1.308 -1.577 0 C-N-CA 122.339 2.026 . . . . 0.0 111.285 179.614 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -74.15 150.77 43.12 Favored 'Trans proline' 0 N--CA 1.49 1.284 0 C-N-CA 121.992 1.795 . . . . 0.0 113.143 -179.11 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.449 ' O ' ' C ' ' A' ' 85' ' ' GLU . 14.5 p -104.31 138.5 28.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 179.389 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.449 ' C ' ' O ' ' A' ' 84' ' ' VAL . 95.9 mt-10 41.88 47.27 3.64 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.184 -0.947 . . . . 0.0 109.329 -179.813 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -56.15 150.37 14.22 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.362 -0.836 . . . . 0.0 109.801 -179.564 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.42 ' HD3' HH21 ' A' ' 67' ' ' ARG . 53.2 mttm -56.31 -34.89 66.96 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.254 -0.904 . . . . 0.0 109.396 -179.983 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 88' ' ' LEU . . . . . 0.406 ' O ' ' O ' ' A' ' 89' ' ' GLN . 52.3 mt -93.18 142.44 27.31 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.28 -0.887 . . . . 0.0 109.377 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 89' ' ' GLN . . . . . 0.406 ' O ' ' O ' ' A' ' 88' ' ' LEU . 59.4 tp60 . . . . . 0 N--CA 1.49 1.57 0 CA-C-O 118.024 -0.988 . . . . 0.0 109.348 179.934 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' -1' ' ' SER . . . . . . . . . . . . . 25.4 t . . . . . 0 N--CA 1.49 1.545 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 0' ' ' GLU . . . . . 0.457 ' HG2' ' H ' ' A' ' 2' ' ' GLN . 84.2 tt0 -101.35 133.96 45.16 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.278 -0.889 . . . . 0.0 109.36 -179.992 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.739 ' HB3' ' HB2' ' A' ' 4' ' ' ALA . 64.7 mtt -60.56 -35.12 75.27 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.304 -0.873 . . . . 0.0 109.693 -179.852 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 2' ' ' GLN . . . . . 0.457 ' H ' ' HG2' ' A' ' 0' ' ' GLU . 94.5 mt-30 56.48 94.1 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.386 -0.821 . . . . 0.0 109.581 -179.678 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 50.4 m-70 66.14 41.77 3.41 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.626 -0.671 . . . . 0.0 110.575 179.687 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.739 ' HB2' ' HB3' ' A' ' 1' ' ' MET . . . -61.01 -38.42 86.0 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.96 -1.088 . . . . 0.0 109.299 179.468 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 25.5 m -60.18 -35.75 76.05 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.328 -0.857 . . . . 0.0 109.914 -179.797 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 53.0 t -61.39 -45.72 98.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.193 -0.942 . . . . 0.0 109.589 -179.69 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 70.2 mt -60.04 -43.88 93.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.475 0 O-C-N 121.247 -0.908 . . . . 0.0 109.113 179.79 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -60.41 -35.89 76.84 Favored 'General case' 0 C--N 1.303 -1.424 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 179.752 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 59.5 tt0 -64.18 -38.12 89.9 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.458 -0.776 . . . . 0.0 110.137 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.684 ' CG ' ' CZ2' ' A' ' 47' ' ' TRP . 25.8 m-85 -66.52 -49.29 67.01 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 120.908 -1.12 . . . . 0.0 111.028 -179.219 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 11' ' ' VAL . . . . . 0.443 HG23 ' N ' ' A' ' 12' ' ' VAL . 11.6 m -59.74 -48.14 88.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.08 -1.013 . . . . 0.0 110.428 -178.518 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.573 ' O ' ' N ' ' A' ' 16' ' ' LEU . 30.6 m -64.89 -43.44 96.31 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.407 0 O-C-N 120.766 -1.208 . . . . 0.0 110.03 -179.838 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 13' ' ' GLU . . . . . 0.511 ' N ' HG23 ' A' ' 12' ' ' VAL . 95.0 mt-10 -65.16 -26.51 68.19 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.755 -1.215 . . . . 0.0 109.945 -179.981 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 81.4 tt0 -64.28 -31.04 72.08 Favored 'General case' 0 C--N 1.299 -1.614 0 O-C-N 121.328 -0.857 . . . . 0.0 109.767 -179.277 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 85.9 m-85 -141.5 -35.89 0.45 Allowed 'General case' 0 N--CA 1.494 1.734 0 O-C-N 120.897 -1.127 . . . . 0.0 110.816 -179.9 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.573 ' N ' ' O ' ' A' ' 12' ' ' VAL . 8.6 mt -122.17 79.79 43.83 Favored Pre-proline 0 N--CA 1.494 1.737 0 O-C-N 121.124 -0.985 . . . . 0.0 110.418 -179.01 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 43.0 Cg_endo -75.77 -12.03 20.08 Favored 'Trans proline' 0 C--N 1.308 -1.562 0 C-N-CA 122.412 2.075 . . . . 0.0 112.545 179.79 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -93.87 13.09 23.66 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.224 -0.922 . . . . 0.0 110.385 -179.399 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 58.5 t -109.46 134.98 49.78 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.247 -0.908 . . . . 0.0 110.008 -179.724 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 20' ' ' ALA . . . . . 0.494 ' O ' ' OD1' ' A' ' 23' ' ' ASP . . . -73.58 117.88 64.43 Favored Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.429 -0.794 . . . . 0.0 109.337 -179.965 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_exo -52.62 -27.24 32.28 Favored 'Trans proline' 0 N--CA 1.494 1.509 0 C-N-CA 121.832 1.688 . . . . 0.0 112.394 179.786 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.85 -25.4 67.88 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.263 -0.898 . . . . 0.0 110.035 -179.561 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.494 ' OD1' ' O ' ' A' ' 20' ' ' ALA . 47.4 p30 -86.54 8.15 23.24 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.133 -0.979 . . . . 0.0 110.112 -179.566 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 11.3 t -101.11 131.64 48.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 120.972 -1.08 . . . . 0.0 109.418 -179.907 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 61.6 t0 -89.29 119.71 30.0 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.096 -1.002 . . . . 0.0 109.094 179.435 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 22.1 m -76.3 4.45 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 O-C-N 121.252 -0.905 . . . . 0.0 109.173 179.687 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -96.24 0.25 50.75 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 121.266 -0.896 . . . . 0.0 109.214 179.61 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 38.4 tp -94.62 143.22 26.61 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.43 -0.794 . . . . 0.0 109.192 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -66.79 118.78 10.79 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.091 -1.006 . . . . 0.0 109.005 -179.75 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 1.027 HD23 HD11 ' A' ' 36' ' ' ILE . 41.6 tp -62.33 -37.86 87.26 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.605 -0.685 . . . . 0.0 111.09 -178.872 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 53.2 t -66.78 -38.29 81.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 120.807 -1.183 . . . . 0.0 110.863 -179.012 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -52.89 -33.36 49.87 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 120.913 -1.117 . . . . 0.0 108.212 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 20.9 m120 -71.05 -33.91 70.74 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.698 -0.626 . . . . 0.0 109.941 179.528 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 91.31 5.6 67.24 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 108.871 -1.691 . . . . 0.0 108.871 -179.231 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 78.0 t -60.19 -30.56 46.19 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 O-C-N 121.479 -1.012 . . . . 0.0 108.825 179.526 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 1.027 HD11 HD23 ' A' ' 30' ' ' LEU . 65.5 mt -94.72 130.5 43.46 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.344 0 O-C-N 121.386 -0.821 . . . . 0.0 109.558 -179.763 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.545 ' CG ' ' H ' ' A' ' 38' ' ' ALA . 49.1 t0 -137.92 -163.67 1.48 Allowed 'General case' 0 C--N 1.301 -1.52 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 179.948 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.545 ' H ' ' CG ' ' A' ' 37' ' ' ASP . . . -63.54 -54.76 31.13 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.995 -1.066 . . . . 0.0 108.665 179.879 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 39' ' ' LEU . . . . . 0.712 HD12 ' N ' ' A' ' 39' ' ' LEU . 6.9 mp -71.25 -34.04 70.37 Favored 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 107.323 -1.362 . . . . 0.0 107.323 178.206 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.425 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.47 -45.55 95.36 Favored Glycine 0 N--CA 1.482 1.725 0 N-CA-C 109.019 -1.632 . . . . 0.0 109.019 179.562 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.4 tt -64.08 -39.95 95.17 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.462 -1.022 . . . . 0.0 109.092 179.303 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 tp -60.04 -46.03 90.89 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.432 -0.792 . . . . 0.0 109.327 179.902 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 17.6 mttp -59.82 -37.11 78.28 Favored 'General case' 0 C--N 1.296 -1.729 0 O-C-N 121.474 -0.766 . . . . 0.0 109.381 -179.906 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.425 HG23 ' O ' ' A' ' 40' ' ' GLY . 84.9 t -64.64 -41.49 92.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.5 -0.75 . . . . 0.0 110.2 -179.699 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.485 ' O ' ' OE1' ' A' ' 49' ' ' GLU . 1.3 mp -64.89 -50.76 73.58 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.646 0 O-C-N 121.066 -1.021 . . . . 0.0 111.208 -178.84 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 46' ' ' ALA . . . . . 0.411 ' N ' HG22 ' A' ' 45' ' ' ILE . . . -67.68 -49.51 62.4 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.083 -1.011 . . . . 0.0 112.843 -177.531 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.684 ' CZ2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -74.8 -48.86 23.05 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 120.613 -1.304 . . . . 0.0 111.358 -177.758 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.594 ' O ' HD13 ' A' ' 48' ' ' LEU . 0.2 OUTLIER -58.86 -44.52 91.04 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 120.812 -1.18 . . . . 0.0 109.345 -178.582 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.628 ' HG2' ' HB2' ' A' ' 56' ' ' ALA . 0.0 OUTLIER -63.97 -38.72 92.11 Favored 'General case' 0 N--CA 1.485 1.324 0 O-C-N 120.706 -1.246 . . . . 0.0 109.818 -179.958 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 55.1 t0 -61.68 -37.25 83.4 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.298 -0.876 . . . . 0.0 110.513 -179.502 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 18.4 mmt180 -58.27 -36.51 73.39 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.089 -1.007 . . . . 0.0 111.055 -179.029 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.752 ' CE1' HG11 ' A' ' 76' ' ' VAL . 87.4 m-85 -96.32 -6.18 38.36 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 120.789 -1.194 . . . . 0.0 110.474 -179.144 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 73.25 30.44 62.79 Favored Glycine 0 N--CA 1.488 2.121 0 N-CA-C 108.739 -1.745 . . . . 0.0 108.739 179.761 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 20.7 pt -112.68 153.9 14.21 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 O-C-N 121.75 -0.853 . . . . 0.0 109.701 -179.436 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -93.99 130.17 40.21 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.217 -0.927 . . . . 0.0 109.407 -179.873 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.628 ' HB2' ' HG2' ' A' ' 49' ' ' GLU . . . -64.39 -32.24 73.78 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.202 -0.936 . . . . 0.0 109.552 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -58.06 -34.49 70.17 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.383 -0.823 . . . . 0.0 110.051 -179.835 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -53.53 -37.93 63.3 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.28 -0.888 . . . . 0.0 109.939 -179.469 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.486 ' O ' ' O ' ' A' ' 56' ' ' ALA . 13.7 p -133.67 142.72 40.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.253 -0.905 . . . . 0.0 109.567 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -100.19 128.73 46.21 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.21 -0.931 . . . . 0.0 109.322 179.781 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 51.7 mt -105.75 143.46 33.88 Favored 'General case' 0 C--N 1.305 -1.361 0 O-C-N 121.314 -0.866 . . . . 0.0 109.707 -179.719 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -97.32 151.25 37.56 Favored Pre-proline 0 C--N 1.305 -1.337 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 179.131 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -55.39 -23.25 37.41 Favored 'Trans proline' 0 C--N 1.305 -1.743 0 C-N-CA 122.366 2.044 . . . . 0.0 112.032 -179.403 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 91.9 mt-10 -71.79 -29.85 64.9 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.345 -0.847 . . . . 0.0 109.774 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 65' ' ' HIS . . . . . 0.453 ' CE1' ' HB2' ' A' ' 75' ' ' PHE . 63.0 t60 -65.92 -21.17 66.42 Favored 'General case' 0 C--N 1.299 -1.588 0 O-C-N 121.102 -0.999 . . . . 0.0 109.186 -179.668 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.599 ' HB3' HD13 ' A' ' 36' ' ' ILE . 26.0 m-85 -86.93 13.98 8.13 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.405 -0.809 . . . . 0.0 109.223 -179.659 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 67' ' ' ARG . . . . . 0.416 HH21 ' HE3' ' A' ' 87' ' ' LYS . 5.8 ptt180 -52.73 -34.31 52.05 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.66 -0.65 . . . . 0.0 110.088 179.852 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 68' ' ' SER . . . . . 0.48 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 32.4 t -149.82 151.11 32.99 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.067 -1.021 . . . . 0.0 110.088 -179.771 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.665 ' H ' HD12 ' A' ' 69' ' ' ILE . 2.0 mp -60.19 -39.14 79.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.428 0 O-C-N 121.48 -0.762 . . . . 0.0 109.888 -179.862 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 9.8 ptm180 -58.12 -40.99 82.64 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.493 -0.754 . . . . 0.0 110.283 -179.225 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 60.7 p -64.98 -42.91 94.12 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.201 -0.937 . . . . 0.0 110.221 -179.455 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 72' ' ' ILE . . . . . 0.421 ' HA ' ' NE2' ' A' ' 65' ' ' HIS . 69.6 mt -61.5 -47.39 93.63 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 O-C-N 121.136 -0.978 . . . . 0.0 110.406 -179.405 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 73' ' ' ASP . . . . . 0.492 ' OD2' ' O ' ' A' ' 1' ' ' MET . 39.4 t0 -60.63 -37.49 81.64 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 121.184 -0.948 . . . . 0.0 109.825 -179.723 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -67.86 -46.84 70.59 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.216 -0.927 . . . . 0.0 110.604 -178.985 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 75' ' ' PHE . . . . . 0.453 ' HB2' ' CE1' ' A' ' 65' ' ' HIS . 58.4 t80 -65.88 -44.52 85.1 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.098 -1.001 . . . . 0.0 109.2 -179.728 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.752 HG11 ' CE1' ' A' ' 52' ' ' PHE . 55.2 t -60.76 -45.34 97.97 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 O-C-N 121.31 -0.869 . . . . 0.0 109.157 179.585 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 54.7 t -69.15 -41.16 81.27 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.281 0 O-C-N 121.214 -0.929 . . . . 0.0 108.989 179.349 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.492 ' O ' ' O ' ' A' ' 81' ' ' THR . . . -59.99 -28.13 65.74 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 110.029 -1.228 . . . . 0.0 110.029 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.02 -37.02 83.39 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.207 -1.172 . . . . 0.0 109.947 -179.391 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 44.9 p -83.38 -31.08 26.9 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.149 -0.97 . . . . 0.0 109.535 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.492 ' O ' ' O ' ' A' ' 78' ' ' GLY . 0.2 OUTLIER -133.4 153.17 80.35 Favored Pre-proline 0 C--N 1.303 -1.428 0 O-C-N 121.504 -0.747 . . . . 0.0 109.788 -179.523 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 27.4 Cg_endo -66.07 111.75 2.08 Favored 'Trans proline' 0 C--N 1.309 -1.547 0 C-N-CA 122.346 2.031 . . . . 0.0 111.449 179.557 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -76.67 152.37 33.12 Favored 'Trans proline' 0 N--CA 1.489 1.232 0 C-N-CA 122.111 1.874 . . . . 0.0 113.201 -179.11 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.45 ' O ' ' C ' ' A' ' 85' ' ' GLU . 32.7 m -103.12 135.81 38.82 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.52 0 N-CA-C 108.404 -0.962 . . . . 0.0 108.404 178.98 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.45 ' C ' ' O ' ' A' ' 84' ' ' VAL . 96.0 mt-10 42.25 70.34 0.29 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.225 -0.922 . . . . 0.0 109.059 -179.394 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -48.62 148.51 2.05 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.409 -0.807 . . . . 0.0 110.047 -179.291 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.416 ' HE3' HH21 ' A' ' 67' ' ' ARG . 54.5 tttp -56.48 -36.56 69.24 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.417 -0.802 . . . . 0.0 109.298 179.901 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 33.1 tp -100.06 130.69 46.24 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.298 -0.876 . . . . 0.0 109.401 179.917 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 21.4 pt20 . . . . . 0 N--CA 1.49 1.544 0 CA-C-O 117.988 -1.006 . . . . 0.0 109.473 -179.95 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' -1' ' ' SER . . . . . 0.535 ' OG ' ' N ' ' A' ' 0' ' ' GLU . 0.3 OUTLIER . . . . . 0 N--CA 1.49 1.533 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 . . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 0' ' ' GLU . . . . . 0.535 ' N ' ' OG ' ' A' ' -1' ' ' SER . 84.5 tt0 51.04 104.11 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.333 -0.854 . . . . 0.0 109.643 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 1' ' ' MET . . . . . 0.449 ' HB2' ' HB2' ' A' ' 4' ' ' ALA . 95.8 mmm -57.51 -44.32 84.95 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.288 -0.882 . . . . 0.0 109.444 179.887 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 69.2 tp60 174.97 -80.96 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.733 0 N-CA-C 106.47 -1.678 . . . . 0.0 106.47 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 77.5 m80 -100.17 16.2 24.97 Favored 'General case' 0 C--N 1.302 -1.457 0 N-CA-C 106.683 -1.599 . . . . 0.0 106.683 177.219 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.449 ' HB2' ' HB2' ' A' ' 1' ' ' MET . . . -51.88 -39.48 59.07 Favored 'General case' 0 N--CA 1.487 1.417 0 CA-C-O 121.233 0.539 . . . . 0.0 109.92 -179.052 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.8 m -59.8 -37.78 80.09 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.256 -0.902 . . . . 0.0 109.746 -179.747 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 6' ' ' VAL . . . . . 0.546 HG11 ' CZ ' ' A' ' 51' ' ' ARG . 55.5 t -62.63 -42.93 97.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.251 -0.906 . . . . 0.0 109.545 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 79.3 mt -59.54 -41.43 84.82 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 O-C-N 121.348 -0.845 . . . . 0.0 109.241 179.858 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -62.21 -38.42 89.09 Favored 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.405 -0.809 . . . . 0.0 109.558 -179.789 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 46.5 mt-30 -61.87 -42.07 98.62 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.108 -0.995 . . . . 0.0 109.545 179.921 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 10' ' ' PHE . . . . . 0.669 ' CG ' ' CE2' ' A' ' 47' ' ' TRP . 34.1 m-85 -61.81 -42.07 98.55 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.247 -0.908 . . . . 0.0 109.407 179.421 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 43.3 t -61.13 -45.29 98.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.367 -0.833 . . . . 0.0 109.548 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 12' ' ' VAL . . . . . 0.614 HG21 ' HG3' ' A' ' 21' ' ' PRO . 93.6 t -63.21 -46.83 94.81 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 O-C-N 121.479 -0.763 . . . . 0.0 109.735 -179.821 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -73.52 -16.46 61.28 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.396 -0.815 . . . . 0.0 110.265 -179.492 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -63.54 -31.88 73.17 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.171 -0.956 . . . . 0.0 110.299 -178.801 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 65.7 t80 -151.32 -28.99 0.19 Allowed 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.829 -1.169 . . . . 0.0 110.436 -179.761 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 16' ' ' LEU . . . . . 0.546 HD22 ' CG2' ' A' ' 19' ' ' VAL . 6.2 mt -121.77 80.14 40.6 Favored Pre-proline 0 N--CA 1.492 1.647 0 O-C-N 121.231 -0.918 . . . . 0.0 110.08 -179.405 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -77.08 -13.03 17.41 Favored 'Trans proline' 0 C--N 1.307 -1.607 0 C-N-CA 122.476 2.117 . . . . 0.0 112.375 179.759 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -93.95 9.74 36.24 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.189 -0.944 . . . . 0.0 110.263 -179.423 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 19' ' ' VAL . . . . . 0.546 ' CG2' HD22 ' A' ' 16' ' ' LEU . 46.4 t -109.88 137.77 40.57 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.274 -0.891 . . . . 0.0 109.691 -179.769 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -78.41 117.44 66.34 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.147 -0.971 . . . . 0.0 109.442 179.941 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 21' ' ' PRO . . . . . 0.614 ' HG3' HG21 ' A' ' 12' ' ' VAL . 38.3 Cg_exo -53.83 -24.79 32.35 Favored 'Trans proline' 0 N--CA 1.494 1.535 0 C-N-CA 121.842 1.695 . . . . 0.0 112.068 179.547 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.0 -24.51 67.74 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.304 -0.872 . . . . 0.0 109.301 -179.936 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 23' ' ' ASP . . . . . 0.409 ' O ' ' OD1' ' A' ' 23' ' ' ASP . 59.6 t0 -81.66 3.31 25.85 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.331 -0.856 . . . . 0.0 109.332 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 13.0 t -109.66 133.94 53.32 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.375 -0.828 . . . . 0.0 109.298 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 63.9 t0 -88.7 119.75 29.47 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.097 -1.002 . . . . 0.0 109.05 179.56 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 29.9 m -74.43 4.15 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.35 0 O-C-N 121.137 -0.977 . . . . 0.0 109.261 179.656 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 91.8 m-20 -90.43 -4.83 56.74 Favored 'General case' 0 N--CA 1.487 1.381 0 O-C-N 121.29 -0.881 . . . . 0.0 108.819 179.45 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 45.3 tp -98.03 139.58 33.64 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 179.832 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -58.77 137.51 57.64 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.211 -0.931 . . . . 0.0 109.655 -179.419 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 30' ' ' LEU . . . . . 0.905 HD13 HD11 ' A' ' 36' ' ' ILE . 1.4 tt -66.04 -38.91 89.57 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.713 -0.617 . . . . 0.0 110.069 -179.272 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 74.6 t -63.19 -35.78 73.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 120.979 -1.076 . . . . 0.0 110.67 -178.782 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 91.0 m-20 -52.58 -33.79 47.62 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 120.984 -1.073 . . . . 0.0 108.24 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 33' ' ' ASN . . . . . 0.445 ' HB3' HG23 ' A' ' 35' ' ' VAL . 97.2 m-20 -71.15 -34.66 71.2 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.614 -0.679 . . . . 0.0 110.047 179.516 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 84.09 5.54 87.43 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 108.99 -1.644 . . . . 0.0 108.99 -179.385 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 35' ' ' VAL . . . . . 0.445 HG23 ' HB3' ' A' ' 33' ' ' ASN . 70.4 t -60.55 -33.86 56.15 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 O-C-N 121.407 -1.055 . . . . 0.0 108.634 179.557 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 36' ' ' ILE . . . . . 0.905 HD11 HD13 ' A' ' 30' ' ' LEU . 95.0 mt -84.32 124.12 39.54 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.398 0 O-C-N 121.471 -0.768 . . . . 0.0 109.63 179.842 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 37' ' ' ASP . . . . . 0.556 ' CG ' ' H ' ' A' ' 38' ' ' ALA . 48.5 t0 -127.51 -159.53 0.94 Allowed 'General case' 0 C--N 1.301 -1.515 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 179.56 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 38' ' ' ALA . . . . . 0.556 ' H ' ' CG ' ' A' ' 37' ' ' ASP . . . -66.26 -55.07 17.93 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.848 -1.158 . . . . 0.0 108.681 179.792 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 36.5 mt -71.3 -34.37 70.55 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 107.412 -1.329 . . . . 0.0 107.412 178.237 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 40' ' ' GLY . . . . . 0.55 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.53 -40.29 96.08 Favored Glycine 0 N--CA 1.482 1.735 0 N-CA-C 108.783 -1.727 . . . . 0.0 108.783 179.256 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 41' ' ' LEU . . . . . 0.407 ' O ' HD12 ' A' ' 45' ' ' ILE . 4.5 tt -65.44 -45.49 83.63 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.528 -0.984 . . . . 0.0 109.326 179.225 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 17.1 tp -59.51 -44.75 93.05 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.415 -0.803 . . . . 0.0 109.811 -179.829 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 32.0 mttp -61.74 -34.74 76.37 Favored 'General case' 0 C--N 1.298 -1.664 0 O-C-N 120.973 -1.079 . . . . 0.0 109.583 -179.875 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 44' ' ' VAL . . . . . 0.55 HG23 ' O ' ' A' ' 40' ' ' GLY . 53.6 t -62.29 -50.23 80.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.328 -0.858 . . . . 0.0 110.296 -179.439 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 45' ' ' ILE . . . . . 0.497 ' CG1' HD12 ' A' ' 61' ' ' LEU . 3.5 mp -68.15 -32.66 56.91 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.216 -0.927 . . . . 0.0 110.934 -179.607 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.27 -49.85 62.69 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 120.971 -1.08 . . . . 0.0 111.757 -177.909 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 47' ' ' TRP . . . . . 0.669 ' CE2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -80.84 -43.51 19.88 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.677 -1.265 . . . . 0.0 110.089 -178.984 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 48' ' ' LEU . . . . . 0.4 ' N ' ' CG ' ' A' ' 47' ' ' TRP . 28.1 tp -58.93 -41.46 87.38 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.25 -0.906 . . . . 0.0 110.082 -179.085 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.436 ' CG ' ' N ' ' A' ' 50' ' ' ASP . 16.9 pt-20 -73.14 -37.7 66.52 Favored 'General case' 0 C--N 1.303 -1.427 0 O-C-N 121.082 -1.012 . . . . 0.0 109.589 -179.859 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 50' ' ' ASP . . . . . 0.436 ' N ' ' CG ' ' A' ' 49' ' ' GLU . 22.1 t70 -58.73 -38.16 77.77 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.406 -0.809 . . . . 0.0 110.618 -179.462 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 51' ' ' ARG . . . . . 0.546 ' CZ ' HG11 ' A' ' 6' ' ' VAL . 71.1 mtp180 -61.07 -38.66 86.99 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.156 -0.965 . . . . 0.0 111.434 -178.808 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 52' ' ' PHE . . . . . 0.764 ' CE1' HG11 ' A' ' 76' ' ' VAL . 75.0 m-85 -97.24 -7.42 32.31 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 120.872 -1.143 . . . . 0.0 110.582 -179.075 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 72.81 30.73 63.27 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.207 -1.557 . . . . 0.0 109.207 179.307 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 30.3 pt -106.81 153.4 8.03 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.354 0 O-C-N 121.483 -1.01 . . . . 0.0 109.571 -179.756 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -101.75 137.93 39.4 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.209 -0.932 . . . . 0.0 109.681 -179.562 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 56' ' ' ALA . . . . . 0.495 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -66.63 -26.57 67.13 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.365 -0.835 . . . . 0.0 109.724 179.899 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 57' ' ' ASP . . . . . 0.629 ' OD1' ' N ' ' A' ' 58' ' ' ASP . 54.9 p30 -60.42 -32.06 70.99 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.123 -0.986 . . . . 0.0 110.257 -179.606 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 58' ' ' ASP . . . . . 0.629 ' N ' ' OD1' ' A' ' 57' ' ' ASP . 53.8 t0 -57.95 -39.96 79.39 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.016 -1.052 . . . . 0.0 109.72 -179.908 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 59' ' ' VAL . . . . . 0.495 ' O ' ' O ' ' A' ' 56' ' ' ALA . 13.3 p -137.15 143.47 34.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.301 -0.874 . . . . 0.0 109.497 -179.969 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -90.36 132.63 35.48 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.115 -0.991 . . . . 0.0 109.221 179.847 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 61' ' ' LEU . . . . . 0.497 HD12 ' CG1' ' A' ' 45' ' ' ILE . 57.2 mt -97.74 137.26 36.88 Favored 'General case' 0 C--N 1.305 -1.338 0 O-C-N 121.222 -0.924 . . . . 0.0 109.771 -179.668 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -110.18 156.44 40.14 Favored Pre-proline 0 N--CA 1.488 1.43 0 N-CA-C 108.841 -0.799 . . . . 0.0 108.841 179.391 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 8.0 Cg_endo -53.18 -23.28 22.2 Favored 'Trans proline' 0 C--N 1.302 -1.899 0 C-N-CA 122.388 2.059 . . . . 0.0 111.685 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -70.73 -27.78 64.22 Favored 'General case' 0 C--N 1.305 -1.34 0 O-C-N 121.335 -0.853 . . . . 0.0 109.561 179.686 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 65' ' ' HIS . . . . . 0.566 ' C ' ' CD2' ' A' ' 65' ' ' HIS . 0.4 OUTLIER -65.69 -17.81 64.88 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 121.336 -0.852 . . . . 0.0 109.056 -179.835 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 66' ' ' PHE . . . . . 0.546 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 11.6 m-85 -97.57 15.89 22.0 Favored 'General case' 0 C--N 1.301 -1.538 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 179.704 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 67' ' ' ARG . . . . . 0.594 ' NE ' ' OG ' ' A' ' 71' ' ' SER . 6.7 ptt180 -48.95 -38.58 23.4 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.796 -0.565 . . . . 0.0 110.558 -179.526 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 43.8 t -161.52 158.98 27.29 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.905 -1.122 . . . . 0.0 110.234 -179.803 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 69' ' ' ILE . . . . . 0.464 ' CD1' HD12 ' A' ' 30' ' ' LEU . 31.6 mm -57.97 -44.01 85.97 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.361 0 O-C-N 121.319 -0.863 . . . . 0.0 109.628 179.876 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 70' ' ' ARG . . . . . 0.7 ' NH1' ' HZ1' ' A' ' 87' ' ' LYS . 0.0 OUTLIER -58.65 -39.3 80.18 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.276 -0.89 . . . . 0.0 109.596 -179.57 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 71' ' ' SER . . . . . 0.594 ' OG ' ' NE ' ' A' ' 67' ' ' ARG . 41.6 t -62.59 -41.51 99.0 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.275 -0.891 . . . . 0.0 109.689 179.821 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 80.7 mt -61.01 -47.75 92.19 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 O-C-N 121.306 -0.871 . . . . 0.0 109.911 -179.62 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 32.9 t0 -60.26 -43.14 96.42 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.168 -0.958 . . . . 0.0 109.167 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 74' ' ' ALA . . . . . 0.54 ' O ' ' N ' ' A' ' 78' ' ' GLY . . . -66.84 -38.89 87.27 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.52 -0.738 . . . . 0.0 109.952 -179.829 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 71.6 t80 -61.64 -51.24 69.29 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.174 -0.953 . . . . 0.0 109.271 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 76' ' ' VAL . . . . . 0.764 HG11 ' CE1' ' A' ' 52' ' ' PHE . 77.6 t -69.51 -48.03 68.69 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 O-C-N 121.328 -0.857 . . . . 0.0 109.878 179.972 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 72.3 t -69.55 -47.0 74.23 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.328 0 O-C-N 121.175 -0.953 . . . . 0.0 109.756 -179.887 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 78' ' ' GLY . . . . . 0.54 ' N ' ' O ' ' A' ' 74' ' ' ALA . . . -61.93 -37.88 95.11 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.826 -1.309 . . . . 0.0 109.826 -179.752 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.61 -39.45 84.73 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.183 -1.187 . . . . 0.0 110.025 -179.508 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 80' ' ' THR . . . . . 0.523 HG23 ' O ' ' A' ' 76' ' ' VAL . 50.2 p -81.33 -31.61 33.41 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.286 -0.884 . . . . 0.0 109.594 -179.859 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 81' ' ' THR . . . . . 0.493 ' O ' ' O ' ' A' ' 78' ' ' GLY . 0.4 OUTLIER -133.2 152.87 80.3 Favored Pre-proline 0 C--N 1.304 -1.389 0 O-C-N 121.403 -0.811 . . . . 0.0 109.908 -179.646 . . . . . . . . 3 3 . 1 . 020 nuclear build full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -44.82 111.2 0.27 Allowed 'Trans proline' 0 C--N 1.311 -1.408 0 C-N-CA 122.254 1.969 . . . . 0.0 111.823 179.286 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 22.2 Cg_exo -57.05 143.53 92.58 Favored 'Trans proline' 0 N--CA 1.492 1.4 0 C-N-CA 121.81 1.674 . . . . 0.0 111.98 179.917 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.583 ' O ' ' N ' ' A' ' 86' ' ' ALA . 44.4 t -103.68 132.41 50.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.32 -0.862 . . . . 0.0 109.773 -179.998 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 85' ' ' GLU . . . . . 0.468 ' C ' ' O ' ' A' ' 84' ' ' VAL . 96.1 mt-10 37.33 26.0 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.584 -0.698 . . . . 0.0 110.136 179.625 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 86' ' ' ALA . . . . . 0.583 ' N ' ' O ' ' A' ' 84' ' ' VAL . . . 42.39 -147.34 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.2 -0.937 . . . . 0.0 109.543 -179.912 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 87' ' ' LYS . . . . . 0.7 ' HZ1' ' NH1' ' A' ' 70' ' ' ARG . 48.9 tttm -73.63 146.53 44.53 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.194 -0.941 . . . . 0.0 109.783 -179.91 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 7.2 tt -53.47 -38.74 63.88 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.311 -0.868 . . . . 0.0 109.336 179.488 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.3 mt-30 . . . . . 0 N--CA 1.49 1.56 0 CA-C-O 118.022 -0.989 . . . . 0.0 109.5 -179.971 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 20.4 m-70 . . . . . 0 N--CA 1.495 1.821 0 CA-C-O 121.086 0.469 . . . . 0.0 109.831 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -60.32 -39.97 88.91 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.105 -0.997 . . . . 0.0 109.343 179.898 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.2 m -61.76 -36.86 82.27 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.465 -0.772 . . . . 0.0 110.019 -179.754 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 64.3 t -62.35 -44.98 99.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.23 -0.919 . . . . 0.0 109.631 -179.762 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.493 ' O ' HG13 ' A' ' 11' ' ' VAL . 78.3 mt -59.78 -46.96 93.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.326 -0.858 . . . . 0.0 108.799 179.624 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.679 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -62.38 -35.12 78.19 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 108.969 -0.752 . . . . 0.0 108.969 179.328 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 7.3 tt0 -58.76 -41.12 85.81 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.084 -1.01 . . . . 0.0 109.526 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.672 ' CG ' ' CZ2' ' A' ' 47' ' ' TRP . 52.4 m-85 -68.7 -50.16 53.1 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.045 -1.035 . . . . 0.0 110.508 -179.807 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.493 HG13 ' O ' ' A' ' 7' ' ' ILE . 1.0 OUTLIER -66.12 -39.0 83.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.02 -1.05 . . . . 0.0 108.99 -179.498 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.679 HG23 ' O ' ' A' ' 8' ' ' ALA . 74.8 t -63.56 -46.67 94.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.28 -0.888 . . . . 0.0 109.266 179.45 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -71.71 -23.6 61.66 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.23 -0.919 . . . . 0.0 109.825 179.665 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -64.09 -30.3 71.38 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.428 -0.795 . . . . 0.0 110.395 -179.078 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 72.6 t80 -139.0 -40.48 0.48 Allowed 'General case' 0 N--CA 1.494 1.731 0 O-C-N 120.969 -1.082 . . . . 0.0 110.765 -179.413 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.484 HD22 ' CG2' ' A' ' 19' ' ' VAL . 5.0 mt -120.76 80.11 32.17 Favored Pre-proline 0 N--CA 1.491 1.613 0 O-C-N 121.089 -1.007 . . . . 0.0 110.338 -179.18 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 40.7 Cg_endo -75.73 -14.78 19.48 Favored 'Trans proline' 0 C--N 1.309 -1.536 0 C-N-CA 122.439 2.093 . . . . 0.0 112.285 179.437 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -90.03 7.87 35.45 Favored 'General case' 0 N--CA 1.487 1.381 0 O-C-N 121.221 -0.925 . . . . 0.0 109.758 -179.715 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.484 ' CG2' HD22 ' A' ' 16' ' ' LEU . 43.2 t -111.69 134.86 52.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.417 -0.802 . . . . 0.0 109.644 -179.882 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.27 119.62 75.82 Favored Pre-proline 0 N--CA 1.489 1.477 0 O-C-N 121.263 -0.898 . . . . 0.0 109.353 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_exo -51.2 -28.23 25.21 Favored 'Trans proline' 0 N--CA 1.493 1.483 0 C-N-CA 121.75 1.633 . . . . 0.0 112.109 179.531 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.91 -24.69 67.61 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.264 -0.898 . . . . 0.0 109.31 179.881 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.426 ' O ' ' OD1' ' A' ' 23' ' ' ASP . 60.0 t0 -81.87 7.23 13.42 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.319 -0.863 . . . . 0.0 109.789 -179.746 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 10.9 t -103.96 132.89 49.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.03 -1.043 . . . . 0.0 109.393 -179.884 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 87.3 m-20 -89.12 120.49 30.56 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.106 -0.996 . . . . 0.0 109.104 179.469 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 17.8 m -77.34 3.92 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.446 0 O-C-N 121.175 -0.953 . . . . 0.0 109.137 179.687 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -87.26 -13.2 44.44 Favored 'General case' 0 N--CA 1.486 1.354 0 O-C-N 121.351 -0.843 . . . . 0.0 109.149 179.518 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 41.5 tp -95.29 138.67 32.67 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.459 -0.775 . . . . 0.0 109.143 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -58.93 141.43 53.66 Favored 'General case' 0 C--N 1.303 -1.441 0 O-C-N 121.237 -0.914 . . . . 0.0 109.527 -179.605 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.979 HD13 HD11 ' A' ' 36' ' ' ILE . 1.3 tt -67.36 -38.66 85.16 Favored 'General case' 0 C--N 1.299 -1.589 0 O-C-N 121.706 -0.621 . . . . 0.0 110.322 -179.016 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 69.1 t -65.36 -36.25 77.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.103 -0.998 . . . . 0.0 110.497 -178.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -52.79 -33.59 49.61 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.455 ' HB3' HG23 ' A' ' 35' ' ' VAL . 19.7 m120 -71.05 -34.4 71.22 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.675 -0.641 . . . . 0.0 109.805 179.433 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 85.3 6.28 84.33 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 108.984 -1.646 . . . . 0.0 108.984 -179.481 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.455 HG23 ' HB3' ' A' ' 33' ' ' ASN . 79.4 t -61.73 -34.32 61.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.468 -1.019 . . . . 0.0 109.158 179.795 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.979 HD11 HD13 ' A' ' 30' ' ' LEU . 96.6 mt -87.06 117.34 31.05 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.315 -0.865 . . . . 0.0 109.78 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -117.43 -168.2 1.45 Allowed 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 179.703 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -63.2 -54.77 32.37 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.034 -1.041 . . . . 0.0 108.532 179.626 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 41.9 mt -70.96 -34.71 71.7 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 178.063 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.618 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.66 -39.64 95.44 Favored Glycine 0 N--CA 1.481 1.656 0 N-CA-C 108.614 -1.795 . . . . 0.0 108.614 179.105 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.601 HD11 ' CZ ' ' A' ' 66' ' ' PHE . 7.6 tt -65.2 -42.62 93.36 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.579 -0.953 . . . . 0.0 108.993 179.36 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.4 tp -61.42 -46.09 91.6 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.414 -0.804 . . . . 0.0 109.234 179.601 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 24.2 mttp -61.15 -35.99 78.57 Favored 'General case' 0 C--N 1.296 -1.721 0 O-C-N 121.504 -0.748 . . . . 0.0 109.76 -179.654 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.618 HG23 ' O ' ' A' ' 40' ' ' GLY . 60.6 t -61.2 -50.57 79.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.374 -0.829 . . . . 0.0 109.715 -179.663 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.547 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 1.7 mp -69.05 -31.98 52.46 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.535 0 O-C-N 121.454 -0.779 . . . . 0.0 110.721 -179.906 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -63.52 -49.42 73.58 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.108 -0.995 . . . . 0.0 111.369 -178.127 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.672 ' CZ2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -80.87 -45.13 17.32 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 120.723 -1.235 . . . . 0.0 109.876 -179.544 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.887 HD12 HH21 ' A' ' 51' ' ' ARG . 9.7 tp -58.33 -42.51 86.99 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.307 -0.87 . . . . 0.0 109.817 -179.169 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.547 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 1.0 OUTLIER -72.66 -35.61 67.76 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.102 -0.999 . . . . 0.0 109.772 179.999 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.1 t70 -61.13 -39.15 88.95 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.159 -0.963 . . . . 0.0 110.713 -179.456 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.887 HH21 HD12 ' A' ' 48' ' ' LEU . 66.9 mtm180 -61.51 -36.77 81.47 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.167 -0.958 . . . . 0.0 111.429 -178.727 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.531 ' CZ ' ' CG1' ' A' ' 76' ' ' VAL . 94.3 m-85 -97.13 -9.9 27.03 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.774 -1.204 . . . . 0.0 110.334 -179.057 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 71.72 31.28 65.19 Favored Glycine 0 N--CA 1.486 2.01 0 N-CA-C 108.803 -1.719 . . . . 0.0 108.803 179.874 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.48 ' O ' ' OE1' ' A' ' 49' ' ' GLU . 25.3 pt -108.48 153.26 10.14 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 O-C-N 121.593 -0.945 . . . . 0.0 109.83 -179.331 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -101.77 131.34 48.12 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.077 -1.014 . . . . 0.0 109.667 -179.735 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.503 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -67.65 -27.47 66.89 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.276 -0.89 . . . . 0.0 109.506 179.827 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -55.37 -35.09 64.9 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.156 -0.965 . . . . 0.0 109.971 -179.724 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 54.4 t0 -53.19 -36.96 61.51 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.175 -0.953 . . . . 0.0 109.953 -179.592 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.503 ' O ' ' O ' ' A' ' 56' ' ' ALA . 13.7 p -132.84 143.82 38.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.258 -0.901 . . . . 0.0 109.653 -179.859 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -88.79 134.9 33.78 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.158 -0.964 . . . . 0.0 109.331 179.93 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 67.8 mt -97.16 137.49 36.13 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 121.261 -0.899 . . . . 0.0 109.926 -179.616 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -110.37 157.01 39.36 Favored Pre-proline 0 N--CA 1.487 1.406 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 179.478 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 9.3 Cg_endo -54.08 -23.16 27.7 Favored 'Trans proline' 0 C--N 1.301 -1.955 0 C-N-CA 122.392 2.061 . . . . 0.0 111.675 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -70.31 -27.5 64.43 Favored 'General case' 0 N--CA 1.486 1.344 0 O-C-N 121.338 -0.851 . . . . 0.0 109.447 179.653 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . 0.524 ' C ' ' CD2' ' A' ' 65' ' ' HIS . 0.9 OUTLIER -65.97 -17.89 64.98 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.357 -0.84 . . . . 0.0 109.036 -179.858 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.601 ' CZ ' HD11 ' A' ' 41' ' ' LEU . 10.5 m-85 -98.12 15.1 25.32 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 179.622 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . 0.411 ' HG2' ' H ' ' A' ' 68' ' ' SER . 6.1 ptt180 -49.67 -39.28 35.98 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.77 -0.581 . . . . 0.0 110.225 -179.661 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . 0.511 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 80.1 p -163.39 159.23 22.12 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 120.903 -1.123 . . . . 0.0 110.101 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.63 ' H ' HD12 ' A' ' 69' ' ' ILE . 3.6 mp -57.74 -34.85 48.86 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 N-CA-C 108.211 -1.033 . . . . 0.0 108.211 178.93 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 21.3 mtp180 -57.31 -40.48 77.99 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 179.904 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 15.2 t -63.47 -38.51 91.41 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.401 -0.812 . . . . 0.0 109.51 179.834 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.416 ' CD1' ' NE2' ' A' ' 65' ' ' HIS . 32.4 mm -58.94 -46.73 91.25 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 O-C-N 121.269 -0.894 . . . . 0.0 109.294 -179.845 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 46.7 t0 -59.43 -43.25 93.13 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.21 -0.932 . . . . 0.0 109.102 179.813 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.44 -40.87 89.71 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.552 -0.717 . . . . 0.0 109.78 -179.858 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 69.2 t80 -62.32 -46.42 88.79 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.35 -0.844 . . . . 0.0 109.524 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.644 HG21 HD11 ' A' ' 48' ' ' LEU . 53.5 t -61.76 -46.24 96.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 O-C-N 121.235 -0.915 . . . . 0.0 109.337 179.884 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.517 ' O ' ' O ' ' A' ' 81' ' ' THR . 53.4 t -68.62 -42.6 83.44 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 O-C-N 121.262 -0.899 . . . . 0.0 109.329 179.53 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.45 -30.27 64.73 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 110.181 -1.168 . . . . 0.0 110.181 -179.903 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -68.37 -41.23 80.91 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.264 -1.139 . . . . 0.0 111.135 -178.739 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 27.8 p -101.68 -34.59 9.41 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.971 -1.081 . . . . 0.0 110.877 -178.808 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.517 ' O ' ' O ' ' A' ' 77' ' ' VAL . 0.1 OUTLIER . . . . . 0 C--N 1.301 -1.5 0 O-C-N 121.311 -0.868 . . . . 0.0 109.834 -179.274 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 14.1 m-70 . . . . . 0 N--CA 1.496 1.864 0 CA-C-O 121.214 0.531 . . . . 0.0 109.639 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -61.19 -40.08 92.6 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.245 -0.909 . . . . 0.0 109.368 179.852 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.1 p -63.24 -34.05 76.83 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.269 -0.894 . . . . 0.0 109.658 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.664 HG11 ' NH2' ' A' ' 51' ' ' ARG . 55.4 t -62.22 -44.82 99.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.149 -0.969 . . . . 0.0 109.418 179.8 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 77.0 mt -60.13 -41.07 85.29 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 O-C-N 121.371 -0.831 . . . . 0.0 108.934 179.47 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.471 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -60.93 -38.87 87.3 Favored 'General case' 0 C--N 1.305 -1.36 0 O-C-N 121.561 -0.712 . . . . 0.0 109.543 -179.912 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . 0.446 HE21 ' HA ' ' A' ' 6' ' ' VAL . 52.1 mt-30 -63.63 -40.8 97.8 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.135 -0.978 . . . . 0.0 110.092 -179.833 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.694 ' CG ' ' CE2' ' A' ' 47' ' ' TRP . 33.7 m-85 -62.05 -50.12 73.25 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.002 -1.062 . . . . 0.0 110.628 -179.357 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.467 HG23 ' N ' ' A' ' 12' ' ' VAL . 30.0 m -66.43 -41.74 89.22 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 O-C-N 121.006 -1.059 . . . . 0.0 109.18 -179.874 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.471 HG23 ' O ' ' A' ' 8' ' ' ALA . 77.0 t -64.02 -45.17 97.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.219 -0.926 . . . . 0.0 109.49 179.436 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -72.25 -23.43 61.21 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.22 -0.925 . . . . 0.0 110.341 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -64.02 -30.02 71.13 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.333 -0.854 . . . . 0.0 110.466 -178.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 71.3 t80 -138.31 -42.29 0.51 Allowed 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.012 -1.055 . . . . 0.0 110.887 -179.391 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.513 HD22 ' CG2' ' A' ' 19' ' ' VAL . 5.2 mt -120.03 80.2 26.39 Favored Pre-proline 0 N--CA 1.493 1.677 0 O-C-N 121.095 -1.003 . . . . 0.0 110.397 -179.119 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -74.77 -14.5 21.71 Favored 'Trans proline' 0 C--N 1.309 -1.511 0 C-N-CA 122.337 2.024 . . . . 0.0 112.319 179.463 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -91.59 8.87 34.63 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.22 -0.925 . . . . 0.0 109.954 -179.666 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.513 ' CG2' HD22 ' A' ' 16' ' ' LEU . 48.8 t -110.87 135.55 49.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.281 -0.887 . . . . 0.0 109.742 -179.815 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.67 119.21 73.99 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.298 -0.877 . . . . 0.0 109.305 179.86 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_exo -51.36 -27.23 23.23 Favored 'Trans proline' 0 N--CA 1.494 1.507 0 C-N-CA 121.781 1.654 . . . . 0.0 112.01 179.676 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.8 -25.24 67.83 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.259 -0.901 . . . . 0.0 109.253 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.411 ' O ' ' OD1' ' A' ' 23' ' ' ASP . 58.6 t0 -81.8 7.35 12.92 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.362 -0.837 . . . . 0.0 109.693 -179.863 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 11.8 t -101.89 133.11 46.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.192 -0.943 . . . . 0.0 109.303 -179.851 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 86.9 m-20 -88.34 120.68 29.94 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.148 -0.97 . . . . 0.0 109.131 179.385 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 29.9 m -71.39 4.47 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 O-C-N 121.122 -0.987 . . . . 0.0 109.107 179.651 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -95.38 0.21 53.26 Favored 'General case' 0 N--CA 1.485 1.32 0 O-C-N 121.397 -0.814 . . . . 0.0 109.094 179.549 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 46.0 tp -100.68 132.97 45.8 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.409 -0.807 . . . . 0.0 109.331 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.7 m-20 -68.78 138.06 54.51 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.285 -0.885 . . . . 0.0 109.822 -179.549 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.577 HD11 HG13 ' A' ' 69' ' ' ILE . 90.5 mt -65.5 -38.88 90.99 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.365 -0.834 . . . . 0.0 110.817 -179.899 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 75.6 t -66.08 -38.6 82.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 120.972 -1.08 . . . . 0.0 110.671 -178.737 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -52.91 -34.02 53.1 Favored 'General case' 0 N--CA 1.489 1.475 0 N-CA-C 108.122 -1.066 . . . . 0.0 108.122 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.539 ' HB3' HG23 ' A' ' 35' ' ' VAL . 97.4 m-20 -71.05 -34.65 71.44 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.643 -0.661 . . . . 0.0 109.927 179.513 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 82.03 4.06 90.38 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 108.754 -1.738 . . . . 0.0 108.754 -179.205 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.539 HG23 ' HB3' ' A' ' 33' ' ' ASN . 70.2 t -62.7 -32.9 57.17 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 O-C-N 121.526 -0.984 . . . . 0.0 108.894 179.612 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 81.1 mt -88.57 121.24 38.58 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.368 0 O-C-N 121.318 -0.864 . . . . 0.0 110.041 -179.838 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -115.82 -159.68 0.72 Allowed 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 108.966 -0.753 . . . . 0.0 108.966 179.697 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -67.77 -54.27 20.55 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.134 -0.979 . . . . 0.0 108.959 179.691 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 43.1 mt -67.08 -32.57 73.84 Favored 'General case' 0 C--N 1.303 -1.414 0 N-CA-C 107.189 -1.412 . . . . 0.0 107.189 178.447 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.486 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -58.74 -40.4 94.89 Favored Glycine 0 N--CA 1.48 1.611 0 N-CA-C 108.465 -1.854 . . . . 0.0 108.465 179.308 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.0 tt -65.45 -42.21 92.61 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 121.578 -0.954 . . . . 0.0 108.916 178.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.5 tp -60.47 -45.83 92.31 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.429 -0.795 . . . . 0.0 109.173 179.605 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 59.9 mttp -59.69 -35.59 74.8 Favored 'General case' 0 C--N 1.297 -1.712 0 O-C-N 121.547 -0.721 . . . . 0.0 109.618 -179.727 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.486 HG23 ' O ' ' A' ' 40' ' ' GLY . 54.7 t -61.68 -49.71 83.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.357 -0.839 . . . . 0.0 110.071 -179.519 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.531 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 3.3 mp -68.0 -31.83 53.6 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 O-C-N 121.281 -0.887 . . . . 0.0 110.811 -179.659 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.99 -49.99 65.87 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 120.799 -1.188 . . . . 0.0 111.359 -178.2 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.694 ' CE2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -81.17 -44.94 17.13 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.774 -1.204 . . . . 0.0 110.046 -179.385 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.82 HD11 HG21 ' A' ' 76' ' ' VAL . 22.4 tp -58.58 -42.07 87.16 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 121.326 -0.859 . . . . 0.0 110.095 -178.858 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.531 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 2.3 pp20? -72.59 -36.54 68.18 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.195 -0.941 . . . . 0.0 109.777 -179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . 0.402 ' N ' ' CG ' ' A' ' 49' ' ' GLU . 55.9 t0 -60.3 -38.27 83.15 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.24 -0.913 . . . . 0.0 110.713 -179.463 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.664 ' NH2' HG11 ' A' ' 6' ' ' VAL . 77.0 mtp180 -61.81 -38.64 88.87 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.195 -0.941 . . . . 0.0 111.738 -178.581 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.553 ' CE1' HG11 ' A' ' 76' ' ' VAL . 87.7 m-85 -97.93 -9.39 26.32 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.803 -1.186 . . . . 0.0 110.482 -178.951 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 70.92 31.44 67.05 Favored Glycine 0 N--CA 1.487 2.092 0 N-CA-C 108.703 -1.759 . . . . 0.0 108.703 179.824 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.485 ' O ' ' OE1' ' A' ' 49' ' ' GLU . 26.4 pt -107.24 153.27 8.52 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.367 0 O-C-N 121.703 -0.881 . . . . 0.0 109.787 -179.392 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -99.23 134.04 42.66 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.12 -0.988 . . . . 0.0 109.806 -179.551 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.511 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -68.21 -22.99 64.77 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.312 -0.867 . . . . 0.0 109.533 179.725 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -54.71 -35.65 63.86 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.266 -0.896 . . . . 0.0 109.961 -179.626 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -55.66 -39.53 71.05 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.202 -0.936 . . . . 0.0 110.019 -179.65 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.511 ' O ' ' O ' ' A' ' 56' ' ' ALA . 13.9 p -136.3 142.31 38.9 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.291 -0.881 . . . . 0.0 109.685 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -91.92 133.39 35.73 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.029 -1.044 . . . . 0.0 109.275 179.736 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.475 HD12 ' CG1' ' A' ' 45' ' ' ILE . 32.5 mt -97.92 138.75 34.78 Favored 'General case' 0 C--N 1.305 -1.363 0 O-C-N 121.332 -0.855 . . . . 0.0 109.661 -179.613 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -110.09 157.11 38.81 Favored Pre-proline 0 N--CA 1.487 1.42 0 N-CA-C 108.952 -0.758 . . . . 0.0 108.952 179.518 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_endo -54.01 -24.52 32.65 Favored 'Trans proline' 0 C--N 1.302 -1.91 0 C-N-CA 122.536 2.157 . . . . 0.0 111.567 179.891 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -71.23 -27.78 63.72 Favored 'General case' 0 C--N 1.306 -1.307 0 O-C-N 121.365 -0.834 . . . . 0.0 109.531 179.825 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . 0.525 ' NE2' ' CB ' ' A' ' 75' ' ' PHE . 8.2 t-80 -65.76 -20.3 66.21 Favored 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.185 -0.947 . . . . 0.0 108.975 -179.738 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.502 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 21.9 m-85 -91.36 16.54 9.93 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 179.901 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . 0.453 ' NE ' ' CB ' ' A' ' 71' ' ' SER . 7.7 ptt180 -50.07 -37.24 32.62 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.808 -0.557 . . . . 0.0 110.254 -179.753 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 19.0 t -163.15 157.65 20.81 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.977 -1.077 . . . . 0.0 110.29 -179.626 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.665 ' H ' HD12 ' A' ' 69' ' ' ILE . 2.0 mp -58.03 -39.31 71.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.424 -0.797 . . . . 0.0 109.266 179.862 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 7.6 ptm180 -58.03 -40.68 81.49 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.574 -0.704 . . . . 0.0 109.452 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . 0.453 ' CB ' ' NE ' ' A' ' 67' ' ' ARG . 83.5 p -65.14 -37.16 86.54 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.325 -0.859 . . . . 0.0 109.722 179.914 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.455 ' O ' HG23 ' A' ' 76' ' ' VAL . 75.3 mt -64.86 -44.94 96.24 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.268 0 O-C-N 121.245 -0.91 . . . . 0.0 109.809 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 40.4 t0 -59.75 -41.7 91.57 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.291 -0.88 . . . . 0.0 109.396 -179.828 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.75 -43.86 83.02 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.405 -0.81 . . . . 0.0 110.084 -179.777 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . 0.525 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 56.8 t80 -62.1 -46.52 88.69 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.338 -0.851 . . . . 0.0 109.537 -179.764 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.82 HG21 HD11 ' A' ' 48' ' ' LEU . 99.2 t -61.67 -44.43 98.69 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.394 0 O-C-N 121.269 -0.895 . . . . 0.0 109.027 179.92 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.522 ' O ' ' O ' ' A' ' 81' ' ' THR . 53.3 t -66.64 -43.22 90.48 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 121.374 -0.829 . . . . 0.0 109.255 179.554 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.81 -23.15 49.82 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.771 -1.332 . . . . 0.0 109.771 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.05 -28.88 68.57 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.259 -1.142 . . . . 0.0 110.353 -179.475 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 9.8 p -129.65 -32.73 1.9 Allowed 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.128 -0.983 . . . . 0.0 110.752 -179.274 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.522 ' O ' ' O ' ' A' ' 77' ' ' VAL . 0.1 OUTLIER . . . . . 0 N--CA 1.489 1.498 0 O-C-N 121.188 -0.945 . . . . 0.0 109.682 -179.396 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 46.0 m80 . . . . . 0 N--CA 1.485 1.322 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -55.81 -39.77 71.81 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.392 -0.817 . . . . 0.0 109.562 -179.433 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.1 m -60.75 -36.33 78.63 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.213 -0.93 . . . . 0.0 109.553 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 75.8 t -63.3 -45.67 97.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.21 -0.932 . . . . 0.0 109.45 -179.895 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.523 ' O ' HG13 ' A' ' 11' ' ' VAL . 78.8 mt -59.69 -45.6 94.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.373 -0.829 . . . . 0.0 108.799 179.622 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.588 ' O ' HG22 ' A' ' 12' ' ' VAL . . . -62.21 -35.27 78.38 Favored 'General case' 0 C--N 1.304 -1.374 0 N-CA-C 108.763 -0.828 . . . . 0.0 108.763 179.5 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 32.5 tt0 -59.97 -38.37 82.32 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.259 -0.901 . . . . 0.0 109.472 179.733 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.65 ' CG ' ' CZ2' ' A' ' 47' ' ' TRP . 44.0 m-85 -70.17 -47.74 60.31 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.971 -1.081 . . . . 0.0 111.205 -179.551 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.523 HG13 ' O ' ' A' ' 7' ' ' ILE . 0.9 OUTLIER -61.64 -46.88 95.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 120.881 -1.137 . . . . 0.0 110.312 -178.143 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.592 ' O ' ' N ' ' A' ' 16' ' ' LEU . 35.5 m -64.75 -46.0 93.46 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.394 0 O-C-N 120.799 -1.188 . . . . 0.0 109.552 179.758 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . 0.536 ' N ' HG23 ' A' ' 12' ' ' VAL . 96.9 mt-10 -64.55 -26.96 68.64 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 120.813 -1.179 . . . . 0.0 109.737 179.798 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -64.43 -31.47 72.69 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.445 -0.785 . . . . 0.0 110.14 -179.479 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 86.6 t80 -142.84 -33.31 0.46 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.981 -1.074 . . . . 0.0 110.794 -179.436 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.592 ' N ' ' O ' ' A' ' 12' ' ' VAL . 3.4 mt -121.95 79.8 41.95 Favored Pre-proline 0 N--CA 1.492 1.66 0 O-C-N 121.07 -1.019 . . . . 0.0 109.976 -179.32 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -76.07 -18.54 16.42 Favored 'Trans proline' 0 C--N 1.309 -1.507 0 C-N-CA 122.537 2.158 . . . . 0.0 112.873 -179.756 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.442 ' C ' ' OD1' ' A' ' 18' ' ' ASP . 50.4 p30 -89.43 12.86 15.18 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.031 -1.043 . . . . 0.0 110.131 -179.565 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 84.1 t -106.79 134.41 48.52 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.187 -0.946 . . . . 0.0 109.574 179.669 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.06 118.45 65.74 Favored Pre-proline 0 N--CA 1.488 1.443 0 O-C-N 121.323 -0.861 . . . . 0.0 108.918 179.634 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -51.31 -36.41 57.2 Favored 'Trans proline' 0 N--CA 1.492 1.389 0 C-N-CA 121.571 1.514 . . . . 0.0 111.912 179.966 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -68.58 -18.56 64.36 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.246 -0.909 . . . . 0.0 108.885 179.386 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.451 ' O ' ' OD1' ' A' ' 23' ' ' ASP . 60.4 t0 -81.97 7.11 13.94 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.479 -0.763 . . . . 0.0 109.91 -179.644 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 15.1 t -104.56 131.66 53.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.167 -0.958 . . . . 0.0 109.433 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 62.4 t0 -88.44 119.68 29.11 Favored 'General case' 0 C--N 1.303 -1.445 0 O-C-N 121.213 -0.929 . . . . 0.0 108.689 179.256 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.2 m -75.29 3.18 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 O-C-N 121.138 -0.977 . . . . 0.0 109.484 -179.886 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -85.49 -19.18 31.6 Favored 'General case' 0 N--CA 1.487 1.375 0 O-C-N 121.137 -0.977 . . . . 0.0 109.116 179.368 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 48.7 tp -88.84 134.04 34.07 Favored 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 108.541 -0.911 . . . . 0.0 108.541 179.552 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 89.1 m-20 -60.37 135.12 57.64 Favored 'General case' 0 C--N 1.301 -1.539 0 C-N-CA 119.185 -1.006 . . . . 0.0 109.2 -179.423 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 1.043 HD23 HD11 ' A' ' 36' ' ' ILE . 39.0 tp -62.59 -36.42 82.68 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.509 -0.745 . . . . 0.0 110.257 -179.322 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 69.2 t -64.22 -35.76 74.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.047 -1.033 . . . . 0.0 110.466 -179.384 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -52.62 -33.72 47.88 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.446 ' HB3' HG23 ' A' ' 35' ' ' VAL . 97.1 m-20 -70.82 -34.55 71.83 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.606 -0.684 . . . . 0.0 110.001 179.468 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 85.71 5.16 84.53 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 108.858 -1.697 . . . . 0.0 108.858 -179.324 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.446 HG23 ' HB3' ' A' ' 33' ' ' ASN . 73.6 t -61.7 -33.05 55.72 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 121.554 -0.968 . . . . 0.0 108.979 179.678 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 1.043 HD11 HD23 ' A' ' 30' ' ' LEU . 80.2 mt -83.68 114.47 24.33 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.411 0 O-C-N 121.339 -0.851 . . . . 0.0 109.723 -179.728 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -112.6 -178.82 3.49 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 179.542 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -58.82 -52.3 66.29 Favored 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 108.245 -1.021 . . . . 0.0 108.245 179.7 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 42.3 mt -70.28 -32.65 70.53 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 106.849 -1.538 . . . . 0.0 106.849 177.922 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.606 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.27 -41.01 96.61 Favored Glycine 0 N--CA 1.481 1.67 0 N-CA-C 108.525 -1.83 . . . . 0.0 108.525 179.14 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 2.9 tt -64.87 -44.49 89.52 Favored 'General case' 0 C--N 1.305 -1.35 0 O-C-N 121.636 -0.92 . . . . 0.0 109.212 179.096 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 16.7 tp -59.55 -44.78 93.14 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.353 -0.842 . . . . 0.0 109.578 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 31.7 mttp -62.05 -34.81 76.93 Favored 'General case' 0 C--N 1.298 -1.669 0 O-C-N 121.076 -1.015 . . . . 0.0 109.541 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.606 HG23 ' O ' ' A' ' 40' ' ' GLY . 69.4 t -61.2 -48.63 88.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.387 -0.821 . . . . 0.0 109.993 -179.528 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.541 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 3.0 mp -67.84 -32.44 56.51 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.515 0 O-C-N 121.405 -0.81 . . . . 0.0 110.948 -179.677 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.43 -50.36 63.64 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 120.982 -1.074 . . . . 0.0 111.373 -178.112 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.65 ' CZ2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -81.18 -44.62 17.57 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 120.708 -1.245 . . . . 0.0 109.853 -179.502 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.5 ' N ' ' CG ' ' A' ' 47' ' ' TRP . 38.9 tp -58.55 -42.26 87.45 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.332 -0.855 . . . . 0.0 109.958 -179.022 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.541 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 1.2 pp20? -72.63 -35.85 67.91 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.0 -1.063 . . . . 0.0 109.635 179.887 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.1 t0 -60.2 -38.25 82.73 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.237 -0.914 . . . . 0.0 110.288 -179.77 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.467 ' HD2' ' HE1' ' A' ' 47' ' ' TRP . 71.9 mtp85 -61.19 -38.12 85.4 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.244 -0.91 . . . . 0.0 111.16 -178.956 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.634 ' CE2' HG11 ' A' ' 76' ' ' VAL . 86.6 m-85 -99.53 -10.36 22.18 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 120.859 -1.151 . . . . 0.0 110.031 -179.388 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 69.98 33.49 70.14 Favored Glycine 0 N--CA 1.486 2.027 0 N-CA-C 108.558 -1.817 . . . . 0.0 108.558 179.856 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 38.5 pt -103.08 149.06 7.44 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 O-C-N 121.535 -0.979 . . . . 0.0 109.994 -179.239 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -94.2 120.1 33.96 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.3 -0.875 . . . . 0.0 109.459 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.492 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -66.65 -28.99 68.91 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.403 -0.81 . . . . 0.0 109.495 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 54.6 t0 -56.41 -35.03 67.34 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.387 -0.821 . . . . 0.0 110.249 -179.453 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -53.75 -39.11 65.07 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.055 -1.028 . . . . 0.0 109.65 -179.582 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.492 ' O ' ' O ' ' A' ' 56' ' ' ALA . 46.5 t -127.46 136.57 60.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.521 -0.737 . . . . 0.0 109.544 179.851 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -85.5 128.43 34.74 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.119 -0.988 . . . . 0.0 108.765 179.547 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 54.8 mt -98.46 141.21 31.61 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.142 -0.974 . . . . 0.0 109.997 -179.158 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -105.55 151.15 39.72 Favored Pre-proline 0 C--N 1.305 -1.361 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 179.403 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -53.67 -21.87 20.89 Favored 'Trans proline' 0 C--N 1.306 -1.659 0 C-N-CA 122.227 1.951 . . . . 0.0 111.998 -179.54 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -70.07 -28.27 65.29 Favored 'General case' 0 N--CA 1.486 1.351 0 O-C-N 121.265 -0.897 . . . . 0.0 109.586 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . 0.586 ' CD2' ' O ' ' A' ' 65' ' ' HIS . 6.5 t-160 -65.72 -20.93 66.46 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.259 -0.901 . . . . 0.0 109.277 -179.713 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.552 ' HB3' HD13 ' A' ' 36' ' ' ILE . 7.8 m-85 -96.51 15.99 19.96 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.525 -0.734 . . . . 0.0 109.078 -179.65 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . 0.405 ' HG2' ' N ' ' A' ' 68' ' ' SER . 1.3 ptt85 -54.36 -35.93 63.3 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.645 -0.659 . . . . 0.0 110.243 -179.765 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . 0.555 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 90.4 p -157.54 160.38 38.13 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 120.912 -1.117 . . . . 0.0 110.287 -179.95 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.605 ' H ' HD12 ' A' ' 69' ' ' ILE . 3.1 mp -59.14 -34.03 52.26 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 179.007 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 57.6 mtp85 -56.95 -42.9 80.92 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.707 -0.621 . . . . 0.0 109.948 -179.266 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 78.8 p -68.71 -35.82 77.65 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.298 -0.876 . . . . 0.0 110.115 -179.601 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.434 ' O ' HG23 ' A' ' 76' ' ' VAL . 56.3 mt -65.93 -48.51 81.65 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 O-C-N 121.216 -0.928 . . . . 0.0 110.122 -179.38 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 43.9 t0 -60.17 -43.16 96.03 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.18 -0.95 . . . . 0.0 109.49 -179.757 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.95 -43.63 82.66 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.494 -0.754 . . . . 0.0 110.251 -179.579 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . 0.553 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 70.4 t80 -62.51 -45.29 93.66 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.263 -0.898 . . . . 0.0 109.697 -179.641 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.634 HG11 ' CE2' ' A' ' 52' ' ' PHE . 95.9 t -64.84 -47.06 90.0 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.361 0 O-C-N 121.206 -0.934 . . . . 0.0 109.665 -179.945 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 54.9 t -69.53 -45.98 76.93 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.329 0 O-C-N 121.1 -1.0 . . . . 0.0 109.731 179.857 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.48 ' O ' ' O ' ' A' ' 81' ' ' THR . . . -63.9 -30.73 78.55 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 110.307 -1.117 . . . . 0.0 110.307 -179.633 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -66.81 -39.53 87.74 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.137 -1.214 . . . . 0.0 110.516 -179.019 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 65.2 p -84.18 -28.81 27.09 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.036 -1.04 . . . . 0.0 109.778 -179.727 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.48 ' O ' ' O ' ' A' ' 78' ' ' GLY . 0.3 OUTLIER . . . . . 0 C--N 1.302 -1.471 0 O-C-N 121.478 -0.764 . . . . 0.0 109.737 -179.546 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 20.8 m170 . . . . . 0 N--CA 1.493 1.696 0 CA-C-O 121.12 0.486 . . . . 0.0 109.926 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -61.99 -33.05 73.61 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.141 -0.974 . . . . 0.0 109.547 179.856 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.3 t -57.86 -37.56 74.13 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.284 -0.885 . . . . 0.0 109.879 -179.497 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 77.2 t -63.52 -45.41 97.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.169 -0.957 . . . . 0.0 109.514 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 77.7 mt -60.06 -42.72 90.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.405 -0.809 . . . . 0.0 109.096 179.727 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.58 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -60.89 -35.83 77.65 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.54 -0.725 . . . . 0.0 109.224 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 30.9 tt0 -64.62 -41.77 95.97 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.234 -0.916 . . . . 0.0 110.191 -179.839 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.679 ' CG ' ' CZ2' ' A' ' 47' ' ' TRP . 37.4 m-85 -64.28 -50.62 67.16 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.975 -1.078 . . . . 0.0 110.719 -179.371 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.422 HG13 ' N ' ' A' ' 12' ' ' VAL . 4.5 p -63.57 -41.0 91.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.047 -1.033 . . . . 0.0 109.383 -179.575 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.58 HG23 ' O ' ' A' ' 8' ' ' ALA . 70.5 t -63.31 -46.34 95.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.121 -0.987 . . . . 0.0 109.339 179.558 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -71.13 -26.09 62.86 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.25 -0.906 . . . . 0.0 109.846 179.715 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -64.45 -30.61 71.65 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.46 -0.775 . . . . 0.0 110.664 -179.029 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 72.9 t80 -135.82 -42.9 0.67 Allowed 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.016 -1.053 . . . . 0.0 110.826 -179.084 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.483 HD22 ' CG2' ' A' ' 19' ' ' VAL . 4.2 mt -119.49 80.09 21.96 Favored Pre-proline 0 N--CA 1.493 1.723 0 O-C-N 121.088 -1.008 . . . . 0.0 110.377 -179.094 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -75.53 -14.13 20.13 Favored 'Trans proline' 0 C--N 1.309 -1.522 0 C-N-CA 122.292 1.995 . . . . 0.0 112.217 179.404 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.42 ' OD1' ' O ' ' A' ' 18' ' ' ASP . 59.9 t0 -89.55 7.02 38.4 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.274 -0.891 . . . . 0.0 109.683 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.483 ' CG2' HD22 ' A' ' 16' ' ' LEU . 46.1 t -111.76 135.44 51.0 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.432 -0.793 . . . . 0.0 109.651 -179.859 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.468 ' O ' ' OD1' ' A' ' 23' ' ' ASP . . . -73.49 117.88 64.26 Favored Pre-proline 0 N--CA 1.489 1.514 0 O-C-N 121.304 -0.872 . . . . 0.0 109.325 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_exo -51.45 -25.53 19.14 Favored 'Trans proline' 0 N--CA 1.493 1.47 0 C-N-CA 121.858 1.705 . . . . 0.0 112.192 179.568 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.03 -23.67 67.26 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.307 -0.871 . . . . 0.0 109.739 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.468 ' OD1' ' O ' ' A' ' 20' ' ' ALA . 52.5 p30 -84.6 7.75 19.12 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.222 -0.924 . . . . 0.0 110.024 -179.635 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 10.9 t -104.57 131.39 53.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.192 -0.942 . . . . 0.0 109.397 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 87.6 m-20 -89.43 120.5 30.81 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.213 -0.93 . . . . 0.0 109.091 179.369 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.0 m -78.83 3.38 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 O-C-N 121.153 -0.967 . . . . 0.0 109.095 179.53 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 89.8 m-20 -83.5 -20.65 33.56 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 121.291 -0.881 . . . . 0.0 109.135 179.33 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 43.2 tp -88.69 137.9 31.9 Favored 'General case' 0 N--CA 1.487 1.41 0 N-CA-C 108.844 -0.798 . . . . 0.0 108.844 179.798 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 89.1 m-20 -57.33 136.27 56.55 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 121.158 -0.964 . . . . 0.0 109.35 -179.454 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.746 HD12 HG13 ' A' ' 69' ' ' ILE . 1.9 tt -66.0 -37.95 87.22 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.716 -0.615 . . . . 0.0 110.171 -179.179 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 69.9 t -63.14 -35.19 70.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.068 -1.02 . . . . 0.0 110.421 -178.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 90.8 m-20 -52.66 -33.89 49.18 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 108.062 -1.088 . . . . 0.0 108.062 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.452 ' HB3' HG23 ' A' ' 35' ' ' VAL . 97.5 m-20 -71.11 -34.62 71.27 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.571 -0.706 . . . . 0.0 109.864 179.488 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 84.4 6.83 85.59 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 108.962 -1.655 . . . . 0.0 108.962 -179.474 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.452 HG23 ' HB3' ' A' ' 33' ' ' ASN . 71.1 t -61.88 -35.03 65.65 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 O-C-N 121.392 -1.064 . . . . 0.0 108.95 179.74 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.699 HD11 HD13 ' A' ' 30' ' ' LEU . 99.1 mt -80.17 111.94 17.57 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.318 -0.864 . . . . 0.0 109.807 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -113.02 -166.02 1.04 Allowed 'General case' 0 C--N 1.302 -1.458 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 179.777 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -65.18 -54.38 30.55 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.146 -0.971 . . . . 0.0 108.71 179.712 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 34.0 mt -70.57 -33.29 70.94 Favored 'General case' 0 C--N 1.302 -1.489 0 N-CA-C 107.213 -1.402 . . . . 0.0 107.213 178.4 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.529 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.4 -41.18 96.89 Favored Glycine 0 N--CA 1.48 1.589 0 N-CA-C 108.61 -1.796 . . . . 0.0 108.61 179.205 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.7 tt -65.68 -41.55 92.29 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.519 -0.989 . . . . 0.0 109.085 179.201 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.5 tp -61.22 -46.03 92.11 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.434 -0.791 . . . . 0.0 109.361 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 63.5 mttp -60.28 -35.91 76.62 Favored 'General case' 0 C--N 1.296 -1.733 0 O-C-N 121.443 -0.786 . . . . 0.0 109.452 -179.708 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.529 HG23 ' O ' ' A' ' 40' ' ' GLY . 63.2 t -62.18 -45.82 97.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.357 -0.839 . . . . 0.0 109.668 -179.916 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.701 HG23 ' HB2' ' A' ' 56' ' ' ALA . 1.5 mp -67.96 -39.44 81.63 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 O-C-N 121.555 -0.716 . . . . 0.0 111.262 -179.375 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.09 -49.92 63.41 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.545 -1.347 . . . . 0.0 112.268 -177.603 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.679 ' CZ2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -77.85 -46.05 22.55 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 120.637 -1.29 . . . . 0.0 110.681 -178.546 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.857 HD12 HH21 ' A' ' 51' ' ' ARG . 8.8 tp -58.65 -44.59 90.16 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.173 -0.955 . . . . 0.0 110.195 -178.825 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 65.4 mm-40 -69.93 -36.21 75.14 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.135 -0.978 . . . . 0.0 109.797 -179.667 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.3 t0 -62.24 -38.43 89.19 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.367 -0.833 . . . . 0.0 111.431 -179.2 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.857 HH21 HD12 ' A' ' 48' ' ' LEU . 66.6 mtm180 -59.34 -38.92 81.58 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.023 -1.048 . . . . 0.0 111.574 -178.392 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.61 ' CE1' ' CG1' ' A' ' 76' ' ' VAL . 48.7 m-85 -90.14 -2.61 58.1 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 120.759 -1.213 . . . . 0.0 110.544 -179.199 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 73.98 29.2 63.19 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 108.797 -1.721 . . . . 0.0 108.797 179.546 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 31.4 pt -113.1 153.47 14.66 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 O-C-N 121.694 -0.886 . . . . 0.0 109.758 -179.397 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -101.83 138.76 38.37 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.255 -0.903 . . . . 0.0 109.426 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.701 ' HB2' HG23 ' A' ' 45' ' ' ILE . . . -64.65 -30.61 71.63 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.298 -0.876 . . . . 0.0 109.681 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 53.8 t0 -55.48 -36.02 66.17 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.132 -0.98 . . . . 0.0 109.827 -179.74 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -57.36 -39.89 76.94 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.199 -0.938 . . . . 0.0 110.169 -179.561 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.506 ' O ' ' O ' ' A' ' 56' ' ' ALA . 13.6 p -136.51 142.15 39.07 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.272 -0.892 . . . . 0.0 109.783 -179.941 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -101.71 137.02 40.57 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.156 -0.965 . . . . 0.0 109.433 179.815 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.492 HD23 ' ND1' ' A' ' 65' ' ' HIS . 5.5 mp -103.27 144.06 31.84 Favored 'General case' 0 C--N 1.305 -1.34 0 O-C-N 121.256 -0.902 . . . . 0.0 109.732 -179.843 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -103.34 153.13 38.7 Favored Pre-proline 0 C--N 1.305 -1.351 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 179.81 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 8.5 Cg_endo -53.75 -24.54 30.78 Favored 'Trans proline' 0 C--N 1.306 -1.665 0 C-N-CA 122.264 1.976 . . . . 0.0 111.82 -179.832 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -70.42 -28.39 65.01 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 121.392 -0.818 . . . . 0.0 109.257 179.69 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . 0.524 ' NE2' ' CB ' ' A' ' 75' ' ' PHE . 7.6 t-80 -66.02 -20.04 66.05 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 121.375 -0.828 . . . . 0.0 109.027 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.516 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 15.5 m-85 -91.98 15.1 13.93 Favored 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . 0.536 ' CZ ' ' OG ' ' A' ' 71' ' ' SER . 7.2 ptt180 -48.6 -37.33 17.79 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.7 -0.625 . . . . 0.0 109.866 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . 0.518 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 92.4 p -159.55 155.86 27.08 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.092 -1.005 . . . . 0.0 109.919 179.811 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.746 HG13 HD12 ' A' ' 30' ' ' LEU . 3.5 mp -58.58 -34.83 52.36 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 179.045 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 58.6 mtp180 -57.44 -43.25 83.73 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.67 -0.644 . . . . 0.0 109.462 -179.76 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . 0.536 ' OG ' ' CZ ' ' A' ' 67' ' ' ARG . 22.7 t -65.54 -39.9 92.27 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.465 -0.772 . . . . 0.0 109.81 179.935 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.401 ' HA ' ' NE2' ' A' ' 65' ' ' HIS . 68.5 mt -61.02 -46.41 96.7 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.313 0 O-C-N 121.313 -0.867 . . . . 0.0 110.109 -179.541 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 39.4 t0 -60.28 -42.88 96.38 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.176 -0.952 . . . . 0.0 109.364 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -67.13 -41.94 85.29 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.427 -0.796 . . . . 0.0 110.466 -179.708 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . 0.524 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 62.5 t80 -62.05 -45.72 92.3 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.103 -0.998 . . . . 0.0 109.637 -179.563 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.678 ' CG2' HD21 ' A' ' 48' ' ' LEU . 69.9 t -67.12 -48.7 78.07 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 O-C-N 121.245 -0.909 . . . . 0.0 110.014 -179.853 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 78.3 t -70.0 -43.35 79.37 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.338 0 O-C-N 121.109 -0.994 . . . . 0.0 109.571 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -61.11 -34.04 86.44 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 110.436 -1.066 . . . . 0.0 110.436 -179.461 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.78 -41.28 83.47 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.262 -1.14 . . . . 0.0 111.051 -178.692 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.467 HG21 ' CD2' ' A' ' 52' ' ' PHE . 49.4 p -82.79 -32.75 27.53 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.04 -1.038 . . . . 0.0 109.679 -179.511 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.301 -1.53 0 O-C-N 121.468 -0.77 . . . . 0.0 109.626 -179.383 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 93.6 m-70 . . . . . 0 N--CA 1.49 1.541 0 N-CA-C 109.486 -0.561 . . . . 0.0 109.486 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -62.1 -34.71 76.83 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.229 -0.919 . . . . 0.0 109.634 -179.871 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.2 m -59.38 -38.9 81.68 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.293 -0.88 . . . . 0.0 109.864 -179.617 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 51.8 t -66.97 -46.34 85.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.121 -0.987 . . . . 0.0 109.742 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.742 HG21 ' OD1' ' A' ' 73' ' ' ASP . 87.3 mt -59.81 -50.27 80.7 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.456 0 O-C-N 121.379 -0.826 . . . . 0.0 109.847 -179.617 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.76 -42.3 97.85 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.272 -0.892 . . . . 0.0 110.78 -179.664 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 47.3 tt0 -69.41 -47.59 63.68 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 120.976 -1.078 . . . . 0.0 111.043 -178.582 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.688 ' CD1' ' N ' ' A' ' 11' ' ' VAL . 0.0 OUTLIER -71.66 -44.14 64.8 Favored 'General case' 0 C--N 1.298 -1.659 0 O-C-N 120.921 -1.112 . . . . 0.0 110.815 -179.226 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.688 ' N ' ' CD1' ' A' ' 10' ' ' PHE . 5.2 p -61.02 -47.84 91.78 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 120.996 -1.065 . . . . 0.0 110.692 -178.711 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.566 ' N ' HG13 ' A' ' 11' ' ' VAL . 8.6 p -63.62 -39.14 84.25 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 120.805 -1.184 . . . . 0.0 109.817 -179.686 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . 0.407 ' N ' HG13 ' A' ' 12' ' ' VAL . 96.8 mt-10 -65.78 -36.17 82.77 Favored 'General case' 0 N--CA 1.486 1.33 0 O-C-N 120.93 -1.106 . . . . 0.0 110.131 -179.919 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -65.95 -42.41 90.02 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.166 -0.959 . . . . 0.0 110.196 -179.694 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 86.5 m-85 -91.47 -45.04 8.75 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.183 -0.948 . . . . 0.0 110.512 -179.691 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.537 HD22 ' CG2' ' A' ' 19' ' ' VAL . 8.5 mt -122.31 80.22 45.13 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.421 -0.799 . . . . 0.0 110.223 -178.942 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_endo -70.17 -15.47 35.55 Favored 'Trans proline' 0 C--N 1.312 -1.373 0 C-N-CA 122.099 1.866 . . . . 0.0 112.333 179.704 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -96.07 9.74 39.86 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.163 -0.961 . . . . 0.0 110.229 -179.581 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.537 ' CG2' HD22 ' A' ' 16' ' ' LEU . 44.3 t -114.73 135.28 55.09 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.239 -0.913 . . . . 0.0 109.837 -179.782 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -74.71 118.69 72.13 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.349 -0.844 . . . . 0.0 109.122 179.743 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_exo -51.17 -36.89 57.38 Favored 'Trans proline' 0 N--CA 1.493 1.444 0 C-N-CA 121.765 1.643 . . . . 0.0 112.008 179.635 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.71 -23.0 66.06 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.282 -0.886 . . . . 0.0 108.948 179.471 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 87.6 m-20 -87.98 7.13 32.55 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.406 -0.809 . . . . 0.0 109.872 -179.729 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.466 HG21 HG21 ' A' ' 12' ' ' VAL . 10.6 t -107.07 128.49 61.91 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.188 -0.945 . . . . 0.0 109.406 179.942 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 86.9 m-20 -89.81 120.29 30.92 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.137 -0.977 . . . . 0.0 109.169 179.275 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.4 m -78.87 3.36 1.74 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.465 0 O-C-N 121.125 -0.985 . . . . 0.0 108.741 179.321 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 90.5 m-20 -83.59 -19.4 35.61 Favored 'General case' 0 N--CA 1.486 1.358 0 O-C-N 121.545 -0.722 . . . . 0.0 109.073 179.392 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 42.8 tp -88.94 138.01 31.8 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 121.481 -0.762 . . . . 0.0 109.024 179.863 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -58.61 136.92 57.75 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.11 -0.993 . . . . 0.0 109.517 -179.376 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.757 HD12 HG13 ' A' ' 69' ' ' ILE . 2.4 tt -66.46 -38.0 86.38 Favored 'General case' 0 C--N 1.299 -1.613 0 O-C-N 121.757 -0.59 . . . . 0.0 110.134 -179.232 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.418 HG23 ' O ' ' A' ' 66' ' ' PHE . 75.7 t -62.55 -34.72 66.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.121 -0.987 . . . . 0.0 110.436 -178.987 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -52.45 -33.97 46.73 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 120.975 -1.078 . . . . 0.0 108.104 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.421 ' HB3' HG23 ' A' ' 35' ' ' VAL . 97.2 m-20 -71.08 -34.46 71.19 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.643 -0.66 . . . . 0.0 109.949 179.389 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 85.37 6.52 83.85 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 -179.446 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.421 HG23 ' HB3' ' A' ' 33' ' ' ASN . 76.3 t -61.52 -34.49 61.82 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.438 -1.036 . . . . 0.0 109.094 179.695 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.629 HD11 HD13 ' A' ' 30' ' ' LEU . 93.9 mt -83.14 114.4 23.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.274 -0.891 . . . . 0.0 109.735 -179.876 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.402 ' H ' ' HA3' ' A' ' 40' ' ' GLY . 92.4 m-20 -118.66 -158.41 0.72 Allowed 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 179.657 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -64.78 -54.15 35.81 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.046 -1.034 . . . . 0.0 108.506 179.631 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.597 ' N ' ' CD2' ' A' ' 39' ' ' LEU . 1.5 mm? -68.74 -32.52 72.36 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 107.32 -1.363 . . . . 0.0 107.32 178.264 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.402 ' HA3' ' H ' ' A' ' 37' ' ' ASP . . . -58.79 -45.94 94.18 Favored Glycine 0 N--CA 1.483 1.781 0 N-CA-C 109.06 -1.616 . . . . 0.0 109.06 179.6 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.9 tt -64.24 -39.06 93.18 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.426 -1.043 . . . . 0.0 108.762 179.035 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.1 tp -59.68 -45.76 91.11 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.311 -0.868 . . . . 0.0 108.798 179.543 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 54.5 mttp -60.2 -35.59 75.74 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.498 -0.751 . . . . 0.0 109.536 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 68.3 t -60.17 -46.89 93.97 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.345 -0.847 . . . . 0.0 109.567 -179.925 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.643 HD11 HD12 ' A' ' 61' ' ' LEU . 1.7 mp -68.22 -33.23 59.52 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 O-C-N 121.359 -0.838 . . . . 0.0 110.802 -179.915 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.17 -49.1 65.93 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.095 -1.003 . . . . 0.0 111.466 -178.359 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.524 ' C ' ' CD1' ' A' ' 47' ' ' TRP . 0.0 OUTLIER -80.8 -41.51 23.22 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 120.583 -1.323 . . . . 0.0 109.663 -179.548 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.449 HD11 ' CG2' ' A' ' 76' ' ' VAL . 8.3 tt -59.55 -41.78 90.87 Favored 'General case' 0 C--N 1.3 -1.567 0 O-C-N 121.377 -0.827 . . . . 0.0 109.909 -179.331 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.52 ' O ' ' N ' ' A' ' 53' ' ' GLY . 18.4 pt-20 -73.15 -36.92 66.75 Favored 'General case' 0 C--N 1.304 -1.371 0 O-C-N 121.099 -1.001 . . . . 0.0 109.562 -179.817 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . 0.405 ' N ' ' CG ' ' A' ' 49' ' ' GLU . 55.9 t0 -59.06 -38.49 79.5 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.321 -0.862 . . . . 0.0 110.838 -179.319 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.46 ' NH2' HG21 ' A' ' 76' ' ' VAL . 75.1 mtm180 -61.56 -41.18 97.0 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 120.986 -1.072 . . . . 0.0 111.473 -178.649 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.898 ' CE2' HG21 ' A' ' 80' ' ' THR . 36.7 m-85 -105.87 -12.54 15.81 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 120.923 -1.11 . . . . 0.0 110.173 -179.451 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.52 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 70.85 30.45 68.15 Favored Glycine 0 N--CA 1.486 2.017 0 N-CA-C 109.054 -1.618 . . . . 0.0 109.054 179.574 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 16.2 pt -97.82 129.72 47.6 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 O-C-N 121.336 -1.097 . . . . 0.0 109.756 -179.549 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -67.37 135.53 53.37 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.155 -0.966 . . . . 0.0 109.651 -179.666 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.504 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -66.37 -31.5 72.31 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.297 -0.877 . . . . 0.0 109.441 179.804 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 54.2 t0 -56.94 -36.69 70.53 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.277 -0.89 . . . . 0.0 109.999 -179.75 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 54.5 t0 -56.11 -40.38 73.61 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.182 -0.949 . . . . 0.0 109.892 -179.598 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.504 ' O ' ' O ' ' A' ' 56' ' ' ALA . 42.6 t -129.33 134.74 63.23 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.425 -0.797 . . . . 0.0 109.603 179.926 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -91.81 131.06 37.43 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.15 -0.969 . . . . 0.0 109.277 179.763 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.643 HD12 HD11 ' A' ' 45' ' ' ILE . 54.6 mt -97.82 139.27 33.92 Favored 'General case' 0 C--N 1.305 -1.327 0 O-C-N 121.297 -0.877 . . . . 0.0 109.674 -179.752 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -110.0 157.12 38.71 Favored Pre-proline 0 N--CA 1.489 1.495 0 N-CA-C 108.849 -0.796 . . . . 0.0 108.849 179.606 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 7.1 Cg_endo -52.83 -22.9 19.1 Favored 'Trans proline' 0 C--N 1.302 -1.903 0 C-N-CA 122.368 2.045 . . . . 0.0 111.72 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -70.45 -27.52 64.31 Favored 'General case' 0 N--CA 1.485 1.304 0 O-C-N 121.386 -0.821 . . . . 0.0 109.507 179.6 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . 0.566 ' C ' ' CD2' ' A' ' 65' ' ' HIS . 0.7 OUTLIER -65.67 -19.8 66.05 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.315 -0.865 . . . . 0.0 108.95 -179.882 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.551 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 6.0 m-85 -98.25 16.11 22.42 Favored 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 179.839 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . 0.424 ' HG2' ' H ' ' A' ' 68' ' ' SER . 5.3 ptt180 -49.87 -38.49 35.69 Favored 'General case' 0 C--N 1.3 -1.547 0 O-C-N 121.79 -0.569 . . . . 0.0 110.031 -179.798 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . 0.542 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 84.2 p -161.66 157.59 24.76 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.006 -1.059 . . . . 0.0 109.969 179.838 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.757 HG13 HD12 ' A' ' 30' ' ' LEU . 3.4 mp -57.97 -35.04 50.4 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 179.034 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 59.6 mtp180 -57.51 -42.18 82.29 Favored 'General case' 0 N--CA 1.488 1.427 0 CA-C-O 121.442 0.639 . . . . 0.0 109.291 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 60.5 p -70.46 -36.39 73.88 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.446 -0.784 . . . . 0.0 110.047 -179.707 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 81.0 mt -62.73 -51.35 73.15 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 O-C-N 121.216 -0.928 . . . . 0.0 109.626 -179.636 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.742 ' OD1' HG21 ' A' ' 7' ' ' ILE . 35.0 m-20 -63.24 -42.85 99.27 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.301 -0.875 . . . . 0.0 108.651 179.883 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -67.1 -37.43 83.93 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.571 -0.706 . . . . 0.0 109.891 179.677 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 70.4 t80 -58.87 -47.62 84.28 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.028 -1.045 . . . . 0.0 109.915 -179.387 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.592 ' CG1' ' CE1' ' A' ' 52' ' ' PHE . 76.4 t -68.11 -48.56 73.66 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 O-C-N 121.238 -0.914 . . . . 0.0 110.255 -179.559 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 50.0 t -69.69 -45.27 78.16 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.306 0 O-C-N 121.047 -1.033 . . . . 0.0 109.847 -179.796 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.458 ' O ' ' O ' ' A' ' 81' ' ' THR . . . -61.19 -39.16 96.78 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 110.208 -1.157 . . . . 0.0 110.208 -179.573 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.72 -41.02 84.15 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.189 -1.183 . . . . 0.0 110.366 -179.242 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.898 HG21 ' CE2' ' A' ' 52' ' ' PHE . 49.5 p -82.83 -29.86 29.14 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.05 -1.031 . . . . 0.0 109.691 -179.614 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.458 ' O ' ' O ' ' A' ' 78' ' ' GLY . 0.3 OUTLIER . . . . . 0 C--N 1.303 -1.452 0 O-C-N 121.519 -0.738 . . . . 0.0 109.668 -179.561 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 60.5 m-70 . . . . . 0 N--CA 1.487 1.392 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -58.92 -41.93 88.46 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.542 -0.723 . . . . 0.0 109.746 -179.395 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 85.8 p -63.79 -31.35 72.5 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.308 -0.87 . . . . 0.0 109.666 -179.873 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 73.7 t -65.05 -45.26 94.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.182 -0.949 . . . . 0.0 109.432 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.447 ' CG2' HG23 ' A' ' 69' ' ' ILE . 76.0 mt -60.25 -43.58 93.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.445 -0.784 . . . . 0.0 109.165 179.771 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.476 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -60.33 -35.96 76.86 Favored 'General case' 0 C--N 1.305 -1.369 0 O-C-N 121.499 -0.75 . . . . 0.0 109.23 -179.898 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 7.3 tt0 -64.97 -41.19 95.67 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.22 -0.925 . . . . 0.0 110.142 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.693 ' CG ' ' CZ2' ' A' ' 47' ' ' TRP . 30.2 m-85 -62.6 -50.36 71.57 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.041 -1.037 . . . . 0.0 110.688 -179.381 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.452 HG23 ' N ' ' A' ' 12' ' ' VAL . 24.9 m -63.82 -41.78 93.69 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 O-C-N 121.062 -1.024 . . . . 0.0 109.343 -179.473 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.476 HG23 ' O ' ' A' ' 8' ' ' ALA . 71.2 t -63.82 -46.73 93.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.138 -0.976 . . . . 0.0 109.351 179.498 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -70.4 -29.0 65.52 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.226 -0.921 . . . . 0.0 110.124 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 83.9 tt0 -64.58 -29.98 71.0 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.346 -0.846 . . . . 0.0 110.611 -178.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 75.3 t80 -132.83 -46.1 0.87 Allowed 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.01 -1.056 . . . . 0.0 110.959 -179.075 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.453 ' C ' ' O ' ' A' ' 12' ' ' VAL . 3.3 mt -118.03 80.01 14.57 Favored Pre-proline 0 N--CA 1.493 1.72 0 O-C-N 121.216 -0.928 . . . . 0.0 110.424 -178.855 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -77.82 -11.97 16.56 Favored 'Trans proline' 0 C--N 1.308 -1.57 0 C-N-CA 122.551 2.168 . . . . 0.0 112.483 179.569 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.8 ' OD1' HG23 ' A' ' 19' ' ' VAL . 53.2 p30 -90.19 8.38 33.31 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 121.092 -1.005 . . . . 0.0 110.125 -179.651 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.8 HG23 ' OD1' ' A' ' 18' ' ' ASP . 51.6 t -119.34 135.51 59.49 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.365 -0.834 . . . . 0.0 109.688 179.95 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.34 120.44 79.71 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.258 -0.901 . . . . 0.0 109.421 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_exo -51.53 -27.54 25.47 Favored 'Trans proline' 0 N--CA 1.493 1.478 0 C-N-CA 121.764 1.643 . . . . 0.0 112.036 179.478 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.77 -25.83 68.09 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.317 -0.864 . . . . 0.0 109.357 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.445 ' O ' ' OD1' ' A' ' 23' ' ' ASP . 60.0 t0 -81.78 5.82 17.43 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.368 -0.832 . . . . 0.0 109.721 -179.826 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 11.7 t -108.25 132.47 55.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.24 -0.912 . . . . 0.0 109.462 -179.952 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 86.3 m-20 -89.19 120.51 30.63 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.144 -0.973 . . . . 0.0 109.004 179.356 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.9 m -77.12 2.49 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 O-C-N 121.005 -1.059 . . . . 0.0 108.991 179.592 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 87.6 m-20 -78.83 -28.56 44.4 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.305 -0.872 . . . . 0.0 108.808 178.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 45.9 tp -83.16 139.32 33.24 Favored 'General case' 0 N--CA 1.487 1.388 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 179.53 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.5 m-20 -56.64 132.63 52.39 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.035 -1.04 . . . . 0.0 109.556 -178.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 1.045 HD23 HD11 ' A' ' 36' ' ' ILE . 50.8 tp -64.9 -36.87 85.75 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.7 -0.625 . . . . 0.0 110.552 -179.471 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 78.9 t -63.38 -34.89 69.94 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.089 -1.007 . . . . 0.0 110.54 -179.11 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 90.6 m-20 -52.58 -33.35 45.68 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.001 -1.062 . . . . 0.0 108.181 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 97.5 m-20 -70.81 -34.21 71.51 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.625 -0.672 . . . . 0.0 109.98 179.483 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 90.68 3.62 70.99 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 108.974 -1.65 . . . . 0.0 108.974 -179.267 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 75.7 t -60.92 -29.2 45.0 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 121.431 -1.041 . . . . 0.0 108.66 179.415 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 1.045 HD11 HD23 ' A' ' 30' ' ' LEU . 71.0 mt -95.56 134.67 32.18 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 O-C-N 121.478 -0.764 . . . . 0.0 109.406 -179.88 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.534 ' CG ' ' H ' ' A' ' 38' ' ' ALA . 50.2 t0 -138.9 -169.82 2.72 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.534 ' H ' ' CG ' ' A' ' 37' ' ' ASP . . . -62.0 -54.16 45.5 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.147 -0.971 . . . . 0.0 108.765 179.911 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.695 HD12 ' N ' ' A' ' 39' ' ' LEU . 6.9 mp -69.76 -32.71 71.38 Favored 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 107.201 -1.407 . . . . 0.0 107.201 178.091 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.548 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.39 -44.74 96.39 Favored Glycine 0 N--CA 1.483 1.805 0 N-CA-C 108.971 -1.652 . . . . 0.0 108.971 179.456 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.705 HD11 ' CE1' ' A' ' 66' ' ' PHE . 7.9 tt -65.0 -40.4 94.89 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.423 -1.046 . . . . 0.0 109.195 179.367 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.1 tp -59.68 -46.02 90.31 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.1 -1.0 . . . . 0.0 108.887 179.675 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 59.7 mttp -61.3 -34.89 75.96 Favored 'General case' 0 C--N 1.297 -1.71 0 O-C-N 121.546 -0.722 . . . . 0.0 109.448 -180.0 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.548 HG23 ' O ' ' A' ' 40' ' ' GLY . 73.8 t -59.47 -43.27 90.22 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 O-C-N 121.299 -0.876 . . . . 0.0 109.142 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.525 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 6.7 mm -66.95 -38.74 81.98 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 121.395 -0.815 . . . . 0.0 110.752 -179.363 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.21 -49.77 68.44 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.128 -0.983 . . . . 0.0 111.716 -178.064 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.693 ' CZ2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -80.84 -44.34 18.59 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.648 -1.283 . . . . 0.0 109.99 -179.277 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.735 HD21 ' CG2' ' A' ' 76' ' ' VAL . 20.8 tp -58.93 -41.97 88.63 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.209 -0.932 . . . . 0.0 110.094 -178.921 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.525 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 1.2 pp20? -72.25 -36.87 69.19 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.009 -1.057 . . . . 0.0 109.589 -179.889 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.7 t0 -61.19 -38.18 85.61 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.232 -0.917 . . . . 0.0 110.441 -179.834 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 14.8 mmm180 -61.69 -37.09 82.86 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.308 -0.87 . . . . 0.0 111.432 -178.703 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.634 ' CZ ' ' CG1' ' A' ' 76' ' ' VAL . 72.6 m-85 -96.82 -8.0 32.16 Favored 'General case' 0 N--CA 1.487 1.375 0 O-C-N 120.769 -1.207 . . . . 0.0 110.172 -178.956 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 71.18 31.22 66.55 Favored Glycine 0 N--CA 1.485 1.945 0 N-CA-C 108.82 -1.712 . . . . 0.0 108.82 179.771 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.487 ' O ' ' OE1' ' A' ' 49' ' ' GLU . 24.7 pt -108.81 153.13 10.62 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 O-C-N 121.598 -0.942 . . . . 0.0 109.84 -179.3 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -103.79 155.49 18.56 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.411 -0.805 . . . . 0.0 109.436 -179.638 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -58.46 -26.32 63.24 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.317 -0.865 . . . . 0.0 109.325 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 60.9 t0 59.13 38.29 23.81 Favored 'General case' 0 N--CA 1.486 1.336 0 O-C-N 121.445 -0.784 . . . . 0.0 109.109 -179.79 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 54.27 44.97 28.24 Favored 'General case' 0 N--CA 1.486 1.328 0 O-C-N 121.588 -0.695 . . . . 0.0 110.354 179.272 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 52.9 t -120.85 134.08 65.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.387 -0.82 . . . . 0.0 109.091 179.339 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -102.52 130.7 49.43 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.282 -0.886 . . . . 0.0 109.664 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 60.8 mt -99.24 143.88 29.0 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.394 -0.816 . . . . 0.0 109.17 179.834 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 11.6 p -90.09 148.17 38.8 Favored Pre-proline 0 C--N 1.305 -1.346 0 O-C-N 121.053 -1.029 . . . . 0.0 108.707 179.821 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -57.62 -19.78 38.99 Favored 'Trans proline' 0 C--N 1.305 -1.754 0 C-N-CA 122.24 1.96 . . . . 0.0 111.858 -179.714 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -67.41 -30.78 70.63 Favored 'General case' 0 N--CA 1.485 1.304 0 O-C-N 121.376 -0.828 . . . . 0.0 109.226 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . 0.568 ' CD2' ' O ' ' A' ' 65' ' ' HIS . 2.7 t-80 -66.47 -19.47 65.8 Favored 'General case' 0 C--N 1.3 -1.584 0 O-C-N 121.262 -0.899 . . . . 0.0 108.815 179.82 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.705 ' CE1' HD11 ' A' ' 41' ' ' LEU . 6.6 m-85 -98.31 13.3 31.94 Favored 'General case' 0 C--N 1.3 -1.571 0 N-CA-C 108.89 -0.781 . . . . 0.0 108.89 -179.753 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . 0.405 ' O ' ' N ' ' A' ' 30' ' ' LEU . 1.5 ptt180 -49.82 -34.74 20.58 Favored 'General case' 0 C--N 1.299 -1.587 0 O-C-N 121.716 -0.615 . . . . 0.0 110.167 -179.778 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . 0.501 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 23.3 t -153.17 154.88 35.63 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.101 -1.0 . . . . 0.0 110.041 -179.577 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.605 ' H ' HD12 ' A' ' 69' ' ' ILE . 3.3 mp -57.45 -33.99 45.53 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 178.886 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 60.4 mtp180 -56.99 -45.61 82.85 Favored 'General case' 0 N--CA 1.488 1.453 0 CA-C-O 121.395 0.617 . . . . 0.0 109.567 -179.516 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 22.9 t -65.82 -41.43 91.86 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.283 -0.886 . . . . 0.0 109.87 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 68.5 mt -61.38 -45.38 98.75 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 O-C-N 121.265 -0.897 . . . . 0.0 110.022 -179.566 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 41.4 t0 -60.15 -40.79 91.08 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.178 -0.951 . . . . 0.0 109.573 -179.846 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.36 -46.06 78.02 Favored 'General case' 0 C--N 1.304 -1.393 0 O-C-N 121.232 -0.917 . . . . 0.0 109.593 -179.75 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . 0.51 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 63.5 t80 -63.19 -44.07 96.41 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.247 -0.908 . . . . 0.0 109.127 179.621 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.735 ' CG2' HD21 ' A' ' 48' ' ' LEU . 55.4 t -62.57 -46.66 95.84 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.309 0 O-C-N 121.407 -0.808 . . . . 0.0 109.404 179.607 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.504 ' O ' ' O ' ' A' ' 81' ' ' THR . 72.5 t -68.87 -41.71 82.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 O-C-N 121.262 -0.899 . . . . 0.0 109.402 179.803 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.38 -23.45 53.78 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.798 -1.321 . . . . 0.0 109.798 179.903 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.08 -33.2 74.97 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.283 -1.128 . . . . 0.0 110.639 -179.149 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 26.2 p -121.46 -33.75 3.58 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.232 -0.918 . . . . 0.0 110.776 -179.179 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.504 ' O ' ' O ' ' A' ' 77' ' ' VAL . 0.0 OUTLIER . . . . . 0 N--CA 1.49 1.533 0 O-C-N 121.247 -0.908 . . . . 0.0 109.759 -179.388 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 38.4 m170 . . . . . 0 N--CA 1.485 1.276 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -58.89 -43.8 91.03 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.652 -0.655 . . . . 0.0 109.944 -179.224 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 94.9 p -65.95 -32.18 73.53 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.324 -0.86 . . . . 0.0 110.083 -179.663 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 79.1 t -65.26 -47.13 88.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.101 -1.0 . . . . 0.0 109.584 -179.718 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.545 ' O ' HG12 ' A' ' 11' ' ' VAL . 81.2 mt -59.96 -48.82 86.35 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 O-C-N 121.315 -0.865 . . . . 0.0 109.702 179.988 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.719 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.29 -43.5 97.7 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.421 -0.799 . . . . 0.0 110.7 -179.349 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 44.4 tt0 -68.67 -47.58 66.14 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.97 -1.081 . . . . 0.0 110.861 -178.859 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.531 ' C ' ' CD1' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -70.96 -48.12 55.2 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.149 -0.97 . . . . 0.0 110.36 -179.651 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.545 HG12 ' O ' ' A' ' 7' ' ' ILE . 4.2 p -59.92 -38.95 78.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.089 -1.007 . . . . 0.0 109.742 -179.542 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.719 HG23 ' O ' ' A' ' 8' ' ' ALA . 52.0 t -63.22 -43.26 98.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.099 -1.0 . . . . 0.0 109.839 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -63.81 -38.74 92.2 Favored 'General case' 0 N--CA 1.487 1.377 0 O-C-N 121.086 -1.008 . . . . 0.0 110.252 -179.638 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 85.5 tt0 -69.95 -42.17 73.57 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.0 -1.063 . . . . 0.0 110.218 -179.698 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 79.6 t80 -84.97 -52.96 5.61 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.16 -0.963 . . . . 0.0 110.798 -179.259 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.501 HD22 ' CG2' ' A' ' 19' ' ' VAL . 6.3 mt -122.53 80.08 46.93 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.341 -0.85 . . . . 0.0 110.371 -179.004 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 22.0 Cg_endo -68.39 -14.54 40.32 Favored 'Trans proline' 0 C--N 1.311 -1.403 0 C-N-CA 122.012 1.808 . . . . 0.0 112.33 179.464 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.459 ' OD1' ' O ' ' A' ' 18' ' ' ASP . 60.2 t0 -94.61 6.22 49.5 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.187 -0.945 . . . . 0.0 110.137 -179.705 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.501 ' CG2' HD22 ' A' ' 16' ' ' LEU . 25.9 t -118.57 135.89 57.53 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.268 -0.895 . . . . 0.0 109.636 -179.896 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.491 ' O ' ' OD1' ' A' ' 23' ' ' ASP . . . -77.14 117.19 63.56 Favored Pre-proline 0 N--CA 1.489 1.489 0 O-C-N 121.234 -0.916 . . . . 0.0 108.935 179.722 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_exo -51.71 -26.23 22.75 Favored 'Trans proline' 0 N--CA 1.492 1.407 0 C-N-CA 121.8 1.666 . . . . 0.0 112.211 179.693 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.09 -24.94 67.58 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.35 -0.844 . . . . 0.0 109.775 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.503 ' OD1' HG23 ' A' ' 24' ' ' VAL . 49.2 p30 -86.38 7.07 27.15 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.104 -0.998 . . . . 0.0 110.008 -179.555 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.503 HG23 ' OD1' ' A' ' 23' ' ' ASP . 15.6 t -110.4 131.9 60.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.73 0 O-C-N 121.315 -0.866 . . . . 0.0 109.504 179.868 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . 0.513 ' C ' ' H ' ' A' ' 27' ' ' ASP . 62.9 t0 -89.25 119.37 29.68 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.148 -0.97 . . . . 0.0 108.981 179.223 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.439 ' O ' HG13 ' A' ' 26' ' ' VAL . 0.3 OUTLIER -63.87 4.25 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.421 0 O-C-N 121.172 -0.955 . . . . 0.0 109.315 179.874 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.513 ' H ' ' C ' ' A' ' 25' ' ' ASP . 92.0 m-20 -105.02 6.63 33.54 Favored 'General case' 0 N--CA 1.485 1.301 0 O-C-N 121.263 -0.898 . . . . 0.0 109.32 179.772 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . 0.404 HD23 ' OD1' ' A' ' 33' ' ' ASN . 45.5 tp -96.8 136.29 37.56 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.373 -0.829 . . . . 0.0 109.238 -179.828 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 80.5 m-20 -64.7 142.52 58.4 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.231 -0.918 . . . . 0.0 109.967 -179.167 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.576 ' N ' ' O ' ' A' ' 67' ' ' ARG . 76.0 mt -70.3 -35.07 73.46 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.468 -0.77 . . . . 0.0 110.987 -179.577 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.61 HG23 ' N ' ' A' ' 32' ' ' ASP . 35.1 m -57.75 -47.09 86.69 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.515 0 O-C-N 121.123 -0.986 . . . . 0.0 110.177 -178.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.61 ' N ' HG23 ' A' ' 31' ' ' VAL . 90.8 m-20 -61.18 -34.24 74.73 Favored 'General case' 0 C--N 1.302 -1.489 0 N-CA-C 108.439 -0.948 . . . . 0.0 108.439 179.403 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.404 ' OD1' HD23 ' A' ' 28' ' ' LEU . 96.6 m-20 -70.8 -34.18 71.49 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.752 -0.592 . . . . 0.0 110.115 -179.883 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 86.61 6.36 80.48 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 108.872 -1.691 . . . . 0.0 108.872 -179.516 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 70.8 t -59.06 -32.21 47.36 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 O-C-N 121.464 -1.021 . . . . 0.0 108.293 179.42 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 79.8 mt -85.82 129.56 37.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 CA-C-O 121.656 0.741 . . . . 0.0 109.735 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.49 ' CG ' ' H ' ' A' ' 38' ' ' ALA . 51.2 t0 -148.85 -170.84 3.72 Favored 'General case' 0 C--N 1.298 -1.647 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 179.776 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.49 ' H ' ' CG ' ' A' ' 37' ' ' ASP . . . -61.35 -54.66 40.89 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 120.893 -1.129 . . . . 0.0 108.422 179.772 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.718 HD12 ' N ' ' A' ' 39' ' ' LEU . 6.8 mp -71.61 -33.22 68.79 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 107.468 -1.308 . . . . 0.0 107.468 178.094 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.535 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.77 -46.61 93.77 Favored Glycine 0 N--CA 1.484 1.885 0 N-CA-C 109.255 -1.538 . . . . 0.0 109.255 179.833 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 3.4 tt -63.81 -43.28 96.73 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.419 -1.047 . . . . 0.0 109.654 179.563 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 17.2 tp -59.75 -45.22 92.89 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.313 -0.867 . . . . 0.0 109.728 -179.653 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 24.8 mttm -63.36 -34.45 77.74 Favored 'General case' 0 C--N 1.297 -1.678 0 O-C-N 121.052 -1.03 . . . . 0.0 109.705 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.591 HG11 ' CE2' ' A' ' 66' ' ' PHE . 54.7 t -61.38 -50.79 78.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.332 -0.855 . . . . 0.0 110.624 -179.077 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.497 ' H ' HD12 ' A' ' 45' ' ' ILE . 3.5 mp -68.27 -40.08 82.06 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 O-C-N 121.17 -0.957 . . . . 0.0 111.34 -179.431 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.66 -49.63 61.91 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.081 -1.012 . . . . 0.0 112.215 -177.692 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.551 ' C ' ' CD1' ' A' ' 47' ' ' TRP . 0.0 OUTLIER -78.76 -43.43 25.61 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.671 -1.268 . . . . 0.0 110.37 -178.717 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.848 HD11 HG21 ' A' ' 76' ' ' VAL . 16.7 tp -59.99 -41.78 92.79 Favored 'General case' 0 C--N 1.3 -1.562 0 O-C-N 121.195 -0.941 . . . . 0.0 110.326 -178.754 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.413 ' CG ' ' N ' ' A' ' 50' ' ' ASP . 17.8 pt-20 -73.02 -37.15 67.03 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.117 -0.99 . . . . 0.0 109.856 -179.673 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . 0.413 ' N ' ' CG ' ' A' ' 49' ' ' GLU . 56.8 t0 -60.0 -39.26 85.14 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.375 -0.828 . . . . 0.0 111.036 -179.269 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.464 ' HD2' ' HE1' ' A' ' 47' ' ' TRP . 80.6 mtp180 -61.07 -37.61 83.28 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.105 -0.997 . . . . 0.0 111.603 -178.649 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.644 ' CZ ' ' CG1' ' A' ' 76' ' ' VAL . 48.6 m-85 -98.48 -8.18 27.14 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 120.79 -1.194 . . . . 0.0 110.456 -179.012 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 69.87 31.7 70.04 Favored Glycine 0 N--CA 1.488 2.117 0 N-CA-C 108.752 -1.739 . . . . 0.0 108.752 179.653 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 27.9 pt -108.51 153.44 10.12 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 O-C-N 121.62 -0.929 . . . . 0.0 109.908 -179.372 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -100.09 129.95 46.18 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.152 -0.968 . . . . 0.0 109.51 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.502 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -66.51 -28.82 68.86 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.294 -0.879 . . . . 0.0 109.581 179.895 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 53.9 t0 -55.41 -36.09 66.08 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.305 -0.872 . . . . 0.0 109.998 -179.642 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -56.88 -40.3 75.95 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.201 -0.937 . . . . 0.0 109.952 -179.584 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.502 ' O ' ' O ' ' A' ' 56' ' ' ALA . 42.1 t -129.16 134.81 63.31 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.393 -0.817 . . . . 0.0 109.543 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -79.25 126.63 31.03 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.097 -1.002 . . . . 0.0 109.436 179.896 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.482 HD12 ' O ' ' A' ' 59' ' ' VAL . 5.3 mp -108.04 139.54 42.53 Favored 'General case' 0 C--N 1.305 -1.333 0 O-C-N 121.372 -0.83 . . . . 0.0 109.651 -179.904 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -107.02 145.34 30.92 Favored Pre-proline 0 N--CA 1.484 1.267 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 179.098 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -60.73 -19.94 63.35 Favored 'Trans proline' 0 C--N 1.306 -1.699 0 C-N-CA 122.107 1.871 . . . . 0.0 112.021 -179.55 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 90.1 mt-10 -69.25 -28.39 66.29 Favored 'General case' 0 C--N 1.305 -1.364 0 O-C-N 121.439 -0.788 . . . . 0.0 109.676 -179.613 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . 0.59 ' CD2' ' O ' ' A' ' 65' ' ' HIS . 0.0 OUTLIER -66.55 -19.12 65.7 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.199 -0.938 . . . . 0.0 109.182 -179.563 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.591 ' CE2' HG11 ' A' ' 44' ' ' VAL . 16.5 m-85 -96.15 11.03 35.77 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.291 -0.881 . . . . 0.0 109.317 179.794 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . 0.576 ' O ' ' N ' ' A' ' 30' ' ' LEU . 1.7 ptt180 -50.08 -21.86 1.43 Allowed 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.381 -0.824 . . . . 0.0 110.049 -179.671 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . 0.444 ' O ' ' OG ' ' A' ' 71' ' ' SER . 34.4 t -147.14 147.03 30.13 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.137 -0.977 . . . . 0.0 109.883 -179.875 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.713 ' H ' HD12 ' A' ' 69' ' ' ILE . 2.3 mp -59.92 -38.72 77.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.288 -0.883 . . . . 0.0 109.566 -179.826 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.429 ' O ' ' OD2' ' A' ' 73' ' ' ASP . 6.1 ptm180 -57.6 -40.14 78.4 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.427 -0.796 . . . . 0.0 109.447 -179.748 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . 0.444 ' OG ' ' O ' ' A' ' 68' ' ' SER . 95.8 p -65.07 -35.83 82.39 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.332 -0.855 . . . . 0.0 110.123 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.433 ' O ' HG23 ' A' ' 76' ' ' VAL . 64.6 mt -63.31 -46.59 95.17 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.326 0 O-C-N 121.191 -0.943 . . . . 0.0 110.148 -179.419 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.584 ' OD1' ' N ' ' A' ' 74' ' ' ALA . 1.3 p30 -63.14 -40.02 96.35 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.088 -1.007 . . . . 0.0 109.448 -179.648 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . 0.584 ' N ' ' OD1' ' A' ' 73' ' ' ASP . . . -66.76 -45.52 78.3 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.312 -0.867 . . . . 0.0 109.768 -179.882 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . 0.544 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 55.0 t80 -63.32 -43.87 96.55 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.326 -0.859 . . . . 0.0 109.073 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.848 HG21 HD11 ' A' ' 48' ' ' LEU . 55.8 t -60.79 -46.8 95.48 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 O-C-N 121.493 -0.754 . . . . 0.0 109.047 179.655 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 54.7 t -69.14 -42.07 81.63 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 O-C-N 121.455 -0.778 . . . . 0.0 109.084 179.298 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.516 ' O ' ' O ' ' A' ' 81' ' ' THR . . . -68.8 -21.19 74.92 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 110.001 -1.24 . . . . 0.0 110.001 179.901 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -66.48 -36.79 83.62 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 120.955 -1.32 . . . . 0.0 109.783 -179.411 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 56.1 p -87.91 -25.58 23.16 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.216 -0.927 . . . . 0.0 109.732 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.516 ' O ' ' O ' ' A' ' 78' ' ' GLY . 0.1 OUTLIER . . . . . 0 N--CA 1.486 1.366 0 O-C-N 121.358 -0.839 . . . . 0.0 109.75 -179.63 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 66.7 m-70 . . . . . 0 N--CA 1.487 1.418 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -58.26 -37.68 75.44 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.491 -0.755 . . . . 0.0 109.577 -179.3 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 87.4 p -61.45 -32.89 72.88 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.202 -0.936 . . . . 0.0 109.469 -179.884 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.455 ' HA ' HE21 ' A' ' 9' ' ' GLN . 70.0 t -62.95 -43.9 99.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.237 -0.914 . . . . 0.0 109.196 179.75 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 79.2 mt -60.21 -40.97 85.18 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.396 -0.815 . . . . 0.0 109.024 179.606 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.428 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -60.84 -38.12 84.39 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 121.52 -0.738 . . . . 0.0 109.537 -179.724 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . 0.455 HE21 ' HA ' ' A' ' 6' ' ' VAL . 52.3 mt-30 -64.51 -40.53 95.82 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.122 -0.986 . . . . 0.0 110.105 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.688 ' CG ' ' CE2' ' A' ' 47' ' ' TRP . 30.6 m-85 -63.55 -50.43 69.53 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.146 -0.972 . . . . 0.0 110.951 -179.196 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.473 HG23 ' N ' ' A' ' 12' ' ' VAL . 27.2 m -65.64 -41.37 90.46 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 120.995 -1.066 . . . . 0.0 109.426 -179.474 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.473 ' N ' HG23 ' A' ' 11' ' ' VAL . 66.6 t -63.88 -47.0 92.66 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 O-C-N 121.26 -0.9 . . . . 0.0 109.685 179.554 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -70.53 -27.83 64.47 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.04 -1.037 . . . . 0.0 110.231 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -64.57 -33.21 75.38 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.271 -0.893 . . . . 0.0 110.845 -178.708 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 92.1 m-85 -134.11 -29.78 1.24 Allowed 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.036 -1.04 . . . . 0.0 111.123 -179.354 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.561 HD22 ' CG2' ' A' ' 19' ' ' VAL . 12.3 mt -124.74 79.68 63.09 Favored Pre-proline 0 N--CA 1.491 1.604 0 O-C-N 121.078 -1.014 . . . . 0.0 110.248 -179.157 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -78.73 -17.72 12.27 Favored 'Trans proline' 0 C--N 1.307 -1.63 0 C-N-CA 122.586 2.19 . . . . 0.0 112.317 179.642 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -93.01 7.56 43.57 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.232 -0.917 . . . . 0.0 110.125 -179.601 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.561 ' CG2' HD22 ' A' ' 16' ' ' LEU . 46.8 t -113.18 136.04 50.76 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.353 -0.842 . . . . 0.0 109.775 -179.844 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.414 ' O ' ' CG ' ' A' ' 23' ' ' ASP . . . -72.42 117.3 57.68 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.298 -0.876 . . . . 0.0 109.499 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_exo -52.03 -25.24 21.83 Favored 'Trans proline' 0 N--CA 1.494 1.503 0 C-N-CA 121.995 1.797 . . . . 0.0 112.344 179.333 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.74 -21.5 66.77 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.268 -0.895 . . . . 0.0 109.83 -179.604 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.448 ' C ' ' OD1' ' A' ' 23' ' ' ASP . 52.8 p30 -84.45 7.56 19.33 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.245 -0.909 . . . . 0.0 110.144 -179.599 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 11.4 t -104.88 129.81 56.9 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.156 -0.965 . . . . 0.0 109.463 -179.922 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 64.0 t0 -89.58 119.86 30.37 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.142 -0.974 . . . . 0.0 109.218 179.325 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.8 m -74.84 3.95 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.428 0 O-C-N 121.172 -0.955 . . . . 0.0 109.314 179.755 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -88.99 -11.24 44.82 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 121.295 -0.878 . . . . 0.0 109.157 179.543 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 43.6 tp -95.83 138.72 33.07 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.412 -0.805 . . . . 0.0 109.016 179.793 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.0 m-20 -58.34 133.6 55.86 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.147 -0.971 . . . . 0.0 109.272 -179.625 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.725 HD12 HG13 ' A' ' 69' ' ' ILE . 2.0 tt -67.14 -38.25 85.21 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 121.724 -0.61 . . . . 0.0 110.099 -179.136 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.563 HG23 ' O ' ' A' ' 66' ' ' PHE . 75.5 t -63.14 -35.54 72.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.011 -1.056 . . . . 0.0 110.379 -178.964 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 55.7 t0 -52.52 -33.52 45.62 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 120.957 -1.09 . . . . 0.0 108.151 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.446 ' HB3' HG23 ' A' ' 35' ' ' VAL . 97.4 m-20 -71.25 -34.61 70.89 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.634 -0.666 . . . . 0.0 109.974 179.464 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 84.98 6.44 85.02 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.083 -1.607 . . . . 0.0 109.083 -179.399 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.446 HG23 ' HB3' ' A' ' 33' ' ' ASN . 71.5 t -61.32 -34.5 61.2 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.428 0 O-C-N 121.412 -1.052 . . . . 0.0 109.056 179.636 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.696 HD11 HD13 ' A' ' 30' ' ' LEU . 91.8 mt -82.07 114.53 23.12 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 O-C-N 121.353 -0.842 . . . . 0.0 109.665 -179.836 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -111.58 -168.61 1.33 Allowed 'General case' 0 C--N 1.304 -1.401 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 179.745 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -64.24 -54.15 37.88 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.214 -0.929 . . . . 0.0 108.696 179.708 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 38.6 mt -70.39 -33.16 71.08 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 107.171 -1.418 . . . . 0.0 107.171 178.338 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.621 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.57 -40.53 96.46 Favored Glycine 0 N--CA 1.481 1.678 0 N-CA-C 108.546 -1.822 . . . . 0.0 108.546 179.131 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.7 tt -65.45 -42.8 91.95 Favored 'General case' 0 C--N 1.305 -1.36 0 O-C-N 121.492 -1.005 . . . . 0.0 109.136 179.336 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.2 tp -60.88 -46.16 91.71 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.448 -0.782 . . . . 0.0 109.269 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 51.2 mttp -61.13 -35.21 76.46 Favored 'General case' 0 C--N 1.296 -1.732 0 O-C-N 121.427 -0.795 . . . . 0.0 109.623 -179.754 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.621 HG23 ' O ' ' A' ' 40' ' ' GLY . 60.5 t -61.64 -48.67 87.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.295 -0.878 . . . . 0.0 109.8 -179.605 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.518 ' CG1' HD12 ' A' ' 61' ' ' LEU . 1.6 mp -68.26 -32.62 56.52 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 O-C-N 121.501 -0.75 . . . . 0.0 110.871 -179.568 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.14 -49.76 63.68 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.0 -1.063 . . . . 0.0 111.807 -178.026 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.688 ' CE2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -80.81 -43.48 20.0 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.766 -1.209 . . . . 0.0 110.015 -179.195 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.477 HD21 ' CG2' ' A' ' 76' ' ' VAL . 24.3 tp -58.82 -41.55 87.09 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.334 -0.854 . . . . 0.0 110.1 -178.948 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.438 ' CG ' ' N ' ' A' ' 50' ' ' ASP . 17.1 pt-20 -72.99 -37.92 66.83 Favored 'General case' 0 C--N 1.305 -1.362 0 O-C-N 121.079 -1.013 . . . . 0.0 109.716 -179.835 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . 0.438 ' N ' ' CG ' ' A' ' 49' ' ' GLU . 57.2 t0 -58.17 -39.13 78.09 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.36 -0.837 . . . . 0.0 110.457 -179.509 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.465 ' HD2' ' HE1' ' A' ' 47' ' ' TRP . 22.3 mtp-105 -62.63 -36.32 82.41 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.135 -0.978 . . . . 0.0 111.411 -178.866 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.783 ' CE2' HG11 ' A' ' 76' ' ' VAL . 86.5 m-85 -95.55 -8.88 33.89 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 120.75 -1.218 . . . . 0.0 110.258 -179.191 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 72.86 30.72 63.16 Favored Glycine 0 N--CA 1.487 2.073 0 N-CA-C 108.905 -1.678 . . . . 0.0 108.905 179.723 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 23.1 pt -109.73 153.63 11.44 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.335 0 O-C-N 121.557 -0.967 . . . . 0.0 109.782 -179.501 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -101.68 135.96 42.32 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.264 -0.897 . . . . 0.0 109.54 -179.776 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.499 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -66.35 -28.51 68.71 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.329 -0.857 . . . . 0.0 109.647 179.878 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -56.05 -35.78 67.3 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.158 -0.964 . . . . 0.0 109.935 -179.732 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 54.5 t0 -55.0 -38.93 68.49 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.173 -0.954 . . . . 0.0 110.141 -179.569 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.499 ' O ' ' O ' ' A' ' 56' ' ' ALA . 13.6 p -135.59 142.63 38.87 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.199 -0.938 . . . . 0.0 109.721 -179.91 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -93.62 132.57 37.83 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.098 -1.001 . . . . 0.0 109.328 179.682 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.518 HD12 ' CG1' ' A' ' 45' ' ' ILE . 56.5 mt -99.06 140.34 33.36 Favored 'General case' 0 C--N 1.305 -1.362 0 O-C-N 121.309 -0.869 . . . . 0.0 109.865 -179.67 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -109.67 156.31 39.93 Favored Pre-proline 0 N--CA 1.487 1.412 0 N-CA-C 108.633 -0.876 . . . . 0.0 108.633 179.503 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 8.1 Cg_endo -53.36 -25.08 29.82 Favored 'Trans proline' 0 C--N 1.303 -1.83 0 C-N-CA 122.41 2.073 . . . . 0.0 111.729 -179.85 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -71.65 -27.15 62.88 Favored 'General case' 0 N--CA 1.486 1.369 0 O-C-N 121.368 -0.833 . . . . 0.0 109.508 179.757 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . 0.556 ' NE2' ' CB ' ' A' ' 75' ' ' PHE . 6.6 t-160 -65.79 -21.1 66.47 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.311 -0.868 . . . . 0.0 109.092 -179.749 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.563 ' O ' HG23 ' A' ' 31' ' ' VAL . 15.3 m-85 -92.34 14.65 15.84 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 179.909 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . 0.407 ' HG2' ' H ' ' A' ' 68' ' ' SER . 6.9 ptt180 -47.9 -39.08 17.86 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.651 -0.656 . . . . 0.0 109.85 -179.972 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . 0.535 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 86.9 p -160.04 156.55 27.14 Favored 'General case' 0 N--CA 1.487 1.401 0 O-C-N 120.993 -1.067 . . . . 0.0 110.014 179.913 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.725 HG13 HD12 ' A' ' 30' ' ' LEU . 3.3 mp -58.84 -34.76 53.24 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 179.189 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 47.0 mtp180 -56.88 -43.78 81.6 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.721 -0.612 . . . . 0.0 109.642 -179.601 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 82.5 p -69.47 -33.67 73.24 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.364 -0.835 . . . . 0.0 110.012 -179.706 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.539 HD12 ' HA ' ' A' ' 69' ' ' ILE . 80.6 mt -62.24 -51.02 77.45 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 O-C-N 121.177 -0.952 . . . . 0.0 109.944 -179.656 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 42.8 t0 -61.01 -42.06 97.73 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.197 -0.94 . . . . 0.0 109.241 179.871 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.79 -38.68 87.01 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.568 -0.708 . . . . 0.0 110.403 -179.514 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . 0.556 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 58.9 t80 -62.28 -46.88 86.8 Favored 'General case' 0 C--N 1.302 -1.462 0 O-C-N 121.105 -0.997 . . . . 0.0 109.82 -179.572 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.783 HG11 ' CE2' ' A' ' 52' ' ' PHE . 77.0 t -66.35 -48.65 80.24 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 121.164 -0.96 . . . . 0.0 109.816 -179.806 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.595 ' O ' HG22 ' A' ' 81' ' ' THR . 53.3 t -70.04 -46.9 71.33 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.276 0 O-C-N 121.056 -1.028 . . . . 0.0 109.67 179.882 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.475 ' O ' ' O ' ' A' ' 81' ' ' THR . . . -61.86 -30.86 76.38 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 110.317 -1.113 . . . . 0.0 110.317 -179.642 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.67 -41.13 84.19 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.149 -1.207 . . . . 0.0 110.318 -179.028 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 56.1 p -79.15 -31.79 44.11 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.127 -0.983 . . . . 0.0 109.39 -179.872 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.595 HG22 ' O ' ' A' ' 77' ' ' VAL . 2.6 t . . . . . 0 C--N 1.305 -1.341 0 O-C-N 121.52 -0.737 . . . . 0.0 109.452 -179.766 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 50.5 m80 . . . . . 0 N--CA 1.494 1.73 0 CA-C-O 120.988 0.423 . . . . 0.0 110.655 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -62.71 -40.22 96.49 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.016 -1.052 . . . . 0.0 109.313 179.486 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.0 t -60.19 -33.96 72.94 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.392 -0.817 . . . . 0.0 109.664 -179.955 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 55.9 t -60.24 -45.45 96.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.297 -0.877 . . . . 0.0 109.579 -179.854 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 75.5 mt -60.94 -45.26 98.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.326 -0.859 . . . . 0.0 109.025 179.65 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.484 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -61.56 -36.39 80.49 Favored 'General case' 0 N--CA 1.486 1.344 0 O-C-N 121.481 -0.762 . . . . 0.0 109.001 179.595 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 31.0 tt0 -64.78 -40.74 95.75 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.297 -0.877 . . . . 0.0 110.107 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.703 ' CG ' ' CE2' ' A' ' 47' ' ' TRP . 19.0 m-85 -61.71 -50.42 72.53 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.12 -0.987 . . . . 0.0 110.504 -179.452 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.439 HG23 ' N ' ' A' ' 12' ' ' VAL . 23.2 m -64.58 -41.07 91.21 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.5 0 O-C-N 121.051 -1.031 . . . . 0.0 109.185 -179.64 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.484 HG23 ' O ' ' A' ' 8' ' ' ALA . 79.6 t -63.95 -46.2 94.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.246 -0.909 . . . . 0.0 109.436 179.497 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -70.55 -27.7 64.35 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.171 -0.956 . . . . 0.0 110.171 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -64.46 -30.68 71.71 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.333 -0.855 . . . . 0.0 110.558 -178.883 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.454 ' CD2' ' CG1' ' A' ' 35' ' ' VAL . 96.2 m-85 -134.11 -38.64 0.86 Allowed 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.033 -1.042 . . . . 0.0 111.075 -179.317 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.523 HD22 ' CG2' ' A' ' 19' ' ' VAL . 9.1 mt -123.23 79.83 52.5 Favored Pre-proline 0 N--CA 1.493 1.684 0 O-C-N 121.067 -1.02 . . . . 0.0 110.571 -178.835 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -74.93 -15.53 20.88 Favored 'Trans proline' 0 C--N 1.309 -1.525 0 C-N-CA 122.305 2.003 . . . . 0.0 112.199 179.39 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -91.97 8.6 36.82 Favored 'General case' 0 C--N 1.305 -1.357 0 O-C-N 121.199 -0.938 . . . . 0.0 109.883 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.523 ' CG2' HD22 ' A' ' 16' ' ' LEU . 44.6 t -113.61 135.08 54.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 121.387 -0.82 . . . . 0.0 109.654 -179.746 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -73.9 119.67 77.35 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.321 -0.862 . . . . 0.0 109.288 179.877 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -51.14 -26.07 18.63 Favored 'Trans proline' 0 N--CA 1.494 1.502 0 C-N-CA 121.75 1.634 . . . . 0.0 112.132 179.482 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.81 -24.68 67.62 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.347 -0.846 . . . . 0.0 109.404 179.863 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.436 ' O ' ' OD1' ' A' ' 23' ' ' ASP . 60.2 t0 -81.83 6.83 14.43 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.32 -0.863 . . . . 0.0 109.759 -179.731 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 12.3 t -107.64 133.89 51.07 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.275 -0.89 . . . . 0.0 109.275 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 87.2 m-20 -89.06 120.47 30.5 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.085 -1.01 . . . . 0.0 109.0 179.324 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.0 m -76.4 4.47 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 O-C-N 121.19 -0.944 . . . . 0.0 109.124 179.655 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -91.45 -5.13 54.78 Favored 'General case' 0 C--N 1.305 -1.351 0 O-C-N 121.344 -0.847 . . . . 0.0 109.164 179.673 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 40.8 tp -98.65 138.5 35.74 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.323 -0.86 . . . . 0.0 109.34 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -60.61 134.69 57.32 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.247 -0.908 . . . . 0.0 109.484 -179.735 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.969 HD13 HD11 ' A' ' 36' ' ' ILE . 0.8 OUTLIER -69.06 -39.66 78.99 Favored 'General case' 0 C--N 1.301 -1.5 0 O-C-N 121.631 -0.668 . . . . 0.0 110.221 -179.293 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 70.8 t -64.04 -36.29 76.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 121.107 -0.996 . . . . 0.0 110.606 -178.759 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 56.7 t0 -52.52 -33.36 44.9 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 120.926 -1.109 . . . . 0.0 108.238 -179.904 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.508 ' HB3' HG23 ' A' ' 35' ' ' VAL . 97.3 m-20 -71.24 -34.69 71.01 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.661 -0.65 . . . . 0.0 110.049 179.608 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 83.24 6.16 88.22 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 108.831 -1.708 . . . . 0.0 108.831 -179.22 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.508 HG23 ' HB3' ' A' ' 33' ' ' ASN . 72.9 t -60.61 -30.9 47.77 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 O-C-N 121.503 -0.998 . . . . 0.0 108.356 179.329 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.969 HD11 HD13 ' A' ' 30' ' ' LEU . 89.7 mt -86.87 131.54 34.62 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.382 0 O-C-N 121.489 -0.757 . . . . 0.0 109.74 179.908 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.547 ' CG ' ' H ' ' A' ' 38' ' ' ALA . 52.0 t0 -128.01 -166.22 1.59 Allowed 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 108.646 -0.872 . . . . 0.0 108.646 179.582 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.547 ' H ' ' CG ' ' A' ' 37' ' ' ASP . . . -64.36 -54.58 30.75 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.126 -0.984 . . . . 0.0 108.886 179.849 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 34.4 mt -69.8 -32.76 71.39 Favored 'General case' 0 C--N 1.302 -1.475 0 N-CA-C 107.233 -1.395 . . . . 0.0 107.233 178.358 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.503 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.24 -41.39 96.75 Favored Glycine 0 N--CA 1.48 1.618 0 N-CA-C 108.668 -1.773 . . . . 0.0 108.668 179.271 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.6 tt -65.54 -41.9 92.51 Favored 'General case' 0 C--N 1.304 -1.38 0 O-C-N 121.426 -1.044 . . . . 0.0 108.942 179.219 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.2 tp -60.13 -45.98 91.18 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.435 -0.791 . . . . 0.0 109.208 179.801 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 28.5 mttp -60.11 -35.5 75.37 Favored 'General case' 0 C--N 1.296 -1.742 0 O-C-N 121.491 -0.755 . . . . 0.0 109.512 -179.783 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.503 HG23 ' O ' ' A' ' 40' ' ' GLY . 69.3 t -61.98 -48.23 89.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.335 -0.853 . . . . 0.0 109.927 -179.673 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.526 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 1.7 mp -68.15 -33.26 59.83 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.569 0 O-C-N 121.507 -0.746 . . . . 0.0 110.831 -179.652 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.0 -49.84 66.37 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 120.898 -1.126 . . . . 0.0 111.344 -178.179 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.703 ' CE2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -81.17 -44.54 17.71 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.718 -1.239 . . . . 0.0 109.936 -179.452 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.906 HD12 HH21 ' A' ' 51' ' ' ARG . 10.0 tp -58.43 -42.67 87.78 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.275 -0.891 . . . . 0.0 109.773 -179.07 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.526 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 2.3 pp20? -72.61 -35.93 67.98 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.094 -1.004 . . . . 0.0 109.786 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.2 t70 -60.02 -38.72 83.51 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.282 -0.886 . . . . 0.0 110.66 -179.517 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.906 HH21 HD12 ' A' ' 48' ' ' LEU . 62.6 mtm180 -62.09 -38.04 87.37 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.12 -0.987 . . . . 0.0 111.418 -178.824 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.834 ' CE2' HG11 ' A' ' 76' ' ' VAL . 95.6 m-85 -97.8 -11.94 22.78 Favored 'General case' 0 N--CA 1.487 1.391 0 O-C-N 120.738 -1.226 . . . . 0.0 110.164 -179.039 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 72.3 30.98 64.1 Favored Glycine 0 N--CA 1.488 2.102 0 N-CA-C 108.804 -1.718 . . . . 0.0 108.804 179.912 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.469 ' O ' ' OE1' ' A' ' 49' ' ' GLU . 34.5 pt -102.89 148.37 8.19 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.4 0 O-C-N 121.414 -1.05 . . . . 0.0 109.758 -179.436 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -89.87 112.42 23.76 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.184 -0.948 . . . . 0.0 109.679 -179.728 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.502 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -68.41 -27.14 65.95 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.332 -0.855 . . . . 0.0 109.585 179.686 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -55.73 -35.9 66.66 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.168 -0.957 . . . . 0.0 110.087 -179.587 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -55.55 -38.52 69.4 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.133 -0.979 . . . . 0.0 109.857 -179.631 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.502 ' O ' ' O ' ' A' ' 56' ' ' ALA . 42.7 t -124.95 136.16 61.74 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.419 -0.801 . . . . 0.0 109.658 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -89.18 131.09 35.46 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.028 -1.045 . . . . 0.0 109.297 179.872 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.502 HD12 HD11 ' A' ' 45' ' ' ILE . 38.1 mt -99.86 142.16 31.71 Favored 'General case' 0 C--N 1.305 -1.338 0 O-C-N 121.265 -0.897 . . . . 0.0 109.701 -179.7 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -109.49 157.18 38.1 Favored Pre-proline 0 N--CA 1.487 1.375 0 O-C-N 121.437 -0.789 . . . . 0.0 108.942 179.64 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_endo -55.33 -24.04 40.77 Favored 'Trans proline' 0 C--N 1.304 -1.77 0 C-N-CA 122.604 2.203 . . . . 0.0 111.827 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -69.06 -29.22 67.31 Favored 'General case' 0 C--N 1.304 -1.374 0 O-C-N 121.364 -0.835 . . . . 0.0 109.139 179.703 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . 0.531 ' CD2' ' O ' ' A' ' 65' ' ' HIS . 2.9 t-80 -66.33 -18.5 65.39 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.359 -0.838 . . . . 0.0 108.895 179.938 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.521 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 11.4 m-85 -94.69 13.77 23.3 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 179.582 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . 0.478 ' CZ ' ' OG ' ' A' ' 71' ' ' SER . 7.5 ptt180 -44.2 -38.92 4.05 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.811 -0.556 . . . . 0.0 110.545 -179.594 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 80.1 p -155.7 161.42 40.74 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.806 -1.184 . . . . 0.0 110.3 -179.629 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.479 ' CD1' HD12 ' A' ' 30' ' ' LEU . 31.3 mm -60.66 -44.14 96.39 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 O-C-N 121.39 -0.819 . . . . 0.0 110.172 -179.774 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.412 ' HG2' ' H ' ' A' ' 71' ' ' SER . 0.0 OUTLIER -58.88 -39.74 82.29 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.214 -0.929 . . . . 0.0 109.656 -179.304 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . 0.478 ' OG ' ' CZ ' ' A' ' 67' ' ' ARG . 23.2 t -63.08 -40.61 98.17 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.248 -0.907 . . . . 0.0 109.643 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 86.0 mt -61.95 -50.56 79.64 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 O-C-N 121.214 -0.929 . . . . 0.0 110.107 -179.755 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 40.9 t0 -59.28 -41.13 88.2 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.234 -0.916 . . . . 0.0 109.357 -179.842 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . 0.439 ' O ' ' N ' ' A' ' 78' ' ' GLY . . . -66.49 -37.42 85.03 Favored 'General case' 0 C--N 1.302 -1.458 0 O-C-N 121.505 -0.747 . . . . 0.0 110.266 -179.587 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . 0.531 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 62.6 t80 -61.99 -48.12 81.77 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.022 -1.049 . . . . 0.0 109.886 -179.502 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.834 HG11 ' CE2' ' A' ' 52' ' ' PHE . 87.6 t -64.92 -48.25 84.96 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.323 0 O-C-N 121.097 -1.002 . . . . 0.0 109.671 -179.801 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 60.8 t -69.31 -39.18 78.69 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 O-C-N 121.214 -0.929 . . . . 0.0 109.142 179.585 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.439 ' N ' ' O ' ' A' ' 74' ' ' ALA . . . -59.1 -35.35 83.66 Favored Glycine 0 N--CA 1.487 2.088 0 N-CA-C 110.207 -1.157 . . . . 0.0 110.207 -179.678 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -70.35 -41.68 72.86 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.265 -1.138 . . . . 0.0 111.044 -178.791 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 44.6 p -81.78 -34.79 30.15 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.094 -1.004 . . . . 0.0 109.497 -179.622 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.299 -1.592 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 -179.848 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 58.9 m-70 . . . . . 0 N--CA 1.494 1.762 0 CA-C-O 121.066 0.46 . . . . 0.0 110.316 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -62.25 -38.82 90.73 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.06 -1.025 . . . . 0.0 109.484 179.718 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.4 m -60.28 -36.88 78.85 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.368 -0.832 . . . . 0.0 110.107 -179.645 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 48.9 t -62.15 -44.81 99.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.124 -0.985 . . . . 0.0 109.723 -179.757 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.439 ' O ' HG12 ' A' ' 11' ' ' VAL . 89.7 mt -59.53 -49.8 82.29 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.613 0 O-C-N 121.341 -0.849 . . . . 0.0 110.037 -179.504 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.714 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.5 -43.97 95.72 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.378 -0.826 . . . . 0.0 111.111 -179.136 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 53.0 mt-30 -69.22 -46.0 68.45 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 120.844 -1.16 . . . . 0.0 111.284 -178.607 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.705 ' CD1' ' N ' ' A' ' 11' ' ' VAL . 0.0 OUTLIER -69.82 -47.01 64.38 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 120.951 -1.093 . . . . 0.0 110.519 -179.142 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.705 ' N ' ' CD1' ' A' ' 10' ' ' PHE . 5.1 p -61.54 -38.91 81.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.062 -1.024 . . . . 0.0 109.731 -179.671 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.714 HG23 ' O ' ' A' ' 8' ' ' ALA . 56.0 t -63.33 -43.44 98.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.133 -0.979 . . . . 0.0 109.821 -179.949 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -63.9 -39.02 93.22 Favored 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.166 -0.958 . . . . 0.0 110.187 -179.519 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 85.2 tt0 -70.02 -42.26 73.2 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.182 -0.949 . . . . 0.0 110.0 -179.849 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 77.7 t80 -83.58 -52.18 6.68 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.221 -0.924 . . . . 0.0 110.618 -179.435 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.478 HD22 ' CG2' ' A' ' 19' ' ' VAL . 7.3 mt -123.64 80.07 55.26 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.378 -0.826 . . . . 0.0 110.292 -179.04 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -67.02 -15.65 47.36 Favored 'Trans proline' 0 N--CA 1.492 1.401 0 C-N-CA 122.056 1.837 . . . . 0.0 112.466 179.682 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -95.26 7.34 46.47 Favored 'General case' 0 N--CA 1.486 1.335 0 O-C-N 121.083 -1.011 . . . . 0.0 110.429 -179.499 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.478 ' CG2' HD22 ' A' ' 16' ' ' LEU . 21.8 t -119.47 136.21 57.37 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.214 -0.929 . . . . 0.0 109.843 -179.825 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.487 ' O ' ' OD1' ' A' ' 23' ' ' ASP . . . -77.58 118.69 73.71 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.241 -0.912 . . . . 0.0 108.978 179.516 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_exo -51.15 -25.75 17.84 Favored 'Trans proline' 0 N--CA 1.493 1.487 0 C-N-CA 121.798 1.665 . . . . 0.0 112.223 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.88 -27.46 68.87 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.183 -0.948 . . . . 0.0 109.726 -179.854 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.487 ' OD1' ' O ' ' A' ' 20' ' ' ALA . 47.3 p30 -87.28 7.72 27.36 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.136 -0.977 . . . . 0.0 109.84 -179.678 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.463 HG23 ' OD1' ' A' ' 23' ' ' ASP . 16.4 t -110.16 132.06 59.5 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 O-C-N 121.311 -0.868 . . . . 0.0 109.446 179.88 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 62.2 t0 -89.26 119.47 29.77 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.197 -0.94 . . . . 0.0 108.993 179.308 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.637 HG22 ' O ' ' A' ' 26' ' ' VAL . 1.9 p -74.66 4.85 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 O-C-N 121.102 -0.999 . . . . 0.0 108.914 179.632 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -98.21 3.4 48.92 Favored 'General case' 0 N--CA 1.486 1.371 0 O-C-N 121.198 -0.938 . . . . 0.0 109.253 179.636 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 40.0 tp -97.95 134.6 40.84 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.354 -0.841 . . . . 0.0 109.37 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 82.2 m-20 -65.67 142.06 58.17 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.226 -0.921 . . . . 0.0 109.298 -179.71 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.58 HD11 HG13 ' A' ' 69' ' ' ILE . 91.4 mt -70.7 -33.73 71.2 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.325 -0.859 . . . . 0.0 110.698 -179.411 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.66 HG23 ' N ' ' A' ' 32' ' ' ASP . 20.0 m -53.56 -47.74 59.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 O-C-N 121.146 -0.971 . . . . 0.0 110.155 -178.686 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.66 ' N ' HG23 ' A' ' 31' ' ' VAL . 90.8 m-20 -61.11 -35.04 75.96 Favored 'General case' 0 C--N 1.3 -1.568 0 O-C-N 121.248 -0.908 . . . . 0.0 108.624 179.496 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 96.4 m-20 -70.84 -34.32 71.55 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.686 -0.634 . . . . 0.0 110.11 -179.842 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 86.17 5.32 83.1 Favored Glycine 0 N--CA 1.491 2.367 0 N-CA-C 109.158 -1.577 . . . . 0.0 109.158 -179.685 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 71.9 t -60.85 -34.41 59.25 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 O-C-N 121.402 -1.058 . . . . 0.0 108.93 179.672 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 92.1 mt -66.46 95.21 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.428 0 O-C-N 121.467 -0.771 . . . . 0.0 110.313 -179.559 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -102.95 169.36 8.62 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 178.85 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -55.55 -48.65 74.4 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 107.761 -1.2 . . . . 0.0 107.761 179.659 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.719 HD12 ' N ' ' A' ' 39' ' ' LEU . 6.8 mp -71.14 -32.16 68.62 Favored 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 106.984 -1.488 . . . . 0.0 106.984 177.592 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.5 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -58.77 -48.1 86.93 Favored Glycine 0 N--CA 1.483 1.795 0 N-CA-C 109.181 -1.568 . . . . 0.0 109.181 179.705 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.5 tt -63.08 -40.29 97.22 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.367 -1.078 . . . . 0.0 109.187 179.314 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.1 tp -59.73 -46.22 89.8 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.264 -0.897 . . . . 0.0 109.23 179.956 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 63.8 mttp -61.67 -34.35 75.57 Favored 'General case' 0 C--N 1.297 -1.7 0 O-C-N 121.443 -0.786 . . . . 0.0 109.604 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.5 HG23 ' O ' ' A' ' 40' ' ' GLY . 78.9 t -60.8 -47.07 94.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.377 -0.827 . . . . 0.0 110.036 -179.512 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.403 HD12 ' N ' ' A' ' 45' ' ' ILE . 1.7 mp -67.89 -36.56 76.12 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 O-C-N 121.295 -0.878 . . . . 0.0 111.35 -179.474 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.3 -49.38 64.46 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 120.965 -1.084 . . . . 0.0 111.853 -178.031 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.549 ' HE1' ' NE ' ' A' ' 51' ' ' ARG . 0.0 OUTLIER -78.37 -42.59 29.95 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 120.541 -1.349 . . . . 0.0 110.105 -179.062 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.458 HD11 ' CG2' ' A' ' 76' ' ' VAL . 7.4 tt -59.78 -42.08 92.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.242 -0.911 . . . . 0.0 110.667 -179.239 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 18.9 pt-20 -72.69 -36.51 67.9 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.101 -1.0 . . . . 0.0 109.94 -179.4 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.7 t0 -61.17 -39.61 90.76 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.362 -0.836 . . . . 0.0 111.247 -179.186 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.549 ' NE ' ' HE1' ' A' ' 47' ' ' TRP . 94.0 mtt-85 -63.18 -38.91 93.04 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.094 -1.004 . . . . 0.0 112.567 -178.074 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.732 ' CD1' HG11 ' A' ' 76' ' ' VAL . 85.5 m-85 -99.2 -7.63 26.23 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 120.656 -1.278 . . . . 0.0 110.635 -178.682 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 69.82 30.54 70.34 Favored Glycine 0 N--CA 1.486 2.012 0 N-CA-C 108.924 -1.67 . . . . 0.0 108.924 179.425 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 26.5 pt -106.59 153.23 7.91 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 O-C-N 121.634 -0.921 . . . . 0.0 109.544 -179.557 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -98.59 134.19 41.88 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.138 -0.977 . . . . 0.0 109.639 -179.498 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.518 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -65.84 -30.29 70.89 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.28 -0.887 . . . . 0.0 109.58 179.903 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -57.71 -34.56 69.59 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.212 -0.93 . . . . 0.0 110.242 -179.741 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -54.93 -39.38 68.78 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.196 -0.94 . . . . 0.0 110.403 -179.297 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.518 ' O ' ' O ' ' A' ' 56' ' ' ALA . 31.5 m -128.67 157.05 41.41 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 O-C-N 121.275 -0.891 . . . . 0.0 109.804 -179.503 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -96.54 128.95 43.96 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.986 -1.071 . . . . 0.0 109.167 179.724 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 58.1 mt -101.39 135.33 43.05 Favored 'General case' 0 C--N 1.305 -1.334 0 O-C-N 121.214 -0.929 . . . . 0.0 109.798 -179.815 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -109.97 156.05 40.62 Favored Pre-proline 0 N--CA 1.487 1.393 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 179.395 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 10.8 Cg_endo -56.94 -24.1 55.07 Favored 'Trans proline' 0 C--N 1.303 -1.839 0 C-N-CA 122.406 2.071 . . . . 0.0 111.74 179.891 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -69.47 -29.35 67.0 Favored 'General case' 0 C--N 1.306 -1.315 0 O-C-N 121.338 -0.851 . . . . 0.0 109.172 179.721 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . 0.592 ' CD2' ' O ' ' A' ' 65' ' ' HIS . 4.3 t-160 -65.97 -17.69 64.84 Favored 'General case' 0 C--N 1.3 -1.562 0 O-C-N 121.417 -0.802 . . . . 0.0 108.966 -179.911 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.493 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 17.3 m-85 -93.14 14.86 16.71 Favored 'General case' 0 C--N 1.303 -1.445 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 179.532 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 8.9 ptt180 -48.38 -38.53 19.64 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.816 -0.552 . . . . 0.0 110.822 -179.498 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 31.9 t -158.53 150.24 21.19 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 120.76 -1.213 . . . . 0.0 110.362 -179.667 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.734 ' H ' HD12 ' A' ' 69' ' ' ILE . 0.1 OUTLIER -57.74 -42.86 82.74 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.365 -0.835 . . . . 0.0 109.255 179.688 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 5.8 ptm180 -57.88 -40.66 80.77 Favored 'General case' 0 C--N 1.303 -1.427 0 O-C-N 121.42 -0.8 . . . . 0.0 109.326 -179.89 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 84.9 p -66.42 -34.39 77.85 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.236 -0.915 . . . . 0.0 109.514 179.538 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.556 HD12 ' HA ' ' A' ' 69' ' ' ILE . 91.5 mt -59.99 -51.14 76.4 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.243 0 O-C-N 121.163 -0.961 . . . . 0.0 109.749 179.969 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 42.4 t0 -59.49 -42.07 91.28 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.172 -0.955 . . . . 0.0 108.976 179.823 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . 0.556 ' O ' ' N ' ' A' ' 78' ' ' GLY . . . -66.72 -37.11 84.03 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.661 -0.649 . . . . 0.0 110.148 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . 0.459 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 64.6 t80 -61.3 -49.7 75.97 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.004 -1.06 . . . . 0.0 109.686 -179.604 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.732 HG11 ' CD1' ' A' ' 52' ' ' PHE . 44.3 t -68.66 -48.89 69.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.307 0 O-C-N 121.216 -0.927 . . . . 0.0 109.875 -179.568 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 82.1 t -69.62 -41.91 80.38 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.305 0 O-C-N 121.211 -0.931 . . . . 0.0 109.151 179.803 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.556 ' N ' ' O ' ' A' ' 74' ' ' ALA . . . -60.48 -39.42 96.31 Favored Glycine 0 N--CA 1.488 2.134 0 N-CA-C 109.895 -1.282 . . . . 0.0 109.895 -179.872 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -68.33 -41.07 81.33 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.159 -1.201 . . . . 0.0 110.245 -179.428 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 45.0 p -82.32 -29.86 30.8 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.189 -0.944 . . . . 0.0 109.594 -179.768 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.495 ' O ' ' O ' ' A' ' 78' ' ' GLY . 0.3 OUTLIER . . . . . 0 C--N 1.302 -1.461 0 O-C-N 121.522 -0.736 . . . . 0.0 109.457 -179.659 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 14.9 m-70 . . . . . 0 N--CA 1.496 1.842 0 CA-C-O 121.037 0.446 . . . . 0.0 110.127 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -62.26 -38.34 88.92 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.045 -1.034 . . . . 0.0 109.396 179.719 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.3 t -60.66 -38.03 83.53 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.36 -0.837 . . . . 0.0 110.049 -179.585 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 73.4 t -61.53 -43.12 96.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.203 -0.935 . . . . 0.0 109.539 -179.836 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 75.3 mt -60.32 -46.04 95.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.395 -0.816 . . . . 0.0 109.283 179.742 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.529 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -61.47 -39.24 90.18 Favored 'General case' 0 N--CA 1.486 1.372 0 O-C-N 121.268 -0.895 . . . . 0.0 108.675 179.546 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 33.2 tt0 -64.99 -35.11 80.13 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.419 -0.801 . . . . 0.0 109.143 179.289 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.612 ' CZ ' ' CD1' ' A' ' 47' ' ' TRP . 0.3 OUTLIER -60.51 -50.9 71.72 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.495 -0.753 . . . . 0.0 110.184 -179.569 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.734 HG11 HD11 ' A' ' 30' ' ' LEU . 22.7 m -66.55 -38.26 81.3 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 O-C-N 121.164 -0.96 . . . . 0.0 109.117 -179.743 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.529 HG23 ' O ' ' A' ' 8' ' ' ALA . 73.9 t -63.47 -44.87 98.99 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.439 0 O-C-N 121.24 -0.912 . . . . 0.0 109.351 179.496 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -73.3 -19.27 61.08 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.266 -0.896 . . . . 0.0 109.939 179.746 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -63.9 -32.28 73.75 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.33 -0.857 . . . . 0.0 110.449 -178.983 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 64.8 t80 -142.28 -36.62 0.41 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 120.958 -1.089 . . . . 0.0 110.463 -179.62 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.507 HD22 ' CG2' ' A' ' 19' ' ' VAL . 5.6 mt -119.55 79.89 22.26 Favored Pre-proline 0 N--CA 1.491 1.615 0 O-C-N 121.211 -0.93 . . . . 0.0 110.017 -179.495 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_endo -77.97 -14.16 15.45 Favored 'Trans proline' 0 C--N 1.308 -1.58 0 C-N-CA 122.604 2.203 . . . . 0.0 112.235 179.592 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -90.31 7.25 39.37 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 121.343 -0.848 . . . . 0.0 109.9 -179.699 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.507 ' CG2' HD22 ' A' ' 16' ' ' LEU . 44.7 t -109.28 134.86 49.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.303 -0.873 . . . . 0.0 109.588 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.489 ' O ' ' OD1' ' A' ' 23' ' ' ASP . . . -72.52 117.15 56.53 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.275 -0.89 . . . . 0.0 109.382 -179.942 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_exo -52.5 -26.16 27.64 Favored 'Trans proline' 0 N--CA 1.493 1.468 0 C-N-CA 121.891 1.728 . . . . 0.0 112.095 179.446 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.88 -23.42 67.23 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.355 -0.841 . . . . 0.0 109.731 -179.762 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.489 ' OD1' ' O ' ' A' ' 20' ' ' ALA . 52.6 p30 -84.69 7.85 19.02 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.16 -0.963 . . . . 0.0 110.003 -179.615 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 12.2 t -103.0 131.74 50.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.162 -0.961 . . . . 0.0 109.5 -179.868 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 63.5 t0 -89.0 119.94 29.98 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.101 -1.0 . . . . 0.0 108.93 179.247 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.5 m -73.12 4.28 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 O-C-N 121.079 -1.013 . . . . 0.0 109.547 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -89.67 -8.22 52.9 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.215 -0.928 . . . . 0.0 109.111 179.577 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 40.5 tp -101.62 139.46 37.23 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.427 -0.796 . . . . 0.0 109.313 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.5 m-20 -58.88 142.17 51.4 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.249 -0.907 . . . . 0.0 109.388 -179.78 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.841 HD13 HD11 ' A' ' 36' ' ' ILE . 1.4 tt -69.12 -38.6 78.95 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.607 -0.683 . . . . 0.0 110.743 -178.846 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 75.4 t -64.5 -36.16 76.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.086 -1.009 . . . . 0.0 110.542 -178.903 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 91.3 m-20 -52.58 -33.66 47.09 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 120.969 -1.082 . . . . 0.0 108.218 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.428 ' HB3' HG23 ' A' ' 35' ' ' VAL . 97.6 m-20 -70.94 -34.37 71.4 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.615 -0.678 . . . . 0.0 109.99 179.534 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 86.05 6.04 82.48 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.315 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.428 HG23 ' HB3' ' A' ' 33' ' ' ASN . 71.6 t -61.51 -33.01 55.14 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.411 0 O-C-N 121.413 -1.051 . . . . 0.0 109.07 179.755 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.841 HD11 HD13 ' A' ' 30' ' ' LEU . 84.7 mt -91.95 123.85 44.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.276 -0.89 . . . . 0.0 109.802 -179.859 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -114.97 -168.44 1.38 Allowed 'General case' 0 C--N 1.301 -1.501 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 179.61 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -63.77 -53.84 44.6 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.103 -0.998 . . . . 0.0 108.717 179.683 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.585 HD12 ' N ' ' A' ' 39' ' ' LEU . 6.6 mp -68.88 -32.9 72.88 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 107.007 -1.479 . . . . 0.0 107.007 178.222 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.492 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.04 -41.91 96.7 Favored Glycine 0 N--CA 1.48 1.627 0 N-CA-C 108.691 -1.763 . . . . 0.0 108.691 179.211 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.407 HD11 ' CE1' ' A' ' 66' ' ' PHE . 7.7 tt -65.16 -41.09 95.03 Favored 'General case' 0 C--N 1.304 -1.393 0 O-C-N 121.454 -1.027 . . . . 0.0 108.851 179.066 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.1 tp -59.88 -45.81 91.31 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.365 -0.834 . . . . 0.0 109.051 179.728 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 78.6 mttt -60.34 -35.73 76.35 Favored 'General case' 0 C--N 1.298 -1.672 0 O-C-N 121.471 -0.768 . . . . 0.0 109.456 -179.863 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.492 HG23 ' O ' ' A' ' 40' ' ' GLY . 77.7 t -62.03 -43.32 97.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.308 -0.87 . . . . 0.0 109.795 -179.884 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.706 ' CD1' HD12 ' A' ' 61' ' ' LEU . 1.5 mp -67.33 -39.56 83.04 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.541 0 O-C-N 121.549 -0.719 . . . . 0.0 111.196 -179.382 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.36 -50.19 60.86 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 120.637 -1.289 . . . . 0.0 112.015 -177.72 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.612 ' CD1' ' CZ ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -78.65 -45.01 22.45 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.665 -1.272 . . . . 0.0 110.647 -178.701 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.697 HD11 HG21 ' A' ' 76' ' ' VAL . 29.4 tp -58.5 -44.19 89.34 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.12 -0.987 . . . . 0.0 110.062 -178.862 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 68.9 mm-40 -68.06 -37.75 81.66 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.117 -0.989 . . . . 0.0 109.582 -179.819 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.1 t70 -62.37 -36.94 83.83 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.358 -0.839 . . . . 0.0 110.792 -179.754 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 35.5 mmt180 -58.1 -39.07 77.67 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.09 -1.007 . . . . 0.0 111.162 -178.641 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.604 ' CE1' ' CG1' ' A' ' 76' ' ' VAL . 9.0 m-85 -91.89 -3.57 55.84 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.842 -1.161 . . . . 0.0 110.319 -179.286 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 73.87 29.8 62.49 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 108.52 -1.832 . . . . 0.0 108.52 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 31.9 pt -113.45 153.61 14.98 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 O-C-N 121.714 -0.874 . . . . 0.0 109.866 -179.17 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -97.06 139.92 32.34 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.307 -0.871 . . . . 0.0 109.259 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.585 ' HB2' HG23 ' A' ' 45' ' ' ILE . . . -62.85 -30.71 71.71 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.24 -0.912 . . . . 0.0 109.715 -179.796 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -56.72 -38.77 72.81 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.054 -1.029 . . . . 0.0 109.681 -179.758 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 90.7 m-20 -61.36 -41.29 96.83 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.204 -0.935 . . . . 0.0 109.945 -179.878 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.482 ' O ' ' O ' ' A' ' 56' ' ' ALA . 46.8 t -130.35 133.73 63.49 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 121.408 -0.808 . . . . 0.0 109.728 -179.845 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -104.15 134.27 47.68 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.295 -0.878 . . . . 0.0 109.402 179.677 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.706 HD12 ' CD1' ' A' ' 45' ' ' ILE . 40.2 mt -96.23 141.82 29.13 Favored 'General case' 0 C--N 1.304 -1.387 0 O-C-N 121.217 -0.927 . . . . 0.0 109.521 -179.759 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -109.58 156.33 39.82 Favored Pre-proline 0 C--N 1.305 -1.343 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 179.684 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 1.4 Cg_endo -48.92 -22.23 4.62 Favored 'Trans proline' 0 C--N 1.305 -1.729 0 C-N-CA 121.924 1.75 . . . . 0.0 110.837 179.604 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 87.1 tt0 -71.13 -30.14 66.12 Favored 'General case' 0 N--CA 1.486 1.351 0 O-C-N 121.563 -0.711 . . . . 0.0 109.477 179.094 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . 0.54 ' C ' ' CD2' ' A' ' 65' ' ' HIS . 1.2 t60 -65.84 -16.49 63.87 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.397 -0.814 . . . . 0.0 108.97 -179.794 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.558 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 12.5 m-85 -97.53 15.38 23.45 Favored 'General case' 0 C--N 1.299 -1.598 0 CA-C-O 121.739 0.78 . . . . 0.0 108.896 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . 0.598 ' NE ' ' OG ' ' A' ' 71' ' ' SER . 6.6 ptt180 -50.71 -36.13 34.72 Favored 'General case' 0 C--N 1.301 -1.5 0 O-C-N 121.701 -0.624 . . . . 0.0 110.002 -179.719 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . 0.462 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 88.8 p -162.86 153.35 16.56 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.982 -1.074 . . . . 0.0 110.216 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.67 ' H ' HD12 ' A' ' 69' ' ' ILE . 3.5 mp -58.42 -43.4 86.51 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 O-C-N 121.34 -0.85 . . . . 0.0 109.046 179.68 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 10.0 ptm180 -58.17 -40.11 80.62 Favored 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 108.96 -0.756 . . . . 0.0 108.96 179.5 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . 0.598 ' OG ' ' NE ' ' A' ' 67' ' ' ARG . 25.9 t -63.46 -41.14 98.62 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.434 -0.792 . . . . 0.0 109.827 179.542 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 81.8 mt -58.91 -48.7 85.57 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.315 0 O-C-N 121.239 -0.913 . . . . 0.0 109.603 -179.615 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 37.4 t0 -60.07 -43.76 95.21 Favored 'General case' 0 N--CA 1.487 1.406 0 O-C-N 121.22 -0.925 . . . . 0.0 108.728 179.756 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.99 -38.77 86.63 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.658 -0.651 . . . . 0.0 109.932 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . 0.577 ' O ' ' HB2' ' A' ' 79' ' ' ALA . 53.5 t80 -62.76 -47.99 81.13 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.177 -0.952 . . . . 0.0 109.473 -179.698 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.697 HG21 HD11 ' A' ' 48' ' ' LEU . 50.0 t -64.99 -48.33 84.49 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.294 0 O-C-N 121.255 -0.903 . . . . 0.0 109.774 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.625 ' O ' HG22 ' A' ' 81' ' ' THR . 88.7 t -69.88 -49.06 60.0 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 O-C-N 121.2 -0.937 . . . . 0.0 109.356 179.705 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.493 ' O ' ' O ' ' A' ' 81' ' ' THR . . . -65.6 -26.58 72.01 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 -179.778 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . 0.577 ' HB2' ' O ' ' A' ' 75' ' ' PHE . . . -67.12 -39.39 86.65 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.145 -1.209 . . . . 0.0 110.019 -179.31 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 56.6 p -82.19 -28.7 31.89 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.197 -0.939 . . . . 0.0 109.585 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.625 HG22 ' O ' ' A' ' 77' ' ' VAL . 2.0 t . . . . . 0 N--CA 1.489 1.522 0 O-C-N 121.389 -0.819 . . . . 0.0 109.65 -179.857 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 13.4 m-70 . . . . . 0 N--CA 1.495 1.786 0 CA-C-O 121.108 0.48 . . . . 0.0 110.225 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -62.74 -41.36 99.15 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.078 -1.014 . . . . 0.0 109.509 179.77 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.3 p -62.75 -34.57 77.47 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.204 -0.935 . . . . 0.0 109.685 -179.731 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 65.3 t -64.62 -41.66 92.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.228 -0.92 . . . . 0.0 109.183 179.75 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 77.7 mt -59.67 -44.61 93.91 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 O-C-N 121.481 -0.762 . . . . 0.0 109.238 179.875 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -62.12 -38.33 88.53 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.333 -0.854 . . . . 0.0 109.235 179.875 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 7.2 tt0 -59.09 -41.14 87.36 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.273 -0.892 . . . . 0.0 109.185 179.72 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.699 ' CG ' ' CE2' ' A' ' 47' ' ' TRP . 23.0 m-85 -63.32 -40.74 98.16 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.012 -1.055 . . . . 0.0 109.955 179.586 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 55.9 t -59.53 -50.63 79.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.276 -0.89 . . . . 0.0 110.726 -178.558 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.472 ' O ' ' C ' ' A' ' 16' ' ' LEU . 17.1 m -66.12 -39.6 84.86 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.428 0 O-C-N 120.656 -1.277 . . . . 0.0 109.813 -179.955 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -67.21 -20.54 65.71 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.136 -0.977 . . . . 0.0 110.39 -179.785 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 -63.34 -30.11 71.3 Favored 'General case' 0 C--N 1.299 -1.606 0 O-C-N 121.275 -0.891 . . . . 0.0 109.731 -179.309 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 63.6 t80 -149.27 -33.23 0.21 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.997 -1.064 . . . . 0.0 110.253 -179.917 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.472 ' C ' ' O ' ' A' ' 12' ' ' VAL . 3.8 mt -121.89 79.93 41.47 Favored Pre-proline 0 N--CA 1.492 1.671 0 O-C-N 121.189 -0.945 . . . . 0.0 110.126 -179.383 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -74.62 -11.98 22.3 Favored 'Trans proline' 0 C--N 1.308 -1.573 0 C-N-CA 122.403 2.068 . . . . 0.0 112.438 179.881 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -93.9 12.83 24.61 Favored 'General case' 0 N--CA 1.487 1.377 0 O-C-N 121.246 -0.909 . . . . 0.0 110.371 -179.413 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 60.5 t -111.15 134.71 52.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 121.238 -0.914 . . . . 0.0 109.831 -179.784 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.49 ' O ' ' OD1' ' A' ' 23' ' ' ASP . . . -75.96 118.43 71.09 Favored Pre-proline 0 N--CA 1.489 1.515 0 O-C-N 121.338 -0.851 . . . . 0.0 109.326 179.912 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_exo -51.41 -25.63 19.15 Favored 'Trans proline' 0 N--CA 1.493 1.486 0 C-N-CA 121.77 1.647 . . . . 0.0 112.146 179.611 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.81 -25.61 67.98 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.261 -0.9 . . . . 0.0 109.732 -179.896 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.49 ' OD1' ' O ' ' A' ' 20' ' ' ALA . 49.8 p30 -85.81 7.46 23.76 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.195 -0.941 . . . . 0.0 109.925 -179.611 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . 0.47 HG23 ' OD1' ' A' ' 23' ' ' ASP . 17.3 t -109.7 133.32 55.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.321 -0.862 . . . . 0.0 109.397 179.844 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 63.4 t0 -88.47 119.66 29.12 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.141 -0.974 . . . . 0.0 108.892 179.348 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.6 m -75.89 3.81 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 O-C-N 121.182 -0.949 . . . . 0.0 109.285 179.851 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -87.55 -11.38 48.93 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.333 -0.854 . . . . 0.0 108.966 179.424 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 36.4 tp -94.98 136.91 34.73 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 179.778 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -59.51 134.16 56.76 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.114 -0.991 . . . . 0.0 109.409 -179.493 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.727 HD23 ' O ' ' A' ' 30' ' ' LEU . 2.3 tt -67.15 -37.81 84.41 Favored 'General case' 0 C--N 1.299 -1.6 0 O-C-N 121.732 -0.605 . . . . 0.0 110.154 -179.18 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.535 HG23 ' O ' ' A' ' 66' ' ' PHE . 78.2 t -63.79 -34.96 71.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.05 -1.031 . . . . 0.0 110.396 -178.994 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 56.9 t0 -52.36 -33.66 44.08 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 120.984 -1.073 . . . . 0.0 108.11 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.409 ' HB3' HG23 ' A' ' 35' ' ' VAL . 21.8 m120 -71.16 -34.48 71.01 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.55 -0.719 . . . . 0.0 109.897 179.433 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 86.37 6.52 80.95 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.056 -1.617 . . . . 0.0 109.056 -179.374 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.409 HG23 ' HB3' ' A' ' 33' ' ' ASN . 79.6 t -61.66 -34.3 61.41 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 O-C-N 121.455 -1.026 . . . . 0.0 109.152 179.719 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.662 HD11 HD13 ' A' ' 30' ' ' LEU . 85.4 mt -86.07 117.84 31.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.324 -0.86 . . . . 0.0 109.656 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -114.01 -164.59 0.94 Allowed 'General case' 0 C--N 1.302 -1.463 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 179.845 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -64.74 -54.21 34.94 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.109 -0.994 . . . . 0.0 108.682 179.704 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 38.5 mt -68.71 -32.81 72.86 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 107.105 -1.443 . . . . 0.0 107.105 178.264 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.547 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.15 -40.7 96.04 Favored Glycine 0 N--CA 1.48 1.592 0 N-CA-C 108.403 -1.879 . . . . 0.0 108.403 179.16 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.597 ' CD1' ' CZ ' ' A' ' 66' ' ' PHE . 7.3 tt -65.47 -41.67 93.07 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.479 -1.012 . . . . 0.0 108.888 178.978 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 tp -59.71 -45.74 91.22 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 179.443 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 25.2 mttp -60.51 -35.44 75.96 Favored 'General case' 0 C--N 1.297 -1.698 0 O-C-N 121.577 -0.702 . . . . 0.0 109.553 -179.881 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.547 HG23 ' O ' ' A' ' 40' ' ' GLY . 72.5 t -60.11 -43.3 92.59 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 O-C-N 121.296 -0.877 . . . . 0.0 109.445 -179.916 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.484 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 6.4 mm -67.45 -40.03 83.74 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.559 0 O-C-N 121.476 -0.765 . . . . 0.0 111.144 -179.088 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.48 -49.09 67.78 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.038 -1.038 . . . . 0.0 112.162 -177.596 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.699 ' CE2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -78.77 -46.73 18.21 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.448 -1.407 . . . . 0.0 110.679 -178.55 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.741 HD13 ' C ' ' A' ' 48' ' ' LEU . 3.2 tm? -58.4 -43.54 88.6 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.005 -1.06 . . . . 0.0 109.921 -178.301 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.484 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 1.2 pp20? -69.76 -36.83 76.12 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 120.943 -1.098 . . . . 0.0 109.66 -179.911 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.2 t0 -62.82 -37.88 88.54 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.181 -0.949 . . . . 0.0 110.321 179.895 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 9.7 mmt180 -60.95 -38.47 85.97 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.322 -0.861 . . . . 0.0 111.724 -178.81 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.74 ' CZ ' HG11 ' A' ' 76' ' ' VAL . 84.5 m-85 -96.82 -6.89 34.97 Favored 'General case' 0 C--N 1.304 -1.392 0 O-C-N 120.817 -1.177 . . . . 0.0 110.239 -178.947 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 70.92 30.81 67.58 Favored Glycine 0 N--CA 1.486 1.971 0 N-CA-C 108.72 -1.752 . . . . 0.0 108.72 179.653 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.47 ' O ' ' OE1' ' A' ' 49' ' ' GLU . 24.7 pt -108.59 153.07 10.35 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 O-C-N 121.587 -0.949 . . . . 0.0 109.765 -179.408 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -104.14 156.28 18.01 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.383 -0.823 . . . . 0.0 109.554 -179.78 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -58.22 -25.54 61.78 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.234 -0.916 . . . . 0.0 109.151 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . 0.402 ' O ' HG23 ' A' ' 59' ' ' VAL . 61.2 t0 59.07 39.62 23.05 Favored 'General case' 0 N--CA 1.485 1.286 0 O-C-N 121.517 -0.739 . . . . 0.0 109.075 -179.761 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 54.38 44.87 28.27 Favored 'General case' 0 N--CA 1.487 1.379 0 O-C-N 121.706 -0.621 . . . . 0.0 110.202 179.367 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.402 HG23 ' O ' ' A' ' 57' ' ' ASP . 52.6 t -121.33 134.46 64.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.446 -0.784 . . . . 0.0 109.137 179.382 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -102.29 132.44 48.24 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.19 -0.944 . . . . 0.0 109.599 -179.914 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 53.1 mt -95.24 147.3 23.62 Favored 'General case' 0 C--N 1.304 -1.394 0 O-C-N 121.347 -0.846 . . . . 0.0 109.293 179.792 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -104.4 157.67 33.59 Favored Pre-proline 0 N--CA 1.486 1.349 0 O-C-N 121.282 -0.886 . . . . 0.0 108.92 179.872 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 2.1 Cg_endo -49.4 -19.65 3.19 Favored 'Trans proline' 0 C--N 1.302 -1.869 0 C-N-CA 122.398 2.065 . . . . 0.0 110.985 -179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 87.4 tt0 -68.54 -32.32 72.18 Favored 'General case' 0 N--CA 1.486 1.375 0 O-C-N 121.606 -0.683 . . . . 0.0 109.56 179.404 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . 0.553 ' C ' ' CD2' ' A' ' 65' ' ' HIS . 1.5 t60 -66.33 -17.89 65.03 Favored 'General case' 0 C--N 1.3 -1.558 0 O-C-N 121.384 -0.823 . . . . 0.0 108.829 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.602 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 4.2 m-85 -101.97 14.99 30.39 Favored 'General case' 0 C--N 1.298 -1.642 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . 0.422 ' NE ' ' OG ' ' A' ' 71' ' ' SER . 4.8 ptt180 -46.17 -38.31 8.11 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.875 -0.516 . . . . 0.0 109.985 -179.684 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . 0.55 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 83.8 p -163.86 159.5 21.14 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.081 -1.012 . . . . 0.0 109.905 179.578 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.683 HG13 HD12 ' A' ' 30' ' ' LEU . 3.4 mp -57.83 -35.35 51.08 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 179.087 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 57.9 mtp180 -57.85 -42.35 84.25 Favored 'General case' 0 C--N 1.304 -1.397 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 179.644 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . 0.422 ' OG ' ' NE ' ' A' ' 67' ' ' ARG . 8.8 t -65.18 -38.81 91.69 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.652 -0.655 . . . . 0.0 109.987 -179.935 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.454 HD12 ' HA ' ' A' ' 69' ' ' ILE . 71.5 mt -58.93 -51.45 72.29 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 O-C-N 121.189 -0.944 . . . . 0.0 109.713 -179.286 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.447 ' O ' HG23 ' A' ' 77' ' ' VAL . 43.1 t0 -62.1 -41.07 97.83 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.15 -0.969 . . . . 0.0 108.67 179.446 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.33 -37.6 85.72 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.667 -0.646 . . . . 0.0 109.952 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 64.3 t80 -60.36 -49.23 78.41 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.225 -0.922 . . . . 0.0 109.808 -179.626 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.74 HG11 ' CZ ' ' A' ' 52' ' ' PHE . 93.7 t -66.45 -46.84 85.61 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 O-C-N 121.201 -0.937 . . . . 0.0 109.626 -179.89 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.491 ' O ' ' O ' ' A' ' 81' ' ' THR . 74.9 t -66.41 -40.51 86.78 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 O-C-N 121.261 -0.9 . . . . 0.0 109.229 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.05 -37.52 92.89 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 -179.72 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -73.25 -41.86 63.2 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.217 -1.166 . . . . 0.0 111.105 -178.929 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 43.6 p -83.36 -36.7 24.14 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.962 -1.086 . . . . 0.0 109.425 -179.598 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.491 ' O ' ' O ' ' A' ' 77' ' ' VAL . 0.6 OUTLIER . . . . . 0 C--N 1.299 -1.593 0 O-C-N 121.541 -0.724 . . . . 0.0 109.081 -179.762 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 81.3 m-70 . . . . . 0 N--CA 1.492 1.638 0 CA-C-O 121.116 0.484 . . . . 0.0 110.018 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -60.72 -34.44 74.41 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.127 -0.983 . . . . 0.0 109.522 179.805 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.8 t -58.69 -38.61 78.62 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.295 -0.878 . . . . 0.0 109.876 -179.602 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 78.9 t -64.06 -46.28 94.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.143 -0.973 . . . . 0.0 109.353 179.936 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.714 HD13 ' OD1' ' A' ' 73' ' ' ASP . 77.5 mt -61.27 -46.25 96.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 179.491 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.765 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -62.22 -35.36 78.66 Favored 'General case' 0 C--N 1.303 -1.419 0 O-C-N 121.619 -0.675 . . . . 0.0 109.29 179.734 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 31.4 tt0 -62.11 -41.76 98.54 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.19 -0.944 . . . . 0.0 110.419 -179.611 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.672 ' CG ' ' CE2' ' A' ' 47' ' ' TRP . 49.6 m-85 -68.13 -50.75 52.64 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 120.896 -1.127 . . . . 0.0 111.065 -179.268 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.449 HG11 HD11 ' A' ' 30' ' ' LEU . 36.0 m -66.01 -38.95 83.21 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 O-C-N 120.972 -1.08 . . . . 0.0 109.247 -179.315 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.765 HG23 ' O ' ' A' ' 8' ' ' ALA . 89.2 t -63.68 -46.27 95.16 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 O-C-N 121.261 -0.899 . . . . 0.0 109.204 179.479 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -75.09 -16.92 60.54 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.14 -0.975 . . . . 0.0 110.076 179.824 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -63.81 -33.67 76.19 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.285 -0.884 . . . . 0.0 110.439 -178.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 67.2 t80 -154.08 -19.16 0.13 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.86 -1.15 . . . . 0.0 110.471 -179.634 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.469 HD22 HG21 ' A' ' 19' ' ' VAL . 5.6 mt -121.57 80.05 38.86 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.198 -0.939 . . . . 0.0 109.835 -179.497 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -79.73 -17.41 11.07 Favored 'Trans proline' 0 C--N 1.307 -1.656 0 C-N-CA 122.665 2.244 . . . . 0.0 112.628 -179.877 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . 0.555 ' OD1' HG23 ' A' ' 19' ' ' VAL . 51.8 p30 -90.09 9.99 26.04 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.166 -0.959 . . . . 0.0 110.172 -179.575 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.555 HG23 ' OD1' ' A' ' 18' ' ' ASP . 67.5 t -111.25 135.98 48.74 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.207 -0.933 . . . . 0.0 109.532 179.754 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -78.27 117.39 65.86 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.312 -0.867 . . . . 0.0 109.443 -179.908 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_exo -51.95 -35.83 61.96 Favored 'Trans proline' 0 N--CA 1.491 1.368 0 C-N-CA 121.709 1.606 . . . . 0.0 111.817 179.326 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.84 -23.73 66.73 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.3 -0.875 . . . . 0.0 108.925 179.529 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -84.71 7.46 20.41 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.418 -0.801 . . . . 0.0 109.743 -179.795 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 13.0 t -101.63 132.51 47.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.145 -0.972 . . . . 0.0 109.264 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 63.8 t0 -89.01 119.39 29.49 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.151 -0.968 . . . . 0.0 109.223 179.587 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . 0.448 ' O ' HG13 ' A' ' 26' ' ' VAL . 0.3 OUTLIER -69.33 4.25 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 O-C-N 121.204 -0.935 . . . . 0.0 109.452 179.782 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -95.02 -2.77 49.62 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.251 -0.905 . . . . 0.0 109.239 179.66 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 39.8 tp -99.56 136.42 39.52 Favored 'General case' 0 C--N 1.303 -1.441 0 O-C-N 121.394 -0.816 . . . . 0.0 108.92 179.714 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -58.62 137.12 57.7 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.105 -0.997 . . . . 0.0 109.196 -179.502 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.713 HD13 HD11 ' A' ' 36' ' ' ILE . 1.8 tt -68.35 -36.73 79.68 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.635 -0.665 . . . . 0.0 110.36 -178.981 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 69.6 t -64.75 -35.51 75.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.101 -0.999 . . . . 0.0 110.557 -179.004 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -52.54 -33.61 46.34 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 120.996 -1.065 . . . . 0.0 108.178 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.445 ' HB3' HG23 ' A' ' 35' ' ' VAL . 3.2 m120 -70.98 -34.52 71.47 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.604 -0.685 . . . . 0.0 109.982 179.485 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 85.96 6.05 82.72 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 108.88 -1.688 . . . . 0.0 108.88 -179.24 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.445 HG23 ' HB3' ' A' ' 33' ' ' ASN . 78.5 t -61.1 -31.21 49.43 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.398 0 O-C-N 121.495 -1.003 . . . . 0.0 108.68 179.512 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.713 HD11 HD13 ' A' ' 30' ' ' LEU . 81.5 mt -93.99 132.3 38.48 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 O-C-N 121.438 -0.789 . . . . 0.0 109.677 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.53 ' CG ' ' H ' ' A' ' 38' ' ' ALA . 52.4 t0 -138.97 -167.69 2.27 Favored 'General case' 0 C--N 1.301 -1.528 0 N-CA-C 108.562 -0.903 . . . . 0.0 108.562 179.602 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.53 ' H ' ' CG ' ' A' ' 37' ' ' ASP . . . -62.6 -55.22 29.14 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.928 -1.107 . . . . 0.0 108.588 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 37.4 mt -71.47 -34.79 70.51 Favored 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 107.063 -1.458 . . . . 0.0 107.063 178.024 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.762 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.85 -39.85 95.98 Favored Glycine 0 N--CA 1.481 1.671 0 N-CA-C 108.703 -1.759 . . . . 0.0 108.703 179.169 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.794 ' C ' HD13 ' A' ' 41' ' ' LEU . 2.5 tm? -65.04 -43.89 90.87 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.49 -1.006 . . . . 0.0 108.622 179.386 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.2 tp -59.09 -46.03 89.33 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.343 -0.848 . . . . 0.0 109.066 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 63.2 mttp -61.49 -34.79 76.07 Favored 'General case' 0 C--N 1.295 -1.778 0 O-C-N 121.537 -0.727 . . . . 0.0 109.481 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.762 HG23 ' O ' ' A' ' 40' ' ' GLY . 91.6 t -62.56 -50.43 79.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.451 -0.781 . . . . 0.0 110.166 -179.347 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.7 mp -68.34 -29.85 45.65 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 O-C-N 121.314 -0.866 . . . . 0.0 110.566 -179.774 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.47 -49.2 67.44 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.108 -0.995 . . . . 0.0 111.657 -178.177 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.672 ' CE2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -81.08 -40.99 23.26 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 120.592 -1.317 . . . . 0.0 110.3 -179.015 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.543 ' O ' HD13 ' A' ' 48' ' ' LEU . 0.2 OUTLIER -61.23 -41.62 97.19 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.154 -0.966 . . . . 0.0 109.298 -179.357 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.419 ' CG ' ' N ' ' A' ' 50' ' ' ASP . 17.0 pt-20 -73.13 -36.07 66.63 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 120.638 -1.289 . . . . 0.0 109.165 179.907 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . 0.419 ' N ' ' CG ' ' A' ' 49' ' ' GLU . 59.0 t0 -65.6 -40.84 93.12 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.632 -0.667 . . . . 0.0 111.766 -179.072 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.433 HH21 HG11 ' A' ' 76' ' ' VAL . 24.3 ptt180 -71.39 -36.59 71.46 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 120.864 -1.148 . . . . 0.0 111.484 -177.712 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.414 ' CE1' ' CG1' ' A' ' 76' ' ' VAL . 5.7 m-85 -81.21 -14.74 57.21 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.577 -1.327 . . . . 0.0 109.756 -179.726 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.27 20.67 71.9 Favored Glycine 0 N--CA 1.486 2.025 0 N-CA-C 108.693 -1.763 . . . . 0.0 108.693 -179.745 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 23.1 pt -113.19 153.65 14.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.737 -0.86 . . . . 0.0 109.695 -179.573 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -101.03 132.29 46.53 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.249 -0.907 . . . . 0.0 109.519 -179.789 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.503 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -69.0 -23.55 64.12 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.316 -0.865 . . . . 0.0 109.692 179.859 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 91.3 m-20 -54.98 -36.08 65.01 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.268 -0.895 . . . . 0.0 110.146 -179.487 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -56.13 -39.36 72.12 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.18 -0.95 . . . . 0.0 110.001 -179.547 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.503 ' O ' ' O ' ' A' ' 56' ' ' ALA . 41.7 t -126.86 136.68 60.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.337 -0.852 . . . . 0.0 109.666 -179.894 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -87.58 127.23 35.27 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.117 -0.989 . . . . 0.0 109.185 179.864 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 39.4 mt -104.53 142.05 35.31 Favored 'General case' 0 C--N 1.306 -1.295 0 O-C-N 121.279 -0.888 . . . . 0.0 109.831 -179.649 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -108.75 152.54 42.31 Favored Pre-proline 0 N--CA 1.485 1.316 0 N-CA-C 108.696 -0.854 . . . . 0.0 108.696 179.377 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 12.8 Cg_endo -58.44 -21.16 52.44 Favored 'Trans proline' 0 C--N 1.304 -1.768 0 C-N-CA 122.505 2.137 . . . . 0.0 112.196 -179.748 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -69.6 -30.1 67.77 Favored 'General case' 0 N--CA 1.486 1.335 0 O-C-N 121.272 -0.892 . . . . 0.0 109.731 -179.726 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . 0.457 ' CE1' ' HB2' ' A' ' 75' ' ' PHE . 76.3 t60 -66.16 -20.66 66.21 Favored 'General case' 0 C--N 1.299 -1.588 0 O-C-N 121.233 -0.917 . . . . 0.0 108.918 -179.874 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.496 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 21.8 m-85 -89.17 12.73 15.0 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.394 -0.816 . . . . 0.0 109.203 -179.68 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . 0.402 ' HG2' ' N ' ' A' ' 68' ' ' SER . 4.2 ptt85 -49.88 -34.56 20.58 Favored 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.628 -0.67 . . . . 0.0 109.513 179.719 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . 0.518 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 89.2 p -151.65 153.54 34.62 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.154 -0.966 . . . . 0.0 109.895 179.794 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.644 ' H ' HD12 ' A' ' 69' ' ' ILE . 3.5 mp -59.83 -34.81 57.11 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.485 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 179.3 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 30.2 mtp85 -57.11 -45.18 83.66 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.604 -0.685 . . . . 0.0 109.765 -179.272 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . 0.424 ' HG ' ' CE1' ' A' ' 65' ' ' HIS . 22.9 t -64.9 -46.07 83.25 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.307 -0.871 . . . . 0.0 109.781 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.431 ' HA ' ' NE2' ' A' ' 65' ' ' HIS . 68.0 mt -58.95 -42.89 87.38 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 O-C-N 121.176 -0.952 . . . . 0.0 109.913 -179.735 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.714 ' OD1' HD13 ' A' ' 7' ' ' ILE . 2.0 m-20 -61.14 -37.95 84.66 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.292 -0.88 . . . . 0.0 109.842 -179.584 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -67.4 -46.91 71.85 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.035 -1.041 . . . . 0.0 110.541 -179.304 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . 0.457 ' HB2' ' CE1' ' A' ' 65' ' ' HIS . 65.8 t80 -66.03 -44.08 85.71 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.135 -0.978 . . . . 0.0 109.57 -179.737 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.433 HG11 HH21 ' A' ' 51' ' ' ARG . 43.4 t -60.68 -41.83 89.68 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 O-C-N 121.301 -0.874 . . . . 0.0 108.81 179.334 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.661 HG23 ' O ' ' A' ' 73' ' ' ASP . 65.3 t -65.0 -40.52 89.34 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.256 0 O-C-N 121.306 -0.871 . . . . 0.0 109.042 179.338 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.53 -17.23 32.47 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.753 -1.339 . . . . 0.0 109.753 179.794 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -66.71 -34.82 78.68 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.288 -1.125 . . . . 0.0 110.573 -179.176 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 49.7 p -134.49 -20.5 1.82 Allowed 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.009 -1.057 . . . . 0.0 110.709 -179.381 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.499 ' O ' ' O ' ' A' ' 77' ' ' VAL . 0.1 OUTLIER . . . . . 0 N--CA 1.49 1.528 0 O-C-N 121.144 -0.973 . . . . 0.0 109.39 -179.919 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 97.2 m-70 . . . . . 0 N--CA 1.486 1.348 0 N-CA-C 108.034 -1.099 . . . . 0.0 108.034 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.585 ' N ' ' OD2' ' A' ' 73' ' ' ASP . . . -52.94 -41.04 64.1 Favored 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.518 -0.739 . . . . 0.0 109.861 -179.078 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 21.3 m -61.11 -39.28 89.4 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.178 -0.951 . . . . 0.0 109.602 179.975 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 54.6 t -61.61 -43.88 97.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.331 -0.855 . . . . 0.0 109.483 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 82.5 mt -59.78 -40.27 82.08 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.45 0 O-C-N 121.363 -0.835 . . . . 0.0 109.076 179.697 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.401 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -60.92 -36.25 78.8 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 179.897 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 26.5 mt-30 -65.8 -39.16 90.64 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.296 -0.878 . . . . 0.0 109.967 179.757 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.66 ' CG ' ' CZ2' ' A' ' 47' ' ' TRP . 28.5 m-85 -64.2 -50.44 68.08 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.167 -0.958 . . . . 0.0 111.057 -179.28 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.439 HG13 ' N ' ' A' ' 12' ' ' VAL . 2.9 p -59.89 -42.74 90.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.016 -1.053 . . . . 0.0 109.579 -179.19 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.464 ' O ' ' C ' ' A' ' 16' ' ' LEU . 86.9 t -63.46 -47.3 92.32 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 O-C-N 121.115 -0.99 . . . . 0.0 109.396 179.833 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -71.53 -24.12 61.9 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.172 -0.955 . . . . 0.0 109.96 179.825 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -64.19 -32.07 73.51 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.363 -0.836 . . . . 0.0 110.893 -178.763 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 63.1 t80 -140.83 -35.12 0.49 Allowed 'General case' 0 N--CA 1.494 1.758 0 O-C-N 120.849 -1.157 . . . . 0.0 110.742 -179.254 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.464 ' C ' ' O ' ' A' ' 12' ' ' VAL . 5.2 mt -119.17 80.04 19.4 Favored Pre-proline 0 N--CA 1.493 1.693 0 O-C-N 121.167 -0.958 . . . . 0.0 109.939 -179.397 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_endo -77.86 -15.3 15.08 Favored 'Trans proline' 0 C--N 1.308 -1.603 0 C-N-CA 122.546 2.164 . . . . 0.0 112.198 179.755 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -88.43 5.32 42.88 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 121.32 -0.862 . . . . 0.0 109.788 -179.729 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.45 ' CG2' HD22 ' A' ' 16' ' ' LEU . 46.3 t -110.64 134.92 51.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.387 -0.821 . . . . 0.0 109.564 -179.88 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.46 118.63 69.34 Favored Pre-proline 0 N--CA 1.489 1.503 0 O-C-N 121.279 -0.888 . . . . 0.0 109.24 179.902 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.461 ' HA ' HG21 ' A' ' 12' ' ' VAL . 40.4 Cg_exo -51.3 -28.62 27.25 Favored 'Trans proline' 0 N--CA 1.492 1.397 0 C-N-CA 121.728 1.619 . . . . 0.0 111.866 179.659 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.42 -23.31 66.91 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.198 -0.939 . . . . 0.0 109.286 179.688 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.45 ' O ' ' OD1' ' A' ' 23' ' ' ASP . 60.2 t0 -81.65 4.03 23.18 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.326 -0.859 . . . . 0.0 109.762 -179.762 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 13.5 t -108.75 133.32 54.19 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.245 -0.909 . . . . 0.0 109.351 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 86.9 m-20 -88.29 120.53 29.74 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.084 -1.01 . . . . 0.0 108.964 179.379 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 32.8 m -75.68 4.42 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 O-C-N 121.237 -0.915 . . . . 0.0 109.178 179.601 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -93.17 -2.75 54.98 Favored 'General case' 0 C--N 1.306 -1.318 0 O-C-N 121.316 -0.865 . . . . 0.0 108.941 179.518 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 39.8 tp -97.13 138.32 34.83 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.494 -0.754 . . . . 0.0 109.016 179.819 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 87.3 m-20 -60.09 138.5 57.87 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.154 -0.966 . . . . 0.0 109.531 -179.407 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.715 HD12 HG13 ' A' ' 69' ' ' ILE . 1.3 tt -75.62 -36.74 60.17 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.716 -0.615 . . . . 0.0 110.454 -179.203 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.614 HG13 ' O ' ' A' ' 66' ' ' PHE . 12.9 m -64.1 -38.4 82.36 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.659 0 O-C-N 121.111 -0.993 . . . . 0.0 110.583 -178.903 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -54.5 -33.45 59.87 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.142 -0.974 . . . . 0.0 108.375 179.67 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 96.1 m-20 -70.5 -34.56 72.47 Favored 'General case' 0 C--N 1.303 -1.445 0 O-C-N 121.656 -0.653 . . . . 0.0 110.0 179.875 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 82.37 5.86 89.2 Favored Glycine 0 N--CA 1.493 2.479 0 N-CA-C 109.516 -1.433 . . . . 0.0 109.516 -179.904 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 78.3 t -61.35 -34.36 60.69 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 O-C-N 121.276 -1.132 . . . . 0.0 108.697 179.501 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.705 HD11 HD13 ' A' ' 30' ' ' LEU . 96.7 mt -77.34 112.17 14.98 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 121.454 -0.779 . . . . 0.0 109.954 179.91 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -111.33 -164.53 0.92 Allowed 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 179.595 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -66.71 -54.25 25.01 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.125 -0.984 . . . . 0.0 108.874 179.694 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.692 HD12 ' N ' ' A' ' 39' ' ' LEU . 6.9 mp -69.77 -32.89 71.64 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 107.397 -1.334 . . . . 0.0 107.397 178.432 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.607 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.41 -43.0 97.76 Favored Glycine 0 N--CA 1.482 1.704 0 N-CA-C 109.053 -1.619 . . . . 0.0 109.053 179.509 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.442 HD11 ' CZ ' ' A' ' 66' ' ' PHE . 7.5 tt -65.13 -42.73 93.59 Favored 'General case' 0 C--N 1.303 -1.415 0 O-C-N 121.413 -1.051 . . . . 0.0 109.327 179.449 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 tp -60.06 -46.25 90.18 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.375 -0.828 . . . . 0.0 109.274 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 12.7 mttm -62.39 -34.44 76.73 Favored 'General case' 0 C--N 1.297 -1.7 0 O-C-N 121.44 -0.787 . . . . 0.0 109.789 -179.694 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.607 HG23 ' O ' ' A' ' 40' ' ' GLY . 53.8 t -61.47 -50.42 80.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.291 -0.881 . . . . 0.0 110.322 -179.215 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.537 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 3.5 mp -68.36 -33.73 62.0 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 121.331 -0.856 . . . . 0.0 111.011 -179.67 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.42 -49.77 67.96 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.013 -1.054 . . . . 0.0 111.655 -178.007 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.66 ' CZ2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -81.2 -43.78 18.79 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.75 -1.219 . . . . 0.0 109.905 -179.3 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.582 HD21 ' CG2' ' A' ' 76' ' ' VAL . 31.4 tp -58.82 -42.35 88.98 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.215 -0.928 . . . . 0.0 109.95 -179.267 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.537 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 1.1 pp20? -72.53 -36.02 68.2 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.082 -1.011 . . . . 0.0 109.749 -179.959 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.5 t0 -60.43 -38.51 84.35 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.251 -0.905 . . . . 0.0 110.608 -179.653 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.464 ' HD2' ' HE1' ' A' ' 47' ' ' TRP . 77.7 mtp85 -61.81 -37.83 85.87 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.167 -0.958 . . . . 0.0 111.602 -178.668 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.799 ' CE2' HG11 ' A' ' 76' ' ' VAL . 88.0 m-85 -95.86 -8.5 33.95 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 120.67 -1.269 . . . . 0.0 110.339 -178.97 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 71.98 30.37 65.69 Favored Glycine 0 N--CA 1.486 2.021 0 N-CA-C 108.872 -1.691 . . . . 0.0 108.872 179.682 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.501 ' O ' ' OE1' ' A' ' 49' ' ' GLU . 26.0 pt -107.55 151.13 9.66 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.402 0 O-C-N 121.654 -0.909 . . . . 0.0 109.653 -179.502 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . 0.475 ' O ' ' OD1' ' A' ' 58' ' ' ASP . . . -101.76 132.48 47.47 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.233 -0.917 . . . . 0.0 109.645 -179.661 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.5 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -67.0 -26.88 67.02 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.335 -0.853 . . . . 0.0 109.396 179.751 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 52.3 t0 -54.87 -34.79 63.36 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.317 -0.864 . . . . 0.0 110.042 -179.571 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.632 ' OD1' ' N ' ' A' ' 59' ' ' VAL . 55.3 p30 -59.47 -34.53 72.66 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.196 -0.94 . . . . 0.0 110.301 -179.459 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.632 ' N ' ' OD1' ' A' ' 58' ' ' ASP . 14.5 p -136.86 140.96 41.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.025 -1.047 . . . . 0.0 109.585 179.92 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -85.3 139.35 31.67 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.053 -1.03 . . . . 0.0 109.299 179.818 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 5.1 mp -97.72 136.9 37.41 Favored 'General case' 0 C--N 1.305 -1.345 0 O-C-N 121.198 -0.939 . . . . 0.0 109.712 -179.835 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -110.0 155.35 41.83 Favored Pre-proline 0 N--CA 1.488 1.457 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 179.489 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 7.8 Cg_endo -53.2 -23.55 23.29 Favored 'Trans proline' 0 C--N 1.302 -1.904 0 C-N-CA 122.286 1.991 . . . . 0.0 111.685 -179.898 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -70.69 -26.54 63.47 Favored 'General case' 0 N--CA 1.486 1.336 0 O-C-N 121.344 -0.847 . . . . 0.0 109.507 179.655 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . 0.546 ' C ' ' CD2' ' A' ' 65' ' ' HIS . 1.9 t60 -65.62 -20.41 66.3 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.23 -0.919 . . . . 0.0 109.215 -179.703 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.614 ' O ' HG13 ' A' ' 31' ' ' VAL . 6.7 m-85 -98.2 16.24 21.95 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 121.447 -0.783 . . . . 0.0 108.965 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . 0.588 ' NE ' ' OG ' ' A' ' 71' ' ' SER . 4.8 ptt180 -52.16 -36.34 51.27 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 121.754 -0.591 . . . . 0.0 110.08 -179.775 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . 0.525 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 35.2 p -164.9 153.31 12.12 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.016 -1.053 . . . . 0.0 110.281 -179.702 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.715 HG13 HD12 ' A' ' 30' ' ' LEU . 3.3 mp -57.94 -40.68 77.57 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 O-C-N 121.362 -0.836 . . . . 0.0 109.161 179.904 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.401 ' CG ' ' N ' ' A' ' 71' ' ' SER . 18.9 ptt180 -58.16 -42.24 85.53 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.643 -0.66 . . . . 0.0 109.266 179.806 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . 0.588 ' OG ' ' NE ' ' A' ' 67' ' ' ARG . 26.5 t -64.92 -39.25 93.22 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.204 -0.935 . . . . 0.0 109.677 179.488 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.425 HD12 ' HA ' ' A' ' 69' ' ' ILE . 87.8 mt -58.92 -47.14 90.59 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.289 0 O-C-N 121.176 -0.953 . . . . 0.0 109.736 -179.73 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . 0.585 ' OD2' ' N ' ' A' ' 4' ' ' ALA . 26.5 t0 -58.91 -44.23 91.23 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.147 -0.971 . . . . 0.0 108.723 179.864 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . 0.535 ' O ' ' N ' ' A' ' 78' ' ' GLY . . . -66.96 -37.36 84.13 Favored 'General case' 0 C--N 1.304 -1.399 0 O-C-N 121.432 -0.792 . . . . 0.0 109.595 179.667 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 61.9 t80 -62.82 -48.83 77.37 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.19 -0.944 . . . . 0.0 109.644 -179.833 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.799 HG11 ' CE2' ' A' ' 52' ' ' PHE . 71.1 t -67.56 -48.8 75.51 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.282 0 O-C-N 121.201 -0.937 . . . . 0.0 109.782 -179.847 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.533 ' O ' HG22 ' A' ' 81' ' ' THR . 55.3 t -69.89 -43.77 79.33 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.274 0 O-C-N 121.106 -0.996 . . . . 0.0 109.034 179.38 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.535 ' N ' ' O ' ' A' ' 74' ' ' ALA . . . -59.38 -30.93 68.82 Favored Glycine 0 N--CA 1.488 2.127 0 N-CA-C 110.211 -1.155 . . . . 0.0 110.211 -179.606 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -68.63 -41.5 79.36 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.153 -1.204 . . . . 0.0 110.586 -178.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 47.1 p -79.74 -32.02 41.06 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.161 -0.962 . . . . 0.0 109.326 -179.83 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.533 HG22 ' O ' ' A' ' 77' ' ' VAL . 1.8 t . . . . . 0 N--CA 1.487 1.401 0 O-C-N 121.447 -0.783 . . . . 0.0 108.911 179.93 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 16.9 m-70 . . . . . 0 N--CA 1.494 1.757 0 CA-C-O 121.205 0.526 . . . . 0.0 109.82 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -59.74 -40.92 89.71 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.068 -1.02 . . . . 0.0 109.29 179.786 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.3 m -61.29 -39.17 89.44 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.256 -0.902 . . . . 0.0 109.65 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 58.8 t -61.13 -41.35 89.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.205 -0.935 . . . . 0.0 109.454 179.911 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 79.7 mt -59.69 -45.62 94.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 O-C-N 121.409 -0.807 . . . . 0.0 109.287 179.866 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -62.14 -42.78 99.58 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.291 -0.881 . . . . 0.0 109.109 179.723 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 26.8 mt-30 -64.7 -33.46 76.0 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.249 -0.907 . . . . 0.0 109.128 179.255 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.535 ' CG ' ' CZ2' ' A' ' 47' ' ' TRP . 0.2 OUTLIER -60.43 -50.27 74.24 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.4 -0.813 . . . . 0.0 110.235 -179.521 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 13.4 m -64.39 -39.59 86.08 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 O-C-N 121.142 -0.973 . . . . 0.0 109.33 -179.723 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.405 ' O ' ' C ' ' A' ' 16' ' ' LEU . 77.6 t -63.99 -45.29 97.18 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.166 -0.959 . . . . 0.0 109.678 179.654 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -69.4 -34.47 74.54 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.17 -0.956 . . . . 0.0 110.23 -179.842 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -65.35 -32.67 74.44 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.292 -0.88 . . . . 0.0 110.458 -179.253 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -118.47 -54.08 2.29 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.263 -0.898 . . . . 0.0 111.336 -178.713 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.575 HD22 ' CG2' ' A' ' 19' ' ' VAL . 9.0 mt -119.41 80.18 21.48 Favored Pre-proline 0 N--CA 1.493 1.688 0 O-C-N 121.19 -0.944 . . . . 0.0 111.054 -178.285 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -75.1 -16.41 20.0 Favored 'Trans proline' 0 C--N 1.309 -1.511 0 C-N-CA 122.274 1.982 . . . . 0.0 112.186 178.825 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -90.99 5.7 47.72 Favored 'General case' 0 N--CA 1.487 1.384 0 O-C-N 121.213 -0.929 . . . . 0.0 109.893 -179.844 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.575 ' CG2' HD22 ' A' ' 16' ' ' LEU . 44.5 t -112.84 138.37 42.42 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.456 -0.778 . . . . 0.0 109.492 -179.857 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.487 ' O ' ' OD1' ' A' ' 23' ' ' ASP . . . -70.37 117.27 53.25 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.275 -0.89 . . . . 0.0 109.469 -179.831 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -51.8 -26.21 23.26 Favored 'Trans proline' 0 N--CA 1.494 1.512 0 C-N-CA 122.017 1.812 . . . . 0.0 112.229 179.505 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.63 -23.66 67.33 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.281 -0.887 . . . . 0.0 109.815 -179.744 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.487 ' OD1' ' O ' ' A' ' 20' ' ' ALA . 51.5 p30 -85.64 7.63 22.58 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.192 -0.942 . . . . 0.0 110.007 -179.428 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 11.8 t -107.88 130.07 60.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.147 -0.97 . . . . 0.0 109.329 179.927 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 87.2 m-20 -89.73 120.33 30.9 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.18 -0.95 . . . . 0.0 109.097 179.28 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 6.3 m -78.1 4.42 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 O-C-N 121.129 -0.982 . . . . 0.0 108.941 179.457 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -88.73 -10.63 47.67 Favored 'General case' 0 N--CA 1.485 1.302 0 O-C-N 121.386 -0.821 . . . . 0.0 109.043 179.408 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 42.4 tp -94.24 140.57 29.61 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 109.076 -0.713 . . . . 0.0 109.076 179.844 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 83.3 m-20 -59.08 142.0 52.58 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.133 -0.979 . . . . 0.0 109.433 -179.361 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 1.078 HD23 HD11 ' A' ' 36' ' ' ILE . 27.8 tp -73.57 -37.74 65.41 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.421 -0.799 . . . . 0.0 110.343 -179.251 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.608 HG13 ' O ' ' A' ' 66' ' ' PHE . 33.1 m -66.73 -43.15 90.2 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 121.263 -0.898 . . . . 0.0 110.428 -179.005 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . 0.584 ' N ' HG23 ' A' ' 31' ' ' VAL . 92.1 m-20 -53.94 -33.37 56.6 Favored 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 179.747 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 97.1 m-20 -70.47 -34.12 72.04 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.619 -0.676 . . . . 0.0 109.995 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 87.47 7.2 76.31 Favored Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.183 -1.567 . . . . 0.0 109.183 -179.656 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 72.6 t -61.64 -26.93 41.04 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 O-C-N 121.469 -1.018 . . . . 0.0 108.78 179.575 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 1.078 HD11 HD23 ' A' ' 30' ' ' LEU . 67.6 mt -93.05 123.87 45.28 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.398 0 O-C-N 121.457 -0.777 . . . . 0.0 109.929 -179.458 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -115.79 -174.87 2.61 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 108.636 -0.876 . . . . 0.0 108.636 179.339 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -61.36 -53.45 56.43 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.056 -1.028 . . . . 0.0 108.432 179.594 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.693 HD12 ' N ' ' A' ' 39' ' ' LEU . 7.0 mp -70.39 -32.65 70.39 Favored 'General case' 0 C--N 1.301 -1.532 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 178.008 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.458 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.23 -43.65 97.04 Favored Glycine 0 N--CA 1.482 1.755 0 N-CA-C 109.01 -1.636 . . . . 0.0 109.01 179.574 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.3 tt -65.13 -42.05 94.22 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.463 -1.022 . . . . 0.0 109.163 179.32 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.5 tp -59.97 -46.12 90.47 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.294 -0.879 . . . . 0.0 109.405 179.871 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 86.6 mttt -61.44 -35.7 78.31 Favored 'General case' 0 C--N 1.297 -1.701 0 O-C-N 121.443 -0.786 . . . . 0.0 109.854 -179.678 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.458 HG23 ' O ' ' A' ' 40' ' ' GLY . 55.3 t -61.48 -50.75 79.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.287 -0.883 . . . . 0.0 110.36 -179.27 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.521 HG12 HD12 ' A' ' 61' ' ' LEU . 3.5 mp -68.72 -34.3 64.15 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 O-C-N 121.279 -0.888 . . . . 0.0 111.181 -179.636 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.56 -49.94 60.86 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 120.986 -1.071 . . . . 0.0 111.998 -177.913 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.535 ' CZ2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -80.18 -43.62 21.23 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.655 -1.278 . . . . 0.0 110.036 -179.045 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.558 HD11 HG21 ' A' ' 76' ' ' VAL . 21.7 tp -58.88 -41.63 87.56 Favored 'General case' 0 C--N 1.299 -1.606 0 O-C-N 121.294 -0.879 . . . . 0.0 110.197 -179.03 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.416 ' CG ' ' N ' ' A' ' 50' ' ' ASP . 17.3 pt-20 -73.18 -37.45 66.51 Favored 'General case' 0 C--N 1.305 -1.362 0 O-C-N 121.059 -1.026 . . . . 0.0 109.636 -179.708 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . 0.416 ' N ' ' CG ' ' A' ' 49' ' ' GLU . 56.9 t0 -58.86 -39.15 80.51 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.354 -0.841 . . . . 0.0 110.64 -179.447 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.443 ' HD2' ' HE1' ' A' ' 47' ' ' TRP . 73.4 mtp85 -61.64 -36.76 81.72 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.169 -0.957 . . . . 0.0 111.322 -178.86 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.613 ' CZ ' ' CG1' ' A' ' 76' ' ' VAL . 87.5 m-85 -94.77 -8.0 38.83 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 120.745 -1.222 . . . . 0.0 110.407 -179.129 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 73.15 29.29 64.77 Favored Glycine 0 N--CA 1.487 2.089 0 N-CA-C 108.95 -1.66 . . . . 0.0 108.95 179.712 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 20.5 pt -109.68 153.21 11.51 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 O-C-N 121.699 -0.883 . . . . 0.0 109.551 -179.587 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -103.92 134.99 46.28 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.238 -0.914 . . . . 0.0 109.7 -179.614 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.506 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -68.09 -28.39 67.31 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.334 -0.853 . . . . 0.0 109.63 179.732 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -56.36 -36.89 69.31 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.125 -0.984 . . . . 0.0 109.995 -179.625 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 21.4 t70 -56.53 -40.01 74.34 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.146 -0.971 . . . . 0.0 109.987 -179.538 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.506 ' O ' ' O ' ' A' ' 56' ' ' ALA . 42.6 t -128.67 136.21 60.44 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.311 -0.868 . . . . 0.0 109.726 -179.846 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -86.14 132.94 33.91 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.063 -1.023 . . . . 0.0 109.242 179.835 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.521 HD12 HG12 ' A' ' 45' ' ' ILE . 57.6 mt -96.12 140.81 30.3 Favored 'General case' 0 C--N 1.305 -1.336 0 O-C-N 121.219 -0.926 . . . . 0.0 109.742 -179.64 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -109.77 155.92 40.68 Favored Pre-proline 0 N--CA 1.487 1.418 0 N-CA-C 108.787 -0.82 . . . . 0.0 108.787 179.479 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 7.2 Cg_endo -52.59 -23.02 18.34 Favored 'Trans proline' 0 C--N 1.303 -1.831 0 C-N-CA 122.335 2.023 . . . . 0.0 111.926 -179.772 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -70.26 -26.95 64.06 Favored 'General case' 0 N--CA 1.486 1.37 0 O-C-N 121.339 -0.851 . . . . 0.0 109.472 179.592 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . 0.551 ' C ' ' CD2' ' A' ' 65' ' ' HIS . 1.5 t60 -65.65 -19.39 65.89 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.412 -0.805 . . . . 0.0 109.046 -179.883 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.608 ' O ' HG13 ' A' ' 31' ' ' VAL . 7.0 m-85 -100.14 16.35 24.44 Favored 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.521 -0.737 . . . . 0.0 109.174 -179.686 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -53.24 -37.89 62.47 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.59 -0.694 . . . . 0.0 110.621 -179.452 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . 0.528 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 51.8 p -167.91 166.53 13.35 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.653 -1.279 . . . . 0.0 110.699 -179.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.83 HD11 HD13 ' A' ' 30' ' ' LEU . 19.8 mm -58.89 -35.28 55.58 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.201 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 178.913 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 34.7 mtp180 -57.51 -43.96 84.66 Favored 'General case' 0 C--N 1.303 -1.455 0 CA-C-O 121.446 0.641 . . . . 0.0 109.468 -179.354 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 11.8 t -67.06 -39.41 86.89 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.368 -0.832 . . . . 0.0 109.953 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.415 HD12 ' HA ' ' A' ' 69' ' ' ILE . 76.9 mt -59.84 -50.1 81.35 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 O-C-N 121.265 -0.897 . . . . 0.0 110.074 -179.277 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 44.3 t0 -59.66 -42.78 93.58 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.13 -0.981 . . . . 0.0 109.04 -179.871 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.55 -42.21 87.5 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.535 -0.728 . . . . 0.0 109.756 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 60.0 t80 -63.58 -46.2 86.95 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.185 -0.947 . . . . 0.0 109.411 -179.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.613 ' CG1' ' CZ ' ' A' ' 52' ' ' PHE . 54.6 t -60.89 -47.22 94.36 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.297 0 O-C-N 121.367 -0.833 . . . . 0.0 109.138 179.854 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 55.5 t -69.26 -42.38 81.43 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 O-C-N 121.213 -0.929 . . . . 0.0 109.107 179.338 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.493 ' O ' ' O ' ' A' ' 81' ' ' THR . . . -65.22 -28.27 73.36 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 -179.831 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.04 -38.67 86.27 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.153 -1.204 . . . . 0.0 110.299 -178.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 52.1 p -82.42 -31.33 29.6 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.111 -0.993 . . . . 0.0 109.539 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.493 ' O ' ' O ' ' A' ' 78' ' ' GLY . 0.3 OUTLIER . . . . . 0 C--N 1.302 -1.464 0 O-C-N 121.51 -0.744 . . . . 0.0 109.605 -179.864 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 62.1 m80 . . . . . 0 N--CA 1.485 1.288 0 N-CA-C 108.114 -1.069 . . . . 0.0 108.114 . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -57.25 -39.48 75.69 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.518 -0.739 . . . . 0.0 109.798 -179.33 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.1 p -63.04 -33.7 75.98 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.146 -0.971 . . . . 0.0 109.491 -179.895 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 75.9 t -65.9 -43.49 92.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.222 -0.924 . . . . 0.0 109.539 179.87 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.515 ' O ' HG12 ' A' ' 11' ' ' VAL . 82.6 mt -59.59 -47.3 91.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.4 -0.812 . . . . 0.0 109.845 -179.859 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.716 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.26 -45.13 92.94 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.28 -0.888 . . . . 0.0 110.924 -179.181 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 53.9 mt-30 -69.09 -46.65 67.21 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.835 -1.165 . . . . 0.0 110.854 -178.723 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.549 ' C ' ' CD1' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -70.28 -48.75 55.31 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.075 -1.016 . . . . 0.0 110.298 -179.392 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.515 HG12 ' O ' ' A' ' 7' ' ' ILE . 4.0 p -59.88 -38.81 77.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.072 -1.017 . . . . 0.0 109.678 -179.604 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.716 HG23 ' O ' ' A' ' 8' ' ' ALA . 49.5 t -63.18 -43.22 98.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.224 -0.922 . . . . 0.0 109.963 -179.928 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -63.13 -34.51 77.76 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.104 -0.997 . . . . 0.0 109.941 -179.812 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -65.43 -31.74 72.99 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.269 -0.894 . . . . 0.0 110.197 -179.649 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.779 ' CD2' HG13 ' A' ' 35' ' ' VAL . 77.4 t80 -113.65 -61.4 1.75 Allowed 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.326 -0.859 . . . . 0.0 111.299 -178.818 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 4.8 mt -116.08 80.19 9.06 Favored Pre-proline 0 N--CA 1.494 1.726 0 O-C-N 121.219 -0.926 . . . . 0.0 111.017 -178.354 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_endo -74.64 -14.55 22.03 Favored 'Trans proline' 0 C--N 1.31 -1.5 0 C-N-CA 122.311 2.008 . . . . 0.0 112.156 178.848 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -84.93 0.84 49.83 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.286 -0.883 . . . . 0.0 109.601 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 42.3 t -115.36 134.93 56.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 121.43 -0.794 . . . . 0.0 109.568 -179.908 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.34 117.84 60.52 Favored Pre-proline 0 N--CA 1.489 1.486 0 O-C-N 121.183 -0.948 . . . . 0.0 109.405 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_exo -51.44 -30.06 33.54 Favored 'Trans proline' 0 N--CA 1.493 1.464 0 C-N-CA 121.757 1.638 . . . . 0.0 112.064 179.614 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.8 -25.12 67.78 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.239 -0.913 . . . . 0.0 109.291 179.769 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -81.88 4.45 22.38 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.368 -0.833 . . . . 0.0 109.777 -179.755 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 10.5 t -107.79 128.91 62.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.216 -0.927 . . . . 0.0 109.485 -179.923 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 88.1 m-20 -89.7 120.72 31.22 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.239 -0.913 . . . . 0.0 109.078 179.213 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 28.9 m -70.9 3.89 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 O-C-N 121.11 -0.993 . . . . 0.0 109.123 179.598 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -94.25 -5.24 47.29 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.363 -0.836 . . . . 0.0 109.154 179.466 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 42.0 tp -95.32 138.14 33.42 Favored 'General case' 0 C--N 1.303 -1.421 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 179.599 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -57.2 135.62 56.42 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.068 -1.02 . . . . 0.0 109.354 -179.269 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 1.041 HD23 HD11 ' A' ' 36' ' ' ILE . 39.4 tp -64.59 -37.48 87.71 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.595 -0.69 . . . . 0.0 110.467 -179.336 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 70.2 t -66.2 -37.24 79.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.022 -1.049 . . . . 0.0 110.708 -179.15 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -52.93 -33.05 48.94 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 120.956 -1.09 . . . . 0.0 108.254 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.438 ' HB3' HG23 ' A' ' 35' ' ' VAL . 98.4 m-20 -70.68 -34.33 71.86 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.631 -0.668 . . . . 0.0 109.946 179.457 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 86.6 5.26 82.07 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 108.824 -1.71 . . . . 0.0 108.824 -179.245 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.779 HG13 ' CD2' ' A' ' 15' ' ' PHE . 76.2 t -61.1 -32.69 53.41 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 O-C-N 121.582 -0.952 . . . . 0.0 108.924 179.637 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 1.041 HD11 HD23 ' A' ' 30' ' ' LEU . 80.7 mt -83.82 116.26 27.44 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.403 -0.811 . . . . 0.0 109.843 -179.872 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.406 ' H ' ' HA3' ' A' ' 40' ' ' GLY . 92.0 m-20 -114.99 -176.08 2.83 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 179.406 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -58.95 -53.38 59.08 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.021 -1.049 . . . . 0.0 108.205 179.601 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 35.8 mt -68.57 -32.44 72.36 Favored 'General case' 0 C--N 1.301 -1.528 0 N-CA-C 106.887 -1.523 . . . . 0.0 106.887 177.868 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.494 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -58.97 -40.93 96.05 Favored Glycine 0 N--CA 1.48 1.594 0 N-CA-C 108.718 -1.753 . . . . 0.0 108.718 179.274 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.3 tt -65.21 -41.61 94.31 Favored 'General case' 0 C--N 1.305 -1.34 0 O-C-N 121.386 -1.067 . . . . 0.0 108.693 178.893 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 tp -60.17 -45.72 92.14 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 179.322 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 21.0 mttp -60.71 -35.48 76.42 Favored 'General case' 0 C--N 1.298 -1.663 0 O-C-N 121.551 -0.718 . . . . 0.0 109.522 -179.935 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.494 HG23 ' O ' ' A' ' 40' ' ' GLY . 53.3 t -59.81 -50.59 79.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.325 -0.859 . . . . 0.0 109.469 -179.657 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.482 ' H ' HD12 ' A' ' 45' ' ' ILE . 3.5 mp -68.33 -30.36 47.4 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 O-C-N 121.256 -0.903 . . . . 0.0 110.459 179.704 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.84 -49.2 71.53 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.107 -0.996 . . . . 0.0 111.306 -178.473 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.498 ' C ' ' CD1' ' A' ' 47' ' ' TRP . 0.0 OUTLIER -81.39 -43.23 19.28 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.759 -1.213 . . . . 0.0 110.032 -179.384 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.674 HD11 HG22 ' A' ' 76' ' ' VAL . 0.4 OUTLIER -58.75 -43.19 90.22 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.118 -0.989 . . . . 0.0 109.113 -179.328 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.548 ' O ' ' N ' ' A' ' 53' ' ' GLY . 2.1 pp20? -72.18 -35.62 69.02 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.054 -1.029 . . . . 0.0 109.8 179.905 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.2 t0 -60.44 -38.42 84.09 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.247 -0.908 . . . . 0.0 110.567 -179.641 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.445 ' HD2' ' HE1' ' A' ' 47' ' ' TRP . 49.9 mtp180 -60.47 -40.73 92.29 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.131 -0.981 . . . . 0.0 111.189 -178.873 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.861 ' CE2' HG21 ' A' ' 80' ' ' THR . 73.4 m-85 -106.49 -11.92 15.77 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.974 -1.078 . . . . 0.0 110.041 -179.358 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . 0.548 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 70.16 30.16 69.89 Favored Glycine 0 N--CA 1.485 1.939 0 N-CA-C 109.072 -1.611 . . . . 0.0 109.072 179.5 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 12.7 pt -93.57 124.31 45.97 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 O-C-N 121.358 -1.084 . . . . 0.0 109.623 -179.604 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -65.59 140.23 58.51 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.154 -0.966 . . . . 0.0 109.817 -179.535 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.503 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -65.45 -31.86 73.17 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.429 -0.794 . . . . 0.0 109.398 179.805 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -58.46 -37.36 75.3 Favored 'General case' 0 C--N 1.303 -1.45 0 O-C-N 121.183 -0.948 . . . . 0.0 109.952 -179.815 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -58.28 -40.11 81.04 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.225 -0.922 . . . . 0.0 109.964 -179.636 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.503 ' O ' ' O ' ' A' ' 56' ' ' ALA . 42.4 t -127.12 133.67 67.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.311 -0.868 . . . . 0.0 109.555 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . 0.51 ' C ' HD22 ' A' ' 61' ' ' LEU . 84.3 tt0 -89.26 129.73 35.78 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.044 -1.035 . . . . 0.0 109.336 179.803 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.675 ' N ' HD22 ' A' ' 61' ' ' LEU . 3.5 mm? -95.9 134.15 39.23 Favored 'General case' 0 C--N 1.305 -1.347 0 O-C-N 121.322 -0.861 . . . . 0.0 109.726 -179.821 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -109.96 156.35 40.11 Favored Pre-proline 0 N--CA 1.487 1.382 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 179.582 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_endo -54.22 -22.88 27.56 Favored 'Trans proline' 0 C--N 1.302 -1.902 0 C-N-CA 122.295 1.997 . . . . 0.0 111.68 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -69.96 -27.36 64.67 Favored 'General case' 0 N--CA 1.485 1.308 0 O-C-N 121.297 -0.877 . . . . 0.0 109.355 179.63 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . 0.545 ' C ' ' CD2' ' A' ' 65' ' ' HIS . 1.7 t60 -65.65 -19.94 66.11 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.307 -0.87 . . . . 0.0 109.003 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.55 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 7.9 m-85 -98.43 15.78 23.75 Favored 'General case' 0 C--N 1.299 -1.622 0 CA-C-O 121.601 0.715 . . . . 0.0 109.076 -179.765 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . 0.404 ' HG2' ' H ' ' A' ' 68' ' ' SER . 1.4 ptt85 -53.66 -36.6 62.29 Favored 'General case' 0 C--N 1.299 -1.61 0 O-C-N 121.679 -0.638 . . . . 0.0 110.55 -179.378 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . 0.553 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 41.6 t -168.07 161.23 12.51 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.754 -1.216 . . . . 0.0 110.364 -179.787 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.636 ' H ' HD12 ' A' ' 69' ' ' ILE . 2.4 mp -57.69 -34.15 46.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 179.026 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 52.0 mtp85 -56.65 -41.71 77.68 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 109.081 -0.711 . . . . 0.0 109.081 -179.897 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 61.6 p -67.92 -32.98 73.81 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.444 -0.785 . . . . 0.0 109.596 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.521 HD12 ' HA ' ' A' ' 69' ' ' ILE . 56.5 mt -61.45 -50.6 79.69 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.361 0 O-C-N 121.294 -0.879 . . . . 0.0 109.567 -179.578 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 43.4 t0 -61.41 -41.44 97.16 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.216 -0.927 . . . . 0.0 108.894 179.655 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.21 -37.55 85.84 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.56 -0.712 . . . . 0.0 109.873 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . 0.53 ' CZ ' HD11 ' A' ' 61' ' ' LEU . 67.2 t80 -61.48 -46.5 89.78 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.167 -0.958 . . . . 0.0 109.64 -179.772 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.674 HG22 HD11 ' A' ' 48' ' ' LEU . 41.9 t -61.36 -47.76 91.99 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 O-C-N 121.268 -0.895 . . . . 0.0 109.358 179.692 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . 0.416 ' O ' ' O ' ' A' ' 81' ' ' THR . 47.3 t -69.0 -43.42 82.02 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 O-C-N 121.399 -0.813 . . . . 0.0 109.762 179.855 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -63.28 -40.73 99.33 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 110.284 -1.126 . . . . 0.0 110.284 -179.571 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -70.57 -41.62 72.18 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.229 -1.16 . . . . 0.0 110.833 -178.989 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.861 HG21 ' CE2' ' A' ' 52' ' ' PHE . 69.5 p -86.52 -31.15 21.44 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 120.906 -1.121 . . . . 0.0 109.955 -179.341 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.416 ' O ' ' O ' ' A' ' 77' ' ' VAL . 0.2 OUTLIER . . . . . 0 C--N 1.302 -1.496 0 O-C-N 121.466 -0.771 . . . . 0.0 109.376 -179.752 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 6.7 m80 . . . . . 0 N--CA 1.495 1.819 0 CA-C-O 120.999 0.428 . . . . 0.0 110.091 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -61.78 -41.71 98.06 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 120.981 -1.074 . . . . 0.0 109.173 179.685 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.4 m -60.97 -37.5 82.64 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.434 -0.791 . . . . 0.0 109.895 -179.801 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 49.6 t -60.33 -44.13 95.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.174 -0.954 . . . . 0.0 109.496 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . 0.453 ' O ' HG12 ' A' ' 11' ' ' VAL . 78.6 mt -59.5 -50.18 80.87 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 O-C-N 121.397 -0.815 . . . . 0.0 109.641 -179.799 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.659 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.96 -43.82 94.62 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.315 -0.866 . . . . 0.0 110.918 -179.569 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 27.2 mt-30 -69.08 -46.08 68.67 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 120.92 -1.112 . . . . 0.0 111.435 -178.446 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.711 ' CD1' ' N ' ' A' ' 11' ' ' VAL . 0.0 OUTLIER -70.42 -46.71 63.4 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.884 -1.135 . . . . 0.0 110.492 -179.177 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.711 ' N ' ' CD1' ' A' ' 10' ' ' PHE . 4.8 p -62.03 -40.33 86.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.085 -1.01 . . . . 0.0 109.807 -179.523 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.659 HG23 ' O ' ' A' ' 8' ' ' ALA . 55.8 t -63.28 -43.54 98.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.173 -0.955 . . . . 0.0 109.866 179.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -65.82 -37.3 85.86 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.214 -0.929 . . . . 0.0 110.278 -179.536 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 85.7 tt0 -65.76 -39.58 91.2 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.159 -0.963 . . . . 0.0 110.116 -179.558 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . 0.922 ' CD2' HG13 ' A' ' 35' ' ' VAL . 75.6 t80 -93.77 -50.72 5.23 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.174 -0.954 . . . . 0.0 110.783 -179.218 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.52 HD22 ' CG2' ' A' ' 19' ' ' VAL . 5.4 mt -120.26 80.59 28.64 Favored Pre-proline 0 N--CA 1.491 1.622 0 O-C-N 121.285 -0.884 . . . . 0.0 110.525 -178.776 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 23.5 Cg_endo -69.05 -14.52 38.49 Favored 'Trans proline' 0 N--CA 1.493 1.451 0 C-N-CA 122.095 1.863 . . . . 0.0 112.353 179.614 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -94.92 7.1 47.12 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.179 -0.95 . . . . 0.0 110.387 -179.613 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.52 ' CG2' HD22 ' A' ' 16' ' ' LEU . 39.3 t -119.11 136.33 56.65 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 121.271 -0.893 . . . . 0.0 109.788 -179.779 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -78.53 117.96 69.49 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.301 -0.874 . . . . 0.0 109.081 179.608 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_exo -51.76 -27.77 27.96 Favored 'Trans proline' 0 N--CA 1.493 1.478 0 C-N-CA 121.787 1.658 . . . . 0.0 112.23 179.855 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.52 -27.01 68.67 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.203 -0.936 . . . . 0.0 109.305 -179.946 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.452 ' O ' ' OD1' ' A' ' 23' ' ' ASP . 60.0 t0 -82.19 3.55 26.87 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.303 -0.873 . . . . 0.0 109.7 -179.778 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 9.7 t -109.43 128.33 65.51 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.263 -0.898 . . . . 0.0 109.561 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 87.2 m-20 -89.96 120.56 31.28 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.189 -0.945 . . . . 0.0 109.097 179.06 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 33.7 m -70.93 4.14 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.378 0 O-C-N 121.102 -0.999 . . . . 0.0 108.941 179.47 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -92.13 -5.45 52.66 Favored 'General case' 0 N--CA 1.486 1.341 0 O-C-N 121.373 -0.829 . . . . 0.0 109.031 179.423 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 44.3 tp -96.52 141.1 30.21 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.473 -0.767 . . . . 0.0 108.957 179.86 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -58.59 128.57 37.86 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.176 -0.952 . . . . 0.0 109.504 -179.407 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 1.033 HD23 HD11 ' A' ' 36' ' ' ILE . 48.7 tp -66.85 -37.23 84.07 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.551 -0.718 . . . . 0.0 110.648 -179.417 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 70.6 t -63.67 -35.96 74.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 120.928 -1.107 . . . . 0.0 110.693 -178.911 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 56.3 t0 -52.43 -33.59 44.68 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 120.974 -1.079 . . . . 0.0 108.186 -179.908 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.426 ' HB3' HG23 ' A' ' 35' ' ' VAL . 97.5 m-20 -71.46 -34.45 70.23 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.698 -0.626 . . . . 0.0 110.232 179.476 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 87.22 4.87 80.74 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 108.58 -1.808 . . . . 0.0 108.58 -179.043 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.922 HG13 ' CD2' ' A' ' 15' ' ' PHE . 67.8 t -59.87 -29.55 43.39 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 O-C-N 121.484 -1.009 . . . . 0.0 108.412 179.254 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 1.033 HD11 HD23 ' A' ' 30' ' ' LEU . 71.8 mt -88.07 132.5 33.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 CA-C-O 121.616 0.722 . . . . 0.0 109.627 -179.897 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.554 ' CG ' ' H ' ' A' ' 38' ' ' ALA . 45.7 t0 -139.07 -160.81 1.1 Allowed 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 179.845 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.554 ' H ' ' CG ' ' A' ' 37' ' ' ASP . . . -65.48 -54.31 30.19 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.117 -0.99 . . . . 0.0 108.716 179.817 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.693 HD12 ' N ' ' A' ' 39' ' ' LEU . 7.0 mp -69.63 -32.81 71.72 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 107.35 -1.352 . . . . 0.0 107.35 178.405 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.455 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.26 -44.06 96.77 Favored Glycine 0 N--CA 1.481 1.663 0 N-CA-C 109.008 -1.637 . . . . 0.0 109.008 179.545 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.4 ' O ' HD12 ' A' ' 45' ' ' ILE . 2.8 tt -65.12 -42.06 94.28 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.473 -1.016 . . . . 0.0 109.369 179.168 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 15.8 tp -59.74 -44.69 93.67 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.227 -0.921 . . . . 0.0 109.339 179.857 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 18.8 mttt -62.2 -34.29 76.18 Favored 'General case' 0 C--N 1.299 -1.589 0 O-C-N 121.156 -0.965 . . . . 0.0 109.62 179.874 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.455 HG23 ' O ' ' A' ' 40' ' ' GLY . 54.0 t -60.75 -50.18 81.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.27 -0.894 . . . . 0.0 110.06 -179.488 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.525 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 3.6 mp -68.48 -34.63 66.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.247 -0.908 . . . . 0.0 111.257 -179.669 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.81 -50.16 65.65 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 120.943 -1.098 . . . . 0.0 111.758 -177.867 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.678 ' HE1' ' NE ' ' A' ' 51' ' ' ARG . 0.0 OUTLIER -80.05 -43.8 21.22 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.75 -1.219 . . . . 0.0 109.78 -179.457 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.98 HD12 HH21 ' A' ' 51' ' ' ARG . 15.0 tp -58.73 -43.16 90.1 Favored 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.382 -0.824 . . . . 0.0 110.12 -179.12 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.525 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 1.2 pp20? -72.67 -35.85 67.78 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.135 -0.978 . . . . 0.0 109.905 -179.762 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.1 t70 -61.51 -39.72 92.02 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.226 -0.921 . . . . 0.0 111.16 -179.317 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.98 HH21 HD12 ' A' ' 48' ' ' LEU . 70.5 mtm180 -62.65 -36.8 83.99 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.19 -0.944 . . . . 0.0 112.028 -178.291 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.79 ' CE1' HG11 ' A' ' 76' ' ' VAL . 88.5 m-85 -95.96 -6.13 39.73 Favored 'General case' 0 N--CA 1.487 1.389 0 O-C-N 120.714 -1.242 . . . . 0.0 110.454 -178.718 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 70.33 29.39 70.21 Favored Glycine 0 N--CA 1.486 1.979 0 N-CA-C 108.882 -1.687 . . . . 0.0 108.882 179.349 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.488 ' O ' ' OE1' ' A' ' 49' ' ' GLU . 24.7 pt -107.28 152.38 8.87 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 O-C-N 121.557 -0.966 . . . . 0.0 109.559 -179.571 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -105.23 154.51 20.12 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.36 -0.837 . . . . 0.0 109.721 -179.472 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.833 ' O ' HG12 ' A' ' 59' ' ' VAL . . . -59.8 -21.19 60.5 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.339 -0.85 . . . . 0.0 109.177 179.904 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 56.3 t0 61.95 36.6 15.6 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 121.526 -0.734 . . . . 0.0 109.328 -179.789 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 53.32 48.61 21.61 Favored 'General case' 0 C--N 1.305 -1.366 0 O-C-N 121.439 -0.788 . . . . 0.0 110.357 178.941 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.833 HG12 ' O ' ' A' ' 56' ' ' ALA . 8.8 p -127.86 142.87 42.53 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.364 -0.835 . . . . 0.0 109.105 179.593 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -99.19 133.5 43.39 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.177 -0.952 . . . . 0.0 109.628 -179.792 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 59.3 mt -92.52 145.38 24.49 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.43 -0.794 . . . . 0.0 109.248 179.92 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -91.71 150.73 41.42 Favored Pre-proline 0 C--N 1.305 -1.34 0 O-C-N 121.14 -0.975 . . . . 0.0 108.765 179.8 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 11.4 Cg_endo -57.23 -19.82 36.06 Favored 'Trans proline' 0 C--N 1.304 -1.81 0 C-N-CA 122.335 2.023 . . . . 0.0 112.035 -179.67 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -67.96 -31.62 71.47 Favored 'General case' 0 N--CA 1.484 1.243 0 O-C-N 121.285 -0.885 . . . . 0.0 109.453 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . 0.586 ' CD2' ' O ' ' A' ' 65' ' ' HIS . 5.2 t-160 -66.04 -20.54 66.21 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.347 -0.846 . . . . 0.0 108.737 179.787 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.586 ' HB3' HD13 ' A' ' 36' ' ' ILE . 8.5 m-85 -94.63 14.65 20.37 Favored 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 -179.915 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . 0.587 ' NE ' ' OG ' ' A' ' 71' ' ' SER . 6.4 ptt180 -46.47 -37.65 8.09 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.739 -0.601 . . . . 0.0 110.381 -179.59 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . 0.485 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 46.7 t -159.71 155.05 25.33 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.933 -1.104 . . . . 0.0 110.06 -179.764 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.717 ' H ' HD12 ' A' ' 69' ' ' ILE . 1.6 mp -57.69 -41.75 80.1 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 O-C-N 121.29 -0.881 . . . . 0.0 109.142 179.931 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 11.1 ptm180 -58.33 -42.05 85.93 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.406 -0.809 . . . . 0.0 109.1 179.795 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . 0.587 ' OG ' ' NE ' ' A' ' 67' ' ' ARG . 26.4 t -62.97 -40.9 99.13 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.333 -0.854 . . . . 0.0 109.359 179.471 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 86.1 mt -60.12 -49.78 82.77 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 O-C-N 121.218 -0.926 . . . . 0.0 109.437 179.928 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 37.2 t0 -59.53 -40.6 87.71 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.366 -0.834 . . . . 0.0 109.013 179.695 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.45 -37.76 85.87 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.637 -0.665 . . . . 0.0 110.153 -179.882 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . 0.554 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 64.4 t80 -60.73 -47.77 84.78 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.145 -0.972 . . . . 0.0 109.836 -179.413 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.79 HG11 ' CE1' ' A' ' 52' ' ' PHE . 98.5 t -62.47 -46.3 96.74 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.294 0 O-C-N 121.064 -1.023 . . . . 0.0 109.18 179.809 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 78.8 t -66.9 -40.24 85.31 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.389 0 O-C-N 121.472 -0.768 . . . . 0.0 109.217 179.641 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.489 ' O ' ' O ' ' A' ' 81' ' ' THR . . . -59.46 -38.57 93.72 Favored Glycine 0 N--CA 1.488 2.127 0 N-CA-C 109.913 -1.275 . . . . 0.0 109.913 -179.781 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -69.15 -41.31 77.45 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.335 -1.097 . . . . 0.0 110.489 -179.3 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 44.9 p -81.81 -31.08 31.94 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.068 -1.02 . . . . 0.0 109.449 -179.781 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.489 ' O ' ' O ' ' A' ' 78' ' ' GLY . 0.5 OUTLIER . . . . . 0 C--N 1.3 -1.558 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 -179.869 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 97.1 m-70 . . . . . 0 N--CA 1.486 1.366 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -54.37 -42.64 70.56 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.524 -0.735 . . . . 0.0 109.836 -179.181 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 24.2 m -62.11 -38.08 87.55 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.28 -0.887 . . . . 0.0 109.868 -179.84 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 53.7 t -64.19 -45.44 96.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.165 -0.959 . . . . 0.0 109.781 -179.777 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 79.4 mt -59.77 -42.43 88.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.386 -0.821 . . . . 0.0 109.279 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . 0.516 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -60.51 -36.93 79.55 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.374 -0.828 . . . . 0.0 109.18 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 7.3 tt0 -65.28 -40.23 93.6 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.271 -0.893 . . . . 0.0 110.077 179.924 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.677 ' CG ' ' CZ2' ' A' ' 47' ' ' TRP . 20.7 m-85 -62.01 -50.04 73.63 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.102 -0.999 . . . . 0.0 110.676 -179.426 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.42 HG23 ' N ' ' A' ' 12' ' ' VAL . 22.2 m -64.08 -40.48 89.19 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 O-C-N 121.06 -1.025 . . . . 0.0 109.302 -179.629 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.516 HG23 ' O ' ' A' ' 8' ' ' ALA . 69.0 t -63.66 -46.52 94.51 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.206 -0.934 . . . . 0.0 109.309 179.571 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -70.12 -29.39 66.32 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.305 -0.872 . . . . 0.0 109.895 179.818 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -64.82 -30.42 71.42 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.48 -0.762 . . . . 0.0 110.615 -179.094 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 75.9 t80 -131.89 -46.06 0.95 Allowed 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.083 -1.01 . . . . 0.0 111.125 -178.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.47 HD22 ' CG2' ' A' ' 19' ' ' VAL . 4.7 mt -117.98 80.16 14.55 Favored Pre-proline 0 N--CA 1.494 1.755 0 O-C-N 121.097 -1.002 . . . . 0.0 110.442 -178.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -76.15 -14.26 18.8 Favored 'Trans proline' 0 C--N 1.308 -1.604 0 C-N-CA 122.411 2.074 . . . . 0.0 112.255 179.324 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -89.08 5.19 45.63 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.279 -0.888 . . . . 0.0 109.761 -179.928 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.47 ' CG2' HD22 ' A' ' 16' ' ' LEU . 45.1 t -112.64 135.33 52.38 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.378 -0.826 . . . . 0.0 109.59 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.435 ' O ' ' CG ' ' A' ' 23' ' ' ASP . . . -73.18 117.52 60.83 Favored Pre-proline 0 N--CA 1.489 1.52 0 O-C-N 121.26 -0.9 . . . . 0.0 109.443 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_exo -51.98 -25.14 21.18 Favored 'Trans proline' 0 N--CA 1.493 1.5 0 C-N-CA 121.805 1.67 . . . . 0.0 112.039 179.486 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.72 -22.92 67.09 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.29 -0.881 . . . . 0.0 109.708 -179.828 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.45 ' C ' ' OD1' ' A' ' 23' ' ' ASP . 52.3 p30 -83.98 7.62 17.81 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.249 -0.907 . . . . 0.0 109.831 -179.74 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 11.8 t -104.97 133.57 48.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.218 -0.926 . . . . 0.0 109.348 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 86.5 m-20 -88.89 120.61 30.46 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.054 -1.029 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 17.0 m -74.96 3.83 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 O-C-N 121.26 -0.9 . . . . 0.0 109.386 179.849 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . 0.449 ' C ' ' OD1' ' A' ' 27' ' ' ASP . 52.0 p30 -94.95 1.12 55.2 Favored 'General case' 0 N--CA 1.486 1.349 0 O-C-N 121.245 -0.909 . . . . 0.0 109.227 179.454 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 46.0 tp -100.44 134.61 43.12 Favored 'General case' 0 C--N 1.303 -1.437 0 N-CA-C 108.358 -0.978 . . . . 0.0 108.358 179.313 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -57.72 126.71 28.56 Favored 'General case' 0 C--N 1.3 -1.546 0 C-N-CA 118.942 -1.103 . . . . 0.0 108.998 -179.335 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 1.023 HD23 HD11 ' A' ' 36' ' ' ILE . 43.0 tp -66.08 -37.97 87.11 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.654 -0.654 . . . . 0.0 110.654 -179.153 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 54.1 t -67.43 -37.47 78.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 120.931 -1.106 . . . . 0.0 110.774 -179.155 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 84.4 m-20 -52.69 -33.17 46.25 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 120.859 -1.151 . . . . 0.0 108.111 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 20.3 m120 -70.72 -33.48 70.9 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.639 -0.663 . . . . 0.0 109.784 179.325 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 91.65 5.56 66.62 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 108.879 -1.688 . . . . 0.0 108.879 -179.304 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 74.4 t -61.44 -32.99 54.92 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 O-C-N 121.498 -1.001 . . . . 0.0 109.209 179.793 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 1.023 HD11 HD23 ' A' ' 30' ' ' LEU . 72.6 mt -92.31 121.13 42.62 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.396 0 O-C-N 121.302 -0.874 . . . . 0.0 109.651 -179.726 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -120.42 -169.5 1.82 Allowed 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 109.076 -0.713 . . . . 0.0 109.076 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -63.46 -54.24 39.65 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.221 -0.924 . . . . 0.0 108.615 179.702 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.686 HD12 ' N ' ' A' ' 39' ' ' LEU . 7.0 mp -70.78 -33.47 70.79 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 107.193 -1.41 . . . . 0.0 107.193 178.148 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.497 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.49 -43.12 97.79 Favored Glycine 0 N--CA 1.483 1.813 0 N-CA-C 108.809 -1.716 . . . . 0.0 108.809 179.388 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.407 HD11 ' CE1' ' A' ' 66' ' ' PHE . 6.6 tt -64.73 -41.63 95.81 Favored 'General case' 0 C--N 1.304 -1.374 0 O-C-N 121.384 -1.068 . . . . 0.0 109.066 179.286 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.4 tp -59.73 -45.93 90.68 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.222 -0.924 . . . . 0.0 109.044 179.705 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 56.6 mttt -60.97 -34.75 75.25 Favored 'General case' 0 C--N 1.297 -1.717 0 O-C-N 121.492 -0.755 . . . . 0.0 109.671 -179.812 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.497 HG23 ' O ' ' A' ' 40' ' ' GLY . 54.3 t -61.85 -49.87 82.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.366 -0.834 . . . . 0.0 110.162 -179.401 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.547 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 3.4 mp -67.89 -32.9 58.38 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 O-C-N 121.206 -0.934 . . . . 0.0 110.678 -179.621 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.7 -50.29 67.55 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.861 -1.15 . . . . 0.0 111.13 -178.302 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.677 ' CZ2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -81.28 -44.84 17.11 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.758 -1.214 . . . . 0.0 109.829 -179.657 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.646 HD21 ' CG2' ' A' ' 76' ' ' VAL . 18.1 tp -58.37 -41.32 84.53 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.328 -0.858 . . . . 0.0 109.936 -178.955 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.547 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 1.1 pp20? -73.35 -35.63 66.02 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 120.895 -1.128 . . . . 0.0 109.521 179.769 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.4 t0 -63.48 -41.02 98.59 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.376 -0.828 . . . . 0.0 111.619 -179.111 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.504 ' HD3' HD12 ' A' ' 48' ' ' LEU . 8.8 ptm180 -65.0 -37.08 86.47 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.869 -1.144 . . . . 0.0 111.632 -178.122 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.858 ' CE2' HG11 ' A' ' 76' ' ' VAL . 72.9 m-85 -90.9 -12.14 37.02 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 120.443 -1.41 . . . . 0.0 110.021 -179.505 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 74.47 28.83 62.84 Favored Glycine 0 N--CA 1.487 2.045 0 N-CA-C 108.832 -1.707 . . . . 0.0 108.832 179.919 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . 0.49 ' O ' ' OE1' ' A' ' 49' ' ' GLU . 25.2 pt -109.18 153.4 10.95 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.575 -0.956 . . . . 0.0 109.798 -179.42 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -102.44 126.3 49.44 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.228 -0.92 . . . . 0.0 109.561 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.497 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -68.55 -28.16 66.72 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.238 -0.914 . . . . 0.0 109.525 179.784 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 21.0 t70 -55.12 -33.49 62.9 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.262 -0.899 . . . . 0.0 110.082 -179.638 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -52.76 -38.29 60.77 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.133 -0.979 . . . . 0.0 109.852 -179.465 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.497 ' O ' ' O ' ' A' ' 56' ' ' ALA . 32.7 m -127.66 157.74 39.43 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.335 0 O-C-N 121.319 -0.863 . . . . 0.0 109.557 -179.721 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -97.6 125.82 42.55 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.14 -0.975 . . . . 0.0 109.353 179.725 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.412 HD21 ' CE2' ' A' ' 75' ' ' PHE . 5.1 mp -107.12 141.06 38.98 Favored 'General case' 0 C--N 1.306 -1.325 0 O-C-N 121.394 -0.816 . . . . 0.0 109.699 -179.73 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -109.22 153.09 42.84 Favored Pre-proline 0 N--CA 1.487 1.406 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 179.295 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo -54.53 -23.22 30.96 Favored 'Trans proline' 0 C--N 1.303 -1.817 0 C-N-CA 122.338 2.026 . . . . 0.0 112.086 -179.548 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -70.15 -26.46 63.94 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 121.352 -0.842 . . . . 0.0 109.403 179.906 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . 0.504 ' NE2' ' CB ' ' A' ' 75' ' ' PHE . 2.2 t-80 -66.03 -20.88 66.33 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.419 -0.8 . . . . 0.0 109.289 -179.843 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.584 ' HB3' HD13 ' A' ' 36' ' ' ILE . 9.5 m-85 -97.1 15.48 22.41 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 121.406 -0.809 . . . . 0.0 109.166 -179.815 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 1.7 ptt85 -51.99 -34.39 42.31 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.644 -0.66 . . . . 0.0 109.999 -179.938 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . 0.546 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 44.2 t -151.4 154.05 35.89 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.071 -1.018 . . . . 0.0 109.969 179.884 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.637 ' H ' HD12 ' A' ' 69' ' ' ILE . 3.2 mp -57.36 -33.91 44.99 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 179.222 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 32.1 mtp180 -56.79 -44.11 81.56 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.67 -0.644 . . . . 0.0 109.407 -179.693 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 17.0 t -66.47 -40.58 89.42 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.382 -0.823 . . . . 0.0 109.829 -179.96 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 62.8 mt -62.18 -50.26 80.73 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.37 0 O-C-N 121.305 -0.872 . . . . 0.0 110.286 -179.222 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 37.0 t0 -61.0 -41.88 97.35 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.11 -0.994 . . . . 0.0 109.409 -179.842 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -67.02 -40.69 87.31 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.478 -0.764 . . . . 0.0 110.353 -179.443 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . 0.504 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 66.9 t80 -62.7 -46.71 86.86 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.049 -1.032 . . . . 0.0 109.663 -179.676 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.858 HG11 ' CE2' ' A' ' 52' ' ' PHE . 90.7 t -67.23 -48.21 79.05 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.343 0 O-C-N 121.192 -0.943 . . . . 0.0 109.78 -179.938 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 53.0 t -69.66 -41.99 80.29 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.333 0 O-C-N 121.134 -0.978 . . . . 0.0 109.63 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.486 ' O ' ' O ' ' A' ' 81' ' ' THR . . . -59.53 -36.0 87.7 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 -179.477 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.48 -40.98 85.29 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.209 -1.171 . . . . 0.0 110.475 -179.183 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 49.0 p -81.93 -30.74 31.67 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.144 -0.972 . . . . 0.0 109.698 -179.685 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.486 ' O ' ' O ' ' A' ' 78' ' ' GLY . 0.5 OUTLIER . . . . . 0 C--N 1.302 -1.458 0 O-C-N 121.541 -0.725 . . . . 0.0 109.666 -179.615 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 50.4 m-70 . . . . . 0 N--CA 1.494 1.753 0 CA-C-O 121.052 0.454 . . . . 0.0 110.575 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -61.01 -38.42 86.0 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.96 -1.088 . . . . 0.0 109.299 179.468 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 25.5 m -60.18 -35.75 76.05 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.328 -0.857 . . . . 0.0 109.914 -179.797 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 53.0 t -61.39 -45.72 98.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.193 -0.942 . . . . 0.0 109.589 -179.69 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 70.2 mt -60.04 -43.88 93.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.475 0 O-C-N 121.247 -0.908 . . . . 0.0 109.113 179.79 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -60.41 -35.89 76.84 Favored 'General case' 0 C--N 1.303 -1.424 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 179.752 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 7.3 tt0 -64.18 -38.12 89.9 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.458 -0.776 . . . . 0.0 110.137 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.684 ' CG ' ' CZ2' ' A' ' 47' ' ' TRP . 25.8 m-85 -66.52 -49.29 67.01 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 120.908 -1.12 . . . . 0.0 111.028 -179.219 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . 0.443 HG23 ' N ' ' A' ' 12' ' ' VAL . 11.6 m -59.74 -48.14 88.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.08 -1.013 . . . . 0.0 110.428 -178.518 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.573 ' O ' ' N ' ' A' ' 16' ' ' LEU . 30.6 m -64.89 -43.44 96.31 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.407 0 O-C-N 120.766 -1.208 . . . . 0.0 110.03 -179.838 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . 0.511 ' N ' HG23 ' A' ' 12' ' ' VAL . 95.0 mt-10 -65.16 -26.51 68.19 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.755 -1.215 . . . . 0.0 109.945 -179.981 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 81.4 tt0 -64.28 -31.04 72.08 Favored 'General case' 0 C--N 1.299 -1.614 0 O-C-N 121.328 -0.857 . . . . 0.0 109.767 -179.277 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 85.9 m-85 -141.5 -35.89 0.45 Allowed 'General case' 0 N--CA 1.494 1.734 0 O-C-N 120.897 -1.127 . . . . 0.0 110.816 -179.9 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.573 ' N ' ' O ' ' A' ' 12' ' ' VAL . 8.6 mt -122.17 79.79 43.83 Favored Pre-proline 0 N--CA 1.494 1.737 0 O-C-N 121.124 -0.985 . . . . 0.0 110.418 -179.01 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 43.0 Cg_endo -75.77 -12.03 20.08 Favored 'Trans proline' 0 C--N 1.308 -1.562 0 C-N-CA 122.412 2.075 . . . . 0.0 112.545 179.79 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -93.87 13.09 23.66 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.224 -0.922 . . . . 0.0 110.385 -179.399 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 58.5 t -109.46 134.98 49.78 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.247 -0.908 . . . . 0.0 110.008 -179.724 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . 0.494 ' O ' ' OD1' ' A' ' 23' ' ' ASP . . . -73.58 117.88 64.43 Favored Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.429 -0.794 . . . . 0.0 109.337 -179.965 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_exo -52.62 -27.24 32.28 Favored 'Trans proline' 0 N--CA 1.494 1.509 0 C-N-CA 121.832 1.688 . . . . 0.0 112.394 179.786 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.85 -25.4 67.88 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.263 -0.898 . . . . 0.0 110.035 -179.561 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.494 ' OD1' ' O ' ' A' ' 20' ' ' ALA . 47.4 p30 -86.54 8.15 23.24 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.133 -0.979 . . . . 0.0 110.112 -179.566 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 11.3 t -101.11 131.64 48.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 120.972 -1.08 . . . . 0.0 109.418 -179.907 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 61.6 t0 -89.29 119.71 30.0 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.096 -1.002 . . . . 0.0 109.094 179.435 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 22.1 m -76.3 4.45 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 O-C-N 121.252 -0.905 . . . . 0.0 109.173 179.687 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -96.24 0.25 50.75 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 121.266 -0.896 . . . . 0.0 109.214 179.61 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 38.4 tp -94.62 143.22 26.61 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.43 -0.794 . . . . 0.0 109.192 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -66.79 118.78 10.79 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.091 -1.006 . . . . 0.0 109.005 -179.75 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 1.027 HD23 HD11 ' A' ' 36' ' ' ILE . 41.6 tp -62.33 -37.86 87.26 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.605 -0.685 . . . . 0.0 111.09 -178.872 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 53.2 t -66.78 -38.29 81.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 120.807 -1.183 . . . . 0.0 110.863 -179.012 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -52.89 -33.36 49.87 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 120.913 -1.117 . . . . 0.0 108.212 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 20.9 m120 -71.05 -33.91 70.74 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.698 -0.626 . . . . 0.0 109.941 179.528 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 91.31 5.6 67.24 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 108.871 -1.691 . . . . 0.0 108.871 -179.231 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 78.0 t -60.19 -30.56 46.19 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 O-C-N 121.479 -1.012 . . . . 0.0 108.825 179.526 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 1.027 HD11 HD23 ' A' ' 30' ' ' LEU . 65.5 mt -94.72 130.5 43.46 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.344 0 O-C-N 121.386 -0.821 . . . . 0.0 109.558 -179.763 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.545 ' CG ' ' H ' ' A' ' 38' ' ' ALA . 49.1 t0 -137.92 -163.67 1.48 Allowed 'General case' 0 C--N 1.301 -1.52 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 179.948 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.545 ' H ' ' CG ' ' A' ' 37' ' ' ASP . . . -63.54 -54.76 31.13 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.995 -1.066 . . . . 0.0 108.665 179.879 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . 0.712 HD12 ' N ' ' A' ' 39' ' ' LEU . 6.9 mp -71.25 -34.04 70.37 Favored 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 107.323 -1.362 . . . . 0.0 107.323 178.206 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.425 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.47 -45.55 95.36 Favored Glycine 0 N--CA 1.482 1.725 0 N-CA-C 109.019 -1.632 . . . . 0.0 109.019 179.562 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.4 tt -64.08 -39.95 95.17 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.462 -1.022 . . . . 0.0 109.092 179.303 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 tp -60.04 -46.03 90.89 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.432 -0.792 . . . . 0.0 109.327 179.902 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 17.6 mttp -59.82 -37.11 78.28 Favored 'General case' 0 C--N 1.296 -1.729 0 O-C-N 121.474 -0.766 . . . . 0.0 109.381 -179.906 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.425 HG23 ' O ' ' A' ' 40' ' ' GLY . 84.9 t -64.64 -41.49 92.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.5 -0.75 . . . . 0.0 110.2 -179.699 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.485 ' O ' ' OE1' ' A' ' 49' ' ' GLU . 1.3 mp -64.89 -50.76 73.58 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.646 0 O-C-N 121.066 -1.021 . . . . 0.0 111.208 -178.84 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . 0.411 ' N ' HG22 ' A' ' 45' ' ' ILE . . . -67.68 -49.51 62.4 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.083 -1.011 . . . . 0.0 112.843 -177.531 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.684 ' CZ2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -74.8 -48.86 23.05 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 120.613 -1.304 . . . . 0.0 111.358 -177.758 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.594 ' O ' HD13 ' A' ' 48' ' ' LEU . 0.2 OUTLIER -58.86 -44.52 91.04 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 120.812 -1.18 . . . . 0.0 109.345 -178.582 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.628 ' HG2' ' HB2' ' A' ' 56' ' ' ALA . 0.0 OUTLIER -63.97 -38.72 92.11 Favored 'General case' 0 N--CA 1.485 1.324 0 O-C-N 120.706 -1.246 . . . . 0.0 109.818 -179.958 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 55.1 t0 -61.68 -37.25 83.4 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.298 -0.876 . . . . 0.0 110.513 -179.502 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 18.4 mmt180 -58.27 -36.51 73.39 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.089 -1.007 . . . . 0.0 111.055 -179.029 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.752 ' CE1' HG11 ' A' ' 76' ' ' VAL . 87.4 m-85 -96.32 -6.18 38.36 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 120.789 -1.194 . . . . 0.0 110.474 -179.144 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 73.25 30.44 62.79 Favored Glycine 0 N--CA 1.488 2.121 0 N-CA-C 108.739 -1.745 . . . . 0.0 108.739 179.761 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 20.7 pt -112.68 153.9 14.21 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 O-C-N 121.75 -0.853 . . . . 0.0 109.701 -179.436 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -93.99 130.17 40.21 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.217 -0.927 . . . . 0.0 109.407 -179.873 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.628 ' HB2' ' HG2' ' A' ' 49' ' ' GLU . . . -64.39 -32.24 73.78 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.202 -0.936 . . . . 0.0 109.552 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -58.06 -34.49 70.17 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.383 -0.823 . . . . 0.0 110.051 -179.835 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -53.53 -37.93 63.3 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.28 -0.888 . . . . 0.0 109.939 -179.469 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.486 ' O ' ' O ' ' A' ' 56' ' ' ALA . 13.7 p -133.67 142.72 40.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.253 -0.905 . . . . 0.0 109.567 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -100.19 128.73 46.21 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.21 -0.931 . . . . 0.0 109.322 179.781 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 51.7 mt -105.75 143.46 33.88 Favored 'General case' 0 C--N 1.305 -1.361 0 O-C-N 121.314 -0.866 . . . . 0.0 109.707 -179.719 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -97.32 151.25 37.56 Favored Pre-proline 0 C--N 1.305 -1.337 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 179.131 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -55.39 -23.25 37.41 Favored 'Trans proline' 0 C--N 1.305 -1.743 0 C-N-CA 122.366 2.044 . . . . 0.0 112.032 -179.403 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 91.9 mt-10 -71.79 -29.85 64.9 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.345 -0.847 . . . . 0.0 109.774 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . 0.453 ' CE1' ' HB2' ' A' ' 75' ' ' PHE . 63.0 t60 -65.92 -21.17 66.42 Favored 'General case' 0 C--N 1.299 -1.588 0 O-C-N 121.102 -0.999 . . . . 0.0 109.186 -179.668 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.599 ' HB3' HD13 ' A' ' 36' ' ' ILE . 26.0 m-85 -86.93 13.98 8.13 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.405 -0.809 . . . . 0.0 109.223 -179.659 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . . . . . . . . . 5.8 ptt180 -52.73 -34.31 52.05 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.66 -0.65 . . . . 0.0 110.088 179.852 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . 0.48 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 32.4 t -149.82 151.11 32.99 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.067 -1.021 . . . . 0.0 110.088 -179.771 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.665 ' H ' HD12 ' A' ' 69' ' ' ILE . 2.0 mp -60.19 -39.14 79.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.428 0 O-C-N 121.48 -0.762 . . . . 0.0 109.888 -179.862 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 9.8 ptm180 -58.12 -40.99 82.64 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.493 -0.754 . . . . 0.0 110.283 -179.225 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 60.7 p -64.98 -42.91 94.12 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.201 -0.937 . . . . 0.0 110.221 -179.455 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . 0.421 ' HA ' ' NE2' ' A' ' 65' ' ' HIS . 69.6 mt -61.5 -47.39 93.63 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 O-C-N 121.136 -0.978 . . . . 0.0 110.406 -179.405 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 39.4 t0 -60.63 -37.49 81.64 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 121.184 -0.948 . . . . 0.0 109.825 -179.723 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -67.86 -46.84 70.59 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.216 -0.927 . . . . 0.0 110.604 -178.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . 0.453 ' HB2' ' CE1' ' A' ' 65' ' ' HIS . 58.4 t80 -65.88 -44.52 85.1 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.098 -1.001 . . . . 0.0 109.2 -179.728 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.752 HG11 ' CE1' ' A' ' 52' ' ' PHE . 55.2 t -60.76 -45.34 97.97 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 O-C-N 121.31 -0.869 . . . . 0.0 109.157 179.585 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 54.7 t -69.15 -41.16 81.27 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.281 0 O-C-N 121.214 -0.929 . . . . 0.0 108.989 179.349 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.492 ' O ' ' O ' ' A' ' 81' ' ' THR . . . -59.99 -28.13 65.74 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 110.029 -1.228 . . . . 0.0 110.029 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.02 -37.02 83.39 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.207 -1.172 . . . . 0.0 109.947 -179.391 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 44.9 p -83.38 -31.08 26.9 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.149 -0.97 . . . . 0.0 109.535 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.492 ' O ' ' O ' ' A' ' 78' ' ' GLY . 0.2 OUTLIER . . . . . 0 C--N 1.303 -1.428 0 O-C-N 121.504 -0.747 . . . . 0.0 109.788 -179.523 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 77.5 m80 . . . . . 0 N--CA 1.483 1.208 0 N-CA-C 106.683 -1.599 . . . . 0.0 106.683 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . . . . . . . . . . . -51.88 -39.48 59.07 Favored 'General case' 0 N--CA 1.487 1.417 0 CA-C-O 121.233 0.539 . . . . 0.0 109.92 -179.052 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.8 m -59.8 -37.78 80.09 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.256 -0.902 . . . . 0.0 109.746 -179.747 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 6' ' ' VAL . . . . . 0.546 HG11 ' CZ ' ' A' ' 51' ' ' ARG . 55.5 t -62.63 -42.93 97.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.251 -0.906 . . . . 0.0 109.545 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 79.3 mt -59.54 -41.43 84.82 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 O-C-N 121.348 -0.845 . . . . 0.0 109.241 179.858 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -62.21 -38.42 89.09 Favored 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.405 -0.809 . . . . 0.0 109.558 -179.789 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 9' ' ' GLN . . . . . 0.442 HE21 ' HA ' ' A' ' 6' ' ' VAL . 52.5 mt-30 -61.87 -42.07 98.62 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.108 -0.995 . . . . 0.0 109.545 179.921 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 10' ' ' PHE . . . . . 0.669 ' CG ' ' CE2' ' A' ' 47' ' ' TRP . 34.1 m-85 -61.81 -42.07 98.55 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.247 -0.908 . . . . 0.0 109.407 179.421 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 43.3 t -61.13 -45.29 98.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.367 -0.833 . . . . 0.0 109.548 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 12' ' ' VAL . . . . . 0.614 HG21 ' HG3' ' A' ' 21' ' ' PRO . 93.6 t -63.21 -46.83 94.81 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 O-C-N 121.479 -0.763 . . . . 0.0 109.735 -179.821 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -73.52 -16.46 61.28 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.396 -0.815 . . . . 0.0 110.265 -179.492 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -63.54 -31.88 73.17 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.171 -0.956 . . . . 0.0 110.299 -178.801 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 65.7 t80 -151.32 -28.99 0.19 Allowed 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.829 -1.169 . . . . 0.0 110.436 -179.761 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 16' ' ' LEU . . . . . 0.546 HD22 ' CG2' ' A' ' 19' ' ' VAL . 6.2 mt -121.77 80.14 40.6 Favored Pre-proline 0 N--CA 1.492 1.647 0 O-C-N 121.231 -0.918 . . . . 0.0 110.08 -179.405 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -77.08 -13.03 17.41 Favored 'Trans proline' 0 C--N 1.307 -1.607 0 C-N-CA 122.476 2.117 . . . . 0.0 112.375 179.759 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -93.95 9.74 36.24 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.189 -0.944 . . . . 0.0 110.263 -179.423 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 19' ' ' VAL . . . . . 0.546 ' CG2' HD22 ' A' ' 16' ' ' LEU . 46.4 t -109.88 137.77 40.57 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.274 -0.891 . . . . 0.0 109.691 -179.769 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -78.41 117.44 66.34 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.147 -0.971 . . . . 0.0 109.442 179.941 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 21' ' ' PRO . . . . . 0.614 ' HG3' HG21 ' A' ' 12' ' ' VAL . 38.3 Cg_exo -53.83 -24.79 32.35 Favored 'Trans proline' 0 N--CA 1.494 1.535 0 C-N-CA 121.842 1.695 . . . . 0.0 112.068 179.547 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.0 -24.51 67.74 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.304 -0.872 . . . . 0.0 109.301 -179.936 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 23' ' ' ASP . . . . . 0.409 ' O ' ' OD1' ' A' ' 23' ' ' ASP . 59.6 t0 -81.66 3.31 25.85 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.331 -0.856 . . . . 0.0 109.332 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 13.0 t -109.66 133.94 53.32 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.375 -0.828 . . . . 0.0 109.298 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 63.9 t0 -88.7 119.75 29.47 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.097 -1.002 . . . . 0.0 109.05 179.56 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 29.9 m -74.43 4.15 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.35 0 O-C-N 121.137 -0.977 . . . . 0.0 109.261 179.656 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 91.8 m-20 -90.43 -4.83 56.74 Favored 'General case' 0 N--CA 1.487 1.381 0 O-C-N 121.29 -0.881 . . . . 0.0 108.819 179.45 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 45.3 tp -98.03 139.58 33.64 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 179.832 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -58.77 137.51 57.64 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.211 -0.931 . . . . 0.0 109.655 -179.419 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 30' ' ' LEU . . . . . 0.905 HD13 HD11 ' A' ' 36' ' ' ILE . 1.4 tt -66.04 -38.91 89.57 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.713 -0.617 . . . . 0.0 110.069 -179.272 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 74.6 t -63.19 -35.78 73.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 120.979 -1.076 . . . . 0.0 110.67 -178.782 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 91.0 m-20 -52.58 -33.79 47.62 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 120.984 -1.073 . . . . 0.0 108.24 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 33' ' ' ASN . . . . . 0.445 ' HB3' HG23 ' A' ' 35' ' ' VAL . 97.2 m-20 -71.15 -34.66 71.2 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.614 -0.679 . . . . 0.0 110.047 179.516 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 84.09 5.54 87.43 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 108.99 -1.644 . . . . 0.0 108.99 -179.385 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 35' ' ' VAL . . . . . 0.445 HG23 ' HB3' ' A' ' 33' ' ' ASN . 70.4 t -60.55 -33.86 56.15 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 O-C-N 121.407 -1.055 . . . . 0.0 108.634 179.557 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 36' ' ' ILE . . . . . 0.905 HD11 HD13 ' A' ' 30' ' ' LEU . 95.0 mt -84.32 124.12 39.54 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.398 0 O-C-N 121.471 -0.768 . . . . 0.0 109.63 179.842 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 37' ' ' ASP . . . . . 0.556 ' CG ' ' H ' ' A' ' 38' ' ' ALA . 48.5 t0 -127.51 -159.53 0.94 Allowed 'General case' 0 C--N 1.301 -1.515 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 179.56 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 38' ' ' ALA . . . . . 0.556 ' H ' ' CG ' ' A' ' 37' ' ' ASP . . . -66.26 -55.07 17.93 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.848 -1.158 . . . . 0.0 108.681 179.792 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 36.5 mt -71.3 -34.37 70.55 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 107.412 -1.329 . . . . 0.0 107.412 178.237 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 40' ' ' GLY . . . . . 0.55 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.53 -40.29 96.08 Favored Glycine 0 N--CA 1.482 1.735 0 N-CA-C 108.783 -1.727 . . . . 0.0 108.783 179.256 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 41' ' ' LEU . . . . . 0.407 ' O ' HD12 ' A' ' 45' ' ' ILE . 4.5 tt -65.44 -45.49 83.63 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.528 -0.984 . . . . 0.0 109.326 179.225 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 17.1 tp -59.51 -44.75 93.05 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.415 -0.803 . . . . 0.0 109.811 -179.829 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 32.0 mttp -61.74 -34.74 76.37 Favored 'General case' 0 C--N 1.298 -1.664 0 O-C-N 120.973 -1.079 . . . . 0.0 109.583 -179.875 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 44' ' ' VAL . . . . . 0.55 HG23 ' O ' ' A' ' 40' ' ' GLY . 53.6 t -62.29 -50.23 80.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.328 -0.858 . . . . 0.0 110.296 -179.439 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 45' ' ' ILE . . . . . 0.497 ' CG1' HD12 ' A' ' 61' ' ' LEU . 3.5 mp -68.15 -32.66 56.91 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.216 -0.927 . . . . 0.0 110.934 -179.607 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.27 -49.85 62.69 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 120.971 -1.08 . . . . 0.0 111.757 -177.909 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 47' ' ' TRP . . . . . 0.669 ' CE2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -80.84 -43.51 19.88 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.677 -1.265 . . . . 0.0 110.089 -178.984 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 48' ' ' LEU . . . . . 0.4 ' N ' ' CG ' ' A' ' 47' ' ' TRP . 28.1 tp -58.93 -41.46 87.38 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.25 -0.906 . . . . 0.0 110.082 -179.085 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.436 ' CG ' ' N ' ' A' ' 50' ' ' ASP . 16.9 pt-20 -73.14 -37.7 66.52 Favored 'General case' 0 C--N 1.303 -1.427 0 O-C-N 121.082 -1.012 . . . . 0.0 109.589 -179.859 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 50' ' ' ASP . . . . . 0.436 ' N ' ' CG ' ' A' ' 49' ' ' GLU . 22.1 t70 -58.73 -38.16 77.77 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.406 -0.809 . . . . 0.0 110.618 -179.462 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 51' ' ' ARG . . . . . 0.546 ' CZ ' HG11 ' A' ' 6' ' ' VAL . 71.1 mtp180 -61.07 -38.66 86.99 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.156 -0.965 . . . . 0.0 111.434 -178.808 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 52' ' ' PHE . . . . . 0.764 ' CE1' HG11 ' A' ' 76' ' ' VAL . 75.0 m-85 -97.24 -7.42 32.31 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 120.872 -1.143 . . . . 0.0 110.582 -179.075 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 72.81 30.73 63.27 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.207 -1.557 . . . . 0.0 109.207 179.307 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 30.3 pt -106.81 153.4 8.03 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.354 0 O-C-N 121.483 -1.01 . . . . 0.0 109.571 -179.756 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -101.75 137.93 39.4 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.209 -0.932 . . . . 0.0 109.681 -179.562 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 56' ' ' ALA . . . . . 0.495 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -66.63 -26.57 67.13 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.365 -0.835 . . . . 0.0 109.724 179.899 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 57' ' ' ASP . . . . . 0.629 ' OD1' ' N ' ' A' ' 58' ' ' ASP . 54.9 p30 -60.42 -32.06 70.99 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.123 -0.986 . . . . 0.0 110.257 -179.606 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 58' ' ' ASP . . . . . 0.629 ' N ' ' OD1' ' A' ' 57' ' ' ASP . 53.8 t0 -57.95 -39.96 79.39 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.016 -1.052 . . . . 0.0 109.72 -179.908 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 59' ' ' VAL . . . . . 0.495 ' O ' ' O ' ' A' ' 56' ' ' ALA . 13.3 p -137.15 143.47 34.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.301 -0.874 . . . . 0.0 109.497 -179.969 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -90.36 132.63 35.48 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.115 -0.991 . . . . 0.0 109.221 179.847 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 61' ' ' LEU . . . . . 0.497 HD12 ' CG1' ' A' ' 45' ' ' ILE . 57.2 mt -97.74 137.26 36.88 Favored 'General case' 0 C--N 1.305 -1.338 0 O-C-N 121.222 -0.924 . . . . 0.0 109.771 -179.668 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -110.18 156.44 40.14 Favored Pre-proline 0 N--CA 1.488 1.43 0 N-CA-C 108.841 -0.799 . . . . 0.0 108.841 179.391 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 8.0 Cg_endo -53.18 -23.28 22.2 Favored 'Trans proline' 0 C--N 1.302 -1.899 0 C-N-CA 122.388 2.059 . . . . 0.0 111.685 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -70.73 -27.78 64.22 Favored 'General case' 0 C--N 1.305 -1.34 0 O-C-N 121.335 -0.853 . . . . 0.0 109.561 179.686 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 65' ' ' HIS . . . . . 0.566 ' C ' ' CD2' ' A' ' 65' ' ' HIS . 0.4 OUTLIER -65.69 -17.81 64.88 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 121.336 -0.852 . . . . 0.0 109.056 -179.835 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 66' ' ' PHE . . . . . 0.546 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 11.6 m-85 -97.57 15.89 22.0 Favored 'General case' 0 C--N 1.301 -1.538 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 179.704 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 67' ' ' ARG . . . . . 0.594 ' NE ' ' OG ' ' A' ' 71' ' ' SER . 6.7 ptt180 -48.95 -38.58 23.4 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.796 -0.565 . . . . 0.0 110.558 -179.526 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 43.8 t -161.52 158.98 27.29 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.905 -1.122 . . . . 0.0 110.234 -179.803 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 69' ' ' ILE . . . . . 0.464 ' CD1' HD12 ' A' ' 30' ' ' LEU . 31.6 mm -57.97 -44.01 85.97 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.361 0 O-C-N 121.319 -0.863 . . . . 0.0 109.628 179.876 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 70' ' ' ARG . . . . . 0.41 ' HG2' ' H ' ' A' ' 71' ' ' SER . 0.0 OUTLIER -58.65 -39.3 80.18 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.276 -0.89 . . . . 0.0 109.596 -179.57 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild core ' A' A ' 71' ' ' SER . . . . . 0.594 ' OG ' ' NE ' ' A' ' 67' ' ' ARG . 41.6 t -62.59 -41.51 99.0 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.275 -0.891 . . . . 0.0 109.689 179.821 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 80.7 mt -61.01 -47.75 92.19 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 O-C-N 121.306 -0.871 . . . . 0.0 109.911 -179.62 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 32.9 t0 -60.26 -43.14 96.42 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.168 -0.958 . . . . 0.0 109.167 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 74' ' ' ALA . . . . . 0.54 ' O ' ' N ' ' A' ' 78' ' ' GLY . . . -66.84 -38.89 87.27 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.52 -0.738 . . . . 0.0 109.952 -179.829 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 71.6 t80 -61.64 -51.24 69.29 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.174 -0.953 . . . . 0.0 109.271 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' VAL . . . . . 0.764 HG11 ' CE1' ' A' ' 52' ' ' PHE . 77.6 t -69.51 -48.03 68.69 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 O-C-N 121.328 -0.857 . . . . 0.0 109.878 179.972 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 72.3 t -69.55 -47.0 74.23 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.328 0 O-C-N 121.175 -0.953 . . . . 0.0 109.756 -179.887 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' GLY . . . . . 0.54 ' N ' ' O ' ' A' ' 74' ' ' ALA . . . -61.93 -37.88 95.11 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.826 -1.309 . . . . 0.0 109.826 -179.752 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.61 -39.45 84.73 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.183 -1.187 . . . . 0.0 110.025 -179.508 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' THR . . . . . 0.523 HG23 ' O ' ' A' ' 76' ' ' VAL . 50.2 p -81.33 -31.61 33.41 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.286 -0.884 . . . . 0.0 109.594 -179.859 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' THR . . . . . 0.493 ' O ' ' O ' ' A' ' 78' ' ' GLY . 0.4 OUTLIER . . . . . 0 C--N 1.304 -1.389 0 O-C-N 121.403 -0.811 . . . . 0.0 109.908 -179.646 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' -1' ' ' SER . . . . . 0.582 ' O ' ' NE2' ' A' ' 2' ' ' GLN . 13.0 t . . . . . 0 N--CA 1.49 1.531 0 N-CA-C 109.442 -0.577 . . . . 0.0 109.442 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 0' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -56.51 -33.09 65.69 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.314 -0.866 . . . . 0.0 109.453 179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.5 ' O ' ' OD2' ' A' ' 73' ' ' ASP . 65.6 mtt -59.41 -35.67 74.4 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.225 -0.922 . . . . 0.0 109.933 -179.96 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.582 ' NE2' ' O ' ' A' ' -1' ' ' SER . 99.2 mm-40 55.02 49.49 17.5 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.132 -0.98 . . . . 0.0 109.068 -179.488 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.427 ' CB ' ' O ' ' A' ' 2' ' ' GLN . 20.4 m-70 74.23 54.31 0.09 Allowed 'General case' 0 N--CA 1.495 1.821 0 O-C-N 121.741 -0.6 . . . . 0.0 109.831 -179.754 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.462 ' HB2' ' HB3' ' A' ' 1' ' ' MET . . . -60.32 -39.97 88.91 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.105 -0.997 . . . . 0.0 109.343 179.898 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.2 m -61.76 -36.86 82.27 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.465 -0.772 . . . . 0.0 110.019 -179.754 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 64.3 t -62.35 -44.98 99.78 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.587 0 O-C-N 121.23 -0.919 . . . . 0.0 109.631 -179.762 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.493 ' O ' HG13 ' A' ' 11' ' ' VAL . 78.3 mt -59.78 -46.96 93.04 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.517 0 O-C-N 121.326 -0.858 . . . . 0.0 108.799 179.624 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.679 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -62.38 -35.12 78.19 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 108.969 -0.752 . . . . 0.0 108.969 179.328 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 7.3 tt0 -58.76 -41.12 85.81 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.084 -1.01 . . . . 0.0 109.526 -179.948 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.672 ' CG ' ' CZ2' ' A' ' 47' ' ' TRP . 52.4 m-85 -68.7 -50.16 53.1 Favored 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.045 -1.035 . . . . 0.0 110.508 -179.807 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.493 HG13 ' O ' ' A' ' 7' ' ' ILE . 1.0 OUTLIER -66.12 -39.0 83.22 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 O-C-N 121.02 -1.05 . . . . 0.0 108.99 -179.498 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.679 HG23 ' O ' ' A' ' 8' ' ' ALA . 74.8 t -63.56 -46.67 94.35 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.28 -0.888 . . . . 0.0 109.266 179.45 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 97.7 mt-10 -71.71 -23.6 61.66 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.23 -0.919 . . . . 0.0 109.825 179.665 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -64.09 -30.3 71.38 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 121.428 -0.795 . . . . 0.0 110.395 -179.078 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 72.6 t80 -139.0 -40.48 0.48 Allowed 'General case' 0 N--CA 1.494 1.731 0 O-C-N 120.969 -1.082 . . . . 0.0 110.765 -179.413 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.484 HD22 ' CG2' ' A' ' 19' ' ' VAL . 5.0 mt -120.76 80.11 32.17 Favored Pre-proline 0 N--CA 1.491 1.613 0 O-C-N 121.089 -1.007 . . . . 0.0 110.338 -179.18 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 40.7 Cg_endo -75.73 -14.78 19.48 Favored 'Trans proline' 0 C--N 1.309 -1.536 0 C-N-CA 122.439 2.093 . . . . 0.0 112.285 179.437 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -90.03 7.87 35.45 Favored 'General case' 0 N--CA 1.487 1.381 0 O-C-N 121.221 -0.925 . . . . 0.0 109.758 -179.715 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.484 ' CG2' HD22 ' A' ' 16' ' ' LEU . 43.2 t -111.69 134.86 52.77 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.665 0 O-C-N 121.417 -0.802 . . . . 0.0 109.644 -179.882 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.27 119.62 75.82 Favored Pre-proline 0 N--CA 1.489 1.477 0 O-C-N 121.263 -0.898 . . . . 0.0 109.353 179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 47.0 Cg_exo -51.2 -28.23 25.21 Favored 'Trans proline' 0 N--CA 1.493 1.483 0 C-N-CA 121.75 1.633 . . . . 0.0 112.109 179.531 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.91 -24.69 67.61 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.264 -0.898 . . . . 0.0 109.31 179.881 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.426 ' O ' ' OD1' ' A' ' 23' ' ' ASP . 60.0 t0 -81.87 7.23 13.42 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.319 -0.863 . . . . 0.0 109.789 -179.746 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 10.9 t -103.96 132.89 49.41 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.61 0 O-C-N 121.03 -1.043 . . . . 0.0 109.393 -179.884 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 87.3 m-20 -89.12 120.49 30.56 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.106 -0.996 . . . . 0.0 109.104 179.469 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 17.8 m -77.34 3.92 1.37 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.446 0 O-C-N 121.175 -0.953 . . . . 0.0 109.137 179.687 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -87.26 -13.2 44.44 Favored 'General case' 0 N--CA 1.486 1.354 0 O-C-N 121.351 -0.843 . . . . 0.0 109.149 179.518 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 41.5 tp -95.29 138.67 32.67 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.459 -0.775 . . . . 0.0 109.143 179.953 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -58.93 141.43 53.66 Favored 'General case' 0 C--N 1.303 -1.441 0 O-C-N 121.237 -0.914 . . . . 0.0 109.527 -179.605 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.979 HD13 HD11 ' A' ' 36' ' ' ILE . 1.3 tt -67.36 -38.66 85.16 Favored 'General case' 0 C--N 1.299 -1.589 0 O-C-N 121.706 -0.621 . . . . 0.0 110.322 -179.016 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 69.1 t -65.36 -36.25 77.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.103 -0.998 . . . . 0.0 110.497 -178.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 91.5 m-20 -52.79 -33.59 49.61 Favored 'General case' 0 C--N 1.301 -1.514 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 -179.917 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.455 ' HB3' HG23 ' A' ' 35' ' ' VAL . 19.7 m120 -71.05 -34.4 71.22 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.675 -0.641 . . . . 0.0 109.805 179.433 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 85.3 6.28 84.33 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 108.984 -1.646 . . . . 0.0 108.984 -179.481 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.455 HG23 ' HB3' ' A' ' 33' ' ' ASN . 79.4 t -61.73 -34.32 61.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.468 -1.019 . . . . 0.0 109.158 179.795 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.979 HD11 HD13 ' A' ' 30' ' ' LEU . 96.6 mt -87.06 117.34 31.05 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.429 0 O-C-N 121.315 -0.865 . . . . 0.0 109.78 -179.938 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -117.43 -168.2 1.45 Allowed 'General case' 0 C--N 1.302 -1.472 0 N-CA-C 108.773 -0.825 . . . . 0.0 108.773 179.703 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -63.2 -54.77 32.37 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.034 -1.041 . . . . 0.0 108.532 179.626 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 41.9 mt -70.96 -34.71 71.7 Favored 'General case' 0 C--N 1.303 -1.455 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 178.063 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.618 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.66 -39.64 95.44 Favored Glycine 0 N--CA 1.481 1.656 0 N-CA-C 108.614 -1.795 . . . . 0.0 108.614 179.105 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.601 HD11 ' CZ ' ' A' ' 66' ' ' PHE . 7.6 tt -65.2 -42.62 93.36 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.579 -0.953 . . . . 0.0 108.993 179.36 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.4 tp -61.42 -46.09 91.6 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.414 -0.804 . . . . 0.0 109.234 179.601 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 24.2 mttp -61.15 -35.99 78.57 Favored 'General case' 0 C--N 1.296 -1.721 0 O-C-N 121.504 -0.748 . . . . 0.0 109.76 -179.654 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.618 HG23 ' O ' ' A' ' 40' ' ' GLY . 60.6 t -61.2 -50.57 79.93 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.524 0 O-C-N 121.374 -0.829 . . . . 0.0 109.715 -179.663 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.547 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 1.7 mp -69.05 -31.98 52.46 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.535 0 O-C-N 121.454 -0.779 . . . . 0.0 110.721 -179.906 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -63.52 -49.42 73.58 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.108 -0.995 . . . . 0.0 111.369 -178.127 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.672 ' CZ2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -80.87 -45.13 17.32 Favored 'General case' 0 N--CA 1.492 1.643 0 O-C-N 120.723 -1.235 . . . . 0.0 109.876 -179.544 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.887 HD12 HH21 ' A' ' 51' ' ' ARG . 9.7 tp -58.33 -42.51 86.99 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.307 -0.87 . . . . 0.0 109.817 -179.169 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.547 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 1.0 OUTLIER -72.66 -35.61 67.76 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.102 -0.999 . . . . 0.0 109.772 179.999 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.1 t70 -61.13 -39.15 88.95 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.159 -0.963 . . . . 0.0 110.713 -179.456 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.887 HH21 HD12 ' A' ' 48' ' ' LEU . 66.9 mtm180 -61.51 -36.77 81.47 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.167 -0.958 . . . . 0.0 111.429 -178.727 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.531 ' CZ ' ' CG1' ' A' ' 76' ' ' VAL . 94.3 m-85 -97.13 -9.9 27.03 Favored 'General case' 0 N--CA 1.487 1.416 0 O-C-N 120.774 -1.204 . . . . 0.0 110.334 -179.057 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 71.72 31.28 65.19 Favored Glycine 0 N--CA 1.486 2.01 0 N-CA-C 108.803 -1.719 . . . . 0.0 108.803 179.874 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.48 ' O ' ' OE1' ' A' ' 49' ' ' GLU . 25.3 pt -108.48 153.26 10.14 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.416 0 O-C-N 121.593 -0.945 . . . . 0.0 109.83 -179.331 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -101.77 131.34 48.12 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.077 -1.014 . . . . 0.0 109.667 -179.735 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.503 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -67.65 -27.47 66.89 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.276 -0.89 . . . . 0.0 109.506 179.827 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -55.37 -35.09 64.9 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 121.156 -0.965 . . . . 0.0 109.971 -179.724 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 54.4 t0 -53.19 -36.96 61.51 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.175 -0.953 . . . . 0.0 109.953 -179.592 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.503 ' O ' ' O ' ' A' ' 56' ' ' ALA . 13.7 p -132.84 143.82 38.44 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.636 0 O-C-N 121.258 -0.901 . . . . 0.0 109.653 -179.859 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -88.79 134.9 33.78 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.158 -0.964 . . . . 0.0 109.331 179.93 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 67.8 mt -97.16 137.49 36.13 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 121.261 -0.899 . . . . 0.0 109.926 -179.616 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -110.37 157.01 39.36 Favored Pre-proline 0 N--CA 1.487 1.406 0 N-CA-C 108.842 -0.799 . . . . 0.0 108.842 179.478 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 9.3 Cg_endo -54.08 -23.16 27.7 Favored 'Trans proline' 0 C--N 1.301 -1.955 0 C-N-CA 122.392 2.061 . . . . 0.0 111.675 179.932 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.7 mt-10 -70.31 -27.5 64.43 Favored 'General case' 0 N--CA 1.486 1.344 0 O-C-N 121.338 -0.851 . . . . 0.0 109.447 179.653 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . 0.524 ' C ' ' CD2' ' A' ' 65' ' ' HIS . 0.9 OUTLIER -65.97 -17.89 64.98 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.357 -0.84 . . . . 0.0 109.036 -179.858 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.601 ' CZ ' HD11 ' A' ' 41' ' ' LEU . 10.5 m-85 -98.12 15.1 25.32 Favored 'General case' 0 C--N 1.301 -1.523 0 N-CA-C 108.714 -0.847 . . . . 0.0 108.714 179.622 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . 0.411 ' HG2' ' H ' ' A' ' 68' ' ' SER . 6.1 ptt180 -49.67 -39.28 35.98 Favored 'General case' 0 C--N 1.301 -1.54 0 O-C-N 121.77 -0.581 . . . . 0.0 110.225 -179.661 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.511 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 80.1 p -163.39 159.23 22.12 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 120.903 -1.123 . . . . 0.0 110.101 -179.965 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.63 ' H ' HD12 ' A' ' 69' ' ' ILE . 3.6 mp -57.74 -34.85 48.86 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 N-CA-C 108.211 -1.033 . . . . 0.0 108.211 178.93 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.403 ' HB3' ' HZ1' ' A' ' 87' ' ' LYS . 21.3 mtp180 -57.31 -40.48 77.99 Favored 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.907 -0.775 . . . . 0.0 108.907 179.904 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 15.2 t -63.47 -38.51 91.41 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.401 -0.812 . . . . 0.0 109.51 179.834 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.416 ' CD1' ' NE2' ' A' ' 65' ' ' HIS . 32.4 mm -58.94 -46.73 91.25 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.32 0 O-C-N 121.269 -0.894 . . . . 0.0 109.294 -179.845 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.5 ' OD2' ' O ' ' A' ' 1' ' ' MET . 46.7 t0 -59.43 -43.25 93.13 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 121.21 -0.932 . . . . 0.0 109.102 179.813 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.44 -40.87 89.71 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.552 -0.717 . . . . 0.0 109.78 -179.858 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 69.2 t80 -62.32 -46.42 88.79 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.35 -0.844 . . . . 0.0 109.524 -179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.644 HG21 HD11 ' A' ' 48' ' ' LEU . 53.5 t -61.76 -46.24 96.95 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 O-C-N 121.235 -0.915 . . . . 0.0 109.337 179.884 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.517 ' O ' ' O ' ' A' ' 81' ' ' THR . 53.4 t -68.62 -42.6 83.44 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.355 0 O-C-N 121.262 -0.899 . . . . 0.0 109.329 179.53 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.45 -30.27 64.73 Favored Glycine 0 N--CA 1.492 2.371 0 N-CA-C 110.181 -1.168 . . . . 0.0 110.181 -179.903 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -68.37 -41.23 80.91 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 121.264 -1.139 . . . . 0.0 111.135 -178.739 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 27.8 p -101.68 -34.59 9.41 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 120.971 -1.081 . . . . 0.0 110.877 -178.808 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.517 ' O ' ' O ' ' A' ' 77' ' ' VAL . 0.1 OUTLIER -133.21 152.63 79.87 Favored Pre-proline 0 C--N 1.301 -1.5 0 O-C-N 121.311 -0.868 . . . . 0.0 109.834 -179.274 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_exo -45.38 142.9 6.02 Favored 'Trans proline' 0 C--N 1.31 -1.496 0 C-N-CA 121.864 1.71 . . . . 0.0 111.35 179.399 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 14.8 Cg_endo -63.32 145.74 93.08 Favored 'Trans proline' 0 C--N 1.313 -1.34 0 C-N-CA 122.02 1.814 . . . . 0.0 112.622 -179.557 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.477 ' O ' ' C ' ' A' ' 85' ' ' GLU . 44.8 t -103.69 130.01 54.84 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 N-CA-C 109.157 -0.683 . . . . 0.0 109.157 179.546 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.477 ' C ' ' O ' ' A' ' 84' ' ' VAL . 96.1 mt-10 36.96 49.63 0.81 Allowed 'General case' 0 N--CA 1.493 1.719 0 O-C-N 121.586 -0.697 . . . . 0.0 109.895 179.87 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -53.29 144.58 15.9 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.18 -0.95 . . . . 0.0 109.528 -179.733 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.404 ' HD2' ' HE ' ' A' ' 67' ' ' ARG . 12.4 mttm -58.24 -34.76 70.8 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.246 -0.909 . . . . 0.0 109.446 -179.932 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.73 ' N ' HD12 ' A' ' 88' ' ' LEU . 6.7 mp -59.83 -35.35 74.55 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.26 -0.9 . . . . 0.0 109.452 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.0 mt-30 . . . . . 0 N--CA 1.49 1.56 0 CA-C-O 117.97 -1.014 . . . . 0.0 109.493 179.906 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' -1' ' ' SER . . . . . . . . . . . . . 1.5 m . . . . . 0 N--CA 1.49 1.573 0 CA-C-O 121.291 0.567 . . . . 0.0 109.474 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 0' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -58.08 144.03 41.5 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.181 -0.95 . . . . 0.0 109.536 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.692 ' HB2' ' HB2' ' A' ' 4' ' ' ALA . 59.8 mtt -91.98 63.01 4.38 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.301 -0.874 . . . . 0.0 109.17 -179.993 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.514 ' C ' ' CG ' ' A' ' 3' ' ' HIS . 95.0 mm-40 59.42 53.1 5.38 Favored 'General case' 0 N--CA 1.492 1.627 0 O-C-N 121.608 -0.683 . . . . 0.0 109.541 -179.838 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.514 ' CG ' ' C ' ' A' ' 2' ' ' GLN . 14.1 m-70 77.85 45.27 0.07 Allowed 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.701 -0.624 . . . . 0.0 109.639 -179.899 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.692 ' HB2' ' HB2' ' A' ' 1' ' ' MET . . . -61.19 -40.08 92.6 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.245 -0.909 . . . . 0.0 109.368 179.852 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.1 p -63.24 -34.05 76.83 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.269 -0.894 . . . . 0.0 109.658 -179.898 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.664 HG11 ' NH2' ' A' ' 51' ' ' ARG . 55.4 t -62.22 -44.82 99.55 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.149 -0.969 . . . . 0.0 109.418 179.8 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 77.0 mt -60.13 -41.07 85.29 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 O-C-N 121.371 -0.831 . . . . 0.0 108.934 179.47 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.471 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -60.93 -38.87 87.3 Favored 'General case' 0 C--N 1.305 -1.36 0 O-C-N 121.561 -0.712 . . . . 0.0 109.543 -179.912 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . 0.446 HE21 ' HA ' ' A' ' 6' ' ' VAL . 52.1 mt-30 -63.63 -40.8 97.8 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.135 -0.978 . . . . 0.0 110.092 -179.833 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.694 ' CG ' ' CE2' ' A' ' 47' ' ' TRP . 33.7 m-85 -62.05 -50.12 73.25 Favored 'General case' 0 N--CA 1.492 1.65 0 O-C-N 121.002 -1.062 . . . . 0.0 110.628 -179.357 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.467 HG23 ' N ' ' A' ' 12' ' ' VAL . 30.0 m -66.43 -41.74 89.22 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.546 0 O-C-N 121.006 -1.059 . . . . 0.0 109.18 -179.874 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.471 HG23 ' O ' ' A' ' 8' ' ' ALA . 77.0 t -64.02 -45.17 97.44 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.219 -0.926 . . . . 0.0 109.49 179.436 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 97.4 mt-10 -72.25 -23.43 61.21 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.22 -0.925 . . . . 0.0 110.341 -179.941 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 83.6 tt0 -64.02 -30.02 71.13 Favored 'General case' 0 N--CA 1.491 1.585 0 O-C-N 121.333 -0.854 . . . . 0.0 110.466 -178.944 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 71.3 t80 -138.31 -42.29 0.51 Allowed 'General case' 0 N--CA 1.494 1.737 0 O-C-N 121.012 -1.055 . . . . 0.0 110.887 -179.391 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.513 HD22 ' CG2' ' A' ' 19' ' ' VAL . 5.2 mt -120.03 80.2 26.39 Favored Pre-proline 0 N--CA 1.493 1.677 0 O-C-N 121.095 -1.003 . . . . 0.0 110.397 -179.119 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 37.8 Cg_endo -74.77 -14.5 21.71 Favored 'Trans proline' 0 C--N 1.309 -1.511 0 C-N-CA 122.337 2.024 . . . . 0.0 112.319 179.463 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -91.59 8.87 34.63 Favored 'General case' 0 N--CA 1.488 1.441 0 O-C-N 121.22 -0.925 . . . . 0.0 109.954 -179.666 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.513 ' CG2' HD22 ' A' ' 16' ' ' LEU . 48.8 t -110.87 135.55 49.66 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.281 -0.887 . . . . 0.0 109.742 -179.815 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.67 119.21 73.99 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.298 -0.877 . . . . 0.0 109.305 179.86 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 42.8 Cg_exo -51.36 -27.23 23.23 Favored 'Trans proline' 0 N--CA 1.494 1.507 0 C-N-CA 121.781 1.654 . . . . 0.0 112.01 179.676 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.8 -25.24 67.83 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.259 -0.901 . . . . 0.0 109.253 179.93 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.411 ' O ' ' OD1' ' A' ' 23' ' ' ASP . 58.6 t0 -81.8 7.35 12.92 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.362 -0.837 . . . . 0.0 109.693 -179.863 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 11.8 t -101.89 133.11 46.37 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 O-C-N 121.192 -0.943 . . . . 0.0 109.303 -179.851 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 86.9 m-20 -88.34 120.68 29.94 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.148 -0.97 . . . . 0.0 109.131 179.385 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 29.9 m -71.39 4.47 0.68 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.41 0 O-C-N 121.122 -0.987 . . . . 0.0 109.107 179.651 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -95.38 0.21 53.26 Favored 'General case' 0 N--CA 1.485 1.32 0 O-C-N 121.397 -0.814 . . . . 0.0 109.094 179.549 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 46.0 tp -100.68 132.97 45.8 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.409 -0.807 . . . . 0.0 109.331 -179.975 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.7 m-20 -68.78 138.06 54.51 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.285 -0.885 . . . . 0.0 109.822 -179.549 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.577 HD11 HG13 ' A' ' 69' ' ' ILE . 90.5 mt -65.5 -38.88 90.99 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.365 -0.834 . . . . 0.0 110.817 -179.899 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 75.6 t -66.08 -38.6 82.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.581 0 O-C-N 120.972 -1.08 . . . . 0.0 110.671 -178.737 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 89.7 m-20 -52.91 -34.02 53.1 Favored 'General case' 0 N--CA 1.489 1.475 0 N-CA-C 108.122 -1.066 . . . . 0.0 108.122 179.954 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.539 ' HB3' HG23 ' A' ' 35' ' ' VAL . 97.4 m-20 -71.05 -34.65 71.44 Favored 'General case' 0 C--N 1.302 -1.481 0 O-C-N 121.643 -0.661 . . . . 0.0 109.927 179.513 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 82.03 4.06 90.38 Favored Glycine 0 N--CA 1.49 2.242 0 N-CA-C 108.754 -1.738 . . . . 0.0 108.754 -179.205 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.539 HG23 ' HB3' ' A' ' 33' ' ' ASN . 70.2 t -62.7 -32.9 57.17 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.451 0 O-C-N 121.526 -0.984 . . . . 0.0 108.894 179.612 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 81.1 mt -88.57 121.24 38.58 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.368 0 O-C-N 121.318 -0.864 . . . . 0.0 110.041 -179.838 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -115.82 -159.68 0.72 Allowed 'General case' 0 C--N 1.303 -1.443 0 N-CA-C 108.966 -0.753 . . . . 0.0 108.966 179.697 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -67.77 -54.27 20.55 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.134 -0.979 . . . . 0.0 108.959 179.691 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 43.1 mt -67.08 -32.57 73.84 Favored 'General case' 0 C--N 1.303 -1.414 0 N-CA-C 107.189 -1.412 . . . . 0.0 107.189 178.447 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.486 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -58.74 -40.4 94.89 Favored Glycine 0 N--CA 1.48 1.611 0 N-CA-C 108.465 -1.854 . . . . 0.0 108.465 179.308 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.0 tt -65.45 -42.21 92.61 Favored 'General case' 0 C--N 1.303 -1.414 0 O-C-N 121.578 -0.954 . . . . 0.0 108.916 178.982 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.5 tp -60.47 -45.83 92.31 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.429 -0.795 . . . . 0.0 109.173 179.605 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 59.9 mttp -59.69 -35.59 74.8 Favored 'General case' 0 C--N 1.297 -1.712 0 O-C-N 121.547 -0.721 . . . . 0.0 109.618 -179.727 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.486 HG23 ' O ' ' A' ' 40' ' ' GLY . 54.7 t -61.68 -49.71 83.21 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.483 0 O-C-N 121.357 -0.839 . . . . 0.0 110.071 -179.519 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.531 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 3.3 mp -68.0 -31.83 53.6 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 O-C-N 121.281 -0.887 . . . . 0.0 110.811 -179.659 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.99 -49.99 65.87 Favored 'General case' 0 N--CA 1.493 1.694 0 O-C-N 120.799 -1.188 . . . . 0.0 111.359 -178.2 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.694 ' CE2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -81.17 -44.94 17.13 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.774 -1.204 . . . . 0.0 110.046 -179.385 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.82 HD11 HG21 ' A' ' 76' ' ' VAL . 22.4 tp -58.58 -42.07 87.16 Favored 'General case' 0 C--N 1.299 -1.592 0 O-C-N 121.326 -0.859 . . . . 0.0 110.095 -178.858 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.531 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 2.3 pp20? -72.59 -36.54 68.18 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.195 -0.941 . . . . 0.0 109.777 -179.976 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . 0.402 ' N ' ' CG ' ' A' ' 49' ' ' GLU . 55.9 t0 -60.3 -38.27 83.15 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.24 -0.913 . . . . 0.0 110.713 -179.463 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.664 ' NH2' HG11 ' A' ' 6' ' ' VAL . 77.0 mtp180 -61.81 -38.64 88.87 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.195 -0.941 . . . . 0.0 111.738 -178.581 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.553 ' CE1' HG11 ' A' ' 76' ' ' VAL . 87.7 m-85 -97.93 -9.39 26.32 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.803 -1.186 . . . . 0.0 110.482 -178.951 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 70.92 31.44 67.05 Favored Glycine 0 N--CA 1.487 2.092 0 N-CA-C 108.703 -1.759 . . . . 0.0 108.703 179.824 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.485 ' O ' ' OE1' ' A' ' 49' ' ' GLU . 26.4 pt -107.24 153.27 8.52 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.367 0 O-C-N 121.703 -0.881 . . . . 0.0 109.787 -179.392 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -99.23 134.04 42.66 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.12 -0.988 . . . . 0.0 109.806 -179.551 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.511 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -68.21 -22.99 64.77 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.312 -0.867 . . . . 0.0 109.533 179.725 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -54.71 -35.65 63.86 Favored 'General case' 0 N--CA 1.488 1.443 0 O-C-N 121.266 -0.896 . . . . 0.0 109.961 -179.626 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -55.66 -39.53 71.05 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.202 -0.936 . . . . 0.0 110.019 -179.65 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.511 ' O ' ' O ' ' A' ' 56' ' ' ALA . 13.9 p -136.3 142.31 38.9 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.703 0 O-C-N 121.291 -0.881 . . . . 0.0 109.685 -179.968 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -91.92 133.39 35.73 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.029 -1.044 . . . . 0.0 109.275 179.736 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.475 HD12 ' CG1' ' A' ' 45' ' ' ILE . 32.5 mt -97.92 138.75 34.78 Favored 'General case' 0 C--N 1.305 -1.363 0 O-C-N 121.332 -0.855 . . . . 0.0 109.661 -179.613 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -110.09 157.11 38.81 Favored Pre-proline 0 N--CA 1.487 1.42 0 N-CA-C 108.952 -0.758 . . . . 0.0 108.952 179.518 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_endo -54.01 -24.52 32.65 Favored 'Trans proline' 0 C--N 1.302 -1.91 0 C-N-CA 122.536 2.157 . . . . 0.0 111.567 179.891 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -71.23 -27.78 63.72 Favored 'General case' 0 C--N 1.306 -1.307 0 O-C-N 121.365 -0.834 . . . . 0.0 109.531 179.825 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . 0.525 ' NE2' ' CB ' ' A' ' 75' ' ' PHE . 8.2 t-80 -65.76 -20.3 66.21 Favored 'General case' 0 C--N 1.3 -1.544 0 O-C-N 121.185 -0.947 . . . . 0.0 108.975 -179.738 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.502 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 21.9 m-85 -91.36 16.54 9.93 Favored 'General case' 0 C--N 1.299 -1.603 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 179.901 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . 0.454 HH21 ' HB3' ' A' ' 87' ' ' LYS . 7.7 ptt180 -50.07 -37.24 32.62 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.808 -0.557 . . . . 0.0 110.254 -179.753 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 19.0 t -163.15 157.65 20.81 Favored 'General case' 0 N--CA 1.492 1.642 0 O-C-N 120.977 -1.077 . . . . 0.0 110.29 -179.626 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.665 ' H ' HD12 ' A' ' 69' ' ' ILE . 2.0 mp -58.03 -39.31 71.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.488 0 O-C-N 121.424 -0.797 . . . . 0.0 109.266 179.862 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 7.6 ptm180 -58.03 -40.68 81.49 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.574 -0.704 . . . . 0.0 109.452 179.971 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.453 ' CB ' ' NE ' ' A' ' 67' ' ' ARG . 83.5 p -65.14 -37.16 86.54 Favored 'General case' 0 C--N 1.303 -1.442 0 O-C-N 121.325 -0.859 . . . . 0.0 109.722 179.914 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.455 ' O ' HG23 ' A' ' 76' ' ' VAL . 75.3 mt -64.86 -44.94 96.24 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.268 0 O-C-N 121.245 -0.91 . . . . 0.0 109.809 179.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.427 ' OD2' ' O ' ' A' ' 1' ' ' MET . 40.4 t0 -59.75 -41.7 91.57 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.291 -0.88 . . . . 0.0 109.396 -179.828 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.75 -43.86 83.02 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.405 -0.81 . . . . 0.0 110.084 -179.777 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . 0.525 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 56.8 t80 -62.1 -46.52 88.69 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.338 -0.851 . . . . 0.0 109.537 -179.764 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.82 HG21 HD11 ' A' ' 48' ' ' LEU . 99.2 t -61.67 -44.43 98.69 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.394 0 O-C-N 121.269 -0.895 . . . . 0.0 109.027 179.92 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.522 ' O ' ' O ' ' A' ' 81' ' ' THR . 53.3 t -66.64 -43.22 90.48 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 121.374 -0.829 . . . . 0.0 109.255 179.554 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -57.81 -23.15 49.82 Favored Glycine 0 N--CA 1.492 2.409 0 N-CA-C 109.771 -1.332 . . . . 0.0 109.771 179.964 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.05 -28.88 68.57 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.259 -1.142 . . . . 0.0 110.353 -179.475 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 9.8 p -129.65 -32.73 1.9 Allowed 'General case' 0 N--CA 1.495 1.79 0 O-C-N 121.128 -0.983 . . . . 0.0 110.752 -179.274 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.522 ' O ' ' O ' ' A' ' 77' ' ' VAL . 0.1 OUTLIER -132.37 153.13 81.11 Favored Pre-proline 0 N--CA 1.489 1.498 0 O-C-N 121.188 -0.945 . . . . 0.0 109.682 -179.396 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 13.0 Cg_endo -59.51 134.18 56.57 Favored 'Trans proline' 0 C--N 1.308 -1.573 0 C-N-CA 122.22 1.947 . . . . 0.0 111.606 179.984 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 33.7 Cg_endo -71.15 152.53 62.15 Favored 'Trans proline' 0 N--CA 1.49 1.317 0 C-N-CA 122.134 1.889 . . . . 0.0 112.58 -179.606 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.453 ' O ' ' C ' ' A' ' 85' ' ' GLU . 28.8 m -102.64 134.27 44.0 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.474 0 O-C-N 121.471 -0.768 . . . . 0.0 108.959 179.516 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.453 ' C ' ' O ' ' A' ' 84' ' ' VAL . 84.0 tt0 40.66 67.8 0.48 Allowed 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.412 -0.805 . . . . 0.0 109.441 -179.739 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -52.51 148.09 7.43 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.185 -0.947 . . . . 0.0 109.599 -179.793 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.454 ' HB3' HH21 ' A' ' 67' ' ' ARG . 20.5 tttm -56.95 -36.4 70.21 Favored 'General case' 0 N--CA 1.492 1.625 0 O-C-N 121.332 -0.855 . . . . 0.0 109.427 -179.845 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 55.4 mt -90.95 142.42 27.8 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.224 -0.923 . . . . 0.0 109.448 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 63.6 tt0 . . . . . 0 N--CA 1.49 1.555 0 CA-C-O 117.954 -1.022 . . . . 0.0 109.489 179.996 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' -1' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 N--CA 1.49 1.53 0 N-CA-C 109.459 -0.571 . . . . 0.0 109.459 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 0' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -57.46 143.63 39.72 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.335 -0.853 . . . . 0.0 109.327 -179.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.413 ' HB2' ' HB2' ' A' ' 4' ' ' ALA . 68.9 mtp -110.35 -121.63 0.27 Allowed 'General case' 0 N--CA 1.486 1.363 0 O-C-N 121.306 -0.871 . . . . 0.0 108.962 -179.817 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.452 ' C ' ' N ' ' A' ' 4' ' ' ALA . 94.2 mm-40 -116.87 124.18 48.87 Favored 'General case' 0 C--N 1.3 -1.557 0 N-CA-C 107.67 -1.233 . . . . 0.0 107.67 178.752 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.43 ' C ' ' O ' ' A' ' 2' ' ' GLN . 46.0 m80 46.93 22.39 0.2 Allowed 'General case' 0 C--N 1.299 -1.601 0 N-CA-C 108.154 -1.054 . . . . 0.0 108.154 -178.919 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.452 ' N ' ' C ' ' A' ' 2' ' ' GLN . . . -55.81 -39.77 71.81 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.392 -0.817 . . . . 0.0 109.562 -179.433 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.1 m -60.75 -36.33 78.63 Favored 'General case' 0 N--CA 1.489 1.484 0 O-C-N 121.213 -0.93 . . . . 0.0 109.553 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 75.8 t -63.3 -45.67 97.61 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.575 0 O-C-N 121.21 -0.932 . . . . 0.0 109.45 -179.895 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.523 ' O ' HG13 ' A' ' 11' ' ' VAL . 78.8 mt -59.69 -45.6 94.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.373 -0.829 . . . . 0.0 108.799 179.622 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.588 ' O ' HG22 ' A' ' 12' ' ' VAL . . . -62.21 -35.27 78.38 Favored 'General case' 0 C--N 1.304 -1.374 0 N-CA-C 108.763 -0.828 . . . . 0.0 108.763 179.5 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 32.5 tt0 -59.97 -38.37 82.32 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.259 -0.901 . . . . 0.0 109.472 179.733 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.65 ' CG ' ' CZ2' ' A' ' 47' ' ' TRP . 44.0 m-85 -70.17 -47.74 60.31 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 120.971 -1.081 . . . . 0.0 111.205 -179.551 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.523 HG13 ' O ' ' A' ' 7' ' ' ILE . 0.9 OUTLIER -61.64 -46.88 95.62 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 120.881 -1.137 . . . . 0.0 110.312 -178.143 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.592 ' O ' ' N ' ' A' ' 16' ' ' LEU . 35.5 m -64.75 -46.0 93.46 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.394 0 O-C-N 120.799 -1.188 . . . . 0.0 109.552 179.758 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.536 ' N ' HG23 ' A' ' 12' ' ' VAL . 96.9 mt-10 -64.55 -26.96 68.64 Favored 'General case' 0 N--CA 1.488 1.437 0 O-C-N 120.813 -1.179 . . . . 0.0 109.737 179.798 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -64.43 -31.47 72.69 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.445 -0.785 . . . . 0.0 110.14 -179.479 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 86.6 t80 -142.84 -33.31 0.46 Allowed 'General case' 0 N--CA 1.492 1.669 0 O-C-N 120.981 -1.074 . . . . 0.0 110.794 -179.436 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.592 ' N ' ' O ' ' A' ' 12' ' ' VAL . 3.4 mt -121.95 79.8 41.95 Favored Pre-proline 0 N--CA 1.492 1.66 0 O-C-N 121.07 -1.019 . . . . 0.0 109.976 -179.32 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 44.6 Cg_endo -76.07 -18.54 16.42 Favored 'Trans proline' 0 C--N 1.309 -1.507 0 C-N-CA 122.537 2.158 . . . . 0.0 112.873 -179.756 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.442 ' C ' ' OD1' ' A' ' 18' ' ' ASP . 50.4 p30 -89.43 12.86 15.18 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.031 -1.043 . . . . 0.0 110.131 -179.565 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 84.1 t -106.79 134.41 48.52 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.782 0 O-C-N 121.187 -0.946 . . . . 0.0 109.574 179.669 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.06 118.45 65.74 Favored Pre-proline 0 N--CA 1.488 1.443 0 O-C-N 121.323 -0.861 . . . . 0.0 108.918 179.634 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 32.3 Cg_exo -51.31 -36.41 57.2 Favored 'Trans proline' 0 N--CA 1.492 1.389 0 C-N-CA 121.571 1.514 . . . . 0.0 111.912 179.966 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -68.58 -18.56 64.36 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.246 -0.909 . . . . 0.0 108.885 179.386 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.451 ' O ' ' OD1' ' A' ' 23' ' ' ASP . 60.4 t0 -81.97 7.11 13.94 Favored 'General case' 0 N--CA 1.489 1.477 0 O-C-N 121.479 -0.763 . . . . 0.0 109.91 -179.644 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 15.1 t -104.56 131.66 53.03 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.167 -0.958 . . . . 0.0 109.433 -179.954 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 62.4 t0 -88.44 119.68 29.11 Favored 'General case' 0 C--N 1.303 -1.445 0 O-C-N 121.213 -0.929 . . . . 0.0 108.689 179.256 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.2 m -75.29 3.18 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.452 0 O-C-N 121.138 -0.977 . . . . 0.0 109.484 -179.886 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 89.6 m-20 -85.49 -19.18 31.6 Favored 'General case' 0 N--CA 1.487 1.375 0 O-C-N 121.137 -0.977 . . . . 0.0 109.116 179.368 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 48.7 tp -88.84 134.04 34.07 Favored 'General case' 0 C--N 1.303 -1.418 0 N-CA-C 108.541 -0.911 . . . . 0.0 108.541 179.552 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 89.1 m-20 -60.37 135.12 57.64 Favored 'General case' 0 C--N 1.301 -1.539 0 C-N-CA 119.185 -1.006 . . . . 0.0 109.2 -179.423 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 1.043 HD23 HD11 ' A' ' 36' ' ' ILE . 39.0 tp -62.59 -36.42 82.68 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.509 -0.745 . . . . 0.0 110.257 -179.322 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 69.2 t -64.22 -35.76 74.93 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.588 0 O-C-N 121.047 -1.033 . . . . 0.0 110.466 -179.384 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -52.62 -33.72 47.88 Favored 'General case' 0 N--CA 1.489 1.521 0 N-CA-C 108.163 -1.051 . . . . 0.0 108.163 -179.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.446 ' HB3' HG23 ' A' ' 35' ' ' VAL . 97.1 m-20 -70.82 -34.55 71.83 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.606 -0.684 . . . . 0.0 110.001 179.468 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 85.71 5.16 84.53 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 108.858 -1.697 . . . . 0.0 108.858 -179.324 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.446 HG23 ' HB3' ' A' ' 33' ' ' ASN . 73.6 t -61.7 -33.05 55.72 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 121.554 -0.968 . . . . 0.0 108.979 179.678 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 1.043 HD11 HD23 ' A' ' 30' ' ' LEU . 80.2 mt -83.68 114.47 24.33 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.411 0 O-C-N 121.339 -0.851 . . . . 0.0 109.723 -179.728 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -112.6 -178.82 3.49 Favored 'General case' 0 C--N 1.302 -1.492 0 N-CA-C 108.804 -0.813 . . . . 0.0 108.804 179.542 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -58.82 -52.3 66.29 Favored 'General case' 0 N--CA 1.49 1.566 0 N-CA-C 108.245 -1.021 . . . . 0.0 108.245 179.7 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 42.3 mt -70.28 -32.65 70.53 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 106.849 -1.538 . . . . 0.0 106.849 177.922 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.606 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.27 -41.01 96.61 Favored Glycine 0 N--CA 1.481 1.67 0 N-CA-C 108.525 -1.83 . . . . 0.0 108.525 179.14 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 2.9 tt -64.87 -44.49 89.52 Favored 'General case' 0 C--N 1.305 -1.35 0 O-C-N 121.636 -0.92 . . . . 0.0 109.212 179.096 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 16.7 tp -59.55 -44.78 93.14 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.353 -0.842 . . . . 0.0 109.578 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 31.7 mttp -62.05 -34.81 76.93 Favored 'General case' 0 C--N 1.298 -1.669 0 O-C-N 121.076 -1.015 . . . . 0.0 109.541 -179.979 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.606 HG23 ' O ' ' A' ' 40' ' ' GLY . 69.4 t -61.2 -48.63 88.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.387 -0.821 . . . . 0.0 109.993 -179.528 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.541 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 3.0 mp -67.84 -32.44 56.51 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.515 0 O-C-N 121.405 -0.81 . . . . 0.0 110.948 -179.677 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.43 -50.36 63.64 Favored 'General case' 0 N--CA 1.494 1.747 0 O-C-N 120.982 -1.074 . . . . 0.0 111.373 -178.112 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.65 ' CZ2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -81.18 -44.62 17.57 Favored 'General case' 0 N--CA 1.492 1.671 0 O-C-N 120.708 -1.245 . . . . 0.0 109.853 -179.502 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.5 ' N ' ' CG ' ' A' ' 47' ' ' TRP . 38.9 tp -58.55 -42.26 87.45 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.332 -0.855 . . . . 0.0 109.958 -179.022 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.541 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 1.2 pp20? -72.63 -35.85 67.91 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.0 -1.063 . . . . 0.0 109.635 179.887 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.1 t0 -60.2 -38.25 82.73 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.237 -0.914 . . . . 0.0 110.288 -179.77 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.467 ' HD2' ' HE1' ' A' ' 47' ' ' TRP . 71.9 mtp85 -61.19 -38.12 85.4 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.244 -0.91 . . . . 0.0 111.16 -178.956 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.634 ' CE2' HG11 ' A' ' 76' ' ' VAL . 86.6 m-85 -99.53 -10.36 22.18 Favored 'General case' 0 N--CA 1.487 1.398 0 O-C-N 120.859 -1.151 . . . . 0.0 110.031 -179.388 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 69.98 33.49 70.14 Favored Glycine 0 N--CA 1.486 2.027 0 N-CA-C 108.558 -1.817 . . . . 0.0 108.558 179.856 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 38.5 pt -103.08 149.06 7.44 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 O-C-N 121.535 -0.979 . . . . 0.0 109.994 -179.239 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -94.2 120.1 33.96 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.3 -0.875 . . . . 0.0 109.459 179.978 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.492 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -66.65 -28.99 68.91 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.403 -0.81 . . . . 0.0 109.495 179.918 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 54.6 t0 -56.41 -35.03 67.34 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.387 -0.821 . . . . 0.0 110.249 -179.453 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -53.75 -39.11 65.07 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.055 -1.028 . . . . 0.0 109.65 -179.582 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.492 ' O ' ' O ' ' A' ' 56' ' ' ALA . 46.5 t -127.46 136.57 60.19 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.521 -0.737 . . . . 0.0 109.544 179.851 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -85.5 128.43 34.74 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.119 -0.988 . . . . 0.0 108.765 179.547 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 54.8 mt -98.46 141.21 31.61 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.142 -0.974 . . . . 0.0 109.997 -179.158 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -105.55 151.15 39.72 Favored Pre-proline 0 C--N 1.305 -1.361 0 N-CA-C 108.328 -0.99 . . . . 0.0 108.328 179.403 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -53.67 -21.87 20.89 Favored 'Trans proline' 0 C--N 1.306 -1.659 0 C-N-CA 122.227 1.951 . . . . 0.0 111.998 -179.54 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -70.07 -28.27 65.29 Favored 'General case' 0 N--CA 1.486 1.351 0 O-C-N 121.265 -0.897 . . . . 0.0 109.586 179.935 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . 0.586 ' CD2' ' O ' ' A' ' 65' ' ' HIS . 6.5 t-160 -65.72 -20.93 66.46 Favored 'General case' 0 C--N 1.299 -1.599 0 O-C-N 121.259 -0.901 . . . . 0.0 109.277 -179.713 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.552 ' HB3' HD13 ' A' ' 36' ' ' ILE . 7.8 m-85 -96.51 15.99 19.96 Favored 'General case' 0 C--N 1.3 -1.573 0 O-C-N 121.525 -0.734 . . . . 0.0 109.078 -179.65 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . 0.682 ' NH2' ' NZ ' ' A' ' 87' ' ' LYS . 1.3 ptt85 -54.36 -35.93 63.3 Favored 'General case' 0 C--N 1.3 -1.583 0 O-C-N 121.645 -0.659 . . . . 0.0 110.243 -179.765 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.555 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 90.4 p -157.54 160.38 38.13 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 120.912 -1.117 . . . . 0.0 110.287 -179.95 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.605 ' H ' HD12 ' A' ' 69' ' ' ILE . 3.1 mp -59.14 -34.03 52.26 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.444 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 179.007 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 57.6 mtp85 -56.95 -42.9 80.92 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.707 -0.621 . . . . 0.0 109.948 -179.266 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 78.8 p -68.71 -35.82 77.65 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.298 -0.876 . . . . 0.0 110.115 -179.601 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.434 ' O ' HG23 ' A' ' 76' ' ' VAL . 56.3 mt -65.93 -48.51 81.65 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 O-C-N 121.216 -0.928 . . . . 0.0 110.122 -179.38 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 43.9 t0 -60.17 -43.16 96.03 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.18 -0.95 . . . . 0.0 109.49 -179.757 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.95 -43.63 82.66 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.494 -0.754 . . . . 0.0 110.251 -179.579 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . 0.553 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 70.4 t80 -62.51 -45.29 93.66 Favored 'General case' 0 C--N 1.301 -1.52 0 O-C-N 121.263 -0.898 . . . . 0.0 109.697 -179.641 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.634 HG11 ' CE2' ' A' ' 52' ' ' PHE . 95.9 t -64.84 -47.06 90.0 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.361 0 O-C-N 121.206 -0.934 . . . . 0.0 109.665 -179.945 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 54.9 t -69.53 -45.98 76.93 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.329 0 O-C-N 121.1 -1.0 . . . . 0.0 109.731 179.857 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.48 ' O ' ' O ' ' A' ' 81' ' ' THR . . . -63.9 -30.73 78.55 Favored Glycine 0 N--CA 1.489 2.221 0 N-CA-C 110.307 -1.117 . . . . 0.0 110.307 -179.633 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -66.81 -39.53 87.74 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.137 -1.214 . . . . 0.0 110.516 -179.019 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 65.2 p -84.18 -28.81 27.09 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.036 -1.04 . . . . 0.0 109.778 -179.727 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.48 ' O ' ' O ' ' A' ' 78' ' ' GLY . 0.3 OUTLIER -133.27 153.9 80.84 Favored Pre-proline 0 C--N 1.302 -1.471 0 O-C-N 121.478 -0.764 . . . . 0.0 109.737 -179.546 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 14.9 Cg_endo -60.5 110.73 0.85 Allowed 'Trans proline' 0 C--N 1.308 -1.569 0 C-N-CA 122.328 2.018 . . . . 0.0 111.278 179.564 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 44.4 Cg_endo -76.13 152.12 35.29 Favored 'Trans proline' 0 C--N 1.313 -1.303 0 C-N-CA 122.074 1.849 . . . . 0.0 113.139 -179.011 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.452 ' O ' ' C ' ' A' ' 85' ' ' GLU . 47.0 t -102.88 133.99 45.14 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 N-CA-C 108.478 -0.934 . . . . 0.0 108.478 179.137 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.452 ' C ' ' O ' ' A' ' 84' ' ' VAL . 96.1 mt-10 43.3 70.2 0.33 Allowed 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.105 -0.997 . . . . 0.0 108.845 -179.315 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -50.36 148.37 3.7 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.359 -0.838 . . . . 0.0 109.842 -179.367 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.682 ' NZ ' ' NH2' ' A' ' 67' ' ' ARG . 11.2 tttm -56.71 160.37 3.39 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.356 -0.84 . . . . 0.0 109.155 179.949 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 65.8 mt -51.42 -38.02 51.41 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.15 -0.969 . . . . 0.0 109.454 -179.666 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.6 mt-30 . . . . . 0 N--CA 1.49 1.531 0 CA-C-O 117.977 -1.011 . . . . 0.0 109.513 179.914 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' -1' ' ' SER . . . . . . . . . . . . . 1.7 m . . . . . 0 N--CA 1.49 1.574 0 N-CA-C 109.413 -0.588 . . . . 0.0 109.413 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 0' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -58.76 145.91 38.8 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.315 -0.866 . . . . 0.0 109.547 179.99 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.694 ' HB2' ' HB2' ' A' ' 4' ' ' ALA . 11.7 ptt? -179.19 106.07 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.228 -0.92 . . . . 0.0 109.273 179.962 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.584 ' N ' ' OD2' ' A' ' 73' ' ' ASP . 67.3 tp60 -88.13 127.13 35.42 Favored 'General case' 0 C--N 1.3 -1.553 0 O-C-N 121.359 -0.838 . . . . 0.0 109.502 -179.874 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.474 ' CD2' HE21 ' A' ' 2' ' ' GLN . 20.8 m170 59.59 36.55 22.74 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 121.491 -0.756 . . . . 0.0 109.926 179.813 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.694 ' HB2' ' HB2' ' A' ' 1' ' ' MET . . . -61.99 -33.05 73.61 Favored 'General case' 0 N--CA 1.491 1.594 0 O-C-N 121.141 -0.974 . . . . 0.0 109.547 179.856 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.3 t -57.86 -37.56 74.13 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.284 -0.885 . . . . 0.0 109.879 -179.497 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 77.2 t -63.52 -45.41 97.86 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.169 -0.957 . . . . 0.0 109.514 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 77.7 mt -60.06 -42.72 90.79 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.501 0 O-C-N 121.405 -0.809 . . . . 0.0 109.096 179.727 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.58 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -60.89 -35.83 77.65 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.54 -0.725 . . . . 0.0 109.224 -179.982 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 30.9 tt0 -64.62 -41.77 95.97 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.234 -0.916 . . . . 0.0 110.191 -179.839 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.679 ' CG ' ' CZ2' ' A' ' 47' ' ' TRP . 37.4 m-85 -64.28 -50.62 67.16 Favored 'General case' 0 N--CA 1.494 1.764 0 O-C-N 120.975 -1.078 . . . . 0.0 110.719 -179.371 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.422 HG13 ' N ' ' A' ' 12' ' ' VAL . 4.5 p -63.57 -41.0 91.15 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.56 0 O-C-N 121.047 -1.033 . . . . 0.0 109.383 -179.575 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.58 HG23 ' O ' ' A' ' 8' ' ' ALA . 70.5 t -63.31 -46.34 95.83 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.121 -0.987 . . . . 0.0 109.339 179.558 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -71.13 -26.09 62.86 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.25 -0.906 . . . . 0.0 109.846 179.715 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -64.45 -30.61 71.65 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.46 -0.775 . . . . 0.0 110.664 -179.029 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 72.9 t80 -135.82 -42.9 0.67 Allowed 'General case' 0 N--CA 1.494 1.771 0 O-C-N 121.016 -1.053 . . . . 0.0 110.826 -179.084 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.483 HD22 ' CG2' ' A' ' 19' ' ' VAL . 4.2 mt -119.49 80.09 21.96 Favored Pre-proline 0 N--CA 1.493 1.723 0 O-C-N 121.088 -1.008 . . . . 0.0 110.377 -179.094 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 40.4 Cg_endo -75.53 -14.13 20.13 Favored 'Trans proline' 0 C--N 1.309 -1.522 0 C-N-CA 122.292 1.995 . . . . 0.0 112.217 179.404 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.42 ' OD1' ' O ' ' A' ' 18' ' ' ASP . 59.9 t0 -89.55 7.02 38.4 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.274 -0.891 . . . . 0.0 109.683 179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.483 ' CG2' HD22 ' A' ' 16' ' ' LEU . 46.1 t -111.76 135.44 51.0 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.432 -0.793 . . . . 0.0 109.651 -179.859 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.468 ' O ' ' OD1' ' A' ' 23' ' ' ASP . . . -73.49 117.88 64.26 Favored Pre-proline 0 N--CA 1.489 1.514 0 O-C-N 121.304 -0.872 . . . . 0.0 109.325 179.975 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 47.6 Cg_exo -51.45 -25.53 19.14 Favored 'Trans proline' 0 N--CA 1.493 1.47 0 C-N-CA 121.858 1.705 . . . . 0.0 112.192 179.568 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.03 -23.67 67.26 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.307 -0.871 . . . . 0.0 109.739 -179.93 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.468 ' OD1' ' O ' ' A' ' 20' ' ' ALA . 52.5 p30 -84.6 7.75 19.12 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.222 -0.924 . . . . 0.0 110.024 -179.635 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 10.9 t -104.57 131.39 53.68 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.64 0 O-C-N 121.192 -0.942 . . . . 0.0 109.397 179.981 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 87.6 m-20 -89.43 120.5 30.81 Favored 'General case' 0 C--N 1.302 -1.459 0 O-C-N 121.213 -0.93 . . . . 0.0 109.091 179.369 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.0 m -78.83 3.38 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 O-C-N 121.153 -0.967 . . . . 0.0 109.095 179.53 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 89.8 m-20 -83.5 -20.65 33.56 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 121.291 -0.881 . . . . 0.0 109.135 179.33 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 43.2 tp -88.69 137.9 31.9 Favored 'General case' 0 N--CA 1.487 1.41 0 N-CA-C 108.844 -0.798 . . . . 0.0 108.844 179.798 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 89.1 m-20 -57.33 136.27 56.55 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 121.158 -0.964 . . . . 0.0 109.35 -179.454 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.746 HD12 HG13 ' A' ' 69' ' ' ILE . 1.9 tt -66.0 -37.95 87.22 Favored 'General case' 0 C--N 1.3 -1.576 0 O-C-N 121.716 -0.615 . . . . 0.0 110.171 -179.179 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 69.9 t -63.14 -35.19 70.8 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.557 0 O-C-N 121.068 -1.02 . . . . 0.0 110.421 -178.976 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 90.8 m-20 -52.66 -33.89 49.18 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 108.062 -1.088 . . . . 0.0 108.062 179.953 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.452 ' HB3' HG23 ' A' ' 35' ' ' VAL . 97.5 m-20 -71.11 -34.62 71.27 Favored 'General case' 0 C--N 1.302 -1.47 0 O-C-N 121.571 -0.706 . . . . 0.0 109.864 179.488 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 84.4 6.83 85.59 Favored Glycine 0 N--CA 1.491 2.365 0 N-CA-C 108.962 -1.655 . . . . 0.0 108.962 -179.474 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.452 HG23 ' HB3' ' A' ' 33' ' ' ASN . 71.1 t -61.88 -35.03 65.65 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 O-C-N 121.392 -1.064 . . . . 0.0 108.95 179.74 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.699 HD11 HD13 ' A' ' 30' ' ' LEU . 99.1 mt -80.17 111.94 17.57 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.318 -0.864 . . . . 0.0 109.807 -179.942 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -113.02 -166.02 1.04 Allowed 'General case' 0 C--N 1.302 -1.458 0 N-CA-C 108.916 -0.772 . . . . 0.0 108.916 179.777 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -65.18 -54.38 30.55 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.146 -0.971 . . . . 0.0 108.71 179.712 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 34.0 mt -70.57 -33.29 70.94 Favored 'General case' 0 C--N 1.302 -1.489 0 N-CA-C 107.213 -1.402 . . . . 0.0 107.213 178.4 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.529 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.4 -41.18 96.89 Favored Glycine 0 N--CA 1.48 1.589 0 N-CA-C 108.61 -1.796 . . . . 0.0 108.61 179.205 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.7 tt -65.68 -41.55 92.29 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.519 -0.989 . . . . 0.0 109.085 179.201 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.5 tp -61.22 -46.03 92.11 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.434 -0.791 . . . . 0.0 109.361 179.888 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 63.5 mttp -60.28 -35.91 76.62 Favored 'General case' 0 C--N 1.296 -1.733 0 O-C-N 121.443 -0.786 . . . . 0.0 109.452 -179.708 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.529 HG23 ' O ' ' A' ' 40' ' ' GLY . 63.2 t -62.18 -45.82 97.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.484 0 O-C-N 121.357 -0.839 . . . . 0.0 109.668 -179.916 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.701 HG23 ' HB2' ' A' ' 56' ' ' ALA . 1.5 mp -67.96 -39.44 81.63 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.531 0 O-C-N 121.555 -0.716 . . . . 0.0 111.262 -179.375 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.09 -49.92 63.41 Favored 'General case' 0 N--CA 1.494 1.732 0 O-C-N 120.545 -1.347 . . . . 0.0 112.268 -177.603 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.679 ' CZ2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -77.85 -46.05 22.55 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 120.637 -1.29 . . . . 0.0 110.681 -178.546 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.857 HD12 HH21 ' A' ' 51' ' ' ARG . 8.8 tp -58.65 -44.59 90.16 Favored 'General case' 0 C--N 1.3 -1.572 0 O-C-N 121.173 -0.955 . . . . 0.0 110.195 -178.825 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 65.4 mm-40 -69.93 -36.21 75.14 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.135 -0.978 . . . . 0.0 109.797 -179.667 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.3 t0 -62.24 -38.43 89.19 Favored 'General case' 0 N--CA 1.492 1.647 0 O-C-N 121.367 -0.833 . . . . 0.0 111.431 -179.2 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.857 HH21 HD12 ' A' ' 48' ' ' LEU . 66.6 mtm180 -59.34 -38.92 81.58 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.023 -1.048 . . . . 0.0 111.574 -178.392 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.61 ' CE1' ' CG1' ' A' ' 76' ' ' VAL . 48.7 m-85 -90.14 -2.61 58.1 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 120.759 -1.213 . . . . 0.0 110.544 -179.199 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 73.98 29.2 63.19 Favored Glycine 0 N--CA 1.489 2.203 0 N-CA-C 108.797 -1.721 . . . . 0.0 108.797 179.546 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 31.4 pt -113.1 153.47 14.66 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 O-C-N 121.694 -0.886 . . . . 0.0 109.758 -179.397 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -101.83 138.76 38.37 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.255 -0.903 . . . . 0.0 109.426 179.97 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.701 ' HB2' HG23 ' A' ' 45' ' ' ILE . . . -64.65 -30.61 71.63 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.298 -0.876 . . . . 0.0 109.681 179.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 53.8 t0 -55.48 -36.02 66.17 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.132 -0.98 . . . . 0.0 109.827 -179.74 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -57.36 -39.89 76.94 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.199 -0.938 . . . . 0.0 110.169 -179.561 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.506 ' O ' ' O ' ' A' ' 56' ' ' ALA . 13.6 p -136.51 142.15 39.07 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.663 0 O-C-N 121.272 -0.892 . . . . 0.0 109.783 -179.941 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -101.71 137.02 40.57 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.156 -0.965 . . . . 0.0 109.433 179.815 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.492 HD23 ' ND1' ' A' ' 65' ' ' HIS . 5.5 mp -103.27 144.06 31.84 Favored 'General case' 0 C--N 1.305 -1.34 0 O-C-N 121.256 -0.902 . . . . 0.0 109.732 -179.843 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.2 OUTLIER -103.34 153.13 38.7 Favored Pre-proline 0 C--N 1.305 -1.351 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 179.81 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 8.5 Cg_endo -53.75 -24.54 30.78 Favored 'Trans proline' 0 C--N 1.306 -1.665 0 C-N-CA 122.264 1.976 . . . . 0.0 111.82 -179.832 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 95.0 mt-10 -70.42 -28.39 65.01 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 121.392 -0.818 . . . . 0.0 109.257 179.69 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . 0.524 ' NE2' ' CB ' ' A' ' 75' ' ' PHE . 7.6 t-80 -66.02 -20.04 66.05 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 121.375 -0.828 . . . . 0.0 109.027 -179.921 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.516 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 15.5 m-85 -91.98 15.1 13.93 Favored 'General case' 0 C--N 1.3 -1.554 0 N-CA-C 108.812 -0.81 . . . . 0.0 108.812 179.981 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . 0.611 ' NH1' HD11 ' A' ' 88' ' ' LEU . 7.2 ptt180 -48.6 -37.33 17.79 Favored 'General case' 0 C--N 1.301 -1.517 0 O-C-N 121.7 -0.625 . . . . 0.0 109.866 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.518 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 92.4 p -159.55 155.86 27.08 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.092 -1.005 . . . . 0.0 109.919 179.811 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.746 HG13 HD12 ' A' ' 30' ' ' LEU . 3.5 mp -58.58 -34.83 52.36 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 N-CA-C 108.502 -0.925 . . . . 0.0 108.502 179.045 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 58.6 mtp180 -57.44 -43.25 83.73 Favored 'General case' 0 N--CA 1.488 1.468 0 O-C-N 121.67 -0.644 . . . . 0.0 109.462 -179.76 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.536 ' OG ' ' CZ ' ' A' ' 67' ' ' ARG . 22.7 t -65.54 -39.9 92.27 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.465 -0.772 . . . . 0.0 109.81 179.935 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.401 ' HA ' ' NE2' ' A' ' 65' ' ' HIS . 68.5 mt -61.02 -46.41 96.7 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.313 0 O-C-N 121.313 -0.867 . . . . 0.0 110.109 -179.541 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.584 ' OD2' ' N ' ' A' ' 2' ' ' GLN . 39.4 t0 -60.28 -42.88 96.38 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.176 -0.952 . . . . 0.0 109.364 179.96 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -67.13 -41.94 85.29 Favored 'General case' 0 N--CA 1.488 1.431 0 O-C-N 121.427 -0.796 . . . . 0.0 110.466 -179.708 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . 0.524 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 62.5 t80 -62.05 -45.72 92.3 Favored 'General case' 0 N--CA 1.488 1.473 0 O-C-N 121.103 -0.998 . . . . 0.0 109.637 -179.563 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.678 ' CG2' HD21 ' A' ' 48' ' ' LEU . 69.9 t -67.12 -48.7 78.07 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.366 0 O-C-N 121.245 -0.909 . . . . 0.0 110.014 -179.853 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.49 HG21 ' HB3' ' A' ' 2' ' ' GLN . 78.3 t -70.0 -43.35 79.37 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.338 0 O-C-N 121.109 -0.994 . . . . 0.0 109.571 179.831 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -61.11 -34.04 86.44 Favored Glycine 0 N--CA 1.49 2.297 0 N-CA-C 110.436 -1.066 . . . . 0.0 110.436 -179.461 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.78 -41.28 83.47 Favored 'General case' 0 N--CA 1.493 1.692 0 O-C-N 121.262 -1.14 . . . . 0.0 111.051 -178.692 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.467 HG21 ' CD2' ' A' ' 52' ' ' PHE . 49.4 p -82.79 -32.75 27.53 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.04 -1.038 . . . . 0.0 109.679 -179.511 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER -133.47 153.93 80.61 Favored Pre-proline 0 C--N 1.301 -1.53 0 O-C-N 121.468 -0.77 . . . . 0.0 109.626 -179.383 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -63.91 115.58 3.18 Favored 'Trans proline' 0 C--N 1.307 -1.634 0 C-N-CA 122.263 1.975 . . . . 0.0 110.913 179.408 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 37.5 Cg_endo -74.48 150.61 41.13 Favored 'Trans proline' 0 N--CA 1.488 1.201 0 C-N-CA 121.862 1.708 . . . . 0.0 113.213 -179.043 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.454 ' O ' ' C ' ' A' ' 85' ' ' GLU . 34.5 m -103.45 137.94 29.87 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.472 0 N-CA-C 108.603 -0.888 . . . . 0.0 108.603 179.28 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.454 ' C ' ' O ' ' A' ' 84' ' ' VAL . 96.1 mt-10 42.35 64.34 1.15 Allowed 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.206 -0.934 . . . . 0.0 109.233 -179.677 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -44.88 151.59 0.29 Allowed 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.307 -0.871 . . . . 0.0 109.812 -179.61 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.44 ' HD3' HH21 ' A' ' 67' ' ' ARG . 16.6 tttm -55.42 -34.82 64.76 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.465 -0.772 . . . . 0.0 109.367 -179.858 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.611 HD11 ' NH1' ' A' ' 67' ' ' ARG . 50.6 mt -90.05 142.26 27.88 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.242 -0.911 . . . . 0.0 109.401 179.804 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 25.8 mt-30 . . . . . 0 N--CA 1.49 1.53 0 CA-C-O 117.94 -1.028 . . . . 0.0 109.511 -179.965 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' -1' ' ' SER . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 N--CA 1.489 1.507 0 CA-C-O 121.292 0.568 . . . . 0.0 109.475 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 0' ' ' GLU . . . . . 0.449 ' O ' ' C ' ' A' ' 1' ' ' MET . 84.8 tt0 -101.87 135.11 43.97 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.245 -0.909 . . . . 0.0 109.352 -179.931 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.591 ' HB3' ' HB2' ' A' ' 4' ' ' ALA . 68.2 mtt 41.01 88.68 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.369 -0.832 . . . . 0.0 109.493 -179.772 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.514 ' O ' ' CG ' ' A' ' 3' ' ' HIS . 94.8 mt-30 -57.73 -35.26 70.44 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.487 -0.758 . . . . 0.0 109.579 -179.863 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.514 ' CG ' ' O ' ' A' ' 2' ' ' GLN . 93.6 m-70 -156.53 60.73 0.55 Allowed 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.187 -0.946 . . . . 0.0 109.486 179.957 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.591 ' HB2' ' HB3' ' A' ' 1' ' ' MET . . . -62.1 -34.71 76.83 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.229 -0.919 . . . . 0.0 109.634 -179.871 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.2 m -59.38 -38.9 81.68 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.293 -0.88 . . . . 0.0 109.864 -179.617 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 51.8 t -66.97 -46.34 85.09 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.121 -0.987 . . . . 0.0 109.742 -179.962 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.742 HG21 ' OD1' ' A' ' 73' ' ' ASP . 87.3 mt -59.81 -50.27 80.7 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.456 0 O-C-N 121.379 -0.826 . . . . 0.0 109.847 -179.617 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -63.76 -42.3 97.85 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.272 -0.892 . . . . 0.0 110.78 -179.664 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 47.3 tt0 -69.41 -47.59 63.68 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 120.976 -1.078 . . . . 0.0 111.043 -178.582 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.688 ' CD1' ' N ' ' A' ' 11' ' ' VAL . 0.0 OUTLIER -71.66 -44.14 64.8 Favored 'General case' 0 C--N 1.298 -1.659 0 O-C-N 120.921 -1.112 . . . . 0.0 110.815 -179.226 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.688 ' N ' ' CD1' ' A' ' 10' ' ' PHE . 5.2 p -61.02 -47.84 91.78 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.652 0 O-C-N 120.996 -1.065 . . . . 0.0 110.692 -178.711 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.566 ' N ' HG13 ' A' ' 11' ' ' VAL . 8.6 p -63.62 -39.14 84.25 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 120.805 -1.184 . . . . 0.0 109.817 -179.686 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.407 ' N ' HG13 ' A' ' 12' ' ' VAL . 96.8 mt-10 -65.78 -36.17 82.77 Favored 'General case' 0 N--CA 1.486 1.33 0 O-C-N 120.93 -1.106 . . . . 0.0 110.131 -179.919 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -65.95 -42.41 90.02 Favored 'General case' 0 N--CA 1.491 1.625 0 O-C-N 121.166 -0.959 . . . . 0.0 110.196 -179.694 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 86.5 m-85 -91.47 -45.04 8.75 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.183 -0.948 . . . . 0.0 110.512 -179.691 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.537 HD22 ' CG2' ' A' ' 19' ' ' VAL . 8.5 mt -122.31 80.22 45.13 Favored Pre-proline 0 N--CA 1.49 1.539 0 O-C-N 121.421 -0.799 . . . . 0.0 110.223 -178.942 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 27.8 Cg_endo -70.17 -15.47 35.55 Favored 'Trans proline' 0 C--N 1.312 -1.373 0 C-N-CA 122.099 1.866 . . . . 0.0 112.333 179.704 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -96.07 9.74 39.86 Favored 'General case' 0 N--CA 1.488 1.436 0 O-C-N 121.163 -0.961 . . . . 0.0 110.229 -179.581 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.537 ' CG2' HD22 ' A' ' 16' ' ' LEU . 44.3 t -114.73 135.28 55.09 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.747 0 O-C-N 121.239 -0.913 . . . . 0.0 109.837 -179.782 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -74.71 118.69 72.13 Favored Pre-proline 0 N--CA 1.49 1.562 0 O-C-N 121.349 -0.844 . . . . 0.0 109.122 179.743 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_exo -51.17 -36.89 57.38 Favored 'Trans proline' 0 N--CA 1.493 1.444 0 C-N-CA 121.765 1.643 . . . . 0.0 112.008 179.635 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -66.71 -23.0 66.06 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.282 -0.886 . . . . 0.0 108.948 179.471 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 87.6 m-20 -87.98 7.13 32.55 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.406 -0.809 . . . . 0.0 109.872 -179.729 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.466 HG21 HG21 ' A' ' 12' ' ' VAL . 10.6 t -107.07 128.49 61.91 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.664 0 O-C-N 121.188 -0.945 . . . . 0.0 109.406 179.942 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 86.9 m-20 -89.81 120.29 30.92 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.137 -0.977 . . . . 0.0 109.169 179.275 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.4 m -78.87 3.36 1.74 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.465 0 O-C-N 121.125 -0.985 . . . . 0.0 108.741 179.321 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 90.5 m-20 -83.59 -19.4 35.61 Favored 'General case' 0 N--CA 1.486 1.358 0 O-C-N 121.545 -0.722 . . . . 0.0 109.073 179.392 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 42.8 tp -88.94 138.01 31.8 Favored 'General case' 0 C--N 1.304 -1.401 0 O-C-N 121.481 -0.762 . . . . 0.0 109.024 179.863 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.1 m-20 -58.61 136.92 57.75 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.11 -0.993 . . . . 0.0 109.517 -179.376 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.757 HD12 HG13 ' A' ' 69' ' ' ILE . 2.4 tt -66.46 -38.0 86.38 Favored 'General case' 0 C--N 1.299 -1.613 0 O-C-N 121.757 -0.59 . . . . 0.0 110.134 -179.232 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.418 HG23 ' O ' ' A' ' 66' ' ' PHE . 75.7 t -62.55 -34.72 66.47 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.582 0 O-C-N 121.121 -0.987 . . . . 0.0 110.436 -178.987 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -52.45 -33.97 46.73 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 120.975 -1.078 . . . . 0.0 108.104 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.421 ' HB3' HG23 ' A' ' 35' ' ' VAL . 97.2 m-20 -71.08 -34.46 71.19 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.643 -0.66 . . . . 0.0 109.949 179.389 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 85.37 6.52 83.85 Favored Glycine 0 N--CA 1.49 2.246 0 N-CA-C 109.057 -1.617 . . . . 0.0 109.057 -179.446 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.421 HG23 ' HB3' ' A' ' 33' ' ' ASN . 76.3 t -61.52 -34.49 61.82 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.471 0 O-C-N 121.438 -1.036 . . . . 0.0 109.094 179.695 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.629 HD11 HD13 ' A' ' 30' ' ' LEU . 93.9 mt -83.14 114.4 23.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.519 0 O-C-N 121.274 -0.891 . . . . 0.0 109.735 -179.876 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.402 ' H ' ' HA3' ' A' ' 40' ' ' GLY . 92.4 m-20 -118.66 -158.41 0.72 Allowed 'General case' 0 C--N 1.302 -1.47 0 N-CA-C 108.942 -0.762 . . . . 0.0 108.942 179.657 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -64.78 -54.15 35.81 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.046 -1.034 . . . . 0.0 108.506 179.631 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.597 ' N ' ' CD2' ' A' ' 39' ' ' LEU . 1.5 mm? -68.74 -32.52 72.36 Favored 'General case' 0 C--N 1.302 -1.488 0 N-CA-C 107.32 -1.363 . . . . 0.0 107.32 178.264 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.402 ' HA3' ' H ' ' A' ' 37' ' ' ASP . . . -58.79 -45.94 94.18 Favored Glycine 0 N--CA 1.483 1.781 0 N-CA-C 109.06 -1.616 . . . . 0.0 109.06 179.6 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.9 tt -64.24 -39.06 93.18 Favored 'General case' 0 C--N 1.303 -1.436 0 O-C-N 121.426 -1.043 . . . . 0.0 108.762 179.035 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.1 tp -59.68 -45.76 91.11 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.311 -0.868 . . . . 0.0 108.798 179.543 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 54.5 mttp -60.2 -35.59 75.74 Favored 'General case' 0 C--N 1.298 -1.635 0 O-C-N 121.498 -0.751 . . . . 0.0 109.536 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . . . . . . . . . 68.3 t -60.17 -46.89 93.97 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.345 -0.847 . . . . 0.0 109.567 -179.925 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.643 HD11 HD12 ' A' ' 61' ' ' LEU . 1.7 mp -68.22 -33.23 59.52 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 O-C-N 121.359 -0.838 . . . . 0.0 110.802 -179.915 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.17 -49.1 65.93 Favored 'General case' 0 N--CA 1.496 1.833 0 O-C-N 121.095 -1.003 . . . . 0.0 111.466 -178.359 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.524 ' C ' ' CD1' ' A' ' 47' ' ' TRP . 0.0 OUTLIER -80.8 -41.51 23.22 Favored 'General case' 0 N--CA 1.494 1.734 0 O-C-N 120.583 -1.323 . . . . 0.0 109.663 -179.548 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.449 HD11 ' CG2' ' A' ' 76' ' ' VAL . 8.3 tt -59.55 -41.78 90.87 Favored 'General case' 0 C--N 1.3 -1.567 0 O-C-N 121.377 -0.827 . . . . 0.0 109.909 -179.331 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.52 ' O ' ' N ' ' A' ' 53' ' ' GLY . 18.4 pt-20 -73.15 -36.92 66.75 Favored 'General case' 0 C--N 1.304 -1.371 0 O-C-N 121.099 -1.001 . . . . 0.0 109.562 -179.817 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . 0.405 ' N ' ' CG ' ' A' ' 49' ' ' GLU . 55.9 t0 -59.06 -38.49 79.5 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.321 -0.862 . . . . 0.0 110.838 -179.319 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.46 ' NH2' HG21 ' A' ' 76' ' ' VAL . 75.1 mtm180 -61.56 -41.18 97.0 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 120.986 -1.072 . . . . 0.0 111.473 -178.649 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.898 ' CE2' HG21 ' A' ' 80' ' ' THR . 36.7 m-85 -105.87 -12.54 15.81 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 120.923 -1.11 . . . . 0.0 110.173 -179.451 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.52 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 70.85 30.45 68.15 Favored Glycine 0 N--CA 1.486 2.017 0 N-CA-C 109.054 -1.618 . . . . 0.0 109.054 179.574 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 16.2 pt -97.82 129.72 47.6 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.353 0 O-C-N 121.336 -1.097 . . . . 0.0 109.756 -179.549 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -67.37 135.53 53.37 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.155 -0.966 . . . . 0.0 109.651 -179.666 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.504 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -66.37 -31.5 72.31 Favored 'General case' 0 N--CA 1.489 1.475 0 O-C-N 121.297 -0.877 . . . . 0.0 109.441 179.804 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 54.2 t0 -56.94 -36.69 70.53 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.277 -0.89 . . . . 0.0 109.999 -179.75 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 54.5 t0 -56.11 -40.38 73.61 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.182 -0.949 . . . . 0.0 109.892 -179.598 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.504 ' O ' ' O ' ' A' ' 56' ' ' ALA . 42.6 t -129.33 134.74 63.23 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.425 -0.797 . . . . 0.0 109.603 179.926 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -91.81 131.06 37.43 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.15 -0.969 . . . . 0.0 109.277 179.763 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.643 HD12 HD11 ' A' ' 45' ' ' ILE . 54.6 mt -97.82 139.27 33.92 Favored 'General case' 0 C--N 1.305 -1.327 0 O-C-N 121.297 -0.877 . . . . 0.0 109.674 -179.752 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -110.0 157.12 38.71 Favored Pre-proline 0 N--CA 1.489 1.495 0 N-CA-C 108.849 -0.796 . . . . 0.0 108.849 179.606 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 7.1 Cg_endo -52.83 -22.9 19.1 Favored 'Trans proline' 0 C--N 1.302 -1.903 0 C-N-CA 122.368 2.045 . . . . 0.0 111.72 -179.952 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 97.1 mt-10 -70.45 -27.52 64.31 Favored 'General case' 0 N--CA 1.485 1.304 0 O-C-N 121.386 -0.821 . . . . 0.0 109.507 179.6 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . 0.566 ' C ' ' CD2' ' A' ' 65' ' ' HIS . 0.7 OUTLIER -65.67 -19.8 66.05 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.315 -0.865 . . . . 0.0 108.95 -179.882 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.551 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 6.0 m-85 -98.25 16.11 22.42 Favored 'General case' 0 C--N 1.3 -1.573 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 179.839 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . 0.43 HH21 ' HB3' ' A' ' 87' ' ' LYS . 5.3 ptt180 -49.87 -38.49 35.69 Favored 'General case' 0 C--N 1.3 -1.547 0 O-C-N 121.79 -0.569 . . . . 0.0 110.031 -179.798 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.542 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 84.2 p -161.66 157.59 24.76 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.006 -1.059 . . . . 0.0 109.969 179.838 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.757 HG13 HD12 ' A' ' 30' ' ' LEU . 3.4 mp -57.97 -35.04 50.4 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 N-CA-C 108.344 -0.984 . . . . 0.0 108.344 179.034 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 59.6 mtp180 -57.51 -42.18 82.29 Favored 'General case' 0 N--CA 1.488 1.427 0 CA-C-O 121.442 0.639 . . . . 0.0 109.291 -179.968 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 60.5 p -70.46 -36.39 73.88 Favored 'General case' 0 C--N 1.303 -1.434 0 O-C-N 121.446 -0.784 . . . . 0.0 110.047 -179.707 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 81.0 mt -62.73 -51.35 73.15 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 O-C-N 121.216 -0.928 . . . . 0.0 109.626 -179.636 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.742 ' OD1' HG21 ' A' ' 7' ' ' ILE . 35.0 m-20 -63.24 -42.85 99.27 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.301 -0.875 . . . . 0.0 108.651 179.883 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -67.1 -37.43 83.93 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.571 -0.706 . . . . 0.0 109.891 179.677 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 70.4 t80 -58.87 -47.62 84.28 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.028 -1.045 . . . . 0.0 109.915 -179.387 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.592 ' CG1' ' CE1' ' A' ' 52' ' ' PHE . 76.4 t -68.11 -48.56 73.66 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.372 0 O-C-N 121.238 -0.914 . . . . 0.0 110.255 -179.559 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 50.0 t -69.69 -45.27 78.16 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.306 0 O-C-N 121.047 -1.033 . . . . 0.0 109.847 -179.796 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.458 ' O ' ' O ' ' A' ' 81' ' ' THR . . . -61.19 -39.16 96.78 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 110.208 -1.157 . . . . 0.0 110.208 -179.573 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.72 -41.02 84.15 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.189 -1.183 . . . . 0.0 110.366 -179.242 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.898 HG21 ' CE2' ' A' ' 52' ' ' PHE . 49.5 p -82.83 -29.86 29.14 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.05 -1.031 . . . . 0.0 109.691 -179.614 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.458 ' O ' ' O ' ' A' ' 78' ' ' GLY . 0.3 OUTLIER -133.21 153.64 80.8 Favored Pre-proline 0 C--N 1.303 -1.452 0 O-C-N 121.519 -0.738 . . . . 0.0 109.668 -179.561 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 33.2 Cg_endo -68.31 112.38 2.77 Favored 'Trans proline' 0 C--N 1.308 -1.565 0 C-N-CA 122.414 2.076 . . . . 0.0 111.438 179.655 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 37.3 Cg_endo -76.18 152.8 35.76 Favored 'Trans proline' 0 C--N 1.315 -1.212 0 C-N-CA 122.113 1.875 . . . . 0.0 112.772 -179.379 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.423 ' O ' ' C ' ' A' ' 85' ' ' GLU . 29.8 m -102.46 140.4 20.95 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.464 0 N-CA-C 108.724 -0.843 . . . . 0.0 108.724 179.453 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.423 ' C ' ' O ' ' A' ' 84' ' ' VAL . 84.3 tt0 43.96 68.51 0.52 Allowed 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.192 -0.943 . . . . 0.0 109.003 -179.446 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -47.04 150.83 0.72 Allowed 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.307 -0.871 . . . . 0.0 109.797 -179.598 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.43 ' HB3' HH21 ' A' ' 67' ' ' ARG . 34.1 tttm -55.63 -36.17 66.71 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.43 -0.794 . . . . 0.0 109.535 -179.852 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 53.6 mt -91.74 142.02 28.05 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.178 -0.951 . . . . 0.0 109.393 179.868 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.2 mt-30 . . . . . 0 N--CA 1.49 1.554 0 CA-C-O 117.975 -1.012 . . . . 0.0 109.457 179.983 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' -1' ' ' SER . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 N--CA 1.49 1.563 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 0' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -57.65 -36.06 71.36 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.193 -0.942 . . . . 0.0 109.398 179.975 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.614 ' HB2' ' HB2' ' A' ' 4' ' ' ALA . 50.3 mtt -111.59 -121.5 0.28 Allowed 'General case' 0 N--CA 1.486 1.326 0 O-C-N 121.299 -0.876 . . . . 0.0 108.881 179.937 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.433 ' O ' ' C ' ' A' ' 3' ' ' HIS . 61.4 tp60 -114.43 112.11 22.5 Favored 'General case' 0 C--N 1.301 -1.528 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 178.709 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.433 ' C ' ' O ' ' A' ' 2' ' ' GLN . 60.5 m-70 47.2 29.62 1.23 Allowed 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 -178.701 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.614 ' HB2' ' HB2' ' A' ' 1' ' ' MET . . . -58.92 -41.93 88.46 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.542 -0.723 . . . . 0.0 109.746 -179.395 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 85.8 p -63.79 -31.35 72.5 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.308 -0.87 . . . . 0.0 109.666 -179.873 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 73.7 t -65.05 -45.26 94.95 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.491 0 O-C-N 121.182 -0.949 . . . . 0.0 109.432 -179.929 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.447 ' CG2' HG23 ' A' ' 69' ' ' ILE . 76.0 mt -60.25 -43.58 93.74 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.521 0 O-C-N 121.445 -0.784 . . . . 0.0 109.165 179.771 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.476 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -60.33 -35.96 76.86 Favored 'General case' 0 C--N 1.305 -1.369 0 O-C-N 121.499 -0.75 . . . . 0.0 109.23 -179.898 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 7.3 tt0 -64.97 -41.19 95.67 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.22 -0.925 . . . . 0.0 110.142 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.693 ' CG ' ' CZ2' ' A' ' 47' ' ' TRP . 30.2 m-85 -62.6 -50.36 71.57 Favored 'General case' 0 N--CA 1.493 1.718 0 O-C-N 121.041 -1.037 . . . . 0.0 110.688 -179.381 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.452 HG23 ' N ' ' A' ' 12' ' ' VAL . 24.9 m -63.82 -41.78 93.69 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.508 0 O-C-N 121.062 -1.024 . . . . 0.0 109.343 -179.473 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.476 HG23 ' O ' ' A' ' 8' ' ' ALA . 71.2 t -63.82 -46.73 93.56 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.476 0 O-C-N 121.138 -0.976 . . . . 0.0 109.351 179.498 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -70.4 -29.0 65.52 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.226 -0.921 . . . . 0.0 110.124 179.945 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 83.9 tt0 -64.58 -29.98 71.0 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.346 -0.846 . . . . 0.0 110.611 -178.996 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 75.3 t80 -132.83 -46.1 0.87 Allowed 'General case' 0 N--CA 1.496 1.855 0 O-C-N 121.01 -1.056 . . . . 0.0 110.959 -179.075 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.453 ' C ' ' O ' ' A' ' 12' ' ' VAL . 3.3 mt -118.03 80.01 14.57 Favored Pre-proline 0 N--CA 1.493 1.72 0 O-C-N 121.216 -0.928 . . . . 0.0 110.424 -178.855 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -77.82 -11.97 16.56 Favored 'Trans proline' 0 C--N 1.308 -1.57 0 C-N-CA 122.551 2.168 . . . . 0.0 112.483 179.569 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.8 ' OD1' HG23 ' A' ' 19' ' ' VAL . 53.2 p30 -90.19 8.38 33.31 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 121.092 -1.005 . . . . 0.0 110.125 -179.651 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.8 HG23 ' OD1' ' A' ' 18' ' ' ASP . 51.6 t -119.34 135.51 59.49 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.749 0 O-C-N 121.365 -0.834 . . . . 0.0 109.688 179.95 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.34 120.44 79.71 Favored Pre-proline 0 N--CA 1.49 1.527 0 O-C-N 121.258 -0.901 . . . . 0.0 109.421 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 43.8 Cg_exo -51.53 -27.54 25.47 Favored 'Trans proline' 0 N--CA 1.493 1.478 0 C-N-CA 121.764 1.643 . . . . 0.0 112.036 179.478 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.77 -25.83 68.09 Favored 'General case' 0 N--CA 1.489 1.525 0 O-C-N 121.317 -0.864 . . . . 0.0 109.357 179.932 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.445 ' O ' ' OD1' ' A' ' 23' ' ' ASP . 60.0 t0 -81.78 5.82 17.43 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.368 -0.832 . . . . 0.0 109.721 -179.826 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 11.7 t -108.25 132.47 55.95 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.647 0 O-C-N 121.24 -0.912 . . . . 0.0 109.462 -179.952 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 86.3 m-20 -89.19 120.51 30.63 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.144 -0.973 . . . . 0.0 109.004 179.356 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.9 m -77.12 2.49 1.73 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 O-C-N 121.005 -1.059 . . . . 0.0 108.991 179.592 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 87.6 m-20 -78.83 -28.56 44.4 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 121.305 -0.872 . . . . 0.0 108.808 178.974 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 45.9 tp -83.16 139.32 33.24 Favored 'General case' 0 N--CA 1.487 1.388 0 N-CA-C 108.529 -0.915 . . . . 0.0 108.529 179.53 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.5 m-20 -56.64 132.63 52.39 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.035 -1.04 . . . . 0.0 109.556 -178.969 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 1.045 HD23 HD11 ' A' ' 36' ' ' ILE . 50.8 tp -64.9 -36.87 85.75 Favored 'General case' 0 C--N 1.301 -1.505 0 O-C-N 121.7 -0.625 . . . . 0.0 110.552 -179.471 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 78.9 t -63.38 -34.89 69.94 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.089 -1.007 . . . . 0.0 110.54 -179.11 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 90.6 m-20 -52.58 -33.35 45.68 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.001 -1.062 . . . . 0.0 108.181 -179.922 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 97.5 m-20 -70.81 -34.21 71.51 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.625 -0.672 . . . . 0.0 109.98 179.483 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 90.68 3.62 70.99 Favored Glycine 0 N--CA 1.49 2.285 0 N-CA-C 108.974 -1.65 . . . . 0.0 108.974 -179.267 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 75.7 t -60.92 -29.2 45.0 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.373 0 O-C-N 121.431 -1.041 . . . . 0.0 108.66 179.415 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 1.045 HD11 HD23 ' A' ' 30' ' ' LEU . 71.0 mt -95.56 134.67 32.18 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 O-C-N 121.478 -0.764 . . . . 0.0 109.406 -179.88 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.534 ' CG ' ' H ' ' A' ' 38' ' ' ALA . 50.2 t0 -138.9 -169.82 2.72 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 -179.97 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.534 ' H ' ' CG ' ' A' ' 37' ' ' ASP . . . -62.0 -54.16 45.5 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.147 -0.971 . . . . 0.0 108.765 179.911 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.695 HD12 ' N ' ' A' ' 39' ' ' LEU . 6.9 mp -69.76 -32.71 71.38 Favored 'General case' 0 C--N 1.301 -1.519 0 N-CA-C 107.201 -1.407 . . . . 0.0 107.201 178.091 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.548 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.39 -44.74 96.39 Favored Glycine 0 N--CA 1.483 1.805 0 N-CA-C 108.971 -1.652 . . . . 0.0 108.971 179.456 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.705 HD11 ' CE1' ' A' ' 66' ' ' PHE . 7.9 tt -65.0 -40.4 94.89 Favored 'General case' 0 C--N 1.303 -1.437 0 O-C-N 121.423 -1.046 . . . . 0.0 109.195 179.367 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.1 tp -59.68 -46.02 90.31 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.1 -1.0 . . . . 0.0 108.887 179.675 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 59.7 mttp -61.3 -34.89 75.96 Favored 'General case' 0 C--N 1.297 -1.71 0 O-C-N 121.546 -0.722 . . . . 0.0 109.448 -180.0 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.548 HG23 ' O ' ' A' ' 40' ' ' GLY . 73.8 t -59.47 -43.27 90.22 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.455 0 O-C-N 121.299 -0.876 . . . . 0.0 109.142 179.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.525 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 6.7 mm -66.95 -38.74 81.98 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 121.395 -0.815 . . . . 0.0 110.752 -179.363 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.21 -49.77 68.44 Favored 'General case' 0 N--CA 1.495 1.78 0 O-C-N 121.128 -0.983 . . . . 0.0 111.716 -178.064 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.693 ' CZ2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -80.84 -44.34 18.59 Favored 'General case' 0 N--CA 1.493 1.691 0 O-C-N 120.648 -1.283 . . . . 0.0 109.99 -179.277 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.735 HD21 ' CG2' ' A' ' 76' ' ' VAL . 20.8 tp -58.93 -41.97 88.63 Favored 'General case' 0 C--N 1.3 -1.559 0 O-C-N 121.209 -0.932 . . . . 0.0 110.094 -178.921 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.525 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 1.2 pp20? -72.25 -36.87 69.19 Favored 'General case' 0 N--CA 1.489 1.491 0 O-C-N 121.009 -1.057 . . . . 0.0 109.589 -179.889 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.7 t0 -61.19 -38.18 85.61 Favored 'General case' 0 N--CA 1.49 1.571 0 O-C-N 121.232 -0.917 . . . . 0.0 110.441 -179.834 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 14.8 mmm180 -61.69 -37.09 82.86 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.308 -0.87 . . . . 0.0 111.432 -178.703 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.634 ' CZ ' ' CG1' ' A' ' 76' ' ' VAL . 72.6 m-85 -96.82 -8.0 32.16 Favored 'General case' 0 N--CA 1.487 1.375 0 O-C-N 120.769 -1.207 . . . . 0.0 110.172 -178.956 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 71.18 31.22 66.55 Favored Glycine 0 N--CA 1.485 1.945 0 N-CA-C 108.82 -1.712 . . . . 0.0 108.82 179.771 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.487 ' O ' ' OE1' ' A' ' 49' ' ' GLU . 24.7 pt -108.81 153.13 10.62 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.329 0 O-C-N 121.598 -0.942 . . . . 0.0 109.84 -179.3 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -103.79 155.49 18.56 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.411 -0.805 . . . . 0.0 109.436 -179.638 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -58.46 -26.32 63.24 Favored 'General case' 0 N--CA 1.488 1.469 0 O-C-N 121.317 -0.865 . . . . 0.0 109.325 -179.959 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 60.9 t0 59.13 38.29 23.81 Favored 'General case' 0 N--CA 1.486 1.336 0 O-C-N 121.445 -0.784 . . . . 0.0 109.109 -179.79 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 54.27 44.97 28.24 Favored 'General case' 0 N--CA 1.486 1.328 0 O-C-N 121.588 -0.695 . . . . 0.0 110.354 179.272 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . . . . . . . . . 52.9 t -120.85 134.08 65.45 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.387 -0.82 . . . . 0.0 109.091 179.339 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -102.52 130.7 49.43 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.282 -0.886 . . . . 0.0 109.664 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 60.8 mt -99.24 143.88 29.0 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.394 -0.816 . . . . 0.0 109.17 179.834 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 11.6 p -90.09 148.17 38.8 Favored Pre-proline 0 C--N 1.305 -1.346 0 O-C-N 121.053 -1.029 . . . . 0.0 108.707 179.821 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 11.8 Cg_endo -57.62 -19.78 38.99 Favored 'Trans proline' 0 C--N 1.305 -1.754 0 C-N-CA 122.24 1.96 . . . . 0.0 111.858 -179.714 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -67.41 -30.78 70.63 Favored 'General case' 0 N--CA 1.485 1.304 0 O-C-N 121.376 -0.828 . . . . 0.0 109.226 -179.977 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . 0.568 ' CD2' ' O ' ' A' ' 65' ' ' HIS . 2.7 t-80 -66.47 -19.47 65.8 Favored 'General case' 0 C--N 1.3 -1.584 0 O-C-N 121.262 -0.899 . . . . 0.0 108.815 179.82 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.705 ' CE1' HD11 ' A' ' 41' ' ' LEU . 6.6 m-85 -98.31 13.3 31.94 Favored 'General case' 0 C--N 1.3 -1.571 0 N-CA-C 108.89 -0.781 . . . . 0.0 108.89 -179.753 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . 0.446 HH21 ' HD2' ' A' ' 87' ' ' LYS . 1.5 ptt180 -49.82 -34.74 20.58 Favored 'General case' 0 C--N 1.299 -1.587 0 O-C-N 121.716 -0.615 . . . . 0.0 110.167 -179.778 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.501 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 23.3 t -153.17 154.88 35.63 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.101 -1.0 . . . . 0.0 110.041 -179.577 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.605 ' H ' HD12 ' A' ' 69' ' ' ILE . 3.3 mp -57.45 -33.99 45.53 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.494 0 N-CA-C 108.121 -1.066 . . . . 0.0 108.121 178.886 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.703 ' NE ' ' HZ1' ' A' ' 87' ' ' LYS . 60.4 mtp180 -56.99 -45.61 82.85 Favored 'General case' 0 N--CA 1.488 1.453 0 CA-C-O 121.395 0.617 . . . . 0.0 109.567 -179.516 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 22.9 t -65.82 -41.43 91.86 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.283 -0.886 . . . . 0.0 109.87 -179.944 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 68.5 mt -61.38 -45.38 98.75 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.365 0 O-C-N 121.265 -0.897 . . . . 0.0 110.022 -179.566 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 41.4 t0 -60.15 -40.79 91.08 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.178 -0.951 . . . . 0.0 109.573 -179.846 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.36 -46.06 78.02 Favored 'General case' 0 C--N 1.304 -1.393 0 O-C-N 121.232 -0.917 . . . . 0.0 109.593 -179.75 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . 0.51 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 63.5 t80 -63.19 -44.07 96.41 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.247 -0.908 . . . . 0.0 109.127 179.621 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.735 ' CG2' HD21 ' A' ' 48' ' ' LEU . 55.4 t -62.57 -46.66 95.84 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.309 0 O-C-N 121.407 -0.808 . . . . 0.0 109.404 179.607 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.504 ' O ' ' O ' ' A' ' 81' ' ' THR . 72.5 t -68.87 -41.71 82.23 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.384 0 O-C-N 121.262 -0.899 . . . . 0.0 109.402 179.803 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.38 -23.45 53.78 Favored Glycine 0 N--CA 1.492 2.374 0 N-CA-C 109.798 -1.321 . . . . 0.0 109.798 179.903 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.08 -33.2 74.97 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.283 -1.128 . . . . 0.0 110.639 -179.149 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 26.2 p -121.46 -33.75 3.58 Favored 'General case' 0 N--CA 1.496 1.846 0 O-C-N 121.232 -0.918 . . . . 0.0 110.776 -179.179 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.504 ' O ' ' O ' ' A' ' 77' ' ' VAL . 0.0 OUTLIER -132.88 152.72 80.34 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.247 -0.908 . . . . 0.0 109.759 -179.388 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 50.7 Cg_exo -43.9 148.47 0.98 Allowed 'Trans proline' 0 C--N 1.311 -1.415 0 C-N-CA 122.052 1.835 . . . . 0.0 111.491 179.63 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 18.1 Cg_endo -63.01 150.29 89.1 Favored 'Trans proline' 0 C--N 1.31 -1.492 0 C-N-CA 122.245 1.963 . . . . 0.0 112.543 -179.589 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.453 ' O ' ' C ' ' A' ' 85' ' ' GLU . 45.6 t -102.79 130.78 52.29 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.478 0 N-CA-C 108.871 -0.789 . . . . 0.0 108.871 179.496 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.453 ' C ' ' O ' ' A' ' 84' ' ' VAL . 81.5 tt0 41.04 61.13 1.82 Allowed 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.418 -0.801 . . . . 0.0 109.169 -179.688 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -52.08 147.05 7.85 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.214 -0.929 . . . . 0.0 109.538 -179.593 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.703 ' HZ1' ' NE ' ' A' ' 70' ' ' ARG . 68.0 mttm -76.41 -169.14 1.12 Allowed 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.347 -0.846 . . . . 0.0 109.891 -179.808 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 32.6 mt -81.25 144.74 31.35 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.452 -0.78 . . . . 0.0 109.483 -179.56 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 25.9 mt-30 . . . . . 0 N--CA 1.49 1.56 0 CA-C-O 117.963 -1.018 . . . . 0.0 109.463 179.981 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' -1' ' ' SER . . . . . 0.47 ' HB2' ' H ' ' A' ' 4' ' ' ALA . 2.4 p . . . . . 0 N--CA 1.49 1.574 0 CA-C-O 121.303 0.573 . . . . 0.0 109.489 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 0' ' ' GLU . . . . . . . . . . . . . 96.9 mt-10 -61.56 -33.95 74.74 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.209 -0.932 . . . . 0.0 109.343 179.932 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.605 ' HB2' ' HB2' ' A' ' 4' ' ' ALA . 70.7 mtp -111.12 -121.03 0.28 Allowed 'General case' 0 C--N 1.306 -1.324 0 O-C-N 121.414 -0.804 . . . . 0.0 108.938 -179.903 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.431 ' O ' ' C ' ' A' ' 3' ' ' HIS . 61.8 tp60 -109.91 112.35 24.32 Favored 'General case' 0 C--N 1.301 -1.512 0 N-CA-C 107.822 -1.177 . . . . 0.0 107.822 178.926 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.431 ' C ' ' O ' ' A' ' 2' ' ' GLN . 38.4 m170 47.39 27.19 0.87 Allowed 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 107.849 -1.167 . . . . 0.0 107.849 -178.765 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.605 ' HB2' ' HB2' ' A' ' 1' ' ' MET . . . -58.89 -43.8 91.03 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.652 -0.655 . . . . 0.0 109.944 -179.224 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 94.9 p -65.95 -32.18 73.53 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.324 -0.86 . . . . 0.0 110.083 -179.663 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 79.1 t -65.26 -47.13 88.5 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.523 0 O-C-N 121.101 -1.0 . . . . 0.0 109.584 -179.718 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.545 ' O ' HG12 ' A' ' 11' ' ' VAL . 81.2 mt -59.96 -48.82 86.35 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.521 0 O-C-N 121.315 -0.865 . . . . 0.0 109.702 179.988 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.719 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.29 -43.5 97.7 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.421 -0.799 . . . . 0.0 110.7 -179.349 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 44.4 tt0 -68.67 -47.58 66.14 Favored 'General case' 0 N--CA 1.492 1.67 0 O-C-N 120.97 -1.081 . . . . 0.0 110.861 -178.859 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.531 ' C ' ' CD1' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -70.96 -48.12 55.2 Favored 'General case' 0 N--CA 1.491 1.599 0 O-C-N 121.149 -0.97 . . . . 0.0 110.36 -179.651 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.545 HG12 ' O ' ' A' ' 7' ' ' ILE . 4.2 p -59.92 -38.95 78.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.089 -1.007 . . . . 0.0 109.742 -179.542 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.719 HG23 ' O ' ' A' ' 8' ' ' ALA . 52.0 t -63.22 -43.26 98.66 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.543 0 O-C-N 121.099 -1.0 . . . . 0.0 109.839 179.947 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -63.81 -38.74 92.2 Favored 'General case' 0 N--CA 1.487 1.377 0 O-C-N 121.086 -1.008 . . . . 0.0 110.252 -179.638 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 85.5 tt0 -69.95 -42.17 73.57 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.0 -1.063 . . . . 0.0 110.218 -179.698 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 79.6 t80 -84.97 -52.96 5.61 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.16 -0.963 . . . . 0.0 110.798 -179.259 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.501 HD22 ' CG2' ' A' ' 19' ' ' VAL . 6.3 mt -122.53 80.08 46.93 Favored Pre-proline 0 N--CA 1.491 1.593 0 O-C-N 121.341 -0.85 . . . . 0.0 110.371 -179.004 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 22.0 Cg_endo -68.39 -14.54 40.32 Favored 'Trans proline' 0 C--N 1.311 -1.403 0 C-N-CA 122.012 1.808 . . . . 0.0 112.33 179.464 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.459 ' OD1' ' O ' ' A' ' 18' ' ' ASP . 60.2 t0 -94.61 6.22 49.5 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.187 -0.945 . . . . 0.0 110.137 -179.705 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.501 ' CG2' HD22 ' A' ' 16' ' ' LEU . 25.9 t -118.57 135.89 57.53 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.786 0 O-C-N 121.268 -0.895 . . . . 0.0 109.636 -179.896 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.491 ' O ' ' OD1' ' A' ' 23' ' ' ASP . . . -77.14 117.19 63.56 Favored Pre-proline 0 N--CA 1.489 1.489 0 O-C-N 121.234 -0.916 . . . . 0.0 108.935 179.722 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_exo -51.71 -26.23 22.75 Favored 'Trans proline' 0 N--CA 1.492 1.407 0 C-N-CA 121.8 1.666 . . . . 0.0 112.211 179.693 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.09 -24.94 67.58 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.35 -0.844 . . . . 0.0 109.775 -179.913 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.503 ' OD1' HG23 ' A' ' 24' ' ' VAL . 49.2 p30 -86.38 7.07 27.15 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.104 -0.998 . . . . 0.0 110.008 -179.555 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.503 HG23 ' OD1' ' A' ' 23' ' ' ASP . 15.6 t -110.4 131.9 60.23 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.73 0 O-C-N 121.315 -0.866 . . . . 0.0 109.504 179.868 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . 0.513 ' C ' ' H ' ' A' ' 27' ' ' ASP . 62.9 t0 -89.25 119.37 29.68 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.148 -0.97 . . . . 0.0 108.981 179.223 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.439 ' O ' HG13 ' A' ' 26' ' ' VAL . 0.3 OUTLIER -63.87 4.25 0.24 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.421 0 O-C-N 121.172 -0.955 . . . . 0.0 109.315 179.874 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.513 ' H ' ' C ' ' A' ' 25' ' ' ASP . 92.0 m-20 -105.02 6.63 33.54 Favored 'General case' 0 N--CA 1.485 1.301 0 O-C-N 121.263 -0.898 . . . . 0.0 109.32 179.772 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . 0.404 HD23 ' OD1' ' A' ' 33' ' ' ASN . 45.5 tp -96.8 136.29 37.56 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.373 -0.829 . . . . 0.0 109.238 -179.828 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 80.5 m-20 -64.7 142.52 58.4 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.231 -0.918 . . . . 0.0 109.967 -179.167 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.576 ' N ' ' O ' ' A' ' 67' ' ' ARG . 76.0 mt -70.3 -35.07 73.46 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.468 -0.77 . . . . 0.0 110.987 -179.577 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.61 HG23 ' N ' ' A' ' 32' ' ' ASP . 35.1 m -57.75 -47.09 86.69 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.515 0 O-C-N 121.123 -0.986 . . . . 0.0 110.177 -178.958 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.61 ' N ' HG23 ' A' ' 31' ' ' VAL . 90.8 m-20 -61.18 -34.24 74.73 Favored 'General case' 0 C--N 1.302 -1.489 0 N-CA-C 108.439 -0.948 . . . . 0.0 108.439 179.403 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.404 ' OD1' HD23 ' A' ' 28' ' ' LEU . 96.6 m-20 -70.8 -34.18 71.49 Favored 'General case' 0 C--N 1.301 -1.534 0 O-C-N 121.752 -0.592 . . . . 0.0 110.115 -179.883 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 86.61 6.36 80.48 Favored Glycine 0 N--CA 1.491 2.307 0 N-CA-C 108.872 -1.691 . . . . 0.0 108.872 -179.516 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 70.8 t -59.06 -32.21 47.36 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.423 0 O-C-N 121.464 -1.021 . . . . 0.0 108.293 179.42 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 79.8 mt -85.82 129.56 37.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 CA-C-O 121.656 0.741 . . . . 0.0 109.735 179.889 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.49 ' CG ' ' H ' ' A' ' 38' ' ' ALA . 51.2 t0 -148.85 -170.84 3.72 Favored 'General case' 0 C--N 1.298 -1.647 0 N-CA-C 108.359 -0.978 . . . . 0.0 108.359 179.776 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.49 ' H ' ' CG ' ' A' ' 37' ' ' ASP . . . -61.35 -54.66 40.89 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 120.893 -1.129 . . . . 0.0 108.422 179.772 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.718 HD12 ' N ' ' A' ' 39' ' ' LEU . 6.8 mp -71.61 -33.22 68.79 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 107.468 -1.308 . . . . 0.0 107.468 178.094 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.535 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.77 -46.61 93.77 Favored Glycine 0 N--CA 1.484 1.885 0 N-CA-C 109.255 -1.538 . . . . 0.0 109.255 179.833 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 3.4 tt -63.81 -43.28 96.73 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 121.419 -1.047 . . . . 0.0 109.654 179.563 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 17.2 tp -59.75 -45.22 92.89 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.313 -0.867 . . . . 0.0 109.728 -179.653 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 24.8 mttm -63.36 -34.45 77.74 Favored 'General case' 0 C--N 1.297 -1.678 0 O-C-N 121.052 -1.03 . . . . 0.0 109.705 -179.967 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.591 HG11 ' CE2' ' A' ' 66' ' ' PHE . 54.7 t -61.38 -50.79 78.98 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.332 -0.855 . . . . 0.0 110.624 -179.077 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.497 ' H ' HD12 ' A' ' 45' ' ' ILE . 3.5 mp -68.27 -40.08 82.06 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.523 0 O-C-N 121.17 -0.957 . . . . 0.0 111.34 -179.431 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.66 -49.63 61.91 Favored 'General case' 0 N--CA 1.496 1.873 0 O-C-N 121.081 -1.012 . . . . 0.0 112.215 -177.692 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.551 ' C ' ' CD1' ' A' ' 47' ' ' TRP . 0.0 OUTLIER -78.76 -43.43 25.61 Favored 'General case' 0 N--CA 1.493 1.684 0 O-C-N 120.671 -1.268 . . . . 0.0 110.37 -178.717 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.848 HD11 HG21 ' A' ' 76' ' ' VAL . 16.7 tp -59.99 -41.78 92.79 Favored 'General case' 0 C--N 1.3 -1.562 0 O-C-N 121.195 -0.941 . . . . 0.0 110.326 -178.754 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.413 ' CG ' ' N ' ' A' ' 50' ' ' ASP . 17.8 pt-20 -73.02 -37.15 67.03 Favored 'General case' 0 C--N 1.304 -1.375 0 O-C-N 121.117 -0.99 . . . . 0.0 109.856 -179.673 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . 0.413 ' N ' ' CG ' ' A' ' 49' ' ' GLU . 56.8 t0 -60.0 -39.26 85.14 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.375 -0.828 . . . . 0.0 111.036 -179.269 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.464 ' HD2' ' HE1' ' A' ' 47' ' ' TRP . 80.6 mtp180 -61.07 -37.61 83.28 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.105 -0.997 . . . . 0.0 111.603 -178.649 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.644 ' CZ ' ' CG1' ' A' ' 76' ' ' VAL . 48.6 m-85 -98.48 -8.18 27.14 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 120.79 -1.194 . . . . 0.0 110.456 -179.012 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 69.87 31.7 70.04 Favored Glycine 0 N--CA 1.488 2.117 0 N-CA-C 108.752 -1.739 . . . . 0.0 108.752 179.653 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 27.9 pt -108.51 153.44 10.12 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 O-C-N 121.62 -0.929 . . . . 0.0 109.908 -179.372 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -100.09 129.95 46.18 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.152 -0.968 . . . . 0.0 109.51 -179.809 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.502 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -66.51 -28.82 68.86 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.294 -0.879 . . . . 0.0 109.581 179.895 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 53.9 t0 -55.41 -36.09 66.08 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.305 -0.872 . . . . 0.0 109.998 -179.642 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -56.88 -40.3 75.95 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.201 -0.937 . . . . 0.0 109.952 -179.584 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.502 ' O ' ' O ' ' A' ' 56' ' ' ALA . 42.1 t -129.16 134.81 63.31 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.696 0 O-C-N 121.393 -0.817 . . . . 0.0 109.543 179.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 95.9 mt-10 -79.25 126.63 31.03 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.097 -1.002 . . . . 0.0 109.436 179.896 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.482 HD12 ' O ' ' A' ' 59' ' ' VAL . 5.3 mp -108.04 139.54 42.53 Favored 'General case' 0 C--N 1.305 -1.333 0 O-C-N 121.372 -0.83 . . . . 0.0 109.651 -179.904 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -107.02 145.34 30.92 Favored Pre-proline 0 N--CA 1.484 1.267 0 N-CA-C 108.326 -0.99 . . . . 0.0 108.326 179.098 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 17.7 Cg_endo -60.73 -19.94 63.35 Favored 'Trans proline' 0 C--N 1.306 -1.699 0 C-N-CA 122.107 1.871 . . . . 0.0 112.021 -179.55 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 90.1 mt-10 -69.25 -28.39 66.29 Favored 'General case' 0 C--N 1.305 -1.364 0 O-C-N 121.439 -0.788 . . . . 0.0 109.676 -179.613 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . 0.59 ' CD2' ' O ' ' A' ' 65' ' ' HIS . 0.0 OUTLIER -66.55 -19.12 65.7 Favored 'General case' 0 C--N 1.3 -1.555 0 O-C-N 121.199 -0.938 . . . . 0.0 109.182 -179.563 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.591 ' CE2' HG11 ' A' ' 44' ' ' VAL . 16.5 m-85 -96.15 11.03 35.77 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.291 -0.881 . . . . 0.0 109.317 179.794 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . 0.576 ' O ' ' N ' ' A' ' 30' ' ' LEU . 1.7 ptt180 -50.08 -21.86 1.43 Allowed 'General case' 0 C--N 1.3 -1.554 0 O-C-N 121.381 -0.824 . . . . 0.0 110.049 -179.671 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.444 ' O ' ' OG ' ' A' ' 71' ' ' SER . 34.4 t -147.14 147.03 30.13 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.137 -0.977 . . . . 0.0 109.883 -179.875 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.713 ' H ' HD12 ' A' ' 69' ' ' ILE . 2.3 mp -59.92 -38.72 77.67 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.532 0 O-C-N 121.288 -0.883 . . . . 0.0 109.566 -179.826 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.429 ' O ' ' OD2' ' A' ' 73' ' ' ASP . 6.1 ptm180 -57.6 -40.14 78.4 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.427 -0.796 . . . . 0.0 109.447 -179.748 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.453 ' CB ' ' HZ1' ' A' ' 87' ' ' LYS . 95.8 p -65.07 -35.83 82.39 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.332 -0.855 . . . . 0.0 110.123 -179.974 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.433 ' O ' HG23 ' A' ' 76' ' ' VAL . 64.6 mt -63.31 -46.59 95.17 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.326 0 O-C-N 121.191 -0.943 . . . . 0.0 110.148 -179.419 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.584 ' OD1' ' N ' ' A' ' 74' ' ' ALA . 1.3 p30 -63.14 -40.02 96.35 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.088 -1.007 . . . . 0.0 109.448 -179.648 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.584 ' N ' ' OD1' ' A' ' 73' ' ' ASP . . . -66.76 -45.52 78.3 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.312 -0.867 . . . . 0.0 109.768 -179.882 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . 0.544 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 55.0 t80 -63.32 -43.87 96.55 Favored 'General case' 0 N--CA 1.489 1.488 0 O-C-N 121.326 -0.859 . . . . 0.0 109.073 179.974 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.848 HG21 HD11 ' A' ' 48' ' ' LEU . 55.8 t -60.79 -46.8 95.48 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.391 0 O-C-N 121.493 -0.754 . . . . 0.0 109.047 179.655 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 54.7 t -69.14 -42.07 81.63 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.378 0 O-C-N 121.455 -0.778 . . . . 0.0 109.084 179.298 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.516 ' O ' ' O ' ' A' ' 81' ' ' THR . . . -68.8 -21.19 74.92 Favored Glycine 0 N--CA 1.49 2.259 0 N-CA-C 110.001 -1.24 . . . . 0.0 110.001 179.901 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -66.48 -36.79 83.62 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 120.955 -1.32 . . . . 0.0 109.783 -179.411 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 56.1 p -87.91 -25.58 23.16 Favored 'General case' 0 N--CA 1.488 1.467 0 O-C-N 121.216 -0.927 . . . . 0.0 109.732 179.946 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.516 ' O ' ' O ' ' A' ' 78' ' ' GLY . 0.1 OUTLIER -133.19 153.03 80.56 Favored Pre-proline 0 N--CA 1.486 1.366 0 O-C-N 121.358 -0.839 . . . . 0.0 109.75 -179.63 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 76.0 Cg_exo -41.14 103.33 0.04 OUTLIER 'Trans proline' 0 C--N 1.309 -1.525 0 C-N-CA 122.493 2.128 . . . . 0.0 112.058 179.644 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . 0.443 ' HB2' ' HB2' ' A' ' 86' ' ' ALA . 23.6 Cg_exo -57.56 145.66 87.92 Favored 'Trans proline' 0 N--CA 1.492 1.42 0 C-N-CA 122.251 1.967 . . . . 0.0 112.275 -179.903 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.443 ' O ' ' C ' ' A' ' 85' ' ' GLU . 32.7 m -103.72 140.23 22.47 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.354 -0.841 . . . . 0.0 109.337 179.74 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.443 ' C ' ' O ' ' A' ' 84' ' ' VAL . 96.2 mt-10 40.73 43.14 1.58 Allowed 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.297 -0.877 . . . . 0.0 109.703 179.748 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.443 ' HB2' ' HB2' ' A' ' 83' ' ' PRO . . . -59.52 146.26 41.17 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.207 -0.933 . . . . 0.0 109.573 -179.912 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.514 ' C ' HD22 ' A' ' 88' ' ' LEU . 47.4 mttp -57.73 -35.64 70.96 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.262 -0.899 . . . . 0.0 109.549 -179.982 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.793 ' N ' HD22 ' A' ' 88' ' ' LEU . 2.5 mm? -95.47 141.04 29.48 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.276 -0.89 . . . . 0.0 109.413 179.754 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.6 mt-30 . . . . . 0 N--CA 1.491 1.585 0 CA-C-O 117.994 -1.003 . . . . 0.0 109.408 -179.96 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' -1' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.49 1.56 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 0' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -61.52 -34.3 75.28 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.266 -0.896 . . . . 0.0 109.546 179.968 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.436 ' HB2' ' HB2' ' A' ' 4' ' ' ALA . 83.6 mmm -95.52 -121.41 0.11 Allowed 'General case' 0 C--N 1.307 -1.275 0 O-C-N 121.233 -0.917 . . . . 0.0 109.048 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.478 ' O ' ' OD2' ' A' ' 73' ' ' ASP . 67.6 tp60 -113.53 114.48 26.56 Favored 'General case' 0 C--N 1.3 -1.574 0 N-CA-C 107.897 -1.149 . . . . 0.0 107.897 178.959 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.422 ' C ' ' O ' ' A' ' 2' ' ' GLN . 66.7 m-70 46.94 29.87 1.12 Allowed 'General case' 0 N--CA 1.487 1.418 0 N-CA-C 108.024 -1.102 . . . . 0.0 108.024 -178.713 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.436 ' HB2' ' HB2' ' A' ' 1' ' ' MET . . . -58.26 -37.68 75.44 Favored 'General case' 0 N--CA 1.49 1.532 0 O-C-N 121.491 -0.755 . . . . 0.0 109.577 -179.3 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 87.4 p -61.45 -32.89 72.88 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.202 -0.936 . . . . 0.0 109.469 -179.884 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.455 ' HA ' HE21 ' A' ' 9' ' ' GLN . 70.0 t -62.95 -43.9 99.3 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.503 0 O-C-N 121.237 -0.914 . . . . 0.0 109.196 179.75 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 79.2 mt -60.21 -40.97 85.18 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.396 -0.815 . . . . 0.0 109.024 179.606 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.428 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -60.84 -38.12 84.39 Favored 'General case' 0 C--N 1.304 -1.409 0 O-C-N 121.52 -0.738 . . . . 0.0 109.537 -179.724 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . 0.455 HE21 ' HA ' ' A' ' 6' ' ' VAL . 52.3 mt-30 -64.51 -40.53 95.82 Favored 'General case' 0 N--CA 1.491 1.591 0 O-C-N 121.122 -0.986 . . . . 0.0 110.105 -179.934 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.688 ' CG ' ' CE2' ' A' ' 47' ' ' TRP . 30.6 m-85 -63.55 -50.43 69.53 Favored 'General case' 0 N--CA 1.495 1.791 0 O-C-N 121.146 -0.972 . . . . 0.0 110.951 -179.196 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.473 HG23 ' N ' ' A' ' 12' ' ' VAL . 27.2 m -65.64 -41.37 90.46 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 120.995 -1.066 . . . . 0.0 109.426 -179.474 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.473 ' N ' HG23 ' A' ' 11' ' ' VAL . 66.6 t -63.88 -47.0 92.66 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.426 0 O-C-N 121.26 -0.9 . . . . 0.0 109.685 179.554 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -70.53 -27.83 64.47 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.04 -1.037 . . . . 0.0 110.231 -179.913 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 85.0 tt0 -64.57 -33.21 75.38 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.271 -0.893 . . . . 0.0 110.845 -178.708 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 92.1 m-85 -134.11 -29.78 1.24 Allowed 'General case' 0 N--CA 1.496 1.841 0 O-C-N 121.036 -1.04 . . . . 0.0 111.123 -179.354 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.561 HD22 ' CG2' ' A' ' 19' ' ' VAL . 12.3 mt -124.74 79.68 63.09 Favored Pre-proline 0 N--CA 1.491 1.604 0 O-C-N 121.078 -1.014 . . . . 0.0 110.248 -179.157 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 56.3 Cg_endo -78.73 -17.72 12.27 Favored 'Trans proline' 0 C--N 1.307 -1.63 0 C-N-CA 122.586 2.19 . . . . 0.0 112.317 179.642 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -93.01 7.56 43.57 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.232 -0.917 . . . . 0.0 110.125 -179.601 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.561 ' CG2' HD22 ' A' ' 16' ' ' LEU . 46.8 t -113.18 136.04 50.76 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.75 0 O-C-N 121.353 -0.842 . . . . 0.0 109.775 -179.844 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.414 ' O ' ' CG ' ' A' ' 23' ' ' ASP . . . -72.42 117.3 57.68 Favored Pre-proline 0 N--CA 1.49 1.529 0 O-C-N 121.298 -0.876 . . . . 0.0 109.499 -179.922 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 38.3 Cg_exo -52.03 -25.24 21.83 Favored 'Trans proline' 0 N--CA 1.494 1.503 0 C-N-CA 121.995 1.797 . . . . 0.0 112.344 179.333 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.74 -21.5 66.77 Favored 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.268 -0.895 . . . . 0.0 109.83 -179.604 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.448 ' C ' ' OD1' ' A' ' 23' ' ' ASP . 52.8 p30 -84.45 7.56 19.33 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.245 -0.909 . . . . 0.0 110.144 -179.599 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 11.4 t -104.88 129.81 56.9 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.156 -0.965 . . . . 0.0 109.463 -179.922 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 64.0 t0 -89.58 119.86 30.37 Favored 'General case' 0 C--N 1.303 -1.439 0 O-C-N 121.142 -0.974 . . . . 0.0 109.218 179.325 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 18.8 m -74.84 3.95 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.428 0 O-C-N 121.172 -0.955 . . . . 0.0 109.314 179.755 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 91.6 m-20 -88.99 -11.24 44.82 Favored 'General case' 0 N--CA 1.487 1.376 0 O-C-N 121.295 -0.878 . . . . 0.0 109.157 179.543 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 43.6 tp -95.83 138.72 33.07 Favored 'General case' 0 N--CA 1.488 1.454 0 O-C-N 121.412 -0.805 . . . . 0.0 109.016 179.793 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.0 m-20 -58.34 133.6 55.86 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.147 -0.971 . . . . 0.0 109.272 -179.625 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.725 HD12 HG13 ' A' ' 69' ' ' ILE . 2.0 tt -67.14 -38.25 85.21 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 121.724 -0.61 . . . . 0.0 110.099 -179.136 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.563 HG23 ' O ' ' A' ' 66' ' ' PHE . 75.5 t -63.14 -35.54 72.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.586 0 O-C-N 121.011 -1.056 . . . . 0.0 110.379 -178.964 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 55.7 t0 -52.52 -33.52 45.62 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 120.957 -1.09 . . . . 0.0 108.151 -179.986 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.446 ' HB3' HG23 ' A' ' 35' ' ' VAL . 97.4 m-20 -71.25 -34.61 70.89 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.634 -0.666 . . . . 0.0 109.974 179.464 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 84.98 6.44 85.02 Favored Glycine 0 N--CA 1.491 2.303 0 N-CA-C 109.083 -1.607 . . . . 0.0 109.083 -179.399 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.446 HG23 ' HB3' ' A' ' 33' ' ' ASN . 71.5 t -61.32 -34.5 61.2 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.428 0 O-C-N 121.412 -1.052 . . . . 0.0 109.056 179.636 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.696 HD11 HD13 ' A' ' 30' ' ' LEU . 91.8 mt -82.07 114.53 23.12 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 O-C-N 121.353 -0.842 . . . . 0.0 109.665 -179.836 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -111.58 -168.61 1.33 Allowed 'General case' 0 C--N 1.304 -1.401 0 N-CA-C 108.928 -0.767 . . . . 0.0 108.928 179.745 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -64.24 -54.15 37.88 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.214 -0.929 . . . . 0.0 108.696 179.708 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 38.6 mt -70.39 -33.16 71.08 Favored 'General case' 0 C--N 1.302 -1.474 0 N-CA-C 107.171 -1.418 . . . . 0.0 107.171 178.338 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.621 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.57 -40.53 96.46 Favored Glycine 0 N--CA 1.481 1.678 0 N-CA-C 108.546 -1.822 . . . . 0.0 108.546 179.131 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.7 tt -65.45 -42.8 91.95 Favored 'General case' 0 C--N 1.305 -1.36 0 O-C-N 121.492 -1.005 . . . . 0.0 109.136 179.336 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.2 tp -60.88 -46.16 91.71 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.448 -0.782 . . . . 0.0 109.269 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 51.2 mttp -61.13 -35.21 76.46 Favored 'General case' 0 C--N 1.296 -1.732 0 O-C-N 121.427 -0.795 . . . . 0.0 109.623 -179.754 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.621 HG23 ' O ' ' A' ' 40' ' ' GLY . 60.5 t -61.64 -48.67 87.65 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.295 -0.878 . . . . 0.0 109.8 -179.605 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.518 ' CG1' HD12 ' A' ' 61' ' ' LEU . 1.6 mp -68.26 -32.62 56.52 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 O-C-N 121.501 -0.75 . . . . 0.0 110.871 -179.568 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.14 -49.76 63.68 Favored 'General case' 0 N--CA 1.494 1.767 0 O-C-N 121.0 -1.063 . . . . 0.0 111.807 -178.026 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.688 ' CE2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -80.81 -43.48 20.0 Favored 'General case' 0 N--CA 1.493 1.716 0 O-C-N 120.766 -1.209 . . . . 0.0 110.015 -179.195 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.477 HD21 ' CG2' ' A' ' 76' ' ' VAL . 24.3 tp -58.82 -41.55 87.09 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.334 -0.854 . . . . 0.0 110.1 -178.948 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.438 ' CG ' ' N ' ' A' ' 50' ' ' ASP . 17.1 pt-20 -72.99 -37.92 66.83 Favored 'General case' 0 C--N 1.305 -1.362 0 O-C-N 121.079 -1.013 . . . . 0.0 109.716 -179.835 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . 0.438 ' N ' ' CG ' ' A' ' 49' ' ' GLU . 57.2 t0 -58.17 -39.13 78.09 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.36 -0.837 . . . . 0.0 110.457 -179.509 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.465 ' HD2' ' HE1' ' A' ' 47' ' ' TRP . 22.3 mtp-105 -62.63 -36.32 82.41 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.135 -0.978 . . . . 0.0 111.411 -178.866 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.783 ' CE2' HG11 ' A' ' 76' ' ' VAL . 86.5 m-85 -95.55 -8.88 33.89 Favored 'General case' 0 N--CA 1.488 1.458 0 O-C-N 120.75 -1.218 . . . . 0.0 110.258 -179.191 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 72.86 30.72 63.16 Favored Glycine 0 N--CA 1.487 2.073 0 N-CA-C 108.905 -1.678 . . . . 0.0 108.905 179.723 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 23.1 pt -109.73 153.63 11.44 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.335 0 O-C-N 121.557 -0.967 . . . . 0.0 109.782 -179.501 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -101.68 135.96 42.32 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.264 -0.897 . . . . 0.0 109.54 -179.776 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.499 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -66.35 -28.51 68.71 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.329 -0.857 . . . . 0.0 109.647 179.878 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -56.05 -35.78 67.3 Favored 'General case' 0 N--CA 1.488 1.448 0 O-C-N 121.158 -0.964 . . . . 0.0 109.935 -179.732 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 54.5 t0 -55.0 -38.93 68.49 Favored 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.173 -0.954 . . . . 0.0 110.141 -179.569 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.499 ' O ' ' O ' ' A' ' 56' ' ' ALA . 13.6 p -135.59 142.63 38.87 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.698 0 O-C-N 121.199 -0.938 . . . . 0.0 109.721 -179.91 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -93.62 132.57 37.83 Favored 'General case' 0 N--CA 1.49 1.536 0 O-C-N 121.098 -1.001 . . . . 0.0 109.328 179.682 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.518 HD12 ' CG1' ' A' ' 45' ' ' ILE . 56.5 mt -99.06 140.34 33.36 Favored 'General case' 0 C--N 1.305 -1.362 0 O-C-N 121.309 -0.869 . . . . 0.0 109.865 -179.67 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -109.67 156.31 39.93 Favored Pre-proline 0 N--CA 1.487 1.412 0 N-CA-C 108.633 -0.876 . . . . 0.0 108.633 179.503 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 8.1 Cg_endo -53.36 -25.08 29.82 Favored 'Trans proline' 0 C--N 1.303 -1.83 0 C-N-CA 122.41 2.073 . . . . 0.0 111.729 -179.85 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 95.4 mt-10 -71.65 -27.15 62.88 Favored 'General case' 0 N--CA 1.486 1.369 0 O-C-N 121.368 -0.833 . . . . 0.0 109.508 179.757 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . 0.556 ' NE2' ' CB ' ' A' ' 75' ' ' PHE . 6.6 t-160 -65.79 -21.1 66.47 Favored 'General case' 0 C--N 1.302 -1.478 0 O-C-N 121.311 -0.868 . . . . 0.0 109.092 -179.749 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.563 ' O ' HG23 ' A' ' 31' ' ' VAL . 15.3 m-85 -92.34 14.65 15.84 Favored 'General case' 0 C--N 1.3 -1.563 0 N-CA-C 108.718 -0.845 . . . . 0.0 108.718 179.909 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . 0.567 ' NH1' HD11 ' A' ' 88' ' ' LEU . 6.9 ptt180 -47.9 -39.08 17.86 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 121.651 -0.656 . . . . 0.0 109.85 -179.972 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.535 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 86.9 p -160.04 156.55 27.14 Favored 'General case' 0 N--CA 1.487 1.401 0 O-C-N 120.993 -1.067 . . . . 0.0 110.014 179.913 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.725 HG13 HD12 ' A' ' 30' ' ' LEU . 3.3 mp -58.84 -34.76 53.24 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 N-CA-C 108.583 -0.895 . . . . 0.0 108.583 179.189 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 47.0 mtp180 -56.88 -43.78 81.6 Favored 'General case' 0 N--CA 1.49 1.531 0 O-C-N 121.721 -0.612 . . . . 0.0 109.642 -179.601 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 82.5 p -69.47 -33.67 73.24 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.364 -0.835 . . . . 0.0 110.012 -179.706 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.539 HD12 ' HA ' ' A' ' 69' ' ' ILE . 80.6 mt -62.24 -51.02 77.45 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.386 0 O-C-N 121.177 -0.952 . . . . 0.0 109.944 -179.656 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.478 ' OD2' ' O ' ' A' ' 2' ' ' GLN . 42.8 t0 -61.01 -42.06 97.73 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.197 -0.94 . . . . 0.0 109.241 179.871 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.79 -38.68 87.01 Favored 'General case' 0 C--N 1.302 -1.474 0 O-C-N 121.568 -0.708 . . . . 0.0 110.403 -179.514 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . 0.556 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 58.9 t80 -62.28 -46.88 86.8 Favored 'General case' 0 C--N 1.302 -1.462 0 O-C-N 121.105 -0.997 . . . . 0.0 109.82 -179.572 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.783 HG11 ' CE2' ' A' ' 52' ' ' PHE . 77.0 t -66.35 -48.65 80.24 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 O-C-N 121.164 -0.96 . . . . 0.0 109.816 -179.806 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.595 ' O ' HG22 ' A' ' 81' ' ' THR . 53.3 t -70.04 -46.9 71.33 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.276 0 O-C-N 121.056 -1.028 . . . . 0.0 109.67 179.882 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.475 ' O ' ' O ' ' A' ' 81' ' ' THR . . . -61.86 -30.86 76.38 Favored Glycine 0 N--CA 1.49 2.235 0 N-CA-C 110.317 -1.113 . . . . 0.0 110.317 -179.642 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.67 -41.13 84.19 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.149 -1.207 . . . . 0.0 110.318 -179.028 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 56.1 p -79.15 -31.79 44.11 Favored 'General case' 0 N--CA 1.489 1.501 0 O-C-N 121.127 -0.983 . . . . 0.0 109.39 -179.872 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.595 HG22 ' O ' ' A' ' 77' ' ' VAL . 2.6 t -133.3 149.15 71.71 Favored Pre-proline 0 C--N 1.305 -1.341 0 O-C-N 121.52 -0.737 . . . . 0.0 109.452 -179.766 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 14.4 Cg_endo -61.11 117.57 4.37 Favored 'Trans proline' 0 C--N 1.31 -1.473 0 C-N-CA 121.915 1.743 . . . . 0.0 111.086 179.128 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 35.5 Cg_endo -74.49 152.48 43.56 Favored 'Trans proline' 0 C--N 1.315 -1.19 0 C-N-CA 122.043 1.829 . . . . 0.0 112.993 -179.218 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.402 ' O ' ' C ' ' A' ' 85' ' ' GLU . 44.4 t -102.49 135.08 41.36 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 N-CA-C 108.719 -0.845 . . . . 0.0 108.719 179.449 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.402 ' C ' ' O ' ' A' ' 84' ' ' VAL . 84.5 tt0 44.98 70.4 0.35 Allowed 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.166 -0.959 . . . . 0.0 108.997 -179.404 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -46.03 153.69 0.29 Allowed 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.326 -0.859 . . . . 0.0 109.855 -179.674 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.419 ' HB3' HH21 ' A' ' 67' ' ' ARG . 29.0 tttm -54.91 -35.65 64.36 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 121.396 -0.815 . . . . 0.0 109.548 -179.855 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.567 HD11 ' NH1' ' A' ' 67' ' ' ARG . 54.6 mt -90.17 142.13 28.02 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.21 -0.932 . . . . 0.0 109.396 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 13.8 pt20 . . . . . 0 N--CA 1.491 1.615 0 CA-C-O 118.11 -0.948 . . . . 0.0 109.407 179.998 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' -1' ' ' SER . . . . . 0.583 ' O ' ' NE2' ' A' ' 2' ' ' GLN . 0.1 OUTLIER . . . . . 0 N--CA 1.49 1.568 0 N-CA-C 109.516 -0.55 . . . . 0.0 109.516 . . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 0' ' ' GLU . . . . . 0.656 ' OE1' HG21 ' A' ' 84' ' ' VAL . 97.2 mt-10 -61.32 -32.31 72.18 Favored 'General case' 0 N--CA 1.49 1.54 0 O-C-N 121.303 -0.873 . . . . 0.0 109.471 -179.918 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.729 ' HB3' ' HB2' ' A' ' 4' ' ' ALA . 93.7 mmm -59.86 -33.75 72.22 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.21 -0.931 . . . . 0.0 109.345 -179.968 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.583 ' NE2' ' O ' ' A' ' -1' ' ' SER . 99.3 mm-40 57.37 94.71 0.03 OUTLIER 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.416 -0.802 . . . . 0.0 110.415 179.891 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 50.5 m80 59.17 46.14 13.46 Favored 'General case' 0 N--CA 1.494 1.73 0 O-C-N 121.516 -0.74 . . . . 0.0 110.655 179.068 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.729 ' HB2' ' HB3' ' A' ' 1' ' ' MET . . . -62.71 -40.22 96.49 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.016 -1.052 . . . . 0.0 109.313 179.486 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.0 t -60.19 -33.96 72.94 Favored 'General case' 0 N--CA 1.488 1.462 0 O-C-N 121.392 -0.817 . . . . 0.0 109.664 -179.955 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 55.9 t -60.24 -45.45 96.15 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.497 0 O-C-N 121.297 -0.877 . . . . 0.0 109.579 -179.854 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 75.5 mt -60.94 -45.26 98.69 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.477 0 O-C-N 121.326 -0.859 . . . . 0.0 109.025 179.65 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.484 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -61.56 -36.39 80.49 Favored 'General case' 0 N--CA 1.486 1.344 0 O-C-N 121.481 -0.762 . . . . 0.0 109.001 179.595 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 31.0 tt0 -64.78 -40.74 95.75 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.297 -0.877 . . . . 0.0 110.107 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.703 ' CG ' ' CE2' ' A' ' 47' ' ' TRP . 19.0 m-85 -61.71 -50.42 72.53 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.12 -0.987 . . . . 0.0 110.504 -179.452 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.439 HG23 ' N ' ' A' ' 12' ' ' VAL . 23.2 m -64.58 -41.07 91.21 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.5 0 O-C-N 121.051 -1.031 . . . . 0.0 109.185 -179.64 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.484 HG23 ' O ' ' A' ' 8' ' ' ALA . 79.6 t -63.95 -46.2 94.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.509 0 O-C-N 121.246 -0.909 . . . . 0.0 109.436 179.497 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -70.55 -27.7 64.35 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.171 -0.956 . . . . 0.0 110.171 179.903 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.5 tt0 -64.46 -30.68 71.71 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.333 -0.855 . . . . 0.0 110.558 -178.883 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.454 ' CD2' ' CG1' ' A' ' 35' ' ' VAL . 96.2 m-85 -134.11 -38.64 0.86 Allowed 'General case' 0 N--CA 1.496 1.826 0 O-C-N 121.033 -1.042 . . . . 0.0 111.075 -179.317 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.523 HD22 ' CG2' ' A' ' 19' ' ' VAL . 9.1 mt -123.23 79.83 52.5 Favored Pre-proline 0 N--CA 1.493 1.684 0 O-C-N 121.067 -1.02 . . . . 0.0 110.571 -178.835 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -74.93 -15.53 20.88 Favored 'Trans proline' 0 C--N 1.309 -1.525 0 C-N-CA 122.305 2.003 . . . . 0.0 112.199 179.39 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -91.97 8.6 36.82 Favored 'General case' 0 C--N 1.305 -1.357 0 O-C-N 121.199 -0.938 . . . . 0.0 109.883 -179.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.523 ' CG2' HD22 ' A' ' 16' ' ' LEU . 44.6 t -113.61 135.08 54.34 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.671 0 O-C-N 121.387 -0.82 . . . . 0.0 109.654 -179.746 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -73.9 119.67 77.35 Favored Pre-proline 0 N--CA 1.491 1.583 0 O-C-N 121.321 -0.862 . . . . 0.0 109.288 179.877 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 50.5 Cg_exo -51.14 -26.07 18.63 Favored 'Trans proline' 0 N--CA 1.494 1.502 0 C-N-CA 121.75 1.634 . . . . 0.0 112.132 179.482 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.81 -24.68 67.62 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.347 -0.846 . . . . 0.0 109.404 179.863 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.436 ' O ' ' OD1' ' A' ' 23' ' ' ASP . 60.2 t0 -81.83 6.83 14.43 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.32 -0.863 . . . . 0.0 109.759 -179.731 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 12.3 t -107.64 133.89 51.07 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.275 -0.89 . . . . 0.0 109.275 -179.981 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 87.2 m-20 -89.06 120.47 30.5 Favored 'General case' 0 C--N 1.304 -1.411 0 O-C-N 121.085 -1.01 . . . . 0.0 109.0 179.324 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.0 m -76.4 4.47 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 O-C-N 121.19 -0.944 . . . . 0.0 109.124 179.655 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -91.45 -5.13 54.78 Favored 'General case' 0 C--N 1.305 -1.351 0 O-C-N 121.344 -0.847 . . . . 0.0 109.164 179.673 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 40.8 tp -98.65 138.5 35.74 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.323 -0.86 . . . . 0.0 109.34 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -60.61 134.69 57.32 Favored 'General case' 0 C--N 1.303 -1.455 0 O-C-N 121.247 -0.908 . . . . 0.0 109.484 -179.735 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.969 HD13 HD11 ' A' ' 36' ' ' ILE . 0.8 OUTLIER -69.06 -39.66 78.99 Favored 'General case' 0 C--N 1.301 -1.5 0 O-C-N 121.631 -0.668 . . . . 0.0 110.221 -179.293 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 70.8 t -64.04 -36.29 76.35 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.625 0 O-C-N 121.107 -0.996 . . . . 0.0 110.606 -178.759 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 56.7 t0 -52.52 -33.36 44.9 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 120.926 -1.109 . . . . 0.0 108.238 -179.904 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.508 ' HB3' HG23 ' A' ' 35' ' ' VAL . 97.3 m-20 -71.24 -34.69 71.01 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.661 -0.65 . . . . 0.0 110.049 179.608 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 83.24 6.16 88.22 Favored Glycine 0 N--CA 1.493 2.434 0 N-CA-C 108.831 -1.708 . . . . 0.0 108.831 -179.22 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.508 HG23 ' HB3' ' A' ' 33' ' ' ASN . 72.9 t -60.61 -30.9 47.77 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.461 0 O-C-N 121.503 -0.998 . . . . 0.0 108.356 179.329 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.969 HD11 HD13 ' A' ' 30' ' ' LEU . 89.7 mt -86.87 131.54 34.62 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.382 0 O-C-N 121.489 -0.757 . . . . 0.0 109.74 179.908 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.547 ' CG ' ' H ' ' A' ' 38' ' ' ALA . 52.0 t0 -128.01 -166.22 1.59 Allowed 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 108.646 -0.872 . . . . 0.0 108.646 179.582 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.547 ' H ' ' CG ' ' A' ' 37' ' ' ASP . . . -64.36 -54.58 30.75 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.126 -0.984 . . . . 0.0 108.886 179.849 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 34.4 mt -69.8 -32.76 71.39 Favored 'General case' 0 C--N 1.302 -1.475 0 N-CA-C 107.233 -1.395 . . . . 0.0 107.233 178.358 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.503 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.24 -41.39 96.75 Favored Glycine 0 N--CA 1.48 1.618 0 N-CA-C 108.668 -1.773 . . . . 0.0 108.668 179.271 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.6 tt -65.54 -41.9 92.51 Favored 'General case' 0 C--N 1.304 -1.38 0 O-C-N 121.426 -1.044 . . . . 0.0 108.942 179.219 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.2 tp -60.13 -45.98 91.18 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.435 -0.791 . . . . 0.0 109.208 179.801 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 28.5 mttp -60.11 -35.5 75.37 Favored 'General case' 0 C--N 1.296 -1.742 0 O-C-N 121.491 -0.755 . . . . 0.0 109.512 -179.783 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.503 HG23 ' O ' ' A' ' 40' ' ' GLY . 69.3 t -61.98 -48.23 89.53 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.498 0 O-C-N 121.335 -0.853 . . . . 0.0 109.927 -179.673 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.526 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 1.7 mp -68.15 -33.26 59.83 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.569 0 O-C-N 121.507 -0.746 . . . . 0.0 110.831 -179.652 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.0 -49.84 66.37 Favored 'General case' 0 N--CA 1.494 1.742 0 O-C-N 120.898 -1.126 . . . . 0.0 111.344 -178.179 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.703 ' CE2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -81.17 -44.54 17.71 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.718 -1.239 . . . . 0.0 109.936 -179.452 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.906 HD12 HH21 ' A' ' 51' ' ' ARG . 10.0 tp -58.43 -42.67 87.78 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.275 -0.891 . . . . 0.0 109.773 -179.07 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.526 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 2.3 pp20? -72.61 -35.93 67.98 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.094 -1.004 . . . . 0.0 109.786 179.958 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.2 t70 -60.02 -38.72 83.51 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.282 -0.886 . . . . 0.0 110.66 -179.517 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.906 HH21 HD12 ' A' ' 48' ' ' LEU . 62.6 mtm180 -62.09 -38.04 87.37 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.12 -0.987 . . . . 0.0 111.418 -178.824 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.834 ' CE2' HG11 ' A' ' 76' ' ' VAL . 95.6 m-85 -97.8 -11.94 22.78 Favored 'General case' 0 N--CA 1.487 1.391 0 O-C-N 120.738 -1.226 . . . . 0.0 110.164 -179.039 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 72.3 30.98 64.1 Favored Glycine 0 N--CA 1.488 2.102 0 N-CA-C 108.804 -1.718 . . . . 0.0 108.804 179.912 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.469 ' O ' ' OE1' ' A' ' 49' ' ' GLU . 34.5 pt -102.89 148.37 8.19 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.4 0 O-C-N 121.414 -1.05 . . . . 0.0 109.758 -179.436 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -89.87 112.42 23.76 Favored 'General case' 0 N--CA 1.491 1.614 0 O-C-N 121.184 -0.948 . . . . 0.0 109.679 -179.728 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.502 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -68.41 -27.14 65.95 Favored 'General case' 0 N--CA 1.489 1.497 0 O-C-N 121.332 -0.855 . . . . 0.0 109.585 179.686 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -55.73 -35.9 66.66 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.168 -0.957 . . . . 0.0 110.087 -179.587 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -55.55 -38.52 69.4 Favored 'General case' 0 N--CA 1.49 1.539 0 O-C-N 121.133 -0.979 . . . . 0.0 109.857 -179.631 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.502 ' O ' ' O ' ' A' ' 56' ' ' ALA . 42.7 t -124.95 136.16 61.74 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.702 0 O-C-N 121.419 -0.801 . . . . 0.0 109.658 179.963 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -89.18 131.09 35.46 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.028 -1.045 . . . . 0.0 109.297 179.872 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.502 HD12 HD11 ' A' ' 45' ' ' ILE . 38.1 mt -99.86 142.16 31.71 Favored 'General case' 0 C--N 1.305 -1.338 0 O-C-N 121.265 -0.897 . . . . 0.0 109.701 -179.7 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -109.49 157.18 38.1 Favored Pre-proline 0 N--CA 1.487 1.375 0 O-C-N 121.437 -0.789 . . . . 0.0 108.942 179.64 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_endo -55.33 -24.04 40.77 Favored 'Trans proline' 0 C--N 1.304 -1.77 0 C-N-CA 122.604 2.203 . . . . 0.0 111.827 -179.956 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -69.06 -29.22 67.31 Favored 'General case' 0 C--N 1.304 -1.374 0 O-C-N 121.364 -0.835 . . . . 0.0 109.139 179.703 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . 0.531 ' CD2' ' O ' ' A' ' 65' ' ' HIS . 2.9 t-80 -66.33 -18.5 65.39 Favored 'General case' 0 C--N 1.301 -1.53 0 O-C-N 121.359 -0.838 . . . . 0.0 108.895 179.938 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.521 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 11.4 m-85 -94.69 13.77 23.3 Favored 'General case' 0 C--N 1.302 -1.49 0 N-CA-C 108.607 -0.886 . . . . 0.0 108.607 179.582 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . 0.478 ' CZ ' ' OG ' ' A' ' 71' ' ' SER . 7.5 ptt180 -44.2 -38.92 4.05 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.811 -0.556 . . . . 0.0 110.545 -179.594 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 80.1 p -155.7 161.42 40.74 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 120.806 -1.184 . . . . 0.0 110.3 -179.629 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.479 ' CD1' HD12 ' A' ' 30' ' ' LEU . 31.3 mm -60.66 -44.14 96.39 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.369 0 O-C-N 121.39 -0.819 . . . . 0.0 110.172 -179.774 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.618 ' HG3' ' HZ1' ' A' ' 87' ' ' LYS . 0.0 OUTLIER -58.88 -39.74 82.29 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.214 -0.929 . . . . 0.0 109.656 -179.304 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.478 ' OG ' ' CZ ' ' A' ' 67' ' ' ARG . 23.2 t -63.08 -40.61 98.17 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.248 -0.907 . . . . 0.0 109.643 179.863 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 86.0 mt -61.95 -50.56 79.64 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.336 0 O-C-N 121.214 -0.929 . . . . 0.0 110.107 -179.755 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.489 ' OD2' ' O ' ' A' ' 1' ' ' MET . 40.9 t0 -59.28 -41.13 88.2 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.234 -0.916 . . . . 0.0 109.357 -179.842 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.439 ' O ' ' N ' ' A' ' 78' ' ' GLY . . . -66.49 -37.42 85.03 Favored 'General case' 0 C--N 1.302 -1.458 0 O-C-N 121.505 -0.747 . . . . 0.0 110.266 -179.587 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . 0.531 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 62.6 t80 -61.99 -48.12 81.77 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.022 -1.049 . . . . 0.0 109.886 -179.502 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.834 HG11 ' CE2' ' A' ' 52' ' ' PHE . 87.6 t -64.92 -48.25 84.96 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.323 0 O-C-N 121.097 -1.002 . . . . 0.0 109.671 -179.801 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 60.8 t -69.31 -39.18 78.69 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.356 0 O-C-N 121.214 -0.929 . . . . 0.0 109.142 179.585 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.439 ' N ' ' O ' ' A' ' 74' ' ' ALA . . . -59.1 -35.35 83.66 Favored Glycine 0 N--CA 1.487 2.088 0 N-CA-C 110.207 -1.157 . . . . 0.0 110.207 -179.678 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -70.35 -41.68 72.86 Favored 'General case' 0 N--CA 1.494 1.754 0 O-C-N 121.265 -1.138 . . . . 0.0 111.044 -178.791 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 44.6 p -81.78 -34.79 30.15 Favored 'General case' 0 N--CA 1.49 1.561 0 O-C-N 121.094 -1.004 . . . . 0.0 109.497 -179.622 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . . . . . . . . . 0.5 OUTLIER -133.29 153.78 80.76 Favored Pre-proline 0 C--N 1.299 -1.592 0 N-CA-C 108.991 -0.744 . . . . 0.0 108.991 -179.848 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo -43.65 143.57 2.66 Favored 'Trans proline' 0 C--N 1.307 -1.631 0 C-N-CA 121.737 1.625 . . . . 0.0 111.003 179.521 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . 0.538 ' HB2' ' HB2' ' A' ' 86' ' ' ALA . 10.9 Cg_endo -60.93 141.59 95.02 Favored 'Trans proline' 0 C--N 1.311 -1.434 0 C-N-CA 121.896 1.731 . . . . 0.0 112.748 -179.18 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.656 HG21 ' OE1' ' A' ' 0' ' ' GLU . 14.7 p -104.53 129.92 56.21 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 N-CA-C 109.066 -0.716 . . . . 0.0 109.066 179.393 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.5 ' C ' ' O ' ' A' ' 84' ' ' VAL . 96.2 mt-10 36.25 40.17 0.1 Allowed 'General case' 0 N--CA 1.493 1.714 0 O-C-N 121.596 -0.69 . . . . 0.0 109.909 179.839 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.538 ' HB2' ' HB2' ' A' ' 83' ' ' PRO . . . -50.23 145.23 6.27 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.116 -0.99 . . . . 0.0 109.599 -179.611 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.618 ' HZ1' ' HG3' ' A' ' 70' ' ' ARG . 69.0 mttm -57.67 -34.75 69.73 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.282 -0.886 . . . . 0.0 109.443 -179.914 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 55.5 mt -93.15 142.03 27.75 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.171 -0.955 . . . . 0.0 109.424 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.3 mt-30 . . . . . 0 N--CA 1.491 1.582 0 CA-C-O 117.936 -1.031 . . . . 0.0 109.407 -179.972 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' -1' ' ' SER . . . . . . . . . . . . . 1.8 p . . . . . 0 N--CA 1.492 1.634 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 0' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -61.79 -33.44 74.11 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.19 -0.944 . . . . 0.0 109.449 -179.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.749 ' HB3' ' HB2' ' A' ' 4' ' ' ALA . 96.6 mmm -58.15 -34.1 69.93 Favored 'General case' 0 N--CA 1.489 1.523 0 O-C-N 121.304 -0.872 . . . . 0.0 109.485 179.973 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.573 ' CB ' ' O ' ' A' ' 1' ' ' MET . 28.6 tp60 84.66 66.98 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.726 0 CA-C-O 121.338 0.589 . . . . 0.0 109.541 -179.788 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 58.9 m-70 63.15 47.54 4.09 Favored 'General case' 0 N--CA 1.494 1.762 0 O-C-N 121.42 -0.8 . . . . 0.0 110.316 179.661 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.749 ' HB2' ' HB3' ' A' ' 1' ' ' MET . . . -62.25 -38.82 90.73 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.06 -1.025 . . . . 0.0 109.484 179.718 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.4 m -60.28 -36.88 78.85 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 121.368 -0.832 . . . . 0.0 110.107 -179.645 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 48.9 t -62.15 -44.81 99.51 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.541 0 O-C-N 121.124 -0.985 . . . . 0.0 109.723 -179.757 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.439 ' O ' HG12 ' A' ' 11' ' ' VAL . 89.7 mt -59.53 -49.8 82.29 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.613 0 O-C-N 121.341 -0.849 . . . . 0.0 110.037 -179.504 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.714 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.5 -43.97 95.72 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.378 -0.826 . . . . 0.0 111.111 -179.136 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 53.0 mt-30 -69.22 -46.0 68.45 Favored 'General case' 0 N--CA 1.493 1.714 0 O-C-N 120.844 -1.16 . . . . 0.0 111.284 -178.607 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.705 ' CD1' ' N ' ' A' ' 11' ' ' VAL . 0.0 OUTLIER -69.82 -47.01 64.38 Favored 'General case' 0 N--CA 1.493 1.717 0 O-C-N 120.951 -1.093 . . . . 0.0 110.519 -179.142 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.705 ' N ' ' CD1' ' A' ' 10' ' ' PHE . 5.1 p -61.54 -38.91 81.26 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.616 0 O-C-N 121.062 -1.024 . . . . 0.0 109.731 -179.671 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.714 HG23 ' O ' ' A' ' 8' ' ' ALA . 56.0 t -63.33 -43.44 98.6 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.133 -0.979 . . . . 0.0 109.821 -179.949 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 98.2 mt-10 -63.9 -39.02 93.22 Favored 'General case' 0 C--N 1.305 -1.367 0 O-C-N 121.166 -0.958 . . . . 0.0 110.187 -179.519 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 85.2 tt0 -70.02 -42.26 73.2 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.182 -0.949 . . . . 0.0 110.0 -179.849 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 77.7 t80 -83.58 -52.18 6.68 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.221 -0.924 . . . . 0.0 110.618 -179.435 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.478 HD22 ' CG2' ' A' ' 19' ' ' VAL . 7.3 mt -123.64 80.07 55.26 Favored Pre-proline 0 N--CA 1.49 1.555 0 O-C-N 121.378 -0.826 . . . . 0.0 110.292 -179.04 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -67.02 -15.65 47.36 Favored 'Trans proline' 0 N--CA 1.492 1.401 0 C-N-CA 122.056 1.837 . . . . 0.0 112.466 179.682 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -95.26 7.34 46.47 Favored 'General case' 0 N--CA 1.486 1.335 0 O-C-N 121.083 -1.011 . . . . 0.0 110.429 -179.499 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.478 ' CG2' HD22 ' A' ' 16' ' ' LEU . 21.8 t -119.47 136.21 57.37 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.814 0 O-C-N 121.214 -0.929 . . . . 0.0 109.843 -179.825 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.487 ' O ' ' OD1' ' A' ' 23' ' ' ASP . . . -77.58 118.69 73.71 Favored Pre-proline 0 N--CA 1.49 1.536 0 O-C-N 121.241 -0.912 . . . . 0.0 108.978 179.516 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 42.5 Cg_exo -51.15 -25.75 17.84 Favored 'Trans proline' 0 N--CA 1.493 1.487 0 C-N-CA 121.798 1.665 . . . . 0.0 112.223 179.869 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.88 -27.46 68.87 Favored 'General case' 0 N--CA 1.491 1.579 0 O-C-N 121.183 -0.948 . . . . 0.0 109.726 -179.854 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.487 ' OD1' ' O ' ' A' ' 20' ' ' ALA . 47.3 p30 -87.28 7.72 27.36 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.136 -0.977 . . . . 0.0 109.84 -179.678 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.463 HG23 ' OD1' ' A' ' 23' ' ' ASP . 16.4 t -110.16 132.06 59.5 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.723 0 O-C-N 121.311 -0.868 . . . . 0.0 109.446 179.88 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 62.2 t0 -89.26 119.47 29.77 Favored 'General case' 0 C--N 1.303 -1.416 0 O-C-N 121.197 -0.94 . . . . 0.0 108.993 179.308 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.637 HG22 ' O ' ' A' ' 26' ' ' VAL . 1.9 p -74.66 4.85 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.412 0 O-C-N 121.102 -0.999 . . . . 0.0 108.914 179.632 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -98.21 3.4 48.92 Favored 'General case' 0 N--CA 1.486 1.371 0 O-C-N 121.198 -0.938 . . . . 0.0 109.253 179.636 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 40.0 tp -97.95 134.6 40.84 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.354 -0.841 . . . . 0.0 109.37 -179.9 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 82.2 m-20 -65.67 142.06 58.17 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.226 -0.921 . . . . 0.0 109.298 -179.71 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.58 HD11 HG13 ' A' ' 69' ' ' ILE . 91.4 mt -70.7 -33.73 71.2 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 121.325 -0.859 . . . . 0.0 110.698 -179.411 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.66 HG23 ' N ' ' A' ' 32' ' ' ASP . 20.0 m -53.56 -47.74 59.9 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.532 0 O-C-N 121.146 -0.971 . . . . 0.0 110.155 -178.686 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.66 ' N ' HG23 ' A' ' 31' ' ' VAL . 90.8 m-20 -61.11 -35.04 75.96 Favored 'General case' 0 C--N 1.3 -1.568 0 O-C-N 121.248 -0.908 . . . . 0.0 108.624 179.496 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 96.4 m-20 -70.84 -34.32 71.55 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.686 -0.634 . . . . 0.0 110.11 -179.842 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 86.17 5.32 83.1 Favored Glycine 0 N--CA 1.491 2.367 0 N-CA-C 109.158 -1.577 . . . . 0.0 109.158 -179.685 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 71.9 t -60.85 -34.41 59.25 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.47 0 O-C-N 121.402 -1.058 . . . . 0.0 108.93 179.672 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . . . . . . . . . 92.1 mt -66.46 95.21 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.428 0 O-C-N 121.467 -0.771 . . . . 0.0 110.313 -179.559 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -102.95 169.36 8.62 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 178.85 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -55.55 -48.65 74.4 Favored 'General case' 0 C--N 1.3 -1.562 0 N-CA-C 107.761 -1.2 . . . . 0.0 107.761 179.659 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.719 HD12 ' N ' ' A' ' 39' ' ' LEU . 6.8 mp -71.14 -32.16 68.62 Favored 'General case' 0 C--N 1.301 -1.531 0 N-CA-C 106.984 -1.488 . . . . 0.0 106.984 177.592 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.5 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -58.77 -48.1 86.93 Favored Glycine 0 N--CA 1.483 1.795 0 N-CA-C 109.181 -1.568 . . . . 0.0 109.181 179.705 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.5 tt -63.08 -40.29 97.22 Favored 'General case' 0 C--N 1.302 -1.473 0 O-C-N 121.367 -1.078 . . . . 0.0 109.187 179.314 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.1 tp -59.73 -46.22 89.8 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.264 -0.897 . . . . 0.0 109.23 179.956 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 63.8 mttp -61.67 -34.35 75.57 Favored 'General case' 0 C--N 1.297 -1.7 0 O-C-N 121.443 -0.786 . . . . 0.0 109.604 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.5 HG23 ' O ' ' A' ' 40' ' ' GLY . 78.9 t -60.8 -47.07 94.83 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.443 0 O-C-N 121.377 -0.827 . . . . 0.0 110.036 -179.512 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.403 HD12 ' N ' ' A' ' 45' ' ' ILE . 1.7 mp -67.89 -36.56 76.12 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.516 0 O-C-N 121.295 -0.878 . . . . 0.0 111.35 -179.474 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.3 -49.38 64.46 Favored 'General case' 0 N--CA 1.497 1.88 0 O-C-N 120.965 -1.084 . . . . 0.0 111.853 -178.031 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.549 ' HE1' ' NE ' ' A' ' 51' ' ' ARG . 0.0 OUTLIER -78.37 -42.59 29.95 Favored 'General case' 0 N--CA 1.493 1.68 0 O-C-N 120.541 -1.349 . . . . 0.0 110.105 -179.062 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.458 HD11 ' CG2' ' A' ' 76' ' ' VAL . 7.4 tt -59.78 -42.08 92.55 Favored 'General case' 0 C--N 1.301 -1.524 0 O-C-N 121.242 -0.911 . . . . 0.0 110.667 -179.239 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 18.9 pt-20 -72.69 -36.51 67.9 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.101 -1.0 . . . . 0.0 109.94 -179.4 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.7 t0 -61.17 -39.61 90.76 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.362 -0.836 . . . . 0.0 111.247 -179.186 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.549 ' NE ' ' HE1' ' A' ' 47' ' ' TRP . 94.0 mtt-85 -63.18 -38.91 93.04 Favored 'General case' 0 N--CA 1.492 1.673 0 O-C-N 121.094 -1.004 . . . . 0.0 112.567 -178.074 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.732 ' CD1' HG11 ' A' ' 76' ' ' VAL . 85.5 m-85 -99.2 -7.63 26.23 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 120.656 -1.278 . . . . 0.0 110.635 -178.682 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 69.82 30.54 70.34 Favored Glycine 0 N--CA 1.486 2.012 0 N-CA-C 108.924 -1.67 . . . . 0.0 108.924 179.425 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 26.5 pt -106.59 153.23 7.91 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.416 0 O-C-N 121.634 -0.921 . . . . 0.0 109.544 -179.557 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -98.59 134.19 41.88 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.138 -0.977 . . . . 0.0 109.639 -179.498 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.518 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -65.84 -30.29 70.89 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.28 -0.887 . . . . 0.0 109.58 179.903 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -57.71 -34.56 69.59 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 121.212 -0.93 . . . . 0.0 110.242 -179.741 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -54.93 -39.38 68.78 Favored 'General case' 0 N--CA 1.492 1.662 0 O-C-N 121.196 -0.94 . . . . 0.0 110.403 -179.297 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.518 ' O ' ' O ' ' A' ' 56' ' ' ALA . 31.5 m -128.67 157.05 41.41 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.394 0 O-C-N 121.275 -0.891 . . . . 0.0 109.804 -179.503 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -96.54 128.95 43.96 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 120.986 -1.071 . . . . 0.0 109.167 179.724 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 58.1 mt -101.39 135.33 43.05 Favored 'General case' 0 C--N 1.305 -1.334 0 O-C-N 121.214 -0.929 . . . . 0.0 109.798 -179.815 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -109.97 156.05 40.62 Favored Pre-proline 0 N--CA 1.487 1.393 0 N-CA-C 108.816 -0.809 . . . . 0.0 108.816 179.395 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 10.8 Cg_endo -56.94 -24.1 55.07 Favored 'Trans proline' 0 C--N 1.303 -1.839 0 C-N-CA 122.406 2.071 . . . . 0.0 111.74 179.891 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 95.2 mt-10 -69.47 -29.35 67.0 Favored 'General case' 0 C--N 1.306 -1.315 0 O-C-N 121.338 -0.851 . . . . 0.0 109.172 179.721 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . 0.592 ' CD2' ' O ' ' A' ' 65' ' ' HIS . 4.3 t-160 -65.97 -17.69 64.84 Favored 'General case' 0 C--N 1.3 -1.562 0 O-C-N 121.417 -0.802 . . . . 0.0 108.966 -179.911 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.493 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 17.3 m-85 -93.14 14.86 16.71 Favored 'General case' 0 C--N 1.303 -1.445 0 N-CA-C 108.597 -0.89 . . . . 0.0 108.597 179.532 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . 0.445 HH21 ' HB3' ' A' ' 87' ' ' LYS . 8.9 ptt180 -48.38 -38.53 19.64 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.816 -0.552 . . . . 0.0 110.822 -179.498 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 31.9 t -158.53 150.24 21.19 Favored 'General case' 0 N--CA 1.494 1.76 0 O-C-N 120.76 -1.213 . . . . 0.0 110.362 -179.667 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.734 ' H ' HD12 ' A' ' 69' ' ' ILE . 0.1 OUTLIER -57.74 -42.86 82.74 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.642 0 O-C-N 121.365 -0.835 . . . . 0.0 109.255 179.688 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.411 HH12 ' HG3' ' A' ' 87' ' ' LYS . 5.8 ptm180 -57.88 -40.66 80.77 Favored 'General case' 0 C--N 1.303 -1.427 0 O-C-N 121.42 -0.8 . . . . 0.0 109.326 -179.89 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 84.9 p -66.42 -34.39 77.85 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.236 -0.915 . . . . 0.0 109.514 179.538 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.556 HD12 ' HA ' ' A' ' 69' ' ' ILE . 91.5 mt -59.99 -51.14 76.4 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.243 0 O-C-N 121.163 -0.961 . . . . 0.0 109.749 179.969 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.474 ' OD2' ' O ' ' A' ' 1' ' ' MET . 42.4 t0 -59.49 -42.07 91.28 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.172 -0.955 . . . . 0.0 108.976 179.823 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.556 ' O ' ' N ' ' A' ' 78' ' ' GLY . . . -66.72 -37.11 84.03 Favored 'General case' 0 C--N 1.303 -1.452 0 O-C-N 121.661 -0.649 . . . . 0.0 110.148 -179.925 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . 0.459 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 64.6 t80 -61.3 -49.7 75.97 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.004 -1.06 . . . . 0.0 109.686 -179.604 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.732 HG11 ' CD1' ' A' ' 52' ' ' PHE . 44.3 t -68.66 -48.89 69.32 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.307 0 O-C-N 121.216 -0.927 . . . . 0.0 109.875 -179.568 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.414 HG21 ' CB ' ' A' ' 2' ' ' GLN . 82.1 t -69.62 -41.91 80.38 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.305 0 O-C-N 121.211 -0.931 . . . . 0.0 109.151 179.803 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.556 ' N ' ' O ' ' A' ' 74' ' ' ALA . . . -60.48 -39.42 96.31 Favored Glycine 0 N--CA 1.488 2.134 0 N-CA-C 109.895 -1.282 . . . . 0.0 109.895 -179.872 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -68.33 -41.07 81.33 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.159 -1.201 . . . . 0.0 110.245 -179.428 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 45.0 p -82.32 -29.86 30.8 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.189 -0.944 . . . . 0.0 109.594 -179.768 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.495 ' O ' ' O ' ' A' ' 78' ' ' GLY . 0.3 OUTLIER -133.31 153.74 80.73 Favored Pre-proline 0 C--N 1.302 -1.461 0 O-C-N 121.522 -0.736 . . . . 0.0 109.457 -179.659 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 19.4 Cg_endo -62.39 111.17 1.22 Allowed 'Trans proline' 0 C--N 1.308 -1.603 0 C-N-CA 122.293 1.995 . . . . 0.0 111.528 179.755 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 42.4 Cg_endo -76.34 152.09 34.33 Favored 'Trans proline' 0 N--CA 1.489 1.247 0 C-N-CA 122.116 1.877 . . . . 0.0 113.069 -179.224 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.474 ' O ' ' C ' ' A' ' 85' ' ' GLU . 43.9 t -103.77 131.67 51.89 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 O-C-N 121.561 -0.712 . . . . 0.0 109.087 179.43 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.474 ' C ' ' O ' ' A' ' 84' ' ' VAL . 84.2 tt0 38.88 69.03 0.3 Allowed 'General case' 0 N--CA 1.494 1.758 0 O-C-N 121.454 -0.779 . . . . 0.0 109.762 179.994 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -60.37 150.15 31.64 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.209 -0.932 . . . . 0.0 109.833 -179.768 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.445 ' HB3' HH21 ' A' ' 67' ' ' ARG . 21.1 tttm -55.96 -38.72 70.76 Favored 'General case' 0 N--CA 1.491 1.623 0 O-C-N 121.341 -0.849 . . . . 0.0 109.431 179.874 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 36.1 tp -58.97 -37.24 76.36 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.315 -0.865 . . . . 0.0 109.396 -179.978 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.0 mt-30 . . . . . 0 N--CA 1.489 1.522 0 CA-C-O 118.046 -0.978 . . . . 0.0 109.486 -179.914 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' -1' ' ' SER . . . . . . . . . . . . . 74.3 m . . . . . 0 N--CA 1.491 1.616 0 N-CA-C 109.479 -0.563 . . . . 0.0 109.479 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 0' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -58.66 140.44 54.57 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.216 -0.927 . . . . 0.0 109.513 -179.92 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.507 ' HB3' ' HB2' ' A' ' 4' ' ' ALA . 65.4 mtt -60.99 -36.68 80.08 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.211 -0.93 . . . . 0.0 109.823 179.971 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.763 ' OE1' HG22 ' A' ' 77' ' ' VAL . 87.3 mt-30 56.35 49.78 14.46 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.386 -0.821 . . . . 0.0 109.34 -179.44 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.484 ' CG ' ' C ' ' A' ' 2' ' ' GLN . 14.9 m-70 76.63 54.68 0.04 OUTLIER 'General case' 0 N--CA 1.496 1.842 0 O-C-N 121.705 -0.622 . . . . 0.0 110.127 179.874 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.507 ' HB2' ' HB3' ' A' ' 1' ' ' MET . . . -62.26 -38.34 88.92 Favored 'General case' 0 N--CA 1.49 1.554 0 O-C-N 121.045 -1.034 . . . . 0.0 109.396 179.719 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.3 t -60.66 -38.03 83.53 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.36 -0.837 . . . . 0.0 110.049 -179.585 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 73.4 t -61.53 -43.12 96.37 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.203 -0.935 . . . . 0.0 109.539 -179.836 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 75.3 mt -60.32 -46.04 95.54 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.395 -0.816 . . . . 0.0 109.283 179.742 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.529 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -61.47 -39.24 90.18 Favored 'General case' 0 N--CA 1.486 1.372 0 O-C-N 121.268 -0.895 . . . . 0.0 108.675 179.546 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 33.2 tt0 -64.99 -35.11 80.13 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.419 -0.801 . . . . 0.0 109.143 179.289 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.612 ' CZ ' ' CD1' ' A' ' 47' ' ' TRP . 0.3 OUTLIER -60.51 -50.9 71.72 Favored 'General case' 0 N--CA 1.492 1.629 0 O-C-N 121.495 -0.753 . . . . 0.0 110.184 -179.569 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.734 HG11 HD11 ' A' ' 30' ' ' LEU . 22.7 m -66.55 -38.26 81.3 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 O-C-N 121.164 -0.96 . . . . 0.0 109.117 -179.743 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.529 HG23 ' O ' ' A' ' 8' ' ' ALA . 73.9 t -63.47 -44.87 98.99 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.439 0 O-C-N 121.24 -0.912 . . . . 0.0 109.351 179.496 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 97.6 mt-10 -73.3 -19.27 61.08 Favored 'General case' 0 N--CA 1.488 1.43 0 O-C-N 121.266 -0.896 . . . . 0.0 109.939 179.746 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -63.9 -32.28 73.75 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.33 -0.857 . . . . 0.0 110.449 -178.983 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 64.8 t80 -142.28 -36.62 0.41 Allowed 'General case' 0 N--CA 1.492 1.644 0 O-C-N 120.958 -1.089 . . . . 0.0 110.463 -179.62 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.507 HD22 ' CG2' ' A' ' 19' ' ' VAL . 5.6 mt -119.55 79.89 22.26 Favored Pre-proline 0 N--CA 1.491 1.615 0 O-C-N 121.211 -0.93 . . . . 0.0 110.017 -179.495 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 51.4 Cg_endo -77.97 -14.16 15.45 Favored 'Trans proline' 0 C--N 1.308 -1.58 0 C-N-CA 122.604 2.203 . . . . 0.0 112.235 179.592 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -90.31 7.25 39.37 Favored 'General case' 0 N--CA 1.487 1.42 0 O-C-N 121.343 -0.848 . . . . 0.0 109.9 -179.699 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.507 ' CG2' HD22 ' A' ' 16' ' ' LEU . 44.7 t -109.28 134.86 49.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.624 0 O-C-N 121.303 -0.873 . . . . 0.0 109.588 -179.98 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.489 ' O ' ' OD1' ' A' ' 23' ' ' ASP . . . -72.52 117.15 56.53 Favored Pre-proline 0 N--CA 1.49 1.533 0 O-C-N 121.275 -0.89 . . . . 0.0 109.382 -179.942 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 34.3 Cg_exo -52.5 -26.16 27.64 Favored 'Trans proline' 0 N--CA 1.493 1.468 0 C-N-CA 121.891 1.728 . . . . 0.0 112.095 179.446 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.88 -23.42 67.23 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.355 -0.841 . . . . 0.0 109.731 -179.762 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.489 ' OD1' ' O ' ' A' ' 20' ' ' ALA . 52.6 p30 -84.69 7.85 19.02 Favored 'General case' 0 N--CA 1.491 1.611 0 O-C-N 121.16 -0.963 . . . . 0.0 110.003 -179.615 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 12.2 t -103.0 131.74 50.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.162 -0.961 . . . . 0.0 109.5 -179.868 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 63.5 t0 -89.0 119.94 29.98 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.101 -1.0 . . . . 0.0 108.93 179.247 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.5 m -73.12 4.28 0.83 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.403 0 O-C-N 121.079 -1.013 . . . . 0.0 109.547 -179.983 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -89.67 -8.22 52.9 Favored 'General case' 0 N--CA 1.488 1.438 0 O-C-N 121.215 -0.928 . . . . 0.0 109.111 179.577 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 40.5 tp -101.62 139.46 37.23 Favored 'General case' 0 N--CA 1.489 1.476 0 O-C-N 121.427 -0.796 . . . . 0.0 109.313 -179.969 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.5 m-20 -58.88 142.17 51.4 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.249 -0.907 . . . . 0.0 109.388 -179.78 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.841 HD13 HD11 ' A' ' 36' ' ' ILE . 1.4 tt -69.12 -38.6 78.95 Favored 'General case' 0 C--N 1.301 -1.542 0 O-C-N 121.607 -0.683 . . . . 0.0 110.743 -178.846 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 75.4 t -64.5 -36.16 76.52 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.583 0 O-C-N 121.086 -1.009 . . . . 0.0 110.542 -178.903 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 91.3 m-20 -52.58 -33.66 47.09 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 120.969 -1.082 . . . . 0.0 108.218 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.428 ' HB3' HG23 ' A' ' 35' ' ' VAL . 97.6 m-20 -70.94 -34.37 71.4 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 121.615 -0.678 . . . . 0.0 109.99 179.534 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 86.05 6.04 82.48 Favored Glycine 0 N--CA 1.491 2.323 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 -179.315 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.428 HG23 ' HB3' ' A' ' 33' ' ' ASN . 71.6 t -61.51 -33.01 55.14 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.411 0 O-C-N 121.413 -1.051 . . . . 0.0 109.07 179.755 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.841 HD11 HD13 ' A' ' 30' ' ' LEU . 84.7 mt -91.95 123.85 44.22 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.466 0 O-C-N 121.276 -0.89 . . . . 0.0 109.802 -179.859 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -114.97 -168.44 1.38 Allowed 'General case' 0 C--N 1.301 -1.501 0 N-CA-C 109.029 -0.73 . . . . 0.0 109.029 179.61 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -63.77 -53.84 44.6 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.103 -0.998 . . . . 0.0 108.717 179.683 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.585 HD12 ' N ' ' A' ' 39' ' ' LEU . 6.6 mp -68.88 -32.9 72.88 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 107.007 -1.479 . . . . 0.0 107.007 178.222 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.492 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.04 -41.91 96.7 Favored Glycine 0 N--CA 1.48 1.627 0 N-CA-C 108.691 -1.763 . . . . 0.0 108.691 179.211 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.407 HD11 ' CE1' ' A' ' 66' ' ' PHE . 7.7 tt -65.16 -41.09 95.03 Favored 'General case' 0 C--N 1.304 -1.393 0 O-C-N 121.454 -1.027 . . . . 0.0 108.851 179.066 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.1 tp -59.88 -45.81 91.31 Favored 'General case' 0 N--CA 1.489 1.505 0 O-C-N 121.365 -0.834 . . . . 0.0 109.051 179.728 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 78.6 mttt -60.34 -35.73 76.35 Favored 'General case' 0 C--N 1.298 -1.672 0 O-C-N 121.471 -0.768 . . . . 0.0 109.456 -179.863 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.492 HG23 ' O ' ' A' ' 40' ' ' GLY . 77.7 t -62.03 -43.32 97.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.489 0 O-C-N 121.308 -0.87 . . . . 0.0 109.795 -179.884 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.706 ' CD1' HD12 ' A' ' 61' ' ' LEU . 1.5 mp -67.33 -39.56 83.04 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.541 0 O-C-N 121.549 -0.719 . . . . 0.0 111.196 -179.382 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.36 -50.19 60.86 Favored 'General case' 0 N--CA 1.493 1.698 0 O-C-N 120.637 -1.289 . . . . 0.0 112.015 -177.72 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.612 ' CD1' ' CZ ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -78.65 -45.01 22.45 Favored 'General case' 0 N--CA 1.493 1.679 0 O-C-N 120.665 -1.272 . . . . 0.0 110.647 -178.701 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.697 HD11 HG21 ' A' ' 76' ' ' VAL . 29.4 tp -58.5 -44.19 89.34 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 121.12 -0.987 . . . . 0.0 110.062 -178.862 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 68.9 mm-40 -68.06 -37.75 81.66 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.117 -0.989 . . . . 0.0 109.582 -179.819 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.1 t70 -62.37 -36.94 83.83 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.358 -0.839 . . . . 0.0 110.792 -179.754 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 35.5 mmt180 -58.1 -39.07 77.67 Favored 'General case' 0 N--CA 1.493 1.695 0 O-C-N 121.09 -1.007 . . . . 0.0 111.162 -178.641 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.604 ' CE1' ' CG1' ' A' ' 76' ' ' VAL . 9.0 m-85 -91.89 -3.57 55.84 Favored 'General case' 0 N--CA 1.491 1.608 0 O-C-N 120.842 -1.161 . . . . 0.0 110.319 -179.286 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 73.87 29.8 62.49 Favored Glycine 0 N--CA 1.488 2.144 0 N-CA-C 108.52 -1.832 . . . . 0.0 108.52 179.971 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 31.9 pt -113.45 153.61 14.98 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.437 0 O-C-N 121.714 -0.874 . . . . 0.0 109.866 -179.17 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -97.06 139.92 32.34 Favored 'General case' 0 N--CA 1.489 1.515 0 O-C-N 121.307 -0.871 . . . . 0.0 109.259 179.951 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.585 ' HB2' HG23 ' A' ' 45' ' ' ILE . . . -62.85 -30.71 71.71 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.24 -0.912 . . . . 0.0 109.715 -179.796 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 91.7 m-20 -56.72 -38.77 72.81 Favored 'General case' 0 C--N 1.303 -1.422 0 O-C-N 121.054 -1.029 . . . . 0.0 109.681 -179.758 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 90.7 m-20 -61.36 -41.29 96.83 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.204 -0.935 . . . . 0.0 109.945 -179.878 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.482 ' O ' ' O ' ' A' ' 56' ' ' ALA . 46.8 t -130.35 133.73 63.49 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.695 0 O-C-N 121.408 -0.808 . . . . 0.0 109.728 -179.845 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.3 tt0 -104.15 134.27 47.68 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.295 -0.878 . . . . 0.0 109.402 179.677 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.706 HD12 ' CD1' ' A' ' 45' ' ' ILE . 40.2 mt -96.23 141.82 29.13 Favored 'General case' 0 C--N 1.304 -1.387 0 O-C-N 121.217 -0.927 . . . . 0.0 109.521 -179.759 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -109.58 156.33 39.82 Favored Pre-proline 0 C--N 1.305 -1.343 0 N-CA-C 108.407 -0.96 . . . . 0.0 108.407 179.684 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 1.4 Cg_endo -48.92 -22.23 4.62 Favored 'Trans proline' 0 C--N 1.305 -1.729 0 C-N-CA 121.924 1.75 . . . . 0.0 110.837 179.604 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 87.1 tt0 -71.13 -30.14 66.12 Favored 'General case' 0 N--CA 1.486 1.351 0 O-C-N 121.563 -0.711 . . . . 0.0 109.477 179.094 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . 0.54 ' C ' ' CD2' ' A' ' 65' ' ' HIS . 1.2 t60 -65.84 -16.49 63.87 Favored 'General case' 0 C--N 1.302 -1.494 0 O-C-N 121.397 -0.814 . . . . 0.0 108.97 -179.794 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.558 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 12.5 m-85 -97.53 15.38 23.45 Favored 'General case' 0 C--N 1.299 -1.598 0 CA-C-O 121.739 0.78 . . . . 0.0 108.896 -179.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . 0.598 ' NE ' ' OG ' ' A' ' 71' ' ' SER . 6.6 ptt180 -50.71 -36.13 34.72 Favored 'General case' 0 C--N 1.301 -1.5 0 O-C-N 121.701 -0.624 . . . . 0.0 110.002 -179.719 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.462 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 88.8 p -162.86 153.35 16.56 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 120.982 -1.074 . . . . 0.0 110.216 -179.92 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.67 ' H ' HD12 ' A' ' 69' ' ' ILE . 3.5 mp -58.42 -43.4 86.51 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 O-C-N 121.34 -0.85 . . . . 0.0 109.046 179.68 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 10.0 ptm180 -58.17 -40.11 80.62 Favored 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 108.96 -0.756 . . . . 0.0 108.96 179.5 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.598 ' OG ' ' NE ' ' A' ' 67' ' ' ARG . 25.9 t -63.46 -41.14 98.62 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.434 -0.792 . . . . 0.0 109.827 179.542 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 81.8 mt -58.91 -48.7 85.57 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.315 0 O-C-N 121.239 -0.913 . . . . 0.0 109.603 -179.615 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 37.4 t0 -60.07 -43.76 95.21 Favored 'General case' 0 N--CA 1.487 1.406 0 O-C-N 121.22 -0.925 . . . . 0.0 108.728 179.756 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.99 -38.77 86.63 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.658 -0.651 . . . . 0.0 109.932 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . 0.577 ' O ' ' HB2' ' A' ' 79' ' ' ALA . 53.5 t80 -62.76 -47.99 81.13 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.177 -0.952 . . . . 0.0 109.473 -179.698 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.697 HG21 HD11 ' A' ' 48' ' ' LEU . 50.0 t -64.99 -48.33 84.49 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.294 0 O-C-N 121.255 -0.903 . . . . 0.0 109.774 -179.951 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.763 HG22 ' OE1' ' A' ' 2' ' ' GLN . 88.7 t -69.88 -49.06 60.0 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.298 0 O-C-N 121.2 -0.937 . . . . 0.0 109.356 179.705 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.493 ' O ' ' O ' ' A' ' 81' ' ' THR . . . -65.6 -26.58 72.01 Favored Glycine 0 N--CA 1.49 2.277 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 -179.778 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . 0.577 ' HB2' ' O ' ' A' ' 75' ' ' PHE . . . -67.12 -39.39 86.65 Favored 'General case' 0 N--CA 1.491 1.602 0 O-C-N 121.145 -1.209 . . . . 0.0 110.019 -179.31 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 56.6 p -82.19 -28.7 31.89 Favored 'General case' 0 N--CA 1.489 1.478 0 O-C-N 121.197 -0.939 . . . . 0.0 109.585 -179.992 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.625 HG22 ' O ' ' A' ' 77' ' ' VAL . 2.0 t -133.04 148.77 70.66 Favored Pre-proline 0 N--CA 1.489 1.522 0 O-C-N 121.389 -0.819 . . . . 0.0 109.65 -179.857 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 87.6 Cg_exo -40.76 109.41 0.1 Allowed 'Trans proline' 0 C--N 1.311 -1.435 0 C-N-CA 122.252 1.968 . . . . 0.0 111.862 179.248 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 22.4 Cg_exo -57.55 146.43 84.18 Favored 'Trans proline' 0 N--CA 1.49 1.317 0 C-N-CA 121.966 1.777 . . . . 0.0 112.158 -179.807 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.463 ' O ' ' C ' ' A' ' 85' ' ' GLU . 45.8 t -102.76 130.79 52.24 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.382 -0.824 . . . . 0.0 109.12 179.58 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.463 ' C ' ' O ' ' A' ' 84' ' ' VAL . 96.2 mt-10 38.59 63.59 0.86 Allowed 'General case' 0 N--CA 1.491 1.624 0 O-C-N 121.437 -0.789 . . . . 0.0 109.839 -179.988 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.401 ' C ' ' O ' ' A' ' 85' ' ' GLU . . . -45.3 149.11 0.55 Allowed 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.19 -0.944 . . . . 0.0 109.513 -179.844 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 12.6 tttm -55.88 -33.48 64.63 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.308 -0.87 . . . . 0.0 109.519 -179.8 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 55.6 mt -80.73 143.07 33.23 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.277 -0.89 . . . . 0.0 109.46 -179.915 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 63.6 tt0 . . . . . 0 N--CA 1.49 1.541 0 CA-C-O 118.042 -0.98 . . . . 0.0 109.479 -179.924 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' -1' ' ' SER . . . . . . . . . . . . . 13.4 m . . . . . 0 N--CA 1.49 1.549 0 N-CA-C 109.478 -0.564 . . . . 0.0 109.478 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 0' ' ' GLU . . . . . 0.472 ' HG2' HG21 ' A' ' 84' ' ' VAL . 44.7 tp10 -58.03 -34.12 69.72 Favored 'General case' 0 N--CA 1.491 1.577 0 O-C-N 121.301 -0.874 . . . . 0.0 109.277 179.952 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.555 ' HB3' ' HB2' ' A' ' 4' ' ' ALA . 65.4 mtt -60.52 -33.7 73.02 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 121.36 -0.837 . . . . 0.0 109.767 179.826 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.612 ' CD ' HG22 ' A' ' 77' ' ' VAL . 90.7 mt-30 58.48 48.99 11.27 Favored 'General case' 0 N--CA 1.491 1.588 0 O-C-N 121.512 -0.742 . . . . 0.0 109.469 -179.452 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.493 ' CG ' ' C ' ' A' ' 2' ' ' GLN . 13.4 m-70 76.42 57.38 0.04 OUTLIER 'General case' 0 N--CA 1.495 1.786 0 O-C-N 121.637 -0.664 . . . . 0.0 110.225 179.677 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.555 ' HB2' ' HB3' ' A' ' 1' ' ' MET . . . -62.74 -41.36 99.15 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.078 -1.014 . . . . 0.0 109.509 179.77 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.3 p -62.75 -34.57 77.47 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.204 -0.935 . . . . 0.0 109.685 -179.731 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 65.3 t -64.62 -41.66 92.9 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.54 0 O-C-N 121.228 -0.92 . . . . 0.0 109.183 179.75 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 77.7 mt -59.67 -44.61 93.91 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.461 0 O-C-N 121.481 -0.762 . . . . 0.0 109.238 179.875 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -62.12 -38.33 88.53 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.333 -0.854 . . . . 0.0 109.235 179.875 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 7.2 tt0 -59.09 -41.14 87.36 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.273 -0.892 . . . . 0.0 109.185 179.72 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.699 ' CG ' ' CE2' ' A' ' 47' ' ' TRP . 23.0 m-85 -63.32 -40.74 98.16 Favored 'General case' 0 C--N 1.299 -1.604 0 O-C-N 121.012 -1.055 . . . . 0.0 109.955 179.586 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 55.9 t -59.53 -50.63 79.23 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.276 -0.89 . . . . 0.0 110.726 -178.558 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.472 ' O ' ' C ' ' A' ' 16' ' ' LEU . 17.1 m -66.12 -39.6 84.86 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.428 0 O-C-N 120.656 -1.277 . . . . 0.0 109.813 -179.955 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -67.21 -20.54 65.71 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.136 -0.977 . . . . 0.0 110.39 -179.785 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 82.4 tt0 -63.34 -30.11 71.3 Favored 'General case' 0 C--N 1.299 -1.606 0 O-C-N 121.275 -0.891 . . . . 0.0 109.731 -179.309 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 63.6 t80 -149.27 -33.23 0.21 Allowed 'General case' 0 N--CA 1.491 1.602 0 O-C-N 120.997 -1.064 . . . . 0.0 110.253 -179.917 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.472 ' C ' ' O ' ' A' ' 12' ' ' VAL . 3.8 mt -121.89 79.93 41.47 Favored Pre-proline 0 N--CA 1.492 1.671 0 O-C-N 121.189 -0.945 . . . . 0.0 110.126 -179.383 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_endo -74.62 -11.98 22.3 Favored 'Trans proline' 0 C--N 1.308 -1.573 0 C-N-CA 122.403 2.068 . . . . 0.0 112.438 179.881 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -93.9 12.83 24.61 Favored 'General case' 0 N--CA 1.487 1.377 0 O-C-N 121.246 -0.909 . . . . 0.0 110.371 -179.413 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 60.5 t -111.15 134.71 52.6 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.766 0 O-C-N 121.238 -0.914 . . . . 0.0 109.831 -179.784 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.49 ' O ' ' OD1' ' A' ' 23' ' ' ASP . . . -75.96 118.43 71.09 Favored Pre-proline 0 N--CA 1.489 1.515 0 O-C-N 121.338 -0.851 . . . . 0.0 109.326 179.912 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 43.2 Cg_exo -51.41 -25.63 19.15 Favored 'Trans proline' 0 N--CA 1.493 1.486 0 C-N-CA 121.77 1.647 . . . . 0.0 112.146 179.611 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.81 -25.61 67.98 Favored 'General case' 0 N--CA 1.49 1.528 0 O-C-N 121.261 -0.9 . . . . 0.0 109.732 -179.896 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.49 ' OD1' ' O ' ' A' ' 20' ' ' ALA . 49.8 p30 -85.81 7.46 23.76 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.195 -0.941 . . . . 0.0 109.925 -179.611 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . 0.47 HG23 ' OD1' ' A' ' 23' ' ' ASP . 17.3 t -109.7 133.32 55.37 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.321 -0.862 . . . . 0.0 109.397 179.844 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 63.4 t0 -88.47 119.66 29.12 Favored 'General case' 0 C--N 1.302 -1.464 0 O-C-N 121.141 -0.974 . . . . 0.0 108.892 179.348 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 19.6 m -75.89 3.81 1.2 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.4 0 O-C-N 121.182 -0.949 . . . . 0.0 109.285 179.851 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -87.55 -11.38 48.93 Favored 'General case' 0 N--CA 1.488 1.427 0 O-C-N 121.333 -0.854 . . . . 0.0 108.966 179.424 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 36.4 tp -94.98 136.91 34.73 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 108.881 -0.785 . . . . 0.0 108.881 179.778 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -59.51 134.16 56.76 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.114 -0.991 . . . . 0.0 109.409 -179.493 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.727 HD23 ' O ' ' A' ' 30' ' ' LEU . 2.3 tt -67.15 -37.81 84.41 Favored 'General case' 0 C--N 1.299 -1.6 0 O-C-N 121.732 -0.605 . . . . 0.0 110.154 -179.18 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.535 HG23 ' O ' ' A' ' 66' ' ' PHE . 78.2 t -63.79 -34.96 71.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.554 0 O-C-N 121.05 -1.031 . . . . 0.0 110.396 -178.994 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 56.9 t0 -52.36 -33.66 44.08 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 120.984 -1.073 . . . . 0.0 108.11 179.953 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.409 ' HB3' HG23 ' A' ' 35' ' ' VAL . 21.8 m120 -71.16 -34.48 71.01 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.55 -0.719 . . . . 0.0 109.897 179.433 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 86.37 6.52 80.95 Favored Glycine 0 N--CA 1.49 2.26 0 N-CA-C 109.056 -1.617 . . . . 0.0 109.056 -179.374 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.409 HG23 ' HB3' ' A' ' 33' ' ' ASN . 79.6 t -61.66 -34.3 61.41 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.433 0 O-C-N 121.455 -1.026 . . . . 0.0 109.152 179.719 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.662 HD11 HD13 ' A' ' 30' ' ' LEU . 85.4 mt -86.07 117.84 31.49 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.49 0 O-C-N 121.324 -0.86 . . . . 0.0 109.656 -179.95 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -114.01 -164.59 0.94 Allowed 'General case' 0 C--N 1.302 -1.463 0 N-CA-C 109.073 -0.714 . . . . 0.0 109.073 179.845 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -64.74 -54.21 34.94 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.109 -0.994 . . . . 0.0 108.682 179.704 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 38.5 mt -68.71 -32.81 72.86 Favored 'General case' 0 C--N 1.303 -1.432 0 N-CA-C 107.105 -1.443 . . . . 0.0 107.105 178.264 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.547 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.15 -40.7 96.04 Favored Glycine 0 N--CA 1.48 1.592 0 N-CA-C 108.403 -1.879 . . . . 0.0 108.403 179.16 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.597 ' CD1' ' CZ ' ' A' ' 66' ' ' PHE . 7.3 tt -65.47 -41.67 93.07 Favored 'General case' 0 C--N 1.303 -1.429 0 O-C-N 121.479 -1.012 . . . . 0.0 108.888 178.978 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 tp -59.71 -45.74 91.22 Favored 'General case' 0 N--CA 1.488 1.436 0 N-CA-C 108.818 -0.808 . . . . 0.0 108.818 179.443 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 25.2 mttp -60.51 -35.44 75.96 Favored 'General case' 0 C--N 1.297 -1.698 0 O-C-N 121.577 -0.702 . . . . 0.0 109.553 -179.881 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.547 HG23 ' O ' ' A' ' 40' ' ' GLY . 72.5 t -60.11 -43.3 92.59 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.462 0 O-C-N 121.296 -0.877 . . . . 0.0 109.445 -179.916 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.484 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 6.4 mm -67.45 -40.03 83.74 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.559 0 O-C-N 121.476 -0.765 . . . . 0.0 111.144 -179.088 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.48 -49.09 67.78 Favored 'General case' 0 N--CA 1.496 1.835 0 O-C-N 121.038 -1.038 . . . . 0.0 112.162 -177.596 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.699 ' CE2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -78.77 -46.73 18.21 Favored 'General case' 0 N--CA 1.493 1.706 0 O-C-N 120.448 -1.407 . . . . 0.0 110.679 -178.55 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.741 HD13 ' C ' ' A' ' 48' ' ' LEU . 3.2 tm? -58.4 -43.54 88.6 Favored 'General case' 0 C--N 1.301 -1.501 0 O-C-N 121.005 -1.06 . . . . 0.0 109.921 -178.301 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.484 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 1.2 pp20? -69.76 -36.83 76.12 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 120.943 -1.098 . . . . 0.0 109.66 -179.911 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.2 t0 -62.82 -37.88 88.54 Favored 'General case' 0 N--CA 1.49 1.568 0 O-C-N 121.181 -0.949 . . . . 0.0 110.321 179.895 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 9.7 mmt180 -60.95 -38.47 85.97 Favored 'General case' 0 N--CA 1.491 1.578 0 O-C-N 121.322 -0.861 . . . . 0.0 111.724 -178.81 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.74 ' CZ ' HG11 ' A' ' 76' ' ' VAL . 84.5 m-85 -96.82 -6.89 34.97 Favored 'General case' 0 C--N 1.304 -1.392 0 O-C-N 120.817 -1.177 . . . . 0.0 110.239 -178.947 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 70.92 30.81 67.58 Favored Glycine 0 N--CA 1.486 1.971 0 N-CA-C 108.72 -1.752 . . . . 0.0 108.72 179.653 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.47 ' O ' ' OE1' ' A' ' 49' ' ' GLU . 24.7 pt -108.59 153.07 10.35 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 O-C-N 121.587 -0.949 . . . . 0.0 109.765 -179.408 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -104.14 156.28 18.01 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.383 -0.823 . . . . 0.0 109.554 -179.78 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . . . . . . . . . . . -58.22 -25.54 61.78 Favored 'General case' 0 N--CA 1.489 1.486 0 O-C-N 121.234 -0.916 . . . . 0.0 109.151 -179.997 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . 0.402 ' O ' HG23 ' A' ' 59' ' ' VAL . 61.2 t0 59.07 39.62 23.05 Favored 'General case' 0 N--CA 1.485 1.286 0 O-C-N 121.517 -0.739 . . . . 0.0 109.075 -179.761 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 54.38 44.87 28.27 Favored 'General case' 0 N--CA 1.487 1.379 0 O-C-N 121.706 -0.621 . . . . 0.0 110.202 179.367 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.402 HG23 ' O ' ' A' ' 57' ' ' ASP . 52.6 t -121.33 134.46 64.62 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.681 0 O-C-N 121.446 -0.784 . . . . 0.0 109.137 179.382 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -102.29 132.44 48.24 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.19 -0.944 . . . . 0.0 109.599 -179.914 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 53.1 mt -95.24 147.3 23.62 Favored 'General case' 0 C--N 1.304 -1.394 0 O-C-N 121.347 -0.846 . . . . 0.0 109.293 179.792 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -104.4 157.67 33.59 Favored Pre-proline 0 N--CA 1.486 1.349 0 O-C-N 121.282 -0.886 . . . . 0.0 108.92 179.872 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 2.1 Cg_endo -49.4 -19.65 3.19 Favored 'Trans proline' 0 C--N 1.302 -1.869 0 C-N-CA 122.398 2.065 . . . . 0.0 110.985 -179.963 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 87.4 tt0 -68.54 -32.32 72.18 Favored 'General case' 0 N--CA 1.486 1.375 0 O-C-N 121.606 -0.683 . . . . 0.0 109.56 179.404 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . 0.553 ' C ' ' CD2' ' A' ' 65' ' ' HIS . 1.5 t60 -66.33 -17.89 65.03 Favored 'General case' 0 C--N 1.3 -1.558 0 O-C-N 121.384 -0.823 . . . . 0.0 108.829 179.999 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.602 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 4.2 m-85 -101.97 14.99 30.39 Favored 'General case' 0 C--N 1.298 -1.642 0 N-CA-C 108.46 -0.941 . . . . 0.0 108.46 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . 0.422 ' NE ' ' OG ' ' A' ' 71' ' ' SER . 4.8 ptt180 -46.17 -38.31 8.11 Favored 'General case' 0 C--N 1.301 -1.522 0 O-C-N 121.875 -0.516 . . . . 0.0 109.985 -179.684 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.55 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 83.8 p -163.86 159.5 21.14 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.081 -1.012 . . . . 0.0 109.905 179.578 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.683 HG13 HD12 ' A' ' 30' ' ' LEU . 3.4 mp -57.83 -35.35 51.08 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.467 0 N-CA-C 108.128 -1.064 . . . . 0.0 108.128 179.087 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 57.9 mtp180 -57.85 -42.35 84.25 Favored 'General case' 0 C--N 1.304 -1.397 0 N-CA-C 108.884 -0.784 . . . . 0.0 108.884 179.644 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.422 ' OG ' ' NE ' ' A' ' 67' ' ' ARG . 8.8 t -65.18 -38.81 91.69 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.652 -0.655 . . . . 0.0 109.987 -179.935 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.454 HD12 ' HA ' ' A' ' 69' ' ' ILE . 71.5 mt -58.93 -51.45 72.29 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.339 0 O-C-N 121.189 -0.944 . . . . 0.0 109.713 -179.286 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.447 ' O ' HG23 ' A' ' 77' ' ' VAL . 43.1 t0 -62.1 -41.07 97.83 Favored 'General case' 0 N--CA 1.487 1.418 0 O-C-N 121.15 -0.969 . . . . 0.0 108.67 179.446 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.33 -37.6 85.72 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.667 -0.646 . . . . 0.0 109.952 179.969 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 64.3 t80 -60.36 -49.23 78.41 Favored 'General case' 0 N--CA 1.49 1.544 0 O-C-N 121.225 -0.922 . . . . 0.0 109.808 -179.626 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.74 HG11 ' CZ ' ' A' ' 52' ' ' PHE . 93.7 t -66.45 -46.84 85.61 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.331 0 O-C-N 121.201 -0.937 . . . . 0.0 109.626 -179.89 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.612 HG22 ' CD ' ' A' ' 2' ' ' GLN . 74.9 t -66.41 -40.51 86.78 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.36 0 O-C-N 121.261 -0.9 . . . . 0.0 109.229 -179.928 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -60.05 -37.52 92.89 Favored Glycine 0 N--CA 1.489 2.213 0 N-CA-C 110.268 -1.133 . . . . 0.0 110.268 -179.72 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -73.25 -41.86 63.2 Favored 'General case' 0 N--CA 1.493 1.707 0 O-C-N 121.217 -1.166 . . . . 0.0 111.105 -178.929 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 43.6 p -83.36 -36.7 24.14 Favored 'General case' 0 N--CA 1.49 1.57 0 O-C-N 120.962 -1.086 . . . . 0.0 109.425 -179.598 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.491 ' O ' ' O ' ' A' ' 77' ' ' VAL . 0.6 OUTLIER -133.33 153.49 80.59 Favored Pre-proline 0 C--N 1.299 -1.593 0 O-C-N 121.541 -0.724 . . . . 0.0 109.081 -179.762 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 51.8 Cg_exo -43.56 144.46 2.12 Favored 'Trans proline' 0 C--N 1.307 -1.629 0 C-N-CA 121.874 1.716 . . . . 0.0 110.994 179.49 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . 0.558 ' HB2' ' HB2' ' A' ' 86' ' ' ALA . 10.4 Cg_endo -60.26 140.54 92.52 Favored 'Trans proline' 0 C--N 1.311 -1.441 0 C-N-CA 121.996 1.798 . . . . 0.0 112.747 -179.252 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.476 ' O ' ' C ' ' A' ' 85' ' ' GLU . 46.8 t -104.1 128.1 57.77 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.552 0 N-CA-C 109.024 -0.732 . . . . 0.0 109.024 179.345 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.476 ' C ' ' O ' ' A' ' 84' ' ' VAL . 96.0 mt-10 36.74 39.55 0.11 Allowed 'General case' 0 N--CA 1.493 1.706 0 O-C-N 121.566 -0.709 . . . . 0.0 109.787 179.895 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.558 ' HB2' ' HB2' ' A' ' 83' ' ' PRO . . . -50.67 144.48 8.06 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.219 -0.925 . . . . 0.0 109.669 -179.551 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . . . . . . . . . 42.6 mttm -58.25 -33.67 69.63 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.365 -0.834 . . . . 0.0 109.39 -179.971 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 55.4 mt -88.06 142.33 27.86 Favored 'General case' 0 N--CA 1.49 1.572 0 O-C-N 121.223 -0.923 . . . . 0.0 109.446 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 50.9 tt0 . . . . . 0 N--CA 1.492 1.645 0 CA-C-O 118.031 -0.985 . . . . 0.0 109.398 -179.968 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' -1' ' ' SER . . . . . . . . . . . . . 54.5 p . . . . . 0 N--CA 1.491 1.58 0 N-CA-C 109.4 -0.593 . . . . 0.0 109.4 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 0' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -57.94 -33.57 68.97 Favored 'General case' 0 N--CA 1.49 1.555 0 O-C-N 121.234 -0.916 . . . . 0.0 109.484 179.912 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.65 ' HB3' ' HB2' ' A' ' 4' ' ' ALA . 71.4 mtm -57.97 -35.98 71.93 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 121.231 -0.918 . . . . 0.0 109.583 -179.919 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.453 HE21 ' CD2' ' A' ' 3' ' ' HIS . 70.2 tp60 45.24 74.1 0.14 Allowed 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.221 -0.924 . . . . 0.0 109.58 179.989 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.453 ' CD2' HE21 ' A' ' 2' ' ' GLN . 81.3 m-70 59.61 58.58 2.84 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 121.351 -0.843 . . . . 0.0 110.018 179.789 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.65 ' HB2' ' HB3' ' A' ' 1' ' ' MET . . . -60.72 -34.44 74.41 Favored 'General case' 0 N--CA 1.492 1.628 0 O-C-N 121.127 -0.983 . . . . 0.0 109.522 179.805 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.8 t -58.69 -38.61 78.62 Favored 'General case' 0 N--CA 1.489 1.524 0 O-C-N 121.295 -0.878 . . . . 0.0 109.876 -179.602 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 78.9 t -64.06 -46.28 94.21 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.555 0 O-C-N 121.143 -0.973 . . . . 0.0 109.353 179.936 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.714 HD13 ' OD1' ' A' ' 73' ' ' ASP . 77.5 mt -61.27 -46.25 96.99 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.486 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 179.491 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.765 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -62.22 -35.36 78.66 Favored 'General case' 0 C--N 1.303 -1.419 0 O-C-N 121.619 -0.675 . . . . 0.0 109.29 179.734 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 31.4 tt0 -62.11 -41.76 98.54 Favored 'General case' 0 N--CA 1.489 1.49 0 O-C-N 121.19 -0.944 . . . . 0.0 110.419 -179.611 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.672 ' CG ' ' CE2' ' A' ' 47' ' ' TRP . 49.6 m-85 -68.13 -50.75 52.64 Favored 'General case' 0 N--CA 1.493 1.701 0 O-C-N 120.896 -1.127 . . . . 0.0 111.065 -179.268 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.449 HG11 HD11 ' A' ' 30' ' ' LEU . 36.0 m -66.01 -38.95 83.21 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.427 0 O-C-N 120.972 -1.08 . . . . 0.0 109.247 -179.315 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.765 HG23 ' O ' ' A' ' 8' ' ' ALA . 89.2 t -63.68 -46.27 95.16 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 O-C-N 121.261 -0.899 . . . . 0.0 109.204 179.479 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 97.3 mt-10 -75.09 -16.92 60.54 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.14 -0.975 . . . . 0.0 110.076 179.824 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -63.81 -33.67 76.19 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.285 -0.884 . . . . 0.0 110.439 -178.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 67.2 t80 -154.08 -19.16 0.13 Allowed 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.86 -1.15 . . . . 0.0 110.471 -179.634 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.469 HD22 HG21 ' A' ' 19' ' ' VAL . 5.6 mt -121.57 80.05 38.86 Favored Pre-proline 0 N--CA 1.49 1.558 0 O-C-N 121.198 -0.939 . . . . 0.0 109.835 -179.497 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 57.2 Cg_endo -79.73 -17.41 11.07 Favored 'Trans proline' 0 C--N 1.307 -1.656 0 C-N-CA 122.665 2.244 . . . . 0.0 112.628 -179.877 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . 0.555 ' OD1' HG23 ' A' ' 19' ' ' VAL . 51.8 p30 -90.09 9.99 26.04 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.166 -0.959 . . . . 0.0 110.172 -179.575 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.555 HG23 ' OD1' ' A' ' 18' ' ' ASP . 67.5 t -111.25 135.98 48.74 Favored 'Isoleucine or valine' 0 N--CA 1.495 1.803 0 O-C-N 121.207 -0.933 . . . . 0.0 109.532 179.754 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -78.27 117.39 65.86 Favored Pre-proline 0 N--CA 1.49 1.534 0 O-C-N 121.312 -0.867 . . . . 0.0 109.443 -179.908 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 34.2 Cg_exo -51.95 -35.83 61.96 Favored 'Trans proline' 0 N--CA 1.491 1.368 0 C-N-CA 121.709 1.606 . . . . 0.0 111.817 179.326 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.84 -23.73 66.73 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.3 -0.875 . . . . 0.0 108.925 179.529 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -84.71 7.46 20.41 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.418 -0.801 . . . . 0.0 109.743 -179.795 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 13.0 t -101.63 132.51 47.36 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.584 0 O-C-N 121.145 -0.972 . . . . 0.0 109.264 179.95 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 63.8 t0 -89.01 119.39 29.49 Favored 'General case' 0 C--N 1.302 -1.46 0 O-C-N 121.151 -0.968 . . . . 0.0 109.223 179.587 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . 0.448 ' O ' HG13 ' A' ' 26' ' ' VAL . 0.3 OUTLIER -69.33 4.25 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 O-C-N 121.204 -0.935 . . . . 0.0 109.452 179.782 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -95.02 -2.77 49.62 Favored 'General case' 0 N--CA 1.487 1.423 0 O-C-N 121.251 -0.905 . . . . 0.0 109.239 179.66 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 39.8 tp -99.56 136.42 39.52 Favored 'General case' 0 C--N 1.303 -1.441 0 O-C-N 121.394 -0.816 . . . . 0.0 108.92 179.714 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -58.62 137.12 57.7 Favored 'General case' 0 C--N 1.303 -1.454 0 O-C-N 121.105 -0.997 . . . . 0.0 109.196 -179.502 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.713 HD13 HD11 ' A' ' 36' ' ' ILE . 1.8 tt -68.35 -36.73 79.68 Favored 'General case' 0 C--N 1.299 -1.608 0 O-C-N 121.635 -0.665 . . . . 0.0 110.36 -178.981 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 69.6 t -64.75 -35.51 75.15 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.597 0 O-C-N 121.101 -0.999 . . . . 0.0 110.557 -179.004 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 90.4 m-20 -52.54 -33.61 46.34 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 120.996 -1.065 . . . . 0.0 108.178 -179.966 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.445 ' HB3' HG23 ' A' ' 35' ' ' VAL . 3.2 m120 -70.98 -34.52 71.47 Favored 'General case' 0 C--N 1.303 -1.453 0 O-C-N 121.604 -0.685 . . . . 0.0 109.982 179.485 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 85.96 6.05 82.72 Favored Glycine 0 N--CA 1.49 2.295 0 N-CA-C 108.88 -1.688 . . . . 0.0 108.88 -179.24 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.445 HG23 ' HB3' ' A' ' 33' ' ' ASN . 78.5 t -61.1 -31.21 49.43 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.398 0 O-C-N 121.495 -1.003 . . . . 0.0 108.68 179.512 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.713 HD11 HD13 ' A' ' 30' ' ' LEU . 81.5 mt -93.99 132.3 38.48 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.419 0 O-C-N 121.438 -0.789 . . . . 0.0 109.677 -179.98 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.53 ' CG ' ' H ' ' A' ' 38' ' ' ALA . 52.4 t0 -138.97 -167.69 2.27 Favored 'General case' 0 C--N 1.301 -1.528 0 N-CA-C 108.562 -0.903 . . . . 0.0 108.562 179.602 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.53 ' H ' ' CG ' ' A' ' 37' ' ' ASP . . . -62.6 -55.22 29.14 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 120.928 -1.107 . . . . 0.0 108.588 179.96 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 37.4 mt -71.47 -34.79 70.51 Favored 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 107.063 -1.458 . . . . 0.0 107.063 178.024 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.762 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.85 -39.85 95.98 Favored Glycine 0 N--CA 1.481 1.671 0 N-CA-C 108.703 -1.759 . . . . 0.0 108.703 179.169 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.794 ' C ' HD13 ' A' ' 41' ' ' LEU . 2.5 tm? -65.04 -43.89 90.87 Favored 'General case' 0 C--N 1.304 -1.382 0 O-C-N 121.49 -1.006 . . . . 0.0 108.622 179.386 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.2 tp -59.09 -46.03 89.33 Favored 'General case' 0 N--CA 1.488 1.46 0 O-C-N 121.343 -0.848 . . . . 0.0 109.066 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 63.2 mttp -61.49 -34.79 76.07 Favored 'General case' 0 C--N 1.295 -1.778 0 O-C-N 121.537 -0.727 . . . . 0.0 109.481 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.762 HG23 ' O ' ' A' ' 40' ' ' GLY . 91.6 t -62.56 -50.43 79.84 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.495 0 O-C-N 121.451 -0.781 . . . . 0.0 110.166 -179.347 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . . . . . . . . . 1.7 mp -68.34 -29.85 45.65 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.568 0 O-C-N 121.314 -0.866 . . . . 0.0 110.566 -179.774 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -66.47 -49.2 67.44 Favored 'General case' 0 N--CA 1.495 1.778 0 O-C-N 121.108 -0.995 . . . . 0.0 111.657 -178.177 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.672 ' CE2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -81.08 -40.99 23.26 Favored 'General case' 0 N--CA 1.495 1.794 0 O-C-N 120.592 -1.317 . . . . 0.0 110.3 -179.015 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.543 ' O ' HD13 ' A' ' 48' ' ' LEU . 0.2 OUTLIER -61.23 -41.62 97.19 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 121.154 -0.966 . . . . 0.0 109.298 -179.357 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.419 ' CG ' ' N ' ' A' ' 50' ' ' ASP . 17.0 pt-20 -73.13 -36.07 66.63 Favored 'General case' 0 C--N 1.301 -1.506 0 O-C-N 120.638 -1.289 . . . . 0.0 109.165 179.907 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . 0.419 ' N ' ' CG ' ' A' ' 49' ' ' GLU . 59.0 t0 -65.6 -40.84 93.12 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.632 -0.667 . . . . 0.0 111.766 -179.072 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.433 HH21 HG11 ' A' ' 76' ' ' VAL . 24.3 ptt180 -71.39 -36.59 71.46 Favored 'General case' 0 N--CA 1.489 1.511 0 O-C-N 120.864 -1.148 . . . . 0.0 111.484 -177.712 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.414 ' CE1' ' CG1' ' A' ' 76' ' ' VAL . 5.7 m-85 -81.21 -14.74 57.21 Favored 'General case' 0 N--CA 1.492 1.668 0 O-C-N 120.577 -1.327 . . . . 0.0 109.756 -179.726 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 78.27 20.67 71.9 Favored Glycine 0 N--CA 1.486 2.025 0 N-CA-C 108.693 -1.763 . . . . 0.0 108.693 -179.745 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 23.1 pt -113.19 153.65 14.72 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.482 0 O-C-N 121.737 -0.86 . . . . 0.0 109.695 -179.573 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -101.03 132.29 46.53 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.249 -0.907 . . . . 0.0 109.519 -179.789 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.503 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -69.0 -23.55 64.12 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.316 -0.865 . . . . 0.0 109.692 179.859 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 91.3 m-20 -54.98 -36.08 65.01 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.268 -0.895 . . . . 0.0 110.146 -179.487 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -56.13 -39.36 72.12 Favored 'General case' 0 N--CA 1.491 1.605 0 O-C-N 121.18 -0.95 . . . . 0.0 110.001 -179.547 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.503 ' O ' ' O ' ' A' ' 56' ' ' ALA . 41.7 t -126.86 136.68 60.11 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.337 -0.852 . . . . 0.0 109.666 -179.894 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -87.58 127.23 35.27 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.117 -0.989 . . . . 0.0 109.185 179.864 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 39.4 mt -104.53 142.05 35.31 Favored 'General case' 0 C--N 1.306 -1.295 0 O-C-N 121.279 -0.888 . . . . 0.0 109.831 -179.649 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -108.75 152.54 42.31 Favored Pre-proline 0 N--CA 1.485 1.316 0 N-CA-C 108.696 -0.854 . . . . 0.0 108.696 179.377 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 12.8 Cg_endo -58.44 -21.16 52.44 Favored 'Trans proline' 0 C--N 1.304 -1.768 0 C-N-CA 122.505 2.137 . . . . 0.0 112.196 -179.748 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 95.1 mt-10 -69.6 -30.1 67.77 Favored 'General case' 0 N--CA 1.486 1.335 0 O-C-N 121.272 -0.892 . . . . 0.0 109.731 -179.726 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . 0.457 ' CE1' ' HB2' ' A' ' 75' ' ' PHE . 76.3 t60 -66.16 -20.66 66.21 Favored 'General case' 0 C--N 1.299 -1.588 0 O-C-N 121.233 -0.917 . . . . 0.0 108.918 -179.874 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.496 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 21.8 m-85 -89.17 12.73 15.0 Favored 'General case' 0 C--N 1.3 -1.556 0 O-C-N 121.394 -0.816 . . . . 0.0 109.203 -179.68 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . 0.429 HH21 ' CD ' ' A' ' 87' ' ' LYS . 4.2 ptt85 -49.88 -34.56 20.58 Favored 'General case' 0 C--N 1.3 -1.57 0 O-C-N 121.628 -0.67 . . . . 0.0 109.513 179.719 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.518 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 89.2 p -151.65 153.54 34.62 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.154 -0.966 . . . . 0.0 109.895 179.794 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.644 ' H ' HD12 ' A' ' 69' ' ' ILE . 3.5 mp -59.83 -34.81 57.11 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.485 0 N-CA-C 108.854 -0.795 . . . . 0.0 108.854 179.3 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.609 ' HE ' ' HZ1' ' A' ' 87' ' ' LYS . 30.2 mtp85 -57.11 -45.18 83.66 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.604 -0.685 . . . . 0.0 109.765 -179.272 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.424 ' HG ' ' CE1' ' A' ' 65' ' ' HIS . 22.9 t -64.9 -46.07 83.25 Favored 'General case' 0 N--CA 1.491 1.583 0 O-C-N 121.307 -0.871 . . . . 0.0 109.781 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.431 ' HA ' ' NE2' ' A' ' 65' ' ' HIS . 68.0 mt -58.95 -42.89 87.38 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 O-C-N 121.176 -0.952 . . . . 0.0 109.913 -179.735 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.714 ' OD1' HD13 ' A' ' 7' ' ' ILE . 2.0 m-20 -61.14 -37.95 84.66 Favored 'General case' 0 C--N 1.3 -1.577 0 O-C-N 121.292 -0.88 . . . . 0.0 109.842 -179.584 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -67.4 -46.91 71.85 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.035 -1.041 . . . . 0.0 110.541 -179.304 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . 0.457 ' HB2' ' CE1' ' A' ' 65' ' ' HIS . 65.8 t80 -66.03 -44.08 85.71 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.135 -0.978 . . . . 0.0 109.57 -179.737 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.433 HG11 HH21 ' A' ' 51' ' ' ARG . 43.4 t -60.68 -41.83 89.68 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.491 0 O-C-N 121.301 -0.874 . . . . 0.0 108.81 179.334 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.661 HG23 ' O ' ' A' ' 73' ' ' ASP . 65.3 t -65.0 -40.52 89.34 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.256 0 O-C-N 121.306 -0.871 . . . . 0.0 109.042 179.338 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -58.53 -17.23 32.47 Favored Glycine 0 N--CA 1.492 2.386 0 N-CA-C 109.753 -1.339 . . . . 0.0 109.753 179.794 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -66.71 -34.82 78.68 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.288 -1.125 . . . . 0.0 110.573 -179.176 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 49.7 p -134.49 -20.5 1.82 Allowed 'General case' 0 N--CA 1.494 1.775 0 O-C-N 121.009 -1.057 . . . . 0.0 110.709 -179.381 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.499 ' O ' ' O ' ' A' ' 77' ' ' VAL . 0.1 OUTLIER -132.74 152.59 80.16 Favored Pre-proline 0 N--CA 1.49 1.528 0 O-C-N 121.144 -0.973 . . . . 0.0 109.39 -179.919 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo -66.5 136.98 44.93 Favored 'Trans proline' 0 C--N 1.307 -1.613 0 C-N-CA 122.263 1.975 . . . . 0.0 111.593 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 19.6 Cg_endo -67.28 147.62 78.66 Favored 'Trans proline' 0 N--CA 1.49 1.291 0 C-N-CA 122.111 1.874 . . . . 0.0 112.576 -179.593 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.459 ' O ' ' C ' ' A' ' 85' ' ' GLU . 41.2 t -103.57 133.0 48.68 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.476 0 O-C-N 121.497 -0.752 . . . . 0.0 109.087 179.481 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.459 ' C ' ' O ' ' A' ' 84' ' ' VAL . 95.9 mt-10 40.67 54.96 3.03 Favored 'General case' 0 N--CA 1.492 1.664 0 O-C-N 121.411 -0.806 . . . . 0.0 109.587 -179.977 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -52.59 151.92 3.98 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.275 -0.891 . . . . 0.0 109.558 -179.874 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.609 ' HZ1' ' HE ' ' A' ' 70' ' ' ARG . 68.4 mttm -64.57 144.68 57.04 Favored 'General case' 0 N--CA 1.491 1.582 0 O-C-N 121.3 -0.875 . . . . 0.0 109.365 -179.841 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.418 ' C ' ' O ' ' A' ' 87' ' ' LYS . 53.8 mt 43.76 87.43 0.02 OUTLIER 'General case' 0 N--CA 1.491 1.586 0 O-C-N 121.214 -0.929 . . . . 0.0 109.479 -179.893 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.0 mt-30 . . . . . 0 N--CA 1.491 1.591 0 CA-C-O 117.999 -1.0 . . . . 0.0 109.459 -179.98 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' -1' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 N--CA 1.49 1.552 0 N-CA-C 109.519 -0.549 . . . . 0.0 109.519 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 0' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -61.78 -34.04 75.18 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.208 -0.933 . . . . 0.0 109.498 -179.937 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.564 ' HB2' ' HB2' ' A' ' 4' ' ' ALA . 87.0 mmm -94.58 -121.42 0.1 Allowed 'General case' 0 C--N 1.306 -1.305 0 O-C-N 121.2 -0.937 . . . . 0.0 109.026 -179.881 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 93.5 mt-30 -110.19 -72.99 0.7 Allowed 'General case' 0 N--CA 1.491 1.592 0 N-CA-C 108.282 -1.007 . . . . 0.0 108.282 179.166 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 97.2 m-70 -103.55 22.15 14.82 Favored 'General case' 0 C--N 1.303 -1.438 0 N-CA-C 108.034 -1.099 . . . . 0.0 108.034 178.764 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.585 ' N ' ' OD2' ' A' ' 73' ' ' ASP . . . -52.94 -41.04 64.1 Favored 'General case' 0 N--CA 1.487 1.41 0 O-C-N 121.518 -0.739 . . . . 0.0 109.861 -179.078 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 21.3 m -61.11 -39.28 89.4 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.178 -0.951 . . . . 0.0 109.602 179.975 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 54.6 t -61.61 -43.88 97.74 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.58 0 O-C-N 121.331 -0.855 . . . . 0.0 109.483 179.952 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 82.5 mt -59.78 -40.27 82.08 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.45 0 O-C-N 121.363 -0.835 . . . . 0.0 109.076 179.697 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.401 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -60.92 -36.25 78.8 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 179.897 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 26.5 mt-30 -65.8 -39.16 90.64 Favored 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.296 -0.878 . . . . 0.0 109.967 179.757 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.66 ' CG ' ' CZ2' ' A' ' 47' ' ' TRP . 28.5 m-85 -64.2 -50.44 68.08 Favored 'General case' 0 N--CA 1.495 1.783 0 O-C-N 121.167 -0.958 . . . . 0.0 111.057 -179.28 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.439 HG13 ' N ' ' A' ' 12' ' ' VAL . 2.9 p -59.89 -42.74 90.27 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.016 -1.053 . . . . 0.0 109.579 -179.19 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.464 ' O ' ' C ' ' A' ' 16' ' ' LEU . 86.9 t -63.46 -47.3 92.32 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.444 0 O-C-N 121.115 -0.99 . . . . 0.0 109.396 179.833 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 97.2 mt-10 -71.53 -24.12 61.9 Favored 'General case' 0 N--CA 1.488 1.456 0 O-C-N 121.172 -0.955 . . . . 0.0 109.96 179.825 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.1 tt0 -64.19 -32.07 73.51 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.363 -0.836 . . . . 0.0 110.893 -178.763 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 63.1 t80 -140.83 -35.12 0.49 Allowed 'General case' 0 N--CA 1.494 1.758 0 O-C-N 120.849 -1.157 . . . . 0.0 110.742 -179.254 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.464 ' C ' ' O ' ' A' ' 12' ' ' VAL . 5.2 mt -119.17 80.04 19.4 Favored Pre-proline 0 N--CA 1.493 1.693 0 O-C-N 121.167 -0.958 . . . . 0.0 109.939 -179.397 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 51.7 Cg_endo -77.86 -15.3 15.08 Favored 'Trans proline' 0 C--N 1.308 -1.603 0 C-N-CA 122.546 2.164 . . . . 0.0 112.198 179.755 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -88.43 5.32 42.88 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 121.32 -0.862 . . . . 0.0 109.788 -179.729 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.45 ' CG2' HD22 ' A' ' 16' ' ' LEU . 46.3 t -110.64 134.92 51.33 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.678 0 O-C-N 121.387 -0.821 . . . . 0.0 109.564 -179.88 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -72.46 118.63 69.34 Favored Pre-proline 0 N--CA 1.489 1.503 0 O-C-N 121.279 -0.888 . . . . 0.0 109.24 179.902 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.461 ' HA ' HG21 ' A' ' 12' ' ' VAL . 40.4 Cg_exo -51.3 -28.62 27.25 Favored 'Trans proline' 0 N--CA 1.492 1.397 0 C-N-CA 121.728 1.619 . . . . 0.0 111.866 179.659 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -65.42 -23.31 66.91 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.198 -0.939 . . . . 0.0 109.286 179.688 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.45 ' O ' ' OD1' ' A' ' 23' ' ' ASP . 60.2 t0 -81.65 4.03 23.18 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.326 -0.859 . . . . 0.0 109.762 -179.762 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 13.5 t -108.75 133.32 54.19 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.684 0 O-C-N 121.245 -0.909 . . . . 0.0 109.351 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 86.9 m-20 -88.29 120.53 29.74 Favored 'General case' 0 C--N 1.302 -1.465 0 O-C-N 121.084 -1.01 . . . . 0.0 108.964 179.379 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 32.8 m -75.68 4.42 1.05 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.448 0 O-C-N 121.237 -0.915 . . . . 0.0 109.178 179.601 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -93.17 -2.75 54.98 Favored 'General case' 0 C--N 1.306 -1.318 0 O-C-N 121.316 -0.865 . . . . 0.0 108.941 179.518 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 39.8 tp -97.13 138.32 34.83 Favored 'General case' 0 N--CA 1.488 1.446 0 O-C-N 121.494 -0.754 . . . . 0.0 109.016 179.819 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 87.3 m-20 -60.09 138.5 57.87 Favored 'General case' 0 C--N 1.302 -1.479 0 O-C-N 121.154 -0.966 . . . . 0.0 109.531 -179.407 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.715 HD12 HG13 ' A' ' 69' ' ' ILE . 1.3 tt -75.62 -36.74 60.17 Favored 'General case' 0 C--N 1.3 -1.546 0 O-C-N 121.716 -0.615 . . . . 0.0 110.454 -179.203 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.614 HG13 ' O ' ' A' ' 66' ' ' PHE . 12.9 m -64.1 -38.4 82.36 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.659 0 O-C-N 121.111 -0.993 . . . . 0.0 110.583 -178.903 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 92.5 m-20 -54.5 -33.45 59.87 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.142 -0.974 . . . . 0.0 108.375 179.67 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 96.1 m-20 -70.5 -34.56 72.47 Favored 'General case' 0 C--N 1.303 -1.445 0 O-C-N 121.656 -0.653 . . . . 0.0 110.0 179.875 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 82.37 5.86 89.2 Favored Glycine 0 N--CA 1.493 2.479 0 N-CA-C 109.516 -1.433 . . . . 0.0 109.516 -179.904 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 78.3 t -61.35 -34.36 60.69 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.453 0 O-C-N 121.276 -1.132 . . . . 0.0 108.697 179.501 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.705 HD11 HD13 ' A' ' 30' ' ' LEU . 96.7 mt -77.34 112.17 14.98 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.46 0 O-C-N 121.454 -0.779 . . . . 0.0 109.954 179.91 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -111.33 -164.53 0.92 Allowed 'General case' 0 C--N 1.303 -1.447 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 179.595 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -66.71 -54.25 25.01 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.125 -0.984 . . . . 0.0 108.874 179.694 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.692 HD12 ' N ' ' A' ' 39' ' ' LEU . 6.9 mp -69.77 -32.89 71.64 Favored 'General case' 0 C--N 1.303 -1.446 0 N-CA-C 107.397 -1.334 . . . . 0.0 107.397 178.432 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.607 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.41 -43.0 97.76 Favored Glycine 0 N--CA 1.482 1.704 0 N-CA-C 109.053 -1.619 . . . . 0.0 109.053 179.509 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.442 HD11 ' CZ ' ' A' ' 66' ' ' PHE . 7.5 tt -65.13 -42.73 93.59 Favored 'General case' 0 C--N 1.303 -1.415 0 O-C-N 121.413 -1.051 . . . . 0.0 109.327 179.449 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 tp -60.06 -46.25 90.18 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.375 -0.828 . . . . 0.0 109.274 179.906 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 12.7 mttm -62.39 -34.44 76.73 Favored 'General case' 0 C--N 1.297 -1.7 0 O-C-N 121.44 -0.787 . . . . 0.0 109.789 -179.694 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.607 HG23 ' O ' ' A' ' 40' ' ' GLY . 53.8 t -61.47 -50.42 80.42 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.291 -0.881 . . . . 0.0 110.322 -179.215 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.537 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 3.5 mp -68.36 -33.73 62.0 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.503 0 O-C-N 121.331 -0.856 . . . . 0.0 111.011 -179.67 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.42 -49.77 67.96 Favored 'General case' 0 N--CA 1.495 1.812 0 O-C-N 121.013 -1.054 . . . . 0.0 111.655 -178.007 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.66 ' CZ2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -81.2 -43.78 18.79 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.75 -1.219 . . . . 0.0 109.905 -179.3 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.582 HD21 ' CG2' ' A' ' 76' ' ' VAL . 31.4 tp -58.82 -42.35 88.98 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.215 -0.928 . . . . 0.0 109.95 -179.267 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.537 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 1.1 pp20? -72.53 -36.02 68.2 Favored 'General case' 0 N--CA 1.488 1.451 0 O-C-N 121.082 -1.011 . . . . 0.0 109.749 -179.959 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 56.5 t0 -60.43 -38.51 84.35 Favored 'General case' 0 N--CA 1.492 1.626 0 O-C-N 121.251 -0.905 . . . . 0.0 110.608 -179.653 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.464 ' HD2' ' HE1' ' A' ' 47' ' ' TRP . 77.7 mtp85 -61.81 -37.83 85.87 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.167 -0.958 . . . . 0.0 111.602 -178.668 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.799 ' CE2' HG11 ' A' ' 76' ' ' VAL . 88.0 m-85 -95.86 -8.5 33.95 Favored 'General case' 0 N--CA 1.488 1.433 0 O-C-N 120.67 -1.269 . . . . 0.0 110.339 -178.97 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 71.98 30.37 65.69 Favored Glycine 0 N--CA 1.486 2.021 0 N-CA-C 108.872 -1.691 . . . . 0.0 108.872 179.682 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.501 ' O ' ' OE1' ' A' ' 49' ' ' GLU . 26.0 pt -107.55 151.13 9.66 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.402 0 O-C-N 121.654 -0.909 . . . . 0.0 109.653 -179.502 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.475 ' O ' ' OD1' ' A' ' 58' ' ' ASP . . . -101.76 132.48 47.47 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.233 -0.917 . . . . 0.0 109.645 -179.661 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.5 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -67.0 -26.88 67.02 Favored 'General case' 0 N--CA 1.489 1.519 0 O-C-N 121.335 -0.853 . . . . 0.0 109.396 179.751 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 52.3 t0 -54.87 -34.79 63.36 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.317 -0.864 . . . . 0.0 110.042 -179.571 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.632 ' OD1' ' N ' ' A' ' 59' ' ' VAL . 55.3 p30 -59.47 -34.53 72.66 Favored 'General case' 0 N--CA 1.491 1.609 0 O-C-N 121.196 -0.94 . . . . 0.0 110.301 -179.459 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.632 ' N ' ' OD1' ' A' ' 58' ' ' ASP . 14.5 p -136.86 140.96 41.98 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.674 0 O-C-N 121.025 -1.047 . . . . 0.0 109.585 179.92 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 95.3 mt-10 -85.3 139.35 31.67 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.053 -1.03 . . . . 0.0 109.299 179.818 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 5.1 mp -97.72 136.9 37.41 Favored 'General case' 0 C--N 1.305 -1.345 0 O-C-N 121.198 -0.939 . . . . 0.0 109.712 -179.835 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -110.0 155.35 41.83 Favored Pre-proline 0 N--CA 1.488 1.457 0 N-CA-C 108.727 -0.842 . . . . 0.0 108.727 179.489 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 7.8 Cg_endo -53.2 -23.55 23.29 Favored 'Trans proline' 0 C--N 1.302 -1.904 0 C-N-CA 122.286 1.991 . . . . 0.0 111.685 -179.898 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.2 mt-10 -70.69 -26.54 63.47 Favored 'General case' 0 N--CA 1.486 1.336 0 O-C-N 121.344 -0.847 . . . . 0.0 109.507 179.655 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . 0.546 ' C ' ' CD2' ' A' ' 65' ' ' HIS . 1.9 t60 -65.62 -20.41 66.3 Favored 'General case' 0 C--N 1.302 -1.488 0 O-C-N 121.23 -0.919 . . . . 0.0 109.215 -179.703 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.614 ' O ' HG13 ' A' ' 31' ' ' VAL . 6.7 m-85 -98.2 16.24 21.95 Favored 'General case' 0 C--N 1.3 -1.571 0 O-C-N 121.447 -0.783 . . . . 0.0 108.965 179.985 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . 0.588 ' NE ' ' OG ' ' A' ' 71' ' ' SER . 4.8 ptt180 -52.16 -36.34 51.27 Favored 'General case' 0 C--N 1.299 -1.596 0 O-C-N 121.754 -0.591 . . . . 0.0 110.08 -179.775 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.525 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 35.2 p -164.9 153.31 12.12 Favored 'General case' 0 N--CA 1.487 1.421 0 O-C-N 121.016 -1.053 . . . . 0.0 110.281 -179.702 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.715 HG13 HD12 ' A' ' 30' ' ' LEU . 3.3 mp -57.94 -40.68 77.57 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.418 0 O-C-N 121.362 -0.836 . . . . 0.0 109.161 179.904 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.433 ' HE ' ' HE3' ' A' ' 87' ' ' LYS . 18.9 ptt180 -58.16 -42.24 85.53 Favored 'General case' 0 C--N 1.301 -1.539 0 O-C-N 121.643 -0.66 . . . . 0.0 109.266 179.806 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.588 ' OG ' ' NE ' ' A' ' 67' ' ' ARG . 26.5 t -64.92 -39.25 93.22 Favored 'General case' 0 N--CA 1.489 1.506 0 O-C-N 121.204 -0.935 . . . . 0.0 109.677 179.488 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.425 HD12 ' HA ' ' A' ' 69' ' ' ILE . 87.8 mt -58.92 -47.14 90.59 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.289 0 O-C-N 121.176 -0.953 . . . . 0.0 109.736 -179.73 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.585 ' OD2' ' N ' ' A' ' 4' ' ' ALA . 26.5 t0 -58.91 -44.23 91.23 Favored 'General case' 0 N--CA 1.488 1.445 0 O-C-N 121.147 -0.971 . . . . 0.0 108.723 179.864 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.535 ' O ' ' N ' ' A' ' 78' ' ' GLY . . . -66.96 -37.36 84.13 Favored 'General case' 0 C--N 1.304 -1.399 0 O-C-N 121.432 -0.792 . . . . 0.0 109.595 179.667 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 61.9 t80 -62.82 -48.83 77.37 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.19 -0.944 . . . . 0.0 109.644 -179.833 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.799 HG11 ' CE2' ' A' ' 52' ' ' PHE . 71.1 t -67.56 -48.8 75.51 Favored 'Isoleucine or valine' 0 N--CA 1.485 1.282 0 O-C-N 121.201 -0.937 . . . . 0.0 109.782 -179.847 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.533 ' O ' HG22 ' A' ' 81' ' ' THR . 55.3 t -69.89 -43.77 79.33 Favored 'Isoleucine or valine' 0 N--CA 1.484 1.274 0 O-C-N 121.106 -0.996 . . . . 0.0 109.034 179.38 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.535 ' N ' ' O ' ' A' ' 74' ' ' ALA . . . -59.38 -30.93 68.82 Favored Glycine 0 N--CA 1.488 2.127 0 N-CA-C 110.211 -1.155 . . . . 0.0 110.211 -179.606 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -68.63 -41.5 79.36 Favored 'General case' 0 N--CA 1.493 1.687 0 O-C-N 121.153 -1.204 . . . . 0.0 110.586 -178.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 47.1 p -79.74 -32.02 41.06 Favored 'General case' 0 N--CA 1.489 1.481 0 O-C-N 121.161 -0.962 . . . . 0.0 109.326 -179.83 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.533 HG22 ' O ' ' A' ' 77' ' ' VAL . 1.8 t -133.13 150.42 75.41 Favored Pre-proline 0 N--CA 1.487 1.401 0 O-C-N 121.447 -0.783 . . . . 0.0 108.911 179.93 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 76.0 Cg_exo -42.79 138.01 3.95 Favored 'Trans proline' 0 C--N 1.309 -1.506 0 C-N-CA 121.603 1.535 . . . . 0.0 111.197 179.312 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . 0.423 ' HB2' ' HB2' ' A' ' 86' ' ' ALA . 14.7 Cg_endo -64.18 144.58 87.2 Favored 'Trans proline' 0 N--CA 1.49 1.283 0 C-N-CA 121.957 1.771 . . . . 0.0 112.943 -179.003 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.492 ' O ' ' C ' ' A' ' 85' ' ' GLU . 13.8 p -104.52 130.86 54.72 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.579 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 179.525 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.492 ' C ' ' O ' ' A' ' 84' ' ' VAL . 96.1 mt-10 34.72 45.68 0.16 Allowed 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.681 -0.637 . . . . 0.0 110.249 179.647 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.423 ' HB2' ' HB2' ' A' ' 83' ' ' PRO . . . -52.7 149.59 5.97 Favored 'General case' 0 N--CA 1.492 1.634 0 O-C-N 121.162 -0.962 . . . . 0.0 109.416 -179.866 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.433 ' HE3' ' HE ' ' A' ' 70' ' ' ARG . 68.4 mttm -56.07 -35.49 67.04 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.233 -0.917 . . . . 0.0 109.345 -179.839 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 55.0 mt -95.97 141.43 29.4 Favored 'General case' 0 N--CA 1.49 1.563 0 O-C-N 121.25 -0.907 . . . . 0.0 109.469 179.86 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.5 mt-30 . . . . . 0 N--CA 1.49 1.548 0 CA-C-O 118.031 -0.985 . . . . 0.0 109.406 -179.946 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' -1' ' ' SER . . . . . . . . . . . . . 2.2 m . . . . . 0 N--CA 1.49 1.574 0 N-CA-C 109.462 -0.569 . . . . 0.0 109.462 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 0' ' ' GLU . . . . . . . . . . . . . 96.1 mt-10 -57.9 144.2 39.94 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.265 -0.897 . . . . 0.0 109.466 179.927 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.518 ' HB3' ' HB2' ' A' ' 4' ' ' ALA . 70.7 mtm -58.81 -34.92 72.06 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.259 -0.9 . . . . 0.0 109.776 179.984 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.637 ' OE1' HG22 ' A' ' 77' ' ' VAL . 92.8 mt-30 56.27 49.54 15.05 Favored 'General case' 0 N--CA 1.49 1.533 0 O-C-N 121.26 -0.9 . . . . 0.0 109.123 -179.575 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.451 ' CG ' ' C ' ' A' ' 2' ' ' GLN . 16.9 m-70 74.37 56.36 0.08 Allowed 'General case' 0 N--CA 1.494 1.757 0 O-C-N 121.689 -0.632 . . . . 0.0 109.82 -179.912 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.518 ' HB2' ' HB3' ' A' ' 1' ' ' MET . . . -59.74 -40.92 89.71 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.068 -1.02 . . . . 0.0 109.29 179.786 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.3 m -61.29 -39.17 89.44 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.256 -0.902 . . . . 0.0 109.65 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 58.8 t -61.13 -41.35 89.07 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.534 0 O-C-N 121.205 -0.935 . . . . 0.0 109.454 179.911 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 79.7 mt -59.69 -45.62 94.23 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.42 0 O-C-N 121.409 -0.807 . . . . 0.0 109.287 179.866 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -62.14 -42.78 99.58 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.291 -0.881 . . . . 0.0 109.109 179.723 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 26.8 mt-30 -64.7 -33.46 76.0 Favored 'General case' 0 N--CA 1.488 1.474 0 O-C-N 121.249 -0.907 . . . . 0.0 109.128 179.255 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.535 ' CG ' ' CZ2' ' A' ' 47' ' ' TRP . 0.2 OUTLIER -60.43 -50.27 74.24 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.4 -0.813 . . . . 0.0 110.235 -179.521 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 13.4 m -64.39 -39.59 86.08 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.506 0 O-C-N 121.142 -0.973 . . . . 0.0 109.33 -179.723 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.405 ' O ' ' C ' ' A' ' 16' ' ' LEU . 77.6 t -63.99 -45.29 97.18 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.473 0 O-C-N 121.166 -0.959 . . . . 0.0 109.678 179.654 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 98.3 mt-10 -69.4 -34.47 74.54 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.17 -0.956 . . . . 0.0 110.23 -179.842 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 83.8 tt0 -65.35 -32.67 74.44 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.292 -0.88 . . . . 0.0 110.458 -179.253 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 98.3 m-85 -118.47 -54.08 2.29 Favored 'General case' 0 N--CA 1.495 1.807 0 O-C-N 121.263 -0.898 . . . . 0.0 111.336 -178.713 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.575 HD22 ' CG2' ' A' ' 19' ' ' VAL . 9.0 mt -119.41 80.18 21.48 Favored Pre-proline 0 N--CA 1.493 1.688 0 O-C-N 121.19 -0.944 . . . . 0.0 111.054 -178.285 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -75.1 -16.41 20.0 Favored 'Trans proline' 0 C--N 1.309 -1.511 0 C-N-CA 122.274 1.982 . . . . 0.0 112.186 178.825 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -90.99 5.7 47.72 Favored 'General case' 0 N--CA 1.487 1.384 0 O-C-N 121.213 -0.929 . . . . 0.0 109.893 -179.844 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.575 ' CG2' HD22 ' A' ' 16' ' ' LEU . 44.5 t -112.84 138.37 42.42 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.69 0 O-C-N 121.456 -0.778 . . . . 0.0 109.492 -179.857 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.487 ' O ' ' OD1' ' A' ' 23' ' ' ASP . . . -70.37 117.27 53.25 Favored Pre-proline 0 N--CA 1.489 1.524 0 O-C-N 121.275 -0.89 . . . . 0.0 109.469 -179.831 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 32.4 Cg_exo -51.8 -26.21 23.26 Favored 'Trans proline' 0 N--CA 1.494 1.512 0 C-N-CA 122.017 1.812 . . . . 0.0 112.229 179.505 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.63 -23.66 67.33 Favored 'General case' 0 N--CA 1.491 1.604 0 O-C-N 121.281 -0.887 . . . . 0.0 109.815 -179.744 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.487 ' OD1' ' O ' ' A' ' 20' ' ' ALA . 51.5 p30 -85.64 7.63 22.58 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.192 -0.942 . . . . 0.0 110.007 -179.428 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 11.8 t -107.88 130.07 60.94 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.708 0 O-C-N 121.147 -0.97 . . . . 0.0 109.329 179.927 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 87.2 m-20 -89.73 120.33 30.9 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.18 -0.95 . . . . 0.0 109.097 179.28 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 6.3 m -78.1 4.42 1.36 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 O-C-N 121.129 -0.982 . . . . 0.0 108.941 179.457 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 92.0 m-20 -88.73 -10.63 47.67 Favored 'General case' 0 N--CA 1.485 1.302 0 O-C-N 121.386 -0.821 . . . . 0.0 109.043 179.408 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 42.4 tp -94.24 140.57 29.61 Favored 'General case' 0 N--CA 1.49 1.548 0 N-CA-C 109.076 -0.713 . . . . 0.0 109.076 179.844 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 83.3 m-20 -59.08 142.0 52.58 Favored 'General case' 0 C--N 1.302 -1.476 0 O-C-N 121.133 -0.979 . . . . 0.0 109.433 -179.361 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 1.078 HD23 HD11 ' A' ' 36' ' ' ILE . 27.8 tp -73.57 -37.74 65.41 Favored 'General case' 0 N--CA 1.491 1.619 0 O-C-N 121.421 -0.799 . . . . 0.0 110.343 -179.251 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.608 HG13 ' O ' ' A' ' 66' ' ' PHE . 33.1 m -66.73 -43.15 90.2 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.526 0 O-C-N 121.263 -0.898 . . . . 0.0 110.428 -179.005 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . 0.584 ' N ' HG23 ' A' ' 31' ' ' VAL . 92.1 m-20 -53.94 -33.37 56.6 Favored 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 179.747 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 97.1 m-20 -70.47 -34.12 72.04 Favored 'General case' 0 C--N 1.301 -1.528 0 O-C-N 121.619 -0.676 . . . . 0.0 109.995 179.898 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 87.47 7.2 76.31 Favored Glycine 0 N--CA 1.493 2.464 0 N-CA-C 109.183 -1.567 . . . . 0.0 109.183 -179.656 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 72.6 t -61.64 -26.93 41.04 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.487 0 O-C-N 121.469 -1.018 . . . . 0.0 108.78 179.575 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 1.078 HD11 HD23 ' A' ' 30' ' ' LEU . 67.6 mt -93.05 123.87 45.28 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.398 0 O-C-N 121.457 -0.777 . . . . 0.0 109.929 -179.458 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -115.79 -174.87 2.61 Favored 'General case' 0 C--N 1.302 -1.469 0 N-CA-C 108.636 -0.876 . . . . 0.0 108.636 179.339 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -61.36 -53.45 56.43 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.056 -1.028 . . . . 0.0 108.432 179.594 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.693 HD12 ' N ' ' A' ' 39' ' ' LEU . 7.0 mp -70.39 -32.65 70.39 Favored 'General case' 0 C--N 1.301 -1.532 0 N-CA-C 107.33 -1.359 . . . . 0.0 107.33 178.008 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.458 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.23 -43.65 97.04 Favored Glycine 0 N--CA 1.482 1.755 0 N-CA-C 109.01 -1.636 . . . . 0.0 109.01 179.574 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.3 tt -65.13 -42.05 94.22 Favored 'General case' 0 C--N 1.303 -1.44 0 O-C-N 121.463 -1.022 . . . . 0.0 109.163 179.32 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.5 tp -59.97 -46.12 90.47 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.294 -0.879 . . . . 0.0 109.405 179.871 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 86.6 mttt -61.44 -35.7 78.31 Favored 'General case' 0 C--N 1.297 -1.701 0 O-C-N 121.443 -0.786 . . . . 0.0 109.854 -179.678 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.458 HG23 ' O ' ' A' ' 40' ' ' GLY . 55.3 t -61.48 -50.75 79.08 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.5 0 O-C-N 121.287 -0.883 . . . . 0.0 110.36 -179.27 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.521 HG12 HD12 ' A' ' 61' ' ' LEU . 3.5 mp -68.72 -34.3 64.15 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.504 0 O-C-N 121.279 -0.888 . . . . 0.0 111.181 -179.636 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.56 -49.94 60.86 Favored 'General case' 0 N--CA 1.496 1.855 0 O-C-N 120.986 -1.071 . . . . 0.0 111.998 -177.913 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.535 ' CZ2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -80.18 -43.62 21.23 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.655 -1.278 . . . . 0.0 110.036 -179.045 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.558 HD11 HG21 ' A' ' 76' ' ' VAL . 21.7 tp -58.88 -41.63 87.56 Favored 'General case' 0 C--N 1.299 -1.606 0 O-C-N 121.294 -0.879 . . . . 0.0 110.197 -179.03 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.416 ' CG ' ' N ' ' A' ' 50' ' ' ASP . 17.3 pt-20 -73.18 -37.45 66.51 Favored 'General case' 0 C--N 1.305 -1.362 0 O-C-N 121.059 -1.026 . . . . 0.0 109.636 -179.708 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . 0.416 ' N ' ' CG ' ' A' ' 49' ' ' GLU . 56.9 t0 -58.86 -39.15 80.51 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.354 -0.841 . . . . 0.0 110.64 -179.447 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.443 ' HD2' ' HE1' ' A' ' 47' ' ' TRP . 73.4 mtp85 -61.64 -36.76 81.72 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.169 -0.957 . . . . 0.0 111.322 -178.86 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.613 ' CZ ' ' CG1' ' A' ' 76' ' ' VAL . 87.5 m-85 -94.77 -8.0 38.83 Favored 'General case' 0 N--CA 1.487 1.388 0 O-C-N 120.745 -1.222 . . . . 0.0 110.407 -179.129 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 73.15 29.29 64.77 Favored Glycine 0 N--CA 1.487 2.089 0 N-CA-C 108.95 -1.66 . . . . 0.0 108.95 179.712 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 20.5 pt -109.68 153.21 11.51 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.424 0 O-C-N 121.699 -0.883 . . . . 0.0 109.551 -179.587 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -103.92 134.99 46.28 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.238 -0.914 . . . . 0.0 109.7 -179.614 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.506 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -68.09 -28.39 67.31 Favored 'General case' 0 N--CA 1.49 1.541 0 O-C-N 121.334 -0.853 . . . . 0.0 109.63 179.732 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -56.36 -36.89 69.31 Favored 'General case' 0 N--CA 1.487 1.404 0 O-C-N 121.125 -0.984 . . . . 0.0 109.995 -179.625 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 21.4 t70 -56.53 -40.01 74.34 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.146 -0.971 . . . . 0.0 109.987 -179.538 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.506 ' O ' ' O ' ' A' ' 56' ' ' ALA . 42.6 t -128.67 136.21 60.44 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.699 0 O-C-N 121.311 -0.868 . . . . 0.0 109.726 -179.846 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -86.14 132.94 33.91 Favored 'General case' 0 N--CA 1.489 1.521 0 O-C-N 121.063 -1.023 . . . . 0.0 109.242 179.835 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.521 HD12 HG12 ' A' ' 45' ' ' ILE . 57.6 mt -96.12 140.81 30.3 Favored 'General case' 0 C--N 1.305 -1.336 0 O-C-N 121.219 -0.926 . . . . 0.0 109.742 -179.64 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -109.77 155.92 40.68 Favored Pre-proline 0 N--CA 1.487 1.418 0 N-CA-C 108.787 -0.82 . . . . 0.0 108.787 179.479 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 7.2 Cg_endo -52.59 -23.02 18.34 Favored 'Trans proline' 0 C--N 1.303 -1.831 0 C-N-CA 122.335 2.023 . . . . 0.0 111.926 -179.772 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.8 mt-10 -70.26 -26.95 64.06 Favored 'General case' 0 N--CA 1.486 1.37 0 O-C-N 121.339 -0.851 . . . . 0.0 109.472 179.592 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . 0.551 ' C ' ' CD2' ' A' ' 65' ' ' HIS . 1.5 t60 -65.65 -19.39 65.89 Favored 'General case' 0 C--N 1.303 -1.433 0 O-C-N 121.412 -0.805 . . . . 0.0 109.046 -179.883 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.608 ' O ' HG13 ' A' ' 31' ' ' VAL . 7.0 m-85 -100.14 16.35 24.44 Favored 'General case' 0 C--N 1.3 -1.566 0 O-C-N 121.521 -0.737 . . . . 0.0 109.174 -179.686 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . 0.633 HH21 ' CD ' ' A' ' 87' ' ' LYS . 0.6 OUTLIER -53.24 -37.89 62.47 Favored 'General case' 0 C--N 1.299 -1.595 0 O-C-N 121.59 -0.694 . . . . 0.0 110.621 -179.452 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.528 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 51.8 p -167.91 166.53 13.35 Favored 'General case' 0 N--CA 1.493 1.696 0 O-C-N 120.653 -1.279 . . . . 0.0 110.699 -179.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.83 HD11 HD13 ' A' ' 30' ' ' LEU . 19.8 mm -58.89 -35.28 55.58 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.201 0 N-CA-C 108.241 -1.022 . . . . 0.0 108.241 178.913 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 34.7 mtp180 -57.51 -43.96 84.66 Favored 'General case' 0 C--N 1.303 -1.455 0 CA-C-O 121.446 0.641 . . . . 0.0 109.468 -179.354 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 11.8 t -67.06 -39.41 86.89 Favored 'General case' 0 N--CA 1.489 1.482 0 O-C-N 121.368 -0.832 . . . . 0.0 109.953 179.949 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.415 HD12 ' HA ' ' A' ' 69' ' ' ILE . 76.9 mt -59.84 -50.1 81.35 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.381 0 O-C-N 121.265 -0.897 . . . . 0.0 110.074 -179.277 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 44.3 t0 -59.66 -42.78 93.58 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.13 -0.981 . . . . 0.0 109.04 -179.871 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.55 -42.21 87.5 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.535 -0.728 . . . . 0.0 109.756 -179.987 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 60.0 t80 -63.58 -46.2 86.95 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.185 -0.947 . . . . 0.0 109.411 -179.955 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.613 ' CG1' ' CZ ' ' A' ' 52' ' ' PHE . 54.6 t -60.89 -47.22 94.36 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.297 0 O-C-N 121.367 -0.833 . . . . 0.0 109.138 179.854 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.637 HG22 ' OE1' ' A' ' 2' ' ' GLN . 55.5 t -69.26 -42.38 81.43 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.324 0 O-C-N 121.213 -0.929 . . . . 0.0 109.107 179.338 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.493 ' O ' ' O ' ' A' ' 81' ' ' THR . . . -65.22 -28.27 73.36 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 110.248 -1.141 . . . . 0.0 110.248 -179.831 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.04 -38.67 86.27 Favored 'General case' 0 N--CA 1.491 1.601 0 O-C-N 121.153 -1.204 . . . . 0.0 110.299 -178.944 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 52.1 p -82.42 -31.33 29.6 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.111 -0.993 . . . . 0.0 109.539 -179.889 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.493 ' O ' ' O ' ' A' ' 78' ' ' GLY . 0.3 OUTLIER -133.38 152.65 79.68 Favored Pre-proline 0 C--N 1.302 -1.464 0 O-C-N 121.51 -0.744 . . . . 0.0 109.605 -179.864 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 64.0 Cg_endo -76.25 111.49 3.28 Favored 'Trans proline' 0 N--CA 1.496 1.652 0 C-N-CA 122.474 2.116 . . . . 0.0 111.884 179.474 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 43.1 Cg_endo -77.13 148.49 27.44 Favored 'Trans proline' 0 N--CA 1.49 1.3 0 C-N-CA 122.079 1.852 . . . . 0.0 113.112 -179.606 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.597 ' O ' ' N ' ' A' ' 86' ' ' ALA . 42.3 t -104.44 121.93 56.77 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.516 0 O-C-N 121.528 -0.733 . . . . 0.0 109.069 178.894 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.504 ' C ' ' O ' ' A' ' 84' ' ' VAL . 96.1 mt-10 32.62 31.42 0.01 OUTLIER 'General case' 0 N--CA 1.498 1.96 0 O-C-N 121.735 -0.603 . . . . 0.0 110.383 179.693 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.597 ' N ' ' O ' ' A' ' 84' ' ' VAL . . . -69.75 139.16 53.28 Favored 'General case' 0 N--CA 1.491 1.61 0 O-C-N 121.047 -1.033 . . . . 0.0 110.159 -179.419 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.633 ' CD ' HH21 ' A' ' 67' ' ' ARG . 43.4 tttp 42.15 53.2 4.39 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 121.452 -0.78 . . . . 0.0 109.599 179.436 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.591 ' N ' HD12 ' A' ' 88' ' ' LEU . 7.7 mp 45.31 86.48 0.02 OUTLIER 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.195 -0.94 . . . . 0.0 109.487 -179.951 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 59.2 tp60 . . . . . 0 N--CA 1.49 1.575 0 CA-C-O 118.009 -0.996 . . . . 0.0 109.464 179.979 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' -1' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER . . . . . 0 N--CA 1.49 1.543 0 CA-C-O 121.299 0.571 . . . . 0.0 109.492 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 0' ' ' GLU . . . . . . . . . . . . . 96.0 mt-10 -57.93 145.03 37.14 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.211 -0.931 . . . . 0.0 109.504 179.948 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.49 ' HB2' ' HB2' ' A' ' 4' ' ' ALA . 74.5 mtp -105.48 -119.66 0.22 Allowed 'General case' 0 C--N 1.305 -1.346 0 O-C-N 121.295 -0.878 . . . . 0.0 108.794 179.897 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.422 ' O ' ' C ' ' A' ' 3' ' ' HIS . 97.5 mm-40 -119.87 113.75 21.05 Favored 'General case' 0 C--N 1.3 -1.559 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 178.665 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.422 ' C ' ' O ' ' A' ' 2' ' ' GLN . 62.1 m80 46.65 31.17 1.3 Allowed 'General case' 0 C--N 1.304 -1.392 0 N-CA-C 108.114 -1.069 . . . . 0.0 108.114 -178.913 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.49 ' HB2' ' HB2' ' A' ' 1' ' ' MET . . . -57.25 -39.48 75.69 Favored 'General case' 0 N--CA 1.49 1.53 0 O-C-N 121.518 -0.739 . . . . 0.0 109.798 -179.33 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 86.1 p -63.04 -33.7 75.98 Favored 'General case' 0 N--CA 1.489 1.516 0 O-C-N 121.146 -0.971 . . . . 0.0 109.491 -179.895 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 75.9 t -65.9 -43.49 92.94 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.51 0 O-C-N 121.222 -0.924 . . . . 0.0 109.539 179.87 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.515 ' O ' HG12 ' A' ' 11' ' ' VAL . 82.6 mt -59.59 -47.3 91.48 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.507 0 O-C-N 121.4 -0.812 . . . . 0.0 109.845 -179.859 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.716 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.26 -45.13 92.94 Favored 'General case' 0 N--CA 1.49 1.558 0 O-C-N 121.28 -0.888 . . . . 0.0 110.924 -179.181 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 53.9 mt-30 -69.09 -46.65 67.21 Favored 'General case' 0 N--CA 1.492 1.665 0 O-C-N 120.835 -1.165 . . . . 0.0 110.854 -178.723 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.549 ' C ' ' CD1' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -70.28 -48.75 55.31 Favored 'General case' 0 N--CA 1.493 1.703 0 O-C-N 121.075 -1.016 . . . . 0.0 110.298 -179.392 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.515 HG12 ' O ' ' A' ' 7' ' ' ILE . 4.0 p -59.88 -38.81 77.94 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.568 0 O-C-N 121.072 -1.017 . . . . 0.0 109.678 -179.604 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.716 HG23 ' O ' ' A' ' 8' ' ' ALA . 49.5 t -63.18 -43.22 98.71 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.653 0 O-C-N 121.224 -0.922 . . . . 0.0 109.963 -179.928 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 97.8 mt-10 -63.13 -34.51 77.76 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.104 -0.997 . . . . 0.0 109.941 -179.812 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.4 tt0 -65.43 -31.74 72.99 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.269 -0.894 . . . . 0.0 110.197 -179.649 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.779 ' CD2' HG13 ' A' ' 35' ' ' VAL . 77.4 t80 -113.65 -61.4 1.75 Allowed 'General case' 0 N--CA 1.495 1.82 0 O-C-N 121.326 -0.859 . . . . 0.0 111.299 -178.818 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . . . . . . . . . 4.8 mt -116.08 80.19 9.06 Favored Pre-proline 0 N--CA 1.494 1.726 0 O-C-N 121.219 -0.926 . . . . 0.0 111.017 -178.354 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 39.7 Cg_endo -74.64 -14.55 22.03 Favored 'Trans proline' 0 C--N 1.31 -1.5 0 C-N-CA 122.311 2.008 . . . . 0.0 112.156 178.848 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -84.93 0.84 49.83 Favored 'General case' 0 N--CA 1.487 1.399 0 O-C-N 121.286 -0.883 . . . . 0.0 109.601 179.969 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 42.3 t -115.36 134.93 56.99 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.66 0 O-C-N 121.43 -0.794 . . . . 0.0 109.568 -179.908 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -71.34 117.84 60.52 Favored Pre-proline 0 N--CA 1.489 1.486 0 O-C-N 121.183 -0.948 . . . . 0.0 109.405 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 40.3 Cg_exo -51.44 -30.06 33.54 Favored 'Trans proline' 0 N--CA 1.493 1.464 0 C-N-CA 121.757 1.638 . . . . 0.0 112.064 179.614 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.8 -25.12 67.78 Favored 'General case' 0 N--CA 1.488 1.471 0 O-C-N 121.239 -0.913 . . . . 0.0 109.291 179.769 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . . . . . . . . . 23.0 t70 -81.88 4.45 22.38 Favored 'General case' 0 N--CA 1.489 1.493 0 O-C-N 121.368 -0.833 . . . . 0.0 109.777 -179.755 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 10.5 t -107.79 128.91 62.66 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 121.216 -0.927 . . . . 0.0 109.485 -179.923 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 88.1 m-20 -89.7 120.72 31.22 Favored 'General case' 0 C--N 1.301 -1.502 0 O-C-N 121.239 -0.913 . . . . 0.0 109.078 179.213 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 28.9 m -70.9 3.89 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.414 0 O-C-N 121.11 -0.993 . . . . 0.0 109.123 179.598 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -94.25 -5.24 47.29 Favored 'General case' 0 N--CA 1.487 1.402 0 O-C-N 121.363 -0.836 . . . . 0.0 109.154 179.466 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 42.0 tp -95.32 138.14 33.42 Favored 'General case' 0 C--N 1.303 -1.421 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 179.599 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -57.2 135.62 56.42 Favored 'General case' 0 C--N 1.301 -1.507 0 O-C-N 121.068 -1.02 . . . . 0.0 109.354 -179.269 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 1.041 HD23 HD11 ' A' ' 36' ' ' ILE . 39.4 tp -64.59 -37.48 87.71 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 121.595 -0.69 . . . . 0.0 110.467 -179.336 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 70.2 t -66.2 -37.24 79.3 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.547 0 O-C-N 121.022 -1.049 . . . . 0.0 110.708 -179.15 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 91.4 m-20 -52.93 -33.05 48.94 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 120.956 -1.09 . . . . 0.0 108.254 -179.987 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.438 ' HB3' HG23 ' A' ' 35' ' ' VAL . 98.4 m-20 -70.68 -34.33 71.86 Favored 'General case' 0 C--N 1.301 -1.511 0 O-C-N 121.631 -0.668 . . . . 0.0 109.946 179.457 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 86.6 5.26 82.07 Favored Glycine 0 N--CA 1.491 2.33 0 N-CA-C 108.824 -1.71 . . . . 0.0 108.824 -179.245 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.779 HG13 ' CD2' ' A' ' 15' ' ' PHE . 76.2 t -61.1 -32.69 53.41 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.431 0 O-C-N 121.582 -0.952 . . . . 0.0 108.924 179.637 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 1.041 HD11 HD23 ' A' ' 30' ' ' LEU . 80.7 mt -83.82 116.26 27.44 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.441 0 O-C-N 121.403 -0.811 . . . . 0.0 109.843 -179.872 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.406 ' H ' ' HA3' ' A' ' 40' ' ' GLY . 92.0 m-20 -114.99 -176.08 2.83 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 108.716 -0.846 . . . . 0.0 108.716 179.406 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -58.95 -53.38 59.08 Favored 'General case' 0 N--CA 1.489 1.485 0 O-C-N 121.021 -1.049 . . . . 0.0 108.205 179.601 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 35.8 mt -68.57 -32.44 72.36 Favored 'General case' 0 C--N 1.301 -1.528 0 N-CA-C 106.887 -1.523 . . . . 0.0 106.887 177.868 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.494 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -58.97 -40.93 96.05 Favored Glycine 0 N--CA 1.48 1.594 0 N-CA-C 108.718 -1.753 . . . . 0.0 108.718 179.274 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.3 tt -65.21 -41.61 94.31 Favored 'General case' 0 C--N 1.305 -1.34 0 O-C-N 121.386 -1.067 . . . . 0.0 108.693 178.893 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 tp -60.17 -45.72 92.14 Favored 'General case' 0 C--N 1.303 -1.427 0 N-CA-C 108.675 -0.861 . . . . 0.0 108.675 179.322 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 21.0 mttp -60.71 -35.48 76.42 Favored 'General case' 0 C--N 1.298 -1.663 0 O-C-N 121.551 -0.718 . . . . 0.0 109.522 -179.935 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.494 HG23 ' O ' ' A' ' 40' ' ' GLY . 53.3 t -59.81 -50.59 79.5 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.572 0 O-C-N 121.325 -0.859 . . . . 0.0 109.469 -179.657 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.482 ' H ' HD12 ' A' ' 45' ' ' ILE . 3.5 mp -68.33 -30.36 47.4 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.538 0 O-C-N 121.256 -0.903 . . . . 0.0 110.459 179.704 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.84 -49.2 71.53 Favored 'General case' 0 N--CA 1.494 1.744 0 O-C-N 121.107 -0.996 . . . . 0.0 111.306 -178.473 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.498 ' C ' ' CD1' ' A' ' 47' ' ' TRP . 0.0 OUTLIER -81.39 -43.23 19.28 Favored 'General case' 0 N--CA 1.492 1.656 0 O-C-N 120.759 -1.213 . . . . 0.0 110.032 -179.384 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.674 HD11 HG22 ' A' ' 76' ' ' VAL . 0.4 OUTLIER -58.75 -43.19 90.22 Favored 'General case' 0 N--CA 1.488 1.442 0 O-C-N 121.118 -0.989 . . . . 0.0 109.113 -179.328 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.548 ' O ' ' N ' ' A' ' 53' ' ' GLY . 2.1 pp20? -72.18 -35.62 69.02 Favored 'General case' 0 N--CA 1.487 1.419 0 O-C-N 121.054 -1.029 . . . . 0.0 109.8 179.905 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.2 t0 -60.44 -38.42 84.09 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.247 -0.908 . . . . 0.0 110.567 -179.641 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.445 ' HD2' ' HE1' ' A' ' 47' ' ' TRP . 49.9 mtp180 -60.47 -40.73 92.29 Favored 'General case' 0 N--CA 1.491 1.584 0 O-C-N 121.131 -0.981 . . . . 0.0 111.189 -178.873 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.861 ' CE2' HG21 ' A' ' 80' ' ' THR . 73.4 m-85 -106.49 -11.92 15.77 Favored 'General case' 0 N--CA 1.489 1.489 0 O-C-N 120.974 -1.078 . . . . 0.0 110.041 -179.358 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . 0.548 ' N ' ' O ' ' A' ' 49' ' ' GLU . . . 70.16 30.16 69.89 Favored Glycine 0 N--CA 1.485 1.939 0 N-CA-C 109.072 -1.611 . . . . 0.0 109.072 179.5 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 12.7 pt -93.57 124.31 45.97 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.44 0 O-C-N 121.358 -1.084 . . . . 0.0 109.623 -179.604 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -65.59 140.23 58.51 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.154 -0.966 . . . . 0.0 109.817 -179.535 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.503 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -65.45 -31.86 73.17 Favored 'General case' 0 N--CA 1.488 1.475 0 O-C-N 121.429 -0.794 . . . . 0.0 109.398 179.805 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -58.46 -37.36 75.3 Favored 'General case' 0 C--N 1.303 -1.45 0 O-C-N 121.183 -0.948 . . . . 0.0 109.952 -179.815 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -58.28 -40.11 81.04 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.225 -0.922 . . . . 0.0 109.964 -179.636 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.503 ' O ' ' O ' ' A' ' 56' ' ' ALA . 42.4 t -127.12 133.67 67.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.689 0 O-C-N 121.311 -0.868 . . . . 0.0 109.555 -179.945 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . 0.51 ' C ' HD22 ' A' ' 61' ' ' LEU . 84.3 tt0 -89.26 129.73 35.78 Favored 'General case' 0 N--CA 1.489 1.517 0 O-C-N 121.044 -1.035 . . . . 0.0 109.336 179.803 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.675 ' N ' HD22 ' A' ' 61' ' ' LEU . 3.5 mm? -95.9 134.15 39.23 Favored 'General case' 0 C--N 1.305 -1.347 0 O-C-N 121.322 -0.861 . . . . 0.0 109.726 -179.821 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -109.96 156.35 40.11 Favored Pre-proline 0 N--CA 1.487 1.382 0 N-CA-C 108.668 -0.864 . . . . 0.0 108.668 179.582 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_endo -54.22 -22.88 27.56 Favored 'Trans proline' 0 C--N 1.302 -1.902 0 C-N-CA 122.295 1.997 . . . . 0.0 111.68 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.5 mt-10 -69.96 -27.36 64.67 Favored 'General case' 0 N--CA 1.485 1.308 0 O-C-N 121.297 -0.877 . . . . 0.0 109.355 179.63 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . 0.545 ' C ' ' CD2' ' A' ' 65' ' ' HIS . 1.7 t60 -65.65 -19.94 66.11 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.307 -0.87 . . . . 0.0 109.003 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.55 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 7.9 m-85 -98.43 15.78 23.75 Favored 'General case' 0 C--N 1.299 -1.622 0 CA-C-O 121.601 0.715 . . . . 0.0 109.076 -179.765 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . 0.665 HH21 ' CD ' ' A' ' 87' ' ' LYS . 1.4 ptt85 -53.66 -36.6 62.29 Favored 'General case' 0 C--N 1.299 -1.61 0 O-C-N 121.679 -0.638 . . . . 0.0 110.55 -179.378 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.553 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 41.6 t -168.07 161.23 12.51 Favored 'General case' 0 N--CA 1.492 1.638 0 O-C-N 120.754 -1.216 . . . . 0.0 110.364 -179.787 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.636 ' H ' HD12 ' A' ' 69' ' ' ILE . 2.4 mp -57.69 -34.15 46.86 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 N-CA-C 107.955 -1.128 . . . . 0.0 107.955 179.026 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 52.0 mtp85 -56.65 -41.71 77.68 Favored 'General case' 0 N--CA 1.488 1.426 0 N-CA-C 109.081 -0.711 . . . . 0.0 109.081 -179.897 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 61.6 p -67.92 -32.98 73.81 Favored 'General case' 0 C--N 1.304 -1.397 0 O-C-N 121.444 -0.785 . . . . 0.0 109.596 -179.972 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.521 HD12 ' HA ' ' A' ' 69' ' ' ILE . 56.5 mt -61.45 -50.6 79.69 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.361 0 O-C-N 121.294 -0.879 . . . . 0.0 109.567 -179.578 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 43.4 t0 -61.41 -41.44 97.16 Favored 'General case' 0 N--CA 1.49 1.548 0 O-C-N 121.216 -0.927 . . . . 0.0 108.894 179.655 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.21 -37.55 85.84 Favored 'General case' 0 C--N 1.303 -1.425 0 O-C-N 121.56 -0.712 . . . . 0.0 109.873 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . 0.53 ' CZ ' HD11 ' A' ' 61' ' ' LEU . 67.2 t80 -61.48 -46.5 89.78 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 121.167 -0.958 . . . . 0.0 109.64 -179.772 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.674 HG22 HD11 ' A' ' 48' ' ' LEU . 41.9 t -61.36 -47.76 91.99 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 O-C-N 121.268 -0.895 . . . . 0.0 109.358 179.692 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.416 ' O ' ' O ' ' A' ' 81' ' ' THR . 47.3 t -69.0 -43.42 82.02 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.393 0 O-C-N 121.399 -0.813 . . . . 0.0 109.762 179.855 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . . . . . . . . . . . -63.28 -40.73 99.33 Favored Glycine 0 N--CA 1.49 2.28 0 N-CA-C 110.284 -1.126 . . . . 0.0 110.284 -179.571 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -70.57 -41.62 72.18 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.229 -1.16 . . . . 0.0 110.833 -178.989 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.861 HG21 ' CE2' ' A' ' 52' ' ' PHE . 69.5 p -86.52 -31.15 21.44 Favored 'General case' 0 N--CA 1.489 1.51 0 O-C-N 120.906 -1.121 . . . . 0.0 109.955 -179.341 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.416 ' O ' ' O ' ' A' ' 77' ' ' VAL . 0.2 OUTLIER -133.0 153.58 81.02 Favored Pre-proline 0 C--N 1.302 -1.496 0 O-C-N 121.466 -0.771 . . . . 0.0 109.376 -179.752 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 51.2 Cg_exo -43.57 155.18 0.18 Allowed 'Trans proline' 0 C--N 1.308 -1.567 0 C-N-CA 122.04 1.827 . . . . 0.0 111.496 179.644 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 9.2 Cg_endo -57.7 145.3 90.43 Favored 'Trans proline' 0 C--N 1.307 -1.632 0 C-N-CA 122.4 2.067 . . . . 0.0 112.446 -179.689 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.59 ' O ' ' N ' ' A' ' 86' ' ' ALA . 44.1 t -103.55 129.93 54.75 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.569 0 O-C-N 121.442 -0.786 . . . . 0.0 109.545 179.878 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.461 ' C ' ' O ' ' A' ' 84' ' ' VAL . 96.1 mt-10 38.58 23.39 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.551 -0.718 . . . . 0.0 110.005 179.729 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.59 ' N ' ' O ' ' A' ' 84' ' ' VAL . . . 39.77 90.4 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.663 0 O-C-N 121.379 -0.826 . . . . 0.0 109.646 -179.826 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.665 ' CD ' HH21 ' A' ' 67' ' ' ARG . 13.4 tttm -57.74 -38.82 76.01 Favored 'General case' 0 N--CA 1.49 1.574 0 O-C-N 121.301 -0.875 . . . . 0.0 109.49 -179.927 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 69.2 mt -60.45 -35.3 75.52 Favored 'General case' 0 N--CA 1.49 1.542 0 O-C-N 121.234 -0.916 . . . . 0.0 109.51 179.995 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.2 mt-30 . . . . . 0 N--CA 1.49 1.563 0 CA-C-O 118.044 -0.979 . . . . 0.0 109.405 -179.973 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' -1' ' ' SER . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 N--CA 1.491 1.586 0 N-CA-C 109.431 -0.581 . . . . 0.0 109.431 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 0' ' ' GLU . . . . . . . . . . . . . 97.0 mt-10 -61.66 -33.43 73.97 Favored 'General case' 0 N--CA 1.489 1.52 0 O-C-N 121.293 -0.88 . . . . 0.0 109.488 -179.951 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.485 ' O ' ' OD2' ' A' ' 73' ' ' ASP . 64.8 mtt -60.03 -36.22 76.8 Favored 'General case' 0 N--CA 1.49 1.551 0 O-C-N 121.251 -0.906 . . . . 0.0 109.874 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.684 ' CD ' HG22 ' A' ' 77' ' ' VAL . 25.0 mt-30 56.08 48.05 18.42 Favored 'General case' 0 N--CA 1.488 1.459 0 O-C-N 121.329 -0.857 . . . . 0.0 109.034 -179.391 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . 0.579 ' ND1' ' O ' ' A' ' 2' ' ' GLN . 6.7 m80 76.85 52.73 0.04 OUTLIER 'General case' 0 N--CA 1.495 1.819 0 O-C-N 121.678 -0.639 . . . . 0.0 110.091 179.937 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.436 ' HB2' ' HB3' ' A' ' 1' ' ' MET . . . -61.78 -41.71 98.06 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 120.981 -1.074 . . . . 0.0 109.173 179.685 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 23.4 m -60.97 -37.5 82.64 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.434 -0.791 . . . . 0.0 109.895 -179.801 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 49.6 t -60.33 -44.13 95.18 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.511 0 O-C-N 121.174 -0.954 . . . . 0.0 109.496 -179.981 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . 0.453 ' O ' HG12 ' A' ' 11' ' ' VAL . 78.6 mt -59.5 -50.18 80.87 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.56 0 O-C-N 121.397 -0.815 . . . . 0.0 109.641 -179.799 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.659 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -63.96 -43.82 94.62 Favored 'General case' 0 N--CA 1.491 1.598 0 O-C-N 121.315 -0.866 . . . . 0.0 110.918 -179.569 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 27.2 mt-30 -69.08 -46.08 68.67 Favored 'General case' 0 N--CA 1.494 1.761 0 O-C-N 120.92 -1.112 . . . . 0.0 111.435 -178.446 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.711 ' CD1' ' N ' ' A' ' 11' ' ' VAL . 0.0 OUTLIER -70.42 -46.71 63.4 Favored 'General case' 0 N--CA 1.492 1.659 0 O-C-N 120.884 -1.135 . . . . 0.0 110.492 -179.177 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.711 ' N ' ' CD1' ' A' ' 10' ' ' PHE . 4.8 p -62.03 -40.33 86.96 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.596 0 O-C-N 121.085 -1.01 . . . . 0.0 109.807 -179.523 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.659 HG23 ' O ' ' A' ' 8' ' ' ALA . 55.8 t -63.28 -43.54 98.72 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.565 0 O-C-N 121.173 -0.955 . . . . 0.0 109.866 179.998 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 97.9 mt-10 -65.82 -37.3 85.86 Favored 'General case' 0 N--CA 1.487 1.417 0 O-C-N 121.214 -0.929 . . . . 0.0 110.278 -179.536 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 85.7 tt0 -65.76 -39.58 91.2 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.159 -0.963 . . . . 0.0 110.116 -179.558 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . 0.922 ' CD2' HG13 ' A' ' 35' ' ' VAL . 75.6 t80 -93.77 -50.72 5.23 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.174 -0.954 . . . . 0.0 110.783 -179.218 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.52 HD22 ' CG2' ' A' ' 19' ' ' VAL . 5.4 mt -120.26 80.59 28.64 Favored Pre-proline 0 N--CA 1.491 1.622 0 O-C-N 121.285 -0.884 . . . . 0.0 110.525 -178.776 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 23.5 Cg_endo -69.05 -14.52 38.49 Favored 'Trans proline' 0 N--CA 1.493 1.451 0 C-N-CA 122.095 1.863 . . . . 0.0 112.353 179.614 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -94.92 7.1 47.12 Favored 'General case' 0 N--CA 1.487 1.424 0 O-C-N 121.179 -0.95 . . . . 0.0 110.387 -179.613 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.52 ' CG2' HD22 ' A' ' 16' ' ' LEU . 39.3 t -119.11 136.33 56.65 Favored 'Isoleucine or valine' 0 N--CA 1.496 1.828 0 O-C-N 121.271 -0.893 . . . . 0.0 109.788 -179.779 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -78.53 117.96 69.49 Favored Pre-proline 0 N--CA 1.49 1.549 0 O-C-N 121.301 -0.874 . . . . 0.0 109.081 179.608 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 31.8 Cg_exo -51.76 -27.77 27.96 Favored 'Trans proline' 0 N--CA 1.493 1.478 0 C-N-CA 121.787 1.658 . . . . 0.0 112.23 179.855 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.52 -27.01 68.67 Favored 'General case' 0 N--CA 1.489 1.508 0 O-C-N 121.203 -0.936 . . . . 0.0 109.305 -179.946 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.452 ' O ' ' OD1' ' A' ' 23' ' ' ASP . 60.0 t0 -82.19 3.55 26.87 Favored 'General case' 0 N--CA 1.489 1.513 0 O-C-N 121.303 -0.873 . . . . 0.0 109.7 -179.778 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 9.7 t -109.43 128.33 65.51 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.659 0 O-C-N 121.263 -0.898 . . . . 0.0 109.561 -179.901 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 87.2 m-20 -89.96 120.56 31.28 Favored 'General case' 0 C--N 1.302 -1.487 0 O-C-N 121.189 -0.945 . . . . 0.0 109.097 179.06 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 33.7 m -70.93 4.14 0.68 Allowed 'Isoleucine or valine' 0 N--CA 1.487 1.378 0 O-C-N 121.102 -0.999 . . . . 0.0 108.941 179.47 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 -92.13 -5.45 52.66 Favored 'General case' 0 N--CA 1.486 1.341 0 O-C-N 121.373 -0.829 . . . . 0.0 109.031 179.423 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 44.3 tp -96.52 141.1 30.21 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.473 -0.767 . . . . 0.0 108.957 179.86 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -58.59 128.57 37.86 Favored 'General case' 0 C--N 1.303 -1.428 0 O-C-N 121.176 -0.952 . . . . 0.0 109.504 -179.407 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 1.033 HD23 HD11 ' A' ' 36' ' ' ILE . 48.7 tp -66.85 -37.23 84.07 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.551 -0.718 . . . . 0.0 110.648 -179.417 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 70.6 t -63.67 -35.96 74.76 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.594 0 O-C-N 120.928 -1.107 . . . . 0.0 110.693 -178.911 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 56.3 t0 -52.43 -33.59 44.68 Favored 'General case' 0 C--N 1.301 -1.531 0 O-C-N 120.974 -1.079 . . . . 0.0 108.186 -179.908 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.426 ' HB3' HG23 ' A' ' 35' ' ' VAL . 97.5 m-20 -71.46 -34.45 70.23 Favored 'General case' 0 C--N 1.302 -1.486 0 O-C-N 121.698 -0.626 . . . . 0.0 110.232 179.476 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 87.22 4.87 80.74 Favored Glycine 0 N--CA 1.492 2.388 0 N-CA-C 108.58 -1.808 . . . . 0.0 108.58 -179.043 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.922 HG13 ' CD2' ' A' ' 15' ' ' PHE . 67.8 t -59.87 -29.55 43.39 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.396 0 O-C-N 121.484 -1.009 . . . . 0.0 108.412 179.254 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 1.033 HD11 HD23 ' A' ' 30' ' ' LEU . 71.8 mt -88.07 132.5 33.01 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 CA-C-O 121.616 0.722 . . . . 0.0 109.627 -179.897 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.554 ' CG ' ' H ' ' A' ' 38' ' ' ALA . 45.7 t0 -139.07 -160.81 1.1 Allowed 'General case' 0 C--N 1.3 -1.583 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 179.845 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.554 ' H ' ' CG ' ' A' ' 37' ' ' ASP . . . -65.48 -54.31 30.19 Favored 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.117 -0.99 . . . . 0.0 108.716 179.817 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.693 HD12 ' N ' ' A' ' 39' ' ' LEU . 7.0 mp -69.63 -32.81 71.72 Favored 'General case' 0 C--N 1.302 -1.478 0 N-CA-C 107.35 -1.352 . . . . 0.0 107.35 178.405 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.455 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.26 -44.06 96.77 Favored Glycine 0 N--CA 1.481 1.663 0 N-CA-C 109.008 -1.637 . . . . 0.0 109.008 179.545 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.4 ' O ' HD12 ' A' ' 45' ' ' ILE . 2.8 tt -65.12 -42.06 94.28 Favored 'General case' 0 C--N 1.302 -1.469 0 O-C-N 121.473 -1.016 . . . . 0.0 109.369 179.168 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 15.8 tp -59.74 -44.69 93.67 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.227 -0.921 . . . . 0.0 109.339 179.857 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 18.8 mttt -62.2 -34.29 76.18 Favored 'General case' 0 C--N 1.299 -1.589 0 O-C-N 121.156 -0.965 . . . . 0.0 109.62 179.874 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.455 HG23 ' O ' ' A' ' 40' ' ' GLY . 54.0 t -60.75 -50.18 81.54 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.542 0 O-C-N 121.27 -0.894 . . . . 0.0 110.06 -179.488 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.525 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 3.6 mp -68.48 -34.63 66.65 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.487 0 O-C-N 121.247 -0.908 . . . . 0.0 111.257 -179.669 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -65.81 -50.16 65.65 Favored 'General case' 0 N--CA 1.496 1.827 0 O-C-N 120.943 -1.098 . . . . 0.0 111.758 -177.867 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.678 ' HE1' ' NE ' ' A' ' 51' ' ' ARG . 0.0 OUTLIER -80.05 -43.8 21.22 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.75 -1.219 . . . . 0.0 109.78 -179.457 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.98 HD12 HH21 ' A' ' 51' ' ' ARG . 15.0 tp -58.73 -43.16 90.1 Favored 'General case' 0 C--N 1.301 -1.533 0 O-C-N 121.382 -0.824 . . . . 0.0 110.12 -179.12 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.525 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 1.2 pp20? -72.67 -35.85 67.78 Favored 'General case' 0 C--N 1.302 -1.485 0 O-C-N 121.135 -0.978 . . . . 0.0 109.905 -179.762 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 22.1 t70 -61.51 -39.72 92.02 Favored 'General case' 0 N--CA 1.491 1.622 0 O-C-N 121.226 -0.921 . . . . 0.0 111.16 -179.317 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.98 HH21 HD12 ' A' ' 48' ' ' LEU . 70.5 mtm180 -62.65 -36.8 83.99 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.19 -0.944 . . . . 0.0 112.028 -178.291 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.79 ' CE1' HG11 ' A' ' 76' ' ' VAL . 88.5 m-85 -95.96 -6.13 39.73 Favored 'General case' 0 N--CA 1.487 1.389 0 O-C-N 120.714 -1.242 . . . . 0.0 110.454 -178.718 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 70.33 29.39 70.21 Favored Glycine 0 N--CA 1.486 1.979 0 N-CA-C 108.882 -1.687 . . . . 0.0 108.882 179.349 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.488 ' O ' ' OE1' ' A' ' 49' ' ' GLU . 24.7 pt -107.28 152.38 8.87 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.376 0 O-C-N 121.557 -0.966 . . . . 0.0 109.559 -179.571 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -105.23 154.51 20.12 Favored 'General case' 0 N--CA 1.49 1.557 0 O-C-N 121.36 -0.837 . . . . 0.0 109.721 -179.472 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.833 ' O ' HG12 ' A' ' 59' ' ' VAL . . . -59.8 -21.19 60.5 Favored 'General case' 0 N--CA 1.488 1.466 0 O-C-N 121.339 -0.85 . . . . 0.0 109.177 179.904 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 56.3 t0 61.95 36.6 15.6 Favored 'General case' 0 N--CA 1.486 1.365 0 O-C-N 121.526 -0.734 . . . . 0.0 109.328 -179.789 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.2 m-20 53.32 48.61 21.61 Favored 'General case' 0 C--N 1.305 -1.366 0 O-C-N 121.439 -0.788 . . . . 0.0 110.357 178.941 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.833 HG12 ' O ' ' A' ' 56' ' ' ALA . 8.8 p -127.86 142.87 42.53 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.682 0 O-C-N 121.364 -0.835 . . . . 0.0 109.105 179.593 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -99.19 133.5 43.39 Favored 'General case' 0 N--CA 1.489 1.494 0 O-C-N 121.177 -0.952 . . . . 0.0 109.628 -179.792 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 59.3 mt -92.52 145.38 24.49 Favored 'General case' 0 C--N 1.304 -1.408 0 O-C-N 121.43 -0.794 . . . . 0.0 109.248 179.92 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -91.71 150.73 41.42 Favored Pre-proline 0 C--N 1.305 -1.34 0 O-C-N 121.14 -0.975 . . . . 0.0 108.765 179.8 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 11.4 Cg_endo -57.23 -19.82 36.06 Favored 'Trans proline' 0 C--N 1.304 -1.81 0 C-N-CA 122.335 2.023 . . . . 0.0 112.035 -179.67 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 95.8 mt-10 -67.96 -31.62 71.47 Favored 'General case' 0 N--CA 1.484 1.243 0 O-C-N 121.285 -0.885 . . . . 0.0 109.453 -179.991 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . 0.586 ' CD2' ' O ' ' A' ' 65' ' ' HIS . 5.2 t-160 -66.04 -20.54 66.21 Favored 'General case' 0 C--N 1.301 -1.538 0 O-C-N 121.347 -0.846 . . . . 0.0 108.737 179.787 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.586 ' HB3' HD13 ' A' ' 36' ' ' ILE . 8.5 m-85 -94.63 14.65 20.37 Favored 'General case' 0 C--N 1.298 -1.639 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 -179.915 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . 0.587 ' NE ' ' OG ' ' A' ' 71' ' ' SER . 6.4 ptt180 -46.47 -37.65 8.09 Favored 'General case' 0 C--N 1.302 -1.498 0 O-C-N 121.739 -0.601 . . . . 0.0 110.381 -179.59 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.485 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 46.7 t -159.71 155.05 25.33 Favored 'General case' 0 N--CA 1.49 1.566 0 O-C-N 120.933 -1.104 . . . . 0.0 110.06 -179.764 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.717 ' H ' HD12 ' A' ' 69' ' ' ILE . 1.6 mp -57.69 -41.75 80.1 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.437 0 O-C-N 121.29 -0.881 . . . . 0.0 109.142 179.931 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 11.1 ptm180 -58.33 -42.05 85.93 Favored 'General case' 0 C--N 1.303 -1.438 0 O-C-N 121.406 -0.809 . . . . 0.0 109.1 179.795 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.587 ' OG ' ' NE ' ' A' ' 67' ' ' ARG . 26.4 t -62.97 -40.9 99.13 Favored 'General case' 0 N--CA 1.489 1.498 0 O-C-N 121.333 -0.854 . . . . 0.0 109.359 179.471 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 86.1 mt -60.12 -49.78 82.77 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.272 0 O-C-N 121.218 -0.926 . . . . 0.0 109.437 179.928 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.485 ' OD2' ' O ' ' A' ' 1' ' ' MET . 37.2 t0 -59.53 -40.6 87.71 Favored 'General case' 0 N--CA 1.488 1.44 0 O-C-N 121.366 -0.834 . . . . 0.0 109.013 179.695 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -66.45 -37.76 85.87 Favored 'General case' 0 N--CA 1.488 1.465 0 O-C-N 121.637 -0.665 . . . . 0.0 110.153 -179.882 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . 0.554 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 64.4 t80 -60.73 -47.77 84.78 Favored 'General case' 0 N--CA 1.492 1.635 0 O-C-N 121.145 -0.972 . . . . 0.0 109.836 -179.413 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.79 HG11 ' CE1' ' A' ' 52' ' ' PHE . 98.5 t -62.47 -46.3 96.74 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.294 0 O-C-N 121.064 -1.023 . . . . 0.0 109.18 179.809 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . 0.684 HG22 ' CD ' ' A' ' 2' ' ' GLN . 78.8 t -66.9 -40.24 85.31 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.389 0 O-C-N 121.472 -0.768 . . . . 0.0 109.217 179.641 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.489 ' O ' ' O ' ' A' ' 81' ' ' THR . . . -59.46 -38.57 93.72 Favored Glycine 0 N--CA 1.488 2.127 0 N-CA-C 109.913 -1.275 . . . . 0.0 109.913 -179.781 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -69.15 -41.31 77.45 Favored 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.335 -1.097 . . . . 0.0 110.489 -179.3 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 44.9 p -81.81 -31.08 31.94 Favored 'General case' 0 N--CA 1.49 1.545 0 O-C-N 121.068 -1.02 . . . . 0.0 109.449 -179.781 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.489 ' O ' ' O ' ' A' ' 78' ' ' GLY . 0.5 OUTLIER -133.01 153.9 81.14 Favored Pre-proline 0 C--N 1.3 -1.558 0 N-CA-C 109.173 -0.677 . . . . 0.0 109.173 -179.869 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 18.5 Cg_endo -63.6 136.77 55.87 Favored 'Trans proline' 0 C--N 1.306 -1.703 0 C-N-CA 122.132 1.888 . . . . 0.0 111.411 179.909 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 19.3 Cg_endo -65.56 147.22 86.34 Favored 'Trans proline' 0 N--CA 1.492 1.416 0 C-N-CA 121.974 1.783 . . . . 0.0 112.671 -179.465 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.61 ' O ' ' N ' ' A' ' 86' ' ' ALA . 42.4 t -103.8 126.68 58.31 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.551 0 O-C-N 121.491 -0.756 . . . . 0.0 109.459 179.586 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.499 ' O ' ' O ' ' A' ' 86' ' ' ALA . 96.1 mt-10 38.2 22.53 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.794 0 O-C-N 121.615 -0.678 . . . . 0.0 110.237 179.61 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.61 ' N ' ' O ' ' A' ' 84' ' ' VAL . . . 50.28 174.69 0.01 OUTLIER 'General case' 0 N--CA 1.492 1.639 0 O-C-N 121.186 -0.946 . . . . 0.0 109.692 -179.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.453 ' HD2' HH21 ' A' ' 67' ' ' ARG . 31.0 tttm -59.38 -37.95 79.26 Favored 'General case' 0 N--CA 1.491 1.607 0 O-C-N 121.195 -0.941 . . . . 0.0 109.517 179.927 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.449 ' O ' ' OXT' ' A' ' 89' ' ' GLN . 52.8 mt -94.38 142.14 27.77 Favored 'General case' 0 N--CA 1.49 1.562 0 O-C-N 121.314 -0.866 . . . . 0.0 109.506 -179.905 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . 0.449 ' OXT' ' O ' ' A' ' 88' ' ' LEU . 94.1 mt-30 . . . . . 0 N--CA 1.491 1.58 0 CA-C-O 117.985 -1.007 . . . . 0.0 109.439 179.974 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' -1' ' ' SER . . . . . . . . . . . . . 59.6 p . . . . . 0 N--CA 1.489 1.525 0 N-CA-C 109.472 -0.566 . . . . 0.0 109.472 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 0' ' ' GLU . . . . . . . . . . . . . 95.6 mt-10 -108.71 155.23 20.96 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.422 -0.799 . . . . 0.0 109.5 179.986 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.618 ' HB2' ' HB2' ' A' ' 4' ' ' ALA . 79.9 mtp -102.99 -122.31 0.19 Allowed 'General case' 0 C--N 1.304 -1.4 0 O-C-N 121.225 -0.922 . . . . 0.0 108.98 -179.893 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 98.8 mm-40 -105.24 -69.42 0.82 Allowed 'General case' 0 C--N 1.3 -1.553 0 N-CA-C 108.402 -0.962 . . . . 0.0 108.402 179.153 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 97.1 m-70 -102.76 16.64 25.93 Favored 'General case' 0 C--N 1.302 -1.464 0 N-CA-C 108.175 -1.046 . . . . 0.0 108.175 178.725 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.618 ' HB2' ' HB2' ' A' ' 1' ' ' MET . . . -54.37 -42.64 70.56 Favored 'General case' 0 N--CA 1.487 1.405 0 O-C-N 121.524 -0.735 . . . . 0.0 109.836 -179.181 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 24.2 m -62.11 -38.08 87.55 Favored 'General case' 0 N--CA 1.491 1.58 0 O-C-N 121.28 -0.887 . . . . 0.0 109.868 -179.84 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 53.7 t -64.19 -45.44 96.34 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.535 0 O-C-N 121.165 -0.959 . . . . 0.0 109.781 -179.777 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 79.4 mt -59.77 -42.43 88.82 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.607 0 O-C-N 121.386 -0.821 . . . . 0.0 109.279 -179.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . 0.516 ' O ' HG23 ' A' ' 12' ' ' VAL . . . -60.51 -36.93 79.55 Favored 'General case' 0 C--N 1.303 -1.431 0 O-C-N 121.374 -0.828 . . . . 0.0 109.18 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 7.3 tt0 -65.28 -40.23 93.6 Favored 'General case' 0 N--CA 1.488 1.47 0 O-C-N 121.271 -0.893 . . . . 0.0 110.077 179.924 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.677 ' CG ' ' CZ2' ' A' ' 47' ' ' TRP . 20.7 m-85 -62.01 -50.04 73.63 Favored 'General case' 0 N--CA 1.493 1.685 0 O-C-N 121.102 -0.999 . . . . 0.0 110.676 -179.426 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.42 HG23 ' N ' ' A' ' 12' ' ' VAL . 22.2 m -64.08 -40.48 89.19 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.519 0 O-C-N 121.06 -1.025 . . . . 0.0 109.302 -179.629 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.516 HG23 ' O ' ' A' ' 8' ' ' ALA . 69.0 t -63.66 -46.52 94.51 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.44 0 O-C-N 121.206 -0.934 . . . . 0.0 109.309 179.571 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 98.1 mt-10 -70.12 -29.39 66.32 Favored 'General case' 0 N--CA 1.489 1.487 0 O-C-N 121.305 -0.872 . . . . 0.0 109.895 179.818 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 84.0 tt0 -64.82 -30.42 71.42 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.48 -0.762 . . . . 0.0 110.615 -179.094 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 75.9 t80 -131.89 -46.06 0.95 Allowed 'General case' 0 N--CA 1.495 1.781 0 O-C-N 121.083 -1.01 . . . . 0.0 111.125 -178.97 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.47 HD22 ' CG2' ' A' ' 19' ' ' VAL . 4.7 mt -117.98 80.16 14.55 Favored Pre-proline 0 N--CA 1.494 1.755 0 O-C-N 121.097 -1.002 . . . . 0.0 110.442 -178.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -76.15 -14.26 18.8 Favored 'Trans proline' 0 C--N 1.308 -1.604 0 C-N-CA 122.411 2.074 . . . . 0.0 112.255 179.324 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.3 m-20 -89.08 5.19 45.63 Favored 'General case' 0 N--CA 1.487 1.4 0 O-C-N 121.279 -0.888 . . . . 0.0 109.761 -179.928 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.47 ' CG2' HD22 ' A' ' 16' ' ' LEU . 45.1 t -112.64 135.33 52.38 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.722 0 O-C-N 121.378 -0.826 . . . . 0.0 109.59 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.435 ' O ' ' CG ' ' A' ' 23' ' ' ASP . . . -73.18 117.52 60.83 Favored Pre-proline 0 N--CA 1.489 1.52 0 O-C-N 121.26 -0.9 . . . . 0.0 109.443 -179.99 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 38.8 Cg_exo -51.98 -25.14 21.18 Favored 'Trans proline' 0 N--CA 1.493 1.5 0 C-N-CA 121.805 1.67 . . . . 0.0 112.039 179.486 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.72 -22.92 67.09 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.29 -0.881 . . . . 0.0 109.708 -179.828 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.45 ' C ' ' OD1' ' A' ' 23' ' ' ASP . 52.3 p30 -83.98 7.62 17.81 Favored 'General case' 0 N--CA 1.491 1.587 0 O-C-N 121.249 -0.907 . . . . 0.0 109.831 -179.74 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 11.8 t -104.97 133.57 48.8 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.609 0 O-C-N 121.218 -0.926 . . . . 0.0 109.348 179.935 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 86.5 m-20 -88.89 120.61 30.46 Favored 'General case' 0 C--N 1.302 -1.466 0 O-C-N 121.054 -1.029 . . . . 0.0 108.93 179.405 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 17.0 m -74.96 3.83 1.08 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 O-C-N 121.26 -0.9 . . . . 0.0 109.386 179.849 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . 0.449 ' C ' ' OD1' ' A' ' 27' ' ' ASP . 52.0 p30 -94.95 1.12 55.2 Favored 'General case' 0 N--CA 1.486 1.349 0 O-C-N 121.245 -0.909 . . . . 0.0 109.227 179.454 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 46.0 tp -100.44 134.61 43.12 Favored 'General case' 0 C--N 1.303 -1.437 0 N-CA-C 108.358 -0.978 . . . . 0.0 108.358 179.313 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 88.9 m-20 -57.72 126.71 28.56 Favored 'General case' 0 C--N 1.3 -1.546 0 C-N-CA 118.942 -1.103 . . . . 0.0 108.998 -179.335 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 1.023 HD23 HD11 ' A' ' 36' ' ' ILE . 43.0 tp -66.08 -37.97 87.11 Favored 'General case' 0 C--N 1.301 -1.519 0 O-C-N 121.654 -0.654 . . . . 0.0 110.654 -179.153 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 54.1 t -67.43 -37.47 78.96 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.637 0 O-C-N 120.931 -1.106 . . . . 0.0 110.774 -179.155 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 84.4 m-20 -52.69 -33.17 46.25 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 120.859 -1.151 . . . . 0.0 108.111 179.999 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 20.3 m120 -70.72 -33.48 70.9 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.639 -0.663 . . . . 0.0 109.784 179.325 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 91.65 5.56 66.62 Favored Glycine 0 N--CA 1.49 2.294 0 N-CA-C 108.879 -1.688 . . . . 0.0 108.879 -179.304 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 74.4 t -61.44 -32.99 54.92 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 O-C-N 121.498 -1.001 . . . . 0.0 109.209 179.793 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 1.023 HD11 HD23 ' A' ' 30' ' ' LEU . 72.6 mt -92.31 121.13 42.62 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.396 0 O-C-N 121.302 -0.874 . . . . 0.0 109.651 -179.726 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . . . . . . . . . 92.6 m-20 -120.42 -169.5 1.82 Allowed 'General case' 0 C--N 1.304 -1.396 0 N-CA-C 109.076 -0.713 . . . . 0.0 109.076 179.921 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . . . . . . . . . . . -63.46 -54.24 39.65 Favored 'General case' 0 N--CA 1.491 1.592 0 O-C-N 121.221 -0.924 . . . . 0.0 108.615 179.702 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.686 HD12 ' N ' ' A' ' 39' ' ' LEU . 7.0 mp -70.78 -33.47 70.79 Favored 'General case' 0 C--N 1.302 -1.476 0 N-CA-C 107.193 -1.41 . . . . 0.0 107.193 178.148 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.497 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.49 -43.12 97.79 Favored Glycine 0 N--CA 1.483 1.813 0 N-CA-C 108.809 -1.716 . . . . 0.0 108.809 179.388 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.407 HD11 ' CE1' ' A' ' 66' ' ' PHE . 6.6 tt -64.73 -41.63 95.81 Favored 'General case' 0 C--N 1.304 -1.374 0 O-C-N 121.384 -1.068 . . . . 0.0 109.066 179.286 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.4 tp -59.73 -45.93 90.68 Favored 'General case' 0 N--CA 1.49 1.535 0 O-C-N 121.222 -0.924 . . . . 0.0 109.044 179.705 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 56.6 mttt -60.97 -34.75 75.25 Favored 'General case' 0 C--N 1.297 -1.717 0 O-C-N 121.492 -0.755 . . . . 0.0 109.671 -179.812 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.497 HG23 ' O ' ' A' ' 40' ' ' GLY . 54.3 t -61.85 -49.87 82.48 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.562 0 O-C-N 121.366 -0.834 . . . . 0.0 110.162 -179.401 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.547 ' O ' ' CG ' ' A' ' 49' ' ' GLU . 3.4 mp -67.89 -32.9 58.38 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.497 0 O-C-N 121.206 -0.934 . . . . 0.0 110.678 -179.621 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -64.7 -50.29 67.55 Favored 'General case' 0 N--CA 1.492 1.661 0 O-C-N 120.861 -1.15 . . . . 0.0 111.13 -178.302 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.677 ' CZ2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -81.28 -44.84 17.11 Favored 'General case' 0 N--CA 1.491 1.62 0 O-C-N 120.758 -1.214 . . . . 0.0 109.829 -179.657 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.646 HD21 ' CG2' ' A' ' 76' ' ' VAL . 18.1 tp -58.37 -41.32 84.53 Favored 'General case' 0 C--N 1.302 -1.483 0 O-C-N 121.328 -0.858 . . . . 0.0 109.936 -178.955 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.547 ' CG ' ' O ' ' A' ' 45' ' ' ILE . 1.1 pp20? -73.35 -35.63 66.02 Favored 'General case' 0 C--N 1.302 -1.497 0 O-C-N 120.895 -1.128 . . . . 0.0 109.521 179.769 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 57.4 t0 -63.48 -41.02 98.59 Favored 'General case' 0 N--CA 1.492 1.66 0 O-C-N 121.376 -0.828 . . . . 0.0 111.619 -179.111 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.504 ' HD3' HD12 ' A' ' 48' ' ' LEU . 8.8 ptm180 -65.0 -37.08 86.47 Favored 'General case' 0 N--CA 1.493 1.681 0 O-C-N 120.869 -1.144 . . . . 0.0 111.632 -178.122 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.858 ' CE2' HG11 ' A' ' 76' ' ' VAL . 72.9 m-85 -90.9 -12.14 37.02 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 120.443 -1.41 . . . . 0.0 110.021 -179.505 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 74.47 28.83 62.84 Favored Glycine 0 N--CA 1.487 2.045 0 N-CA-C 108.832 -1.707 . . . . 0.0 108.832 179.919 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . 0.49 ' O ' ' OE1' ' A' ' 49' ' ' GLU . 25.2 pt -109.18 153.4 10.95 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.459 0 O-C-N 121.575 -0.956 . . . . 0.0 109.798 -179.42 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -102.44 126.3 49.44 Favored 'General case' 0 N--CA 1.49 1.565 0 O-C-N 121.228 -0.92 . . . . 0.0 109.561 -179.972 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.497 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -68.55 -28.16 66.72 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.238 -0.914 . . . . 0.0 109.525 179.784 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 21.0 t70 -55.12 -33.49 62.9 Favored 'General case' 0 N--CA 1.492 1.651 0 O-C-N 121.262 -0.899 . . . . 0.0 110.082 -179.638 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 92.1 m-20 -52.76 -38.29 60.77 Favored 'General case' 0 N--CA 1.491 1.596 0 O-C-N 121.133 -0.979 . . . . 0.0 109.852 -179.465 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.497 ' O ' ' O ' ' A' ' 56' ' ' ALA . 32.7 m -127.66 157.74 39.43 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.335 0 O-C-N 121.319 -0.863 . . . . 0.0 109.557 -179.721 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 95.7 mt-10 -97.6 125.82 42.55 Favored 'General case' 0 N--CA 1.489 1.518 0 O-C-N 121.14 -0.975 . . . . 0.0 109.353 179.725 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.412 HD21 ' CE2' ' A' ' 75' ' ' PHE . 5.1 mp -107.12 141.06 38.98 Favored 'General case' 0 C--N 1.306 -1.325 0 O-C-N 121.394 -0.816 . . . . 0.0 109.699 -179.73 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -109.22 153.09 42.84 Favored Pre-proline 0 N--CA 1.487 1.406 0 N-CA-C 108.543 -0.91 . . . . 0.0 108.543 179.295 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 9.9 Cg_endo -54.53 -23.22 30.96 Favored 'Trans proline' 0 C--N 1.303 -1.817 0 C-N-CA 122.338 2.026 . . . . 0.0 112.086 -179.548 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 95.5 mt-10 -70.15 -26.46 63.94 Favored 'General case' 0 N--CA 1.487 1.378 0 O-C-N 121.352 -0.842 . . . . 0.0 109.403 179.906 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . 0.504 ' NE2' ' CB ' ' A' ' 75' ' ' PHE . 2.2 t-80 -66.03 -20.88 66.33 Favored 'General case' 0 C--N 1.3 -1.548 0 O-C-N 121.419 -0.8 . . . . 0.0 109.289 -179.843 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.584 ' HB3' HD13 ' A' ' 36' ' ' ILE . 9.5 m-85 -97.1 15.48 22.41 Favored 'General case' 0 C--N 1.3 -1.56 0 O-C-N 121.406 -0.809 . . . . 0.0 109.166 -179.815 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . 0.42 HH21 ' HD3' ' A' ' 87' ' ' LYS . 1.7 ptt85 -51.99 -34.39 42.31 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 121.644 -0.66 . . . . 0.0 109.999 -179.938 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.546 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 44.2 t -151.4 154.05 35.89 Favored 'General case' 0 N--CA 1.489 1.507 0 O-C-N 121.071 -1.018 . . . . 0.0 109.969 179.884 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.637 ' H ' HD12 ' A' ' 69' ' ' ILE . 3.2 mp -57.36 -33.91 44.99 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.466 0 N-CA-C 108.409 -0.96 . . . . 0.0 108.409 179.222 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 32.1 mtp180 -56.79 -44.11 81.56 Favored 'General case' 0 N--CA 1.487 1.403 0 O-C-N 121.67 -0.644 . . . . 0.0 109.407 -179.693 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 17.0 t -66.47 -40.58 89.42 Favored 'General case' 0 N--CA 1.491 1.589 0 O-C-N 121.382 -0.823 . . . . 0.0 109.829 -179.96 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 62.8 mt -62.18 -50.26 80.73 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.37 0 O-C-N 121.305 -0.872 . . . . 0.0 110.286 -179.222 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 37.0 t0 -61.0 -41.88 97.35 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 121.11 -0.994 . . . . 0.0 109.409 -179.842 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -67.02 -40.69 87.31 Favored 'General case' 0 C--N 1.302 -1.461 0 O-C-N 121.478 -0.764 . . . . 0.0 110.353 -179.443 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . 0.504 ' CB ' ' NE2' ' A' ' 65' ' ' HIS . 66.9 t80 -62.7 -46.71 86.86 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.049 -1.032 . . . . 0.0 109.663 -179.676 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.858 HG11 ' CE2' ' A' ' 52' ' ' PHE . 90.7 t -67.23 -48.21 79.05 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.343 0 O-C-N 121.192 -0.943 . . . . 0.0 109.78 -179.938 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 53.0 t -69.66 -41.99 80.29 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.333 0 O-C-N 121.134 -0.978 . . . . 0.0 109.63 179.913 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.486 ' O ' ' O ' ' A' ' 81' ' ' THR . . . -59.53 -36.0 87.7 Favored Glycine 0 N--CA 1.489 2.198 0 N-CA-C 110.285 -1.126 . . . . 0.0 110.285 -179.477 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.48 -40.98 85.29 Favored 'General case' 0 N--CA 1.491 1.621 0 O-C-N 121.209 -1.171 . . . . 0.0 110.475 -179.183 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 49.0 p -81.93 -30.74 31.67 Favored 'General case' 0 N--CA 1.489 1.492 0 O-C-N 121.144 -0.972 . . . . 0.0 109.698 -179.685 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.486 ' O ' ' O ' ' A' ' 78' ' ' GLY . 0.5 OUTLIER -133.18 153.94 80.96 Favored Pre-proline 0 C--N 1.302 -1.458 0 O-C-N 121.541 -0.725 . . . . 0.0 109.666 -179.615 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 18.7 Cg_endo -62.71 111.65 1.41 Allowed 'Trans proline' 0 C--N 1.308 -1.577 0 C-N-CA 122.339 2.026 . . . . 0.0 111.285 179.614 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 36.7 Cg_endo -74.15 150.77 43.12 Favored 'Trans proline' 0 N--CA 1.49 1.284 0 C-N-CA 121.992 1.795 . . . . 0.0 113.143 -179.11 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.449 ' O ' ' C ' ' A' ' 85' ' ' GLU . 14.5 p -104.31 138.5 28.7 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 179.389 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.449 ' C ' ' O ' ' A' ' 84' ' ' VAL . 95.9 mt-10 41.88 47.27 3.64 Favored 'General case' 0 N--CA 1.491 1.612 0 O-C-N 121.184 -0.947 . . . . 0.0 109.329 -179.813 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -56.15 150.37 14.22 Favored 'General case' 0 N--CA 1.49 1.55 0 O-C-N 121.362 -0.836 . . . . 0.0 109.801 -179.564 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.42 ' HD3' HH21 ' A' ' 67' ' ' ARG . 53.2 mttm -56.31 -34.89 66.96 Favored 'General case' 0 N--CA 1.489 1.504 0 O-C-N 121.254 -0.904 . . . . 0.0 109.396 -179.983 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . 0.406 ' O ' ' O ' ' A' ' 89' ' ' GLN . 52.3 mt -93.18 142.44 27.31 Favored 'General case' 0 N--CA 1.49 1.552 0 O-C-N 121.28 -0.887 . . . . 0.0 109.377 -179.985 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . 0.406 ' O ' ' O ' ' A' ' 88' ' ' LEU . 59.4 tp60 . . . . . 0 N--CA 1.49 1.57 0 CA-C-O 118.024 -0.988 . . . . 0.0 109.348 179.934 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' -1' ' ' SER . . . . . . . . . . . . . 25.4 t . . . . . 0 N--CA 1.49 1.545 0 N-CA-C 109.437 -0.579 . . . . 0.0 109.437 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 0' ' ' GLU . . . . . 0.457 ' HG2' ' H ' ' A' ' 2' ' ' GLN . 84.2 tt0 -101.35 133.96 45.16 Favored 'General case' 0 N--CA 1.491 1.593 0 O-C-N 121.278 -0.889 . . . . 0.0 109.36 -179.992 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.739 ' HB3' ' HB2' ' A' ' 4' ' ' ALA . 64.7 mtt -60.56 -35.12 75.27 Favored 'General case' 0 N--CA 1.492 1.637 0 O-C-N 121.304 -0.873 . . . . 0.0 109.693 -179.852 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . 0.457 ' H ' ' HG2' ' A' ' 0' ' ' GLU . 94.5 mt-30 56.48 94.1 0.03 OUTLIER 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.386 -0.821 . . . . 0.0 109.581 -179.678 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 50.4 m-70 66.14 41.77 3.41 Favored 'General case' 0 N--CA 1.494 1.753 0 O-C-N 121.626 -0.671 . . . . 0.0 110.575 179.687 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.739 ' HB2' ' HB3' ' A' ' 1' ' ' MET . . . -61.01 -38.42 86.0 Favored 'General case' 0 N--CA 1.492 1.633 0 O-C-N 120.96 -1.088 . . . . 0.0 109.299 179.468 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 25.5 m -60.18 -35.75 76.05 Favored 'General case' 0 N--CA 1.491 1.581 0 O-C-N 121.328 -0.857 . . . . 0.0 109.914 -179.797 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . . . . . . . . . 53.0 t -61.39 -45.72 98.05 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.549 0 O-C-N 121.193 -0.942 . . . . 0.0 109.589 -179.69 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 70.2 mt -60.04 -43.88 93.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.475 0 O-C-N 121.247 -0.908 . . . . 0.0 109.113 179.79 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -60.41 -35.89 76.84 Favored 'General case' 0 C--N 1.303 -1.424 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 179.752 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . . . . . . . . . 7.3 tt0 -64.18 -38.12 89.9 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.458 -0.776 . . . . 0.0 110.137 -179.996 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.684 ' CG ' ' CZ2' ' A' ' 47' ' ' TRP . 25.8 m-85 -66.52 -49.29 67.01 Favored 'General case' 0 N--CA 1.494 1.726 0 O-C-N 120.908 -1.12 . . . . 0.0 111.028 -179.219 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . 0.443 HG23 ' N ' ' A' ' 12' ' ' VAL . 11.6 m -59.74 -48.14 88.64 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.52 0 O-C-N 121.08 -1.013 . . . . 0.0 110.428 -178.518 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.573 ' O ' ' N ' ' A' ' 16' ' ' LEU . 30.6 m -64.89 -43.44 96.31 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.407 0 O-C-N 120.766 -1.208 . . . . 0.0 110.03 -179.838 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . 0.511 ' N ' HG23 ' A' ' 12' ' ' VAL . 95.0 mt-10 -65.16 -26.51 68.19 Favored 'General case' 0 N--CA 1.49 1.567 0 O-C-N 120.755 -1.215 . . . . 0.0 109.945 -179.981 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 81.4 tt0 -64.28 -31.04 72.08 Favored 'General case' 0 C--N 1.299 -1.614 0 O-C-N 121.328 -0.857 . . . . 0.0 109.767 -179.277 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 85.9 m-85 -141.5 -35.89 0.45 Allowed 'General case' 0 N--CA 1.494 1.734 0 O-C-N 120.897 -1.127 . . . . 0.0 110.816 -179.9 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.573 ' N ' ' O ' ' A' ' 12' ' ' VAL . 8.6 mt -122.17 79.79 43.83 Favored Pre-proline 0 N--CA 1.494 1.737 0 O-C-N 121.124 -0.985 . . . . 0.0 110.418 -179.01 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 43.0 Cg_endo -75.77 -12.03 20.08 Favored 'Trans proline' 0 C--N 1.308 -1.562 0 C-N-CA 122.412 2.075 . . . . 0.0 112.545 179.79 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.7 m-20 -93.87 13.09 23.66 Favored 'General case' 0 N--CA 1.488 1.455 0 O-C-N 121.224 -0.922 . . . . 0.0 110.385 -179.399 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . . . . . . . . . 58.5 t -109.46 134.98 49.78 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.746 0 O-C-N 121.247 -0.908 . . . . 0.0 110.008 -179.724 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . 0.494 ' O ' ' OD1' ' A' ' 23' ' ' ASP . . . -73.58 117.88 64.43 Favored Pre-proline 0 N--CA 1.491 1.584 0 O-C-N 121.429 -0.794 . . . . 0.0 109.337 -179.965 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . . . . . . . . . 36.8 Cg_exo -52.62 -27.24 32.28 Favored 'Trans proline' 0 N--CA 1.494 1.509 0 C-N-CA 121.832 1.688 . . . . 0.0 112.394 179.786 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.85 -25.4 67.88 Favored 'General case' 0 N--CA 1.492 1.657 0 O-C-N 121.263 -0.898 . . . . 0.0 110.035 -179.561 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.494 ' OD1' ' O ' ' A' ' 20' ' ' ALA . 47.4 p30 -86.54 8.15 23.24 Favored 'General case' 0 N--CA 1.49 1.526 0 O-C-N 121.133 -0.979 . . . . 0.0 110.112 -179.566 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 11.3 t -101.11 131.64 48.41 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.631 0 O-C-N 120.972 -1.08 . . . . 0.0 109.418 -179.907 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 61.6 t0 -89.29 119.71 30.0 Favored 'General case' 0 C--N 1.303 -1.421 0 O-C-N 121.096 -1.002 . . . . 0.0 109.094 179.435 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 22.1 m -76.3 4.45 1.12 Allowed 'Isoleucine or valine' 0 C--N 1.302 -1.458 0 O-C-N 121.252 -0.905 . . . . 0.0 109.173 179.687 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -96.24 0.25 50.75 Favored 'General case' 0 N--CA 1.486 1.374 0 O-C-N 121.266 -0.896 . . . . 0.0 109.214 179.61 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 38.4 tp -94.62 143.22 26.61 Favored 'General case' 0 N--CA 1.49 1.537 0 O-C-N 121.43 -0.794 . . . . 0.0 109.192 -179.997 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -66.79 118.78 10.79 Favored 'General case' 0 C--N 1.304 -1.391 0 O-C-N 121.091 -1.006 . . . . 0.0 109.005 -179.75 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 1.027 HD23 HD11 ' A' ' 36' ' ' ILE . 41.6 tp -62.33 -37.86 87.26 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.605 -0.685 . . . . 0.0 111.09 -178.872 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 53.2 t -66.78 -38.29 81.2 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 120.807 -1.183 . . . . 0.0 110.863 -179.012 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 88.7 m-20 -52.89 -33.36 49.87 Favored 'General case' 0 C--N 1.301 -1.503 0 O-C-N 120.913 -1.117 . . . . 0.0 108.212 179.986 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . . . . . . . . . 20.9 m120 -71.05 -33.91 70.74 Favored 'General case' 0 C--N 1.3 -1.564 0 O-C-N 121.698 -0.626 . . . . 0.0 109.941 179.528 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 91.31 5.6 67.24 Favored Glycine 0 N--CA 1.49 2.258 0 N-CA-C 108.871 -1.691 . . . . 0.0 108.871 -179.231 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . . . . . . . . . 78.0 t -60.19 -30.56 46.19 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.42 0 O-C-N 121.479 -1.012 . . . . 0.0 108.825 179.526 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 1.027 HD11 HD23 ' A' ' 30' ' ' LEU . 65.5 mt -94.72 130.5 43.46 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.344 0 O-C-N 121.386 -0.821 . . . . 0.0 109.558 -179.763 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.545 ' CG ' ' H ' ' A' ' 38' ' ' ALA . 49.1 t0 -137.92 -163.67 1.48 Allowed 'General case' 0 C--N 1.301 -1.52 0 N-CA-C 108.772 -0.825 . . . . 0.0 108.772 179.948 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.545 ' H ' ' CG ' ' A' ' 37' ' ' ASP . . . -63.54 -54.76 31.13 Favored 'General case' 0 N--CA 1.491 1.586 0 O-C-N 120.995 -1.066 . . . . 0.0 108.665 179.879 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . 0.712 HD12 ' N ' ' A' ' 39' ' ' LEU . 6.9 mp -71.25 -34.04 70.37 Favored 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 107.323 -1.362 . . . . 0.0 107.323 178.206 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.425 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.47 -45.55 95.36 Favored Glycine 0 N--CA 1.482 1.725 0 N-CA-C 109.019 -1.632 . . . . 0.0 109.019 179.562 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . . . . . . . . . 7.4 tt -64.08 -39.95 95.17 Favored 'General case' 0 C--N 1.303 -1.426 0 O-C-N 121.462 -1.022 . . . . 0.0 109.092 179.303 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.3 tp -60.04 -46.03 90.89 Favored 'General case' 0 N--CA 1.489 1.512 0 O-C-N 121.432 -0.792 . . . . 0.0 109.327 179.902 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 17.6 mttp -59.82 -37.11 78.28 Favored 'General case' 0 C--N 1.296 -1.729 0 O-C-N 121.474 -0.766 . . . . 0.0 109.381 -179.906 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.425 HG23 ' O ' ' A' ' 40' ' ' GLY . 84.9 t -64.64 -41.49 92.39 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.522 0 O-C-N 121.5 -0.75 . . . . 0.0 110.2 -179.699 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.485 ' O ' ' OE1' ' A' ' 49' ' ' GLU . 1.3 mp -64.89 -50.76 73.58 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.646 0 O-C-N 121.066 -1.021 . . . . 0.0 111.208 -178.84 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . 0.411 ' N ' HG22 ' A' ' 45' ' ' ILE . . . -67.68 -49.51 62.4 Favored 'General case' 0 N--CA 1.496 1.864 0 O-C-N 121.083 -1.011 . . . . 0.0 112.843 -177.531 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.684 ' CZ2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -74.8 -48.86 23.05 Favored 'General case' 0 N--CA 1.493 1.723 0 O-C-N 120.613 -1.304 . . . . 0.0 111.358 -177.758 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.594 ' O ' HD13 ' A' ' 48' ' ' LEU . 0.2 OUTLIER -58.86 -44.52 91.04 Favored 'General case' 0 C--N 1.301 -1.515 0 O-C-N 120.812 -1.18 . . . . 0.0 109.345 -178.582 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.628 ' HG2' ' HB2' ' A' ' 56' ' ' ALA . 0.0 OUTLIER -63.97 -38.72 92.11 Favored 'General case' 0 N--CA 1.485 1.324 0 O-C-N 120.706 -1.246 . . . . 0.0 109.818 -179.958 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . . . . . . . . . 55.1 t0 -61.68 -37.25 83.4 Favored 'General case' 0 N--CA 1.493 1.686 0 O-C-N 121.298 -0.876 . . . . 0.0 110.513 -179.502 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . . . . . . . . . 18.4 mmt180 -58.27 -36.51 73.39 Favored 'General case' 0 N--CA 1.49 1.529 0 O-C-N 121.089 -1.007 . . . . 0.0 111.055 -179.029 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.752 ' CE1' HG11 ' A' ' 76' ' ' VAL . 87.4 m-85 -96.32 -6.18 38.36 Favored 'General case' 0 N--CA 1.487 1.413 0 O-C-N 120.789 -1.194 . . . . 0.0 110.474 -179.144 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 73.25 30.44 62.79 Favored Glycine 0 N--CA 1.488 2.121 0 N-CA-C 108.739 -1.745 . . . . 0.0 108.739 179.761 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 20.7 pt -112.68 153.9 14.21 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.397 0 O-C-N 121.75 -0.853 . . . . 0.0 109.701 -179.436 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -93.99 130.17 40.21 Favored 'General case' 0 N--CA 1.491 1.575 0 O-C-N 121.217 -0.927 . . . . 0.0 109.407 -179.873 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.628 ' HB2' ' HG2' ' A' ' 49' ' ' GLU . . . -64.39 -32.24 73.78 Favored 'General case' 0 N--CA 1.49 1.559 0 O-C-N 121.202 -0.936 . . . . 0.0 109.552 179.974 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -58.06 -34.49 70.17 Favored 'General case' 0 N--CA 1.489 1.495 0 O-C-N 121.383 -0.823 . . . . 0.0 110.051 -179.835 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . . . . . . . . . 91.9 m-20 -53.53 -37.93 63.3 Favored 'General case' 0 N--CA 1.492 1.641 0 O-C-N 121.28 -0.888 . . . . 0.0 109.939 -179.469 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.486 ' O ' ' O ' ' A' ' 56' ' ' ALA . 13.7 p -133.67 142.72 40.75 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.694 0 O-C-N 121.253 -0.905 . . . . 0.0 109.567 -179.978 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -100.19 128.73 46.21 Favored 'General case' 0 N--CA 1.489 1.502 0 O-C-N 121.21 -0.931 . . . . 0.0 109.322 179.781 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . . . . . . . . . 51.7 mt -105.75 143.46 33.88 Favored 'General case' 0 C--N 1.305 -1.361 0 O-C-N 121.314 -0.866 . . . . 0.0 109.707 -179.719 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.0 OUTLIER -97.32 151.25 37.56 Favored Pre-proline 0 C--N 1.305 -1.337 0 N-CA-C 108.368 -0.975 . . . . 0.0 108.368 179.131 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 9.4 Cg_endo -55.39 -23.25 37.41 Favored 'Trans proline' 0 C--N 1.305 -1.743 0 C-N-CA 122.366 2.044 . . . . 0.0 112.032 -179.403 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 91.9 mt-10 -71.79 -29.85 64.9 Favored 'General case' 0 C--N 1.304 -1.407 0 O-C-N 121.345 -0.847 . . . . 0.0 109.774 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . 0.453 ' CE1' ' HB2' ' A' ' 75' ' ' PHE . 63.0 t60 -65.92 -21.17 66.42 Favored 'General case' 0 C--N 1.299 -1.588 0 O-C-N 121.102 -0.999 . . . . 0.0 109.186 -179.668 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.599 ' HB3' HD13 ' A' ' 36' ' ' ILE . 26.0 m-85 -86.93 13.98 8.13 Favored 'General case' 0 C--N 1.3 -1.55 0 O-C-N 121.405 -0.809 . . . . 0.0 109.223 -179.659 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . 0.416 HH21 ' HE3' ' A' ' 87' ' ' LYS . 5.8 ptt180 -52.73 -34.31 52.05 Favored 'General case' 0 C--N 1.301 -1.508 0 O-C-N 121.66 -0.65 . . . . 0.0 110.088 179.852 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.48 ' HA ' ' H ' ' A' ' 30' ' ' LEU . 32.4 t -149.82 151.11 32.99 Favored 'General case' 0 N--CA 1.49 1.56 0 O-C-N 121.067 -1.021 . . . . 0.0 110.088 -179.771 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.665 ' H ' HD12 ' A' ' 69' ' ' ILE . 2.0 mp -60.19 -39.14 79.73 Favored 'Isoleucine or valine' 0 N--CA 1.488 1.428 0 O-C-N 121.48 -0.762 . . . . 0.0 109.888 -179.862 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . . . . . . . . . 9.8 ptm180 -58.12 -40.99 82.64 Favored 'General case' 0 N--CA 1.489 1.483 0 O-C-N 121.493 -0.754 . . . . 0.0 110.283 -179.225 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . . . . . . . . . 60.7 p -64.98 -42.91 94.12 Favored 'General case' 0 C--N 1.302 -1.495 0 O-C-N 121.201 -0.937 . . . . 0.0 110.221 -179.455 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . 0.421 ' HA ' ' NE2' ' A' ' 65' ' ' HIS . 69.6 mt -61.5 -47.39 93.63 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.382 0 O-C-N 121.136 -0.978 . . . . 0.0 110.406 -179.405 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . 0.492 ' OD2' ' O ' ' A' ' 1' ' ' MET . 39.4 t0 -60.63 -37.49 81.64 Favored 'General case' 0 C--N 1.3 -1.58 0 O-C-N 121.184 -0.948 . . . . 0.0 109.825 -179.723 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . . . . . . . . . . . -67.86 -46.84 70.59 Favored 'General case' 0 N--CA 1.488 1.425 0 O-C-N 121.216 -0.927 . . . . 0.0 110.604 -178.985 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . 0.453 ' HB2' ' CE1' ' A' ' 65' ' ' HIS . 58.4 t80 -65.88 -44.52 85.1 Favored 'General case' 0 C--N 1.302 -1.477 0 O-C-N 121.098 -1.001 . . . . 0.0 109.2 -179.728 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.752 HG11 ' CE1' ' A' ' 52' ' ' PHE . 55.2 t -60.76 -45.34 97.97 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.433 0 O-C-N 121.31 -0.869 . . . . 0.0 109.157 179.585 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 54.7 t -69.15 -41.16 81.27 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.281 0 O-C-N 121.214 -0.929 . . . . 0.0 108.989 179.349 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.492 ' O ' ' O ' ' A' ' 81' ' ' THR . . . -59.99 -28.13 65.74 Favored Glycine 0 N--CA 1.489 2.23 0 N-CA-C 110.029 -1.228 . . . . 0.0 110.029 -179.987 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.02 -37.02 83.39 Favored 'General case' 0 N--CA 1.49 1.575 0 O-C-N 121.207 -1.172 . . . . 0.0 109.947 -179.391 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . . . . . . . . . 44.9 p -83.38 -31.08 26.9 Favored 'General case' 0 N--CA 1.489 1.479 0 O-C-N 121.149 -0.97 . . . . 0.0 109.535 -179.981 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.492 ' O ' ' O ' ' A' ' 78' ' ' GLY . 0.2 OUTLIER -133.4 153.17 80.35 Favored Pre-proline 0 C--N 1.303 -1.428 0 O-C-N 121.504 -0.747 . . . . 0.0 109.788 -179.523 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 27.4 Cg_endo -66.07 111.75 2.08 Favored 'Trans proline' 0 C--N 1.309 -1.547 0 C-N-CA 122.346 2.031 . . . . 0.0 111.449 179.557 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 53.0 Cg_endo -76.67 152.37 33.12 Favored 'Trans proline' 0 N--CA 1.489 1.232 0 C-N-CA 122.111 1.874 . . . . 0.0 113.201 -179.11 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.45 ' O ' ' C ' ' A' ' 85' ' ' GLU . 32.7 m -103.12 135.81 38.82 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.52 0 N-CA-C 108.404 -0.962 . . . . 0.0 108.404 178.98 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.45 ' C ' ' O ' ' A' ' 84' ' ' VAL . 96.0 mt-10 42.25 70.34 0.29 Allowed 'General case' 0 N--CA 1.491 1.595 0 O-C-N 121.225 -0.922 . . . . 0.0 109.059 -179.394 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . . . . . . . . . . . -48.62 148.51 2.05 Favored 'General case' 0 N--CA 1.49 1.569 0 O-C-N 121.409 -0.807 . . . . 0.0 110.047 -179.291 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.416 ' HE3' HH21 ' A' ' 67' ' ' ARG . 54.5 tttp -56.48 -36.56 69.24 Favored 'General case' 0 N--CA 1.491 1.597 0 O-C-N 121.417 -0.802 . . . . 0.0 109.298 179.901 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 33.1 tp -100.06 130.69 46.24 Favored 'General case' 0 N--CA 1.49 1.543 0 O-C-N 121.298 -0.876 . . . . 0.0 109.401 179.917 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 21.4 pt20 . . . . . 0 N--CA 1.49 1.544 0 CA-C-O 117.988 -1.006 . . . . 0.0 109.473 -179.95 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' -1' ' ' SER . . . . . 0.535 ' OG ' ' N ' ' A' ' 0' ' ' GLU . 0.3 OUTLIER . . . . . 0 N--CA 1.49 1.533 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 . . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 0' ' ' GLU . . . . . 0.535 ' N ' ' OG ' ' A' ' -1' ' ' SER . 84.5 tt0 51.04 104.11 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.618 0 O-C-N 121.333 -0.854 . . . . 0.0 109.643 179.998 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 1' ' ' MET . . . . . 0.449 ' HB2' ' HB2' ' A' ' 4' ' ' ALA . 95.8 mmm -57.51 -44.32 84.95 Favored 'General case' 0 N--CA 1.49 1.549 0 O-C-N 121.288 -0.882 . . . . 0.0 109.444 179.887 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 2' ' ' GLN . . . . . . . . . . . . . 69.2 tp60 174.97 -80.96 0.0 OUTLIER 'General case' 0 N--CA 1.494 1.733 0 N-CA-C 106.47 -1.678 . . . . 0.0 106.47 179.94 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 3' ' ' HIS . . . . . . . . . . . . . 77.5 m80 -100.17 16.2 24.97 Favored 'General case' 0 C--N 1.302 -1.457 0 N-CA-C 106.683 -1.599 . . . . 0.0 106.683 177.219 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.449 ' HB2' ' HB2' ' A' ' 1' ' ' MET . . . -51.88 -39.48 59.07 Favored 'General case' 0 N--CA 1.487 1.417 0 CA-C-O 121.233 0.539 . . . . 0.0 109.92 -179.052 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 5' ' ' SER . . . . . . . . . . . . . 22.8 m -59.8 -37.78 80.09 Favored 'General case' 0 N--CA 1.49 1.573 0 O-C-N 121.256 -0.902 . . . . 0.0 109.746 -179.747 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 6' ' ' VAL . . . . . 0.546 HG11 ' CZ ' ' A' ' 51' ' ' ARG . 55.5 t -62.63 -42.93 97.89 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.546 0 O-C-N 121.251 -0.906 . . . . 0.0 109.545 179.955 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 7' ' ' ILE . . . . . . . . . . . . . 79.3 mt -59.54 -41.43 84.82 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.479 0 O-C-N 121.348 -0.845 . . . . 0.0 109.241 179.858 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 8' ' ' ALA . . . . . . . . . . . . . . . -62.21 -38.42 89.09 Favored 'General case' 0 C--N 1.304 -1.398 0 O-C-N 121.405 -0.809 . . . . 0.0 109.558 -179.789 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 9' ' ' GLN . . . . . 0.442 HE21 ' HA ' ' A' ' 6' ' ' VAL . 52.5 mt-30 -61.87 -42.07 98.62 Favored 'General case' 0 N--CA 1.49 1.564 0 O-C-N 121.108 -0.995 . . . . 0.0 109.545 179.921 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 10' ' ' PHE . . . . . 0.669 ' CG ' ' CE2' ' A' ' 47' ' ' TRP . 34.1 m-85 -61.81 -42.07 98.55 Favored 'General case' 0 N--CA 1.493 1.712 0 O-C-N 121.247 -0.908 . . . . 0.0 109.407 179.421 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 11' ' ' VAL . . . . . . . . . . . . . 43.3 t -61.13 -45.29 98.86 Favored 'Isoleucine or valine' 0 N--CA 1.489 1.514 0 O-C-N 121.367 -0.833 . . . . 0.0 109.548 -179.999 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 12' ' ' VAL . . . . . 0.614 HG21 ' HG3' ' A' ' 21' ' ' PRO . 93.6 t -63.21 -46.83 94.81 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.533 0 O-C-N 121.479 -0.763 . . . . 0.0 109.735 -179.821 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 13' ' ' GLU . . . . . . . . . . . . . 93.9 mt-10 -73.52 -16.46 61.28 Favored 'General case' 0 C--N 1.302 -1.467 0 O-C-N 121.396 -0.815 . . . . 0.0 110.265 -179.492 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 14' ' ' GLU . . . . . . . . . . . . . 83.5 tt0 -63.54 -31.88 73.17 Favored 'General case' 0 N--CA 1.49 1.553 0 O-C-N 121.171 -0.956 . . . . 0.0 110.299 -178.801 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 15' ' ' PHE . . . . . . . . . . . . . 65.7 t80 -151.32 -28.99 0.19 Allowed 'General case' 0 N--CA 1.491 1.614 0 O-C-N 120.829 -1.169 . . . . 0.0 110.436 -179.761 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 16' ' ' LEU . . . . . 0.546 HD22 ' CG2' ' A' ' 19' ' ' VAL . 6.2 mt -121.77 80.14 40.6 Favored Pre-proline 0 N--CA 1.492 1.647 0 O-C-N 121.231 -0.918 . . . . 0.0 110.08 -179.405 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 17' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_endo -77.08 -13.03 17.41 Favored 'Trans proline' 0 C--N 1.307 -1.607 0 C-N-CA 122.476 2.117 . . . . 0.0 112.375 179.759 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 18' ' ' ASP . . . . . . . . . . . . . 92.4 m-20 -93.95 9.74 36.24 Favored 'General case' 0 N--CA 1.488 1.472 0 O-C-N 121.189 -0.944 . . . . 0.0 110.263 -179.423 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 19' ' ' VAL . . . . . 0.546 ' CG2' HD22 ' A' ' 16' ' ' LEU . 46.4 t -109.88 137.77 40.57 Favored 'Isoleucine or valine' 0 N--CA 1.494 1.742 0 O-C-N 121.274 -0.891 . . . . 0.0 109.691 -179.769 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 20' ' ' ALA . . . . . . . . . . . . . . . -78.41 117.44 66.34 Favored Pre-proline 0 N--CA 1.49 1.573 0 O-C-N 121.147 -0.971 . . . . 0.0 109.442 179.941 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 21' ' ' PRO . . . . . 0.614 ' HG3' HG21 ' A' ' 12' ' ' VAL . 38.3 Cg_exo -53.83 -24.79 32.35 Favored 'Trans proline' 0 N--CA 1.494 1.535 0 C-N-CA 121.842 1.695 . . . . 0.0 112.068 179.547 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 22' ' ' ALA . . . . . . . . . . . . . . . -64.0 -24.51 67.74 Favored 'General case' 0 N--CA 1.491 1.6 0 O-C-N 121.304 -0.872 . . . . 0.0 109.301 -179.936 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 23' ' ' ASP . . . . . 0.409 ' O ' ' OD1' ' A' ' 23' ' ' ASP . 59.6 t0 -81.66 3.31 25.85 Favored 'General case' 0 N--CA 1.489 1.514 0 O-C-N 121.331 -0.856 . . . . 0.0 109.332 179.89 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 24' ' ' VAL . . . . . . . . . . . . . 13.0 t -109.66 133.94 53.32 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.633 0 O-C-N 121.375 -0.828 . . . . 0.0 109.298 179.969 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 25' ' ' ASP . . . . . . . . . . . . . 63.9 t0 -88.7 119.75 29.47 Favored 'General case' 0 C--N 1.302 -1.475 0 O-C-N 121.097 -1.002 . . . . 0.0 109.05 179.56 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 26' ' ' VAL . . . . . . . . . . . . . 29.9 m -74.43 4.15 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.486 1.35 0 O-C-N 121.137 -0.977 . . . . 0.0 109.261 179.656 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 27' ' ' ASP . . . . . . . . . . . . . 91.8 m-20 -90.43 -4.83 56.74 Favored 'General case' 0 N--CA 1.487 1.381 0 O-C-N 121.29 -0.881 . . . . 0.0 108.819 179.45 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 28' ' ' LEU . . . . . . . . . . . . . 45.3 tp -98.03 139.58 33.64 Favored 'General case' 0 N--CA 1.488 1.473 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 179.832 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 29' ' ' ASP . . . . . . . . . . . . . 90.9 m-20 -58.77 137.51 57.64 Favored 'General case' 0 C--N 1.302 -1.457 0 O-C-N 121.211 -0.931 . . . . 0.0 109.655 -179.419 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 30' ' ' LEU . . . . . 0.905 HD13 HD11 ' A' ' 36' ' ' ILE . 1.4 tt -66.04 -38.91 89.57 Favored 'General case' 0 C--N 1.302 -1.499 0 O-C-N 121.713 -0.617 . . . . 0.0 110.069 -179.272 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 74.6 t -63.19 -35.78 73.32 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 120.979 -1.076 . . . . 0.0 110.67 -178.782 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 32' ' ' ASP . . . . . . . . . . . . . 91.0 m-20 -52.58 -33.79 47.62 Favored 'General case' 0 C--N 1.301 -1.532 0 O-C-N 120.984 -1.073 . . . . 0.0 108.24 179.959 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 33' ' ' ASN . . . . . 0.445 ' HB3' HG23 ' A' ' 35' ' ' VAL . 97.2 m-20 -71.15 -34.66 71.2 Favored 'General case' 0 C--N 1.301 -1.509 0 O-C-N 121.614 -0.679 . . . . 0.0 110.047 179.516 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 34' ' ' GLY . . . . . . . . . . . . . . . 84.09 5.54 87.43 Favored Glycine 0 N--CA 1.491 2.359 0 N-CA-C 108.99 -1.644 . . . . 0.0 108.99 -179.385 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 35' ' ' VAL . . . . . 0.445 HG23 ' HB3' ' A' ' 33' ' ' ASN . 70.4 t -60.55 -33.86 56.15 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.399 0 O-C-N 121.407 -1.055 . . . . 0.0 108.634 179.557 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 36' ' ' ILE . . . . . 0.905 HD11 HD13 ' A' ' 30' ' ' LEU . 95.0 mt -84.32 124.12 39.54 Favored 'Isoleucine or valine' 0 N--CA 1.487 1.398 0 O-C-N 121.471 -0.768 . . . . 0.0 109.63 179.842 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 37' ' ' ASP . . . . . 0.556 ' CG ' ' H ' ' A' ' 38' ' ' ALA . 48.5 t0 -127.51 -159.53 0.94 Allowed 'General case' 0 C--N 1.301 -1.515 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 179.56 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 38' ' ' ALA . . . . . 0.556 ' H ' ' CG ' ' A' ' 37' ' ' ASP . . . -66.26 -55.07 17.93 Favored 'General case' 0 N--CA 1.49 1.546 0 O-C-N 120.848 -1.158 . . . . 0.0 108.681 179.792 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 39' ' ' LEU . . . . . . . . . . . . . 36.5 mt -71.3 -34.37 70.55 Favored 'General case' 0 C--N 1.303 -1.456 0 N-CA-C 107.412 -1.329 . . . . 0.0 107.412 178.237 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 40' ' ' GLY . . . . . 0.55 ' O ' HG23 ' A' ' 44' ' ' VAL . . . -59.53 -40.29 96.08 Favored Glycine 0 N--CA 1.482 1.735 0 N-CA-C 108.783 -1.727 . . . . 0.0 108.783 179.256 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 41' ' ' LEU . . . . . 0.407 ' O ' HD12 ' A' ' 45' ' ' ILE . 4.5 tt -65.44 -45.49 83.63 Favored 'General case' 0 C--N 1.304 -1.403 0 O-C-N 121.528 -0.984 . . . . 0.0 109.326 179.225 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 17.1 tp -59.51 -44.75 93.05 Favored 'General case' 0 C--N 1.301 -1.526 0 O-C-N 121.415 -0.803 . . . . 0.0 109.811 -179.829 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 43' ' ' LYS . . . . . . . . . . . . . 32.0 mttp -61.74 -34.74 76.37 Favored 'General case' 0 C--N 1.298 -1.664 0 O-C-N 120.973 -1.079 . . . . 0.0 109.583 -179.875 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 44' ' ' VAL . . . . . 0.55 HG23 ' O ' ' A' ' 40' ' ' GLY . 53.6 t -62.29 -50.23 80.78 Favored 'Isoleucine or valine' 0 N--CA 1.49 1.544 0 O-C-N 121.328 -0.858 . . . . 0.0 110.296 -179.439 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 45' ' ' ILE . . . . . 0.497 ' CG1' HD12 ' A' ' 61' ' ' LEU . 3.5 mp -68.15 -32.66 56.91 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.48 0 O-C-N 121.216 -0.927 . . . . 0.0 110.934 -179.607 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 46' ' ' ALA . . . . . . . . . . . . . . . -67.27 -49.85 62.69 Favored 'General case' 0 N--CA 1.496 1.851 0 O-C-N 120.971 -1.08 . . . . 0.0 111.757 -177.909 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 47' ' ' TRP . . . . . 0.669 ' CE2' ' CG ' ' A' ' 10' ' ' PHE . 0.0 OUTLIER -80.84 -43.51 19.88 Favored 'General case' 0 N--CA 1.492 1.667 0 O-C-N 120.677 -1.265 . . . . 0.0 110.089 -178.984 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 48' ' ' LEU . . . . . 0.4 ' N ' ' CG ' ' A' ' 47' ' ' TRP . 28.1 tp -58.93 -41.46 87.38 Favored 'General case' 0 C--N 1.3 -1.579 0 O-C-N 121.25 -0.906 . . . . 0.0 110.082 -179.085 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.436 ' CG ' ' N ' ' A' ' 50' ' ' ASP . 16.9 pt-20 -73.14 -37.7 66.52 Favored 'General case' 0 C--N 1.303 -1.427 0 O-C-N 121.082 -1.012 . . . . 0.0 109.589 -179.859 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 50' ' ' ASP . . . . . 0.436 ' N ' ' CG ' ' A' ' 49' ' ' GLU . 22.1 t70 -58.73 -38.16 77.77 Favored 'General case' 0 N--CA 1.49 1.556 0 O-C-N 121.406 -0.809 . . . . 0.0 110.618 -179.462 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 51' ' ' ARG . . . . . 0.546 ' CZ ' HG11 ' A' ' 6' ' ' VAL . 71.1 mtp180 -61.07 -38.66 86.99 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.156 -0.965 . . . . 0.0 111.434 -178.808 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 52' ' ' PHE . . . . . 0.764 ' CE1' HG11 ' A' ' 76' ' ' VAL . 75.0 m-85 -97.24 -7.42 32.31 Favored 'General case' 0 N--CA 1.488 1.439 0 O-C-N 120.872 -1.143 . . . . 0.0 110.582 -179.075 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 53' ' ' GLY . . . . . . . . . . . . . . . 72.81 30.73 63.27 Favored Glycine 0 N--CA 1.489 2.178 0 N-CA-C 109.207 -1.557 . . . . 0.0 109.207 179.307 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 54' ' ' ILE . . . . . . . . . . . . . 30.3 pt -106.81 153.4 8.03 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.354 0 O-C-N 121.483 -1.01 . . . . 0.0 109.571 -179.756 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -101.75 137.93 39.4 Favored 'General case' 0 N--CA 1.489 1.509 0 O-C-N 121.209 -0.932 . . . . 0.0 109.681 -179.562 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 56' ' ' ALA . . . . . 0.495 ' O ' ' O ' ' A' ' 59' ' ' VAL . . . -66.63 -26.57 67.13 Favored 'General case' 0 N--CA 1.49 1.547 0 O-C-N 121.365 -0.835 . . . . 0.0 109.724 179.899 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 57' ' ' ASP . . . . . 0.629 ' OD1' ' N ' ' A' ' 58' ' ' ASP . 54.9 p30 -60.42 -32.06 70.99 Favored 'General case' 0 N--CA 1.489 1.503 0 O-C-N 121.123 -0.986 . . . . 0.0 110.257 -179.606 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 58' ' ' ASP . . . . . 0.629 ' N ' ' OD1' ' A' ' 57' ' ' ASP . 53.8 t0 -57.95 -39.96 79.39 Favored 'General case' 0 N--CA 1.491 1.603 0 O-C-N 121.016 -1.052 . . . . 0.0 109.72 -179.908 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 59' ' ' VAL . . . . . 0.495 ' O ' ' O ' ' A' ' 56' ' ' ALA . 13.3 p -137.15 143.47 34.56 Favored 'Isoleucine or valine' 0 N--CA 1.492 1.638 0 O-C-N 121.301 -0.874 . . . . 0.0 109.497 -179.969 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 60' ' ' GLU . . . . . . . . . . . . . 84.2 tt0 -90.36 132.63 35.48 Favored 'General case' 0 N--CA 1.491 1.606 0 O-C-N 121.115 -0.991 . . . . 0.0 109.221 179.847 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 61' ' ' LEU . . . . . 0.497 HD12 ' CG1' ' A' ' 45' ' ' ILE . 57.2 mt -97.74 137.26 36.88 Favored 'General case' 0 C--N 1.305 -1.338 0 O-C-N 121.222 -0.924 . . . . 0.0 109.771 -179.668 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 62' ' ' SER . . . . . . . . . . . . . 0.1 OUTLIER -110.18 156.44 40.14 Favored Pre-proline 0 N--CA 1.488 1.43 0 N-CA-C 108.841 -0.799 . . . . 0.0 108.841 179.391 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 63' ' ' PRO . . . . . . . . . . . . . 8.0 Cg_endo -53.18 -23.28 22.2 Favored 'Trans proline' 0 C--N 1.302 -1.899 0 C-N-CA 122.388 2.059 . . . . 0.0 111.685 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 64' ' ' GLU . . . . . . . . . . . . . 96.6 mt-10 -70.73 -27.78 64.22 Favored 'General case' 0 C--N 1.305 -1.34 0 O-C-N 121.335 -0.853 . . . . 0.0 109.561 179.686 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 65' ' ' HIS . . . . . 0.566 ' C ' ' CD2' ' A' ' 65' ' ' HIS . 0.4 OUTLIER -65.69 -17.81 64.88 Favored 'General case' 0 C--N 1.303 -1.451 0 O-C-N 121.336 -0.852 . . . . 0.0 109.056 -179.835 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 66' ' ' PHE . . . . . 0.546 ' N ' ' CD1' ' A' ' 66' ' ' PHE . 11.6 m-85 -97.57 15.89 22.0 Favored 'General case' 0 C--N 1.301 -1.538 0 N-CA-C 108.591 -0.892 . . . . 0.0 108.591 179.704 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 67' ' ' ARG . . . . . 0.594 ' NE ' ' OG ' ' A' ' 71' ' ' SER . 6.7 ptt180 -48.95 -38.58 23.4 Favored 'General case' 0 C--N 1.301 -1.512 0 O-C-N 121.796 -0.565 . . . . 0.0 110.558 -179.526 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 43.8 t -161.52 158.98 27.29 Favored 'General case' 0 N--CA 1.491 1.615 0 O-C-N 120.905 -1.122 . . . . 0.0 110.234 -179.803 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 69' ' ' ILE . . . . . 0.464 ' CD1' HD12 ' A' ' 30' ' ' LEU . 31.6 mm -57.97 -44.01 85.97 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.361 0 O-C-N 121.319 -0.863 . . . . 0.0 109.628 179.876 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' ARG . . . . . 0.7 ' NH1' ' HZ1' ' A' ' 87' ' ' LYS . 0.0 OUTLIER -58.65 -39.3 80.18 Favored 'General case' 0 N--CA 1.488 1.435 0 O-C-N 121.276 -0.89 . . . . 0.0 109.596 -179.57 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' SER . . . . . 0.594 ' OG ' ' NE ' ' A' ' 67' ' ' ARG . 41.6 t -62.59 -41.51 99.0 Favored 'General case' 0 N--CA 1.489 1.522 0 O-C-N 121.275 -0.891 . . . . 0.0 109.689 179.821 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' ILE . . . . . . . . . . . . . 80.7 mt -61.01 -47.75 92.19 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.344 0 O-C-N 121.306 -0.871 . . . . 0.0 109.911 -179.62 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' ASP . . . . . . . . . . . . . 32.9 t0 -60.26 -43.14 96.42 Favored 'General case' 0 N--CA 1.49 1.527 0 O-C-N 121.168 -0.958 . . . . 0.0 109.167 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' ALA . . . . . 0.54 ' O ' ' N ' ' A' ' 78' ' ' GLY . . . -66.84 -38.89 87.27 Favored 'General case' 0 C--N 1.302 -1.489 0 O-C-N 121.52 -0.738 . . . . 0.0 109.952 -179.829 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' PHE . . . . . . . . . . . . . 71.6 t80 -61.64 -51.24 69.29 Favored 'General case' 0 C--N 1.301 -1.529 0 O-C-N 121.174 -0.953 . . . . 0.0 109.271 -179.914 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' VAL . . . . . 0.764 HG11 ' CE1' ' A' ' 52' ' ' PHE . 77.6 t -69.51 -48.03 68.69 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 O-C-N 121.328 -0.857 . . . . 0.0 109.878 179.972 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' VAL . . . . . . . . . . . . . 72.3 t -69.55 -47.0 74.23 Favored 'Isoleucine or valine' 0 N--CA 1.486 1.328 0 O-C-N 121.175 -0.953 . . . . 0.0 109.756 -179.887 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' GLY . . . . . 0.54 ' N ' ' O ' ' A' ' 74' ' ' ALA . . . -61.93 -37.88 95.11 Favored Glycine 0 N--CA 1.49 2.279 0 N-CA-C 109.826 -1.309 . . . . 0.0 109.826 -179.752 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' ALA . . . . . . . . . . . . . . . -67.61 -39.45 84.73 Favored 'General case' 0 N--CA 1.49 1.538 0 O-C-N 121.183 -1.187 . . . . 0.0 110.025 -179.508 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' THR . . . . . 0.523 HG23 ' O ' ' A' ' 76' ' ' VAL . 50.2 p -81.33 -31.61 33.41 Favored 'General case' 0 N--CA 1.488 1.426 0 O-C-N 121.286 -0.884 . . . . 0.0 109.594 -179.859 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' THR . . . . . 0.493 ' O ' ' O ' ' A' ' 78' ' ' GLY . 0.4 OUTLIER -133.2 152.87 80.3 Favored Pre-proline 0 C--N 1.304 -1.389 0 O-C-N 121.403 -0.811 . . . . 0.0 109.908 -179.646 . . . . . . . . 3 3 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' PRO . . . . . . . . . . . . . 50.1 Cg_exo -44.82 111.2 0.27 Allowed 'Trans proline' 0 C--N 1.311 -1.408 0 C-N-CA 122.254 1.969 . . . . 0.0 111.823 179.286 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' PRO . . . . . . . . . . . . . 22.2 Cg_exo -57.05 143.53 92.58 Favored 'Trans proline' 0 N--CA 1.492 1.4 0 C-N-CA 121.81 1.674 . . . . 0.0 111.98 179.917 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.583 ' O ' ' N ' ' A' ' 86' ' ' ALA . 44.4 t -103.68 132.41 50.12 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.608 0 O-C-N 121.32 -0.862 . . . . 0.0 109.773 -179.998 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' GLU . . . . . 0.468 ' C ' ' O ' ' A' ' 84' ' ' VAL . 96.1 mt-10 37.33 26.0 0.01 OUTLIER 'General case' 0 N--CA 1.494 1.768 0 O-C-N 121.584 -0.698 . . . . 0.0 110.136 179.625 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' ALA . . . . . 0.583 ' N ' ' O ' ' A' ' 84' ' ' VAL . . . 42.39 -147.34 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.613 0 O-C-N 121.2 -0.937 . . . . 0.0 109.543 -179.912 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' LYS . . . . . 0.7 ' HZ1' ' NH1' ' A' ' 70' ' ' ARG . 48.9 tttm -73.63 146.53 44.53 Favored 'General case' 0 N--CA 1.491 1.576 0 O-C-N 121.194 -0.941 . . . . 0.0 109.783 -179.91 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' LEU . . . . . . . . . . . . . 7.2 tt -53.47 -38.74 63.88 Favored 'General case' 0 N--CA 1.488 1.461 0 O-C-N 121.311 -0.868 . . . . 0.0 109.336 179.488 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' GLN . . . . . . . . . . . . . 94.3 mt-30 . . . . . 0 N--CA 1.49 1.56 0 CA-C-O 118.022 -0.989 . . . . 0.0 109.5 -179.971 . . . . . . . . 0 0 . 1 stop_ save_